,CID,name,smiles,7.1-Drug Indication,8.1-Pharmacodynamics,8.2-MeSH Pharmacological Classification,"8.5-Absorption, Distribution and Excretion",8.6-Metabolism/Metabolites,8.7-Biological Half-Life
0,34695,CID 34695,C1CC=CC=CC=C1,,,,,,
1,34696,CID 34696,C1C=CCC=CC=C1,,,,,,
2,34697,Isodecyl diphenyl phosphate,CC(C)CCCCCCCOP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
3,34698,Teniposidum,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)C8=CC=CS8)O)O,,,,,,
4,34699,CID 34699,C1CC=C=CC1.C1CC=CC=C1.C1C=CCC=C1,,,,,,
5,34700,"Cyclohexa-1,2-diene",C1CC=C=CC1,,,,,,
6,34701,CID 34701,CC1=CC(=C(C=C1)Cl)Cl.CC1=C(C(=CC=C1)Cl)Cl.CC1=C(C=C(C=C1)Cl)Cl.CC1=CC(=CC(=C1)Cl)Cl.CC1=C(C=CC=C1Cl)Cl,,,,,,
7,34702,"2,3-Dichlorotoluene",CC1=C(C(=CC=C1)Cl)Cl,,,,,,
8,34703,"2,4,6-Tris(2,2,2-trichloroethoxy)-1,3,5-triazine",C(C(Cl)(Cl)Cl)OC1=NC(=NC(=N1)OCC(Cl)(Cl)Cl)OCC(Cl)(Cl)Cl,,,,,,
9,34704,O-Decylhydroxylamine,CCCCCCCCCCON,,,,,,
10,34705,Bis(o-methoxyphenoxy)acetic acid,COC1=CC=CC=C1OC(C(=O)O)OC2=CC=CC=C2OC,,,,,,
11,34706,Bis(4-chlorophenoxy)acetic acid,C1=CC(=CC=C1OC(C(=O)O)OC2=CC=C(C=C2)Cl)Cl,,,,,,
12,34707,"5,5-Diethyltetrahydro-3-furanol",CCC1(CC(CO1)O)CC,,,,,,
13,34708,5-Isobutyl-5-methyltetrahydro-3-furanol,CC(C)CC1(CC(CO1)O)C,,,,,,
14,34709,5-Methyl-5-propyltetrahydro-3-furanol,CCCC1(CC(CO1)O)C,,,,,,
15,34710,5-Butyl-5-methyltetrahydro-3-furanol,CCCCC1(CC(CO1)O)C,,,,,,
16,34711,"5,5-Dipropyltetrahydro-3-furanol",CCCC1(CC(CO1)O)CCC,,,,,,
17,34712,"5,5-Diisopropyltetrahydro-3-furanol",CC(C)C1(CC(CO1)O)C(C)C,,,,,,
18,34713,5-Methyl-5-nonyltetrahydro-3-furanol,CCCCCCCCCC1(CC(CO1)O)C,,,,,,
19,34714,"2,5,5-Trimethyltetrahydro-3-furanol",CC1C(CC(O1)(C)C)O,,,,,,
20,34715,"3-Ethyl-2,2,5-trimethyltetrahydrofuran-3-ol",CCC1(CC(OC1(C)C)C)O,,,,,,
21,34716,"5,5-Dimethyl-2-ethyltetrahydro-3-furanol",CCC1C(CC(O1)(C)C)O,,,,,,
22,34717,"2,5-Dimethyl-5-ethyltetrahydro-3-furanol",CCC1(CC(C(O1)C)O)C,,,,,,
23,34718,6-Oxaspiro[4.5]decan-8-ol,C1CCC2(C1)CCC(CO2)O,,,,,,
24,34719,2-Methyl-1-oxaspiro(4.4)nonan-3-ol,CC1C(CC2(O1)CCCC2)O,,,,,,
25,34720,"2,5-Diethyl-2-methyltetrahydro-3-furanol",CCC1CC(C(O1)(C)CC)O,,,,,,
26,34721,"5,5-Dimethyl-2-propyltetrahydro-3-furanol",CCCC1C(CC(O1)(C)C)O,,,,,,
27,34722,"5,5-Dimethyl-2-isopropyltetrahydro-3-furanol",CC(C)C1C(CC(O1)(C)C)O,,,,,,
28,34723,"2,2,5,5-Tetramethyltetrahydro-3,4-furandiol",CC1(C(C(C(O1)(C)C)O)O)C,,,,,,
29,34724,"4,4-Dihydroxy-2,2,5,5-tetramethyltetrahydro-3-furamide",CC1(C(C(C(O1)(C)C)(O)O)C(=O)N)C,,,,,,
30,34725,"4-Hydroxy-2,2,5,5-tetramethyltetrahydro-3-furanmethanol",CC1(C(C(C(O1)(C)C)O)CO)C,,,,,,
31,34726,"2,5,5-Triethyltetrahydro-3-furanol",CCC1C(CC(O1)(CC)CC)O,,,,,,
32,34727,"2-Butyl-5,5-dimethyltetrahydro-3-furanol",CCCCC1C(CC(O1)(C)C)O,,,,,,
33,34728,5-Ethyl-5-methyl-2-propyltetrahydro-3-furanol,CCCC1C(CC(O1)(C)CC)O,,,,,,
34,34729,2-Ethyl-5-methyl-5-propyltetrahydro-3-furanol,CCCC1(CC(C(O1)CC)O)C,,,,,,
35,34730,"2,2,5,5-Tetramethyloxolan-3-ol",CC1(CC(C(O1)(C)C)O)C,,,,,,
36,34731,"2,2,3,5,5-Pentamethyltetrahydro-3-furanol",CC1(CC(C(O1)(C)C)(C)O)C,,,,,,
37,34732,"2,2,4,5,5-Pentamethyltetrahydro-3-furanol",CC1C(C(OC1(C)C)(C)C)O,,,,,,
38,34733,"5,5-Diethyl-2,2-dimethyltetrahydro-3-furanol",CCC1(CC(C(O1)(C)C)O)CC,,,,,,
39,34734,"2,2,5,5-Tetraethyltetrahydro-3-furanol",CCC1(CC(C(O1)(CC)CC)O)CC,,,,,,
40,34735,3-[4-Chloro-2-[[3-(trifluoromethyl)benzoyl]amino]phenyl]prop-2-enoic acid,C1=CC(=CC(=C1)C(F)(F)F)C(=O)NC2=C(C=CC(=C2)Cl)C=CC(=O)O,,,,,,
41,34736,"2,4,6-Trimethylcarbanilic acid 2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride",CC1=CC(=C(C(=C1)C)NC(=O)OC2CCCCC2[NH+]3CCCC3)C.[Cl-],,,,,,
42,34737,"(2-pyrrolidin-1-ylcyclohexyl) N-(2,4,6-trimethylphenyl)carbamate",CC1=CC(=C(C(=C1)C)NC(=O)OC2CCCCC2N3CCCC3)C,,,,,,
43,34738,o-Methylcarbanilic acid 2-morpholinocyclohexyl ester hydrochloride,CC1=CC=CC=C1NC(=O)OC2CCCCC2[NH+]3CCOCC3.[Cl-],,,,,,
44,34739,(2-morpholin-4-ylcyclohexyl) N-(2-methylphenyl)carbamate,CC1=CC=CC=C1NC(=O)OC2CCCCC2N3CCOCC3,,,,,,
45,34740,4-Methyloxolan-3-ol,CC1COCC1O,,,,,,
46,34741,5-Methyltetrahydro-3-furanol,CC1CC(CO1)O,,,,,,
47,34742,2-Methyloxolan-3-ol,CC1C(CCO1)O,,,,,,
48,34743,5-Methyl-2-pentyltetrahydro-3-furanol,CCCCCC1C(CC(O1)C)O,,,,,,
49,34744,"3-Furanol, tetrahydro-5,5-dimethyl-",CC1(CC(CO1)O)C,,,,,,
50,34745,(5-Amino-2-hydroxyphenyl)azanium;chloride,C1=CC(=C(C=C1N)[NH3+])O.[Cl-],,,,,,
51,34746,"BENZO(a)PYRENE, 5-(CHLOROMETHYL)-",C1=CC=C2C3=C4C(=CC2=C1)C(=CC5=CC=CC(=C54)C=C3)CCl,,,,,,
52,34747,7-Deoxy-D-glycero-D-gluco-heptose,CC(C(C(C(C(C=O)O)O)O)O)O,,,,,,
53,34748,"1,1'-Dipropyl-4,4'-bipyridinium diiodide",CCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCC.[I-].[I-],,,,,,
54,34749,"1,1'-Dipropyl-4,4'-bipyridinium",CCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCC,,,,,,
55,34750,Dimethyl suberimidate,COC(=N)CCCCCCC(=N)OC,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
56,34751,Amygdaloside,C1=CC=C(C=C1)C(C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,,,"['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",['THE MAX CYANIDE LEVEL AFTER ORAL ADMIN OF AMYGDALIN TO MICE WAS REACHED AT ABOUT 1 1/2-2 HR & WAS WITHIN THE RANGE OF VALUES SEEN AFTER KCN ADMIN. THE ABILITY OF THE CONTENTS OF VARIOUS REGIONS OF THE GI TRACT & OF TUMOR TISSUE TO RELEASE CYANIDE FROM AMYGDALIN WAS ASSESSED. THE STOMACH & UPPER INTESTINE HAD LITTLE ACTIVITY WHILE THE LOWER INTESTINE & FECES RELEASED LARGE AMOUNTS. THERE WAS A LARGE VARIATION BETWEEN MICE.'],"['AMYGDALIN IS A CHEMICAL COMBINATION OF GLUCOSE, BENZALDEHYDE, & CYANIDE FROM WHICH THE LATTER CAN BE RELEASED BY THE ACTION OF BETA-GLUCOSIDASE OR EMULSIN. ALTHOUGH THESE ENZYMES ARE NOT FOUND IN MAMMALIAN TISSUES, THE HUMAN INTESTINAL MICROFLORA APPEARS TO POSSESS THESE OR SIMILAR ENZYMES CAPABLE OF EFFECTING CYANIDE RELEASE RESULTING IN HUMAN POISONING. FOR THIS REASON AMYGDALIN MAY BE AS MUCH AS 40 TIMES MORE TOXIC BY THE ORAL ROUTE AS COMPARED WITH IV INJECTION.', '...PLANT GLYCOSIDES ARE CHARACTERIZED BY PRODN OF CYANIDE, TOGETHER WITH A SUGAR & AROMATIC ALDEHYDE, ON ENZYMIC OR ACID HYDROLYSIS. COMMON EXAMPLES ARE AMYGDALIN (GENTIOBIOSE + BENZALDEHYDE + HCN) WHICH IS PRESENT IN BITTER ALMONDS... AN ENZYME COMPLEX, EMULSIN, IS PRESENT TOGETHER WITH GLYCOSIDES IN PLANT TISSUES & CATALYZES THE HYDROLYSIS OF GLYCOSIDES, FIRST TO MANDELONITRILE OR P-HYDROXYMANDELONITRILE, & THEN TO BENZALDEHYDE OR P-HYDROXYBENZALDEHYDE, & HCN. ... THE ALDEHYDES ARE OXIDIZED TO CORRESPONDING AROMATIC ACIDS & EXCRETED AS PEPTIDE CONJUGATES.', '...VARIOUS PRUNUS SPECIES CONTAIN...AMYGDALIN, WHICH IS HYDROLYZED BY ENZYME EMULSIN... IN INTACT PLANT NO SUCH ACTION TAKES PLACE; IT IS NOT UNTIL PLANT TISSUE IS DAMAGED OR STARTS TO DECAY THAT LIBERATION OF HCN BEGINS.', 'BREAKDOWN /OF GLYCOSIDES/ OFTEN OCCURS MORE READILY OR MORE RAPIDLY IN RUMEN THAN IN DIGESTIVE TRACT OF MONOGASTRIC ANIMALS. ALSO, SMALL MOLECULES CAN BE ABSORBED AT THE RUMEN & THUS ENTER CIRCULATION RAPIDLY. BREAKDOWN OF CYANOGENIC GLYCOSIDES, SUCH AS AMYGDALIN, FROM MEMBERS OF ROSE FAMILY...IS AN EXAMPLE.', 'For more Metabolism/Metabolites (Complete) data for AMYGDALIN (9 total), please visit the HSDB record page.']","['PLASMA & URINE CONCN OF AMYGDALIN, WHOLE-BLOOD CONCN OF CN- & SCN- CONCN IN SERUM & URINE WERE DETERMINED IN CANCER PT FOLLOWING IV (4.5 G/SQUARE M) & ORAL (500-MG TABLET) ADMIN OF AMYGDALIN. FOLLOWING IV ADMIN, CONCN OF PARENT DRUG AS HIGH AS 1401 MUG/ML WERE OBSERVED WITH NO INCR IN PLASMA CONCN OF CN- OR SERUM CONCN OF SCN-. PLASMA ELIM OF AMYGDALIN WAS BEST DESCRIBED BY 2-COMPARTMENT OPEN MODEL WITH MEAN DISTRIBUTIVE PHASE T/2 OF 6.2 MIN, MEAN ELIM PHASE T/2 OF 120.3 MIN, & MEAN CLEARANCE OF 99.3 ML/MIN. FOLLOWING ORAL ADMIN OF AMYGDALIN, PLASMA CONCN WERE MUCH LOWER, WITH PEAK VALUES OF LESS THAN 525 NG/ML. CN- CONCN INCR TO VALUES AS HIGH AS 2.1 MUG/ML WHOLE BLOOD. SCN- CONCN DID NOT INCR FOR SEVERAL DAYS, PLATEAUING AT VALUES AS HIGH AS 38 MUG/ML SERUM.']"
57,34752,Pentenyl acetic acid,CCCC=CCC(=O)O,,,,,,
58,34753,"Peroxide, bis(1-naphthalenylcarbonyl)",C1=CC=C2C(=C1)C=CC=C2C(=O)OOC(=O)C3=CC=CC4=CC=CC=C43,,,,,,
59,34754,"1,2,3,4-Tetrahydro-6,7-dimethoxy-1-phenethylisoquinoline",COC1=C(C=C2C(NCCC2=C1)CCC3=CC=CC=C3)OC,,,,,,
60,34755,S-adenosylmethionine,C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,"['S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.']","['S-adenosylmethionine is an intermediate metabolite of methionine. Its involvement in methylation assists in cellular growth and repair, maintains the phospho-bilipid layer in cell membranes. It also helps in the maintenance of the action of several hormones and neurotransmitters that affect mood. Highest concentration are found in the brain and the liver.']",,"['S-Adenosylmethionine is absorbed from the small intestine following oral intake. As absorption is affected by food, it is best to take on an empty stomach. Bioavailability is low following oral intake.']","['Significant first-pass metabolism in the liver. Approximately 50% of S-Adenosylmethionine (SAMe) is metabolized in the liver. SAMe is metabolized to S-adenosylhomocysteine, which is then metabolized to homocysteine. Homocysteine can either be metabolized to cystathionine and then cysteine or to methionine. The cofactor in the metabolism of homocysteine to cysteine is vitamin B6. Cofactors for the metabolism of homocysteine to methionine are folic acid, vitamin B12 and betaine.']",
61,34756,S-adenosyl-L-methionine,C[S+](CC[C@@H](C(=O)O)N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
62,34757,"2-Amino-5,6-dimethylbenzothiazole",CC1=CC2=C(C=C1C)SC(=N2)N,,,,,,
63,34758,"Acetophenone, 4'-(hexahydro-1H-azepinyl)carbonylmethoxy-",CC(=O)C1=CC=C(C=C1)OCC(=O)N2CCCCCC2,,,,,,
64,34759,2-[4-(Hydroxyiminomethyl)phenoxy]-1-morpholin-4-ylethanone,C1COCCN1C(=O)COC2=CC=C(C=C2)C=NO,,,,,,
65,34760,2-[4-(N-hydroxy-C-methylcarbonimidoyl)phenoxy]-1-morpholin-4-ylethanone,CC(=NO)C1=CC=C(C=C1)OCC(=O)N2CCOCC2,,,,,,
66,34761,1-(azepan-1-yl)-2-[4-(N-hydroxy-C-methylcarbonimidoyl)phenoxy]ethanone,CC(=NO)C1=CC=C(C=C1)OCC(=O)N2CCCCCC2,,,,,,
67,34762,1-[4-(2-Morpholin-4-yl-2-oxoethoxy)phenyl]ethanone,CC(=O)C1=CC=C(C=C1)OCC(=O)N2CCOCC2,,,,,,
68,34763,Isodecyl methacrylate,CC(C)CCCCCCCOC(=O)C(=C)C,,,,,"['Small quantities of methacrylates may readily be metabolized by saponification into the alcohol and methacrylic acid. The latter may form an acetyl-coenzyme derivative, which then enters the normal lipid metabolism. /Methacrylates/', 'Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Methacrylates/']",
69,34764,"Benzohydroxamic acid, N-fluoren-1-YL-",C1C2=CC=CC=C2C3=C1C(=CC=C3)N(C(=O)C4=CC=CC=C4)O,,,,,,
70,34765,"N-Fluoren-2-ylbenzohydroxamic acid, acetate",CC(=O)ON(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)C4=CC=CC=C4,,,,,,
71,34766,Ethiofencarb,CCSCC1=CC=CC=C1OC(=O)NC,,,,"['In animals, 14C-ethiofencarb is rapidly excreted.', 'When administered as a single oral dose to rats, 41% of the carbonyl-labelled compound was eliminated in the urine and 7% in the feces (within 72 hr), while 47% was eliminated as 14CO2. When similarly administered but in ring-labelled form, 96% was eliminated in the urine and 2% in the feces within 72 hr. The compound, therefore, undergoes hydrolysis, producing a phenol and a carbamic acid derivative which breaks down further to CO2.', ""Maintenance of rats on a diet containing 6.6 ppm of ethiofencarb gave ...total excretion (urine plus feces) decreasing to 1% of one day's intake by the third day after return of the animals to the normal diet. The major metabolites identified were the sulfoxide and sulfone of ethiofencarb and the sulfoxide and sulfone of the phenol; the latter two compounds were excreted mainly as conjugates, and the parent compound was detected in the urine only in trace amounts. Tissue residues detected after either a single oral dose of 0.5 mg/kg bw or administration of 6.6 ppm in the diet for one week were below 1 mg/kg, and these declined more rapidly after administration of the ring-labelled than the carbonyl-labelled compound. This suggests that the carbonyl-labelled residues were incorporated into normal tissues components, as would be expected."", 'Bile-duct-cannulated rats were orally administered 14C-ethiofencarb. Biliary radioactive carbon measurements made two days after administration revealed the following percentage of the dose 20.2%. /Most/ of the dose was eliminated in the urine, while the feces did not exceed an elimination rate of 3%. Enterohepatic circulation of metabolites is suggested by these findings.', 'A lactating Holstein cow and a male Yorkshire pig treated with a single oral dose (0.5 mg/kg) of ring (14C) croneton excreted 97.8% and 90.0% of the dose, respectively, in the urine after 24 hr. None of the swine tissues examined 24 hr after treatment contained detectable residues, and of the bovine tissues, only the kidney, liver, and skin contained detectable activity (0.016, 0.017, and 0.05 ppm 14C-croneton equivalents, respectively). Milk collected from the cow 6 hr after treatment contained 128 ppb 14C residues; 60% of this was as the free carbamate metabolites, croneton sulfoxide and sulfone. White Leghorn hens given ring 14C-croneton as a single oral dose (0.5 mg/kg) or in twice-daily doses (0.5 mg/kg) over 7 consecutive days showed patterns of metabolism and excretion similar to those observed in the pig and cow. Birds sacrificed 4 hr after the last dose contained from 0.019 ppm 14C-croneton equivalents in the fat to 0.324 ppm in the kidney. By 24 hr, only the liver and kidney (0.044 and 0.022 ppm, respectively) contained residues in excess of 0.01 ppm, and within 4 days the residues in these organs were 0.01 ppm or less. Residues in eggs laid by these hens were 0.03 to 0.04 ppm 14C-croneton equivalents 2 days after treatment; egg residues reached a maximum of 0.06 to 0.07 ppm 7 days after treatment and declined rapidly following the termination of treatment. About 75% of the radiocarbon in the eggs occurred as free phenol sulfoxide and sulfone, 10% occurred as free croneton sulfoxide and croneton sulfone, 5% occurred as water-soluble metabolites, and 5% occurred as unextracted residues. The remaining 5% was accounted for by unknown metabolites in the organo-extractable fraction.']","['The main metabolites are ethiofencarb sulfoxide and sulfone, ethiofencarb phenol and the corresponding sulfoxide and sulfone.', 'The first step in the metabolism of carbamates is hydrolysis to carbamic acid, which decomposes to carbon dioxide (CO2) and the corresponding amine. The mechanism of hydrolysis is different for  N -methyl and  N -dimethyl derivatives.  The  N -methyl carbamates pass through an isocyanate intermediate, whereas in the hydrolysis of  N - dimethylcarbamates, an addition product with a hydroxyl ion is formed yielding the alcohol and  N -dimethyl substituted acid.  The rate of hydrolysis by esterases is faster in mammals than in plants and insects. Apart from hydrolysis, oxidation also takes place including: hydroxylation of the aromatic ring,  O -dealkylation,  N -methyl hydroxylation,  N -dealkylation, oxidation of aliphatic side chains, and sulfoxidation to the corresponding sulfone. Oxidation is associated with the mixed-function oxidase (MFO) enzymes. Conjugation leads to the formation of  O - and  N -glucuronides, sulfates, and mercapturic acid derivatives in mammals.  Glycosides and phosphates are conjugation products more common in plants. /Carbamate Pesticides/', 'The fate of Croneton, 2-ethylthiomethylphenyl N-methylcarbamate, was determined in rats following single oral or dietary exposure to the 14C-carbonyl- and 14C-ring-labeled insecticide. Greater than 95% of the (14C)Croneton equivalents was excreted in the urine or as a combination of 14CO2 (47%) and urinary products (41%) 72 hr after a single oral dose. The feces contained 27% of the dose. A similar excretion pattern was observed during a 7-day feeding period. The principal urinary metabolites were Croneton sulfoxide (23-28% of the dose), phenol sulfoxide (20-23%), phenol sulfone (9-25%), and Croneton sulfone (3-11%) after a single oral dose and similar in the long term study. The carbamates were excreted primarily as free metabolites while the phenolic constituents were eliminated as acid labile conjugates.', 'The comparative ester hydrolysis and selective toxicity of carbamate insecticides were studied in 4 mammalian species. Hydrolysis rates of carbaryl and ethiofencarb (Croneton) were examined in the rat, mouse, guinea pig and gerbil. Respiratory 14CO2 resulting from the hydrolysis of orally administered (carbonyl-14C)carbamates (0.2 mg/kg) was taken as measure of in vivo hydrolytic capabilities. Ester hydrolysis was greater for ethiofencarb in all species tested, although the relative order of hydrolysis among species was the same with both compounds. After 24 hr, gerbils had hydrolyzed 91% of the ethiofencarb an 65% of the carbaryl. Guinea pigs hydrolyzed somewhat less of the compounds, 65 and 85%, but more than rats and mice, 40 and 25%.', 'About 75% of the radiocarbon in the eggs /from White Leghorn hens given one to 14 oral doses of croneton/ occurred as free phenol sulfoxide and sulfone, 10% occurred as free croneton sulfoxide and croneton sulfone, 5% occurred as water-soluble metabolites, and 5% occurred as unextracted residues. The remaining 5% was accounted for by unknown metabolites in the organo-extractable fraction.']",
72,34767,N-Carbethoxy-4-piperidone,CCOC(=O)N1CCC(=O)CC1,,,,,,
73,34768,Vidarabine phosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N,,,"['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
74,34769,"2,5-Dimethyltetrahydro-3-furanol",CC1CC(C(O1)C)O,,,,,,
75,34770,"2,5-Dipropyltetrahydro-3-furanol",CCCC1CC(C(O1)CCC)O,,,,,,
76,34771,"3,4-Dihydro-2-(((p-hydroxyphenethyl)amino)methyl)-1(2H)-naphthalenone hydrochloride",C1CC2=CC=CC=C2C(=O)C1C[NH2+]CCC3=CC=C(C=C3)O.[Cl-],,,,,,
77,34772,"2-[[2-(4-hydroxyphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one",C1CC2=CC=CC=C2C(=O)C1CNCCC3=CC=C(C=C3)O,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
78,34773,5-Ethyl-5-methyltetrahydro-3-furanol,CCC1(CC(CO1)O)C,,,,,,
79,34774,"2,5-Diethyl-2,5-dimethyltetrahydro-3-furanol",CCC1(CC(C(O1)(C)CC)O)C,,,,,,
80,34775,p-Cyclopropyl-alpha-((methylamino)methyl)-benzyl alcohol cyclohexanesulfamate,C[NH2+]CC(C1=CC=C(C=C1)C2CC2)O.C1CCC(CC1)NS(=O)(=O)[O-],,,,,,
81,34776,1-(4-Cyclopropylphenyl)-2-(methylamino)ethanol,CNCC(C1=CC=C(C=C1)C2CC2)O,,,,,,
82,34777,Isophthalaldehyde,C1=CC(=CC(=C1)C=O)C=O,,,,,,
83,34778,"Benzo(b)thiophene, dimethyl-",CC1=C2C(=CSC2=CC=C1)C,,,,,,
84,34779,CID 34779,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@H](C4=CC=CC=C4)O)SC2)C(=O)[O-].[Na+],,,,,,
85,34780,"(6R,7R)-7-[[(2S)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@H](C4=CC=CC=C4)O)SC2)C(=O)O,,,,,,
86,34781,Dehydrocorydaline,CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC,,,,,,
87,34782,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-, hydrochloride, (S)-",COC1=C2CCC[C@@H](C2=C(C=C1)Cl)[NH3+].[Cl-],,,,,,
88,34783,"(1S)-8-chloro-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=C2CCC[C@@H](C2=C(C=C1)Cl)N,,,,,,
89,34784,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-, hydrochloride, (R)-",COC1=C2CCCC(C2=C(C=C1)Cl)[NH3+].[Cl-],,,,,,
90,34785,"8-Chloro-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=C2CCCC(C2=C(C=C1)Cl)N,,,,,,
91,34786,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-methoxy-, hydrochloride, (S)-",C[NH+](C)[C@H]1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
92,34787,"(1S)-8-chloro-5-methoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)[C@H]1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
93,34788,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-methoxy-, hydrochloride, (R)-",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
94,34789,Lometraline,CN(C)C1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
95,34790,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-N-methyl-, hydrochloride, (S)-",C[NH2+][C@H]1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
96,34791,"(1S)-8-chloro-5-methoxy-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN[C@H]1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
97,34792,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-N-methyl-, hydrochloride",C[NH2+]C1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
98,34793,"8-chloro-5-methoxy-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",CNC1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
99,34794,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N-ethyl-5-methoxy-, hydrochloride, (S)-",CC[NH2+][C@H]1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
100,34795,"(1S)-8-chloro-N-ethyl-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CCN[C@H]1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
101,34796,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N-ethyl-5-methoxy-, hydrochloride, (R)-",CC[NH2+]C1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
102,34797,"8-chloro-N-ethyl-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CCNC1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
103,34798,"1-Naphthylamine, N-ethyl-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",CC[NH2+]C1CCCC2=C1C=CC=C2OC.[Cl-],,,,,,
104,34799,"N-ethyl-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CCNC1CCCC2=C1C=CC=C2OC,,,,,,
105,34800,"1-Naphthylamine, N-ethyl-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride, (S)-",CC[NH2+][C@H]1CCCC2=C1C=CC=C2OC.[Cl-],,,,,,
106,34801,"2-[3-[4-(Acetoxy)-3,5-dimethoxyphenyl]-1-oxo-2-propenyl]isoxazolidine",CC(=O)OC1=C(C=C(C=C1OC)C=CC(=O)N2CCCO2)OC,,,,,,
107,34802,"Arsine, (2-chloroethyl)dichloro-",C(C[As](Cl)Cl)Cl,,,,,,
108,34803,"3,3'-[(6-Chloro-1,3,5-triazine-2,4-diyl)bisimino]bis(1-propanol)",C(CNC1=NC(=NC(=N1)Cl)NCCCO)CO,,,,,,
109,34804,Fluorene-2-carboxaldehyde,C1C2=CC=CC=C2C3=C1C=C(C=C3)C=O,,,,,,
110,34805,"Octa-3,6-dien-2-one",CC=CCC=CC(=O)C,,,,,,
111,34806,"o-ACETOTOLUIDIDE, 4'-BENZOYL-2-ETHOXY-",CCOCC(=O)NC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)C,,,,,,
112,34807,alpha-(2-(Dimethylamino)ethyl)benzyl alcohol benzoate (ester) hydrochloride,C[NH+](C)CCC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
113,34808,[3-(Dimethylamino)-1-phenylpropyl] benzoate,CN(C)CCC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2,,,,,,
114,34809,"1,9-Anthracenediol",C1=CC=C2C(=C1)C=C3C=CC=C(C3=C2O)O,,,,,,
115,34810,Fenethacarb,CCC1=CC(=CC(=C1)OC(=O)NC)CC,,,,,,
116,34811,Hexamethylenebis((carboxymethyl)dimethylammonium) dichloride dioctyl ester,CCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCC.[Cl-].[Cl-],,,,,,
117,34812,"N,N'-Bis[[octyloxycarbonyl]methyl]-N,N,N',N'-tetramethyl(hexane-1,6-diaminium)",CCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCC,,,,,,
118,34813,"Hexamethylenebis(dimethylhexadecylammonium), dichloride",CCCCCCCCCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCCCCCCCCC.[Cl-].[Cl-],,,,,,
119,34814,"1,6-Hexanediylbis(dimethylcetylaminium)",CCCCCCCCCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCCCCCCCCC,,,,,,
120,34815,Hexamethylenebis(dimethylnonylammonium) diiodide,CCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCC.[I-].[I-],,,,,,
121,34816,"Hexamethylenebis(dimethyldecylammonium), diiodide",CCCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCCC.[I-].[I-],,,,,,
122,34817,"(Carboxymethyl)dimethyl(dimethylaminoethyl)ammonium, chloride, dodecyl ester",CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCN(C)C.[Cl-],,,,,,
123,34818,2-(Dimethylamino)ethyl-(2-dodecoxy-2-oxoethyl)-dimethylazanium,CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCN(C)C,,,,,,
124,34819,Hexamethylenebis(dimethylheptylammonium) diiodide,CCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCC.[I-].[I-],,,,,,
125,34820,"n,n'-Diheptyl-n,n,n',n'-tetramethylhexane-1,6-diaminium",CCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCC,,,,,,
126,34821,Hexamethylenebis(dimethyloctylammonium) diiodide,CCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCC.[I-].[I-],,,,,,
127,34822,"N,N'-Hexamethylenebis(N,N-dimethyloctylaminium)",CCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCC,,,,,,
128,34823,"6H-Dibenz(c,g)azonine, 5,7,12,13-tetrahydro-6-(2-(diethylamino)ethyl)-, hydrochloride",CC[NH+](CC)CCN1CC2=CC=CC=C2CCC3=CC=CC=C3C1.[Cl-],,,,,,
129,34824,"N,N-diethyl-2-(5,7,12,13-tetrahydrobenzo[d][2]benzazonin-6-yl)ethanamine",CCN(CC)CCN1CC2=CC=CC=C2CCC3=CC=CC=C3C1,,,,,,
130,34825,"6H-Dibenz(c,g)azonine, 5,7,12,13-tetrahydro-6-(2-(dimethylamino)propyl)-, hydrochloride",CC(CN1CC2=CC=CC=C2CCC3=CC=CC=C3C1)[NH+](C)C.[Cl-],,,,,,
131,34826,"N,N-dimethyl-1-(5,7,12,13-tetrahydrobenzo[d][2]benzazonin-6-yl)propan-2-amine",CC(CN1CC2=CC=CC=C2CCC3=CC=CC=C3C1)N(C)C,,,,,,
132,34827,"6H-DIBENZ(c,g)AZONINE, 5,7,12,13-TETRAHYDRO-6-ALLYL-",C=CCN1CC2=CC=CC=C2CCC3=CC=CC=C3C1,,,,,,
133,34828,2-(5-Methoxy-1-benzothiophen-3-yl)ethylazanium;chloride,COC1=CC2=C(C=C1)SC=C2CC[NH3+].[Cl-],,,,,,
134,34829,"BENZO(b)THIOPHENE-3-ETHYLAMINE, 5-METHOXY-",COC1=CC2=C(C=C1)SC=C2CCN,,,,,,
135,34830,"BENZO(b)THIOPHENE-3-ACETIC ACID, 5-METHOXY-",COC1=CC2=C(C=C1)SC=C2CC(=O)O,,,,,,
136,34831,"Thiophene, bis(1,1-dimethylethyl)-",CC(C)(C)C1=C(SC=C1)C(C)(C)C.CC(C)(C)C1=CC=C(S1)C(C)(C)C.CC(C)(C)C1=CSC=C1C(C)(C)C,,,,,,
137,34832,"2,3-Ditert-butylthiophene",CC(C)(C)C1=C(SC=C1)C(C)(C)C,,,,,,
138,34833,"Thiophene, 2,5-bis(1,1-dimethylethyl)-",CC(C)(C)C1=CC=C(S1)C(C)(C)C,,,,,,
139,34834,"3,4-Ditert-butylthiophene",CC(C)(C)C1=CSC=C1C(C)(C)C,,,,,,
140,34835,"Isoquinoline, 1,2,3,4-tetrahydro-2-((4-amino-6-piperidino-s-triazin-2-yl)methyl)-",C1CCN(CC1)C2=NC(=NC(=N2)N)CN3CCC4=CC=CC=C4C3,,,,,,
141,34836,"Isoquinoline, 1,2,3,4-tetrahydro-2-((4-amino-6-morpholino-s-triazin-2-yl)methyl)-",C1CN(CC2=CC=CC=C21)CC3=NC(=NC(=N3)N4CCOCC4)N,,,,,,
142,34837,"Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-(piperidinomethyl)-s-triazin-2-yl)-",C1CCN(CC1)CC2=NC(=NC(=N2)N3CCC4=CC=CC=C4C3)N,,,,,,
143,34838,"Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-(1-pyrrolidinylmethyl)-s-triazin-2-yl)-",C1CCN(C1)CC2=NC(=NC(=N2)N3CCC4=CC=CC=C4C3)N,,,,,,
144,34839,"Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-((4-methyl-1-piperazinyl)methyl)-s-triazin-2-yl)-",CN1CCN(CC1)CC2=NC(=NC(=N2)N3CCC4=CC=CC=C4C3)N,,,,,,
145,34840,"Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-((4-phenyl-1-piperazinyl)methyl)-s-triazin-2-yl)-",C1CN(CC2=CC=CC=C21)C3=NC(=NC(=N3)N)CN4CCN(CC4)C5=CC=CC=C5,,,,,,
146,34841,CID 34841,C[NH+](C)CCC[NH+]1CC2=CC=CC=C2CCC3=CC=CC=C3C1.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
147,34842,"N,N-dimethyl-3-(5,7,12,13-tetrahydrobenzo[d][2]benzazonin-6-yl)propan-1-amine",CN(C)CCCN1CC2=CC=CC=C2CCC3=CC=CC=C3C1,,,,,,
148,34843,"Benzamide, 4-amino-N-(2-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)ethyl)-, trihydrochloride",C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)N)CC3=CC4=C(C=C3)OCO4.Cl.Cl.Cl,,,,,,
149,34844,"4-amino-N-[2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]ethyl]benzamide",C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)N)CC3=CC4=C(C=C3)OCO4,,,,,,
150,34845,"Benzamide, 4-amino-N-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-",C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)N)C3=NC=CC=N3,,,,,,
151,34846,"Benzamide, 4-amino-N-(2-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)ethyl)-2-chloro-, trihydrochloride",C1C[NH+](CC[NH+]1CC[NH2+]C(=O)C2=C(C=C(C=C2)N)Cl)CC3=CC4=C(C=C3)OCO4.[Cl-].[Cl-].[Cl-],,,,,,
152,34847,"4-amino-N-[2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]ethyl]-2-chlorobenzamide",C1CN(CCN1CCNC(=O)C2=C(C=C(C=C2)N)Cl)CC3=CC4=C(C=C3)OCO4,,,,,,
153,34848,4-Amino-N-(2-(4-(4-pyridinyl)-1-piperazinyl)ethyl)benzamide dihydrate,C1CN=CC=C1[N+]2=CC=[N+](C=C2)CCNC(=O)C3=CC=C(C=C3)N.O.O,,,,,,
154,34849,"4-amino-N-[2-[4-(2,3-dihydropyridin-4-yl)pyrazine-1,4-diium-1-yl]ethyl]benzamide",C1CN=CC=C1[N+]2=CC=[N+](C=C2)CCNC(=O)C3=CC=C(C=C3)N,,,,,,
155,34850,"Hydantoin, 1-benzyloxy-",C1C(=O)NC(=O)N1OCC2=CC=CC=C2,,,,,,
156,34851,1-Benzyloxy-5-methyl-hydantoin,CC1C(=O)NC(=O)N1OCC2=CC=CC=C2,,,,,,
157,34852,"HYDANTOIN, 1-((p-CHLOROBENZYL)OXY)-3-METHYL-",CN1C(=O)CN(C1=O)OCC2=CC=C(C=C2)Cl,,,,,,
158,34853,"Hydantoin, 1-(2-(2,4-dichlorophenoxy)ethoxy)-",C1C(=O)NC(=O)N1OCCOC2=C(C=C(C=C2)Cl)Cl,,,,,,
159,34854,"Hydantoin, 3-benzyloxy-",C1C(=O)N(C(=O)N1)OCC2=CC=CC=C2,,,,,,
160,34855,"N,N-dimethyl-1-(5-methyl-1H-indol-3-yl)methanamine",CC1=CC2=C(C=C1)NC=C2CN(C)C,,,,,,
161,34856,Ethylmethylphenol (mixed isomers),CCC1=CC(=C(C=C1)O)C.CCC1=C(C(=CC=C1)O)C.CCC1=C(C=C(C=C1)C)O,,,,,,
162,34857,4-Ethyl-2-methylphenol,CCC1=CC(=C(C=C1)O)C,,,,,,
163,34858,3-Ethyl-o-cresol,CCC1=C(C(=CC=C1)O)C,,,,,,
164,34859,"Phenanthrene, trimethyl-",CC1=C2C=C(C3=CC=CC(=C3C2=CC=C1)C)C,,,,,,
165,34860,"Hexamethylenebis(dimethylhexadecylammonium), diiodide",CCCCCCCCCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCCCCCCCCC.[I-].[I-],,,,,,
166,34861,CID 34861,C1C(C(OC1N2C=NC3=C2N=C(N=C3S)N)CO)O,,,,,,
167,34862,"7-Amino-3-[(5-methyl-1,3,4-thiadiazol-2-YL)thiomethyl]cephalosphoranic acid",CC1=NN=C(S1)SCC2=C(N3C([C@@H](C3=O)N)SC2)C(=O)O,,,,,,
168,34863,"Indole, 3-(dimethylaminoacetyl)-",CN(C)CC(=O)C1=CNC2=CC=CC=C21,,,,,,
169,34864,"Ketone, 3-indolyl piperidinomethyl",C1CCN(CC1)CC(=O)C2=CNC3=CC=CC=C32,,,,,,
170,34865,"Ketone, 3-indolyl morpholinomethyl",C1COCCN1CC(=O)C2=CNC3=CC=CC=C32,,,,,,
171,34866,"2-Butanone, 1,1-dibromo-3,3-dimethyl-",CC(C)(C)C(=O)C(Br)Br,,,,,,
172,34867,"1,2-Ethanediaminium, N,N'-bis(2-(hexadecyloxy)-2-oxoethyl)-N,N,N',N'-tetramethyl-, dichloride",CCCCCCCCCCCCCCCCOC(=O)C[N+](C)(C)CC[N+](C)(C)CC(=O)OCCCCCCCCCCCCCCCC.[Cl-].[Cl-],,,,,,
173,34868,(2-Hexadecoxy-2-oxoethyl)-[2-[(2-hexadecoxy-2-oxoethyl)-dimethylazaniumyl]ethyl]-dimethylazanium,CCCCCCCCCCCCCCCCOC(=O)C[N+](C)(C)CC[N+](C)(C)CC(=O)OCCCCCCCCCCCCCCCC,,,,,,
174,34869,Survector,C1CC2=CC=CC=C2C(C3=CC=CC=C31)[NH2+]CCCCCCC(=O)O.[Cl-],,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
175,34870,Amineptine,C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O,['For the treatment of depression.'],['Amineptine is an atypical tricyclic antidepressant.'],"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,['Hepatic.'],['48 minutes for the parent drug and 2.5 hours for the metabolites.']
176,34871,4-Chloro-2-ethylaniline,CCC1=C(C=CC(=C1)Cl)N,,,,,,
177,34872,"3-Methyl-4-(2,5-xylyl)butanoic acid",CC1=CC(=C(C=C1)C)CC(C)CC(=O)O,,,,,,
178,34873,13-Methylpicene,CC1=CC2=C(C=CC3=CC=CC=C32)C4=C1C5=CC=CC=C5C=C4,,,,,,
179,34874,CID 34874,C1CC(=O)C2=CC=CC=C21.C1C(=O)CC2=CC=CC=C21,,,,,,
180,34875,Oxitropium (Bromide),CC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-],,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
181,34876,"2-(3,4-Dimethoxybenzoyl)isoxazolidine",COC1=C(C=C(C=C1)C(=O)N2CCCO2)OC,,,,,,
182,34877,9-Phenyl-2-(4-phenyl-1-piperazinyl)bicyclo(3.3.1)nonan-9-ol,C1CC2CCC(C(C1)C2(C3=CC=CC=C3)O)N4CCN(CC4)C5=CC=CC=C5,,,,,,
183,34878,1-Cyclohexyl-3-guanidinoazetidine sulfate,C1CCC(CC1)N=C(N)NC2C[NH2+]C2.OS(=O)(=O)[O-],,,,,,
184,34879,1-(Azetidin-3-yl)-2-cyclohexylguanidine,C1CCC(CC1)N=C(N)NC2CNC2,,,,,,
185,34880,Diethyl 2-thenylidenemalonate,CCOC(=O)C(=CC1=CC=CS1)C(=O)OCC,,,,,,
186,34881,"tert-BUTYROPHENONE, 3',4'-DIMETHOXY-",CC(C)(C)C(=O)C1=CC(=C(C=C1)OC)OC,,,,,,
187,34882,"4-(2,5-Dimethylphenyl)-2-methylbutanoic acid",CC1=CC(=C(C=C1)C)CCC(C)C(=O)O,,,,,,
188,34883,"1,4-Dihydro-2,5,8-trimethylnaphthalene",CC1=CCC2=C(C=CC(=C2C1)C)C,,,,,,
189,34884,"1,2-Dihydro-2,5,8-trimethylnaphthalene",CC1CC2=C(C=CC(=C2C=C1)C)C,,,,,,
190,34885,"Ammonium, (2-(4-methyl-3-oxo-6-phenyl-2-(2H)pyridazinyl)ethyl)trimethyl-, iodide",CC1=CC(=NN(C1=O)CC[N+](C)(C)C)C2=CC=CC=C2.[I-],,,,,,
191,34886,Trimethyl-[2-(5-methyl-6-oxo-3-phenylpyridazin-1-yl)ethyl]azanium,CC1=CC(=NN(C1=O)CC[N+](C)(C)C)C2=CC=CC=C2,,,,,,
192,34887,5-Methoxy-2-nitrobenzofuran,COC1=CC2=C(C=C1)OC(=C2)[N+](=O)[O-],,,,,,
193,34888,"4,6-Bis(dibromomethyl)-N-ethyl-1,3,5-triazine-2-amine",CCNC1=NC(=NC(=N1)C(Br)Br)C(Br)Br,,,,,,
194,34889,"4-Methyl-6-(tribromomethyl)-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)N)C(Br)(Br)Br,,,,,,
195,34890,"N-Ethyl-4-methyl-6-(tribromomethyl)-1,3,5-triazine-2-amine",CCNC1=NC(=NC(=N1)C(Br)(Br)Br)C,,,,,,
196,34891,"4,6-Bis(tribromomethyl)-1,3,5-triazine-2-amine",C1(=NC(=NC(=N1)N)C(Br)(Br)Br)C(Br)(Br)Br,,,,,,
197,34892,"N-Methyl-4,6-bis(tribromomethyl)-1,3,5-triazine-2-amine",CNC1=NC(=NC(=N1)C(Br)(Br)Br)C(Br)(Br)Br,,,,,,
198,34893,"N-Ethyl-4,6-bis(tribromomethyl)-1,3,5-triazine-2-amine",CCNC1=NC(=NC(=N1)C(Br)(Br)Br)C(Br)(Br)Br,,,,,,
199,34894,"N-Phenyl-4,6-bis(tribromomethyl)-1,3,5-triazine-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Br)(Br)Br)C(Br)(Br)Br,,,,,,
200,34895,"4-Ethyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
201,34896,"4-(2-Chloroethyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",C(CCl)C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
202,34897,"4-(1,1,2-Trichloroethyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",C(C(C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
203,34898,"4-(2-Bromoethyl)-6-(trichloromethyl)-1,3,5-triazine-2-amine",C(CBr)C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
204,34899,"4-Ethenyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",C=CC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
205,34900,"4,6-diethyl-N-methyl-1,3,5-triazin-2-amine",CCC1=NC(=NC(=N1)NC)CC,,,,,,
206,34901,"4,6-Bis(1,1-dichloroethyl)-1,3,5-triazine-2-amine",CC(C1=NC(=NC(=N1)N)C(C)(Cl)Cl)(Cl)Cl,,,,,,
207,34902,"4,6-Bis(1,1-dichloroethyl)-N-methyl-1,3,5-triazine-2-amine",CC(C1=NC(=NC(=N1)NC)C(C)(Cl)Cl)(Cl)Cl,,,,,,
208,34903,"4,6-Bis(1,1-dichloroethyl)-N-ethyl-1,3,5-triazine-2-amine",CCNC1=NC(=NC(=N1)C(C)(Cl)Cl)C(C)(Cl)Cl,,,,,,
209,34904,"4,6-Bis(1,1,2-trichloroethyl)-1,3,5-triazin-2-amine",C(C(C1=NC(=NC(=N1)N)C(CCl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
210,34905,"4-Isopropyl-6-(trichloromethyl)-1,3,5-triazine-2-amine",CC(C)C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
211,34906,"1,3,5-Triazin-2-amine, 4-butyl-6-(trichloromethyl)-",CCCCC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
212,34907,"4-Butan-2-yl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCC(C)C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
213,34908,4-Pentyl-6-(trichloromethyl)-s-triazine-2-amine,CCCCCC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
214,34909,"N-(4-chlorophenyl)-4,6-bis(tribromomethyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)C(Br)(Br)Br)C(Br)(Br)Br)Cl,,,,,,
215,34910,4-Isobutyl-6-(trichloromethyl)-s-triazine-2-amine,CC(C)CC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
216,34911,"4-Propyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCCC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
217,34912,"boranylformonitrile;N,N-dimethylmethanamine",BC#N.CN(C)C,,,,,,
218,34913,Boranylformonitrile,BC#N,,,,,,
219,34914,CID 34914,BC#N.BC#N.CN(C)CCN(C)C,,,,,,
220,34915,"6-(2-Chloropropan-2-yl)-1,3,5-triazine-2,4-diamine",CC(C)(C1=NC(=NC(=N1)N)N)Cl,,,,,,
221,34916,"6-(2-Methylpropyl)-1,3,5-triazine-2,4-diamine",CC(C)CC1=NC(=NC(=N1)N)N,,,,,,
222,34917,"1,3,5-Triazine-2,4-diamine, 6-(1-methylpropyl)-",CCC(C)C1=NC(=NC(=N1)N)N,,,,,,
223,34918,"N,N'-Diisopropyl-6-nonyl-s-triazine-2,4-diamine",CCCCCCCCCC1=NC(=NC(=N1)NC(C)C)NC(C)C,,,,,,
224,34919,"6-(1,1-Dichloroheptadecyl)-s-triazine-2,4-diamine",CCCCCCCCCCCCCCCCC(C1=NC(=NC(=N1)N)N)(Cl)Cl,,,,,,
225,34920,"6-(3,4-Dichlorophenyl)-s-triazine-2,4-diamine",C1=CC(=C(C=C1C2=NC(=NC(=N2)N)N)Cl)Cl,,,,,,
226,34921,"6-(4-Methoxyphenyl)-1,3,5-triazine-2,4-diamine",COC1=CC=C(C=C1)C2=NC(=NC(=N2)N)N,,,,,,
227,34922,"6-(1-Naphthyl)-s-triazine-2,4-diamine",C1=CC=C2C(=C1)C=CC=C2C3=NC(=NC(=N3)N)N,,,,,,
228,34923,"6-(2-Ethoxyethyl)-1,3,5-triazine-2,4-diamine",CCOCCC1=NC(=NC(=N1)N)N,,,,,,
229,34924,"1-(4,6-Diamino-1,3,5-triazin-2-yl)propan-2-one",CC(=O)CC1=NC(=NC(=N1)N)N,,,,,,
230,34925,"1-(4,6-Diamino-1,3,5-triazin-2-yl)butan-2-one",CCC(=O)CC1=NC(=NC(=N1)N)N,,,,,,
231,34926,"6-fluoro-2-N,4-N-di(propan-2-yl)-1,3,5-triazine-2,4-diamine",CC(C)NC1=NC(=NC(=N1)F)NC(C)C,,,,,,
232,34927,"N-Allyl-6-chloro-s-triazine-2,4-diamine",C=CCNC1=NC(=NC(=N1)N)Cl,,,,,,
233,34928,"6-Chloro-N,N'-dihexyl-s-triazine-2,4-diamine",CCCCCCNC1=NC(=NC(=N1)Cl)NCCCCCC,,,,,,
234,34929,Agn-PC-0jko2N,CCCCCCCCCCCCNC1=NC(=NC(=N1)Cl)NCCCCCCCCCCCC,,,,,,
235,34930,"N,N'-Dibenzyl-6-chloro-[1,3,5]triazine-2,4-diamine",C1=CC=C(C=C1)CNC2=NC(=NC(=N2)Cl)NCC3=CC=CC=C3,,,,,,
236,34931,"6-chloro-4-N-(4-chlorophenyl)-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine",CC(C)NC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)Cl,,,,,,
237,34932,"6-chloro-N,N'-bis(3,4-dichlorophenyl)-1,3,5-triazine-2,4-diamine",C1=CC(=C(C=C1NC2=NC(=NC(=N2)Cl)NC3=CC(=C(C=C3)Cl)Cl)Cl)Cl,,,,,,
238,34933,"6-chloro-2-N-naphthalen-1-yl-4-N-naphthalen-2-yl-1,3,5-triazine-2,4-diamine",C1=CC=C2C=C(C=CC2=C1)NC3=NC(=NC(=N3)Cl)NC4=CC=CC5=CC=CC=C54,,,,,,
239,34934,"3,3',3'',3'''-[(6-Methyl-s-triazine-2,4-diyl)bisnitrilo]tetrapropionitrile",CC1=NC(=NC(=N1)N(CCC#N)CCC#N)N(CCC#N)CCC#N,,,,,,
240,34935,"N-(4-amino-6-methyl-1,3,5-triazin-2-yl)acetamide",CC1=NC(=NC(=N1)NC(=O)C)N,,,,,,
241,34936,"N-(4-acetamido-6-methyl-1,3,5-triazin-2-yl)acetamide",CC1=NC(=NC(=N1)NC(=O)C)NC(=O)C,,,,,,
242,34937,CID 34937,CC1=NC(=NC(=N1)NN=CC2=CC=C(O2)[N+](=O)[O-])NC,,,,,,
243,34938,"6-(Diazomethyl)-s-triazine-2,4-diamine",C(=[N+]=[N-])C1=NC(=NC(=N1)N)N,,,,,,
244,34939,"N,N'-Diethyl-6-(diazomethyl)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)C=[N+]=[N-])NCC,,,,,,
245,34940,"2-N-ethyl-6-(trifluoromethyl)-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)C(F)(F)F,,,,,,
246,34941,"N-Ethyl-6-(chloromethyl)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)CCl,,,,,,
247,34942,"6-(Chloromethyl)-N-Phenyl-1,3,5-Triazine-2,4-Diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)CCl,,,,,,
248,34943,"6-(chloromethyl)-N-(4-chlorophenyl)-1,3,5-triazine-2,4-diamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)N)CCl)Cl,,,,,,
249,34944,"N,N'-Diethyl-6-(chloromethyl)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)CCl)NCC,,,,,,
250,34945,"6-(Dichloromethyl)-1,3,5-triazine-2,4-diamine",C1(=NC(=NC(=N1)N)N)C(Cl)Cl,,,,,,
251,34946,"N-Ethyl-6-(dichloromethyl)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)C(Cl)Cl,,,,,,
252,34947,"N-Phenyl-6-(dichloromethyl)-s-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)C(Cl)Cl,,,,,,
253,34948,"6-(dichloromethyl)-2-N,4-N-diethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)C(Cl)Cl)NCC,,,,,,
254,34949,"2-N-phenyl-6-(trichloromethyl)-1,3,5-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
255,34950,[2-(Dimethylamino)-6-(trichloromethyl)-s-triazine-4-yl]hydrazine,CN(C)C1=NC(=NC(=N1)NN)C(Cl)(Cl)Cl,,,,,,
256,34951,"2-N-(4-chlorophenyl)-6-(trichloromethyl)-1,3,5-triazine-2,4-diamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)N)C(Cl)(Cl)Cl)Cl,,,,,,
257,34952,"N,N'-Diphenyl-6-(trichloromethyl)-s-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)NC3=CC=CC=C3,,,,,,
258,34953,"N,N'-Bis(4-chlorophenyl)-6-(trichloromethyl)-s-triazine-2,4-diamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)NC3=CC=C(C=C3)Cl)Cl,,,,,,
259,34954,"N-[4-amino-6-(trichloromethyl)-1,3,5-triazin-2-yl]propanamide",CCC(=O)NC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
260,34955,"N,N-dibutyl-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",CCCCN(CCCC)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
261,34956,"N,N-Diisobutyl-4,6-bis(trichloromethyl)-s-triazine-2-amine",CC(C)CN(CC(C)C)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
262,34957,"N-Phenyl-4,6-bis(trichloromethyl)-s-triazine-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
263,34958,"N-(2-Chlorophenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
264,34959,"N-(3-chlorophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=CC(=C1)Cl)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
265,34960,"N-(2,5-Dichlorophenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",C1=CC(=C(C=C1Cl)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
266,34961,"N-(3,4-Dichlorophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=C(C=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl)Cl,,,,,,
267,34962,"N-(2,4,5-Trichlorophenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",C1=C(C(=CC(=C1Cl)Cl)Cl)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
268,34963,"N-(2,3,4,5,6-Pentachlorophenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
269,34964,"N-(3-Bromophenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",C1=CC(=CC(=C1)Br)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
270,34965,"N-(4-bromophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Br,,,,,,
271,34966,"N-(2-Methylphenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",CC1=CC=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
272,34967,"N-(3-methylphenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",CC1=CC(=CC=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
273,34968,"N-(4-Methylphenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",CC1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
274,34969,"N-(2-Methoxyphenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",COC1=CC=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
275,34970,"N-(4-methoxyphenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",COC1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
276,34971,"N-(2-Ethoxyphenyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",CCOC1=CC=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
277,34972,"N-(4-nitrophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)[N+](=O)[O-],,,,,,
278,34973,"1,3,5-Triazin-2-amine, N-methyl-N-phenyl-4,6-bis(trichloromethyl)-",CN(C1=CC=CC=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
279,34974,"N-naphthalen-1-yl-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC=C2C(=C1)C=CC=C2NC3=NC(=NC(=N3)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
280,34975,"N-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]-1,3-thiazol-2-amine",C1=CSC(=N1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
281,34976,"N-pyridin-2-yl-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC=NC(=C1)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
282,34977,"N-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]-4-methylbenzenesulfonamide",CC1=CC=C(C=C1)S(=O)(=O)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
283,34978,"N'-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]-4-methylbenzenesulfonohydrazide",CC1=CC=C(C=C1)S(=O)(=O)NNC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
284,34979,"N-[4,6-Bis(trichloromethyl)-s-triazine-2-yl]trichloromethanesulfenamide",C1(=NC(=NC(=N1)NSC(Cl)(Cl)Cl)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
285,34980,"N-butyl-4,6-bis(trichloromethyl)-N-(trichloromethylsulfanyl)-1,3,5-triazin-2-amine",CCCCN(C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)SC(Cl)(Cl)Cl,,,,,,
286,34981,"N-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]acetamide",CC(=O)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
287,34982,"N-[4,6-Bis(trichloromethyl)-s-triazine-2-yl]propionamide",CCC(=O)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
288,34983,"4-(Dibromomethyl)-6-methyl-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)N)C(Br)Br,,,,,,
289,34984,"4,6-Bis(dibromomethyl)-1,3,5-triazin-2-amine",C1(=NC(=NC(=N1)N)C(Br)Br)C(Br)Br,,,,,,
290,34985,"N-tert-butyl-4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)NC(C)(C)C)C(Cl)(Cl)Cl,,,,,,
291,34986,N-(1-Ethylhexyl)-4-methyl-6-(trichloromethyl)-s-triazine-2-amine,CCCCCC(CC)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
292,34987,"N-(1,1,3,3-Tetramethylbutyl)-4-methyl-6-(trichloromethyl)-s-triazine-2-amine",CC1=NC(=NC(=N1)NC(C)(C)CC(C)(C)C)C(Cl)(Cl)Cl,,,,,,
293,34988,"N,N-Dipropyl-4-methyl-6-(trichloromethyl)-s-triazine-2-amine",CCCN(CCC)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
294,34989,"N,N-dibutyl-4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCCCN(CCCC)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
295,34990,"4-methyl-N-phenyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)NC2=CC=CC=C2)C(Cl)(Cl)Cl,,,,,,
296,34991,"3,3'-[[4-Methyl-6-(trichloromethyl)-s-triazine-2-yl]imino]bispropionitrile",CC1=NC(=NC(=N1)N(CCC#N)CCC#N)C(Cl)(Cl)Cl,,,,,,
297,34992,"N-[4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]formamide",CC1=NC(=NC(=N1)NC=O)C(Cl)(Cl)Cl,,,,,,
298,34993,"N-[4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]acetamide",CC1=NC(=NC(=N1)NC(=O)C)C(Cl)(Cl)Cl,,,,,,
299,34994,N-[4-Methyl-6-(trichloromethyl)-s-triazine-2-yl]propionamide,CCC(=O)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
300,34995,N-[4-Methyl-6-(trichloromethyl)-s-triazine-2-yl]-2-methylpropionamide,CC1=NC(=NC(=N1)NC(=O)C(C)C)C(Cl)(Cl)Cl,,,,,,
301,34996,4-(Dichloromethyl)-6-(trichloromethyl)-s-triazine-2-amine,C1(=NC(=NC(=N1)N)C(Cl)(Cl)Cl)C(Cl)Cl,,,,,,
302,34997,"N-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]hydroxylamine",C1(=NC(=NC(=N1)NO)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
303,34998,"N-(1,1,3,3-Tetramethylbutyl)-4,6-bis(trichloromethyl)-s-triazine-2-amine",CC(C)(C)CC(C)(C)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
304,34999,"4-methyl-6-(trichloromethyl)-N-(trichloromethylsulfanyl)-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)NSC(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
305,35000,"4-(Chloromethyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",C(C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl)Cl,,,,,,
306,35001,"N'-(4,6-Dichloro-s-triazine-2-yl)-4-chlorobenzenesulfonic acid hydrazide",C1=CC(=CC=C1S(=O)(=O)NNC2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
307,35002,"N'-(4,6-dichloro-1,3,5-triazin-2-yl)-4-methylbenzenesulfonohydrazide",CC1=CC=C(C=C1)S(=O)(=O)NNC2=NC(=NC(=N2)Cl)Cl,,,,,,
308,35003,"4,6-dibromo-N-ethyl-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)Br)Br,,,,,,
309,35004,"4,6-Dibromo-N-phenyl-s-triazine-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)Br)Br,,,,,,
310,35005,"4,6-dibromo-N-(4-chlorophenyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)Br)Br)Cl,,,,,,
311,35006,"4-chloro-N-hexyl-6-methoxy-1,3,5-triazin-2-amine",CCCCCCNC1=NC(=NC(=N1)Cl)OC,,,,,,
312,35007,"(4-Chloro-6-methoxy-[1,3,5]triazin-2-yl)-phenyl-amine",COC1=NC(=NC(=N1)NC2=CC=CC=C2)Cl,,,,,,
313,35008,4-Chloro-N-ethyl-6-isobutoxy-s-triazine-2-amine,CCNC1=NC(=NC(=N1)Cl)OCC(C)C,,,,,,
314,35009,"4-Fluoro-6-phenoxy-1,3,5-triazin-2-amine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)N)F,,,,,,
315,35010,2-Amino-4-(hydroxyphenoxy)-6-chloro-s-triazine,C1=CC=C(C=C1)OC2=NC(=NC(=N2)N)Cl,,,,,,
316,35011,"4-chloro-N-ethyl-6-phenoxy-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)Cl)OC2=CC=CC=C2,,,,,,
317,35012,"4-Bromo-6-phenoxy-1,3,5-triazin-2-amine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)N)Br,,,,,,
318,35013,4-Chloro-6-(methylthio)-s-triazine-2-amine,CSC1=NC(=NC(=N1)N)Cl,,,,,,
319,35014,N-Ethyl-4-chloro-6-(methylthio)-s-triazine-2-amine,CCNC1=NC(=NC(=N1)Cl)SC,,,,,,
320,35015,N-Phenyl-4-chloro-6-(methylthio)-s-triazine-2-amine,CSC1=NC(=NC(=N1)NC2=CC=CC=C2)Cl,,,,,,
321,35016,"4-Chloro-6-phenylsulfanyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)N)Cl,,,,,,
322,35017,"4,6-dimethoxy-N-methyl-1,3,5-triazin-2-amine",CNC1=NC(=NC(=N1)OC)OC,,,,,,
323,35018,"4,6-Dimethoxy-N-butyl-s-triazine-2-amine",CCCCNC1=NC(=NC(=N1)OC)OC,,,,,,
324,35019,"N-benzyl-4,6-dimethoxy-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)NCC2=CC=CC=C2)OC,,,,,,
325,35020,"4,6-dimethoxy-N-phenyl-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)NC2=CC=CC=C2)OC,,,,,,
326,35021,"4,6-Dimethoxy-N-(4-bromophenyl)-s-triazine-2-amine",COC1=NC(=NC(=N1)NC2=CC=C(C=C2)Br)OC,,,,,,
327,35022,"4,6-dimethoxy-N-(4-nitrophenyl)-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)NC2=CC=C(C=C2)[N+](=O)[O-])OC,,,,,,
328,35023,"4,6-Dimethoxy-N-phenyl-N-methyl-s-triazine-2-amine",CN(C1=CC=CC=C1)C2=NC(=NC(=N2)OC)OC,,,,,,
329,35024,"4,6-diethoxy-N-ethyl-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)OCC)OCC,,,,,,
330,35025,"4,6-diethoxy-N-phenyl-1,3,5-triazin-2-amine",CCOC1=NC(=NC(=N1)NC2=CC=CC=C2)OCC,,,,,,
331,35026,"N-(2-chlorophenyl)-4,6-diethoxy-1,3,5-triazin-2-amine",CCOC1=NC(=NC(=N1)NC2=CC=CC=C2Cl)OCC,,,,,,
332,35027,"4,6-Dipropoxy-1,3,5-triazin-2-amine",CCCOC1=NC(=NC(=N1)N)OCCC,,,,,,
333,35028,"2,4-Diallyloxy-6-amino-1,3,5-triazine",C=CCOC1=NC(=NC(=N1)N)OCC=C,,,,,,
334,35029,"4,6-Bis(allyloxy)-N-ethyl-s-triazine-2-amine",CCNC1=NC(=NC(=N1)OCC=C)OCC=C,,,,,,
335,35030,"4,6-Di(propan-2-yloxy)-1,3,5-triazin-2-amine",CC(C)OC1=NC(=NC(=N1)N)OC(C)C,,,,,,
336,35031,"4,6-Bis(2-chlorophenoxy)-1,3,5-triazin-2-amine",C1=CC=C(C(=C1)OC2=NC(=NC(=N2)N)OC3=CC=CC=C3Cl)Cl,,,,,,
337,35032,"4,6-bis(2-chlorophenoxy)-N-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)OC3=CC=CC=C3Cl)OC4=CC=CC=C4Cl,,,,,,
338,35033,"4,6-Bis(4-chlorophenoxy)-1,3,5-triazin-2-amine",C1=CC(=CC=C1OC2=NC(=NC(=N2)N)OC3=CC=C(C=C3)Cl)Cl,,,,,,
339,35034,"4,6-Bis(4-chlorophenoxy)-N-phenyl-s-triazine-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)OC3=CC=C(C=C3)Cl)OC4=CC=C(C=C4)Cl,,,,,,
340,35035,"4-Methoxy-6-(methylthio)-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)N)SC,,,,,,
341,35036,"4,6-Bis(methylsulfanyl)-1,3,5-triazin-2-amine",CSC1=NC(=NC(=N1)N)SC,,,,,,
342,35037,"N,N'-[6-(Trichloromethyl)-s-triazine-2,4-diyl]bisacetamide",CC(=O)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)NC(=O)C,,,,,,
343,35038,"N-[4-[acetyl(ethyl)amino]-6-(trichloromethyl)-1,3,5-triazin-2-yl]-N-ethylacetamide",CCN(C1=NC(=NC(=N1)C(Cl)(Cl)Cl)N(CC)C(=O)C)C(=O)C,,,,,,
344,35039,CID 35039,CN(C)C1=NC(=NC(=N1)NN=CC2=CC=CC=C2)C(Cl)(Cl)Cl,,,,,,
345,35040,CID 35040,CN(C)C1=NC(=NC(=N1)NN=CC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)C(Cl)(Cl)Cl,,,,,,
346,35041,"6-(bromomethyl)-2-N-phenyl-1,3,5-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)CBr,,,,,,
347,35042,"6-(bromomethyl)-2-N,4-N-diethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)CBr)NCC,,,,,,
348,35043,"6-(Dibromomethyl)-1,3,5-triazine-2,4-diamine",C1(=NC(=NC(=N1)N)N)C(Br)Br,,,,,,
349,35044,"6-(Dibromomethyl)-N-ethyl-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)C(Br)Br,,,,,,
350,35045,"6-(dibromomethyl)-2-N,4-N-diethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)C(Br)Br)NCC,,,,,,
351,35046,"6-(Tribromomethyl)-N-ethyl-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)C(Br)(Br)Br,,,,,,
352,35047,"6-(Tribromomethyl)-N-phenyl-s-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)C(Br)(Br)Br,,,,,,
353,35048,"N,N'-Diphenyl-6-(tribromomethyl)-s-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Br)(Br)Br)NC3=CC=CC=C3,,,,,,
354,35049,"6-(Iodomethyl)-1,3,5-triazine-2,4-diamine",C(C1=NC(=NC(=N1)N)N)I,,,,,,
355,35050,"N,N'-Diethyl-6-(iodomethyl)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)CI)NCC,,,,,,
356,35051,"6-(Diiodomethyl)-s-triazine-2,4-diamine",C1(=NC(=NC(=N1)N)N)C(I)I,,,,,,
357,35052,"N,N'-Diethyl-6-(diiodomethyl)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)C(I)I)NCC,,,,,,
358,35053,"N-Phenyl-6-ethyl-s-triazine-2,4-diamine",CCC1=NC(=NC(=N1)NC2=CC=CC=C2)N,,,,,,
359,35054,"6-(1-Chloroethyl)-s-triazine-2,4-diamine",CC(C1=NC(=NC(=N1)N)N)Cl,,,,,,
360,35055,"6-(2-Chloroethyl)-1,3,5-triazine-2,4-diamine",C(CCl)C1=NC(=NC(=N1)N)N,,,,,,
361,35056,"6-(1,1-Dichloroethyl)-1,3,5-triazine-2,4-diamine",CC(C1=NC(=NC(=N1)N)N)(Cl)Cl,,,,,,
362,35057,"6-(1,2-Dichloroethyl)-1,3,5-triazine-2,4-diamine",C(C(C1=NC(=NC(=N1)N)N)Cl)Cl,,,,,,
363,35058,"6-(1,1,2-Trichloroethyl)-1,3,5-triazine-2,4-diamine",C(C(C1=NC(=NC(=N1)N)N)(Cl)Cl)Cl,,,,,,
364,35059,"6-(1,1,2,2-Tetrachloroethyl)-1,3,5-triazine-2,4-diamine",C1(=NC(=NC(=N1)N)N)C(C(Cl)Cl)(Cl)Cl,,,,,,
365,35060,"6-(Pentachloroethyl)-s-triazine-2,4-diamine",C1(=NC(=NC(=N1)N)N)C(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
366,35061,"6-(1,2-Dibromoethyl)-1,3,5-triazine-2,4-diamine",C(C(C1=NC(=NC(=N1)N)N)Br)Br,,,,,,
367,35062,"N-Phenyl-6-propyl-s-triazine-2,4-diamine",CCCC1=NC(=NC(=N1)NC2=CC=CC=C2)N,,,,,,
368,35063,"6-(1,1,2-Trichloropropyl)-s-triazine-2,4-diamine",CC(C(C1=NC(=NC(=N1)N)N)(Cl)Cl)Cl,,,,,,
369,35064,"[4,6-Bis(prop-2-enylamino)-1,3,5-triazin-2-yl] thiocyanate",C=CCNC1=NC(=NC(=N1)SC#N)NCC=C,,,,,,
370,35065,"(4,6-Dianilino-1,3,5-triazin-2-yl) thiocyanate",C1=CC=C(C=C1)NC2=NC(=NC(=N2)SC#N)NC3=CC=CC=C3,,,,,,
371,35066,"4,6-Bis(ethylamino)-s-triazine-2-yl isothiocyanate",CCNC1=NC(=NC(=N1)N=C=S)NCC,,,,,,
372,35067,"6-isothiocyanato-2-N,4-N-di(propan-2-yl)-1,3,5-triazine-2,4-diamine",CC(C)NC1=NC(=NC(=N1)N=C=S)NC(C)C,,,,,,
373,35068,"4,6-Dianilino-1,3,5-triazine-2-carbonitrile",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C#N)NC3=CC=CC=C3,,,,,,
374,35069,CID 35069,C1=CC=C(C=C1)NC2=NC(=NC(=NC3=CC=CC=C3)[N-]2)N[N+]#N,,,,,,
375,35070,CID 35070,C1=CC=C(C=C1)NC2=NC(=NC(=N2)N[N+]#N)NC3=CC=CC=C3,,,,,,
376,35071,"N2-(2-chlorophenyl)-1,3,5-triazine-2,4,6-triamine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)N)N)Cl,,,,,,
377,35072,(P-Chlorophenyl)melamine,C1=CC(=CC=C1NC2=NC(=NC(=N2)N)N)Cl,,,,,,
378,35073,(P-Nitrophenyl)melamine,C1=CC(=CC=C1NC2=NC(=NC(=N2)N)N)[N+](=O)[O-],,,,,,
379,35074,"2-N-methyl-2-N-phenyl-1,3,5-triazine-2,4,6-triamine",CN(C1=CC=CC=C1)C2=NC(=NC(=N2)N)N,,,,,,
380,35075,"1,3,5-Triazine-2,4,6-triamine, N,N'-di-2-propenyl-",C=CCNC1=NC(=NC(=N1)N)NCC=C,,,,,,
381,35076,"4-N-(4-chlorophenyl)-2-N-propan-2-yl-1,3,5-triazine-2,4,6-triamine",CC(C)NC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)N,,,,,,
382,35077,"2-N,4-N-bis(4-chlorophenyl)-1,3,5-triazine-2,4,6-triamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)N)NC3=CC=C(C=C3)Cl)Cl,,,,,,
383,35078,"N,N'-Diethyl-N''-isopropyl-1,3,5-triazine-2,4,6-triamine",CCNC1=NC(=NC(=N1)NC(C)C)NCC,,,,,,
384,35079,"N~2~-(4-chlorophenyl)-N~4~,N~6~-diethyl-1,3,5-triazine-2,4,6-triamine",CCNC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)NCC,,,,,,
385,35080,"2,4,6-Triallylamino-sym-triazine",C=CCNC1=NC(=NC(=N1)NCC=C)NCC=C,,,,,,
386,35081,"2-N,4-N-bis(4-chlorophenyl)-6-N-ethyl-1,3,5-triazine-2,4,6-triamine",CCNC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Cl,,,,,,
387,35082,"2-N,4-N,6-N-trinaphthalen-1-yl-1,3,5-triazine-2,4,6-triamine",C1=CC=C2C(=C1)C=CC=C2NC3=NC(=NC(=N3)NC4=CC=CC5=CC=CC=C54)NC6=CC=CC7=CC=CC=C76,,,,,,
388,35083,"N,N',N''-(1,3,5-Triazine-2,4,6-triyl)tris(2-chloroacetamide)",C(C(=O)NC1=NC(=NC(=N1)NC(=O)CCl)NC(=O)CCl)Cl,,,,,,
389,35084,"N,N',N''-s-Triazine-2,4,6-triyltris(2,2-dichloroacetamide)",C1(=NC(=NC(=N1)NC(=O)C(Cl)Cl)NC(=O)C(Cl)Cl)NC(=O)C(Cl)Cl,,,,,,
390,35085,"N-[4,6-bis[(2,2,2-trichloroacetyl)amino]-1,3,5-triazin-2-yl]-2,2,2-trichloroacetamide",C1(=NC(=NC(=N1)NC(=O)C(Cl)(Cl)Cl)NC(=O)C(Cl)(Cl)Cl)NC(=O)C(Cl)(Cl)Cl,,,,,,
391,35086,"N-(4-chlorophenyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC=NC=N2)Cl,,,,,,
392,35087,"N-ethyl-4-methyl-1,3,5-triazin-2-amine",CCNC1=NC=NC(=N1)C,,,,,,
393,35088,"4-(Trichloromethyl)-1,3,5-triazin-2-amine",C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
394,35089,"4-Ethyl-1,3,5-triazin-2-amine",CCC1=NC(=NC=N1)N,,,,,,
395,35090,"4,6-dimethyl-N-phenyl-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)NC2=CC=CC=C2)C,,,,,,
396,35091,"4,6-Bis(chloromethyl)-s-triazine-2-amine",C(C1=NC(=NC(=N1)N)CCl)Cl,,,,,,
397,35092,"N-Ethyl-4,6-bis(chloromethyl)-s-triazine-2-amine",CCNC1=NC(=NC(=N1)CCl)CCl,,,,,,
398,35093,"N,N-Dimethyl-4,6-bis(chloromethyl)-s-triazine-2-amine",CN(C)C1=NC(=NC(=N1)CCl)CCl,,,,,,
399,35094,"4,6-bis(chloromethyl)-N-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)CCl)CCl,,,,,,
400,35095,"4,6-bis(chloromethyl)-N-(4-chlorophenyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)CCl)CCl)Cl,,,,,,
401,35096,"4,6-Bis(dichloromethyl)-s-triazine-2-amine",C1(=NC(=NC(=N1)N)C(Cl)Cl)C(Cl)Cl,,,,,,
402,35097,"N-Ethyl-4,6-bis(dichloromethyl)-s-triazine-2-amine",CCNC1=NC(=NC(=N1)C(Cl)Cl)C(Cl)Cl,,,,,,
403,35098,"N,N-Dimethyl-4,6-bis(dichloromethyl)-s-triazine-2-amine",CN(C)C1=NC(=NC(=N1)C(Cl)Cl)C(Cl)Cl,,,,,,
404,35099,"4,6-bis(dichloromethyl)-N-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C(Cl)Cl)C(Cl)Cl,,,,,,
405,35100,"N-(4-chlorophenyl)-4,6-dimethyl-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)C,,,,,,
406,35101,"1,3,5-Triazin-2-amine, N-(1-methylethyl)-",CC(C)NC1=NC=NC=N1,,,,,,
407,35102,"6-bromo-4-N-ethyl-2-N-propyl-1,3,5-triazine-2,4-diamine",CCCNC1=NC(=NC(=N1)NCC)Br,,,,,,
408,35103,4-Bromo-N-ethyl-6-(allylamino)-s-triazine-2-amine,CCNC1=NC(=NC(=N1)Br)NCC=C,,,,,,
409,35104,4-Bromo-N-ethyl-6-(isopropylamino)-s-triazine-2-amine,CCNC1=NC(=NC(=N1)Br)NC(C)C,,,,,,
410,35105,"6-bromo-2-N,4-N-di(propan-2-yl)-1,3,5-triazine-2,4-diamine",CC(C)NC1=NC(=NC(=N1)Br)NC(C)C,,,,,,
411,35106,"6-bromo-2-N,2-N,4-N-triethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)Br)N(CC)CC,,,,,,
412,35107,2-Amino-4-ethylamino-6-methoxy-s-triazine,CCNC1=NC(=NC(=N1)N)OC,,,,,,
413,35108,"N,N'-Dimethyl-6-methoxy-s-triazine-2,4-diamine",CNC1=NC(=NC(=N1)OC)NC,,,,,,
414,35109,"N,N'-Diphenyl-6-methoxy-s-triazine-2,4-diamine",COC1=NC(=NC(=N1)NC2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
415,35110,"6-ethoxy-2-N,4-N-diethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)OCC)NCC,,,,,,
416,35111,"6-ethoxy-2-N,2-N,4-N,4-N-tetraethyl-1,3,5-triazine-2,4-diamine",CCN(CC)C1=NC(=NC(=N1)OCC)N(CC)CC,,,,,,
417,35112,"2-N,4-N-diethyl-6-propoxy-1,3,5-triazine-2,4-diamine",CCCOC1=NC(=NC(=N1)NCC)NCC,,,,,,
418,35113,"2-N,4-N-di(propan-2-yl)-6-propan-2-yloxy-1,3,5-triazine-2,4-diamine",CC(C)NC1=NC(=NC(=N1)OC(C)C)NC(C)C,,,,,,
419,35114,"N,N,N',N'-Tetraethyl-6-isopropoxy-s-triazine-2,4-diamine",CCN(CC)C1=NC(=NC(=N1)OC(C)C)N(CC)CC,,,,,,
420,35115,"2-Butoxy-4,6-bis(ethylamino)-S-triazine",CCCCOC1=NC(=NC(=N1)NCC)NCC,,,,,,
421,35116,"N,N'-Diethyl-6-(allyloxy)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)OCC=C)NCC,,,,,,
422,35117,"s-Triazine, 4,6-diamino-2-pentoxy-",CCCCCOC1=NC(=NC(=N1)N)N,,,,,,
423,35118,"N,N'-Diethyl-6-(2-ethoxyethoxy)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)OCCOCC)NCC,,,,,,
424,35119,"2,4-Diamino-6-benzyloxy-s-triazine",C1=CC=C(C=C1)COC2=NC(=NC(=N2)N)N,,,,,,
425,35120,"N,N'-Diphenyl-6-phenoxy-s-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)OC3=CC=CC=C3)NC4=CC=CC=C4,,,,,,
426,35121,"6-(2-Chlorophenoxy)-1,3,5-triazine-2,4-diamine",C1=CC=C(C(=C1)OC2=NC(=NC(=N2)N)N)Cl,,,,,,
427,35122,"6-(4-Chlorophenoxy)-1,3,5-triazine-2,4-diamine",C1=CC(=CC=C1OC2=NC(=NC(=N2)N)N)Cl,,,,,,
428,35123,"6-(p-Nitrophenoxy)-s-triazine-2,4-diamine",C1=CC(=CC=C1[N+](=O)[O-])OC2=NC(=NC(=N2)N)N,,,,,,
429,35124,"N,N,N',N'-Tetraethyl-6-(methylthio)-s-triazine-2,4-diamine",CCN(CC)C1=NC(=NC(=N1)SC)N(CC)CC,,,,,,
430,35125,"6-(Ethylthio)-s-triazine-2,4-diamine",CCSC1=NC(=NC(=N1)N)N,,,,,,
431,35126,"N,N'-Diethyl-6-(ethylthio)-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)SCC)NCC,,,,,,
432,35127,"6-(Butylthio)-s-triazine-2,4-diamine",CCCCSC1=NC(=NC(=N1)N)N,,,,,,
433,35128,"2-(Allylthio)-4,6-diamino-S-triazine",C=CCSC1=NC(=NC(=N1)N)N,,,,,,
434,35129,"6-(Benzylthio)-s-triazine-2,4-diamine",C1=CC=C(C=C1)CSC2=NC(=NC(=N2)N)N,,,,,,
435,35130,"6-(Phenylthio)-s-triazine-2,4-diamine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)N)N,,,,,,
436,35131,"N,N'-Diphenyl-6-(phenylthio)-s-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)SC3=CC=CC=C3)NC4=CC=CC=C4,,,,,,
437,35132,"2-[[4,6-Bis(ethylamino)-1,3,5-triazin-2-yl]sulfanyl]acetonitrile",CCNC1=NC(=NC(=N1)SCC#N)NCC,,,,,,
438,35133,"2-[[4-(Ethylamino)-6-(propan-2-ylamino)-1,3,5-triazin-2-yl]sulfanyl]acetonitrile",CCNC1=NC(=NC(=N1)SCC#N)NC(C)C,,,,,,
439,35134,CID 35134,C1=CC=C(C=C1)NC2=NC(=O)N=C(N2)NC3=CC=CC=C3,,,,,,
440,35135,"[4,6-Bis(propan-2-ylamino)-1,3,5-triazin-2-yl] thiocyanate",CC(C)NC1=NC(=NC(=N1)SC#N)NC(C)C,,,,,,
441,35136,"(4,6-Diamino-1,3,5-triazin-2-yl) thiocyanate",C(#N)SC1=NC(=NC(=N1)N)N,,,,,,
442,35137,"Thiocyanic acid 4,6-bis(ethylamino)-s-triazine-2-yl ester",CCNC1=NC(=NC(=N1)SC#N)NCC,,,,,,
443,35138,"2-(Chloromethyl)-1,3,5-triazine",C1=NC=NC(=N1)CCl,,,,,,
444,35139,"2-(Trichloromethyl)-1,3,5-triazine",C1=NC=NC(=N1)C(Cl)(Cl)Cl,,,,,,
445,35140,2-(Bromomethyl)-S-triazine,C1=NC=NC(=N1)CBr,,,,,,
446,35141,"2-(1-Chloroethyl)-1,3,5-triazine",CC(C1=NC=NC=N1)Cl,,,,,,
447,35142,"2-(1,1-Dichloroethyl)-1,3,5-triazine",CC(C1=NC=NC=N1)(Cl)Cl,,,,,,
448,35143,2-Isopropyl-S-triazine,CC(C)C1=NC=NC=N1,,,,,,
449,35144,"2-(2-Chloropropan-2-yl)-1,3,5-triazine",CC(C)(C1=NC=NC=N1)Cl,,,,,,
450,35145,"2-Benzyl-1,3,5-triazine",C1=CC=C(C=C1)CC2=NC=NC=N2,,,,,,
451,35146,"2-(3-Nitrophenyl)-1,3,5-triazine",C1=CC(=CC(=C1)[N+](=O)[O-])C2=NC=NC=N2,,,,,,
452,35147,"2-Methyl-4-(trichloromethyl)-1,3,5-triazine",CC1=NC(=NC=N1)C(Cl)(Cl)Cl,,,,,,
453,35148,"2,4-Dibenzyl-S-triazine",C1=CC=C(C=C1)CC2=NC(=NC=N2)CC3=CC=CC=C3,,,,,,
454,35149,"2-Methyl-4,6-bis(trifluoromethyl)-S-triazine",CC1=NC(=NC(=N1)C(F)(F)F)C(F)(F)F,,,,,,
455,35150,"2,4-Bis(chloromethyl)-6-(dichloromethyl)-1,3,5-triazine",C(C1=NC(=NC(=N1)C(Cl)Cl)CCl)Cl,,,,,,
456,35151,2-[Di(methylthio)methyl]-4-(dichloromethyl)-6-methyl-s-triazine,CC1=NC(=NC(=N1)C(Cl)Cl)C(SC)SC,,,,,,
457,35152,"2-(Chloromethyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",C(C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
458,35153,"2-(Bromomethyl)-4,6-dimethyl-S-triazine",CC1=NC(=NC(=N1)CBr)C,,,,,,
459,35154,"2,4,6-Tris(bromomethyl)-1,3,5-triazine",C(C1=NC(=NC(=N1)CBr)CBr)Br,,,,,,
460,35155,"2,4-Bis(dibromomethyl)-6-methyl-S-triazine",CC1=NC(=NC(=N1)C(Br)Br)C(Br)Br,,,,,,
461,35156,"1,3,5-Triazine, 2,4,6-tris(dibromomethyl)-",C1(=NC(=NC(=N1)C(Br)Br)C(Br)Br)C(Br)Br,,,,,,
462,35157,"2-Methyl-4,6-bis(tribromomethyl)-1,3,5-triazine",CC1=NC(=NC(=N1)C(Br)(Br)Br)C(Br)(Br)Br,,,,,,
463,35158,"2-Ethyl-4,6-dimethyl-S-triazine",CCC1=NC(=NC(=N1)C)C,,,,,,
464,35159,"2-(3-Chloropropyl)-4,6-dimethyl-1,3,5-triazine",CC1=NC(=NC(=N1)CCCCl)C,,,,,,
465,35160,"2-Butyl-4,6-dimethyl-1,3,5-triazine",CCCCC1=NC(=NC(=N1)C)C,,,,,,
466,35161,"2-Isobutyl-4,6-dimethyl-S-triazine",CC1=NC(=NC(=N1)CC(C)C)C,,,,,,
467,35162,"2,4-Dimethyl-6-(2-phenylethyl)-1,3,5-triazine",CC1=NC(=NC(=N1)CCC2=CC=CC=C2)C,,,,,,
468,35163,"2-(4-Chlorophenyl)-4,6-dimethyl-1,3,5-triazine",CC1=NC(=NC(=N1)C2=CC=C(C=C2)Cl)C,,,,,,
469,35164,"2-(m-Nitrophenyl)-4,6-dimethyl-s-triazine",CC1=NC(=NC(=N1)C2=CC(=CC=C2)[N+](=O)[O-])C,,,,,,
470,35165,"2-Ethyl-4,6-bis(trifluoromethyl)-S-triazine",CCC1=NC(=NC(=N1)C(F)(F)F)C(F)(F)F,,,,,,
471,35166,"N-methyl-4,6-bis(methylsulfanyl)-1,3,5-triazin-2-amine",CNC1=NC(=NC(=N1)SC)SC,,,,,,
472,35167,"N-ethyl-4,6-bis(methylsulfanyl)-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)SC)SC,,,,,,
473,35168,"4,6-bis(methylsulfanyl)-N-phenyl-1,3,5-triazin-2-amine",CSC1=NC(=NC(=N1)NC2=CC=CC=C2)SC,,,,,,
474,35169,"4,6-Bis(ethylthio)-s-triazine-2-amine",CCSC1=NC(=NC(=N1)N)SCC,,,,,,
475,35170,"4,6-Bis(butylthio)-s-triazine-2-amine",CCCCSC1=NC(=NC(=N1)N)SCCCC,,,,,,
476,35171,CID 35171,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)S)S)Cl,,,,,,
477,35172,"Diethyl 6-amino-1,3,5-triazine-2,4-dicarboxylate",CCOC(=O)C1=NC(=NC(=N1)N)C(=O)OCC,,,,,,
478,35173,"Ethyl 4-amino-6-(trichloromethyl)-1,3,5-triazine-2-carboxylate",CCOC(=O)C1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
479,35174,"4-Methyl-6-(trichloromethyl)-1,3,5-triazine-2-carboxamide",CC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(=O)N,,,,,,
480,35175,CID 35175,C1(=NC(=O)N=C(N1)N)C(=O)N,,,,,,
481,35176,"N-(2-chlorophenyl)-4,6-diisothiocyanato-1,3,5-triazin-2-amine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)N=C=S)N=C=S)Cl,,,,,,
482,35177,"N-(p-Chlorophenyl)-4,6-diisothiocyanato-s-triazine-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)N=C=S)N=C=S)Cl,,,,,,
483,35178,"[4-(2-Chloroanilino)-6-thiocyanato-1,3,5-triazin-2-yl] thiocyanate",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)SC#N)SC#N)Cl,,,,,,
484,35179,CID 35179,CC[N-]C1=NC(=NC(=N1)N[N+]#N)Br,,,,,,
485,35180,CID 35180,CCNC1=NC(=NC(=N1)Br)N[N+]#N,,,,,,
486,35181,CID 35181,CC[N-]C1=NC(=NC(=N1)N[N+]#N)OC2=CC=CC=C2,,,,,,
487,35182,CID 35182,CCNC1=NC(=NC(=N1)OC2=CC=CC=C2)N[N+]#N,,,,,,
488,35183,CID 35183,CC[N-]C1=NC(=NC(=N1)N[N+]#N)SCC,,,,,,
489,35184,CID 35184,CCNC1=NC(=NC(=N1)SCC)N[N+]#N,,,,,,
490,35185,CID 35185,COC1=NC(=NC(=NC2=CC=CC=C2)[N-]1)N[N+]#N,,,,,,
491,35186,CID 35186,COC1=NC(=NC(=N1)N[N+]#N)NC2=CC=CC=C2,,,,,,
492,35187,"s-Triazine, 2-(dichloromethyl)-4,6-bis(trichloromethyl)-",C1(=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)C(Cl)Cl,,,,,,
493,35188,"2-Phenyl-4,6-bis(trifluoromethyl)-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C(F)(F)F)C(F)(F)F,,,,,,
494,35189,2-Methyl-4-phenyl-6-(trichloromethyl)-s-triazine,CC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C2=CC=CC=C2,,,,,,
495,35190,"2-(Pentachloroethyl)-4,6-bis(trichloromethyl)-s-triazine",C1(=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)C(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
496,35191,"[4,6-Bis(trichloromethyl)-1,3,5-triazin-2-yl]methyl acetate",CC(=O)OCC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
497,35192,"1-[4,6-Bis(trichloromethyl)-1,3,5-triazin-2-yl]ethyl acetate",CC(C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)OC(=O)C,,,,,,
498,35193,"alpha,4,6-Tris(trichloromethyl)-s-triazine-2-methanol acetate",CC(=O)OC(C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
499,35194,"2-[4,6-Bis(trichloromethyl)-1,3,5-triazin-2-yl]propan-2-yl acetate",CC(=O)OC(C)(C)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
500,35195,"2-Cyclohexyl-4,6-bis(trichloromethyl)-s-triazine",C1CCC(CC1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
501,35196,"2-(2,3,4,5,6-Pentachlorophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
502,35197,"2-Pyridin-3-yl-4,6-bis(trichloromethyl)-1,3,5-triazine",C1=CC(=CN=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
503,35198,"2,4-Diethyl-6-methyl-1,3,5-triazine",CCC1=NC(=NC(=N1)C)CC,,,,,,
504,35199,"2-Methyl-4,6-bis(3-nitrophenyl)-1,3,5-triazine",CC1=NC(=NC(=N1)C2=CC(=CC=C2)[N+](=O)[O-])C3=CC(=CC=C3)[N+](=O)[O-],,,,,,
505,35200,"2,4-Diethyl-6-(trichloromethyl)-S-triazine",CCC1=NC(=NC(=N1)C(Cl)(Cl)Cl)CC,,,,,,
506,35201,"2,4-Diphenyl-6-(trichloromethyl)-S-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C3=CC=CC=C3,,,,,,
507,35202,"2,4-Bis(p-chlorophenyl)-6-(trichloromethyl)-s-triazine",C1=CC(=CC=C1C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C3=CC=C(C=C3)Cl)Cl,,,,,,
508,35203,"2,4-DI-P-Tolyl-6-(trichloromethyl)-S-triazine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C3=CC=C(C=C3)C,,,,,,
509,35204,"2,4-Diethyl-6-(1-bromoethyl)-s-triazine",CCC1=NC(=NC(=N1)C(C)Br)CC,,,,,,
510,35205,"2-Ethenyl-4,6-diethyl-1,3,5-triazine",CCC1=NC(=NC(=N1)C=C)CC,,,,,,
511,35206,"2,4-Diethyl-6-phenyl-S-triazine",CCC1=NC(=NC(=N1)C2=CC=CC=C2)CC,,,,,,
512,35207,"1-(4,6-Diethyl-1,3,5-triazin-2-yl)ethyl acetate",CCC1=NC(=NC(=N1)C(C)OC(=O)C)CC,,,,,,
513,35208,"2,4-Diphenyl-6-ethyl-s-triazine",CCC1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
514,35209,"2,4,6-Tris(1-chloroethyl)-S-triazine",CC(C1=NC(=NC(=N1)C(C)Cl)C(C)Cl)Cl,,,,,,
515,35210,"2-(1-Chloroethyl)-4,6-diphenyl-S-triazine",CC(C1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)Cl,,,,,,
516,35211,"2,4,6-Tris(1,1-dichloroethyl)-1,3,5-triazine",CC(C1=NC(=NC(=N1)C(C)(Cl)Cl)C(C)(Cl)Cl)(Cl)Cl,,,,,,
517,35212,"2,4,6-Tris(1,1,2-trichloroethyl)-1,3,5-triazine",C(C(C1=NC(=NC(=N1)C(CCl)(Cl)Cl)C(CCl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
518,35213,"2,4,6-Tris(1,1,2,2-tetrachloroethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)C(C(Cl)Cl)(Cl)Cl)C(C(Cl)Cl)(Cl)Cl)C(C(Cl)Cl)(Cl)Cl,,,,,,
519,35214,"2,4,6-Tris(1,1,2,2,2-pentachloroethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)C(C(Cl)(Cl)Cl)(Cl)Cl)C(C(Cl)(Cl)Cl)(Cl)Cl)C(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
520,35215,"2,4,6-Tris(1-bromoethyl)-S-triazine",CC(C1=NC(=NC(=N1)C(C)Br)C(C)Br)Br,,,,,,
521,35216,"2-(1-Bromoethyl)-4,6-diphenyl-S-triazine",CC(C1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)Br,,,,,,
522,35217,"2,4,6-Tris(1,1-dibromoethyl)-S-triazine",CC(C1=NC(=NC(=N1)C(C)(Br)Br)C(C)(Br)Br)(Br)Br,,,,,,
523,35218,"2,4-Diphenyl-6-propyl-S-triazine",CCCC1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
524,35219,"2,4,6-Tri(nonyl)-1,3,5-triazine",CCCCCCCCCC1=NC(=NC(=N1)CCCCCCCCC)CCCCCCCCC,,,,,,
525,35220,CID 35220,C1=CC(=CC=C1C=CC2=NC(=NC(=N2)C=CC3=CC=C(C=C3)Cl)C=CC4=CC=C(C=C4)Cl)Cl,,,,,,
526,35221,"2,4-Diphenyl-6-(m-aminophenyl)-s-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC(=CC=C3)N)C4=CC=CC=C4,,,,,,
527,35222,"2,4-Bis(3-nitrophenyl)-6-phenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC(=CC=C3)[N+](=O)[O-])C4=CC(=CC=C4)[N+](=O)[O-],,,,,,
528,35223,"2,4-Bis(P-nitrophenyl)-6-phenyl-S-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=C(C=C3)[N+](=O)[O-])C4=CC=C(C=C4)[N+](=O)[O-],,,,,,
529,35224,"2,4,6-Tris(4-bromophenyl)-1,3,5-triazine",C1=CC(=CC=C1C2=NC(=NC(=N2)C3=CC=C(C=C3)Br)C4=CC=C(C=C4)Br)Br,,,,,,
530,35225,"alpha,alpha',alpha''-Tris(o-chlorophenyl)-s-triazine 2,4,6-triethanol",C1=CC=C(C(=C1)C(CC2=NC(=NC(=N2)CC(C3=CC=CC=C3Cl)O)CC(C4=CC=CC=C4Cl)O)O)Cl,,,,,,
531,35226,"alpha,alpha',alpha''-Tris(2,4-dichlorophenyl)-s-triazine 2,4,6-triethanol",C1=CC(=C(C=C1Cl)Cl)C(CC2=NC(=NC(=N2)CC(C3=C(C=C(C=C3)Cl)Cl)O)CC(C4=C(C=C(C=C4)Cl)Cl)O)O,,,,,,
532,35227,Butyl mercury phosphorodithioate,CCCCOP(=S)(OCCCC)[S-].CCCCOP(=S)(OCCCC)[S-].[Hg+2],,,,,,
533,35228,Dibutyl dithiophosphate,CCCCOP(=S)(OCCCC)S,,,,,,
534,35229,"2-N-ethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC=NC(=N1)N,,,,,,
535,35230,"2,4-Bis(methylamino)-1,3,5-triazine",CNC1=NC(=NC=N1)NC,,,,,,
536,35231,"N-Ethyl-6-methyl-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)C,,,,,,
537,35232,"N,4-Dimethyl-6-hydrazino-s-triazine-2-amine",CC1=NC(=NC(=N1)NN)NC,,,,,,
538,35233,"2-N,2-N-diethyl-4-N,4-N,6-trimethyl-1,3,5-triazine-2,4-diamine",CCN(CC)C1=NC(=NC(=N1)N(C)C)C,,,,,,
539,35234,"2,6-Di[4-chloroanilino]-4-methyl-S-triazine",CC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)Cl,,,,,,
540,35235,"2-N,4-N-bis(2-methoxyethyl)-6-methyl-1,3,5-triazine-2,4-diamine",CC1=NC(=NC(=N1)NCCOC)NCCOC,,,,,,
541,35236,"3,3'-(6-Methyl-s-triazine-2,4-diyldiimino)bispropionitrile",CC1=NC(=NC(=N1)NCCC#N)NCCC#N,,,,,,
542,35237,"4,6-Dipentyl-s-triazine-2-amine",CCCCCC1=NC(=NC(=N1)N)CCCCC,,,,,,
543,35238,"4-Nonyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCCCCCCCCC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
544,35239,4-Heptadecyl-6-(trichloromethyl)-s-triazine-2-amine,CCCCCCCCCCCCCCCCCC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
545,35240,"s-Triazine, 2-amino-4-phenyl-6-(trichloromethyl)-",C1=CC=C(C=C1)C2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
546,35241,"4-(2,4-Dichlorophenyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
547,35242,"4-(4-Methylphenyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
548,35243,4-(p-Methoxyphenyl)-6-(trichloromethyl)-s-triazine-2-amine,COC1=CC=C(C=C1)C2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
549,35244,"4-(3-Nitrophenyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=CC(=C1)[N+](=O)[O-])C2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
550,35245,"N,4,6-triphenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)C2=NC(=NC(=N2)NC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
551,35246,"4,6-Bis(4-chlorophenyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1C2=NC(=NC(=N2)N)C3=CC=C(C=C3)Cl)Cl,,,,,,
552,35247,"4-chloro-N-ethyl-6-methyl-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)C)Cl,,,,,,
553,35248,4-Chloro-6-(diazomethyl)-s-triazine-2-amine,C(=[N+]=[N-])C1=NC(=NC(=N1)Cl)N,,,,,,
554,35249,"4-Chloro-6-ethyl-1,3,5-triazin-2-amine",CCC1=NC(=NC(=N1)Cl)N,,,,,,
555,35250,"4-chloro-N,6-diethyl-1,3,5-triazin-2-amine",CCC1=NC(=NC(=N1)Cl)NCC,,,,,,
556,35251,"4-Chloro-6-propyl-1,3,5-triazin-2-amine",CCCC1=NC(=NC(=N1)Cl)N,,,,,,
557,35252,2-Amino-4-chloro-6-(4-chlorophenyl)-s-triazine,C1=CC(=CC=C1C2=NC(=NC(=N2)Cl)N)Cl,,,,,,
558,35253,N-Phenyl-4-methoxy-6-methyl-s-triazine-2-amine,CC1=NC(=NC(=N1)OC)NC2=CC=CC=C2,,,,,,
559,35254,"4-Methoxy-6-phenyl-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)N)C2=CC=CC=C2,,,,,,
560,35255,"N-ethyl-4-methoxy-6-phenyl-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)C2=CC=CC=C2)OC,,,,,,
561,35256,"N-ethyl-4-methyl-6-phenoxy-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)C)OC2=CC=CC=C2,,,,,,
562,35257,N-Ethyl-4-(methylthio)-6-(trichloromethyl)-s-triazine-2-amine,CCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
563,35258,N-Propyl-4-(methylthio)-6-(trichloromethyl)-s-triazine-2-amine,CCCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
564,35259,"4-methylsulfanyl-N-prop-2-enyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CSC1=NC(=NC(=N1)NCC=C)C(Cl)(Cl)Cl,,,,,,
565,35260,"4-methylsulfanyl-N-propan-2-yl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CC(C)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
566,35261,N-Butyl-4-(methylthio)-6-(trichloromethyl)-s-triazine-2-amine,CCCCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
567,35262,N-Isobutyl-4-(methylthio)-6-(trichloromethyl)-s-triazine-2-amine,CC(C)CNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
568,35263,"N-dodecyl-4-methylsulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCCCCCCCCCCCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
569,35264,"N,N-diethyl-4-methylsulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCN(CC)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
570,35265,"4-Ethylsulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCSC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
571,35266,"4-ethylsulfanyl-N-methyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCSC1=NC(=NC(=N1)NC)C(Cl)(Cl)Cl,,,,,,
572,35267,N-Methyl-4-(isopropylthio)-6-(trichloromethyl)-s-triazine-2-amine,CC(C)SC1=NC(=NC(=N1)NC)C(Cl)(Cl)Cl,,,,,,
573,35268,4-(Butylthio)-6-(trichloromethyl)-s-triazine-2-amine,CCCCSC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
574,35269,"4-(2-Methylpropylsulfanyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",CC(C)CSC1=NC(=NC(=N1)N)C(Cl)(Cl)Cl,,,,,,
575,35270,N-Methyl-4-(hexylthio)-6-(trichloromethyl)-s-triazine-2-amine,CCCCCCSC1=NC(=NC(=N1)NC)C(Cl)(Cl)Cl,,,,,,
576,35271,"4-Phenylsulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
577,35272,"N-methyl-4-phenylsulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC2=CC=CC=C2,,,,,,
578,35273,4-(p-Chlorophenylthio)-6-(trichloromethyl)-s-triazine-2-amine,C1=CC(=CC=C1SC2=NC(=NC(=N2)N)C(Cl)(Cl)Cl)Cl,,,,,,
579,35274,N-Methyl-4-(p-chlorophenylthio)-6-(trichloromethyl)-s-triazine-2-amine,CNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl,,,,,,
580,35275,"4-(4-chlorophenyl)sulfanyl-N-ethyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl,,,,,,
581,35276,"4-(4-chlorophenyl)sulfanyl-N-propan-2-yl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CC(C)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl,,,,,,
582,35277,"N-Methyl-4-(2,4-dichlorophenylthio)-6-(trichloromethyl)-s-triazine-2-amine",CNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC2=C(C=C(C=C2)Cl)Cl,,,,,,
583,35278,"4-(2,4,5-Trichlorophenylthio)-6-(trichloromethyl)-s-triazine-2-amine",C1=C(C(=CC(=C1Cl)Cl)Cl)SC2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
584,35279,"N-methyl-4-(trichloromethyl)-6-(2,4,5-trichlorophenyl)sulfanyl-1,3,5-triazin-2-amine",CNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
585,35280,CID 35280,CCNC1=NC(=O)N=C(N1)C,,,,,,
586,35281,CID 35281,C1(=NC(=O)N=C(N1)N)C(Cl)(Cl)Cl,,,,,,
587,35282,CID 35282,CCC1=NC(=O)N=C(N1)N,,,,,,
588,35283,CID 35283,CC(C)CC1=NC(=O)N=C(N1)N,,,,,,
589,35284,CID 35284,C1=CC=C(C=C1)CC2=NC(=O)N=C(N2)N,,,,,,
590,35285,CID 35285,C1=CC(=CC=C1C2=NC(=O)N=C(N2)N)[N+](=O)[O-],,,,,,
591,35286,CID 35286,CC1=NC(=NC(=N1)S)N,,,,,,
592,35287,CID 35287,CCC1=NC(=NC(=N1)S)N,,,,,,
593,35288,CID 35288,CC(C)CC1=NC(=NC(=N1)S)N,,,,,,
594,35289,CID 35289,C1=CC=C(C=C1)CC2=NC(=NC(=N2)S)N,,,,,,
595,35290,CID 35290,C1=CC=C(C=C1)C2=NC(=NC(=N2)S)N,,,,,,
596,35291,CID 35291,C1=CC(=CC=C1C2=NC(=NC(=N2)S)N)Cl,,,,,,
597,35292,"N-Ethyl-4,6-difluoro-s-triazine-2-amine",CCNC1=NC(=NC(=N1)F)F,,,,,,
598,35293,"N-(4-Chlorophenyl)-4,6-difluoro-s-triazine-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)F)F)Cl,,,,,,
599,35294,"N-Allyl-4,6-dichloro-1,3,5-triazin-2-amine",C=CCNC1=NC(=NC(=N1)Cl)Cl,,,,,,
600,35295,"N-benzyl-4,6-dichloro-1,3,5-triazin-2-amine",C1=CC=C(C=C1)CNC2=NC(=NC(=N2)Cl)Cl,,,,,,
601,35296,"N-(2-bromophenyl)-4,6-dichloro-1,3,5-triazin-2-amine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Br,,,,,,
602,35297,"N-(3-bromophenyl)-4,6-dichloro-1,3,5-triazin-2-amine",C1=CC(=CC(=C1)Br)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
603,35298,"N-(4-Biphenylyl)-4,6-dichloro-s-triazine-2-amine",C1=CC=C(C=C1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)Cl)Cl,,,,,,
604,35299,"4,6-Dichloro-N-(2-methoxyphenyl)-1,3,5-triazin-2-amine",COC1=CC=CC=C1NC2=NC(=NC(=N2)Cl)Cl,,,,,,
605,35300,"s-Triazine, 2,4-dichloro-6-(1-naphthylamino)-",C1=CC=C2C(=C1)C=CC=C2NC3=NC(=NC(=N3)Cl)Cl,,,,,,
606,35301,"N-(4,6-Dichloro-1,3,5-triazin-2-yl)benzenesulphonamide",C1=CC=C(C=C1)S(=O)(=O)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
607,35302,"2-Methyl-4,6-bis(4-methylphenyl)-1,3,5-triazine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)C)C3=CC=C(C=C3)C,,,,,,
608,35303,"2-N,4-N-diethyl-6-(trichloromethyl)-2-N-(trichloromethylsulfanyl)-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)N(CC)SC(Cl)(Cl)Cl,,,,,,
609,35304,"6-(bromomethyl)-2-N-ethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)N)CBr,,,,,,
610,35305,"2-N,4-N-bis(4-chlorophenyl)-6-(tribromomethyl)-1,3,5-triazine-2,4-diamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)C(Br)(Br)Br)NC3=CC=C(C=C3)Cl)Cl,,,,,,
611,35306,"6-Ethoxy-N,N'-diisopropyl-[1,3,5]triazine-2,4-diamine",CCOC1=NC(=NC(=N1)NC(C)C)NC(C)C,,,,,,
612,35307,"N~2~,N~4~-Dimethyl-N~2~,N~4~-diphenyl-1,3,5-triazine-2,4,6-triamine",CN(C1=CC=CC=C1)C2=NC(=NC(=N2)N)N(C)C3=CC=CC=C3,,,,,,
613,35308,"N-benzyl-4-methyl-1,3,5-triazin-2-amine",CC1=NC(=NC=N1)NCC2=CC=CC=C2,,,,,,
614,35309,"N-ethyl-4,6-dimethyl-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)C)C,,,,,,
615,35310,"4-(4-Chlorophenyl)-6-(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1C2=NC(=NC(=N2)N)C(Cl)(Cl)Cl)Cl,,,,,,
616,35311,N-Methyl-4-(methylthio)-6-(trichloromethyl)-s-triazine-2-amine,CNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
617,35312,"4,6-dichloro-N-(4-methoxyphenyl)-1,3,5-triazin-2-amine",COC1=CC=C(C=C1)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
618,35313,"Benzylamine, N,N-bis(2-chloroethyl)-2,4,6-trimethyl-",CC1=CC(=C(C(=C1)C)CN(CCCl)CCCl)C,,,,,,
619,35314,"N,N-Bis(2-chloroethyl)-o-methylbenzylamine",CC1=CC=CC=C1CN(CCCl)CCCl,,,,,,
620,35315,N-Phenethyl-N-(1-phenethyl-3-pyrrolidinylmethyl)-2-phenylacetamide,C1CN(CC1CN(CCC2=CC=CC=C2)C(=O)CC3=CC=CC=C3)CCC4=CC=CC=C4,,,,,,
621,35316,"N-Phenyl-4,6-bis(allyloxy)-s-triazine-2-amine",C=CCOC1=NC(=NC(=N1)NC2=CC=CC=C2)OCC=C,,,,,,
622,35317,"4,6-Dibutoxy-s-triazine-2-amine",CCCCOC1=NC(=NC(=N1)N)OCCCC,,,,,,
623,35318,"N-ethyl-4,6-diphenoxy-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
624,35319,Asperlin,CC1C(O1)C2C(C=CC(=O)O2)OC(=O)C,,,,,,
625,35320,"N,N'-Bis(2-methoxyethyl)-6-(trichloromethyl)-s-triazine-2,4-diamine",COCCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)NCCOC,,,,,,
626,35321,"N-Ethyl-N'-(3-methoxypropyl)-6-fluoro-s-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)F)NCCCOC,,,,,,
627,35322,"2-[Cyanomethyl-[4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]amino]acetonitrile",CC1=NC(=NC(=N1)N(CC#N)CC#N)C(Cl)(Cl)Cl,,,,,,
628,35323,N-[4-Methyl-6-(trichloromethyl)-s-triazine-2-yl]trichloroacetamide,CC1=NC(=NC(=N1)NC(=O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
629,35324,"N-(2-Chlorophenyl)-4,6-dibromo-s-triazine-2-amine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Br)Br)Cl,,,,,,
630,35325,N-Ethyl-4-chloro-6-(ethylthio)-s-triazine-2-amine,CCNC1=NC(=NC(=N1)Cl)SCC,,,,,,
631,35326,"N,N-Bis(2-chloroethyl)-m-methylbenzylamine",CC1=CC(=CC=C1)CN(CCCl)CCCl,,,,,,
632,35327,"BENZYLAMINE, N,N-BIS(2-CHLOROETHYL)-p-ETHYL-",CCC1=CC=C(C=C1)CN(CCCl)CCCl,,,,,,
633,35328,"Benzylamine, N,N-bis(2-chloroethyl)-2,4,5-trimethyl-",CC1=CC(=C(C=C1C)CN(CCCl)CCCl)C,,,,,,
634,35329,Bitolterol mesylate,CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C.CS(=O)(=O)O,,,"['Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
635,35330,Bitolterol,CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C,['Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).'],"['Bitolterol, an adrenergic bronchodilator, is a prodrug that widens constricted airways in the lungs by relaxing the smooth muscles that surround the bronchial passages. Bitolterol probably does not affect the inflammation in the lung, such as in bronchitis. Bitolterol is unique in that it is a prodrug because it must first be metabolized by the body before it becomes active.']","['Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
636,35331,"1,2,3,4-Tetrachlorodibenzofuran",C1=CC=C2C(=C1)C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
637,35332,"1,2,4,6,9-Pentachlorodibenzofuran",C1=CC(=C2C(=C1Cl)C3=C(O2)C(=CC(=C3Cl)Cl)Cl)Cl,,,,,,
638,35333,"N,N-Dipropyl-4-pentyloxy-1-naphthamidine hydrochloride",CCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCC)CCC.[Cl-],,,,,,
639,35334,"4-pentoxy-N,N-dipropylnaphthalene-1-carboximidamide",CCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCC)CCC,,,,,,
640,35335,"N-{2-[2-(2,4-Dinitrophenyl)hydrazinylidene]propyl}ethanimidic acid",CC(=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])CNC(=O)C,,,,,,
641,35336,CID 35336,CC(=NOC(=O)N(C)C(=O)C)SC,,,,,,
642,35337,CID 35337,CC(=NOC(=O)NC(=O)CCl)SCCC#N,,,,,,
643,35338,CID 35338,CCSC(=NOC(=O)N(C)C(=O)C)C,,,,,,
644,35339,2-cyanoethyl N-[acetyl(methyl)carbamoyl]oxyethanimidothioate,CC(=NOC(=O)N(C)C(=O)C)SCCC#N,,,,,,
645,35340,CID 35340,CC(=NOC(=O)N(C)C(=O)CCl)SCCC#N,,,,,,
646,35341,"Ammonium, hexamethylenebis(dimethyl(diphenylmethyl)-, dibromide",C[N+](C)(CCCCCC[N+](C)(C)C(C1=CC=CC=C1)C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4.[Br-].[Br-],,,,,,
647,35342,Benzhydryl-[6-[benzhydryl(dimethyl)azaniumyl]hexyl]-dimethylazanium,C[N+](C)(CCCCCC[N+](C)(C)C(C1=CC=CC=C1)C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
648,35343,"1,4-Dibromo-2,3-bis(bromomethyl)but-2-ene",C(C(=C(CBr)CBr)CBr)Br,,,,,,
649,35344,9-Methyl-2-(4-phenyl-1-piperazinyl)bicyclo(3.3.1)nonan-9-ol hydrochloride,CC1(C2CCCC1C(CC2)[NH+]3CCN(CC3)C4=CC=CC=C4)O.[Cl-],,,,,,
650,35345,9-Methyl-2-(4-phenylpiperazin-1-yl)bicyclo[3.3.1]nonan-9-ol,CC1(C2CCCC1C(CC2)N3CCN(CC3)C4=CC=CC=C4)O,,,,,,
651,35346,"2H-Isoindole, 4,7-dihydro-2-phenyl-",C1C=CCC2=CN(C=C21)C3=CC=CC=C3,,,,,,
652,35347,"2H-Isoindole, 4,7-dihydro-5-methyl-2-phenyl-",CC1=CCC2=CN(C=C2C1)C3=CC=CC=C3,,,,,,
653,35348,"5-Methyl-2-phenyl-4,5,6,7-tetrahydroisoindole",CC1CCC2=CN(C=C2C1)C3=CC=CC=C3,,,,,,
654,35349,Ethyl propyl disulfide,CCCSSCC,,,,,,
655,35350,"Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-2,6-dimethyl-",CCN(CC)CCNC(=O)C1=C(C=C(C=C1C)N)C,,,,,,
656,35351,"10-(Iodomethyl)-17-(6-methylheptan-2-yl)-1,2,3,4,7,8,9,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol",CC(C)CCCC(C)C1CCC2C1CCC3C2CC=C4C3(CCC(C4)O)CI,,,,,,
657,35352,"Barbituric acid, 5-acetonyl-5-allyl-1,3-dimethyl-",CC(=O)CC1(C(=O)N(C(=O)N(C1=O)C)C)CC=C,,,,,,
658,35353,1-[Bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-enyl)piperazine;dihydrochloride,C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,,,,,,
659,35354,"Benzimidazole, 2-amino-5-butyl-",CCCCC1=CC2=C(C=C1)N=C(N2)N,,,,,,
660,35355,"2,5-Dibromo-4-[2-(3,5-dibromo-4-hydroxyphenyl)propan-2-yl]phenol",CC(C)(C1=CC(=C(C(=C1)Br)O)Br)C2=CC(=C(C=C2Br)O)Br,,,,,,
661,35356,"1,2-Benzenedicarboxylic acid, methyl-",CC1=CC(=C(C=C1)C(=O)O)C(=O)O.CC1=C(C(=CC=C1)C(=O)O)C(=O)O,,,,,,
662,35357,3-Methylphthalic acid,CC1=C(C(=CC=C1)C(=O)O)C(=O)O,,,,,,
663,35358,"Benzene, dichloro(trifluoromethyl)-",C1=CC(=C(C(=C1)Cl)C(F)(F)F)Cl.C1=CC(=C(C=C1C(F)(F)F)Cl)Cl.C1=CC(=C(C=C1Cl)Cl)C(F)(F)F.C1=CC(=C(C=C1Cl)C(F)(F)F)Cl.C1=C(C=C(C=C1Cl)Cl)C(F)(F)F,,,,,,
664,35359,"1,3-Dichloro-2-(trifluoromethyl)benzene",C1=CC(=C(C(=C1)Cl)C(F)(F)F)Cl,,,,,,
665,35360,"2,5-Dichlorobenzotrifluoride",C1=CC(=C(C=C1Cl)C(F)(F)F)Cl,,,,,,
666,35361,"1,3-Dichloro-5-(trifluoromethyl)benzene",C1=C(C=C(C=C1Cl)Cl)C(F)(F)F,,,,,,
667,35362,CID 35362,CC1CCC(CC1)(C)C.CC1CCCC(C1)(C)C.CC1CCCC(C1C)C.CC1CCCCC1(C)C.CC1CC(CC(C1)C)C,,,,,,
668,35363,"1,1,2-Trimethylcyclohexane",CC1CCCCC1(C)C,,,,,,
669,35364,"1,3,5-Trimethylcyclohexane",CC1CC(CC(C1)C)C,,,,,,
670,35365,"1,1,4-Trimethylcyclohexane",CC1CCC(CC1)(C)C,,,,,,
671,35366,CID 35366,CC1CCC(C1)(C)C.CC1CCC(C1C)C.CC1CCCC1(C)C.CC1CC(C(C1)C)C,,,,,,
672,35367,"1,1,2-Trimethylcyclopentane",CC1CCCC1(C)C,,,,,,
673,35368,"1,2,3-Trimethylcyclopentane",CC1CCC(C1C)C,,,,,,
674,35369,CID 35369,CCCCCC(C)(C)C.CCCCC(C)C(C)C.CCCC(C)CC(C)C,,,,,,
675,35370,Zidovudine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],['Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.'],"[""Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zidovudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.""]","['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']","['Rapid and nearly complete absorption from the gastrointestinal tract following oral administration; however, because of first-pass metabolism, systemic bioavailability of zidovudine capsules and solution is approximately 65% (range, 52 to 75%). Bioavailability in neonates up to 14 days of age is approximately 89%, and it decreases to approximately 61% and 65% in neonates over 14 days of age and children 3 months to 12 years, respectively. Administration with a high-fat meal may decrease the rate and extent of absorption.', 'As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged and about 45% of the dose was excreted as GZDV.', 'Apparent volume of distribution, HIV-infected patients, IV administration = 1.6  0.6 L/kg', '0.65\xa0+/- 0.29 L/hr/kg [HIV-infected, Birth to 14\xa0Days of Age]', 'In patients with impaired renal function, plasma concentrations of zidovudine may be increased and the half-life prolonged. In one study in adults with impaired renal function (creatinine clearances ranging from 6-31 ml/minute) without HIV infections beta half life of zidovudine averaged 1.4 hours and was similar to that reported for adults with HIV infections who had normal renal function. However, the beta half life of glucuronide in these adults with impaired renal function averaged 8 hours and was considerably prolonged compared with that reported for adults with HIV infections who had normal renal function. In one study in adults with hemophilia and HIV infections who had elevated serum concentrations of aspartate aminotransferase (serum glutamic-oxaloacetic transaminase), alanine aminotransferase (serum glutamic-pyruvic transaminase), pharmacokinetics of zidovudine after a single 300 mg oral dose showed considerable interindividual variation.', ""Following oral administration of zidovudine in patients with HIV infections, 63-95% of the dose is excreted in urine; approximately 14-18% of the dose is excreted as unchanged zidovudine and 72-74% is excreted as zidovudine 5'-O-glucuronide within 6 hours. Following iv administration of the drug in adults or children with HIV infections, approximately 18-29% of the dose is excreted in urine as unchanged drug and 45-60% is excreted as zidovudine 5'-O-glucuronide within 6 hours."", ""Zidovudine and 3'-azodp-3'-deoxy-5'-O-beta-d-glucopyranuronosylthymidine are eliminated principally in urine via both glomerular filtration and tubular secretion. Following oral or IV administration in adults with HIV infection, total body clearance of zidovudine averages 1.6 l/hr per kg (range: 0.8-2.7 l/hr per kg) and renal clearance of the drug averages 0.34 l/hr per kg. In children 3 months to 12 years of age, the total body clearance averaged 1.85 l/hr per kg. In one limited study in neonates and infants younger than 3 months of age, total body clearance of the drug averaged 0.65 l/hr per kg in those 14 days of age or younger and 1.14 l/hr per kg in those older than 14 days of age."", ""Zidovudine is rapidly metabolized via glucuronidation in the liver to zidovudine 5'-O-glucuronide (GAZT); the metabolite has an apparent elimination half life of 1 hour (range: 0.6-1.7 hours). Zidovudine 5'-O-glucuronide does not appear to have antiviral activity against HIV."", 'For more Absorption, Distribution and Excretion (Complete) data for ZIDOVUDINE (21 total), please visit the HSDB record page.']","[""Hepatic. Metabolized by glucuronide conjugation to major, inactive metabolite, 3&prime;-azido-3&prime;-deoxy-5&prime;- O-beta-D-glucopyranuronosylthymidine (GZDV). UGT2B7 is the primary UGT isoform that is responsible for glucuronidation. Compared to zidovudine, GZDV's area under the curve is approximately 3-fold greater. The cytochrome P450 isozymes are responsible for the reduction of the azido moiety to form 3'-amino-3'- deoxythymidine (AMT)."", 'Zidovudine is rapidly metabolized via glucuronidation in the liver principally to 3-azido-3-deoxy-5-O-beta-d-glucopyranuronosylthymidine (GZDV; formerly GAZT); zidovudine is also metabolized to GZDV in renal microsomes. GZDV has an apparent elimination half-life of 1 hour (range: 0.6-1.7 hours) and does not appear to have antiviral activity against HIV. In addition, two other hepatic metabolites of zidovudine have been identified as 3-amino-3-deoxythymidine (AMT) and its glucuronide derivative (GAMT). Intracellularly, in both virus-infected and uninfected cells, zidovudine is converted to zidovudine monophosphate by cellular thymidine kinase; the monophosphate derivative is phosphorylated to zidovudine diphosphate via cellular dTMP kinase (thymidylate kinase) and then to zidovudine triphosphate via other cellular enzymes. Intracellular (host cell) conversion of zidovudine to the triphosphate derivative is necessary for the antiviral activity of the drug. Activation for antibacterial action, however, does not depend on phosphorylation within host cells but rather depends on conversion within bacterial cells.', 'The mechanisms of intestinal mucosal transport and metabolism of zidovudine and other thymidine analogs were studied. No zidovudine metabolites appeared in any part of the gastrointestinal tract. Other thymidine analogs were rapidly metabolized in the upper gastrointestinal tract, but not in the colon.']","['Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)', 'The plasma half-life of zidovudine in adults averages approximately 0.53 hours following oral or IV administration. Following IV administration of zidovudine in adults or children, plasma concentrations of the drug appear to decline in a biphasic manner. Half-life in adults is less than 10 minutes in the initial phase and 1 hour in the terminal phase.  Following IV administration over 1 hour of a single 80-, 120-, or 160-mg/sq m , dose in children 1-13 years of age with symptomatic HIV infection, the alpha half-life of zidovudine averaged 0.16-0.25 hours and the beta half-life averaged 1-1.7 hours. Plasma half-life of zidovudine generally is longer in neonates than in older children and adults but decreases with neonatal maturity. In one limited study in neonates and infants younger than 3 months of age, plasma half-life of zidovudine averaged 3.1 hours in those 14 days of age or younger and 1.9 hours in those older than 14 days of age. In a study in premature neonates (26-32 weeks gestation; birthweight 0.7-1.9 kg), the serum half-life of zidovudine averaged 7.3 hours at an average postnatal age of 6.3 days and averaged 4.4 hours at an average postnatal age of 17.7 days.', 'The value for half-life of zidovudine is 1-2 hr.']"
676,35371,"Benzamide, 5-amino-N-butyl-4-chloro-2-(2-propynyloxy)-",CCCCNC(=O)C1=CC(=C(C=C1OCC#C)Cl)N,,,,,,
677,35372,"Adamantane, 1-(1-piperazinyl)-, dihydrochloride",C1CN(CCN1)C23CC4CC(C2)CC(C4)C3.Cl.Cl,,,,,,
678,35373,1-(1-Adamantyl)piperazine,C1CN(CCN1)C23CC4CC(C2)CC(C4)C3,,,,,,
679,35374,"Carbamodithioic acid, dimethyl-, 3-oxobutyl ester",CC(=O)CCSC(=S)N(C)C,,,,,,
680,35375,Etofenamate,C1=CC=C(C(=C1)C(=O)OCCOCCO)NC2=CC=CC(=C2)C(F)(F)F,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
681,35376,"BUTYRIC ACID, 4-(N-(alpha,alpha,alpha-TRIFLUORO-m-TOLYL)ACETAMIDO)-",CC(=O)N(CCCC(=O)O)C1=CC=CC(=C1)C(F)(F)F,,,,,,
682,35377,"BUTYRIC ACID, 4-(N-(m-CHLOROPHENYL)ACETAMIDO)-",CC(=O)N(CCCC(=O)O)C1=CC(=CC=C1)Cl,,,,,,
683,35378,Clanobutin,COC1=CC=C(C=C1)N(CCCC(=O)O)C(=O)C2=CC=C(C=C2)Cl,,,,,,
684,35379,"BUTYRIC ACID, 4-(p-CHLORO-N-(p-ETHOXYPHENYL)BENZAMIDO)-",CCOC1=CC=C(C=C1)N(CCCC(=O)O)C(=O)C2=CC=C(C=C2)Cl,,,,,,
685,35380,"BUTYRIC ACID, 4-(p-CHLORO-N-(2,4-DIMETHOXYPHENYL)BENZAMIDO)-",COC1=CC(=C(C=C1)N(CCCC(=O)O)C(=O)C2=CC=C(C=C2)Cl)OC,,,,,,
686,35381,"BUTYRIC ACID, 4-(p-CHLORO-N-(3,4-DIMETHOXYPHENYL)BENZAMIDO)-",COC1=C(C=C(C=C1)N(CCCC(=O)O)C(=O)C2=CC=C(C=C2)Cl)OC,,,,,,
687,35382,"BUTYRIC ACID, 4-(o-CHLORO-N-2,6-XYLYLBENZAMIDO)-",CC1=C(C(=CC=C1)C)N(CCCC(=O)O)C(=O)C2=CC=CC=C2Cl,,,,,,
688,35383,"BUTYRIC ACID, 4-(p-CHLORO-N-2,6-XYLYLBENZAMIDO)-",CC1=C(C(=CC=C1)C)N(CCCC(=O)O)C(=O)C2=CC=C(C=C2)Cl,,,,,,
689,35384,"beta-ALANINE, N-(p-CHLOROBENZOYL)-N-2,6-XYLYL-",CC1=C(C(=CC=C1)C)N(CCC(=O)O)C(=O)C2=CC=C(C=C2)Cl,,,,,,
690,35385,Tetrahydroanthracene,C1CCC2=CC3=CC=CC=C3C=C2C1.C1CC2=CC3=C(CCC=C3)C=C2C=C1,,,,,,
691,35386,"1,2,3,4-Tetrahydroanthracene",C1CCC2=CC3=CC=CC=C3C=C2C1,,,,,,
692,35387,"1,2,5,6-Tetrahydroanthracene",C1CC2=CC3=C(CCC=C3)C=C2C=C1,,,,,,
693,35388,"Acridine, 9-(4-quinolylmethyl)-",C1=CC=C2C(=C1)C(=CC=N2)CC3=C4C=CC=CC4=NC5=CC=CC=C53,,,,,,
694,35389,"Acetamide, N-(4-(2-oxo-2-phenylethyl)phenyl)-",CC(=O)NC1=CC=C(C=C1)CC(=O)C2=CC=CC=C2,,,,,,
695,35390,"Butyramide, 2-ethyl-2-phenyl-",CCC(CC)(C1=CC=CC=C1)C(=O)N,,,,,,
696,35391,"N,N-Dimethyl-4-{2-[(5-nitrofuran-2-yl)methyl]hydrazinyl}-6-(trichloromethyl)-1,3,5-triazin-2-amine",CN(C)C1=NC(=NC(=N1)NNCC2=CC=C(O2)[N+](=O)[O-])C(Cl)(Cl)Cl,,,,,,
697,35392,4-(Dichloromethyl)-6-methyl-s-triazine-2-amine,CC1=NC(=NC(=N1)N)C(Cl)Cl,,,,,,
698,35393,"N-hexyl-4-methylsulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",CCCCCCNC1=NC(=NC(=N1)C(Cl)(Cl)Cl)SC,,,,,,
699,35394,"4-(2,4-Dichlorophenyl)sulfanyl-6-(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=C(C=C1Cl)Cl)SC2=NC(=NC(=N2)N)C(Cl)(Cl)Cl,,,,,,
700,35395,"4,6-Diethoxy-1,3,5-triazin-2-amine",CCOC1=NC(=NC(=N1)N)OCC,,,,,,
701,35396,CID 35396,CC1=C(C(=C(C=C1)Cl)Cl)Cl.CC1=CC(=C(C(=C1)Cl)Cl)Cl.CC1=C(C=CC(=C1Cl)Cl)Cl,,,,,,
702,35397,"1,2,3-Trichloro-5-methylbenzene",CC1=CC(=C(C(=C1)Cl)Cl)Cl,,,,,,
703,35398,"Benzoic acid, dimethyl-",CC1=CC(=C(C=C1)C(=O)O)C.CC1=C(C(=CC=C1)C(=O)O)C.CC1=CC(=CC(=C1)C(=O)O)C,,,,,,
704,35399,"Diethyl 3,4-furandicarboxylate",CCOC(=O)C1=COC=C1C(=O)OCC,,,,,,
705,35400,"ACETIC ACID, BIS(p-CHLOROPHENOXY)-, CYCLOHEXYL ESTER",C1CCC(CC1)OC(=O)C(OC2=CC=C(C=C2)Cl)OC3=CC=C(C=C3)Cl,,,,,,
706,35401,Trimethyl-1H-indole,CC1=C2C(=CNC2=C(C=C1)C)C.CC1=CC(=C2C=CNC2=C1C)C,,,,,,
707,35402,"3,4,7-trimethyl-1H-indole",CC1=C2C(=CNC2=C(C=C1)C)C,,,,,,
708,35403,"4,6,7-trimethyl-1H-indole",CC1=CC(=C2C=CNC2=C1C)C,,,,,,
709,35404,"Butyramide, N-(1-adamantyl)-4-(dimethylamino)-",CN(C)CCCC(=O)NC12CC3CC(C1)CC(C3)C2,,,,,,
710,35405,"O,P'-Methoxychlor",COC1=CC=C(C=C1)C(C2=CC=CC=C2OC)C(Cl)(Cl)Cl,,,,,,
711,35406,"Carbamodithioic acid, dimethyl-, 3-oxo-3-phenylpropyl ester",CN(C)C(=S)SCCC(=O)C1=CC=CC=C1,,,,,,
712,35407,"Acridine, 9-(2-quinolylmethyl)-",C1=CC=C2C(=C1)C=CC(=N2)CC3=C4C=CC=CC4=NC5=CC=CC=C53,,,,,,
713,35408,Butyl decanoate,CCCCCCCCCC(=O)OCCCC,,,,,,
714,35409,2-Isocyanatoethyl methacrylate,CC(=C)C(=O)OCCN=C=O,,,,,,
715,35410,CID 35410,CCC1CCCC(C1)C.CCC1CCCCC1C.CCC1(CCCCC1)C,,,,,,
716,35411,1-Ethyl-1-methylcyclohexane,CCC1(CCCCC1)C,,,,,,
717,35412,1-Ethyl-3-methylcyclohexane,CCC1CCCC(C1)C,,,,,,
718,35413,1-Ethyl-2-methylcyclohexane,CCC1CCCCC1C,,,,,,
719,35414,Naphthalene-1-carbaldehyde;naphthalene-2-carbaldehyde,C1=CC=C2C=C(C=CC2=C1)C=O.C1=CC=C2C(=C1)C=CC=C2C=O,,,,,,
720,35415,"Propylamine, 3-phenyl-, hydrochloride",C1=CC=C(C=C1)CCC[NH3+].[Cl-],,,,,,
721,35416,"Propylamine, N-methyl-3-phenyl-, hydrochloride",C[NH2+]CCCC1=CC=CC=C1.[Cl-],,,,,,
722,35417,N-methyl-3-phenylpropan-1-amine,CNCCCC1=CC=CC=C1,,,,,,
723,35418,"3-[(3S,5R,8R,9S,10S,12R,13S,14S)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)OC,,,,,,
724,35419,N-(2-chloroethyl)-3-phenylprop-2-enamide,C1=CC=C(C=C1)C=CC(=O)NCCCl,,,,,,
725,35420,3-(4-chlorophenyl)-N-(2-hydroxyethyl)prop-2-enamide,C1=CC(=CC=C1C=CC(=O)NCCO)Cl,,,,,,
726,35421,N-(2-chloroethyl)-3-(4-chlorophenyl)prop-2-enamide,C1=CC(=CC=C1C=CC(=O)NCCCl)Cl,,,,,,
727,35422,"2-Propenamide,n-(2-hydroxyethyl)-3-(4-methoxyphenyl)-",COC1=CC=C(C=C1)C=CC(=O)NCCO,,,,,,
728,35423,CID 35423,COC1=CC=C(C=C1)C=CC(=O)NCCCl,,,,,,
729,35424,"N-(2-Hydroxy-1,1-dimethylethyl)-3-phenyl-2-propenamide",CC(C)(CO)NC(=O)C=CC1=CC=CC=C1,,,,,,
730,35425,2-(3-phenylprop-2-enoylamino)ethyl N-ethylcarbamate,CCNC(=O)OCCNC(=O)C=CC1=CC=CC=C1,,,,,,
731,35426,2-(3-phenylprop-2-enoylamino)ethyl N-phenylcarbamate,C1=CC=C(C=C1)C=CC(=O)NCCOC(=O)NC2=CC=CC=C2,,,,,,
732,35427,"N-(2-hydroxyethyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enamide",COC1=CC(=CC(=C1OC)OC)C=CC(=O)NCCO,,,,,,
733,35428,2-(3-Phenylprop-2-enoylamino)ethyl carbamate,C1=CC=C(C=C1)C=CC(=O)NCCOC(=O)N,,,,,,
734,35429,N-(3-hydroxypropyl)-3-phenylprop-2-enamide,C1=CC=C(C=C1)C=CC(=O)NCCCO,,,,,,
735,35430,N-(2-hydroxypropyl)-3-phenylprop-2-enamide,CC(CNC(=O)C=CC1=CC=CC=C1)O,,,,,,
736,35431,"N-(1,3-dihydroxy-2-methylpropan-2-yl)-3-phenylprop-2-enamide",CC(CO)(CO)NC(=O)C=CC1=CC=CC=C1,,,,,,
737,35432,N-(2-hydroxyethyl)-N-methyl-3-phenylprop-2-enamide,CN(CCO)C(=O)C=CC1=CC=CC=C1,,,,,,
738,35433,"N,N-Bis(2-hydroxyethyl)-3-phenyl-2-propenamide",C1=CC=C(C=C1)C=CC(=O)N(CCO)CCO,,,,,,
739,35434,N-(2-Hydroxy-1-methylethyl)-3-phenylpropenamide,CC(CO)NC(=O)C=CC1=CC=CC=C1,,,,,,
740,35435,"N-(1,3-dihydroxypropan-2-yl)-3-phenylprop-2-enamide",C1=CC=C(C=C1)C=CC(=O)NC(CO)CO,,,,,,
741,35436,"N,N-Bis(2-hydroxyethyl)-3-(4-methoxyphenyl)propenamide",COC1=CC=C(C=C1)C=CC(=O)N(CCO)CCO,,,,,,
742,35437,"3-(4-chlorophenyl)-N,N-bis(2-hydroxyethyl)prop-2-enamide",C1=CC(=CC=C1C=CC(=O)N(CCO)CCO)Cl,,,,,,
743,35438,"3-(3,4-dimethoxyphenyl)-N-(2-hydroxyethyl)prop-2-enamide",COC1=C(C=C(C=C1)C=CC(=O)NCCO)OC,,,,,,
744,35439,CID 35439,CCNC(=O)OCCN(CCOC(=O)NCC)C(=O)C=CC1=CC=CC=C1,,,,,,
745,35440,CID 35440,CC(CNC(=O)C=CC1=CC=C(C=C1)Cl)O,,,,,,
746,35441,"N-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]-3-phenylprop-2-enamide",C1=CC=C(C=C1)C=CC(=O)NC(CO)(CO)CO,,,,,,
747,35442,3-(4-chlorophenyl)-N-(2-hydroxyethyl)-N-methylprop-2-enamide,CN(CCO)C(=O)C=CC1=CC=C(C=C1)Cl,,,,,,
748,35443,"N-(2,3-dihydroxypropyl)-3-phenylprop-2-enamide",C1=CC=C(C=C1)C=CC(=O)NCC(CO)O,,,,,,
749,35444,"N-(2-hydroxyethyl)-N,3-diphenylprop-2-enamide",C1=CC=C(C=C1)C=CC(=O)N(CCO)C2=CC=CC=C2,,,,,,
750,35445,CID 35445,CC(=CC1=CC=CC=C1)C(=O)NCCO,,,,,,
751,35446,CID 35446,CC(=CC(=O)NCCO)C1=CC=CC=C1,,,,,,
752,35447,N-(2-hydroxyethyl)-3-(4-methylphenyl)prop-2-enamide,CC1=CC=C(C=C1)C=CC(=O)NCCO,,,,,,
753,35448,N-(2-hydroxyethyl)-3-(2-methylphenyl)prop-2-enamide,CC1=CC=CC=C1C=CC(=O)NCCO,,,,,,
754,35449,"Methyl 6-chloro-3,4-dimethoxybenzoate",COC1=C(C=C(C(=C1)C(=O)OC)Cl)OC,,,,,,
755,35450,Gossypol hexaacetate,CC1=CC2=C(C(=C(C(=C2C(C)C)OC(=O)C)OC(=O)C)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)OC(=O)C)OC(=O)C)C(C)C)OC(=O)C)OC(=O)C,,,,,,
756,35451,"Ether, octyl 1,1,2,2-tetrafluoroethyl",CCCCCCCCOC(C(F)F)(F)F,,,,,,
757,35452,2-[3-(4-Chlorophenyl)prop-2-enoylamino]ethyl carbamate,C1=CC(=CC=C1C=CC(=O)NCCOC(=O)N)Cl,,,,,,
758,35453,"2(3H)-Benzoxazolone, 3-ethyl-",CCN1C2=CC=CC=C2OC1=O,,,,,,
759,35454,"1,2,3,4-Tetrachlorodibenzo-P-dioxin",C1=CC=C2C(=C1)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
760,35455,Feprazone,CC(=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
761,35456,"Cyclobutanecarbonitrile, 2,2-dimethyl-3-methylene-",CC1(C(CC1=C)C#N)C,,,,,,
762,35457,"BENZOIC ACID, p-(((5,7-DIAMINOPYRIDO(3,4-b)PYRAZIN-3-YL)METHYL)METHYLAMINO)-",CN(CC1=NC2=C(N=C(C=C2N=C1)N)N)C3=CC=C(C=C3)C(=O)O,,,,,,
763,35458,"1,1'-(Phenylene)bisethanone",CC(=O)C1=CC=C(C=C1)C(=O)C.CC(=O)C1=CC(=CC=C1)C(=O)C.CC(=O)C1=CC=CC=C1C(=O)C,,,,,,
764,35459,"1,2-Diacetylbenzene",CC(=O)C1=CC=CC=C1C(=O)C,,,,,,
765,35460,Tetradecylbenzenesulfonic acid,CCCCCCCCCCCCCCC1=CC(=CC=C1)S(=O)(=O)O,,,,,,
766,35461,"N,N-Diethyl-3,3-diphenylallylamine hydrochloride",CC[NH+](CC)CC=C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
767,35462,"N,N-diethyl-3,3-diphenylprop-2-en-1-amine",CCN(CC)CC=C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
768,35463,"Phenanthro[4,5-bcd]thiophene",C1=CC2=C3C(=C1)SC4=CC=CC(=C43)C=C2,,,,,,
769,35464,"N,N-Diisopropyl-4-octyloxy-1-naphthamidine hydrochloride",CCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](C(C)C)C(C)C.[Cl-],,,,,,
770,35465,"4-octoxy-N,N-di(propan-2-yl)naphthalene-1-carboximidamide",CCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(C(C)C)C(C)C,,,,,,
771,35466,"N,N-Dibutyl-4-octyloxy-1-naphthamidine hydrochloride",CCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCC)CCCC.[Cl-],,,,,,
772,35467,"N,N-dibutyl-4-octoxynaphthalene-1-carboximidamide",CCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC,,,,,,
773,35468,"N,N-Dipropyl-4-nonyloxy-1-naphthamidine hydrochloride",CCCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCC)CCC.[Cl-],,,,,,
774,35469,"4-nonoxy-N,N-dipropylnaphthalene-1-carboximidamide",CCCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCC)CCC,,,,,,
775,35470,"N,N-Dibutyl-4-nonyloxy-1-naphthamidine hydrochloride",CCCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCC)CCCC.[Cl-],,,,,,
776,35471,"N,N-dibutyl-4-nonoxynaphthalene-1-carboximidamide",CCCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC,,,,,,
777,35472,"N,N-Dibutyl-4-decyloxy-1-naphthamidine hydrochloride",CCCCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCC)CCCC.[Cl-],,,,,,
778,35473,"N,N-dibutyl-4-decoxynaphthalene-1-carboximidamide",CCCCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC,,,,,,
779,35474,"N,N-Dipropyl-4-heptyloxy-1-naphthamidine hydrochloride",CCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCC)CCC.[Cl-],,,,,,
780,35475,"4-heptoxy-N,N-dipropylnaphthalene-1-carboximidamide",CCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCC)CCC,,,,,,
781,35476,"N,N-Dibutyl-4-heptyloxy-1-naphthamidine hydrochloride",CCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCC)CCCC.[Cl-],,,,,,
782,35477,"N,N-dibutyl-4-heptoxynaphthalene-1-carboximidamide",CCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC,,,,,,
783,35478,"N,N-Diheptyl-4-heptyloxy-1-naphthamidine hydrochloride",CCCCCCC[NH+](CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCCCC.[Cl-],,,,,,
784,35479,"4-heptoxy-N,N-diheptylnaphthalene-1-carboximidamide",CCCCCCCN(CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCCCC,,,,,,
785,35480,"N,N-Dioctyl-4-heptyloxy-1-naphthamidine hydrochloride",CCCCCCCC[NH+](CCCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCCCC.[Cl-],,,,,,
786,35481,"4-heptoxy-N,N-dioctylnaphthalene-1-carboximidamide",CCCCCCCCN(CCCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCCCC,,,,,,
787,35482,CID 35482,CCCC(=CCO)C,,,,,,
788,35483,"1,1-Dimethyl-3-[4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]urea",CC1=NC(=NC(=N1)NC(=O)N(C)C)C(Cl)(Cl)Cl,,,,,,
789,35484,1-Phenyl-3-[4-methyl-6-(trichloromethyl)-s-triazine-2-yl]urea,CC1=NC(=NC(=N1)NC(=O)NC2=CC=CC=C2)C(Cl)(Cl)Cl,,,,,,
790,35485,1-(o-Chlorophenyl)-3-[4-methyl-6-(trichloromethyl)-s-triazine-2-yl]urea,CC1=NC(=NC(=N1)NC(=O)NC2=CC=CC=C2Cl)C(Cl)(Cl)Cl,,,,,,
791,35486,"1-(3-Chlorophenyl)-3-[4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]urea",CC1=NC(=NC(=N1)NC(=O)NC2=CC(=CC=C2)Cl)C(Cl)(Cl)Cl,,,,,,
792,35487,"1-(4-Chlorophenyl)-3-[4-methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]urea",CC1=NC(=NC(=N1)NC(=O)NC2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl,,,,,,
793,35488,"1-(2,4-Dichlorophenyl)-3-[4-methyl-6-(trichloromethyl)-s-triazine-2-yl]urea",CC1=NC(=NC(=N1)NC(=O)NC2=C(C=C(C=C2)Cl)Cl)C(Cl)(Cl)Cl,,,,,,
794,35489,1-p-Tolyl-3-[4-methyl-6-(trichloromethyl)-s-triazine-2-yl]urea,CC1=CC=C(C=C1)NC(=O)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C,,,,,,
795,35490,1-(m-Nitrophenyl)-3-[4-methyl-6-(trichloromethyl)-s-triazine-2-yl]urea,CC1=NC(=NC(=N1)NC(=O)NC2=CC(=CC=C2)[N+](=O)[O-])C(Cl)(Cl)Cl,,,,,,
796,35491,"1,1-Dimethyl-3-[4,6-bis(trichloromethyl)-s-triazine-2-yl]urea",CN(C)C(=O)NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
797,35492,"1-Phenyl-3-[4,6-bis(trichloromethyl)-s-triazine-2-yl]urea",C1=CC=C(C=C1)NC(=O)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
798,35493,"1,1'-(6-Methyl-s-triazine-2,4-diyl)bis(3-phenylurea)",CC1=NC(=NC(=N1)NC(=O)NC2=CC=CC=C2)NC(=O)NC3=CC=CC=C3,,,,,,
799,35494,"1,1'-[6-(Trichloromethyl)-s-triazine-2,4-diyl]bis(3-phenylurea)",C1=CC=C(C=C1)NC(=O)NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)NC(=O)NC3=CC=CC=C3,,,,,,
800,35495,"1-[4-Ethyl-6-(phenylcarbamoylamino)-1,3,5-triazin-2-yl]-3-phenylurea",CCC1=NC(=NC(=N1)NC(=O)NC2=CC=CC=C2)NC(=O)NC3=CC=CC=C3,,,,,,
801,35496,"1,1'-(6-Phenyl-s-triazine-2,4-diyl)bis(3-phenylurea)",C1=CC=C(C=C1)C2=NC(=NC(=N2)NC(=O)NC3=CC=CC=C3)NC(=O)NC4=CC=CC=C4,,,,,,
802,35497,"1-[4,6-Bis(phenylcarbamoylamino)-1,3,5-triazin-2-yl]-3-phenylurea",C1=CC=C(C=C1)NC(=O)NC2=NC(=NC(=N2)NC(=O)NC3=CC=CC=C3)NC(=O)NC4=CC=CC=C4,,,,,,
803,35498,"2-Azido-4,6-dichloro-S-triazine",C1(=NC(=NC(=N1)Cl)Cl)N=[N+]=[N-],,,,,,
804,35499,"2-Azido-4,6-dimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)N=[N+]=[N-])OC,,,,,,
805,35500,"2-Azido-4,6-dimethyl-S-triazine",CC1=NC(=NC(=N1)N=[N+]=[N-])C,,,,,,
806,35501,"2-Azido-4,6-bis(trichloromethyl)-S-triazine",C1(=NC(=NC(=N1)N=[N+]=[N-])C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
807,35502,"1-Hydroxy-6-imino-4-(trichloromethyl)-1,3,5-triazin-2-amine",C1(=NC(=N)N(C(=N1)N)O)C(Cl)(Cl)Cl,,,,,,
808,35503,"1-Hydroxy-6-methyl-4-(trichloromethyl)-1,3,5-triazin-2-imine",CC1=NC(=NC(=N)N1O)C(Cl)(Cl)Cl,,,,,,
809,35504,"1,3,5-Tris(P-chlorophenyl)hexahydro-S-triazine",C1N(CN(CN1C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl,,,,,,
810,35505,"1,3,5-Tris(trichloroacetyl)hexahydro-s-triazine",C1N(CN(CN1C(=O)C(Cl)(Cl)Cl)C(=O)C(Cl)(Cl)Cl)C(=O)C(Cl)(Cl)Cl,,,,,,
811,35506,"Hexahydro-1,3,5-tripropionyl-S-triazine",CCC(=O)N1CN(CN(C1)C(=O)CC)C(=O)CC,,,,,,
812,35507,"1,3,5-Tris(2,2,3-trichloropropanoyl)hexahydro-s-triazine",C1N(CN(CN1C(=O)C(CCl)(Cl)Cl)C(=O)C(CCl)(Cl)Cl)C(=O)C(CCl)(Cl)Cl,,,,,,
813,35508,"1,3,5-Tris(trichloromethyl)-1,3,5-triazinane",C1N(CN(CN1C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
814,35509,"1,2-Dihydro-2,2,4,6-tetraphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(N=C(N2)C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
815,35510,"1-(4-Chloro-phenyl)-6-methyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine",CC1N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N,,,,,,
816,35511,"1-(4-chlorophenyl)-2-propan-2-yl-2H-1,3,5-triazine-4,6-diamine",CC(C)C1N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N,,,,,,
817,35512,"1-(3,4-Dichlorophenyl)-1,6-dihydro-6-isopropyl-s-triazine-2,4-diamine",CC(C)C1N=C(N=C(N1C2=CC(=C(C=C2)Cl)Cl)N)N,,,,,,
818,35513,"6,6-Dimethyl-1-(3-nitrophenyl)-1,3,5-triazine-2,4-diamine",CC1(N=C(N=C(N1C2=CC(=CC=C2)[N+](=O)[O-])N)N)C,,,,,,
819,35514,"1-Ethyl-S-triazine-2,4,6(1H,3H,5H)-trione",CCN1C(=O)NC(=O)NC1=O,,,,,,
820,35515,Benzylidenebiuret,C1=CC=C(C=C1)C2NC(=O)NC(=O)N2,,,,,,
821,35516,"4-amino-2-phenyl-2,5-dihydro-1H-1,3,5-triazin-6-one",C1=CC=C(C=C1)C2NC(=O)NC(=N2)N,,,,,,
822,35517,CID 35517,C1=CC=C(C=C1)C2N=C(NC(=N2)S)S,,,,,,
823,35518,"4,6-Dimethyl-1,3,5-triazinan-2-one",CC1NC(NC(=O)N1)C,,,,,,
824,35519,"3,4,5,6-Tetrahydro-4,6-dimethyl-s-triazine-2(1H)-imine",CC1NC(N=C(N1)N)C,,,,,,
825,35520,"3,4,5,6-Tetrahydro-4,6-bis(trichloromethyl)-s-triazine-2(1H)-one",C1(NC(NC(=O)N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
826,35521,CID 35521,C1(NC(N=C(N1)S)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
827,35522,"Tetrahydro-4,6-diisopropyl-S-triazin-2(1H)-one",CC(C)C1NC(NC(=O)N1)C(C)C,,,,,,
828,35523,"[(7R,8S)-11-(dimethylamino)-7-hydroxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)O)N4C)N(C)C,,,,,,
829,35524,Selinan,CC1CCCC2(C1CC(CC2)C(C)C)C,,,,,,
830,35525,"1,3-Bis(prop-1-enyl)imidazolidin-2-one",CC=CN1CCN(C1=O)C=CC,,,,,,
831,35526,"1,3-Diethyl-2-imidazolidinethione",CCN1CCN(C1=S)CC,,,,,,
832,35527,"2-Imidazolidinethione, 1,3-dibutyl-",CCCCN1CCN(C1=S)CCCC,,,,,,
833,35528,"3-Benzothiazolinecarboxylic acid, ethyl ester",CCOC(=O)N1CSC2=CC=CC=C21,,,,,,
834,35529,"2-Methoxy-3-benzoxazolecarboxylic acid, ethyl ester",CCOC(=O)N1C(OC2=CC=CC=C21)OC,,,,,,
835,35530,"4-Butoxy-N,N-dioctyl-1-naphthamidine, hydrochloride",CCCCCCCC[NH+](CCCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC.[Cl-],,,,,,
836,35531,"4-butoxy-N,N-dioctylnaphthalene-1-carboximidamide",CCCCCCCCN(CCCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC,,,,,,
837,35532,"N,N-Diheptyl-4-ethoxy-1-naphthamidine hydrochloride",CCCCCCC[NH+](CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC.[Cl-],,,,,,
838,35533,"4-ethoxy-N,N-diheptylnaphthalene-1-carboximidamide",CCCCCCCN(CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC,,,,,,
839,35534,"N,N-Diheptyl-4-propoxy-1-naphthamidine hydrochloride",CCCCCCC[NH+](CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCC.[Cl-],,,,,,
840,35535,"N,N-diheptyl-4-propoxynaphthalene-1-carboximidamide",CCCCCCCN(CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCC,,,,,,
841,35536,"2,4-Bis(1,1-dichloroethyl)-6-(methylthio)-s-triazine",CC(C1=NC(=NC(=N1)SC)C(C)(Cl)Cl)(Cl)Cl,,,,,,
842,35537,"2,4-Bis(1,1,2-trichloroethyl)-6-(phenylthio)-s-triazine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)C(CCl)(Cl)Cl)C(CCl)(Cl)Cl,,,,,,
843,35538,"2,4-Bis(pentachloroethyl)-6-(methylthio)-s-triazine",CSC1=NC(=NC(=N1)C(C(Cl)(Cl)Cl)(Cl)Cl)C(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
844,35539,"2,4-Diphenyl-6-(phenylthio)-S-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)SC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
845,35540,"[4-chloro-6-(dimethylcarbamothioylsulfanyl)-1,3,5-triazin-2-yl] N,N-dimethylcarbamodithioate",CN(C)C(=S)SC1=NC(=NC(=N1)Cl)SC(=S)N(C)C,,,,,,
846,35541,"[4-chloro-6-(diethylcarbamothioylsulfanyl)-1,3,5-triazin-2-yl] N,N-diethylcarbamodithioate",CCN(CC)C(=S)SC1=NC(=NC(=N1)Cl)SC(=S)N(CC)CC,,,,,,
847,35542,CID 35542,CC(C)N=C(S)SC1=NC(=NC(=N1)Cl)SC(=NC(C)C)S,,,,,,
848,35543,CID 35543,C1=CC=C(C=C1)N=C(S)SC2=NC(=NC(=N2)Cl)SC(=NC3=CC=CC=C3)S,,,,,,
849,35544,CID 35544,C1=CC(=CC=C1N=C(S)SC2=NC(=NC(=N2)Cl)SC(=NC3=CC=C(C=C3)Cl)S)Cl,,,,,,
850,35545,"Bis(dimethyldithiocarbamic acid)6-(dimethylamino)-s-triazine-2,4-diyl ester",CN(C)C1=NC(=NC(=N1)SC(=S)N(C)C)SC(=S)N(C)C,,,,,,
851,35546,"[4-(diethylamino)-6-(diethylcarbamothioylsulfanyl)-1,3,5-triazin-2-yl] N,N-diethylcarbamodithioate",CCN(CC)C1=NC(=NC(=N1)SC(=S)N(CC)CC)SC(=S)N(CC)CC,,,,,,
852,35547,"Tris(diethyldithiocarbamic acid)s-triazine-2,4,6-triyl ester",CCN(CC)C(=S)SC1=NC(=NC(=N1)SC(=S)N(CC)CC)SC(=S)N(CC)CC,,,,,,
853,35548,"Phosphorodithioic acid S-(4,6-dimethoxy-s-triazine-2-yl)O,O-diethyl ester",CCOP(=S)(OCC)SC1=NC(=NC(=N1)OC)OC,,,,,,
854,35549,"(4,6-Dimethyl-1,3,5-triazin-2-yl)sulfanyl-diethoxy-sulfanylidene-lambda5-phosphane",CCOP(=S)(OCC)SC1=NC(=NC(=N1)C)C,,,,,,
855,35550,"1-[4-Methyl-6-(trichloromethyl)-s-triazine-2-ylamino]-2,2,2-trichloroethanol",CC1=NC(=NC(=N1)NC(C(Cl)(Cl)Cl)O)C(Cl)(Cl)Cl,,,,,,
856,35551,"1,1'-(6-Methyl-s-triazine-2,4-diyldiimino)bis(2,2,2-trichloroethanol)",CC1=NC(=NC(=N1)NC(C(Cl)(Cl)Cl)O)NC(C(Cl)(Cl)Cl)O,,,,,,
857,35552,"1,1'-[6-(Trichloromethyl)-s-triazine-2,4-diyldiimino]bis(2,2,2-trichloroethanol)",C1(=NC(=NC(=N1)NC(C(Cl)(Cl)Cl)O)NC(C(Cl)(Cl)Cl)O)C(Cl)(Cl)Cl,,,,,,
858,35553,"Tris(2-methylpropyl) 1,3,5-triazine-2,4,6-tricarboxylate",CC(C)COC(=O)C1=NC(=NC(=N1)C(=O)OCC(C)C)C(=O)OCC(C)C,,,,,,
859,35554,"N,N',N''-Trimethyl-s-triazine-2,4,6-tricarboxamide",CNC(=O)C1=NC(=NC(=N1)C(=O)NC)C(=O)NC,,,,,,
860,35555,"Diethyl 6-(trichloromethyl)-1,3,5-triazine-2,4-dicarboxylate",CCOC(=O)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(=O)OCC,,,,,,
861,35556,"Ethyl 4,6-bis(trichloromethyl)-1,3,5-triazine-2-carboxylate",CCOC(=O)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
862,35557,"(4,6-Dithiocyanato-1,3,5-triazin-2-yl) thiocyanate",C(#N)SC1=NC(=NC(=N1)SC#N)SC#N,,,,,,
863,35558,"2-Isothiocyanato-4,6-bis(trichloromethyl)-1,3,5-triazine",C(=NC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)=S,,,,,,
864,35559,CID 35559,CC(C)OC(=NC1=NC(=NC(=N1)Cl)Cl)S,,,,,,
865,35560,CID 35560,CC1=NC(=NC(=N1)N=C(NC2=CC=CC=C2)S)C(Cl)(Cl)Cl,,,,,,
866,35561,"1,1-dichloro-N-[4-chloro-6-(dichloromethylideneamino)-1,3,5-triazin-2-yl]methanimine",C1(=NC(=NC(=N1)Cl)N=C(Cl)Cl)N=C(Cl)Cl,,,,,,
867,35562,"1-[4-Methyl-6-(trichloromethyl)-1,3,5-triazin-2-yl]-3-propan-2-ylurea",CC1=NC(=NC(=N1)NC(=O)NC(C)C)C(Cl)(Cl)Cl,,,,,,
868,35563,"Trimethyl 1,3,5-triazine-2,4,6-tricarboxylate",COC(=O)C1=NC(=NC(=N1)C(=O)OC)C(=O)OC,,,,,,
869,35564,"Phosphorodithioic acid S-(4,6-diamino-s-triazine-2-yl)O,O-diethyl ester",CCOP(=S)(OCC)SC1=NC(=NC(=N1)N)N,,,,,,
870,35565,"2,4,6-Tris(ethylthio)-S-triazine",CCSC1=NC(=NC(=N1)SCC)SCC,,,,,,
871,35566,"2,4,6-Tris(allylthio)-S-triazine",C=CCSC1=NC(=NC(=N1)SCC=C)SCC=C,,,,,,
872,35567,"2-(Chloromethyl)-4,6-dimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)CCl)OC,,,,,,
873,35568,"2,4-Diethoxy-6-(trichloromethyl)-1,3,5-triazine",CCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)OCC,,,,,,
874,35569,"2,4-Di(propan-2-yloxy)-6-(trichloromethyl)-1,3,5-triazine",CC(C)OC1=NC(=NC(=N1)C(Cl)(Cl)Cl)OC(C)C,,,,,,
875,35570,"2-(Trichloromethyl)-4,6-dibutoxy-s-triazine",CCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)OCCCC,,,,,,
876,35571,"2-(Bromomethyl)-4,6-dimethoxy-S-triazine",COC1=NC(=NC(=N1)CBr)OC,,,,,,
877,35572,"2-(Dibromomethyl)-4,6-dimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)C(Br)Br)OC,,,,,,
878,35573,"2-Methoxy-4-methyl-6-(trichloromethyl)-1,3,5-triazine",CC1=NC(=NC(=N1)OC)C(Cl)(Cl)Cl,,,,,,
879,35574,"2-Ethoxy-4-methyl-6-(trichloromethyl)-1,3,5-triazine",CCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
880,35575,2-(Trichloromethyl)-4-isopropoxy-6-methyl-s-triazine,CC1=NC(=NC(=N1)OC(C)C)C(Cl)(Cl)Cl,,,,,,
881,35576,2-(Trichloromethyl)-4-butoxy-6-methyl-s-triazine,CCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
882,35577,"2-Hexoxy-4-methyl-6-(trichloromethyl)-1,3,5-triazine",CCCCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C,,,,,,
883,35578,"2-Methoxy-4,6-bis(trichloromethyl)-S-triazine",COC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
884,35579,"2-Ethoxy-4,6-bis(trichloromethyl)-1,3,5-triazine",CCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
885,35580,"2-Propoxy-4,6-bis(trichloromethyl)-S-triazine",CCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
886,35581,"2-(Allyloxy)-4,6-bis(trichloromethyl)-S-triazine",C=CCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
887,35582,"2-Isopropoxy-4,6-bis(trichloromethyl)-S-triazine",CC(C)OC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
888,35583,"2-Butoxy-4,6-bis(trichloromethyl)-S-triazine",CCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
889,35584,"2-(Pentyloxy)-4,6-bis(trichloromethyl)-s-triazine",CCCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
890,35585,"2-Hexoxy-4,6-bis(trichloromethyl)-1,3,5-triazine",CCCCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
891,35586,"2-(Dodecyloxy)-4,6-bis(trichloromethyl)-s-triazine",CCCCCCCCCCCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
892,35587,2-(Trichloromethyl)-4-methoxy-6-phenyl-s-triazine,COC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C2=CC=CC=C2,,,,,,
893,35588,2-(Trichloromethyl)-4-ethoxy-6-phenyl-s-triazine,CCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C2=CC=CC=C2,,,,,,
894,35589,2-(Trichloromethyl)-4-methoxy-6-(p-chlorophenyl)-s-triazine,COC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C2=CC=C(C=C2)Cl,,,,,,
895,35590,"2-Methoxy-4,6-bis(tribromomethyl)-S-triazine",COC1=NC(=NC(=N1)C(Br)(Br)Br)C(Br)(Br)Br,,,,,,
896,35591,"2-(Diazomethyl)-4,6-bis(methylthio)-S-triazine",CSC1=NC(=NC(=N1)C=[N+]=[N-])SC,,,,,,
897,35592,"2,4,6-Tris(phenylsulfanyl)-1,3,5-triazine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)SC3=CC=CC=C3)SC4=CC=CC=C4,,,,,,
898,35593,"2,4-Dipropoxy-6-(trichloromethyl)-1,3,5-triazine",CCCOC1=NC(=NC(=N1)C(Cl)(Cl)Cl)OCCC,,,,,,
899,35594,CID 35594,CC(=C(C)N=O)NO.[Na+],,,,,,
900,35595,CID 35595,C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=C(C(=NN2)C(=O)N)O)O)O)O,,,,,,
901,35596,"6-Methoxy-s-triazine-2,4(1H,3H)-dione",COC1=NC(=O)NC(=O)N1,,,,,,
902,35597,"6-Isopropyl-S-triazine-2,4-diol",CC(C)C1=NC(=O)NC(=O)N1,,,,,,
903,35598,"6-(P-Chlorophenyl)-S-triazine-2,4-diol",C1=CC(=CC=C1C2=NC(=O)NC(=O)N2)Cl,,,,,,
904,35599,CID 35599,CC1=NC(=O)N=C(N1)C,,,,,,
905,35600,CID 35600,C(C1=NC(=O)N=C(N1)CCl)Cl.C(C(=N)N)Cl,,,,,,
906,35601,CID 35601,C(C1=NC(=O)N=C(N1)CCl)Cl,,,,,,
907,35602,2-Chloroacetimidamide,C(C(=N)N)Cl,,,,,,
908,35603,CID 35603,C1(=NC(=O)N=C(N1)C(Cl)Cl)C(Cl)Cl.C(C(=N)N)(Cl)Cl,,,,,,
909,35604,CID 35604,C1(=NC(=O)N=C(N1)C(Cl)Cl)C(Cl)Cl,,,,,,
910,35605,"2,2-Dichloroethanimidamide",C(C(=N)N)(Cl)Cl,,,,,,
911,35606,CID 35606,C1(=NC(=O)N=C(N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl.C(=N)(C(Cl)(Cl)Cl)N,,,,,,
912,35607,CID 35607,C1(=NC(=O)N=C(N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
913,35608,"2,2,2-Trichloroethanimidamide",C(=N)(C(Cl)(Cl)Cl)N,,,,,,
914,35609,CID 35609,CCN(CC)CC.C1(=NC(=O)N=C(N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
915,35610,CID 35610,CC(C1=NC(=O)N=C(N1)C(C)(Cl)Cl)(Cl)Cl.CC(C(=N)N)(Cl)Cl,,,,,,
916,35611,CID 35611,CC(C1=NC(=O)N=C(N1)C(C)(Cl)Cl)(Cl)Cl,,,,,,
917,35612,"2,2-Dichloropropanimidamide",CC(C(=N)N)(Cl)Cl,,,,,,
918,35613,CID 35613,C(C(C1=NC(=O)N=C(N1)C(CCl)(Cl)Cl)(Cl)Cl)Cl.C(C(C(=N)N)(Cl)Cl)Cl,,,,,,
919,35614,CID 35614,C(C(C1=NC(=O)N=C(N1)C(CCl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
920,35615,"2,2,3-Trichloropropanimidamide",C(C(C(=N)N)(Cl)Cl)Cl,,,,,,
921,35616,CID 35616,C1=CC(=CC=C1C2=NC(=O)N=C(N2)C3=CC=C(C=C3)Cl)Cl,,,,,,
922,35617,CID 35617,CC1=CC=C(C=C1)C2=NC(=O)N=C(N2)C3=CC=C(C=C3)C,,,,,,
923,35618,CID 35618,C1=CC(=CC(=C1)[N+](=O)[O-])C2=NC(=O)N=C(N2)C3=CC(=CC=C3)[N+](=O)[O-],,,,,,
924,35619,CID 35619,C1=CC=C(C=C1)C2=NC(=NC(=N2)S)S,,,,,,
925,35620,CID 35620,COC1=NC(=NC(=N1)S)OC,,,,,,
926,35621,CID 35621,CC1=NC(=NC(=N1)S)C,,,,,,
927,35622,CID 35622,C1=CC=C(C=C1)C2=NC(=NC(=N2)S)C3=CC=CC=C3,,,,,,
928,35623,CID 35623,CC1=CC=C(C=C1)C2=NC(=NC(=N2)S)C3=CC=C(C=C3)C,,,,,,
929,35624,"2,4-Difluoro-6-phenoxy-1,3,5-triazine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)F)F,,,,,,
930,35625,"2,4-Dichloro-6-isobutoxy-S-triazine",CC(C)COC1=NC(=NC(=N1)Cl)Cl,,,,,,
931,35626,"2-Benzyloxy-4,6-dichloro-[1,3,5]triazine",C1=CC=C(C=C1)COC2=NC(=NC(=N2)Cl)Cl,,,,,,
932,35627,"2,4-Dichloro-6-(2-chlorophenoxy)-1,3,5-triazine",C1=CC=C(C(=C1)OC2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
933,35628,"2,4-Dichloro-6-(4-chlorophenoxy)-1,3,5-triazine",C1=CC(=CC=C1OC2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
934,35629,"2,4-Dichloro-6-(2,4,5-trichlorophenoxy)-1,3,5-triazine",C1=C(C(=CC(=C1Cl)Cl)Cl)OC2=NC(=NC(=N2)Cl)Cl,,,,,,
935,35630,"2,4-Dichloro-6-(4-nitrophenoxy)-1,3,5-triazine",C1=CC(=CC=C1[N+](=O)[O-])OC2=NC(=NC(=N2)Cl)Cl,,,,,,
936,35631,"2,4-Dichloro-6-(1-naphthyloxy)-S-triazine",C1=CC=C2C(=C1)C=CC=C2OC3=NC(=NC(=N3)Cl)Cl,,,,,,
937,35632,Dimethyl(2-hydroxyethyl)propylammonium iodide acetate,CCC[N+](C)(C)CCOC(=O)C.[I-],,,,,,
938,35633,2-Acetyloxyethyl-dimethyl-propylazanium,CCC[N+](C)(C)CCOC(=O)C,,,,,,
939,35634,6-tert-Butyl-4-chloro-m-cresol,CC1=CC(=C(C=C1Cl)C(C)(C)C)O,,,,,,
940,35635,"2,4-Dichloro-6-(propylthio)-S-triazine",CCCSC1=NC(=NC(=N1)Cl)Cl,,,,,,
941,35636,"2,4-Dichloro-6-propan-2-ylsulfanyl-1,3,5-triazine",CC(C)SC1=NC(=NC(=N1)Cl)Cl,,,,,,
942,35637,"s-Triazine, 2-butylthio-4,6-dichloro-",CCCCSC1=NC(=NC(=N1)Cl)Cl,,,,,,
943,35638,"2,4-Dichloro-6-(p-chlorophenylthio)-s-triazine",C1=CC(=CC=C1SC2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
944,35639,"2,4-Dichloro-6-(chloromethyl)-1,3,5-triazine",C(C1=NC(=NC(=N1)Cl)Cl)Cl,,,,,,
945,35640,"2,4-Dichloro-6-(dichloromethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)Cl)C(Cl)Cl,,,,,,
946,35641,"2-(Bromomethyl)-4,6-dichloro-1,3,5-triazine",C(C1=NC(=NC(=N1)Cl)Cl)Br,,,,,,
947,35642,"2,4-Dichloro-6-(dibromomethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)Cl)C(Br)Br,,,,,,
948,35643,"2,4-Dichloro-6-(iodomethyl)-1,3,5-triazine",C(C1=NC(=NC(=N1)Cl)Cl)I,,,,,,
949,35644,"2,4-Dichloro-6-(diiodomethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)Cl)C(I)I,,,,,,
950,35645,"2,4-Dichloro-6-(1,1-dichloroethyl)-S-triazine",CC(C1=NC(=NC(=N1)Cl)Cl)(Cl)Cl,,,,,,
951,35646,"2,4-Dichloro-6-(1,1,2-trichloroethyl)-s-triazine",C(C(C1=NC(=NC(=N1)Cl)Cl)(Cl)Cl)Cl,,,,,,
952,35647,"2,4-Dichloro-6-propyl-1,3,5-triazine",CCCC1=NC(=NC(=N1)Cl)Cl,,,,,,
953,35648,"2,4-Dichloro-6-isopropyl-1,3,5-triazine",CC(C)C1=NC(=NC(=N1)Cl)Cl,,,,,,
954,35649,"2-Chloro-4,6-diethoxy-1,3,5-triazine",CCOC1=NC(=NC(=N1)Cl)OCC,,,,,,
955,35650,"2-Chloro-4,6-diisopropoxy-S-triazine",CC(C)OC1=NC(=NC(=N1)Cl)OC(C)C,,,,,,
956,35651,"2-Chloro-4,6-bis(O-chlorophenoxy)-S-triazine",C1=CC=C(C(=C1)OC2=NC(=NC(=N2)Cl)OC3=CC=CC=C3Cl)Cl,,,,,,
957,35652,"2-Chloro-4,6-bis(4-chlorophenoxy)-1,3,5-triazine",C1=CC(=CC=C1OC2=NC(=NC(=N2)Cl)OC3=CC=C(C=C3)Cl)Cl,,,,,,
958,35653,"2-Chloro-4,6-bis(4-methylphenoxy)-1,3,5-triazine",CC1=CC=C(C=C1)OC2=NC(=NC(=N2)Cl)OC3=CC=C(C=C3)C,,,,,,
959,35654,"2-Chloro-4,6-bis(4-nitrophenoxy)-1,3,5-triazine",C1=CC(=CC=C1[N+](=O)[O-])OC2=NC(=NC(=N2)Cl)OC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
960,35655,"2-Chloro-4-ethoxy-6-ethylsulfanyl-1,3,5-triazine",CCOC1=NC(=NC(=N1)Cl)SCC,,,,,,
961,35656,"2-Butoxy-4-(butylthio)-6-chloro-1,3,5-triazine",CCCCOC1=NC(=NC(=N1)Cl)SCCCC,,,,,,
962,35657,"2-Chloro-4,6-bis(ethylsulfanyl)-1,3,5-triazine",CCSC1=NC(=NC(=N1)Cl)SCC,,,,,,
963,35658,"2-Chloro-4,6-dimethyl-1,3,5-triazine",CC1=NC(=NC(=N1)Cl)C,,,,,,
964,35659,"2-Chloro-4-methyl-6-(trichloromethyl)-1,3,5-triazine",CC1=NC(=NC(=N1)Cl)C(Cl)(Cl)Cl,,,,,,
965,35660,"2-Chloro-4-(diazomethyl)-6-methyl-1,3,5-triazine",CC1=NC(=NC(=N1)Cl)C=[N+]=[N-],,,,,,
966,35661,"2-Chloro-4,6-bis(chloromethyl)-1,3,5-triazine",C(C1=NC(=NC(=N1)Cl)CCl)Cl,,,,,,
967,35662,"2-Chloro-4,6-bis(dichloromethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)C(Cl)Cl)C(Cl)Cl,,,,,,
968,35663,"2-Chloro-4,6-bis(trichloromethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
969,35664,"2-Chloro-4,6-bis(1,1-dichloroethyl)-1,3,5-triazine",CC(C1=NC(=NC(=N1)Cl)C(C)(Cl)Cl)(Cl)Cl,,,,,,
970,35665,"2-Chloro-4,6-bis(1,1,2-trichloroethyl)-1,3,5-triazine",C(C(C1=NC(=NC(=N1)Cl)C(CCl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
971,35666,"2-Chloro-4-(diazomethyl)-6-phenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C=[N+]=[N-])Cl,,,,,,
972,35667,"2-Chloro-4-(4-chlorophenyl)-6-phenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)Cl)C3=CC=C(C=C3)Cl,,,,,,
973,35668,"2-Chloro-4,6-bis(4-chlorophenyl)-1,3,5-triazine",C1=CC(=CC=C1C2=NC(=NC(=N2)Cl)C3=CC=C(C=C3)Cl)Cl,,,,,,
974,35669,"2-Chloro-4,6-bis(3-nitrophenyl)-1,3,5-triazine",C1=CC(=CC(=C1)[N+](=O)[O-])C2=NC(=NC(=N2)Cl)C3=CC(=CC=C3)[N+](=O)[O-],,,,,,
975,35670,"2,4-Dibromo-6-phenoxy-1,3,5-triazine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)Br)Br,,,,,,
976,35671,"2,4-Dibromo-6-phenylsulfanyl-1,3,5-triazine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)Br)Br,,,,,,
977,35672,"2,4-Dibromo-6-(1,1,2-trichloroethyl)-1,3,5-triazine",C(C(C1=NC(=NC(=N1)Br)Br)(Cl)Cl)Cl,,,,,,
978,35673,"2-Bromo-4,6-bis(1,1,2-trichloroethyl)-1,3,5-triazine",C(C(C1=NC(=NC(=N1)Br)C(CCl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
979,35674,"2,4,6-Tris(2,2,3,3,3-pentachloropropoxy)-1,3,5-triazine",C(C(C(Cl)(Cl)Cl)(Cl)Cl)OC1=NC(=NC(=N1)OCC(C(Cl)(Cl)Cl)(Cl)Cl)OCC(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
980,35675,"2,4,6-Tris(isobutyloxy)-1,3,5-triazine",CC(C)COC1=NC(=NC(=N1)OCC(C)C)OCC(C)C,,,,,,
981,35676,Calcium ureidosuccinate,C(C(C(=O)[O-])NC(=O)N)C(=O)[O-].[Ca+2],,,,,,
982,35677,CID 35677,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=CC=CC=C42,,,,,,
983,35678,Treloxinate,COC(=O)C1OC2=C(CC3=C(O1)C=CC(=C3)Cl)C=C(C=C2)Cl,,,,,,
984,35679,"5-Isopropyl-3,4,5,6-tetrahydro-1,3,5-triazine-2(1H)-one",CC(C)N1CNC(=O)NC1,,,,,,
985,35680,"Benzoic acid, m-chloro-, 2-(3,6-dihydro-2,2,6,6-tetramethyl-1(2H)-pyridyl)ethyl ester",CC1(CC=CC(N1CCC2=C(C=CC=C2Cl)C(=O)O)(C)C)C,,,,,,
986,35681,(Chloromethyl)phenol,C1=CC=C(C(=C1)CCl)O.C1=CC(=CC(=C1)O)CCl.C1=CC(=CC=C1CCl)O,,,,,,
987,35682,2-(Chloromethyl)phenol,C1=CC=C(C(=C1)CCl)O,,,,,,
988,35683,3-(Chloromethyl)phenol,C1=CC(=CC(=C1)O)CCl,,,,,,
989,35684,4-Hydroxybenzyl chloride,C1=CC(=CC=C1CCl)O,,,,,,
990,35685,Cafaminol,CN1C2=C(N=C1N(C)CCO)N(C(=O)N(C2=O)C)C,,,,,,
991,35686,"4-[(4,5-Dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-YL)azo]benzoic acid",CC1=NN(C(=O)C1N=NC2=CC=C(C=C2)C(=O)O)C3=CC=CC=C3,,,,,,
992,35687,"Ammonium 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonate)",CCN1C2=C(C=C(C=C2)S(=O)(=O)[O-])SC1=NN=C3N(C4=C(S3)C=C(C=C4)S(=O)(=O)[O-])CC.[NH4+].[NH4+],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
993,35688,"2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)",CCN1C2=C(C=C(C=C2)S(=O)(=O)O)SC1=NN=C3N(C4=C(S3)C=C(C=C4)S(=O)(=O)O)CC,,,,,,
994,35689,"2-Chloro-4-methyl-6-phenyl-1,3,5-triazine",CC1=NC(=NC(=N1)Cl)C2=CC=CC=C2,,,,,,
995,35690,"2,4-Diguanidinopyrimidine dihydrochloride",C1=CN=C(N=C1N=C(N)N)N=C(N)N.Cl.Cl,,,,,,
996,35691,"Guanidine, 1,1'-(pyrimidine-2,4-diyl)DI-",C1=CN=C(N=C1N=C(N)N)N=C(N)N,,,,,,
997,35692,2-(Aminoethylguanidinoethylguanidino)pyridine sulfate,C1=CC=NC(=C1)NC(=NCCNC(=NCC[NH3+])N)N.OS(=O)(=O)[O-],,,,,,
998,35693,2-(2-Aminoethyl)-1-[2-[[amino-(pyridin-2-ylamino)methylidene]amino]ethyl]guanidine,C1=CC=NC(=C1)NC(=NCCNC(=NCCN)N)N,,,,,,
999,35694,"Hydrazine, (2,6-dimethylphenethyl)-",CC1=C(C(=CC=C1)C)CCNN,,,,,,
1000,35695,"3-Hydroxybutyric acid, 2-heptyl ester",CCCCCC(C)OC(=O)CC(C)O,,,,,,
1001,35696,p-((3-Methyl-5-oxo-1-phenyl-2-pyrazolin-4-yl)azo)benzoic acid 2-(diethylamino)ethyl ester,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N=NC2C(=NN(C2=O)C3=CC=CC=C3)C,,,,,,
1002,35697,"Caffeine, 8-morpholino-",CN1C2=C(N=C1N3CCOCC3)N(C(=O)N(C2=O)C)C,,,,,,
1003,35698,8-Nonynoic acid,C#CCCCCCCC(=O)O,,,,,,
1004,35699,Isocarbamid,CC(C)CNC(=O)N1CCNC1=O,,,,,,
1005,35700,2-Methyldibenzothiophene,CC1=CC2=C(C=C1)SC3=CC=CC=C32,,,,,,
1006,35701,"Phenanthrene, ethyl-",CCC1=C2C=CC3=CC=CC=C3C2=CC=C1,,,,,,
1007,35702,2-Methylfluoranthene,CC1=CC2=C3C(=CC=C2)C4=CC=CC=C4C3=C1,,,,,,
1008,35703,7-Ethoxycoumarin,CCOC1=CC2=C(C=C1)C=CC(=O)O2,,,,,"['7-ethoxycoumarin has known human metabolites that include 2H-1-Benzopyran-2-one, 7-ethoxy-4-hydroxy- and 7-Hydroxycoumarin.']",
1009,35704,"4-(Diethylamino)-1,2-dithiolane oxalate",CC[NH+](CC)C1CSSC1.C(=O)(C(=O)[O-])O,,,,,,
1010,35705,"N,N-diethyldithiolan-4-amine",CCN(CC)C1CSSC1,,,,,,
1011,35706,"1,2-Dithiolan-4-yldiethylmethylammonium iodide",CC[N+](C)(CC)C1CSSC1.[I-],,,,,,
1012,35707,Dithiolan-4-yl-diethyl-methylazanium,CC[N+](C)(CC)C1CSSC1,,,,,,
1013,35708,"4-(Dibutylamino)-1,2-dithiolane oxalate",CCCC[NH+](CCCC)C1CSSC1.C(=O)(C(=O)[O-])O,,,,,,
1014,35709,"N,N-dibutyldithiolan-4-amine",CCCCN(CCCC)C1CSSC1,,,,,,
1015,35710,"Dibutyl-1,2-dithiolan-4-ylmethylammonium iodide",CCCC[N+](C)(CCCC)C1CSSC1.[I-],,,,,,
1016,35711,"N,N-Dibutyl-N-(1,2-dithiolan-4-yl)methanaminium",CCCC[N+](C)(CCCC)C1CSSC1,,,,,,
1017,35712,"1-(1,2-Dithiolan-4-yl)-1-methylhexahydro-1H-azepinium iodide",C[N+]1(CCCCCC1)C2CSSC2.[I-],,,,,,
1018,35713,"Hexahydro-1-(1,2-dithiolan-4-yl)-1-methyl-1H-azepin-1-ium",C[N+]1(CCCCCC1)C2CSSC2,,,,,,
1019,35714,"2-(2,3,4,5,6-Pentachlorophenyl)sulfanyl-4,6-bis(trichloromethyl)-1,3,5-triazine",C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)SC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
1020,35715,"N,N-Dipropyl-4-octyloxy-1-naphthamidine hydrochloride",CCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCC)CCC.[Cl-],,,,,,
1021,35716,"4-octoxy-N,N-dipropylnaphthalene-1-carboximidamide",CCCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCC)CCC,,,,,,
1022,35717,N-Acetyl-D-Galactosamine,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](OC1O)CO)O)O,,,,,,
1023,35718,Phenamacide hydrochloride,CC(C)CCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
1024,35719,Phenamacide,CC(C)CCOC(=O)C(C1=CC=CC=C1)N,,,,,,
1025,35720,3-Ketobutyltrimethylammonium iodide,CC(=O)CC[N+](C)(C)C.[I-],,,,,,
1026,35721,"n,n,n-Trimethyl-3-oxobutan-1-aminium",CC(=O)CC[N+](C)(C)C,,,,,,
1027,35722,CID 35722,CCCCC(CC)COP(=O)(O)[O-].[Na+],,,,,,
1028,35723,Methargen,C1=CC=C2C=C(C(=CC2=C1)CC3=CC4=CC=CC=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-].[Ag+].[Ag+],,,,,,
1029,35724,3-[(3-Sulfonaphthalen-2-yl)methyl]naphthalene-2-sulfonic acid,C1=CC=C2C=C(C(=CC2=C1)CC3=CC4=CC=CC=C4C=C3S(=O)(=O)O)S(=O)(=O)O,,,,,,
1030,35725,1-Hydroxyhomoadamantane,C1CC2CC3CC1CC(C2)(C3)O,,,,,,
1031,35726,Paradryl,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.CBr,,,,,,
1032,35727,2-Methyl-2-propylhexanoic acid,CCCCC(C)(CCC)C(=O)O,,,,,,
1033,35728,2-Propylheptanoic acid,CCCCCC(CCC)C(=O)O,,,,,,
1034,35729,"Benzoxazole, 5-chloro-2-methoxy-",COC1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
1035,35730,"3-[(3S,5R,10S,13R,14S,17R)-14-hydroxy-3-[(2S,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)OC)O,,,,,,
1036,35731,Arabinosyl cytosine palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
1037,35732,CID 35732,C(CO)N(CCO)CCO.[Cu],,,,,,
1038,35733,"1,2,3,4,6,7,8,9,10,10,11,11-Dodecachloro-1,4,4a,5a,6,9,9a,9b-octahydro-1,4:6,9-dimethanodibenzofuran",C12C3C(C4(C(=C(C3(C4(Cl)Cl)Cl)Cl)Cl)Cl)OC1C5(C(=C(C2(C5(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
1039,35734,"3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(2S,5S)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)NC2[C@H](OC([C@H](C2O)O)CO)O)I)N(C)C(=O)C)I,,,,,,
1040,35735,"2,4-Dimethoxy-6-(1,1,2-trichloroethyl)-1,3,5-triazine",COC1=NC(=NC(=N1)C(CCl)(Cl)Cl)OC,,,,,,
1041,35736,Isofenphos oxon,CCOP(=O)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C,,,,,,
1042,35737,3-(Cyclohexylamino)propan-1-ol,C1CCC(CC1)NCCCO,,,,,,
1043,35738,"6,8-Dimorpholinomethyl-3,3',4',5,7-pentahydroxyflavone, dihydrochloride",C1COCC[NH+]1CC2=C(C(=C3C(=C2O)C(=O)C(=C(O3)C4=CC(=C(C=C4)O)O)O)C[NH+]5CCOCC5)O.[Cl-].[Cl-],,,,,,
1044,35739,"2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-6,8-bis(morpholin-4-ylmethyl)chromen-4-one",C1COCCN1CC2=C(C(=C3C(=C2O)C(=O)C(=C(O3)C4=CC(=C(C=C4)O)O)O)CN5CCOCC5)O,,,,,,
1045,35740,Iodoxamic acid,C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
1046,35741,CID 35741,C[NH+]1CCCC(=C(C2=CC=CS2)C3=CC=CS3)C1.C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)O)C(=O)[O-],,,,,,
1047,35742,"HYDANTOIN, 1-((p-CHLOROBENZYL)OXY)-",C1C(=O)NC(=O)N1OCC2=CC=C(C=C2)Cl,,,,,,
1048,35743,"m-Cresol, 6-propyl-",CCCC1=C(C=C(C=C1)C)O,,,,,,
1049,35744,CID 35744,C1=CC(=C(C(=C1)Cl)Cl)C=O.C1=CC(=C(C(=C1)Cl)C=O)Cl.C1=C(C=C(C=C1Cl)Cl)C=O,,,,,,
1050,35745,"2,3-Dichlorobenzaldehyde",C1=CC(=C(C(=C1)Cl)Cl)C=O,,,,,,
1051,35746,"3,5-Dichlorobenzaldehyde",C1=C(C=C(C=C1Cl)Cl)C=O,,,,,,
1052,35747,"5-Allyl-1,3-bis(methoxymethyl)-5-(1-methylbutyl)barbituric acid",CCCC(C)C1(C(=O)N(C(=O)N(C1=O)COC)COC)CC=C,,,,,,
1053,35748,2-[[1-Methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethanol,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCO,,,,,,
1054,35749,"Imidazolidine, 2-heptafluoropropyl-",C1CNC(N1)C(C(C(F)(F)F)(F)F)(F)F,,,,,,
1055,35750,"Anthranilic acid, N-(6-(2-aminopyrimidinyl))-",C1=CC=C(C(=C1)C(=O)O)NC2=NC(=NC=C2)N,,,,,,
1056,35751,4'-Piperidinylcarbonylmethoxyacetophenone,CC(=O)C1=CC=C(C=C1)OCC(=O)N2CCCCC2,,,,,,
1057,35752,"Acetophenone, 4'-(4-methylpiperidinocarbonylmethoxy)-",CC1CCN(CC1)C(=O)COC2=CC=C(C=C2)C(=O)C,,,,,,
1058,35753,"Maleimide, N-ethyl-2-methyl-",CCN1C(=O)C=C(C1=O)C,,,,,,
1059,35754,1-Methylethyl 3-[[(ethylamino)methoxyphosphinothioyl]oxy]-2-butenoate,CCNP(=S)(OC)OC(=CC(=O)OC(C)C)C,,,,,,
1060,35755,Pifoxima,CC(=NO)C1=CC=C(C=C1)OCC(=O)N2CCCCC2,,,,,,
1061,35756,Fukinane,CC1CCCC2C1(CC(C2)(C)C(C)C)C,,,,,,
1062,35757,Methyl 5-acetamidofuran-2-carboxylate,CC(=O)NC1=CC=C(O1)C(=O)OC,,,,,,
1063,35758,Danitracen,CN1CCC(=C2C3=CC=CC=C3C(C4=CC=CC=C42)O)CC1,,,,,,
1064,35759,"9,10-Dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol hydrochloride",C[NH+]1CCC(=C2C3=CC=CC=C3C(C4=CC=CC=C42)O)CC1.[Cl-],,,,,,
1065,35760,2-Bromocyclododecanone,C1CCCCCC(=O)C(CCCC1)Br,,,,,,
1066,35761,"2,2',4,4',6,6'-Hexachlorodiphenyl ether",C1=C(C=C(C(=C1Cl)OC2=C(C=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
1067,35762,"2,2',3,4'-Tetrachlorodiphenyl ether",C1=CC(=C(C(=C1)Cl)Cl)OC2=C(C=C(C=C2)Cl)Cl,,,,,,
1068,35763,"2,4,5-Tribromo-1-propyl-1H-imidazole",CCCN1C(=C(N=C1Br)Br)Br,,,,,,
1069,35764,Bis(4-methoxyphenyl) but-2-enedioate,COC1=CC=C(C=C1)OC(=O)C=CC(=O)OC2=CC=C(C=C2)OC,,,,,,
1070,35765,"(5-Amino-1,3-dimethylpyrazol-4-yl)-(2-fluorophenyl)methanone",CC1=NN(C(=C1C(=O)C2=CC=CC=C2F)N)C,,,,,,
1071,35766,Hygrovetine,CN[C@H]1C[C@H]([C@@H]([C@H]([C@@H]1O)O[C@H]2[C@@H]3[C@H]([C@H]([C@H](O2)CO)O)OC4(O3)[C@@H]([C@@H]([C@H]([C@H](O4)[C@H](CO)N)O)O)O)O)N,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)']",,,
1072,35767,CID 35767,CC1CCCC2=CC=CC=C12.CC1=C2CCCCC2=CC=C1,,,,,,
1073,35768,"2,6,11-Trimethyldodecane",CC(C)CCCCC(C)CCCC(C)C,,,,,,
1074,35769,CID 35769,CC(=O)[O-].O.[Na+],,,,,,
1075,35770,CID 35770,COP(=O)(OC1=CC=C(C=C1)C#N)S,,,,,,
1076,35771,"Phosphoric acid, mono(4-cyanophenyl) monomethyl ester",COP(=O)(O)OC1=CC=C(C=C1)C#N,,,,,,
1077,35772,Veratroylzygadenine,C[C@H]1CC[C@H]2[C@@](C3[C@H]([C@@H]([C@]4(C5CCC6[C@]7([C@]5(CC4C3CN2C1)O[C@@]6([C@H](CC7)OC(=O)C8=CC(=C(C=C8)OC)OC)O)C)O)O)O)(C)O,,,,,,
1078,35773,"gamma-Butyrolactone, 2-acetyl-2-benzyl-4-propargyloxymethyl-",CC(=O)C1(CC(OC1=O)COCC#C)CC2=CC=CC=C2,,,,,,
1079,35774,"calcium;2,2-dichloro-N-[1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;3-[(2,4-dihydroxy-3,3-dimethylbutanoyl)amino]propanoate",CC(C)(CO)C(C(=O)NCCC(=O)[O-])O.C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-].[Ca+2],,,,,,
1080,35775,Zolazepam,CC1=NN(C2=C1C(=NCC(=O)N2C)C3=CC=CC=C3F)C,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)']",,,
1081,35776,Desoxynigericin,C[C@H]1CC[C@@H](OC1C(C)C(=O)O)C[C@@H]2C[C@H]([C@H]([C@@]3(O2)C(CC(O3)(C)C4CCC(O4)(C)C5[C@H](C[C@@H](O5)[C@@H]6[C@H](C[C@H]([C@@](O6)(C)O)C)C)C)C)C)OC,,,,,,
1082,35777,"1,3-DITHIOLANE, 2-(p-(DIMETHYLAMINO)PHENYL)-",CN(C)C1=CC=C(C=C1)C2SCCS2,,,,,,
1083,35778,2-(Diethylamino)ethyl m-butoxycarbanilate hydrochloride,CCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
1084,35779,3-(Butoxy)phenylcarbamic acid 2-(diethylamino)ethyl ester,CCCCOC1=CC=CC(=C1)NC(=O)OCCN(CC)CC,,,,,,
1085,35780,"1H-Indole, 3-(2-aminoethyl)-5-phenoxy-",C1=CC=C(C=C1)OC2=CC3=C(C=C2)NC=C3CCN,,,,,,
1086,35781,"5,7-Dihydroxytryptamine",C1=C(C=C(C2=C1C(=CN2)CCN)O)O,,,"['Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)']",,,
1087,35782,2-Ethyl-2-methylhexanoic acid 3-(4-methyl-1-piperazinyl)propyl ester hydrochloride,CCCCC(C)(CC)C(=O)OCCC[NH+]1CCN(CC1)C.[Cl-],,,,,,
1088,35783,2-Ethyl-2-methylhexanoic acid 3-(4-methyl-1-piperazinyl)propyl ester,CCCCC(C)(CC)C(=O)OCCCN1CCN(CC1)C,,,,,,
1089,35784,3-Methyl-2-heptanol,CCCCC(C)C(C)O,,,,,,
1090,35785,Nerone,CCC(=O)C1CC(CC=C1C)C(C)C,,,,,,
1091,35786,Magnesium fluorogermanate,F[Ge-2](F)(F)(F)(F)F.[Mg+2],,,,,,
1092,35787,2-(Benzoylamino)-isoquinolinium chloride,C1=CC=C(C=C1)C(=O)N[N+]2=CC3=CC=CC=C3C=C2.[Cl-],,,,,,
1093,35788,N-isoquinolin-2-ium-2-ylbenzamide,C1=CC=C(C=C1)C(=O)N[N+]2=CC3=CC=CC=C3C=C2,,,,,,
1094,35789,"1,1,2,3,4-Pentachlorobutane",C(C(C(C(Cl)Cl)Cl)Cl)Cl,,,,,,
1095,35790,6-Methylbenzo[b]thiophene,CC1=CC2=C(C=C1)C=CS2,,,,,,
1096,35791,"6-Methyl-1,4-dithiaspiro(4.5)decane",CC1CCCCC12SCCS2,,,,,,
1097,35792,"1,3-Dithiolane, 2-(2-thienyl)-",C1CSC(S1)C2=CC=CS2,,,,,,
1098,35793,"4H-1,2,4-Triazol-3-ol, 5-(p-chlorophenyl)-4-ethyl-",CCN1C(=NNC1=O)C2=CC=C(C=C2)Cl,,,,,,
1099,35794,1-Allylimidazole,C=CCN1C=CN=C1,,,,,,
1100,35795,"1,1'-(5-Methylpyrimidine-2,4-diyl)diguanidine",CC1=CN=C(N=C1N=C(N)N)N=C(N)N,,,,,,
1101,35796,"Guanidine, 1,1'-((pyrimidine-2,4-diyl)diimino)DI-",C1=CN=C(N=C1NN=C(N)N)NN=C(N)N,,,,,,
1102,35797,"Guanidine, 1,1'-((5-methylpyrimidine-2,4-diyl)diimino)DI-",CC1=CN=C(N=C1NN=C(N)N)NN=C(N)N,,,,,,
1103,35798,"Guanidine, ((2-amino-6-methyl-4-pyrimidinyl)amino)-",CC1=CC(=NC(=N1)N)NN=C(N)N,,,,,,
1104,35799,alpha-Aminomethyl-3-fluorobenzyl alcohol hydrobromide,C1=CC(=CC(=C1)F)C(C[NH3+])O.[Br-],,,,,,
1105,35800,2-Amino-1-(3-fluorophenyl)ethanol,C1=CC(=CC(=C1)F)C(CN)O,,,,,,
1106,35801,"1,4-Dichlorobut-1-ene",C(CCl)C=CCl,,,,,,
1107,35802,Flubendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,,,['Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)'],,,
1108,35803,Ciclobendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3CC3,,,,,,
1109,35804,Isodecyl isooctyl adipate,CC(C)CCCCCCCOC(=O)CCCCC(=O)OCCCCCC(C)C,,,,,,
1110,35805,Levormeloxifene,CC1([C@H]([C@@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C,,,,,,
1111,35806,"Guanidine, 1,1'-((6-methylpyrimidine-2,4-diyl)diimino)DI-",CC1=CC(=NC(=N1)NN=C(N)N)NN=C(N)N,,,,,,
1112,35807,"Benzimidazole-3-ethylamine, N-ethyl-, dioxalate",CC[NH2+]CC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
1113,35808,2-(3H-benzimidazol-1-ium-1-yl)-N-ethylethanamine,CCNCC[N+]1=CNC2=CC=CC=C21,,,,,,
1114,35809,"Benzimidazole-3-ethylamine, N-propyl-, dioxalate",CCC[NH2+]CC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
1115,35810,N-[2-(3H-benzimidazol-1-ium-1-yl)ethyl]propan-1-amine,CCCNCC[N+]1=CNC2=CC=CC=C21,,,,,,
1116,35811,"Benzimidazole-3-ethylamine, N-pentyl-, sesquioxalate",CCCCC[NH2+]CC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])[O-],,,,,,
1117,35812,N-[2-(3H-benzimidazol-1-ium-1-yl)ethyl]pentan-1-amine,CCCCCNCC[N+]1=CNC2=CC=CC=C21,,,,,,
1118,35813,"Benzimidazole-3-ethylamine, N-isopentyl-, sesquioxalate",CC(C)CC[NH2+]CC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])[O-],,,,,,
1119,35814,N-[2-(3H-benzimidazol-1-ium-1-yl)ethyl]-3-methylbutan-1-amine,CC(C)CCNCC[N+]1=CNC2=CC=CC=C21,,,,,,
1120,35815,"Benzimidazole-3-ethylamine, N-benzyl-, dioxalate",C1=CC=C(C=C1)C[NH2+]CC[N+]2=CNC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
1121,35816,2-(3H-benzimidazol-1-ium-1-yl)-N-benzylethanamine,C1=CC=C(C=C1)CNCC[N+]2=CNC3=CC=CC=C32,,,,,,
1122,35817,"BENZIMIDAZOLE-3-ETHYLAMINE, N-p-METHOXYBENZYL-, DIOXALATE",COC1=CC=C(C=C1)C[NH2+]CC[N+]2=CNC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
1123,35818,2-(3H-benzimidazol-1-ium-1-yl)-N-[(4-methoxyphenyl)methyl]ethanamine,COC1=CC=C(C=C1)CNCC[N+]2=CNC3=CC=CC=C32,,,,,,
1124,35819,"Benzimidazole-3-ethylamine, N-(3,4,5-trimethoxybenzyl)-, dioxalate",COC1=CC(=CC(=C1OC)OC)C[NH2+]CC[N+]2=CNC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
1125,35820,"2-(3H-benzimidazol-1-ium-1-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]ethanamine",COC1=CC(=CC(=C1OC)OC)CNCC[N+]2=CNC3=CC=CC=C32,,,,,,
1126,35821,Dihydro-alpha-ionone,CC1=CCCC(C1CCC(=O)C)(C)C,,,,,,
1127,35822,Oct-5-ene-carboxylic,CCC=CCCCCC(=O)O,,,,,,
1128,35823,"2,3',4,4',5-Pentachlorobiphenyl",C1=CC(=C(C=C1C2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
1129,35824,"Ammonium, (2,3-dihydro-3-hydroxy-2-methyl-5-benzofuranyl)trimethyl-, (Z)-, iodide",C[C@@H]1[C@@H](C2=C(O1)C=CC(=C2)[N+](C)(C)C)O.[I-],,,,,,
1130,35825,"[(2R,3R)-3-hydroxy-2-methyl-2,3-dihydro-1-benzofuran-5-yl]-trimethylazanium",C[C@@H]1[C@@H](C2=C(O1)C=CC(=C2)[N+](C)(C)C)O,,,,,,
1131,35826,"trans-(2,3-Dihydro-3-hydroxy-2-methyl-5-benzofuranyl)trimethylammonium iodide",C[C@@H]1[C@H](C2=C(O1)C=CC(=C2)[N+](C)(C)C)O.[I-],,,,,,
1132,35827,"[(2R,3S)-3-hydroxy-2-methyl-2,3-dihydro-1-benzofuran-5-yl]-trimethylazanium",C[C@@H]1[C@H](C2=C(O1)C=CC(=C2)[N+](C)(C)C)O,,,,,,
1133,35828,"Ammonium, (2,3-dihydro-3-hydroxy-2-methyl-7-benzofuranyl)trimethyl-, (E)-, iodide",C[C@@H]1[C@H](C2=C(O1)C(=CC=C2)[N+](C)(C)C)O.[I-],,,,,,
1134,35829,"[(2R,3S)-3-hydroxy-2-methyl-2,3-dihydro-1-benzofuran-7-yl]-trimethylazanium",C[C@@H]1[C@H](C2=C(O1)C(=CC=C2)[N+](C)(C)C)O,,,,,,
1135,35830,"(2,3-Dihydro-2-methyl-3-oxo-5-benzofuranyl)trimethylammonium iodide",CC1C(=O)C2=C(O1)C=CC(=C2)[N+](C)(C)C.[I-],,,,,,
1136,35831,Trimethyl-(2-methyl-3-oxo-1-benzofuran-5-yl)azanium,CC1C(=O)C2=C(O1)C=CC(=C2)[N+](C)(C)C,,,,,,
1137,35832,"(2,3-Dihydro-2-methyl-3-oxo-7-benzofuranyl)trimethylammonium iodide",CC1C(=O)C2=C(O1)C(=CC=C2)[N+](C)(C)C.[I-],,,,,,
1138,35833,Trimethyl-(2-methyl-3-oxo-1-benzofuran-7-yl)azanium,CC1C(=O)C2=C(O1)C(=CC=C2)[N+](C)(C)C,,,,,,
1139,35834,"1-Azabicyclo(2.2.2)oct-2-ene-3-carboxylic acid, methyl ester",COC(=O)C1=CN2CCC1CC2,,,,,,
1140,35835,"4'-Fluoro-4-(8-fluoro-1,3,4,5-tetrahydro-2H-pyrido(4,3-b)indol-2-yl)butyrophenone hydrochloride",C1C[NH+](CC2=C1NC3=C2C=C(C=C3)F)CCCC(=O)C4=CC=C(C=C4)F.[Cl-],,,,,,
1141,35836,"1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one",C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
1142,35837,"Benzo(H)naphtho(1,2,3,4-rst)pentaphene",C1=CC=C2C(=C1)C=C3C4=CC=CC=C4C5=CC6=CC=CC=C6C7=C5C3=C2C8=CC=CC=C87,,,,,,
1143,35838,Benzo(fgh)trinaphthylene,C1=CC=C2C=C3C(=CC2=C1)C4=CC5=CC=CC=C5C6=C4C7=C(C=C6)C8=CC=CC=C8C=C37,,,,,,
1144,35839,"Anthra(1,2,3,4-rst)pentaphene",C1=CC=C2C=C3C(=CC2=C1)C4=C5C(=CC6=CC=CC=C64)C=CC7=CC8=CC=CC=C8C3=C75,,,,,,
1145,35840,"Dinaphtho(3,2,1-FG:1',2',3'-ST)pentacene",C1=CC=C2C=C3C(=CC2=C1)C4=C5C(=CC6=CC=CC=C64)C7=CC=CC=C7C8=CC9=CC=CC=C9C3=C85,,,,,,
1146,35841,2-Methylpent-2-enenitrile,CCC=C(C)C#N,,,,,,
1147,35842,"2,7-Dinitro-9-fluorenone",C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C3=C2C=CC(=C3)[N+](=O)[O-],,,,,,
1148,35843,CID 35843,COC1=CC=CC=C1OCCNC2=NC3CC4CC(C3)CC2C4.Cl,,,,,,
1149,35844,CID 35844,COC1=CC=CC=C1OCCNC2=NC3CC4CC(C3)CC2C4,,,,,,
1150,35845,5-Hydrazino-4-azahomoadamant-4-ene hydrochloride,C1C2CC3CC1CC(C2)N=C3NN.Cl,,,,,,
1151,35846,"4-Azatricyclo[4.3.1.13,8]undec-4-en-5-ylhydrazine",C1C2CC3CC1CC(C2)N=C3NN,,,,,,
1152,35847,Tridecyl stearate,CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCC,,,,,,
1153,35848,EGTA disodium,C(COCCOCCN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+],,,,,,
1154,35849,"ANTHRAQUINONE, 1-AMINO-2-(tert-BUTYLPHENYL)THIO-4-HYDROXY-",CC(C)(C)C1=CC=C(C=C1)SC2=C(C3=C(C(=C2)O)C(=O)C4=CC=CC=C4C3=O)N,,,,,,
1155,35850,4-[4-Chloro-2-[3-(2-methoxyphenyl)prop-2-enoyl]phenoxy]butanoic acid,COC1=CC=CC=C1C=CC(=O)C2=C(C=CC(=C2)Cl)OCCCC(=O)O,,,,,,
1156,35851,"BENZIMIDAZOLE-3-ETHYLAMINE, N-p-METHYLBENZYL-, DIOXALATE",CC1=CC=C(C=C1)C[NH2+]CC[N+]2=CNC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
1157,35852,2-(3H-benzimidazol-1-ium-1-yl)-N-[(4-methylphenyl)methyl]ethanamine,CC1=CC=C(C=C1)CNCC[N+]2=CNC3=CC=CC=C32,,,,,,
1158,35853,"2,3-Bis(chloromethyl)-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C(=C(C2=O)CCl)CCl,,,,,,
1159,35854,CID 35854,CC(C)N1CC(N=C1S)(C)C,,,,,,
1160,35855,((2-Methoxyethoxy)methyl)benzene,COCCOCC1=CC=CC=C1,,,,,,
1161,35856,4-Biphenylacetonitrile,C1=CC=C(C=C1)C2=CC=C(C=C2)CC#N,,,,,,
1162,35857,"Acetanilide, dichloro-",C1=CC=C(C=C1)NC(=O)C(Cl)Cl,,,,,,
1163,35858,Isopropylbicyclohexyl,CC(C)C1CCCC(C1)C2CCCCC2,,,,,,
1164,35859,6-Nonadecenoic acid,CCCCCCCCCCCCC=CCCCCC(=O)O,,,,,,
1165,35860,8-Nonenoic acid,C=CCCCCCCC(=O)O,,,,,,
1166,35861,5-Methylbenzo(a)pyrene,CC1=CC2=CC=CC3=C2C4=C(C=C3)C5=CC=CC=C5C=C14,,,,,,
1167,35862,N-(Cyano(methylthio)methyl)-p-nitrobenzamide,CSC(C#N)NC(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
1168,35863,N-(Cyano(methylthio)methyl)-p-methoxybenzamide,COC1=CC=C(C=C1)C(=O)NC(C#N)SC,,,,,,
1169,35864,Anthracenecarboxaldehyde,C1=CC=C2C=C3C(=CC2=C1)C=CC=C3C=O,,,,,,
1170,35865,Agn-PC-0jkopo,CC1CC2C3C=C(C4=CC5=C(CC4(C3C(CC2(C1(C(=O)CO)O)C)O)C)C=NN5C6=CC=C(C=C6)F)C,,,,,,
1171,35866,CID 35866,C(C(=O)O)NCC(=O)[O-].[Na+],,,,,,
1172,35867,CID 35867,C[NH2+]CCOC1C2=CC=CC=C2CCC3=CC=CC=C13.C(=CC(=O)[O-])C(=O)O,,,,,,
1173,35868,"N-methyl-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)ethanamine",CNCCOC1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
1174,35869,"9-Anthracenemethanol, 10-methyl-, acetate",CC1=C2C=CC=CC2=C(C3=CC=CC=C13)COC(=O)C,,,,,,
1175,35870,"6-Hydroxydibenzo(b,e)thiepin-11(6H)-one acetate",CC(=O)OC1C2=CC=CC=C2C(=O)C3=CC=CC=C3S1,,,,,,
1176,35871,"Indole, 3-(5-aminopentyl)-, adipate",C1=CC=C2C(=C1)C(=CN2)CCCCC[NH3+].C(CCC(=O)[O-])CC(=O)O,,,,,,
1177,35872,5-(1H-indol-3-yl)pentylamine,C1=CC=C2C(=C1)C(=CN2)CCCCCN,,,,,,
1178,35873,"Indole, 3-(7-aminoheptyl)-, adipate (1:1)",C1=CC=C2C(=C1)C(=CN2)CCCCCCC[NH3+].C(CCC(=O)[O-])CC(=O)O,,,,,,
1179,35874,Indolylheptylamine,C1=CC=C2C(=C1)C(=CN2)CCCCCCCN,,,,,,
1180,35875,"1,1,3-Trichloro-2-methyl-1-propene",CC(=C(Cl)Cl)CCl,,,,,,
1181,35876,Decachlorodiphenyl ether,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
1182,35877,"N,N'-Diisobutyl-1,4-butanediamine",CC(C)CNCCCCNCC(C)C,,,,,,
1183,35878,"Ethyl 10,11-dihydro-5H-dibenzo(a,d)cycloheptene-10-carbamate",CCOC(=O)NC1CC2=CC=CC=C2CC3=CC=CC=C13,,,,,,
1184,35879,"(7-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-2-ylideneamino) N-methylcarbamate",CNC(=O)ON=C1C2=C(CCC3=CC=CC=C31)N=CC=C2,,,,,,
1185,35880,(2-Benzoyloxy-2-phenylethyl)-dimethylazanium chloride,C[NH+](C)CC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
1186,35881,"1-Aza-5H-dibenzo(a,d)cyclohepten-5-ol, 10,11-dihydro-5-ethynyl-",C#CC1(C2=C(CCC3=CC=CC=C31)N=CC=C2)O,,,,,,
1187,35882,"5H-BENZO(4,5)CYCLOHEPTA(1,2-b)PYRIDIN-5-ONE, 10,11-DIHYDRO-7-CHLORO-",C1CC2=C(C=CC=N2)C(=O)C3=C1C=CC(=C3)Cl,,,,,,
1188,35883,Anidoxime hydrochloride,CCN(CC)CCC(=NOC(=O)NC1=CC=C(C=C1)OC)C2=CC=CC=C2.Cl,,,,,,
1189,35884,Anidoxima,CCN(CC)CCC(=NOC(=O)NC1=CC=C(C=C1)OC)C2=CC=CC=C2,,,,,,
1190,35885,"(4R,6'S,11'S,14'S,16'R)-2-butyl-6'-fluoro-2,11'-dihydroxy-10',13',16'-trimethylspiro[1,3-dioxane-4,17'-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene]-3',5-dione",CCCCC1(OCC(=O)[C@@]2(O1)[C@@H](C[C@@H]3C2(C[C@@H](C4C3C[C@@H](C5=CC(=O)C=CC45C)F)O)C)C)O,,,,,,
1191,35886,"1-[(16S,17R)-7-(4-fluorophenyl)-17,20-dihydroxy-2,11,16,18-tetramethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9,11-tetraen-17-yl]-2-hydroxyethanone",C[C@H]1CC2C3C=C(C4=CC5=C(CC4(C3C(CC2([C@]1(C(=O)CO)O)C)O)C)C=NN5C6=CC=C(C=C6)F)C,,,,,,
1192,35887,"2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N-methylethanamine",CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3,,,,,,
1193,35888,"trans-2,4-Diphenyl-2,4,6,6-tetramethylcyclotrisiloxane",C[Si]1(O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C3=CC=CC=C3)C,,,,,,
1194,35889,CID 35889,C[NH+](C)CCOC1=CC2=CC=CC=C2SC3=CC=CC=C31.C(=CC(=O)[O-])C(=O)O,,,,,,
1195,35890,"2-benzo[b][1]benzothiepin-5-yloxy-N,N-dimethylethanamine",CN(C)CCOC1=CC2=CC=CC=C2SC3=CC=CC=C31,,,,,,
1196,35891,CID 35891,CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)OC)O)O,,,,,,
1197,35892,N-tert-Butyl-3-pyrrolidyl 2-chloro-6-methylphenylcarbamate,CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCN(C2)C(C)(C)C,,,,,,
1198,35893,"N-Ethyl-3-pyrrolidinyl 2,6-dimethylcarbanilate",CCN1CCC(C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
1199,35894,"N-Propyl-3-pyrrolidyl 2,6-dimethylphenylcarbamate",CCCN1CCC(C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
1200,35895,"N-Isopropyl-3-pyrrolidyl 2,6-dimethylphenylcarbamate",CC1=C(C(=CC=C1)C)NC(=O)OC2CCN(C2)C(C)C,,,,,,
1201,35896,"N-Methyl-3-piperidyl 2,6-dimethylphenylcarbamate",CC1=C(C(=CC=C1)C)NC(=O)OC2CCCN(C2)C,,,,,,
1202,35897,N-Methyl-3-piperidyl 2-chloro-6-methylphenylcarbamate,CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCCN(C2)C,,,,,,
1203,35898,"N-Ethyl-3-piperidyl 2,6-dimethylphenylcarbamate",CCN1CCCC(C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
1204,35899,N-Ethyl-3-piperidyl 2-chloro-6-methylphenylcarbamate,CCN1CCCC(C1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1205,35900,"N-Propyl-3-piperidyl 2,6-dimethylphenylcarbamate",CCCN1CCCC(C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
1206,35901,N-Propyl-3-piperidyl 2-chloro-6-methylphenylcarbamate,CCCN1CCCC(C1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1207,35902,"N-Isopropyl-3-piperidyl 2,6-dimethylphenylcarbamate hydrochloride",CC1=C(C(=CC=C1)C)NC(=O)OC2CCC[NH+](C2)C(C)C.[Cl-],,,,,,
1208,35903,"(1-propan-2-ylpiperidin-3-yl) N-(2,6-dimethylphenyl)carbamate",CC1=C(C(=CC=C1)C)NC(=O)OC2CCCN(C2)C(C)C,,,,,,
1209,35904,N-Isopropyl-3-piperidyl 2-chloro-6-methylphenylcarbamate hydrochloride,CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCC[NH+](C2)C(C)C.[Cl-],,,,,,
1210,35905,(1-propan-2-ylpiperidin-3-yl) N-(2-chloro-6-methylphenyl)carbamate,CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCCN(C2)C(C)C,,,,,,
1211,35906,"N-tert-Butyl-3-piperidyl 2,6-dimethylphenylcarbamate",CC1=C(C(=CC=C1)C)NC(=O)OC2CCCN(C2)C(C)(C)C,,,,,,
1212,35907,N-tert-Butyl-3-piperidyl 2-chloro-6-methylphenylcarbamate hydrochloride,CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCC[NH+](C2)C(C)(C)C.[Cl-],,,,,,
1213,35908,(1-tert-butylpiperidin-3-yl) N-(2-chloro-6-methylphenyl)carbamate,CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCCN(C2)C(C)(C)C,,,,,,
1214,35909,N-Butyl-3-piperidyl 2-chloro-6-methylphenylcarbamate,CCCCN1CCCC(C1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1215,35910,"N-Butyl-3-piperidyl 2,6-dimethylphenylcarbamate hydrochloride",CCCC[NH+]1CCCC(C1)OC(=O)NC2=C(C=CC=C2C)C.[Cl-],,,,,,
1216,35911,"(1-butylpiperidin-3-yl) N-(2,6-dimethylphenyl)carbamate",CCCCN1CCCC(C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
1217,35912,"o-Methylcarbanilic acid, N-methyl-3-piperidinyl ester",CC1=CC=CC=C1NC(=O)OC2CCCN(C2)C,,,,,,
1218,35913,"2-Benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH+](CCC2=C1)CC3=CC=CC=C3)OC.[Br-],,,,,,
1219,35914,"2-Benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CN(CCC2=C1)CC3=CC=CC=C3)OC,,,,,,
1220,35915,"2-(p-Chlorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH+](CCC2=C1)CC3=CC=C(C=C3)Cl)OC.[Br-],,,,,,
1221,35916,"2-(4-Chlorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CN(CCC2=C1)CC3=CC=C(C=C3)Cl)OC,,,,,,
1222,35917,"6,7-Dimethoxy-2-(o-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH+](CCC2=C1)CC3=CC=CC=C3F)OC.[Br-],,,,,,
1223,35918,"2-(2-Fluorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CN(CCC2=C1)CC3=CC=CC=C3F)OC,,,,,,
1224,35919,"6,7-Dimethoxy-2-(m-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH+](CCC2=C1)CC3=CC(=CC=C3)F)OC.[Br-],,,,,,
1225,35920,"2-(3-Fluorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CN(CCC2=C1)CC3=CC(=CC=C3)F)OC,,,,,,
1226,35921,"6,7-Dimethoxy-2-(p-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH+](CCC2=C1)CC3=CC=C(C=C3)F)OC.[Br-],,,,,,
1227,35922,"2-[(4-fluorophenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline",COC1=C(C=C2CN(CCC2=C1)CC3=CC=C(C=C3)F)OC,,,,,,
1228,35923,CID 35923,C[NH+](C)CCC1=C(C2=CC=CC=C2SC3=CC=CC=C31)OCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
1229,35924,"2-[5-[2-(dimethylamino)ethoxy]benzo[b][1]benzothiepin-6-yl]-N,N-dimethylethanamine",CN(C)CCC1=C(C2=CC=CC=C2SC3=CC=CC=C31)OCCN(C)C,,,,,,
1230,35925,CID 35925,C[NH+](C)CCC1C2=CC=CC=C2C(=O)C3=CC=CC=C3S1.C(=CC(=O)[O-])C(=O)O,,,,,,
1231,35926,6-[2-(dimethylamino)ethyl]-6H-benzo[c][1]benzothiepin-11-one,CN(C)CCC1C2=CC=CC=C2C(=O)C3=CC=CC=C3S1,,,,,,
1232,35927,CID 35927,C[NH+](C)CCCC1=C(C2=C(C=CC(=C2)Cl)SC3=CC=CC=C31)OCCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
1233,35928,"3-[3-chloro-5-[3-(dimethylamino)propoxy]benzo[b][1]benzothiepin-6-yl]-N,N-dimethylpropan-1-amine",CN(C)CCCC1=C(C2=C(C=CC(=C2)Cl)SC3=CC=CC=C31)OCCCN(C)C,,,,,,
1234,35929,N-Propyl-3-pyrrolidyl 2-chloro-6-methylphenylcarbamate,CCCN1CCC(C1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1235,35930,"2-Chloro-6-methylcarbanilic acid, N-isopropyl-3-pyrrolidinyl ester",CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCN(C2)C(C)C,,,,,,
1236,35931,3-Methyl-2H-azirine-2-carboxylic acid,CC1=NC1C(=O)O,,,,,,
1237,35932,"2-(o-Chlorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH+](CCC2=C1)CC3=CC=CC=C3Cl)OC.[Br-],,,,,,
1238,35933,"2-(2-Chlorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CN(CCC2=C1)CC3=CC=CC=C3Cl)OC,,,,,,
1239,35934,"Pregn-4-ene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-16,17-((1-phenylethylidene)bis(oxy))-, (11beta,16alpha)-",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C6=CC=CC=C6)C(=O)CO)C)O)F,,,,,,
1240,35935,Pirprofen,CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
1241,35936,"10-(4-Phenyl-1-piperazinyl)-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-11-one",C1CN(CCN1C2C3=CC=CC=C3CC4=CC=CC=C4C2=O)C5=CC=CC=C5,,,,,,
1242,35937,CID 35937,C1=CC=C(C=C1)N=C(NNC(=O)CC2=CC=CC3=CC=CC=C32)S,,,,,,
1243,35938,2-Piperidinoacetophenone hydrobromide,C1CC[NH+](CC1)CC(=O)C2=CC=CC=C2.[Br-],,,,,,
1244,35939,1-Phenyl-2-(1-piperidinyl)ethanone,C1CCN(CC1)CC(=O)C2=CC=CC=C2,,,,,,
1245,35940,"Ketone, 10-(3-(4-methoxypiperidino)propyl)phenothiazin-2-YL methyl",CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)OC,,,,,,
1246,35941,(+-)-1-Methyl-3-benzoyl-(p-aminobenzoyloxy)piperidine hydrochloride,C[NH+]1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=C(C=C3)N.[Cl-],,,,,,
1247,35942,(3-Benzoyl-1-methylpiperidin-3-yl) 4-aminobenzoate,CN1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=C(C=C3)N,,,,,,
1248,35943,N-benzyl-2-methoxy-N-methyl-2-[3-(trifluoromethyl)phenyl]ethanamine,CN(CC1=CC=CC=C1)CC(C2=CC(=CC=C2)C(F)(F)F)OC,,,,,,
1249,35944,"3-Biphenylamine, 3'-nitro-",C1=CC(=CC(=C1)N)C2=CC(=CC=C2)[N+](=O)[O-],,,,,,
1250,35945,1-Bromobut-1-ene,CCC=CBr,,,,,,
1251,35946,"1H-2,3-Benzothiazin-4(3H)-one, 3-(2-propynyl)-, 2,2-dioxide",C#CCN1C(=O)C2=CC=CC=C2CS1(=O)=O,,,,,,
1252,35947,"3,5-Dimethoxy-4-(2-morpholinoethoxy)benzophenone hydrochloride",COC1=CC(=CC(=C1OCC[NH+]2CCOCC2)OC)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
1253,35948,"[3,5-Dimethoxy-4-(2-morpholin-4-ylethoxy)phenyl]-phenylmethanone",COC1=CC(=CC(=C1OCCN2CCOCC2)OC)C(=O)C3=CC=CC=C3,,,,,,
1254,35949,Morclofone,COC1=CC(=CC(=C1OCCN2CCOCC2)OC)C(=O)C3=CC=C(C=C3)Cl,,,,,,
1255,35950,"4'-Chloro-3,5-dimethoxy-4-(2-morpholinoethoxy)benzophenone hydrochloride",COC1=CC(=CC(=C1OCC[NH+]2CCOCC2)OC)C(=O)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
1256,35951,"3,5-Dimethoxy-4-(2-(2-morpholinoethoxy)ethoxy)benzophenone hydrochloride",COC1=CC(=CC(=C1OCCOCC[NH+]2CCOCC2)OC)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
1257,35952,"[3,5-Dimethoxy-4-[2-(2-morpholin-4-ylethoxy)ethoxy]phenyl]-phenylmethanone",COC1=CC(=CC(=C1OCCOCCN2CCOCC2)OC)C(=O)C3=CC=CC=C3,,,,,,
1258,35953,Carbamorph,CN(C)C(=S)SCN1CCOCC1,,,,,,
1259,35954,"2H-1,2-Benzothiazin-3(4H)-one, 2-propyl-, 1,1-dioxide",CCCN1C(=O)CC2=CC=CC=C2S1(=O)=O,,,,,,
1260,35955,"2H-1,2-Benzothiazin-3(4H)-one, 2-(2-propynyl)-, 1,1-dioxide",C#CCN1C(=O)CC2=CC=CC=C2S1(=O)=O,,,,,,
1261,35956,"2-(1-Chloroethyl)-4,6-diethyl-1,3,5-triazine",CCC1=NC(=NC(=N1)C(C)Cl)CC,,,,,,
1262,35957,"2,4-Bis(ethylamino)-6-(2-methoxyethoxy)-1,3,5-triazine",CCNC1=NC(=NC(=N1)OCCOC)NCC,,,,,,
1263,35958,"Benzophenone, 4'-chloro-3,5-dimethoxy-4-(2-(2-morpholinoethoxy)ethoxy)-",COC1=CC(=CC(=C1OCCOCCN2CCOCC2)OC)C(=O)C3=CC=C(C=C3)Cl,,,,,,
1264,35959,N-(4-tert-Butylcyclohexyl)benzamide,CC(C)(C)C1CCC(CC1)NC(=O)C2=CC=CC=C2,,,,,,
1265,35960,"2,6-Dimethoxy-4-vinylphenol",COC1=CC(=CC(=C1O)OC)C=C,,,,,,
1266,35961,2-(4-(2-Furanyl)-2-thiazolyl)hydrazinecarboxaldehyde,C1=COC(=C1)C2=CSC(=N2)NNC=O,,,,,,
1267,35962,Unii-I8FL9GD5ZW,CC(CCN(CCCl)C1=CC=C(C=C1)N)C2=CC=C(C=C2)N,,,,,,
1268,35963,"1-ADAMANTANEMETHANOL, alpha-(2-DIMETHYLAMINOETHYL)-, HYDROCHLORIDE",CN(C)CCC(C12CC3CC(C1)CC(C3)C2)O.Cl,,,,,,
1269,35964,3-(1-Adamantyl)-1-(dimethylamino)propan-3-ol,CN(C)CCC(C12CC3CC(C1)CC(C3)C2)O,,,,,,
1270,35965,"Adamantane, 2-chloro-1-(2-isopropylaminopropyl)-, hydrochloride",CC(C)NC(C)CC12CC3CC(C1)CC(C3)C2Cl.Cl,,,,,,
1271,35966,1-(2-chloro-1-adamantyl)-N-propan-2-ylpropan-2-amine,CC(C)NC(C)CC12CC3CC(C1)CC(C3)C2Cl,,,,,,
1272,35967,Sulfanilate-ZINC,C1=CC(=CC=C1N)S(=O)(=O)O.C1=CC(=CC=C1N)S(=O)(=O)O.[Zn],,,,,,
1273,35968,"2,2-Diethyl-5-methyltetrahydrofuran-3,4-diol",CCC1(C(C(C(O1)C)O)O)CC,,,,,,
1274,35969,Thiocyclam hydrogen oxalate,CN(C)C1CSSSC1.C(=O)(C(=O)O)O,,,,,,
1275,35970,Thiocyclam,CN(C)C1CSSSC1,,,,,,
1276,35971,"Adamantane, 1-(2-methylaminopropyl)-3,5,7-trimethyl-, hydrochloride",CC(CC12CC3(CC(C1)(CC(C3)(C2)C)C)C)NC.Cl,,,,,,
1277,35972,"N-methyl-1-(3,5,7-trimethyl-1-adamantyl)propan-2-amine",CC(CC12CC3(CC(C1)(CC(C3)(C2)C)C)C)NC,,,,,,
1278,35973,N-Methyl-1-(2-phenyladamantan-1-yl)propan-2-amine hydrochloride,CC(CC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4)NC.Cl,,,,,,
1279,35974,1-(2-Phenyladamant-1-yl)-2-methylaminopropane,CC(CC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4)NC,,,,,,
1280,35975,"Adamantane, 2-chloro-1-(2-dimethylaminopropyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2Cl)N(C)C.Cl,,,,,,
1281,35976,"1-(2-chloro-1-adamantyl)-N,N-dimethylpropan-2-amine",CC(CC12CC3CC(C1)CC(C3)C2Cl)N(C)C,,,,,,
1282,35977,"Adamantane, 1-(2-dimethylaminopropyl)-3,5,7-trimethyl-, hydrochloride",CC(CC12CC3(CC(C1)(CC(C3)(C2)C)C)C)N(C)C.Cl,,,,,,
1283,35978,"N,N-dimethyl-1-(3,5,7-trimethyl-1-adamantyl)propan-2-amine",CC(CC12CC3(CC(C1)(CC(C3)(C2)C)C)C)N(C)C,,,,,,
1284,35979,"Adamantane, 2-chloro-1-(2-dimethylaminopropyl)-3,5,7-trimethyl-, hydrochloride",CC(CC12CC3(CC(C1)(CC(C3)(C2Cl)C)C)C)N(C)C.Cl,,,,,,
1285,35980,"1-(2-chloro-3,5,7-trimethyl-1-adamantyl)-N,N-dimethylpropan-2-amine",CC(CC12CC3(CC(C1)(CC(C3)(C2Cl)C)C)C)N(C)C,,,,,,
1286,35981,1-(2-Dimethylaminopropyl)adamantane hydrochloride,CC(CC12CC3CC(C1)CC(C3)C2)N(C)C.Cl,,,,,,
1287,35982,"1-(1-adamantyl)-N,N-dimethylpropan-2-amine",CC(CC12CC3CC(C1)CC(C3)C2)N(C)C,,,,,,
1288,35983,"2-Propylamine, 1-(1-adamantyl)-N-isopropyl-N-methyl-, hydrochloride",CC(C)N(C)C(C)CC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
1289,35984,1-(1-adamantyl)-N-methyl-N-propan-2-ylpropan-2-amine,CC(C)N(C)C(C)CC12CC3CC(C1)CC(C3)C2,,,,,,
1290,35985,"Adamantane, 1-(2-isopropylaminopropyl)-, hydrochloride",CC(C)NC(C)CC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
1291,35986,1-(1-adamantyl)-N-propan-2-ylpropan-2-amine,CC(C)NC(C)CC12CC3CC(C1)CC(C3)C2,,,,,,
1292,35987,"Adamantane, 1-(2-benzylaminopropyl)-, hydrochloride",C1C2CC3CC1CC(C2)(C3)CCCNCC4=CC=CC=C4.Cl,,,,,,
1293,35988,3-(1-adamantyl)-N-benzylpropan-1-amine,C1C2CC3CC1CC(C2)(C3)CCCNCC4=CC=CC=C4,,,,,,
1294,35989,"2-Propylamine, 1-(1-adamantyl)-N-benzyl-N-methyl-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2)N(C)CC4=CC=CC=C4.Cl,,,,,,
1295,35990,1-(1-adamantyl)-N-benzyl-N-methylpropan-2-amine,CC(CC12CC3CC(C1)CC(C3)C2)N(C)CC4=CC=CC=C4,,,,,,
1296,35991,"Adamantane, 2-bromo-1-(2-methylaminopropyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2Br)NC.Cl,,,,,,
1297,35992,1-(2-bromo-1-adamantyl)-N-methylpropan-2-amine,CC(CC12CC3CC(C1)CC(C3)C2Br)NC,,,,,,
1298,35993,"Adamantane, 1-(2-dimethylaminoethyl)-, hydrochloride",CN(C)CCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
1299,35994,(1-Adamantylethyl)dimethylamine,CN(C)CCC12CC3CC(C1)CC(C3)C2,,,,,,
1300,35995,1-(2-Methylaminoethyl)adamantane hydrochloride,CNCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
1301,35996,2-(1-Adamantyl)-N-methylethylamine,CNCCC12CC3CC(C1)CC(C3)C2,,,,,,
1302,35997,"Adamantane, 1-(3-aminopropyl)-, hydrochloride",C1C2CC3CC1CC(C2)(C3)CCCN.Cl,,,,,,
1303,35998,3-(Adamantan-1-yl)propan-1-amine,C1C2CC3CC1CC(C2)(C3)CCCN,,,,,,
1304,35999,"Adamantane, 2-cyclohexyl-1-(2-methylaminopropyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2C4CCCCC4)NC.Cl,,,,,,
1305,36000,1-(2-cyclohexyl-1-adamantyl)-N-methylpropan-2-amine,CC(CC12CC3CC(C1)CC(C3)C2C4CCCCC4)NC,,,,,,
1306,36001,"Adamantane, 2,8-dichloro-1-(2-methylaminopropyl)-, hydrochloride",CC(CC12CC3CC(C1Cl)CC(C3)C2Cl)NC.Cl,,,,,,
1307,36002,"1-(2,8-dichloro-1-adamantyl)-N-methylpropan-2-amine",CC(CC12CC3CC(C1Cl)CC(C3)C2Cl)NC,,,,,,
1308,36003,"Adamantane, 1-(3-methylaminopropyl)-, hydrochloride",CNCCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
1309,36004,3-(1-adamantyl)-N-methylpropan-1-amine,CNCCCC12CC3CC(C1)CC(C3)C2,,,,,,
1310,36005,"Adamantane, 1-(3-dimethylaminopropyl)-, hydrochloride",CN(C)CCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
1311,36006,"3-(1-adamantyl)-N,N-dimethylpropan-1-amine",CN(C)CCCC12CC3CC(C1)CC(C3)C2,,,,,,
1312,36007,"Adamantane, 1-(2-(1-pyrrolidinyl)propyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2)N4CCCC4.Cl,,,,,,
1313,36008,1-[1-(1-Adamantyl)propan-2-yl]pyrrolidine,CC(CC12CC3CC(C1)CC(C3)C2)N4CCCC4,,,,,,
1314,36009,"2-Propylamine, 1-(1-adamantyl)-N-(2-hydroxyethyl)-N-methyl-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2)N(C)CCO.Cl,,,,,,
1315,36010,2-[1-(1-Adamantyl)propan-2-yl-methylamino]ethanol,CC(CC12CC3CC(C1)CC(C3)C2)N(C)CCO,,,,,,
1316,36011,"Adamantane, 1-(2-(2-hydroxyethyl)aminopropyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)C2)NCCO.Cl,,,,,,
1317,36012,2-[1-(1-Adamantyl)propan-2-ylamino]ethanol,CC(CC12CC3CC(C1)CC(C3)C2)NCCO,,,,,,
1318,36013,"Adamantane, 3-bromo-1-(2-methylaminopropyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)(C2)Br)NC.Cl,,,,,,
1319,36014,1-(3-bromo-1-adamantyl)-N-methylpropan-2-amine,CC(CC12CC3CC(C1)CC(C3)(C2)Br)NC,,,,,,
1320,36015,"3-Adamantanol, 1-(2-methylaminopropyl)-, hydrochloride",CC(CC12CC3CC(C1)CC(C3)(C2)O)NC.Cl,,,,,,
1321,36016,3-[2-(Methylamino)propyl]adamantan-1-ol,CC(CC12CC3CC(C1)CC(C3)(C2)O)NC,,,,,,
1322,36017,"Hexanoic acid, 6-(9H-purin-6-ylamino)-",C1=NC2=C(N1)C(=NC=N2)NCCCCCC(=O)O,,,,,,
1323,36018,"5H-Dibenzo(a,d)cyclohepten-10-ol, 10,11-dihydro-11-(4-methyl-1-piperazinyl)-, (Z)-",CN1CCN(CC1)[C@@H]2[C@@H](C3=CC=CC=C3CC4=CC=CC=C24)O,,,,,,
1324,36019,"5H-Dibenzo(a,d)cyclohepten-10-ol, 10,11-dihydro-11-(ethylamino)-, hydrochloride, (Z)-",C1C2=CC=CC=C2[C@@H]([C@@H](C3=CC=CC=C31)O)CC[NH3+].[Cl-],,,,,,
1325,36020,"(9S,10S)-10-(2-aminoethyl)tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaen-9-ol",C1C2=CC=CC=C2[C@@H]([C@@H](C3=CC=CC=C31)O)CCN,,,,,,
1326,36021,alpha-Allyl-alpha-benzimidazolyl-gamma-methyl-gamma-butyrolactone,CC1CC(C(=O)O1)(CC=C)C2=NC3=CC=CC=C3N2,,,,,,
1327,36022,5-Chloro-3-methylcatechol,CC1=CC(=CC(=C1O)O)Cl,,,,,,
1328,36023,3-Bromophenylacetonitrile,C1=CC(=CC(=C1)Br)CC#N,,,,,,
1329,36024,CID 36024,C1(=NC(=O)N=C(N1)N)C(Br)(Br)Br,,,,,,
1330,36025,"Adamantane, 1-(3-methylaminobutyl)-, hydrochloride",CC(CCC12CC3CC(C1)CC(C3)C2)NC.Cl,,,,,,
1331,36026,4-(1-adamantyl)-N-methylbutan-2-amine,CC(CCC12CC3CC(C1)CC(C3)C2)NC,,,,,,
1332,36027,Fenamiphos sulfoxide,CCOP(=O)(NC(C)C)OC1=CC(=C(C=C1)S(=O)C)C,,,,,,
1333,36028,Fenamiphos sulfone,CCOP(=O)(NC(C)C)OC1=CC(=C(C=C1)S(=O)(=O)C)C,,,,,,
1334,36029,"N-tert-Butyl-3-pyrrolidyl 2,6-dimethylphenylcarbamate hydrochloride",CC1=C(C(=CC=C1)C)NC(=O)OC2CC[NH+](C2)C(C)(C)C.[Cl-],,,,,,
1335,36030,"(1-tert-butylpyrrolidin-3-yl) N-(2,6-dimethylphenyl)carbamate",CC1=C(C(=CC=C1)C)NC(=O)OC2CCN(C2)C(C)(C)C,,,,,,
1336,36031,"Benz[e]-as-indacene-7,10-dione, 1,2,3,4,5,6,6a,6b,8,9,10a,10b-dodecahydro-",C1CC2C3C(C4CCCC4=C2C1)C(=O)CCC3=O,,,,,,
1337,36032,"2-Propen-1-one, 1-(4-methylphenyl)-3-(5-nitro-2-furanyl)-, (E)-",CC1=CC=C(C=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1338,36033,"11H-Dibenzo(b,e)(1,4)diazepin-11-one, 5,10-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-, hydrochloride",C[NH+](C)CCCN1C2=CC=CC=C2NC(=O)C3=C1C=C(C=C3)Cl.[Cl-],,,,,,
1339,36034,"9-chloro-11-[3-(dimethylamino)propyl]-5H-benzo[b][1,4]benzodiazepin-6-one",CN(C)CCCN1C2=CC=CC=C2NC(=O)C3=C1C=C(C=C3)Cl,,,,,,
1340,36035,"5H-DIBENZO(b,e)(1,4)DIAZEPINE, 10,11-DIHYDRO-5-(3-(DIETHYLAMINO)PROPYL)-",CCN(CC)CCCN1C2=CC=CC=C2CNC3=CC=CC=C31,,,,,,
1341,36036,"5H-Dibenzo(b,e)(1,4)diazepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, dihydrochloride",C[NH2+]CCCN1C2=CC=CC=C2C[NH2+]C3=CC=CC=C31.[Cl-].[Cl-],,,,,,
1342,36037,"3-(5,6-dihydrobenzo[b][1,4]benzodiazepin-11-yl)-N-methylpropan-1-amine",CNCCCN1C2=CC=CC=C2CNC3=CC=CC=C31,,,,,,
1343,36038,"5H-Dibenzo(b,e)(1,4)diazepine, 10,11-dihydro-10-(3-(methylamino)propyl)-, dihydrochloride",C[NH2+]CCC[NH+]1CC2=CC=CC=C2NC3=CC=CC=C31.[Cl-].[Cl-],,,,,,
1344,36039,"3-(6,11-dihydrobenzo[b][1,4]benzodiazepin-5-yl)-N-methylpropan-1-amine",CNCCCN1CC2=CC=CC=C2NC3=CC=CC=C31,,,,,,
1345,36040,"3-Chloro-10-(3-(dimethylamino)propyl)-5H-dibenzo(b,e)(1,4)diazepine dihydrochloride",C[NH+](C)CCC[NH+]1CC2=C(C=C(C=C2)Cl)NC3=CC=CC=C31.[Cl-].[Cl-],,,,,,
1346,36041,"3-(9-chloro-6,11-dihydrobenzo[b][1,4]benzodiazepin-5-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1CC2=C(C=C(C=C2)Cl)NC3=CC=CC=C31,,,,,,
1347,36042,"11H-DIBENZO(b,e)(1,4)DIAZEPIN-11-ONE, 5,10-DIHYDRO-10-METHYL-",CN1C2=CC=CC=C2NC3=CC=CC=C3C1=O,,,,,,
1348,36043,"10-(2-(Diethylamino)ethyl)-10,11-dihydro-5H-dibenzo(b,e)(1,4)diazepine",CC[NH+](CC)CCN1CC2=CC=CC=C2NC3=CC=CC=C31.[Cl-],,,,,,
1349,36044,"2-(6,11-dihydrobenzo[b][1,4]benzodiazepin-5-yl)-N,N-diethylethanamine",CCN(CC)CCN1CC2=CC=CC=C2NC3=CC=CC=C31,,,,,,
1350,36045,"10,11-Dihydro-5H-dibenzo(b,e)(1,4)diazepine hydrochloride",C1C2=CC=CC=C2NC3=CC=CC=C3[NH2+]1.[Cl-],,,,,,
1351,36046,"10,11-Dihydro-5h-dibenzo[b,e][1,4]diazepine",C1C2=CC=CC=C2NC3=CC=CC=C3N1,,,,,,
1352,36047,"5H-DIBENZO(b,e)(1,4)DIAZEPINE, 10,11-DIHYDRO-5,10-DIMETHYL-",CN1CC2=CC=CC=C2N(C3=CC=CC=C31)C,,,,,,
1353,36048,CID 36048,C1=CC=C2C(=C1)C(=NC3=CC=CC=C3N2)S,,,,,,
1354,36049,N-(4-Methoxyphenyl)-N-phenylacetamide,CC(=O)N(C1=CC=CC=C1)C2=CC=C(C=C2)OC,,,,,,
1355,36050,3-(Diethylamino)propyl 2-ethyl-2-methylhexanoate,CCCCC(C)(CC)C(=O)OCCCN(CC)CC,,,,,,
1356,36051,3-Piperidin-1-ylpropyl 2-ethyl-2-methylhexanoate,CCCCC(C)(CC)C(=O)OCCCN1CCCCC1,,,,,,
1357,36052,(3-Carboxyoxy-2-hydroxypropyl) acetate,CC(=O)OCC(COC(=O)O)O,,,,,,
1358,36053,"Carbanilic acid, 4-((2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl)carbamoyl)-, ethyl ester",CCOC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(N(N(C2=O)C3=CC=CC=C3)C)C,,,,,,
1359,36054,Guanazodine,C1CCCNC(CC1)CN=C(N)N,,,,,,
1360,36055,"2,3-Dimethyl-4-((p-methoxybenzylidene)amino)-1-phenyl-3-pyrazolin-5-one",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=CC3=CC=C(C=C3)OC,,,,,,
1361,36056,3-Butyl-3-hexen-2-one,CCCCC(=CCC)C(=O)C,,,,,,
1362,36057,"Benzoic acid, 3,4,5-trimethoxy-, 4-(diethylamino)butyl ester",CCN(CC)CCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
1363,36058,CID 36058,CC1=CN=C(N=C1N=C([NH3+])N)N=C([NH3+])N.[Cl-].[Cl-],,,,,,
1364,36059,beta-Aminoethyl benzhydryl ether hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[NH3+].[Cl-],,,,,,
1365,36060,2-Benzhydryloxyethanamine,C1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN,,,,,"['N,N-Didesmethyldiphenhydramine is a known human metabolite of N-Desmethyldiphenhydramine.']",
1366,36061,1-Phenyl-1-(2-tolyl)-1-(2-dimethylaminoethoxy)ethane hydrochloride,CC1=CC=CC=C1C(C)(C2=CC=CC=C2)OCC[NH+](C)C.[Cl-],,,,,,
1367,36062,"N,N-dimethyl-2-[1-(2-methylphenyl)-1-phenylethoxy]ethanamine",CC1=CC=CC=C1C(C)(C2=CC=CC=C2)OCCN(C)C,,,,,,
1368,36063,"Ethylamine, N,N-dimethyl-2-((alpha-methyl-o-(methylthio)-alpha-phenylbenzyl)oxy)-, hydrochloride",CC(C1=CC=CC=C1)(C2=CC=CC=C2SC)OCC[NH+](C)C.[Cl-],,,,,,
1369,36064,"N,N-dimethyl-2-[1-(2-methylsulfanylphenyl)-1-phenylethoxy]ethanamine",CC(C1=CC=CC=C1)(C2=CC=CC=C2SC)OCCN(C)C,,,,,,
1370,36065,2-Acetyl-4-nitropyrrole,CC(=O)C1=CC(=CN1)[N+](=O)[O-],,,,,,
1371,36066,2-Acetyl-5-nitropyrrole,CC(=O)C1=CC=C(N1)[N+](=O)[O-],,,,,,
1372,36067,4-Bromo-3-chlorophenyl isothiocyanate,C1=CC(=C(C=C1N=C=S)Cl)Br,,,,,,
1373,36068,CID 36068,CSC(=NCCCCCCN=C(S)SC)S,,,,,,
1374,36069,CID 36069,CCSC(=NCCCCCCN=C(S)SCC)S,,,,,,
1375,36070,A 100 (polyamide),[CH]CCCCCNC(=O)CCCCC(=O)[N],,,,,,
1376,36071,CID 36071,CCCCC(C(=O)N1C2=CC=CC=C2C(=O)NC3=CC=CC=C31)C(=O)[O-].[Na+],,,,,,
1377,36072,"2-(6-oxo-5H-benzo[b][1,4]benzodiazepine-11-carbonyl)hexanoic acid",CCCCC(C(=O)N1C2=CC=CC=C2C(=O)NC3=CC=CC=C31)C(=O)O,,,,,,
1378,36073,"S-(-)-2-Chloro-6-methylcarbanilic acid, N-n-butyl-3-piperidyl ester",CCCCN1CCC[C@@H](C1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1379,36074,"ACETAMIDE, 2-(o-TOLYLTHIO)-",CC1=CC=CC=C1SCC(=O)N,,,,,,
1380,36075,3-Aminomethyl-1-(p-chlorobenzyl)-3-hydroxyindolin-2-one hydrochloride,C1=CC=C2C(=C1)C(C(=O)N2CC3=CC=C(C=C3)Cl)(C[NH3+])O.[Cl-],,,,,,
1381,36076,3-(Aminomethyl)-1-[(4-chlorophenyl)methyl]-3-hydroxyindol-2-one,C1=CC=C2C(=C1)C(C(=O)N2CC3=CC=C(C=C3)Cl)(CN)O,,,,,,
1382,36077,1-Methyl-5-chloroindoline methylbromide,C[N+]1(CCC2=C1C=CC(=C2)Cl)C.[Br-],,,,,,
1383,36078,"1,1-Dimethyl-5-chloro-2,3-dihydro-1H-indolium",C[N+]1(CCC2=C1C=CC(=C2)Cl)C,,,,,,
1384,36079,Benzyldimethyl(2-hydroxyethyl)ammonium bromide acetate,CC(=O)OCC[N+](C)(C)CC1=CC=CC=C1.[Br-],,,,,,
1385,36080,2-Acetyloxyethyl-benzyl-dimethylazanium,CC(=O)OCC[N+](C)(C)CC1=CC=CC=C1,,,,,,
1386,36081,4-tert-Butylcyclohexyl acetate,CC(=O)OC1CCC(CC1)C(C)(C)C,,,,,,
1387,36082,Cyclindole,CN(C)C1CCC2=C(C1)C3=CC=CC=C3N2,,,,,,
1388,36083,CID 36083,CC(CCCC(C)(C)O)[C@H]1CCC2[C@@]1(CCCC2=CC=C3C[C@H](CC(C3=C)O)O)C,,,,,,
1389,36084,2-(Diethylamino)ethyl o-butoxycarbanilate hydrochloride,CCCCOC1=CC=CC=C1NC(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
1390,36085,2-Butoxyphenylcarbamic acid 2-(diethylamino)ethyl ester,CCCCOC1=CC=CC=C1NC(=O)OCCN(CC)CC,,,,,,
1391,36086,2-(Diethylamino)ethyl p-butoxycarbanilate hydrochloride,CCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
1392,36087,p-Butoxycarbanilic acid 2-diethylaminoethyl ester,CCCCOC1=CC=C(C=C1)NC(=O)OCCN(CC)CC,,,,,,
1393,36088,CID 36088,CC(C)CN(CC(C)C)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1394,36089,Sobrepin,CC1=CCC(C[C@@H]1O)C(C)(C)O,,,"['Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']",,,
1395,36090,"(1)BENZOTHIOPYRANO(4,3-b)INDOLE, 2-CHLOROBENZO(e)-",C1=CC=C2C(=C1)C=CC3=C2C4=CSC5=C(C4=N3)C=C(C=C5)Cl,,,,,,
1396,36091,"2-Fluorenamine, N-phenyl-",C1C2=CC=CC=C2C3=C1C=C(C=C3)NC4=CC=CC=C4,,,,,,
1397,36092,"(R)-(+)-2-Chloro-6-methylcarbanilic acid, 1-butyl-3-piperidyl ester",CCCCN1CCC[C@H](C1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1398,36093,"1,2,3,4,5,6,8-Heptachloronaphthalene",C1=C(C2=C(C(=C1Cl)Cl)C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
1399,36094,Delaprem,C1=CC(=C(C=C1C(C[NH2+]CCCCCC[NH2+]CC(C2=CC(=C(C=C2)O)O)O)O)O)O.[O-]S(=O)(=O)[O-],,,,,,
1400,36095,CID 36095,CCCC(=O)NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)COC(=O)CCC)OP(=O)(O4)O,,,,,,
1401,36096,Calcium;4-[3-[(butanoylamino)methyl]heptan-4-yloxy]-4-oxobutanoate,CCCC(C(CC)CNC(=O)CCC)OC(=O)CCC(=O)[O-].CCCC(C(CC)CNC(=O)CCC)OC(=O)CCC(=O)[O-].[Ca+2],,,,,,
1402,36097,4-[3-[(Butanoylamino)methyl]heptan-4-yloxy]-4-oxobutanoic acid,CCCC(C(CC)CNC(=O)CCC)OC(=O)CCC(=O)O,,,,,,
1403,36098,"2,5-Dimethyl-4-ethylthiazole",CCC1=C(SC(=N1)C)C,,,,,,
1404,36099,Octahydro-1-methylpentalene,CC1CCC2C1CCC2,,,,,,
1405,36100,"1,2,3,4-Tetrahydro-4,5,7-trimethyl-1-naphthol",CC1CCC(C2=CC(=CC(=C12)C)C)O,,,,,,
1406,36101,Diethyl dimethyldiphosphonate,CCOP(=O)(C)OP(=O)(C)OCC,,,,,,
1407,36102,Tosifen,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H](C)CC2=CC=CC=C2,,,,,,
1408,36103,CID 36103,COCCCN=C(C(=NCCCOC)S)S,,,,,,
1409,36104,"3,4'-Diaminobiphenyl",C1=CC(=CC(=C1)N)C2=CC=C(C=C2)N,,,,,,
1410,36105,Ethyl 4-(p-hydroxybenzylidene)aminobenzoate,CCOC(=O)C1=CC=C(C=C1)N=CC2=CC=C(C=C2)O,,,,,,
1411,36106,"Phosphorothioic acid, O,O-diethyl O-phenyl ester",CCOP(=S)(OCC)OC1=CC=CC=C1,,,,,,
1412,36107,"2-Butoxyethyl 4-(2,4-dichlorophenoxy)butyrate",CCCCOCCOC(=O)CCCOC1=C(C=C(C=C1)Cl)Cl,,,,,,
1413,36108,"Hexane, 1-(pentyloxy)-",CCCCCCOCCCCC,,,,,,
1414,36109,Medifoxamine,CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
1415,36110,"6,11-Dimethylbenzo(b)naphtho(2,3-d)thiophene",CC1=C2C3=CC=CC=C3SC2=C(C4=CC=CC=C14)C,,,,,,
1416,36111,2-Ethyltetralin,CCC1CCC2=CC=CC=C2C1,,,,,,
1417,36112,Peroxybenzoyl nitrate,C1=CC=C(C=C1)C(=O)OO[N+](=O)[O-],,,,,,
1418,36113,9-Phenyl-9H-fluorene-4-carbonitrile,C1=CC=C(C=C1)C2C3=CC=CC=C3C4=C(C=CC=C24)C#N,,,,,,
1419,36114,7-phenyl-7H-benzo[c]fluorene,C1=CC=C(C=C1)C2C3=C(C4=CC=CC=C4C=C3)C5=CC=CC=C25,,,,,,
1420,36115,9-(3-Chlorophenyl)-9H-fluorene,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C4=CC(=CC=C4)Cl,,,,,,
1421,36116,9-(3-(Trifluoromethyl)phenyl)-9H-fluorene,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C4=CC(=CC=C4)C(F)(F)F,,,,,,
1422,36117,9-(3-Methoxyphenyl)-9H-fluorene,COC1=CC=CC(=C1)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
1423,36118,"4-(9H-Fluoren-9-YL)-N,N-dimethylbenzenamine",CN(C)C1=CC=C(C=C1)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
1424,36119,Sisomicin,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
1425,36120,4-Bromocyclohexanol,C1CC(CCC1O)Br,,,,,,
1426,36121,2-Cyclododecyloxyethanol,C1CCCCCC(CCCCC1)OCCO,,,,,,
1427,36122,Steponine chloride,C[N+]12CCC3=CC(=C(C=C3C1CC4=C(C2)C(=C(C=C4)OC)O)OC)O.[Cl-],,,,,,
1428,36123,"2,10-dimethoxy-7-methyl-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolin-7-ium-3,9-diol",C[N+]12CCC3=CC(=C(C=C3C1CC4=C(C2)C(=C(C=C4)OC)O)OC)O,,,,,,
1429,36124,"Benzylamine, N-(2-chloroethyl)-N-(2-phenoxyethyl)-, hydrochloride",C1=CC=C(C=C1)C[NH+](CCOC2=CC=CC=C2)CCCl.[Cl-],,,,,,
1430,36125,N-benzyl-N-(2-chloroethyl)-2-phenoxyethanamine,C1=CC=C(C=C1)CN(CCOC2=CC=CC=C2)CCCl,,,,,,
1431,36126,CID 36126,CN(C)CCCN=C(C1=CC=C(C=C1)Cl)S,,,,,,
1432,36127,"2-(1-(Diisopropylamino)ethyl)-1,3,4-oxadiazole",CC(C)N(C(C)C)C(C)C1=NN=CO1,,,,,,
1433,36128,"1,3,4-Oxadiazole, 2-(2-piperidino-2-propyl)-",CC(CC1=NN=CO1)N2CCCCC2,,,,,,
1434,36129,"2-(1-Piperidino-1-propyl)-1,3,4-oxadiazole",CCC(C1=NN=CO1)N2CCCCC2,,,,,,
1435,36130,"1-Naphthalenecarboxamide, N-(2-(diethylamino)ethyl)-",CCN(CC)CCNC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
1436,36131,Bunaftine,CCCCN(CCN(CC)CC)C(=O)C1=CC=CC2=CC=CC=C21,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
1437,36132,"1-Naphthalenecarboxamide, 6-chloro-N-(2-(diethylamino)ethyl)-",CCN(CC)CCNC(=O)C1=CC=CC2=C1C=CC(=C2)Cl,,,,,,
1438,36133,"N-(2-(Diethylamino)ethyl)-1,2,3,4-tetrahydro-1-naphthalenecarboxamide",CCN(CC)CCNC(=O)C1CCCC2=CC=CC=C12,,,,,,
1439,36134,"1,2,3,4-Tetrahydro-N-(2-(diethylamino)ethyl)-3-isoquinolinecarboxamide",CCN(CC)CCNC(=O)C1CC2=CC=CC=C2CN1,,,,,,
1440,36135,"1,2,3,4-Tetrahydro-N-(2-(isopropylamino)ethyl)-3-isoquinolinecarboxamide",CC(C)NCCNC(=O)C1CC2=CC=CC=C2CN1,,,,,,
1441,36136,N-((2-Imidazolin-2-yl)methyl)-N-phenyl-1-naphthalenecarboxamide,C1CN=C(N1)CN(C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43,,,,,,
1442,36137,"(2,4-Dichlorophenyl)methyl 3-dimethoxyphosphoryloxybut-2-enoate",CC(=CC(=O)OCC1=C(C=C(C=C1)Cl)Cl)OP(=O)(OC)OC,,,,,,
1443,36138,"2,2'-Dimethylinsularinium diiodide",C[N+]1(CCC2=CC(=C3C4=C2C1CC5=CC=C(C=C5)OC6=C7C(CC8=CC(=C(O4)C=C8)CO3)[N+](CCC7=CC(=C6OC)OC)(C)C)OC)C.[I-].[I-],,,,,,
1444,36139,"9,10,26-Trimethoxy-15,15,31,31-tetramethyl-7,24,34-trioxa-15,31-diazoniaoctacyclo[19.10.3.23,6.18,12.118,22.025,33.028,32.016,36]octatriaconta-3(38),4,6(37),8(36),9,11,18(35),19,21,25,27,32-dodecaene",C[N+]1(CCC2=CC(=C3C4=C2C1CC5=CC=C(C=C5)OC6=C7C(CC8=CC(=C(O4)C=C8)CO3)[N+](CCC7=CC(=C6OC)OC)(C)C)OC)C,,,,,,
1445,36140,CID 36140,CC[NH2+]N=CSCC[N+](C)(C)C.[Br-].[Br-],,,,,,
1446,36141,2-[(Ethylhydrazinylidene)methylsulfanyl]ethyl-trimethylazanium,CCNN=CSCC[N+](C)(C)C,,,,,,
1447,36142,CID 36142,CCCCCCN=C(C(=NCCCCCC)S)S,,,,,,
1448,36143,Oxfenicine,C1=CC(=CC=C1[C@@H](C(=O)O)N)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
1449,36144,"4,5-Dimethylbatrachotoxin",CC1=C(NC=C1C(=O)OC(C)C2=CC[C@@]34C2(C[C@H](C56C3=CC[C@H]7[C@@]5(CC[C@@](C7)(O6)O)C)O)CN(CCO4)C)C,,,,,,
1450,36145,"3-[(3S,5S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C)OC)O,,,,,,
1451,36146,CID 36146,CC1=CC(=NC(=N1)N=C([NH3+])N)N=C([NH3+])N.[Cl-].[Cl-],,,,,,
1452,36147,2-[2-(Diaminomethylideneamino)-6-methylpyrimidin-4-yl]guanidine,CC1=CC(=NC(=N1)N=C(N)N)N=C(N)N,,,,,,
1453,36148,CID 36148,C1=CC=C2C(=C1)NC(=N2)[NH2+]C(=N)[NH3+].[Cl-].[Cl-],,,,,,
1454,36149,2-Guanidinobenzimidazole,C1=CC=C2C(=C1)NC(=N2)N=C(N)N,,,,,,
1455,36150,"CARBAMIC ACID, N-(5-CHLORO-o-TOLYL)-, 2-PROPYNYL ESTER",CC1=C(C=C(C=C1)Cl)NC(=O)OCC#C,,,,,,
1456,36151,3-Methyl-1-pentyn-3-yl carbanilate,CCC(C)(C#C)OC(=O)NC1=CC=CC=C1,,,,,,
1457,36152,"HYDRAZINE, (m-METHYLPHENETHYL)-",CC1=CC(=CC=C1)CCNN,,,,,,
1458,36153,(+)-trans-Chrysanthemic acid-carboxy-14C,CC(=CC1C(C1(C)C)[14C](=O)O)C,,,,,,
1459,36154,"1,3,4-Oxadiazole, 2-(2-pyrrolidino-2-propyl)-",CC(CC1=NN=CO1)C2CCCN2,,,,,,
1460,36155,"2,4-Hexadiyne-1,6-diol, bis(4-methylbenzenesulfonate)",CC1=CC=C(C=C1)S(=O)(=O)OCC#CC#CCOS(=O)(=O)C2=CC=C(C=C2)C,,,,,,
1461,36156,5-Chloro-3-(4-(2-hydroxy-2-methylethyl)piperazin-1-yl)carbonylmethyl-2-benzothiazolinone HCl,CC(C[NH+]1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O)O.[Cl-],,,,,,
1462,36157,"5-Chloro-3-[2-[4-(2-hydroxypropyl)piperazin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one",CC(CN1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O)O,,,,,,
1463,36158,Dimethyl dithiophosphate,CSP(=O)(O)SC,,,,,,
1464,36159,"2,2',4,4',5-Pentabromodiphenyl ether",C1=CC(=C(C=C1Br)Br)OC2=CC(=C(C=C2Br)Br)Br,,,,"['The substance accumulates in fat tissues and can be excreted in breast milk.', '... As part of a larger study examining the effects of PBDEs on mink (Mustela vison) reproduction and development, ... congener-specific tissue distribution, maternal transfer, biotransformation, and biomagnification of the technical penta-BDE mixture, DE-71, /were examined/ in farmed mink. Adult female mink were fed one of four concentrations of DE-71 (0-2.5 ug/g) in the diet from breeding through gestation and until weaning at 6 weeks postparturition. Parent PBDEs were measured in tissues and excreta of adult mink, kits, and juveniles, whereas hydroxylated PBDEs (OH-PBDEs) were measured in juveniles only. Similar lipid-normalized concentrations of PBDEs were detected in most tissues of adult mink with the exception of brain, in which concentrations were significantly lower. Kits, however, had a higher proportion of PBDEs in brain compared with adults, presumably because of incomplete development of the blood-brain barrier. Maternal transfer favored lower-brominated PBDE congeners, and the bulk of the body burden in kits at weaning resulted from lactational rather than transplacental transfer. Lipid-normalized, whole-body biomagnification factors ranged from 0.5 to 5.2 for the major congeners and were highest for BDEs 47 and 153. Metabolism clearly limited the biomagnification of some PBDEs, and OH-PBDEs were detectable in plasma, liver, and feces. On a mass basis, OH-PBDEs accounted for 28 to 32% of the excreted fraction, indicating metabolism was an important elimination pathway. /DE-71/', 'Using rats as a model, ... tissue distribution of PBDEs /was investigated/ after oral administration and ... a suitable matrix /was evaluated/ for body burden estimation. Male rats were administered dust or corn oil containing 8 or 6 ug PBDEs/kg bw, respectively, in the diet for 21 days (N=4 rats per treatment), and the concentration of 15 PBDEs were measured in various tissues, plasma, and feces. PBDEs were found in all tissues, including the brain, and showed no difference in distribution patterns between treatments for most PBDEs. Tri- to hexa-BDEs comprised >80% of the total PBDEs in the adipose, brain, kidney, lung, and residual carcass, but <40% in the liver and plasma. The ratio of the lipid-weight concentration of tri- to hexa-BDEs in adipose tissue, residual carcass, and plasma was 1:1:2. For the hepta- to nona-BDEs, lipid-weight concentrations increased from adipose tissue to residual carcass to plasma in the ratio 0.3:1:>4. BDE-209 was the dominant congener in the liver and plasma, but was not detected in the adipose tissue or carcass. In summary, the lower brominated congeners tended to distribute equally into lipids implying both adipose tissue and plasma would be suitable matrices for biomonitoring. Plasma was the best matrix for detection of the higher brominated congeners (especially BDE-209), although on a lipid-weight basis tended to overestimate the total body burdens.', 'Male and female rats were given a single oral dose of 300 mg/kg Bromkal 70 in peanut oil. Control groups were given vehicle only. Groups of 4 rats of either sex were sacrificed at weekly intervals up to 10 weeks post-dosing for HPLC and GC/MS analysis of the brominated diphenyl ether content of perirenal fat. The results showed the presence of two isomers of pentaBPDE in the perirenal fat, pentaBDPE1 and pentaBDPE2, in addition to tetra- and hexabromodiphenyl ethers. The half-lives of elimination of the pentaBDPE isomers ranged from 25-47 days in males and females respectively. These results provide evidence that pentaBDPE is absorbed across the GI tract with subsequent distribution to adipose tissue from where it is slowly eliminated ... /Bromkal 70/', 'For more Absorption, Distribution and Excretion (Complete) data for Pentabromodiphenyl ethers (8 total), please visit the HSDB record page.']","['In a study primarily designed to investigate the binding of polyBDE-OH metabolites to human transthyretin (T4-TTr) groups of Wistar rats were pre-treated with stimulants of hepatic xenobiotic metabolism. Once day post pre-treatment animals were sacrificed, the livers excised and hepatic microsomes prepared. The microsomes were subsequently incubated in vitro with 1 of 2 pure congeners of pentaBDPE (BDE-47 or BDE-99) (concentration not reported) in the presence of NADPH for 30 min. The microsomes suspension was then used in T4-TTr competion binding studies. The limited results presented (qualitative tabulated information only) indicate that both BDE-47 and BDE-99 inhibit T4-TTr binding in penobarbitol induced microsomes by approx. 60 and 20%, respectively suggesting that the parent molecule may be metabolized to hydroxylated metabolites. /BDE-47 and BDE-99/', ""Groups of 6 conventional and 6 bile-cannulated Sprague-Dawley rats were administered a single oral dose of 2.2 mg/ rat 2,2',4,4',5-{14C}pentaBDPE (BDE-99) in peanut oil. Urine, feces, and bile (from cannulated animals) were collected at 24 hr intervals over a 72 hr period post-dosing. ... Chromatographic analysis of the bile indicated the presence of 4 metabolites; two monohydroxy pentabromodiphenyl ethers and two dihydroxy pentabromodiphenyl ethers. No glucuronide or sulfate conjugates were identified. ... Of the radioactivity measured in the feces of conventional rats only 72% could be extracted for chromatographic analysis of its nature. Analysis indicated that >90% of the recovered radioactivity was present as parent BDE-99. The remaining recovered radioactivity was determined as being 1 of 4 metabolites, these being: two monomethyoxy pentabromodiphenyl ethers or two debrominated monomethoxy tetrabromodiphenyl ethers.""]",['Male and female rats were given a single oral dose of 300 mg/kg Bromkal 70 in peanut oil. ... The half-lives of elimination of the pentaBDPE isomers ranged from 25-47 days in males and females respectively. ... /Bromkal 70/']
1465,36160,"2,2',3,4,4',5,5',6-Octabromodiphenyl ether",C1=C(C(=CC(=C1Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,,,,,,
1466,36161,"4-(2-Guanidinoethyl)-4-azatricyclo(4.3.1.1(sup 3,8))undecane dihydrochloride",C1C2CC3CC1CC(C2)NC3CCN=C(N)N.Cl.Cl,,,,,,
1467,36162,"2-[2-(4-Azatricyclo[4.3.1.13,8]undecan-5-yl)ethyl]guanidine",C1C2CC3CC1CC(C2)NC3CCN=C(N)N,,,,,,
1468,36163,"5-Amino-4-azatricyclo(4.3.1.1(sup 3,8))undec-4-ene nitrate",C1C2CC3CC1CC(C2)N=C3N.[N+](=O)(O)[O-],,,,,,
1469,36164,"4-Azatricyclo[4.3.1.13,8]undec-4-en-5-amine",C1C2CC3CC1CC(C2)N=C3N,,,,,,
1470,36165,"5-(2-Phenylhydrazino)-4-azatricyclo(4.3.1.1(sup 3,8))undec-4-ene hydrochloride",C1C2CC3CC1CC(C2)N=C3NNC4=CC=CC=C4.[Cl-],,,,,,
1471,36166,"1-(4-Azatricyclo[4.3.1.13,8]undec-4-en-5-yl)-2-phenylhydrazine",C1C2CC3CC1CC(C2)N=C3NNC4=CC=CC=C4,,,,,,
1472,36167,"5-(2-(p-Methoxyphenyl)hydrazino)-4-azatricyclo(4.3.1.1(sup 3,8))undec-4-ene hydrochloride",COC1=CC=C(C=C1)NNC2=NC3CC4CC(C3)CC2C4.[Cl-],,,,,,
1473,36168,"1-(4-Azatricyclo[4.3.1.13,8]undec-4-en-5-yl)-2-(4-methoxyphenyl)hydrazine",COC1=CC=C(C=C1)NNC2=NC3CC4CC(C3)CC2C4,,,,,,
1474,36169,CID 36169,CN(C)CCNC1=NC2CC3CC(C2)CC1C3.Cl.Cl,,,,,,
1475,36170,CID 36170,CN(C)CCNC1=NC2CC3CC(C2)CC1C3,,,,,,
1476,36171,CID 36171,CCN(CC)CCNC1=NC2CC3CC(C2)CC1C3.Cl.Cl,,,,,,
1477,36172,CID 36172,CCN(CC)CCNC1=NC2CC3CC(C2)CC1C3,,,,,,
1478,36173,CID 36173,CN(C)CCCNC1=NC2CC3CC(C2)CC1C3.Cl.Cl,,,,,,
1479,36174,CID 36174,CN(C)CCCNC1=NC2CC3CC(C2)CC1C3,,,,,,
1480,36175,CID 36175,C1C2CC3CC1CC(C2)N=C3NCCNC4=CC=CC=C4.Cl,,,,,,
1481,36176,CID 36176,C1C2CC3CC1CC(C2)N=C3NCCNC4=CC=CC=C4,,,,,,
1482,36177,CID 36177,CN(CCNC1=NC2CC3CC(C2)CC1C3)C4=CC=CC=C4.Cl,,,,,,
1483,36178,CID 36178,CN(CCNC1=NC2CC3CC(C2)CC1C3)C4=CC=CC=C4,,,,,,
1484,36179,"2,6-Dimethylcarbanilic acid, N-methyl-3-pyrrolidinyl ester",CC1=C(C(=CC=C1)C)NC(=O)OC2CCN(C2)C,,,,,,
1485,36180,"4-Methyl-1,2,5-oxadiazole-3-carboxamide",CC1=NON=C1C(=O)N,,,,,,
1486,36181,3-Methyl-4-furazancarbohydrazide,CC1=NON=C1C(=O)NN,,,,,,
1487,36182,"Ethyl 3-[3,5-bis(1-methylethyl)phenyl]-2-propenoate",CCOC(=O)C=CC1=CC(=CC(=C1)C(C)C)C(C)C,,,,,,
1488,36183,"N,N-Ethylene-bis(tetrabromophthalimide)",C(CN1C(=O)C2=C(C1=O)C(=C(C(=C2Br)Br)Br)Br)N3C(=O)C4=C(C3=O)C(=C(C(=C4Br)Br)Br)Br,,,,"['14C-labelled BT93 was administered orally by gavage in corn oil to 5 female Sprague-Dawley rats for 14 consecutive days. Two rats were sacrificed 24 hr after the last dose; remainder sacrificed 7, 14, and 30 days after the last dose. Liver, kidney, brain, leg muscle and body fat were collected at each sacrifice. Urine, feces and expired air was collected 24 hr after the last dose. The compound was excreted mainly in the feces (approximately 65% of the total dose). Approximately 15% of the total dose was found in the urine. The amount of the radiolabel excreted in expired air was negligible. A minor trace amount of 14C-label was temporarily detected in tissues; residues were <0.5 ppm in any tissue. Tissues from animals sacrificed during the withdrawal period showed a dissipation of residue levels in all tissues within the 30 withdrawal period. Kidney level went from 0.32 ppm 24 hr after the last dose to 0.043 ppm at day 30 post dosing; liver went from 0.424 ppm 24 hr after the last dose to 0.024 ppm at day 30 post dosing.']",,
1489,36184,CID 36184,CC1(CN(C(=N1)S)C2=CC=CC=C2)C,,,,,,
1490,36185,"2,3',4,4'-Tetrachlorobiphenyl",C1=CC(=C(C=C1C2=C(C=C(C=C2)Cl)Cl)Cl)Cl,,,,,,
1491,36186,"2,3',4',5-Tetrachlorobiphenyl",C1=CC(=C(C=C1C2=C(C=CC(=C2)Cl)Cl)Cl)Cl,,,,,,
1492,36187,"3,3',4,4'-Tetrachlorobiphenyl",C1=CC(=C(C=C1C2=CC(=C(C=C2)Cl)Cl)Cl)Cl,,,,"[""3,3',4,4'-TETRACHLOROBIPHENYL (TCB) WAS ADMIN ORALLY TO ADULT FEMALE SPRAGUE-DAWLEY RATS IN DOSAGE REGIMENS OF 0.2, 0.5, & 2 MG/KG/DAY FOR 10 DAYS AT 5 MG/KG/DAY FOR 4 DAYS. IT WAS DISTRIBUTED PREFERENTIALLY INTO ADIPOSE TISSUE & LIVER, WHERE THE XENOBIOTIC CONCN WAS GREATER THAN IN ADIPOSE TISSUE. THE ADIPOSE TISSUE & HEPATIC TCB CONCN WERE DEPENDENT ON BOTH ABSOLUTE DOSE & DOSING SCHEDULE. ONLY TRACE AMOUNTS WERE DETECTABLE BY GLC IN THE SERUM, BRAIN, & KIDNEY. FECAL EXCRETION WAS GREATER THAN URINARY EXCRETION IN THOSE RATS ADMIN 5 MG/KG/DAY FOR 4 DAYS."", 'DISPOSITION OF 37 PCB CONGENERS & ADIPOSE TISSUE-PLASMA PARTITION OF 28 PCB CONGENERS WERE STUDIED IN 26 PERSONS OCCUPATIONALLY EXPOSED TO VARIOUS PCBS (20-54% CL). CONCN OF PCBS IN ADIPOSE TISSUE & PLASMA WERE RELATED TO DURATION & INTENSITY OF EXPOSURE. PCB CONCN IN ADIPOSE TISSUE WAS PROPORTIONAL TO THAT IN PLASMA, WITH A PARTITION FOR TOTAL PCBS OF APPROX 190:1 INDICATED FROM REGRESSION ANALYSIS. PCB CONGENERS WITH CL IN BOTH 4-POSITIONS OF BIPHENYL RING WERE MAJOR COMPONENTS IN PLASMA & ADIPOSE TISSUE. CONGENERS WITH UNSUBSTITUTED 3,4-POSITIONS ON 1 OR BOTH OF BIPHENYL RINGS WERE OBSERVED AT LOWER CONCENTRATIONS. IN CONTRAST, THOSE COMPOUNDS WITH SUBSTITUENTS AT 2,4- & 3,4-POSITIONS ON BOTH RINGS WERE PRESENT IN MUCH HIGHER PROPORTIONS IN BLOOD OR ADIPOSE TISSUE THAN IN PCB MIXTURES USED. THESE COMPONENTS ALSO HAD HIGHER ADIPOSE TISSUE-PLASMA PARTITION THAN THOSE WITH UNSUBSTITUTED 3,4-POSITIONS, REGARDLESS OF DEGREE OF CHLORINATION.', ""3,3'4,4'-TETRACHLOROBIPHENYL SHOWED RELATIVE ACCUMULATION FACTORS WHICH AT STEADY STATE WERE PRACTICALLY CONSTANT FOR ANY KIND OF FISH EXAMINED. THE ACCUMULATION FACTORS FOR A PARTICULAR PCB COMPOUND IN DIFFERENT FISH WERE PROPORTIONAL TO THE LIPID CONTENTS OF THE FISH."", ""A COMPARATIVE STUDY OF THE DISTRIBUTION & EXCRETION OF 3,4,3',4'-TETRACHLOROBIPHENYL (3,4,3'4'-TCB) WAS CONDUCTED IN MALE & FEMALE RATS & FEMALE RHESUS MONKEYS IN AN EFFORT TO ACCOUNT FOR THE TOXICITY OF THIS POLYCHLORINATED BIPHENYL (PCB). DISTRIBUTION & CLEARANCE OF 3,4,3',4'-TCB WERE SIMILAR IN MALE & FEMALE RATS. ALTHOUGH TCB WAS CLEARED MORE SLOWLY BY MONKEYS THAN BY RATS, THE MONKEYS WERE ABLE TO CLEAR IT AT AN APPRECIABLE RATE SO THAT TISSUE LEVELS WERE NEGLIGIBLE 6 WK AFTER ADMIN. TOXICITY COULD NOT BE ATTRIBUTED TO INABILITY OF THE ANIMALS TO METABOLIZE & EXCRETE IT OR TO ITS PERSISTENCE IN ANY TISSUE, WITH THE POSSIBLE EXCEPTION OF BLOOD. 3,4,3',4'-TCB &/OR ITS METABOLITES APPEARED TO BE MORE PERSISTENT IN BLOOD THAN ANY PCB STUDIED TO DATE.""]","[""PREDOMINANT ROUTE OF PCB METABOLISM IS HYDROXYLATION. SOME CHLOROBIPHENYLS MAY BE HYDROXYLATED VIA ARENE OXIDE INTERMEDIATES. IN THE RAT 3,3',4,4'-TETRACHLOROBIPHENYL IS HYDROXYLATED TO THE 2- & 5-HYDROXYLATED DERIVATIVE AND 3- & 5-HYDROXYLATED DERIVATIVE."", ""25 MG OF 3,3'4,4'-TETRACHLOROBIPHENYL (TCB) IN SOYBEAN OIL WAS ADMIN ORALLY TO RATS EVERY 3RD DAY FOR 9 DAYS, AFTER 12 DAYS ONLY THE CHLOROFORM EXTRACT OF FECES CONTAINED UNCHANGED TCB OR 3 TCB METABOLITES. THE MAJOR METABOLITE WAS EITHER 2-HYDROXY-3,3'4,4'-TETRACHLOROBIPHENYL OR 5-HYDROXY-3,3',4,4'-TETRACHLOROBIPHENYL. DURING 14 DAYS AFTER ORAL ADMIN OF SINGLE DOSE OF 25 MG TCB, 64% OF DOSE WAS EXCRETED UNCHANGED, MOST OF WHICH WAS UNABSORBED MATERIAL FROM GI TRACT. FECAL EXCRETION OF MAJOR METABOLITE ACCOUNTED FOR ONLY 3.3% OF DOSE."", ""OF 36 PURE ISOMERS (CHLORINE NUMBERS 1-5) OF POLYCHLORINATED BIPHENYLS EXAM, 23 COMPOUNDS WERE METABOLIZED BY ALCALIGENS SPECIES STRAIN Y42 & 33 COMPOUNDS WERE METABOLIZED BY ACINETOBACTER SPECIES STRAIN P6. MAJOR PATHWAY OF MANY POLYCHLORINATED BIPHENYL ISOMERS EXAM WAS CONSIDERED TO PROCEED THROUGH 2',3'-DIHYDRO-2',3'-DIOL COMPOUNDS, CONCOMITANT DEHYDROGENATED 2',3'-DIHYDROXY COMPOUNDS, SUBSEQUENTLY THE 1',2'-META-CLEAVAGE COMPOUNDS (CHLORINATED DERIV OF 2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACIDS), & THEN CHLOROBENZOIC ACIDS."", ""Incubation of (14)C-labeled 3,4,3',4'-tetrachlorobiphenyl with a reconstituted monooxygenase system containing cytochrome p450 isolated from 3-methylcholanthrene treated rats /was conducted/. ... Increases in incorporation and covalent binding to the proteins were dependent on incubation time and required cytochrome p450-linked monooxygenase activity. In the absence of erythrocytes, the reactive 3,4,3',4'-tetrachlorobiphenyl metabolites were bound to cytochrome p450, nicotinamide adenine dinucleotide phosphate reductase cytochrome p450, and high-mol wt aggregates whereas inclusion of the cells in the reaction mixt caused marked alkylation of Hb and a decrease in binding to the electron transfer proteins. Several metabolites other than protein-bound metabolites were detected."", ""For more Metabolism/Metabolites (Complete) data for 3,3',4,4'-TETRACHLOROBIPHENYL (7 total), please visit the HSDB record page.""]","['BIOLOGICAL HALF-LIFE OF 31 DICHLORO- TO DECHLOROBIPHENYL CONGENERS WERE MONITORED FOR 105 DAYS IN ADULT RAINBOW TROUT THAT WERE EXPOSED TO A SINGLE ORAL DOSE. IN WHOLE FISH, HALF-LIFE INCR FROM 5 DAYS TO NO APPARENT ELIM AS THE NUMBER OF CHLORINES ON THE BIPHENYL INCR. THIS STRUCTURE-ACTIVITY RELATION WAS NOT AS EVIDENT IN MUSCLE WHERE HALF-LIFE RANGED FROM LESS THAN 5 DAYS TO 127 DAYS. DECLINE IN MUSCLE PCB MAY BE RELATED TO THE DECR IN LIPID LEVELS & REDISTRIBUTION OF CONGENERS WITHIN THE FISH. FROM STRUCTURE-ACTIVITY ANALYSIS OF HALF-LIFE IN WHOLE FISH, ELIM IS ENHANCED FOR THOSE CONGENERS WITH LOWER CHLORINE CONTENT, WITH NO CHLORINE SUBSTITUTIONS IN THE ORTHO POSITIONS, & THOSE WITH 2 UNSUBSTITUTED CARBONS THAT ARE ADJACENT (VICINAL) ON THE BIPHENYL. A SIGNIFICANT DECLINE IN TOTAL PCB CONTENT IN WHOLE FISH, EQUIV TO HALF-LIFE OF 219 DAYS, WAS PARTLY DUE TO DECOMP OF THE PCB MIXTURE ADMIN, & SELECTIVE ELIM OF LOWER CHLORINATED BIPHENYLS.', ""Female NR mice were administered 1 mg/kg of 3,4,3',4'-HCB for 20 day in the diet. Whole body half-life was 0.9 days. /From table/""]"
1493,36188,"2,3,3',4,4'-Pentachlorobiphenyl",C1=CC(=C(C=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl,,,"['Substances or energies, for example heat or light, which when introduced into the air, water, or land threaten life or health of individuals or ECOSYSTEMS. (See all compounds classified as Environmental Pollutants.)']",,,
1494,36189,2-Methoxyphenoxyethyldiethylamine hydrochloride,CC[NH+](CC)CCOC1=CC=CC=C1OC.[Cl-],,,,,,
1495,36190,Guaiactamine,CCN(CC)CCOC1=CC=CC=C1OC,,,,,,
1496,36191,CID 36191,CC1=C(N(C2=CC=CC=C2C1=O)C)O,,,,,,
1497,36192,"Carbostyril, 1,3-dimethyl-4-methoxy-",CC1=C(C2=CC=CC=C2N(C1=O)C)OC,,,,,,
1498,36193,"Hydrazine, (2-fluorophenethyl)-",C1=CC=C(C(=C1)CCNN)F,,,,,,
1499,36194,"Anthranilic acid, N-(4-(1-adamantylmethyl)phenyl)-",C1C2CC3CC1CC(C2)(C3)CC4=CC=C(C=C4)NC5=CC=CC=C5C(=O)O,,,,,,
1500,36195,"1,4-Dimethylcinnolinium iodide",CC1=CN=[N+](C2=CC=CC=C12)C.[I-],,,,,,
1501,36196,"1,4-Dimethylcinnolin-1-ium",CC1=CN=[N+](C2=CC=CC=C12)C,,,,,,
1502,36197,Benzamido furan-3-carboxylate,C1=CC=C(C=C1)C(=O)NOC(=O)C2=COC=C2,,,,,,
1503,36198,"Benzoic acid, p-((2-hydroxy-1-naphthyl)azo)-",C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)C(=O)O)O,,,,,,
1504,36199,3-[(2-Hydroxy-1-naphthyl)azo]benzoic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=CC(=C3)C(=O)O)O,,,,,,
1505,36200,3-Acetamido-5-[2-(methylamino)-2-oxoethyl]benzoic acid,CC(=O)NC1=CC(=CC(=C1)C(=O)O)CC(=O)NC,,,,,,
1506,36201,2-(1-Adamantylamino)benzoic acid,C1C2CC3CC1CC(C2)(C3)NC4=CC=CC=C4C(=O)O,,,,,,
1507,36202,Methyl ((2-aminoethyl)thio)glycolate hydrochloride,COC(=O)C(O)SCC[NH3+].[Cl-],,,,,,
1508,36203,Methyl 2-(2-aminoethylsulfanyl)-2-hydroxyacetate,COC(=O)C(O)SCCN,,,,,,
1509,36204,CID 36204,CCN=C(NN=C(C)C1=CC=CC=N1)S,,,,,,
1510,36205,4-Acetoxyaminoquinoline,C1=CC=C2C(=C1)C(=CC=N2)NCC(=O)O,,,,,,
1511,36206,2-(Phenylsulfinyl)benzoic acid,C1=CC=C(C=C1)S(=O)C2=CC=CC=C2C(=O)O,,,,,,
1512,36207,Mesoridazine besylate,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C.C1=CC=C(C=C1)S(=O)(=O)O,,,,,,
1513,36208,Tributylmethylammonium hydroxide,CCCC[N+](C)(CCCC)CCCC.[OH-],,,,,,
1514,36209,Tributylmethylammonium,CCCC[N+](C)(CCCC)CCCC,,,,,,
1515,36210,Bis(L-tyrosinato)cobalt,C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.[Co],,,,,,
1516,36211,"((2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)benzoic acid",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC3=CC=C(C=C3)C(=O)O,,,,,,
1517,36212,CID 36212,CC1=CC(=NC(=N1)NC(=N[NH3+])N)NC(=N[NH3+])N.[O-]S(=O)(=O)[O-],,,,,,
1518,36213,1-Amino-2-[2-[[amino(hydrazinyl)methylidene]amino]-6-methylpyrimidin-4-yl]guanidine,CC1=CC(=NC(=N1)N=C(N)NN)N=C(N)NN,,,,,,
1519,36214,CID 36214,CC1=CN=C(N=C1NC(=N[NH3+])N)NC(=N[NH3+])N.[O-]S(=O)(=O)[O-],,,,,,
1520,36215,1-Amino-2-[2-[[amino(hydrazinyl)methylidene]amino]-5-methylpyrimidin-4-yl]guanidine,CC1=CN=C(N=C1N=C(N)NN)N=C(N)NN,,,,,,
1521,36216,CID 36216,C1=CN=C(N=C1NC(=N[NH3+])N)NC(=N[NH3+])N.[O-]S(=O)(=O)[O-],,,,,,
1522,36217,1-Amino-2-[2-[[amino(hydrazinyl)methylidene]amino]pyrimidin-4-yl]guanidine,C1=CN=C(N=C1N=C(N)NN)N=C(N)NN,,,,,,
1523,36218,"2,4,4',5-Tetrachlorobiphenyl",C1=CC(=CC=C1C2=CC(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
1524,36219,5-Nitroindoline,C1CNC2=C1C=C(C=C2)[N+](=O)[O-],,,,,,
1525,36220,"1,1,1,2,3,3,4,4-Octachlorobutane",C(C(C(Cl)Cl)(Cl)Cl)(C(Cl)(Cl)Cl)Cl,,,,,,
1526,36221,Pentylmercury;pentylmercury(1+);sulfanide,CCCCC[Hg].CCCCC[Hg+].[SH-],,,,,,
1527,36222,Pentylmercury(1+),CCCCC[Hg+],,,,,,
1528,36223,Mercurhexan,CCCCC[Hg],,,,,,
1529,36224,2-Ethyl-6-vinylpyrazine,CCC1=CN=CC(=N1)C=C,,,,,,
1530,36225,"2,5-Diethyl-3-methylpyrazine",CCC1=CN=C(C(=N1)C)CC,,,,,,
1531,36226,CID 36226,C1=CC=C(C(=C1)O)Br.C1=CC(=CC(=C1)Br)O.C1=CC(=CC=C1O)Br,,,,,,
1532,36227,CID 36227,C(C(C1C(=O)C(=C(O1)O)N)O)O,,,,,,
1533,36228,2-Methylbenzothiazol-5-ylamine dihydrochloride,CC1=[NH+]C2=C(S1)C=CC(=C2)[NH3+].[Cl-].[Cl-],,,,,,
1534,36229,5-Amino-2-methylbenzothiazole,CC1=NC2=C(S1)C=CC(=C2)N,,,,,,
1535,36230,"4H-1-Benzopyran-2-carboxamide, N,N-diethyl-4-oxo-",CCN(CC)C(=O)C1=CC(=O)C2=CC=CC=C2O1,,,,,,
1536,36231,"3,3',4,4',5,5'-Hexachlorobiphenyl",C1=C(C=C(C(=C1Cl)Cl)Cl)C2=CC(=C(C(=C2)Cl)Cl)Cl,,,,"[""FOLLOWING ORAL ADMIN TO LACTATING COW, LEVELS OF 3,3',4,4',5,5'-HEXACHLOROBIPHENYL REACHED PEAK CONCENTRATIONS IN MILK BETWEEN THE 2ND & 3RD DAY, & RAPIDLY DECLINED THEREAFTER."", 'DISPOSITION OF 37 PCB CONGENERS & ADIPOSE TISSUE-PLASMA PARTITION OF 28 PCB CONGENERS WERE STUDIED IN 26 PERSONS OCCUPATIONALLY EXPOSED TO VARIOUS PCBS (20-54% CL). CONCN OF PCBS IN ADIPOSE TISSUE & PLASMA WERE RELATED TO DURATION & INTENSITY OF EXPOSURE. PCB CONCN IN ADIPOSE TISSUE WAS PROPORTIONAL TO THAT IN PLASMA, WITH A PARTITION FOR TOTAL PCBS OF APPROX 190:1 INDICATED FROM REGRESSION ANALYSIS. PCB CONGENERS WITH CL IN BOTH 4-POSITIONS OF BIPHENYL RING WERE MAJOR COMPONENTS IN PLASMA & ADIPOSE TISSUE. CONGENERS WITH UNSUBSTITUTED 3,4-POSITIONS ON 1 OR BOTH OF BIPHENYL RINGS WERE OBSERVED AT LOWER CONCENTRATIONS. IN CONTRAST, THOSE COMPOUNDS WITH SUBSTITUENTS AT 2,4- & 3,4-POSITIONS ON BOTH RINGS WERE PRESENT IN MUCH HIGHER PROPORTIONS IN BLOOD OR ADIPOSE TISSUE THAN IN PCB MIXTURES USED. THESE COMPONENTS ALSO HAD HIGHER ADIPOSE TISSUE-PLASMA PARTITION THAN THOSE WITH UNSUBSTITUTED 3,4-POSITIONS, REGARDLESS OF DEGREE OF CHLORINATION.']",,"['BIOLOGICAL HALF-LIFE OF 31 DICHLORO- TO DECHLOROBIPHENYL CONGENERS WERE MONITORED FOR 105 DAYS IN ADULT RAINBOW TROUT THAT WERE EXPOSED TO A SINGLE ORAL DOSE. IN WHOLE FISH, HALF-LIFE INCR FROM 5 DAYS TO NO APPARENT ELIM AS THE NUMBER OF CHLORINES ON THE BIPHENYL INCR. THIS STRUCTURE-ACTIVITY RELATION WAS NOT AS EVIDENT IN MUSCLE WHERE HALF-LIFE RANGED FROM LESS THAN 5 DAYS TO 127 DAYS. DECLINE IN MUSCLE PCB MAY BE RELATED TO THE DECR IN LIPID LEVELS & REDISTRIBUTION OF CONGENERS WITHIN THE FISH. FROM STRUCTURE-ACTIVITY ANALYSIS OF HALF-LIFE IN WHOLE FISH, ELIM IS ENHANCED FOR THOSE CONGENERS WITH LOWER CHLORINE CONTENT, WITH NO CHLORINE SUBSTITUTIONS IN THE ORTHO POSITIONS, & THOSE WITH 2 UNSUBSTITUTED CARBONS THAT ARE ADJACENT (VICINAL) ON THE BIPHENYL. A SIGNIFICANT DECLINE IN TOTAL PCB CONTENT IN WHOLE FISH, EQUIV TO HALF-LIFE OF 219 DAYS, WAS PARTLY DUE TO DECOMP OF THE PCB MIXTURE ADMIN, & SELECTIVE ELIM OF LOWER CHLORINATED BIPHENYLS.']"
1537,36232,Trimethyl-(1-methyl-2-(10-phenothiazinyl)ethyl)ammonium sulfate,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)[N+](C)(C)C.OS(=O)(=O)[O-],,,,,,
1538,36233,"Glycine, N-nitro-N-(2,2,2-trinitroethyl)-, ethyl ester",CCOC(=O)CN(CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1539,36234,"Glycine, N-(2-chloro-2,2-dinitroethyl)-N-nitro-, ethyl ester",CCOC(=O)CN(CC([N+](=O)[O-])([N+](=O)[O-])Cl)[N+](=O)[O-],,,,,,
1540,36235,"Glycine, N-(2-chloro-2,2-dinitroethyl)-N-nitro-",C(C(=O)O)N(CC([N+](=O)[O-])([N+](=O)[O-])Cl)[N+](=O)[O-],,,,,,
1541,36236,Methylmercury;phosphoric acid,C[Hg].OP(=O)(O)O,,,,,,
1542,36237,"BENZOIC ACID, p-CHLORO-, 2,4-DINITROPHENYL ESTER",C1=CC(=CC=C1C(=O)OC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])Cl,,,,,,
1543,36238,"4',4'''-Sulfonylbis(2-(sec-butylamino)acetanilide)",CCC(C)NCC(=O)NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)CNC(C)CC,,,,,,
1544,36239,"4-Hydroxy-4-oxobut-2-enoate;2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-2-ium-8-amine",C[NH+]1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
1545,36240,Methyl 4-chloroacetoacetate,COC(=O)CC(=O)CCl,,,,,,
1546,36241,"Butyric acid, 4-(3-chloro-4-cyclohexylphenyl)-",C1CCC(CC1)C2=C(C=C(C=C2)CCCC(=O)O)Cl,,,,,,
1547,36242,Procymidone,CC12CC1(C(=O)N(C2=O)C3=CC(=CC(=C3)Cl)Cl)C,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']",,,
1548,36243,"1,1,1-Trichlorobutane-2,3-diol",CC(C(C(Cl)(Cl)Cl)O)O,,,,,,
1549,36244,"7-Methoxy-6-methyl-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride",CC1=CC2=C(CC(CC2)[NH3+])C=C1OC.[Cl-],,,,,,
1550,36245,"7-Methoxy-6-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CC1=CC2=C(CC(CC2)N)C=C1OC,,,,,,
1551,36246,3-Chloro-5-ethoxy-2(5H)-furanone,CCOC1C=C(C(=O)O1)Cl,,,,,,
1552,36247,14-Methylpentadecanoic acid,CC(C)CCCCCCCCCCCCC(=O)O,,,,,,
1553,36248,2-(4-Methyl-2-thiazolyl)hydrazinecarboxaldehyde,CC1=CSC(=N1)NNC=O,,,,,,
1554,36249,"Ethanone, 1-(3-phenoxyphenyl)-",CC(=O)C1=CC(=CC=C1)OC2=CC=CC=C2,,,,,,
1555,36250,Chlomethoxyfen,COC1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],,,,,,
1556,36251,3-(3-Bromophenyl)acrylic acid,C1=CC(=CC(=C1)Br)C=CC(=O)O,,,,,,
1557,36252,"p,p'-Oxamidodibenzoic acid bis(2-(diethylamino)ethyl) ester dihydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C(=O)NC2=CC=C(C=C2)C(=O)OCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
1558,36253,2-(Diethylamino)ethyl 4-[[2-[4-[2-(diethylamino)ethoxycarbonyl]anilino]-2-oxoacetyl]amino]benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C(=O)NC2=CC=C(C=C2)C(=O)OCCN(CC)CC,,,,,,
1559,36254,"BENZAMIDE, 5-((p-(BIS(2-CHLOROETHYL)AMINO)PHENYL)THIO)-2,4-DINITRO-",C1=CC(=CC=C1N(CCCl)CCCl)SC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1560,36255,"BENZAMIDE, 5-((p-(BIS(2-BROMOETHYL)AMINO)PHENYL)THIO)-2,4-DINITRO-",C1=CC(=CC=C1N(CCBr)CCBr)SC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1561,36256,"5-((p-((2-Chloropropyl)ethylamino)phenyl)thio)-2,4-dinitrobenzamide",CCN(CC(C)Cl)C1=CC=C(C=C1)SC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1562,36257,"BENZAMIDE, 5-((p-((2-CHLOROETHYL)ETHYLAMINO)BENZYL)AMINO)-2,4-DINITRO-",CCN(CCCl)C1=CC=C(C=C1)CNC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1563,36258,"5-(p-((2-Chloropropyl)ethylamino)anilino)-2,4-dinitrobenzamide",CCN(CC(C)Cl)C1=CC=C(C=C1)NC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1564,36259,"BENZAMIDE, 5-((p-(BIS(2-IODOETHYL)AMINO)PHENYL)THIO)-2,4-DINITRO-",C1=CC(=CC=C1N(CCI)CCI)SC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1565,36260,"6,7-Dimethoxy-4-(o-fluorobenzyl)isoquinoline hydrobromide",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC=CC=C3F)OC.[Br-],,,,,,
1566,36261,"4-(2-Fluorobenzyl)-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC=CC=C3F)OC,,,,,,
1567,36262,"6,7-Dimethoxy-4-(m-fluorobenzyl)isoquinoline hydrobromide",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC(=CC=C3)F)OC.[Br-],,,,,,
1568,36263,"4-(3-Fluorobenzyl)-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC(=CC=C3)F)OC,,,,,,
1569,36264,"6,7-Dimethoxy-4-(p-fluorobenzyl)isoquinoline hydrobromide",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC=C(C=C3)F)OC.[Br-],,,,,,
1570,36265,"4-[(4-Fluorophenyl)methyl]-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC=C(C=C3)F)OC,,,,,,
1571,36266,"4-Benzyl-6,7-dimethoxyisoquinoline hydrobromide",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC=CC=C3)OC.[Br-],,,,,,
1572,36267,"4-Benzyl-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC=CC=C3)OC,,,,,,
1573,36268,"6,7-Dimethoxy-4-(3,4-dimethoxybenzyl)isoquinoline hydrobromide",COC1=C(C=C(C=C1)CC2=C[NH+]=CC3=CC(=C(C=C32)OC)OC)OC.[Br-],,,,,,
1574,36269,"4-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline",COC1=C(C=C(C=C1)CC2=CN=CC3=CC(=C(C=C32)OC)OC)OC,,,,,,
1575,36270,"4-(p-Chlorobenzyl)-6,7-dimethoxyisoquinoline hydrobromide",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC=C(C=C3)Cl)OC.[Br-],,,,,,
1576,36271,"6,7-Dimethoxy-4-(4-chlorobenzyl)isoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC=C(C=C3)Cl)OC,,,,,,
1577,36272,"2,2-dimethylpropanoyloxymethyl (5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1(C(N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C,,,,,,
1578,36273,Mecillinam,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C,['Used in the treatment of urinary tract infections caused by some strains of E. coli and klebsiella and enterobacter species. Used mainly against Gram negative organisms.'],"['Amdinocillin is a novel, semisynthetic penicillin effective against many gram-negative bacteria. The antibacterial activity of amdinocillin is derived from its ability to bind specifically and avidly to Penicillin Binding Protein-2 (PBP 2). Amdinocillin is active alone against many gram-negative organisms. Pseudomonas and non-fermenting gram-negative bacteria, however, are usually resistant. Amdinocillin, in combination with many beta-lactams, exhibits marked synergy against many enterobacteriaceae. No such synergy can be demonstrated for gram-positive organisms or pseudomonas species. Amdinocillin is not beta-lactamase stable. Organisms which produce high levels of plasma-mediated beta-lactamase are resistant to the drug. Co-administration of probenecid results in markedly elevated plasma levels of amdinocillin and delays its excretion.']","['Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",['Poorly absorbed if given orally.'],,['Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.']
1579,36274,Procyazine,CC(C)(C#N)NC1=NC(=NC(=N1)NC2CC2)Cl,,,,,,
1580,36275,CID 36275,CCCCN=C(NCC)S,,,,,,
1581,36276,Dimethylheptylpyran,CCCCCC(C)C(C)C1=CC(=C2C3=C(CCC(C3)C)C(OC2=C1)(C)C)O,,,,,,
1582,36277,4-(Cyclohexylcarbonyl)pyridine,C1CCC(CC1)C(=O)C2=CC=NC=C2,,,,,,
1583,36278,"Indoline-1-acetic acid, 5-methoxy-3,3-diphenyl-2-oxo-",COC1=CC2=C(C=C1)N(C(=O)C2(C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)O,,,,,,
1584,36279,"2,2',5-Trimethoxybenzophenone",COC1=CC(=C(C=C1)OC)C(=O)C2=CC=CC=C2OC,,,,,,
1585,36280,"1,2,3,3a,8,8a-Hexahydro-1-methyl-3a-propylindeno(2,1-b)pyrrole hydrochloride",CCCC12CC[NH+](C1CC3=CC=CC=C23)C.[Cl-],,,,,,
1586,36281,"1,2,3,3a,8,8a-Hexahydro-1-methyl-3a-propylindeno[2,1-b]pyrrole",CCCC12CCN(C1CC3=CC=CC=C23)C,,,,,,
1587,36282,"1-Heptanone, 1-(4-pyridyl)-",CCCCCCC(=O)C1=CC=NC=C1,,,,,,
1588,36283,"3,4-Dihydroxy-alpha-(2-piperidyl)benzyl alcohol hydrobromide",C1CCN[C@H](C1)[C@H](C2=CC(=C(C=C2)O)O)O,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],,,
1589,36284,4-Ipomeanol,CC(CCC(=O)C1=COC=C1)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,"['URINARY EXCRETION & METABOLISM OF 4-IPOMEANOL WAS STUDIED IN RATS INJECTED IP WITH THE RADIOLABELED COMPD. THERE WAS RAPID ELIMINATION OF RADIOACTIVITY IN THE URINE, AMOUNTING TO 47% OF THE ADMINISTERED DOSE WITHIN 4 HR. ONE MAJOR METABOLITE, IPOMEANOL 4-GLUCURONIDE, WAS IDENTIFIED. THE LARGE AMOUNT OF THIS METABOLITE EXCRETED SUGGESTS THAT 4-GLUCURONIDATION IS AN IMPORTANT DETOXICATION REACTION IN VIVO FOR 4-IPOMEANOL IN RATS.']",
1590,36285,"OXAMIDE, N,N'-BIS(p-((2-(DIETHYLAMINO)ETHYL)CARBAMOYL)PHENYL)-, DIHYDROCHLORIDE",CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(=O)NC2=CC=C(C=C2)C(=O)NCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
1591,36286,"N,N'-bis[4-[2-(diethylamino)ethylcarbamoyl]phenyl]oxamide",CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C(=O)NC2=CC=C(C=C2)C(=O)NCCN(CC)CC,,,,,,
1592,36287,"Benzoic acid, p,p'-succinamidodi-, bis(2-(diethylamino)ethyl) ester, dihydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)CCC(=O)NC2=CC=C(C=C2)C(=O)OCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
1593,36288,2-(Diethylamino)ethyl 4-[[4-[4-[2-(diethylamino)ethoxycarbonyl]anilino]-4-oxobutanoyl]amino]benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)CCC(=O)NC2=CC=C(C=C2)C(=O)OCCN(CC)CC,,,,,,
1594,36289,"Benzoic acid, p-(p-(N-N-diethylsulfamoyl)benzamido)-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)S(=O)(=O)N(CC)CC.[Cl-],,,,,,
1595,36290,2-(Diethylamino)ethyl 4-[[4-(diethylsulfamoyl)benzoyl]amino]benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)S(=O)(=O)N(CC)CC,,,,,,
1596,36291,"BENZOXAZOLE, 2-(o-(2-DIETHYLAMINOETHOXY)PHENYL)-",CCN(CC)CCOC1=CC=CC=C1C2=NC3=CC=CC=C3O2,,,,,,
1597,36292,2-(tert-Butoxy)butane,CCC(C)OC(C)(C)C,,,,,,
1598,36293,Ethylnitrosobiuret,CCN(C(=O)NC(=O)N)N=O,,,,,,
1599,36294,Tobramycin,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,"['Inhaled tobramycin is indicated for the management of cystic fibrosis patients with _Pseudomonas aeruginosa_, but is not recommended in patients under six years of age, those with forced expiratory volume in 1 second (FEV<sub>1</sub>) <25 or >80% predicted, or in those with _Burkholderia cepacia_.  Tobramycin applied topically to the eyes is indicated for the treatment of external eye (and adjoining structure) infections by susceptible bacteria.   Tobramycin injection is indicated in adult and pediatric patients for the treatment of serious bacterial infections, including septicemia (caused by _P. aeruginosa_, _Escherichia coli_, and _Klebsiella_ spp.), lower respiratory tract infections (caused by _P. aeruginosa_, _Klebsiella_ spp., _Enterobacter_ spp., _Serratia_ spp., _E. coli_, and _Staphylococcus aureus_, both penicillinase and non-penicillinase-producing strains), serious central-nervous-system infections (meningitis, caused by susceptible organisms), intra-abdominal infections including peritonitis (caused by _E. coli_, _Klebsiella_ spp., and _Enterobacter_ spp.), skin, bone, and skin structure infections (caused by _P. aeruginosa_, _Proteus_ spp., _E. coli_, _Klebsiella_ spp., _Enterobacter_ spp., _Serratia_ spp. and _S. aureus_), and complicated and recurrent urinary tract infections (caused by _P. aeruginosa_, _Proteus_ spp., _E. coli_, _Klebsiella_ spp., _Enterobacter_ spp., _Serratia_ spp., _S. aureus_, _Providencia_ spp., and _Citrobacter_ spp.). Aminoglycosides, including tobramycin, should generally not be used in uncomplicated urinary tract infections or staphylococcal infections unless less toxic antibiotics cannot be used and the bacteria in question are known to be sensitive to aminoglycosides.  As with all antibiotics, tobramycin use should be limited to cases where bacterial infections are known or strongly suspected to be caused by sensitive organisms, and the possible emergence of resistance should be monitored closely.']","[""Tobramycin is an aminoglycoside antibiotic derived from the actinomycete _Streptomyces tenebrarius_. It has a broad spectrum of activity against Gram-negative bacteria, including _Enterobacteriaceae_, _Escherichia coli_, _Klebsiella pneumoniae_, _Morganella morganii_, _Moraxella lacunata_, _Proteus_ spp., _Haemophilus_ spp., _Acinetobacter_ spp., _Neisseria_ spp., and, importantly, _Pseudomonas aeruginosa_. Aminoglycosides also generally retain activity against the biothreat agents _Yersinia pestis_ and _Francisella tularensis_. In addition, aminoglycosides are active against some Gram-positive bacteria such as _Staphylococcus_ spp., including methicillin-resistant (MRSA) and vancomycin-resistant strains, _Streptococcus_ spp., and _Mycobacterium_ spp.  Like other aminoglycosides, tobramycin is taken up and retained by proximal tubule and cochlear cells in the kidney and ear, respectively, and hence carries a risk of nephrotoxicity and ototoxicity. There is also a risk of neuromuscular block, which may be more pronounced in patients with preexisting neuromuscular disorders such as myasthenia gravis or Parkinson's disease. Aminoglycosides can cross the placenta, resulting in total, irreversible, bilateral congenital deafness in babies born to mothers who were administered an aminoglycoside during pregnancy. Due to the low systemic absorption of inhaled and topical tobramycin formulations, these effects are more pronounced with injected tobramycin than with other formulations. However, all formulations carry a risk of hypersensitivity reactions, including potentially fatal cutaneous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.""]",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Tobramycin administered by inhalation in cystic fibrosis patients showed greater variability in sputum as compared to serum. After a single 112 mg dose, the serum C<sub>max</sub> was 1.02  0.53 g/mL, which was reached in one hour (T<sub>max</sub>), while the sputum C<sub>max</sub> was 1048  1080 g/g. Comparatively, for a 300 mg dose, the serum C<sub>max</sub> was 1.04  0.58 g/mL, which was also reached within one hour, while the sputum C<sub>max</sub> was 737  1028 g/g. The systemic exposure (AUC<sub>0-12</sub>) was also similar between the two doses, at 4.6  2.0 gh/mL for the 112 mg dose and 4.8  2.5 gh/mL for the 300 mg dose. When tobramycin was administered over a four-week cycle at 112 mg twice daily, the C<sub>max</sub> measured one hour after dosing ranged from 1.48  0.69 g/mL to 1.99  0.59 g/mL.', 'Tobramycin is primarily excreted unchanged in the urine.', 'Inhalation tobramycin had an apparent volume of distribution in the central compartment of 85.1 L for a typical cystic fibrosis patient.', 'Inhaled tobramycin has an apparent serum clearance of 14.5 L/h in cystic fibrosis patients aged 6-58 years.', 'Tobramycin is poorly absorbed from the GI tract.', 'Tobramycin is rapidly absorbed following IM administration. Following IM administration of a single dose of tobramycin of 1 mg/kg in adults with normal renal function, peak serum tobramycin concentrations average 4-6 ug/mL and are attained within 30-90 minutes; at 6-8 hours after the dose, serum concentrations are 1 ug/mL or less. When the same dose is administered by IV infusion over 30-60 minutes, similar plasma concentrations of the drug are attained.', 'In one study in neonates receiving IM tobramycin in a dosage of 2 mg/kg every 12 hours, peak serum concentrations of the drug were attained 0.5-1 hour after a dose and ranged from 4.9-5.2 ug/mL after the first dose and 4.5-5.1 ug/mL after 10-16 doses. In neonates 2-7 days of age receiving tobramycin in a dosage of 2.5 mg/kg by IV infusion every 12 hours, steady-state peak serum concentrations ranged from 3.5-9.9 ug/mL and trough serum concentrations ranged from 1.1-3.6 ug/mL in those weighing less than 2 kg. In those weighing 2 kg or more, peak serum concentrations ranged from 5-10.2 ug/mL and trough serum concentrations ranged from 0.7-2 ug/mL.', 'Bioavailability of tobramycin administered by oral inhalation via a nebulizer may be variable because of individual differences in nebulizer performance and airway pathology. Following oral inhalation via nebulization, tobramycin remains concentrated principally in the airways; the drug does not readily cross epithelial membranes. Tobramycin sputum concentrations are highly variable following oral inhalation, but the drug does not appear to accumulate in sputum following multiple doses. Following an initial 300-mg dose of commercially available tobramycin solution for oral inhalation given via a nebulizer, sputum concentrations of the drug at 10 minutes averaged 1237 ug/g (range: 35-7414 ug/g). After 20 weeks of intermittent therapy (300-mg twice daily for 28 days followed by 28 days without the drug), sputum concentrations 10 minutes after administration averaged 1154 ug/g (range: 39-8085 ug/g) and sputum concentrations 2 hours after administration were approximately 14% of those obtained 10 minutes after administration. Following a single 300-mg dose of the commercially available tobramycin solution for oral inhalation given via nebulization in patients with cystic fibrosis, serum tobramycin concentrations averaged 0.95 ug/mL at 1 hour after administration; after 20 weeks of intermittent therapy (300 mg twice daily for 28 days followed by 28 days without the drug), serum tobramycin concentrations averaged 1.05 ug/mL at 1 hour after administration.', 'For more Absorption, Distribution and Excretion (Complete) data for Tobramycin (15 total), please visit the HSDB record page.']","['Tobramycin is not appreciably metabolized.', 'Aminoglycosides are not metabolized and are excreted unchanged in the urine primarily by glomerular filtration. /Aminoglycosides/']","['Tobramycin has an apparent serum terminal half-life of ~3 hours following a single 112 mg inhaled dose in cystic fibrosis patients.', 'Total body clearance of tobramycin is approximately 20% higher in patients with cystic fibrosis than in patients without the disease; however, renal clearance is similar.', 'When tobramycin is administered by oral inhalation using a nebulizer, any drug that is not absorbed systemically probably is eliminated principally in expectorated sputum.', '... Terminal elimination half-lives of greater than 100 hours have been reported in adults with normal renal function following repeated IM or IV administration of the drug.', 'The plasma elimination half-life of tobramycin following parenteral administration usually is 2-3 hours in adults with normal renal function and has ranged from 50-70 hours in adults with impaired renal function. The serum elimination half-life of tobramycin is reported to average 4.6 hours in full-term infants weighing more than 2.5 kg and 8.7 hours in infants weighing less than 1.5 kg. In one study in neonates 2-7 days of age, elimination half-life ranged from 5.68-13.6 hours in those weighing less than 2 kg and 3.54-6.73 hours in those weighing 2 kg or more.']"
1600,36295,CID 36295,C1[C@@H](N=C(NC1[C@@H]2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CO)CO)NC(=O)CC(CCCN)N)N)O,,,,,,
1601,36296,"Acetic acid, (3-phenyl-1,2,4-thiadiazol-5-YL)thio-",C1=CC=C(C=C1)C2=NSC(=N2)SCC(=O)O,,,,,,
1602,36297,4-[(2-chlorophenyl)methylene]-2-methyl-5(4H)-Oxazolone,CC1=NC(=CC2=CC=CC=C2Cl)C(=O)O1,,,,,,
1603,36298,N-Methyl-N-phenylhydrazine sulfate,C[NH+](C1=CC=CC=C1)N.OS(=O)(=O)[O-],,,,,,
1604,36299,1-Methyl-1-phenylhydrazine,CN(C1=CC=CC=C1)N,,,,,,
1605,36300,Isopropylmercury hydroxide,CC(C)[Hg].O,,,,,,
1606,36301,Isopropylmer-cury,CC(C)[Hg],,,,,,
1607,36302,Proroxan hydrochloride,C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4.Cl,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
1608,36303,Proroxan,C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4,,,"['A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
1609,36304,"2,3,4,4'-Tetrachlorobiphenyl",C1=CC(=CC=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl,,,,,,
1610,36305,"2,4-Bis(chloromethyl)-6-(methylthio)-1,3,5-triazine",CSC1=NC(=NC(=N1)CCl)CCl,,,,,,
1611,36306,"1-Bromo-2,3-dichloropropane",C(C(CBr)Cl)Cl,,,,,,
1612,36307,p-Nitrophenylthioacetophenone,C1=CC=C(C=C1)C(=O)CSC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1613,36308,CID 36308,CC(C)CCC=CC(=O)C,,,,,,
1614,36309,"Benzoic acid, 4-(3-(2-chloroethyl)-3-nitrosoureido)-2,6-dimethyl-",CC1=CC(=CC(=C1C(=O)O)C)NC(=O)N(CCCl)N=O,,,,,,
1615,36310,"(2R)-N-[(2S)-2-chloro-1-[(3R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-pentylpyrrolidin-1-ium-2-carboxamide;chloride",CCCCCC1C[C@@H]([NH2+]C1)C(=O)NC(C2[C@@H](C(C([C@H](O2)SC)O)O)O)[C@H](C)Cl.[Cl-],,,,,,
1616,36311,"(2R)-N-[(2S)-2-chloro-1-[(3R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-pentylpyrrolidine-2-carboxamide",CCCCCC1C[C@@H](NC1)C(=O)NC(C2[C@@H](C(C([C@H](O2)SC)O)O)O)[C@H](C)Cl,,,,,,
1617,36312,1-Methyl-3-cyclohexen-1-OL,CC1(CCC=CC1)O,,,,,,
1618,36313,17-beta-Bis(2-chloroethyl)aminoandrost-4-en-3-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2N(CCCl)CCCl)CCC4=CC(=O)CC[C@]34C,,,,,,
1619,36314,Paclitaxel,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,"[""Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.""]","['Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or ""bundles"" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.']",,"['When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ngh/mL.', 'In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.', '227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]', '21.7 L/h/m2 [Dose 135 mg/m2, infusion duration 24 h]', 'Paclitaxel bound to nanoparticles of the serum protein albumin is delivered via endothelial transport mediated by albumin receptors, and the resulting concentration of paclitaxel in tumor cells is increased compared with that achieved using an equivalent dose of conventional paclitaxel. Like conventional paclitaxel, albumin-bound paclitaxel has a large volume of distribution. Following 30-minute or 3-hour IV infusion of 80-375 mg/sq m albumin-bound paclitaxel, the volume of distribution averaged 632 L/sq m. The volume of distribution of albumin-bound paclitaxel 260 mg/sq m by 30-minute IV infusion was 53% larger than the volume of distribution of conventional paclitaxel 175 mg/sq m by 3-hour IV infusion. /Paclitaxel (albumin-bound)/', 'Following IV administration, paclitaxel is widely distributed into body fluids and tissues. Paclitaxel has a large volume of distribution that appears to be affected by dose and duration of infusion. Following administration of paclitaxel doses of 135 or 175 mg/sq m by IV infusion over 24 hours in patients with advanced ovarian cancer, the mean apparent volume of distribution at steady state ranged from 227-688 L/sq m. The steady-state volume of distribution ranged from 18.9-260 L/sq m in children with solid tumors or refractory leukemia receiving paclitaxel 200-500 mg/sq m by 24-hour IV infusion. Paclitaxel does not appear to readily penetrate the CNS, but paclitaxel has been detected in ascitic fluid following IV infusion of the drug. It is not known whether paclitaxel is distributed into human milk, but in lactating rats given radiolabeled paclitaxel, concentrations of radioactivity in milk were higher than those in plasma and declined in parallel with plasma concentrations of the drug.', 'For the dose range 80-375 mg/sq m, increase in dose of albumin-bound paclitaxel was associated with a proportional increase in AUC.354 The duration of infusion did not affect the pharmacokinetic disposition of albumin-bound paclitaxel. Following 30-minute or 3-hour IV infusion of albumin-bound paclitaxel 260 mg/sq m, the peak plasma concentration averaged 18,741 ng/mL. /Paclitaxel (albumin-bound)/', 'Peak plasma concentrations and areas under the plasma concentration-time curve (AUCs) following IV administration of paclitaxel exhibit marked interindividual variation. Plasma concentrations of paclitaxel increase during continuous IV administration of the drug and decline immediately following completion of the infusion. Following 24-hour IV infusion of paclitaxel at doses of 135 or 175 mg/sq m in patients with advanced ovarian cancer, peak plasma concentrations averaged 195 or 365 ng/mL, respectively; the increase in dose (30%) was associated with a disproportionately greater increase in peak plasma concentration (87%), but the increase in AUC was proportional. When paclitaxel was administered by continuous IV infusion over 3 hours at doses of 135 or 175 mg/sq m in patients with advanced ovarian cancer, peak plasma concentrations averaged 2.17 or 3.65 ug/mL, respectively; the increase in dose (30%) was associated with disproportionately greater increases in peak plasma concentration (68%) and AUC (89%).', 'For more Absorption, Distribution and Excretion (Complete) data for TAXOL (8 total), please visit the HSDB record page.']","['Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3&rsquo;-p-hydroxypaclitaxel and 6a, 3&rsquo;-p-dihydroxypaclitaxel, by CYP3A4.', ""Paclitaxel is extensively metabolized in the liver. Metabolism of paclitaxel to its major metabolite, 6alpha-hydroxypaclitaxel, is mediated by cytochrome P-450 isoenzyme CYP2C8,1 185 187 202 354 while metabolism to 2 of its minor metabolites, 3'-p-hydroxypaclitaxel and 6alpha,3'-p-dihydroxypaclitaxel, is catalyzed by CYP3A4."", 'The elimination of nonradioactive taxol in bile and urine was investigated in the rat after administration via the caudal vein (10 mg/kg). As in humans, no metabolites of taxol were detected by HPLC in rat urine, and only 10% of the injected taxol was recovered in urine over a 24 hr period. In contrast, 11.5% and 29% of the injected taxol was recovered in rat bile as unchanged taxol and metabolites, respectively. Among the nine taxol metabolites detected by HPLC, the side chain at C13, which is required for pharmacological activity, had been removed in only one minor metabolite, baccatin III. The chemical structures of the two major hydroxylated metabolites were determined by MS (fast atom bombardment and desorption chemical ionization) and (1)H NMR spectroscopy. One was a taxol derivative hydroxylated on the phenyl group at C3 of the side chain at C13, while the other corresponded to a taxol derivative hydroxylated in the m-position on the benzoate of the side chain at C2. Although these two major taxol metabolites were as active as taxol in preventing cold microtubule disassembly, they were, respectively, 9 and 39 times less cytotoxic as taxol on in vitro L1210 leukemia growth. These results show for the first time that there is a significant hepatic metabolism of taxol.', ""To investigate how taxane's substituents at C3' affect its metabolism, ... the metabolism of cephalomannine and paclitaxel, a pair of analogs that differ slightly at the C3' position /was compared/. After cephalomannine was incubated with human liver microsomes in an NADPH-generating system, two monohydroxylated metabolites (M1 and M2) were detected by liquid chromatography/tandem mass spectrometry. C4'' (M1) and C6alpha (M2) were proposed as the possible hydroxylation sites, and the structure of M1 was confirmed by (1)H NMR. Chemical inhibition studies and assays with recombinant human cytochromes P450 (P450s) indicated that 4''-hydroxycephalomannine was generated predominantly by CYP3A4 and 6alpha-hydroxycephalomannine by CYP2C8. The overall biotransformation rate between paclitaxel and cephalomannine differed slightly (184 vs. 145 pmol/min/mg), but the average ratio of metabolites hydroxylated at the C13 side chain to C6alpha for paclitaxel and cephalomannine varied significantly (15:85 vs. 64:36) in five human liver samples. Compared with paclitaxel, the major hydroxylation site transferred from C6alpha to C4'', and the main metabolizing P450 changed from CYP2C8 to CYP3A4 for cephalomannine. In the incubation system with rat or minipig liver microsomes, only 4''-hydroxycephalomannine was detected, and its formation was inhibited by CYP3A inhibitors. Molecular docking by AutoDock suggested that cephalomannine adopted an orientation in favor of 4''-hydroxylation, whereas paclitaxel adopted an orientation favoring 3'-p-hydroxylation. Kinetic studies showed that CYP3A4 catalyzed cephalomannine more efficiently than paclitaxel due to an increased V(m). Our results demonstrate that relatively minor modification of taxane at C3' has major consequence on the metabolism.""]","['When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.', '5.3-17.4 hours after 1 and 6 hour  infusions at dosing levels of 15-275 mg/sq m', 'Following IV infusion of paclitaxel over periods ranging from 6-24 hours in adults with malignancy, plasma concentrations of paclitaxel appeared to decline in a biphasic manner in some studies, with an average distribution half-life  of 0.34 hours and an average elimination half-life of 5.8 hours. However, additional studies, particularly those in which paclitaxel is administered over shorter periods of infusion, show that the drug exhibits nonlinear pharmacokinetic behavior. In patients receiving paclitaxel 175 mg/sq m administered by 3-hour IV infusion, the distribution half-life  averages 0.27 hours and the elimination half-life averages 2.33 hours.', 'Following 30-minute or 3-hour IV infusion of 80-375 mg/sq m albumin-bound paclitaxel, ... terminal half-life albumin-bound paclitaxel was about 27 hours. ... /Paclitaxel (albumin-bound)/']"
1620,36315,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-(dimethylamino)phenyl)-5-(2-hydroxypropyl)-5-(2-propenyl)-",CC(CC1(C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)N(C)C)CC=C)O,,,,,,
1621,36316,p-Ethoxyphenyl 4-pyridyl ketone,CCOC1=CC=C(C=C1)C(=O)C2=CC=NC=C2,,,,,,
1622,36317,p-Hydroxyphenyl 2-pyridyl ketone,C1=CC=NC(=C1)C(=O)C2=CC=C(C=C2)O,,,,,,
1623,36318,CID 36318,CN1CCN(CC1)C2=NC(=O)C3=C(N2)CCCCC3,,,,,,
1624,36319,CID 36319,C1CCC2=C(CC1)NC(=NC2=O)N3CCN(CC3)C4=CC=CC=C4,,,,,,
1625,36320,CID 36320,CSC1=NC(=O)C2=C(N1)CCCCC2,,,,,,
1626,36321,CID 36321,C1CCC2=C(CC1)NC(=NC2=O)N3CCCCC3,,,,,,
1627,36322,"BENZAMIDE, 5-(p-((2-CHLOROETHYL)ETHYLAMINO)ANILINO)-2,4-DINITRO-",CCN(CCCl)C1=CC=C(C=C1)NC2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1628,36323,"1,1,1-Trichloro-2,2-bis(chlorophenyl)ethane",C1=CC(=CC(=C1)Cl)C(C2=CC(=CC=C2)Cl)C(Cl)(Cl)Cl,,,,,,
1629,36324,Amitraz,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,"['Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and fleas (Ctenocephalides felis and Ctenocephalides canis). Treatment of infestations by chewing lice (Trichodectes canis). Prevention of environmental flea contamination by inhibiting the development of all flea immature stages. The product can be used as part of a treatment strategy for the control of flea-allergy dermatitis. Elimination of fleas and ticks within 24 hours. One treatment prevents further infestations for five weeks by ticks and for up to five weeks by fleas.']",,"['Substances causing insects to turn away from them or reject them as food. (See all compounds classified as Insect Repellents.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Chemicals that, while not possessing inherent pesticidal activity, nonetheless promote or enhance the effectiveness of other pesticides when combined. (See all compounds classified as Pesticide Synergists.)']","[""In all species examined, urine was the major route of excretion, accounting for 65-84% of the dose (55-76% within the first 24 hr). ... In both rats and mice, increasing the dose of amitraz from 1 to 100 mg/kg bw increased the excretion of N-methyl- N'-(2,4-xylyl)formamidine from approximately 5 to 30% of the total excretion."", 'In separate studies, groups of two male and two female beagle dogs were dosed orally (4 mg/kg bw by capsule) or dermally (20-21 mg on an area of 400-500 cm sq) with (14)C-amitraz (specific activity, 8.6 mCi/g). Peak blood concentrations of radiolabel were observed during the first 8 hr after oral administration. About 80% of the oral dose was excreted within the first 24 hr and 100% within 72 hr, preferentially in the urine. After dermal treatment, peak blood concentrations occurred within 24-72 hr, and only 25-40% was recovered in urine and feces over a 10-day collection period, demonstrating the poor dermal absorption of amitraz.']","[""Analysis of urine obtained from volunteers dosed with (14)C-amitraz indicated that the metabolism of amitraz was qualitatively similar to that in the other species. The major metabolites were 4-formamido- meta-toluic acid, 4-acetamido- meta-toluic acid and N-methyl- N'-(2,4-xylyl)formamidine. In addition, 40-60% of the metabolites excreted in urine were accounted for by a polar fraction containing conjugates of 4-formamido- meta-toluic acid and 4-acetamido- meta-toluic acid. The minor metabolites included 4-amino- meta-toluic acid and form-2',4'-xylidide. Excretion of N-methyl- N'-(2,4-xylyl)formamidine was dose-dependent. The metabolites identified in the volunteers were 4-formamido- meta-toluic acid plus 4-acetamido- meta-toluic acid (27% of the total radiolabel in urine), N-methyl- N'-(2,4-xylyl)formamidine (6%), 4-amino- meta-toluic acid (4%), form-2',4'-xylidide (4 %), the product of acid hydrolysis of  N-methyl- N'-(2,4-xylyl)formamidine and form-2',4'-xylidide (1%), and polar material (57%)."", ""When (14)C-amitraz was applied to Boophilus microplus, penetration occurred readily. Cleavage to 2,4-dimethylformanilide and N-2,4-dimethylphenyl N'-methylformamidine and large amounts of polar material occurred. 2,4-dimethylaniline adn CO2 were also produced."", ""... Pear samples were extracted with ethyl acetate and anhydrous sodium sulphate. Amitraz was found to be rapidly decomposed into four related compounds, of which N-(2,4-dimethylphenyl)formamidine (DMPF) was the most abundant and persistent. N,N'-bisdimethylphenylformamidine (BDMPF), 2,4-dimethylformamidine (DMF) and 2,4-dimethyl aniline (DMA) were also main metabolites of amitraz."", ""In separate studies, groups of two male and two female beagle dogs were dosed orally (4 mg/kg bw by capsule) or dermally (20-21 mg on an area of 400-500 cm sq) with (14)C-amitraz (specific activity, 8.6 mCi/g). ... /The/ metabolism of amitraz was essentially the same after oral and dermal administration. 4-Formamido- meta-toluic acid was the predominant residue in both blood and urine. The parent compound and the first hydrolysis products, N-methyl- N'-(2,4-xylyl)formamidine and form-2',4'-xylidide, were not observed at measurable concentrations in either blood or urine."", ""The hydrolyzed metabolic products of amitraz include 2,4-dimethylaniline, and N-(2,4-dimethylphenyl)-N'-methylformamidine. These metabolites are further metabolized to 2,4-dimethylaniline and ultimately to 4-amino-3-methylbenzoic acid, the principal amitraz metabolite found in the urine and liver.""]",
1630,36325,CID 36325,CC1=CC(=C(C=C1)[NH2+]C=NC)C.[Cl-],,,,,,
1631,36326,"N'-(2,4-Dimethylphenyl)-N-methylformamidine",CC1=CC(=C(C=C1)NC=NC)C,,,,,,
1632,36327,"2,2',3,3',4,4',6,6'-Octachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)Cl)C2=C(C(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
1633,36328,2-Nitrobenzofuran,C1=CC=C2C(=C1)C=C(O2)[N+](=O)[O-],,,,,,
1634,36329,5-Chloro-3-methyl-2-nitrobenzofuran,CC1=C(OC2=C1C=C(C=C2)Cl)[N+](=O)[O-],,,,,,
1635,36330,"1,3-DIOXOLO(4,5-g)QUINAZOLIN-6(5H)-ONE, 8-(3-FLUOROPHENYL)-5-(1-METHYLETHYL)-",CC(C)N1C2=CC3=C(C=C2C(=NC1=O)C4=CC(=CC=C4)F)OCO3,,,,,,
1636,36331,"1,3-DIOXOLO(4,5-g)QUINAZOLIN-6(5H)-ONE, 5-(1-METHYLETHYL)-8-PHENYL-",CC(C)N1C2=CC3=C(C=C2C(=NC1=O)C4=CC=CC=C4)OCO3,,,,,,
1637,36332,2-Ethylacetanilide,CCC1=CC=CC=C1NC(=O)C,,,,,['2-Ethylacetanilide is a known human metabolite of 2-ethylaniline.'],
1638,36333,"n-BUTYRANILIDE, 2,6-DIMETHYL-",CCCC(=O)NC1=C(C=CC=C1C)C,,,,,,
1639,36334,"2,6-Dimethylisobutyranilide",CC1=C(C(=CC=C1)C)NC(=O)C(C)C,,,,,,
1640,36335,"Acetanilide, 2',6'-dibromo-",CC(=O)NC1=C(C=CC=C1Br)Br,,,,,,
1641,36336,"1,4,7,10,13-Pentaoxacyclopentadecane",C1COCCOCCOCCOCCO1,,,,,,
1642,36337,"1,3-DIOXOLO(4,5-g)QUINAZOLIN-6(5H)-ONE, 8-(4-FLUOROPHENYL)-5-(1-METHYLETHYL)-",CC(C)N1C2=CC3=C(C=C2C(=NC1=O)C4=CC=C(C=C4)F)OCO3,,,,,,
1643,36338,CID 36338,C1CN=C(NC1[C@@H]2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CO)CO)NC(=O)CC(C(CCN)O)N)N,,,,,,
1644,36339,Amidate,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,,,,,,
1645,36340,N-Dodecylbenzamide,CCCCCCCCCCCCNC(=O)C1=CC=CC=C1,,,,,,
1646,36341,Broperamole,C1CCN(CC1)C(=O)CCN2N=C(N=N2)C3=CC(=CC=C3)Br,,,,,,
1647,36342,"2,6-Dichlorobiphenyl",C1=CC=C(C=C1)C2=C(C=CC=C2Cl)Cl,,,,,,
1648,36343,o-(Phenylacetyl)benzoic acid,C1=CC=C(C=C1)CC(=O)C2=CC=CC=C2C(=O)O,,,,,,
1649,36344,"6-(1-Butenyl)-cyclohepta-1,4-diene",CCC=CC1CC=CCC=C1,,,,,,
1650,36345,"Acetamide, N-((4,5-diphenyl-2-oxazolyl)methyl)-N-methyl-",CC(=O)N(C)CC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1651,36346,"Carbamic acid, ((4,5-diphenyl-2-oxazolyl)methyl)methyl-, ethyl ester",CCOC(=O)N(C)CC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1652,36347,CID 36347,C1=CC=C(C=C1)C2=C(OC(=N2)C[NH2+]C(=N)[NH3+])C3=CC=CC=C3.[O-]S(=O)(=O)[O-],,,,,,
1653,36348,"2-[(4,5-Diphenyl-1,3-oxazol-2-yl)methyl]guanidine",C1=CC=C(C=C1)C2=C(OC(=N2)CN=C(N)N)C3=CC=CC=C3,,,,,,
1654,36349,"Carbamic acid, ((4,5-diphenyl-2-oxazolyl)methyl)-, ethyl ester",CCOC(=O)NCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1655,36350,CID 36350,CCN1CCN(CC1)CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1656,36351,CID 36351,CCCN1CCN(CC1)CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1657,36352,"2-[4-(3,7-dimethylocta-2,6-dienyl)piperazin-1-yl]-N-[(5-nitrofuran-2-yl)methylideneamino]acetamide",CC(=CCCC(=CCN1CCN(CC1)CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-])C)C,,,,,,
1658,36353,"Acetamide, N-((4,5-diphenyl-2-oxazolyl)methyl)-",CC(=O)NCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1659,36354,Alinidine,C=CCN(C1=C(C=CC=C1Cl)Cl)C2=NCCN2,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)']",,,
1660,36355,(5-Chloro-2-methylphenyl)phenylmethanone,CC1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
1661,36356,"Cyclotetrasiloxane, 2,4-diphenyl-2,4,6,6,8,8-hexamethyl-, (Z)-",C[Si@]1(O[Si@](O[Si](O[Si](O1)(C)C)(C)C)(C)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1662,36357,2-(dipentylamino)-N-[(5-nitrofuran-2-yl)methylideneamino]acetamide,CCCCCN(CCCCC)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1663,36358,CID 36358,C1CC[NH+](C1)CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-].[Cl-],,,,,,
1664,36359,CID 36359,C1CCN(C1)CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1665,36360,CID 36360,CC(=O)[O-].C[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1666,36361,CID 36361,CNCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1667,36362,CID 36362,CC[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].CC(=O)[O-],,,,,,
1668,36363,CID 36363,CCNCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1669,36364,CID 36364,CC(C)[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].CC(=O)[O-],,,,,,
1670,36365,CID 36365,CC(C)NCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1671,36366,CID 36366,CCCC[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].CC(=O)[O-],,,,,,
1672,36367,CID 36367,CCCCNCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1673,36368,CID 36368,CC(C)CNCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1674,36369,CID 36369,CC(C)C[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].CC(=O)[O-],,,,,,
1675,36370,CID 36370,CC(=O)[O-].C=CC[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1676,36371,CID 36371,C=CCNCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1677,36372,CID 36372,CCCN(CCC)C(=CC1=CC=C(O1)N(O)O)C(=O)N=N,,,,,,
1678,36373,CID 36373,CCCCN(CCCC)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1679,36374,CID 36374,CCC[NH2+]CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].CC(=O)[O-],,,,,,
1680,36375,CID 36375,CCCNCC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1681,36376,"Methanone, 9H-fluoren-2-yl(4-methoxyphenyl)-",COC1=CC=C(C=C1)C(=O)C2=CC3=C(CC4=CC=CC=C43)C=C2,,,,,,
1682,36377,"4,5,6,7-Tetrahydro-2-(p-chloro-alpha-ethoxybenzyl)-1H-1,3-diazepine",CCOC(C1=CC=C(C=C1)Cl)C2=NCCCCN2,,,,,,
1683,36378,"4,5,6,7-Tetrahydro-2-(alpha-ethoxybenzyl)-1H-1,3-diazepine",CCOC(C1=CC=CC=C1)C2=NCCCCN2,,,,,,
1684,36379,"2-(o-Chloro-alpha-ethoxybenzyl)-4,5,6,7-tetrahydro-1H-1,3-diazepine",CCOC(C1=CC=CC=C1Cl)C2=NCCCCN2,,,,,,
1685,36380,"CARBAMIC ACID, m-TOLYL ESTER",CC1=CC(=CC=C1)OC(=O)N,,,,,,
1686,36381,"2,6,3,5-Ethanediylidenepentaleno(1,6-bc)pyrrol-2(1H)-ol, octahydro-1-(phenylmethyl)-",C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O,,,,,,
1687,36382,4-Hexylaniline,CCCCCCC1=CC=C(C=C1)N,,,,,,
1688,36383,HC Blue no. 2,C1=CC(=C(C=C1N(CCO)CCO)[N+](=O)[O-])NCCO,,,,"['About 85 g of a commercial semi-permanent hair dye formulation containing 1.77% HC Blue No. 2 enriched with 378.6 uCi/mg (14)C-labelled HC Blue No. 2 was applied to the hair of human volunteers, worked in gently for 5-8 min and allowed to remain in contact with the hair and scalp for an additional 30 min. After 30 days, radiolabel accounting for less than 0.1% of that applied was detected in the urine; half was excreted in urine after 52 hr. (The Working Group noted that urinary metabolites were not identified, so that the metabolic fate of HC Blue No. 2 in humans remains unknown.)', 'Up to 40% of radiolabel was recovered in the urine of B6C3F1 mice and Fischer 344/N rats after oral administration by gavage of 100 mg/kg bw (14)C-labelled HC Blue No. 2 (0.1 mCi/mmol (35 uCi/mg); 98% pure).', 'The safety of HC Blue No 2 for use as a colorant in hair dyes was evaluated, based on a review of available data. ... An in vivo metabolic radioassay with B6C3F1 mice indicated less than 5% of the initial radioactivity was excreted as the parent cmpd; the remainder was excreted as more polar metabolites, with the majority in one peak. An in vitro metabolic study indicated the production of a beta-glucuronidase metabolite. ...']","['Metabolism of HC Blue No. 2 (200 uM (57 mg) by hepatocytes isolated from mice and rats yielded profiles similar to those seen in vivo. High performance liquid chromatography separation showed that HC Blue No. 2 is metabolized extensively in mice to one major metabolite, which has not been characterized.', 'Previous studies indicated that HC Blue 1 induced hepatocellular carcinomas in B6C3F1 mice whereas the structurally similar nitroaromatic amine HC Blue 2 did not. ... Comparative metabolism and genetic toxicity studies were undertaken. Eighteen hour urinary recovery of admin radioactivity was equivalent for both cmpd following oral gavage (100 mg/kg) in female B6C3Fl mice. By HPLC analysis, HC Blue 1 yielded 3 major polar metabolite peaks, one of which was susceptible to glucuronidase. In vivo metabolism of HC Blue 2 yielded a single major metabolite peak which was not hydrolyzed by glucuronidase. Metabolism by B6C3Fl mouse hepatocytes yielded metabolite profiles which were qualitatively similar to the profiles observed after in vivo metabolism. HC Blue 1 was metabolized by hepatocytes at approximately twice the rate of HC Blue 2. Cytogenetic evaluations of mouse hepatocytes after in vitro treatment indicated HC Blue 1 was more potent than HC Blue 2 in inducing chromosomal aberrations while both chemicals showed weak activity for inducing sister-chromatid exchanges. Furthermore, in the V79 cell metabolic cooperation assay, HC Blue 1, but not HC Blue 2, inhibited cell-to-cell communication suggesting a non-genotoxic activity may be present for HC Blue 1. ...']",
1689,36384,1-Butyl-2-(alpha-ethoxybenzyl)-2-imidazoline,CCCCN1CCN=C1C(C2=CC=CC=C2)OCC,,,,,,
1690,36385,2-(alpha-Ethoxybenzyl)-5-methyl-2-imidazoline,CCOC(C1=CC=CC=C1)C2=NCC(N2)C,,,,,,
1691,36386,2-(alpha-Propoxybenzyl)-2-imidazoline-,CCCOC(C1=CC=CC=C1)C2=NCCN2,,,,,,
1692,36387,"2-(3,4-Dichloro-alpha-ethoxybenzyl)-2-imidazoline",CCOC(C1=CC(=C(C=C1)Cl)Cl)C2=NCCN2,,,,,,
1693,36388,3-Nitroanilinium chloride,C1=CC(=CC(=C1)[N+](=O)[O-])[NH3+].[Cl-],,,,,,
1694,36389,"Ethanol, 1-(1-ethyl-1-methyl-2-propynyloxy)-2,2,2-trichloro-",CCC(C)(C#C)OC(C(Cl)(Cl)Cl)O,,,,,,
1695,36390,"ACRIDINE, 3,6-DIAMINO-2,7-DI-tert-BUTYL-",CC(C)(C)C1=CC2=CC3=CC(=C(C=C3N=C2C=C1N)N)C(C)(C)C,,,,,,
1696,36391,"N-(1,1-Dimethyl-2-propynyl)benzamide",CC(C)(C#C)NC(=O)C1=CC=CC=C1,,,,,,
1697,36392,Fluchloralin,CCCN(CCCl)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],,,,['Little or no foliar absorption. Fluchloralin is used for soil incorporated applications. Translocation characteristics; root uptake and acropetal movement throughout the entire plant occurs.'],"['Three structurallyrelated (14)C dinitroaniline herbicides including fluchloralin, were extensively metabolized in vitro by both normal and phenobarbital-induced rat liver microsomes. Identification of the metabolites in the ethyl acetate extracts indicated that aliphatic hydroxylation, N-dealkylation, reduction of a nitro group, and cyclization were the predominant metabolic routes in vitro. Of particular interest was the formation of a benzimidazole metabolite.', 'Soybean roots and shoots metabolized fluchloralin to at least 10 nonpolar metabolites, 6 polar metabolites, and some methanol soluble residue. TLC, GLC, and MS were used to identify metabolites: 1-(2-chloroethyl)2-ethyl-7-nitro-5-trifluoromethylbenzimidazole; alpha-alpha-alpha-trifluoro-N-(2-chloroethyl)-N-propyl-5-nitrotoluene- 3,4-diamine, obtained from excised leaves and roots; 2-chloromethyl-7-nitro-1-propyl-5-trifluoromethylbenzimidazole; and 2-amino-N-(2-chloroethyl)-6-nitro-N-propyl-4-trifluoromethylaniline.', 'Fluchloralin was extensively metabolized in vitro by normal and phenobarbital induced rat liver microsomes. Metabolites produced indicated that fluchloralin metabolism involved N-dealkylation, aliphatic hydroxylation, nitro reduction and cyclization. Analyses with TLC and GC-MS indicated the formation of 2,6-dinitro-N-(n-propan-3-ol)-alpha,alpha,alpha- trifluoro-p-toluidine and the corresponding N-(n-propan-2-ol) analog. N-dealkylation of fluchloralin gave the des-2-chloroethyl analog and di- dealkylated analogs. Other metabolites observed included 2-amino-6-nitro-alpha,alpha,alpha-trifluoro-p-toluidine, 5-nitro-7-trifluoromethylquinoxaline, and 2-ethyl-7-nitro-5-trifluoromethyl benzimidazole.']",
1698,36393,2-(Diethylamino)ethyl 2-phenyl-2-p-tolylacetate,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=C(C=C2)C,,,,,,
1699,36394,"2-Acetyl-2-methyl-1,3-dithiolane",CC(=O)C1(SCCS1)C,,,,,,
1700,36395,"3,4-Dihydro-6-methoxy-2-(piperidinomethyl)-1(2H)-naphthalenone hydrochloride",COC1=CC2=C(C=C1)C(=O)C(CC2)C[NH+]3CCCCC3.[Cl-],,,,,,
1701,36396,6-Methoxy-2-(1-piperidylmethyl)tetralin-1-one,COC1=CC2=C(C=C1)C(=O)C(CC2)CN3CCCCC3,,,,,,
1702,36397,"5-beta-Card-20(22)-enolide, 3-beta-((6-deoxy-2-O-beta-D-glucopyranosyl-3-O-methyl-alpha-L-glucopyranosyl)oxy)-14-hydroxy-",CC1[C@H](C(C([C@@H](O1)O)OCC2[C@H](C(C([C@H](O2)O[C@H]3CC[C@]4([C@@H](C3)CCC5C4CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)C)O)OC)O)O)O,,,,,,
1703,36398,"(3S,5S,8R,9S,10S,13R,14S)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-4-methoxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5(C(CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O,,,,,,
1704,36399,"2,4-Dichlorobiphenyl",C1=CC=C(C=C1)C2=C(C=C(C=C2)Cl)Cl,,,,,,
1705,36400,"3,3',5,5'-Tetrachlorobiphenyl",C1=C(C=C(C=C1Cl)Cl)C2=CC(=CC(=C2)Cl)Cl,,,,"[""In experimental animals, the absorption of PCBs by the gastrointestinal tract is well documented; however, few studies provided quantitative estimates. In rats, individual congeners (mono- to hexachlorobiphenyls) were readily absorbed when administered by gavage (vehicle not reported) in doses between 5 and 100 mg/kg. Retention was > 90% of the administered dose over a 4 day period, and was apparently dose independent. No relationship between substitution pattern and degree of absorption could be established due to the low levels of excretion, although a later study reported that absorption efficiency decreased in rats as the number of chlorine atoms increased such that dichlorobiphenyls were absorbed with a 95% efficiency, whereas octachlorobiphenyls had an absorption efficiency of only 75%. Results similar to those obtained in rats were reported in monkeys administered a single dose of 1.5 or 3.0 g Aroclor 1248/kg by gavage and in ferrets given 0.05 mg (14)C-labeled Aroclor 1254 in the food on days 14 and 35 of gestation. Retention was estimated to be > 90% and 85.4% of the administered dose in the monkeys and ferrets, respectively. Over 90% of a single dose of 10 mg PCB 105 was absorbed by minks. In mice, absorption of a gavage dose of 8 mg/kg of PCB 52 /2,2',5,5'-tetrachlorobiphenyl/ or 100 mg/kg of PCB 77 /3,3',4,4'-tetrachlorobiphenyl/ was rapid, with serum concentrations increasing 4-7-fold in 30-60 minutes; peak serum concentrations were achieved 2 hours after dosing."", 'In monkeys, a single dose of 1.5 or 3.0 g/kg Aroclor 1248 resulted in a dose-dependent liver concentration of Aroclor 1248 (25 or 53 ug/g) 2 times higher than that found in the kidney (12 or 27 ug/g) and brain (17 or 28 ug/g) 4 days after dosing. This difference was greatly increased 14 days after treatment due to both a reduction in kidney and brain concentration and an increase in liver concentration. The blood levels of Aroclor 1254 increased rapidly in monkeys during 10 months of treatment (from approximately 1.2 ug/g at time zero to about 100 ug/g in the high-dose group) with doses between 20 and 80 ug/kg/day, but this increase leveled off during the remaining 27 months of treatment. A dose of 5 ug/kg/day induced only a slight increase in blood PCB levels during the total treatment period of 37 months. When the data were expressed as relative concentration, it appeared that absorption and bioaccumulation were dose-dependent. However, the concentration/dose levels were, to some extent, affected by background PCB levels of the control group, which would have a greater impact on the relative concentrations of the lowest dose groups rather than on the higher dose groups.', '4 wk after ip injection of 1 g Aroclor 1248 into rats, adipose tissue contained 338 ug tetrachlorinated biphenyl (TCB) residues/g, and there was a shift to pentachlorobiphenyls and hexachlorobiphenyls (up to 63%) in chromatographic and spectrometric analysis patterns of residue. Only 5% of higher chlorinated components were present in the TCB admin.', 'Over 90% of a single oral dose (1.5 or 3.0 g/kg body weight) of Aroclor 1248 was absorbed from the gastrointestinal tract of monkeys as determined by chromatographic analysis of excreta. The major route was by biliary excretion into the gastrointestinal tract. By the 14th day after PCB administration, 5.6% of the original dose had been eliminated in the urine and feces.']",,
1706,36401,"2,3,4,5-Tetrachlorobiphenyl",C1=CC=C(C=C1)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
1707,36402,"2,3,5,6-Tetrachlorobiphenyl",C1=CC=C(C=C1)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl,,,,,,
1708,36403,Dipotassium carboxyatractyloside,CC(C)CC(=O)OC1C(C(C(OC1OC2C[C@@]3(C4CC[C@@H]5C[C@]4(CCC3C(C2)(C(=O)[O-])C(=O)[O-])[C@@H](C5=C)O)C)CO)OS(=O)(=O)O)OS(=O)(=O)O.[K+].[K+],,,,,,
1709,36404,"(1S,9R,13R,15R)-15-hydroxy-7-[6-(hydroxymethyl)-3-(3-methylbutanoyloxy)-4,5-disulfooxyoxan-2-yl]oxy-9-methyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5,5-dicarboxylic acid",CC(C)CC(=O)OC1C(C(C(OC1OC2C[C@@]3(C4CC[C@@H]5C[C@]4(CCC3C(C2)(C(=O)O)C(=O)O)[C@@H](C5=C)O)C)CO)OS(=O)(=O)O)OS(=O)(=O)O,,,,,,
1710,36405,Dosulepin Sulfone,CN(C)CCC=C1C2=CC=CC=C2CS(=O)(=O)C3=CC=CC=C31,,,,,,
1711,36406,"1-Naphthalenepropylamine, gamma,gamma'-nitrilodimethylenebis(N-benzyl-gamma-isopropyl-N-methyl-",CC(C)C(CCN(C)CC1=CC=CC=C1)(CN=CC(CCN(C)CC2=CC=CC=C2)(C3=CC=CC4=CC=CC=C43)C(C)C)C5=CC=CC6=CC=CC=C65,,,,,,
1712,36407,"1-Aza-5H-dibenzo(a,d)cycloheptene, 10,11-dihydro-5-carbamoyl-",C1CC2=C(C=CC=N2)C(C3=CC=CC=C31)C(=O)N,,,,,,
1713,36408,"1-Naphthalenepropylamine, gamma,gamma'-nitrilodimethylenebis(gamma-sec-butyl-N,N-diethyl-",CCC(C)C(CCN(CC)CC)(CN=CC(CCN(CC)CC)(C1=CC=CC2=CC=CC=C21)C(C)CC)C3=CC=CC4=CC=CC=C43,,,,,,
1714,36409,2-(2-Nitroprop-1-en-1-yl)furan,CC(=CC1=CC=CO1)[N+](=O)[O-],,,,,,
1715,36410,CID 36410,CCCCOC1=CC=C(C=C1)NC(=NC2=CC=C(C3=CC=CC=C32)S(=O)(=O)[O-])S.[Na+],,,,,,
1716,36411,CID 36411,CCCCOC1=CC=C(C=C1)NC(=NC2=CC=C(C3=CC=CC=C32)S(=O)(=O)O)S,,,,,,
1717,36412,"2-Benzoyl-1,1-bis(2-chloroethyl)hydrazine",C1=CC=C(C=C1)C(=O)NN(CCCl)CCCl,,,,,,
1718,36413,"7,8-Methylenedioxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1C[NH2+]CC2=C1C=CC3=C2OCO3.[Cl-],,,,,,
1719,36414,"6,7,8,9-Tetrahydro-[1,3]dioxolo [4,5-h]isoquinoline",C1CNCC2=C1C=CC3=C2OCO3,,,,,,
1720,36415,"Biphenyl, 2-methyl-4'-nitro-",CC1=CC=CC=C1C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1721,36416,CID 36416,C[NH+]1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O.[Cl-],,,,,,
1722,36417,"2-Benzothiazolinone, 5-chloro-3-(4-methylpiperazin-1-YL)carbonylmethyl-",CN1CCN(CC1)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O,,,,,,
1723,36418,"2,3-Dihydro-7-methoxy-2-benzofuranmethylamine hydrochloride",COC1=CC=CC2=C1OC(C2)C[NH3+].[Cl-],,,,,,
1724,36419,"(7-Methoxy-2,3-dihydro-1-benzofuran-2-yl)methanamine",COC1=CC=CC2=C1OC(C2)CN,,,,,,
1725,36420,"2,3-Dihydro-5,7-dichloro-2-benzofuranmethylamine hydrochloride",C1C(OC2=C1C=C(C=C2Cl)Cl)C[NH3+].[Cl-],,,,,,
1726,36421,"(5,7-Dichloro-2,3-dihydro-1-benzofuran-2-yl)methanamine",C1C(OC2=C1C=C(C=C2Cl)Cl)CN,,,,,,
1727,36422,"2,3-Dihydro-4,5,7-trichloro-2-benzofuranmethylamine hydrochloride",C1C(OC2=C1C(=C(C=C2Cl)Cl)Cl)C[NH3+].[Cl-],,,,,,
1728,36423,"(4,5,7-Trichloro-2,3-dihydro-1-benzofuran-2-yl)methanamine",C1C(OC2=C1C(=C(C=C2Cl)Cl)Cl)CN,,,,,,
1729,36424,"Acetic acid, 2,2-bis(2-chloroethyl)hydrazide",C(CCl)C(CCCl)C(=O)NN,,,,,,
1730,36425,CID 36425,CC1C(=O)NC(=N1)S,,,,,,
1731,36426,Butoxyethyl butyl phthalate,CCCCOCCOC(=O)C1=CC=CC=C1C(=O)OCCCC,,,,,,
1732,36427,"9-AZABICYCLO(3.3.1)NONAN-3-beta-OL, 9-METHYL-, BENZILATE (ester), HYDROCHLORIDE",C[NH+]1C2CCCC1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
1733,36428,"(1S,3S)-3-(2-carboxyprop-1-enyl)-2,2-dimethylcyclopropane-1-carboxylic acid",CC(=C[C@H]1[C@@H](C1(C)C)C(=O)O)C(=O)O,,,,,,
1734,36429,"Acetamide, N-(4-(2-phenylethyl)phenyl)-",CC(=O)NC1=CC=C(C=C1)CCC2=CC=CC=C2,,,,,,
1735,36430,N-Hydroxy-4'-phenethylacetanilide,CC(=O)N(C1=CC=C(C=C1)CCC2=CC=CC=C2)O,,,,,,
1736,36431,Buspirone hydrochloride,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
1737,36432,"Bicyclo(2.2.1)hept-5-ene-2,3-dicarboximide, N-pentyl-",CCCCCN1C(=O)C2C3CC(C2C1=O)C=C3,,,,,,
1738,36433,Bikaverin,CC1=CC(=CC2=C1C(=O)C3=C(O2)C(=O)C4=C(C3=O)C(=CC(=C4O)OC)O)OC,,,,,,
1739,36434,"10H-Benzo(b)xanthene-7,10,12-trione, 6,11-dihydroxy-3,8-dimethoxy-1-methyl-, diacetate",CC1=CC(=CC2=C1C(=O)C3=C(O2)C(=C4C(=C3OC(=O)C)C(=O)C=C(C4=O)OC)OC(=O)C)OC,,,,,,
1740,36435,"10H-Benzo(b)xanthene-7,10,12-trione, 6,11-dihydroxy-3,8-dimethoxy-1-methyl-, dibenzoate",CC1=CC(=CC2=C1C(=O)C3=C(O2)C(=C4C(=C3OC(=O)C5=CC=CC=C5)C(=O)C=C(C4=O)OC)OC(=O)C6=CC=CC=C6)OC,,,,,,
1741,36436,"11H-BENZO(b)XANTHENE-6,11,12-TRIONE, 4,9-DIBROMO-1-METHYL-3,7,8,10-TETRAMETHOXY-",CC1=CC(=C(C2=C1C(=O)C3=C(O2)C(=O)C4=C(C3=O)C(=C(C(=C4OC)OC)Br)OC)Br)OC,,,,,,
1742,36437,1-((m-Chlorobenzyl)methylamino)-3-(3-(dimethylamino)propyl)-3-phenyl-2-indolinone,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC(=CC=C3)Cl)C4=CC=CC=C4,,,,,,
1743,36438,1-((p-Chlorobenzyl)methylamino)-3-(2-(dimethylamino)ethyl)-3-phenyl-2-indolinone,CN(C)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
1744,36439,1-((p-Chlorobenzyl)methylamino)-3-(2-(diethylamino)ethyl)-3-phenyl-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
1745,36440,"2-Indolinone, 1-((p-chlorobenzyl)methylamino)-3-(3-(dimethylamino)propyl)-3-phenyl-, monohydrochloride",C[NH+](C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)Cl)C4=CC=CC=C4.[Cl-],,,,,,
1746,36441,1-[(4-Chlorophenyl)methyl-methylamino]-3-[3-(dimethylamino)propyl]-3-phenylindol-2-one,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
1747,36442,3-(3-(Dimethylamino)propyl)-1-((o-fluorobenzyl)methylamino)-3-phenyl-2-indolinone,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3F)C4=CC=CC=C4,,,,,,
1748,36443,3-(3-(Dimethylamino)propyl)-1-(methyl(o-methylbenzyl)amino)-3-phenyl-2-indolinone,CC1=CC=CC=C1CN(C)N2C3=CC=CC=C3C(C2=O)(CCCN(C)C)C4=CC=CC=C4,,,,,,
1749,36444,3-(2-(Dimethylamino)ethyl)-1-((o-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CN(C)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3OC)C4=CC=CC=C4,,,,,,
1750,36445,3-(3-(Dimethylamino)propyl)-1-((o-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3OC)C4=CC=CC=C4,,,,,,
1751,36446,3-(2-(Diethylamino)ethyl)-1-((m-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC(=CC=C3)OC)C4=CC=CC=C4,,,,,,
1752,36447,3-(3-(Dimethylamino)propyl)-1-((m-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC(=CC=C3)OC)C4=CC=CC=C4,,,,,,
1753,36448,3-(2-(Dimethylamino)ethyl)-1-((p-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CN(C)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)OC)C4=CC=CC=C4,,,,,,
1754,36449,3-(2-(Diethylamino)ethyl)-1-((p-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)OC)C4=CC=CC=C4,,,,,,
1755,36450,3-(3-(Dimethylamino)propyl)-1-((p-methoxybenzyl)methylamino)-3-phenyl-2-indolinone,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)OC)C4=CC=CC=C4,,,,,,
1756,36451,3-(2-(Diethylamino)ethyl)-1-(methyl(p-(methylthio)benzyl)amino)-3-phenyl-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=C(C=C3)SC)C4=CC=CC=C4,,,,,,
1757,36452,"2-Indolinone, 1-((2-chloro-3-methoxybenzyl)methylamino)-3-(2-(diethylamino)ethyl)-3-phenyl-",CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=C(C(=CC=C3)OC)Cl)C4=CC=CC=C4,,,,,,
1758,36453,"2-Indolinone, 3-(3-(dimethylamino)propyl)-1-(furfurylmethylamino)-3-phenyl-",CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CO3)C4=CC=CC=C4,,,,,,
1759,36454,3-(3-(Dimethylamino)propyl)-1-(methyl-2-thenylamino)-3-phenyl-2-indolinone,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CS3)C4=CC=CC=C4,,,,,,
1760,36455,"5-[(3S,10R,13R,14S,17R)-3-[(2S,5R)-3,4-dihydroxy-5-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",CC1[C@@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)OC,,,,,,
1761,36456,"(2R,3R)-2,3-dihydroxybutanedioic acid;1-methyl-2-(2-thiophen-2-ylethenyl)-5,6-dihydro-4H-pyrimidine",CN1CCCN=C1C=CC2=CC=CS2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
1762,36457,"3-(2-amino-1-hydroxypropyl)phenol;(2R,3R)-2,3-dihydroxybutanedioic acid",CC(C(C1=CC(=CC=C1)O)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
1763,36458,"Acetic acid, (2-(3,6-diamino-5-hydroxyhexanoyl)-1-methylhydrazino)-",CN(CC(=O)O)NC(=O)CC(CC(CN)O)N,,,,,,
1764,36459,"Acetophenone, 2-(butylamino)-3',4'-dihydroxy-",CCCCNCC(=O)C1=CC(=C(C=C1)O)O,,,,,,
1765,36460,"3-Hydroxy-3-(2-oxopropyl)-1,3-dihydro-2H-indol-2-one",CC(=O)CC1(C2=CC=CC=C2NC1=O)O,,,,,,
1766,36461,2-amino-9H-fluoren-9-ol,C1=CC=C2C3=C(C=C(C=C3)N)C(C2=C1)O,,,,,,
1767,36462,Etoposide,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,"['For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.']","['Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 &micro;g/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 &micro;g/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.']","['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']","['Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50% (range of 25% - 75%). Cmax and AUC values for orally administered etoposide capsules display intra- and inter-subject variability. There is no evidence of first-pass effect for etoposide.', 'Etoposide is cleared by both renal and nonrenal processes, i.e., metabolism and biliary excretion. Glucuronide and/or sulfate conjugates of etoposide are also excreted in human urine. Biliary excretion of unchanged drug and/or metabolites is an important route of etoposide elimination as fecal recovery of radioactivity is 44% of the intravenous dose. 56% of the dose was in the urine, 45% of which was excreted as etoposide.', 'The disposition of etoposide is a biphasic process with a distribution half-life of 1.5 hours. It does not cross into cerebrospinal fluid well.  Volume of distribution, steady state = 18 - 29 L.', 'Total body clearance = 33 - 48 mL/min [IV administration, adults]', 'Excretion of etoposide in breast milk was demonstrated in a woman with acute promyelocytic leukemia receiving daily doses of 80 mg/sq m (route not stated). Peak concentrations of 0.6 to 0.8 ug/mL were measured immediately after dosing but had decreased to undetectable levels by 24 hr.', 'Thirty minutes after intravenous administration of etoposide to rats, the highest concentrations were found in the liver, kidneys and small intestine. By 24 hr after the dose, the tissue concentrations were negligible.', 'After intravenous infusion (5 min) of etoposide phosphate to beagle dogs at doses of 57-461 mg/sq m, a dose-proportional increase was seen in the maximal plasma concentration and AUC for etoposide. The total plasma clearance rate (342-435 mL/min per sq m) and the distribution volume (22-27 L/sq m) were not dose-dependent. The peak plasma concentration occurred at the end of the infusion of etoposide phosphate, indicating rapid conversion of the pro-drug to etoposide.', 'Less than 4% of a dose was recovered in the bile after 48 hr in patients with biliary drainage tubes. The fecal recovery of radiolabel after intravenous administration of 3(H)etoposide (130-290 mg/sq m) was variable, representing 0-16% of dose, but the collections were known to be incomplete because of fecal retention and other difficulties associated with the poor general condition of many of the patients). In a study reported as an abstract in four patients with small-cell lung cancer given 14(C)-glucopyranoside etoposide, 56% of the radiolabel was recovered in urine and 44% in feces over five days, for a total recovery of 100 +/- 6%.', 'For more Absorption, Distribution and Excretion (Complete) data for ETOPOSIDE (18 total), please visit the HSDB record page.']","['Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine. Etoposide also undergoes glutathione and glucuronide conjugation which are catalyzed by GSTT1/GSTP1 and UGT1A1, respectively. Prostaglandin synthases are also responsible for the conversion of etoposide to O-demethylated metabolites (quinone).', 'The proposed hydroxy acid metabolite of etoposide, formed by opening of the lactone ring, has been detected in human urine, but only at low concentrations, accounting for 0.2-2.2% of the administered dose.', 'The major urinary metabolite of etoposide in humans is reported to be the glucuronide conjugate. Although urinary glucuronide and/or sulfate conjugates were reported to account for 5-22% of an intravenous dose of etoposide, other studies suggest that the glucuronide predominates. Etoposide glucuronide in the urine of treated patients accounted for 8-17% of a dose of 0.5-3.5 g/sq m etoposide  and 29% of a dose of 100-800 mg/sq m etoposide, with no other metabolites other than etoposide glucuronide detected in the latter study. In patients with renal or liver impairment given somewhat lower doses of 70-150 mg/sq m, 3-17% of the dose was excreted in the urine within 72 hr as etoposide glucuronide.', 'Etoposide appears to be metabolized principally at the D ring to produce the resulting hydroxy acid (probably the trans-hydroxy acid); this metabolite appears to be pharmacologically inactive. The picrolactone isomer of etoposide has been detected in two concentrations in the plasma and urine of some patients but not in others. The aglycone of etoposide and/or its conjugates have not been detected to date in patients receiving the drug. In vitro, the picrolactone isomer and aglycone of etoposide have minimal cytotoxic activity.', 'Generally, few or no etoposide metabolites have been detected in plasma. Etoposide is administered as the trans-lactone, but cis-etoposide can also be detected in human urine. This might be a storage phenomenon, since isomerization sometimes occurs during freezing of plasma samples under slightly basic conditions. The cis isomer accounts for < 1% of the dose. The catechol metabolite has also been reported in patients receiving 600 mg/sq m etoposide, with an AUC of around 2.5% that of etoposide. In patients given 90 mg/sq m etoposide, the catechol metabolite represented 1.4-7.1% of the urinary etoposide and < 2% of the administered dose.', 'In rat liver homogenates, liver microsomes and in rats in vivo, etoposide was extensively metabolized to only one major metabolite, which was not formally identified. In perfused isolated rat liver incubated with etoposide, the total recovery in bile was 60-85%, with roughly equal amounts of etoposide and two glucuronide metabolites, confirmed as glucuronide species by liquid chromatography and mass spectrometry. After intravenous injection of 3(H)etoposide to rabbits, the total urinary excretion of radiolabel was 30% after five days, with very little thereafter. A single glucuronide metabolite was identified in rabbit urine, which was present in larger amounts than etoposide. No hydroxy acid was identified in either species.']","['4-11 hours', '... In adults with normal renal and hepatic function, the half-life of etoposide averages 0.6-2 hours ... in the initial phase and 5.3-10.8 hours ... in the terminal phase. In one adult with impaired hepatic function, the terminal elimination half-life was reportedly 78 hours. In children with normal renal and hepatic function, the half-life of etoposide averages 0.6-1.4 hours in the initial phase and 3-5.8 hours in the terminal phase.', '... Elimination half-life of 3 to 7 hr in children and 4 to 8 hr in adults.']"
1768,36463,"2,2'-Bipyridine, 1-oxide",C1=CC=NC(=C1)C2=CC=CC=[N+]2[O-],,,,,,
1769,36464,(+-)-1-Methyl-3-benzoyl-3-(o-chlorobenzoyloxy)piperidine hydrochloride,C[NH+]1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3Cl.[Cl-],,,,,,
1770,36465,(3-Benzoyl-1-methylpiperidin-3-yl) 2-chlorobenzoate,CN1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3Cl,,,,,,
1771,36466,(+-)-1-Methyl-3-benzoyl-3-(o-bromobenzoyloxy)piperidine hydrochloride,C[NH+]1CCC(C(C1)OC(=O)C2=CC=CC=C2Br)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
1772,36467,(4-Benzoyl-1-methylpiperidin-3-yl) 2-bromobenzoate,CN1CCC(C(C1)OC(=O)C2=CC=CC=C2Br)C(=O)C3=CC=CC=C3,,,,,,
1773,36468,(+-)-1-Methyl-3-benzoyl-3-(o-chloro-p-aminobenzoyloxy)piperidine hydrochloride,C[NH+]1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=C(C=C(C=C3)N)Cl.[Cl-],,,,,,
1774,36469,(3-Benzoyl-1-methylpiperidin-3-yl) 4-amino-2-chlorobenzoate,CN1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=C(C=C(C=C3)N)Cl,,,,,,
1775,36470,(+-)-1-n-Propyl-3-benzoyl-3-benzoyloxypiperidine hydrochloride,C1CC(C[NH+](C1)CCCOC(=O)C2=CC=CC=C2)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
1776,36471,3-(3-Benzoylpiperidin-1-yl)propyl benzoate,C1CC(CN(C1)CCCOC(=O)C2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
1777,36472,(+-)-1-Isopropyl-3-benzoyl-3-benzoyloxypiperidine hydrochloride,CC(C)[NH+]1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
1778,36473,(3-Benzoyl-1-propan-2-ylpiperidin-3-yl) benzoate,CC(C)N1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3,,,,,,
1779,36474,"1,3,6,8-Tetrachlorodibenzo-P-dioxin",C1=C(C=C(C2=C1OC3=C(O2)C=C(C=C3Cl)Cl)Cl)Cl,,,,,,
1780,36475,(+)-1-Methyl-3-benzoyl-3-benzoyloxypiperidine hydrochloride,C[NH+]1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
1781,36476,(3-Benzoyl-1-methylpiperidin-3-yl) benzoate,CN1CCCC(C1)(C(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3,,,,,,
1782,36477,"Acetic acid, (2,3,5-trichlorophenoxy)-",C1=C(C=C(C(=C1OCC(=O)O)Cl)Cl)Cl,,,,,,
1783,36478,"3-(3-Chloro-4-(chlorodifluoromethyl)thiophenyl)-1,1-dimethylurea",CN(C)C(=O)NC1=CC(=C(C=C1)SC(F)(F)Cl)Cl,,,,,,
1784,36479,"1,2,3,6,9,10,10-Heptachloropentacyclo[5.3.0.02,5.03,9.04,8]decane",C12C3C4C(C1C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
1785,36480,"2,3-Dihydro-7-methyl-2-benzofuranmethylamine hydrochloride",CC1=C2C(=CC=C1)CC(O2)C[NH3+].[Cl-],,,,,,
1786,36481,"(7-Methyl-2,3-dihydro-1-benzofuran-2-yl)methanamine",CC1=C2C(=CC=C1)CC(O2)CN,,,,,,
1787,36482,"5,6,7,8-Tetrahydronaphtho(2,3-d)-1,3-dioxol-6-amine hydrochloride",C1CC2=CC3=C(C=C2CC1[NH3+])OCO3.[Cl-],,,,,,
1788,36483,"5,6,7,8-Tetrahydronaphtho[2,3-d][1,3]dioxol-6-amine",C1CC2=CC3=C(C=C2CC1N)OCO3,,,,,,
1789,36484,5-Methoxysulfinyloxyhexan-2-yl methyl sulfite,CC(CCC(C)OS(=O)OC)OS(=O)OC,,,,,,
1790,36485,"6-Methyl-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride",CC1=CC2=C(CC(CC2)[NH3+])C=C1.[Cl-],,,,,,
1791,36486,"6-Methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CC1=CC2=C(CC(CC2)N)C=C1,,,,,,
1792,36487,"beta-Alanine, N-(2,3-dihydrophenalen-2-yl)-N-methyl-, methyl ester, hydrochloride",C[NH+](CCC(=O)OC)C1CC2=CC=CC3=C2C(=CC=C3)C1.[Cl-],,,,,,
1793,36488,"methyl 3-[2,3-dihydro-1H-phenalen-2-yl(methyl)amino]propanoate",CN(CCC(=O)OC)C1CC2=CC=CC3=C2C(=CC=C3)C1,,,,,,
1794,36489,Ciproquazone,COC1=CC2=C(C=C1)N(C(=O)N=C2C3=CC=CC=C3)CC4CC4,,,,,,
1795,36490,"1,1,4,4-Tetrachlorobutane",C(CC(Cl)Cl)C(Cl)Cl,,,,,,
1796,36491,1-(Benzylmethylamino)-3-(3-(diethylamino)propyl)-3-phenyl-2-indolinone,CCN(CC)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1797,36492,1-(Benzylmethylamino)-3-phenyl-3-(3-(1-pyrrolidinyl)propyl)-2-indolinone,CN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCCN4CCCC4)C5=CC=CC=C5,,,,,,
1798,36493,1-(Benzylmethylamino)-3-(3-(3-methylpiperidino)propyl)-3-phenyl-2-indolinone,CC1CCCN(C1)CCCC2(C3=CC=CC=C3N(C2=O)N(C)CC4=CC=CC=C4)C5=CC=CC=C5,,,,,,
1799,36494,3-(2-(Dimethylamino)ethyl)-1-(methylphenethylamino)-3-phenyl-2-indolinone hydrochloride,C[NH+](C)CCC1(C2=CC=CC=C2N(C1=O)N(C)CCC3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
1800,36495,3-[2-(Dimethylamino)ethyl]-1-[methyl(2-phenylethyl)amino]-3-phenylindol-2-one,CN(C)CCC1(C2=CC=CC=C2N(C1=O)N(C)CCC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1801,36496,3-(2-(Diethylamino)ethyl)-1-(methylphenethylamino)-3-phenyl-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CCC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1802,36497,3-(3-(Dimethylamino)propyl)-1-(methylphenethylamino)-3-phenyl-2-indolinone hydrochloride,C[NH+](C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CCC3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
1803,36498,3-[3-(Dimethylamino)propyl]-1-[methyl(2-phenylethyl)amino]-3-phenylindol-2-one,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CCC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1804,36499,1-(Benzylethylamino)-3-(3-(dimethylamino)propyl)-3-phenyl-2-indolinone hydrochloride,CCN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCC[NH+](C)C)C4=CC=CC=C4.[Cl-],,,,,,
1805,36500,1-[Benzyl(ethyl)amino]-3-[3-(dimethylamino)propyl]-3-phenylindol-2-one,CCN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCCN(C)C)C4=CC=CC=C4,,,,,,
1806,36501,1-((o-Chlorobenzyl)methylamino)-3-(3-(diethylamino)propyl)-3-phenyl-2-indolinone,CCN(CC)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3Cl)C4=CC=CC=C4,,,,,,
1807,36502,Hex-3-EN-1-YL formate,CCC=CCCOC=O,,,,,,
1808,36503,Hex-3-enyl propanoate,CCC=CCCOC(=O)CC,,,,,,
1809,36504,Hept-2-en-1-ol,CCCCC=CCO,,,,,,
1810,36505,"1H-NAPHTHO(2,1-b)PYRAN-1-ONE, 3-(DIETHYLAMINO)-",CCN(CC)C1=CC(=O)C2=C(O1)C=CC3=CC=CC=C32,,,,,,
1811,36506,o-Methylcarbanilic acid N-ethyl-3-pyrrolidinyl ester oxalate,CC[NH+]1CCC(C1)OC(=O)NC2=CC=CC=C2C.C(=O)(C(=O)[O-])O,,,,,,
1812,36507,(1-ethylpyrrolidin-3-yl) N-(2-methylphenyl)carbamate,CCN1CCC(C1)OC(=O)NC2=CC=CC=C2C,,,,,,
1813,36508,"o-Methylcarbanilic acid, N-methyl-3-pyrrolidinyl ester",CC1=CC=CC=C1NC(=O)OC2CCN(C2)C,,,,,,
1814,36509,"2,3-Dihydro-7-chloro-2-benzofuranmethylamine hydrochloride",C1C(OC2=C1C=CC=C2Cl)C[NH3+].[Cl-],,,,,,
1815,36510,"(7-Chloro-2,3-dihydrobenzofuran-2-yl)methanamine",C1C(OC2=C1C=CC=C2Cl)CN,,,,,,
1816,36511,Substance P,CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N,['For the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.'],"['Crofelemer is an inhibitor of secretory diarrhea via inhibition of the CFTR chloride transporter. Crofelemer is not an antimicrobial, and therefore does not drive the emergence of resistance; it does not inhibit motility, and therefore does not cause constipation or rebound diarrhea; and it is not systemically absorbed, reducing the potential for adverse drug interactions and toxicity.']","['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']","['The absorption of crofelemer is minimal and crofelemer concentrations in plasma are below the level of quantitation (50 ng/mL).', 'Since crofelemer is not significantly absorbed, the route of elimination has not been identified.', 'Since crofelemer is not significantly absorbed, volume of distribution was not quantified.', 'Since crofelemer is not significantly absorbed, clearance was not determined.']","['Since crofelemer is not significantly absorbed, no metabolites have been identified.']","['Since crofelemer is not significantly absorbed, the half life was not determined.']"
1817,36512,"1,1,2-Trimethyl-3-phenylindan",CC1C(C2=CC=CC=C2C1(C)C)C3=CC=CC=C3,,,,,,
1818,36513,"2-Indolinone, 1-((o-chlorobenzyl)methylamino)-3-(3-(dimethylamino)propyl)-3-phenyl-, monohydrochloride",C[NH+](C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3Cl)C4=CC=CC=C4.[Cl-],,,,,,
1819,36514,1-[(2-Chlorophenyl)methyl-methylamino]-3-[3-(dimethylamino)propyl]-3-phenylindol-2-one,CN(C)CCCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3Cl)C4=CC=CC=C4,,,,,,
1820,36515,CID 36515,CC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC(C(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)Br)C)C,,,,,,
1821,36516,CID 36516,C[C@]12CCC(=NOC3=CC=C(C=C3)[N+](=O)[O-])CC1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CCC5=O)C,,,,,,
1822,36517,CID 36517,CC12CCC3C(C1CC[C@@H]2O)CCC4=CC(=NOC5=CC=C(C=C5)[N+](=O)[O-])CCC34,,,,,,
1823,36518,CID 36518,CC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)C)C,,,,,,
1824,36519,CID 36519,CC12CCC3C(C1CC[C@@H]2O)CCC4=CC(=NOC5=C(C=C(C=C5)[N+](=O)[O-])[N+](=O)[O-])CCC34,,,,,,
1825,36520,CID 36520,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=NOC5=C(C=C(C=C5)[N+](=O)[O-])[N+](=O)[O-])C=C[C@]34C,,,,,,
1826,36521,"17-beta-Hydroxyandrost-4-en-3-one O-(2,4-dinitrophenyl)oxime",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=NOC5=C(C=C(C=C5)[N+](=O)[O-])[N+](=O)[O-])CC[C@]34C,,,,,,
1827,36522,17-beta-Hydroxyandrost-4-en-3-one O-(p-nitrophenyl)oxime,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=NOC5=CC=C(C=C5)[N+](=O)[O-])CC[C@]34C,,,,,,
1828,36523,Gonadorelin diacetate,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,['For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.'],"['Gonadorelin is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use']",,['Rapidly absorbed when injected'],['Rapidly hydrolyzed to inactive peptide components'],"['Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes']"
1829,36524,CID 36524,C[N+](C)(CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])N.[Br-],,,,,,
1830,36525,CID 36525,C[N+](C)(CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])N,,,,,,
1831,36526,CID 36526,CC[N+](CC)(CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])N.[Br-],,,,,,
1832,36527,CID 36527,CC[N+](CC)(CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])N,,,,,,
1833,36528,"Carbanilic acid, 2-chloro-6-methyl-, N-isopropyl-4-piperidinyl ester",CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCN(CC2)C(C)C,,,,,,
1834,36529,"Carbanilic acid, 2-chloro-6-methyl-, N-propyl-4-piperidinyl ester",CCCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1835,36530,"Carbanilic acid, 2-chloro-6-methyl-, N-ethyl-4-piperidinyl ester",CCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
1836,36531,"Carbanilic acid, 2-chloro-6-methyl-, N-methyl-4-piperidinyl ester",CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCN(CC2)C,,,,,,
1837,36532,"Carbanilic acid, 2,6-dimethyl-, N-isopropyl-4-piperidinyl ester",CC1=C(C(=CC=C1)C)NC(=O)OC2CCN(CC2)C(C)C,,,,,,
1838,36533,"Carbanilic acid, 2,6-dimethyl-, N-propyl-4-piperidinyl ester",CCCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
1839,36534,"Carbanilic acid, 2,6-dimethyl-, N-methyl-4-piperidinyl ester",CC1=C(C(=CC=C1)C)NC(=O)OC2CCN(CC2)C,,,,,,
1840,36535,N-Ethyl-3-piperidinyl p-acetylcarbanilate,CCN1CCCC(C1)OC(=O)NC2=CC=C(C=C2)C(=O)C,,,,,,
1841,36536,"p-Methoxycarbanilic acid, N-ethyl-3-piperidinyl ester",CCN1CCCC(C1)OC(=O)NC2=CC=C(C=C2)OC,,,,,,
1842,36537,N-Ethyl-3-piperidinyl p-bromocarbanilate,CCN1CCCC(C1)OC(=O)NC2=CC=C(C=C2)Br,,,,,,
1843,36538,N-Ethyl-3-piperidinyl m-bromocarbanilate,CCN1CCCC(C1)OC(=O)NC2=CC(=CC=C2)Br,,,,,,
1844,36539,N-Ethyl-3-piperidinyl p-chlorocarbanilate,CCN1CCCC(C1)OC(=O)NC2=CC=C(C=C2)Cl,,,,,,
1845,36540,N-Ethyl-3-piperidinyl m-chlorocarbanilate,CCN1CCCC(C1)OC(=O)NC2=CC(=CC=C2)Cl,,,,,,
1846,36541,o-Chlorocarbanilic acid N-ethyl-2-piperidinyl ester oxalate,CC[NH+]1CCCC(C1)OC(=O)NC2=CC=CC=C2Cl.C(=O)(C(=O)[O-])O,,,,,,
1847,36542,(1-ethylpiperidin-3-yl) N-(2-chlorophenyl)carbamate,CCN1CCCC(C1)OC(=O)NC2=CC=CC=C2Cl,,,,,,
1848,36543,"p-Methylcarbanilic acid, N-ethyl-3-piperidinyl ester",CCN1CCCC(C1)OC(=O)NC2=CC=C(C=C2)C,,,,,,
1849,36544,"m-Methylcarbanilic acid, N-ethyl-3-piperidinyl ester",CCN1CCCC(C1)OC(=O)NC2=CC=CC(=C2)C,,,,,,
1850,36545,N-Ethyl-3-piperidyl 2-methylphenylcarbamate,CCN1CCCC(C1)OC(=O)NC2=CC=CC=C2C,,,,,,
1851,36546,"2-Chloro-6-methylcarbanilic acid, N-methyl-3-pyrrolidinyl ester",CC1=C(C(=CC=C1)Cl)NC(=O)OC2CCN(C2)C,,,,,,
1852,36547,2-((1-Phenylethoxy)carbonyl)benzoic acid,CC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2C(=O)O,,,,,,
1853,36548,Mono(p-(tert-butyl)-alpha-methylbenzyl) phrhalate,CC(C1=CC=C(C=C1)C(C)(C)C)OC(=O)C2=CC=CC=C2C(=O)O,,,,,,
1854,36549,Mono(P-methoxy-alpha-methylbenzyl) phthalate,CC(C1=CC=C(C=C1)OC)OC(=O)C2=CC=CC=C2C(=O)O,,,,,,
1855,36550,"2-chloro-N-(3,5-dichlorophenyl)acetamide",C1=C(C=C(C=C1Cl)Cl)NC(=O)CCl,,,,,,
1856,36551,CID 36551,CO[C@]1([C@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3=CC=CS3.[Na+],,,,,,
1857,36552,"(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CO[C@]1([C@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3,,,,,,
1858,36553,Trimethoxy(3-methoxypropyl)silane,COCCC[Si](OC)(OC)OC,,,,,,
1859,36554,"2,5,8-Trimethyl-1-naphthol",CC1=C2C=CC(=C(C2=C(C=C1)C)O)C,,,,,,
1860,36555,"2-Indolinone, 1-(benzylmethylamino)-3-phenyl-3-(3-piperidinopropyl)-, monohydrochloride",CN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCC[NH+]4CCCCC4)C5=CC=CC=C5.[Cl-],,,,,,
1861,36556,1-[Benzyl(methyl)amino]-3-phenyl-3-(3-piperidin-1-ylpropyl)indol-2-one,CN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCCN4CCCCC4)C5=CC=CC=C5,,,,,,
1862,36557,"Aniline, 2-isopropyl-N-(2-oxazolin-2-YL)-",CC(C)C1=CC=CC=C1NC2=NCCO2,,,,,,
1863,36558,"p-Cyanocarbanilic acid, N-ethyl-3-piperidinyl ester",CCN1CCCC(C1)OC(=O)NC2=CC=C(C=C2)C#N,,,,,,
1864,36559,"1,2,3-Trimethyl-1-phenylindan",CC1C(C(C2=CC=CC=C12)(C)C3=CC=CC=C3)C,,,,,,
1865,36560,"Phosphorodithioic acid O,O-bis(1-methylpropyl)S-sodium salt",CCC(C)OP(=S)(OC(C)CC)[S-].[Na+],,,,,,
1866,36561,"Phosphorodithioic acid, O,O-bis(1-methylpropyl) ester",CCC(C)OP(=S)(OC(C)CC)S,,,,,,
1867,36562,"Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, bromide, methyl ester, (L)-",C[N+](C)(C)C[C@H](CC(=O)OC)O.[Br-],,,,,,
1868,36563,[(2S)-2-hydroxy-4-methoxy-4-oxobutyl]-trimethylazanium,C[N+](C)(C)C[C@H](CC(=O)OC)O,,,,,,
1869,36564,"3-(4-hydroxy-5,7-dimethyl-3-methylene-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl)propyl acetate",CC1C(C2C(CC(=C1CCCOC(=O)C)C)OC(=O)C2=C)O,,,,,,
1870,36565,Butralin,CCC(C)NC1=C(C=C(C=C1[N+](=O)[O-])C(C)(C)C)[N+](=O)[O-],,,,"['Extensively metabolized and excreted in urine and feces. ...The majority (85%) of applied butralin was excreted in the urine within 48 hr /(in rats)/. None was in the organs after 72 hr.', 'In a metabolism study, rats were dosed by gavage with butralin (ring labeled) in corn oil at 8 mg/kg/day (low dose levels) for single and multiple dosing and biliary excretion studies and at 800 mg/kg/day (high dose single dosing) and the distribution and excretion of butralin followed over a 7 day period. Low dose results indicate that about 100% of the dosed material was excreted in about 2 days, with 55 to 60% excreted in the feces and 35-45% in urine. The feces contained about 10% unmetabolized butralin. The excretory half life was about 12 hours. Tissues retained only about 1% of the labeled butralin. A similar excretion pattern was seen in the repeat low dose group. High dose administration of butralin took 5-7 days to achieve 100% excretion of butralin in the urine and feces. The excretory half life was between 2 and 4 days. Of the various tissues, fat and liver tended to retain more butralin residues. Females excreted the butralin residues more slowly than males and retained more metabolite in the tissue (especially the liver and fat).']","['In a bile excretion study using low dose levels (8 mg butralin/kg), enterohepatic circulation was determined to be a primary pathway for butralin excretion and metabolism. Twelve butralin metabolites were identified in pooled urine, feces and/or bile samples. Metabolites identified at concentrations of 5% to 10% of the administered dose were: 2-methyl- 5(6)[1-(1-carboxy-1-methyl)ethyl]-7(4)-nitrobenzimidazole, 2-methyl- 5(6)[2-(1-hydroxy-2-methyl)propyl]-7(4)-nitrobenzimidazole, 2-methyl-2(4- amino-3,5-dinitrophenyl)propionic acid and 2-methyl-2(4-amino-3,5- dinitrophenyl)propanol-glucuronide. Butralin, the parent chemical, was present at 10% of the administered dose. There were no metabolites at concentrations >10% of the administered dose identified in the study.', '...Metabolized in the rat by the primary metabolic processes of N-dealkylation, oxidation and nitro reduction, and by secondary processes of N-acetyl and glucuronic acid conjugation. ...Butralin is ultimately metabolized to carbon dioxide.']",
1871,36566,1-Acetyl-5-nitroindoline,CC(=O)N1CCC2=C1C=CC(=C2)[N+](=O)[O-],,,,,,
1872,36567,CID 36567,CCC1=C(C(=C(C=C1)CC)CC)CC.CCC1=CC(=C(C(=C1)CC)CC)CC.CCC1=CC(=C(C=C1CC)CC)CC,,,,,,
1873,36568,"1,2,3,4-Tetraethylbenzene",CCC1=C(C(=C(C=C1)CC)CC)CC,,,,,,
1874,36569,"1,2,3,5-Tetraethylbenzene",CCC1=CC(=C(C(=C1)CC)CC)CC,,,,,,
1875,36570,"1,2,4,5-Tetraethylbenzene",CCC1=CC(=C(C=C1CC)CC)CC,,,,,,
1876,36571,(4-Methoxyphenyl)glycolonitrile,COC1=CC=C(C=C1)C(C#N)O,,,,,,
1877,36572,beta-(p-Chlorophenyl)phenethyl 4-(2-pyrimidyl)piperazinyl ketone,C1CN(CCN1C2=NC=CC=N2)C(=O)CC(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
1878,36573,Acesulfame,CC1=CC(=O)NS(=O)(=O)O1,,,,"[""/MILK/ Nonnutritive sweeteners (NNS), including saccharin, sucralose, aspartame, and acesulfame-potassium, are commonly consumed in the general population, and all except for saccharin are considered safe for use during pregnancy and lactation. Sucralose (Splenda) currently holds the majority of the NNS market share and is often combined with acesulfame-potassium in a wide variety of foods and beverages. To date, saccharin is the only NNS reported to be found in human breast milk after maternal consumption, while there is no apparent information on the other NNS. Breast milk samples were collected from 20 lactating volunteers, irrespective of their habitual NNS intake. Saccharin, sucralose, and acesulfame-potassium were present in 65% of participants' milk samples, whereas aspartame was not detected. These data indicate that NNS are frequently ingested by nursing infants, and thus prospective clinical studies are necessary to determine whether early NNS exposure via breast milk may have clinical implications. /Acesulfame potassium/"", 'Single oral doses of 10 mg (14)C-Acesulfame K/kg bw given to rats and dogs were rapidly absorbed. Maximum blood levels reached were 0.75  plus or minus 0.2 g/mL in rats, 0.5 hr after dosing, and 6.56 plus or minus 2.08 g/mL in dogs, 1-1.5 hr after dosing. In rats, 82-100% of the dose, and in dogs, 85-100% of the dose was excreted in the urine;  in both  species, 97-100% of the total radioactivity was excreted in feces, and total recovery approximated 100%. Rats given 10 consecutive daily doses of 10 mg/kg orally did not show evidence of accumulation. Three days after dosing, the concn in the organs and plasma was 0.4 nMol/g in liver, and  <0.2  nMol/g in other tissues. Seven days after dosing, the concn in dogs was <0.2 nMol/g in all tissues examined. /Acesulfame K/', 'After pretreatment for seven days with a diet containing 3% Acesulfame K, male rats were given a dose of 250 mg Acesulfame K containing (14)C-Acesulfame K (9.6 x 108 dpm) by oral gavage. After eight hours the animals were killed and liver and spleen excised; DNA and chromatin protein was isolated from these organs. No radioactivity could be detected on any DNA sample. A low level of activity (8-11 dpm/mg protein) was associated with chromatin protein and this was claimed to be due to non-covalent interactions of unchanged Acesulfame K. /Acesulfame K/', 'Single oral doses of approximately 15 mg (14)C-Acesulfame K/kg bw were administered to male and female rats which had been pretreated with unlabeled Acesulfame K at a level of 300 mg/kg diet for 60 days. Control animals without pretreatment were also similarly dosed with (14)C-Acesulfame K. In all animals 95.1-98.2% of the dose was recovered in urine and cage washings and 0.95-2.86% in feces. Total recoveries were 96.3-99.2%. Excretion of radioactivity was rapid and displayed biphasic kinetics; 92.6-96.8% of the dose was  excreted in 24 hours.  ... No significant differences in route or rate of excretion were observed between sexes nor between controls and animals pretreated with Acesulfame K for 60 days. /Acesulfame K/', 'For more Absorption, Distribution and Excretion (Complete) data for Acesulfame (8 total), please visit the HSDB record page.']","['The metabolism of Acesulfame K was investigated in the urine and feces of rats and dogs which had received single oral doses of 10 mg/kg bw, and in the urine and bile of pigs dosed orally with 5 mg/kg bw. The analytical methods used (thin-layer chromatography, mass spectrometry and isotope dilution) detected only the original substance in these samples. Separation by TLC of urinary extracts from rats used in the above study revealed only one peak which was identical  with Acesulfame K. No metabolites were detected in control or Acesulfame K-pretreated animals. Similarly, no metabolites were detected in animals which had been pretreated with 1% Acesulfame K for 7 days. /Acesulfame K/', 'The metabolism of Acesulfame K was studied in serum and urine from human volunteers following a single dose of 30 mg/individual. Only the original substance was detected in all samples. /Acesulfame K/']","['/After/ single oral doses of approximately 15 mg (14)C-Acesulfame K/kg bw were administered to male and female rats which had been pretreated with unlabeled Acesulfame K at a level of 300 mg/kg diet for 60 days; ... the half-life of the rapid  phase was 4-4.5 hours and of the slower phase (accounting for <0.5% of the dose) was 109-257 hours. /Acesulfame K/', 'After iv admin of a single dose of 10 mg (14C)-Acesulfame K/kg bw to rats, the radioactivity  was excreted quantitatively in urine and the plasma half-life was  0.23 hr. /Acesulfame K/', 'In lactating rats given a single oral dose of (14)C-Acesulfame K of about 10.6 mg/kg bw, ...the biological half-lives were similar in milk (5.6 hr) and blood (4 hr). /Acesulfame K/', 'The purpose of this work was...the determination of acesulfame-K (AcK) in C57BL mouse plasma and urine.  Male and female animals were dosed orally (gavage) and intravenously at 10 mg/kg and then plasma and urine collected at up to 24 hours post dose. Plasma samples were analyzed with an HPLC method... and urine was analyzed with a second HPLC method .... Both methods used saccharin as internal standard with detection by UV absorbance at 230 nm. Following IV administration, plasma AcK concentrations declined rapidly and linearly within 120 min and a second AcK peak was observed at 240 minutes. Half-life was estimated to be 11-15 minutes. Plasma concentrations of AcK reached maximal levels within 45 minutes and rapidly declined following oral doses. Plasma AcK were below limits of detection by 480 minutes post dose. A second peak was also observed following oral administration, suggesting enterohepatic recirculation. Following IV and PO administration, 45% (males) and 70% (females) of the dose was excreted in urine by 24 hr. Oral bioavailability was estimated to be 90-100% based on urinary data.']"
1879,36574,"P-Menthane-1,2-diol",CC(C)C1CCC(C(C1)O)(C)O,,,,,,
1880,36575,2-Chloro-2-nitrosoadamantane,C1C2CC3CC1CC(C2)C3(N=O)Cl,,,,,,
1881,36576,Isopropyl phenyl methyl phosphonic acid,CC(C)OP(=O)(C)OC1=CC=CC=C1,,,,,,
1882,36577,3-Oxidoiminobutan-2-one;tetrabutylazanium,CCCC[N+](CCCC)(CCCC)CCCC.CC(=N[O-])C(=O)C,,,,,,
1883,36578,"Tetrabutyl ammonium, benzohydroxamate",CCCC[N+](CCCC)(CCCC)CCCC.C1=CC=C(C=C1)C(=O)N[O-],,,,,,
1884,36579,[(Phenylcarbonyl)amino]oxidanide,C1=CC=C(C=C1)C(=O)N[O-],,,,,,
1885,36580,"Tetrabutyl ammonium, salt with 4'-hydroxy-3',5'-",CCCC[N+](CCCC)(CCCC)CCCC.CC1=CC(=CC(=C1[O-])C)C(=O)C,,,,,,
1886,36581,"4'-Hydroxy-3',5'-dimethylacetophenone",CC1=CC(=CC(=C1O)C)C(=O)C,,,,,,
1887,36582,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(o-fluorophenyl)-1-(2-(methylsulfonyl)ethyl)-",CS(=O)(=O)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
1888,36583,2-Chloro-4-(methylamino)-6-(sec-butylamino)-s-triazine,CCC(C)NC1=NC(=NC(=N1)NC)Cl,,,,,,
1889,36584,Terbumeton,CCNC1=NC(=NC(=N1)OC)NC(C)(C)C,,,,,,
1890,36585,"Ketone, 3-adamantyl hydroxymethyl",C1C2CC3CC1CC(C2)(C3)C(=O)CO,,,,,,
1891,36586,"1-(3,4,5-Trihydroxyphenyl)ethanone",CC(=O)C1=CC(=C(C(=C1)O)O)O,,,,,,
1892,36587,(3-Adamantylcarbonyl)methyl acetate,CC(=O)OCC(=O)C12CC3CC(C1)CC(C3)C2,,,,,,
1893,36588,"3,5-Dichloroanisole",COC1=CC(=CC(=C1)Cl)Cl,,,,,,
1894,36589,"3,7-Bis(morpholinomethyl)-2,5-dihydroxy-2,4,6-cycloheptatrien-1-one",C1COCCN1CC2=CC(=O)C=C(C(=C2O)O)CN3CCOCC3,,,,,,
1895,36590,"2,4,6-Cycloheptatrien-1-one, 3-carboxy-2-hydroxy-",C1=CC(=C(C(=O)C=C1)O)C(=O)O,,,,,,
1896,36591,N-(quinolin-8-yl)acetamide,CC(=O)NC1=CC=CC2=C1N=CC=C2,,,,,,
1897,36592,"(9S,14S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one",CCC1C[C@H]2C3CCC4=CC(=O)CCC4[C@H]3CCC2([C@H]1O)C,,,,,,
1898,36593,"[(16S,17S)-16-ethyl-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate",CC[C@H]1CC2C3CCC4=CC(=O)CCC4C3CCC2([C@H]1OC(=O)C)C,,,,,,
1899,36594,Alkylsevin,CC1=C(C2=CC=CC=C2C=C1)OC(=O)NC,,,,,,
1900,36595,"1,1,1-Trimethyl-2-(1-phenylethylidene)hydrazin-1-ium iodide",CC(=N[N+](C)(C)C)C1=CC=CC=C1.[I-],,,,,,
1901,36596,"Hydrazinium, 1,1,1-trimethyl-2-(1-phenylethylidene)-",CC(=N[N+](C)(C)C)C1=CC=CC=C1,,,,,,
1902,36597,"10H-Benzo(b)xanthene-7,10,12-trione, 6,11-dihydroxy-3,8-dimethoxy-1-methyl-, 6-acetate",CC1=CC(=CC2=C1C(=O)C3=C(C4=C(C(=C3O2)OC(=O)C)C(=O)C(=CC4=O)OC)O)OC,,,,,,
1903,36598,CID 36598,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3O)S(=O)(=O)[O-])O.[Na+],,,,,,
1904,36599,3-Hydroxynonanoic acid,CCCCCCC(CC(=O)O)O,,,,,,
1905,36600,"Acetamide, N-(4-((4-(dimethylamino)phenyl)azo)phenyl)-N-methyl-",CC(=O)N(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
1906,36601,CID 36601,CC(C1=CC=CC=C1)N=C(C(=NC(C)C2=CC=CC=C2)S)S,,,,,,
1907,36602,"N,N-bis((dimethylamino)thiocarbonyl)aniline",CN(C)C(=S)N(C1=CC=CC=C1)C(=S)N(C)C,,,,,,
1908,36603,Endodan,C1CN2C(=N1)SSC2=S,,,,,,
1909,36604,Levmetamfetamine,C[C@H](CC1=CC=CC=C1)NC,['Used over-the-counter for nasal congestion.'],['Levomethamphetamine increases norepinephrine release resulting in increased vasocontriction.'],,,['Methamphetamine is a known human metabolite of selegiline.'],['The elimination half-life of levomethamphetamine is between 13.3 and 15 hours.']
1910,36605,Citicoline sodium,C[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O.[Na+],,,"['Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
1911,36606,Isopropalin,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(C)C)[N+](=O)[O-],,,,,"['Selective herbicide, which affects physiological growth processes associated with seed germination.']",
1912,36607,CID 36607,C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC2=O,,,,,,
1913,36608,"Methane, bromochlorodinitro-",C([N+](=O)[O-])([N+](=O)[O-])(Cl)Br,,,,,,
1914,36609,5-(2-Hydroxypropyl)-5-isopropylbarbituric acid,CC(C)C1(C(=O)NC(=O)NC1=O)CC(C)O,,,,,,
1915,36610,CID 36610,CC[NH+](C)CCN(CC1=CC=C(C=C1)Br)C2=CC=CC=N2.C(=CC(=O)[O-])C(=O)O,,,,,,
1916,36611,WV-761 free base,CCN(C)CCN(CC1=CC=C(C=C1)Br)C2=CC=CC=N2,,,,,,
1917,36612,Amiprophos,CCOP(=S)(NC(C)C)OC1=C(C=C(C=C1)C)[N+](=O)[O-],,,,,,
1918,36613,"2,7-Dichlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=C(O2)C=C(C=C3)Cl,,,,"['The polychlorinated dibenzo-p-dioxins and the polychlorinated dibenzofurans are predominantly stored in fat, but they are also excreted in milk and pass the placenta. They also appear in the blood and vital organs at lower concentrations. /Polychlorinated dibenzo-p-dioxins/']","['IN RATS, 2,7-DICHLORODIBENZO-P-DIOXIN IS METABOLIZED TO MONO- & DIHYDROXY DERIVATIVES. PRIMARY HYDROXYLATION OF DIBENZO-P-DIOXINS TAKES PLACE EXCLUSIVELY AT 2, 3, 7, OR 8 POSITION.', 'Dioxins were administered to rats. Urine and feces were collected and analyzed. ... 2,7-Dichlorodibenzo-p-dioxin yielded two monohydroxy, one monochloro-dihydroxy and one dihydroxy metabolite.']",
1919,36614,"2,3,7-Trichlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=CC(=C(C=C3O2)Cl)Cl,,,,,,
1920,36615,CID 36615,C1=CC=C(C=C1)C(=NO)C[N+]2=CC3=CC=CC=C3C=C2.[Cl-],,,,,,
1921,36616,CID 36616,C1=CC=C(C=C1)C(=NO)C[N+]2=CC3=CC=CC=C3C=C2,,,,,,
1922,36617,"2(3H)-Furanone, dihydro-4,4-diethyl-",CCC1(CC(=O)OC1)CC,,,,,,
1923,36618,Methylnitrosocyanamide,CN(C#N)N=O,,,,,,
1924,36619,"1,2,3,3A-Tetrahydroazulene",C1CC2C=CC=CC=C2C1,,,,,,
1925,36620,5-Methoxy-1-tetralone,COC1=CC=CC2=C1CCCC2=O,,,,,,
1926,36621,"2,4,6-Cycloheptatrien-1-one, 2-hydroxy-3,5,7-tris(morpholinomethyl)-",C1COCCN1CC2=CC(=C(C(=O)C(=C2)CN3CCOCC3)O)CN4CCOCC4,,,,,,
1927,36622,CID 36622,COC1=C(OC2=C(C(=O)C=C(C2=C1O)O)O)C3=CC=CC=C3,,,,,,
1928,36623,"Ethylamine, 2-((o-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)-N,N-dimethyl-, hydrochloride",CC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)OCC[NH+](C)C.[Cl-],,,,,,
1929,36624,"2-[1-(2-chlorophenyl)-1-phenylethoxy]-N,N-dimethylethanamine",CC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)OCCN(C)C,,,,,,
1930,36625,"Cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methylpropenyl)-, (5-benzyl-3-furyl)methyl ester, (-)-(E)-",CC(=C[C@@H]1[C@H](C1(C)C)C(=O)OCC2=CC=C(O2)CC3=CC=CC=C3)C,,,,,,
1931,36626,CID 36626,C1=CC=C(C=C1)[NH3+].OP(=O)[O-],,,,,,
1932,36627,4-Ethoxybutyl butanoate,CCCC(=O)OCCCCOCC,,,,,,
1933,36628,2-Methyl-5-propylthiophene,CCCC1=CC=C(S1)C,,,,,,
1934,36629,4-Ethylhept-3-ene,CCCC(=CCC)CC,,,,,,
1935,36630,"DIBENZO(b,def)CHRYSENE, 5-METHYL-",CC1=CC2=CC3=CC=CC=C3C4=C2C5=C1C6=CC=CC=C6C=C5C=C4,,,,,,
1936,36631,"BENZO(rat)PENTAPHENE, 5-METHYL-",CC1=C2C=CC3=CC4=CC=CC=C4C5=C3C2=C(C=C5)C6=CC=CC=C16,,,,,,
1937,36632,"BENZ(c)ACRIDINE, 9-METHYL-",CC1=CC2=C(C=C1)N=C3C(=C2)C=CC4=CC=CC=C43,,,,,,
1938,36633,1-(2-Chloroethyl)-2-nitro-1-nitrosoguanidine,C(CCl)N(C(=N[N+](=O)[O-])N)N=O,,,,,,
1939,36634,Duboisene,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.Cl,,,,,,
1940,36635,"5H-Dibenzo(a,d)cycloheptene-4-methylamine 10,11-dihydro-N,N-dimethyl-5-methylene-",CN(C)CC1=CC=CC2=C1C(=C)C3=CC=CC=C3CC2,,,,,,
1941,36636,6-Hydroxybenzo[a]pyrene,C1=CC=C2C(=C1)C3=C4C(=C2O)C=CC5=CC=CC(=C54)C=C3,,,,,,
1942,36637,CID 36637,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)NCCO)I.[Na+],,,,,,
1943,36638,"2-(2,6-dichlorophenyl)-2-ethoxy-N'-hydroxyethanimidamide",CCOC(C1=C(C=CC=C1Cl)Cl)C(=NO)N,,,,,,
1944,36639,2-(2-chlorophenyl)-2-ethoxy-N'-hydroxyethanimidamide,CCOC(C1=CC=CC=C1Cl)C(=NO)N,,,,,,
1945,36640,"2-(3,4-dichlorophenyl)-2-ethoxy-N'-hydroxyethanimidamide",CCOC(C1=CC(=C(C=C1)Cl)Cl)C(=NO)N,,,,,,
1946,36641,N'-hydroxy-2-phenyl-2-propoxyethanimidamide,CCCOC(C1=CC=CC=C1)C(=NO)N,,,,,,
1947,36642,CID 36642,CCC1CC2CCC(O2)C(C(=O)OC(CC3CCC(O3)C(C(=O)OC(CC4CCC(O4)C(C(=O)OC(CC5CCC(O5)C(C(=O)O1)C)CC)C)CC)C)CC)C,,,,,,
1948,36643,"1,4-Diethyl-2,3,5,6-tetramethylbenzene",CCC1=C(C(=C(C(=C1C)C)CC)C)C,,,,,,
1949,36644,"1-(3,4-Dimethylphenyl)ethanol",CC1=C(C=C(C=C1)C(C)O)C,,,,,,
1950,36645,CID 36645,CCCCC(C)(CC)C(=O)[O-].[Na+],,,,,,
1951,36646,2-Ethyl-2-methylhexanoic acid,CCCCC(C)(CC)C(=O)O,,,,,,
1952,36647,"2,2',4,4',6,6'-Hexachlorobiphenyl",C1=C(C=C(C(=C1Cl)C2=C(C=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
1953,36648,"2-(3,4-Dichlorophenacylthio)-2-imidazoline hydrobromide",C1CN=C([NH2+]1)SCC(=O)C2=CC(=C(C=C2)Cl)Cl.[Br-],,,,,,
1954,36649,"1-(3,4-Dichlorophenyl)-2-((4,5-dihydro-1H-imidazol-2-yl)thio)ethanone",C1CN=C(N1)SCC(=O)C2=CC(=C(C=C2)Cl)Cl,,,,,,
1955,36650,"2-Chloro-3',3''-di-2-imidazolin-2-yl-terephthalanilide",C1=CC(=CC=C1C2=NC=CN2)NC(=O)C3=CC(=C(C=C3)C(=O)NC4=CC=C(C=C4)C5=NC=CN5)Cl,,,,,,
1956,36651,Usaf A-8104,C[NH2+]CC#N.OS(=O)(=O)[O-],,,,,,
1957,36652,Methylaminoacetonitrile,CNCC#N,,,,,,
1958,36653,4-Hydroxyoctahydro-1-naphthalenone,C1CCC2C(C1)C(CCC2=O)O,,,,,,
1959,36654,5-Butyl-2(3H)-furanone,CCCCC1=CCC(=O)O1,,,,,,
1960,36655,Butyl methyl phthalate,CCCCOC(=O)C1=CC=CC=C1C(=O)OC,,,,,,
1961,36656,Methyl ethyl phthalate,CCOC(=O)C1=CC=CC=C1C(=O)OC,,,,,,
1962,36657,Tetradec-11-en-1-ol,CCC=CCCCCCCCCCCO,,,,,,
1963,36658,"Acetohydroxamic acid, 2-(1-allyl-5-methoxy-2-methyl-3-indolyl)-",CC1=C(C2=C(N1CC=C)C=CC(=C2)OC)CC(=O)NO,,,,,,
1964,36659,"Acetohydroxamic acid, 2-(1-benzyl-5-methoxy-2-methyl-3-indolyl)-",CC1=C(C2=C(N1CC3=CC=CC=C3)C=CC(=C2)OC)CC(=O)NO,,,,,,
1965,36660,Deboxamet,CC1=C(C2=C(N1)C=CC(=C2)OC)CC(=O)NO,,,,,,
1966,36661,2-(4-Chlorophenyl)-2-hydroxyacetaldehyde,C1=CC(=CC=C1C(C=O)O)Cl,,,,,,
1967,36662,p-Fluorophenyl 4-(p-fluorophenyl)-4-hydroxy-1-methyl-3-piperidyl ketone hydrochloride,CN1CCC(C(C1)C(=O)C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)O.Cl,,,,,,
1968,36663,Flazalone,CN1CCC(C(C1)C(=O)C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)O,,,,,,
1969,36664,Methyl 4-(chloromethyl)benzoate,COC(=O)C1=CC=C(C=C1)CCl,,,,,,
1970,36665,CID 36665,CN1C(=C(NC2=NC=CS2)O)C(=O)C3=CC=CC=C3S1(=O)=O,,,,,,
1971,36666,"3-Azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaene;hydrochloride",C1CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1.Cl,,,,,,
1972,36667,Taclamine,C1CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1,,,,,,
1973,36668,1-Pent-3-enoxypentane,CCCCCOCCC=CC,,,,,,
1974,36669,"2,2,2-trifluoro-N'-phenylacetohydrazide",C1=CC=C(C=C1)NNC(=O)C(F)(F)F,,,,,,
1975,36670,4-Nitrobenzoic acid cyclohexylamine salt,C1CCC(CC1)[NH3+].C1=CC(=CC=C1C(=O)[O-])[N+](=O)[O-],,,,,,
1976,36671,3-Propylcyclopentene,CCCC1CCC=C1,,,,,,
1977,36672,"Butane-1,4-diol; oxalic acid",C(CCO)CO.C(=O)(C(=O)O)O,,,,,,
1978,36673,"[2-[(6S,9R,16R)-9-chloro-6-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate",C[C@@H]1CC2C3C[C@@H](C4=CC(=O)C=CC4([C@]3(C(CC2(C1C(=O)COC(=O)C(C)(C)C)C)O)Cl)C)F,,,,,,
1979,36674,CID 36674,C[N+](C)(C)CC=CC1=CC=CC=C1.[I-],,,,,,
1980,36675,Trimethyl(3-phenylprop-2-enyl)azanium,C[N+](C)(C)CC=CC1=CC=CC=C1,,,,,,
1981,36676,"1,2-Bis(3,4-dimethylphenyl)ethane",CC1=C(C=C(C=C1)CCC2=CC(=C(C=C2)C)C)C,,,,,,
1982,36677,2-(Pyridine-3-carbonylamino)ethyl pyridine-3-carboxylate,C1=CC(=CN=C1)C(=O)NCCOC(=O)C2=CN=CC=C2,,,,,,
1983,36678,2-(o-Chlorophenyl)-2-(p-chlorophenyl)acetic acid,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(=O)O)Cl,,,,,,
1984,36679,Isoproturon,CC(C)C1=CC=C(C=C1)NC(=O)N(C)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Toxicokinetic behavior and recoveries of isoproturon from feces, urine, and different tissues of goat were determined after 4, 5, 6, and 7 days following single oral administration at 500 mg/kg. Isoproturon was rapidly absorbed and attained blood concentration within 15 min of administration. The kinetic behavior followed a two-compartment open model. The higher half-life (beta) (9.78 +/- 0.33 hr) and V(d)()area (4.49 +/- 0.41 L/kg) associated with lower Cl(B) (0.32 +/- 0.02 L/kg/hr) suggested slow elimination from the blood. Approximately 56% of the total administered compound was recovered from feces. The rate of excretion of isoproturon through feces was maximum at 48 hr and could not be detected beyond 120 hr. The excretion pattern of isoproturon through urine resembled that of feces, and approximately 10-11% was eliminated in urine. A maximum quantity of residue was detected in all tissues of goats slaughtered after 4 days followed by a substantial decline after day 5, and nothing could be detected after day 7. Histopathological study revealed that isoproturon produced moderate cellular changes like fatty degeneration in the liver and kidney and emphysema in the lung after 7 days post administration.']","['Using ring-(14)C-labeled isoproturon (1 ug/L), the uptake into spawn and tadpoles of Bombina bombina and Bombina variegata was investigated. Two percent of the applied radioactivity was found per gram fresh weight in the embryo after 24 hr. Results indicate that the jelly mass of the spawn does not act as a sufficient physical barrier for protection against the uptake and influence of isoproturon (IPU) on the embryo. In vivo metabolism of ring-(14)C-labeled IPU by the cytochrome P-450 system was analyzed in tadpoles. Different metabolites of IPU, such as N-demethylated and C-hydroxylated derivatives, and the olefinic metabolite were detected. In tadpoles of B. variegata, the activity of microsomal and soluble glutathione-S-transferase (sGSTs) toward different model substrates was measured after treatment with IPU. Activities of sGST increased corresponding to elevated stress by IPU dependent on exposure time and dose. Compared to the pure active ingredient IPU, the commercial phenyl-urea herbicide Tolkan Flo, consisting of IPU and an emulsifier, also caused significantly elevated enzymatic response.']","['Toxicokinetic behavior and recoveries of isoproturon from feces, urine, and different tissues of goat were determined after 4, 5, 6, and 7 days following single oral administration at 500 mg/kg. ... The higher half-life (beta) (9.78 +/- 0.33 hr) and V(d)()area (4.49 +/- 0.41 L/kg) associated with lower Cl(B) (0.32 +/- 0.02 L/kg/hr) suggested slow elimination from the blood. ...']"
1985,36680,Trisodium (carboxylatomethoxy)succinate,C(C(C(=O)[O-])OCC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],,,,,,
1986,36681,(Carboxymethoxy)succinic acid,C(C(C(=O)O)OCC(=O)O)C(=O)O,,,,,,
1987,36682,"2,6-dinitro-N-(oxolan-2-ylmethyl)-N-propyl-4-(trifluoromethyl)aniline",CCCN(CC1CCCO1)C2=C(C=C(C=C2[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],,,,,,
1988,36683,"N-Ethyltetrahydro-N-(alpha,alpha,alpha-trifluoro-2,6-dinitro-p-tolyl)furfurylamine",CCN(CC1CCCO1)C2=C(C=C(C=C2[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],,,,,,
1989,36684,2-[(3-Methylphenyl)methoxy]ethanol,CC1=CC(=CC=C1)COCCO,,,,,,
1990,36685,CID 36685,CC1=CC(=CC=C1)C[NH+]2CCN(CC2)C3C4=C(CCC5=CC=CC=C35)[NH+]=CC=C4.C(=CC(=O)[O-])C(=O)[O-],,,,,,
1991,36686,"2-[4-[(3-Methylphenyl)methyl]piperazin-1-yl]-7-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene",CC1=CC(=CC=C1)CN2CCN(CC2)C3C4=C(CCC5=CC=CC=C35)N=CC=C4,,,,,,
1992,36687,CID 36687,C[NH+](C)CCOC(=O)C1C2=C(CCC3=CC=CC=C13)[NH+]=CC=C2.C(=CC(=O)[O-])C(=O)[O-],,,,,,
1993,36688,"2-(Dimethylamino)ethyl 7-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene-2-carboxylate",CN(C)CCOC(=O)C1C2=C(CCC3=CC=CC=C13)N=CC=C2,,,,,,
1994,36689,CID 36689,CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
1995,36690,"5H-Benzo(4,5)cyclohepta(1,2-b)pyridine-5-carboxylic acid, 10,11-dihydro-5-hydroxy-, 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)C1(C2=C(CCC3=CC=CC=C31)N=CC=C2)O,,,,,,
1996,36691,"5H-Benzo(4,5)cyclohepta(1,2-b)pyridine-5-carboxylic acid, 10,11-dihydro-5-hydroxy-, (1-methyl-2-piperidyl)methyl ester",CN1CCCCC1COC(=O)C2(C3=C(CCC4=CC=CC=C42)N=CC=C3)O,,,,,,
1997,36692,CID 36692,C[NH+](C)CCO[NH+]=C1C2=C(CCC3=CC=CC=C31)N=CC=C2.C(=O)(C(=O)[O-])[O-],,,,,,
1998,36693,CID 36693,CN(C)CCON=C1C2=C(CCC3=CC=CC=C31)N=CC=C2,,,,,,
1999,36694,CID 36694,CC(C)(C)NC(=O)ON=C1C2=C(CCC3=CC=CC=C31)N=CC=C2,,,,,,
2000,36695,CID 36695,C1CC2=C(C=CC=N2)C(=NOC(=O)N3CCOCC3)C4=CC=CC=C41,,,,,,
2001,36696,CID 36696,CCC(=O)ON=C1C2=C(C=CC3=CC=CC=C31)N=CC=C2,,,,,,
2002,36697,"10,11-Dihydro-5-amino-5H-benzo(4,5)cyclohepta(1,2-b)pyridine oxalate",C1CC2=C(C=CC=[NH+]2)C(C3=CC=CC=C31)[NH3+].C(=O)(C(=O)[O-])[O-],,,,,,
2003,36698,"10,11-Dihydro-5h-benzo[4,5]cyclohepta[1,2-b]pyridin-5-amine",C1CC2=C(C=CC=N2)C(C3=CC=CC=C31)N,,,,,,
2004,36699,"10,11-Dihydro-N-methyl-5H-benzo(4,5)cyclohepta(1,2-b)pyridine-5-carboxamide",CNC(=O)C1C2=C(CCC3=CC=CC=C13)N=CC=C2,,,,,,
2005,36700,"10,11-Dihydro-5-(4-methyl-1-piperazinyl)-5H-benzo(4,5)cyclohepta(1,2-b)pyridine",CN1CCN(CC1)C2C3=C(CCC4=CC=CC=C24)N=CC=C3,,,,,,
2006,36701,"3,4,5-Tribromo-N,N,alpha-trimethyl-1H-pyrazole-1-acetamide",CC(C(=O)N(C)C)N1C(=C(C(=N1)Br)Br)Br,,,,,,
2007,36702,"Acetyl chloride, dichlorophosphono-",C(C(=O)Cl)P(=O)(Cl)Cl,,,,,,
2008,36703,(Diethoxyphosphinyl)acetic acid potassium salt,CCOP(=O)(CC(=O)[O-])OCC.[K+],,,,,,
2009,36704,2-(Diethoxyphosphoryl)acetic acid,CCOP(=O)(CC(=O)O)OCC,,,,,,
2010,36705,"1H-Cyclodecapyrazole, 4,5,6,7,8,9,10,11-octahydro-",C1CCCCC2=C(CCC1)C=NN2,,,,,,
2011,36706,CID 36706,CCCC(=O)OCCCN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)OC.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
2012,36707,"3-[4-(3-Methoxy-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]propyl butanoate",CCCC(=O)OCCCN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)OC,,,,,,
2013,36708,Propafenone hydrochloride,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O.Cl,,,"['A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
2014,36709,Promegestone,CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C,,,,,,
2015,36710,"Benzaldehyde, 3-chloro-4-hydroxy-, oxime",C1=CC(=C(C=C1C=NO)Cl)O,,,,,,
2016,36711,N-((4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)methyl)acetamide,CC(C)NCC(COC1=CC=C(C=C1)CNC(=O)C)O,,,,,,
2017,36712,"1-Ethoxy-4-[2,2,2-trichloro-1-(4-methylphenyl)ethyl]benzene",CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)C(Cl)(Cl)Cl,,,,,,
2018,36713,"2-(p-Butoxyphenyl)-2-(p-methoxyphenyl)-1,1,1-trichloroethane",CCCCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,,,,,,
2019,36714,"2-(p-Methoxyphenyl)-2-(p-(methylthio)phenyl)-1,1,1-trichloroethane",COC1=CC=C(C=C1)C(C2=CC=C(C=C2)SC)C(Cl)(Cl)Cl,,,,,,
2020,36715,"1,1'-(2-Nitropropylidene)bis(4-methoxybenzene)",CC(C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC)[N+](=O)[O-],,,,,,
2021,36716,1-(2-Chloropropyl)-4-nitrobenzene,CC(CC1=CC=C(C=C1)[N+](=O)[O-])Cl,,,,,,
2022,36717,CID 36717,CCCC(CCC(=C1C(=O)CCC1=O)[O-])O.[Na+],,,,,,
2023,36718,"2-(1,4-Dihydroxyheptylidene)cyclopentane-1,3-dione",CCCC(CCC(=C1C(=O)CCC1=O)O)O,,,,,,
2024,36719,Hexafluoroacetone trihydrate,C(=O)(C(F)(F)F)C(F)(F)F.O.O.O,,,,,,
2025,36720,CID 36720,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].O.[Na+],,,,,,
2026,36721,4-Chlorohexadecane,CCCCCCCCCCCCC(CCC)Cl,,,,,,
2027,36722,Chloroundecane,CCCCCCC(CCCC)Cl,,,,,,
2028,36723,Chlorotridecane,CCCCCCCCC(CCCC)Cl,,,,,,
2029,36724,3-Chloropentadecane,CCCCCCCCCCCCC(CC)Cl,,,,,,
2030,36725,CID 36725,C[NH+](C)CCO[NH+]=C1C2=C(C=CC3=CC=CC=C31)N=CC=C2.C(=CC(=O)[O-])C(=O)[O-],,,,,,
2031,36726,CID 36726,CN(C)CCON=C1C2=C(C=CC3=CC=CC=C31)N=CC=C2,,,,,,
2032,36727,"3-Chloro-5-hydroxy-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzodiazepine",CN1CCN(CC1)C2=C3C=CC=CC3=NC4=C(N2O)C=C(C=C4)Cl,,,,,,
2033,36728,"ACETAMIDE, N,N'-p-PHENYLENEBIS(2,2-DICHLORO-N-METHYL-",CN(C1=CC=C(C=C1)N(C)C(=O)C(Cl)Cl)C(=O)C(Cl)Cl,,,,,,
2034,36729,"N-(2,2,2-Trichloro-1-hydroxyethyl)butyramide",CCCC(=O)NC(C(Cl)(Cl)Cl)O,,,,,,
2035,36730,1-Chloropyrene,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)Cl,,,,,,
2036,36731,CID 36731,C[C@H]1C[C@@H]2C([C@@H](C(=O)O2)C)[C@@H]([C@]3([C@H]1C=CC3=O)C)O,,,,,,
2037,36732,Copper terephthalate,C1=CC(=CC=C1C(=O)[O-])C(=O)[O-].[Cu+2],,,,,,
2038,36733,Promacyl,CCCC(=O)CNC(=O)OC1=CC(=CC(=C1)C(C)C)C,,,,,,
2039,36734,"ETHYLAMINE, N,N-DIMETHYL-2-((1-o-TOLYLCYCLOHEXYL)OXY)-",CC1=CC=CC=C1C2(CCCCC2)OCCN(C)C,,,,,,
2040,36735,CID 36735,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)NC(=NC2=O)N,,,,,,
2041,36736,2-[[1-[2-[[2-[[2-[[2-[[5-(diaminomethylideneamino)-2-[(2-methylaminoacetyl)amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid,CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)C)C(=O)NC(CC2=CN=CN2)C(=O)N3CCCC3C(=O)NC(C)C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)CNC,,,,,,
2042,36737,"2-(Morpholinomethyl)-1,4-benzodioxan",C1COCCN1CC2COC3=CC=CC=C3O2,,,,,,
2043,36738,"3,4-Dihydro-7-methoxy-3-phenyl-4-hydroxy-4-(p-(2-(1-pyrrolidyl)ethoxy)phenyl)-1H-2-benzothiapyran hydrochloride",COC1=CC2=C(C=C1)C(C(SC2)C3=CC=CC=C3)(C4=CC=C(C=C4)OCC[NH+]5CCCC5)O.[Cl-],,,,,,
2044,36739,"7-Methoxy-3-phenyl-4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,3-dihydroisothiochromen-4-ol",COC1=CC2=C(C=C1)C(C(SC2)C3=CC=CC=C3)(C4=CC=C(C=C4)OCCN5CCCC5)O,,,,,,
2045,36740,CID 36740,C[NH+](C)CCOC1(CCCCC1)C2=CC=CC=C2.C[NH+](C)CCOC1(CCCCC1)C2=CC=CC=C2.C(=CC(=O)[O-])C(=O)[O-],,,,,,
2046,36741,"N,N-Dimethyl-2-(1-phenylcyclohexyl)oxy-ethanamine",CN(C)CCOC1(CCCCC1)C2=CC=CC=C2,,,,,,
2047,36742,"5-alpha-Card-20(22)-enolide, 3-beta-((6-deoxy-3-O-methyl-alpha-L-glucopyranosyl)oxy)-14-hydroxy-",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)OC)O,,,,,,
2048,36743,3-Chlorononane,CCCCCCC(CC)Cl,,,,,,
2049,36744,"4-Methyl-2,3-dihydrofuran",CC1=COCC1,,,,,,
2050,36745,"2,3-Dihydro-4-(1-methylethyl)furan",CC(C)C1=COCC1,,,,,,
2051,36746,"2-BENZOFURANCARBOXAMIDE, N-(p-METHOXYPHENYL)-3-METHYL-",CC1=C(OC2=CC=CC=C12)C(=O)NC3=CC=C(C=C3)OC,,,,,,
2052,36747,p-Isopropylbenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)C(C)C.[Cl-],,,,,,
2053,36748,2-(Diethylamino)ethyl 4-propan-2-ylbenzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)C(C)C,,,,,,
2054,36749,Phenoxyacetic acid alpha-((diethylamino)methyl)-alpha-methylbenzyl ester hydrochloride,CC[NH+](CC)CC(C)(C1=CC=CC=C1)OC(=O)COC2=CC=CC=C2.[Cl-],,,,,,
2055,36750,[1-(Diethylamino)-2-phenylpropan-2-yl] 2-phenoxyacetate,CCN(CC)CC(C)(C1=CC=CC=C1)OC(=O)COC2=CC=CC=C2,,,,,,
2056,36751,"Anthracene, 9-(bromomethyl)-10-methyl-",CC1=C2C=CC=CC2=C(C3=CC=CC=C13)CBr,,,,,,
2057,36752,"BENZ(c)ACRIDINE, 7-(BROMOMETHYL)-",C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4N=C32)CBr,,,,,,
2058,36753,CID 36753,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OC(=O)CCC(=O)[O-].[Na+],,,,,,
2059,36754,Oxazepam hemisuccinate,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OC(=O)CCC(=O)O,,,,,,
2060,36755,"N-tert-Butyl-6-chloro-N'-methyl-[1,3,5]triazine-2,4-diamine",CC(C)(C)NC1=NC(=NC(=N1)NC)Cl,,,,,,
2061,36756,CID 36756,CC(C)[NH2+]CC1CC2=C(O1)C=CC(=C2)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
2062,36757,"N-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC(C)NCC1CC2=C(O1)C=CC(=C2)OC,,,,,,
2063,36758,CID 36758,C[NH2+]CC1CC2=C(O1)C=CC(=C2)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
2064,36759,"1-(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)-N-methylmethanamine",CNCC1CC2=C(O1)C=CC(=C2)OC,,,,,,
2065,36760,CID 36760,CC1=C2C(=CC=C1)CC(O2)C[NH2+]C(C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
2066,36761,"N-[(7-methyl-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC1=C2C(=CC=C1)CC(O2)CNC(C)C,,,,,,
2067,36762,CID 36762,CC[NH2+]CC1CC2=CC=CC(=C2O1)C.C(=CC(=O)[O-])C(=O)O,,,,,,
2068,36763,"N-[(7-methyl-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=CC=CC(=C2O1)C,,,,,,
2069,36764,CID 36764,CC1=C2C(=CC=C1)CC(O2)C[NH2+]C.C(=CC(=O)[O-])C(=O)O,,,,,,
2070,36765,"N-methyl-1-(7-methyl-2,3-dihydro-1-benzofuran-2-yl)methanamine",CC1=C2C(=CC=C1)CC(O2)CNC,,,,,,
2071,36766,CID 36766,CC1=CC2=C(C=C1)OC(C2)C[NH2+]C(C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
2072,36767,"N-[(5-methyl-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC1=CC2=C(C=C1)OC(C2)CNC(C)C,,,,,,
2073,36768,CID 36768,CC[NH2+]CC1CC2=C(O1)C=CC(=C2)C.C(=CC(=O)[O-])C(=O)O,,,,,,
2074,36769,"N-[(5-methyl-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C=CC(=C2)C,,,,,,
2075,36770,CID 36770,CC1=CC2=C(C=C1)OC(C2)C[NH2+]C.C(=CC(=O)[O-])C(=O)O,,,,,,
2076,36771,"N-methyl-1-(5-methyl-2,3-dihydro-1-benzofuran-2-yl)methanamine",CC1=CC2=C(C=C1)OC(C2)CNC,,,,,,
2077,36772,CID 36772,CC[NH2+]CC1CC2=C(O1)C(=CC(=C2Cl)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2078,36773,"N-[(4,5,7-trichloro-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C(=CC(=C2Cl)Cl)Cl,,,,,,
2079,36774,CID 36774,C[NH2+]CC1CC2=C(O1)C(=CC(=C2Cl)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2080,36775,"N-methyl-1-(4,5,7-trichloro-2,3-dihydro-1-benzofuran-2-yl)methanamine",CNCC1CC2=C(O1)C(=CC(=C2Cl)Cl)Cl,,,,,,
2081,36776,CID 36776,CC[NH2+]CC1CC2=C(O1)C(=CC(=C2)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2082,36777,"N-[(5,7-dichloro-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C(=CC(=C2)Cl)Cl,,,,,,
2083,36778,CID 36778,CC(C)[NH2+]CC1CC2=C(O1)C(=CC=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2084,36779,"N-[(7-chloro-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC(C)NCC1CC2=C(O1)C(=CC=C2)Cl,,,,,,
2085,36780,CID 36780,CC[NH2+]CC1CC2=C(O1)C(=CC=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2086,36781,"N-[(7-chloro-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C(=CC=C2)Cl,,,,,,
2087,36782,CID 36782,C[NH2+]CC1CC2=C(O1)C(=CC=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2088,36783,"1-(7-chloro-2,3-dihydro-1-benzofuran-2-yl)-N-methylmethanamine",CNCC1CC2=C(O1)C(=CC=C2)Cl,,,,,,
2089,36784,CID 36784,CC(C)[NH2+]CC1CC2=C(O1)C=CC(=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2090,36785,"N-[(5-chloro-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC(C)NCC1CC2=C(O1)C=CC(=C2)Cl,,,,,,
2091,36786,CID 36786,CC[NH2+]CC1CC2=C(O1)C=CC(=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2092,36787,"N-[(5-chloro-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C=CC(=C2)Cl,,,,,,
2093,36788,CID 36788,C[NH2+]CC1CC2=C(O1)C=CC(=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2094,36789,"1-(5-chloro-2,3-dihydro-1-benzofuran-2-yl)-N-methylmethanamine",CNCC1CC2=C(O1)C=CC(=C2)Cl,,,,,,
2095,36790,CID 36790,CC(C)[NH2+]CC1CC2=C(O1)C(=CC=C2)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
2096,36791,"N-[(7-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC(C)NCC1CC2=C(O1)C(=CC=C2)OC,,,,,,
2097,36792,CID 36792,CC[NH2+]CC1CC2=C(O1)C(=CC=C2)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
2098,36793,"N-[(7-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C(=CC=C2)OC,,,,,,
2099,36794,CID 36794,C[NH2+]CC1CC2=C(O1)C(=CC=C2)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
2100,36795,"[(7-Methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl](methyl)amine",CNCC1CC2=C(O1)C(=CC=C2)OC,,,,,,
2101,36796,"Hydantoin, 3-(2-(diethylamino)ethyl)-5,5-diphenyl-",CCN(CC)CCN1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2102,36797,Atrigel,CC(C(=O)O)O.C(C(=O)O)O,,,,,,
2103,36798,"3-(3,4,5-Trimethoxyphenyl)-2-propenal",COC1=CC(=CC(=C1OC)OC)C=CC=O,,,,,,
2104,36799,"4-Imidazolidinone, 5-hydroxyimino-2-imino-1-methyl-",CN1C(=C(N=C1N)O)N=O,,,,,,
2105,36800,"Phosphoric acid, (1-methyl-1-phenylethyl)phenyl diphenyl ester",CC(C)C1=CC(=CC(=C1)C2=CC=CC=C2)OP(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4,,,,,,
2106,36801,CID 36801,CC[NH2+]CC1CC2=C(O1)C=CC(=C2)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
2107,36802,"N-[(5-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]ethanamine",CCNCC1CC2=C(O1)C=CC(=C2)OC,,,,,,
2108,36803,CID 36803,C[NH2+]CC1CC2=C(O1)C(=CC(=C2)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2109,36804,"1-(5,7-dichloro-2,3-dihydro-1-benzofuran-2-yl)-N-methylmethanamine",CNCC1CC2=C(O1)C(=CC(=C2)Cl)Cl,,,,,,
2110,36805,CID 36805,CC(C)[NH2+]CC1CC2=C(O1)C(=CC(=C2)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2111,36806,"N-[(5,7-dichloro-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC(C)NCC1CC2=C(O1)C(=CC(=C2)Cl)Cl,,,,,,
2112,36807,CID 36807,CC(C)[NH2+]CC1CC2=C(O1)C(=CC(=C2Cl)Cl)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
2113,36808,"N-[(4,5,7-trichloro-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine",CC(C)NCC1CC2=C(O1)C(=CC(=C2Cl)Cl)Cl,,,,,,
2114,36809,CID 36809,C1=CC(=CC=C1C(=NN=C([NH3+])N)C2=CC=C(C=C2)Cl)C(F)(F)F.[Cl-],,,,,,
2115,36810,CID 36810,C1=CC(=CC=C1C(=NN=C(N)N)C2=CC=C(C=C2)Cl)C(F)(F)F,,,,,,
2116,36811,Dobutamine,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,['Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.'],"['Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine.']","['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Agonists.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']","['In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.']",,['2 minutes']
2117,36812,"6H-Dibenzo(b,d)pyran-1-ol, 3-(1'-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-",CCCCCCCC(C)C1=CC(=C2C3=C(CCC(C3)C)C(OC2=C1)(C)C)O,,,,,,
2118,36813,CID 36813,CC(=NNC(=[NH+]N=C(C)CC1=CC=CC=C1)N)CC2=CC=CC=C2.[Cl-],,,,,,
2119,36814,CID 36814,CC(=NNC(=NN=C(C)CC1=CC=CC=C1)N)CC2=CC=CC=C2,,,,,,
2120,36815,CID 36815,CCC(=NC(=O)OCC)NOCC,,,,,,
2121,36816,[3-[2-Acetyl-4-(butanoylamino)phenoxy]-2-hydroxypropyl]-propan-2-ylazanium;chloride,CCCC(=O)NC1=CC(=C(C=C1)OCC(C[NH2+]C(C)C)O)C(=O)C.[Cl-],,,,,,
2122,36817,"(1)BENZOTHIENO(2,3-d)PYRIMIDIN-4-ONE, 5,6,7,8-TETRAHYDRO-2-METHYL-3-(p-TOLYL)-",CC1=CC=C(C=C1)N2C(=NC3=C(C2=O)C4=C(S3)CCCC4)C,,,,,,
2123,36818,"(1)Benzothieno(2,3-d)pyrimidin-4-one, 5,6,7,8-tetrahydro-3-(4-fluorophenyl)-2-methyl-",CC1=NC2=C(C3=C(S2)CCCC3)C(=O)N1C4=CC=C(C=C4)F,,,,,,
2124,36819,Methothrin,CC(=CC1C(C1(C)C)C(=O)OCC2=CC=C(C=C2)COC)C,,,,,,
2125,36820,"5-Cyclopentyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",C=CCC1(C(=O)NC(=O)NC1=O)C2CCCC2,,,,,,
2126,36821,"Methyl 2,5-dichloro-3-nitrobenzoate",COC(=O)C1=C(C(=CC(=C1)Cl)[N+](=O)[O-])Cl,,,,,,
2127,36822,"5,6,7,8-Tetrahydroquinoxaline",C1CCC2=NC=CN=C2C1,,,,,,
2128,36823,"6H-p-DITHIINO(2,3-c)PYRROLE-5,7-DIONE, 2,3,5,7-TETRAHYDRO-6-METHYL-",CN1C(=O)C2=C(C1=O)SCCS2,,,,,,
2129,36824,"p-DITHIIN-2,3-DICARBOXIMIDE, 5,6-DIHYDRO-N-ETHYL-",CCN1C(=O)C2=C(C1=O)SCCS2,,,,,,
2130,36825,"p-DITHIIN-2,3-DICARBOXIMIDE, 5,6-DIHYDRO-N-ALLYL-",C=CCN1C(=O)C2=C(C1=O)SCCS2,,,,,,
2131,36826,"p-DITHIIN-2,3-DICARBOXIMIDE, 5,6-DIHYDRO-N-(2-(DIETHYLAMINO)ETHYL)-",CCN(CC)CCN1C(=O)C2=C(C1=O)SCCS2,,,,,,
2132,36827,"p-DITHIIN-2,3-DICARBOXIMIDE, 5,6-DIHYDRO-N-HYDROXY-",C1CSC2=C(S1)C(=O)N(C2=O)O,,,,,,
2133,36828,"1-Octanamine, N-methyl-N-nitroso-",CCCCCCCCN(C)N=O,,,,,,
2134,36829,Dimethyl arsenate,CO[As](=O)(O)OC,,,,,,
2135,36830,N-(4-Hydroxyphenyl)acrylamide,C=CC(=O)NC1=CC=C(C=C1)O,,,,,,
2136,36831,(R/S)-cefamandole,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(C4=CC=CC=C4)O)SC2)C(=O)O,,,,,,
2137,36832,2-Ethyl-2-hydroxybutanenitrile,CCC(CC)(C#N)O,,,,,,
2138,36833,Bumadizone calcium,CCCCC(C(=O)N(C1=CC=CC=C1)NC2=CC=CC=C2)C(=O)[O-].CCCCC(C(=O)N(C1=CC=CC=C1)NC2=CC=CC=C2)C(=O)[O-].[Ca+2],,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
2139,36834,Fletazepam,C1CN(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F,,,,,,
2140,36835,"2,5-dimethyl-N-phenylpyrrolidine-1-carboxamide",CC1CCC(N1C(=O)NC2=CC=CC=C2)C,,,,,,
2141,36836,"Barbituric acid, 5,5-diallyl-1-phenethyl-",C=CCC1(C(=O)NC(=O)N(C1=O)CCC2=CC=CC=C2)CC=C,,,,,,
2142,36837,CID 36837,CCC(=CN=O)O,,,,,,
2143,36838,"BENZ(5,6)ANTHRA(1,2-b)OXIRENE, 1a,11b-DIHYDRO-",C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5C4O5)C=C32,,,,,,
2144,36839,CID 36839,C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O.[Na+].[Na+].[SbH3].[SbH3],,,,,,
2145,36840,CID 36840,CC[N+](CC)(CC)CCSC(=N)[NH3+].[Br-].[Br-],,,,,,
2146,36841,2-Carbamimidoylsulfanylethyl(triethyl)azanium,CC[N+](CC)(CC)CCSC(=N)N,,,,,,
2147,36842,"(2-((4,5-Dihydro-1H-imidazol-2-yl)thio)ethyl)triethylammonium bromide hydrobromide",CC[N+](CC)(CC)CCSC1=NCC[NH2+]1.[Br-].[Br-],,,,,,
2148,36843,"2-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)ethyl-triethylazanium",CC[N+](CC)(CC)CCSC1=NCCN1,,,,,,
2149,36844,"N,N-Dimethyl-4-((3,4,5-trimethylphenyl)azo)benzenamine",CC1=CC(=CC(=C1C)C)N=NC2=CC=C(C=C2)N(C)C,,,,,,
2150,36845,CID 36845,CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34.C(=CC(=O)O)C(=O)O,,,,,,
2151,36846,Oxetorona,CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34,,,,,,
2152,36847,CID 36847,CCCCCCCCCCCC[N+](C)(C)CCOC(=NCC)S.[Br-],,,,,,
2153,36848,CID 36848,CCCCCCCCCCCC[N+](C)(C)CCOC(=NCC)S,,,,,,
2154,36849,3-Methyl-2-(methylimino)benzoxazoline,CN=C1N(C2=CC=CC=C2O1)C,,,,,,
2155,36850,"Benzamide, N-(5-chloro-2-pyridinyl)-3-(trifluoromethyl)-",C1=CC(=CC(=C1)C(F)(F)F)C(=O)NC2=NC=C(C=C2)Cl,,,,,,
2156,36851,"Benzamide, N-(5-chloro-2-pyridinyl)-2-fluoro-",C1=CC=C(C(=C1)C(=O)NC2=NC=C(C=C2)Cl)F,,,,,,
2157,36852,"Ketone, 2-indolyl methoxymethyl-",COCC(=O)C1=CC2=CC=CC=C2N1,,,,,,
2158,36853,gamma-Aminobutyric acid cetyl ester,CCCCCCCCCCCCCCCCOC(=O)CCCN,,,,,,
2159,36854,Feniodium chloride,C1=CC(=C(C=C1Cl)Cl)[I+]C2=C(C=C(C=C2)Cl)Cl.[Cl-],,,,,,
2160,36855,Feniodium,C1=CC(=C(C=C1Cl)Cl)[I+]C2=C(C=C(C=C2)Cl)Cl,,,,,,
2161,36856,"(E)-but-2-enedioic acid;2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.0^{3,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one",CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1.C(=CC(=O)O)C(=O)O,,,,,,
2162,36857,"((1-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)oxy)acetic acid",C1=CC(=CC(=C1)N2C3=C(C=CC=N3)C(=N2)OCC(=O)O)C(F)(F)F,,,,,,
2163,36858,"Acetic acid, ((1-(alpha,alpha,alpha-trifluoro-m-tolyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)oxy)-, ethyl ester",CCOC(=O)COC1=NN(C2=C1C=CC=N2)C3=CC=CC(=C3)C(F)(F)F,,,,,,
2164,36859,"3-Chloro-1,2-butadiene",CC(=C=C)Cl,,,,,,
2165,36860,CID 36860,CC(=CC(=O)OC)NC(C1=CC=CC=C1)C(=O)[O-].[K+],,,,,,
2166,36861,2-[(4-Methoxy-4-oxobut-2-en-2-yl)amino]-2-phenylacetic acid,CC(=CC(=O)OC)NC(C1=CC=CC=C1)C(=O)O,,,,,,
2167,36862,CID 36862,C1=CC2=C(C=CC=C2Br)C(=C1)NCCC(=O)[O-].[Na+],,,,,,
2168,36863,N-(5-bromo-1-naphthyl)-beta-alanine,C1=CC2=C(C=CC=C2Br)C(=C1)NCCC(=O)O,,,,,,
2169,36864,"4-Tert-butyl-2,6-dichlorophenol",CC(C)(C)C1=CC(=C(C(=C1)Cl)O)Cl,,,,,,
2170,36865,5-((o-Chlorobenzylidene)amino)isoquinoline,C1=CC=C(C(=C1)C=NC2=CC=CC3=C2C=CN=C3)Cl,,,,,,
2171,36866,CID 36866,C1CCC2=C(CC1)NC(=NC2=O)S,,,,,,
2172,36867,Orbencarb,CCN(CC)C(=O)SCC1=CC=CC=C1Cl,,,,,,
2173,36868,1'-Acetoxysafrole,CC(=O)OC(C=C)C1=CC2=C(C=C1)OCO2,,,,,,
2174,36869,Ethylhydrazine sulphate,CCN[NH3+].OS(=O)(=O)[O-],,,,,,
2175,36870,Prothiofos,CCCSP(=S)(OCC)OC1=C(C=C(C=C1)Cl)Cl,,,,,,
2176,36871,CID 36871,CNC(=O)OC1=CC=CC=C1C=NOC(=O)NC,,,,,,
2177,36872,1-Bromo-1-chloropropane,CCC(Cl)Br,,,,,,
2178,36873,(p-Chlorophenoxy)acetic acid 2-morpholinoethyl ester hydrochloride,C1COCC[NH+]1CCOC(=O)COC2=CC=C(C=C2)Cl.[Cl-],,,,,,
2179,36874,(p-Chlorophenoxy)acetic acid 2-morpholinoethyl ester,C1COCCN1CCOC(=O)COC2=CC=C(C=C2)Cl,,,,,,
2180,36875,(p-Methoxyphenoxy)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=C(C=C1)OC.[Cl-],,,,,,
2181,36876,2-(Diethylamino)ethyl (4-methoxyphenoxy)acetate,CCN(CC)CCOC(=O)COC1=CC=C(C=C1)OC,,,,,,
2182,36877,(p-Methoxyphenoxy)acetic acid 2-morpholinoethyl ester hydrochloride,COC1=CC=C(C=C1)OCC(=O)OCCC2C[NH2+]CCO2.[Cl-],,,,,,
2183,36878,2-Morpholin-2-ylethyl 2-(4-methoxyphenoxy)acetate,COC1=CC=C(C=C1)OCC(=O)OCCC2CNCCO2,,,,,,
2184,36879,Butocarboxim,CC(C(=NOC(=O)NC)C)SC,,,,"['Little information is available on the distribution of carbamates in the various organs and tissues in mammals following exposure by inhalation or the oral route. The organs in which residues have been reported are the liver, kidneys, brain, fat, and muscle. The half-life in the rat is of the order of 3-8 hr. ...It seems that the excretion of carbamates via urine is also rapid in man, and that the metabolic pathways in man are the same as those in the rat. /Carbamate Pesticides/']","['In mammals, following oral administration, metabolised to butoxycarboxim, and excreted in the urine as butoxycarboxim and its...products.', 'The first step in the metabolism of carbamates is hydrolysis to carbamic acid, which decomposes to carbon dioxide (CO2) and the corresponding amine. The mechanism of hydrolysis is different for  N -methyl and  N -dimethyl derivatives.  The  N -methyl carbamates pass through an isocyanate intermediate, whereas in the hydrolysis of  N - dimethylcarbamates, an addition product with a hydroxyl ion is formed yielding the alcohol and  N -dimethyl substituted acid.  The rate of hydrolysis by esterases is faster in mammals than in plants and insects. Apart from hydrolysis, oxidation also takes place including: hydroxylation of the aromatic ring,  O -dealkylation,  N -methyl hydroxylation,  N -dealkylation, oxidation of aliphatic side chains, and sulfoxidation to the corresponding sulfone. Oxidation is associated with the mixed-function oxidase (MFO) enzymes. Conjugation leads to the formation of  O - and  N -glucuronides, sulfates, and mercapturic acid derivatives in mammals.  Glycosides and phosphates are conjugation products more common in plants. /Carbamate Pesticides/']",['The half-life in the rat is of the order of 3-8 hr.']
2185,36880,CID 36880,CC(=NO)CSC(=S)N(C)C,,,,,,
2186,36881,"2,5-Diaminotropone hydrochloride",C1=CC(=O)C(=CC=C1N)[NH3+].[Cl-],,,,,,
2187,36882,"2,5-Diaminotropone",C1=CC(=O)C(=CC=C1N)N,,,,,,
2188,36883,"Anthranilic acid, N-((3-(1-adamantyl)-5,6-dimethyl)phenyl)-",CC1=CC(=CC(=C1C)NC2=CC=CC=C2C(=O)O)C34CC5CC(C3)CC(C5)C4,,,,,,
2189,36884,1-sec-Butoxymethyl benzimidazole oxalate,CCC(C)OC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])O,,,,,,
2190,36885,3-(butan-2-yloxymethyl)-1H-benzimidazol-3-ium,CCC(C)OC[N+]1=CNC2=CC=CC=C21,,,,,,
2191,36886,"Benzimidazole, 1-((2-aminoethoxy)methyl)-, oxalate",C1=CC=C2C(=C1)N=CN2COCC[NH3+].C(=O)(C(=O)[O-])O,,,,,,
2192,36887,2-(1h-Benzimidazol-1-ylmethoxy)ethanamine,C1=CC=C2C(=C1)N=CN2COCCN,,,,,,
2193,36888,"Benzimidazole, 1-((3-aminopropoxy)methyl)-, picrate",C1=CC=C2C(=C1)N=CN2COCCC[NH3+].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2194,36889,3-(Benzimidazol-1-ylmethoxy)propan-1-amine,C1=CC=C2C(=C1)N=CN2COCCCN,,,,,,
2195,36890,1-((2-(Benzylamino)ethoxy)methyl)-benzimidazole oxalate,C1=CC=C(C=C1)C[NH2+]CCOC[N+]2=CNC3=CC=CC=C32.C(=O)(C(=O)[O-])[O-],,,,,,
2196,36891,2-(3H-benzimidazol-1-ium-1-ylmethoxy)-N-benzylethanamine,C1=CC=C(C=C1)CNCCOC[N+]2=CNC3=CC=CC=C32,,,,,,
2197,36892,"Benzimidazole, 1-((2-(dimethylamino)ethoxy)methyl)-, dioxalate",C[NH+](C)CCOC[N+]1=CNC2=CC=CC=C21.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
2198,36893,"2-(3H-benzimidazol-1-ium-1-ylmethoxy)-N,N-dimethylethanamine",CN(C)CCOC[N+]1=CNC2=CC=CC=C21,,,,,,
2199,36894,"Benzenesulfonic acid, p-nitro-, 2-(1-benzimidazolyl)ethyl ester, oxalate, hydrate",C1=CC=C2C(=C1)NC=[N+]2CCOS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-].C(=O)(C(=O)[O-])O,,,,,,
2200,36895,2-(3H-benzimidazol-1-ium-1-yl)ethyl 4-nitrobenzenesulfonate,C1=CC=C2C(=C1)NC=[N+]2CCOS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
2201,36896,CID 36896,C1=CC=C2C(=C1)NC=[N+]2CCOC(=O)C3=CC=C(C=C3)F.C(=CC(=O)[O-])C(=O)O,,,,,,
2202,36897,2-(3H-benzimidazol-1-ium-1-yl)ethyl 4-fluorobenzoate,C1=CC=C2C(=C1)NC=[N+]2CCOC(=O)C3=CC=C(C=C3)F,,,,,,
2203,36898,1-(2-(Diphenylmethoxy)ethyl)-benzimidazole hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[N+]3=CNC4=CC=CC=C43.[Cl-],,,,,,
2204,36899,3-(2-benzhydryloxyethyl)-1H-benzimidazol-3-ium,C1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[N+]3=CNC4=CC=CC=C43,,,,,,
2205,36900,"Anthranilic acid, N-((3-(1-adamantyl)-6-methyl)phenyl)-",CC1=C(C=C(C=C1)C23CC4CC(C2)CC(C4)C3)NC5=CC=CC=C5C(=O)O,,,,,,
2206,36901,"5,7-Bis(morpholinomethyl)-2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one",CC(C)C1=CC(=CC(=C(C1=O)O)CN2CCOCC2)CN3CCOCC3,,,,,,
2207,36902,(p-Methoxyphenoxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=C(C=C1)OC.[Cl-],,,,,,
2208,36903,2-(Dimethylamino)ethyl (4-methoxyphenoxy)acetate,CN(C)CCOC(=O)COC1=CC=C(C=C1)OC,,,,,,
2209,36904,"2,3,4-Trichlorobenzenesulfonyl chloride",C1=CC(=C(C(=C1S(=O)(=O)Cl)Cl)Cl)Cl,,,,,,
2210,36905,1-(5-methoxy-1H-indol-3-yl)propan-2-ylazanium;chloride,CC(CC1=CNC2=C1C=C(C=C2)OC)[NH3+].[Cl-],,,,,,
2211,36906,5-Methoxy-alpha-methyltryptamine,CC(CC1=CNC2=C1C=C(C=C2)OC)N,,,,,,
2212,36907,"Dipropylamine, 3,3'-dichloro-N-methyl-, picrate",C[NH+](CCCCl)CCCCl.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2213,36908,"1-Propanamine, 3-chloro-N-(3-chloropropyl)-N-methyl-",CN(CCCCl)CCCCl,,,,,,
2214,36909,Zipeprol dihydrochloride,COC(CN1CCN(CC1)CC(C(C2=CC=CC=C2)OC)O)C3=CC=CC=C3.Cl.Cl,,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
2215,36910,Zipeprol,COC(CN1CCN(CC1)CC(C(C2=CC=CC=C2)OC)O)C3=CC=CC=C3,,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
2216,36911,"3,5-Dimethyl-4-nitroaniline",CC1=CC(=CC(=C1[N+](=O)[O-])C)N,,,,,,
2217,36912,"3,7-Dimethyl-6-(1-pyrrolidinyl)-3-azabicyclo(3.3.1)nonan-9-ol",CC1CC2CN(CC(C1N3CCCC3)C2O)C,,,,,,
2218,36913,CID 36913,CC(=NO)CCC1CC2=C(C=CC=C2SC3=C1C=C(C=C3)Cl)[NH+]4CCNCC4.[Cl-],,,,,,
2219,36914,CID 36914,CC(=NO)CCC1CC2=C(C=CC=C2SC3=C1C=C(C=C3)Cl)N4CCNCC4,,,,,,
2220,36915,CID 36915,COC1=CC(=CC(=C1OC)OC)C(=O)OCCN2CCN(CC2)C3CC4=CC=CC=C4SC5=C3C=C(C=C5)Cl.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
2221,36916,"2-[4-(3-Chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]ethyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCN2CCN(CC2)C3CC4=CC=CC=C4SC5=C3C=C(C=C5)Cl,,,,,,
2222,36917,3-Hydroxytropolone,C1=CC(=C(C(=O)C=C1)O)O,,,,,,
2223,36918,1H-Benzo[c]carbazole,C1C=CC=C2C1=C3C(=NC4=CC=CC=C43)C=C2,,,,,,
2224,36919,"(3-Chloro-4-bicyclo[3.2.0]hepta-3,6-dienyl) dimethyl phosphate",COP(=O)(OC)OC1=C(CC2C1C=C2)Cl,,,,,,
2225,36920,Tertatolol,CC(C)(C)NCC(COC1=CC=CC2=C1SCCC2)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
2226,36921,Ticarcillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C,['For the treatment of bacterial infections.'],"['Ticarcillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is, however, susceptible to degradation by -lactamases, and therefore, the spectrum of activity does not normally include organisms which produce these enzymes.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,['1.1 hours']
2227,36922,CID 36922,C[C@@H]1[C@H]([C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5([C@@H](C6([C@H]4O6)CO)O)O)C)OC(O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)C=CC=CC8=CC=CC=C8,,,,,,
2228,36923,"9-Acridinamine, 1,2,3,4-tetrahydro-N-(2-methylpropyl)-",CC(C)CNC1=C2CCCCC2=NC3=CC=CC=C31,,,,,,
2229,36924,"1,2,3,4-Tetrahydro-N,7-dimethyl-9-acridinamine",CC1=CC2=C(C=C1)N=C3CCCCC3=C2NC,,,,,,
2230,36925,"9-Acridinamine, 1,2,3,4-tetrahydro-N-ethyl-7-methyl-",CCNC1=C2CCCCC2=NC3=C1C=C(C=C3)C,,,,,,
2231,36926,"1,2,3,4-Tetrahydro-N-butyl-7-methyl-9-acridinamine",CCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)C,,,,,,
2232,36927,"9-Acridinamine, 1,2,3,4-tetrahydro-7-methyl-N-(2-methylpropyl)-",CC1=CC2=C(C=C1)N=C3CCCCC3=C2NCC(C)C,,,,,,
2233,36928,"9-Acridinamine, 1,2,3,4-tetrahydro-N-butyl-7-chloro-",CCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)Cl,,,,,,
2234,36929,"1,2,3,4-Tetrahydro-7-chloro-N-(isobutyl)-9-acridinamine hydrochloride",CC(C)C[NH2+]C1=C2CCCCC2=NC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
2235,36930,"7-chloro-N-(2-methylpropyl)-1,2,3,4-tetrahydroacridin-9-amine",CC(C)CNC1=C2CCCCC2=NC3=C1C=C(C=C3)Cl,,,,,,
2236,36931,"9-Acridinamine, 1,2,3,4-tetrahydro-7-bromo-N-butyl-",CCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)Br,,,,,,
2237,36932,"1,2,3,4-Tetrahydro-7-bromo-N-(isobutyl)-9-acridinamine hydrochloride",CC(C)C[NH2+]C1=C2CCCCC2=NC3=C1C=C(C=C3)Br.[Cl-],,,,,,
2238,36933,"7-bromo-N-(2-methylpropyl)-1,2,3,4-tetrahydroacridin-9-amine",CC(C)CNC1=C2CCCCC2=NC3=C1C=C(C=C3)Br,,,,,,
2239,36934,"1,2,7,8-Tetrachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=CC(=C(C=C3O2)Cl)Cl)Cl)Cl,,,,,,
2240,36935,"4,4,4-Trichloro-1,2-butadiene",C=C=CC(Cl)(Cl)Cl,,,,,,
2241,36936,3-(Bromomethyl)cyclohexene,C1CC=CC(C1)CBr,,,,,,
2242,36937,Norsalsolinol,C1CNCC2=CC(=C(C=C21)O)O,,,,,,
2243,36938,"Acetic acid, nitrilotri-, copper(2+) salt (1:1)",C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Cu+2],,,,,,
2244,36939,Nickel nitrilotriacetate,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Ni+2],,,,,,
2245,36940,CID 36940,CC(=S)[O-].[Na+],,,,,,
2246,36941,2-[(Phenylsulfonyl)amino]benzoic acid,C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)O,,,,,,
2247,36942,CID 36942,CC1=C(N=CN1)CSCCNC(=NC)S,,,,,,
2248,36943,"1,3-DIOXOLO(4,5-g)QUINOLIN-8(5H)-ONE, 7-ACETYL-5-ETHYL-",CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)C,,,,,,
2249,36944,"1,3-Butanediol, 2-methyl-1-phenyl-4,4,4-trifluoro-3-trifluoromethyl-",CC(C(C1=CC=CC=C1)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2250,36945,"2-(1-Hydroxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl)heptanal",CCCCCC(C=O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2251,36946,"7-Chloro-7,7-difluoro-6-hydroxy-2-methyl-6-trifluoromethyl-2-hepten-4-one",CC(=CC(=O)CC(C(F)(F)F)(C(F)(F)Cl)O)C,,,,,,
2252,36947,"cis-Cyclododecanemethanol, 2-hydroxy-alpha,alpha-bis(trifluoromethyl)-",C1CCCCC[C@@H]([C@@H](CCCC1)C(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2253,36948,"1-Naphthol, 1,2,3,4-tetrahydro-2-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)-",C1CC2=CC=CC=C2C(C1C(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2254,36949,"5,5-Dimethyl-1,1,1-trifluoro-2-trifluoromethyl-2,4-hexanediol",CC(C)(C)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2255,36950,"1-Chloro-1,1-difluoro-6-methyl-2-trifluoromethyl-5-heptene-2,4-diol",CC(=CC(CC(C(F)(F)F)(C(F)(F)Cl)O)O)C,,,,,,
2256,36951,"6-Methyl-1,1,1-trifluoro-2-trifluoromethyl-5-heptene-2,4-diol",CC(=CC(CC(C(F)(F)F)(C(F)(F)F)O)O)C,,,,,,
2257,36952,"1-Phenyl-4,4,4-trifluoro-3-trifluoromethyl-1,3-butanediol",C1=CC=C(C=C1)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2258,36953,"1,3-BUTANEDIOL, 1-(m-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-TRIFLUOROMETHYL-",C1=CC(=CC(=C1)Cl)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2259,36954,"1,3-Butanediol, 1-(3-trifluoromethylphenyl)-3-trifluoromethyl-4,4,4-trifluoro-",C1=CC(=CC(=C1)C(F)(F)F)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2260,36955,"1-(m-Nitrophenyl)-4,4,4-trifluoro-3-trifluoromethyl-1,3-butanediol",C1=CC(=CC(=C1)[N+](=O)[O-])C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2261,36956,"1-(2-Thienyl)-4,4,4-trifluoro-3-trifluoromethyl-1,3-butanediol",C1=CSC(=C1)C(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2262,36957,"4-Chloro-3-(chlorodifluoromethyl)-4,4-difluoro-2-methyl-1-phenyl-1,3-butanediol",CC(C(C1=CC=CC=C1)O)C(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
2263,36958,"1,3-Butanediol, 2-ethyl-1-phenyl-3-(trifluoromethyl)-4,4,4-trifluoro-",CCC(C(C1=CC=CC=C1)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2264,36959,"4,4,4-Trifluoro-2-octyl-3-(trifluoromethyl)butane-1,3-diol",CCCCCCCCC(CO)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2265,36960,"1,3-BUTANEDIOL, 1-(p-CHLOROPHENYL)-2-METHYL-4,4,4-TRIFLUORO-3-(TRIFLUOROMETHYL)-",CC(C(C1=CC=C(C=C1)Cl)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2266,36961,"1,3-BUTANEDIOL, 1-(p-CHLOROPHENYL)-2-ETHYL-3-(TRIFLUOROMETHYL)-4,4,4-TRIFLUORO-",CCC(C(C1=CC=C(C=C1)Cl)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2267,36962,"1,3-BUTANEDIOL, 1-(p-FLUOROPHENYL)-2-METHYL-4,4,4-TRIFLUORO-3-(TRIFLUOROMETHYL)-",CC(C(C1=CC=C(C=C1)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2268,36963,"1,3-BUTANEDIOL, 2-ETHYL-1-(p-FLUOROPHENYL)-3-TRIFLUOROMETHYL-4,4,4-TRIFLUORO-",CCC(C(C1=CC=C(C=C1)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2269,36964,"1,3-BUTANEDIOL, 1-(p-BROMOPHENYL)-2-METHYL-3-TRIFLUOROMETHYL-4,4,4-TRIFLUORO-",CC(C(C1=CC=C(C=C1)Br)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2270,36965,"1,3-BUTANEDIOL, 1-(p-ANISYL)-2-METHYL-4,4,4-TRIFLUORO-3-(TRIFLUOROMETHYL)-",CC(C(C1=CC=C(C=C1)OC)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2271,36966,"1,1,1-Trifluoro-6-phenyl-2-(trifluoromethyl)hex-5-ene-2,4-diol",C1=CC=C(C=C1)C=CC(CC(C(F)(F)F)(C(F)(F)F)O)O,,,,,,
2272,36967,"4-Chloro-4,4-difluoro-3-(chlorodifluoromethyl)-1-(2-furyl)-1,3-butanediol",C1=COC(=C1)C(CC(C(F)(F)Cl)(C(F)(F)Cl)O)O,,,,,,
2273,36968,"4-Chloro-3-(chlorodifluoromethyl)-4,4-difluoro-1-(2-thienyl)-1,3-butanediol",C1=CSC(=C1)C(CC(C(F)(F)Cl)(C(F)(F)Cl)O)O,,,,,,
2274,36969,"2-Methyl-1-(2-thienyl)-4,4,4-trifluoro-3-trifluoromethyl-1,3-butanediol",CC(C(C1=CC=CS1)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2275,36970,"2-Ethyl-1-(2-thienyl)-4,4,4-trifluoro-3-trifluoromethyl-1,3-butanediol",CCC(C(C1=CC=CS1)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2276,36971,3-Chloroadamantane-1-carboxylic acid,C1C2CC3(CC1CC(C2)(C3)Cl)C(=O)O,,,,,,
2277,36972,"2-Biphenylamine, 3'-nitro-",C1=CC=C(C(=C1)C2=CC(=CC=C2)[N+](=O)[O-])N,,,,,,
2278,36973,Hokupanon,CC1=C(C=CC(=C1)Cl)N=CN(C)CSC.Cl,,,,,,
2279,36974,N'-(4-chloro-2-methylphenyl)-N-methyl-N-(methylsulfanylmethyl)methanimidamide,CC1=C(C=CC(=C1)Cl)N=CN(C)CSC,,,,,,
2280,36975,Carbuterol hydrochloride,CC(C)(C)NCC(C1=CC(=C(C=C1)O)NC(=O)N)O.Cl,,,,,,
2281,36976,Carbuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)NC(=O)N)O,,,,,,
2282,36977,"trans-2-Methyl-2-(p-isopropylphenyl)-4-carbamoyloxymethyl-1,3-dioxolane",CC1=CC(=C(C(=C1)C)C2(OC[C@H](O2)COC(=O)N)C)C,,,,,,
2283,36978,5-Amino-4-imidazolecarboxamide ureidosuccinate,C1=NC(=C(N1)C(=O)N)N.C(C(C(=O)O)NC(=O)N)C(=O)O,,,,,,
2284,36979,"3-Methoxy-2,4,6-trimethylphenol",CC1=CC(=C(C(=C1O)C)OC)C,,,,,,
2285,36980,"2,5-Dichlorobiphenyl",C1=CC=C(C=C1)C2=C(C=CC(=C2)Cl)Cl,,,,,,
2286,36981,"3,5-Dichlorobiphenyl",C1=CC=C(C=C1)C2=CC(=CC(=C2)Cl)Cl,,,,,,
2287,36982,"2,4'-Dichlorobiphenyl",C1=CC=C(C(=C1)C2=CC=C(C=C2)Cl)Cl,,,,,,
2288,36983,Fenisorex,CN[C@H]1CC2=C(C=C(C=C2)F)[C@H](O1)C3=CC=CC=C3,,,,,,
2289,36984,(Hydroxymethyl)carbamic acid 3-(1-methylbutyl)phenyl ester,CCCC(C)C1=CC(=CC=C1)OC(=O)NCO,,,,,,
2290,36985,5-(4-(Pentyloxy)phenyl)-2-(4-pentylphenyl)pyrimidine,CCCCCC1=CC=C(C=C1)C2=NC=C(C=N2)C3=CC=C(C=C3)OCCCCC,,,,,,
2291,36986,"Acetic acid, 2,2'-(piperonylidenedithio)DI-",C1OC2=C(O1)C=C(C=C2)C(SCC(=O)O)SCC(=O)O,,,,,,
2292,36987,"1-Butanesulfinic acid, 4,4'-dithiobis-, disodium salt",C(CCS(=O)[O-])CSSCCCCS(=O)[O-].[Na+].[Na+],,,,,,
2293,36988,4-(4-Sulfinobutyldisulfanyl)butane-1-sulfinic acid,C(CCS(=O)O)CSSCCCCS(=O)O,,,,,,
2294,36989,p-Hydroxy-alpha-(1-((2-(phenylthio)ethyl)thio)ethyl)benzyl alcohol,C1=CC=C(C=C1)SCCNCCC(C2=CC=C(C=C2)O)O,,,,,,
2295,36990,"Benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-2-(phenylthio)ethyl)amino)ethyl)-, hydrochloride",CC(CSC1=CC=CC=C1)[NH2+]C(C)C(C2=CC=C(C=C2)O)O.[Cl-],,,,,,
2296,36991,4-[1-Hydroxy-2-(1-phenylsulfanylpropan-2-ylamino)propyl]phenol,CC(CSC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O,,,,,,
2297,36992,p-Hydroxy-alpha-(1-((3-(phenylthio)propyl)amino)ethyl)benzyl alcohol hydrochloride,C1=CC=C(C=C1)SCCC[NH2+]CCC(C2=CC=C(C=C2)O)O.[Cl-],,,,,,
2298,36993,4-[1-Hydroxy-3-(3-phenylsulfanylpropylamino)propyl]phenol,C1=CC=C(C=C1)SCCCNCCC(C2=CC=C(C=C2)O)O,,,,,,
2299,36994,1-Benzyl-3-((dimethylamino)methyl)-3-methyl-2-indolinone hydrochloride,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C[NH+](C)C.[Cl-],,,,,,
2300,36995,1-Benzyl-3-[(dimethylamino)methyl]-3-methylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CN(C)C,,,,,,
2301,36996,1-Benzyl-3-methyl-3-piperidinomethyl-2-indolinone hydrochloride,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C[NH+]4CCCCC4.[Cl-],,,,,,
2302,36997,1-Benzyl-3-methyl-3-(piperidin-1-ylmethyl)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CN4CCCCC4,,,,,,
2303,36998,1-Benzyl-3-(2-(dimethylamino)ethyl)-3-methyl-2-indolinone hydrochloride,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CC[NH+](C)C.[Cl-],,,,,,
2304,36999,1-Benzyl-3-[2-(dimethylamino)ethyl]-3-methylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CCN(C)C,,,,,,
2305,37000,1-Benzyl-3-methyl-3-(2-(piperidino)ethyl)-2-indolinone hydrochloride,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CC[NH+]4CCCCC4.[Cl-],,,,,,
2306,37001,1-Benzyl-3-methyl-3-(2-piperidin-1-ylethyl)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CCN4CCCCC4,,,,,,
2307,37002,"2-Indolinone, 1-benzyl-3-methyl-3-(2-(morpholino)ethyl)-, monohydrochloride",CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CC[NH+]4CCOCC4.[Cl-],,,,,,
2308,37003,1-Benzyl-3-methyl-3-(2-morpholin-4-ylethyl)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)CCN4CCOCC4,,,,,,
2309,37004,CID 37004,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)OCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
2310,37005,1-Benzyl-3-[2-(dimethylamino)ethoxy]-3-methylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)OCCN(C)C,,,,,,
2311,37006,1-Benzyl-3-(2-(diethylamino)ethoxy)-3-methyl-2-indolinone hydrochloride,CC[NH+](CC)CCOC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C.[Cl-],,,,,,
2312,37007,1-Benzyl-3-[2-(diethylamino)ethoxy]-3-methylindol-2-one,CCN(CC)CCOC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C,,,,,,
2313,37008,1-Benzyl-3-methyl-3-(2-(piperidino)ethoxy)-2-indolinone oxalate,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)OCCC4CCCC[NH2+]4.C(=O)(C(=O)[O-])O,,,,,,
2314,37009,1-Benzyl-3-methyl-3-(2-piperidin-2-ylethoxy)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)OCCC4CCCCN4,,,,,,
2315,37010,1-Benzyl-3-(3-(diethylamino)propoxy)-3-methyl-2-indolinone oxalate,CC[NH+](CC)CCCOC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C.C(=O)(C(=O)[O-])O,,,,,,
2316,37011,1-Benzyl-3-[3-(diethylamino)propoxy]-3-methylindol-2-one,CCN(CC)CCCOC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)C,,,,,,
2317,37012,2-(Phenylthio)ethanamine hydrochloride,C1=CC=C(C=C1)SCC[NH3+].[Cl-],,,,,,
2318,37013,2-(Phenylthio)ethanamine,C1=CC=C(C=C1)SCCN,,,,,,
2319,37014,Cyclohexylammonium formate,C1CCC(CC1)[NH3+].C(=O)[O-],,,,,,
2320,37015,Cartazolate,CCCCNC1=C2C=NN(C2=NC=C1C(=O)OCC)CC,,,,,,
2321,37016,"2-Imidazolidinone, 3-nitroso-1-(5-nitro-2-thiazolyl)-",C1CN(C(=O)N1C2=NC=C(S2)[N+](=O)[O-])N=O,,,,,,
2322,37017,Bromochloroiodomethane,C(Cl)(Br)I,,,,,,
2323,37018,CID 37018,CN=C(NCCCCC1=CN=CN1)S,,,,,,
2324,37019,2-(p-Chlorophenyl)-5-oxotetrahydro-2-furancarbonitrile,C1CC(OC1=O)(C#N)C2=CC=C(C=C2)Cl,,,,,,
2325,37020,Tetrahydro-2-(p-chlorophenyl)-5-oxo-2-furancarboxamide,C1CC(OC1=O)(C2=CC=C(C=C2)Cl)C(=O)N,,,,,,
2326,37021,"2-(p-Chlorophenyl)-N,N-diethyl-5-oxotetrahydro-2-furamide",CCN(CC)C(=O)C1(CCC(=O)O1)C2=CC=C(C=C2)Cl,,,,,,
2327,37022,2-(p-Chlorophenyl)-N-cyclohexyltetrahydro-2-furamide,C1CCC(CC1)NC(=O)C2(CCC(=O)O2)C3=CC=C(C=C3)Cl,,,,,,
2328,37023,2-(p-Chlorophenyl)-5-oxotetrahydro-2-furanilide,C1CC(OC1=O)(C2=CC=C(C=C2)Cl)C(=O)NC3=CC=CC=C3,,,,,,
2329,37024,"1,1,2,2,3,4,4-Heptachlorobutane",C(C(Cl)Cl)(C(C(Cl)Cl)(Cl)Cl)Cl,,,,,,
2330,37025,Lead(II) methylmercaptide,C[S-].C[S-].[Pb+2],,,,,,
2331,37026,DL-2-Phenyl-N-(phenylacetyl)glycine,C1=CC=C(C=C1)CC(=O)NC(C2=CC=CC=C2)C(=O)O,,,,,,
2332,37027,"Difluoromethyl 1,2,2,3,3-pentafluoropropyl ether",C(C(C(F)F)(F)F)(OC(F)F)F,,,,,,
2333,37028,CID 37028,CC(C)(C)C1=NNC(=NC1=O)SC,,,,,,
2334,37029,CID 37029,C[NH+](C)CCCC1(CCCCC2=CC=CC=C21)O.C(=CC(=O)[O-])C(=O)O,,,,,,
2335,37030,"5-[3-(Dimethylamino)propyl]-6,7,8,9-tetrahydrobenzo[7]annulen-5-ol",CN(C)CCCC1(CCCCC2=CC=CC=C21)O,,,,,,
2336,37031,"5-Acetamido-6,7,8,9-tetrahydro-5H-benzocycloheptene",CC(=O)NC1CCCCC2=CC=CC=C12,,,,,,
2337,37032,"6-Dimethylamino-5,6,7,8-tetrahydro-1,2-naphthalenediol hydrobromide",C[NH+](C)C1CCC2=C(C1)C=CC(=C2O)O.[Br-],,,,,,
2338,37033,"6-(Dimethylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol",CN(C)C1CCC2=C(C1)C=CC(=C2O)O,,,,,,
2339,37034,"2,2',4,4',5,5'-Hexachlorobiphenyl",C1=C(C(=CC(=C1Cl)Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,,,,"[""THE DISPOSITION OF MULTIPLE ORAL DOSES OF ... 2,4,5,2',4',5'-HEXACHLOROBIPHENYL ... STUDIED IN MICE ... INVESTIGATORS FOUND THAT THE RATE OF METABOLISM & EXCRETION DECREASED WITH INCREASING CHLORINATION, BUT WAS MOST PROFOUNDLY AFFECTED BY ELIMINATION OF ADJACENT UNSUBSTITUTED CARBON ATOMS. ACCUMULATION OCCURRRED MAINLY IN ADIPOSE TISSUE, SKIN, MUSCLE."", ""EFFECTS OF RESTRICTING FOOD INTAKE ON THE DISTRIBUTION OF 2,2',4,4',5,5'-HEXACHLOROBIPHENYL (6-CB) IN RATS ADMIN A SINGLE DOSE OF 0.6 MG/KG, IV. GRADUAL DISAPPEARANCE OF ADIPOSE TISSUE WAS INDUCED BY RESTRICTING FOOD INTAKE TO 25% OF AD LIBITUM CONSUMPTION. IN FIRST SERIES OF EXPERIMENTS, 6-CB WAS ADMIN SIMULTANEOUSLY WITH START OF FOOD RESTRICTION. FECAL EXCRETION RATE OF 6-CB INCR, REACHED A MAX IN 2ND WK, & THEN LEVELED OFF. AFTER 7 WK, SOME 50% OF THE DOSE WAS EXCRETED & 26% WAS LOCATED IN SKIN. AMOUNTS IN MUSCLE, LIVER, LUNG, KIDNEY, BRAIN, GI CONTENTS, & RESIDUAL ADIPOSE TISSUE WERE BETWEEN 2.5 & 0.1% OF ADMIN DOSE. IN 2ND SERIES OF EXPERIMENTS, 6-CB WAS ADMIN 2 WK AFTER FOOD RESTRICTION STARTED, IE WHEN ADIPOSE TISSUE RESERVES HAD ALREADY LARGELY DISAPPEARED. FECAL EXCRETION RATE WAS MAXIMAL AT OUTSET & GRADUALLY DECR. CUMULATIVE EXCRETION & DISTRIBUTION VALUES FOR SKIN & OTHER TISSUES WERE NOT SIGNIFICANTLY DIFFERENT FROM VALUES DETERMINED IN ABOVE SERIES AFTER 7 WK. PHARMACOKINETIC OF 6-CB IS INFLUENCED BY ADIPOSE TISSUE MASS."", ""RESULTS FROM A PROCEDURE FOR ANALYZING THE BINDING OF 2,4,5,2',4',5'-HEXACHLOROBIPHENYL (HCB) TO LOW DENSITY LIPOPROTEINS & SERUM ALBUMIN INDICATE THAT ALBUMIN & LOW DENSITY LIPOPROTEIN EFFECTIVELY BIND THIS POLYCHLORINATED BIPHENYL & SUGGEST THAT PLASMA PROTEINS MAY PLAY A ROLE IN ITS DISTRIBUTION TO PERIPHERAL CELLS. LOW DENSITY LIPOPROTEINS BOUND HCB AT SEVERAL NONINTERACTIVE SITES & BOVINE SERUM ALBUMIN AT 1 NONINTERACTIVE SITE."", ""OF ... 2,2',4,4'5,5'-HEXACHLOROBIPHENYL FED TO RATS, LESS THAN 10% WAS EXCRETED IN FECES, INDICATING A HIGH DEGREE OF ABSORPTION, METABOLISM OR LOCALIZATION IN THE TISSUES. ... FOLLOWING IV INJECTION TO RATS OF ... /2,2',4,4',5,5'-HEXACHLOROBIPHENYL, IT WAS/ FOUND IN HAIR, SUGGESTING THAT THIS MAY SERVE AS A ROUTE OF PCB EXCRETION."", ""For more Absorption, Distribution and Excretion (Complete) data for 2,2',4,4',5,5'-HEXACHLOROBIPHENYL (27 total), please visit the HSDB record page.""]","[""METABOLISM OF 2,2',4,4',5,5'-HEXACHLOROBIPHENYL (245-HCB) BY HUMAN HEPATIC MICROSOMES WAS STUDIED. 245-HCB WAS NOT METABOLIZED UNDER VARIOUS CONDITIONS. THE FACT THAT IT WAS NOT METABOLIZED EXPLAINS WHY IT IS THE PREDOMINANT PCB FOUND IN HUMAN ADIPOSE TISSUE."", ""IN MICE & RATS, 2,2',4,4',5,5'-HEXACHLOROBIPHENYL (HCB) IS METABOLIZED TO 2,2',4,4',5,5'-HEXACHLORO-3-BIPHENYLOL. IN RABBITS, THE METABOLIC PRODUCTS ARE A MONOHYDROXYLATED DERIVATIVE, A MONOHYDROXY WITH CHLORINE SHIFT, & A MONOHYDROXYMETHOXYLATED DERIVATIVE. PRODUCTS IN CHICKENS ARE A META-HYDROXYLATED DERIVATIVE, A PENTA-CHLOROBIPHENYL DERIVATIVE, & A PENTA-CHLOROTRIHYDROXYLATED DERIVATIVE."", ""METABOLISM OF (3)H-LABELED 2,2',4,4',5,5'-HEXACHLOROBIPHENYL (2,4,5-HCB) WAS STUDIED IN 2 MONKEYS. 2,4,5-HCB WAS EXCRETED IN THE BILE AS PARENT 2,4,5-HCB, 2,2',4,4',5,5'-HEXACHLORO-3-HYDROXYBIPHENYL, & WATER-SOL CONJUGATES OF 2,4,5-HCB GLUCURONIDE, PROBABLY 2,2',4,4',5,5'-HEXACHLORO-3-HYDROXYBIPHENYL GLUCURONIDE. METABOLISM OF 2,4,5-HCB MAY OR MAY NOT INCLUDE THE FORMATION OF AN ARENE OXIDE."", 'A strain of Alcaligenes eutrophus, designated H850, that rapidly degrades a broad and unusual spectrum of polychlorinated biphenyls (PCBs) has been isolated and characterized. .... This strain was isolated from PCB-containing dredge spoils, grows well on biphenyl and 2-chlorobiphenyl but poorly on 3- and 4-chlorobiphenyl. Capillary gas-chromatographic analysis showed that biphenyl- grown resting cells of H850 degraded the components of 38 of the 41 largest peaks of Aroclor 1242 and 15 of the 44 largest peaks of Aroclor 1254, resulting in an overall reduction of PCBs by 81% for Aroclor 1242 (10 ppm) and 35% for Aroclor 1254 (10 ppm) in 2 days. H850 metabolized the predominantly ortho- substituted PCB congeners. ... The congener selectivity patterns indicate that a two-step process consisting of anaerobic dechlorination followed by oxidation by H850 can effectively degrade all of the congeners in Aroclor 1242 and possibly all those in Aroclor 1254.', ""For more Metabolism/Metabolites (Complete) data for 2,2',4,4',5,5'-HEXACHLOROBIPHENYL (6 total), please visit the HSDB record page."", ""2_2_4_4_5_5-hexachlorobiphenyl has known human metabolites that include (1,1'-Biphenyl)-3-ol, 2,2',4,4',5,5'-hexachloro-.""]","[""THE HALF-LIFE OF (14)C-LABELED 2,5,2',4',5'-PENTACHLOROBIPHENYL & 2,3,4,2',4',6'-HEXACHLOROBIPHENYL FOLLOWING ORAL ADMIN TO MICE WERE APPROX 6 & 1 DAY RESPECTIVELY, WHEREAS THE T 1/2 OF 2,4,5,2',4',5'-HEXACHLOROBIPHENYL WAS MUCH HIGHER (SLOW EXCRETION)."", ""Half-lives of the metabolites of 2,4,5,2',4',5'-HCB in Sprague-Dawley rats are as follows: Fecal: metabolite I= 0.9 days, metabolite II= 8.8 days, metabolite III= 100.5 days; urine I= 0.3 days II= 7.4 days. Metabolites were not characterized. /From table/"", 'BIOLOGICAL HALF-LIFE OF 31 DICHLORO- TO DECHLOROBIPHENYL CONGENERS WERE MONITORED FOR 105 DAYS IN ADULT RAINBOW TROUT THAT WERE EXPOSED TO A SINGLE ORAL DOSE. IN WHOLE FISH, HALF-LIFE INCR FROM 5 DAYS TO NO APPARENT ELIM AS THE NUMBER OF CHLORINES ON THE BIPHENYL INCR. THIS STRUCTURE-ACTIVITY RELATION WAS NOT AS EVIDENT IN MUSCLE WHERE HALF-LIFE RANGED FROM LESS THAN 5 DAYS TO 127 DAYS. DECLINE IN MUSCLE PCB MAY BE RELATED TO THE DECR IN LIPID LEVELS & REDISTRIBUTION OF CONGENERS WITHIN THE FISH. FROM STRUCTURE-ACTIVITY ANALYSIS OF HALF-LIFE IN WHOLE FISH, ELIM IS ENHANCED FOR THOSE CONGENERS WITH LOWER CHLORINE CONTENT, WITH NO CHLORINE SUBSTITUTIONS IN THE ORTHO POSITIONS, & THOSE WITH 2 UNSUBSTITUTED CARBONS THAT ARE ADJACENT (VICINAL) ON THE BIPHENYL. A SIGNIFICANT DECLINE IN TOTAL PCB CONTENT IN WHOLE FISH, EQUIV TO HALF-LIFE OF 219 DAYS, WAS PARTLY DUE TO DECOMP OF THE PCB MIXTURE ADMIN, & SELECTIVE ELIM OF LOWER CHLORINATED BIPHENYLS.']"
2340,37035,"2,2',3,4,4',5'-Hexachlorobiphenyl",C1=CC(=C(C(=C1C2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
2341,37036,"2,2',3,4,4',5,5'-Heptachlorobiphenyl",C1=C(C(=CC(=C1Cl)Cl)Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,"['Substances or energies, for example heat or light, which when introduced into the air, water, or land threaten life or health of individuals or ECOSYSTEMS. (See all compounds classified as Environmental Pollutants.)']",,,
2342,37037,"2,2',3,3',4,4',5-Heptachlorobiphenyl",C1=CC(=C(C(=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
2343,37038,Digitoxigenin-beta-tetraacetyl-d-glucoside,CC(=O)OCC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
2344,37039,1-(3-Butoxypropoxy)-2-propanol,CCCCOCCCOCC(C)O,,,,,,
2345,37040,"1,4-Dibromocyclohexane",C1CC(CCC1Br)Br,,,,,,
2346,37041,"Azobenzene, 4,4'-bis(N-acetyl-N-methylamino)-",CC(=O)N(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)C(=O)C,,,,,,
2347,37042,"(1R,9R,10S,13S,14R,16S,18R)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol",CCC[N+]12[C@H]3CC([C@@H]([C@H]1O)CC)C4[C@@H]2C[C@@]5([C@H]3N(C6=CC=CC=C65)C)[C@@H]4O,,,,,,
2348,37043,"1-Propanol, 1-p-tolyl-2-amino-, hydrochloride",CC1=CC=C(C=C1)C(C(C)[NH3+])O.[Cl-],,,,,,
2349,37044,2-Amino-1-(4-methylphenyl)propan-1-ol,CC1=CC=C(C=C1)C(C(C)N)O,,,,,,
2350,37045,1-Hexyl-2-nitro-1-nitrosoguanidine,CCCCCCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
2351,37046,2-Nitro-1-nitroso-1-(2-phenylethyl)guanidine,C1=CC=C(C=C1)CCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
2352,37047,"Guanidine, N-nitro-N'-propyl-",CCCN=C(N)N[N+](=O)[O-],,,,,,
2353,37048,Domazoline,CC1=CC(=C(C(=C1OC)C)CC2=NCCN2)OC,,,,,,
2354,37049,"11-Hydroxy-6-methylpregna-1,4-diene-3,20-dione",CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)C(=O)C,,,,,,
2355,37050,N-[(4-methoxyphenyl)methyl]acetamide,CC(=O)NCC1=CC=C(C=C1)OC,,,,,,
2356,37051,Ethyl 2-phenylallophanate,CCOC(=O)N(C1=CC=CC=C1)C(=O)N,,,,,,
2357,37052,"BENZYL ALCOHOL, alpha-(1-AMINOPROPYL)-p-METHYL-, HYDROCHLORIDE",CCC(C(C1=CC=C(C=C1)C)O)[NH3+].[Cl-],,,,,,
2358,37053,2-Amino-1-(4-methylphenyl)butan-1-ol,CCC(C(C1=CC=C(C=C1)C)O)N,,,,,,
2359,37054,CID 37054,CCC1(C(=O)N=C(N(C1=O)C)[O-])CC.[Na+],,,,,,
2360,37055,"Methyl 2,4-dichlorobenzoate",COC(=O)C1=C(C=C(C=C1)Cl)Cl,,,,,,
2361,37056,Ethyl4-ethoxy-6-methylnicotinate,CCC(C)C(C(=O)N1CCCC1C(=O)N2CCCC2C(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C3CCCN3C(=O)C(CCCN=C(N)N)NC(=O)C4CCCN4C(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C7CCC(=O)N7,,,,,,
2362,37057,2-Anilino-6-benzamidobenzoic acid,C1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2C(=O)O)NC3=CC=CC=C3,,,,,,
2363,37058,"5-[(4R,5R)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](CC2C1CC(=CCCCC(=O)O)O2)O)O,,,,,,
2364,37059,"4-Bromomethyl-2-phenyl-1,3-dithiolane",C1C(SC(S1)C2=CC=CC=C2)CBr,,,,,,
2365,37060,N-(2-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)ethyl)acetamide,CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)C)O,,,,,,
2366,37061,"(9R,11S,14S,16R,17R)-6,6,9-trifluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-8,11,12,14,15,16-hexahydro-7H-cyclopenta[a]phenanthren-3-one",C[C@@H]1C[C@H]2C3CC(C4=CC(=O)C=CC4([C@]3([C@H](CC2([C@]1(C(=O)CO)O)C)O)F)C)(F)F,,,,,,
2367,37062,"Aspartic acid, N-((2,4-dichlorophenoxy)acetyl)-, L-",C1=CC(=C(C=C1Cl)Cl)OCC(=O)N[C@@H](CC(=O)O)C(=O)O,,,,,,
2368,37063,"Dibenzylamine, 3,4,5,3',4',5'-hexamethoxy-",COC1=CC(=CC(=C1OC)OC)CNCC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
2369,37064,Tetradec-9-en-1-ol,CCCCC=CCCCCCCCCO,,,,,,
2370,37065,cis-3-Hexenyl 3-methylbutanoate,CCC=CCCOC(=O)CC(C)C,,,,,,
2371,37066,"2-Hexenal, 5-methyl-2-(1-methylethyl)-",CC(C)CC=C(C=O)C(C)C,,,,,,
2372,37067,(o-Methoxyphenoxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=CC=C1OC.[Cl-],,,,,,
2373,37068,2-(Dimethylamino)ethyl 2-(2-methoxyphenoxy)acetate,CN(C)CCOC(=O)COC1=CC=CC=C1OC,,,,,,
2374,37069,(o-Methoxyphenoxy)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=CC=C1OC.[Cl-],,,,,,
2375,37070,2-(Diethylamino)ethyl 2-(2-methoxyphenoxy)acetate,CCN(CC)CCOC(=O)COC1=CC=CC=C1OC,,,,,,
2376,37071,(o-Methoxyphenoxy)acetic acid 2-morpholinoethyl ester hydrochloride,COC1=CC=CC=C1OCC(=O)OCCC2C[NH2+]CCO2.[Cl-],,,,,,
2377,37072,2-Morpholin-2-ylethyl 2-(2-methoxyphenoxy)acetate,COC1=CC=CC=C1OCC(=O)OCCC2CNCCO2,,,,,,
2378,37073,(m-Methoxyphenoxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=CC(=C1)OC.[Cl-],,,,,,
2379,37074,2-(Dimethylamino)ethyl 2-(3-methoxyphenoxy)acetate,CN(C)CCOC(=O)COC1=CC=CC(=C1)OC,,,,,,
2380,37075,(m-Methoxyphenoxy)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=CC(=C1)OC.[Cl-],,,,,,
2381,37076,2-(Diethylamino)ethyl 2-(3-methoxyphenoxy)acetate,CCN(CC)CCOC(=O)COC1=CC=CC(=C1)OC,,,,,,
2382,37077,(m-Methoxyphenoxy)acetic acid 2-morpholinoethyl ester hydrochloride,COC1=CC(=CC=C1)OCC(=O)OCCC2C[NH2+]CCO2.[Cl-],,,,,,
2383,37078,2-Morpholin-2-ylethyl 2-(3-methoxyphenoxy)acetate,COC1=CC(=CC=C1)OCC(=O)OCCC2CNCCO2,,,,,,
2384,37079,N-Methylhexylamine,CCCCCCNC,,,,,,
2385,37080,CID 37080,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)[O-])O)O)N.[K+],,,,,,
2386,37081,"BENZ(a)ANTHRACENE, 4,7,12-TRIMETHYL-",CC1=C2C=CC3=C(C4=CC=CC=C4C(=C3C2=CC=C1)C)C,,,,,,
2387,37082,"Benz(a)anthracene, 7,11-dimethyl-",CC1=C2C=C3C(=C(C2=CC=C1)C)C=CC4=CC=CC=C43,,,,,,
2388,37083,Norgestimate,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=CC(=NO)CC[C@H]34,,,"['Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)', 'Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)']","['Norgestimate (NGM) and ethinyl estradiol (EE) are rapidly absorbed following oral administration.', 'Peak serum concentrations of norelgestromin (NGMN) and ethinyl estradiol (EE)  are generally reached by 2 hours after administration of MonoNessa. Accumulation following multiple dosing of the 250 ug Norgestimate (NGM)/ 35 ug dose is approximately 2-fold for NGMN and EE compared with single dose administration. The pharmacokinetics of NGMN is dose proportional following NGM doses of 180 ug to 250 ug. ... Steady-state concentrations of NGMN and NG are achieved by Day 21. Non-linear accumulation (approximately 8 fold) of norgestrel is observed as a result of high affinity binding to SHBG (sex hormone-binding globulin), which limits its biological activity.', 'Norelgestromin and norgestrel are highly bound (>97%) to serum proteins. Norelgestromin is bound to albumin and not to SHBG, while norgestrel is bound primarily to SHBG.', 'The metabolites of norelgestromin and ethinyl estradiol are eliminated by renal and fecal pathways. Following administration of 14C-norgestimate, 47% (45-49%) and 37% (16-49%) of the administered radioactivity was eliminated in the urine and feces, respectively. Unchanged norgestimate was not detected in the urine.']","['Norgestimate is rapidly and completely metabolized by first pass (intestinal and/or hepatic) mechanisms to norelgestromin (NGMN) and norgestrel (NG), which are the major active metabolites of norgestimate.', ""Norgestimate is extensively metabolized by first-pass mechanisms in the gastrointestinal tract and/or liver. Norgestimate's primary active metabolite is norelgestromin. Subsequent hepatic metabolism of norelgestromin occurs and metabolites include norgestrel, which is also active, and various hydroxylated and conjugated metabolites."", 'In addition to 17-deacetyl norgestimate, a number of metabolites of norgestimate have been identified in human urine following administration of radiolabeled norgestimate. These include 18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-hydroxy-13-ethyl,(17alpha)-(-); 18,19-Dinor-5beta-17-pregnan-20-yn,3alpha,17beta-dihydroxy-13-ethyl,(17alpha), various hydroxylated metabolites and conjugates of these metabolites.', 'There is limited information on the metabolism of levonorgestrel, norethindrone and structurally related contraceptive steroids. Both levonorgestrel and norethindrone undergo extensive reduction of the alpha, beta-unsaturated ketone in ring A. Levonorgestrel also undergoes hydroxylation at carbons 2 and 16. The metabolites of both compounds circulate predominantly as sulfates. In urine, levonorgestrel metabolites are found primarily in the glucuronide form, whereas norethindrone metabolites are present in approximately equal amounts as sulfates and glucuronides. Of the progestogens structurally related to norethindrone, norethindrone acetate, ethynodiol diacetate, norethindrone enanthate, and perhaps lynestrenol, undergo rapid hydrolysis and are converted to the parent compound and its metabolites. There is no convincing evidence that norethynodrel is converted to norethindrone. Of the progestogens structurally related to levonorgestrel, it appears that neither desogestrel nor gestodene are transformed to the parent compound. However, there is evidence that norgestimate can be, at least partly, converted to levonorgestrel. ...']",
2389,37084,"7,7-Dimethyl-11-dodecen-2-one",CC(=O)CCCCC(C)(C)CCCC=C,,,,,,
2390,37085,Ethyl 8-nonenoate,CCOC(=O)CCCCCCC=C,,,,,,
2391,37086,1-Methoxyprop-1-en-2-ylcyclopropane,CC(=COC)C1CC1,,,,,,
2392,37087,1-Methyl-2-phenoxyethylamine,CC(COC1=CC=CC=C1)N,,,,,,
2393,37088,"alpha-(Methoxycarbonyl)-N,N,N-trimethyl-1H-indole-3-ethanaminium iodide",C[N+](C)(C)C(CC1=CNC2=CC=CC=C21)C(=O)OC.[I-],,,,,,
2394,37089,[3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl]-trimethylazanium,C[N+](C)(C)C(CC1=CNC2=CC=CC=C21)C(=O)OC,,,,,,
2395,37090,CID 37090,CC(CC1(C(=O)NC(=NC1=O)S)CC=C)O,,,,,,
2396,37091,Nonachloropredioxin,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)O,,,,,,
2397,37092,"Acetic acid, 2,2'-oxybis-, disodium salt",C(C(=O)[O-])OCC(=O)[O-].[Na+].[Na+],,,,,,
2398,37093,"Benzeneacetamide, 4-(((5-(2-methylpropyl)-2-pyrimidinyl)amino)sulfonyl)-N-(1-phenylethyl)-, (S)-",C[C@@H](C1=CC=CC=C1)NC(=O)CC2=CC=C(C=C2)S(=O)(=O)NC3=NC=C(C=N3)CC(C)C,,,,,,
2399,37094,(R)-4-(((5-(2-Methylpropyl)-2-pyrimidinyl)amino)sulfonyl)-N-(1-phenylethyl)benzeneacetamide,C[C@H](C1=CC=CC=C1)NC(=O)CC2=CC=C(C=C2)S(=O)(=O)NC3=NC=C(C=N3)CC(C)C,,,,,,
2400,37095,"1,2-Bis(p-methoxyphenyl)-1-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-1-butanol",CCC(C1=CC=C(C=C1)OC)C(C2=CC=C(C=C2)OC)(C3=CC=C(C=C3)OCCN4CCCC4)O,,,,,,
2401,37096,"Phenol, 2-methyl-4-(methylamino)-, sulfate (2:1) (salt)",CC1=C(C=CC(=C1)[NH2+]C)O.CC1=C(C=CC(=C1)[NH2+]C)O.[O-]S(=O)(=O)[O-],,,,,,
2402,37097,2-Methyl-4-(methylamino)phenol,CC1=C(C=CC(=C1)NC)O,,,,,,
2403,37098,Cetyl lactate,CCCCCCCCCCCCCCCCOC(=O)C(C)O,,,,,,
2404,37099,"9,14-Dihydrobenzo[b]triphenylene",C1C2=CC=CC=C2CC3=C1C4=CC=CC=C4C5=CC=CC=C35,,,,,,
2405,37100,"BENZ(a)ANTHRACENE, 5,6-DIHYDRO-7,12-DIMETHYL-",CC1=C2CCC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,,,,,,
2406,37101,"5,6,7,8,9,10-Hexahydrobenzo(ghi)perylene",C1CC2=C3C(=C4CCCC5=C4C6=C(C=C5)C=CC(=C36)C=C2)C1,,,,,,
2407,37102,"3'-Hydroxymethyl-N,N-dimethyl-4-aminoazobenzene",CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2CO,,,,,,
2408,37103,CID 37103,CCOC(=O)C1=CC=C(C=C1)[O-].[Na+],,,,,,
2409,37104,CID 37104,CCCOC(=O)C1=CC=C(C=C1)[O-].[Na+],,,,,,
2410,37105,"ISONICOTINIC ACID, 2-(((p-ACETAMIDO)PHENYL)SULFONYL)HYDRAZIDE",CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CC=NC=C2,,,,,,
2411,37106,3-Amino-4-butoxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CCCCOC1=C(C=C(C=C1)C(=O)OCC[NH+](CC)CC)N.[Cl-],,,,,,
2412,37107,phenyl N-(3-nitrophenyl)carbamate,C1=CC=C(C=C1)OC(=O)NC2=CC(=CC=C2)[N+](=O)[O-],,,,,,
2413,37108,"1H-NAPHTHO(2,1-b)PYRAN-1-ONE, 3-(DIMETHYLAMINO)-",CN(C)C1=CC(=O)C2=C(O1)C=CC3=CC=CC=C32,,,,,,
2414,37109,2-Ethylcyclobutanol,CCC1CCC1O,,,,,,
2415,37110,CID 37110,CN1C[C@]2(C3CC4[C@]5(C2C1C3CO4)C6=CC=CC=C6NC5=O)C=C.Cl,,,,,,
2416,37111,"3,4,7,8-Tetrahydrodibenzo(a,e)-1,5-diazocinium dibromide",C1C[N+]2=CC=CC=C2CC[N+]3=CC=CC=C31.[Br-].[Br-],,,,,,
2417,37112,"6,7,13,14-Tetrahydrodipyrido[1,2-a:1',2'-e][1,5]diazocine-5,12-diium",C1C[N+]2=CC=CC=C2CC[N+]3=CC=CC=C31,,,,,,
2418,37113,Khlotazol,C1=CSC(=N1)NC(C(Cl)(Cl)Cl)O,,,,,,
2419,37114,Fosazepam,CP(=O)(C)CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
2420,37115,Hexamethyl(silacyclohexyl)cyclotetrasiloxane,C[Si]1(O[Si](O[Si]2(CCCCC2)O[Si](O1)(C)C)(C)C)C,,,,,,
2421,37116,"7,14-Dimethyldibenz(a,h)anthracene",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1C5=CC=CC=C5C=C4)C,,,,,,
2422,37117,"3-Furancarboxylic acid, 5-(methoxymethyl)-2-methyl-, methyl ester",CC1=C(C=C(O1)COC)C(=O)OC,,,,,,
2423,37118,4-(Benzoylamino)butanoic acid,C1=CC=C(C=C1)C(=O)NCCCC(=O)O,,,,,,
2424,37119,2-(alpha-Ethylbenzylamino)-2-oxazoline,CCC(C1=CC=CC=C1)NC2=NCCO2,,,,,,
2425,37120,"BENZAMIDE, N-(BIS(1-AZIRIDINYL)PHOSPHINYL)-p-METHYL-",CC1=CC=C(C=C1)C(=O)NP(=O)(N2CC2)N3CC3,,,,,,
2426,37121,2-(alpha-Methylbenzylamino)-2-oxazoline,CC(C1=CC=CC=C1)NC2=NCCO2,,,,,,
2427,37122,2-(alpha-Cyclopropylbenzylamino)-2-oxazoline,C1CC1C(C2=CC=CC=C2)NC3=NCCO3,,,,,,
2428,37123,Diflubenzuron,C1=CC(=C(C(=C1)F)C(=O)NC(=O)NC2=CC=C(C=C2)Cl)F,,,,"['The intestinal absorption is strongly related to the dosage administered - the higher the dosage, the more is (relatively) excreted unchanged in the feces.', 'Following oral administration, diflubenzuron is absorbed, extensively metabolized, and almost totally excreted by cattle and sheep ... Trace amounts of the larvicide are excreted in milk following high dosages.', 'Orechromis niloticus fingerlings were exposed to the insect growth inhibitor diflubenzuron for 21 days. Diflubenzuron was introduced to the aquariums where fish were maintained at the beginning of the experiment, then its level in water, gills and liver was detected after 1, 7, 14 and 21 days. The fish accumulated diflubenzuron 76 and 99 times greater than the water content when kept in an ambient concentration of 2.5 and 5 mg/L, respectively, indicating a low bioaccumulation potential. Some degradation products of diflubenzuron were found mainly in liver and water.', 'There is limited absorption of diflubenzuron across the skin and intestinal lining of mammals, after which enzymatic hydrolysis and excretion rapidly eliminate the pesticide from tissues.', 'For more Absorption, Distribution and Excretion (Complete) data for DIFLUBENZURON (16 total), please visit the HSDB record page.']","['The mechanisms of detoxification of the benzoylphenylureas, diflubenzuron, and teflubenzuron in the Egyptian cotton leafworm, Spodoptera littoralis, were examined, as were rates of penetration, degradation, and inhibition of benzoyphenylureas hydrolase(s) both in vivo and in vitro. The results were considered in connection with the toxicity of these compounds. Teflubenzuron was 10 times more toxic than diflubenzuron to fourth instar larvae of spodoptera littoralis. Profenofos and S,S,S-tributylphosphorotrithioate synergized both diflubenzuron and teflubenzuron, indicating that the major route of detoxification in spodoptera littoralis was through hydrolysis. Limited synergism by piperonly butoxide indicated that mixed function oxidase enzymes play a relatively small role in benzoyphenylureas detoxification. ... In Spodoptera littoralis, diflubenzuron was metabolized more rapidly than teflubenzuron: based on the relative amount of parent compound present in the larval body, about 58% of extracted radiocarbon was unchanged teflubenzuron compared to only 38% diflubenzuron. In the excreta, unchanged teflubenzuron was excreted more slowly than the metabolites (42% recovered as parent compound), compared to diflubenzuron in which 79% of the total extract was present as parent compound. Pretreatment of the fourth instar with sublethal doses of profenofos resulted in a significant decrease in metabolism, more so with diflubenzuron than with teflubenzuron. A positive correlation was found between in vivo diflubenzuron metabolism inhibition and toxicity. In in vitro assays, diflubenzuron was hydrolyzed more rapidly than teflubenzuron by all tissue extracts. Profenofos was more effective in inhibiting the hydrolysis in vitro of diflubenzuron compared to teflubenzuron, as indicated by a lower I50 value and steeper slope. /The/  results indicate that reduced penetration and fast elimination of unchanged (14)(C)diflubenzuron together with rapid metabolism, which occurs mainly through hydrolysis, are defense mechanisms which contribute to diflubenzuron detoxification in spodoptera littoralis.', ""After oral treatment of a cow and a castrated sheep with labeled diflubenzuron, urine was collected and analyzed. TLC indicated the presence of eight labeled materials. The major compounds in the sheep urine were identified as 2,6-difluorobenzoic acid and the hippurate analog. In the cow's urine, 2,6-difluoro-3-hydroxydiflubenzuron was the major metabolite. Metabolites N-((4-chloro-2-hydroxyphenyl)aminocarbonyl)-2,6-difluorobenzamide and N-((4-chloro-3-hydroxyphenyl)aminocarbonyl)-2,6-difluorobenzamide were also seen in urine of both cow and sheep but the 4-chlorophenylurea was seen only in the urine of the cow. Feces of both animals contained ... 2,6-difluoro-3-hydroxydiflubenzuron, N-((4-chloro-2-hydroxyphenyl)aminocarbonyl)-2,6-difluorobenzamide, and N-((4-chloro-3-hydroxyphenyl)aminocarbonyl)-2,6-difluorobenzamide. In the bile, ... 2,6-difluoro-3-hydroxydiflubenzuron, N-((4-chloro-2-hydroxyphenyl)aminocarbonyl)-2,6-difluorobenzamide, and N-((4-chloro-3-hydroxyphenyl)aminocarbonyl)-2,6-diflurorbenzamide also appeared in addition to unidentified conjugates. Incubation of bile water-soluble metabolites with b-glucuronidase-aryl sulfatase converted about half the labeled material into organic extractable materials. Although TLC indicated eight radioactive compounds, none were identified. Analysis of milk indicated the presence of unchanged diflubenzuron, 2,6-difluorobenzamide, 2,6-difluorohippuric acid, and an unidentified compound. Digestive fluids of sheep and cattle did not significantly degrade diflubenzuron. When metabolite V /2,6-difluoro-3-hydroxydiflubenzuron/ was orally administered to rats, almost all of the material was excreted within 3 days. Analyses indicated the presence of five additional compounds. None were identified."", 'After oral admin to rats of 5 mg diflubenzuron labeled with H3 in the benzoyl and with C14 in the aniline moiety, 95% of the H3 and 70-75% of the C14 radioactivity were retrieved in urine and feces. 2,6-DFBA was shown to constitute more than half of the urinary metabolites. Up to 1% of an oral dose of 5 mg C14-diflubenzuron labeled at the benzoyl moiety was recovered in the expired air of rats.', 'Diflubenzuron was applied topically to adult stable flies and houseflies. Stable flies metabolized only about 2% of the diflubenzuron while in houseflies this amounted to about 10%. Metabolism in the two flies differed qualitatively as well. Extracts of stable flies contained 2,6-difluorobenzamide and 4-chloroacetanilide. Extracts of houseflies did not contain these. Two unidentified metabolites were seen in house flies but not stable flies. In addition to these, 4-chlorophenylurea and one unknown compound were observed in both flies.', 'For more Metabolism/Metabolites (Complete) data for DIFLUBENZURON (13 total), please visit the HSDB record page.']",['... The half life of diflubenzuron appears to be 12 hr in rat and sheep and 18-20 hr in the cow.']
2429,37124,N-Cyclohexyl-2-ethoxy-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=NC2CCCCC2)N,,,,,,
2430,37125,Sulprofos,CCCSP(=S)(OCC)OC1=CC=C(C=C1)SC,,,,"['Sulprofos is rapidly and nearly completely absorbed following oral exposure. In rats, more than 98% of an oral dose of sulprofos was eliminated within 48-72 hr after dosing. Rats that received one 11 mg/kg dose or ten 10 mg/kg doses of sulprofos during 15 days also excreted >96% of the dose (or last dose) within 24 hr. The primary route of excretion was through the urine, and <11% was excreted in the feces. ...Tissues and organs retained </=2% of the dose; the highest residues were in the fat, ovaries, skin, and liver. Less than 1% of the dose was expired as CO2 or volatile organic compounds from any exposure. A previous study had demonstrated that female Sprague-Dawley rats dosed at 10 mg/kg excreted >92% within 24 hr.', 'Pigs rapidly excreted an oral dose of sulprofos. More than 95% of the dose was excreted in urine by 24 hours. ...Maximum blood levels occurred 4 hours posttreatment, at which time tissue levels were <0.01 ppm, except for 0.27- and 0.53-ppm levels in liver and kidney, respectively. Traces of sulprofos and its sulfoxide were found in the omental fat. All tissue residues were <0.05 ppm of sulprofos equivalents at 48 hours posttreatment.', 'A lactating Jersey cow was treated orally with the insecticide O-ethyl O-(4-(methylthio)phenyl-14-C) S-propyl phosphorodithioate (BAY NTN 9306) at 0.12 mg/kg as a single oral dose. The administered radiocarbon was essentially quantiatively excreted during a 6-day post-treatment period; about 90% of the dose appeared in urine, about 0.1% in milk and the rest in feces. Ten days after the 1st treatment, the animal was treated again with the radiochemical at 0.62 mg/kg. Twelve hours later, when radiocarbon residues in the blood were maximal, the cow was sacrificed, and tissue and digestive tract content samples were analyzed for metabolites.']","['After absorption, sulprofos was metabolized rapidly and excreted primarily in the urine. The metabolism involved oxidation of the methylthio sulfur to sulfoxide and sulfone derivates and hydrolysis of the phosphorus O-phenyl ester to phenolic metabolites (rat, cow).', 'Sulprofos is involved in a series of oxidation reactions that may result in replacing the thiono sulfur with oxygen and/or the addition of first one and then two oxygen atoms to the thioether sulfur. The phosphorus-O-phenyl ester of sulprofos and any of these materials may be hydrolyzed to the free phenols, which are then conjugated and eliminated, usually in the urine. The oxidation of the thioether sulfur to its sulfoxide is catalyzed by microsomal flavin-contain monooxygenase. The major sulprofos metabolites are phenol, phenol sulfoxide, phenol sulfone, and their conjugates. Sulprofos sulfoxide, sulprofos sulfone, O-analog and O-analog sulfone were also identified in pigs, goats and cows but not in the rat or hen.', '...Metabolism of this insecticide by the cow involved oxidation of the methylthio sulfur to sulfoxide and sulfone derivatives and hydrolysis of the phosphorus O-phenyl ester to give phenolic metabolites that were excreted primarily in the urine in conjugated form. The low residues secreted into milk were also primarily conjugated phenols.']",
2431,37126,N-(Aminoiminomethyl)-N-methyl-beta-alanine,CN(CCC(=O)O)C(=N)N,,,,,,
2432,37127,"Ethyl N-(2,4-dinitrophenyl)carbamate",CCOC(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2433,37128,"2,3-Dihydrohelenalin",C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1CCC3=O)C)O)C(=C)C(=O)O2,,,,,,
2434,37129,"Acetic acid, (2-((3,4-dichlorophenyl)carbamoyl)-4-ethylphenoxy)-",CCC1=CC(=C(C=C1)OCC(=O)O)NC(=O)C2=CC(=C(C=C2)Cl)Cl,,,,,,
2435,37130,"ACETIC ACID, (o-((3,5-DICHLOROPHENYL)CARBAMOYL)PHENOXY)-",C1=CC=C(C(=C1)NC(=O)C2=CC(=CC(=C2)Cl)Cl)OCC(=O)O,,,,,,
2436,37131,"ACETIC ACID, (4-tert-BUTYL-2-(PHENYLCARBAMOYL)PHENOXY)-",CC(C)(C)C1=CC(=C(C=C1)OCC(=O)O)NC(=O)C2=CC=CC=C2,,,,,,
2437,37132,"Boric acid, tris(diethylaminoethyl) ester",B(OCCN(CC)CC)(OCCN(CC)CC)OCCN(CC)CC,,,,,,
2438,37133,"Crotonophenone, 3'-nitro-4,4,4-trifluoro-3-trifluoromethyl-",C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
2439,37134,"Crotonophenone, 4-chloro-4,4-difluoro-3-(chlorodifluoromethyl)-",C1=CC=C(C=C1)C(=O)C=C(C(F)(F)Cl)C(F)(F)Cl,,,,,,
2440,37135,"Crotonophenone, 2'-nitro-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC=C(C(=C1)C(=O)C=C(C(F)(F)F)C(F)(F)F)[N+](=O)[O-],,,,,,
2441,37136,"Crotonophenone, 4'-nitro-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC(=CC=C1C(=O)C=C(C(F)(F)F)C(F)(F)F)[N+](=O)[O-],,,,,,
2442,37137,"Crotonophenone, 4'-chloro-3'-nitro-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC(=C(C=C1C(=O)C=C(C(F)(F)F)C(F)(F)F)[N+](=O)[O-])Cl,,,,,,
2443,37138,"Crotonophenone, 4,4,4-trifluoro-3-(trifluoromethyl)-3',4',5'-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
2444,37139,"Crotonophenone, 4'-chloro-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC(=CC=C1C(=O)C=C(C(F)(F)F)C(F)(F)F)Cl,,,,,,
2445,37140,"Crotonophenone, 4'-fluoro-4,4,4-trifluoro-3-(trifluoromethyl)-",C1=CC(=CC=C1C(=O)C=C(C(F)(F)F)C(F)(F)F)F,,,,,,
2446,37141,"Crotonophenone, 3'-fluoro-4'-methoxy-4,4,4-trifluoro-3-trifluoromethyl-",COC1=C(C=C(C=C1)C(=O)C=C(C(F)(F)F)C(F)(F)F)F,,,,,,
2447,37142,"p-(4,4,4-Trifluoro-3-trifluoromethylcrotonoyl)benzonitrile",C1=CC(=CC=C1C#N)C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
2448,37143,"4'-Phenyl-4,4,4-trifluoro-3-trifluoromethylcrotonophenone",C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
2449,37144,"1-(1-Naphthyl)-4,4,4-trifluoro-3-trifluoromethyl-2-buten-1-one",C1=CC=C2C(=C1)C=CC=C2C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
2450,37145,"2-Buten-1-one, 1-(2-furyl)-4,4,4-trifluoro-3-trifluoromethyl-",C1=COC(=C1)C(=O)C=C(C(F)(F)F)C(F)(F)F,,,,,,
2451,37146,"2-Buten-1-one, 4-chloro-3-chlorodifluoromethyl-4,4-difluoro-1-(2-thienyl)-",C1=CSC(=C1)C(=O)C=C(C(F)(F)Cl)C(F)(F)Cl,,,,,,
2452,37147,Gemcadiol,CC(C)(CCCCCCC(C)(C)CO)CO,,,,,,
2453,37148,Dimethyl-[[2-methyl-4-(methylcarbamoyloxy)phenyl]iminomethyl]azanium;chloride,CC1=C(C=CC(=C1)OC(=O)NC)N=C[NH+](C)C.[Cl-],,,,,,
2454,37149,CID 37149,C1=CSC=C1CSCC(=O)[O-].[Na+],,,,,,
2455,37150,[(Thien-3-ylmethyl)thio]acetic acid,C1=CSC=C1CSCC(=O)O,,,,,,
2456,37151,"N,N-Dimethylanilinium iodide",C[NH+](C)C1=CC=CC=C1.[I-],,,,,,
2457,37152,Agn-PC-0jkphq,C(CCCCCC(=O)O)CCCCC(=O)O.C(CCCCCO)CCCCO,,,,,,
2458,37153,"1,10-Decanediol",C(CCCCCO)CCCCO,,,,,,
2459,37154,CID 37154,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)[O-].[K+],,,,,,
2460,37155,"1-INDOLIZINEACETIC ACID, 3-(p-CHLOROBENZOYL)-7-METHOXY-2-METHYL-",CC1=C(N2C=CC=C(C2=C1CC(=O)O)OC)C(=O)C3=CC=C(C=C3)Cl,,,,,,
2461,37156,"3-INDOLIZINEACETIC ACID, 1-(p-CHLOROBENZOYL)-6-METHOXY-2-METHYL-",CC1=C(N2C=CC(=CC2=C1C(=O)C3=CC=C(C=C3)Cl)OC)CC(=O)O,,,,,,
2462,37157,CID 37157,COC1=CC2=CC3=C(C(C2C(C1C4C(C5C(C6=C(CC(OC6=O)CC(=O)OC)C=C5C=C4OC)O)O)O)O)C(=O)OC(C3)CC(=O)OC,,,,,,
2463,37158,Agn-PC-0jkphu,CCCCCCCCCCCCC[N+](C)(C)[O-].C1CC2C(C(C1O2)C(=O)O)C(=O)O,,,,,,
2464,37159,"Amines, C10-16-alkyldimethyl, N-oxides",CCCCCCCCCCCCC[N+](C)(C)[O-],,,,,,
2465,37160,4-(4-Fluoro-phenyl)-4-oxo-but-2-enoic acid,C1=CC(=CC=C1C(=O)C=CC(=O)O)F,,,,,,
2466,37161,Bis(4-aminophenyl)diselenide,C1=CC(=CC=C1N)[Se][Se]C2=CC=C(C=C2)N,,,,,,
2467,37162,"5H-DIBENZO(a,d)CYCLOHEPTEN-5-OL, 10,11-DIHYDRO-5-(2-DIMETHYLAMINOETHYL)-",CN(C)CCC1(C2=CC=CC=C2CCC3=CC=CC=C31)O,,,,,,
2468,37163,1-(2-Ethoxy-2-phenylacetimidoyl)hexahydro-1H-azepine,CCOC(C1=CC=CC=C1)C(=N)N2CCCCCC2,,,,,,
2469,37164,2-Amino-3-fluoropropanoic acid,C(C(C(=O)O)N)F,,,,,,
2470,37165,CID 37165,C1CN2C(=N[C@H]([C@H]3[C@]2(C1(O)O)N=C(N3)N)COC(=O)N)N,,,,,,
2471,37166,"Oxalic acid, bis(2-methylhydrazide)",CNNC(=O)C(=O)NNC,,,,,,
2472,37167,"Oxalic acid, bis(2-ethylhydrazide)",CCNNC(=O)C(=O)NNCC,,,,,,
2473,37168,"Carbohydrazide, 1,5-diisopropyl-",CC(C)NNC(=O)NNC(C)C,,,,,,
2474,37169,"3-[(3S,10R,13R,14S)-14-hydroxy-10,13-dimethyl-3-[(2S,5R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5(C(CC[C@@]5(C4CC=C3C2)O)C6=CC(=O)OC6)C)C)O)O)O,,,,,,
2475,37170,"1-[3-(2,4,6-Trimethoxybenzoyl)propyl]pyrrolidinium chloride",COC1=CC(=C(C(=C1)OC)C(=O)CCC[NH+]2CCCC2)OC.[Cl-],,,,,,
2476,37171,"6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol",C1CCC2=CC=CC=C2C(C1)O,,,,,,
2477,37172,"(2,6-diamino-10,10-dihydroxy-3a,4,8,9-tetrahydro-1H-pyrrolo[1,2-c]purin-4-yl)methyl carbamate;dihydrochloride",C1CN2C(=NC(C3C2(C1(O)O)NC(=N3)N)COC(=O)N)N.Cl.Cl,,,,,,
2478,37173,Saxitoxin-t,C1CN2C(=NC(C3C2(C1(O)O)NC(=N3)N)COC(=O)N)N,,,,,,
2479,37174,"CROTONOPHENONE, 4-CHLORO-3-CHLORODIFLUOROMETHYL-4,4-DIFLUORO-m-NITRO-",C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)C=C(C(F)(F)Cl)C(F)(F)Cl,,,,,,
2480,37175,Enilconazole,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['Comparison of the excretion patterns after oral and intravenous dosing suggests that the bioavailability, and therefore the absorption, of imazalil given orally is high.', 'Imazalil technical (purity = 98.7%) and 14C-imazalil (117.1 uCi/mL; purity = 99.9%) was administered to 4 groups of 6-8 Wistar rats. Group A: 5 rats/sex & reserve group I (1/sex) were injected in tail vein with 1.25 mg 14C-imazalil/kg (single dose). Group B: 5/sex were dosed by gastric intubation at 1.25 mg 14C-imazalil/kg (single dose). Group C: 5/sex & reserve group K (3/sex) were dosed by gastric intubation at 1.25 mg imazalil/kg/day for 14 days. At 24 hours after the last unlabelled dose, 5/sex received a single oral dose of 14C-imazalil at 1.25 mg/kg. Group D: 5/sex & reserve group L (1/sex) were dosed by gastric intubation at 20 mg 14C imazalil/kg (single dose). At 96 hours post-dosing (Groups B, C & D) were sacrificed for tissue collection. Group A & reserve rats (those not used) were sacrificed & disposed of.  Distribution showed that after 96 hrs only 1% of 14C-imazalil was recovered in tissues and carcass. There was a dose-response in tissue levels of compound but there was no accumulation after multiple dosing. There were no sex differences. Approximately 50% of tissue 14C-imazalil was recovered in liver 96 hrs after gavage, levels in liver were approximately 20 times higher and kidney, lung and adrenals 4-10 times higher than corresponding blood levels. All other tissues examined had concentrations of 14C-imazalil < that of blood, with none detected in brain. By all routes and methods of administration, the majority (approximately 90%) of radioactivity was excreted within 24 hrs (primarily in urine & slightly higher in females).', 'A striking decrease was found in the effectiveness of thiabendazole (TBZ), benomyl, imazalil and prochloraz in controlling blue and green molds as a result of delaying the fungicidal treatments. Although imazalil and prochloraz gave low protective activity, they had high antisporulation efficiency. On the other hand, thiabendazole and benomyl protected fruits against subsequent infection. Storage was found to have a pronounced effect on the residual activity of imazalil compared with thiabendazole. Residues of imazalil and thiabendazole were found in orange jam made from fungicide-treated fruits.', 'Imazalil is absorbed, distributed, and metabolized rapidly in rodent species. It is a sulfate, of which approximately 90% is excreted within 96 hours.']","['... Little imazalil was excreted unchanged /in rats/: less than 1% of the administered dose in the feces and trace amounts in the urine. The compound was metabolized to at least 25 metabolites. Three major metabolites were identified, (+/-)-1-[2-(2,4-dichlorophenyl)-2-(2,3-dihydroxypropyloxy)ethyl]-imidaxolidine-2,5-dione (metabolite 8), (+/-)-1-[2-(2,4-dichlorophenyl)-2-(2,3-dihydroxypropyloxy)ethyl]-1H-imidazole (metabolite 10), and (+/-)-1-(2,4-dichlorophenyl)-2-imidazol-1-ylethanol (metabolite 11). The main routes of metabolism were epoxidation, epoxide hydratation, oxidative O-dealkylation, oxidation, and scission and oxidative N-dealkylation. The metabolic pattern was similar after oral and intravenous administration and in animals of each sex.']",['The half-time was about 2 hrs /in humans/.']
2481,37176,"Dibenzothiophene-2,8-diylbis((N-carbonylmethylene)dimethylamine) dihydrochloride trihydrate",C[NH+](C)CC(=O)C1=CC2=C(C=C1)SC3=C2C=C(C=C3)C(=O)C[NH+](C)C.[Cl-].[Cl-],,,,,,
2482,37177,"1,1'-(2,8-Dibenzothiophenediyl)bis(2-(dimethylamino)ethanone)",CN(C)CC(=O)C1=CC2=C(C=C1)SC3=C2C=C(C=C3)C(=O)CN(C)C,,,,,,
2483,37178,"2,3-Dihydro-3-(pyrrolidinyl)methyl-4(1H)-carbazolone",C1CCN(C1)CC2CCC3=C(C2=O)C4=CC=CC=C4N3,,,,,,
2484,37179,"2,3-Dihydro-3-(piperidino)methyl-4(1H)-carbazolone",C1CCN(CC1)CC2CCC3=C(C2=O)C4=CC=CC=C4N3,,,,,,
2485,37180,"2,3-Dihydro-3-(morpholino)methyl-4(1H)-carbazolone",C1CC2=C(C3=CC=CC=C3N2)C(=O)C1CN4CCOCC4,,,,,,
2486,37181,"2,3-Dihydro-3-((3-methylpiperidino)methyl)-4(1H)-carbazolone",CC1CCCN(C1)CC2CCC3=C(C2=O)C4=CC=CC=C4N3,,,,,,
2487,37182,"2-Amino-4,6-dinitrotoluene",CC1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])N,,,,,,
2488,37183,Nitrosamine,NN=O,,,,,,
2489,37184,Oxarbazole,COC1=CC2=C(C=C1)N(C3=C2CC(CC3)C(=O)O)C(=O)C4=CC=CC=C4,,,,,,
2490,37185,Ethyl(chloromethyl)phenyl carbamic acid,CCOC(=O)N(CCl)C1=CC=CC=C1,,,,,,
2491,37186,Avridine,CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)']",,,
2492,37187,"3-Hydroxy-4,5-dimethoxybenzoyl aminoguanidine hemisulfate",COC1=CC(=CC(=C1OC)O)C(=O)N[NH+]=C(N)N.COC1=CC(=CC(=C1OC)O)C(=O)N[NH+]=C(N)N.[O-]S(=O)(=O)[O-],,,,,,
2493,37188,"N-(diaminomethylideneamino)-3-hydroxy-4,5-dimethoxybenzamide",COC1=CC(=CC(=C1OC)O)C(=O)NN=C(N)N,,,,,,
2494,37189,"3-Benzyloxy-4,5-dimethoxybenzoyl aminoguanidine hemisulfate",COC1=C(C(=CC(=C1)C(=O)N[NH+]=C(N)N)OCC2=CC=CC=C2)OC.COC1=C(C(=CC(=C1)C(=O)N[NH+]=C(N)N)OCC2=CC=CC=C2)OC.[O-]S(=O)(=O)[O-],,,,,,
2495,37190,"N-(diaminomethylideneamino)-3,4-dimethoxy-5-phenylmethoxybenzamide",COC1=C(C(=CC(=C1)C(=O)NN=C(N)N)OCC2=CC=CC=C2)OC,,,,,,
2496,37191,"3,4-Dihydroxy-5-methoxybenzoyl aminoguanidine hemisulfate",COC1=CC(=CC(=C1O)O)C(=O)N[NH+]=C(N)N.COC1=CC(=CC(=C1O)O)C(=O)N[NH+]=C(N)N.[O-]S(=O)(=O)[O-],,,,,,
2497,37192,"N-(diaminomethylideneamino)-3,4-dihydroxy-5-methoxybenzamide",COC1=CC(=CC(=C1O)O)C(=O)NN=C(N)N,,,,,,
2498,37193,Diphenoxylic acid hydrochloride,C1C[NH+](CCC1(C2=CC=CC=C2)C(=O)O)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
2499,37194,"(6S,7R)-4-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CO[C@]1([C@H]2N(C1=O)C(=CC(S2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3,,,,,,
2500,37195,"Isoxazolidine, 2-(3,4,5-trimethoxythiobenzoyl)-",COC1=CC(=CC(=C1OC)OC)C(=S)N2CCCO2,,,,,,
2501,37196,N-(2-Hydroxyethyl)-N-methylnonanamide,CCCCCCCCC(=O)N(C)CCO,,,,,,
2502,37197,"Acetamide, N-(4-methyl-2-oxazolyl)",CC1=COC(=N1)NC(=O)C,,,,,,
2503,37198,"Acetamide, N-(4,5-dimethyl-2-oxazolyl)-",CC1=C(OC(=N1)NC(=O)C)C,,,,,,
2504,37199,"Acetamide, N-(4-phenyl-2-oxazolyl)-",CC(=O)NC1=NC(=CO1)C2=CC=CC=C2,,,,,,
2505,37200,"Acetamide, N-(4,5-diphenyl-2-oxazolyl)-",CC(=O)NC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2506,37201,"Acetamide, N-acetyl-N-(4,5-diphenyl-2-oxazolyl)-",CC(=O)N(C1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3)C(=O)C,,,,,,
2507,37202,"Acetamide, N-(4-trifluoromethyl-2-oxazolyl)-",CC(=O)NC1=NC(=CO1)C(F)(F)F,,,,,,
2508,37203,"Acetamide, N-(5,6-dimethoxy-2-benzimidazolyl)-",CC(=O)NC1=NC2=CC(=C(C=C2N1)OC)OC,,,,,,
2509,37204,"Acetamide, N-(5,6-dimethyl-1H-benzimidazol-2-YL)-",CC1=CC2=C(C=C1C)N=C(N2)NC(=O)C,,,,,,
2510,37205,(3-Chloro-2-hydroxypropyl)triethylammonium chloride,CC[N+](CC)(CC)CC(CCl)O.[Cl-],,,,,,
2511,37206,(3-Chloro-2-hydroxypropyl)triethylaminium,CC[N+](CC)(CC)CC(CCl)O,,,,,,
2512,37207,1-Chlorodibenzo-p-dioxin,C1=CC=C2C(=C1)OC3=C(O2)C(=CC=C3)Cl,,,"['An agent that causes the production of physical defects in the developing embryo. (See all compounds classified as Teratogens.)', 'Substances or energies, for example heat or light, which when introduced into the air, water, or land threaten life or health of individuals or ECOSYSTEMS. (See all compounds classified as Environmental Pollutants.)']",,,
2513,37208,"N-(2,2-Dichloro-1-hydroxyethyl)benzamide",C1=CC=C(C=C1)C(=O)NC(C(Cl)Cl)O,,,,,,
2514,37209,"3-(3,4-dihydro-2H-pyrrol-5-yl)prop-2-enamide",C1CC(=NC1)C=CC(=O)N,,,,,,
2515,37210,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, 2-morpholinoethyl ester, hydrochloride",C1COCC[NH+]1CCOC(=O)C2=CC3=CC4=C(C=C3O2)OC=CO4.[Cl-],,,,,,
2516,37211,"2-Morpholin-4-ylethyl furo[2,3-g][1,4]benzodioxine-7-carboxylate",C1COCCN1CCOC(=O)C2=CC3=CC4=C(C=C3O2)OC=CO4,,,,,,
2517,37212,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, dimethylaminopropyl ester, hydrochloride",C[NH+](C)CCCOC(=O)C1=CC2=CC3=C(C=C2O1)OC=CO3.[Cl-],,,,,,
2518,37213,"3-(Dimethylamino)propyl furo[2,3-g][1,4]benzodioxine-7-carboxylate",CN(C)CCCOC(=O)C1=CC2=CC3=C(C=C2O1)OC=CO3,,,,,,
2519,37214,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, 8-methyl-, dimethylaminoethyl ester, hydrochloride",CC1=C(OC2=CC3=C(C=C12)OC=CO3)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
2520,37215,"2-(Dimethylamino)ethyl 8-methylfuro[2,3-g][1,4]benzodioxine-7-carboxylate",CC1=C(OC2=CC3=C(C=C12)OC=CO3)C(=O)OCCN(C)C,,,,,,
2521,37216,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, 8-methyl-, 2-piperidinoethyl ester, hydrochloride",CC1=C(OC2=CC3=C(C=C12)OC=CO3)C(=O)OCC[NH+]4CCCCC4.[Cl-],,,,,,
2522,37217,"2-Piperidin-1-ylethyl 8-methylfuro[2,3-g][1,4]benzodioxine-7-carboxylate",CC1=C(OC2=CC3=C(C=C12)OC=CO3)C(=O)OCCN4CCCCC4,,,,,,
2523,37218,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, 8-methyl-, dimethylaminopropyl ester, hydrochloride",CC1=C(OC2=CC3=C(C=C12)OC=CO3)C(=O)OCCC[NH+](C)C.[Cl-],,,,,,
2524,37219,"3-(Dimethylamino)propyl 8-methylfuro[2,3-g][1,4]benzodioxine-7-carboxylate",CC1=C(OC2=CC3=C(C=C12)OC=CO3)C(=O)OCCCN(C)C,,,,,,
2525,37220,"1H-Imidazole, 5-methoxy-2-methyl-4-nitro-",CC1=NC(=C(N1)[N+](=O)[O-])OC,,,,,,
2526,37221,"5-Methoxy-1,2-dimethyl-4-nitro-1H-imidazole",CC1=NC(=C(N1C)OC)[N+](=O)[O-],,,,,,
2527,37222,6-Methoxy-3-methyl-2-benzofurancarboxylic acid dimethylaminoethyl ester hydrochloride,CC1=C(OC2=C1C=CC(=C2)OC)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
2528,37223,2-(Dimethylamino)ethyl 6-methoxy-3-methyl-1-benzofuran-2-carboxylate,CC1=C(OC2=C1C=CC(=C2)OC)C(=O)OCCN(C)C,,,,,,
2529,37224,"2-Benzofurancarboxylic acid, 5-bromo-6-methoxy-3-methyl-, diethylaminoethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C2=CC(=C(C=C2O1)OC)Br)C.[Cl-],,,,,,
2530,37225,2-(Diethylamino)ethyl 5-bromo-6-methoxy-3-methyl-1-benzofuran-2-carboxylate,CCN(CC)CCOC(=O)C1=C(C2=CC(=C(C=C2O1)OC)Br)C,,,,,,
2531,37226,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, dimethylaminoethyl ester, hydrochloride",C[NH+](C)CCOC(=O)C1=CC2=CC3=C(C=C2O1)OC=CO3.[Cl-],,,,,,
2532,37227,"2-(Dimethylamino)ethyl furo[2,3-g][1,4]benzodioxine-7-carboxylate",CN(C)CCOC(=O)C1=CC2=CC3=C(C=C2O1)OC=CO3,,,,,,
2533,37228,6-Methoxy-3-methyl-2-benzofurancarboxylic acid diethylaminoethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=C(C2=C(O1)C=C(C=C2)OC)C.[Cl-],,,,,,
2534,37229,2-(Diethylamino)ethyl 6-methoxy-3-methyl-1-benzofuran-2-carboxylate,CCN(CC)CCOC(=O)C1=C(C2=C(O1)C=C(C=C2)OC)C,,,,,,
2535,37230,"2-Benzofurancarboxylic acid, 5-bromo-6-methoxy-3-methyl-, dimethlyaminoethyl ester, hydrochloride",CC1=C(OC2=CC(=C(C=C12)Br)OC)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
2536,37231,2-(Dimethylamino)ethyl 5-bromo-6-methoxy-3-methyl-1-benzofuran-2-carboxylate,CC1=C(OC2=CC(=C(C=C12)Br)OC)C(=O)OCCN(C)C,,,,,,
2537,37232,"2-Benzofurancarboxylic acid, 5,7-dibromo-6-methoxy-3-methyl-, diethylaminoethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C2=CC(=C(C(=C2O1)Br)OC)Br)C.[Cl-],,,,,,
2538,37233,"2-(Diethylamino)ethyl 5,7-dibromo-6-methoxy-3-methyl-1-benzofuran-2-carboxylate",CCN(CC)CCOC(=O)C1=C(C2=CC(=C(C(=C2O1)Br)OC)Br)C,,,,,,
2539,37234,"Furo(2,3-g)-1,4-benzodioxin-7-carboxylic acid, diethylaminoethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC2=CC3=C(C=C2O1)OC=CO3.[Cl-],,,,,,
2540,37235,"2-(Diethylamino)ethyl furo[2,3-g][1,4]benzodioxine-7-carboxylate",CCN(CC)CCOC(=O)C1=CC2=CC3=C(C=C2O1)OC=CO3,,,,,,
2541,37236,"Ammonium, ((2-bromo-4,5-dimethoxy)benzyl)diethyl(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide",CC[N+](CC)(CCOCCC1CCC2CC1C2(C)C)CC3=CC(=C(C=C3Br)OC)OC.[Br-],,,,,,
2542,37237,"2-Bromo-N-[2-[2-(6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl]-N,N-diethyl-4,5-dimethoxybenzenemethanaminium",CC[N+](CC)(CCOCCC1CCC2CC1C2(C)C)CC3=CC(=C(C=C3Br)OC)OC,,,,,,
2543,37238,"Benzyldimethyl(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)ammonium bromide",CC1(C2CCC(C1C2)CCOCC[N+](C)(C)CC3=CC=CC=C3)C.[Br-],,,,,,
2544,37239,"N-[2-[2-(6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl]-N,N-dimethylbenzenemethanaminium",CC1(C2CCC(C1C2)CCOCC[N+](C)(C)CC3=CC=CC=C3)C,,,,,,
2545,37240,"Allyldiethyl(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)ammonium bromide",CC[N+](CC)(CCOCCC1CCC2CC1C2(C)C)CC=C.[Br-],,,,,,
2546,37241,"N-[2-[2-(6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl]-N,N-diethyl-2-propen-1-aminium",CC[N+](CC)(CCOCCC1CCC2CC1C2(C)C)CC=C,,,,,,
2547,37242,"Benzyldiethyl(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)ammonium bromide",CC[N+](CC)(CCOCCC1CCC2CC1C2(C)C)CC3=CC=CC=C3.[Br-],,,,,,
2548,37243,"N-[2-[2-(6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl]-N,N-diethylbenzenemethanaminium",CC[N+](CC)(CCOCCC1CCC2CC1C2(C)C)CC3=CC=CC=C3,,,,,,
2549,37244,"Ammonium, ((2-bromo-4,5-diethoxy)benzyl)dimethyl(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide",CCOC1=C(C=C(C(=C1)C[N+](C)(C)CCOCCC2CCC3CC2C3(C)C)Br)OCC.[Br-],,,,,,
2550,37245,"2-Bromo-N-[2-[2-(6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl]-4,5-diethoxy-N,N-dimethylbenzenemethanaminium",CCOC1=C(C=C(C(=C1)C[N+](C)(C)CCOCCC2CCC3CC2C3(C)C)Br)OCC,,,,,,
2551,37246,"2-Cyclohexene-1,4-dione, 2-hydroxy-3,5,5-trimethyl-",CC1=C(C(=O)CC(C1=O)(C)C)O,,,,,,
2552,37247,"2,4,6-Trichlorobiphenyl",C1=CC=C(C=C1)C2=C(C=C(C=C2Cl)Cl)Cl,,,,,,
2553,37248,"2,2',5,5'-Tetrachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=C(C=CC(=C2)Cl)Cl)Cl,,,,,,
2554,37249,"2,2',3,3',5,5'-Hexachlorobiphenyl",C1=C(C=C(C(=C1C2=C(C(=CC(=C2)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
2555,37250,"2,2',3,4,4',5-Hexachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
2556,37251,"2,2',3,3',4,4',5,5'-Octachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
2557,37252,"Anthraquinone, 2,6-bis(2-(diethylamino)ethoxy)-, dihydrochloride",CC[NH+](CC)CCOC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=CC(=C3)OCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
2558,37253,"2,6-Bis(2-(diethylamino)ethoxy)anthraquinone",CCN(CC)CCOC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=CC(=C3)OCCN(CC)CC,,,,,,
2559,37254,CID 37254,CCCCC[C@@](C)(C=CC1[C@H](C[C@H]([C@H]1CC=CCCCC(=O)OC)O)O)O,,,,,,
2560,37255,CID 37255,CCCCC[C@@](C)(C=CC1[C@@H](C[C@@H](C1CC=CCCCC(=O)O)O)O)O,,,,,,
2561,37256,N-(4-Cyanophenyl)acetamide,CC(=O)NC1=CC=C(C=C1)C#N,,,,,,
2562,37257,"Holmium(III) nitrate, hexahydrate (1:3:6)",[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].O.O.O.O.O.O.[Ho+3],,,,,,
2563,37258,Tetrahydrothiamine diphosphate,CC1C(SCN1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)O,,,,,,
2564,37259,2-Chloro-2-nitro-1-butanol,CCC(CO)([N+](=O)[O-])Cl,,,,,,
2565,37260,CID 37260,CCCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
2566,37261,"(5-benzylfuran-2-yl)methyl (1S,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate",CC(=C[C@@H]1[C@@H](C1(C)C)C(=O)OCC2=CC=C(O2)CC3=CC=CC=C3)C,,,,,,
2567,37262,"6-Amino-2-methyl-2H-1,3-benzoxazin-4(3H)-one",CC1NC(=O)C2=C(O1)C=CC(=C2)N,,,,,,
2568,37263,"6-Amino-2-ethyl-2H-1,3-benzoxazin-4(3H)-one",CCC1NC(=O)C2=C(O1)C=CC(=C2)N,,,,,,
2569,37264,Trimazosin,CC(C)(COC(=O)N1CCN(CC1)C2=NC3=C(C(=C(C=C3C(=N2)N)OC)OC)OC)O,,,"['Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
2570,37265,"Guanidine, 2-nitro-1-nitroso-1-octyl-",CCCCCCCCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
2571,37266,"5H-1,4-DITHIINO(2,3-c)PYRROLE-5,7(6H)-DIONE, 2,3-DIHYDRO-6-(PHENYLMETHYL)-",C1CSC2=C(S1)C(=O)N(C2=O)CC3=CC=CC=C3,,,,,,
2572,37267,Acetophenonehelveticosol,CC1[C@@H]2C(C[C@@H](O1)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)CO)OC(O2)(C)C8=CC=CC=C8,,,,,,
2573,37268,Aethylbenzylketonhelveticosid,CCC1(O[C@@H]2C(O[C@H](CC2O1)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C=O)C)CC8=CC=CC=C8,,,,,,
2574,37269,"Isocoumarin, 3,4-dihydro-6,8-dihydroxy-3-(6-methyl-tetrahydro-2H-pyran-2-yl)-",CC1CCCC(O1)CC2CC3=C(C(=CC(=C3)O)O)C(=O)O2,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2575,37270,"1,2,3,4,6,7,8-Heptachlorodibenzo-P-dioxin",C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,"['After 21 daily doses of 100 ug octachlorodibenzo-p-dioxin containing 12.6 picograms (35)S-thio-heptachlorodibenzo-p-dioxin to male Sprague-Dawley rats, the radioactivity was mainly recovered in the feces and urine, the percentages of the ingested radioactive doses being 93 (+ or - 6) and 5.2 (+ or - 0.8)% respectively. The high fecal excretion suggests poor absorption. Of the radioactive body burden, 50% was contained in the liver. The microsomal fractioncontained 96.3 (+ or - 8.2)% of the hepatic radioactivity.', 'The polychlorinated dibenzo-p-dioxins and the polychlorinated dibenzofurans are predominantly stored in fat, but they are also excreted in milk and pass the placenta. They also appear in the blood and vital organs at lower concentrations. /Polychlorinated dibenzo-p-dioxins/', ""A defined mixture of polychlorinated dibenzo-p-dioxins and dibenzofurans was subcutaneously administered to a pregnant marmoset monkey (Callithrix jacchus) 11 wk prior to delivery. Transfer of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans via placenta and mother's milk was investigated by measurement of concn in a newborn 1 day after birth and in an infant of the same litter after a lactation period of 33 days. Furthermore, comparative measurements were performed in different tissues of the mother at the end of the lactation period, and in addition, in two groups of four adult monkeys each 1 and 6 wk after treatment. Deposition of the polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans into fell liver was very low for most of the 2,3,7,8-substituted congeners. Highest deposition was observed for 2,3,7,8-tetrachlorodibenzo-p-dioxins and 1,2,3,7,8-pentachlorodibenzo-p-dioxins. For all other compounds concn in the hepatic tissue of newborn shortly after birth were lower than one tenth of corresponding concn in adults. Fetal liver isapparently largely unable to accumulate polychlorinated dibenzo-p-dioxins/polychlorinated dibenzofurans. In contrast to liver, concn of 2,3,7,8-substituted polychlorinated dibenzo-p-dioxins/polychlorinated dibenzofurans in adipose tissue of the newborn were at least one third of the levels in adults. However, concn of octachlorodibenzo-p-dioxin and octachlorodibenzofuran were about three times higher in the newborn than in adult adipose tissue. Transfer of some of the 2,3,7,8-substituted polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans to the offspring via mother's milk was considerable, leading to hepatic concn in the suckled infant at the end of the 33-day nursing period well above corresponding concn in the dam. When hepatic concn in the infant and dam were compared 2- to 4-fold higher concn were found in the infant's liver for 2,3,7,8-tetrachlorodibenzo-p-dioxins/furans and for 1,2,3,7,8-pentachlorodibenzo-p-dioxins. In the case of the 2,3,7,8-substituted hexachlorodibenzo-p-dioxins, hepatic concn in the infant and dam were in the same range at the end of the suckling period. In contrast to this, less than one tenth the concn of octachlorodibenzo-p-dioxin was found in the infant's liver when compared with adult liver. /Hexachlorodibenzo-p-dioxins/"", 'The tissue distribution of 2,3,7,8-chlorine substituted dibenzo-p-dioxins was conducted in 11 patients who died of cancer. The concn of octachlorodibenzo-p-dioxin was the highest in each organ and tissue and heptachlorodibenzo-p-dioxins was also found at relatively high levels, second only to octachlorodibenzo-p-dioxin. The levels of 1,2,3,7,8-pentachlorodibenzo-p-dioxins and 1,2,3,6,7,8-hexachlorodibenzo-p-dioxins in the spleen were the highest, respectively. 2,3,7,8-Tetrachlorodibenzo-p-dioxins was also detected and its concn was the highest in the gonad (0.8-3.2 picogram/g range). From the 2,3,7,8-tetrachlorodibenzo-p-dioxin toxic equivalent calculations, the highest equivalent value was obtained from a 54-year old female who died of cancerous goiter. This individual had the highest concn of 2,3,7,8-substituted penta- and hexa-chlorodibenzo-p-dioxinss among the 11 patients. /Heptachlorodibenzo-p-dioxins/', 'For more Absorption, Distribution and Excretion (Complete) data for HEPTACHLORODIBENZO-P-DIOXIN (8 total), please visit the HSDB record page.']","['The effects of subchronic octachlorodibenzo-p-dioxin exposure was examined in rats over a 13 wk period. Male Fischer 344 rats were treated with 50 ug/kg (14)C labeled octachlorodibenzo-p-dioxin by gavage for 10, 20, 40, or 65 doses (once per day 5 days per wk) and sacrificed 3 days postexposure. Hepatic accumulation was associated with alterations of several biochemical parameters. In animals treated 65 times, ethoxyresorufin-O-deethylase activity was elevated 40 fold over controls; total cytochrome p450 content doubled and exhibited a 2 nanometer blue shift in the Soret maximum for the reduced hemoprotein-CO complex. Cytochrome p450c and cytochrome p450d were significantly increased, while cytochrome p450b levels were unaltered. Nearly all the dioxin congeners present in liver were represented by octachlorodibenzo-p-dioxin, with a slight amount ofheptachlorinated dioxin present. It was concluded that subchronic octachlorodibenzo-p-dioxin exposure causes toxic effects similar to those observed with other dioxins, but with far less potency than 2,3,7,8-tetrachlorodibenzo-p-dioxin. /Octachlorodibenzo-p-dioxin/']","['The half-lives of 1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin, 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin, and octachlorodibenzo-p-dioxin /were calculated/ to be about 3.5, 3.6 and 2 years, respectively. The estimation was based on the analysis of fat tissue biopsies collected with an interval of 28 months from one 14 year old girl who for a period of about 2-3 years had been exposed to technical pentachlorophenol.']"
2576,37271,"2-Methyl-2-phenyl-1,3-dioxolane-4-methanol carbamate",CC1(OCC(O1)COC(=O)N)C2=CC=CC=C2,,,,,,
2577,37272,"1,6-Hexanediamine, N,N'-dimethyl-N,N'-dinitro-",CN(CCCCCCN(C)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2578,37273,"1,3-Dicyclohexylbarbituric acid",C1CCC(CC1)N2C(=O)CC(=O)N(C2=O)C3CCCCC3,,,,,,
2579,37274,Etazolate hydrochloride,CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC.Cl,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
2580,37275,CID 37275,CCCC(C1=CC=C(C=C1)CCCl)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2581,37276,CID 37276,C[C@@H]1[C@@H]2C[C@]([C@@H](C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)C(C)N(C)C(=O)C)C)C)OC)(NC(=O)O2)O,,,,,,
2582,37277,1-Azabicyclo[4.2.0]octane,C1CCN2CCC2C1,,,,,,
2583,37278,N-Formyl-L-sarcolysin,C1=CC(=CC=C1CC(C(=O)O)NC=O)N(CCCl)CCCl,,,,,,
2584,37279,"Ethylamine, 2-((10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)oxy)-N,N-dimethyl-, N-oxide, oxalate",C[N+](C)(CCOC1C2=CC=CC=C2CCC3=CC=CC=C13)O.C(=O)(C(=O)[O-])O,,,,,,
2585,37280,"Hydroxy-dimethyl-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyloxy)ethyl]azanium",C[N+](C)(CCOC1C2=CC=CC=C2CCC3=CC=CC=C13)O,,,,,,
2586,37281,"3-Adamantanecarboxylic acid, phenyl ester",C1C2CC3CC1CC(C2)(C3)C(=O)OC4=CC=CC=C4,,,,,,
2587,37282,"2-(p-Chlorophenyl)-2-methyl-1,3-dioxolane-4-methanol carbamate",CC1(OCC(O1)COC(=O)N)C2=CC=C(C=C2)Cl,,,,,,
2588,37283,"2-(p-Bromophenyl)-2-methyl-1,3-dioxolane-4-methanol carbamate",CC1(OCC(O1)COC(=O)N)C2=CC=C(C=C2)Br,,,,,,
2589,37284,(Phenylthio)acetic acid 2-(dimethylamino)-1-methylethyl ester,CC(CN(C)C)OC(=O)CSC1=CC=CC=C1,,,,,,
2590,37285,(p-Tolylthio)acetic acid 2-(dimethylamino)-1-methylethyl ester,CC1=CC=C(C=C1)SCC(=O)OC(C)CN(C)C,,,,,,
2591,37286,((p-Chlorophenyl)thio)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)CSC1=CC=C(C=C1)Cl.[Cl-],,,,,,
2592,37287,2-(Diethylamino)ethyl 2-(4-chlorophenyl)sulfanylacetate,CCN(CC)CCOC(=O)CSC1=CC=C(C=C1)Cl,,,,,,
2593,37288,"Dichloro-2,6-dimethoxyphenol",COC1=CC(=C(C(=C1O)OC)Cl)Cl,,,,,,
2594,37289,6-Hydroxydodecanoic acid,CCCCCCC(CCCCC(=O)O)O,,,,,,
2595,37290,"Ethylamine, N,N-dimethyl-2-(diphenylmethoxy)-, N-oxide, oxalate",C[N+](C)(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)O.C(=O)(C(=O)[O-])O,,,,,,
2596,37291,2-Benzhydryloxyethyl-hydroxy-dimethylazanium,C[N+](C)(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)O,,,,,,
2597,37292,CID 37292,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[N+](C)(C)O.C(=CC(=O)[O-])C(=O)O,,,,,,
2598,37293,Hydroxy-dimethyl-[2-[(4-methylphenyl)-phenylmethoxy]ethyl]azanium,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[N+](C)(C)O,,,,,,
2599,37294,"Ethylamine, 2-(bis(2,6-dimethylphenyl)methoxy)-N,N-dimethyl-, N-oxide, hydrochloride",CC1=C(C(=CC=C1)C)C(C2=C(C=CC=C2C)C)OCC[N+](C)(C)O.[Cl-],,,,,,
2600,37295,"2-[Bis(2,6-dimethylphenyl)methoxy]ethyl-hydroxy-dimethylazanium",CC1=C(C(=CC=C1)C)C(C2=C(C=CC=C2C)C)OCC[N+](C)(C)O,,,,,,
2601,37296,1-(3-Methylbutyl)-2-nitro-1-nitrosoguanidine,CC(C)CCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
2602,37297,"N,N-Di-2-propynyl-3-azabicyclo(3.2.1)octane-3-ethanamine",C#CCN(CCN1CC2CCC(C2)C1)CC#C,,,,,,
2603,37298,"3-Azabicyclo(3.2.2)nonane-3-propanamine, N,N-DI-2-propynyl-",C#CCN(CCCN1CC2CCC(C1)CC2)CC#C,,,,,,
2604,37299,"Indole, 1-acetyl-3-(2-amino-1-benzylthioethyl)-, hydrochloride",CC(=O)N1C=C(C2=CC=CC=C21)C(C[NH3+])SCC3=CC=CC=C3.[Cl-],,,,,,
2605,37300,1-[3-(2-Amino-1-benzylsulfanylethyl)indol-1-yl]ethanone,CC(=O)N1C=C(C2=CC=CC=C21)C(CN)SCC3=CC=CC=C3,,,,,,
2606,37301,CID 37301,CCCCCCC(=O)CCCCCCC=CC[C@@H]1[C@@H]([C@](C(=O)O1)(CO)N)O,,,,,,
2607,37302,"Acetamide, 2-(butylmethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride",CCCC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
2608,37303,"Acetamide, 2-(butylmethylamino)-N-(2,6-dimethylphenyl)-",CCCCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
2609,37304,"Acetamide, N-(2,6-dimethylphenyl)-2-(methylpentylamino)-, monohydrochloride",CCCCC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
2610,37305,"N-(2,6-Dimethylphenyl)-2-(methylpentylamino)acetamide",CCCCCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
2611,37306,"Acetamide, N-(2,6-dimethylphenyl)-2-(hexylmethylamino)-, monohydrochloride",CCCCCC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
2612,37307,"N-Hexyl-N-methylamino-2,6-xylidide",CCCCCCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
2613,37308,"Acetamide, N-(2,6-dimethylphenyl)-2-(heptylmethylamino)-, monohydrochloride",CCCCCCC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
2614,37309,"N-(2,6-dimethylphenyl)-2-[heptyl(methyl)amino]acetamide",CCCCCCCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
2615,37310,Butyrophenonhelveticosid,CCCC1(O[C@@H]2C(O[C@H](CC2O1)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C=O)C)C8=CC=CC=C8,,,,,,
2616,37311,"6-(cyclopropylmethyl)-1,2-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline",COC1=C(C2=C3C(CC4=CC=CC=C42)N(CCC3=C1)CC5CC5)OC,,,,,,
2617,37312,"5-Chloro-3-[2-[4-(2-hydroxyethyl)piperazin-1-yl]-2-oxoethyl]-3a,7a-dihydro-1,3-benzothiazol-2-one;hydrochloride",C1CN(CCN1CCO)C(=O)CN2C3C=C(C=CC3SC2=O)Cl.Cl,,,,,,
2618,37313,"5-Chloro-3-[2-[4-(2-hydroxyethyl)piperazin-1-yl]-2-oxoethyl]-3a,7a-dihydro-1,3-benzothiazol-2-one",C1CN(CCN1CCO)C(=O)CN2C3C=C(C=CC3SC2=O)Cl,,,,,,
2619,37314,9-Oxo-9H-9-phospha(V)-10-oxaphenanthrene,C1=CC=C2C(=C1)C3=CC=CC=C3P(=O)O2,,,,,,
2620,37315,CID 37315,C1CCC(=NNC(=[NH+]N=C2CCCCC2)N)CC1.[Cl-],,,,,,
2621,37316,CID 37316,C1CCC(=NNC(=NN=C2CCCCC2)N)CC1,,,,,,
2622,37317,CID 37317,CC1CCCCC1=NNC(=[NH+]N=C2CCCCC2C)N.[Cl-],,,,,,
2623,37318,CID 37318,CC1CCCCC1=NNC(=NN=C2CCCCC2C)N,,,,,,
2624,37319,"1,2-Bis(fluoren-9-ylideneamino)guanidine",C1=CC=C2C(=C1)C3=CC=CC=C3C2=NNC(=NN=C4C5=CC=CC=C5C6=CC=CC=C64)N,,,,,,
2625,37320,"3,3'-Dichloro-N,N'-diacetylbenzidine",CC(=O)NC1=C(C=C(C=C1)C2=CC(=C(C=C2)NC(=O)C)Cl)Cl,,,,,,
2626,37321,2-(2-Amino(tritylthio)propionamido)-3-methylbutyric acid methyl ester hydrochloride,CC(C)C(C(=O)OC)NC(=O)C(CSC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)[NH3+].[Cl-],,,,,,
2627,37322,"Valine, methyl ester, monohydrochloride, L-",CC(C)C(C(=O)OC)NC(=O)C(CSC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)N,,,,,,
2628,37323,"L-Cysteine, S-(1,3-benzodioxol-5-yldiphenylmethyl)-",C1OC2=C(O1)C=C(C=C2)C(C3=CC=CC=C3)(C4=CC=CC=C4)SC[C@@H](C(=O)O)N,,,,,,
2629,37324,"2beta,4alpha-Diphenyl-2,4,6,6,8,8-hexamethylcyclotetrasiloxane",C[Si@@]1(O[Si@](O[Si](O[Si](O1)(C)C)(C)C)(C)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2630,37325,"1-(2'-Carboxymethylphenyl)-3,3-dimethyltriazene",CN(C)N=NC1=CC=CC=C1C(=O)OC,,,,,,
2631,37326,"Benzoic acid, m-(3,3-dimethyl-1-triazeno)-, methyl ester",CN(C)N=NC1=CC=CC(=C1)C(=O)OC,,,,,,
2632,37327,"(1)BENZOTHIENO(2,3-d)PYRIMIDIN-4-ONE, 5,6,7,8-TETRAHYDRO-3-BENZYL-2-METHYL-",CC1=NC2=C(C3=C(S2)CCCC3)C(=O)N1CC4=CC=CC=C4,,,,,,
2633,37328,"(1)Benzothieno(2,3-d)pyrimidin-4-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-naphthyl)-",CC1=NC2=C(C3=C(S2)CCCC3)C(=O)N1C4=CC5=CC=CC=C5C=C4,,,,,,
2634,37329,"2,2,2-trifluoro-N-(4-fluorophenyl)acetamide",C1=CC(=CC=C1NC(=O)C(F)(F)F)F,,,,,,
2635,37330,CID 37330,C1=CC=C2C(=C1)C=CC=C2OCC(CC(=N)[NH3+])O.[Cl-],,,,,,
2636,37331,3-Hydroxy-4-naphthalen-1-yloxybutanimidamide,C1=CC=C2C(=C1)C=CC=C2OCC(CC(=N)N)O,,,,,,
2637,37332,CID 37332,C1=CC=C2C(=C1)C=CC=C2OCC(CC(=NO)[NH3+])O.[Cl-],,,,,,
2638,37333,CID 37333,C1=CC=C2C(=C1)C=CC=C2OCC(CC(=NO)N)O,,,,,,
2639,37334,"N,N-Dimethyl-3-hydroxy-4-(1-naphthalenyloxy)butanimidamide hydrochloride",C[NH+](C)C(=N)CC(COC1=CC=CC2=CC=CC=C21)O.[Cl-],,,,,,
2640,37335,"3-hydroxy-N,N-dimethyl-4-naphthalen-1-yloxybutanimidamide",CN(C)C(=N)CC(COC1=CC=CC2=CC=CC=C21)O,,,,,,
2641,37336,"N,N'-Bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid",C1=CC=C(C(=C1)CN(CCN(CC2=CC=CC=C2O)CC(=O)O)CC(=O)O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
2642,37337,CID 37337,C1CN(CCN1)CCN=C(S)S,,,,,,
2643,37338,"3-(3,8-Diamino-5-phenylphenanthridin-5-ium-6-yl)propyl-diethyl-methylazanium",CC[N+](C)(CC)CCCC1=C2C=C(C=CC2=C3C=CC(=CC3=[N+]1C4=CC=CC=C4)N)N,,,,,,
2644,37339,N-P-Chlorophenyl-M-methylbenzohydroxamic acid,CC1=CC(=CC=C1)C(=O)N(C2=CC=C(C=C2)Cl)O,,,,,,
2645,37340,"Benzamide, 3-chloro-N-(4-chlorophenyl)-N-hydroxy",C1=CC(=CC(=C1)Cl)C(=O)N(C2=CC=C(C=C2)Cl)O,,,,,,
2646,37341,N-P-(Chlorophenyl)-M-nitrobenzohydroxamic acid,C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)N(C2=CC=C(C=C2)Cl)O,,,,,,
2647,37342,CID 37342,CCCCCCC(=O)OCCCN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
2648,37343,"3-[4-(3-Chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]propyl heptanoate",CCCCCCC(=O)OCCCN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
2649,37344,"Formamide, N,N-bis(2-chloroethyl)-",C(CCl)N(CCCl)C=O,,,,,,
2650,37345,"1,3-Butadiene, 1,1,4,4-tetrachloro-",C(=C(Cl)Cl)C=C(Cl)Cl,,,,,,
2651,37346,"2,4,6-Cycloheptatrien-1-one, 2-amino-7-bromo-",C1=CC=C(C(=O)C(=C1)N)Br,,,,,,
2652,37347,"2,4,6-Cycloheptatrien-1-one, 5-amino-7-bromo-2-hydroxy-",C1=CC(=O)C(=C(C=C1N)Br)O,,,,,,
2653,37348,CID 37348,C[NH+](C)CCOC1C2=C(CCC3=C1C=C(C=C3)Cl)N=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
2654,37349,"2-[(14-chloro-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)oxy]-N,N-dimethylethanamine",CN(C)CCOC1C2=C(CCC3=C1C=C(C=C3)Cl)N=CC=C2,,,,,,
2655,37350,"10,11-Dihydro-7-chloro-5-(4-methylpiperazinyl)-5H-benzo(4,5)cyclohepta(1,2-b)pyridine",CN1CCN(CC1)C2C3=C(CCC4=C2C=C(C=C4)Cl)N=CC=C3,,,,,,
2656,37351,"1-(14-Chloro-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene)-3-methylurea",CNC(=O)N=C1C2=C(C=CC3=C1C=C(C=C3)Cl)N=CC=C2,,,,,,
2657,37352,"10,11-Dihydro-7-methoxy-5-(N-methylpiperazinyl)-5H-benzo(4,5)cyclohepta(1,2-b)pyridine",CN1CCN(CC1)C2C3=C(CCC4=C2C=C(C=C4)OC)N=CC=C3,,,,,,
2658,37353,3-Chloro-4-piperidinocoumarin,C1CCN(CC1)C2=C(C(=O)OC3=CC=CC=C32)Cl,,,,,,
2659,37354,2-[[2-Amino-3-[(4-amino-4-oxobut-2-enoyl)amino]propanoyl]amino]propanoic acid,CC(C(=O)O)NC(=O)C(CNC(=O)C=CC(=O)N)N,,,,,,
2660,37355,"5H-Dibenzo(a,d)cycloheptene-4-ethylamine, 10,11-dihydro-N,N-dimethyl-5-methylene-",CN(C)CCC1=CC=CC2=C1C(=C)C3=CC=CC=C3CC2,,,,,,
2661,37356,"5H-Dibenzo(a,d)cycloheptene-4-propylamine, 10,11-dihydro-N,N-dimethyl-5-methylene-",CN(C)CCCC1=CC=CC2=C1C(=C)C3=CC=CC=C3CC2,,,,,,
2662,37357,"5H-DIBENZO(a,d)CYCLOHEPTENE-4-METHYLAMINE, 10,11-DIHYDRO-N-METHYL-5-METHYLENE-",CNCC1=CC=CC2=C1C(=C)C3=CC=CC=C3CC2,,,,,,
2663,37358,"5H-DIBENZO(a,d)CYCLOHEPTENE-4-ETHYLAMINE, 10,11-DIHYDRO-5-METHYLENE-",C=C1C2=CC=CC=C2CCC3=C1C(=CC=C3)CCN,,,,,,
2664,37359,"10,11-Dihydro-N,N,5-trimethyl-5H-dibenzo(a,d)cycloheptene-4-propylamine",CC1C2=CC=CC=C2CCC3=C1C(=CC=C3)CCCN(C)C,,,,,,
2665,37360,CID 37360,C1CN=C(N1)CC(=S)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2666,37361,"11-Oxo-17,23-epoxyveratraman-3-yl hexopyranoside",CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4C5CC=C6C[C@H](CCC6(C5C(=O)C4=C3C)C)O[C@H]7C(C([C@@H](C(O7)CO)O)O)O)C)NC1,,,,,,
2667,37362,"[3-hydroxy-10,13-dimethyl-17-[1-(5-methylpiperidin-2-yl)ethyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate",CC1CCC(NC1)C(C)C2C(CC3C2(CCC4C3CC=C5C4(CCC(C5)O)C)C)OC(=O)C,,,,,,
2668,37363,"Acetohydroxamic acid, (3-chloro-4-propargyloxy)phenyl-",C#CCOC1=C(C=C(C=C1)CC(=O)NO)Cl,,,,,,
2669,37364,Thioglycolic acid o-toluidide,CC1=CC=CC=C1NC(=O)CS,,,,,,
2670,37365,5-Ethyl-5-(2-methylbutyl)barbituric acid,CCC(C)CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
2671,37366,"Indole, 3-(1,3-dithiolan-2-YL)-",C1CSC(S1)C2=CNC3=CC=CC=C32,,,,,,
2672,37367,Camazepam,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)OC(=O)N(C)C)C3=CC=CC=C3,['Camazepam has been used in placebo controlled studies for the treatment of patients suffering from anxiety and depression.'],,,"['Almost completely absorbed into the bloodstream after oral administration. 90% bioavailability can be achieved in humans.', 'Renally eliminated.']","['Metabolized by the liver into more than 10 metabolites, some of which are also active and posses anticonvulsant properties. [3] One active metabolite of note is temazepam which has roughly equal in effectiveness as an anxiolytic, but is less anticonvulsant, sedating, and motor-impairing.  Camazepam undergoes enantioselective metabolism by human liver microsomes. [1]']",
2673,37368,Flurazepam monohydrochloride,CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.Cl,,,"['Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,,
2674,37369,Propranolol glycol,C1=CC=C2C(=C1)C=CC=C2OCC(CO)O,,,,,,
2675,37370,"6,7-Dimethoxy-1-(m-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C([NH2+]CCC2=C1)CC3=CC(=CC=C3)F)OC.[Br-],,,,,,
2676,37371,"1-[(3-Fluorophenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2C(NCCC2=C1)CC3=CC(=CC=C3)F)OC,,,,,,
2677,37372,"6,7-Dimethoxy-1-(o-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C([NH2+]CCC2=C1)CC3=CC=CC=C3F)OC.[Br-],,,,,,
2678,37373,"1-[(2-Fluorophenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2C(NCCC2=C1)CC3=CC=CC=C3F)OC,,,,,,
2679,37374,"6,7-Dimethoxy-1-(p-fluorobenzyl)-3,4-dihydroisoquinoline hydrobromide",COC1=C(C=C2C(=C1)CC[NH+]=C2CC3=CC=C(C=C3)F)OC.[Br-],,,,,,
2680,37375,"1-[(4-Fluorophenyl)methyl]-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C(=C1)CCN=C2CC3=CC=C(C=C3)F)OC,,,,,,
2681,37376,"6,7-Dimethoxy-1-(m-fluorobenzyl)-3,4-dihydroisoquinoline hydrobromide",COC1=C(C=C2C(=C1)CC[NH+]=C2CC3=CC(=CC=C3)F)OC.[Br-],,,,,,
2682,37377,"1-[(3-Fluorophenyl)methyl]-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C(=C1)CCN=C2CC3=CC(=CC=C3)F)OC,,,,,,
2683,37378,CID 37378,CN1C2=C(C=C(C=C2)C=NN)C3=CC=CC=C31,,,,,,
2684,37379,N-[(9-methylcarbazol-3-yl)methylideneamino]aniline,CN1C2=C(C=C(C=C2)C=NNC3=CC=CC=C3)C4=CC=CC=C41,,,,,,
2685,37380,CID 37380,CC1=CC=CC=C1NN=CC2=CC3=C(C=C2)N(C4=CC=CC=C43)C,,,,,,
2686,37381,CID 37381,CN1C2=C(C=C(C=C2)C=NNC3=CC4=CC=CC=C4C=C3)C5=CC=CC=C51,,,,,,
2687,37382,CID 37382,CN1C2=C(C=C(C=C2)C=NNC3=CC=C(C=C3)[N+](=O)[O-])C4=CC=CC=C41,,,,,,
2688,37383,"1H-Indole-7-carboxylic acid, 2,3-dihydro-2-oxo-3,3-diphenyl-",C1=CC=C(C=C1)C2(C3=CC=CC(=C3NC2=O)C(=O)O)C4=CC=CC=C4,,,,,,
2689,37384,Diamfenetide,CC(=O)NC1=CC=C(C=C1)OCCOCCOC2=CC=C(C=C2)NC(=O)C,,,"['Agents used to treat cestode, trematode, or other flatworm infestations in man or animals. (See all compounds classified as Antiplatyhelmintic Agents.)']",,,
2690,37385,9-Amino-10-methylacridinium iodide,C[N+]1=C2C=CC=CC2=C(C3=CC=CC=C31)N.[I-],,,,,,
2691,37386,Besunide,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)CC2=CC=CC=C2,,,,,,
2692,37387,"[2,5,7,8-Tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] octadeca-9,12-dienoate",CCCCCC=CCC=CCCCCCCCC(=O)OC1=C(C2=C(C(=C1C)C)OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C,,,,,,
2693,37388,"methyl (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate",C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)OC)OC3C(C(C(C(O3)C)O)N)O,,,,,,
2694,37389,CID 37389,C[C@@H]1C2C(CCC1=CC(=O)OCCNC)[C@]3(CCC[C@](C3CC2O)(C)C(=O)OC)C,,,,,,
2695,37390,CID 37390,CC(=NO)C1=CC=C(C=C1)OCC(=O)N2CCCC2,,,,,,
2696,37391,7-Acetylaminoquinoline,CC(=O)NC1=CC2=C(C=CC=N2)C=C1,,,,,,
2697,37392,Halofantrine hydrochloride,CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O.Cl,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']",,,
2698,37393,Halofantrine,CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O,['For treatment of Severe malaria'],['Halofantrine is a synthetic antimalarial which acts as a blood schizonticide. It is effective against multi drug resistant (including mefloquine resistant) <i>P. falciparum</i> malaria.'],"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']",,['Hepatic'],['6-10 days']
2699,37394,9-((3-((2-Chloroethyl)thio)propyl)amino)-2-methoxyacridine hydrochloride,COC1=CC2=C(C3=CC=CC=C3N=C2C=C1)[NH2+]CCCSCCCl.[Cl-],,,,,,
2700,37395,9-[3-(2-Chloroethylthio)propylamino]-2-methoxyacridine,COC1=CC2=C(C3=CC=CC=C3N=C2C=C1)NCCCSCCCl,,,,,,
2701,37396,Propylbenzilylcholine mustard,CCCN(CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O)CCCl,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
2702,37397,"5,7-Bis(morpholinomethyl)-2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one dihydrochloride",CC(C)C1=CC(=CC(=C(C1=O)O)C[NH+]2CCOCC2)C[NH+]3CCOCC3.[Cl-].[Cl-],,,,,,
2703,37398,5-Chloro-2-(dimethylamino)methyleneaminopyridine,CN(C)C=NC1=NC=C(C=C1)Cl,,,,,,
2704,37399,"Mandelic acid, alpha-cyclopentyl-, (1-methyl-1,2,5,6-tetrahydro-4-pyridyl)methyl ester, hydrochloride",C[NH+]1CCC(=CC1)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
2705,37400,"(1-methyl-3,6-dihydro-2H-pyridin-4-yl)methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate",CN1CCC(=CC1)COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
2706,37401,"3-[(3S,5R,10S,13R,14S,16S,17R)-14,16-dihydroxy-3-[(2S,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)O)O)C)C)OC)O,,,,,,
2707,37402,"N,N-dimethyl-N'-(2,4,6-trimethylphenyl)methanimidamide",CC1=CC(=C(C(=C1)C)N=CN(C)C)C,,,,,,
2708,37403,Methyl 7-[3-hydroxy-2-(3-hydroxy-3-methyloct-1-enyl)-5-oxocyclopentyl]hept-5-enoate,CCCCCC(C)(C=CC1C(CC(=O)C1CC=CCCCC(=O)OC)O)O,,,,,,
2709,37404,2-(4-Chloro-2-methylphenoxy)ethanol,CC1=C(C=CC(=C1)Cl)OCCO,,,,,,
2710,37405,"Barbituric acid, 5-benzyl-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)CC2=CC=CC=C2,,,,,,
2711,37406,"4-ethoxy-N-[2,2,2-trichloro-1-(4-ethoxyphenyl)ethyl]aniline",CCOC1=CC=C(C=C1)C(C(Cl)(Cl)Cl)NC2=CC=C(C=C2)OCC,,,,,,
2712,37407,"4-(Chloromethyl)-2-phenyl-1,3-dioxolane",C1C(OC(O1)C2=CC=CC=C2)CCl,,,,,,
2713,37408,"4-(Chloromethyl)-2-methyl-2-pentyl-1,3-dioxolane",CCCCCC1(OCC(O1)CCl)C,,,,,,
2714,37409,"BENZO(b)THIOPHENE, 3-(p-METHOXYPHENYL)-5-NITRO-2-PHENYL-",COC1=CC=C(C=C1)C2=C(SC3=C2C=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4,,,,,,
2715,37410,"6,7-Dimethoxy-1-(p-fluorobenzyl)-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C([NH2+]CCC2=C1)CC3=CC=C(C=C3)F)OC.[Br-],,,,,,
2716,37411,"1-(4-Fluorobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2C(NCCC2=C1)CC3=CC=C(C=C3)F)OC,,,,,,
2717,37412,2-(p-Chlorophenacylthio)-2-imidazolinium bromide,C1CN=C([NH2+]1)CC(=S)C2=CC=C(C=C2)Cl.[Br-],,,,,,
2718,37413,"1-(4-chlorophenyl)-2-(4,5-dihydro-1H-imidazol-2-yl)ethanethione",C1CN=C(N1)CC(=S)C2=CC=C(C=C2)Cl,,,,,,
2719,37414,"DIBENZO(a,d)CYCLOHEPTENE-4-PROPYLAMINE, 10,11-DIHYDRO-N-METHYL-5-METHYLENE-",CNCCCC1=CC=CC2=C1C(=C)C3=CC=CC=C3CC2,,,,,,
2720,37415,"5H-Benzocyclohepten-5-amine, 6,7,8,9-tetrahydro-N-(3,3-diphenylpropyl)-, hydrochloride",C1CCC2=CC=CC=C2C(C1)[NH2+]CCC(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
2721,37416,"N-(3,3-diphenylpropyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-amine",C1CCC2=CC=CC=C2C(C1)NCCC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2722,37417,(3-Phenylpropyl)aminoguanidine,C1=CC=C(C=C1)CCCNN=C(N)N,,,,,,
2723,37418,"1,3-Bis(dibromomethyl)benzene",C1=CC(=CC(=C1)C(Br)Br)C(Br)Br,,,,,,
2724,37419,Butamifos,CCC(C)NP(=S)(OCC)OC1=C(C=CC(=C1)C)[N+](=O)[O-],,,,,,
2725,37420,"2,2',3,4,4',6-Hexabromobiphenyl",C1=CC(=C(C=C1Br)Br)C2=C(C(=C(C=C2Br)Br)Br)Br,,,,,,
2726,37421,CID 37421,C1CC2CCC(C(C1)C2(CC3=CC=CC=C3)O)[NH+]4CCN(CC4)C5=CC=CC=C5.C(=CC(=O)[O-])C(=O)O,,,,,,
2727,37422,9-Benzyl-2-(4-phenylpiperazin-1-yl)bicyclo[3.3.1]nonan-9-ol,C1CC2CCC(C(C1)C2(CC3=CC=CC=C3)O)N4CCN(CC4)C5=CC=CC=C5,,,,,,
2728,37423,"Bicyclo(3.3.1)nonan-9-ol, 2-(4-acetyl-4-phenyl-1-piperidyl)-9-methyl-, hydrochloride",CC(=O)C1(CC[NH+](CC1)C2CCC3CCCC2C3(C)O)C4=CC=CC=C4.[Cl-],,,,,,
2729,37424,1-[1-(9-Hydroxy-9-methyl-2-bicyclo[3.3.1]nonanyl)-4-phenylpiperidin-4-yl]ethanone,CC(=O)C1(CCN(CC1)C2CCC3CCCC2C3(C)O)C4=CC=CC=C4,,,,,,
2730,37425,Imidazole salicylate,C1=CC=C(C(=C1)C(=O)O)O.C1=CN=CN1,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
2731,37426,"Acridinium, 3,6-bis(dimethylamino)-10-ethyl-",CC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N(C)C)N(C)C,,,,,,
2732,37427,"Acridinium, 3,6-bis(dimethylamino)-10-propyl-",CCC[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N(C)C)N(C)C,,,,,,
2733,37428,2-(2-(2-(2-Phenoxyethoxy)ethoxy)ethoxy)ethanol,C1=CC=C(C=C1)OCCOCCOCCOCCO,,,,,,
2734,37429,1-Phenylazo-2-anthrol,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC4=CC=CC=C4C=C32)O,,,,,,
2735,37430,"2-Indolinone, 1-benzyl-3-methyl-3-(3-(morpholino)propoxy)-, monohydrochloride, hydrate",CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)OCCC[NH+]4CCOCC4.[Cl-],,,,,,
2736,37431,1-Benzyl-3-methyl-3-(3-morpholin-4-ylpropoxy)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CC3=CC=CC=C3)OCCCN4CCOCC4,,,,,,
2737,37432,N-(2-Hydroxyethyl)-N-((3-methyl-2-norbornyl)methyl)acetamide,CC1C2CCC(C2)C1CN(CCO)C(=O)C,,,,,,
2738,37433,2-(N-Butanoyl-N-(2-hydroxyethyl)aminomethyl)-3-methylnorbornane,CCCC(=O)N(CCO)CC1C(C2CCC1C2)C,,,,,,
2739,37434,p-Amino-N-(2-hydroxyethyl)-N-((3-methyl-2-norbornyl)methyl)benzamide,CC1C2CCC(C2)C1CN(CCO)C(=O)C3=CC=C(C=C3)N,,,,,,
2740,37435,N-(2-hydroxyethyl)-N-[(3-methyl-2-bicyclo[2.2.1]heptanyl)methyl]-3-phenylprop-2-enamide,CC1C2CCC(C2)C1CN(CCO)C(=O)C=CC3=CC=CC=C3,,,,,,
2741,37436,"Ethanol, 2-(((3-methyl-2-norbornyl)methyl)amino)-, benzoate (ester), hydrochloride",CC1C2CCC(C2)C1C[NH2+]CCOC(=O)C3=CC=CC=C3.[Cl-],,,,,,
2742,37437,2-[(3-Methyl-2-bicyclo[2.2.1]heptanyl)methylamino]ethyl benzoate,CC1C2CCC(C2)C1CNCCOC(=O)C3=CC=CC=C3,,,,,,
2743,37438,"3,4-Dichloroanisole",COC1=CC(=C(C=C1)Cl)Cl,,,,,,
2744,37439,(+)-Quinic acid,C1[C@@H](C([C@H](CC1(C(=O)O)O)O)O)O,,,,,,
2745,37440,CID 37440,C1=CC=C2C(=C1)C(=C(C(=O)C2=O)C=CC(Cl)Cl)O,,,,,,
2746,37441,"9H-Fluorene-2,7-dicarboxylic acid, bis(5-(dimethylamino)-2,2-dimethylpentyl) ester, dihydrochloride",CC(C)(CCC[NH+](C)C)COC(=O)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)C(=O)OCC(C)(C)CCC[NH+](C)C.[Cl-].[Cl-],,,,,,
2747,37442,"bis[5-(dimethylamino)-2,2-dimethylpentyl] 9H-fluorene-2,7-dicarboxylate",CC(C)(CCCN(C)C)COC(=O)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)C(=O)OCC(C)(C)CCCN(C)C,,,,,,
2748,37443,"9H-Fluorene-2,7-dicarboxylic acid, bis(6-(diethylamino)hexyl) ester, dihydrochloride",CC[NH+](CC)CCCCCCOC(=O)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)C(=O)OCCCCCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
2749,37444,"bis[6-(diethylamino)hexyl] 9H-fluorene-2,7-dicarboxylate",CCN(CC)CCCCCCOC(=O)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)C(=O)OCCCCCCN(CC)CC,,,,,,
2750,37445,"Bis(3-dibutylaminopropyl)9-oxofluorene-2,7-dicarboxylate dihydrochloride hydrate",CCCC[NH+](CCCC)CCCOC(=O)C1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)C(=O)OCCC[NH+](CCCC)CCCC.[Cl-].[Cl-],,,,,,
2751,37446,"Bis[3-(dibutylamino)propyl] 9-oxofluorene-2,7-dicarboxylate",CCCCN(CCCC)CCCOC(=O)C1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)C(=O)OCCCN(CCCC)CCCC,,,,,,
2752,37447,m-(2-Phenoxyethoxy)phenol,C1=CC=C(C=C1)OCCOC2=CC=CC(=C2)O,,,,,,
2753,37448,"Cobalt, bis(L-serinato)-, dihydrate",C([C@@H](C(=O)[O-])N)O.C([C@@H](C(=O)[O-])N)O.O.O.[Co+2],,,,,,
2754,37449,"Ammonium, nonamethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCCCCCCCC[N+](C)(C)C.[I-].[I-],,,,,,
2755,37450,"1,9-Bis(trimethylaminio)nonane",C[N+](C)(C)CCCCCCCCC[N+](C)(C)C,,,,,,
2756,37451,"1,1'-Di-n-octyl-4,4'-bipyridinium Dibromide",CCCCCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCCCCCCC.[Br-].[Br-],,,,,,
2757,37452,"1,1'-Dioctyl-4,4'-bipyridinium",CCCCCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCCCCCCC,,,,,,
2758,37453,CID 37453,CCCCOC(=O)C1=CC=C(C=C1)[O-].[Na+],,,,,,
2759,37454,Hexabromodiphenyl ethers,C1=C(C=C(C(=C1OC2=C(C=C(C=C2Br)Br)Br)Br)Br)Br,,,,"['Using rats as a model, ... tissue distribution of polybromodiphenyl ethers (PBDEs) /was investigated/ after oral administration and ... a suitable matrix /was evaluated/ for body burden estimation. Male rats were administered dust or corn oil containing 8 or 6 ug PBDEs/kg bw, respectively, in the diet for 21 days (N=4 rats per treatment), and the concentration of 15 PBDEs were measured in various tissues, plasma, and feces. PBDEs were found in all tissues, including the brain, and showed no difference in distribution patterns between treatments for most PBDEs. Tri- to hexa-BDEs comprised >80% of the total PBDEs in the adipose, brain, kidney, lung, and residual carcass, but <40% in the liver and plasma. The ratio of the lipid-weight concentration of tri- to hexa-BDEs in adipose tissue, residual carcass, and plasma was 1:1:2. For the hepta- to nona-BDEs, lipid-weight concentrations increased from adipose tissue to residual carcass to plasma in the ratio 0.3:1:>4. BDE-209 was the dominant congener in the liver and plasma, but was not detected in the adipose tissue or carcass. In summary, the lower brominated congeners tended to distribute equally into lipids implying both adipose tissue and plasma would be suitable matrices for biomonitoring. Plasma was the best matrix for detection of the higher brominated congeners (especially BDE-209), although on a lipid-weight basis tended to overestimate the total body burdens.', ""The disposition of the 14C-labelled polybrominated diphenyl ether (PBDE) 2,2',4,4',5,5'-hexaBDE (BDE153) was investigated in rodents following single and multiple doses and in a mixture with radiolabelled 2,2',4,4'-tetraBDE (BDE47) and 2,2',4,4',5-pentaBDE (BDE99). In single exposure studies there was little or no effect of dose on BDE153 disposition in male rats in the range 1-100 umol/kg. No major sex or species differences in the in vivo fate of BDE153 were detected. BDE153 was absorbed in rats or mice following gavage by approximately 70%; retained in tissues; and poorly metabolized and slowly excreted. Mixture studies indicated that, relative to each other, more BDE47 was distributed to adipose tissue, more BDE153 accumulated in the liver, and BDE99 was metabolized to the greatest extent. BDE153 was probably retained in the liver due to minimal metabolism and elimination after first-pass distribution to the tissue following gavage."", 'Twelve paired samples of maternal and cord blood collected in 2001 from women presenting in labor in an Indiana hospital were analyzed for six tetra- to heptaBDE congeners. None of the mothers had work-related potential for exposure to PBDEs, and none smoked. ... TetraBDE-47 was the most abundant congener, followed by pentaBDE-99, pentaBDE-100, and hexaBDE-153. PBDE concentrations were highly correlated between mother and fetal sera, indicating that PBDEs cross the placenta into the fetal circulation. In addition, the results indicate that all tetra- through hepta-substituted congeners have approximately the same potential to cross the placenta. There was a decreasing trend in concentration of PBDE congeners in maternal and fetal sera with increasing degree of bromination.', 'In F344 rats and B6C3F1 mice, about 30% of the radiolabel was found in the feces 24 hours after administration of a single radiolabeled 0.6 mg/kg dose compared to 4% in animals that received the same dose intravenously.', 'For more Absorption, Distribution and Excretion (Complete) data for Hexabromodiphenyl ethers (7 total), please visit the HSDB record page.']","[""A metabolism study of orally administered 2,2',4,4',5,6'-hexabromodiphenyl ether (BDE-154; 11.3 umoles/kg) was conducted in conventional and bile duct-cannulated male Sprague-Dawley rats. In conventional rats, approximately 31% of the radiolabeled dose was retained at 72 hr, and lipophilic tissues were the preferred sites for disposition. Urinary excretion of BDE-154 was very low (1.0%), and parent compound was detected. Cumulative biliary excretion was 1.3%, and glutathione conjugates were suggested. Over 62% of the dose in conventional male rats was excreted in feces, and was composed of parent compound (7.3%), free metabolites (13.1%), and covalently bound residues (41.4%). Fecal metabolites characterized by gas chromatography/mass spectrometry included multiple isomers of monohydroxylated hexa-/penta-/tetrabromodiphenyl ethers, and di-hydroxylated hexa/pentabromodiphenyl ethers. The adipose tissue carbon-14 was extractable BDE-154, but 40% of liver carbon-14 was bound to macromolecules ..."", ""Zebrafish (Danio rerio) were fed a diet containing a mixture of 11 structurally diverse brominated flame retardants (BFRs) at nominal concentrations of either 1 or 100 nmol/g for up to 42 d, followed by an elimination period of 14 d. Uptake rates and elimination constants for five of the BFRs were calculated from measurements of their concentrations in the male fish during the exposure and elimination phases. Observed uptake efficiencies were highest for 2,4,4'-tribromodiphenyl ether (BDE 28) and 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) and were lowest for decabromodiphenyl ether (BDE 209). Estimated half-lives for TBECH and 2,4,6-tribromophenol were short (<2 d). Four BFR metabolites were identified in the fish: 2,2',3,4',5',6-hexabromodiphenyl ether (BDE 149), 2,2',4,4',5,6'-hexabromodiphenyl ether (BDE 154), 2,4,6-tribromoanisole, and 1,2,4,5-hexabromobenzene. These metabolites were still present in the zebrafish after the 14-d elimination period. No relationship between the BFR concentrations in the zebrafish and their log octanol-water partition coefficient (Kow) values was found. Generally, low tendencies to bioaccumulate were observed for perbrominated and hydroxylated compounds. The observed accumulation of BFR metabolites in fish, however, shows that low concentration of a BFR does not provide, in isolation, a sound indication that the BFR poses low risks."", 'In F344 rats, almost all of the radiolabel in feces appeared to be parent compound in the 24-hr period after administration of BDE-153 on 1, 3, or 10 consecutive days or an equimolar mixture of BDE-47, -99, and -153 on 1 or 3 consecutive days. The total radiolabel extracted from the liver after 1 or 3 days of BDE-153 treatment was 85 +/- 1% or 94 +/- 1%, respectively. Unrecovered radioactivity (about 5-10%) was considered to be metabolites bound to liver proteins, and recovered material was considered to be unmetabolized BDE-153 dissolved in liver lipids and not yet transported to other tissues. /BDE-153/', '/An/ examination of the radiolabel in the feces and urine from mice exposed to 1 mg/kg-day BDE-153 intravenously /was performed/. In mice, about two-thirds of the label in the feces and four-fifths of that in the urine were identified as metabolites. Metabolites were extracted, separated using chromatography, and identified by mass spectroscopy. Three isomers were identified as monohydroxylated metabolites that retained all six bromines. Two isomers were identified as monohydroxylated metabolites that had lost one bromine. A single monohydroxylated isomer that had lost two bromines was identified as well as a trace amount of a sulfur-containing metabolite ...']","['The half-life of pentabromodiphenyl ether (Bromkal 70) was investigated in the perirenal fat of groups of 3 male and 3 female Wistar rats (weight 160-180 g), following a single oral dose of 300 mg/kg body weight in peanut oil. The groups were killed on days 1, 2, 3, 4, and 7 and then weekly for 10 weeks. Perirenal fat was collected and analysed. Half-lives in male and female rats of 2 hexabromodiphenyl ethers (HxBDE(1) and HxBDE(2)) were: for female rats, 44.6 (37.4-51.9) days and 90.0 (78.7-103.6) days, and, for male rats, 55.1 (48.4-61.7) and 119.1 (102.8-136.1) days, respectively.']"
2760,37455,"Benzo[a]pyrene-7,8-oxide",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC6C5O6)C=C2,,,,,"['Benzo[a]pyrene-7,8-epoxide has known human metabolites that include (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(8-hydroxy-7,8-dihydrobenzo[a]pyren-7-yl)oxysulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid.']",
2761,37456,"Benzo[a]pyrene-9,10-oxide",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C6C(O6)C=C5)C=C2,,,,,['9-Hydroxybenzo[a]pyrene is a known human metabolite of Benzo[a]pyrene.'],
2762,37457,"7,8-Epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene",C1CC2=C(C=C3C=CC4=C5C3=C2C=CC5=CC=C4)C6C1O6,,,,,,
2763,37458,"(+-)-7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno(3,4-b)oxirene",C1CC2=C(C3C1O3)C4=C5C(=C2)C=CC6=C5C(=CC=C6)C=C4,,,,,,
2764,37459,Butaclamol,CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
2765,37460,Butaclamol hydrochloride,CC(C)(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O.Cl,,,"['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
2766,37461,(+)-Butaclamol,CC(C)(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
2767,37462,Prodolic acid,CCCC1(C2=C(CCO1)C3=CC=CC=C3N2)CC(=O)O,,,,,,
2768,37463,4-Methylhistamine,CC1=C(N=CN1)CCN,,,,,,
2769,37464,Penbutolol,CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O,"['Penbutolol is indicated in the treatment of mild to moderate arterial hypertension. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity.']","['Penbutolol is a -1, -2 (nonselective) adrenergic receptor antagonist. Experimental studies showed a dose-dependent increase in heart rate in reserpinized (norepinephrine-depleted) rats given penbutolol intravenously at doses of 0.25 to 1.0 mg/kg, suggesting that penbutolol has some intrinsic sympathomimetic activity. In human studies, however, heart rate decreases have been similar to those seen with propranolol.']","['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['>90%.', 'The metabolites are excreted principally in the urine.', 'Approximately 90% of the metabolites are excreted in the urine.']",['Metabolized in the liver by hydroxylation and glucuroconjugation forming a glucuronide metabolite and a semi-active 4-hydroxy metabolite.'],"['Plasma= approximately 5h Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.']"
2770,37465,"N-[1-[(2S,4S)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride",CC1C(C(CC(O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC=CC=C6)C)O)N)O.Cl,,,,,,
2771,37466,"N-[1-[(2S,4S)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide",CC1C(C(CC(O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC=CC=C6)C)O)N)O,,,,,,
2772,37467,"2,4-Dibromo-5-(2,3-dibromo-4-hydroxyphenyl)phenol",C1=CC(=C(C(=C1C2=CC(=C(C=C2Br)Br)O)Br)Br)O,,,,,,
2773,37468,"9-Methyl-3-(4-methylpiperidino)methyl-2,3-dihydro-4(1H)-carbazolone",CC1CCN(CC1)CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,,,,,,
2774,37469,CID 37469,C1=CC=C(C(=C1)O)SCC(=O)[O-].O.O.[Na+].[SbH3],,,,,,
2775,37470,[(2-Hydroxyphenyl)sulfanyl]acetic acid,C1=CC=C(C(=C1)O)SCC(=O)O,,,,,,
2776,37471,2-(4-(p-Fluorophenyl)-1-piperazinyl)bicyclo(3.3.1)nonan-9-one hydrochloride,C1CC2CCC(C(C1)C2=O)[NH+]3CCN(CC3)C4=CC=C(C=C4)F.[Cl-],,,,,,
2777,37472,2-[4-(4-Fluorophenyl)piperazin-1-yl]bicyclo[3.3.1]nonan-9-one,C1CC2CCC(C(C1)C2=O)N3CCN(CC3)C4=CC=C(C=C4)F,,,,,,
2778,37473,2-(4-Hydroxy-4-phenyl-1-piperidinyl)bicyclo(3.3.1)nonan-9-one,C1CC2CCC(C(C1)C2=O)N3CCC(CC3)(C4=CC=CC=C4)O,,,,,,
2779,37474,9-Phenyl-2-(1-pyrrolidinyl)bicyclo(3.3.1)nonan-9-ol,C1CCN(C1)C2CCC3CCCC2C3(C4=CC=CC=C4)O,,,,,,
2780,37475,"3-[2-(1-Methyl-1,4,5,6-tetrahydropyrimidin-2-yl)ethenyl]phenol",CN1CCCN=C1C=CC2=CC(=CC=C2)O,,,,,,
2781,37476,"1,5,7-Trimethylindan",CC1CCC2=CC(=CC(=C12)C)C,,,,,,
2782,37477,Methylacenaphthene,CC1CC2=CC=CC3=C2C1=CC=C3,,,,,,
2783,37478,"Dibenzo(b,e)thiepin-11-ol, 6,11-dihydro-8-methoxy-11-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, hydrochloride",COC1=CC2=C(C=C1)C(C3=CC=CC=C3SC2)(C4=CC=C(C=C4)OCC[NH+]5CCCC5)O.[Cl-],,,,,,
2784,37479,8-methoxy-11-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-6H-benzo[c][1]benzothiepin-11-ol,COC1=CC2=C(C=C1)C(C3=CC=CC=C3SC2)(C4=CC=C(C=C4)OCCN5CCCC5)O,,,,,,
2785,37480,"Lutetium(III) nitrate, hexahydrate (1:3:6)",[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].O.O.O.O.O.O.[Lu+3],,,,,,
2786,37481,CID 37481,CCC(C)OC(=S)[S-].[Na+],,,,,,
2787,37482,"6a,7,8,10a-Tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6H-dibenzo(b,d)pyran-9-methanol",CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)CO)O,,,,,,
2788,37483,1-Bromo-2-phenoxybenzene,C1=CC=C(C=C1)OC2=CC=CC=C2Br,,,,,,
2789,37484,"2,3-Dimethyl-4-phenylazoaniline",CC1=C(C=CC(=C1C)N=NC2=CC=CC=C2)N,,,,,,
2790,37485,CID 37485,CCNC1=NC(=O)N=C(N1)NC(C)(C)C(=O)O,,,,,,
2791,37486,"BENZOIC ACID, p-CHLORO-, 2-(p-CHLOROPHENYL)HYDRAZIDE",C1=CC(=CC=C1C(=O)NNC2=CC=C(C=C2)Cl)Cl,,,,,,
2792,37487,4-chloro-N-phenylbenzenecarbohydrazonoyl chloride,C1=CC=C(C=C1)NN=C(C2=CC=C(C=C2)Cl)Cl,,,,,,
2793,37488,Tetrachloroethyl butyrate,CCCC(=O)OC(C(Cl)(Cl)Cl)Cl,,,,,,
2794,37489,propan-2-yl N-(4-methylphenyl)carbamate,CC1=CC=C(C=C1)NC(=O)OC(C)C,,,,,,
2795,37490,Isothioate,CC(C)SCCSP(=S)(OC)OC,,,,,,
2796,37491,"MANDELIC ACID, alpha-CYCLOHEXYL-, 1-METHYL-3-PIPERIDYL ESTER, HYDROCHLORIDE",C[NH+]1CCCC(C1)OC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
2797,37492,1-Methyl-3-piperidyl-alpha-(2-thienyl)mandelate hydrochloride,C[NH+]1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O.[Cl-],,,,,,
2798,37493,1-Methyl-3-piperidyl-alpha-(2-thienyl)mandelate,CN1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O,,,,,,
2799,37494,Fenclorac,C1CCC(CC1)C2=C(C=C(C=C2)C(C(=O)O)Cl)Cl,,,,,,
2800,37495,(2-Bromocyclopropyl)benzene,C1C(C1Br)C2=CC=CC=C2,,,,,,
2801,37496,"N'-(3,5-Dimethylphenyl)-N,N-dimethylurea",CC1=CC(=CC(=C1)NC(=O)N(C)C)C,,,,,,
2802,37497,Etidocaine,CCCN(CC)C(CC)C(=O)NC1=C(C=CC=C1C)C,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
2803,37498,Duranest,CCC[NH+](CC)C(CC)C(=O)NC1=C(C=CC=C1C)C.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
2804,37499,Tributylstannylium,CCCC[Sn+](CCCC)CCCC,,,,,,
2805,37500,Cotarnine hydrochloride,C[NH+]1CCC2=CC3=C(C(=C2C1O)OC)OCO3.[Cl-],,,,,,
2806,37501,CID 37501,C[C@H]1CC=C[C@H]2[C@@H](C(=C)[C@H]([C@@H]3C2(C(=O)CC([C@@](C1=O)(C)O)OC)C(=O)N[C@H]3CC4=CC=CC=C4)C)O,,,,,,
2807,37502,"3-Bromo-1,1-dichloropropane",C(CBr)C(Cl)Cl,,,,,,
2808,37503,"Bis(2,2'-iminodiethanol)sulfatocobalt",C(CO)NCCO.C(CO)NCCO.[O-]S(=O)(=O)[O-].[Co+2],,,,,,
2809,37504,"alpha-(((1,1-Dimethylethyl)amino)methyl)-3-hydroxybenzyl alcohol hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
2810,37505,3-[2-(Tert-butylamino)-1-hydroxyethyl]phenol,CC(C)(C)NCC(C1=CC(=CC=C1)O)O,,,,,,
2811,37506,CID 37506,C(C(=C(C(Br)Br)Br)Br)(Br)Br,,,,,,
2812,37507,Ethyl 4-[4-(4-ethoxy-4-oxobut-2-enoyl)-3-methylpiperazin-1-yl]-4-oxobut-2-enoate,CCOC(=O)C=CC(=O)N1CCN(C(C1)C)C(=O)C=CC(=O)OCC,,,,,,
2813,37508,3-Methoxy-3-methyl-2-butanone,CC(=O)C(C)(C)OC,,,,,,
2814,37509,3-Ethoxy-3-methyl-2-butanone,CCOC(C)(C)C(=O)C,,,,,,
2815,37510,CID 37510,CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
2816,37511,Dimepranol,CC(CN(C)C)O,,,,,,
2817,37512,"3,5-Diamino-1,2-dithiolium chloride",C1=C(SSC1=[NH2+])N.[Cl-],,,,,,
2818,37513,5-Iminodithiol-3-amine,C1=C(SSC1=N)N,,,,,,
2819,37514,trans-2-Methyl-3-Butyltetrahydrofuran,CCCC[C@@H]1CCO[C@H]1C,,,,,,
2820,37515,"2,4,4'-Trinitrobiphenyl",C1=CC(=CC=C1C2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2821,37516,"1,1'-Biphenyl, 2,2',4-trinitro-",C1=CC=C(C(=C1)C2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2822,37517,Iprodione,CC(C)NC(=O)N1CC(=O)N(C1=O)C2=CC(=CC(=C2)Cl)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']",,"['Rapidly metabolized in plants to 3,5-dichloroaniline, following root uptake.']",
2823,37518,Flumizole,COC1=CC=C(C=C1)C2=C(N=C(N2)C(F)(F)F)C3=CC=C(C=C3)OC,,,,,,
2824,37519,Trimethyl-[4-(trimethylazaniumyl)pent-2-enyl]azanium;dibromide,CC(C=CC[N+](C)(C)C)[N+](C)(C)C.[Br-].[Br-],,,,,,
2825,37520,Trimethyl-[4-(trimethylazaniumyl)pent-2-enyl]azanium,CC(C=CC[N+](C)(C)C)[N+](C)(C)C,,,,,,
2826,37521,3-Ethoxypentane,CCC(CC)OCC,,,,,,
2827,37522,"Carbonothioic acid, O-(1,1-dimethylethyl) S-(2-furanylmethyl) ester",CC(C)(C)OC(=O)SCC1=CC=CO1,,,,,,
2828,37523,Tiocarbazil,CCC(C)N(C(C)CC)C(=O)SCC1=CC=CC=C1,,,,,,
2829,37524,"4-Amino-2,2,6,6-tetramethylpiperidine",CC1(CC(CC(N1)(C)C)N)C,,,,,,
2830,37525,"4,6-Dihydroxy-2-methyl-1,2,3,4-tetrahydro-1-isoquinolinecarboxylic acid",CCCOC(=O)C1C2=C(C=C(C=C2)O)C(CN1C)O,,,,,,
2831,37526,"4,6-Dihydroxy-2-methyl-1,2,3,4-tetrahydro-1-isoquinolinecarboxylic acid butyl ester",CCCCOC(=O)C1C2=C(C=C(C=C2)O)C(CN1C)O,,,,,,
2832,37527,"4,6-Dihydroxy-2-methyl-1,2,3,4-tetrahydro-1-isoquinolinecarboxylic acid isobutyl ester",CC(C)COC(=O)C1C2=C(C=C(C=C2)O)C(CN1C)O,,,,,,
2833,37528,cis-4'-Fluoro-4-(4-(p-fluorophenyl)cyclohexylamino)butyrophenone hydrochloride,C1CC(CCC1C2=CC=C(C=C2)F)[NH2+]CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
2834,37529,1-(4-Fluorophenyl)-4-[[4-(4-fluorophenyl)cyclohexyl]amino]butan-1-one,C1CC(CCC1C2=CC=C(C=C2)F)NCCCC(=O)C3=CC=C(C=C3)F,,,,,,
2835,37530,"Butyrophenone, 4'-fluoro-4-(N-(4-(p-fluorophenyl)cyclohexyl)-N-methylamino)-, hydrochloride, (E)-",C[NH+](CCCC(=O)C1=CC=C(C=C1)F)C2CCC(CC2)C3=CC=C(C=C3)F.[Cl-],,,,,,
2836,37531,1-(4-Fluorophenyl)-4-[[4-(4-fluorophenyl)cyclohexyl]-methylamino]butan-1-one,CN(CCCC(=O)C1=CC=C(C=C1)F)C2CCC(CC2)C3=CC=C(C=C3)F,,,,,,
2837,37532,2-(2-Hydroxyphenyl)-5-benzothiazoleacetic acid,C1=CC=C(C(=C1)C2=NC3=C(S2)C=CC(=C3)CC(=O)O)O,,,,,,
2838,37533,"5-Benzothiazoleacetic acid, 2-(4-dimethylaminophenyl)-",CN(C)C1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)CC(=O)O,,,,,,
2839,37534,2-Phenyl-5-benzothiazoleacetic acid,C1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)CC(=O)O,,,,,,
2840,37535,"6-Benzothiazoleacetic acid, 2-phenyl-",C1=CC=C(C=C1)C2=NC3=C(S2)C=C(C=C3)CC(=O)O,,,,,,
2841,37536,2-(2-Hydroxy-m-tolyl)-6-benzothiazoleacetic acid,CC1=C(C(=CC=C1)C2=NC3=C(S2)C=C(C=C3)CC(=O)O)O,,,,,,
2842,37537,"5-BENZOTHIAZOLEACETIC ACID, 2-(p-CUMENYL)-",CC(C)C1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)CC(=O)O,,,,,,
2843,37538,"5-Benzothiazoleacetic acid, 2-(4-chlorophenyl)-",C1=CC(=CC=C1C2=NC3=C(S2)C=CC(=C3)CC(=O)O)Cl,,,,,,
2844,37539,"2-(3,4-Dimethoxyphenyl)-6-benzothiazoleacetic acid",COC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)CC(=O)O)OC,,,,,,
2845,37540,"6-BENZOTHIAZOLEACETIC ACID, 2-(p-CUMENYL)-",CC(C)C1=CC=C(C=C1)C2=NC3=C(S2)C=C(C=C3)CC(=O)O,,,,,,
2846,37541,Floctafenic acid,C1=CC=C(C(=C1)C(=O)O)NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F,,,,,,
2847,37542,Ribavirin,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,['Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates.  The addition of ribavirin in Technivie therapy indicated for treating HCV genotype 1a and 4 infections is recommended in patients with or without cirrhosis.   Resistance: viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined.'],"['Ribavirin mediates direct antiviral activity against a number of DNA and RNA viruses by increasing the mutation frequency in the genomes of several RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to its resemblence to building blocks of the RNA molecules.']","['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']","['Ribavirin is reported to be rapidly and extensively absorbed following oral administration. The average time to reach Cmax was 2 hours after oral administration of 1200 mg ribavirin. The oral bioavailability is 64% following a single oral dose administration of 600mg ribavirin.', 'The metabolites of ribavirin are renally excreted. After the oral administration of 600mg radiolabeled ribavirin, approximately 61% of the drug was detected in the urine and 12% was detected in the feces. 17% of administered dose was in unchanged form.', 'Ribavirin displays a large volume of distribution.', 'The total apparent clearance rate after a single oral dose administration of 1200 mg ribavirin is 26L/h.', 'Ribavirin is absorbed systemically from the respiratory tract following nasal and oral inhalation. The bioavailability of ribavirin administered via nasal and oral inhalation has not been determined but may depend on the method of drug delivery during nebulization (eg, oxygen hood, face mask, oxygen tent). At a constant flow rate, the amount of drug delivered to the respiratory tract theoretically is directly related to the concentration of nebulized drug solution and the duration of inhalation therapy. In addition, alterations in the method of aerosol delivery can affect the amount of drug reaching the respiratory tract. The fraction of an inhaled dose of ribavirin that is deposited in the respiratory tract during oral and nasal inhalation of a nebulized solution containing 190 ug/L using a small particle aerosol generator has been estimated to average about 70%, but the actual amount deposited depends on several factors including respiratory rate and tidal volume.', 'Peak plasma ribavirin concentrations generally appear to occur at the end of the inhalation period when the drug is inhaled orally and nasally using a small particle aerosol generator, and increase with increasing duration of the inhalation period. Following nasal and oral inhalation (via face mask) of 0.82 mg/kg/hr for 2.5 hr daily for 3 days in a limited number of pediatric patients, peak plasma ribavirin concentrations averaged 0.19 (range: 0.11-0.388) ug/mL. Peak plasma ribavirin concentrations averaged 0.275 (range: 0.21-0.35) or 1.1 (range: 0.45-2.18) ug/mL in a limited number of patients inhaling 0.82 mg/kg per hour for 5 or 8 hr daily, respectively, for 3 days, and averaged 1.7 (range: 0.38-3.58) ug/mL in a limited number of pediatric patients inhaling 0.82 mg/kg per hour via face mask, mist tent, or respirator for 20 hr daily for 5 days. Highest plasma concentrations for a given dosage of ribavirin appear to be achieved in patients receiving the drug from the aerosol generator via an endotracheal tube. ... Peak plasma ribavirin concentrations achieved with nasal and oral inhalation of usual dosages of the drug are less than concentrations that reportedly reduce respiratory syncytial virus plaque formation by 85-98%.', 'Concentrations of ribavirin achieved in respiratory tract secretions in patients inhaling the drug nasally and orally are likely to be substantially greater than those achieved in plasma. In a limited number of pediatric patients who received a nasally and orally inhaled ribavirin dose of 0.82 mg/kg per hour for 8 hr daily for 3 days, peak concentrations of the drug in respiratory tract secretions (from endotracheal tube) ranged from 250-1925 ug/mL. In pediatric patients who received 0.82 mg/kg per hour via nasal and oral inhalation for 20 hr daily for 5 days, ribavirin concentrations in respiratory tract secretions (from endotracheal tube) ranged from 313-28,250 ug/mL during therapy, with peak concentrations averaging 3075 (range: 313-7050) ug/mL at the end of therapy. Concentrations of ribavirin achieved in respiratory tract secretions via nasal and oral inhalation are likely to be substantially greater than concentrations necessary to inhibit plaque formation of susceptible strains of respiratory syncytial virus in vitro; however, because respiratory syncytial virus is found within virus infected cells in the respiratory tract, the manufacturer states that intracellular respiratory tract drug concentrations may be more closely related to plasma ribavirin concentrations than to those measured in respiratory tract secretions.', 'Ribavirin is rapidly absorbed following oral administration, with peak plasma concentrations of the drug occurring within 1-3 hr after multiple doses. However, the absolute bioavailability of ribavirin averages only 64% following oral administration because the drug undergoes first-pass metabolism.', 'For more Absorption, Distribution and Excretion (Complete) data for RIBAVIRIN (10 total), please visit the HSDB record page.']","['First and as a step required for activation, ribavirin is phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. After activation and function, ribavirin undergoes two metabolic pathways where it is reversibly phosphorlyated or degraded via deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite. In vitro studies indicate that ribavirin is not a substrate of CYP450 enzymes.', ""Ribavirin is metabolized principally to deribosylated ribavirin (the 1,2,4-triazole-3-carboxamide), probably in the liver; the antiviral activity of 1,2,4-triazole-3-carboxamide against various RNA and DNA viruses is reportedly similar to ribavirin. The drug is also metabolized to 1,2,4-triazole-3-carboxylic acid. In vitro, ribavirin has been shown to be metabolized to ribavirin-5'-monophosphate, -diphosphate, and -triphosphate, principally by intracellular phosphorylation of the drug via adenosine kinase and other cellular enzymes. It is likely that phosphorylation in vivo is necessary for the antiviral activity of the drug. Ribavirin also undergoes phosphorylation in erythrocytes, principally to ribavirin-5'-triphosphate; approximately 81, 16, and 3% of drug metabolized in erythrocytes is present as ribavirin-5'-triphosphate, -diphosphate, and -monophosphate, respectively. It has been suggested that prolonged distribution of the drug in erythrocytes may result from minimal phosphatase activity in these cells with transit of the drug out of cells dependent on dephosphorylation via phosphatases."", 'Ribavirin has two pathways of metabolism: (i) a reversible phosphorylation pathway in nucleated cells; and (ii) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite. Ribavirin and its triazole carboxamide and triazole carboxylic acid metabolites are excreted renally.']","['The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours.', 'Distribution: Intravenous: Approximately 0.2 hours. Elimination: inhalation: 9.5 hours. Intravenous and oral (single dose): 0.5 to 2 hours. In erythrocytes: 40 days. Terminal: Intravenous and oral: Single dose: 27 to 36 hours. Single oral dose tablet: 120 to 170 hours. Steady state: Approximately 151 hours. Mean :multiple oral dosing, capsule: 298 hours.', 'Based on limited data, the half-life of ribavirin in respiratory tract secretions following nasal and oral inhalation for 3 days reportedly is approximately 1.4-2.5 hr.', 'Following nasal and oral inhalation in a limited number of pediatric patients, the plasma half-life of ribavirin averaged about 9.5 (range: 6.5-11) hr. Following oral administration of a single dose of the drug in a limited number of healthy adults, plasma ribavirin concentrations declined in a multiphasic manner, with half-lives averaging 24 hr 10-80 hr after the dose and 48 hr or longer in the terminal phase.']"
2848,37543,"BENZO(b)NAPHTHO(2,3-d)THIOPHENE, 4-METHYL-",CC1=C2C(=CC=C1)C3=CC4=CC=CC=C4C=C3S2,,,,,,
2849,37544,"BENZOIC ACID, p-((1-BENZIMIDAZOLYLMETHYL)AMINO)-, HYDRAZIDE",C1=CC=C2C(=C1)N=CN2CNC3=CC=C(C=C3)C(=O)NN,,,,,,
2850,37545,3-Methoxypentane,CCC(CC)OC,,,,,,
2851,37546,"BENZOIC ACID, p-((2-METHYLBENZIMIDAZOL-1-YLMETHYL)AMINO)-, HYDRAZIDE",CC1=NC2=CC=CC=C2N1CNC3=CC=C(C=C3)C(=O)NN,,,,,,
2852,37547,"BENZOIC ACID, p-((2-ETHYLBENZIMIDAZOL-1-YLMETHYL)AMINO)-, HYDRAZIDE",CCC1=NC2=CC=CC=C2N1CNC3=CC=C(C=C3)C(=O)NN,,,,,,
2853,37548,"BENZOIC ACID, p-((2-PROPYLBENZIMIDAZOL-1-YLMETHYL)AMINO)-, HYDRAZIDE",CCCC1=NC2=CC=CC=C2N1CNC3=CC=C(C=C3)C(=O)NN,,,,,,
2854,37549,2-(p-Amino-N-methylbenzamido)-3-picoline,CC1=C(N=CC=C1)N(C)C(=O)C2=CC=C(C=C2)N,,,,,,
2855,37550,2-amino-N-(3-methylpyridin-2-yl)benzamide,CC1=C(N=CC=C1)NC(=O)C2=CC=CC=C2N,,,,,,
2856,37551,"BENZAMIDE, p-CHLORO-N-(3-METHYL-2-PYRIDYL)-",CC1=C(N=CC=C1)NC(=O)C2=CC=C(C=C2)Cl,,,,,,
2857,37552,"BENZAMIDE, p-AMINO-N-(4-METHYL-2-PYRIDYL)-",CC1=CC(=NC=C1)NC(=O)C2=CC=C(C=C2)N,,,,,,
2858,37553,"BENZAMIDE, p-AMINO-N-(6-METHYL-2-PYRIDYL)-",CC1=NC(=CC=C1)NC(=O)C2=CC=C(C=C2)N,,,,,,
2859,37554,"NICOTINIC ACID, 2-(p-NITROBENZAMIDO)-",C1=CC(=C(N=C1)NC(=O)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)O,,,,,,
2860,37555,O-tert-Butyl S-(1-(methylthio)ethyl) carbonothioate,CC(SC)SC(=O)OC(C)(C)C,,,,,,
2861,37556,"BENZAMIDE, p-AMINO-N-(3-METHYL-4-PYRIDYL)-",CC1=C(C=CN=C1)NC(=O)C2=CC=C(C=C2)N,,,,,,
2862,37557,"Benzamide, 4-amino-N-(2-imidazolyl)-",C1=CC(=CC=C1C(=O)NC2=NC=CN2)N,,,,,,
2863,37558,4-Amino-N-(1H-tetrazol-5-yl)benzamide,C1=CC(=CC=C1C(=O)NC2=NNN=N2)N,,,,,,
2864,37559,CID 37559,CC1=[N+](N=CS1)NC(=O)C2=CC=C(C=C2)N,,,,,,
2865,37560,"Benzamide, 4-amino-N-(benzothiazol-2-YL)-",C1=CC=C2C(=C1)N=C(S2)NC(=O)C3=CC=C(C=C3)N,,,,,,
2866,37561,CID 37561,CCSC1CC(=O)C23[C@@H](C=CC[C@@H](C(=O)[C@]1(C)O)C)[C@@H](C(=C)[C@H]([C@H]2[C@@H](NC3=O)CC4=CC=CC=C4)C)OC(=O)C,,,,,,
2867,37562,CID 37562,CCSC1CC(=O)C23[C@@H](C=CC[C@@H](C(=O)[C@]1(C)O)C)[C@@H](C(=C)[C@H]([C@H]2[C@@H](NC3=O)CC4=CC=CC=C4)C)O,,,,,,
2868,37563,4-Methylbenzylidenecamphor,CC1=CC=C(C=C1)C=C2C3CCC(C2=O)(C3(C)C)C,,,,,,
2869,37564,Ethyl 2-[(3-chlorophenyl)hydrazinylidene]-2-cyanoacetate,CCOC(=O)C(=NNC1=CC(=CC=C1)Cl)C#N,,,,,,
2870,37565,Methyl 2-[(3-chlorophenyl)hydrazinylidene]-2-cyanoacetate,COC(=O)C(=NNC1=CC(=CC=C1)Cl)C#N,,,,,,
2871,37566,"Acetic acid, phenyl-, 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)CC1=CC=CC=C1,,,,,,
2872,37567,3-Butyl-7-methyl-9-phenyl-6-(1-pyrrolidinyl)-3-azabicyclo(3.3.1)nonan-9-ol,CCCCN1CC2CC(C(C(C1)C2(C3=CC=CC=C3)O)N4CCCC4)C,,,,,,
2873,37568,"N,N'-Bis(1-methylpropylidene)-1,6-hexanediamine",CCC(=NCCCCCCN=C(C)CC)C,,,,,,
2874,37569,"2-(Aminomethyl)-6-[4,6-diamino-3-[3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol",CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(C(C(C(O3)CN)O)O)O)N)N)O,,,,,,
2875,37570,"N,N'-Dithiodiethylenebis(4-(p-methoxyphenyl)butylamine) dihydrochloride",COC1=CC=C(C=C1)CCCC[NH2+]CCSSCC[NH2+]CCCCC2=CC=C(C=C2)OC.[Cl-].[Cl-],,,,,,
2876,37571,4-(4-methoxyphenyl)-N-[2-[2-[4-(4-methoxyphenyl)butylamino]ethyldisulfanyl]ethyl]butan-1-amine,COC1=CC=C(C=C1)CCCCNCCSSCCNCCCCC2=CC=C(C=C2)OC,,,,,,
2877,37572,"DISULFIDE, BIS(2-((4-(o-ISOPROPYLPHENOXY)BUTYL)AMINO)ETHYL)-, DIHYDROCHLORIDE",CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1OCCCC[NH2+]CCSSCC[NH2+]CCCCOC.[Cl-].[Cl-],,,,,,
2878,37573,4-methoxy-N-[2-[2-[4-(2-propan-2-ylphenoxy)butylamino]ethyldisulfanyl]ethyl]butan-1-amine,CC(C)C1=CC=CC=C1OCCCCNCCSSCCNCCCCOC,,,,,,
2879,37574,1-(2-(Acetyloxy)ethyl)-1-methylaziridinium chloride,CC(=O)OCC[N+]1(CC1)C.[Cl-],,,,,,
2880,37575,Acetylcholine mustard aziridinium,CC(=O)OCC[N+]1(CC1)C,,,,,,
2881,37576,Dodecylbis(aminoethyl)glycine hydrochloride,CCCCCCCCCCCC[NH2+]CCNCCNCC(=O)O.[Cl-],,,,,,
2882,37577,CID 37577,CN(C)C=NCC1CCC(CC1)CC2CCCCC2,,,,,,
2883,37578,"Benzimidazole, 2-(2-(diethylamino)ethylthio)-1-methyl-5-nitro-",CCN(CC)CCSC1=NC2=C(N1C)C=CC(=C2)[N+](=O)[O-],,,,,,
2884,37579,"Benzimidazole, 1-methyl-2-(2-(4-methyl-1-piperazinyl)ethylthio)-5-nitro-",CN1CCN(CC1)CCSC2=NC3=C(N2C)C=CC(=C3)[N+](=O)[O-],,,,,,
2885,37580,"4-Ethyl-2,6-dimethylpyridine",CCC1=CC(=NC(=C1)C)C,,,,,,
2886,37581,CID 37581,CN1CC(=O)N=C1[NH3+].C1=C2C(=CC(=C1O)O)NC=C2CC[NH3+].[O-]S(=O)(=O)[O-],,,,,,
2887,37582,"Malononitrile, (3-trifluoromethylbenzylidene)-",C1=CC(=CC(=C1)C(F)(F)F)C=C(C#N)C#N,,,,,,
2888,37583,"MALONONITRILE, (p-CYANOBENZYLIDENE)-",C1=CC(=CC=C1C=C(C#N)C#N)C#N,,,,,,
2889,37584,"Malononitrile, (2,3-dimethoxybenzylidene)-",COC1=CC=CC(=C1OC)C=C(C#N)C#N,,,,,,
2890,37585,"Malononitrile, (2-hydroxy-3-methoxybenzylidene)-",COC1=CC=CC(=C1O)C=C(C#N)C#N,,,,,,
2891,37586,Lergo; Lergotril,CN1CC(CC2C1CC3=C(NC4=CC=CC2=C34)Cl)CC#N,,,,,,
2892,37587,2-Cyclohexyl-1H-benzimidazole,C1CCC(CC1)C2=NC3=CC=CC=C3N2,,,,,,
2893,37588,"7-[(2R)-3,5-dihydroxy-2-(3-hydroxydec-1-enyl)cyclopentyl]hept-5-enoic acid",CCCCCCCC(C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
2894,37589,Cicloprofen,CC(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)O,,,,,,
2895,37590,1-Hydroxy-3-methyl-2-butanone,CC(C)C(=O)CO,,,,,,
2896,37591,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-5-phenyl-7-trifluoromethoxy-, bisulfate",CN1C(=O)C[NH+]=C(C2=C1C=CC(=C2)OC(F)(F)F)C3=CC=CC=C3.OS(=O)(=O)[O-],,,,,,
2897,37592,"1-methyl-5-phenyl-7-(trifluoromethoxy)-3H-1,4-benzodiazepin-4-ium-2-one",CN1C(=O)C[NH+]=C(C2=C1C=CC(=C2)OC(F)(F)F)C3=CC=CC=C3,,,,,,
2898,37593,CID 37593,CS(=O)(=O)[O-].C1C(=NC2=C(C=C(C=C2)[N+](=O)[O-])N(C1=O)C3=CC=CC=C3)[NH3+],,,,,,
2899,37594,H92Gfg85YE,C1C(=NC2=C(C=C(C=C2)[N+](=O)[O-])N(C1=O)C3=CC=CC=C3)N,,,,,,
2900,37595,"4-[14-hydroxy-10,13-dimethyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=CCOC5=O)O)C)OC6C(C(C(C(O6)CO)O)O)O,,,,,,
2901,37596,"2H-(1,5)-Benzodiazepin-2-one, 1,3-dihydro-4-amino-8-chloro-1-phenyl-",C1C(=NC2=C(C=C(C=C2)Cl)N(C1=O)C3=CC=CC=C3)N,,,,,,
2902,37597,"2H-1,5-Benzodiazepin-2-one, 1,3-dihydro-4-amino-8-bromo-1-phenyl-",C1C(=NC2=C(C=C(C=C2)Br)N(C1=O)C3=CC=CC=C3)N,,,,,,
2903,37598,"2H-(1,5)-Benzodiazepin-2-one, 1,3-dihydro-4-amino-1-phenyl-8-(trifluoromethyl)-",C1C(=NC2=C(C=C(C=C2)C(F)(F)F)N(C1=O)C3=CC=CC=C3)N,,,,,,
2904,37599,"2H-(1,5)-Benzodiazepin-2-one, 1,3-dihydro-4-(dimethylamino)-1-phenyl-8-(trifluoromethyl)-",CN(C)C1=NC2=C(C=C(C=C2)C(F)(F)F)N(C(=O)C1)C3=CC=CC=C3,,,,,,
2905,37600,CID 37600,CCC1(C(=NC(=NC1=O)S)[O-])C(C)C.[Na+],,,,,,
2906,37601,CID 37601,CCC1(C(=O)NC(=NC1=O)S)C(C)C,,,,,,
2907,37602,"2-Cyclopropylmethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1CC1C[NH+]2CCC3=CC=CC=C3C2.[Cl-],,,,,,
2908,37603,"2-(cyclopropylmethyl)-3,4-dihydro-1H-isoquinoline",C1CC1CN2CCC3=CC=CC=C3C2,,,,,,
2909,37604,"2-Cyclobutylmethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1CC(C1)C[NH+]2CCC3=CC=CC=C3C2.[Cl-],,,,,,
2910,37605,"2-(cyclobutylmethyl)-3,4-dihydro-1H-isoquinoline",C1CC(C1)CN2CCC3=CC=CC=C3C2,,,,,,
2911,37606,"2,3,4,5-Tetrahydro-N,N-dimethyl-5-phenyl-1-benzothiepin-5-propanamine sulfate",C[NH+](C)CCCC1(CCCSC2=CC=CC=C21)C3=CC=CC=C3.OS(=O)(=O)[O-],,,,,,
2912,37607,"N,N-dimethyl-3-(5-phenyl-3,4-dihydro-2H-1-benzothiepin-5-yl)propan-1-amine",CN(C)CCCC1(CCCSC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
2913,37608,"Carbanilic acid, 2,6-dimethyl-, 1-butyl-3-piperidyl ester, (R)-(+)-",CCCCN1CCC[C@H](C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
2914,37609,10-Chlorodecanoic acid,C(CCCCC(=O)O)CCCCCl,,,,,,
2915,37610,Ethyl 5-ethyl-1H-indole-2-carboxylate,CCC1=CC2=C(C=C1)NC(=C2)C(=O)OCC,,,,,,
2916,37611,9-(p-(Methylamino)anilino)acridine hydrobromide,C[NH2+]C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42.[Br-],,,,,,
2917,37612,"ACRIDINE, 9-(p-(METHYLAMINO)ANILINO)-",CNC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
2918,37613,"Malononitrile, (5-chloro-2-nitrobenzylidene)-",C1=CC(=C(C=C1Cl)C=C(C#N)C#N)[N+](=O)[O-],,,,,,
2919,37614,Miloxacin,CON1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O,,,,,,
2920,37615,Ethyl 3-(((phenylamino)carbonyl)oxy)benzoate,CCOC(=O)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,,,,,,
2921,37616,4-(((Phenylamino)carbonyl)oxy)benzonitrile,C1=CC=C(C=C1)NC(=O)OC2=CC=C(C=C2)C#N,,,,,,
2922,37617,4-Acetylphenyl phenylcarbamate,CC(=O)C1=CC=C(C=C1)OC(=O)NC2=CC=CC=C2,,,,,,
2923,37618,3-(((Phenylamino)carbonyl)oxy)benzaldehyde,C1=CC=C(C=C1)NC(=O)OC2=CC=CC(=C2)C=O,,,,,,
2924,37619,Nonyltrimethylammonium iodide,CCCCCCCCC[N+](C)(C)C.[I-],,,,,,
2925,37620,Nonyltrimethylammonium,CCCCCCCCC[N+](C)(C)C,,,,,,
2926,37621,4-(((Phenylamino)carbonyl)oxy)benzaldehyde,C1=CC=C(C=C1)NC(=O)OC2=CC=C(C=C2)C=O,,,,,,
2927,37622,"2,3,3-Trichloropropene",C=C(C(Cl)Cl)Cl,,,,,,
2928,37623,CID 37623,CC1([C@H](N2[C@@H](S1)[C@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)[O-])C.[Na+],,,,,,
2929,37624,"(2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@H](N2[C@@H](S1)[C@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,,,,,,
2930,37625,C20H23N5O6S,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,,,,,,
2931,37626,"alpha-((Dibutylamino)methyl)naphtho(2,1-b)thiophene-4-methanol hydrochloride",CCCC[NH+](CCCC)CC(C1=CC2=CC=CC=C2C3=C1SC=C3)O.[Cl-],,,,,,
2932,37627,1-Benzo[e][1]benzothiol-4-yl-2-(dibutylamino)ethanol,CCCCN(CCCC)CC(C1=CC2=CC=CC=C2C3=C1SC=C3)O,,,,,,
2933,37628,"Naphtho(2,1-b)thiophene-4-methanol, 8-bromo-alpha-((dibutylamino)methyl)-, hydrochloride",CCCC[NH+](CCCC)CC(C1=C2C(=C3C=C(C=CC3=C1)Br)C=CS2)O.[Cl-],,,,,,
2934,37629,1-(8-Bromobenzo[e][1]benzothiol-4-yl)-2-(dibutylamino)ethanol,CCCCN(CCCC)CC(C1=C2C(=C3C=C(C=CC3=C1)Br)C=CS2)O,,,,,,
2935,37630,"6-Amino-5,6,7,8-tetrahydro-1,2-naphthalenediol hydrobromide",C1CC2=C(CC1[NH3+])C=CC(=C2O)O.[Br-],,,,,,
2936,37631,"2-Amino-5,6-dihydroxytetralin",C1CC2=C(CC1N)C=CC(=C2O)O,,,,,,
2937,37632,Adinazolam,CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,['For the treatment of anxiety and status epilepticus.'],"['Adinazolam is a benzodiazepine derivative used to treat anxiety, status epilepticus, and for sedation induction and anterograde amnesia. Adinazolam binds with high affinity to the GABA benzodiazepine receptor complex. Considerable evidence suggest that the central pharmacologic/therapeutic actions of alprazolam are mediated via interaction with this receptor complex.']","['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,"['The drug primarily undergoes hepatic metabolism to form the main metabolite N-desmethyladinazolam, alpha-hydroxyalprazolam, and estazolam.', 'Adinazolam has known human metabolites that include N-demethyladinazolam.']",['Less than 3 hours.']
2938,37633,CID 37633,CC1(CN(C2=CC=CC=C21)CC[NH+]3CCCCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
2939,37634,3-methyl-3-phenyl-1-(2-piperidin-1-ylethyl)-2H-indole,CC1(CN(C2=CC=CC=C21)CCN3CCCCC3)C4=CC=CC=C4,,,,,,
2940,37635,CID 37635,CC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCOCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
2941,37636,3-Methyl-1-(3-morpholin-4-ylpropyl)-3-phenylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCCN3CCOCC3)C4=CC=CC=C4,,,,,,
2942,37637,"1,3-Dihydro-1-(2-(dimethylamino)ethyl)-3-ethyl-3-phenyl-2H-indol-2-one hydrochloride hydrate",CCC1(C2=CC=CC=C2N(C1=O)CC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
2943,37638,1-[2-(Dimethylamino)ethyl]-3-ethyl-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=CC=C3,,,,,,
2944,37639,"1,3-Dihydro-1-(2-(diethylamino)ethyl)-3-ethyl-3-phenyl-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CC[NH+](CC)CC)C3=CC=CC=C3.[Cl-],,,,,,
2945,37640,1-[2-(Diethylamino)ethyl]-3-ethyl-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCN(CC)CC)C3=CC=CC=C3,,,,,,
2946,37641,"1,3-Dihydro-3-ethyl-3-phenyl-1-(2-(piperidino)ethyl)-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CC[NH+]3CCCCC3)C4=CC=CC=C4.[Cl-],,,,,,
2947,37642,3-Ethyl-3-phenyl-1-(2-piperidin-1-ylethyl)indol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCN3CCCCC3)C4=CC=CC=C4,,,,,,
2948,37643,"1,3-Dihydro-1-(3-(dimethylamino)propyl)-3-ethyl-3-phenyl-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CCC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
2949,37644,1-[3-(Dimethylamino)propyl]-3-ethyl-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCCN(C)C)C3=CC=CC=C3,,,,,,
2950,37645,"1,3-Dihydro-1-(3-(diethylamino)propyl)-3-ethyl-3-phenyl-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CCC[NH+](CC)CC)C3=CC=CC=C3.[Cl-],,,,,,
2951,37646,1-[3-(Diethylamino)propyl]-3-ethyl-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCCN(CC)CC)C3=CC=CC=C3,,,,,,
2952,37647,"1,3-Dihydro-3-ethyl-3-phenyl-1-(3-(piperidino)propyl)-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCCCC3)C4=CC=CC=C4.[Cl-],,,,,,
2953,37648,3-Ethyl-3-phenyl-1-(3-piperidin-1-ylpropyl)indol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCCN3CCCCC3)C4=CC=CC=C4,,,,,,
2954,37649,"1,3-Dihydro-3-ethyl-1-(3-(morpholino)propyl)-3-phenyl-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCOCC3)C4=CC=CC=C4.[Cl-],,,,,,
2955,37650,3-Ethyl-1-(3-morpholin-4-ylpropyl)-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCCN3CCOCC3)C4=CC=CC=C4,,,,,,
2956,37651,CID 37651,CC1(CN(C2=CC=CC=C21)CC[NH+](C)C)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
2957,37652,"N,N-dimethyl-2-(3-methyl-3-phenyl-2H-indol-1-yl)ethanamine",CC1(CN(C2=CC=CC=C21)CCN(C)C)C3=CC=CC=C3,,,,,,
2958,37653,"1H-Indole-1-ethylamine, 2,3-dihydro-N,N-diethyl-3-methyl-3-phenyl-, dihydrochloride",CC[NH+](CC)CC[NH+]1CC(C2=CC=CC=C21)(C)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
2959,37654,"N,N-diethyl-2-(3-methyl-3-phenyl-2H-indol-1-yl)ethanamine",CCN(CC)CCN1CC(C2=CC=CC=C21)(C)C3=CC=CC=C3,,,,,,
2960,37655,"2,3-Dihydro-3-methyl-1-(2-morpholinoethyl)-3-phenyl-1H-indole oxalate",CC1(CN(C2=CC=CC=C21)CC[NH+]3CCOCC3)C4=CC=CC=C4.C(=O)(C(=O)[O-])O,,,,,,
2961,37656,4-[2-(3-methyl-3-phenyl-2H-indol-1-yl)ethyl]morpholine,CC1(CN(C2=CC=CC=C21)CCN3CCOCC3)C4=CC=CC=C4,,,,,,
2962,37657,"2,3-Dihydro-3-phenyl-N,N,3-trimethyl-1H-indole-1-propylamine dihydrochloride hydrate",CC1(C[NH+](C2=CC=CC=C21)CCC[NH+](C)C)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
2963,37658,"N,N-dimethyl-3-(3-methyl-3-phenyl-2H-indol-1-yl)propan-1-amine",CC1(CN(C2=CC=CC=C21)CCCN(C)C)C3=CC=CC=C3,,,,,,
2964,37659,"1H-Indole-1-propylamine, 2,3-dihydro-N,N-diethyl-3-methyl-3-phenyl-, dihydrochloride",CC[NH+](CC)CCC[NH+]1CC(C2=CC=CC=C21)(C)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
2965,37660,"N,N-diethyl-3-(3-methyl-3-phenyl-2H-indol-1-yl)propan-1-amine",CCN(CC)CCCN1CC(C2=CC=CC=C21)(C)C3=CC=CC=C3,,,,,,
2966,37661,CID 37661,CC1(CN(C2=CC=CC=C21)CCC[NH+]3CCCCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
2967,37662,3-methyl-3-phenyl-1-(3-piperidin-1-ylpropyl)-2H-indole,CC1(CN(C2=CC=CC=C21)CCCN3CCCCC3)C4=CC=CC=C4,,,,,,
2968,37663,CID 37663,CCC1(CN(C2=CC=CC=C21)CC[NH+](C)C)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
2969,37664,"2-(3-ethyl-3-phenyl-2H-indol-1-yl)-N,N-dimethylethanamine",CCC1(CN(C2=CC=CC=C21)CCN(C)C)C3=CC=CC=C3,,,,,,
2970,37665,CID 37665,CCC1(CN(C2=CC=CC=C21)CC[NH+](CC)CC)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
2971,37666,"N,N-diethyl-2-(3-ethyl-3-phenyl-2H-indol-1-yl)ethanamine",CCC1(CN(C2=CC=CC=C21)CCN(CC)CC)C3=CC=CC=C3,,,,,,
2972,37667,"2,3-Dihydro-3-ethyl-3-phenyl-1-(2-piperidinoethyl)-1H-indole oxalate",CCC1(CN(C2=CC=CC=C21)CC[NH+]3CCCCC3)C4=CC=CC=C4.C(=O)(C(=O)[O-])O,,,,,,
2973,37668,3-ethyl-3-phenyl-1-(2-piperidin-1-ylethyl)-2H-indole,CCC1(CN(C2=CC=CC=C21)CCN3CCCCC3)C4=CC=CC=C4,,,,,,
2974,37669,"2,3-Dihydro-3-ethyl-1-(2-(morpholino)ethyl)-3-phenyl-1H-indole oxalate",CCC1(C(NC2=CC=CC=C21)CC[NH+]3CCOCC3)C4=CC=CC=C4.C(=O)(C(=O)[O-])O,,,,,,
2975,37670,"4-[2-(3-Ethyl-3-phenyl-1,2-dihydroindol-2-yl)ethyl]morpholine",CCC1(C(NC2=CC=CC=C21)CCN3CCOCC3)C4=CC=CC=C4,,,,,,
2976,37671,CID 37671,CCC1(CN(C2=CC=CC=C21)CCC[NH+](C)C)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
2977,37672,"3-(3-ethyl-3-phenyl-2H-indol-1-yl)-N,N-dimethylpropan-1-amine",CCC1(CN(C2=CC=CC=C21)CCCN(C)C)C3=CC=CC=C3,,,,,,
2978,37673,"2,3-Dihydro-3-phenyl-N,N,3-triethyl-1H-indole-1-propylamine dihydrochloride",CCC1(C[NH+](C2=CC=CC=C21)CCC[NH+](CC)CC)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
2979,37674,"N,N-diethyl-3-(3-ethyl-3-phenyl-2H-indol-1-yl)propan-1-amine",CCC1(CN(C2=CC=CC=C21)CCCN(CC)CC)C3=CC=CC=C3,,,,,,
2980,37675,"2,3-Dihydro-3-ethyl-3-phenyl-1-(3-piperidinopropyl)-1H-indole dihydrochloride",CCC1(C[NH+](C2=CC=CC=C21)CCC[NH+]3CCCCC3)C4=CC=CC=C4.[Cl-].[Cl-],,,,,,
2981,37676,3-ethyl-3-phenyl-1-(3-piperidin-1-ylpropyl)-2H-indole,CCC1(CN(C2=CC=CC=C21)CCCN3CCCCC3)C4=CC=CC=C4,,,,,,
2982,37677,"2,3-Dihydro-3-ethyl-1-(3-(morpholino)propyl)-3-phenyl-1H-indole oxalate",CCC1(C(NC2=CC=CC=C21)CCC[NH+]3CCOCC3)C4=CC=CC=C4.C(=O)(C(=O)[O-])O,,,,,,
2983,37678,"4-[3-(3-Ethyl-3-phenyl-1,2-dihydroindol-2-yl)propyl]morpholine",CCC1(C(NC2=CC=CC=C21)CCCN3CCOCC3)C4=CC=CC=C4,,,,,,
2984,37679,2-(1-Methylethyl)-alpha-3-pyridinyl-1H-indole-3-methanimine,CC(C)C1=C(C2=CC=CC=C2N1)C(=N)C3=CN=CC=C3,,,,,,
2985,37680,"1,3-Dihydro-3-methyl-1-(2-(methylamino)ethyl)-3-phenyl-2H-indol-2-one hydrochloride",CC1(C2=CC=CC=C2N(C1=O)CC[NH2+]C)C3=CC=CC=C3.[Cl-],,,,,,
2986,37681,3-Methyl-1-[2-(methylamino)ethyl]-3-phenylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCNC)C3=CC=CC=C3,,,,,,
2987,37682,Ethyl-[2-(3-methyl-2-oxo-3-phenylindol-1-yl)ethyl]azanium;chloride,CC[NH2+]CCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3.[Cl-],,,,,,
2988,37683,1-[2-(Ethylamino)ethyl]-3-methyl-3-phenylindol-2-one,CCNCCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3,,,,,,
2989,37684,"1,3-Dihydro-1-(3-(ethylamino)propyl)-3-methyl-3-phenyl-2H-indol-2-one hydrochloride",CC[NH2+]CCCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3.[Cl-],,,,,,
2990,37685,1-[3-(Ethylamino)propyl]-3-methyl-3-phenylindol-2-one,CCNCCCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3,,,,,,
2991,37686,"1,3-Dihydro-3-ethyl-1-(2-(methylamino)ethyl)-3-phenyl-2H-indol-2-one monohydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CC[NH2+]C)C3=CC=CC=C3.[Cl-],,,,,,
2992,37687,3-Ethyl-1-[2-(methylamino)ethyl]-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCNC)C3=CC=CC=C3,,,,,,
2993,37688,"1,3-Dihydro-3-ethyl-1-(2-(ethylamino)ethyl)-3-phenyl-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CC[NH2+]CC)C3=CC=CC=C3.[Cl-],,,,,,
2994,37689,3-Ethyl-1-[2-(ethylamino)ethyl]-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCNCC)C3=CC=CC=C3,,,,,,
2995,37690,"1,3-Dihydro-3-ethyl-1-(3-(ethylamino)propyl)-3-phenyl-2H-indol-2-one hydrochloride",CCC1(C2=CC=CC=C2N(C1=O)CCC[NH2+]CC)C3=CC=CC=C3.[Cl-],,,,,,
2996,37691,3-Ethyl-1-[3-(ethylamino)propyl]-3-phenylindol-2-one,CCC1(C2=CC=CC=C2N(C1=O)CCCNCC)C3=CC=CC=C3,,,,,,
2997,37692,"1,3-Dihydro-1-(2-(dimethylamino)ethyl)-3-methyl-3-phenyl-2H-indol-2-one hydrochloride",CC1(C2=CC=CC=C2N(C1=O)CC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
2998,37693,1-[2-(Dimethylamino)ethyl]-3-methyl-3-phenylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=CC=C3,,,,,,
2999,37694,"1,3-Dihydro-1-(2-(diethylamino)ethyl)-3-methyl-3-phenyl-2H-indol-2-one hydrochloride",CC[NH+](CC)CCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3.[Cl-],,,,,,
3000,37695,1-[2-(Diethylamino)ethyl]-3-methyl-3-phenylindol-2-one,CCN(CC)CCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3,,,,,,
3001,37696,"1,3-Dihydro-3-methyl-3-phenyl-1-(2-(piperidino)ethyl)-2H-indol-2-one hydrochloride",CC1(C2=CC=CC=C2N(C1=O)CC[NH+]3CCCCC3)C4=CC=CC=C4.[Cl-],,,,,,
3002,37697,3-Methyl-3-phenyl-1-(2-piperidin-1-ylethyl)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCN3CCCCC3)C4=CC=CC=C4,,,,,,
3003,37698,"1,3-Dihydro-3-methyl-1-(2-(morpholino)ethyl)-3-phenyl-2H-indol-2-one hydrochloride",CC1(C2=CC=CC=C2N(C1=O)CC[NH+]3CCOCC3)C4=CC=CC=C4.[Cl-],,,,,,
3004,37699,3-Methyl-1-(2-morpholin-4-ylethyl)-3-phenylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCN3CCOCC3)C4=CC=CC=C4,,,,,,
3005,37700,"1,3-Dihydro-1-(3-(diethylamino)propyl)-3-methyl-3-phenyl-2H-indol-2-one oxalate",CC[NH+](CC)CCCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
3006,37701,1-[3-(Diethylamino)propyl]-3-methyl-3-phenylindol-2-one,CCN(CC)CCCN1C2=CC=CC=C2C(C1=O)(C)C3=CC=CC=C3,,,,,,
3007,37702,CID 37702,CC=CC(=O)NC[C@H](C(C)C)N(N=O)O,,,,,,
3008,37703,"Phenethylamine, N-cyclohexyl-2-hydroxy-N-phenethyl-, hydrochloride",C1CCC(CC1)[NH+](CCC2=CC=CC=C2)CC(C3=CC=CC=C3)O.[Cl-],,,,,,
3009,37704,2-[Cyclohexyl(2-phenylethyl)amino]-1-phenylethanol,C1CCC(CC1)N(CCC2=CC=CC=C2)CC(C3=CC=CC=C3)O,,,,,,
3010,37705,"1,3-Dioxolane, 4,5-diallyloxy-2-(diallyloxymethyl)-",C=CCOC1C(OC(O1)C(OCC=C)OCC=C)OCC=C,,,,,,
3011,37706,"Acetic acid, (2,4-dichloro-6-nitrophenyl) ester",CC(=O)OC1=C(C=C(C=C1Cl)Cl)[N+](=O)[O-],,,,,,
3012,37707,Diacetoxy L-dopa hydrochloride,C1=CC(=C(C=C1CC(C(=O)O)[NH3+])CC(=O)O)CC(=O)O.[Cl-],,,,,,
3013,37708,"2-Amino-3-[3,4-bis(carboxymethyl)phenyl]propanoic acid",C1=CC(=C(C=C1CC(C(=O)O)N)CC(=O)O)CC(=O)O,,,,,,
3014,37709,"1,2-Bis[1-(2,4,6-trioxo-5-prop-2-enyl-1,3-diazinan-5-yl)propan-2-ylideneamino]guanidine",CC(=NNC(=NN=C(C)CC1(C(=O)NC(=O)NC1=O)CC=C)N)CC2(C(=O)NC(=O)NC2=O)CC=C,,,,,,
3015,37710,CID 37710,CC(=NNC(=NN=C(C)CC1(C(=O)NC(=O)N(C1=O)C2CCCCC2)CC=C)N)CC3(C(=O)NC(=O)N(C3=O)C4CCCCC4)CC=C,,,,,,
3016,37711,"3,4-Dihydroxy-L-phenylalanine benzyl ester hydrochloride",C1=CC=C(C=C1)COC(=O)C(CC2=CC(=C(C=C2)O)O)[NH3+].[Cl-],,,,,,
3017,37712,"Benzyl 2-amino-3-(3,4-dihydroxyphenyl)propanoate",C1=CC=C(C=C1)COC(=O)C(CC2=CC(=C(C=C2)O)O)N,,,,,,
3018,37713,"2,6-Dichloro-4-nitroaniline--1,2,3,4,5-pentachloro-6-nitrobenzene (1/1)",C1=C(C=C(C(=C1Cl)N)Cl)[N+](=O)[O-].C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],,,,,,
3019,37714,Propyl carbonate,CCCOC(=O)O,,,,,,
3020,37715,Hafnium tetrachloride,Cl[Hf](Cl)(Cl)Cl,,,,,,
3021,37716,"(2R,3R,4S,5S,6R)-2-[(1S,2S,3R,4R,6S)-2,3-dihydroxy-6-(hydroxymethyl)-4-[[(4S,5R,6R)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol",C1[C@H]([C@@H]([C@H]([C@@H]([C@@H]1NC2C=C([C@@H]([C@H]([C@@H]2O)O)O)CO)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)CO,,,,,,
3022,37717,"(3S)-3,6-diamino-N-[[(2S,5S,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide",C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(=CNC(=O)N)C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N,,,,,,
3023,37718,Rhodamine WT,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)C(=O)[O-])C(=O)[O-].[Na+].[Na+].[Cl-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3024,37719,"3,6-Bis(diethylamino)-9-(2,4-dicarboxyphenyl)xanthylium",CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)C(=O)O)C(=O)O,,,,,,
3025,37720,Pentosan polysulfate,C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O,['For the relief of bladder pain or discomfort associated with interstitial cystitis.'],['Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects.'],['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)'],['Slow'],,['4.8 hours']
3026,37721,"BENZYL ALCOHOL, alpha-AMINOMETHYL-3-FLUORO-4-HYDROXY-, HYDROCHLORIDE",C1=CC(=C(C=C1C(C[NH3+])O)F)O.[Cl-],,,,,,
3027,37722,alpha-(Aminomethyl)-4-hydroxy-3-fluorobenzenemethanol,C1=CC(=C(C=C1C(CN)O)F)O,,,,,,
3028,37723,Lentinan,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)O)O)O)O)O)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3029,37724,Igran-dicuran mixt.,CCNC1=NC(=NC(=N1)SC)NC(C)(C)C.CC1=C(C=C(C=C1)NC(=O)N(C)C)Cl,,,,,,
3030,37725,"8-chloro-3-methyl-1-phenyl-5H-2,3-benzodiazepin-4-one",CN1C(=O)CC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,,,,,,
3031,37726,"1,3-Dihydro-1-(3-(dimethylamino)propyl)-3-methyl-3-phenyl-2H-indol-2-one oxalate",CC1(C2=CC=CC=C2N(C1=O)CCC[NH+](C)C)C3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
3032,37727,1-[3-(Dimethylamino)propyl]-3-methyl-3-phenylindol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCCN(C)C)C3=CC=CC=C3,,,,,,
3033,37728,CID 37728,CC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCCCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
3034,37729,3-Methyl-3-phenyl-1-(3-piperidin-1-ylpropyl)indol-2-one,CC1(C2=CC=CC=C2N(C1=O)CCCN3CCCCC3)C4=CC=CC=C4,,,,,,
3035,37730,"3(2H)-Isoquinolinone, 6,7-dimethoxy-2-methyl-1-veratryl-, hydrochloride",C[NH+]1C(=O)C=C2C=C(C(=CC2=C1CC3=CC(=C(C=C3)OC)OC)OC)OC.[Cl-],,,,,,
3036,37731,"6,7-dimethoxy-2-methyl-1-veratryl-3(2H)-isoquinolone",CN1C(=O)C=C2C=C(C(=CC2=C1CC3=CC(=C(C=C3)OC)OC)OC)OC,,,,,,
3037,37732,N-methyl-2-phenoxyethanamine,CNCCOC1=CC=CC=C1,,,,,,
3038,37733,"Barbituric acid, 5-benzyl-5-propionyloxy-",CCC(=O)OC1(C(=O)NC(=O)NC1=O)CC2=CC=CC=C2,,,,,,
3039,37734,1-Phenyl-3-buten-2-one,C=CC(=O)CC1=CC=CC=C1,,,,,,
3040,37735,Ureidosuccinic acid dihydrazide,C(C(C(=O)NN)NC(=O)N)C(=O)NN,,,,,,
3041,37736,CID 37736,C1=CC=C(C=C1)C2=C(N=NC(=N2)S)C3=CC=CC=C3,,,,,,
3042,37737,"2,4-Dihydroxy-5-hexylbenzaldehyde",CCCCCCC1=CC(=C(C=C1O)O)C=O,,,,,,
3043,37738,"1-Benzoxepin-5-ol, 2,3,4,5-tetrahydro-8-chloro-5-(3-(dimethylamino)propyl)-, hydrochloride",C[NH+](C)CCCC1(CCCOC2=C1C=CC(=C2)Cl)O.[Cl-],,,,,,
3044,37739,"8-chloro-5-[3-(dimethylamino)propyl]-3,4-dihydro-2H-1-benzoxepin-5-ol",CN(C)CCCC1(CCCOC2=C1C=CC(=C2)Cl)O,,,,,,
3045,37740,CID 37740,C[NH+](C)CCCC1=CCCOC2=C1C=CC(=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
3046,37741,"3-(8-chloro-2,3-dihydro-1-benzoxepin-5-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1=CCCOC2=C1C=CC(=C2)Cl,,,,,,
3047,37742,CID 37742,C1CC[NH+](CC1)CC2CCOC3=C(C2=O)C=CC(=C3)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
3048,37743,"8-chloro-4-(piperidin-1-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-one",C1CCN(CC1)CC2CCOC3=C(C2=O)C=CC(=C3)Cl,,,,,,
3049,37744,"trans-(+-)-4-Piperidinomethyl-5-acetoxy-8-chloro-2,3,4,5-tetrahydro-1-benzoxepin HCl",CC(=O)OC1[C@@H](CCOC2=C1C=CC(=C2)Cl)C[NH+]3CCCCC3.[Cl-],,,,,,
3050,37745,"[(4S)-8-chloro-4-(piperidin-1-ylmethyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl] acetate",CC(=O)OC1[C@@H](CCOC2=C1C=CC(=C2)Cl)CN3CCCCC3,,,,,,
3051,37746,"(cis)-(+-)-4-Piperidinomethyl-5-phenyl-8-chloro-2,3,4,5-tetrahydro-1-benzoxepin-5-ol HCl",C1CC[NH+](CC1)CC2CCOC3=C([C@]2(C4=CC=CC=C4)O)C=CC(=C3)Cl.[Cl-],,,,,,
3052,37747,"(5S)-8-chloro-5-phenyl-4-(piperidin-1-ylmethyl)-3,4-dihydro-2H-1-benzoxepin-5-ol",C1CCN(CC1)CC2CCOC3=C([C@]2(C4=CC=CC=C4)O)C=CC(=C3)Cl,,,,,,
3053,37748,"Benzamide, 2-chloro-N-(1,2,3,4-tetrahydro-2-methylisoquinolin-5-YL)-",CN1CCC2=C(C1)C=CC=C2NC(=O)C3=CC=CC=C3Cl,,,,,,
3054,37749,"Benzamide, 2-bromo-N-(1,2,3,4-tetrahydro-2-methylisoquinolin-5-YL)-",CN1CCC2=C(C1)C=CC=C2NC(=O)C3=CC=CC=C3Br,,,,,,
3055,37750,Ethyl 4-(3-chlorophenoxy)butanoate,CCOC(=O)CCCOC1=CC(=CC=C1)Cl,,,,,,
3056,37751,"Butanamide, 4-(3-chlorophenoxy)-",C1=CC(=CC(=C1)Cl)OCCCC(=O)N,,,,,,
3057,37752,CID 37752,C[NH+](C)CCON=C1CCCOC2=C1C=CC(=C2)Cl.[Cl-],,,,,,
3058,37753,"2-[(8-chloro-3,4-dihydro-2H-1-benzoxepin-5-ylidene)amino]oxy-N,N-dimethylethanamine",CN(C)CCON=C1CCCOC2=C1C=CC(=C2)Cl,,,,,,
3059,37754,"5-Amino-8-chloro-2,3,4,5-tetrahydro-1-benzoxepin hydrochloride",C1CC(C2=C(C=C(C=C2)Cl)OC1)[NH3+].[Cl-],,,,,,
3060,37755,"8-Chloro-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",C1CC(C2=C(C=C(C=C2)Cl)OC1)N,,,,,,
3061,37756,CID 37756,C[NH2+]C1CCCOC2=C1C=CC(=C2)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
3062,37757,"8-chloro-N-methyl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CNC1CCCOC2=C1C=CC(=C2)Cl,,,,,,
3063,37758,"5-Diethylamino-8-chloro-2,3,4,5-tetrahydro-1-benzoxepin hydrochloride",C[NH+](C)C1CCCOC2=C1C=CC(=C2)Cl.[Cl-],,,,,,
3064,37759,"8-chloro-N,N-dimethyl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CN(C)C1CCCOC2=C1C=CC(=C2)Cl,,,,,,
3065,37760,"1-Benzoxepin-5-amine, 2,3,4,5-tetrahydro-8-chloro-N-methyl-N-2-propenyl-, hydrochloride",C[NH+](CC=C)C1CCCOC2=C1C=CC(=C2)Cl.[Cl-],,,,,,
3066,37761,"8-chloro-N-methyl-N-prop-2-enyl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CN(CC=C)C1CCCOC2=C1C=CC(=C2)Cl,,,,,,
3067,37762,"1-Benzoxepin-5-amine, 2,3,4,5-tetrahydro-8-chloro-N-methyl-N-2-propynyl-, hydrochloride",C[NH+](CC#C)C1CCCOC2=C1C=CC(=C2)Cl.[Cl-],,,,,,
3068,37763,"8-chloro-N-methyl-N-prop-2-ynyl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CN(CC#C)C1CCCOC2=C1C=CC(=C2)Cl,,,,,,
3069,37764,"2-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC(=C(C=C2C1)O)O,,,,,,
3070,37765,CID 37765,CCCCCCCCC(C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
3071,37766,6-Hydroxychrysene,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)O,,,,,,
3072,37767,Pipotiazine palmitate,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,,,,,,
3073,37768,Amikacin,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,"['The amikacin sulfate injection is indicated in the short-term treatment of serious bacterial infections due to susceptible strains of gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, as well as Acinetobacter (Mima-Herellea) species.  Clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery).  Clinical studies have shown amikacin also to be effective in serious, complicated, and recurrent urinary tract infections due to the above organisms. Aminoglycosides, including amikacin, are not indicated in uncomplicated first-time episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxic.  In September 2018, a new indication with a new dosage route was approved for this drug. Amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease). This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6 of treatment. Clinical benefit has not yet been established.  **Important notes regarding Staphylococcus and Sensitivity testing:**  Staphylococcus aureus, including methicillin-resistant strains, is the principal Gram-positive organism sensitive to amikacin. The use of amikacin in the treatment of staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibiotics.  Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be used as initial therapy in suspected gram-negative infections and therapy may be initiated before obtaining the results of susceptibility testing.']","['Amikacin is an aminoglycoside antibiotic. Aminoglycosides bind to the bacteria, causing misreading of t-RNA, leaving bacteria unable to synthesize proteins vital to their growth. Aminoglycosides are useful mainly in the treatment infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, however, other antibiotics may be more potent and less toxic to humans.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Rapidly absorbed after intramuscular administration. Rapid absorption occurs from the peritoneum and pleura. Poor oral and topical absorption. Poorly absorbed from bladder irrigations and intrathecal administration.  The bioavailability of this drug is expected to vary primarily from individual differences in nebulizer efficiency and airway pathology.  Following IM administration of a single dose of amikacin of 7.5 mg/kg in adults with normal renal function, peak plasma amikacin concentrations of 17-25 micrograms/mL are attained within 45 minutes to 2 hours.  Following IV infusion of the same dose given over 1 hour peak plasma concentrations of the drug average 38 micrograms/mL immediately following the infusion, 5.5 micrograms/mL at 4 hours, and 1.3 micrograms/mL at 8 hours.', 'This drug is eliminated by the kidneys. In adults with normal renal function, 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration in the kidney within 24 hours. Amikacin can be completely recovered within approximately 10-20 days in patients with normal, healthy renal function.  In patients with impaired renal function, the clearance of amikacin is found to be decreased; the more severe the impairment, the slower the clearance. The interval between doses of amikacin should be adjusted according to the level of renal impairment. Endogenous creatinine clearance rate and serum creatinine which have a high correlation with serum half-life of amikacin, may be used as a guide for dosing.', '24 L (28% of body weight healthy adult subjects).  Following administration of usual dosages of amikacin, amikacin has been found in bone, heart, gallbladder, and lung tissue. Amikacin is also distributed into bile, sputum, bronchial secretions, and interstitial, pleural, and synovial fluids.', 'The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function.', 'Emergence of a multiply drug resistant Enterobacter cloacae during a seven-week period in 1980 caused amikacin to become the aminoglycoside of choice in the initial management of suspected sepsis in a neonatal intensive care unit. Recommended doses (7.5-10 mg/kg loading; 15 mg/kg in two divided doses IV) were given to 5 infants < or = 1,000 gm and to 13 larger babies. Trough levels 11.5 hours after a dose were 16.6 +/- 11.9 ug/mL  in infants < or = 1,000 gm and 6.5 +/- 4.3 ug/mL in the larger infants (P < 0.02). Peak levels one hour postinfusion exceeded 40 ug/mL in 3 of 5 < or = 1,000-gm babies and 4 of 12 > 1,000-gm infants (P = NS). Overall, 7 of 10 peak and/or trough levels in < or = 1,000-gm infants were in the range considered toxic in adults, versus 7 of 24 in larger babies (P = 0.03). These data show that ... excessive blood levels of amikacin are likely in infants < or = 1,000 gm and may also occur in larger infants using currently recommended dosage schedules. These ... findings emphasize the need to monitor drug levels and individualize therapy in very low birthweight infants.', 'Amikacin is poorly absorbed from the GI tract. Amikacin is rapidly absorbed following IM administration. Following IM administration of a single 7.5-mg/kg dose of amikacin in adults with normal renal function, peak plasma amikacin concentrations are attained within about 0.5-2 hours and average 17-25 ug/mL; plasma concentrations 10 hours after the dose average 2.1 ug/mL.', 'When a 7.5-mg/kg dose of amikacin is administered by IV infusion over 30 minutes, peak plasma concentrations of the drug average 38 ug/mL immediately following the infusion, 18 ug/mL at 1 hour, and 0.75 ug/mL at 10 hours. In adults receiving 15 mg/kg once daily by IV infusion over 30 minutes, peak serum concentrations (measured 30 minutes after completion of an infusion) were 40.9 ug/mL and trough concentrations (measured immediately before start of an infusion) were 1.8 ug/mL.', 'Accumulation of amikacin does not appear to occur in adult or pediatric patients with normal renal function receiving usual dosages of the drug twice daily for 4-10 days.', 'For more Absorption, Distribution and Excretion (Complete) data for Amikacin (15 total), please visit the HSDB record page.']","[""Amikacin's structure has been altered to reduce the possible route of enzymatic deactivation, thus reducing bacterial resistance. Many strains of Gram-negative organisms resistant to gentamicin and tobramycin have shown to be sensitive to amikacin in vitro."", 'Aminoglycosides are not metabolized and are excreted unchanged in the urine primarily by glomerular filtration. /Aminoglycosides/']","['The plasma elimination half-life of amikacin is usually 2-3 hours in adults with normal renal function and is reported to range from 30-86 hours in adults with severe renal impairment.', 'The plasma elimination half-life of amikacin usually is 2-3 hours in adults with normal renal function and is reported to range from 28-86 hours in adults with severe renal impairment. The plasma elimination half-life of amikacin is reported to be 4-5 hours in full-term infants 7 days of age or older and 7-8 hours in low birth-weight infants 1-3 days of age. In preterm neonates, half-life is inversely related to postconceptional age and has ranged from 4.5-15.6 hours. In one study in infants and children 20 days to 6 years of age, mean plasma half-life after a single 7.5-mg/kg IM dose was about 2 hours.']"
3074,37769,"3,4-Dihydro-6,7-dimethoxy-N-(2-(2-methoxyphenoxy)ethyl)-2(1H)-isoquinolinecarboximidamide",COC1=CC=CC=C1OCCN=C(N)[NH+]2CCC3=CC(=C(C=C3C2)OC)OC.[Br-],,,,,,
3075,37770,"6,7-dimethoxy-N'-[2-(2-methoxyphenoxy)ethyl]-3,4-dihydro-1H-isoquinoline-2-carboximidamide",COC1=CC=CC=C1OCCN=C(N)N2CCC3=CC(=C(C=C3C2)OC)OC,,,,,,
3076,37771,"3(2H)-Isoquinolinone, 1-((3,4-diethoxyphenyl)methyl)-6,7-diethoxy-2-methyl-, hydrochloride",CCOC1=C(C=C(C=C1)CC2=C3C=C(C(=CC3=CC(=O)[NH+]2C)OCC)OCC)OCC.[Cl-],,,,,,
3077,37772,"1-[(3,4-Diethoxyphenyl)methyl]-6,7-diethoxy-2-methylisoquinolin-3-one",CCOC1=C(C=C(C=C1)CC2=C3C=C(C(=CC3=CC(=O)N2C)OCC)OCC)OCC,,,,,,
3078,37773,"Carbamic acid, thiobis(methyl-, bis(2-(1-methylethoxy)phenyl) ester",CC(C)OC1=CC=CC=C1OC(=O)NCSCNC(=O)OC2=CC=CC=C2OC(C)C,,,,,,
3079,37774,Thiobis(methylcarbamic acid) bis(3-(1-methylethyl)phenyl) ester,CC(C)C1=CC(=CC=C1)OC(=O)NCSCNC(=O)OC2=CC=CC(=C2)C(C)C,,,,,,
3080,37775,2-Phenyl-5-acetylbenzothiazole,CC(=O)C1=CC2=C(C=C1)SC(=N2)C3=CC=CC=C3,,,,,,
3081,37776,CID 37776,CCCCOC1=CC=C(C=C1)N=C(NC2=CC3=C(C=C(C=C3C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])S.[Na+].[Na+],,,,,,
3082,37777,CID 37777,CCCCOC1=CC=C(C=C1)N=C(NC2=CC3=C(C=C(C=C3C=C2)S(=O)(=O)O)S(=O)(=O)O)S,,,,,,
3083,37778,CID 37778,CCCCOC1=CC=C(C=C1)N=C(NC2=CC3=C(C=C(C=C3C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])S.[K+].[K+],,,,,,
3084,37779,CID 37779,CCCCCOC1=CC=C(C=C1)N=C(NC2=CC3=C(C=C(C=C3C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])S.[K+].[K+],,,,,,
3085,37780,CID 37780,CCCCCOC1=CC=C(C=C1)N=C(NC2=CC3=C(C=C(C=C3C=C2)S(=O)(=O)O)S(=O)(=O)O)S,,,,,,
3086,37781,Eicosanyl-dimethyl-benzylammonium chloride,CCCCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.[Cl-],,,,,,
3087,37782,Benzyldimethylicosylaminium,CCCCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,,,,,,
3088,37783,"Phorbol 12,13-dibutyrate",CCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)CCC)O)C,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
3089,37784,"Benzeneacetic acid, alpha-((methoxy(methylthio)phosphinyl)thio)-, ethyl ester",CCOC(=O)C(C1=CC=CC=C1)SP(=O)(OC)SC,,,,,,
3090,37785,"trans-4,5-Dihydrobenzo(a)pyrene-4,5-diol",C1=CC=C2C3=C4C(=CC2=C1)[C@H]([C@@H](C5=CC=CC(=C54)C=C3)O)O,,,,,,
3091,37786,"Benzo[a]pyrene-4,5-oxide",C1=CC=C2C3=C4C(=CC2=C1)C5C(O5)C6=CC=CC(=C64)C=C3,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['Benzo[a]pyrene-4,5-epoxide is a known human metabolite of Benzo[a]pyrene.']",
3092,37787,4-Hydroxybenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=C(C5=CC=CC(=C54)C=C3)O,,,,,,
3093,37788,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(p-CHLOROBENZOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=C(C=C4)Cl)OCO3)CC(=O)O,,,,,,
3094,37789,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(p-FLUOROBENZOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=C(C=C4)F)OCO3)CC(=O)O,,,,,,
3095,37790,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 6-METHYL-5-(p-TOLUOYL)-",CC1=CC=C(C=C1)C(=O)N2C(=C(C3=CC4=C(C=C32)OCO4)CC(=O)O)C,,,,,,
3096,37791,1-Phenyl-3-adamantanecarboxylic acid,C1C2CC3(CC1CC(C2)(C3)C(=O)O)C4=CC=CC=C4,,,,,,
3097,37792,CID 37792,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)NC(=NC2=O)N,,,,,,
3098,37793,"Benzoic acid, 3,5-dihydroxy-, butyl ester, hemihydrate",CCCCOC(=O)C1=CC(=CC(=C1)O)O.CCCCOC(=O)C1=CC(=CC(=C1)O)O.O,,,,,,
3099,37794,"3,5-Dihydroxybenzoic acid butyl ester",CCCCOC(=O)C1=CC(=CC(=C1)O)O,,,,,,
3100,37795,"Benzoic acid, 3,5-dihydroxy-, heptyl ester",CCCCCCCOC(=O)C1=CC(=CC(=C1)O)O,,,,,,
3101,37796,"Indole, 3-(2-(methylamino)ethyl)-1-methyl-",CNCCC1=CN(C2=CC=CC=C21)C,,,,,,
3102,37797,2-Trimethylammonioethyl 3-(diethylmethylammonio)propionate diiodide,CC[N+](C)(CC)CCC(=O)OCC[N+](C)(C)C.[I-].[I-],,,,,,
3103,37798,"N-Methyl-N,N-diethyl-3-oxo-3-[2-(trimethylaminio)ethoxy]-1-propanaminium",CC[N+](C)(CC)CCC(=O)OCC[N+](C)(C)C,,,,,,
3104,37799,2-{[(4-Bromophenyl)sulfonyl]amino}-3-phenylpropanoic acid,C1=CC=C(C=C1)CC(C(=O)O)NS(=O)(=O)C2=CC=C(C=C2)Br,,,,,,
3105,37800,"2-[6-Methyl-5-(3-phenylprop-2-enoyl)-[1,3]dioxolo[4,5-f]indol-7-yl]acetic acid",CC1=C(C2=CC3=C(C=C2N1C(=O)C=CC4=CC=CC=C4)OCO3)CC(=O)O,,,,,,
3106,37801,Furaprofen,CC(C1=CC=CC2=C1OC=C2C3=CC=CC=C3)C(=O)O,"['Investigated for use/treatment in hepatitis (viral, C).']",,,,,
3107,37802,"(3,4-Dimethoxyphenyl)dimethylaminoacetonitrile",CN(C)C(C#N)C1=CC(=C(C=C1)OC)OC,,,,,,
3108,37803,"2,2',5-Trichlorobiphenyl",C1=CC=C(C(=C1)C2=C(C=CC(=C2)Cl)Cl)Cl,,,,,,
3109,37804,"2,2',4-Trichlorobiphenyl",C1=CC=C(C(=C1)C2=C(C=C(C=C2)Cl)Cl)Cl,,,,,,
3110,37805,"2,3',5'-Trichlorobiphenyl",C1=CC=C(C(=C1)C2=CC(=CC(=C2)Cl)Cl)Cl,,,,,,
3111,37806,"3,3',4-Trichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=CC(=C(C=C2)Cl)Cl,,,,,,
3112,37807,"2,2',4,5,5'-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=CC(=C(C=C2Cl)Cl)Cl)Cl,,,,,"[""2,2',4,5,5'-pentachlorobiphenyl has known human metabolites that include 2,2',4',5,5'-pentachloro-[1,1'-biphenyl]-4-ol.""]",
3113,37808,Coumazoline,CCC1=C(C2=CC=CC=C2O1)CC3=NCCN3,,,,,,
3114,37809,"AZEPINO(4,5-b)INDOLE, 1,2,3,4,5,6-HEXAHYDRO-6-(3-DIMETHYLAMINOPROPYL)-3-METHYL-",CN1CCC2=C(CC1)N(C3=CC=CC=C23)CCCN(C)C,,,,,,
3115,37810,"Azepino(4,5-b)indole, 1,2,3,4,5,6-hexahydro-6-(3-dimethylaminopropyl)-3,9-dimethyl-",CC1=CC2=C(C=C1)N(C3=C2CCN(CC3)C)CCCN(C)C,,,,,,
3116,37811,"12H-(1)BENZOXEPINO(5,4-b)INDOLE, 6,7-DIHYDRO-12-(2-DIMETHYLAMINOETHYL)-",CN(C)CCN1C2=CC=CC=C2C3=C1C4=CC=CC=C4OCC3,,,,,,
3117,37812,"12H-(1)BENZOXEPINO(5,4-b)INDOLE, 6,7-DIHYDRO-12-(2-DIMETHYLAMINOETHYL)-9-METHYL-",CC1=CC2=C(C=C1)N(C3=C2CCOC4=CC=CC=C43)CCN(C)C,,,,,,
3118,37813,"12H-(1)BENZOXEPINO(5,4-b)INDOLE, 6,7-DIHYDRO-12-(3-DIMETHYLAMINOPROPYL)-",CN(C)CCCN1C2=CC=CC=C2C3=C1C4=CC=CC=C4OCC3,,,,,,
3119,37814,"12H-(1)Benzoxepino(5,4-b)indole, 6,7-dihydro-12-(3-dimethylaminopropyl)-9-methyl-",CC1=CC2=C(C=C1)N(C3=C2CCOC4=CC=CC=C43)CCCN(C)C,,,,,,
3120,37815,"12H-(1)Benzoxepino(5,4-b)indole, 6,7-dihydro-9-chloro-12-(3-dimethylaminopropyl)-",CN(C)CCCN1C2=C(C=C(C=C2)Cl)C3=C1C4=CC=CC=C4OCC3,,,,,,
3121,37816,"1,1-diethyl-3-[(9S)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]urea",CCN(CC)C(=O)N[C@H]1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)C,,,,,,
3122,37817,Antipain,CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O,,,['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)'],,,
3123,37818,Nitro-formaldehyde p-tolylhydrazone,CC1=CC=C(C=C1)NN=C[N+](=O)[O-],,,,,,
3124,37819,"5,5'-(1,3-Propanediyl)bisisoxozole",C1=C(ON=C1)CCCC2=CC=NO2,,,,,,
3125,37820,CID 37820,C1C([NH2+]C(=CC1=CC=[N+]2C3=CC(=C(C=C3C=C2C(=O)O)O)O)C(=O)O)C(=O)[O-].OS(=O)(=O)[O-],,,,,,
3126,37821,"4-[2-(2-Carboxy-5,6-dihydroxyindol-1-yl)ethenyl]-2,3-dihydropyridin-1-ium-2,6-dicarboxylic acid",C1C([NH+]=C(C=C1C=CN2C3=CC(=C(C=C3C=C2C(=O)O)O)O)C(=O)O)C(=O)O,,,,,,
3127,37822,Iopronic acid,CCC(COCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I)C(=O)O,,,,,,
3128,37823,"(1)Benzothieno(2,3-d)pyrimidine, 5,6,7,8-tetrahydro-4-(4-methyl-1-piperazinyl)-, hydrochloride",C[NH+]1CCN(CC1)C2CCCC3=C2C4=CN=CN=C4S3.[Cl-],,,,,,
3129,37824,"5-(4-Methylpiperazin-1-yl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidine",CN1CCN(CC1)C2CCCC3=C2C4=CN=CN=C4S3,,,,,,
3130,37825,Ciclazindol,C1CN=C2C(C3=CC=CC=C3N2C1)(C4=CC(=CC=C4)Cl)O,,,,,,
3131,37826,"2-tert-Butyl-1,3-dithiolane",CC(C)(C)C1SCCS1,,,,,,
3132,37827,CID 37827,CCCCCCCCCCCCCCCCCC(=O)NC(CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)NC(=O)C)OCC(C([C@H]5[C@@H]([C@H](C[C@](O5)(C(=O)O)O)O)NC(=O)C)O)O)O)O)O)C(C=CCCCCCCCCCCCCC)O,,,,,,
3133,37828,1-Bromo-2-(bromomethyl)naphthalene,C1=CC=C2C(=C1)C=CC(=C2Br)CBr,,,,,,
3134,37829,Dichlormid,C=CCN(CC=C)C(=O)C(Cl)Cl,,,,"['Approximately 90% of the orally administered dose was absorbed in rats. Urinary excretion was the major route of elimination of orally administered dichlormid, consistently accounting for 60-78% of the administered dose over 48-168 hours following a single oral dose. Fecal excretion accounted for approximately 8-20% of a single oral dose. Approximately 70-77% of urinary excretion (representing 52-54% of the administered dose) occurred within 24 hours. No gender-related difference in rate or amount of urinary excretion was observed. No significant accumulation in the body was observed.']","['Dichlormid was metabolized via two pathways:  1. Initial dechlorination followed by formation of various chlorinated, water-soluble metabolites, and  2. Formation of various chlorinated metabolites.']",
3135,37830,"1-Butanone, 1,1'-(9H-thioxanthene-2,7-diyl)bis(4-(diethylamino)-, dihydrochloride",CC[NH+](CC)CCCC(=O)C1=CC2=C(C=C1)SC3=C(C2)C=C(C=C3)C(=O)CCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
3136,37831,4-(diethylamino)-1-[7-[4-(diethylamino)butanoyl]-9H-thioxanthen-2-yl]butan-1-one,CCN(CC)CCCC(=O)C1=CC2=C(C=C1)SC3=C(C2)C=C(C=C3)C(=O)CCCN(CC)CC,,,,,,
3137,37832,"Carbostyril, 3-bromo-4-methyl-",CC1=C(C(=O)NC2=CC=CC=C12)Br,,,,,,
3138,37833,Laurifoline chloride,C[N+]1(CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)O)O)OC)C.[Cl-],,,,,,
3139,37834,"4H-Dibenzo(de,g)quinolinium, 5,6,6a,7-tetrahydro-1,9-dihydroxy-2,10-dimethoxy-6,6-dimethyl-, (S)-",C[N+]1(CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)O)O)OC)C,,,,,,
3140,37835,"2,3-Dihydro-9H-isoxazolo(3,2-b)quinazolin-9-one",C1CON2C1=NC3=CC=CC=C3C2=O,,,,,,
3141,37836,"9H-Isoxazolo[3,2-b]quinazolin-9-one, 2,3-dihydro-3-methyl-",CC1CON2C1=NC3=CC=CC=C3C2=O,,,,,,
3142,37837,Strophanthidin 3-benzoate,C[C@]12CCC3C([C@]1(CCC2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)OC(=O)C6=CC=CC=C6)C=O)O,,,,,,
3143,37838,N-Methyl-4-piperidyl cyclopentylphenylglycolate,CN1CCC(CC1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
3144,37839,Isovelleral,C[C@]12C[C@]1(C(=C[C@H]3[C@@H]2CC(C3)(C)C)C=O)C=O,,,,,,
3145,37840,"1,2-Bis(2,4,6-tribromophenoxy)ethane",C1=C(C=C(C(=C1Br)OCCOC2=C(C=C(C=C2Br)Br)Br)Br)Br,,,"['Materials applied to fabrics, bedding, furniture, plastics, etc. to retard their burning; many may leach out and cause allergies or other harm. (See all compounds classified as Flame Retardants.)']","['(14)C1,2-Bis(2,4,6-tribromophenoxy)ethane (FF-680) was administered at 0.05, 0.5, or 5% in the diet for 1 day to three groups (four rats per group) of rats, and daily at 0.05% in the diet for 10 days to another group of five rats. In addition, another group of four rats were given a single oral gavage dose of 200 mg/kg of ((14)C)FF-680 in corn oil and were used for bile collection. At all dose levels, (14)CFF-680-derived radioactivity was excreted almost totally via the fecal route (> 99% of the total excreted (14)C), with < 1% recovered in the urine. No radioactivity was detected in the expired air, and very little radioactivity was excreted in the bile (ca. 0.04% of the dose). At 4 days after the start of administration of the dosed diet for 1 day, no radioactivity was detected in any tissue analyzed, except adipose tissue, skin, and thymus, in which trace concentrations of radioactivity were detected in some animals. At 10 days after the start of administration of dosed diet to rats dosed for 10 days, trace but detectable levels of radioactivity were observed in all tissues analyzed except the brain of some animals. Excluding the gastrointestinal tract, adipose tissue contained the highest concentration of (14)C radioactivity, followed by kidney, skin, and thymus, whereas brain, testes, and spleen contained the lowest concentrations of radioactivity. No parent compound was detected in the urine, while fecal radioactivity was identified as the parent compound. Mean recovery of radioactivity ranged from ca. 86-101% of the ((14)C) FF-680 consumed. The data indicate that FF-680 was very poorly absorbed from the gastrointestinal tract. However, following daily administration for 10 days, trace amounts of radioactivity accumulated in tissues to provide detectable levels.', 'A single oral dose of (14)C 1,2-bis(2,4,6-tribromophenoxy)ethane (BTBPE) was administered to conventional and bile-duct cannulated male Sprague-Dawley rats. Tissue disposition, excretion and metabolism was determined. BTBPE is a low-volume brominated flame retardant used in resins or plastics. ... BTBPE was fairly insoluble in lipophilic solutions, which made dose preparation difficult. The great majority of (14)C (>94%) was excreted in the feces of both groups of rats at 72 hr, and tissue retention was minimal. Lipophilic tissues contained the highest concentrations of BTBPE, e.g. thymus, adipose tissue, adrenals, lung, and skin. Metabolites were excreted in the urine, bile and feces, but at a very low level. ... Despite a limited quantity of stable metabolites extractable in the feces, non-extractable (14)C levels were relatively high (39% of the 0-24 hr fecal (14)C), which suggested that BTBPE could be metabolically activated in the rat and covalently bound to fecal proteins and/or lipids. It was concluded that limited absorption and metabolism of BTBPE would occur by ingestion in mammals.']","['A single oral dose of (14)C 1,2-bis(2,4,6-tribromophenoxy)ethane (BTBPE) was administered to conventional and bile-duct cannulated male Sprague-Dawley rats. ... Metabolites were excreted in the urine, bile and feces, but at a very low level. Fecal metabolites were characterized as monohydroxylated, monohydroxylated with debromination, dihydroxylated/debrominated on a single aromatic ring, monohydroxylated on each aromatic ring with accompanying debromination, and cleavage on either side of the ether linkage to yield tribromophenol and tribromophenoxyethanol. Despite a limited quantity of stable metabolites extractable in the feces, non-extractable 14C levels were relatively high (39% of the 0-24 hr fecal (14)C), which suggested that BTBPE could be metabolically activated in the rat and covalently bound to fecal proteins and/or lipids. It was concluded that limited absorption and metabolism of BTBPE would occur by ingestion in mammals.', '...  Debrominated and hydroxylated metabolites were not detected in liver extracts and suggest that either biotransformation or storage of BTBPE-metabolites in the hepatic system of fish is minor or that our exposure time frame was too short. ...', '... Fathead minnows from each treatment exhibited several brominated transformation products. ...']","['... The elimination of BTBPE from the fish obeyed first-order depuration kinetics (r2 = 0.6427, p < 0.001) with a calculated half-life of 54.1 +/- 8.5 days. ...']"
3146,37841,Tetrabromobisphenol A bismethyl ether,CC(C)(C1=CC(=C(C(=C1)Br)OC)Br)C2=CC(=C(C(=C2)Br)OC)Br,,,,,,
3147,37842,"5H-Furo(3,2-g)(1)benzopyran-5-one, 9-(3-(benzylisopropylamino)-2-hydroxypropoxy)-4-hydroxy-7-methyl-, citrate",CC1=CC2=C(C3=C(C(=C2O1)OCC(C[NH+](CC4=CC=CC=C4)C(C)C)O)OC=CC3=O)O.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3148,37843,"9-[3-[Benzyl(propan-2-yl)amino]-2-hydroxypropoxy]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CC1=CC2=C(C3=C(C(=C2O1)OCC(CN(CC4=CC=CC=C4)C(C)C)O)OC=CC3=O)O,,,,,,
3149,37844,"Furo(3,2-g)chromone, 9-(2-hydroxy-3-isopropylaminopropoxy)-4-hydroxy-7-methyl-,hydrochloride",CC1=CC2=C(C3=C(C(=C2O1)OCC(C[NH2+]C(C)C)O)OC=CC3=O)O.[Cl-],,,,,,
3150,37845,"4-Hydroxy-9-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2-methylfuro[3,2-g]chromen-5-one",CC1=CC2=C(C3=C(C(=C2O1)OCC(CNC(C)C)O)OC=CC3=O)O,,,,,,
3151,37846,"Benzoic acid, 4-(cyclopentylmethyl)-",C1CCC(C1)CC2=CC=C(C=C2)C(=O)O,,,,,,
3152,37847,4-(3-Cyclopentylpropyl)benzoic acid,C1CCC(C1)CCCC2=CC=C(C=C2)C(=O)O,,,,,,
3153,37848,"BENZOIC ACID, (p-(2-NORBORNANYLEMETHYL))-",C1CC2CC1CC2CC3=CC=C(C=C3)C(=O)O,,,,,,
3154,37849,"Formamide, N-(4-(cyclohexylmethyl)-1-cyclohexyl)-",C1CCC(CC1)CC2CCC(CC2)NC=O,,,,,,
3155,37850,Thiocholine chloride,C[N+](C)(C)CCS.[Cl-],,,,,,
3156,37851,2-(Trimethylammonium)ethyl thiol,C[N+](C)(C)CCS,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
3157,37852,"Propargyl 3,7,11-trimethyl-2,4-dodecadienoate",CC(C)CCCC(C)CC=CC(=CC(=O)OCC#C)C,,,,,,
3158,37853,CID 37853,CC1=CC2=CC3=C(C4=C(C5=C(C6=C4C(C3)OCO6)C(=O)C7=C(O5)C(CCC7O)OC)O)C(=O)C2=C(N1N)O,,,,,,
3159,37854,4-Methyl-3-furoxancarboxamide,CC1=NO[N+](=C1C(=O)N)[O-],,,,,,
3160,37855,"Bicyclo(5.1.0)octa-2,4-diene-8-carboxylic acid, 2-(diethylaminoethyl) ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1C2C1C=CC=CC2.[Cl-],,,,,,
3161,37856,"2-(Diethylamino)ethyl bicyclo[5.1.0]octa-2,4-diene-8-carboxylate",CCN(CC)CCOC(=O)C1C2C1C=CC=CC2,,,,,,
3162,37857,"Bicyclo(5.1.0)octa-2,4-diene-8-carboxylic acid, (2-morpholinoethyl) ester, hydrochloride",C1COCC[NH+]1CCOC(=O)C2C3C2C=CC=CC3.[Cl-],,,,,,
3163,37858,"2-Morpholin-4-ylethyl bicyclo[5.1.0]octa-2,4-diene-8-carboxylate",C1COCCN1CCOC(=O)C2C3C2C=CC=CC3,,,,,,
3164,37859,"Bicyclo(5.1.0)octa-2,4-diene-8-carboxylic acid, 2-(1-pyrrolidinyl)ethyl ester, hydrochloride",C1CC[NH+](C1)CCOC(=O)C2C3C2C=CC=CC3.[Cl-],,,,,,
3165,37860,"2-Pyrrolidin-1-ylethyl bicyclo[5.1.0]octa-2,4-diene-8-carboxylate",C1CCN(C1)CCOC(=O)C2C3C2C=CC=CC3,,,,,,
3166,37861,"Bicyclo(5.1.0)octa-2,4-diene-8-carboxylic acid, 2-(4-methylpiperazinyl)ethyl ester, hydrochloride",C[NH+]1CCN(CC1)CCOC(=O)C2C3C2C=CC=CC3.[Cl-],,,,,,
3167,37862,"2-(4-Methylpiperazin-1-yl)ethyl bicyclo[5.1.0]octa-2,4-diene-8-carboxylate",CN1CCN(CC1)CCOC(=O)C2C3C2C=CC=CC3,,,,,,
3168,37863,"Bicyclo(5.1.0)octa-2,4-diene-8-carboxylic acid, 2-piperidinoethyl ester, hydrochloride",C1CC[NH+](CC1)CCOC(=O)C2C3C2C=CC=CC3.[Cl-],,,,,,
3169,37864,"2-Piperidin-1-ylethyl bicyclo[5.1.0]octa-2,4-diene-8-carboxylate",C1CCN(CC1)CCOC(=O)C2C3C2C=CC=CC3,,,,,,
3170,37865,"Bicyclo(5.1.0)octa-2,4-diene-8-carboxylic acid, 3-(piperidinopropyl) ester, hydrochloride",C1CC[NH+](CC1)CCCOC(=O)C2C3C2C=CC=CC3.[Cl-],,,,,,
3171,37866,"3-Piperidin-1-ylpropyl bicyclo[5.1.0]octa-2,4-diene-8-carboxylate",C1CCN(CC1)CCCOC(=O)C2C3C2C=CC=CC3,,,,,,
3172,37867,CID 37867,CN1C=C(C=C1C(=O)N=CC=C(N)N)NC(=O)C2CCC(=N2)N,,,,,,
3173,37868,"Carbazic acid, 3-benzyl-, ethyl ester",CCOC(=O)NNCC1=CC=CC=C1,,,,,,
3174,37869,Perfluidone,CC1=C(C=CC(=C1)S(=O)(=O)C2=CC=CC=C2)NS(=O)(=O)C(F)(F)F,,,,,,
3175,37870,1-Allyl-5-phenylhydantoin,C=CCN1C(C(=O)NC1=O)C2=CC=CC=C2,,,,,,
3176,37871,"(3R,5R,8R,9R,10S,13S,14R)-14-hydroxy-3-[(2S,3R,4S,5S,6S)-3-hydroxy-4-methoxy-6-methyl-5-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-[[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carbaldehyde",C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)O[C@@H]2CC[C@@]3([C@@H](C2)CC[C@@H]4[C@H]3CC[C@@]5([C@]4(CCC5C6=CC(=O)OC6)O)C)C=O)O)OC)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO)O)O)O)O)O)O,,,,,,
3177,37872,CID 37872,C=C(C(=O)[O-])O.[Na+],,,,,,
3178,37873,2-Hydroxyacrylic acid,C=C(C(=O)O)O,,,,,,
3179,37874,"1,1'-(9H-Xanthene-2,7-diyl)bis(2-piperidinoethanone) hydrochloride hydrate (2:4:7)",C1CC[NH+](CC1)CC(=O)C2=CC3=C(C=C2)OC4=C(C3)C=C(C=C4)C(=O)C[NH+]5CCCCC5.[Cl-].[Cl-],,,,,,
3180,37875,2-(1-piperidyl)-1-[7-[2-(1-piperidyl)acetyl]-9H-xanthen-2-yl]ethanone,C1CCN(CC1)CC(=O)C2=CC3=C(C=C2)OC4=C(C3)C=C(C=C4)C(=O)CN5CCCCC5,,,,,,
3181,37876,"1,1'-(9H-Xanthene-2,7-diyl)bis(2-(dimethylamino)ethanone) dihydrochloride",C[NH+](C)CC(=O)C1=CC2=C(C=C1)OC3=C(C2)C=C(C=C3)C(=O)C[NH+](C)C.[Cl-].[Cl-],,,,,,
3182,37877,2-(dimethylamino)-1-[7-[2-(dimethylamino)acetyl]-9H-xanthen-2-yl]ethanone,CN(C)CC(=O)C1=CC2=C(C=C1)OC3=C(C2)C=C(C=C3)C(=O)CN(C)C,,,,,,
3183,37878,"Benzoic acid, 5-amino-2-chloro-, sulfate (1:1)",C1=CC(=C(C=C1[NH3+])C(=O)O)Cl.OS(=O)(=O)[O-],,,,,,
3184,37879,5-Amino-2-chlorobenzoic acid,C1=CC(=C(C=C1N)C(=O)O)Cl,,,,,,
3185,37880,7-Hydroxybenzo(a)pyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC=C5O)C=C2,,,,,,
3186,37881,"Benzophenone, 3,5-dihydroxy-",C1=CC=C(C=C1)C(=O)C2=CC(=CC(=C2)O)O,,,,,,
3187,37882,"Ethylamine, 2,2'-(9H-xanthene-2,7-diylbis(oxy))bis(N,N-dimethyl-",CN(C)CCOC1=CC2=C(C=C1)OC3=C(C2)C=C(C=C3)OCCN(C)C,,,,,,
3188,37883,7-Butoxy-8-(dimethylaminomethyl)-3-methylflavone hydrochloride,CCCCOC1=C(C2=C(C=C1)C(=O)C(=C(O2)C3=CC=CC=C3)C)C[NH+](C)C.[Cl-],,,,,,
3189,37884,7-Butoxy-8-[(dimethylamino)methyl]-3-methyl-2-phenylchromen-4-one,CCCCOC1=C(C2=C(C=C1)C(=O)C(=C(O2)C3=CC=CC=C3)C)CN(C)C,,,,,,
3190,37885,8-(Dimethylaminomethyl)-7-ethoxy-3-methylflavone hydrochloride,CCOC1=C(C2=C(C=C1)C(=O)C(=C(O2)C3=CC=CC=C3)C)C[NH+](C)C.[Cl-],,,,,,
3191,37886,8-[(Dimethylamino)methyl]-7-ethoxy-3-methyl-2-phenylchromen-4-one,CCOC1=C(C2=C(C=C1)C(=O)C(=C(O2)C3=CC=CC=C3)C)CN(C)C,,,,,,
3192,37887,"4H-1-Benzopyran-4-one, 8-((dimethylamino)methyl)-7-ethoxy-2,3-dimethyl-, hydrochloride",CCOC1=C(C2=C(C=C1)C(=O)C(=C(O2)C)C)C[NH+](C)C.[Cl-],,,,,,
3193,37888,"8-[(Dimethylamino)methyl]-7-ethoxy-2,3-dimethylchromen-4-one",CCOC1=C(C2=C(C=C1)C(=O)C(=C(O2)C)C)CN(C)C,,,,,,
3194,37889,"4H-1-Benzopyran-4-one, 8-((dimethylamino)methyl)-7-methoxy-2,3-dimethyl-, hydrochloride",CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+](C)C)OC)C.[Cl-],,,,,,
3195,37890,"8-[(Dimethylamino)methyl]-7-methoxy-2,3-dimethylchromen-4-one",CC1=C(OC2=C(C1=O)C=CC(=C2CN(C)C)OC)C,,,,,,
3196,37891,"2,3-Dimethyl-6-(dimethylaminomethyl)chromone hydrochloride",CC1=C(OC2=C(C1=O)C=C(C=C2)C[NH+](C)C)C.[Cl-],,,,,,
3197,37892,"6-[(Dimethylamino)methyl]-2,3-dimethylchromen-4-one",CC1=C(OC2=C(C1=O)C=C(C=C2)CN(C)C)C,,,,,,
3198,37893,"7,8-Dimethylfluoranthene",CC1=C(C2=C(C=C1)C3=CC=CC4=C3C2=CC=C4)C,,,,,,
3199,37894,2-Methyl-2-isopropenylcyclohexanol,CC(=C)C1(CCCCC1O)C,,,,,,
3200,37895,N-(2-morpholin-4-ylethyl)-2-(1-phenylethylideneamino)oxyacetamide,CC(=NOCC(=O)NCCN1CCOCC1)C2=CC=CC=C2,,,,,,
3201,37896,1-Morpholin-4-yl-2-(1-phenylethylideneamino)oxyethanone,CC(=NOCC(=O)N1CCOCC1)C2=CC=CC=C2,,,,,,
3202,37897,"1-[4-(1,3-Benzodioxol-5-ylmethyl)piperazin-1-yl]-2-(1-phenylethylideneamino)oxyethanone",CC(=NOCC(=O)N1CCN(CC1)CC2=CC3=C(C=C2)OCO3)C4=CC=CC=C4,,,,,,
3203,37898,1-(4-Methylpiperazin-1-yl)-2-(1-phenylethylideneamino)oxyethanone,CC(=NOCC(=O)N1CCN(CC1)C)C2=CC=CC=C2,,,,,,
3204,37899,4-[C-methyl-N-(2-morpholin-4-ylethoxy)carbonimidoyl]aniline,CC(=NOCCN1CCOCC1)C2=CC=C(C=C2)N,,,,,,
3205,37900,2-[1-(4-Aminophenyl)ethylideneamino]oxy-1-morpholin-4-ylethanone,CC(=NOCC(=O)N1CCOCC1)C2=CC=C(C=C2)N,,,,,,
3206,37901,2-chloro-N-[4-[C-methyl-N-(2-morpholin-4-ylethoxy)carbonimidoyl]phenyl]pyridine-3-carboxamide,CC(=NOCCN1CCOCC1)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)Cl,,,,,,
3207,37902,2-chloro-N-[4-[N-[2-(diethylamino)ethoxy]-C-methylcarbonimidoyl]phenyl]pyridine-3-carboxamide,CCN(CC)CCON=C(C)C1=CC=C(C=C1)NC(=O)C2=C(N=CC=C2)Cl,,,,,,
3208,37903,"2,5-dimethyl-N-[4-[C-methyl-N-(2-morpholin-4-ylethoxy)carbonimidoyl]phenyl]furan-3-carboxamide",CC1=CC(=C(O1)C)C(=O)NC2=CC=C(C=C2)C(=NOCCN3CCOCC3)C,,,,,,
3209,37904,(3-Chlorophenyl)-thiophen-2-yliodanium;chloride,C1=CC(=CC(=C1)[I+]C2=CC=CS2)Cl.[Cl-],,,,,,
3210,37905,(3-Chlorophenyl)-thiophen-2-yliodanium,C1=CC(=CC(=C1)[I+]C2=CC=CS2)Cl,,,,,,
3211,37906,Carmantadine,C1CN(C1C(=O)O)C23CC4CC(C2)CC(C4)C3,,,,,,
3212,37907,Climbazole,CC(C)(C)C(=O)C(N1C=CN=C1)OC2=CC=C(C=C2)Cl,,,,,,
3213,37908,Dodecyl-(3-hydroxyprop-1-enyl)-dimethylazanium;chloride,CCCCCCCCCCCC[N+](C)(C)C=CCO.[Cl-],,,,,,
3214,37909,Dodecyl-(3-hydroxyprop-1-enyl)-dimethylazanium,CCCCCCCCCCCC[N+](C)(C)C=CCO,,,,,,
3215,37910,Tolamolol,CC1=CC=CC=C1OCC(CNCCOC2=CC=C(C=C2)C(=O)N)O,,,,,,
3216,37911,N-Acetoxy-3-fluorenylacetamide,CC(=O)N(C1=CC2=C(CC3=CC=CC=C32)C=C1)OC(=O)C,,,,,,
3217,37912,N-(2-Chloroethyl)-N-methyl-4-(phenylazo)aniline,CN(CCCl)C1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
3218,37913,2-((4-(N-(2-Chloroethyl)methylamino)-2-methylphenyl)azo)benzoic acid,CC1=C(C=CC(=C1)N(C)CCCl)N=NC2=CC=CC=C2C(=O)O,,,,,,
3219,37914,"4-Amino-6-hydroxy-3,5-dichloropicolinic acid",C1(=C(C(=O)NC(=C1Cl)C(=O)O)Cl)N,,,,,,
3220,37915,"(2R,3R,5R,6S,8R,10R,17S)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-4,5,8,14-tetrol",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C[C@]4([C@H]5C6O)O)OC)O)C(CC2O)OC)OC)COC,,,,,,
3221,37916,CID 37916,CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6([C@H](C[C@]4([C@H]5C6OC(=O)C)OC(=O)C)OC)OC(=O)C)C(CC2OC(=O)C)OC)OC)COC,,,,,,
3222,37917,"Indole, 2,4-dimethyl-5-methoxy-3-(2-(1-pyrrolidinyl)ethyl)-",CC1=C(C=CC2=C1C(=C(N2)C)CCN3CCCC3)OC,,,,,,
3223,37918,"3-Azabicyclo(3.2.2)nonane, 3-(2-(5-methoxy-2,7-dimethyl-1H-indol-3-YL)ethyl)-",CC1=CC(=CC2=C1NC(=C2CCN3CC4CCC(C3)CC4)C)OC,,,,,,
3224,37919,"Indole, 2,4-dimethyl-5-methoxy-3-(2-(2-methylprop-2-enylamino)ethyl)-, succinate",CC1=C(C=CC2=C1C(=C(N2)C)CC[NH2+]CC(=C)C)OC.C(CC(=O)[O-])C(=O)O,,,,,,
3225,37920,"5-Methoxy-2,4-dimethyl-N-(2-methyl-2-propenyl)-1H-indole-3-ethanamine",CC1=C(C=CC2=C1C(=C(N2)C)CCNCC(=C)C)OC,,,,,,
3226,37921,CID 37921,CC=CC(C)C1=CC=C(C2=CC=CC=C21)C,,,,,,
3227,37922,8-(Dimethylaminomethyl)-3-ethyl-7-methoxyflavone hydrochloride,CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+](C)C)OC)C3=CC=CC=C3.[Cl-],,,,,,
3228,37923,8-[(Dimethylamino)methyl]-3-ethyl-7-methoxy-2-phenylchromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CN(C)C)OC)C3=CC=CC=C3,,,,,,
3229,37924,"1,6-Dichlorodibenzo-P-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(O2)C(=CC=C3)Cl,,,,,,
3230,37925,2-Nitrodibenzo-p-dioxin,C1=CC=C2C(=C1)OC3=C(O2)C=C(C=C3)[N+](=O)[O-],,,,,,
3231,37926,"1,2,4,5,7,8-Hexachloro-9H-xanthene",C1C2=C(C(=CC(=C2Cl)Cl)Cl)OC3=C1C(=C(C=C3Cl)Cl)Cl,,,,,,
3232,37927,Fluorescamine,C1=CC=C(C=C1)C2=COC3(C2=O)C4=CC=CC=C4C(=O)O3,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
3233,37928,"5-Benzoxazoleacetic acid, 2-phenyl-",C1=CC=C(C=C1)C2=NC3=C(O2)C=CC(=C3)CC(=O)O,,,,,,
3234,37929,m-Propoxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2[NH+](CC)CC.[Cl-],,,,,,
3235,37930,"[(1R,2R)-2-(diethylamino)cyclohexyl] N-(3-propoxyphenyl)carbamate",CCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2N(CC)CC,,,,,,
3236,37931,m-Butoxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCCOC1=CC=CC(=C1)NC(=O)OCC[C@@H]2CCCC[C@H]2[NH+](C)C.[Cl-],,,,,,
3237,37932,"2-[(1S,2R)-2-(dimethylamino)cyclohexyl]ethyl N-(3-butoxyphenyl)carbamate",CCCCOC1=CC=CC(=C1)NC(=O)OCC[C@@H]2CCCC[C@H]2N(C)C,,,,,,
3238,37933,m-Pentyloxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2[NH+](CC)CC.[Cl-],,,,,,
3239,37934,"[(1R,2R)-2-(diethylamino)cyclohexyl] N-(3-pentoxyphenyl)carbamate",CCCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2N(CC)CC,,,,,,
3240,37935,m-Hexyloxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+](CC)CC.[Cl-],,,,,,
3241,37936,"[(1S,2S)-2-(diethylamino)cyclohexyl] N-(3-hexoxyphenyl)carbamate",CCCCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2N(CC)CC,,,,,,
3242,37937,m-Propoxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCC3.[Cl-],,,,,,
3243,37938,"[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl] N-(3-propoxyphenyl)carbamate",CCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2N3CCCC3,,,,,,
3244,37939,m-Butoxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCC3.[Cl-],,,,,,
3245,37940,"[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl] N-(3-butoxyphenyl)carbamate",CCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2N3CCCC3,,,,,,
3246,37941,trans-2-(1-Pyrrolidinyl)cyclohexyl 3-pentyloxycarbanilate hydrochloride,CCCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2[NH+]3CCCC3.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)']",,,
3247,37942,CID 37942,CCCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCCC2N3CCCC3,,,,,,
3248,37943,m-Pentyloxycarbanilic acid cis-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@@H]2[NH+]3CCCC3.[Cl-],,,,,,
3249,37944,m-Hexyloxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCC3.[Cl-],,,,,,
3250,37945,"[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl] N-(3-hexoxyphenyl)carbamate",CCCCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2N3CCCC3,,,,,,
3251,37946,o-Pentyloxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCCOC1=CC=CC=C1NC(=O)O[C@@H]2CCCC[C@H]2[NH+]3CCCC3.[Cl-],,,,,,
3252,37947,CID 37947,CCCCCOC1=CC=CC=C1NC(=O)O[C@@H]2CCCCC2N3CCCC3,,,,,,
3253,37948,m-Propoxycarbanilic acid trans-2-piperidinocyclohexyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCCC2[NH+]3CCCCC3.[Cl-],,,,,,
3254,37949,[(1R)-2-piperidin-1-ylcyclohexyl] N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCCC2N3CCCCC3,,,,,,
3255,37950,"Carbamic acid, (3-butoxyphenyl)-, 2-(1-piperidinyl)cyclohexyl ester, monohydrochloride, trans-",CCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2[NH+]3CCCCC3.[Cl-],,,,,,
3256,37951,"[(1R,2R)-2-piperidin-1-ylcyclohexyl] N-(3-butoxyphenyl)carbamate",CCCCOC1=CC=CC(=C1)NC(=O)O[C@@H]2CCCC[C@H]2N3CCCCC3,,,,,,
3257,37952,m-Pentyloxycarbanilic acid trans-2-piperidinocyclohexyl ester hydrochloride,CCCCCOC1=CC=CC(=C1)NC(=O)OC2CCCC[C@H]2[NH+]3CCCCC3.[Cl-],,,,,,
3258,37953,[(2R)-2-piperidin-1-ylcyclohexyl] N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)NC(=O)OC2CCCC[C@H]2N3CCCCC3,,,,,,
3259,37954,(E)-2-Piperidinocyclohexyl m-hexyloxycarbanilate hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCCC3.[Cl-],,,,,,
3260,37955,CID 37955,CCCCCCOC1=CC=CC(=C1)NC(=O)O[C@H]2CCCCC2N3CCCCC3,,,,,,
3261,37956,p-Propoxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCC[C@H]2[NH+](CC)CC.[Cl-],,,,,,
3262,37957,"[(1R,2R)-2-(diethylamino)cyclohexyl] N-(4-propoxyphenyl)carbamate",CCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCC[C@H]2N(CC)CC,,,,,,
3263,37958,p-Pentyloxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCC[C@H]2[NH+](CC)CC.[Cl-],,,,,,
3264,37959,"[(1R,2R)-2-(diethylamino)cyclohexyl] N-(4-pentoxyphenyl)carbamate",CCCCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCC[C@H]2N(CC)CC,,,,,,
3265,37960,p-Hexyloxycarbanilic acid trans-2-(diethylamino)cyclohexyl ester hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+](CC)CC.[Cl-],,,,,,
3266,37961,"[(1S,2S)-2-(diethylamino)cyclohexyl] N-(4-hexoxyphenyl)carbamate",CCCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2N(CC)CC,,,,,,
3267,37962,p-Propoxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)OC2CCCCC2[NH+]3CCCC3.[Cl-],,,,,,
3268,37963,(2-pyrrolidin-1-ylcyclohexyl) N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)OC2CCCCC2N3CCCC3,,,,,,
3269,37964,p-Butoxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCOC1=CC=C(C=C1)NC(=O)OC2CCC(CC2)[NH+]3CCCC3.[Cl-],,,,,,
3270,37965,(4-pyrrolidin-1-ylcyclohexyl) N-(4-butoxyphenyl)carbamate,CCCCOC1=CC=C(C=C1)NC(=O)OC2CCC(CC2)N3CCCC3,,,,,,
3271,37966,p-Pentyloxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCCC2[NH+]3CCCC3.[Cl-],,,,,,
3272,37967,[(1R)-2-pyrrolidin-1-ylcyclohexyl] N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCCC2N3CCCC3,,,,,,
3273,37968,p-Hexyloxycarbanilic acid trans-2-(1-pyrrolidinyl)cyclohexyl ester hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCC3.[Cl-],,,,,,
3274,37969,"[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl] N-(4-hexoxyphenyl)carbamate",CCCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2N3CCCC3,,,,,,
3275,37970,p-Propoxycarbanilic acid trans-2-piperidinocyclohexyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCCC2[NH+]3CCCCC3.[Cl-],,,,,,
3276,37971,[(1R)-2-piperidin-1-ylcyclohexyl] N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)O[C@@H]2CCCCC2N3CCCCC3,,,,,,
3277,37972,Demethoxymitomycin A,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@H]3[C@H]2COC(=O)N)N4)OC,,,,,,
3278,37973,"Carbamic acid, (4-(pentyloxy)phenyl)-, 2-(1-piperidinyl)cyclohexyl ester, monohydrochloride, trans-",CCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCCC3.[Cl-],,,,,,
3279,37974,"[(1S,2S)-2-piperidin-1-ylcyclohexyl] N-(4-pentoxyphenyl)carbamate",CCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2N3CCCCC3,,,,,,
3280,37975,(E)-2-Piperidinocyclohexyl p-hexyloxycarbanilate hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCC[C@@H]2[NH+]3CCCCC3.[Cl-],,,,,,
3281,37976,CID 37976,CCCCCCOC1=CC=C(C=C1)NC(=O)O[C@H]2CCCCC2N3CCCCC3,,,,,,
3282,37977,"Carbamic acid, dimethyldithio-, succinimidomethyl ester",CN(C)C(=S)SCN1C(=O)CCC1=O,,,,,,
3283,37978,"Carbamic acid, dimethyldithio-, nicotinamidomethyl ester",CN(C)C(=S)SCNC(=O)C1=CN=CC=C1,,,,,,
3284,37979,"Carbamic acid, dimethyldithio-, isonicotinamidomethyl ester",CN(C)C(=S)SCNC(=O)C1=CC=NC=C1,,,,,,
3285,37980,N-(Morpholinomethyl)isonicotinamide,C1COCCN1CNC(=O)C2=CC=NC=C2,,,,,,
3286,37981,"Isonicotinamide, N-(4-methyl-1-piperazinylmethyl)-",CN1CCN(CC1)CNC(=O)C2=CC=NC=C2,,,,,,
3287,37982,Hentriacontanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
3288,37983,4'-Aminohexanophenone,CCCCCC(=O)C1=CC=C(C=C1)N,,,,,,
3289,37984,(cis)-2-Mercaptocyclobutylamine hydrochloride,C1C[C@H]([C@H]1[NH3+])S.[Cl-],,,,,,
3290,37985,2-Aminocyclobutane-1-thiol,C1CC(C1N)S,,,,,,
3291,37986,(trans)-2-Mercaptocyclobutylamine hydrochloride,C1C[C@@H]([C@H]1[NH3+])S.[Cl-],,,,,,
3292,37987,"Ethenamine, N-methylene-",C=CN=C,,,,,,
3293,37988,CID 37988,COC1=C(C=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br)OC,,,,,,
3294,37989,Zinterol hydrochloride,CC(C)(CC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)NS(=O)(=O)C)O.Cl,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],,,
3295,37990,Zinterol,CC(C)(CC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)NS(=O)(=O)C)O,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],,,
3296,37991,"3,4,5-Trimethoxybenzoic acid 3-(diethylamino)propyl ester hydrochloride",CC[NH+](CC)CCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[Cl-],,,,,,
3297,37992,"3-(Diethylamino)propyl 3,4,5-trimethoxybenzoate",CCN(CC)CCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
3298,37993,Butyl(3-carboxypropyl)nitrosamine,CCCCN(CCCC(=O)O)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
3299,37994,"Butyric acid, 4-(butylnitrosoamino)-3-hydroxy-",CCCCN(CC(CC(=O)O)O)N=O,,,,,,
3300,37995,Etrimfos,CCC1=NC(=CC(=N1)OP(=S)(OC)OC)OCC,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', '... The organophosphorus insecticides are, in contrast to the chlorinated insecticides, rapidly metabolized & excreted and are not appreciably stored in body tissues. /Organophosphorus insecticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... . /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for ETRIMFOS (8 total), please visit the HSDB record page.']","['Plasma & tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric & phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paroxonase. The enzymes are found in plasma and in the hepatic endoplasmic reticulum & can hydrolyze a large number of organophosphorus compounds ... by splitting the anhydride, P-F, P-CN, or ester bond. /Anticholinesterase agents/', 'These chemicals are detoxified by cytochrome p450-mediated monooxygenases in the liver, but some metabolites are more toxic than parent cmpd ... Metabolites usually are detected from 12 to 48 hr postexposure. /Organophosphate cmpd/', 'When etrimfos was administered to rats, most of the material was excreted in the urine. Five compounds, free and conjugated, were observed: 6-ethoxy-2-ethyl-4- hydroxypyrimidine; 2-ethyl-4,6-dihydroxypyrimidine; 6-ethoxy-4-hydroxy-2-(1- hydroxyethyl)pyrimidine; 6-ethoxy-4-hydroxy-2-(2-hydroxyethoxy)pyrimidine; and 2-ethyl-4-hydroxy-6-(2-hydroxyethoxy)pyrimidine. In urine of goats administered etrimfos, only the first three compounds above were observed.', 'For more Metabolism/Metabolites (Complete) data for ETRIMFOS (11 total), please visit the HSDB record page.']",
3301,37996,CID 37996,C1=CC=C(C(=C1)C(=N)N)C(=O)N[NH3+].C1=CC=C(C(=C1)C(=N)N)C(=O)N[NH3+].[O-]S(=O)(=O)[O-],,,,,,
3302,37997,2-(Hydrazinecarbonyl)benzenecarboximidamide,C1=CC=C(C(=C1)C(=N)N)C(=O)NN,,,,,,
3303,37998,"3,4,5-Trimethoxybenzoic acid 2-(aminoiminomethyl)hydrazide sulfate (2:1)",COC1=CC(=CC(=C1OC)OC)C(=O)N[NH+]=C(N)N.COC1=CC(=CC(=C1OC)OC)C(=O)N[NH+]=C(N)N.[O-]S(=O)(=O)[O-],,,,,,
3304,37999,"[(3,4,5-Trimethoxyphenyl)formohydrazido]methanimidamide",COC1=CC(=CC(=C1OC)OC)C(=O)NN=C(N)N,,,,,,
3305,38000,Benurestat,C1=CC(=CC=C1C(=O)NCC(=O)NO)Cl,,,,,,
3306,38001,"4-Ethyl-5-hexyl-2,2-bis(trifluoromethyl)-1,3-dioxolane",CCCCCCC1C(OC(O1)(C(F)(F)F)C(F)(F)F)CC,,,,,,
3307,38002,4-Nonylbenzoic acid,CCCCCCCCCC1=CC=C(C=C1)C(=O)O,,,,,,
3308,38003,"N-[(2-chloro-1-phenylethylidene)amino]-2,4-dinitroaniline",C1=CC=C(C=C1)C(=NNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])CCl,,,,,,
3309,38004,"6-Methylamino-5,6,7,8-tetrahydro-1,2-naphthalenediol hydrobromide",C[NH2+]C1CCC2=C(C1)C=CC(=C2O)O.[Br-],,,,,,
3310,38005,"5,6-Dihydroxy-2-methylaminotetralin",CNC1CCC2=C(C1)C=CC(=C2O)O,,,,,,
3311,38006,"1-(2,4-Dichlorophenyl)ethenoxy-ethyl-methoxy-sulfanylidene-lambda5-phosphane",CCP(=S)(OC)OC(=C)C1=C(C=C(C=C1)Cl)Cl,,,,,,
3312,38007,"PYRIMIDO(3,4-a)INDOLE, 1,2,3,4-TETRAHYDRO-5,7-DIMETHYL-",CC1=CC2=C(C=C1)N3CNCCC3=C2C,,,,,,
3313,38008,"PYRIMIDO(3,4-a)INDOLE, 1,2,3,4-TETRAHYDRO-7-METHOXY-5-METHYL-",CC1=C2CCNCN2C3=C1C=C(C=C3)OC,,,,,,
3314,38009,"Acetic acid, (p-(bis(2-chloroethyl)amino)phenyl)-, 2-hydroxy-1,3-propanediyl ester",C1=CC(=CC=C1CC(=O)OCC(COC(=O)CC2=CC=C(C=C2)N(CCCl)CCCl)O)N(CCCl)CCCl,,,,,,
3315,38010,Penbutolol sulfate,CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O.CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O.OS(=O)(=O)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
3316,38011,propan-2-yl N-(2-methylphenyl)carbamate,CC1=CC=CC=C1NC(=O)OC(C)C,,,,,,
3317,38012,"2,2',3,5',6-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=C(C=CC(=C2Cl)Cl)Cl)Cl,,,,,,
3318,38013,"2,2',4,4',5-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
3319,38014,"2,2',3,4,5'-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl,,,,,,
3320,38015,"2,3,3',4',6-Pentachlorobiphenyl",C1=CC(=C(C=C1C2=C(C=CC(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3321,38016,"2,2',3,4',5',6-Hexachlorobiphenyl",C1=CC(=C(C(=C1Cl)C2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3322,38017,"2,2',3,3',4,6'-Hexachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C=CC(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
3323,38018,"2,2',3,3',4,4'-Hexachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,,,,"['... For PCB-contaminated soil, the U.S. Environmental Protection Agency uses a dermal absorption factor of 14%, based on a 1993 study of dermal absorption in rhesus monkeys.  /This/ study examined several parameters that can influence the dermal absorption of lipophilic hydrocarbons, including soil organic content, particle size, skin residence time, and contaminant ""aging"" in the soil. Four groups of four female rhesus monkeys each were exposed to radiolabeled Aroclor 1260 either intravenously (100% absorption) or dermally with PCB-spiked soil. Groups exposed for 12 or 24 hr to PCBs aged in soil exhibited percutaneous absorption values of 3.43 +/- 0.35 and 4.26 +/- 0.52%, respectively, while a group exposed for 24 hr to soil freshly spiked with PCBs exhibited a dermal absorption value of 4.07 +/- 0.46%. Evidence strongly suggests that the factor most responsible for modulating the percutaneous absorption of highly lipophilic compounds from soil is its organic content. The base soil used in /this/ study with Aroclor 1260 had an organic content of 5-6% (< or =2 mm particle fraction), a value typical for U.S. soil. The organic content of the soil applied to the skin was 8.7% (< 150 um particle fraction), a value that contrasts sharply with the soil containing 0.9% organics used in the 1993 study with Aroclors 1242 and 1254 that produced a dermal absorption value of 14% for PCBs.', 'Pigeons were injected with a single dose of commercial PCB mixtures (Aroclor 1248 plus Aroclor 1260), killed 120 hr later and the abundance of individual PCBs was determined in adipose tissue, gonads, liver, brain, kidney, heart, muscle and blood. Elimination factors for individual PCBs were calculated. Values of greater than 1 were obtained for PCBs with meta-para-unsubstituted carbon atoms in at least one ring, indicating that elimination exceeded accumulation in all or most tissues. By contrast, ortho-meta unsubstituted PCBs had elimination factors less than 1, thus indicating their impaired removal. Tissues with high microsomal monooxygenase activity had the highest elimination factors for individual PCBs (ie, liver greater than kidney greater than muscle greater than heart). Distribution of individual PCBs was independent of sex and of ortho-chlorine substitution and showed that 90% of total PCBs in cadavers was present in adipose tissue, 2% in kidneys, 1% each in brain, muscle and heart and less than 0.1% in blood. The distribution of the highly toxic non-ortho and mono-ortho substituted PCBs did not differ among all tissues analyzed ... Elimination of PCBs in vivo is favored by the molecular feature of unsubstituted meta-para carbon atoms in the biphenyl moiety. /Aroclor 1248 plus Aroclor 1260 mixture/', 'The use of serum reference materials for assessing exposure to polychlorinated biphenyls (PCBs) was described. Adult female goats were fed 100 (mg/kg) Aroclor-1016, Aroclor-1242, Aroclor-1254, or Aroclor-1260 alone or in combination. The combined doses totalled 200 mg/kg. Thirty days later, the goats were killed, and sera were obtained and analyzed by gas chromatography. Sera from three human cases of suspected PCB exposure were also analyzed. Two of these cases were composite samples of populations allegedly exposed to Aroclor-1260. The samples contained 307 and 31 parts per billion (ppb), reported as Aroclor-1260. The third case contained 172 ppb, alleged to be Aroclor-1254. The chromatographic data was subjected to principal components and Jaccard coefficient analysis in an effort to relate the human sera samples to the sera of the goats. The human sera from the suspected Aroclor-1254 exposure resembled that of Aroclor-1254 in the goat sera. Neither case of alleged Aroclor-1260 exposure resembled that of Aroclor-1260. Principal components analysis of one of the suspected Aroclor-1260 cases showed that the sera resembled that of Aroclor-1216 and Aroclor-1242 in the goat sera. ... Using in vivo reference materials may prove useful in delineating PCB exposures in people living near hazardous waste sites.', 'A number of animal studies have demonstrated that PCB mixtures and specific congeners and isomers can cross the placental barrier and enter the fetus. High levels of lipid soluble PCBs accumulate in the fat portion of the milk, also resulting in high exposure of suckling animals. Significantly increased PCB residues were detected in blastocytes (day 6 postcoitum) from female rabbits administered Aroclor 1260 before insemination, but no residues could be detected in cleavage stage embryos (day 1 postcoitum). In pregnant mice fed PCBs through the first 18 days of gestation, the highest levels of serum PCBs were found in 1-2-week-old offspring compared with 18-day fetuses or with older offspring. In studies that exposed monkeys prior to and during gestation, signs of PCB-induced intoxication were observed in suckling offspring, but not in neonates. PCB blood levels in the offspring continuously increased during lactation, but decreased just before or immediately upon weaning. In rats administered PCBs before gestation, 0.003% of the PCBs accumulated in the dams was transferred to the fetus through the placenta; however, the amount transferred to sucklings increased to 5% of the maternal PCB. Similar results have been reported in ferrets administered single doses of PCBs early or late during gestation. Results such as these have led to the conclusion that suckling may account for higher exposure of young offspring than does placental transfer; the fetus, however, may be more sensitive.', '... Applied Aroclor 1260 to the shaved backs of rabbits and found systemic effects in the kidneys, indicating that PCBs can penetrate the skin.']",,"['Based on human blood serum levels of PCBs in 1977 and in 1984 with occupationally exposed humans and human controls the half-life of less chlorinated congeners (Aroclor 1242 exposed) in human blood serum was 6-7 mo and the half-life of more highly chlorinated congeners (Aroclor 1260 exposed) was 33-34 mo. Evidently, some people continue to be exposed to PCBs or the half-life of the less chlorinated congeners is longer than previously thought.']"
3324,38019,"2,3,3',4,4',5-Hexachlorobiphenyl",C1=CC(=C(C=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
3325,38020,"3,3-Dimethyl-1-indanol",CC1(CC(C2=CC=CC=C21)O)C,,,,,,
3326,38021,"5-(tert-Butyl)-1,1-dimethylindan",CC1(CCC2=C1C=CC(=C2)C(C)(C)C)C,,,,,,
3327,38022,"1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone",CC(=O)[C@H]1CCC2[C@@]1(CCC3C2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,,,,,,
3328,38023,"N-(2,5-Dichloro-4-nitrophenyl)acetamide",CC(=O)NC1=CC(=C(C=C1Cl)[N+](=O)[O-])Cl,,,,,,
3329,38024,"2,2',3,3',6,6'-Hexachlorobiphenyl",C1=CC(=C(C(=C1Cl)C2=C(C=CC(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3330,38025,"2,2',3,3',4,5,6'-Heptachlorobiphenyl",C1=CC(=C(C(=C1Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
3331,38026,"1,3,5,7-Tetramethyl-1,1,3,5,7,7-hexaphenyltetrasiloxane",C[Si](C1=CC=CC=C1)(C2=CC=CC=C2)O[Si](C)(C3=CC=CC=C3)O[Si](C)(C4=CC=CC=C4)O[Si](C)(C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
3332,38027,5-Decenyl acetate,CCCCC=CCCCCOC(=O)C,,,,,,
3333,38028,Nitrocinnamonitrile,C1=CC=C(C=C1)C=C(C#N)[N+](=O)[O-],,,,,,
3334,38029,"2,2',6-Trichlorobiphenyl",C1=CC=C(C(=C1)C2=C(C=CC=C2Cl)Cl)Cl,,,,,,
3335,38030,"2,3',6-Trichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=C(C=CC=C2Cl)Cl,,,,,,
3336,38031,"2,4',6-Trichlorobiphenyl",C1=CC(=C(C(=C1)Cl)C2=CC=C(C=C2)Cl)Cl,,,,,,
3337,38032,"2,2',3-Trichlorobiphenyl",C1=CC=C(C(=C1)C2=C(C(=CC=C2)Cl)Cl)Cl,,,,,,
3338,38033,"2,3',5-Trichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=C(C=CC(=C2)Cl)Cl,,,,,,
3339,38034,"2,3,3'-Trichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=C(C(=CC=C2)Cl)Cl,,,,,,
3340,38035,"2,3,4'-Trichlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=CC=C(C=C2)Cl,,,,,,
3341,38036,"2,3',4'-Trichlorobiphenyl",C1=CC=C(C(=C1)C2=CC(=C(C=C2)Cl)Cl)Cl,,,,,,
3342,38037,Aroclor 1016,C1=CC(=CC(=C1)Cl)C2=CC(=CC(=C2)Cl)Cl,,,,"['Information specifically on the oral absorption of Aroclor 1016 is not available, but studies of individual congeners and PCB mixtures of higher chlorine content in animals indicate, in general, that PCBs are readily and extensively absorbed. These studies have found oral absorption efficiency on the order of 75 to > 90% in rats, mice, monkeys and ferrets. A study of a PCB mixture containing 54% chlorine provides direct evidence of absorption of PCBs in humans after oral exposure, and indirect evidence of oral absorption of PCBs by humans is available from studies of ingestion of contaminated fish by the general population. There are no quantitative data regarding inhalation absorption of PCBs in humans but studies of exposed workers suggest that PCBs are well absorbed by the inhalation and dermal routes. PCBs distribute preferentially to adipose tissue and concentrate in human breast milk due to its high fat content', ""The distribution, metabolism, and excretion of (14)C labeled 2,4,5,2'4'5' hexachloro, or 2,3,6,2'3',6' hexachlorobiphenyl in beagle dogs and cynomolgus monkeys, were studied after a single intravenous dose. The elimination of the test substances from the blood of both species was shown to be biphasic. The results for dichlorobiphenyl showed that the dog eliminated 50% of the dose (urine, 7%; feces, 43%) within 24 hr, while the remainder was found mainly in the adipose tissue. By 5 days, 90% had been eliminated. The monkey eliminated less than 15% of the dose within 24 hr, with less than 1% in the feces. The remainder was found in the adipose tissue. Within 28 days, 59% of the dose had been eliminated, chiefly in the urine. Biliary excretion after 24 hr was shown to be 33% in the dog and only 0.4% in the monkey. The data for 2,4,5,2',4',5' hexachlorobiphenyl showed that the dog eliminated 66% (urine, 3%; feces, 63%) within 3 days; the monkey eliminated 18 % of the dose (of which 17% was in the feces), 90 days following administration. The remainder was found in the adipose tissue. In the studies with 2,3,6,2',3',6' hexachlorobiphenyl, the dog eliminated 52% of the dose within 24 hr (urine, 11%; feces, 41%) and 70% in 3 days. The monkey eliminated 19% during the first 24 hr, divided equally between urine and feces. By 15 days, 61% had been eliminated, primarily in the feces. The 24 hr biliary excretion was 26% and 2.4% in the dog and the monkey, respectively."", 'Rats /were/ fed 100 ppm of Aroclor 1016 (6.6-3.5 mg/kg/day). Plasma, kidneys, urine, brain, liver, and adipose tissue were analyzed for polychlorinated biphenyls (PCBs) at 0.5, 1, 2, 4, 6, and 10 mo of exposure. PCB tissue levels were determined 2, 4, 5, and 6 mo after exposure was discontinued. Levels of PCBs were highest in adipose tissue where a steady state was approached in 2 and reached in 4 mo. Little PCB-residue was excreted in urine. Measureable residues were still present after 5 mo.', 'Toxicity of Aroclor 1016 to different age groups of sheepshead minnows was studied in intermittent-flow bioassays lasting 26 days. 32 and 100 ug/L killed newly hatched fry, juveniles, and adults. Sheepshead minnows accumulated the chemical in proportion to its concentration in test water. Fry contained 2500-8100 times the concentration added to the test water, adults 1700-15000 times, and juveniles 10000-34000 times. As much as 77 ug/L of Aroclor 1016 in eggs from exposed adults apparently did not affect survival of embryos or fry.', 'For more Absorption, Distribution and Excretion (Complete) data for Aroclor 1016 (7 total), please visit the HSDB record page.']","[""The metabolism of PCBs following oral and parenteral administration in animals has been extensively studied and reviewed, but studies in animals following inhalation or dermal exposure are lacking. Information on metabolism of PCBs in humans is limited to occupationally exposed individuals whose intake is derived mainly from inhalation and dermal exposure. In general, metabolism of PCBs depends on the number and position of the chlorine atoms on the phenyl rings of the constituent congeners (i.e., congener profile of the PCB mixture) and animal species. Although only limited data are available on metabolism of PCBs following inhalation exposure, there is no reason to suspect that PCBs are metabolized differently by this route.  Data exist on the in vitro hepatic metabolism and in vivo metabolic clearance of 2,2',3,3',6,6'-hexachlorobiphenyl and 4,4'-dichlorobiphenyl congeners in humans, monkeys, dogs, and rats. Both of these congeners are present in Aroclor 1016, but the hexachlorobiphenyl is only a minor constituent. For each congener, the Vmax values for metabolism in the monkey, dog and rat are consistent with the respective metabolic clearance values found in vivo. Thus, the kinetic constants for PCB metabolism obtained from the dog, monkey, and rat hepatic microsomal preparations were good predictors of in vivo metabolism and clearance for these congeners. In investigations directed at determining which species most accurately predicts the metabolism and disposition of PCBs in humans, the in vitro metabolism of these congeners was also studied using human liver microsomes. Available data suggest that metabolism of PCBs in humans most closely resembles that of the monkey and rat. For example, the in vitro apparent Km and Vmax for humans and monkeys are comparable. These studies show consistency between the in vitro and in vivo findings and collectively indicate that metabolism of the two congeners is similar in monkeys and humans.""]",
3343,38038,"3,4',5-Trichlorobiphenyl",C1=CC(=CC=C1C2=CC(=CC(=C2)Cl)Cl)Cl,,,,,,
3344,38039,"3,4,4'-Trichlorobiphenyl",C1=CC(=CC=C1C2=CC(=C(C=C2)Cl)Cl)Cl,,,,,,
3345,38040,"2,2',3,3'-Tetrachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=CC=C2)Cl)Cl,,,,,,
3346,38041,8beta-Hydroxy-dleta(9)-THC,CCCCCC1=CC(=C2C3C=C([C@@H](CC3C(OC2=C1)(C)C)O)C)O,,,,,,
3347,38042,10-Undecenoyl chloride,C=CCCCCCCCCC(=O)Cl,,,,,,
3348,38043,"5-chloro-3-[7-[(2S)-5,5-dimethyl-4-oxooxolan-2-yl]-3-methylocta-2,6-dienyl]-2,4-dihydroxy-6-methylbenzaldehyde",CC1=C(C(=C(C(=C1Cl)O)CC=C(C)CCC=C(C)[C@@H]2CC(=O)C(O2)(C)C)O)C=O,,,,,,
3349,38044,4-amino-3-nitro-2H-chromen-2-one,C1=CC=C2C(=C1)C(=C(C(=O)O2)[N+](=O)[O-])N,,,,,,
3350,38045,"Coumarin, 3-nitro-4-piperidino-",C1CCN(CC1)C2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
3351,38046,"Coumarin, 3,4-diamino-",C1=CC=C2C(=C1)C(=C(C(=O)O2)N)N,,,,,,
3352,38047,"Coumarin, 3-amino-4-piperidino-",C1CCN(CC1)C2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
3353,38048,2-Methoxy-6-nitrobenzonitrile,COC1=CC=CC(=C1C#N)[N+](=O)[O-],,,,,,
3354,38049,2-(Tridecyloxy)ethanol,CCCCCCCCCCCCCOCCO,,,,,,
3355,38050,2-(p-Acetamidophenyl)-2-ethylglutarimide,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)NC(=O)C,,,,,,
3356,38051,"3-Ethyl-6,7-epoxygeraniol 3,4-methylenedioxy phenyl ether",CCC(=CCOC1=CC2=C(C=C1)OCO2)CCC3C(O3)(C)C,,,,,,
3357,38052,2-Amino-4-(5-nitro-2-furyl)thiazole,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)N,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
3358,38053,Pyrrolidinyl ethoxy anilino benzoxazole,C1CCN(C1)CCOC2=CC=C(C=C2)NC3=NC4=CC=CC=C4O3,,,,,,
3359,38054,"BENZOTHIAZOLE, 5-METHOXY-2-(beta-(1-PYRROLIDINYL)-p-PHENETIDINO)-",COC1=CC2=C(C=C1)SC(=N2)NC3=CC=C(C=C3)OCCN4CCCC4,,,,,,
3360,38055,"(4a-alpha,5-beta,9b-alpha)-2,3,4,4a,5,9b-Hexahydro-5-phenyl-1H-indeno(1,2-b)pyridine",C1C[C@H]2[C@H](C3=CC=CC=C3[C@H]2NC1)C4=CC=CC=C4,,,,,,
3361,38056,N-Benzoyl-3-chloroalanine ethyl ester,CCOC(=O)C(CCl)NC(=O)C1=CC=CC=C1,,,,,,
3362,38057,"1,4-Naphthoquinone, 2-(3-piperidinopropyl)amino-",C1CCN(CC1)CCCNC2=CC(=O)C3=CC=CC=C3C2=O,,,,,,
3363,38058,"1,4-Naphthoquinone, 2-(3-(4-methyl-1-piperazinyl)propylamino)-",CN1CCN(CC1)CCCNC2=CC(=O)C3=CC=CC=C3C2=O,,,,,,
3364,38059,"3,5-Bis(methylamino)-4-ethyl-1,2-dithiol-1-ium chloride",CCC1=C(SSC1=[NH+]C)NC.[Cl-],,,,,,
3365,38060,4-ethyl-N-methyl-5-methyliminodithiol-3-amine,CCC1=C(SSC1=NC)NC,,,,,,
3366,38061,"3-Dimethylamino-5-morpholino-1,2-dithiolium chloride",C[N+](=C1C=C(SS1)N2CCOCC2)C.[Cl-],,,,,,
3367,38062,Dimethyl-(5-morpholin-4-yldithiol-3-ylidene)azanium,C[N+](=C1C=C(SS1)N2CCOCC2)C,,,,,,
3368,38063,CID 38063,CN=C(C(CCN(C)C)C(=NC)S)S,,,,,,
3369,38064,"7-Hydroxymethylbenzanthracene 5,6-oxide",C1=CC=C2C(=C1)C=C3C4=CC=CC=C4C5C(C3=C2CO)O5,,,,,,
3370,38065,o-(2-Hydroxy-3-(isopropylamino)propoxy)benzonitrile,CC(C)NCC(COC1=CC=CC=C1C#N)O,,,,,,
3371,38066,"Benzeneacetic acid, 2-(cyclohexyl(phenylacetyl)amino)-1-phenylethyl ester",C1CCC(CC1)N(CC(C2=CC=CC=C2)OC(=O)CC3=CC=CC=C3)C(=O)CC4=CC=CC=C4,,,,,,
3372,38067,"Acetamide, N-(4-piperidinophenethyl)-2,2,2-trifluoro-",C1CCN(CC1)C2=CC=C(C=C2)CCNC(=O)C(F)(F)F,,,,,,
3373,38068,"N-(beta-Methyl-4-piperidinophenethyl)-2,2,2-trifluoroacetamide",CC(CNC(=O)C(F)(F)F)C1=CC=C(C=C1)N2CCCCC2,,,,,,
3374,38069,"Acetamide, N-methyl-N-(4-piperidinophenethyl)-2,2,2-trifluoro-, hydrochloride",CN(CCC1=CC=C(C=C1)[NH+]2CCCCC2)C(=O)C(F)(F)F.[Cl-],,,,,,
3375,38070,"2,2,2-trifluoro-N-methyl-N-[2-(4-piperidin-1-ylphenyl)ethyl]acetamide",CN(CCC1=CC=C(C=C1)N2CCCCC2)C(=O)C(F)(F)F,,,,,,
3376,38071,"Acetamide, N-(4-piperidinophenethyl)-2-(4-piperidinophenyl)-",C1CCN(CC1)C2=CC=C(C=C2)CCNC(=O)CC3=CC=C(C=C3)N4CCCCC4,,,,,,
3377,38072,Cridanimod,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3N2CC(=O)O,,,"['Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)']",,,
3378,38073,"N-Butylhexane-1,6-diamine",CCCCNCCCCCCN,,,,,,
3379,38074,1-Benzylnaphthalene,C1=CC=C(C=C1)CC2=CC=CC3=CC=CC=C32,,,,,,
3380,38075,Heptylnaphthalene,CCCCCCCC1=CC=CC2=CC=CC=C21,,,,,,
3381,38076,"Phosphoric acid, nonylphenyl diphenyl ester",CC(C)CC(C)CC(C)C1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
3382,38077,CID 38077,C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O.C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O.C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
3383,38078,Glyphosate-isopropylammonium,CC(C)N.C(C(=O)O)NCP(=O)(O)O,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Chemical agents that uncouple oxidation from phosphorylation in the metabolic cycle so that ATP synthesis does not occur. Included here are those IONOPHORES that disrupt electron transfer by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Uncoupling Agents.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']","['Glyphosate and its isopropylamine salt have extremely low oral toxicity. Orally administered glyphosate is incompletely absorbed from the gastrointestinal tract of rats, especially in males. It is excreted unchanged in the urine, although there is evidence of biliary excretion and enterohepatic circulation.', 'The percutaneous absorption of (14)C-labelled glyphosate from 3 formulations of glyphosate was measured in excised human abdominal skin using an in vitro technique. Glyphosate was found to be very poorly absorbed under these conditions, with the epidermis acting as the primary barrier /Glyphosate formulations/.', 'The percutaneous absorption of glyphosate was studied in vivo and in vitro. The ability of Roundup, a commercial glyphosate formulation, applied neat and in 1:20 to 1:32 dilutions to penetrate human thigh skin samples obtained at autopsy was evaluated using flow through cells containing human plasma as the receptor fluid. The ability of 14C-labeled Roundup and the 1:20 and 1:32 dilutions to bind to powdered human stratum corneum was investigated. Adult female rhesus monkeys were administered 500 or 5400 ug per 200 sq cm labeled glyphosate topically or 9 or 93 ug glyphosate iv. Blood and urine samples were collected starting 24 hr before dosing and up to 8 days post dosing and assayed for carbon-14 activity. Selected monkeys were killed 7 days after topical exposure to determine the tissue distribution of glyphosate derived carbon-14 activity. Other monkeys were topically administered a 1:20 dilution of 14C-labeled glyphosate.The application sites were washed with soap and water or water 0 to 24 hr later to assess the ability of these treatments to remove glyphosate. In vitro, less than 2% of the applied glyphosate penetrated human skin. Glyphosate as Roundup or in diluted form did not bind to powdered stratum corneum. Around 95 to 99% of iv administered glyphosate was excreted in the urine, mostly within the first 24 hr. Following topical application only 2.2% of the 5400 ug/200 sq cm dose and 0.8% of the 500 ug/200 sq cm dose were excreted in the urine over 8 days. Based on the iv data, 0.8 to 2.2% of the applied doses was estimated to have been absorbed. Glyphosate was detected in the blood after iv administration, but not topical application. No glyphosate derived radioactivity was detected in any internal organs after topical application. Soap and water, or water removed 89.6 and 83.6% of the applied dose, respectively, 12 hr after treatment. Both treatments removed about 50% of the applied dose 24 hr after exposure. It was concluded that the amounts of glyphosate absorbed through the skin of rhesus monkeys is low, on the order of 0.8 to 2.2%. Since the rhesus monkey is a good model for percutaneous absorption relevant to humans, glyphosate should have little dermal toxicity for humans. /Roundup/', 'Interactions /of glyphosate/ with skin and potential systemic availability through percutaneous absorption was studied by skin binding, skin absorption, residual tissue distribution, and skin decontamination. Glyphosate in a final formulation (Roundup) undiluted and diluted with water 1:20 and 1:32, would not partition into powdered human stratum corneum (<1%). In vitro percutaneous absorption through human skin into human plasma as receptor fluid was no more than 2% over a concentration range of 0.5-154 ug/sq cm and a topical volume range of 0.014-0.14 mL/sq cm. Disposition of glyphosate following iv administration of 93 and 9 ug doses to rhesus monkeys was mainly through urine excretion, 95 + or - 8 and 99 + or - 4% in 7 days, respectively. Percutaneous absorption in vivo in rhesus monkey was 0.8 + or - 0.6% for the low dose (25 ug/sq cm) and 2.2 + or - 0.8% for the high dose (270 ug/sq cm). No residual (14)C was found in organs of the monkeys euthanized 7 days after the topical application. Washing the skin application site with soap and water removed 90 + or - 4% of applied dose, and washing with water only removed 84 + or - 3% of applied dose. Both soap and water and water only were equal in ability to remove glyphosate from skin over a 24 hr skin application period. About 50% of the initially applied dose could be recovered after 24 hr. Glyphosate is very soluble in water and insoluble in most organics (octanol/water log P = -1.70) and therefore not compatible with the lipid-laden stratum corneum. This is consistent with the low skin binding and skin absorption and also consistent with the efficient removal from skin with soap and water or water-only wash. /Roundup/', 'In lactating goats concentrations of carbon-14 label in milk were measured after giving capsules containing a 9:1 mixture of (14)C-glyphosate and (14)C-aminomethylphosphonic acid (AMPA) to a dose level equivalent to 120 mg/kg diet (expressed as free acid) for 5 days. Concentrations in milk (as mg equivalents glyphosate/kg whole milk) ranged from 0.019 to 0.086 mg/kg during the test period; at day 5 after the last dose the concentration was 0.006 mg/kg.']",,['The kinetics of whole body elimination /in Sprague Dawley rats/ were estimated using the radioactivity (carbon-14) measured in urine and feces after a single oral dose of (14)C-glyphosate (10 or 1000 mg/kg body weight). Because of the lack of biotransformation of glyphosate it is valid to base kinetics on total radioactivity. The elimination appeared to be biphasic. The half-life of the alpha elimination phase at 10 mg/kg body weight was 5.87 hr (males) or 6.22 hr (females); at 1000 mg/kg body weight this was 5.26 hr (males)or 6.44 hr (females). The half-life of the beta phase at 10 mg/kg body weight was 79 hr (males) or 106 hr (females); at 1000 mg/kg body weight this was 181 hr (males) or 337 hr (females).']
3384,38079,"1,4-Benzodioxin, octahydro-2-methylene-, trans-",C=C1CO[C@@H]2CCCC[C@H]2O1,,,,,,
3385,38080,CID 38080,C1=C(OC(=C1)[N+](=O)[O-])C=CC(=O)[O-].[Na+],,,,,,
3386,38081,Flunixin,CC1=C(C=CC=C1NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs that are used to reduce body temperature in fever. (See all compounds classified as Antipyretics.)']",,,
3387,38082,4-Amino-N-cyclopropylbenzamide,C1CC1NC(=O)C2=CC=C(C=C2)N,,,,,,
3388,38083,"Ketone, 1-ethyl-3-indolyl hydroxymethyl",CCN1C=C(C2=CC=CC=C21)C(=O)CO,,,,,,
3389,38084,"Glycolic acid, (3-indolylcarbonyl)methyl ester",C1=CC=C2C(=C1)C(=CN2)C(=O)COC(=O)CO,,,,,,
3390,38085,"Glycine, (3-indolylcarbonyl)methyl ester, hydrobromide",C1=CC=C2C(=C1)C(=CN2)C(=O)COC(=O)C[NH3+].[Br-],,,,,,
3391,38086,3-Glycyloxyacetylindole,C1=CC=C2C(=C1)C(=CN2)C(=O)COC(=O)CN,,,,,,
3392,38087,2-hydroxy-1-(1H-indol-5-yl)ethanone,C1=CC2=C(C=CN2)C=C1C(=O)CO,,,,,,
3393,38088,Pranolium iodide,CC(C)[N+](C)(C)CC(COC1=CC=CC2=CC=CC=C21)O.[I-],,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
3394,38089,Pranolium,CC(C)[N+](C)(C)CC(COC1=CC=CC2=CC=CC=C21)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
3395,38090,Diethatyl-ethyl,CCC1=C(C(=CC=C1)CC)N(CC(=O)OCC)C(=O)CCl,,,,,,
3396,38091,(-)-N-(beta-Hydroxy-alpha-methylphenethyl)-N-methylmethacrylamide,CC(C(C1=CC=CC=C1)O)N(C)C(=O)C(=C)C,,,,,,
3397,38092,N-(alpha-Trichloromethyl-p-methoxybenzyl)-p-methoxyaniline,COC1=CC=C(C=C1)C(C(Cl)(Cl)Cl)NC2=CC=C(C=C2)OC,,,,,,
3398,38093,"5-Chloro-2-(4-(2-hydroxy-3-(isopropylamino)propoxy)anilino)-2,4,6-cycloheptatrien-1-one",CC(C)NCC(COC1=CC=C(C=C1)NC2=CC=C(C=CC2=O)Cl)O,,,,,,
3399,38094,"2-(4-(3-(tert-Butylamino)-2-hydroxypropoxy)anilino)-5-chloro-2,4,6-cycloheptatrien-1-one",CC(C)(C)NCC(COC1=CC=C(C=C1)NC2=CC=C(C=CC2=O)Cl)O,,,,,,
3400,38095,"5-Chloro-2-(4-(3-(cyclohexylamino)-2-hydroxypropoxy)anilino)-2,4,6-cycloheptatrien-1-one",C1CCC(CC1)NCC(COC2=CC=C(C=C2)NC3=CC=C(C=CC3=O)Cl)O,,,,,,
3401,38096,"2-((4-(3-(Cyclohexylamino)-2-hydroxypropoxy)phenyl)amino)-2,4,6-cycloheptatrien-1-one",C1CCC(CC1)NCC(COC2=CC=C(C=C2)NC3=CC=CC=CC3=O)O,,,,,,
3402,38097,o-Isopropoxyphenyl methylnitrosocarbamate,CC(C)OC1=CC=CC=C1OC(=O)N(C)N=O,,,,,,
3403,38098,"L-Arabinose, 2-amino-4-((2-amino-1-oxopropyl)amino)-2,4-dideoxy-, (R)-",C[C@H](C(=O)N[C@H]1CO[C@@H]([C@@H]([C@H]1O)N)O)N,,,,,,
3404,38099,"Acetamide, 2-(triphenylphosphoranylidene)-",C1=CC=C(C=C1)P(=CC(=O)N)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3405,38100,"4-Acetoxy-N,N-dimethyl-3-diphenyl-1-methylhexylamine hydrochloride",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.[Cl-],,,,,,
3406,38101,Lodosyn,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,,,"['Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)', 'Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. (See all compounds classified as Aromatic Amino Acid Decarboxylase Inhibitors.)', 'Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)']",,,
3407,38102,Indoramin hydrochloride,C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43.Cl,,,,,,
3408,38103,Cephradine,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Over 90 percent of the drug is excreted unchanged in the urine within six hours.', 'CEPHRADINE IS ALMOST COMPLETELY ABSORBED AFTER ORAL ADMIN; IN PRESENCE OF FOOD, ABSORPTION IS SLOWED BUT NOT DECR. ORAL DOSES OF 250 & 500 MG YIELD PEAK PLASMA LEVELS OF ABOUT 9 & 16.5 UG/ML, WITHIN 40 MIN FROM EMPTY STOMACH. ABSORPTION BY IM ROUTE IS CONSIDERABLY SLOWER.', 'AFTER SINGLE ORAL ADMIN, CEPHRADINE WAS ABSORBED RAPIDLY FROM GI TRACT & PEAK SERUM CONCN ACHIEVED WITHIN 1 HR. 75-100% OF DOSE EXCRETED UNCHANGED IN URINE IN FIRST 6 HOURS.', 'SIX SUBJECTS RECEIVED 1 G EACH OF CEPHRADINE (I) & CEPHALEXIN (II) EVERY 4 HR FOR 7 DOSES & 5 RECEIVED 2 G EVERY 6 HR FOR 5 DOSES. PEAK SERUM LEVELS FOR I & II WERE 29 & 35 UG/ML, RESPECTIVELY, FOLLOWING 1 G & 45-50 UG/ML FOLLOWING 2 G.', 'Cephalosporins are primarily excreted by the kidney ... . /Cephalosporins/', 'For more Absorption, Distribution and Excretion (Complete) data for CEPHRADINE (18 total), please visit the HSDB record page.']","['Cephradine is not metabolized and, after rapid absorption from the gastrointestinal tract, is excreted unchanged in the urine.']",
3409,38104,"6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 2,3-dihydroxypropyl ester",CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCC(CO)O,,,,,,
3410,38105,"2,3,4,5,6-Pentafluoro-N-(2-phenylethyl)benzamide",C1=CC=C(C=C1)CCNC(=O)C2=C(C(=C(C(=C2F)F)F)F)F,,,,,,
3411,38106,1-[Dimethyl-(tetradecanoylamino)azaniumyl]propan-2-olate,CCCCCCCCCCCCCC(=O)N[N+](C)(C)CC(C)[O-],,,,,,
3412,38107,2-Hydroxypropyl-dimethyl-(tetradecanoylamino)azanium,CCCCCCCCCCCCCC(=O)N[N+](C)(C)CC(C)O,,,,,,
3413,38108,"Acetamide, N-(4-hexyl-1-cyclohexyl)-",CCCCCCC1CCC(CC1)NC(=O)C,,,,,,
3414,38109,"BENZOIC ACID, p-METHOXY-, PIPERIDINO ESTER",COC1=CC=C(C=C1)C(=O)ON2CCCCC2,,,,,,
3415,38110,"BENZOIC ACID, p-NITRO-, PIPERIDINO ESTER",C1CCN(CC1)OC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3416,38111,4-Isobutylbenzoic acid,CC(C)CC1=CC=C(C=C1)C(=O)O,,,,,,
3417,38112,"9H-Fluorene-2,7-dicarboxylic acid, 9-oxo-, bis(4-(diethylamino)-1-methylbutyl) ester, hydrochloride, hydrate (3:6:1)",CC[NH+](CC)CCCC(C)OC(=O)C1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)C(=O)OC(C)CCC[NH+](CC)CC.[Cl-].[Cl-],,,,,,
3418,38113,"Bis[5-(diethylamino)pentan-2-yl] 9-oxofluorene-2,7-dicarboxylate",CCN(CC)CCCC(C)OC(=O)C1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)C(=O)OC(C)CCCN(CC)CC,,,,,,
3419,38114,(-)-beta-Methoxy-N-(phenylmethyl)-3-(trifluoromethyl)benzeneethanamine,COC(CNCC1=CC=CC=C1)C2=CC(=CC=C2)C(F)(F)F,,,,,,
3420,38115,"1-Methyl-4,4'-bipyridinium iodide",C[N+]1=CC=C(C=C1)C2=CC=NC=C2.[I-],,,,,,
3421,38116,1-Methyl-4-(pyridin-4-yl)pyridinium,C[N+]1=CC=C(C=C1)C2=CC=NC=C2,,,,,,
3422,38117,Furobufen,C1=CC=C2C(=C1)C3=C(O2)C=CC(=C3)C(=O)CCC(=O)O,,,,,,
3423,38118,N-(3-oxo-1-phenyl-3-piperidin-1-ylprop-1-en-2-yl)benzamide,C1CCN(CC1)C(=O)C(=CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
3424,38119,N-(3-morpholin-4-yl-3-oxo-1-phenylprop-1-en-2-yl)benzamide,C1COCCN1C(=O)C(=CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
3425,38120,CID 38120,CC(=C)CCCC(=CCCC(=CCC(=O)O[C@H]1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C)C,,,,,,
3426,38121,"Acetic acid, ((5-(2-(1H-benzimidazol-2-yl)ethyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)-, ethyl ester",CCOC(=O)CSC1=NN=C(N1C2=CC=CC=C2)CCC3=NC4=CC=CC=C4N3,,,,,,
3427,38122,"Acetic acid, ((5-(2-(1H-benzimidazol-2-yl)ethyl)-4-(p-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)-, ethyl ester",CCOC(=O)CSC1=NN=C(N1C2=CC=C(C=C2)OC)CCC3=NC4=CC=CC=C4N3,,,,,,
3428,38123,"Acetic acid, ((5-(2-(1H-benzimidazol-2-yl)ethyl)-4-cyclohexyl-4H-1,2,4-triazol-3-yl)thio)-, ethyl ester",CCOC(=O)CSC1=NN=C(N1C2CCCCC2)CCC3=NC4=CC=CC=C4N3,,,,,,
3429,38124,CID 38124,CCOC(=O)CSC1=NNC(=[N+]1CC=C)CCC2=NC3=CC=CC=C3N2,,,,,,
3430,38125,"Acetic acid, ((5-(2-(1H-benzimidazol-2-yl)ethyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)-, hydrazide",C1=CC=C(C=C1)N2C(=NN=C2SCC(=O)NN)CCC3=NC4=CC=CC=C4N3,,,,,,
3431,38126,"Acetic acid, ((5-(2-(1H-benzimidazol-2-yl)ethyl)-4-(m-tolyl)-4H-1,2,4-triazol-3-yl)thio)-, hydrazide",CC1=CC(=CC=C1)N2C(=NN=C2SCC(=O)NN)CCC3=NC4=CC=CC=C4N3,,,,,,
3432,38127,"[[5-[2-(1H-Benzimidazol-2-yl)ethyl]-4-(p-tolyl)-4H-1,2,4-triazol-3-yl]thio]acetic acid hydrazide",CC1=CC=C(C=C1)N2C(=NN=C2SCC(=O)NN)CCC3=NC4=CC=CC=C4N3,,,,,,
3433,38128,"Ammonium, (2-(5-methyl-2-furyl)ethyl)dimethylbenzyl-, iodide",CC1=CC=C(O1)CC[N+](C)(C)CC2=CC=CC=C2.[I-],,,,,,
3434,38129,Benzyl-dimethyl-[2-(5-methylfuran-2-yl)ethyl]azanium,CC1=CC=C(O1)CC[N+](C)(C)CC2=CC=CC=C2,,,,,,
3435,38130,"2-Furanethylamine, N,N-dimethyl-, hydrochloride",C[NH+](C)CCC1=CC=CO1.[Cl-],,,,,,
3436,38131,"N,N-Dimethyl-2-furanethanamine",CN(C)CCC1=CC=CO1,,,,,,
3437,38132,"N,N,5-Trimethyl-2-furanethylamine hydrochloride",CC1=CC=C(O1)CC[NH+](C)C.[Cl-],,,,,,
3438,38133,"N,N-dimethyl-2-(5-methylfuran-2-yl)ethanamine",CC1=CC=C(O1)CCN(C)C,,,,,,
3439,38134,9-((2-((2-Chloroethyl)thio)ethyl)amino)acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]CCSCCCl.[Cl-],,,,,,
3440,38135,N-[2-(2-chloroethylsulfanyl)ethyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCSCCCl,,,,,,
3441,38136,9-((3-((2-Chloroethyl)thio)propyl)amino)acridine hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]CCCSCCCl.[Cl-],,,,,,
3442,38137,N-[3-(2-chloroethylsulfanyl)propyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCSCCCl,,,,,,
3443,38138,"1,2,3,4-Tetrahydro-9-((2-((2-chloroethyl)thio)ethyl)amino)acridine hydrochloride",C1CCC2=NC3=CC=CC=C3C(=C2C1)[NH2+]CCSCCCl.[Cl-],,,,,,
3444,38139,"N-[2-(2-chloroethylsulfanyl)ethyl]-1,2,3,4-tetrahydroacridin-9-amine",C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCSCCCl,,,,,,
3445,38140,4-Methoxy-9-(3-(ethyl-2-chloroethyl)aminopropylamino)acridine dihydrochloride,CC[NH+](CCC[NH2+]C1=C2C=CC=C(C2=NC3=CC=CC=C31)OC)CCCl.[Cl-].[Cl-],,,,,,
3446,38141,"N'-(2-chloroethyl)-N'-ethyl-N-(4-methoxyacridin-9-yl)propane-1,3-diamine",CCN(CCCNC1=C2C=CC=C(C2=NC3=CC=CC=C31)OC)CCCl,,,,,,
3447,38142,9-((2-((2-Chloroethyl)thio)ethyl)amino)-4-methoxyacridine hydrochloride hemihydrate,COC1=CC=CC2=C(C3=CC=CC=C3N=C21)[NH2+]CCSCCCl.[Cl-],,,,,,
3448,38143,N-[2-(2-chloroethylsulfanyl)ethyl]-4-methoxyacridin-9-amine,COC1=CC=CC2=C(C3=CC=CC=C3N=C21)NCCSCCCl,,,,,,
3449,38144,6-Chloro-9-((2-((2-chloroethyl)oxy)ethyl)amino)-2-methoxyacridine hydrochloride,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)[NH2+]CCOCCCl.[Cl-],,,,,,
3450,38145,6-chloro-N-[2-(2-chloroethoxy)ethyl]-2-methoxyacridin-9-amine,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCOCCCl,,,,,,
3451,38146,"9-Acridinamine, 6-chloro-N-(2-(2-((2-chloroethyl)ethylamino)ethoxy)ethyl)-2-methoxy-, dihydrochloride",CC[NH+](CCOCC[NH2+]C1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC)CCCl.[Cl-].[Cl-],,,,,,
3452,38147,6-chloro-N-[2-[2-[2-chloroethyl(ethyl)amino]ethoxy]ethyl]-2-methoxyacridin-9-amine,CCN(CCOCCNC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC)CCCl,,,,,,
3453,38148,CID 38148,CC[NH+](CCC[NH+]=C1C2=C(C=C(C=C2)Cl)NC3=C1N=C(C=C3)OC)CCCl.[Cl-].[Cl-],,,,,,
3454,38149,ICR 340 (free base),CCN(CCCNC1=C2C(=NC3=C1C=CC(=C3)Cl)C=CC(=N2)OC)CCCl,,,,,,
3455,38150,CID 38150,COC1=NC2=C(C=C1)NC3=C(C2=[NH+]CCSCCCl)C=CC(=C3)Cl.[Cl-],,,,,,
3456,38151,"7-chloro-N-[2-(2-chloroethylsulfanyl)ethyl]-2-methoxybenzo[b][1,5]naphthyridin-10-amine",COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCSCCCl,,,,,,
3457,38152,CID 38152,COC1=NC2=C(C=C1)NC3=C(C2=[NH+]CCCSCCCl)C=CC(=C3)Cl.[Cl-],,,,,,
3458,38153,"7-chloro-N-[3-(2-chloroethylsulfanyl)propyl]-2-methoxybenzo[b][1,5]naphthyridin-10-amine",COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCSCCCl,,,,,,
3459,38154,CID 38154,CC[NH+](CCOCC[NH+]=C1C2=C(C=C(C=C2)Cl)NC3=C1N=C(C=C3)OC)CCCl.[Cl-].[Cl-],,,,,,
3460,38155,"7-chloro-N-[2-[2-[2-chloroethyl(ethyl)amino]ethoxy]ethyl]-2-methoxybenzo[b][1,5]naphthyridin-10-amine",CCN(CCOCCNC1=C2C(=NC3=C1C=CC(=C3)Cl)C=CC(=N2)OC)CCCl,,,,,,
3461,38156,CID 38156,CCCCOC1=NC2=C(C=C1)NC3=C(C2=[NH+]CCSCCCl)C=CC(=C3)Cl.[Cl-],,,,,,
3462,38157,"2-butoxy-7-chloro-N-[2-(2-chloroethylsulfanyl)ethyl]benzo[b][1,5]naphthyridin-10-amine",CCCCOC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCSCCCl,,,,,,
3463,38158,CID 38158,CCCCOC1=NC2=C(C=C1)NC3=C(C2=[NH+]CCCSCCCl)C=CC(=C3)Cl.[Cl-],,,,,,
3464,38159,"2-butoxy-7-chloro-N-[3-(2-chloroethylsulfanyl)propyl]benzo[b][1,5]naphthyridin-10-amine",CCCCOC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCSCCCl,,,,,,
3465,38160,12-((3-((2-Chloroethyl)thio)propyl)amino)benz(b)acridine hydrochloride,C1=CC=C2C=C3C(=CC2=C1)C(=C4C=CC=CC4=N3)[NH2+]CCCSCCCl.[Cl-],,,,,,
3466,38161,N-[3-[(2-Chloroethyl)thio]propyl]benz[b]acridin-12-amine,C1=CC=C2C=C3C(=CC2=C1)C(=C4C=CC=CC4=N3)NCCCSCCCl,,,,,,
3467,38162,"Benzo(b)(1,10)phenanthroline, 7-(3-(N-(2-chloroethyl)-N-propylamino)propylamino)-, trihydrochloride",CCC[NH+](CCCNC1=C2C=CC3=C(C2=[NH+]C4=CC=CC=C41)[NH+]=CC=C3)CCCl.[Cl-].[Cl-].[Cl-],,,,,,
3468,38163,"N-benzo[b][1,10]phenanthrolin-7-yl-N'-(2-chloroethyl)-N'-propylpropane-1,3-diamine",CCCN(CCCNC1=C2C=CC3=C(C2=NC4=CC=CC=C41)N=CC=C3)CCCl,,,,,,
3469,38164,Tetrasodium N-(3-carboxyl-1-sulfopropyl)-N-stearyl aspartate,CCCCCCCCCCCCCCCCCCN(C(CC(=O)[O-])C(=O)[O-])C(=O)CC(C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
3470,38165,"N-(1,2-Dicarboxyethyl)-N-octadecyl sulfosuccinamic acid",CCCCCCCCCCCCCCCCCCN(C(CC(=O)O)C(=O)O)C(=O)CC(C(=O)O)S(=O)(=O)O,,,,,,
3471,38166,"[(2R,3S,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] phosphono hydrogen phosphate",C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)OP(=O)(O)OP(=O)(O)O)O)NC(=NC2=O)N,,,,,,
3472,38167,"Disulfide, bis(2-((2-cyclohexylbutyl)amino)ethyl)-, dihydrochloride",CCC(C[NH2+]CCSSCC[NH2+]CC(CC)C1CCCCC1)C2CCCCC2.[Cl-].[Cl-],,,,,,
3473,38168,2-cyclohexyl-N-[2-[2-(2-cyclohexylbutylamino)ethyldisulfanyl]ethyl]butan-1-amine,CCC(CNCCSSCCNCC(CC)C1CCCCC1)C2CCCCC2,,,,,,
3474,38169,"N,N'-Dithiodiethylenebis(p-tolyloxybutylamine) dihydrochloride",CC1=CC=C(C=C1)OCCCC[NH2+]CCSSCC[NH2+]CCCCOC2=CC=C(C=C2)C.[Cl-].[Cl-],,,,,,
3475,38170,4-(4-methylphenoxy)-N-[2-[2-[4-(4-methylphenoxy)butylamino]ethyldisulfanyl]ethyl]butan-1-amine,CC1=CC=C(C=C1)OCCCCNCCSSCCNCCCCOC2=CC=C(C=C2)C,,,,,,
3476,38171,"DISULFIDE, BIS(2-((4-(p-METHOXYPHENOXY)BUTYL)AMINO)ETHYL)-, DIHYDROCHLORIDE",COC1=CC=C(C=C1)OCCCC[NH2+]CCSSCC[NH2+]CCCCOC2=CC=C(C=C2)OC.[Cl-].[Cl-],,,,,,
3477,38172,4-(4-methoxyphenoxy)-N-[2-[2-[4-(4-methoxyphenoxy)butylamino]ethyldisulfanyl]ethyl]butan-1-amine,COC1=CC=C(C=C1)OCCCCNCCSSCCNCCCCOC2=CC=C(C=C2)OC,,,,,,
3478,38173,"N,N'-Dithiodiethylenebis(4-(2,5-xylyloxy)butylamine) dihydrochloride",CC1=CC(=C(C=C1)C)OCCCC[NH2+]CCSSCC[NH2+]CCCCOC2=C(C=CC(=C2)C)C.[Cl-].[Cl-],,,,,,
3479,38174,"4-(2,5-dimethylphenoxy)-N-[2-[2-[4-(2,5-dimethylphenoxy)butylamino]ethyldisulfanyl]ethyl]butan-1-amine",CC1=CC(=C(C=C1)C)OCCCCNCCSSCCNCCCCOC2=C(C=CC(=C2)C)C,,,,,,
3480,38175,"N,N'-Dithiodiethylenebis(4-(2,6-xylyloxy)butylamine) dihydrochloride",CC1=C(C(=CC=C1)C)OCCCC[NH2+]CCSSCC[NH2+]CCCCOC2=C(C=CC=C2C)C.[Cl-].[Cl-],,,,,,
3481,38176,"4-(2,6-dimethylphenoxy)-N-[2-[2-[4-(2,6-dimethylphenoxy)butylamino]ethyldisulfanyl]ethyl]butan-1-amine",CC1=C(C(=CC=C1)C)OCCCCNCCSSCCNCCCCOC2=C(C=CC=C2C)C,,,,,,
3482,38177,"Disulfide, bis(2-((6-(o-tolyloxy)hexyl)amino)ethyl)-, dihydrochloride",CC1=CC=CC=C1OCCCCCC[NH2+]CCSSCC[NH2+]CCCCCCOC2=CC=CC=C2C.[Cl-].[Cl-],,,,,,
3483,38178,"N,N'-(Dithiodi-2,1-ethanediyl)bis[6-(2-methylphenoxy)-1-hexanamine]",CC1=CC=CC=C1OCCCCCCNCCSSCCNCCCCCCOC2=CC=CC=C2C,,,,,,
3484,38179,"Disulfide, bis(2-((4-(2,3,6-trimethylphenoxy)butyl)amino)ethyl)-, dihydrochloride",CC1=C(C(=C(C=C1)C)OCCCC[NH2+]CCSSCC[NH2+]CCCCOC2=C(C=CC(=C2C)C)C)C.[Cl-].[Cl-],,,,,,
3485,38180,"4-(2,3,6-trimethylphenoxy)-N-[2-[2-[4-(2,3,6-trimethylphenoxy)butylamino]ethyldisulfanyl]ethyl]butan-1-amine",CC1=C(C(=C(C=C1)C)OCCCCNCCSSCCNCCCCOC2=C(C=CC(=C2C)C)C)C,,,,,,
3486,38181,Acetoxy-methyl acetylcholine chloride,CC(C(=O)OCC[N+](C)(C)C)OC(=O)C.[Cl-],,,,,,
3487,38182,(4-Benzoyl-4-phenylbutyl)triethylammonium iodide,CC[N+](CC)(CC)CCCC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[I-],,,,,,
3488,38183,"(4,5-Diphenyl-5-oxopentyl)triethylaminium",CC[N+](CC)(CC)CCCC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
3489,38184,(5-Benzoyl-5-phenylpentyl)triethylammonium iodide,CC[N+](CC)(CC)CCCCC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[I-],,,,,,
3490,38185,"(5,6-Diphenyl-6-oxohexyl)triethylaminium",CC[N+](CC)(CC)CCCCC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
3491,38186,"9-Methyl-3-(morpholinomethyl)-2,3-dihydro-4(1H)-carbazolone",CN1C2=C(C3=CC=CC=C31)C(=O)C(CC2)CN4CCOCC4,,,,,,
3492,38187,"9-Methyl-3-(1-piperidinomethyl)-2,3-dihydro-4(1H)-carbazolone",CN1C2=C(C3=CC=CC=C31)C(=O)C(CC2)CN4CCCCC4,,,,,,
3493,38188,"9-Methyl-3-(3-methylpiperidino)methyl-2,3-dihydro-4(1H)-carbazolone",CC1CCCN(C1)CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,,,,,,
3494,38189,"1-(1,2-Oxazolidin-2-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCCO2,,,,,,
3495,38190,Tetradecyl glycidyl ether,CCCCCCCCCCCCCCOCC1CO1,,,,,,
3496,38191,Pinadoline,C1C2=CC=CC=C2OC3=C(N1C(=O)NNC(=O)CCCCCl)C=C(C=C3)Cl,,,,,,
3497,38192,cis-Dihydrotodomatuic Acid,CC(C)CC(=O)CC(C)C1CCC(CC1)C(=O)O,,,,,,
3498,38193,"2,8-Dichlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=C(O2)C=CC(=C3)Cl,,,,,,
3499,38194,"(2S,5R,6R,7R,10S,12R,13R)-6,13-bis(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.01,10.02,7]hexadecane-5,13-diol",C[C@]12CC[C@H]([C@@]([C@@H]1CC[C@@H]3C24CC[C@@]([C@H](C3)C4)(CO)O)(C)CO)O,,,,,,
3500,38195,"Ammonium, dodecamethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCCCCCCCCCCC[N+](C)(C)C.[I-].[I-],,,,,,
3501,38196,"1,12-Dodecanediaminium, N,N,N,N',N',N'-hexamethyl-",C[N+](C)(C)CCCCCCCCCCCC[N+](C)(C)C,,,,,,
3502,38197,"N,N'-bis[(5-nitrofuran-2-yl)methylideneamino]hexanediamide",C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)CCCCC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
3503,38198,Coralyne sulfoacetate,CC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC.C(C(=O)O)S(=O)(=O)[O-],,,,,,
3504,38199,"1,2,3,4,6,7,8-Heptachlorodibenzofuran",C1=C2C3=C(C(=C(C(=C3Cl)Cl)Cl)Cl)OC2=C(C(=C1Cl)Cl)Cl,,,,,,
3505,38200,Octachlorodibenzofuran,C12=C(C(=C(C(=C1Cl)Cl)Cl)Cl)OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
3506,38201,"Phosphorothioic acid, O,O-bis(p-nitrophenyl) O-methyl ester",COP(=S)(OC1=CC=C(C=C1)[N+](=O)[O-])OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3507,38202,"5,14-Dihydroxy-19-oxo-3-(propanoyloxy)card-20(22)-enolide",CCC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
3508,38203,CID 38203,CC1=C(C(=C2C(=C1[O-])C3(C(=CC(=C(C3=O)C(=O)C)O)O2)C)C(=O)C)O.[Na+],,,,,,
3509,38204,CID 38204,CCCCOC1=NC2=C(C=C1)NC3=C(C2=[NH+]CCOCC[NH+](CC)CCCl)C=CC(=C3)Cl.[Cl-].[Cl-],,,,,,
3510,38205,"2-butoxy-7-chloro-N-[2-[2-[2-chloroethyl(ethyl)amino]ethoxy]ethyl]benzo[b][1,5]naphthyridin-10-amine",CCCCOC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCOCCN(CC)CCCl,,,,,,
3511,38206,Oxaprotiline hydrochloride,CNCC(CC12CCC(C3=CC=CC=C31)C4=CC=CC=C24)O.Cl,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
3512,38207,Oxaprotiline,CNCC(CC12CCC(C3=CC=CC=C31)C4=CC=CC=C24)O,['Investigated for the treatment of depression.'],,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
3513,38208,(S)-1-(2-(3-Furanyl)-5-methyl-1-cyclopenten-1-yl)-3-methyl-2-buten-1-one,CC1CCC(=C1C(=O)C=C(C)C)C2=COC=C2,,,,,,
3514,38209,"7-((6-(Bis(2-chloroethyl)amino)hexyl)amino)-6-methoxybenzo(b)(1,10)phenanthroline 2HCl 2H2O",COC1=CC2=C(C3=NC4=CC=CC=C4C(=C13)[NH2+]CCCCCC[NH+](CCCl)CCCl)N=CC=C2.[Cl-].[Cl-],,,,,,
3515,38210,"N',N'-bis(2-chloroethyl)-N-(6-methoxybenzo[b][1,10]phenanthrolin-7-yl)hexane-1,6-diamine",COC1=CC2=C(C3=NC4=CC=CC=C4C(=C13)NCCCCCCN(CCCl)CCCl)N=CC=C2,,,,,,
3516,38211,"Carbamic acid, diethyl-, 2,3-dihydro-1,3-dioxo-2-(methylthio)-1H-inden-2-yl ester",CCN(CC)C(=O)OC1(C(=O)C2=CC=CC=C2C1=O)SC,,,,,,
3517,38212,"Carbamic acid, 2-propenyl-, 2,3-dihydro-2-(methylthio)-1,3-dioxo-1H-inden-2-yl ester",CSC1(C(=O)C2=CC=CC=C2C1=O)OC(=O)NCC=C,,,,,,
3518,38213,"2,7-Dibromodibenzo-P-dioxin",C1=CC2=C(C=C1Br)OC3=C(O2)C=C(C=C3)Br,,,,,,
3519,38214,Methyl sec-butylcarbamate,CCC(C)NC(=O)OC,,,,,,
3520,38215,"Butanamide, 4-chloro-3-oxo-N-phenyl-",C1=CC=C(C=C1)NC(=O)CC(=O)CCl,,,,,,
3521,38216,"N-(1,1-Dimethyl-2-propynyl)-4-nitrobenzamide",CC(C)(C#C)NC(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3522,38217,"N-(1,1-Dimethyl-2-propynyl)-4-methoxybenzamide",CC(C)(C#C)NC(=O)C1=CC=C(C=C1)OC,,,,,,
3523,38218,Methylpropyzamide,CC1=CC=C(C=C1)C(=O)NC(C)(C)C#C,,,,,,
3524,38219,CID 38219,CCOP(=O)[O-].CCOP(=O)[O-].CCOP(=O)[O-].[Al+3],,,,,,
3525,38220,7-Nitro-9H-fluorene-2-carbonitrile,C1C2=C(C=CC(=C2)C#N)C3=C1C=C(C=C3)[N+](=O)[O-],,,,,,
3526,38221,"2,4-Diaminoanisole sulfate",COC1=C(C=C(C=C1)N)N.OS(=O)(=O)O,,,,"['2,4-Diaminoanisole sulfate can be absorbed through the skin. It has been recovered after dermal application in the urine of Rhesus monkeys and humans.']",,
3527,38222,4-Undecylbenzenesulfonic acid,CCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)O,,,,,,
3528,38223,"Methanearsonic acid, dipotassium salt",C[As](=O)([O-])[O-].[K+].[K+],,,,,,
3529,38224,N-Phenyl-alpha-propylmandelamide,CCCC(C1=CC=CC=C1)(C(=O)NC2=CC=CC=C2)O,,,,,,
3530,38225,N-(p-Bromophenyl)-alpha-propylmandelamide,CCCC(C1=CC=CC=C1)(C(=O)NC2=CC=C(C=C2)Br)O,,,,,,
3531,38226,N-(p-Chlorophenyl)-alpha-propylmandelamide,CCCC(C1=CC=CC=C1)(C(=O)NC2=CC=C(C=C2)Cl)O,,,,,,
3532,38227,N-(m-Chlorophenyl)-alpha-propylmandelamide,CCCC(C1=CC=CC=C1)(C(=O)NC2=CC(=CC=C2)Cl)O,,,,,,
3533,38228,"4-Biphenylcarboxylic acid, 2-acetamido-, methyl ester",CC(=O)NC1=C(C=CC(=C1)C(=O)OC)C2=CC=CC=C2,,,,,,
3534,38229,Thiofanox-sulfoxide,CC(C)(C)C(=NOC(=O)NC)CS(=O)C,,,,,,
3535,38230,Thiofanox-sulfon,CC(C)(C)C(=NOC(=O)NC)CS(=O)(=O)C,,,,,,
3536,38231,"3(2H)-Isoquinolinone, 1,4-dihydro-2-(methylamino)-",CNN1CC2=CC=CC=C2CC1=O,,,,,,
3537,38232,"3,3-Dimethyl-1-methylthio-2-butanone oxime",CC(C)(C)C(=NO)CSC,,,,,,
3538,38233,"N-(3,3-dimethyl-1-methylsulfonylbutan-2-ylidene)hydroxylamine",CC(C)(C)C(=NO)CS(=O)(=O)C,,,,,,
3539,38234,"N-(3,3-dimethyl-1-methylsulfinylbutan-2-ylidene)hydroxylamine",CC(C)(C)C(=NO)CS(=O)C,,,,,,
3540,38235,Thiofanox,CC(C)(C)C(=NOC(=O)NC)CSC,,,,,"['FULLY EXPANDED LEAVES OF COTTON PLANTS GROWN IN THE FIELD WERE TREATED INDIVIDUALLY WITH (35)S-LABELED DIAMOND SHAMROCK (3,3-DIMETHYL)-1-(METHYLTHIO)-2- BUTANONE O-(METHYLCARBOMYL) OXIME). THE SULFONE & SULFOXIDE WERE FORMED. ... SEEDLINGS GROWN FROM TREATED SEED GAVE SAME RESULTS AS THOSE OBTAINED IN MATURE PLANTS & IN SOIL.', 'IN SOIL THE CHEM CHANGES OF DS-15647 WERE SIMILAR TO THOSE FOUND IN PLANTS, BUT THEY PROCEEDED AT SLOWER RATES. COTTON SEEDS THAT HAD BEEN SURFACE TREATED WITH DIAMOND SHAMROCK (3,3-DIMETHYL)-1-(METHYLTHIO)-2-BUTANONE O-(METHYLCARBOMYL) OXIDE) & PLANTED IN THE GREENHOUSE ABSORBED 20% OF THE DOSE AFTER 1 DAY. THE SULFOXIDE AND SULFONE DERIVATIVES WERE THE PRIMARY PRODUCTS RECOVERED FROM PLANTS GROWN FROM THE TREATED SEEDS.', 'OF THE THREE METABOLITES: 3,3-DIMETHYL-1-(METHYLSULFINYL)-2-BUTANONE, O-((METHYLAMINO) CARBONYL)OXIME SULFOXIDE; 3,3-DIMETHYL-1-(METHYLSULFONYL)-2-BUTANONE O-((DIMETHYLAMINO)CARBONYL)OXIME SULFONE; AND 3,3-DIMETHYL-1-(METHYLSULFONYL) -2-BUTANONE O-((HYDROXYMETHYLAMINO)CARBONYL)OXIME HYDROXYMETHYL SULFONE, INVESTIGATED IN RATS, THE HYDROXYMETHYL SULFONE METABOLITE OF THIOFANOX WAS THE MOST POTENT METABOLITE TO INHIBIT PLASMA & RED BLOOD CELL ACETYLCHOLINESTERASE.', 'The major route of metabolism appears to be the oxidation of thiofanox to its sulfoxide & the subsequent oxidation to its sulfone. The rate of the initial reaction is decisively more rapid than that of the second, particularly in plants. Hydrolysis of carbamoyl moieties to their resulting oximes is also observed. ... Sulfonyl oxime carbamate is ... /more/ toxic /than thiofanox & related compounds in rats based on LD50 values/.', 'For more Metabolism/Metabolites (Complete) data for THIOFANOX (7 total), please visit the HSDB record page.']",
3541,38236,2-Ethyl-1-nitroguanidine,CCN=C(N)N[N+](=O)[O-],,,,,,
3542,38237,"7-chloro-3-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one",CC1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,,,,,,
3543,38238,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-3-(phenylmethyl)-, (S)-",C1=CC=C(C=C1)C[C@H]2C(=O)NC3=C(C=C(C=C3)Cl)C(=N2)C4=CC=CC=C4,,,,,,
3544,38239,4-Cyanobutanoic acid,C(CC#N)CC(=O)O,,,,,,
3545,38240,Escaline,CCOC1=C(C=C(C=C1OC)CCN)OC,,,,,,
3546,38241,"Benzaldehyde, 4-((4-(dimethylamino)phenyl)azo)-",CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C=O,,,,,,
3547,38242,CID 38242,CCCC(=O)N=NC1=CC=C(C=C1)N(O)O,,,,,,
3548,38243,N-(4-nitrophenyl)ethanehydrazonoyl chloride,CC(=NNC1=CC=C(C=C1)[N+](=O)[O-])Cl,,,,,,
3549,38244,CID 38244,CC(=NNC1=CC=CC=C1[N+](=O)[O-])Cl,,,,,,
3550,38245,N-(4-nitrophenyl)butanehydrazonoyl chloride,CCCC(=NNC1=CC=C(C=C1)[N+](=O)[O-])Cl,,,,,,
3551,38246,"Benzimidazole, 5-bromo-6-chloro-2-(trifluoromethyl)-",C1=C2C(=CC(=C1Cl)Br)N=C(N2)C(F)(F)F,,,,,,
3552,38247,"Butanoic acid, 4-((4-cyanophenyl)amino)-4-oxo-3-((trifluoroacetyl)amino)-, (S)-",C1=CC(=CC=C1C#N)NC(=O)[C@H](CC(=O)O)NC(=O)C(F)(F)F,,,,,,
3553,38248,"4,5-Dichloro-2-nitrophenol",C1=C(C(=CC(=C1Cl)Cl)O)[N+](=O)[O-],,,,,,
3554,38249,"1-Naphthylamine, 1,2,3,4-tetrahydro-6-methoxy-, hydrochloride",COC1=CC2=C(C=C1)C(CCC2)[NH3+].[Cl-],,,,,,
3555,38250,"6-Methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=CC2=C(C=C1)C(CCC2)N,,,,,,
3556,38251,"1,2,3,4,7,8-Hexachlorodibenzo-P-dioxin",C1=C2C(=CC(=C1Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
3557,38252,2-Chlorodibenzo-P-dioxin,C1=CC=C2C(=C1)OC3=C(O2)C=C(C=C3)Cl,,,,,,
3558,38253,"1,2,4-Trichlorodibenzo-P-dioxin",C1=CC=C2C(=C1)OC3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
3559,38254,"1,2,3,4,7-Pentachlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
3560,38255,"1,2,4,6,7,9-Hexachlorodibenzo-P-dioxin",C1=C(C2=C(C(=C1Cl)Cl)OC3=C(O2)C(=C(C=C3Cl)Cl)Cl)Cl,,,,,,
3561,38256,"2-Adamantanamine, N-butyl-, hydrochloride",CCCCNC1C2CC3CC(C2)CC1C3.Cl,,,,,,
3562,38257,"(1r,3r,5R,7R)-N-butyltricyclo[3.3.1.1~3,7~]decan-2-amine",CCCCNC1C2CC3CC(C2)CC1C3,,,,,,
3563,38258,Imidazolidinyl urea,C(NC(=O)NC1C(=O)NC(=O)N1CO)NC(=O)NC2C(=O)NC(=O)N2CO,,,,,,
3564,38259,6-Hexyl-m-cresol,CCCCCCC1=C(C=C(C=C1)C)O,,,,,,
3565,38260,"(1,1'-Biphenyl)-3-carboxylic acid, 2',4-dihydroxy-5'-(7-(beta-D-glucopyranosyloxy)-3,4-dihydro-5-hydroxy-6-methyl-4-oxo-2H-1-benzopyran-2-yl)-, intramol. 3,6'''-ester",CC1=C(C2=C3C=C1O[C@H]4C(C([C@@H](C(O4)COC(=O)C5=C(C=CC(=C5)C6=C(C=CC(=C6)C(O3)CC2=O)O)O)O)O)O)O,,,,,,
3566,38261,"(1,1'-Biphenyl)-3-carboxylic acid, 2,2'-dihydroxy-5'-(7-(beta-D-glucopyranosyloxy)-3,4-dihydro-5-hydroxy-6-methyl-4-oxo-2H-1-benzopyran-2-yl)-, intramol. 3,6'''-ester",CC1=C(C2=C3C=C1O[C@H]4C(C([C@@H](C(O4)COC(=O)C5=CC=CC(=C5O)C6=C(C=CC(=C6)C(O3)CC2=O)O)O)O)O)O,,,,,,
3567,38262,CID 38262,CC(=O)N=C([NH3+])N.[Cl-],,,,,,
3568,38263,N-carbamimidoylacetamide,CC(=O)N=C(N)N,,,,,,
3569,38264,Agent orange,CCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl.CCCCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,"['Herbicides that remove leaves from trees and growing plants. They may be either organic or inorganic. Several of the more persistent types have been used in military operations and many are toxic. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Defoliants, Chemical.)']",,,
3570,38265,"Propanoic acid, 2-(2,4-dichlorophenoxy)-, compd. with urea, N-2-benzothiazolyl-N,N'-dimethyl-(1:1)",CC(C(=O)O)OC1=C(C=C(C=C1)Cl)Cl.CNC(=O)N(C)C1=NC2=CC=CC=C2S1,,,,,,
3571,38266,"3-Methyl-1,2-dihydronaphthalene",CC1=CC2=CC=CC=C2CC1,,,,,,
3572,38267,N-(2-Bromoethyl)-N-benzylfluoren-9-amine hydrobromide,C1=CC=C(C=C1)C[NH+](CCBr)C2C3=CC=CC=C3C4=CC=CC=C24.[Br-],,,,,,
3573,38268,N-benzyl-N-(2-bromoethyl)-9H-fluoren-9-amine,C1=CC=C(C=C1)CN(CCBr)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
3574,38269,CID 38269,CC1C=CC=CC=CC=CC=CC=CC=CC(CC(C(C(CC(=O)CC(C(CCC(=O)CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)C(=O)OC)O)O[C@H]2C(C([C@H](C(O2)C)O)[NH3+])O.[Cl-],,,,,,
3575,38270,CID 38270,CC1C=CC=CC=CC=CC=CC=CC=CC(CC(C(C(CC(=O)CC(C(CCC(=O)CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)C(=O)OC)O)O[C@H]2C(C([C@H](C(O2)C)O)N)O,,,,,,
3576,38271,Refrigerant 502,C(F)(F)Cl.C(C(F)(F)Cl)(F)(F)F,,,,,,
3577,38272,"5,8-Diethyl-7-hydroxyiminododecan-6-ol;2-[4-(hydroxyiminomethyl)phenyl]-5-nonylphenol",CCCCCCCCCC1=CC(=C(C=C1)C2=CC=C(C=C2)C=NO)O.CCCCC(CC)C(C(=NO)C(CC)CCCC)O,,,,,,
3578,38273,2-[4-(Hydroxyiminomethyl)phenyl]-5-nonylphenol,CCCCCCCCCC1=CC(=C(C=C1)C2=CC=C(C=C2)C=NO)O,,,,,,
3579,38274,"5,8-Diethyl-7-hydroxydodecan-6-one oxime",CCCCC(CC)C(C(=NO)C(CC)CCCC)O,,,,,,
3580,38275,CID 38275,OP(=O)(O)O.[F-].[Na+],,,,,,
3581,38276,Antibiotic R 588A; Carminomicin I; Carminomycin I,CC1C(C(CC(O1)OC2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(=O)C)O)N)O,,,,,,
3582,38277,"2,2',4,4',6-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C=C(C=C2Cl)Cl)Cl,,,,,,
3583,38278,N-(2-Methyl-4-phenoxyphenyl)-2-(propylamino)acetamide hydrochloride,CCC[NH2+]CC(=O)NC1=C(C=C(C=C1)OC2=CC=CC=C2)C.[Cl-],,,,,,
3584,38279,N-(2-methyl-4-phenoxyphenyl)-2-(propylamino)acetamide,CCCNCC(=O)NC1=C(C=C(C=C1)OC2=CC=CC=C2)C,,,,,,
3585,38280,"2H-1-Benzopyran-3-carboxylic acid, 2-oxo-, propyl ester",CCCOC(=O)C1=CC2=CC=CC=C2OC1=O,,,,,,
3586,38281,"2-Butanone, 1-chloro-4-(N-(3-chloro-2-oxopropyl)-N-nitroamino)-",C(CN(CC(=O)CCl)[N+](=O)[O-])C(=O)CCl,,,,,,
3587,38282,4-(4-Chlorophenyl)-4-hydroxypiperidine,C1CNCCC1(C2=CC=C(C=C2)Cl)O,,,,,['CPHP is a known human metabolite of reduced_haloperidol.'],
3588,38283,Cyphenothrin,CC(=CC1C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,,,,"['(14)C tissue residue levels 7 days after single oral or subcutaneous administration of each of the (14)C-labeled preparations of trans- and cis-cyphenothrin were measured. With the acid- and alcohol-labeled preparations of the trans and cis isomers, the tissue residue levels were generally very low. On the other hand, the CN-labeled preparations showed relatively higher tissue residues than other labeled preparations.', 'Single oral or subcutaneous administration of (14)C-trans or cis-cyphenothrin labeled in the acid or alcohol moiety to rats at 2-4 mg/kg resulted in almost complete elimination of the (14)C from the animal body. Major excretion routes with the acid- or alcohol- (except for the CN group) labeled preparation were the urine and feces. The total recovery of the (14)C within 7 days after administration of these labeled preparations was more than 93% in urine and feces. On the other hand, the (14)C derived from the CN group was more slowly excreted. In addition, 4-6% of the (14)C was expired as (14)CO2. The total (14)C recovery was 60-80% for the trans and cis isomers. The three labeled preparations of the trans and cis isomers showed more urinary excretion of the (14)C with subcutaneous than with oral administration.']","['In vivo and in vitro comparative metabolism studies of phenothrin and cyphenothrin showed the following results: (1) The trans isomers of cyphenothrin and phenothrin were hydrolyzed more rapidly in vitro (liver homogenates) and in vivo than the corresponding cis isomers, and cis-cyphenothrin was hydrolyzed to a larger extent than cis-phenothrin. (2) Plasma esterases showed a different substrate specificity form the liver esterases and hydrolyzed the trans and cis isomers of cyphenothrin and phenothrin to nearly the same extents. From the results of the in vivo and in vitro studies, the CN group introduced into the molecule did not affect the biodegradability of trans-cyphenothrin, but rather made cis-cyphenothrin more biodegradable than cis-phenothrin. These in vivo metabolic profiles (ester hydrolysis rate, excretion pattern into urine and feces) make be mainly determined by activity and/or substrate specificity of the liver esterases.', ""Both the trans and cis isomers underwent the following major metabolic reactions: (1) oxidation at the 2'- and 4'-phenoxy positions of the alcohol moiety; (2) oxidation at the isobutenyl and the gem-dimethyl groups of the acid moiety; (3) cleavage of ester linkage; (4) conversion of the CN ion to SCN ion and CO2; and (5) conjugation of the resulting carboxylic acids and phenols with glucuronic acid, sulfuric acid, and glycine.""]",
3589,38284,3-Phenoxybenzaldehyde,C1=CC=C(C=C1)OC2=CC=CC(=C2)C=O,,,,,,
3590,38285,"BENZOTHIAZOLE, 2-(tert-BUTYLTHIO)-",CC(C)(C)SC1=NC2=CC=CC=C2S1,,,,,,
3591,38286,Befunolol hydrochloride,CC(C)[NH2+]CC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O.[Cl-],,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)']",,,
3592,38287,2-Acetyl-7-(2-hydroxy-3-tert-butylaminopropoxy)benzofuran,CC(=O)C1=CC2=C(O1)C(=CC=C2)OCC(CNC(C)(C)C)O,,,,,,
3593,38288,2-Acetyl-4-(2-hydroxy-3-tert-butylaminopropoxy)benzofuran,CC(=O)C1=CC2=C(O1)C=CC=C2OCC(CNC(C)(C)C)O,,,,,,
3594,38289,"2-Benzofurancarboxylic acid, 7-(2-hydroxy-3-(isopropylamino)propoxy)-, ethyl ester",CCOC(=O)C1=CC2=C(O1)C(=CC=C2)OCC(CNC(C)C)O,,,,,,
3595,38290,2-Acetyl-7-(2-hydroxy-3-sec-butylaminopropoxy)benzofuran,CCC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O,,,,,,
3596,38291,2-Ethyl-4-acetyl-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran,CCC1=CC2=C(C=CC(=C2O1)OCC(CNC(C)C)O)C(=O)C,,,,,,
3597,38292,"Diethylenetriamine, 1-benzyl-",C1=CC=C(C=C1)CNCCNCCN,,,,,,
3598,38293,2-Acetyl-5-nitrothiophene,CC(=O)C1=CC=C(S1)[N+](=O)[O-],,,,,,
3599,38294,"2,3,4,5-Tetrabromo-6-chlorotoluene",CC1=C(C(=C(C(=C1Br)Br)Br)Br)Cl,,,,,,
3600,38295,"Dimethyl bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate",COC(=O)C1C2CC(C1C(=O)OC)C=C2,,,,,,
3601,38296,"5,7-Dimethylisatin",CC1=CC(=C2C(=C1)C(=O)C(=O)N2)C,,,,,,
3602,38297,CID 38297,CN1CCC(=C2C3=C(N=CC=C3)OC4=CC=CC=C42)CC1.C(=CC(=O)O)C(=O)O,,,,,,
3603,38298,Azanator,CN1CCC(=C2C3=C(N=CC=C3)OC4=CC=CC=C42)CC1,,,,,,
3604,38299,CID 38299,CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC=C3)OC)OC.C(=CC(=O)O)C(=O)O,,,,,,
3605,38300,"Phosphorothioic acid, O,O-diethyl O-(6-fluoro-2-pyridyl) ester",CCOP(=S)(OCC)OC1=CN=C(C=C1)F,,,,,,
3606,38301,"Hydrazine, hexyl-, sulfate",CCCCCCNN.OS(=O)(=O)O,,,,,,
3607,38302,Hexylhydrazine,CCCCCCNN,,,,,,
3608,38303,"Hydrazine, heptyl-, sulfate",CCCCCCCNN.OS(=O)(=O)O,,,,,,
3609,38304,2-[[(5-Oxo-1-phenylpyrrolidin-3-yl)carbonyl]amino]benzoic acid,C1C(CN(C1=O)C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C(=O)O,,,,,,
3610,38305,Methyl o-(4-morpholinocarbonyl-2-oxo-1-pyrrolidinyl)benzoate,COC(=O)C1=CC=CC=C1N2CC(CC2=O)C(=O)N3CCOCC3,,,,,,
3611,38306,"2,3,3',4,4',5,5'-Heptachlorobiphenyl",C1=C(C=C(C(=C1Cl)Cl)Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
3612,38307,Bis(2-chloroisopropyl) ether,CC(C)(OC(C)(C)Cl)Cl,,,,"['MALE RATS WERE GIVEN SINGLE ORAL DOSES OF (14)CARBON LABELED BIS(2-CHLOROISOPROPYL) ETHER AT 90 MG/KG. EXCRETION OF (14)CO2 & URINARY (14)CARBON FOLLOWED FOR 48 HR. TIME REQUIRED TO ELIMINATE 0.5 OF DOSE WAS 19 HR. DURING THE 48 HR FOLLOWING A SINGLE ORAL DOSE. 20.3% OF DOSE WAS EXPIRED AS (14)CO2, 47.5% AS URINARY (14)CARBON & 3.8% AS FECAL (14)CARBON.']","['MALE RATS WERE GIVEN SINGLE ORAL DOSES OF (14)CARBON LABELED BIS(2-CHLOROISOPROPYL) ETHER AT 90 MG/KG. METABOLITES IDENTIFIED IN URINE WERE 2-(2-CHLORO-1-METHYLETHOXY)PROPANOIC ACID, APPROX 36% & N-ACETYL-S-(2-HYDROXYPROPYL)-L-CYSTEINE AT 19%.']",
3613,38308,"1,7,8,9,10,10-Hexachlorotricyclo[5.2.1.02,6]deca-3,8-diene-3,5-diol",C1=C(C2C(C1O)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl)O,,,,,,
3614,38309,2-Bromosuccinimide,C1C(C(=O)NC1=O)Br,,,,,,
3615,38310,"4-(Diisopropylamino)-2,2-diphenylbutyramide",CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C,,,,,,
3616,38311,"Azobenzene, 4-bis(2-bromopropyl)amino-",C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(CCCBr)CCCBr,,,,,,
3617,38312,2-[[4-[Bis(2-bromopropyl)amino]-2-tolyl]azo]benzoic acid,CC1=C(C=CC(=C1)N(CC(C)Br)CC(C)Br)N=NC2=CC=CC=C2C(=O)O,,,,,,
3618,38313,"Hexadecanamide, N-[3-(dimethylamino)propyl]-",CCCCCCCCCCCCCCCC(=O)NCCCN(C)C,,,,,,
3619,38314,p-Nitrophenylacetamidine hydrochloride,C1=CC(=CC=C1CC(=[NH2+])N)[N+](=O)[O-].[Cl-],,,,,,
3620,38315,2-(4-Nitrophenyl)ethanimidamide,C1=CC(=CC=C1CC(=N)N)[N+](=O)[O-],,,,,,
3621,38316,"ACETIC ACID, 2-(p-(ALLYLAMINO)PHENYL)-",C=CCNC1=CC=C(C=C1)CC(=O)O,,,,,,
3622,38317,"ACETIC ACID, 2-(p-(ETHYLAMINO)PHENYL)-",CCNC1=CC=C(C=C1)CC(=O)O,,,,,,
3623,38318,"ACETIC ACID, 2-(p-(PROPYLAMINO)PHENYL)-",CCCNC1=CC=C(C=C1)CC(=O)O,,,,,,
3624,38319,"ACETIC ACID, 2-(p-(BUTYLAMINO)PHENYL)-",CCCCNC1=CC=C(C=C1)CC(=O)O,,,,,,
3625,38320,(4-Benzylaminophenyl)acetic acid,C1=CC=C(C=C1)CNC2=CC=C(C=C2)CC(=O)O,,,,,,
3626,38321,"ACETIC ACID, 2-(p-(METHALLYLAMINO)PHENYL)-",CC(=C)CNC1=CC=C(C=C1)CC(=O)O,,,,,,
3627,38322,(4-Propargylaminophenyl)acetic acid,C#CCNC1=CC=C(C=C1)CC(=O)O,,,,,,
3628,38323,CID 38323,C1=CC=C(C=C1)N=NC(=O)C2=CC=C(C=C2)N(O)O,,,,,,
3629,38324,"Benzamide, 4-amino-2,6-dimethyl-N-(2-morpholinoethyl)-",CC1=CC(=CC(=C1C(=O)NCCN2CCOCC2)C)N,,,,,,
3630,38325,"Benzamide, 4-amino-2,6-dimethyl-N-(2-piperidinoethyl)-",CC1=CC(=CC(=C1C(=O)NCCN2CCCCC2)C)N,,,,,,
3631,38326,"Benzamide, 4-amino-2,6-dimethyl-N-(2-(4-phenyl-1-piperazinyl)ethyl)-",CC1=CC(=CC(=C1C(=O)NCCN2CCN(CC2)C3=CC=CC=C3)C)N,,,,,,
3632,38327,"ACETOHYDROXAMIC ACID, 2-(p-NITROBENZAMIDO)-",C1=CC(=CC=C1C(=O)NCC(=O)NO)[N+](=O)[O-],,,,,,
3633,38328,Iodomethyltrimethylammonium iodide,C[N+](C)(C)CI.[I-],,,,,,
3634,38329,Iodotrimethylammonium,C[N+](C)(C)CI,,,,,,
3635,38330,"alpha-(((4,6-Dimethyl-2-pyridyl)amino)methyl)benzyl alcohol hydrochloride",CC1=CC(=[NH+]C(=C1)NCC(C2=CC=CC=C2)O)C.[Cl-],,,,,,
3636,38331,"2-[(4,6-Dimethylpyridin-2-yl)amino]-1-phenylethanol",CC1=CC(=NC(=C1)NCC(C2=CC=CC=C2)O)C,,,,,,
3637,38332,CID 38332,CCCCC(C)(C)[C@@H](C=CC1[C@H](CC(=O)[C@H]1CC=CCCCC(=O)O)O)O,,,,,,
3638,38333,5-Methoxyisatin,COC1=CC2=C(C=C1)NC(=O)C2=O,,,,,,
3639,38334,"trans-2-Ethyl-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CCP1(=O)C(CC(O1)(C)C)(C)O,,,,,,
3640,38335,"cis-2-(Diethylamino)-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CCN(CC)P1(=O)C(CC(O1)(C)C)(C)O,,,,,,
3641,38336,"cis-2-Phenyl-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CC1(CC(P(=O)(O1)C2=CC=CC=C2)(C)O)C,,,,,,
3642,38337,"cis-2-Ethoxy-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CCOP1(=O)C(CC(O1)(C)C)(C)O,,,,,,
3643,38338,"BENZO(b)THIOPHENE, 3-(2-AMINOETHYLAMINO)-2-CHLORO-, 1,1,-DIOXIDE",C1=CC=C2C(=C1)C(=C(S2(=O)=O)Cl)NCCN,,,,,,
3644,38339,"BENZO(b)THIOPHENE, 2-CHLORO-3-(1-PIPERAZINYL)-, 1,1-DIOXIDE",C1CN(CCN1)C2=C(S(=O)(=O)C3=CC=CC=C32)Cl,,,,,,
3645,38340,"BENZO(b)THIOPHENE, 2-CHLORO-3-(4-METHYL-1-PIPERAZINYL)-, 1,1-DIOXIDE",CN1CCN(CC1)C2=C(S(=O)(=O)C3=CC=CC=C32)Cl,,,,,,
3646,38341,"2-Chloro-3-(1-piperazinyl)benzo(b)thiophene 1,1-dioxide hydrochloride",C1CN(CC[NH2+]1)C2=C(S(=O)(=O)C3=CC=CC=C32)Cl.[Cl-],,,,,,
3647,38342,"(+-)-cis-1,2,3,4-Tetrahydro-2-(dimethylamino)-1-naphthol benzoate hydrochloride",C[NH+](C)[C@H]1CCC2=CC=CC=C2[C@H]1OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
3648,38343,"[(1R,2S)-2-(dimethylamino)-1,2,3,4-tetrahydronaphthalen-1-yl] benzoate",CN(C)[C@H]1CCC2=CC=CC=C2[C@H]1OC(=O)C3=CC=CC=C3,,,,,,
3649,38344,"(1S-cis)-1,2,3,4-Tetrahydro-2-(dimethylamino)-1-naphthol benzoate hydrochloride",C[NH+](C)C1CCC2=CC=CC=C2C1OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
3650,38345,"[2-(Dimethylamino)-1,2,3,4-tetrahydronaphthalen-1-yl] benzoate",CN(C)C1CCC2=CC=CC=C2C1OC(=O)C3=CC=CC=C3,,,,,,
3651,38346,Nilestriol,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@]2(C#C)O)O)CCC4=C3C=CC(=C4)OC5CCCC5,,,"['Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. (See all compounds classified as Estrogens.)']",,,
3652,38347,4-Hydroperoxycyclophosphamide,C1COP(=O)(NC1OO)N(CCCl)CCCl,,,,,,
3653,38348,"2H-Isoindole-2-propanethiol, 1,3-dihydro-1,3-dioxo-",CCCSN1C(=O)C2=CC=CC=C2C1=O,,,,,,
3654,38349,"5,6-dichloro-2-(chloromethyl)-1H-benzimidazole",C1=C2C(=CC(=C1Cl)Cl)N=C(N2)CCl,,,,,,
3655,38350,"Platynecine-7,9-senecioate",CC(=CC(=O)OC[C@H]1CCN2[C@H]1[C@@H](CC2)OC(=O)C=C(C)C)C,,,,,,
3656,38351,Amikacin sulfate,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O,"['Treatment of nontuberculous mycobacterial lung infection, Treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis']",,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3657,38352,CID 38352,C1[C@H](C([C@H](C([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C([C@H]([C@@H](O3)CN)O)O)O)N,,,,,,
3658,38353,Tiprenolol,CC(C)NCC(COC1=CC=CC=C1SC)O,,,,,,
3659,38354,"7,12-Dimethylbenz[a]anthracene 5,6-oxide",CC1=C2C3C(O3)C4=CC=CC=C4C2=C(C5=CC=CC=C15)C,,,,,,
3660,38355,"Dibenzo(b,f)thiepin-8-sulfonamide, 10,11-dihydro-N,N-dimethyl-10-(4-methyl-1-piperazinyl)-, methanesulfonate, hydrate (1:1:1)",C[NH+]1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)[O-],,,,,,
3661,38356,"N,N-dimethyl-5-(4-methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepine-3-sulfonamide",CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,,,,,,
3662,38357,2-Methyl-3-nitrosooxazolidine,CC1N(CCO1)N=O,,,,,,
3663,38358,Methoxymethyl-methylnitrosamine,CN(COC)N=O,,,,,,
3664,38359,p-Decyloxyaniline,CCCCCCCCCCOC1=CC=C(C=C1)N,,,,,,
3665,38360,4-Hexyloxyaniline,CCCCCCOC1=CC=C(C=C1)N,,,,,,
3666,38361,Dopamantine,C1C2CC3CC1CC(C2)(C3)C(=O)NCCC4=CC(=C(C=C4)O)O,,,,,,
3667,38362,4'-Morpholinoacetophenone,CC(=O)C1=CC=C(C=C1)N2CCOCC2,,,,,,
3668,38363,4-Piperidinophenylacetic acid,C1CCN(CC1)C2=CC=C(C=C2)CC(=O)O,,,,,,
3669,38364,3-Hydroxyheptyl acetate,CCCCC(CCOC(=O)C)O,,,,,,
3670,38365,CID 38365,C1=CC=C2C(=C1)C=CC=C2C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
3671,38366,(m-Chlorophenyl)dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)ammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC(=CC=C1)Cl.COS(=O)(=O)[O-],,,,,,
3672,38367,(3-Chlorophenyl)-[2-[ethoxy(methyl)phosphoryl]sulfanylethyl]-dimethylazanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC(=CC=C1)Cl,,,,,,
3673,38368,CID 38368,CN1CC(=O)N=C1[NH3+].C1=C(C=C(C2=C1C(=CN2)CCN)O)O.OS(=O)(=O)[O-],,,,,,
3674,38369,"Carbamic acid, (2-bromopropyl)-, benzyl ester",CC(CNC(=O)OCC1=CC=CC=C1)Br,,,,,,
3675,38370,"[(6,7-Dimethoxyisoquinolin-1-yl)(3,4-dimethoxyphenyl)methyl]amine",COC1=C(C=C(C=C1)C(C2=NC=CC3=CC(=C(C=C32)OC)OC)N)OC,,,,,,
3676,38371,"alpha-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-N-(2-phenylethyl)-1-isoquinolinemethanamine",COC1=C(C=C(C=C1)C(C2=NC=CC3=CC(=C(C=C32)OC)OC)NCCC4=CC=CC=C4)OC,,,,,,
3677,38372,N-Cyclohexyl-5-nitro-2-furanpropanamide,C1CCC(CC1)NC(=O)CCC2=CC=C(O2)[N+](=O)[O-],,,,,,
3678,38373,CID 38373,CC(C(=O)NN=CC=CC1=CC=C(O1)[N+](=O)[O-])NC(=O)C2=CC=CO2,,,,,,
3679,38374,1-(1-Adamantyl)-2-aminopropane monohydrochloride,CC(CC12CC3CC(C1)CC(C3)C2)N.Cl,,,,,,
3680,38375,1-(1-Adamantyl)propan-2-amine,CC(CC12CC3CC(C1)CC(C3)C2)N,,,,,,
3681,38376,"Benzoic acid, 4-(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-YL)-",C1CCC2=C(C1)C(=O)N(C2=O)C3=CC=C(C=C3)C(=O)O,,,,,,
3682,38377,N-(2-Chloropropyl)dibenzylamine hydrochloride,CC(C[NH+](CC1=CC=CC=C1)CC2=CC=CC=C2)Cl.[Cl-],,,,,,
3683,38378,"N,N-dibenzyl-2-chloropropan-1-amine",CC(CN(CC1=CC=CC=C1)CC2=CC=CC=C2)Cl,,,,,,
3684,38379,CID 38379,C[C@H](CCC(C(C)(C)O)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](CCC3=C)O)C,,,,,,
3685,38380,CID 38380,CCN1CC(C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3)C(=O)O,,,,,,
3686,38381,"Ethanethiol, 2-(triethoxysilyl)-, thioacetate",CCO[Si](CCSC(=O)C)(OCC)OCC,,,,,,
3687,38382,(2-Chloroethyl)dimethyl(2-hydroxyethyl)ammonium iodide acetate,CC(=O)OCC[N+](C)(C)CCCl.[I-],,,,,,
3688,38383,2-Acetyloxyethyl-(2-chloroethyl)-dimethylazanium,CC(=O)OCC[N+](C)(C)CCCl,,,,,,
3689,38384,2-Bromo-1-(pyridin-2-yl)ethanone,C1=CC=NC(=C1)C(=O)CBr,,,,,,
3690,38385,"2,3,3',4'-Tetrabromobiphenyl",C1=CC(=C(C(=C1)Br)Br)C2=CC(=C(C=C2)Br)Br,,,,,,
3691,38386,Tetrabromodiphenyl ethers,C1=CC(=CC=C1OC2=C(C(=C(C=C2)Br)Br)Br)Br,,,,,,
3692,38387,4-Propan-2-yloxybutan-2-ol,CC(C)OCCC(C)O,,,,,,
3693,38388,"Tris(1,3-dichloropropyl) phosphate",C(CCl)C(OP(=O)(OC(CCCl)Cl)OC(CCCl)Cl)Cl,,,,,,
3694,38389,3-Chloro-3-phenyl-2-propenal,C1=CC=C(C=C1)C(=CC=O)Cl,,,,,,
3695,38390,"Azobenzene, 4-bis(2-bromoethyl)amino-",C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(CCBr)CCBr,,,,,,
3696,38391,"Azobenzene, 4-bis(2-bromoethyl)amino-2'-carboxy-",C1=CC=C(C(=C1)C(=O)O)N=NC2=CC=C(C=C2)N(CCBr)CCBr,,,,,,
3697,38392,"Azobenzene, 4-bis(2-bromoethyl)amino-2'-carboxy-2-methyl-",CC1=C(C=CC(=C1)N(CCBr)CCBr)N=NC2=CC=CC=C2C(=O)O,,,,,,
3698,38393,"Azobenzene, 4-bis(2-(methylsulfonyloxy)ethyl)amino-",CS(=O)(=O)OCCN(CCOS(=O)(=O)C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
3699,38394,"Azobenzene, 4-bis(2-(methylsulfonyloxy)ethyl)amino-2'-carboxy-",CS(=O)(=O)OCCN(CCOS(=O)(=O)C)C1=CC=C(C=C1)N=NC2=CC=CC=C2C(=O)O,,,,,,
3700,38395,"Azobenzene, 4-bis(2-(methylsulfonyloxy)ethyl)-2'-carboxy-2-methyl-",CC1=C(C=CC(=C1)N(CCOS(=O)(=O)C)CCOS(=O)(=O)C)N=NC2=CC=CC=C2C(=O)O,,,,,,
3701,38396,"Azobenzene, 4-bis(2-chloropropyl)amino-",CC(CN(CC(C)Cl)C1=CC=C(C=C1)N=NC2=CC=CC=C2)Cl,,,,,,
3702,38397,"Benzoic acid, 2-((4-(bis(2-chloroethyl)amino)phenyl)azo)-",C1=CC=C(C(=C1)C(=O)O)N=NC2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
3703,38398,"Azobenzene, 4-bis(2-iodoethyl)amino-2'-carboxy-2-methyl-",CC1=C(C=CC(=C1)N(CCI)CCI)N=NC2=CC=CC=C2C(=O)O,,,,,,
3704,38399,"Azobenzene, 4-bis(2-chloropropyl)amino-2'-carboxy-",C1=CC=C(C(=C1)C(=O)O)N=NC2=CC=C(C=C2)N(CCCCl)CCCCl,,,,,,
3705,38400,"Azobenzene, 4-bis(2-chloropropyl)amino-2'-carboxy-2-methyl-",CC1=C(C=CC(=C1)N(CCCCl)CCCCl)N=NC2=CC=CC=C2C(=O)O,,,,,,
3706,38401,"Azobenzene, 4-bis(2-chloroethyl)amino-2'-carboxy-3-methoxy-",COC1=C(C=CC(=C1)N=NC2=CC=CC=C2C(=O)O)N(CCCl)CCCl,,,,,,
3707,38402,"N,N-Bis(2-chloroethyl)-4-nitrobenzylamine hydrochloride",C1=CC(=CC=C1C[NH+](CCCl)CCCl)[N+](=O)[O-].[Cl-],,,,,,
3708,38403,Bis-(2-Chloroethyl)-(4-nitrobenzyl)amine,C1=CC(=CC=C1CN(CCCl)CCCl)[N+](=O)[O-],,,,,,
3709,38404,"Azobenzene, 4-bis(2-bromopropyl)amino-2'-carboxy-2-methoxy-",CC(CN(CC(C)Br)C1=CC(=C(C=C1)N=NC2=CC=CC=C2C(=O)O)OC)Br,,,,,,
3710,38405,Cynaustraline hydrochloride,C[C@@H]([C@](C(C)C)(C(=O)OC[C@H]1CC[NH+]2C1CCC2)O)O.[Cl-],,,,,,
3711,38406,CID 38406,C[C@@H]([C@](C(C)C)(C(=O)OCC1CCN2C1CCC2)O)O,,,,,,
3712,38407,Amidochlor,CCC1=C(C(=CC=C1)CC)N(CNC(=O)C)C(=O)CCl,,,,,,
3713,38408,"2,2,4,4,8,8-Hexamethylspiro(1,3,5,7,2,4,6,8-tetraoxatetrasilocane-6,6'-benzo(c)(2,1)benzoxasiline)",C[Si]1(O[Si](O[Si]2(C3=CC=CC=C3C4=CC=CC=C4O2)O[Si](O1)(C)C)(C)C)C,,,,,,
3714,38409,Tienilic acid,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,['For the treatment of hypertension.'],,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma. (See all compounds classified as Uricosuric Agents.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)']",,"['Ticrynafen has known human metabolites that include Thiophene-4,5-epoxide and Tienilic acid-s-oxide.']",
3715,38410,"2,2',3,3',4,5',6,6'-Octachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3716,38411,"2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
3717,38412,"Methyl 3,6-dichloro-2-nitrobenzoate",COC(=O)C1=C(C=CC(=C1[N+](=O)[O-])Cl)Cl,,,,,,
3718,38413,1-Acetoxy-3-chloroacetone,CC(=O)OCC(=O)CCl,,,,,,
3719,38414,"Cobalt(2+), bis(2,2'-(methylimino)diethanol)-, dichloride",CN(CCO)CCO.CN(CCO)CCO.[Cl-].[Cl-].[Co+2],,,,,,
3720,38415,"2,6-Octadiene, 1-ethoxy-3,7-dimethyl-, (2Z)-",CCOCC=C(C)CCC=C(C)C,,,,,,
3721,38416,2-Methylcyclohexanonhelveticosid,CC1CCCCC12O[C@@H]3C(O[C@H](CC3O2)O[C@H]4CC[C@@]5(C6CC[C@@]7([C@H](CC[C@@]7(C6CC[C@@]5(C4)O)O)C8=CC(=O)OC8)C)C=O)C,,,,,,
3722,38417,3-Methylcyclohexanonhelveticosid,CC1CCCC2(C1)O[C@@H]3C(O[C@H](CC3O2)O[C@H]4CC[C@@]5(C6CC[C@@]7([C@H](CC[C@@]7(C6CC[C@@]5(C4)O)O)C8=CC(=O)OC8)C)C=O)C,,,,,,
3723,38418,4-Methylcyclohexanonhelveticosid,CC1CCC2(CC1)O[C@@H]3C(O[C@H](CC3O2)O[C@H]4CC[C@@]5(C6CC[C@@]7([C@H](CC[C@@]7(C6CC[C@@]5(C4)O)O)C8=CC(=O)OC8)C)C=O)C,,,,,,
3724,38419,Aethyloctylketonhelveticosid,CCCCCCCCC1(O[C@@H]2C(O[C@H](CC2O1)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C=O)C)CC,,,,,,
3725,38420,CID 38420,CC=CCCC1(O[C@@H]2C(O[C@H](CC2O1)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C=O)C)C,,,,,,
3726,38421,"Propionic acid, 2-benzenesulfonamido-3-phenyl-, D-",C1=CC=C(C=C1)CC(C(=O)O)NS(=O)(=O)C2=CC=CC=C2,,,,,,
3727,38422,"Propionic acid, 2-(p-bromobenzenesulfonamido)-3-phenyl-, D-",C1=CC=C(C=C1)C[C@H](C(=O)O)NS(=O)(=O)C2=CC=C(C=C2)Br,,,,,,
3728,38423,"N-(3,4-Dimethoxyphenethyl)-2-mercaptoacetamidine hydrochloride",COC1=C(C=C(C=C1)CC[NH+]=C(CS)N)OC.[Cl-],,,,,,
3729,38424,"N'-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylethanimidamide",COC1=C(C=C(C=C1)CCN=C(CS)N)OC,,,,,,
3730,38425,"Acetamidine, 2-mercapto-N-(3-morpholinopropyl)-, dihydrochloride",C1COCC[NH+]1CCC[NH+]=C(CS)N.[Cl-].[Cl-],,,,,,
3731,38426,N'-(3-morpholin-4-ylpropyl)-2-sulfanylethanimidamide,C1COCCN1CCCN=C(CS)N,,,,,,
3732,38427,"2,2'-Dithiobis(N-cyclopentylmethylacetamidine) dihydrochloride",C1CCC(C1)C[NH+]=C(CSSCC(=[NH+]CC2CCCC2)N)N.[Cl-].[Cl-],,,,,,
3733,38428,2-[[2-amino-2-(cyclopentylmethylimino)ethyl]disulfanyl]-N'-(cyclopentylmethyl)ethanimidamide,C1CCC(C1)CN=C(CSSCC(=NCC2CCCC2)N)N,,,,,,
3734,38429,"2,2'-Dithiobis(N-(3-cyclohexylpropyl)acetamidine) dihydrochloride",C1CCC(CC1)CCC[NH+]=C(CSSCC(=[NH+]CCCC2CCCCC2)N)N.[Cl-].[Cl-],,,,,,
3735,38430,2-[[2-amino-2-(3-cyclohexylpropylimino)ethyl]disulfanyl]-N'-(3-cyclohexylpropyl)ethanimidamide,C1CCC(CC1)CCCN=C(CSSCC(=NCCCC2CCCCC2)N)N,,,,,,
3736,38431,"2,2'-Dithiobis(N-(2-cycloheptyl)ethylacetamidine) dihydrochloride",C1CCCC(CC1)CC[NH+]=C(CSSCC(=[NH+]CCC2CCCCCC2)N)N.[Cl-].[Cl-],,,,,,
3737,38432,2-[[2-amino-2-(2-cycloheptylethylimino)ethyl]disulfanyl]-N'-(2-cycloheptylethyl)ethanimidamide,C1CCCC(CC1)CCN=C(CSSCC(=NCCC2CCCCCC2)N)N,,,,,,
3738,38433,"2,2'-Dithiobis(N-cyclooctylmethylacetamidine) dihydrochloride",C1CCCC(CCC1)C[NH+]=C(CSSCC(=[NH+]CC2CCCCCCC2)N)N.[Cl-].[Cl-],,,,,,
3739,38434,2-[[2-amino-2-(cyclooctylmethylimino)ethyl]disulfanyl]-N'-(cyclooctylmethyl)ethanimidamide,C1CCCC(CCC1)CN=C(CSSCC(=NCC2CCCCCCC2)N)N,,,,,,
3740,38435,"2,2'-Dithiobis(N-(p-tert-butylthio)phenethylacetamidine) dihydrochloride",CC(C)(C)SC1=CC=C(C=C1)CC[NH+]=C(CSSCC(=[NH+]CCC2=CC=C(C=C2)SC(C)(C)C)N)N.[Cl-].[Cl-],,,,,,
3741,38436,2-[[2-amino-2-[2-(4-tert-butylsulfanylphenyl)ethylimino]ethyl]disulfanyl]-N'-[2-(4-tert-butylsulfanylphenyl)ethyl]ethanimidamide,CC(C)(C)SC1=CC=C(C=C1)CCN=C(CSSCC(=NCCC2=CC=C(C=C2)SC(C)(C)C)N)N,,,,,,
3742,38437,"4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-1,2-dimethoxy-6-propyl-",CCCN1CCC2=CC(=C(C3=C2C1CC4=CC=CC=C43)OC)OC,,,,,,
3743,38438,"beta-(2,4-Bis(phenylmethoxy)benozyl)-1,3-benzodioxole-5-acetaldehyde",C1OC2=C(O1)C=C(C=C2)C(C=O)C(=O)C3=C(C=C(C=C3)OCC4=CC=CC=C4)OCC5=CC=CC=C5,,,,,,
3744,38439,"1,2,3,7,8-Pentachlorodibenzo-P-dioxin",C1=C2C(=CC(=C1Cl)Cl)OC3=C(C(=C(C=C3O2)Cl)Cl)Cl,,,,,,
3745,38440,Chloro-bis-(2-chloro-vinyl)-arsine,C(=C[As](C=CCl)Cl)Cl,,,,,,
3746,38441,Rabenzazole,CC1=CC(=NN1C2=NC3=CC=CC=C3N2)C,,,,,,
3747,38442,2-Hydroxyethyl(p-nitrobenzylidene)amine oxide,C1=CC(=CC=C1C=[N+](CCO)[O-])[N+](=O)[O-],,,,,,
3748,38443,2-Hydroxyethyl(m-nitrobenzylidene)amine oxide,C1=CC(=CC(=C1)[N+](=O)[O-])C=[N+](CCO)[O-],,,,,,
3749,38444,2-Methyl-3-nitro-2H-1-benzopyran,CC1C(=CC2=CC=CC=C2O1)[N+](=O)[O-],,,,,,
3750,38445,7-Nitro-1-tetralone,C1CC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)C1,,,,,,
3751,38446,"2,2',3,3',4,4',5,6'-Octachlorodiphenyl ether",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)OC2=C(C(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
3752,38447,"Benzenemethanamine, N,N-bis(2-chloroethyl)-3-iodo-(9CI)",C1=CC(=CC(=C1)I)CN(CCCl)CCCl,,,,,,
3753,38448,"N,N-Bis(2-chloroethyl)-o-iodobenzylamine",C1=CC=C(C(=C1)CN(CCCl)CCCl)I,,,,,,
3754,38449,"1,3-Benzodioxol-4-OL, 2,2-diethyl-, methylcarbamate",CCC1(OC2=C(O1)C(=CC=C2)OC(=O)NC)CC,,,,,,
3755,38450,"Carbamic acid, methyl(1-oxobutyl)-, 2,2-dimethyl-1,3-benzodioxol-4-YL ester",CCCC(=O)N(C)C(=O)OC1=CC=CC2=C1OC(O2)(C)C,,,,,,
3756,38451,"Carbamic acid, methyl(1-oxopentyl)-, 2,2-dimethyl-1,3-benzodioxol-4-YL ester",CCCCC(=O)N(C)C(=O)OC1=CC=CC2=C1OC(O2)(C)C,,,,,,
3757,38452,"Carbamic acid, methyl(1-oxobutyl)-, 1,3-benzodioxol-4-YL ester",CCCC(=O)N(C)C(=O)OC1=CC=CC2=C1OCO2,,,,,,
3758,38453,Acetylseco hemicholinium-3-bromide,CC(=O)OCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCOC(=O)C.[Br-].[Br-],,,,,,
3759,38454,2-Acetyloxyethyl-[2-[4-[4-[2-[2-acetyloxyethyl(dimethyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-dimethylazanium,CC(=O)OCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCOC(=O)C,,,,,,
3760,38455,Hyalodendrin,CN1C(=O)C2(N(C(=O)C1(SS2)CC3=CC=CC=C3)C)CO,,,,,,
3761,38456,"Benzamide, 2-chloro-N-(1-(phenylmethyl)cyclopentyl)-",C1CCC(C1)(CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3Cl,,,,,,
3762,38457,2-((2-Methylpropyl)amino)-N-(1-(phenylmethyl)cyclopentyl)acetamide hydrochloride,CC(C)C[NH2+]CC(=O)NC1(CCCC1)CC2=CC=CC=C2.[Cl-],,,,,,
3763,38458,N-(1-benzylcyclopentyl)-2-(2-methylpropylamino)acetamide,CC(C)CNCC(=O)NC1(CCCC1)CC2=CC=CC=C2,,,,,,
3764,38459,CID 38459,C[NH+](C)CCCC1(C(CCOC2=C1C=CC(=C2)Cl)C3=CC=CC=C3)O.C(=CC(=O)[O-])C(=O)O,,,,,,
3765,38460,"8-chloro-5-[3-(dimethylamino)propyl]-4-phenyl-3,4-dihydro-2H-1-benzoxepin-5-ol",CN(C)CCCC1(C(CCOC2=C1C=CC(=C2)Cl)C3=CC=CC=C3)O,,,,,,
3766,38461,"1-Benzoxepin-5-ol, 2,3,4,5-tetrahydro-4,5-bis(3-(dimethylamino)propyl)-8-chloro-4-phenyl-, dihydrochloride",C[NH+](C)CCCC1(CCOC2=C(C1(CCC[NH+](C)C)O)C=CC(=C2)Cl)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
3767,38462,"8-Chloro-4,5-bis[3-(dimethylamino)propyl]-4-phenyl-2,3-dihydro-1-benzoxepin-5-ol",CN(C)CCCC1(CCOC2=C(C1(CCCN(C)C)O)C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
3768,38463,4-Methyl-1-(bis(2-chloroethyl)amino)-2-heptyn-4-ol hydrochloride,CCCC(C)(C#CC[NH+](CCCl)CCCl)O.[Cl-],,,,,,
3769,38464,1-[Bis(2-chloroethyl)amino]-4-methylhept-2-yn-4-ol,CCCC(C)(C#CCN(CCCl)CCCl)O,,,,,,
3770,38465,4-Methyl-1-bis-(2-chloroethyl)amino-2-octyn-4-ol hydrochloride,CCCCC(C)(CC#C[NH+](CCCl)CCCl)O.[Cl-],,,,,,
3771,38466,1-[Bis(2-chloroethyl)amino]-4-methyloct-1-yn-4-ol,CCCCC(C)(CC#CN(CCCl)CCCl)O,,,,,,
3772,38467,"N,N-Bis(2-chloroethyl)-4-methoxy-4-methyl-2-hexyn-1-amine hydrochloride",CCC(C)(C#CC[NH+](CCCl)CCCl)OC.[Cl-],,,,,,
3773,38468,"N,N-bis(2-chloroethyl)-4-methoxy-4-methylhex-2-yn-1-amine",CCC(C)(C#CCN(CCCl)CCCl)OC,,,,,,
3774,38469,4-Ethyl-1-bis-(2-chloroethyl)amino-2-hexyn-4-ol hydrochloride,CCC(CC)(C#CC[NH+](CCCl)CCCl)O.[Cl-],,,,,,
3775,38470,6-[Bis(2-chloroethyl)amino]-3-ethylhex-4-yn-3-ol,CCC(CC)(C#CCN(CCCl)CCCl)O,,,,,,
3776,38471,"Naphtho(2,1-b)(1,6)naphthyridine, 7,8,9,10,11,12-hexahydro-10-methyl-, hydrochloride",C[NH+]1CCC2=C(C1)CC3=C(N2)C=CC4=CC=CC=C34.[Cl-],,,,,,
3777,38472,"10-methyl-8,9,11,12-tetrahydro-7H-naphtho[2,1-b][1,6]naphthyridine",CN1CCC2=C(C1)CC3=C(N2)C=CC4=CC=CC=C34,,,,,,
3778,38473,1-Cyclohexyl-3-(diphenylmethoxy)azetidine,C1CCC(CC1)N2CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3779,38474,Zoanthoxantin,CC1=CC(=C2C(=NC=N2)C3=C1N(C(=N3)N)C)N(C)C,,,,,,
3780,38475,"3,6-Diamino-2,7,10-trimethylacridinium chloride",CC1=CC2=CC3=C(C=C(C(=C3)C)N)[N+](=C2C=C1N)C.[Cl-],,,,,,
3781,38476,"3,6-Diamino-2,7,10-trimethylacridinium",CC1=CC2=CC3=C(C=C(C(=C3)C)N)[N+](=C2C=C1N)C,,,,,,
3782,38477,N-Amidino-L-cysteine,C([C@@H](C(=O)O)N=C(N)N)S,,,,,,
3783,38478,"Cyclohexane, 1,1,4,4-tetramethyl-2,6-bis(methylene)-",CC1(CC(=C)C(C(=C)C1)(C)C)C,,,,,,
3784,38479,Pendimethalin,CCC(CC)NC1=C(C=C(C(=C1[N+](=O)[O-])C)C)[N+](=O)[O-],,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Pendimethalin is eliminated from body with 70% being excreted in feces, primarily parent compound, and 20% in urine within 24 hr /in rats/.', 'By 24 hr after the administration of 37 mg/kg of radio-labeled pendimethalin to rats, 90.3% of the dose was recovered in the feces and urine. After 96 hr, 95.8% of the dose was recovered in the urine (20.9%) and feces (74.9%). When a lower dose was administered (7.3 mg/kg), 99.8% was recovered in the urine (21.8%) and feces (78.0%) after 12 hr. After 96 hr, residues were less than 0.3 ppm in all body tissues except fat, which had 0.9 ppm. This study indicates that ingested pendimethalin is largely unabsorbed by the bloodstream and excreted through the feces. Pendimethalin which does become absorbed into the bloodstream from the gastrointestinal tract is rapidly metabolized in the kidneys and liver and is then excreted in the urine.']","['The metabolism of the dinitroaniline herbicide pendimethalin was investigated in rats with emphasis on the identification of metabolites in tissues and urine. Royal Hart Wistar rats were administered a single oral dose of radiolabeled methyl labeled or ethyl labeled pendimethalin. Radioactivity was excreted rapidly both in urine and feces at dosage levels of 7.3 and 37 mg/kg of radiolabeled pendimethalin. After 96 hr, the residues were less than 0.3 ppm in all tissues except fat, which had a residue of 0.9 ppm. The major metabolic routes of pendimethalin involved hydroxylation of the 4-methyl and the N-1-ethyl group, oxidation of these alkyl groups to carboxylic acids, nitro reduction, cyclization, and conjugation based on the identification of the 12 metabolites in urine and tissues. Products of cyclization reactions giving rise to methylbenzimidazole carboxylic acids were unique to liver and kidney. All major metabolites retained both radioactive labels of pendimethalin, indicating that N-dealkylation of the isopentyl group was not significant. This investigation extends the knowledge on the fate of dinitroanilines in the rat and demonstrates that pendimethalin is metabolized by several major pathways.']",
3785,38480,"2,2'-Dithiobis(N-cycloheptylmethylacetamidine) dihydrochloride",C1CCCC(CC1)C[NH+]=C(CSSCC(=[NH+]CC2CCCCCC2)N)N.[Cl-].[Cl-],,,,,,
3786,38481,2-[[2-amino-2-(cycloheptylmethylimino)ethyl]disulfanyl]-N'-(cycloheptylmethyl)ethanimidamide,C1CCCC(CC1)CN=C(CSSCC(=NCC2CCCCCC2)N)N,,,,,,
3787,38482,"6,7,8,9-Tetrahydro-5H-benzocycloheptene-5-acetic acid 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)CC1CCCCC2=CC=CC=C12,,,,,,
3788,38483,"6,7,8,9-Tetrahydro-5H-benzocycloheptene-5-acetic acid (1-methyl-2-piperidinyl)methyl ester",CN1CCCCC1COC(=O)CC2C=CC=CC3=C2CCCC3,,,,,,
3789,38484,"5H-Benzocycloheptene-9-acetic acid, 6,7-dihydro-, 2-(dimethylamino)ethyl ester, hydrochloride",C[NH+](C)CCOC(=O)CC1=CC2=C(CCCC=C2)C=C1.[Cl-],,,,,,
3790,38485,"2-(dimethylamino)ethyl 2-(8,9-dihydro-7H-benzo[7]annulen-3-yl)acetate",CN(C)CCOC(=O)CC1=CC2=C(CCCC=C2)C=C1,,,,,,
3791,38486,"5H-Benzocycloheptene-9-acetic acid, 6,7-dihydro-, (1-methyl-2-piperidinyl)methyl ester, hydrochloride",C[NH+]1CCCCC1COC(=O)CC2=CC3=C(CCCC=C3)C=C2.[Cl-],,,,,,
3792,38487,"(1-methylpiperidin-2-yl)methyl 2-(8,9-dihydro-7H-benzo[7]annulen-3-yl)acetate",CN1CCCCC1COC(=O)CC2=CC3=C(CCCC=C3)C=C2,,,,,,
3793,38488,"Ethanamine, N,N-dimethyl-2-((6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)oxy)-, hydrochloride",C[NH+](C)CCOC1CCCCC2=CC=CC=C12.[Cl-],,,,,,
3794,38489,"N,N-dimethyl-2-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yloxy)ethanamine",CN(C)CCOC1CCCCC2=CC=CC=C12,,,,,,
3795,38490,"Ethanamine, N,N-dimethyl-2-((6,7,8,9-tetrahydro-5-phenyl-5H-benzocyclohepten-5-yl)oxy)-, ethandioate (1:1)",C[NH+](C)CCOC1(CCCCC2=CC=CC=C21)C3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
3796,38491,"N,N-dimethyl-2-[(5-phenyl-6,7,8,9-tetrahydrobenzo[7]annulen-5-yl)oxy]ethanamine",CN(C)CCOC1(CCCCC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
3797,38492,"7-(Hydroxymethyl)-12-methyl-5,6-dihydrotetraphene-5,6-diol",CC1=C2C3=CC=CC=C3C(C(C2=C(C4=CC=CC=C14)CO)O)O,,,,,,
3798,38493,"Butyrophenone, 4'-fluoro-4-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)cyclohexylamino)-, hydrochloride, (E)-",C1CC(CCC1C2=CC(=CC=C2)C(F)(F)F)[NH2+]CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
3799,38494,1-(4-Fluorophenyl)-4-[[4-[3-(trifluoromethyl)phenyl]cyclohexyl]amino]butan-1-one,C1CC(CCC1C2=CC(=CC=C2)C(F)(F)F)NCCCC(=O)C3=CC=C(C=C3)F,,,,,,
3800,38495,"Butyrophenone, 4'-fluoro-4-(4-(alpha,alpha,alpha-trifluoro-p-tolyl)cyclohexylamino)-, hydrochloride, (E)-",C1CC(CCC1C2=CC=C(C=C2)C(F)(F)F)[NH2+]CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
3801,38496,1-(4-Fluorophenyl)-4-[[4-[4-(trifluoromethyl)phenyl]cyclohexyl]amino]butan-1-one,C1CC(CCC1C2=CC=C(C=C2)C(F)(F)F)NCCCC(=O)C3=CC=C(C=C3)F,,,,,,
3802,38497,"Acridine, 3,8-diamino-",C1=CC(=C2C=C3C=CC(=CC3=NC2=C1)N)N,,,,,,
3803,38498,"Acridine, 9-amino-2,4-dimethyl-",CC1=CC2=C(C3=CC=CC=C3N=C2C(=C1)C)N,,,,,,
3804,38499,"Acridine, 9-amino-4-phenyl-",C1=CC=C(C=C1)C2=CC=CC3=C(C4=CC=CC=C4N=C32)N,,,,,,
3805,38500,"Acridine, 2-amino-6-chloro-",C1=CC(=CC2=NC3=C(C=C21)C=C(C=C3)N)Cl,,,,,,
3806,38501,"Acridine, 3-amino-6-chloro-",C1=CC(=CC2=NC3=C(C=CC(=C3)Cl)C=C21)N,,,,,,
3807,38502,"Acridine, 3,5-diamino-",C1=CC2=CC3=C(C=C(C=C3)N)N=C2C(=C1)N,,,,,,
3808,38503,Fluproquazone,CC1=CC2=C(C=C1)C(=NC(=O)N2C(C)C)C3=CC=C(C=C3)F,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
3809,38504,6-Chloro-3-(chloromethyl)benzoxazol-2(3H)-one,C1=CC2=C(C=C1Cl)OC(=O)N2CCl,,,,,,
3810,38505,"4,7-Dimethyl-1-bis-(2-chloroethyl)amino-2-octyn-4-ol hydrochloride",CC(C)CCC(C)(CC#C[NH+](CCCl)CCCl)O.[Cl-],,,,,,
3811,38506,"1-[Bis(2-chloroethyl)amino]-4,7-dimethyloct-1-yn-4-ol",CC(C)CCC(C)(CC#CN(CCCl)CCCl)O,,,,,,
3812,38507,"Aniline, N-(2-(diethylamino)ethyl)-2-nitro-",CCN(CC)CCNC1=CC=CC=C1[N+](=O)[O-],,,,,,
3813,38508,"1-Naphthylamine, 5,6,7,8-tetrahydro-4-methoxy-N-(2-oxazolin-2-YL)-",COC1=C2CCCCC2=C(C=C1)NC3=NCCO3,,,,,,
3814,38509,CID 38509,C(C(C(=O)[O-])O)C(=O)O.[Na+],,,,,,
3815,38510,"5,6-Dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indole hydrochloride",CC1=C(C2=CC(=C(C=C2N1)OC)OC)CC[NH+]3CCN(CC3)C4=CC=CC=C4.[Cl-],,,,,,
3816,38511,CID 38511,C[NH+](C)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[N+](=O)[O-])C3=CC=CC=C3.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
3817,38512,"N,N-dimethyl-2-[4-(2-nitro-1,2-diphenylethenyl)phenoxy]ethanamine",CN(C)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
3818,38513,"(17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",CCC12C=CC3=C4CCC(=O)C=C4CCC3C1CC[C@]2(C#C)O,,,,,,
3819,38514,N-(alpha-Methyl-m-trifluoromethylphenethyl)acetamide,CC(CC1=CC(=CC=C1)C(F)(F)F)NC(=O)C,,,,,,
3820,38515,1-Phenylethyl acetoacetate,CC(C1=CC=CC=C1)OC(=O)CC(=O)C,,,,,,
3821,38516,trans-4'-Fluoro-4-(4-(p-anisyl)cyclohexylamino)butyrophenone hydrochloride,COC1=CC=C(C=C1)C2CCC(CC2)[NH2+]CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
3822,38517,1-(4-Fluorophenyl)-4-[[4-(4-methoxyphenyl)cyclohexyl]amino]butan-1-one,COC1=CC=C(C=C1)C2CCC(CC2)NCCCC(=O)C3=CC=C(C=C3)F,,,,,,
3823,38518,"Acridine, 3,6-diamino-4,5-dimethyl-",CC1=C(C=CC2=C1N=C3C(=C(C=CC3=C2)N)C)N,,,,,,
3824,38519,"4-Pentenoic acid, 2-((((cyclohexylamino)carbonyl)amino)carbonyl)-2-(2-propenyl)-",C=CCC(CC=C)(C(=O)NC(=O)NC1CCCCC1)C(=O)O,,,,,,
3825,38520,1-Methylbenzo(a)pyrene,CC1=C2C=CC3=C4C2=C(C=C1)C=CC4=CC5=CC=CC=C35,,,,,,
3826,38521,Guanadrel,C1CCC2(CC1)OCC(O2)CN=C(N)N,['Used to treat and control hypertension.'],"['High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled. Guanadrel works by controlling nerve impulses along certain nerve pathways. As a result, it relaxes the blood vessels so that blood passes through them more easily. This helps to lower blood pressure.']","['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",['Rapidly and readily absorbed from the gastrointestinal tract.'],['Primarily hepatic'],['10 hours']
3827,38522,"Carbonic acid, 1-methylethyl-, 1-oxo-2-(2,4,6-trimethylphenyl)-1H-inden-3-yl ester",CC1=CC(=C(C(=C1)C)C2=C(C3=CC=CC=C3C2=O)OC(=O)OC(C)C)C,,,,,,
3828,38523,1-Nitrosoazacyclotridecane,C1CCCCCCN(CCCCC1)N=O,,,,,,
3829,38524,"1,2,6,7-Tetrachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C=CC(=C3Cl)Cl)Cl)Cl,,,,,,
3830,38525,"1,2,6,9-Tetrachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=C(C=CC(=C3O2)Cl)Cl)Cl)Cl,,,,,,
3831,38526,"1,4,6,9-Tetrachlorodibenzo-P-dioxin",C1=CC(=C2C(=C1Cl)OC3=C(C=CC(=C3O2)Cl)Cl)Cl,,,,,,
3832,38527,"1,4,7,8-Tetrachlorodibenzo-P-dioxin",C1=CC(=C2C(=C1Cl)OC3=CC(=C(C=C3O2)Cl)Cl)Cl,,,,,,
3833,38528,"Benzoic acid, 3-acetamido-5-(carbamoylmethyl)-2,4,6-triiodo-",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)CC(=O)N)I,,,,,,
3834,38529,"Benzoic acid, 3-acetamido-5-(2-hydroxyethylcarbamoylmethyl)-2,4,6-triiodo-",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)CC(=O)NCCO)I,,,,,,
3835,38530,"4-Pentenoic acid, 2-((((cyclohexylamino)carbonyl)amino)carbonyl)-2-(2-propenyl)-, ethyl ester",CCOC(=O)C(CC=C)(CC=C)C(=O)NC(=O)NC1CCCCC1,,,,,,
3836,38531,Flucindole,CN(C)C1CCC2=C(C1)C3=C(N2)C(=CC(=C3)F)F,,,,,,
3837,38532,Altosid,CC(C)OC(=O)C=C(C)C=CCC(C)CCCC(C)(C)OC,,,,,,
3838,38533,"BENZYLAMINE, o-BROMO-N-(2-CHLOROETHYL)-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CCCl)CC1=CC=CC=C1Br.[Cl-],,,,,,
3839,38534,"BENZYLAMINE, o-BROMO-N-(2-CHLOROPROPYL)-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CC1=CC=CC=C1Br)CC(C)Cl.[Cl-],,,,,,
3840,38535,N-[(2-bromophenyl)methyl]-2-chloro-N-ethylpropan-1-amine,CCN(CC1=CC=CC=C1Br)CC(C)Cl,,,,,,
3841,38536,"BENZYLAMINE, o-BROMO-N-(3-CHLOROPROPYL)-, HYDROCHLORIDE",C1=CC=C(C(=C1)C[NH2+]CCCCl)Br.[Cl-],,,,,,
3842,38537,N-[(2-bromophenyl)methyl]-3-chloropropan-1-amine,C1=CC=C(C(=C1)CNCCCCl)Br,,,,,,
3843,38538,"BENZYLAMINE, o-BROMO-N-(3-CHLOROPROPYL)-N-METHYL-, OXALATE",C[NH+](CCCCl)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3844,38539,N-[(2-bromophenyl)methyl]-3-chloro-N-methylpropan-1-amine,CN(CCCCl)CC1=CC=CC=C1Br,,,,,,
3845,38540,"BENZYLAMINE, o-BROMO-N-(3-CHLOROPROPYL)-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CCCCl)CC1=CC=CC=C1Br.[Cl-],,,,,,
3846,38541,N-[(2-bromophenyl)methyl]-3-chloro-N-ethylpropan-1-amine,CCN(CCCCl)CC1=CC=CC=C1Br,,,,,,
3847,38542,"BENZYLAMINE, o-BROMO-N-(3-BROMOPROPYL)-N-ETHYL-, OXALATE",CC[NH+](CCCBr)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3848,38543,3-bromo-N-[(2-bromophenyl)methyl]-N-ethylpropan-1-amine,CCN(CCCBr)CC1=CC=CC=C1Br,,,,,,
3849,38544,"BENZYLAMINE, o-BROMO-N-ETHYL-N-(3-IODOPROPYL)-, OXALATE",CC[NH+](CCCI)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3850,38545,N-[(2-bromophenyl)methyl]-N-ethyl-3-iodopropan-1-amine,CCN(CCCI)CC1=CC=CC=C1Br,,,,,,
3851,38546,"BENZYLAMINE, o-BROMO-N-(3-CHLOROPROPYL)-N-PROPYL-, HYDROCHLORIDE",CCC[NH+](CCCCl)CC1=CC=CC=C1Br.[Cl-],,,,,,
3852,38547,N-[(2-bromophenyl)methyl]-3-chloro-N-propylpropan-1-amine,CCCN(CCCCl)CC1=CC=CC=C1Br,,,,,,
3853,38548,"BENZYLAMINE, o-BROMO-N-(3-CHLOROPROPYL)-N-ISOPROPYL-, HYDROCHLORIDE",CC(C)[NH+](CCCCl)CC1=CC=CC=C1Br.[Cl-],,,,,,
3854,38549,N-[(2-bromophenyl)methyl]-3-chloro-N-propan-2-ylpropan-1-amine,CC(C)N(CCCCl)CC1=CC=CC=C1Br,,,,,,
3855,38550,"BENZYLAMINE, N-ALLYL-o-BROMO-N-(3-CHLOROPROPYL)-, OXALATE",C=CC[NH+](CCCCl)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3856,38551,N-[(2-bromophenyl)methyl]-3-chloro-N-prop-2-enylpropan-1-amine,C=CCN(CCCCl)CC1=CC=CC=C1Br,,,,,,
3857,38552,"BENZYLAMINE, o-BROMO-N-tert-BUTYL-N-(3-CHLOROPROPYL)-, HYDROCHLORIDE",CC(C)(C)[NH+](CCCCl)CC1=CC=CC=C1Br.[Cl-],,,,,,
3858,38553,N-[(2-bromophenyl)methyl]-N-(3-chloropropyl)-2-methylpropan-2-amine,CC(C)(C)N(CCCCl)CC1=CC=CC=C1Br,,,,,,
3859,38554,"BENZYLAMINE, o-BROMO-N-(4-CHLOROBUTYL)-N-ETHYL-, OXALATE",CC[NH+](CCCCCl)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3860,38555,N-[(2-bromophenyl)methyl]-4-chloro-N-ethylbutan-1-amine,CCN(CCCCCl)CC1=CC=CC=C1Br,,,,,,
3861,38556,"BENZYLAMINE, o-BROMO-N-(4-CHLOROPENTYL)-N-ETHYL-, OXALATE",CC[NH+](CCCC(C)Cl)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3862,38557,N-[(2-bromophenyl)methyl]-4-chloro-N-ethylpentan-1-amine,CCN(CCCC(C)Cl)CC1=CC=CC=C1Br,,,,,,
3863,38558,"BENZYLAMINE, o-BROMO-N-(4-BROMOPENTYL)-N-ETHYL-, OXALATE",CC[NH+](CCCC(C)Br)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3864,38559,4-bromo-N-[(2-bromophenyl)methyl]-N-ethylpentan-1-amine,CCN(CCCC(C)Br)CC1=CC=CC=C1Br,,,,,,
3865,38560,"BENZYLAMINE, o-BROMO-N-(5-CHLOROPENTYL)-N-ETHYL-, OXALATE",CC[NH+](CCCCCCl)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3866,38561,N-[(2-bromophenyl)methyl]-5-chloro-N-ethylpentan-1-amine,CCN(CCCCCCl)CC1=CC=CC=C1Br,,,,,,
3867,38562,"BENZYLAMINE, o-BROMO-N-(5-BROMOPENTYL)-N-ETHYL-, OXALATE",CC[NH+](CCCCCBr)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3868,38563,5-bromo-N-[(2-bromophenyl)methyl]-N-ethylpentan-1-amine,CCN(CCCCCBr)CC1=CC=CC=C1Br,,,,,,
3869,38564,"BENZYLAMINE, o-BROMO-N-(6-CHLOROHEXYL)-N-ETHYL-, OXALATE",CC[NH+](CCCCCCCl)CC1=CC=CC=C1Br.C(=O)(C(=O)[O-])O,,,,,,
3870,38565,N-[(2-bromophenyl)methyl]-6-chloro-N-ethylhexan-1-amine,CCN(CCCCCCCl)CC1=CC=CC=C1Br,,,,,,
3871,38566,1-(Tert-butoxy)-2-methylcyclohexene,CC1=C(CCCC1)OC(C)(C)C,,,,,,
3872,38567,1-(4-Amino-phenyl)-3-pyridin-4-YL-propenone,C1=CC(=CC=C1C(=O)C=CC2=CC=NC=C2)N,,,,,,
3873,38568,CID 38568,C1C([C@@H](C(C1O)CC=CCCCC(=O)O)C=C[C@H](COC2=CC=CC=C2)O)O,,,,,,
3874,38569,CID 38569,C1C([C@@H](C(C1O)CC=CCCCC(=O)O)C=C[C@H](COC2=CC=C(C=C2)Cl)O)O,,,,,,
3875,38570,CID 38570,C1[C@@H]([C@@H](C([C@@H]1O)C=C[C@H](COC2=CC(=CC=C2)Cl)O)CC=CCCCC(=O)O)O,,,,,,
3876,38571,CID 38571,C1C([C@@H](C(C1O)CC=CCCCC(=O)O)C=C[C@H](COC2=CC=C(C=C2)F)O)O,,,,,,
3877,38572,CID 38572,COC1=CC=C(C=C1)OC[C@@H](C=C[C@H]2C(CC(C2CC=CCCCC(=O)O)O)O)O,,,,,,
3878,38573,CID 38573,CN(C[C@@H](C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O)C2=CC=CC=C2,,,,,,
3879,38574,CID 38574,C1C([C@@H](C(C1O)CC=CCCCC(=O)O)C=C[C@H](CSC2=CC=C(C=C2)Cl)O)O,,,,,,
3880,38575,"4-N,N-Bis(2-hydroxyethyl)-aminoacetophenone",CC(=O)C1=CC=C(C=C1)N(CCO)CCO,,,,,,
3881,38576,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(4-methoxyphenyl)ethyl)-6-(2-(1-piperidinyl)ethoxy)-",COC1=CC=C(C=C1)CCC(C2=C(C3=C(C(=C2OCCN4CCCCC4)OC)OC=C3)OC)O,,,,,,
3882,38577,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-phenylethyl)-, oxalate (1:1) (salt)",C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=CC=C3)O)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
3883,38578,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-phenylpropan-1-ol",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=CC=C3)O)OC)OC,,,,,,
3884,38579,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-phenylethyl)-6-(2-(1-pyrrolidinyl)ethoxy)-, oxalate (1:1) (salt)",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCC3)C(CCC4=CC=CC=C4)O.C(=O)(C(=O)[O-])O,,,,,,
3885,38580,"1-[4,7-Dimethoxy-6-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-5-yl]-3-phenylpropan-1-ol",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCC3)C(CCC4=CC=CC=C4)O,,,,,,
3886,38581,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-phenylethyl)-6-(2-(1-piperidinyl)ethoxy)-, oxalate (1:1) (salt)",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)C(CCC4=CC=CC=C4)O.C(=O)(C(=O)[O-])O,,,,,,
3887,38582,"1-[4,7-Dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]-3-phenylpropan-1-ol",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(CCC4=CC=CC=C4)O,,,,,,
3888,38583,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(4-morpholinyl)ethoxy)-alpha-(2-phenylethyl)-, oxalate (1:1) (salt)",COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCOCC3)C(CCC4=CC=CC=C4)O.C(=O)(C(=O)[O-])O,,,,,,
3889,38584,"1-[4,7-Dimethoxy-6-(2-morpholin-4-ylethoxy)-1-benzofuran-5-yl]-3-phenylpropan-1-ol",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCOCC3)C(CCC4=CC=CC=C4)O,,,,,,
3890,38585,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(4-methoxyphenyl)ethyl)-, oxalate (1:1) (salt)",C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)OC)O)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
3891,38586,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(4-methoxyphenyl)propan-1-ol",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)OC)O)OC)OC,,,,,,
3892,38587,"5-Benzofuranmethanol, 6-(2-(diethylamino)ethoxy)-4,7-dimethoxy-alpha-(2-(4-methoxyphenyl)ethyl)-",CCN(CC)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)OC)O)OC)OC,,,,,,
3893,38588,"5-Benzofuranmethanol, 6-(2-(bis(1-methylethyl)amino)ethoxy)-4,7-dimethoxy-alpha-(2-(4-methoxyphenyl)ethyl)-",CC(C)N(CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)OC)O)OC)OC)C(C)C,,,,,,
3894,38589,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(4-methoxyphenyl)ethyl)-6-(2-(1-pyrrolidinyl)ethoxy)-",COC1=CC=C(C=C1)CCC(C2=C(C3=C(C(=C2OCCN4CCCC4)OC)OC=C3)OC)O,,,,,,
3895,38590,"5-Benzofuranmethanol, alpha-(2-(4-chlorophenyl)ethyl)-4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)Cl)O)OC)OC,,,,,,
3896,38591,CID 38591,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC(=C(C=C3)Cl)Cl)O)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
3897,38592,"3-(3,4-Dichlorophenyl)-1-[6-[2-(dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]propan-1-ol",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC(=C(C=C3)Cl)Cl)O)OC)OC,,,,,,
3898,38593,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(4-fluorophenyl)ethyl)-, oxalate (1:1) (salt)",C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)F)O)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
3899,38594,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(4-fluorophenyl)propan-1-ol",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)F)O)OC)OC,,,,,,
3900,38595,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(4-hydroxyphenyl)ethyl)-",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=C(C=C3)O)O)OC)OC,,,,,,
3901,38596,Piprofurol,COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(CCC4=CC=C(C=C4)O)O,,,,,,
3902,38597,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(4-propoxyphenyl)ethyl)-, oxalate (1:1) (salt)",CCCOC1=CC=C(C=C1)CCC(C2=C(C3=C(C(=C2OCC[NH+](C)C)OC)OC=C3)OC)O.C(=O)(C(=O)[O-])O,,,,,,
3903,38598,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(4-propoxyphenyl)propan-1-ol",CCCOC1=CC=C(C=C1)CCC(C2=C(C3=C(C(=C2OCCN(C)C)OC)OC=C3)OC)O,,,,,,
3904,38599,"5-Benzofuranmethanol, alpha-(2-(4-butoxyphenyl)ethyl)-4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-, oxalate (1:1) (salt)",CCCCOC1=CC=C(C=C1)CCC(C2=C(C3=C(C(=C2OCC[NH+](C)C)OC)OC=C3)OC)O.C(=O)(C(=O)[O-])O,,,,,,
3905,38600,"3-(4-Butoxyphenyl)-1-[6-[2-(dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]propan-1-ol",CCCCOC1=CC=C(C=C1)CCC(C2=C(C3=C(C(=C2OCCN(C)C)OC)OC=C3)OC)O,,,,,,
3906,38601,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(2-methoxyphenyl)ethyl)-, oxalate (1:1) (salt)",C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=CC=C3OC)O)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
3907,38602,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(2-methoxyphenyl)propan-1-ol",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=CC=C3OC)O)OC)OC,,,,,,
3908,38603,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(3-methoxyphenyl)ethyl)-",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC(=CC=C3)OC)O)OC)OC,,,,,,
3909,38604,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(2-hydroxyphenyl)ethyl)-",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC=CC=C3O)O)OC)OC,,,,,,
3910,38605,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-alpha-(2-(3-hydroxyphenyl)ethyl)-",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(CCC3=CC(=CC=C3)O)O)OC)OC,,,,,,
3911,38606,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(2-hydroxyphenyl)ethyl)-6-(2-(1-pyrrolidinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCC3)C(CCC4=CC=CC=C4O)O,,,,,,
3912,38607,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(3-hydroxyphenyl)ethyl)-6-(2-(1-pyrrolidinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCC3)C(CCC4=CC(=CC=C4)O)O,,,,,,
3913,38608,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(4-hydroxyphenyl)ethyl)-6-(2-(1-pyrrolidinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCC3)C(CCC4=CC=C(C=C4)O)O,,,,,,
3914,38609,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(2-hydroxyphenyl)ethyl)-6-(2-(4-morpholinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCOCC3)C(CCC4=CC=CC=C4O)O,,,,,,
3915,38610,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(3-hydroxyphenyl)ethyl)-6-(2-(4-morpholinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCOCC3)C(CCC4=CC(=CC=C4)O)O,,,,,,
3916,38611,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(4-hydroxyphenyl)ethyl)-6-(2-(4-morpholinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCOCC3)C(CCC4=CC=C(C=C4)O)O,,,,,,
3917,38612,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(2-hydroxyphenyl)ethyl)-6-(2-(1-piperidinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(CCC4=CC=CC=C4O)O,,,,,,
3918,38613,"5-Benzofuranmethanol, 4,7-dimethoxy-alpha-(2-(3-hydroxyphenyl)ethyl)-6-(2-(1-piperidinyl)ethoxy)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(CCC4=CC(=CC=C4)O)O,,,,,,
3919,38614,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(hexahydro-1H-azepin-1-yl)ethoxy)-alpha-(2-(2-hydroxyphenyl)ethyl)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCCC3)C(CCC4=CC=CC=C4O)O,,,,,,
3920,38615,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(hexahydro-1H-azepin-1-yl)ethoxy)-alpha-(2-(3-hydroxyphenyl)ethyl)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCCC3)C(CCC4=CC(=CC=C4)O)O,,,,,,
3921,38616,"5-Benzofuranmethanol, 4,7-dimethoxy-6-(2-(hexahydro-1H-azepin-1-yl)ethoxy)-alpha-(2-(4-hydroxyphenyl)ethyl)-",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCCC3)C(CCC4=CC=C(C=C4)O)O,,,,,,
3922,38617,Tixanox,CS(=O)C1=CC2=C(C=C1)OC3=C(C2=O)C=C(C=C3)C(=O)O,,,,,,
3923,38618,"1,2-Diphenyl-3-aminopropane hydrochloride",C1=CC=C(C=C1)CC(C[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
3924,38619,"2,3-Diphenylpropylamine",C1=CC=C(C=C1)CC(CN)C2=CC=CC=C2,,,,,,
3925,38620,"2,6-Diallylphenyl 2,3-epoxypropyl ether",C=CCC1=C(C(=CC=C1)CC=C)OCC2CO2,,,,,,
3926,38621,"1,3,4-Trimethyl-3-cyclohexen-1-carboxaldehyde",CC1=C(CC(CC1)(C)C=O)C,,,,,,
3927,38622,N-(2-Hydroxypropyl)methacrylamide,CC(CNC(=O)C(=C)C)O,,,,,,
3928,38623,"Diethyl-[2-(4-hydroxy-2-methyl-5-oxofuro[3,2-g]chromen-9-yl)oxyethyl]azanium;chloride",CC[NH+](CC)CCOC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C.[Cl-],,,,,,
3929,38624,"9-[2-(Diethylamino)ethoxy]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CCN(CC)CCOC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C,,,,,,
3930,38625,"Sulfoxide, 2-chloroethyl vinyl",C=CS(=O)CCCl,,,,,,
3931,38626,Nonahexacontanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
3932,38627,1-Hentetracontanol,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO,,,,,,
3933,38628,(3-Propoxyphenyl)carbamic acid 1-methyl-2-(1-piperidinyl)ethyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
3934,38629,1-piperidin-1-ylpropan-2-yl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OC(C)CN2CCCCC2,,,,,,
3935,38630,m-(Pentyloxy)carbanilic acid 1-methyl-2-piperidinoethyl ester monohydrochloride,CCCCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
3936,38631,[1-methyl-2-(1-piperidyl)ethyl] N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)NC(=O)OC(C)CN2CCCCC2,,,,,,
3937,38632,(3-(Hexyloxy)phenyl)carbamic acid 1-methyl-2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
3938,38633,[1-methyl-2-(1-piperidyl)ethyl] N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)NC(=O)OC(C)CN2CCCCC2,,,,,,
3939,38634,3-(2-(tert-Butylamino)ethyl)-1-(dimethylamino)-3-phenyl-2-indolinone hydrochloride,CC(C)(C)[NH2+]CCC1(C2=CC=CC=C2N(C1=O)N(C)C)C3=CC=CC=C3.[Cl-],,,,,,
3940,38635,3-[2-(Tert-butylamino)ethyl]-1-(dimethylamino)-3-phenylindol-2-one,CC(C)(C)NCCC1(C2=CC=CC=C2N(C1=O)N(C)C)C3=CC=CC=C3,,,,,,
3941,38636,1-(Dimethylamino)-3-(5-(dimethylamino)pentyl)-3-phenyl-2-indolinone,CN(C)CCCCCC1(C2=CC=CC=C2N(C1=O)N(C)C)C3=CC=CC=C3,,,,,,
3942,38637,3-(2-(Diethylamino)ethyl)-3-phenyl-1-((o-trifluoromethylbenzyl)methylamino)-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=CC=CC=C3C(F)(F)F)C4=CC=CC=C4,,,,,,
3943,38638,"2-Indolinone, 1-(benzylmethylamino)-3-phenyl-3-(4-piperidinobutyl)-, monohydrochloride",CN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCCC[NH+]4CCCCC4)C5=CC=CC=C5.[Cl-],,,,,,
3944,38639,1-[Benzyl(methyl)amino]-3-phenyl-3-(4-piperidin-1-ylbutyl)indol-2-one,CN(CC1=CC=CC=C1)N2C3=CC=CC=C3C(C2=O)(CCCCN4CCCCC4)C5=CC=CC=C5,,,,,,
3945,38640,1-((p-Chloro-2-methoxybenzyl)methylamino)-3-(2-(diethylamino)ethyl)-3-phenyl-2-indolinone,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=C(C=C(C=C3)Cl)OC)C4=CC=CC=C4,,,,,,
3946,38641,"2-Indolinone, 1-((5-chloro-2-methoxybenzyl)methylamino)-3-(2-(diethylamino)ethyl)-3-phenyl-",CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=C(C=CC(=C3)Cl)OC)C4=CC=CC=C4,,,,,,
3947,38642,"2-Indolinone, 3-(2-(diethylamino)ethyl)-1-((2,3-dimethoxybenzyl)methylamino)-3-phenyl-",CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=C(C(=CC=C3)OC)OC)C4=CC=CC=C4,,,,,,
3948,38643,"3-(2-(Diethylamino)ethyl)-1-((2,5-dimethoxybenzyl)methylamino)-3-phenyl-2-indolinone",CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N(C)CC3=C(C=CC(=C3)OC)OC)C4=CC=CC=C4,,,,,,
3949,38644,3-(2-(Diethylamino)ethyl)-3-phenyl-1-piperidino-2-indolinone hydrochloride,CC[NH+](CC)CCC1(C2=CC=CC=C2N(C1=O)N3CCCCC3)C4=CC=CC=C4.[Cl-],,,,,,
3950,38645,3-[2-(Diethylamino)ethyl]-3-phenyl-1-piperidin-1-ylindol-2-one,CCN(CC)CCC1(C2=CC=CC=C2N(C1=O)N3CCCCC3)C4=CC=CC=C4,,,,,,
3951,38646,CID 38646,CC1=C(C=CC(=C1)NC2=NC(=O)C3=C2C(=C(C(=C3Cl)Cl)Cl)Cl)N=NC4=CC=C(C=C4)NC5=NC(=O)C6=C5C(=C(C(=C6Cl)Cl)Cl)Cl,,,,,,
3952,38647,"1-Butanol, 2-((3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-yl)amino)-, methanesulfonate (ester), P-oxide",CCC(COS(=O)(=O)C)NP1(=O)N(CCCO1)CCCl,,,,,,
3953,38648,CID 38648,CCC(COS(=O)(=O)C)N[P+]1(N(CCCO1)CCCl)O,,,,,,
3954,38649,CID 38649,CC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3955,38650,CID 38650,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3956,38651,CID 38651,CC1=CC(=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br)C,,,,,,
3957,38652,CID 38652,CC1=C(C=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br)C,,,,,,
3958,38653,CID 38653,COC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3959,38654,CID 38654,COC1=CC=CC(=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3960,38655,CID 38655,COC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3961,38656,CID 38656,COC1=CC=CC(=C1OC)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3962,38657,CID 38657,COC1=CC(=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br)OC,,,,,,
3963,38658,CID 38658,COC1=CC(=C(C=C1)OC)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3964,38659,CID 38659,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br)Cl,,,,,,
3965,38660,CID 38660,C1=CC(=CC(=C1)Cl)C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br,,,,,,
3966,38661,"ACETAMIDE, 2-PHENYL-N-(o-TOLYL)-",CC1=CC=CC=C1NC(=O)CC2=CC=CC=C2,,,,,,
3967,38662,"DIBENZO(c,g)(1,2)DIAZOCINE, 11,12-DIHYDRO-, 5-OXIDE",C1CC2=CC=CC=C2[N+](=NC3=CC=CC=C31)[O-],,,,,,
3968,38663,"Butyramide, N-(4-heptyl)-",CCCC(CCC)NC(=O)CCC,,,,,,
3969,38664,"4-Heptylamine, hydrochloride",CCCC(CCC)[NH3+].[Cl-],,,,,,
3970,38665,4-Heptanamine,CCCC(CCC)N,,,,,,
3971,38666,Nolinium bromide,C1=CC=[N+]2C=CC(=CC2=C1)NC3=CC(=C(C=C3)Cl)Cl.[Br-],,,,,,
3972,38667,Nolinium,C1=CC=[N+]2C=CC(=CC2=C1)NC3=CC(=C(C=C3)Cl)Cl,,,,,,
3973,38668,Doxefazepam,C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCO)O)F,,,,,,
3974,38669,"2-(2,4,6-Trimethoxyphenyl)-1,3-dithiolane",COC1=CC(=C(C(=C1)OC)C2SCCS2)OC,,,,,,
3975,38670,CID 38670,C(CN=C([NH3+])N)CS.[Br-],,,,,,
3976,38671,"Guanidine, (3-mercaptopropyl)-",C(CN=C(N)N)CS,,,,,,
3977,38672,(2-((2-Aminoethyl)dithio)ethyl)guanidine dihydriodide,C(CSSCC[NH+]=C([NH3+])N)N.[I-].[I-],,,,,,
3978,38673,2-[2-(2-Aminoethyldisulfanyl)ethyl]guanidine,C(CSSCCN=C(N)N)N,,,,,,
3979,38674,"3-Isoxazolidinone, 2-methyl-",CN1C(=O)CCO1,,,,,,
3980,38675,"3-Isoxazolidinone, 2-ethyl-",CCN1C(=O)CCO1,,,,,,
3981,38676,"3-Isoxazolidinone, 2-propyl-",CCCN1C(=O)CCO1,,,,,,
3982,38677,"3-Isoxazolidinone, 2-isopropyl-",CC(C)N1C(=O)CCO1,,,,,,
3983,38678,"3-Isoxazolidinone, 2-(2,3-epoxypropyl)-",C1CON(C1=O)CC2CO2,,,,,,
3984,38679,3-Mercapto-2-butanone,CC(C(=O)C)S,,,,,,
3985,38680,3-Chloro-3-(4-methylphenyl)prop-2-enal,CC1=CC=C(C=C1)C(=CC=O)Cl,,,,,,
3986,38681,Chloromethyl 21-hydroxyajmalan-17-carboxylate--hydrogen chloride (1/1),CC[C@@H]1[C@H](N2[C@H]3CC1C4[C@@H]2C[C@@]5([C@H]3N(C6=CC=CC=C65)C)C4C(=O)OCCl)O.Cl,,,,,,
3987,38682,CID 38682,CC[C@H]1C2C[C@H]3[C@H]4[C@@]5(C[C@@H](C2C5C(=O)OCCl)N3C1O)C6=CC=CC=C6N4C,,,,,,
3988,38683,Clazolimine,CN1C(=O)CN(C1=N)C2=CC=C(C=C2)Cl,,,,,,
3989,38684,Azolimine,CN1C(=O)CN(C1=N)C2=CC=CC=C2,,,,,,
3990,38685,"trans-4-Phenyl-1,2,3,4-tetrahydro-2,3,8-trimethylisoquinoline",C[C@H]1C(C2=CC=CC(=C2CN1C)C)C3=CC=CC=C3,,,,,,
3991,38686,CID 38686,C1=CC(=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=C(C=C3)Br)Cl,,,,,,
3992,38687,Diclofop,CC(C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl,,,,,,
3993,38688,"2-Hexen-1-ol, 5-methyl-2-(1-methylethyl)-",CC(C)CC=C(CO)C(C)C,,,,,,
3994,38689,(5-Methyl-2-propan-2-ylhex-2-enyl) acetate,CC(C)CC=C(COC(=O)C)C(C)C,,,,,,
3995,38690,2-((5-Nitro-2-furyl)imino)ethanol,C1=C(OC(=C1)[N+](=O)[O-])C=NCCO,,,,,,
3996,38691,"Carbonic acid, (4,5-dimethyl-3,6-dioxo-1,4-cyclohexadien-1,2-diyl)bis(methylene)diphenyl ester",CC1=C(C(=O)C(=C(C1=O)COC(=O)OC2=CC=CC=C2)COC(=O)OC3=CC=CC=C3)C,,,,,,
3997,38692,"Carbazic acid, 3-phenyl-, isopropyl ester",CC(C)OC(=O)NNC1=CC=CC=C1,,,,,,
3998,38693,"Benzohydroxamic acid, N-morpholinomethyl-",C1COCCN1CN(C(=O)C2=CC=CC=C2)O,,,,,,
3999,38694,N-Piperidinomethylbenzohydroxamic acid hydrochloride,C1CC[NH+](CC1)CN(C(=O)C2=CC=CC=C2)O.[Cl-],,,,,,
4000,38695,N-hydroxy-N-(piperidin-1-ylmethyl)benzamide,C1CCN(CC1)CN(C(=O)C2=CC=CC=C2)O,,,,,,
4001,38696,"Benzohydroxamic acid, N-(4-methylpiperidino)methyl-",CC1CCN(CC1)CN(C(=O)C2=CC=CC=C2)O,,,,,,
4002,38697,"Benzohydroxamic acid, N-(4-methylpiperazinyl)methyl-",CN1CCN(CC1)CN(C(=O)C2=CC=CC=C2)O,,,,,,
4003,38698,"Benzohydroxamic acid, 4-methoxy-N-morpholinomethyl-",COC1=CC=C(C=C1)C(=O)N(CN2CCOCC2)O,,,,,,
4004,38699,"Benzohydroxamic acid, 4-methoxy-N-piperidinomethyl-",COC1=CC=C(C=C1)C(=O)N(CN2CCCCC2)O,,,,,,
4005,38700,4-Methoxy-N-(4-methylpiperidino)methylbenzohydroxamic acid,CC1CCN(CC1)CN(C(=O)C2=CC=C(C=C2)OC)O,,,,,,
4006,38701,4-Methoxy-N-(4-methylpiperazinyl)methylbenzohydroxamic acid,CN1CCN(CC1)CN(C(=O)C2=CC=C(C=C2)OC)O,,,,,,
4007,38702,"Benzohydroxamic acid, 4-fluoro-N-piperidinomethyl-",C1CCN(CC1)CN(C(=O)C2=CC=C(C=C2)F)O,,,,,,
4008,38703,"Benzohydroxamic acid, 4-fluoro-N-(4-methylpiperazinyl)methyl-",CN1CCN(CC1)CN(C(=O)C2=CC=C(C=C2)F)O,,,,,,
4009,38704,"2-Butanol, 4-(butylnitrosoamino)-",CCCCN(CCC(C)O)N=O,,,,,,
4010,38705,"Dichloromethyl O,O-diphenyl phosphonate",C1=CC=C(C=C1)OP(=O)(C(Cl)Cl)OC2=CC=CC=C2,,,,,,
4011,38706,Brosotamide,CC1=CC(=CC(=C1O)C(=O)N)Br,,,,,,
4012,38707,"Benzamide, 5-chloro-2-hydroxy-3-methyl-",CC1=CC(=CC(=C1O)C(=O)N)Cl,,,,,,
4013,38708,"Benzamide, 5-bromo-N,3-dimethyl-2-hydroxy-",CC1=CC(=CC(=C1O)C(=O)NC)Br,,,,,,
4014,38709,5-Bromo-N-ethyl-2-hydroxy-3-methylbenzamide,CCNC(=O)C1=C(C(=CC(=C1)Br)C)O,,,,,,
4015,38710,"Benzamide, 5-bromo-N-butyl-2-hydroxy-3-methyl-",CCCCNC(=O)C1=C(C(=CC(=C1)Br)C)O,,,,,,
4016,38711,"Benzamide, 5-bromo-2-hydroxy-3-methyl-N-(2-methylpropyl)-",CC1=CC(=CC(=C1O)C(=O)NCC(C)C)Br,,,,,,
4017,38712,"Benzamide, 5-bromo-3-methyl-2-(2-propenyloxy)-",CC1=CC(=CC(=C1OCC=C)C(=O)N)Br,,,,,,
4018,38713,o-Chlorobenzylmalononitrile,C1=CC=C(C(=C1)CC(C#N)C#N)Cl,,,,,,
4019,38714,CID 38714,CC(C)C1=C2C(=NC(=NC2=O)C(C)(C)C)NS1,,,,,,
4020,38715,"2(3H)-Benzoxazolone, 5-methoxy-",COC1=CC2=C(C=C1)OC(=O)N2,,,,,,
4021,38716,Tris(4-bromophenyl) phosphate,C1=CC(=CC=C1OP(=O)(OC2=CC=C(C=C2)Br)OC3=CC=C(C=C3)Br)Br,,,,,,
4022,38717,Nicotinic acid oxide sodium salt,C1=CC(=C[N+](=C1)[O-])C(=O)[O-].[Na+],,,,,,
4023,38718,CID 38718,C1=CC=C(C=C1)C(CC(=O)[O-])CO.[Na+],,,,,,
4024,38719,3-Phenyl-4-hydroxybutyric acid,C1=CC=C(C=C1)C(CC(=O)O)CO,,,,,,
4025,38720,(2-(Pentyloxy)phenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCCCOC1=CC=CC=C1NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4026,38721,1-(diethylamino)propan-2-yl N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OC(C)CN(CC)CC,,,,,,
4027,38722,2-(Furan-2-yl)-3-(5-nitrofuran-2-yl)prop-2-enenitrile,C1=COC(=C1)C(=CC2=CC=C(O2)[N+](=O)[O-])C#N,,,,,,
4028,38723,"Methane, chlorodinitroiodo-",C([N+](=O)[O-])([N+](=O)[O-])(Cl)I,,,,,,
4029,38724,CID 38724,CC[NH+](CC)CC=CC(C)[NH2+]C1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.[Cl-].[Cl-],,,,,,
4030,38725,CID 38725,CCN(CC)CC=CC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,,,,,,
4031,38726,5-Methoxy-2-(piperidinomethyl)-3-benzofurancarboxylic acid ethyl ester hydrochloride,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)C[NH+]3CCCCC3.[Cl-],,,,,,
4032,38727,Ethyl 5-methoxy-2-(piperidin-1-ylmethyl)-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)CN3CCCCC3,,,,,,
4033,38728,"7-Chloro-1,3-dihydro-3-(2-hydroxyethoxy)-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one",CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)OCCO)C3=CC=CC=C3,,,,,,
4034,38729,"7-Chloro-1,3-dihydro-3-(2-hydroxyethoxy)-5-phenyl-2H-1,4-benzodiazepin-2-one",C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OCCO,,,,,,
4035,38730,"7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-(2-hydroxyethoxy)-2H-1,4-benzodiazepin-2-one",C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OCCO)Cl,,,,,,
4036,38731,"1,3-Dihydro-7-chloro-3-(2,3-dihydroxypropoxy)-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one",CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)OCC(CO)O)C3=CC=CC=C3,,,,,,
4037,38732,"1,3-Dihydro-7-chloro-3-(2,3-dihydroxypropoxy)-5-phenyl-2H-1,4-benzodiazepin-2-one",C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OCC(CO)O,,,,,,
4038,38733,"7-Chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one trichloroacetate",CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)OC(=O)C(Cl)(Cl)Cl)C3=CC=CC=C3,,,,,,
4039,38734,"7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one trichloroacetate",C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OC(=O)C(Cl)(Cl)Cl,,,,,,
4040,38735,"9-[3-Methyl-4-[3,4,5-trihydroxy-5-[[3-(3-hydroxybutan-2-yl)oxiran-2-yl]methyl]oxan-2-yl]but-2-enoyl]oxynonanoic acid",CC(C1C(O1)CC2(COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)O)C(C)O,,,,,,
4041,38736,"3-Methoxy-1,2-benzisothiazole",COC1=NSC2=CC=CC=C21,,,,,,
4042,38737,2-Methylcyclopentanolacetate (cis),C[C@@H]1CCC[C@@H]1OC(=O)C,,,,,,
4043,38738,2-Bromo-1-(3-chlorophenyl)ethanone,C1=CC(=CC(=C1)Cl)C(=O)CBr,,,,,,
4044,38739,Ethyl 3-(4-chloroanilino)but-2-enoate,CCOC(=O)C=C(C)NC1=CC=C(C=C1)Cl,,,,,,
4045,38740,(3-(Hexyloxy)phenyl)carbamic acid 1-methyl-2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+]2CCCC2.[Cl-],,,,,,
4046,38741,1-pyrrolidin-1-ylpropan-2-yl N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)NC(=O)OC(C)CN2CCCC2,,,,,,
4047,38742,"2,3-Dimethyl-7-nitro-1H-indole",CC1=C(NC2=C1C=CC=C2[N+](=O)[O-])C,,,,,,
4048,38743,CID 38743,CC(C)OC(=O)C1=CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,,,,,,
4049,38744,"Benzimidazole, 4,7-dibromo-5,6-dichloro-2-(trifluoromethyl)-",C12=C(C(=C(C(=C1Br)Cl)Cl)Br)N=C(N2)C(F)(F)F,,,,,,
4050,38745,CID 38745,CC1=CC(=C(C(=C1)C)C(=O)C=CCl)C,,,,,,
4051,38746,"Ammonium, (2-methyl-2-(2-(4-(trimethylammoniomethyl)2-dioxolanyl)ethyl)-4-dioxolanylmethyl)trimethyl-, diiodide",CC1(OCC(O1)C[N+](C)(C)C)CCC2OCC(O2)C[N+](C)(C)C.[I-].[I-],,,,,,
4052,38747,"Trimethyl-[[2-[2-[2-methyl-4-[(trimethylazaniumyl)methyl]-1,3-dioxolan-2-yl]ethyl]-1,3-dioxolan-4-yl]methyl]azanium",CC1(OCC(O1)C[N+](C)(C)C)CCC2OCC(O2)C[N+](C)(C)C,,,,,,
4053,38748,"Ammonium, (2-(3-(2-methyl-4-(trimethylammoniomethyl)-2-dioxolanyl)propionyloxy)ethyl)trimethyl-, diiodide",CC1(OCC(O1)C[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C.[I-].[I-],,,,,,
4054,38749,"Trimethyl-[[2-methyl-2-[3-oxo-3-[2-(trimethylazaniumyl)ethoxy]propyl]-1,3-dioxolan-4-yl]methyl]azanium",CC1(OCC(O1)C[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C,,,,,,
4055,38750,"Ethyl (2,3-dioxo-2,3-dihydro-1H-indol-1-yl)acetate",CCOC(=O)CN1C2=CC=CC=C2C(=O)C1=O,,,,,,
4056,38751,CID 38751,C1C(=NC2=CC=CC=C2N=C1S)C3=CC=CC=C3,,,,,,
4057,38752,"Indole, 2-(2-dimethylaminoethyl)-5-methoxy-3-methyl-",CC1=C(NC2=C1C=C(C=C2)OC)CCN(C)C,,,,,,
4058,38753,"1H-2-Benzopyran-3-carboxamide, N,N-dimethyl-1-oxo-4-phenyl-",CN(C)C(=O)C1=C(C2=CC=CC=C2C(=O)O1)C3=CC=CC=C3,,,,,,
4059,38754,"4,4-Diallyl-1,3(2H,4H)-isoquinolinedione",C=CCC1(C2=CC=CC=C2C(=O)NC1=O)CC=C,,,,,,
4060,38755,3-Ethylhexanoic acid,CCCC(CC)CC(=O)O,,,,,,
4061,38756,4-Methylhexanal,CCC(C)CCC=O,,,,,,
4062,38757,CID 38757,C[SnH](C)Cl,,,,,,
4063,38758,4-((Ethoxy(propylthio)phosphinyl)oxy)benzoic acid methyl ester,CCCSP(=O)(OCC)OC1=CC=C(C=C1)C(=O)OC,,,,,,
4064,38759,"Ethyl 3,7,11-trimethyldodeca-2,4-dienoate",CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C,,,,,,
4065,38760,"Ammonium, undecamethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCCCCCCCCCC[N+](C)(C)C.[I-].[I-],,,,,,
4066,38761,"n,n,n,n',n',n'-Hexamethylundecane-1,11-diaminium",C[N+](C)(C)CCCCCCCCCCC[N+](C)(C)C,,,,,,
4067,38762,Ethyl pentadecanoate,CCCCCCCCCCCCCCC(=O)OCC,,,,,,
4068,38763,2-[3-(2-Nitrophenyl)prop-2-enylidene]propanedinitrile,C1=CC=C(C(=C1)C=CC=C(C#N)C#N)[N+](=O)[O-],,,,,,
4069,38764,4-Hexyl-4'-cyanobiphenyl,CCCCCCC1=CC=C(C=C1)C2=CC=C(C=C2)C#N,,,,,,
4070,38765,"N,N'-Di-o-tolylguanidine monohydrochloride",CC1=CC=CC=C1NC(=[NH+]C2=CC=CC=C2C)N.[Cl-],,,,,,
4071,38766,CID 38766,CC(C)OC1=CC2=C(C=C1)OC3=C(C2=O)C=C(C=C3)C(=O)[O-].[Na+],,,,,,
4072,38767,Xanoxic acid,CC(C)OC1=CC2=C(C=C1)OC3=C(C2=O)C=C(C=C3)C(=O)O,,,,,,
4073,38768,"(S)-(-)-2,6-Dimethylcarbanilic acid, 1-butyl-3-piperidyl ester",CCCCN1CCC[C@@H](C1)OC(=O)NC2=C(C=CC=C2C)C,,,,,,
4074,38769,"1,4-Dithiaspiro(4.5)decane, 8-methyl-",CC1CCC2(CC1)SCCS2,,,,,,
4075,38770,"1,3-DITHIOLANE, 2-(p-NITROPHENYL)-",C1CSC(S1)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4076,38771,"2-Mesityl-1,3-dithiolane",CC1=CC(=C(C(=C1)C)C2SCCS2)C,,,,,,
4077,38772,"1,3-DITHIOLANE, 2-(p-METHOXYPHENYL)-2-METHYL-",CC1(SCCS1)C2=CC=C(C=C2)OC,,,,,,
4078,38773,"1,3-DITHIOLANE, 2-METHYL-2-(p-TOLYL)-",CC1=CC=C(C=C1)C2(SCCS2)C,,,,,,
4079,38774,"1,3-DITHIOLANE, 2-METHYL-2-(p-NITROPHENYL)-",CC1(SCCS1)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4080,38775,"1,3-DITHIOLANE, 2-ETHYL-2-(p-FLUOROPHENYL)-",CCC1(SCCS1)C2=CC=C(C=C2)F,,,,,,
4081,38776,"4-(Chloromethyl)-2-phenyl-1,3-dithiolane",C1C(SC(S1)C2=CC=CC=C2)CCl,,,,,,
4082,38777,Triazinate,CCS(=O)(=O)O.CC1(N=C(N=C(N1C2=CC(=C(C=C2)OCC3=CC(=CC=C3)C(=O)N(C)C)Cl)N)N)C,,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4083,38778,Baker's Antifolante,CC1(N=C(N=C(N1C2=CC(=C(C=C2)OCC3=CC(=CC=C3)C(=O)N(C)C)Cl)N)N)C,,,,,,
4084,38779,Profenofos,CCCSP(=O)(OCC)OC1=C(C=C(C=C1)Br)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['... The levels of profenofos in whole blood, urine, and gastric contents were 1200 ng, 350 ng, and 3.35 mg/mL, respectively.', 'Rats rapidly excrete 14C-profenofos after oral admin. The predominant metabolic pathway involves stepwise dealkylation & hydrolysis, followed by conjugation.']",,
4085,38780,o-(3-Allyl-5-methyl-2-oxotetrahydro-3-furyl)benzoic acid methyl ester,CC1CC(C(=O)O1)(CC=C)C2=CC=CC=C2C(=O)OC,,,,,,
4086,38781,alpha-Allyl-alpha-(p-carboxyphenyl)allophanyl-gamma-methyl-gamma-butyrolactone,CC1CC(C(=O)O1)(CC=C)C(=O)NC(=O)NC2=CC=C(C=C2)C(=O)O,,,,,,
4087,38782,"Carbamic acid, (4-(4-bromophenyl)-1H-imidazol-2-YL)-, methyl ester",COC(=O)NC1=NC=C(N1)C2=CC=C(C=C2)Br,,,,,,
4088,38783,Ethyl 4-(4-chlorophenyl)-2-imidazolylcarbamate,CCOC(=O)NC1=NC=C(N1)C2=CC=C(C=C2)Cl,,,,,,
4089,38784,"2-[[5-[3-(4-Chlorophenyl)prop-2-enoyl]-4,7-dimethoxy-1-benzofuran-6-yl]oxy]ethyl-dimethylazanium;2-hydroxy-2-oxoacetate",C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)Cl)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
4090,38785,"3-(4-Chlorophenyl)-1-[6-[2-(dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]prop-2-en-1-one",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)Cl)OC)OC,,,,,,
4091,38786,CID 38786,COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)C(=O)C=CC4=CC=CC=C4.C(=O)(C(=O)[O-])O,,,,,,
4092,38787,CID 38787,COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(=O)C=CC4=CC=CC=C4,,,,,,
4093,38788,CID 38788,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=CC=C3OC)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
4094,38789,CID 38789,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=CC=C3OC)OC)OC,,,,,,
4095,38790,CID 38790,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=CC=C3)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
4096,38791,CID 38791,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=CC=C3)OC)OC)OC,,,,,,
4097,38792,CID 38792,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=C(C(=CC=C3)OC)O)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
4098,38793,CID 38793,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=C(C(=CC=C3)OC)O)OC)OC,,,,,,
4099,38794,CID 38794,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=C(C=C3)OC)O)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
4100,38795,CID 38795,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=C(C=C3)OC)O)OC)OC,,,,,,
4101,38796,CID 38796,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC4=C(C=C3)OCO4)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
4102,38797,CID 38797,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC4=C(C=C3)OCO4)OC)OC,,,,,,
4103,38798,CID 38798,CC[NH+](CC)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)O)OC)OC.[Cl-],,,,,,
4104,38799,CID 38799,CCN(CC)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)O)OC)OC,,,,,,
4105,38800,CID 38800,COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)C(=O)C=CC4=CC=C(C=C4)O.[Cl-],,,,,,
4106,38801,CID 38801,COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(=O)C=CC4=CC=C(C=C4)O,,,,,,
4107,38802,CID 38802,CC[NH+](CC)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
4108,38803,CID 38803,CCN(CC)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)OC)OC)OC,,,,,,
4109,38804,CID 38804,CC(C)[NH+](CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)OC)OC)OC)C(C)C.C(=O)(C(=O)[O-])O,,,,,,
4110,38805,"1-[6-[2-[Di(propan-2-yl)amino]ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(4-methoxyphenyl)prop-2-en-1-one",CC(C)N(CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)OC)OC)OC)C(C)C,,,,,,
4111,38806,CID 38806,COC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCC[NH+]4CCOCC4)OC)OC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4112,38807,CID 38807,COC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCCN4CCOCC4)OC)OC=C3)OC,,,,,,
4113,38808,CID 38808,C[NH+](C)CCCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
4114,38809,CID 38809,CN(C)CCCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)OC)OC)OC,,,,,,
4115,38810,CID 38810,CCOC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCC[NH+](C)C)OC)OC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4116,38811,CID 38811,CCOC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCCN(C)C)OC)OC=C3)OC,,,,,,
4117,38812,CID 38812,CCCOC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCC[NH+](C)C)OC)OC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4118,38813,CID 38813,CCCOC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCCN(C)C)OC)OC=C3)OC,,,,,,
4119,38814,CID 38814,CCCCOC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCC[NH+](C)C)OC)OC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4120,38815,CID 38815,CCCCOC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCCN(C)C)OC)OC=C3)OC,,,,,,
4121,38816,CID 38816,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=CC=C3O)OC)OC.[Cl-],,,,,,
4122,38817,CID 38817,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=CC=C3O)OC)OC,,,,,,
4123,38818,CID 38818,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=CC=C3)O)OC)OC.[Cl-],,,,,,
4124,38819,CID 38819,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=CC=C3)O)OC)OC,,,,,,
4125,38820,CID 38820,COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCCC3)C(=O)C=CC4=CC=CC=C4O.[Cl-],,,,,,
4126,38821,CID 38821,COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCCC3)C(=O)C=CC4=CC=CC=C4O,,,,,,
4127,38822,"2-(Diethylamino)-2'-propoxyacetanilide, hydrochloride",CCCOC1=CC=CC=C1NC(=O)C[NH+](CC)CC.[Cl-],,,,,,
4128,38823,2-(diethylamino)-N-(2-propoxyphenyl)acetamide,CCCOC1=CC=CC=C1NC(=O)CN(CC)CC,,,,,,
4129,38824,Chromium chromate (H2CrO4),[O-][Cr](=O)(=O)[O-].[Cr+2],,,,,,
4130,38825,"Arsine selenide, trimethyl-",C[As](=[Se])(C)C,,,,,,
4131,38826,Dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)phenylammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=CC=C1.COS(=O)(=O)[O-],,,,,,
4132,38827,2-[Ethoxy(methyl)phosphoryl]sulfanylethyl-dimethyl-phenylazanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=CC=C1,,,,,,
4133,38828,Dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)-m-tolylammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=CC(=C1)C.COS(=O)(=O)[O-],,,,,,
4134,38829,2-[Ethoxy(methyl)phosphoryl]sulfanylethyl-dimethyl-(3-methylphenyl)azanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=CC(=C1)C,,,,,,
4135,38830,Dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)-m-methoxyphenylammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC(=CC=C1)OC.COS(=O)(=O)[O-],,,,,,
4136,38831,2-[Ethoxy(methyl)phosphoryl]sulfanylethyl-(3-methoxyphenyl)-dimethylazanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC(=CC=C1)OC,,,,,,
4137,38832,Dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)-p-tolylammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=C(C=C1)C.COS(=O)(=O)[O-],,,,,,
4138,38833,2-[Ethoxy(methyl)phosphoryl]sulfanylethyl-dimethyl-(4-methylphenyl)azanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=C(C=C1)C,,,,,,
4139,38834,Dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)-p-methoxyphenylammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=C(C=C1)OC.COS(=O)(=O)[O-],,,,,,
4140,38835,2-[Ethoxy(methyl)phosphoryl]sulfanylethyl-(4-methoxyphenyl)-dimethylazanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=C(C=C1)OC,,,,,,
4141,38836,(p-Chlorophenyl)dimethyl(2-((ethoxymethylphosphinyl)thio)ethyl)ammonium methyl sulfate,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=C(C=C1)Cl.COS(=O)(=O)[O-],,,,,,
4142,38837,(4-Chlorophenyl)-[2-[ethoxy(methyl)phosphoryl]sulfanylethyl]-dimethylazanium,CCOP(=O)(C)SCC[N+](C)(C)C1=CC=C(C=C1)Cl,,,,,,
4143,38838,CID 38838,C[C@H](CCCC(C)C)[C@H]1CCC2[C@@]1(CCCC2=CC=C3C[C@@H](C[C@H](C3=C)O)O)C,,,,,,
4144,38839,Methoxyphenone,CC1=CC(=CC=C1)C(=O)C2=CC(=C(C=C2)OC)C,,,,,,
4145,38840,"4'-Butoxy-2-(diethylamino)acetanilide, hydrochloride",CCCCOC1=CC=C(C=C1)NC(=O)C[NH+](CC)CC.[Cl-],,,,,,
4146,38841,4'-Butoxy-2-(diethylamino)acetanilide,CCCCOC1=CC=C(C=C1)NC(=O)CN(CC)CC,,,,,,
4147,38842,"12,13-Dimethoxy-5,9,10,14b-tetrahydroisoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one",COC1=C(C=C2C3C4=CC=CC=C4NC(=O)CN3CCC2=C1)OC,,,,,,
4148,38843,"Isoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one, 5,9,10,14b-tetrahydro-12,13-dimethoxy-7-methyl-",CC1C(=O)NC2=CC=CC=C2C3N1CCC4=CC(=C(C=C34)OC)OC,,,,,,
4149,38844,"4-O-[4-(dimethylamino)-2-[[(3R,4S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-O-ethyl butanedioate",CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,,,,,,
4150,38845,13-Methoxydihydronitidine,CN1C(C2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC)OC,,,,,,
4151,38846,Nitidine methyl sulfate,C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.COS(=O)(=O)[O-],,,,,,
4152,38847,CID 38847,C(C(=O)O)N.O.O.[AlH3],,,,,,
4153,38848,CID 38848,CCCCCCC(=NNC(=NN)S)C,,,,,,
4154,38849,"Benzoic acid, 4-((((4-((bis(1-aziridinyl)phosphinyl)oxy)phenyl)amino)carbonyl)oxy)-, methyl ester",COC(=O)C1=CC=C(C=C1)OC(=O)NC2=CC=C(C=C2)OP(=O)(N3CC3)N4CC4,,,,,,
4155,38850,CID 38850,CC(C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)OCCCS(=O)(=O)[O-].[Na+],,,,,,
4156,38851,3-[2-(4-Phenylphenyl)propanoyloxy]propane-1-sulfonic acid,CC(C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)OCCCS(=O)(=O)O,,,,,,
4157,38852,Methyldopa sesquihydrate,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.O.O.O,,,"['Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
4158,38853,Methyldopa,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,['Methyldopa is indicated for the management of hypertension as monotherapy or in combination with hydrochlorothiazide. Methyldopa injection is used to manage hypertensive crises.'],"['Antihypertensive effects of methyldopa are mostly mediated by its pharmacologically active metabolite, alpha-methylnorepinephrine, which works as an agonist at central inhibitory alpha-adrenergic receptors. Stimulation of alpha-adrenergic receptors leads to decreased peripheral sympathetic tone and reduced arterial pressure. Methyldopa causes a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine. Overall, methyldopa lowers both standing blood pressure and especially supine blood pressure, with infrequent symptomatic postural hypotension. Methyldopa also reduces plasma renin activity but has negligible effects on glomerular filtration rate, renal blood flow, or filtration fraction. It also has no direct effect on cardiac function but in some patients, a slowed heart rate may occur.  Following oral administration, blood-pressure-lowering effects are observed within 12 to 24 hours in most patients, and a maximum reduction in blood pressure occurs in 4 to 6 hours. Blood pressure returns to pre-treatment levels within 24 to 48 hours following drug discontinuation. Following intravenous administration, the blood-pressure-lowering effects of methyldopa last for about 10 to 16 hours.']","['Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)']","['Methyldopa is incompletely absorbed from the gastrointestinal tract following oral administration. In healthy individuals, the inactive D-isomer is less readily absorbed than the active L-isomer. The mean bioavailability of methyldopa is 25%, ranging from eight to 62%. Following oral administration, about 50% of the dose is absorbed and T<sub>max</sub> is about three to six hours.', 'Approximately 70% of absorbed methyldopa is excreted in the urine as unchanged parent drug (24%) and -methyldopa mono-O-sulfate (64%), with variability.3-O-methyl--methyldopa accounted for about 4% of urinary excretion products. Other metabolites like 3,4-dihydroxyphenylacetone, -methyldopamine, and 3-O-methyl--methyldopamine are also excreted in urine.   Unabsorbed drug is excreted in feces as the unchanged parent compound. After oral doses, excretion is essentially complete in 36 hours.   Due to attenuated excretion in patients with renal failure, accumulation of the drug and its metabolites may occur, possibly leading to more profound and prolonged hypotensive effects in these patients.', 'The apparent volume of distribution ranges between 0.19 and 0.32L/kg and the total volume of distribution ranges from 0.41 to 0.72L/kg. Since methyldopa is lipid-soluble, it crosses the placental barrier, appears in cord blood, and appears in breast milk.', 'The renal clearance is about 130 mL/min in normal subjects and is decreased in patients with renal insufficiency.', '(14)C-METHYLDOPA ADMIN ORALLY TO HYPERTENSIVE PT IS RECOVERED EQUALLY FROM URINE & FECES; PRODUCT IN FECES IS UNCHANGED METHYLDOPA, & IN URINE METHYLDOPA & ITS ETHEREAL SULFATE, TOGETHER WITH SMALL AMT OF 3-O-METHYL-METHYLDOPA & METHYLDOPAMINE.', 'METHYLDOPA CROSSES THE PLACENTA...', 'Methyldopa is partially absorbed from the GI tract. The degree of absorption varies among individuals and in the same patient from day to day, but generally about 50% of an oral dose is absorbed.']","['Two isomers of methyldopa undergo different metabolic pathways. L--methyldopa is biotransformed to its pharmacologically active metabolite, alpha-methylnorepinephrine. Methyldopa is extensively metabolized in the liver to form the main circulating metabolite in the plasma, alpha ()-methyldopa mono-O-sulfate. Its other metabolites also include 3-O-methyl--methyldopa; 3,4-dihydroxyphenylacetone; -methyldopamine; and 3-O-methyl--methyldopamine. These metabolites are further conjugated in the liver to form sulfate conjugates. After intravenous administration, the most prominent metabolites are alpha-methyldopamine and the glucuronide of dihydroxyphenylacetone, along with other uncharacterized metabolites.  D--methyldopa, which is the inactive isomer of methyldopa, is also metabolized to 3-O-methyl--methyldopa and 3,4-dihydroxyphenylacetone to a minimal extent; however, there are no amines (-methyldopamine and 3-O-methyl--methyldopamine) formed.', 'METHYLDOPA YIELDS 3,4-DIHYDROXY-ALPHA-METHYLPHENETHYLAMINE, 3,4-DIHYDROXY-ALPHA-METHYL-L-PHENYLALANINE-O-SULFATE, & 4-HYDROXY-3-METHOXY-ALPHA-METHYL-L-PHENYLALANINE IN MAN. /FROM TABLE/', 'METHYLDOPA...UNDERGOES DECARBOXYLATION & BETA-HYDROXYLATION IN MOUSE & RABBIT BRAIN TO YIELD ALPHA-METHYLNORADRENALINE.', '...ADMIN IP TO RATS (14)C-METHYLDOPA IS EXCRETED IN URINE AS...3-O-METHYL-METHYLDOPA (14%), METHYLDOPAMINE & ITS CONJUGATES (2%), 3-O-METHYL-METHYLDOPAMINE & ITS CONJUGATES (6%), 3-METHOXY-4-HYDROXYPHENYLACETONE (6%), & 3,4-DIHYDROXYPHENYLACETONE (10%).', 'A REVIEW ON THE METAB OF ALPHA-METHYLDOPA.']","['The plasma half-life of methyldopa is 105 minutes. Following intravenous injection, the plasma half-life of methyldopa ranges from 90 to 127 minutes.', 'The drug is ... eliminated with a half-life of about 2 hr. ... The half-life of methyldopa is prolonged to 4-6 hr in patients with renal failure.', 'DISAPPEARANCE OF THE DRUG FROM PLASMA AFTER IV ADMIN IS BIPHASIC, & THE TERMINAL HALF-TIME OF ELIMINATION FROM PLASMA IS ABOUT 2 HOURS. RENAL EXCRETION ACCOUNTS FOR ABOUT TWO THIRDS OF THE CLEARANCE OF DRUG FROM PLASMA.', 'IN PT WITH SEVERELY IMPAIRED RENAL FUNCTION, ONLY ABOUT 50% OF DRUG IS EXCRETED DURING EARLY PHASE (T/2= 3 1/2 HR), & SOME ACCUMULATION CAN OCCUR DURING CHRONIC ADMIN... BOTH TOTAL QUANTITY ABSORBED & DISTRIBUTION OF METABOLITES IN URINE CAN VARY CONSIDERABLY IN DIFFERENT INDIVIDUALS & IN SAME PT FROM DAY TO DAY.']"
4159,38854,Metamitron,CC1=NN=C(C(=O)N1N)C2=CC=CC=C2,,,,,,
4160,38855,Propylene glycol dipelargonate,CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC,,,,,,
4161,38856,CID 38856,C1=CC=C(C=C1)C(C(=O)[O-])N.[K+],,,,,,
4162,38857,"2,3,3',4,4',5,6-Heptachlorobiphenyl",C1=CC(=C(C=C1C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
4163,38858,"6-Propyl-1,2,10-trimethoxy-6a-alpha-noraporphin-9-ol hydrochloride",CCC[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC.[Cl-],,,,,,
4164,38859,CID 38859,CCCN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)O)OC)OC)OC,,,,,,
4165,38860,"6-Butyl-1,2,10-trimethoxy-6a-alpha-noraporphin-9-ol hydrochloride",CCCC[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC.[Cl-],,,,,,
4166,38861,CID 38861,CCCCN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)O)OC)OC)OC,,,,,,
4167,38862,"6-Isobutyl-1,2,10-trimethoxy-6a-alpha-noraporphin-9-ol hydrochloride",CC(C)C[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC.[Cl-],,,,,,
4168,38863,"(6aS)-1,2,11-trimethoxy-6-(2-methylpropyl)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-ol",CC(C)CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC,,,,,,
4169,38864,"6-Hexyl-1,2,10-trimethoxy-6a-alpha-noraporphin-9-ol hydrochloride",CCCCCC[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)O)OC)OC)OC.[Cl-],,,,,,
4170,38865,CID 38865,CCCCCCN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)O)OC)OC)OC,,,,,,
4171,38866,"3,7-Dimethylnona-2,6-dienal",CCC(=CCCC(=CC=O)C)C,,,,,,
4172,38867,CID 38867,CC1=C(C(=O)C[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@@]([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
4173,38868,"2-Hepta-1,3,5-trienyl-3,6-dihydroxy-5-(3-methylbut-2-enyl)benzaldehyde",CC=CC=CC=CC1=C(C=C(C(=C1C=O)O)CC=C(C)C)O,,,,,,
4174,38869,"alpha-(Phenoxymethyl)-2,2,4,4-tetramethyl-1-azetidineethanol hydrochloride",CC1(CC([NH+]1CC(COC2=CC=CC=C2)O)(C)C)C.[Cl-],,,,,,
4175,38870,"1-Phenoxy-3-(2,2,4,4-tetramethylazetidin-1-yl)propan-2-ol",CC1(CC(N1CC(COC2=CC=CC=C2)O)(C)C)C,,,,,,
4176,38871,"1-Azetidineethanol, alpha-((2-methylphenoxy)methyl)-2,2,4,4-tetramethyl-, hydrochloride",CC1=CC=CC=C1OCC(C[NH+]2C(CC2(C)C)(C)C)O.[Cl-],,,,,,
4177,38872,"1-(2-Methylphenoxy)-3-(2,2,4,4-tetramethylazetidin-1-yl)propan-2-ol",CC1=CC=CC=C1OCC(CN2C(CC2(C)C)(C)C)O,,,,,,
4178,38873,"1-Azetidineethanol, alpha-((2,6-dimethylphenoxy)methyl)-2,2,4,4-tetramethyl-, hydrochloride",CC1=C(C(=CC=C1)C)OCC(C[NH+]2C(CC2(C)C)(C)C)O.[Cl-],,,,,,
4179,38874,"1-(2,6-Dimethylphenoxy)-3-(2,2,4,4-tetramethylazetidin-1-yl)propan-2-ol",CC1=C(C(=CC=C1)C)OCC(CN2C(CC2(C)C)(C)C)O,,,,,,
4180,38875,"2,2',3,5'-Tetrachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=C(C=CC(=C2)Cl)Cl,,,,,,
4181,38876,"2,2',4,5'-Tetrachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C=CC(=C2)Cl)Cl,,,,,,
4182,38877,"2,2',5,6'-Tetrachlorobiphenyl",C1=CC(=C(C(=C1)Cl)C2=C(C=CC(=C2)Cl)Cl)Cl,,,,,,
4183,38878,"2,3',5,5'-Tetrachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=CC(=CC(=C2)Cl)Cl)Cl,,,,,,
4184,38879,"2,3,3',4'-Tetrachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=CC(=C(C=C2)Cl)Cl,,,,,,
4185,38880,"2,3',4',6-Tetrachlorobiphenyl",C1=CC(=C(C(=C1)Cl)C2=CC(=C(C=C2)Cl)Cl)Cl,,,,,,
4186,38881,"2,2',3,4',5'-Pentachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
4187,38882,Pyridoxal phosphate hydrate,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O.O,['Investigated for use/treatment in coronary artery disease.'],,"['A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
4188,38883,2-Hydroxyhexanal,CCCCC(C=O)O,,,,,,
4189,38884,Bupirimate,CCCCC1=C(N=C(N=C1OS(=O)(=O)N(C)C)NCC)C,,,,,,
4190,38885,CID 38885,CCP(=S)(OC)OC(=CCl)C1=C(C=CC(=C1)Cl)Cl,,,,,,
4191,38886,CID 38886,CCCCC=CC=CC=CCCCCCCCC(=O)NNC(C)CC1=CC=CC=C1,,,,,,
4192,38887,1-((5-(p-Acetamidophenyl)-2-furanyl)methyleneamino)-hydantoin,CC(=O)NC1=CC=C(C=C1)C2=CC=C(O2)C=NN3CC(=O)NC3=O,,,,,,
4193,38888,CID 38888,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
4194,38889,CID 38889,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
4195,38890,CID 38890,CC(=O)NC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3,,,,,,
4196,38891,"Ethanol, 2,2'-((4-((2-methoxy-4-nitrophenyl)azo)-3-methylphenyl)imino)bis-",CC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=C(C=C(C=C2)[N+](=O)[O-])OC,,,,,,
4197,38892,"2,2'-[[4-[(2,4-Dinitrophenyl)azo]-3-methylphenyl]imino]bisethanol",CC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4198,38893,"Ethanol, 2,2'-((4-((2-methoxy-4-nitrophenyl)azo)phenyl)imino)bis-",COC1=C(C=CC(=C1)[N+](=O)[O-])N=NC2=CC=C(C=C2)N(CCO)CCO,,,,,,
4199,38894,"Bis(3-dibutylaminopropyl)-9-oxofluorene-2,7-dicarboxylate dimethiodide hydrate",CCCC[N+](C)(CCCC)CCCOC(=O)C1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)C(=O)OCCC[N+](C)(CCCC)CCCC.[I-].[I-],,,,,,
4200,38895,"N,N'-[(9-Oxo-9H-fluorene-2,7-diyl)bis(carbonyloxy-3,1-propanediyl)]bis(N-butyl-N-methyl-1-butanaminium)",CCCC[N+](C)(CCCC)CCCOC(=O)C1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)C(=O)OCCC[N+](C)(CCCC)CCCC,,,,,,
4201,38896,(trans)-2-Mercaptocyclobutylmethylamine hydrochloride,C1C[C@H]([C@@H]1C[NH3+])S.[Cl-],,,,,,
4202,38897,CID 38897,C1CC([C@@H]1S)CN,,,,,,
4203,38898,"1-Naphthylamine, 5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",COC1=CC=CC2=C1CCCC2[NH3+].[Cl-],,,,,,
4204,38899,"5-Methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=CC=CC2=C1CCCC2N,,,,,,
4205,38900,"1-Naphthylamine, N-isopropyl-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",CC(C)[NH2+]C1CCCC2=C1C=CC=C2OC.[Cl-],,,,,,
4206,38901,"1,2,3,4-Tetrahydro-5-methoxy-N-(1-methylethyl)-1-naphthalenamine",CC(C)NC1CCCC2=C1C=CC=C2OC,,,,,,
4207,38902,"7,8-Dichloro-10-(2-(diethylamino)ethyl)isoalloxazine hydrochloride",CC[NH+](CC)CCN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl.[Cl-],,,,,,
4208,38903,"7,8-Dichloro-10-[2-(diethylamino)ethyl]benzo[g]pteridine-2,4-dione",CCN(CC)CCN1C2=CC(=C(C=C2N=C3C1=NC(=O)NC3=O)Cl)Cl,,,,,,
4209,38904,Carboplatinum,C1CC(C1)(C(=O)O)C(=O)O.N.N.[Pt],,,"['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4210,38905,CID 38905,CCCC[NH+]1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.[Cl-],,,,,,
4211,38906,CID 38906,CCCCN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,,,,,,
4212,38907,"6b,10a-Dihydrofluoranthene",C1=CC2C(C=C1)C3=CC=CC4=C3C2=CC=C4,,,,,,
4213,38908,"1,2-Dihydrochrysene",C1CC2=C(C=C1)C3=C(C=C2)C4=CC=CC=C4C=C3,,,,,,
4214,38909,"7-[(1R,2R,5S)-5-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@@H]1[C@H]([C@H](CC1=O)O)CC=CCCCC(=O)O)O,,,,,,
4215,38910,"1,1,4-Trichlorobut-2-ene",C(C=CC(Cl)Cl)Cl,,,,,,
4216,38911,Ciclopirox olamine,CC1=CC(=O)N(C(=C1)C2CCCCC2)O.C(CO)N,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
4217,38912,"Estrone, p-nitrobenzoate",CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=C(C=C5)[N+](=O)[O-],,,,,,
4218,38913,N-(4-Bromophenyl)benzenecarbohydrazonoyl chloride,C1=CC=C(C=C1)C(=NNC2=CC=C(C=C2)Br)Cl,,,,,,
4219,38914,"Carbamic acid, 2-propenyl-, 2,3-dihydro-1,3-dioxo-2-(phenylthio)-1H-inden-2-yl ester",C=CCNC(=O)OC1(C(=O)C2=CC=CC=C2C1=O)SC3=CC=CC=C3,,,,,,
4220,38915,"6,7,8,9-Tetrahydro-5H-benzocycloheptene-2-ethanamine hydrochloride",C1CCC2=C(CC1)C=C(C=C2)CC[NH3+].[Cl-],,,,,,
4221,38916,"2-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanamine",C1CCC2=C(CC1)C=C(C=C2)CCN,,,,,,
4222,38917,"1-(6,7,8,9-Tetrahydro-5H-benzocyclohepten-2-yl)-2-aminopropane hydrochloride",CC(CC1=CC2=C(CCCCC2)C=C1)[NH3+].[Cl-],,,,,,
4223,38918,"1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)propan-2-amine",CC(CC1=CC2=C(CCCCC2)C=C1)N,,,,,,
4224,38919,"5H-Benzocycloheptene-2-ethanamine, 6,7,8,9-tetrahydro-N,alpha-dimethyl-, hydrochloride",CC(CC1=CC2=C(CCCCC2)C=C1)[NH2+]C.[Cl-],,,,,,
4225,38920,"N-methyl-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)propan-2-amine",CC(CC1=CC2=C(CCCCC2)C=C1)NC,,,,,,
4226,38921,"5H-Benzocycloheptene-2-ethanamine, 6,7,8,9-tetrahydro-alpha,alpha-dimethyl-, hydrochloride",CC(C)(CC1=CC2=C(CCCCC2)C=C1)[NH3+].[Cl-],,,,,,
4227,38922,"2-methyl-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)propan-2-amine",CC(C)(CC1=CC2=C(CCCCC2)C=C1)N,,,,,,
4228,38923,"5H-Benzocycloheptene-2-ethanamine, 6,7,8,9-tetrahydro-N,alpha,alpha-trimethyl-, hydrochloride",CC(C)(CC1=CC2=C(CCCCC2)C=C1)[NH2+]C.[Cl-],,,,,,
4229,38924,"N,2-dimethyl-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)propan-2-amine",CC(C)(CC1=CC2=C(CCCCC2)C=C1)NC,,,,,,
4230,38925,"5H-Benzocycloheptene-2-ethanamine, 6,7,8,9-tetrahydro-N,N,alpha,alpha-tetramethyl-, hydrochloride",CC(C)(CC1=CC2=C(CCCCC2)C=C1)[NH+](C)C.[Cl-],,,,,,
4231,38926,"N,N,2-trimethyl-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)propan-2-amine",CC(C)(CC1=CC2=C(CCCCC2)C=C1)N(C)C,,,,,,
4232,38927,Dimethylchrysene,CC1=CC2=C(C=C1)C(=CC3=C2C=CC4=CC=CC=C43)C,,,,,,
4233,38928,CID 38928,CCCOC[C@@H](C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
4234,38929,CID 38929,CCCCCOCC(C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
4235,38930,CID 38930,CCOCCCC[C@@H](C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
4236,38931,CID 38931,CCCCCCOC[C@@H](C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
4237,38932,CID 38932,CCCCOC[C@@H](C=C[C@H]1C(CC(C1CC=CCCCC(=O)O)O)O)O,,,,,,
4238,38933,3-Methylpent-3-enoic acid,CC=C(C)CC(=O)O,,,,,,
4239,38934,5-Methyl-4-oxohexanoic acid,CC(C)C(=O)CCC(=O)O,,,,,,
4240,38935,"2-Methoxy-3,5,5-trimethylcyclohex-2-ene-1,4-dione",CC1=C(C(=O)CC(C1=O)(C)C)OC,,,,,,
4241,38936,2-(3-Methylaminopropylidene)adamantane hydrochloride,CNCCC=C1C2CC3CC(C2)CC1C3.Cl,,,,,,
4242,38937,3-(2-adamantylidene)-N-methylpropan-1-amine,CNCCC=C1C2CC3CC(C2)CC1C3,,,,,,
4243,38938,2-(3-Dimethylaminopropylidene)adamantane hydrochloride,CN(C)CCC=C1C2CC3CC(C2)CC1C3.Cl,,,,,,
4244,38939,"3-(2-adamantylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2CC3CC(C2)CC1C3,,,,,,
4245,38940,"N,N-Dimethyl-1-(adamantan-2-yl)-2-propanamine",CN(C)CCCC1C2CC3CC(C2)CC1C3.Cl,,,,,,
4246,38941,"3-(2-adamantyl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2CC3CC(C2)CC1C3,,,,,,
4247,38942,"5-Chloro-1,3-thiazol-2-amine",C1=C(SC(=N1)N)Cl,,,,,,
4248,38943,(cis)-2-Mercaptocyclobutylmethylamine hydrochloride,C1C[C@H]([C@H]1C[NH3+])S.[Cl-],,,,,,
4249,38944,"BENZO(ghi)PERYLENE, METHYL-",CC1=CC2=C3C4=C(C=CC=C4C5=CC=CC6=C5C3=C1C=C6)C=C2,,,,,,
4250,38945,Tocainide,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,"['For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.']","['Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.']","['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)']","['Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.']",['Negligible first pass hepatic degradation. No active metabolites have been found.'],['The average plasma half-life in patients is approximately 15 hours. May be prolonged up to 35 hours in patients with severe renal function impairment (creatinine clearance less than 30 mL per min per 1.73 square meters of body surface area.']
4251,38946,"Echinatine, N-oxide",CC(C)C(C(C)O)(C(=O)OCC1=CC[N+]2(C1C(CC2)O)[O-])O,,,,,,
4252,38947,"Acetamide, N-(2-(1-methyl-5-nitro-2-imidazolyl)-5-pyrimidinyl)-",CC(=O)NC1=CN=C(N=C1)C2=NC=C(N2C)[N+](=O)[O-],,,,,,
4253,38948,"1-Phenethyl-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline",CN1CCC2=C(C1CCC3=CC=CC=C3)CCCC2,,,,,,
4254,38949,Benzofuran-2-carbonyl chloride,C1=CC=C2C(=C1)C=C(O2)C(=O)Cl,,,,,,
4255,38950,1-Benzofuran-2-carbonitrile,C1=CC=C2C(=C1)C=C(O2)C#N,,,,,,
4256,38951,"4-(Allyloxy)-3,5-dichlorobenzoic acid",C=CCOC1=C(C=C(C=C1Cl)C(=O)O)Cl,,,,,,
4257,38952,"Benzamide, 4-allyloxy-3,5-dichloro-",C=CCOC1=C(C=C(C=C1Cl)C(=O)N)Cl,,,,,,
4258,38953,"Carbazole, 1,2,3,4-tetrahydro-9-(2-dimethylaminoethyl)-6-fluoro-, oxalate",C[NH+](C)CCN1C2=C(CCCC2)C3=C1C=CC(=C3)F.C(=O)(C(=O)[O-])O,,,,,,
4259,38954,"2-(6-fluoro-1,2,3,4-tetrahydrocarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=C(CCCC2)C3=C1C=CC(=C3)F,,,,,,
4260,38955,"Carbazole, 1,2,3,4-tetrahydro-9-(2-diethylaminoethyl)-6-fluoro-, oxalate",CC[NH+](CC)CCN1C2=C(CCCC2)C3=C1C=CC(=C3)F.C(=O)(C(=O)[O-])O,,,,,,
4261,38956,"N,N-diethyl-2-(6-fluoro-1,2,3,4-tetrahydrocarbazol-9-yl)ethanamine",CCN(CC)CCN1C2=C(CCCC2)C3=C1C=CC(=C3)F,,,,,,
4262,38957,"Carbazole, 1,2,3,4-tetrahydro-6-fluoro-9-(2-pyrrolidinoethyl)-, oxalate",C1CCC2=C(C1)C3=C(N2CC[NH+]4CCCC4)C=CC(=C3)F.C(=O)(C(=O)[O-])O,,,,,,
4263,38958,"6-Fluoro-9-(2-(pyrrolidin-1-yl)ethyl)-2,3,4,9-tetrahydro-1h-carbazole",C1CCC2=C(C1)C3=C(N2CCN4CCCC4)C=CC(=C3)F,,,,,,
4264,38959,"Carbazole, 1,2,3,4-tetrahydro-9-(3-dimethylaminopropyl)-6-fluoro-, oxalate",C[NH+](C)CCCN1C2=C(CCCC2)C3=C1C=CC(=C3)F.C(=O)(C(=O)[O-])O,,,,,,
4265,38960,"3-(6-fluoro-1,2,3,4-tetrahydrocarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=C(CCCC2)C3=C1C=CC(=C3)F,,,,,,
4266,38961,"Carbazole, 1,2,3,4-tetrahydro-6-chloro-9-(2-diethylaminoethyl)-, oxalate",CC[NH+](CC)CCN1C2=C(CCCC2)C3=C1C=CC(=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4267,38962,"2-(6-chloro-1,2,3,4-tetrahydrocarbazol-9-yl)-N,N-diethylethanamine",CCN(CC)CCN1C2=C(CCCC2)C3=C1C=CC(=C3)Cl,,,,,,
4268,38963,"Carbazole, 1,2,3,4-tetrahydro-6-chloro-9-(2-pyrrolidinoethyl)-, oxalate",C1CCC2=C(C1)C3=C(N2CC[NH+]4CCCC4)C=CC(=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4269,38964,"6-Chloro-9-(2-(pyrrolidin-1-yl)ethyl)-2,3,4,9-tetrahydro-1h-carbazole",C1CCC2=C(C1)C3=C(N2CCN4CCCC4)C=CC(=C3)Cl,,,,,,
4270,38965,"Carbazole, 1,2,3,4-tetrahydro-6-chloro-9-(3-dimethylaminopropyl)-, oxalate",C[NH+](C)CCCN1C2=C(CCCC2)C3=C1C=CC(=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4271,38966,"3-(6-chloro-1,2,3,4-tetrahydrocarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=C(CCCC2)C3=C1C=CC(=C3)Cl,,,,,,
4272,38967,"5H-Cyclohept(b)indole, 6,7,8,9,10-pentahydro-2-chloro-5-(2-dimethylaminoethyl)-, oxalate",C[NH+](C)CCN1C2=C(CCCCC2)C3=C1C=CC(=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4273,38968,"2-(2-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]indol-5-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=C(CCCCC2)C3=C1C=CC(=C3)Cl,,,,,,
4274,38969,"5H-Cyclohept(b)indole, 6,7,8,9,10-pentahydro-2-chloro-5-(2-pyrrolidinoethyl)-, oxalate",C1CCC2=C(CC1)N(C3=C2C=C(C=C3)Cl)CC[NH+]4CCCC4.C(=O)(C(=O)[O-])O,,,,,,
4275,38970,"2-chloro-5-(2-pyrrolidin-1-ylethyl)-7,8,9,10-tetrahydro-6H-cyclohepta[b]indole",C1CCC2=C(CC1)N(C3=C2C=C(C=C3)Cl)CCN4CCCC4,,,,,,
4276,38971,"5H-Cyclohept(b)indole, 6,7,8,9,10-pentahydro-5-(2-diethylaminoethyl)-2-methoxy-, oxalate",CC[NH+](CC)CCN1C2=C(CCCCC2)C3=C1C=CC(=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4277,38972,"N,N-diethyl-2-(2-methoxy-7,8,9,10-tetrahydro-6H-cyclohepta[b]indol-5-yl)ethanamine",CCN(CC)CCN1C2=C(CCCCC2)C3=C1C=CC(=C3)OC,,,,,,
4278,38973,"5H-Cyclohept(b)indole, 6,7,8,9,10-pentahydro-2-methoxy-5-(2-pyrrolidinoethyl)-, oxalate",COC1=CC2=C(C=C1)N(C3=C2CCCCC3)CC[NH+]4CCCC4.C(=O)(C(=O)[O-])O,,,,,,
4279,38974,"2-methoxy-5-(2-pyrrolidin-1-ylethyl)-7,8,9,10-tetrahydro-6H-cyclohepta[b]indole",COC1=CC2=C(C=C1)N(C3=C2CCCCC3)CCN4CCCC4,,,,,,
4280,38975,"Carbazole, 3-fluoro-9-(2-pyrrolidinoethyl)-, oxalate",C1CC[NH+](C1)CCN2C3=C(C=C(C=C3)F)C4=CC=CC=C42.C(=O)(C(=O)[O-])O,,,,,,
4281,38976,3-Fluoro-9-(2-pyrrolidin-1-ylethyl)carbazole,C1CCN(C1)CCN2C3=C(C=C(C=C3)F)C4=CC=CC=C42,,,,,,
4282,38977,2-Chloro-9-(2-dimethylaminoethyl)carbazole hydrochloride,C[NH+](C)CCN1C2=CC=CC=C2C3=C1C=C(C=C3)Cl.[Cl-],,,,,,
4283,38978,"2-(2-chlorocarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=CC=CC=C2C3=C1C=C(C=C3)Cl,,,,,,
4284,38979,"Carbazole, 2-chloro-9-(2-pyrrolidinoethyl)-, hydrochloride",C1CC[NH+](C1)CCN2C3=CC=CC=C3C4=C2C=C(C=C4)Cl.[Cl-],,,,,,
4285,38980,2-Chloro-9-(2-pyrrolidin-1-ylethyl)carbazole,C1CCN(C1)CCN2C3=CC=CC=C3C4=C2C=C(C=C4)Cl,,,,,,
4286,38981,"Carbazole, 2-chloro-9-(3-dimethylaminopropyl)-, oxalate",C[NH+](C)CCCN1C2=CC=CC=C2C3=C1C=C(C=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4287,38982,"3-(2-chlorocarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=CC=CC=C2C3=C1C=C(C=C3)Cl,,,,,,
4288,38983,"Carbazole, 3-chloro-9-(2-dimethylaminoethyl)-, oxalate",C[NH+](C)CCN1C2=C(C=C(C=C2)Cl)C3=CC=CC=C31.C(=O)(C(=O)[O-])O,,,,,,
4289,38984,"2-(3-chlorocarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=C(C=C(C=C2)Cl)C3=CC=CC=C31,,,,,,
4290,38985,"Carbazole, 3-chloro-9-(2-pyrrolidinoethyl)-, oxalate",C1CC[NH+](C1)CCN2C3=CC=CC=C3C4=C2C=C(C=C4)Cl.C(=O)(C(=O)[O-])O,,,,,,
4291,38986,"Carbazole, 3-chloro-9-(3-dimethylaminopropyl)-, oxalate",C[NH+](C)CCCN1C2=C(C=C(C=C2)Cl)C3=CC=CC=C31.C(=O)(C(=O)[O-])O,,,,,,
4292,38987,"3-(3-chlorocarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=C(C=C(C=C2)Cl)C3=CC=CC=C31,,,,,,
4293,38988,"Carbazole, 9-(2-dimethylaminoethyl)-1-methoxy-, oxalate",C[NH+](C)CCN1C2=CC=CC=C2C3=C1C(=CC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4294,38989,"2-(1-methoxycarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=CC=CC=C2C3=C1C(=CC=C3)OC,,,,,,
4295,38990,"Carbazole, 1-methoxy-9-(2-pyrrolidinoethyl)-, oxalate",COC1=CC=CC2=C1N(C3=CC=CC=C23)CC[NH+]4CCCC4.C(=O)(C(=O)[O-])O,,,,,,
4296,38991,1-Methoxy-9-(2-pyrrolidin-1-ylethyl)carbazole,COC1=CC=CC2=C1N(C3=CC=CC=C23)CCN4CCCC4,,,,,,
4297,38992,"Carbazole, 9-(3-dimethylaminopropyl)-1-methoxy-, oxalate",C[NH+](C)CCCN1C2=CC=CC=C2C3=C1C(=CC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4298,38993,"3-(1-methoxycarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=CC=CC=C2C3=C1C(=CC=C3)OC,,,,,,
4299,38994,9-(2-Dimethylaminoethyl)-2-methoxycarbazole hydrochloride,C[NH+](C)CCN1C2=CC=CC=C2C3=C1C=C(C=C3)OC.[Cl-],,,,,,
4300,38995,"2-(2-methoxycarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=CC=CC=C2C3=C1C=C(C=C3)OC,,,,,,
4301,38996,"Carbazole, 9-(2-diethylaminoethyl)-2-methoxy-, oxalate",CC[NH+](CC)CCN1C2=CC=CC=C2C3=C1C=C(C=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4302,38997,"N,N-diethyl-2-(2-methoxycarbazol-9-yl)ethanamine",CCN(CC)CCN1C2=CC=CC=C2C3=C1C=C(C=C3)OC,,,,,,
4303,38998,"Carbazole, 2-methoxy-9-(2-pyrrolidinoethyl)-, hydrochloride",COC1=CC2=C(C=C1)C3=CC=CC=C3N2CC[NH+]4CCCC4.[Cl-],,,,,,
4304,38999,2-Methoxy-9-(2-pyrrolidin-1-ylethyl)carbazole,COC1=CC2=C(C=C1)C3=CC=CC=C3N2CCN4CCCC4,,,,,,
4305,39000,"Carbazole, 9-(3-dimethylaminopropyl)-2-methoxy-, oxalate",C[NH+](C)CCCN1C2=CC=CC=C2C3=C1C=C(C=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
4306,39001,"3-(2-Methoxy-9H-carbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=CC=CC=C2C3=C1C=C(C=C3)OC,,,,,,
4307,39002,9-(2-Dimethylaminoethyl)-3-methoxycarbazole hydrochloride,C[NH+](C)CCN1C2=C(C=C(C=C2)OC)C3=CC=CC=C31.[Cl-],,,,,,
4308,39003,"2-(3-methoxycarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=C(C=C(C=C2)OC)C3=CC=CC=C31,,,,,,
4309,39004,"Carbazole, 9-(2-diethylaminoethyl)-3-methoxy-, oxalate",CC[NH+](CC)CCN1C2=C(C=C(C=C2)OC)C3=CC=CC=C31.C(=O)(C(=O)[O-])O,,,,,,
4310,39005,"N,N-diethyl-2-(3-methoxycarbazol-9-yl)ethanamine",CCN(CC)CCN1C2=C(C=C(C=C2)OC)C3=CC=CC=C31,,,,,,
4311,39006,"Carbazole, 3-methoxy-9-(2-pyrrolidinoethyl)-, oxalate",COC1=CC2=C(C=C1)N(C3=CC=CC=C32)CC[NH+]4CCCC4.C(=O)(C(=O)[O-])O,,,,,,
4312,39007,3-Methoxy-9-(2-pyrrolidin-1-ylethyl)carbazole,COC1=CC2=C(C=C1)N(C3=CC=CC=C32)CCN4CCCC4,,,,,,
4313,39008,"Carbazole, 9-(3-dimethylaminopropyl)-3-methoxy-, oxalate",C[NH+](C)CCCN1C2=C(C=C(C=C2)OC)C3=CC=CC=C31.C(=O)(C(=O)[O-])O,,,,,,
4314,39009,"3-(3-methoxycarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=C(C=C(C=C2)OC)C3=CC=CC=C31,,,,,,
4315,39010,"Carbazole, 9-(3-dimethylaminopropyl)-4-methoxy-, oxalate",C[NH+](C)CCCN1C2=C(C3=CC=CC=C31)C(=CC=C2)OC.C(=O)(C(=O)[O-])O,,,,,,
4316,39011,"3-(4-methoxycarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=C(C3=CC=CC=C31)C(=CC=C2)OC,,,,,,
4317,39012,2-Chloro-9-(2-dimethylaminoethyl)-7-methoxycarbazole hydrochloride,C[NH+](C)CCN1C2=C(C=CC(=C2)OC)C3=C1C=C(C=C3)Cl.[Cl-],,,,,,
4318,39013,"2-(2-chloro-7-methoxycarbazol-9-yl)-N,N-dimethylethanamine",CN(C)CCN1C2=C(C=CC(=C2)OC)C3=C1C=C(C=C3)Cl,,,,,,
4319,39014,"Carbazole, 2-chloro-9-(2-diethylaminoethyl)-7-methoxy-, oxalate",CC[NH+](CC)CCN1C2=C(C=CC(=C2)OC)C3=C1C=C(C=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4320,39015,"2-(2-chloro-7-methoxycarbazol-9-yl)-N,N-diethylethanamine",CCN(CC)CCN1C2=C(C=CC(=C2)OC)C3=C1C=C(C=C3)Cl,,,,,,
4321,39016,"Carbazole, 2-chloro-7-methoxy-9-(2-pyrrolidinoethyl)-, hydrochloride",COC1=CC2=C(C=C1)C3=C(N2CC[NH+]4CCCC4)C=C(C=C3)Cl.[Cl-],,,,,,
4322,39017,2-Chloro-7-methoxy-9-(2-pyrrolidin-1-ylethyl)carbazole,COC1=CC2=C(C=C1)C3=C(N2CCN4CCCC4)C=C(C=C3)Cl,,,,,,
4323,39018,"Carbazole, 2-chloro-9-(3-dimethylaminopropyl)-7-methoxy-, oxalate",C[NH+](C)CCCN1C2=C(C=CC(=C2)OC)C3=C1C=C(C=C3)Cl.C(=O)(C(=O)[O-])O,,,,,,
4324,39019,"3-(2-chloro-7-methoxycarbazol-9-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=C(C=CC(=C2)OC)C3=C1C=C(C=C3)Cl,,,,,,
4325,39020,9-(2-(Dimethylamino)ethyl)-2-methoxy-1-methylcarbazole hydrochloride,CC1=C(C=CC2=C1N(C3=CC=CC=C23)CC[NH+](C)C)OC.[Cl-],,,,,,
4326,39021,"2-(2-methoxy-1-methylcarbazol-9-yl)-N,N-dimethylethanamine",CC1=C(C=CC2=C1N(C3=CC=CC=C23)CCN(C)C)OC,,,,,,
4327,39022,"9-(2-(Diethylamino)ethyl)-2,7-dimethoxy-1-methylcarbazole hydrochloride",CC[NH+](CC)CCN1C2=C(C=CC(=C2)OC)C3=C1C(=C(C=C3)OC)C.[Cl-],,,,,,
4328,39023,"2-(2,7-dimethoxy-1-methylcarbazol-9-yl)-N,N-diethylethanamine",CCN(CC)CCN1C2=C(C=CC(=C2)OC)C3=C1C(=C(C=C3)OC)C,,,,,,
4329,39024,"2,7-Dimethoxy-1-methyl-9-(2-(1-pyrrolidinyl)ethyl)carbazole hydrochloride",CC1=C(C=CC2=C1N(C3=C2C=CC(=C3)OC)CC[NH+]4CCCC4)OC.[Cl-],,,,,,
4330,39025,"2,7-Dimethoxy-1-methyl-9-(2-pyrrolidin-1-ylethyl)carbazole",CC1=C(C=CC2=C1N(C3=C2C=CC(=C3)OC)CCN4CCCC4)OC,,,,,,
4331,39026,"9-(2-(Dimethylamino)ethyl)-1-methyl-2,6,7-trimethoxycarbazole hydrochloride",CC1=C(C=CC2=C1N(C3=CC(=C(C=C23)OC)OC)CC[NH+](C)C)OC.[Cl-],,,,,,
4332,39027,"N,N-dimethyl-2-(2,6,7-trimethoxy-1-methylcarbazol-9-yl)ethanamine",CC1=C(C=CC2=C1N(C3=CC(=C(C=C23)OC)OC)CCN(C)C)OC,,,,,,
4333,39028,"ACETAMIDE, N-(1-METHYL-5-(5-NITRO-2-FURYL)-s-TRIAZOL-3-YL)-",CC(=O)NC1=NN(C(=N1)C2=CC=C(O2)[N+](=O)[O-])C,,,,,,
4334,39029,"5H-Benzocycloheptene-2-propanoic acid, 6,7,8,9-tetrahydro-alpha-amino-, hydrochloride",C1CCC2=C(CC1)C=C(C=C2)CC(C(=O)O)[NH3+].[Cl-],,,,,,
4335,39030,"2-amino-3-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)propanoic acid",C1CCC2=C(CC1)C=C(C=C2)CC(C(=O)O)N,,,,,,
4336,39031,Sulbenicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)S(=O)(=O)O)C(=O)O)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4337,39032,CID 39032,CCN(C1=CC=CC=C1)C(=NC(=N)S)S,,,,,,
4338,39033,N-Isoamylphthalamide,CC(C)CCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
4339,39034,"butyl 2-[(6S,11S,14S,16R)-6-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoacetate",CCCCOC(=O)C(=O)C1[C@@H](C[C@@H]2C1(C[C@@H](C3C2C[C@@H](C4=CC(=O)C=CC34C)F)O)C)C,,,,,,
4340,39035,"2,3,5,8-Tetrahydroxy-6-methyl-1,4-naphthalenedione",CC1=CC(=O)C2=C(C1=O)C(=C(C(=C2O)O)O)O,,,,,,
4341,39036,"6,7-Dihydro-2,3,5,8-tetrahydroxy-6-methyl-1,4-naphthalenedione",CC1CC(=O)C2=C(C1=O)C(=C(C(=C2O)O)O)O,,,,,,
4342,39037,1-Hydroxy-2-naphthylammonium chloride,C1=CC=C2C(=C1)C=CC(=C2O)[NH3+].[Cl-],,,,,,
4343,39038,2-Amino-1-naphthol,C1=CC=C2C(=C1)C=CC(=C2O)N,,,,,,
4344,39039,"Imidazolidine, 1,3-dimethyl-2-ethyl-",CCC1N(CCN1C)C,,,,,,
4345,39040,Tricyclazole,CC1=C2C(=CC=C1)SC3=NN=CN23,,,,,,
4346,39041,"5-Chloro-1,3-cyclopentadiene",C1=CC(C=C1)Cl,,,,,,
4347,39042,Bezafibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,"['For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).']","['Bezafibrate is an antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. The activity of triglyceride lipases (lipoprotein lipase and hepatic lipoproteinlipase) involved in the catabolism of triglyceride-rich lipoproteins is increased by bezafibrate. In the course of the intensified degradation of triglyceride-rich lipoproteins (chylomicrons, VLDL) precursors for the formation of HDL are formed which explains an increase in HDL. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL-receptor-mediated lipoprotein catabolism. Elevated fibrinogen appears to be an important risk-factor, alongside the lipids, smoking and hypertension, in the development of atheroma. Fibrinogen plays an important role in viscosity, and therefore blood flow, and also appears to play an important role in thrombus development and lysability. Bezafibrate exerts an effect on thrombogenic factors. A significant decrease in elevated plasma fibrinogen levels can be achieved. This may lead, amongst other things, to a reduction in both blood and plasma viscosity. Inhibition of platelet aggregation has also been observed. A reduction in blood glucose concentration due to an increase in glucose tolerance has been reported in diabetic patients. In the same patients, the concentration of fasting and postprandial free fatty acids was reduced by bezafibrate.']",['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)'],['Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%.'],['Hepatic.'],['1-2 hours']
4348,39043,5-Methyl-3-(2-pyridyl)dihydro-2(3H)-furanone,CC1CC(C(=O)O1)C2=CC=CC=N2,,,,,,
4349,39044,(3-Chloro-2-hydroxypropyl)dodecyldimethylammonium chloride,CCCCCCCCCCCC[N+](C)(C)CC(CCl)O.[Cl-],,,,,,
4350,39045,"N-(3-Chloro-2-hydroxypropyl)-N,N-dimethyl-1-dodecanaminium",CCCCCCCCCCCC[N+](C)(C)CC(CCl)O,,,,,,
4351,39046,"2-Ethylhexanoic acid 1-oxo-2-(2,4,6-trimethylphenyl)-1H-inden-3-yl ester",CCCCC(CC)C(=O)OC1=C(C(=O)C2=CC=CC=C21)C3=C(C=C(C=C3C)C)C,,,,,,
4352,39047,"2,6-Dichloroterephthalic acid",C1=C(C=C(C(=C1Cl)C(=O)O)Cl)C(=O)O,,,,,,
4353,39048,"Benzoic acid, 4-(((4-((bis(1-aziridinyl)phosphinyl)oxy)phenoxy)carbonyl)amino)-, methyl ester",COC(=O)C1=CC=C(C=C1)NC(=O)OC2=CC=C(C=C2)OP(=O)(N3CC3)N4CC4,,,,,,
4354,39049,"1(2H)-Isocarbostyril, 6-tert-butyl-3,4-dihydro-2,3-dimethyl-4-phenyl-, (E)-",C[C@H]1[C@@H](C2=C(C=CC(=C2)C(C)(C)C)C(=O)N1C)C3=CC=CC=C3,,,,,,
4355,39050,"trans-6-tert-Butyl-2,3-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline",C[C@H]1C(C2=C(CN1C)C=CC(=C2)C(C)(C)C)C3=CC=CC=C3,,,,,,
4356,39051,"trans-Ethyl 6-tert-butyl-3-methyl-4-phenyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate",CCOC(=O)N1CC2=C(C=C(C=C2)C(C)(C)C)C(C1C)C3=CC=CC=C3,,,,,,
4357,39052,"1(2H)-Isocarbostyril, 3,4-dihydro-2,3-dimethyl-4-phenyl-, (E)-",C[C@H]1[C@@H](C2=CC=CC=C2C(=O)N1C)C3=CC=CC=C3,,,,,,
4358,39053,"trans-3,4-Dihydro-4-phenyl-2,3,7-trimethyl-1(2H)-isocarbostyril",C[C@H]1[C@@H](C2=CC=CC(=C2C(=O)N1C)C)C3=CC=CC=C3,,,,,,
4359,39054,"Isoquinoline, 3-methyl-4-phenyl-1,2,3,4-tetrahydro-, hydrobromide, (E)-",C[C@H]1C(C2=CC=CC=C2C[NH2+]1)C3=CC=CC=C3.[Br-],,,,,,
4360,39055,"(3S)-3-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline",C[C@H]1C(C2=CC=CC=C2CN1)C3=CC=CC=C3,,,,,,
4361,39056,"trans-Ethyl 3-methyl-4-phenyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate",CCOC(=O)N1CC2=CC=CC=C2C(C1C)C3=CC=CC=C3,,,,,,
4362,39057,"Isoquinoline, 1,2,3,4-tetrahydro-6-chloro-2,3-dimethyl-4-phenyl-, hydrochloride, (E)-",C[C@H]1C(C2=C(C[NH+]1C)C=CC(=C2)Cl)C3=CC=CC=C3.[Cl-],,,,,,
4363,39058,"(3S)-6-chloro-2,3-dimethyl-4-phenyl-3,4-dihydro-1H-isoquinoline",C[C@H]1C(C2=C(CN1C)C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
4364,39059,"Isoquinoline, 1,2,3,4-tetrahydro-6,8-dichloro-2,3-dimethyl-4-phenyl-, hydrochloride, (E)-",C[C@H]1C(C2=C(C[NH+]1C)C(=CC(=C2)Cl)Cl)C3=CC=CC=C3.[Cl-],,,,,,
4365,39060,"(3S)-6,8-dichloro-2,3-dimethyl-4-phenyl-3,4-dihydro-1H-isoquinoline",C[C@H]1C(C2=C(CN1C)C(=CC(=C2)Cl)Cl)C3=CC=CC=C3,,,,,,
4366,39061,"trans-6-Amino-2,3-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline",C[C@H]1C(C2=C(CN1C)C=CC(=C2)N)C3=CC=CC=C3,,,,,,
4367,39062,"trans-6-Acetamido-2,3-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline",C[C@H]1C(C2=C(CN1C)C=CC(=C2)NC(=O)C)C3=CC=CC=C3,,,,,,
4368,39063,"trans-3-Methyl-4-phenyl-3,4-dihydro-2(1H)-isoquinolinepropionitrile",C[C@H]1C(C2=CC=CC=C2CN1CCC#N)C3=CC=CC=C3,,,,,,
4369,39064,"trans-3-Methyl-4-phenyl-3,4-dihydro-2(1H)-isoquinolinepropionamide",C[C@H]1C(C2=CC=CC=C2CN1CCC(=O)N)C3=CC=CC=C3,,,,,,
4370,39065,Tolimidone,CC1=CC(=CC=C1)OC2=CNC(=O)N=C2,,,,,,
4371,39066,1-Butyl-1-methyl-2-propylcyclopropane,CCCCC1(CC1CCC)C,,,,,,
4372,39067,1-Methyl-1-(1-methylethyl)-2-nonylcyclopropane,CCCCCCCCCC1CC1(C)C(C)C,,,,,,
4373,39068,1-Methyl-1-(2-methylpropyl)-2-nonylcyclopropane,CCCCCCCCCC1CC1(C)CC(C)C,,,,,,
4374,39069,7-Pentylbicyclo[4.1.0]heptane,CCCCCC1C2C1CCCC2,,,,,,
4375,39070,4-Propylthiazole,CCCC1=CSC=N1,,,,,,
4376,39071,2-Methyl-4-propylthiazole,CCCC1=CSC(=N1)C,,,,,,
4377,39072,"6,7-Dihydro-N,N-dimethyl-indolo(1,7-ab)(1)benzazepine-2-methanamine hydrochloride",C[NH+](C)CC1=CN2C3=CC=CC=C3CCC4=C2C1=CC=C4.[Cl-],,,,,,
4378,39073,"1-(1-azatetracyclo[8.6.1.02,7.014,17]heptadeca-2,4,6,10(17),11,13,15-heptaen-15-yl)-N,N-dimethylmethanamine",CN(C)CC1=CN2C3=CC=CC=C3CCC4=C2C1=CC=C4,,,,,,
4379,39074,Spirogermanium hydrochloride,CC[Ge]1(CCC2(CCN(C2)CCCN(C)C)CC1)CC.Cl.Cl,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4380,39075,Spirogermanium,CC[Ge]1(CCC2(CCN(C2)CCCN(C)C)CC1)CC,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4381,39076,"Propanedioic acid, (carboxymethoxy)-, trisodium salt",C(C(=O)[O-])OC(C(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],,,,,,
4382,39077,"Propanedioic acid, (carboxymethoxy)-",C(C(=O)O)OC(C(=O)O)C(=O)O,,,,,,
4383,39078,"2,2,2-Trifluoro-N-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide",C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC(=O)C(F)(F)F,,,,,,
4384,39079,"4-Isothiazolecarboxylic acid, 5-(2-(diethylamino)acetamido)-3-methyl-",CCN(CC)CC(=O)NC1=C(C(=NS1)C)C(=O)O,,,,,,
4385,39080,5-Oxo-4-phenyltetrahydro-2-furancarbonitrile,C1C(OC(=O)C1C2=CC=CC=C2)C#N,,,,,,
4386,39081,5-Oxo-4-phenyltetrahydro-2-furamide,C1C(C(=O)OC1C(=O)N)C2=CC=CC=C2,,,,,,
4387,39082,5-(Morpholinocarbonyl)-3-phenyldihydro-2(3H)-furanone,C1COCCN1C(=O)C2CC(C(=O)O2)C3=CC=CC=C3,,,,,,
4388,39083,"N,N-Diethyl-5-oxo-4-phenyltetrahydro-2-furamide",CCN(CC)C(=O)C1CC(C(=O)O1)C2=CC=CC=C2,,,,,,
4389,39084,N-Methoxymethylphenobarbital,CCC1(C(=O)NC(=O)N(C1=O)COC)C2=CC=CC=C2,,,,,,
4390,39085,"Butyrophenone, 3-methyl-4'-piperidinocarbonylmethoxy-",CC(C)CC(=O)C1=CC=C(C=C1)OCC(=O)N2CCCCC2,,,,,,
4391,39086,"Acetamide, 2-(4-acetylphenoxy)-N-cyclopentyl-",CC(=O)C1=CC=C(C=C1)OCC(=O)NC2CCCC2,,,,,,
4392,39087,"Acetophenone, 4'-carbazoylmethoxy-",CC(=O)C1=CC=C(C=C1)OCC(=O)NN,,,,,,
4393,39088,"Acetophenone, 4'-pyrrolidinylcarbonylmethoxy-",CC(=O)C1=CC=C(C=C1)OCC(=O)N2CCCC2,,,,,,
4394,39089,"Acetic acid, 2-chloro-2-phenyl-, 2-pyridylmethyl ester, hydrochloride",C1=CC=C(C=C1)C(C(=O)OCC2=CC=CC=[NH+]2)Cl.[Cl-],,,,,,
4395,39090,Pyridin-2-ylmethyl 2-chloro-2-phenylacetate,C1=CC=C(C=C1)C(C(=O)OCC2=CC=CC=N2)Cl,,,,,,
4396,39091,2-Pyridylmethyl alpha-phenylbutyrate hydrochloride,CCC(C1=CC=CC=C1)C(=O)OCC2=CC=CC=[NH+]2.[Cl-],,,,,,
4397,39092,Pyridin-2-ylmethyl 2-phenylbutanoate,CCC(C1=CC=CC=C1)C(=O)OCC2=CC=CC=N2,,,,,,
4398,39093,2-Pyridylmethyl diphenylacetate hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCC3=CC=CC=[NH+]3.[Cl-],,,,,,
4399,39094,"Pyridin-2-ylmethyl 2,2-diphenylacetate",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCC3=CC=CC=N3,,,,,,
4400,39095,"Mandelic acid, 2-pyridylmethyl ester, acetate, hydrochloride",CC(=O)OC(C1=CC=CC=C1)C(=O)OCC2=CC=CC=[NH+]2.[Cl-],,,,,,
4401,39096,Pyridin-2-ylmethyl 2-acetyloxy-2-phenylacetate,CC(=O)OC(C1=CC=CC=C1)C(=O)OCC2=CC=CC=N2,,,,,,
4402,39097,"Acetic acid, acetoxydiphenyl-, 2-pyridylmethyl ester, hydrochloride",CC(=O)OC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3=CC=CC=[NH+]3.[Cl-],,,,,,
4403,39098,"Pyridin-2-ylmethyl 2-acetyloxy-2,2-diphenylacetate",CC(=O)OC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3=CC=CC=N3,,,,,,
4404,39099,2-Pyridylmethyl alpha-ethyl-alpha-methylhexanoate hydrochloride,CCCCC(C)(CC)C(=O)OCC1=CC=CC=[NH+]1.[Cl-],,,,,,
4405,39100,2-Ethyl-2-methylhexanoic acid 2-pyridinylmethyl ester,CCCCC(C)(CC)C(=O)OCC1=CC=CC=N1,,,,,,
4406,39101,2-Pyridylmethyl dibenzylacetate hydrochloride,C1=CC=C(C=C1)CC(CC2=CC=CC=C2)C(=O)OCC3=CC=CC=[NH+]3.[Cl-],,,,,,
4407,39102,Pyridin-2-ylmethyl 2-benzyl-3-phenylpropanoate,C1=CC=C(C=C1)CC(CC2=CC=CC=C2)C(=O)OCC3=CC=CC=N3,,,,,,
4408,39103,"Mandelic acid, 2-pyridylmethyl ester, hydrochloride",C1=CC=C(C=C1)C(C(=O)OCC2=CC=CC=[NH+]2)O.[Cl-],,,,,,
4409,39104,Pyridin-2-ylmethyl 2-hydroxy-2-phenylacetate,C1=CC=C(C=C1)C(C(=O)OCC2=CC=CC=N2)O,,,,,,
4410,39105,3-(((Aminoiminomethyl)thio)methyl)-4-ethoxybenzeneacetic acid methyl ester monohydrochloride,CCOC1=C(C=C(C=C1)CC(=O)OC)CSC(=[NH2+])N.[Cl-],,,,,,
4411,39106,Methyl 2-[3-(carbamimidoylsulfanylmethyl)-4-ethoxyphenyl]acetate,CCOC1=C(C=C(C=C1)CC(=O)OC)CSC(=N)N,,,,,,
4412,39107,3-(((Aminoiminomethyl)thio)methyl)-4-propoxybenzeneacetic acid methylester monohydrochloride,CCCOC1=C(C=C(C=C1)CC(=O)OC)CSC(=[NH2+])N.[Cl-],,,,,,
4413,39108,Methyl 2-[3-(carbamimidoylsulfanylmethyl)-4-propoxyphenyl]acetate,CCCOC1=C(C=C(C=C1)CC(=O)OC)CSC(=N)N,,,,,,
4414,39109,3-(((Aminoiminomethyl)thio)methyl)-4-butoxybenzeneacetic acid methyl ester monohydrochloride,CCCCOC1=C(C=C(C=C1)CC(=O)OC)CSC(=[NH2+])N.[Cl-],,,,,,
4415,39110,3-[[(Aminoiminomethyl)thio]methyl]-4-butoxybenzeneacetic acid methyl ester,CCCCOC1=C(C=C(C=C1)CC(=O)OC)CSC(=N)N,,,,,,
4416,39111,CID 39111,CN(C)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC=CC=C2,,,,,,
4417,39112,CID 39112,CN(C)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC=CC=C2O,,,,,,
4418,39113,CID 39113,CN(C)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC=C(C=C2)OC,,,,,,
4419,39114,CID 39114,CN(C)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC(=C(C=C2)O)OC,,,,,,
4420,39115,CID 39115,CCN(CC)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC=CC=C2,,,,,,
4421,39116,CID 39116,CCN(CC)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC=CC=C2O,,,,,,
4422,39117,CID 39117,CCN(CC)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC=C(C=C2)OC,,,,,,
4423,39118,CID 39118,CCN(CC)CC1=C(C=CC(=C1)Br)OCC(=O)NN=CC2=CC(=C(C=C2)O)OC,,,,,,
4424,39119,CID 39119,C1COCCN1CC2=C(C=CC(=C2)Br)OCC(=O)NN=CC3=CC=CC=C3,,,,,,
4425,39120,CID 39120,C1COCCN1CC2=C(C=CC(=C2)Br)OCC(=O)NN=CC3=CC=CC=C3O,,,,,,
4426,39121,CID 39121,COC1=CC=C(C=C1)C=NNC(=O)COC2=C(C=C(C=C2)Br)CN3CCOCC3,,,,,,
4427,39122,CID 39122,COC1=C(C=CC(=C1)C=NNC(=O)COC2=C(C=C(C=C2)Br)CN3CCOCC3)O,,,,,,
4428,39123,CID 39123,C1CCN(CC1)CC2=C(C=CC(=C2)Br)OCC(=O)NN=CC3=CC=CC=C3,,,,,,
4429,39124,CID 39124,C1CCN(CC1)CC2=C(C=CC(=C2)Br)OCC(=O)NN=CC3=CC=CC=C3O,,,,,,
4430,39125,CID 39125,COC1=CC=C(C=C1)C=NNC(=O)COC2=C(C=C(C=C2)Br)CN3CCCCC3,,,,,,
4431,39126,CID 39126,COC1=C(C=CC(=C1)C=NNC(=O)COC2=C(C=C(C=C2)Br)CN3CCCCC3)O,,,,,,
4432,39127,"6-Chloro-N-ethyl-N-(2-(2,6-xylyloxy)ethyl)-1-hexylamine oxalate",CC[NH+](CCCCCCCl)CCOC1=C(C=CC=C1C)C.C(=O)(C(=O)[O-])O,,,,,,
4433,39128,"6-chloro-N-[2-(2,6-dimethylphenoxy)ethyl]-N-ethylhexan-1-amine",CCN(CCCCCCCl)CCOC1=C(C=CC=C1C)C,,,,,,
4434,39129,Methyl 2-(3-hydroxyphenyl)acetate,COC(=O)CC1=CC(=CC=C1)O,,,,,,
4435,39130,5-Ethyl-3-(methoxymethyl)-1-methyl-5-phenylbarbituric acid,CCC1(C(=O)N(C(=O)N(C1=O)COC)C)C2=CC=CC=C2,,,,,,
4436,39131,alpha-((Dimethylamino)methyl)-1-methylindole-3-methanol,CN1C=C(C2=CC=CC=C21)C(CN(C)C)O,,,,,,
4437,39132,2-Methoxyethyl 2-(2-methoxyethoxy)acetate,COCCOCC(=O)OCCOC,,,,,,
4438,39133,2-Hydroxy-N-(1-hydroxy-2-oxo-2-phenylethyl)benzamide,C1=CC=C(C=C1)C(=O)C(NC(=O)C2=CC=CC=C2O)O,,,,,,
4439,39134,1-(4-Chloro-3-nitrophenyl)-2-ethoxy-2-((4-(methylthio)phenyl)amino)ethanone,CCOC(C(=O)C1=CC(=C(C=C1)Cl)[N+](=O)[O-])NC2=CC=C(C=C2)SC,,,,,,
4440,39135,Methyl 4-chloro-2-nitrobenzoate,COC(=O)C1=C(C=C(C=C1)Cl)[N+](=O)[O-],,,,,,
4441,39136,N-(2-Phenoxyethyl)-N-phenylacetamide,CC(=O)N(CCOC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4442,39137,"Isobutylamine, 2-(4-piperidinophenyl)-, succinate",CC(C)(C[NH3+])C1=CC=C(C=C1)N2CCCCC2.C(CC(=O)[O-])C(=O)O,,,,,,
4443,39138,2-Methyl-2-(4-piperidin-1-ylphenyl)propan-1-amine,CC(C)(CN)C1=CC=C(C=C1)N2CCCCC2,,,,,,
4444,39139,CID 39139,CC1=NC=C(N1CCN=C(OC)S)[N+](=O)[O-],,,,,,
4445,39140,CID 39140,C1=CC2=C(C=C1Br)C(=NN=C(N)S)C3=C2C=CC(=C3)Br,,,,,,
4446,39141,3-Nitro-9-fluorenone,C1=CC=C2C(=C1)C3=C(C2=O)C=CC(=C3)[N+](=O)[O-],,,,,,
4447,39142,"[2-(2,2-Dimethylpropanoyloxy)-2-(3-hydroxyphenyl)ethyl]-ethylazanium;chloride",CC[NH2+]CC(C1=CC(=CC=C1)O)OC(=O)C(C)(C)C.[Cl-],,,,,,
4448,39143,"[2-(Ethylamino)-1-(3-hydroxyphenyl)ethyl] 2,2-dimethylpropanoate",CCNCC(C1=CC(=CC=C1)O)OC(=O)C(C)(C)C,,,,,,
4449,39144,"2,5-Dimethyl-1,2,5,6-diepoxyhex-3-yne",CC1(CO1)C#CC2(CO2)C,,,,,,
4450,39145,(E)-2-Methylhex-3-ene,CCC=CC(C)C,,,,,,
4451,39146,5-Chloro-2-methylbenzofuran,CC1=CC2=C(O1)C=CC(=C2)Cl,,,,,,
4452,39147,Corgard,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,['Nadolol is indicated to treat angina pectoris and hypertension. Another product formulated with [bendroflumethiazide] is indicated to treat hypertension.'],['Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. It has a long duration of action as it is usually taken once daily and a wide therapeutic index as patients start at doses of 40mg daily but may be increased to doses as high as 240mg daily. Patients taking nadolol should not aburptly stop taking it as this may lead to exacerbation of ischemic heart disease.'],"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['Oral doses of nadolol are approximately 30% absorbed. In healthy subjects, nadolol has a T<sub>max</sub> of 2.7h with a C<sub>max</sub> or 6915ng/mL following a 60mg oral dose and 13227ng/mL after a 120mg oral dose. The AUC following a 60mg oral dose was 1021ng\\*h/mL and following a 120mg oral dose was 1913382ng\\*h/mL.', 'Nadolol is not metabolized in the liver and excreted mainly in the urine. In healthy subjects, following intravenous dosing, 60% of a dose is eliminated in the urine and 15% in the feces after 72 hours. The remainder of the dose is expected to be eliminated in the feces afterwards.', 'In healthy subjects, the volume of distribution of nadolol is 147-157L.', 'In healthy subjects, the total body clearance of nadolol is 219-250mL/min and the renal clearance is 131-150mL/min.', ""Following oral administration of nadolol, absorption is variable and averages about 30-40% of a dose. The presence of food in the GI tract does not affect the rate or extent of absorption. After oral administration of 2 mg of nadolol (in a capsule), peak plasma concentrations usually occur in 2-4 hours. In one study in hypertensive adults who received 80 mg, 160 mg, or 320 mg of nadolol daily, mean steady state plasma concentrations were 25.5-35.5 ng/ml, 51.7-74.1 ng/ml, and 154-191.4 ng/ml, respectively. With doses of 40-320 mg daily, the duration of nadolol's antihypertensive and antianginal effects is at least 24 hours."", 'Following oral administration of 2 mg of radiolabeled nadolol (in a capsule) in one study in patients with normal renal function, about 24.6% and 76.9% of the radioactivity was recovered in urine and feces, respectively, in 4 days.', 'Nadolol is widely distributed into body tissues. In dogs, minimal amounts of nadolol were detected in the brain and, in rats, the drug crosses the placenta. The drug is distributed into bile. Nadolol is distributed into milk. About 30% of nadolol in serum is bound to plasma proteins.', 'The beta-adrenoceptor antagonists ... are adequately absorbed, and some like atenolol, sotalol and nadolol which are poorly lipid-soluble are excreted unchanged in the urine, accumulating in renal failure but cleared normally in liver disease. The more lipid-soluble drugs are subject to variable metabolism in the liver, which may be influenced by age, phenotype, environment, disease and other drugs, leading to more variable plasma concentrations. Their clearance is reduced in liver disease but is generally unchanged in renal dysfunction. All the beta-adrenoceptor antagonists reduce cardiac output and this may reduce hepatic clearance of highly extracted drugs. In addition, the metabolised drugs compete with other drugs for enzymatic biotransformation and the potential for interaction is great, but because of the high therapeutic index of beta-adrenoceptor antagonists, any unexpected clinical effects are more likely to be due to changes in the kinetics of the other drug.', 'Nadolol 20 mg was administered orally as a single-blind, single dose to nine patients about to undergo cataract extraction. Intraocular pressures fell by a mean of 24% 3 hr after administration. During the operation, aqueous humor and serum samples were taken for measurement of nadolol concentrations. Aqueous nadolol concentrations ranged from 3.8 to 13.4 ng/mL, and correlated with the serum drug concentrations (r=0.84). The fall in intraocular pressure did not correlate with either the aqueous humor or plasma concentrations of nadolol.']","['Nadolol is not metabolized by the liver in humans.', 'Nadolol is not metabolized.']","['The half life of nadolol is 20 to 24 hours.', 'The elimination half-life of nadolol is 18 hr. /From table/', 'In patients with normal renal function, the plasma half-life of nadolol is 10-24 hr and, with once daily doses, steady state is attained in 6-9 days. In patients with renal impairment, plasma half-life is increased.']"
4453,39148,9-[3-deoxy-3-(dimethylamino)pentofuranosyl]-9H-purin-6-amine,CN(C)C1[C@H](O[C@H](C1O)N2C=NC3=C(N=CN=C32)N)CO,,,,,,
4454,39149,Triethylbenzene,CCC1=C(C(=CC=C1)CC)CC,,,,,,
4455,39150,1-Chloroeicosane,CCCCCCCCCCCCCCCCCCCCCl,,,,,,
4456,39151,"(1,3-Dioxo-5-methoxy-2-phenylindan-2-yl(methoxycarbonyl)methyl)trimethylammonium chloride",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C=C(C=C2)OC)C3=CC=CC=C3.[Cl-],,,,,,
4457,39152,"[2-[(5-Methoxy-1,3-dioxo-2-phenylinden-2-yl)methoxy]-2-oxoethyl]-trimethylazanium",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C=C(C=C2)OC)C3=CC=CC=C3,,,,,,
4458,39153,"2-Trimethylammoniumacetoxymethyl-2-(p-methoxyphenyl)-5-methoxyindan-1,3-dione chloride",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C=C(C=C2)OC)C3=CC=C(C=C3)OC.[Cl-],,,,,,
4459,39154,"[2-[[5-Methoxy-2-(4-methoxyphenyl)-1,3-dioxoinden-2-yl]methoxy]-2-oxoethyl]-trimethylazanium",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C=C(C=C2)OC)C3=CC=C(C=C3)OC,,,,,,
4460,39155,"(4-Chloro-1,3-dioxo-2-phenylindan-2-yl(methoxycarbonyl)methyl)trimethylammonium chloride",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C(=CC=C2)Cl)C3=CC=CC=C3.[Cl-],,,,,,
4461,39156,"[2-[(4-Chloro-1,3-dioxo-2-phenylinden-2-yl)methoxy]-2-oxoethyl]-trimethylazanium",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C(=CC=C2)Cl)C3=CC=CC=C3,,,,,,
4462,39157,"(5-Chloro-1,3-dioxo-2-phenylindan-2-yl(methoxycarbonyl)methyl)trimethylammonium chloride",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C=C(C=C2)Cl)C3=CC=CC=C3.[Cl-],,,,,,
4463,39158,"[2-[(5-Chloro-1,3-dioxo-2-phenylinden-2-yl)methoxy]-2-oxoethyl]-trimethylazanium",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=C(C1=O)C=C(C=C2)Cl)C3=CC=CC=C3,,,,,,
4464,39159,"(1,3-Dioxo-2-phenylindan-2-yl(methoxycarbonyl)methyl)trimethylammonium chloride",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=CC=CC=C2C1=O)C3=CC=CC=C3.[Cl-],,,,,,
4465,39160,"[2-[(1,3-Dioxo-2-phenylinden-2-yl)methoxy]-2-oxoethyl]-trimethylazanium",C[N+](C)(C)CC(=O)OCC1(C(=O)C2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
4466,39161,"2-Butenoic acid,3-bromo-4-oxo-4-[4-(pentyloxy)phenyl]-",CCCCCOC1=CC=C(C=C1)C(=O)C(=CC(=O)O)Br,,,,,,
4467,39162,[N'-[N'-[3-(trifluoromethyl)phenyl]carbamimidoyl]carbamimidoyl]-[6-[[N'-[N'-[3-(trifluoromethyl)phenyl]carbamimidoyl]carbamimidoyl]azaniumyl]hexyl]azanium;dichloride,C1=CC(=CC(=C1)N=C(N)N=C(N)[NH2+]CCCCCC[NH2+]C(=NC(=NC2=CC=CC(=C2)C(F)(F)F)N)N)C(F)(F)F.[Cl-].[Cl-],,,,,,
4468,39163,2-[6-[[Amino-[[amino-[3-(trifluoromethyl)anilino]methylidene]amino]methylidene]amino]hexyl]-1-[amino-[3-(trifluoromethyl)anilino]methylidene]guanidine,C1=CC(=CC(=C1)NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=CC(=C2)C(F)(F)F)N)N)C(F)(F)F,,,,,,
4469,39164,"4-(1-Benzofuran-7-yldiazenyl)-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)N=NC2=CC=CC3=C2OC=C3,,,,,,
4470,39165,"N,N-Dimethyl-p-(5-benzofurylazo)aniline",CN(C)C1=CC=C(C=C1)N=NC2=CC3=C(C=C2)OC=C3,,,,,,
4471,39166,"Cyanamide, N-(4-benzamido-4-carbamoylbutyl)-N-nitroso-",C1=CC=C(C=C1)C(=O)NC(CCCN(C#N)N=O)C(=O)N,,,,,,
4472,39167,3-Hydroxynonachlorodiphenyl ether,C1(=C(C(=C(C(=C1Cl)Cl)Cl)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)O,,,,,,
4473,39168,Perfluorooctanoic acid diethanolamide,C(CO)N(CCO)C(=O)C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4474,39169,"2,3,4,5,6-Pentachlorodiphenyl ether",C1=CC=C(C=C1)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
4475,39170,"(1S,9S,10S)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol",C1CC[C@]2([C@@H]3CC4=C([C@]2(C1)CCN3CC5CC5)C=C(C=C4)O)O,,,,,,
4476,39171,"Benzo[a]pyrene-4,5-dione",C1=CC=C2C3=C4C(=CC2=C1)C(=O)C(=O)C5=CC=CC(=C54)C=C3,,,,,,
4477,39172,5-Methylcoumarin,CC1=C2C=CC(=O)OC2=CC=C1,,,,,,
4478,39173,3-(4-Chlorophenyl)-3-methylbutanoic acid,CC(C)(CC(=O)O)C1=CC=C(C=C1)Cl,,,,,,
4479,39174,"Hexa-1,3-diene;hexa-1,4-diene;hexa-1,5-diene",CCC=CC=C.CC=CCC=C.C=CCCC=C,,,,,,
4480,39175,"1,3-Hexadiene",CC/C=C/C=C,,,,,,
4481,39176,2-Methyl-2-(1-methylpropyl)oxirane,CCC(C)C1(CO1)C,,,,,,
4482,39177,"2,4-Dimethylhexanoic acid",CCC(C)CC(C)C(=O)O,,,,,,
4483,39178,"Ethane, bromodichlorotrifluoro-",C(C(Cl)(Cl)Br)(F)(F)F,,,,,,
4484,39179,Isodecyl isooctyl phthalate,CC(C)CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC(C)C,,,,,,
4485,39180,Butyl isodecyl phthalate,CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC(C)C,,,,,,
4486,39181,"N,N,N-Trimethyl-2-cyanoethylammonium iodide",C[N+](C)(C)CCC#N.[I-],,,,,,
4487,39182,"2-cyano-N,N,N-trimethylethanaminium",C[N+](C)(C)CCC#N,,,,,,
4488,39183,CID 39183,C1=C(C=C(C(=N)C1=N)N(O)O)Cl,,,,,,
4489,39184,"1,6-Dinitropyrene",C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,"['Under argon atmosphere, rat and dog liver cytosol catalyzed the reduction of 1,6-dinitropyrene to 1-amino-6-nitropyrene and 1,6-diaminopyrene ... 1-acetylamino-6-nitropyrene was also detected as a metabolite ...', 'This study was aimed at monitoring N-acetyltransferase activities of continuous cell lines, which differ in their sensitivity to the toxic effects of nitroaromatic compounds. Transferase activities were measured toward the acetyl acceptors sulfamethazine and p-aminobenzoic acid in partially purified preparation of cytosols. Cell lines such as hamster V79, BHK, rat hepatoma H4IIEC3G- or fibroblast 208F, which are sensitive to 1,6-dinitropyrene (1,6-DNP), possess high transferase activities ranging from 120-270 nmol/min x mg protein. In contrast, human lung cells NCI-H322, mouse and rat hepatoma cells BW1J and H5, respectively, which are resistant to 1,6-DNP contain no or low transferase activity of less than 15 nmol/min x mg. There was no apparent correlation between 1,6-DNP sensitivity and acetyltransferase levels in a few cell lines, e.g. rat hepatoma HTC, 2sFou and 5L, which express intermediate transferase activities ranging from 25-50 nmol/min x mg protein. The results suggest that acetylation is an essential step in activating 1,6-DNP to toxic products in mammalian cells.', 'Dinitropyrenes are mutagenic environmental pollutants. Of these compounds, 1,6-dinitropyrene is a potent tumorigen while 1,3-dinitropyrene appears to be weakly or non-tumorigenic. Two-electron reduction of dinitropyrenes yields nitro-nitrosopyrenes, which have been shown previously to be the major aerobic metabolites of these compounds in vitro. Further reduction of nitrosopyrenes is required for their activation to a DNA-reactive N-hydroxylamines. In this work, 1-nitro-3-nitrosopyrene was synthesized and the electrochemical and enzyme-catalyzed reduction of 1-nitro-3-nitrosopyrene has been compared with that of 1-nitro-6-nitrosopyrene. As determined by cyclic voltammetry, the reduction potentials of 1-nitro-3-nitrosopyrene, 1-nitro-6-nitrosopyrene and their parent dinitropyrenes were similar, although 1-nitro-3-nitrosopyrene did have a slightly more negative cathodic peak potential than the other three compounds. The NADPH-mediated reduction of 1-nitro-6-nitrosopyrene to intermediates which reduce succinoylated cytochrome c was faster than that of 1-nitro-3-nitrosopyrene. In the presence of rat liver microsomes or cytosol, the reduction of 1-nitro-6-nitrosopyrene was faster than that of 1-nitro-3-nitrosopyrene. These differences in the rates of nitro-nitrosopyrene reduction may be one factor contributing to the lower tumorigenic potential of 1,3-dinitropyrene relative to 1,6-dinitropyrene.', '1-Nitro-6-nitrosopyrene, 1-amino-6-nitropyrene and 1,6-diaminopyrene were detected as metabolites in rat mammary gland cytosol incubated with 1,6-dinitropyrene under anaerobic conditions.', 'For more Metabolism/Metabolites (Complete) data for 1,6-Dinitropyrene (8 total), please visit the HSDB record page.']",
4490,39185,"1,8-Dinitropyrene",C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['The disposition of ... 1,8-dinitropyrene (DNP) in female BALB/c mice was investigated. In the first 48 hr after oral administration of 1,8-dinitro[4,5,9,10-14C)pyrene ((14C)DNP), 42% of the dose was eliminated in the feces and 12% in the urine. Feces was the major pathway of excretion with 45% of the dose being eliminated by this route in 9 days. Distribution of DNP in various tissues (blood, liver, spleen, lungs, kidneys, stomach, small and large intestine) was studied over 9 days. There was a linear increase in the concentration of radioactive material in the blood, liver and kidneys up to 6 hr after (14)CDNP administration, representing 0.27, 2.9 and 0.21% of the radioactive dose, respectively. The corresponding figures after 24 hr decreased to 0.1, 1.6 and 0.12%, respectively. In comparison, radioactivity present in the spleen and lungs was low and did not significantly change with time. In studies with ligated sections of the gastrointestinal tract, DNP absorption was from the small and large intestine and there was none from the stomach. The rate of absorption of DNP from the small intestine was greater than that from the large intestine, although overall uptake of the compound was poor (more than 80% of the original dose was recovered from the ligated small intestine after 120 min). The data from these studies suggest that although absorption of orally administered DNP is slow, the compound or its metabolites persist in the body for long periods and the liver should be considered as the major target organ.']","['... It has been reported that nitroreduction, the most important pathway of nitroarene toxification, occurs mainly in the liver and intestine. ... Red cells also possess the metabolic competence to reduce nitroarenes. In particular, 1,8-dinitropyrene, the nitroarene chosen as model compound, was reduced to the corresponding mono- and diamino-derivatives, 1-amino-8-nitropyrene and 1,8-diaminopyrene, by human lysate supplemented with cofactors.', 'Dinitropyrenes are contaminants in diesel emissions that are mutagenic in bacteria and mammalian cells, and tumorigenic in laboratory animals. In this project, ...  the factors that contributed to the extreme genotoxicity of dinitropyrenes in bacteria /were investigated/ and ...  if these factors were important in mammalian cells /was determined/. Xanthine oxidase, a mammalian nitroreductase, catalyzed the conversion of the dinitropyrenes to DNA-bound products, but the level of binding did not exceed that observed with 1-nitropyrene. This suggested that factors in addition to nitroreduction were important in the metabolic activation of dinitropyrenes. 1-Nitro-6-nitrosopyrene and 1-nitro-8-nitrosopyrene were synthesized and reacted with DNA under reducing conditions. The same C8-substituted deoxyguanosine adducts were formed that were found in the xanthine oxidase-catalyzed reactions, which confirmed that incubation with this nitroreductase generated reactive N-hydroxy arylamine intermediates. In incubations with rat and human liver microsomes and cytosol, 1-nitropyrene and 1,3-dinitropyrene were reduced to a lesser extent than 1,6- and 1,8-dinitropyrene, which was in accord with their relative mutagenicities. Each of the cytosolic incubations were similar in that oxygen decreased aminopyrene, but not nitrosopyrene, formation. The data indicated that reduced derivatives of the nitrosopyrenes were redox cycling with oxygen, which decreased cytosolic aminopyrene formation. In cytosolic incubations, oxygen inhibited the reduction of 1-nitropyrene and 1,3-dinitropyrene to a greater extent than 1,6- and 1,8-dinitropyrene. By comparison, in microsomal investigations, the nitroreduction of each nitrated pyrene was equally oxygen-sensitive. This apparently was caused by the initial nitroanion radicals reacting with oxygen to decrease nitrosopyrene formation. Although more extensive nitroreduction of each compound was detected in anaerobic incubations, aerobic reduction of these compounds did occur and may be important during in vivo exposure to nitrated pyrenes. When rat liver cytosol was incubated with the nitrated pyrenes, very low levels of DNA binding were detected. Addition of acetyl coenzyme A (AcCoA) to these incubations increased the binding of the dinitropyrenes 20- to 40-fold, while the binding of 1-nitropyrene was not affected. The extent of AcCoA-dependent binding of the dinitropyrenes reflected the amount of nitroreduction; however, the increase in binding did not occur with dog liver cytosol, which was known to be deficient in N-acetylases. These results indicated that cytosolic nitroreductases catalyzed the formation of N-hydroxy arylamine intermediates, which in the case of dinitropyrenes were converted to reactive N-acetoxy arylamines by cytosolic AcCoA-dependent acetylases.', '... The ability of rabbit lung to metabolize 1,8-dinitro(4,5,9,10-3H)pyrene by both oxygen-dependent and oxygen-independent pathways has been investigated. Using lung 9000 g supernatant, the biotransformation of 1,8-dinitropyrene to stable metabolites was more extensive in the absence of oxygen. A major proportion of the metabolites was ether-extractable. Five metabolite peaks (A-E) were detected by HPLC in the absence of oxygen. Formation of metabolites A, C, D and E was decreased under aerobic conditions. Metabolites B and C co-chromatographed with the reference standards 1,8-diaminopyrene and 1-acetyl-amino-8-nitropyrene, respectively. The formation of metabolites A and C was dependent on the presence of acetyl coenzyme A. Binding of radiolabel to calf thymus DNA occurred under both anaerobic and aerobic conditions, although there was significantly higher binding in the presence of oxygen. Omission of acetyl coenzyme A significantly increased DNA binding. In experiments where calf thymus DNA was omitted from the incubation medium, covalent binding of radiolabel to acid-precipitable lung S9 macromolecules was detected only under aerobic conditions (11.1 +/- 4.3 pmol/mg protein). The results indicate that rabbit lung can metabolize 1,8-dinitropyrene  by both reductive and oxidative pathways. Reductive metabolism is the major pathway for formation of stable metabolites while alkylation of cellular macromolecules occurs primarily via oxidation. There was no correlation between acetyl coenzyme A-dependent acetylation and activation of 1,8-dinitropyrene to reactive species which bind to DNA.', 'The metabolic activation of dinitropyrenes occurs by reduction of one nitro group to yield N-hydroxy-1-amino-x-nitropyrene, where x is 3, 6 or 8, depending on the original compound. These N-hydroxyarylamine intermediates can undergo acid-catalyzed DNA binding or, in contrast to 1-nitropyrene, which is only N-acetylated, can be converted into highly reactive O-acetyl metabolites by bacterial and mammalian transacetylases. This activation pathway has been shown to be responsible for their extreme mutagenicity in Salmonella. In rat liver cytosolic incubations, 1-nitropyrene and 1,3-dinitropyrene were reduced to a much lesser extent than 1,6- or 1,8-dinitropyrene, which suggests that there may be fundamental differences in the reduction pathways between these nitroPAHs. /Dinitropyrenes/', 'For more Metabolism/Metabolites (Complete) data for 1,8-Dinitropyrene (10 total), please visit the HSDB record page.', '1,8-dinitropyrene has known human metabolites that include 1-amino-8-nitropyrene.']",
4491,39186,Diltiazem,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,"[""**Oral**  Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.  Indicated for use to improve exercise tolerance in patients with chronic stable angina.  Indicated for the management of variant angina (Prinzmetal's angina).  **Intravenous**  Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.  Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.  **Off-label**  Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.""]","['Diltiazem is an antihypertensive and vasodilating agent that works by relaxing the vascular muscle and reducing blood pressure. This is related to the long-term therapeutic effects, as lowering the blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Diltiazem inhibits the influx of extracellular calcium ions across the myocardial and vascular smooth muscle cell membranes during depolarization. Diltiazem is classified as a negative inotrope (decreased force) and negative chronotrope (decreased rate). It is also considered a rate-control drug as it reduces heart rate. Diltiazem is exerts hemodynamic actions by reducing blood pressure, systemic vascular resistance, the rate-pressure product, and coronary vascular resistance while increasing coronary blood flow. Diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations. In supraventricular tachycardia, diltiazem prolongs AV nodal refractories.  As the magnitude of blood pressure reduction is related to the degree of hypertension, the antihypertensive effect of diltiazem is most pronounced in individuals with hypertension. In a randomized, double-blind, parallel-group, dose-response study involving patients with essential hypertension, there was a reduction in the diastolic blood pressure by 1.9, 5.4, 6.1, and 8.6 mmHg in the patients receiving diltiazem at doses of 120, 240, 360, and 540 mg, respectively. In patients receiving placebo, there was a reduction in the diastolic blood pressure by 2.6 mmHg.In a randomized, double-blind study involving patients with chronic stable angina, variable doses of diltiazem administered at night all caused an increased exercise tolerance in the after 21 hours, compared to placebo. In the NORDIL study of patients with hypertension, the therapeutic effectiveness of diltiazem in reducing cardiovascular morbidity and mortality was assessed. When using the combined primary endpoint as fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death, fatal and non-fatal stroke was shown to be reduced by 25% in the diltiazem group. Although the clinical significance to this effect remains unclear, it is suggested that diltiazem may exert a protective role against cerebral stroke in hypertensive patients.']","['Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']","['Diltiazem is readily absorbed from the gastrointestinal tract. Minimum therapeutic plasma diltiazem concentrations appear to be in the range of 50 to 200 ng/mL. Following oral administration of extended formulations of 360 mg diltiazem, the drug in plasma was detectable within 3 to 4 hours and the peak plasma concentrations were reached between 11 and 18 hours post-dose. Diltiazem peak and systemic exposures were not affected by concurrent food intake. Due to hepatic first-pass metabolism, the absolute bioavailability following oral administration is about 40%, with the value ranging from 24 to 74% due to high interindividual variation in the first pass effect. The bioavailability may increase in patients with hepatic impairment.', 'Due to its extensive metabolism, only 2% to 4% of the unchanged drug can be detected in the urine. The major urinary metabolite in healthy volunnteers was N-monodesmethyl diltiazem, followed by deacetyl N,O-didesmethyl diltiazem, deacetyl N-monodesmethyl diltiazem, and deacetyl diltiazem; however, there seems to be large inter-individual variability in the urinary excretion of DTZ and its metabolites.', 'The apparent volume of distribution of diltiazem was approximately 305 L following a single intravenous injection in healthy male volunteers.', 'Following a single intravenous injection in healthy male volunteers, the systemic clearance of diltiazem was approximately 65 L/h. After constant rate intravenous infusion, the systemic clearance decreased to 48 L/h.', 'The protein binding of diltiazem is 80-90%, & the volume of distribution is approx 5.3 L/kg. Clearance of diltiazem after oral ingestion follows first-order kinetics, with a half-life of 5-10 hr, independent of the amount ingested. In sustained release preparations, however, the peak absorption time is delayed & the half-life may be very prolonged because of continued GI absorption.', ""Although the absorption of ... agents /like diltiazem/ is nearly complete after oral admin, their bioavailability is reduced, in some cases markedly, because of first-pass hepatic metab. The effects of these drugs are evident within 30-60 min of an oral dose ... . During repeated oral admin, bioavailability and half-life may incr because of saturation of hepatic metabolism. A major metabolite of diltiazem is desacetyldiltiazem, which has about 1/2 of diltiazem's potency as a vasodilator."", 'Diltiazem is excreted into human milk.', 'The pharmacokinetic changes of diltiazem ... and its main metabolite, deacetyldiltiazem (DAD) were studied after oral admin of diltiazem to normal rabbits and mild and medium folate-induced renal failure rabbits. Diltiazem 10 mg/kg was given to the rabbits ... orally (n=6). Plasma concns of diltiazem and DAD were determined by a high performance liquid chromatography assay. The area under the plasma concn-time curves (AUC) and max plasma concn (Cmax) of diltiazem were significantly increased in mild and medium folate-induced renal failure rabbits. The metabolite ratio of the diltiazem to DAD were significantly decreased in mild and medium folate-induced renal failure rabbits. The volume of distribution (Vd) and total body clearance (CLt) of diltiazem were significantly decreased in mild and medium folate-induced renal failure rabbits. The elimination rate constant (beta) of diltiazem was significantly decreased in folate-induced renal failure rabbits, but that of DAD was significantly increased. These findings suggest that the hepatic metab of diltiazem was inhibited ... .', 'The pharmacokinetics of diltiazem in rabbits after subconjunctival and topical admin was studied. Diltiazem successfully penetrated the aq humor of rabbit eyes. The peak aq concns were 3.8 +/- 0.4 ug/ml after topical application and 15.3 +/- 1.1 ug/ml after subconjunctival injection. The peak aq concn was achieved 1/2 hrs after admin in both cases.']","['Diltiazem is subject to extensive first-pass metabolism, which explains its relatively low absolute oral bioavailability. It undergoes N-demethylation primarily mediated by CYP3A4. CYP2D6 is responsible for O-demethylation and esterases mediate deacetylation. There was large inter-individual variability in the circulating plasma levels of metabolites in healthy volunteers.  In healthy volunteers, the major circulating metabolites in the plasma are N-monodesmethyl diltilazem, deacetyl diltiazem, and deacetyl N-monodesmethyl diltiazem, which are all pharmacologically active. Deacetyl diltiazem retains about 25-50% of the pharmacological activity to that of the parent compound. Deacetyl diltiazem can be further transformed into deacetyl diltiazem N-oxide or deacetyl O-desmethyl diltiazem. N-monodesmethyl diltilazem can be further metabolized to N,O-didesmethyl diltiazem. Deacetyl N-monodesmethyl diltiazem can be further metabolized to deacetyl N,O-didesmethyl diltiazem, which can be glucuronidated or sulphated. Diltiazem can be O-demethylated by CYP2D6 to form O-desmethyl diltiazem.', ""A major metabolite of diltiazem is desacetyldiltiazem, which has about 1/2 of diltiazem's potency as a vasodilator."", 'Diltiazem undergoes extensive metabolism in hepatic   and extrahepatic tissues. Deacetyldiltiazem (M1) and N-demethyldiltiazem (MA) are 2 of the   main basic metabolites of diltiazem that retain pharmacological activity. This drug impairs   its own metab after chronic admin in the adult patient.', 'Diltiazem has known human metabolites that include N-Demethyldiltiazem and O-Demethyldiltiazem.']","['The plasma elimination half-life is approximately 3.0 to 4.5 hours following single and multiple oral doses. The half-life may slightly increase with dose and the extent of hepatic impairment. The apparent elimination half-life for diltiazem as extended-release tablets after single or multiple dosing is 6 to 9 hours. The plasma elimination half-life is approximately 3.4 hours following administration of a single intravenous injection. The elimination half-lives of pharmacologically active metabolites are longer than that of diltiazem.', 'Clearance of diltiazem after oral ingestion follows first-order kinetics, with a half-life of  5-10 hr ... .']"
4492,39187,Tandamine,CCN1C2=CC=CC=C2C3=C1C(SCC3)(C)CCN(C)C,,,,,,
4493,39188,"(1S,9S,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol",C1CC[C@]2([C@@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,,,,,,
4494,39189,(3-Propoxyphenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4495,39190,1-(diethylamino)propan-2-yl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OC(C)CN(CC)CC,,,,,,
4496,39191,(3-Butoxyphenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4497,39192,1-(diethylamino)propan-2-yl N-(3-butoxyphenyl)carbamate,CCCCOC1=CC=CC(=C1)NC(=O)OC(C)CN(CC)CC,,,,,,
4498,39193,(4-(Pentyloxy)phenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4499,39194,1-(diethylamino)propan-2-yl N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN(CC)CC,,,,,,
4500,39195,(4-(Hexyloxy)phenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4501,39196,1-(diethylamino)propan-2-yl N-(4-hexoxyphenyl)carbamate,CCCCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN(CC)CC,,,,,,
4502,39197,(3-Propoxyphenyl)carbamic acid 1-methyl-2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCOC1=CC=CC(=C1)NC(=O)OC(C)C[NH+]2CCCC2.[Cl-],,,,,,
4503,39198,1-pyrrolidin-1-ylpropan-2-yl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OC(C)CN2CCCC2,,,,,,
4504,39199,(4-Propoxyphenyl)carbamic acid 1-methyl-2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+]2CCCC2.[Cl-],,,,,,
4505,39200,1-pyrrolidin-1-ylpropan-2-yl N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)OC(C)CN2CCCC2,,,,,,
4506,39201,(4-Butoxyphenyl)carbamic acid 1-methyl-2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+]2CCCC2.[Cl-],,,,,,
4507,39202,1-pyrrolidin-1-ylpropan-2-yl N-(4-butoxyphenyl)carbamate,CCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN2CCCC2,,,,,,
4508,39203,(4-(Pentyloxy)phenyl)carbamic acid 1-methyl-2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+]2CCCC2.[Cl-],,,,,,
4509,39204,1-pyrrolidin-1-ylpropan-2-yl N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN2CCCC2,,,,,,
4510,39205,(4-Propoxyphenyl)carbamic acid 1-methyl-2-(1-piperidinyl)ethyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
4511,39206,1-piperidin-1-ylpropan-2-yl N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)OC(C)CN2CCCCC2,,,,,,
4512,39207,(4-(Pentyloxy)phenyl)carbamic acid 1-methyl-2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
4513,39208,[1-methyl-2-(1-piperidyl)ethyl] N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN2CCCCC2,,,,,,
4514,39209,(4-(Hexyloxy)phenyl)carbamic acid 1-methyl-2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
4515,39210,[1-methyl-2-(1-piperidyl)ethyl] N-(4-hexoxyphenyl)carbamate,CCCCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN2CCCCC2,,,,,,
4516,39211,5-Hydroxy-2-nitrobenzaldehyde,C1=CC(=C(C=C1O)C=O)[N+](=O)[O-],,,,,,
4517,39212,Flunixin meglumine,CC1=C(C=CC=C1NC2=C(C=CC=N2)C(=O)O)C(F)(F)F.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs that are used to reduce body temperature in fever. (See all compounds classified as Antipyretics.)']",,,
4518,39213,"5-(3-Bromoprop-1-enyl)-1,3-benzodioxole",C1OC2=C(O1)C=C(C=C2)C=CCBr,,,,,,
4519,39214,Nimustine,CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
4520,39215,syn-9-Methoxy-9-(3-methoxyphenyl)-3-methyl-3-azabicyclo(3.3.1)nonane,CN1CC2CCCC(C1)C2(C3=CC(=CC=C3)OC)OC,,,,,,
4521,39216,"2-Isoindolineacetamide, 1,3-dioxo-N-methyl-",CNC(=O)CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
4522,39217,N-tert-butyl-3-methylaniline,CC1=CC(=CC=C1)NC(C)(C)C,,,,,,
4523,39218,1-Benzyl-3-ethylbenzene,CCC1=CC(=CC=C1)CC2=CC=CC=C2,,,,,,
4524,39219,(4-Propoxyphenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4525,39220,1-(diethylamino)propan-2-yl N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)OC(C)CN(CC)CC,,,,,,
4526,39221,(4-Butoxyphenyl)carbamic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CCCCOC1=CC=C(C=C1)NC(=O)OC(C)C[NH+](CC)CC.[Cl-],,,,,,
4527,39222,1-(diethylamino)propan-2-yl N-(4-butoxyphenyl)carbamate,CCCCOC1=CC=C(C=C1)NC(=O)OC(C)CN(CC)CC,,,,,,
4528,39223,Isazofos,CCOP(=S)(OCC)OC1=NN(C(=N1)Cl)C(C)C,,,,,"['Metabolism occurs principally by oxidation, hydrolysis by esterases, and by transfer of portions of the molecule to glutathione.  Oxidation of organophosphorus insecticides may result in more or less toxic products.  The glutathione transferase reactions produce products, that are, in most cases, of low toxicity. Hydrolytic and transferase reactions affect both thioates and their oxons. /Organophosphorus Pesticides/']",
4529,39224,"Butylamine, N,N-bis(2-chloroethyl)-",CCCCN(CCCl)CCCl,,,,,,
4530,39225,CID 39225,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@H](C4=CC=CC=C4)OC=O)SC2)C(=O)[O-].[Na+],,,,,,
4531,39226,"(6R,7R)-7-[[(2S)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@H](C4=CC=CC=C4)OC=O)SC2)C(=O)O,,,,,,
4532,39227,"6-Nitro-1,2-benzisoxazole-3-carboxylic acid (1-)",C1=CC2=C(C=C1[N+](=O)[O-])ON=C2C(=O)[O-],,,,,,
4533,39228,"6-Nitro-1,2-benzoxazole-3-carboxylic acid",C1=CC2=C(C=C1[N+](=O)[O-])ON=C2C(=O)O,,,,,,
4534,39229,CID 39229,CCCC(=C(C)O)N=O,,,,,,
4535,39230,Bifenox,COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],,,,"['Bifenox is relatively rapidly absorbed and eliminated from the body; 5-(2,4-dichlorophenyl)-2-nitrobenzoic acid was the major urinary metabolite, with no bifenox detected. Bifenox together with 5-(2,4-dichlorophenyl)anthranilate were detected in feces.', '...Bifenox technical grade (98% purity) was administered orally after suspending in 1% carboxymethyl cellulose at 2 g/kg to 6 young adult goats of both sexes for oral kinetics. Blood samples were collected at different time intervals from each goat and concn of bifenox in blood were estimated by GLC. Bifenox in blood was detected at 2 hr (1.32 + or - 0.07 ug/ml) which attained max at 12 hr (6.76 + or - 0.17 ug/ml) followed by gradual decr in concn and reaching at min blood concn at 24 hr. The kinetic behavior of bifenox followed ""two compartment open model"". The .../volume of distribution/ area and /blood clearance/ values were ...2.73 + or - 0.28 l/kg and 0.88 + or - 0.07 l/kg/hr respectively, indicating wide distribution and shorter persistence in the body.']",,['...Bifenox technical grade (98% purity) was administered orally after suspending in 1% carboxymethyl cellulose at 2 g/kg to 6 young adult goats of both sexes for oral kinetics. ...The t1/2... /was/ 2.04 + or - 0.04 hr... .']
4536,39231,"4-Amino-3-methyl-1,2-diphenylbutan-2-YL propanoate",CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN,,,,,,
4537,39232,"5-(Chloromethyl)-2,2-dimethyl-1,3-oxathiolane",CC1(OC(CS1)CCl)C,,,,,,
4538,39233,"2-Acetyl-4-((3-dimethylamino)propyl)-3,4-dihydro-3-phenyl-2H-1,4-benzothiazine",CC(=O)C1C(N(C2=CC=CC=C2S1)CCC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
4539,39234,"1-{4-[3-(Dimethylamino)propyl]-3-phenyl-3,4-dihydro-2h-1,4-benzothiazin-2-yl}ethanone",CC(=O)C1C(N(C2=CC=CC=C2S1)CCCN(C)C)C3=CC=CC=C3,,,,,,
4540,39235,3'-((2-Hydroxy-3-(4-phenylpiperazinyl))propoxy)acetophenone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
4541,39236,"MALEIMIDE, 2-CHLORO-N-(m-CHLOROPHENYL)-",C1=CC(=CC(=C1)Cl)N2C(=O)C=C(C2=O)Cl,,,,,,
4542,39237,2-Phenylthiazolidine-4-carboxylic acid,C1C(NC(S1)C2=CC=CC=C2)C(=O)O,,,,,,
4543,39238,Daimuron,CC1=CC=C(C=C1)NC(=O)NC(C)(C)C2=CC=CC=C2,,,,,,
4544,39239,3-Nitroadamantane-1-carboxylic acid,C1C2CC3(CC1CC(C2)(C3)[N+](=O)[O-])C(=O)O,,,,,,
4545,39240,3-Iodoadamantane-1-carboxylic acid,C1C2CC3(CC1CC(C2)(C3)I)C(=O)O,,,,,,
4546,39241,CID 39241,C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)OC(=O)CN,,,,,,
4547,39242,CID 39242,C[C@@H](C(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C)N,,,,,,
4548,39243,Digitoxigenin 3-acetylaminoacetate,CC(=O)NCC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C,,,,,,
4549,39244,4-Hydroxybutyl methanesulfonate,CS(=O)(=O)OCCCCO,,,,,,
4550,39245,"Benzyl alcohol, 4-(2-chloroethoxy)-alpha-(4-(2-chloroethoxy)phenyl)-alpha-(2-(dimethylamino)-1-methylethyl)-, hydrochloride",CC(C[NH+](C)C)C(C1=CC=C(C=C1)OCCCl)(C2=CC=C(C=C2)OCCCl)O.[Cl-],,,,,,
4551,39246,"1,1-Bis[4-(2-chloroethoxy)phenyl]-3-(dimethylamino)-2-methylpropan-1-ol",CC(CN(C)C)C(C1=CC=C(C=C1)OCCCl)(C2=CC=C(C=C2)OCCCl)O,,,,,,
4552,39247,"Benzyl alcohol, 4-(2-(dimethylamino)ethoxy)-alpha-(4-(2-(dimethylamino)ethoxy)phenyl)-alpha-(2-(dimethylamino)-1-methylethyl)-, trihydrochloride",CC(C[NH+](C)C)C(C1=CC=C(C=C1)OCC[NH+](C)C)(C2=CC=C(C=C2)OCC[NH+](C)C)O.[Cl-].[Cl-].[Cl-],,,,,,
4553,39248,"3-(Dimethylamino)-1,1-bis[4-[2-(dimethylamino)ethoxy]phenyl]-2-methylpropan-1-ol",CC(CN(C)C)C(C1=CC=C(C=C1)OCCN(C)C)(C2=CC=C(C=C2)OCCN(C)C)O,,,,,,
4554,39249,"Benzyl alcohol, 2,4-dichloro-alpha-(4-(2-(diethylamino)ethoxy)phenyl)-, hydrochloride",CC[NH+](CC)CCOC1=CC=C(C=C1)C(C2=C(C=C(C=C2)Cl)Cl)O.[Cl-],,,,,,
4555,39250,"(2,4-Dichlorophenyl)-[4-[2-(diethylamino)ethoxy]phenyl]methanol",CCN(CC)CCOC1=CC=C(C=C1)C(C2=C(C=C(C=C2)Cl)Cl)O,,,,,,
4556,39251,"Benzyl alcohol, 2,4-dichloro-alpha-(4-(2-(diethylamino)ethoxy)phenyl)-, phenylcarbamate (ester), monohydrochloride",CC[NH+](CC)CCOC1=CC=C(C=C1)C(C2=C(C=C(C=C2)Cl)Cl)OC(=O)NC3=CC=CC=C3.[Cl-],,,,,,
4557,39252,"[(2,4-dichlorophenyl)-[4-[2-(diethylamino)ethoxy]phenyl]methyl] N-phenylcarbamate",CCN(CC)CCOC1=CC=C(C=C1)C(C2=C(C=C(C=C2)Cl)Cl)OC(=O)NC3=CC=CC=C3,,,,,,
4558,39253,"2,2',3,3',4,4',5,6'-Octachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C2=C(C(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
4559,39254,2-Hydroxy-5-((4-(((3-methyl-2-pyridinyl)amino)sulfonyl)phenyl)azo)benzoic acid,CC1=C(N=CC=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,,,,,,
4560,39255,"1,3-Dihydro-3-methoxy-1-(2-(methylamino)ethyl)-3-phenyl-2H-indol-2-one hydrochloride",C[NH2+]CCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC.[Cl-],,,,,,
4561,39256,3-Methoxy-1-[2-(methylamino)ethyl]-3-phenylindol-2-one,CNCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC,,,,,,
4562,39257,"1,3-Dihydro-1-(2-(ethylamino)ethyl)-3-methoxy-3-phenyl-2H-indol-2-one hydrochloride",CC[NH2+]CCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC.[Cl-],,,,,,
4563,39258,1-[2-(Ethylamino)ethyl]-3-methoxy-3-phenylindol-2-one,CCNCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC,,,,,,
4564,39259,"1,3-Dihydro-3-methoxy-1-(3-(methylamino)propyl)-3-phenyl-2H-indol-2-one hydrochloride hydrate",C[NH2+]CCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC.[Cl-],,,,,,
4565,39260,3-Methoxy-1-[3-(methylamino)propyl]-3-phenylindol-2-one,CNCCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC,,,,,,
4566,39261,"1,3-Dihydro-1-(3-(ethylamino)propyl)-3-methoxy-3-phenyl-2H-indol-2-one hydrochloride hydrate",CC[NH2+]CCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC.[Cl-],,,,,,
4567,39262,1-[3-(Ethylamino)propyl]-3-methoxy-3-phenylindol-2-one,CCNCCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OC,,,,,,
4568,39263,"1,3-Dihydro-3-ethoxy-1-(2-(methylamino)ethyl)-3-phenyl-2H-indol-2-one hydrochloride",CCOC1(C2=CC=CC=C2N(C1=O)CC[NH2+]C)C3=CC=CC=C3.[Cl-],,,,,,
4569,39264,3-Ethoxy-1-[2-(methylamino)ethyl]-3-phenylindol-2-one,CCOC1(C2=CC=CC=C2N(C1=O)CCNC)C3=CC=CC=C3,,,,,,
4570,39265,"1,3-Dihydro-3-ethoxy-1-(2-(ethylamino)ethyl)-3-ethoxy-3-phenyl-2H-indol-2-one HCl hydrate",CC[NH2+]CCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
4571,39266,3-Ethoxy-1-[2-(ethylamino)ethyl]-3-phenylindol-2-one,CCNCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC,,,,,,
4572,39267,"1,3-Dihydro-3-ethoxy-1-(3-(ethylamino)propyl)-3-phenyl-2H-indol-2-one hydrochloride",CC[NH2+]CCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
4573,39268,3-Ethoxy-1-[3-(ethylamino)propyl]-3-phenylindol-2-one,CCNCCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC,,,,,,
4574,39269,CID 39269,COC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCCCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
4575,39270,3-Methoxy-3-phenyl-1-(3-piperidin-1-ylpropyl)indol-2-one,COC1(C2=CC=CC=C2N(C1=O)CCCN3CCCCC3)C4=CC=CC=C4,,,,,,
4576,39271,CID 39271,COC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCOCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
4577,39272,3-Methoxy-1-(3-morpholin-4-ylpropyl)-3-phenylindol-2-one,COC1(C2=CC=CC=C2N(C1=O)CCCN3CCOCC3)C4=CC=CC=C4,,,,,,
4578,39273,"1,3-Dihydro-1-(2-(dimethylamino)ethyl)-3-ethoxy-3-phenyl-2H-indol-2-one HCl hydrate",CCOC1(C2=CC=CC=C2N(C1=O)CC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
4579,39274,1-[2-(Dimethylamino)ethyl]-3-ethoxy-3-phenylindol-2-one,CCOC1(C2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=CC=C3,,,,,,
4580,39275,CID 39275,CC[NH+](CC)CCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC.C(=CC(=O)[O-])C(=O)O,,,,,,
4581,39276,1-[2-(Diethylamino)ethyl]-3-ethoxy-3-phenylindol-2-one,CCN(CC)CCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC,,,,,,
4582,39277,CID 39277,CCOC1(C2=CC=CC=C2N(C1=O)CC[NH+]3CCCCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
4583,39278,3-Ethoxy-3-phenyl-1-(2-piperidin-1-ylethyl)indol-2-one,CCOC1(C2=CC=CC=C2N(C1=O)CCN3CCCCC3)C4=CC=CC=C4,,,,,,
4584,39279,CID 39279,CCOC1(C2=CC=CC=C2N(C1=O)CCC[NH+](C)C)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
4585,39280,1-[3-(Dimethylamino)propyl]-3-ethoxy-3-phenylindol-2-one,CCOC1(C2=CC=CC=C2N(C1=O)CCCN(C)C)C3=CC=CC=C3,,,,,,
4586,39281,CID 39281,CC[NH+](CC)CCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC.C(=CC(=O)[O-])C(=O)O,,,,,,
4587,39282,1-[3-(Diethylamino)propyl]-3-ethoxy-3-phenylindol-2-one,CCN(CC)CCCN1C2=CC=CC=C2C(C1=O)(C3=CC=CC=C3)OCC,,,,,,
4588,39283,CID 39283,CCOC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCCCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
4589,39284,3-Ethoxy-3-phenyl-1-(3-piperidin-1-ylpropyl)indol-2-one,CCOC1(C2=CC=CC=C2N(C1=O)CCCN3CCCCC3)C4=CC=CC=C4,,,,,,
4590,39285,"1,3-Dihydro-1-(2-(dimethylamino)ethyl)-3-phenyl-2H-indol-2-one hydrochloride",C[NH+](C)CCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3.[Cl-],,,,,,
4591,39286,1-[2-(dimethylamino)ethyl]-3-phenyl-3H-indol-2-one,CN(C)CCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3,,,,,,
4592,39287,"1,3-Dihydro-1-(2-(diethylamino)ethyl)-3-phenyl-2H-indol-2-one oxalate",CC[NH+](CC)CCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3.C(=O)(C(=O)[O-])O,,,,,,
4593,39288,1-[2-(diethylamino)ethyl]-3-phenyl-3H-indol-2-one,CCN(CC)CCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3,,,,,,
4594,39289,"1,3-Dihydro-3-phenyl-1-(2-piperidinoethyl)-2H-indol-2-one hydrochloride",C1CC[NH+](CC1)CCN2C3=CC=CC=C3C(C2=O)C4=CC=CC=C4.[Cl-],,,,,,
4595,39290,3-phenyl-1-(2-piperidin-1-ylethyl)-3H-indol-2-one,C1CCN(CC1)CCN2C3=CC=CC=C3C(C2=O)C4=CC=CC=C4,,,,,,
4596,39291,CID 39291,C[NH+](C)CCCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
4597,39292,1-[3-(dimethylamino)propyl]-3-phenyl-3H-indol-2-one,CN(C)CCCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3,,,,,,
4598,39293,CID 39293,CC[NH+](CC)CCCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3.C(=CC(=O)[O-])C(=O)O,,,,,,
4599,39294,1-[3-(diethylamino)propyl]-3-phenyl-3H-indol-2-one,CCN(CC)CCCN1C2=CC=CC=C2C(C1=O)C3=CC=CC=C3,,,,,,
4600,39295,"1,3-Dihydro-3-phenyl-1-(3-piperidinopropyl)-2H-indol-2-one hydrochloride",C1CC[NH+](CC1)CCCN2C3=CC=CC=C3C(C2=O)C4=CC=CC=C4.[Cl-],,,,,,
4601,39296,3-phenyl-1-(3-piperidin-1-ylpropyl)-3H-indol-2-one,C1CCN(CC1)CCCN2C3=CC=CC=C3C(C2=O)C4=CC=CC=C4,,,,,,
4602,39297,"1,3-Dihydro-1-(3-morpholinopropyl)-3-phenyl-2H-indol-2-one hydrochloride",C1COCC[NH+]1CCCN2C3=CC=CC=C3C(C2=O)C4=CC=CC=C4.[Cl-],,,,,,
4603,39298,1-(3-morpholin-4-ylpropyl)-3-phenyl-3H-indol-2-one,C1COCCN1CCCN2C3=CC=CC=C3C(C2=O)C4=CC=CC=C4,,,,,,
4604,39299,Clopirac,CC1=CC(=C(N1C2=CC=C(C=C2)Cl)C)CC(=O)O,,,,,,
4605,39300,"Benzofuran, 6-decanoyl-4,7-dimethoxy-2,3-dimethyl-",CCCCCCCCCC(=O)C1=CC(=C2C(=C(OC2=C1OC)C)C)OC,,,,,,
4606,39301,Benacyl,COC(=O)NC1=NC2=CC=CC=C2N1C(=O)COC3=CC=CC=C3,,,,,,
4607,39302,o-(4-Biphenylylcarbonyl)benzoic acid,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C3=CC=CC=C3C(=O)O,,,,,,
4608,39303,CID 39303,CCC(=C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OCC[NH+](C)C)C3=CC=C(C=C3)OC.[Cl-],,,,,,
4609,39304,CID 39304,CCC(=C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)OC,,,,,,
4610,39305,"Acridine, 3,6,9-triamino-",C1=CC2=C(C=C1N)N=C3C=C(C=CC3=C2N)N,,,,,,
4611,39306,"Fluoren-9-one, 1-bromo-4-(dimethylamino)methyl-3-methoxy-",CN(C)CC1=C2C3=CC=CC=C3C(=O)C2=C(C=C1OC)Br,,,,,,
4612,39307,"Fluoren-9-one, 1-bromo-4-(diethylamino)methyl-3-methoxy-",CCN(CC)CC1=C2C3=CC=CC=C3C(=O)C2=C(C=C1OC)Br,,,,,,
4613,39308,"Fluoren-9-one, 2-(dimethylamino)methyl-3-methoxy-",CN(C)CC1=CC2=C(C=C1OC)C3=CC=CC=C3C2=O,,,,,,
4614,39309,"Fluoren-9-one, 2-(diethylamino)methyl-3-methoxy-",CCN(CC)CC1=CC2=C(C=C1OC)C3=CC=CC=C3C2=O,,,,,,
4615,39310,"Fluoren-9-one, 3-methoxy-2-piperidinomethyl-",COC1=CC2=C(C=C1CN3CCCCC3)C(=O)C4=CC=CC=C42,,,,,,
4616,39311,"Fluoren-9-one, 3-methoxy-2-morpholinomethyl-",COC1=CC2=C(C=C1CN3CCOCC3)C(=O)C4=CC=CC=C42,,,,,,
4617,39312,2-(Dimethylamino)methyl-3-hydroxyfluoren-9-one hydrochloride,C[NH+](C)CC1=CC2=C(C=C1O)C3=CC=CC=C3C2=O.[Cl-],,,,,,
4618,39313,2-[(Dimethylamino)methyl]-3-hydroxyfluoren-9-one,CN(C)CC1=CC2=C(C=C1O)C3=CC=CC=C3C2=O,,,,,,
4619,39314,2-(Diethylamino)methyl-3-hydroxyfluoren-9-one hydrochloride,CC[NH+](CC)CC1=CC2=C(C=C1O)C3=CC=CC=C3C2=O.[Cl-],,,,,,
4620,39315,2-(Diethylaminomethyl)-3-hydroxyfluoren-9-one,CCN(CC)CC1=CC2=C(C=C1O)C3=CC=CC=C3C2=O,,,,,,
4621,39316,"Fluoren-9-one, 3-hydroxy-2-piperidinomethyl-",C1CCN(CC1)CC2=CC3=C(C=C2O)C4=CC=CC=C4C3=O,,,,,,
4622,39317,"Fluoren-9-one, 3-hydroxy-2-morpholinomethyl-",C1COCCN1CC2=CC3=C(C=C2O)C4=CC=CC=C4C3=O,,,,,,
4623,39318,4-(Dimethylamino)methyl-3-methoxydibenzofuran,CN(C)CC1=C(C=CC2=C1OC3=CC=CC=C23)OC,,,,,,
4624,39319,4-(Diethylamino)methyl-3-methoxydibenzofuran,CCN(CC)CC1=C(C=CC2=C1OC3=CC=CC=C23)OC,,,,,,
4625,39320,3-Methoxy-4-piperidinomethyldibenzofuran,COC1=C(C2=C(C=C1)C3=CC=CC=C3O2)CN4CCCCC4,,,,,,
4626,39321,3-Methoxy-4-morpholinomethyldibenzofuran,COC1=C(C2=C(C=C1)C3=CC=CC=C3O2)CN4CCOCC4,,,,,,
4627,39322,3-Methoxy-4-pyrrolidinylmethyldibenzofuran,COC1=C(C2=C(C=C1)C3=CC=CC=C3O2)CN4CCCC4,,,,,,
4628,39323,"N-(2,2,2-trichloro-1-hydroxyethyl)benzamide",C1=CC=C(C=C1)C(=O)NC(C(Cl)(Cl)Cl)O,,,,,,
4629,39324,Bevantolol hydrochloride,CC1=CC(=CC=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O.Cl,,,['Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)'],,,
4630,39325,2-(3-Benzoylphenyl)propionitrile,CC(C#N)C1=CC(=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
4631,39326,Nitrofluorfen,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)C(F)(F)F)Cl,,,,,,
4632,39327,Oxyfluorfen,CCOC1=C(C=CC(=C1)OC2=C(C=C(C=C2)C(F)(F)F)Cl)[N+](=O)[O-],,,,,,
4633,39328,Pranolium chloride,CC(C)[N+](C)(C)CC(COC1=CC=CC2=CC=CC=C21)O.[Cl-],,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
4634,39329,"Ethanone, 2-(4-methyl-1-piperazinyl)-1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-, hydrochloride, hydrate (2:4:1)",CN1CCN(CC1)CC(=O)C2=CC3=C(CCCCC3)C=C2.Cl.Cl,,,,,,
4635,39330,"2-(4-methylpiperazin-1-yl)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanone",CN1CCN(CC1)CC(=O)C2=CC3=C(CCCCC3)C=C2,,,,,,
4636,39331,"Ethanone, 2-(methyl(phenylmethyl)amino)-1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-, hydrochloride",C[NH+](CC1=CC=CC=C1)CC(=O)C2=CC3=C(CCCCC3)C=C2.[Cl-],,,,,,
4637,39332,"2-[benzyl(methyl)amino]-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanone",CN(CC1=CC=CC=C1)CC(=O)C2=CC3=C(CCCCC3)C=C2,,,,,,
4638,39333,"Ethanone, 2-((1-methylethyl)(phenylmethyl)amino)-1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-, hydrochloride",CC(C)[NH+](CC1=CC=CC=C1)CC(=O)C2=CC3=C(CCCCC3)C=C2.[Cl-],,,,,,
4639,39334,"2-[benzyl(propan-2-yl)amino]-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanone",CC(C)N(CC1=CC=CC=C1)CC(=O)C2=CC3=C(CCCCC3)C=C2,,,,,,
4640,39335,"Ethanone, 2-((3-(4-morpholinyl)propyl)(phenylmethyl)amino)-1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-, hydrochloride, hydrate (1:2:1)",C1CCC2=C(CC1)C=C(C=C2)C(=O)C[NH+](CCC[NH+]3CCOCC3)CC4=CC=CC=C4.[Cl-].[Cl-],,,,,,
4641,39336,"2-[benzyl(3-morpholin-4-ylpropyl)amino]-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanone",C1CCC2=C(CC1)C=C(C=C2)C(=O)CN(CCCN3CCOCC3)CC4=CC=CC=C4,,,,,,
4642,39337,N-(Phenylmethyl)-2-furanmethanamine hydrochloride,C1=CC=C(C=C1)C[NH2+]CC2=CC=CO2.[Cl-],,,,,,
4643,39338,Benzyl-furan-2-ylmethyl-amine,C1=CC=C(C=C1)CNCC2=CC=CO2,,,,,,
4644,39339,CID 39339,CCC[NH+](CCC)CC(C1=CC2=C(CCCCC2)C=C1)O.C(=CC(=O)[O-])C(=O)O,,,,,,
4645,39340,"2-(dipropylamino)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanol",CCCN(CCC)CC(C1=CC2=C(CCCCC2)C=C1)O,,,,,,
4646,39341,"5H-Benzocycloheptene-2-methanol, 6,7,8,9-tetrahydro-alpha-((methylamino)methyl)-, hydrochloride",C[NH2+]CC(C1=CC2=C(CCCCC2)C=C1)O.[Cl-],,,,,,
4647,39342,"2-(methylamino)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanol",CNCC(C1=CC2=C(CCCCC2)C=C1)O,,,,,,
4648,39343,"1-(6,7,8,9-Tetrahydro-5H-benzocyclohepten-2-yl)-2-isopropylaminoethanol hydrochloride",CC(C)[NH2+]CC(C1=CC2=C(CCCCC2)C=C1)O.[Cl-],,,,,,
4649,39344,"2-(propan-2-ylamino)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanol",CC(C)NCC(C1=CC2=C(CCCCC2)C=C1)O,,,,,,
4650,39345,"5H-Benzocycloheptene-2-methanol, 6,7,8,9-tetrahydro-alpha-((cyclohexylamino)methyl)-, hydrochloride",C1CCC(CC1)[NH2+]CC(C2=CC3=C(CCCCC3)C=C2)O.[Cl-],,,,,,
4651,39346,"2-(cyclohexylamino)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanol",C1CCC(CC1)NCC(C2=CC3=C(CCCCC3)C=C2)O,,,,,,
4652,39347,"5H-Benzocycloheptene-2-methanol, 6,7,8,9-tetrahydro-alpha-(((phenylmethyl)amino)methyl)-, dihydrochloride",C1CCC2=C(CC1)C=C(C=C2)C(C[NH2+]CC3=CC=CC=C3)O.[Cl-],,,,,,
4653,39348,"2-(benzylamino)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanol",C1CCC2=C(CC1)C=C(C=C2)C(CNCC3=CC=CC=C3)O,,,,,,
4654,39349,"5H-Benzocycloheptene-2-methanol, 6,7,8,9-tetrahydro-alpha-(((3-(4-morpholinyl)propyl)amino)methyl)-, dihydrochloride",C1CCC2=C(CC1)C=C(C=C2)C(C[NH2+]CCC[NH+]3CCOCC3)O.O.[Cl-].[Cl-],,,,,,
4655,39350,"2-(3-morpholin-4-ylpropylamino)-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanol",C1CCC2=C(CC1)C=C(C=C2)C(CNCCCN3CCOCC3)O,,,,,,
4656,39351,"1-(6,7,8,9-Tetrahydro-5H-benzocyclohepten-2-yl)ethylamine hydrochloride",CC(C1=CC2=C(CCCCC2)C=C1)[NH3+].[Cl-],,,,,,
4657,39352,"1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethanamine",CC(C1=CC2=C(CCCCC2)C=C1)N,,,,,,
4658,39353,"6,7-Dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1C[NH2+]CC2=C1C=CC(=C2O)O.[Cl-],,,,,,
4659,39354,"1,2,3,4-Tetrahydroisoquinoline-7,8-diol",C1CNCC2=C1C=CC(=C2O)O,,,,,,
4660,39355,"Phenol, 4-[(dimethylamino)methyl]-2,6-dimethyl-",CC1=CC(=CC(=C1O)C)CN(C)C,,,,,,
4661,39356,"6-Methoxy-1,2,3,4-tetrahydroisoquinoline",COC1=CC2=C(CNCC2)C=C1,,,,,,
4662,39357,"UREA, n-HEPTYL-",CCCCCCCNC(=O)N,,,,,,
4663,39358,Silicon triethanolamine,C[Si]1(OCCN(CCO1)CCO)C,,,,,,
4664,39359,"N-Ethyl-1-amino-1,3-dimethylbutane",CCNC(C)CC(C)C,,,,,,
4665,39360,"ACETAMIDE, 2-(p-CYCLOHEXYLPHENOXY)-N-(2-(DIETHYLAMINO)ETHYL)-",CCN(CC)CCNC(=O)COC1=CC=C(C=C1)C2CCCCC2,,,,,,
4666,39361,CID 39361,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)[O-].[Na+],,,,,,
4667,39362,"BENZO(a)PYRENE, 6-BENZOYLOXYMETHYL-",C1=CC=C(C=C1)C(=O)OCC2=C3C=CC4=CC=CC5=C4C3=C(C=C5)C6=CC=CC=C62,,,,,,
4668,39363,6-Acetoxymethylbenzo(a)pyrene,CC(=O)OCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C5=CC=CC=C51,,,,,,
4669,39364,"2,6-DI(Tert-butyl)tetralin",CC(C)(C)C1CCC2=C(C1)C=CC(=C2)C(C)(C)C,,,,,,
4670,39365,9-Hydroxy-6'-methoxy-1-methylcinchonan-1-ium iodide,C[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)[C@H](C2)C=C.[I-],,,,,,
4671,39366,"(S)-[(2R,5R)-5-ethenyl-1-methyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol",C[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)[C@H](C2)C=C,,,,,,
4672,39367,"potassium;5,7-dinitro-3-oxido-4H-2,1,3-benzoxadiazol-3-ium-1-id-4-ol",C1=C(C(C2=[N+](O[N-]C2=C1[N+](=O)[O-])[O-])O)[N+](=O)[O-].[K+],,,,,,
4673,39368,"1-Oxylato-4-aci-nitro-6-nitro-7-hydroxy-4,7-dihydrobenzofurazane-1-ium",C\1=C(C(C2=C(/C1=[N+](/[O-])\[O-])NO[N+]2=O)O)[N+](=O)[O-],,,,,,
4674,39369,CID 39369,CN1CCN(CC1)C2CC3=C(N=CC=C3)SC4=CC=CC=C24.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
4675,39370,"6-(4-Methylpiperazin-1-yl)-5,6-dihydro-[1]benzothiepino[2,3-b]pyridine",CN1CCN(CC1)C2CC3=C(N=CC=C3)SC4=CC=CC=C24,,,,,,
4676,39371,Levomethadyl acetate hydrochloride,CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
4677,39372,CID 39372,CN1CCN(CC1)C2=CC3=C(N=CC=C3)SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
4678,39373,"6-(4-Methylpiperazin-1-yl)-[1]benzothiepino[2,3-b]pyridine",CN1CCN(CC1)C2=CC3=C(N=CC=C3)SC4=CC=CC=C42,,,,,,
4679,39374,"DIBENZO(b,e)THIEPIN-2-PROPANOIC ACID, 6,11-DIHYDRO-",C1C2=CC=CC=C2CSC3=C1C=C(C=C3)CCC(=O)O,,,,,,
4680,39375,IA 4 methanesulfonate,CC[NH+](CC)CCN1C2=C3C(=C(C=C2)CO)SC4=C(C3=N1)C=CC(=C4)Cl.CS(=O)(=O)[O-],,,,,,
4681,39376,CID 39376,CC(C)(C)C1=CC2=CC(=C(C=C2C=C1)C(C)(C)C)S(=O)(=O)[O-].[Na+],,,,,,
4682,39377,"3,7-Ditert-butylnaphthalene-2-sulfonic acid",CC(C)(C)C1=CC2=CC(=C(C=C2C=C1)C(C)(C)C)S(=O)(=O)O,,,,,,
4683,39378,2-Acetyl-7-methoxybenzofuran,CC(=O)C1=CC2=C(O1)C(=CC=C2)OC,,,,,,
4684,39379,1-(3-(p-tert-Butylbenzoyl)propyl)-4-(hydroxybenzhydryl)piperidinium chloride,CC(C)(C)C1=CC=C(C=C1)C(=O)CCC[NH+]2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Cl-],,,,,,
4685,39380,4'-tert-Butyl-4-(4-(hydroxybenzhydryl)piperidino)butyrophenone,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
4686,39381,"3-Methoxyestra-1(10),2,4-trien-17-yl hydrogen phenylcarbonimidate",CC12CCC3C(C1CC[C@@H]2OC(=O)NC4=CC=CC=C4)CCC5=C3C=CC(=C5)OC,,,,,,
4687,39382,"Benzothiazole, 5-amino-2-phenyl-",C1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)N,,,,,,
4688,39383,"1-Oxa-4-thiaspiro(4.5)decane, 10-methyl-",CC1CCCC12CSCCO2,,,,,,
4689,39384,"1-Oxa-4-thiaspiro(4.5)decane, 8-methyl-",CC1CCC2(C1)CSCCO2,,,,,,
4690,39385,Triadimefon,CC(C)(C)C(=O)C(N1C=NC=N1)OC2=CC=C(C=C2)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['Non-radiolabeled triadimefon (97.6% purity, [phenyl-UL-14C] triadimefon (15.78 Ci/mmole, 99.3% radiopurity); single (5 or 50 mg/kg, 5 rats/sex/dose) and multiple oral dosing (5 mg/kg, pretreat 10 rats/sex daily with non-labeled triadimefon for 14 days prior to pulsing with a single dose of 14C-triadimefon; triadimefon is rapidly absorbed, metabolized and excreted; <1% of the radioactivity was expired as CO or other volatile organic products; excretion of triadimefon residues in urine and feces was sex dependent; in males, 24-28% of the administered dose was eliminated in urine, and 63-66% in feces, within 96 hrs; in females, 57-67% of the administered radioactivity was excreted in urine, and 32-41% was excreted in the feces, within 96 hrs; total excretion of the administered radioactivity was faster by females: nearly 95% of the dose was excreted by females within 72 hours, whereas males required 96 hrs to reach 90% excretion; no evidence of bioaccumulation after multiple dosing; radioactive residues were highest in the liver and kidneys...', 'Absorbed by the roots & leaves, with ready translocation in young growing tissues, but less ready translocation in older, woody tissues.', 'In mammals, following oral admin, 83-96% is excreted unchanged in the urine & feces within 2 to 3 days.', 'The percutaneous absorption of (14)C phenoxy ring labeled triadimefon was studied in adult & young male & female Sprague Dawley rats. Triadimefon was applied (41.1 to 46.4 ug/sq cm) in 0.2 mL of acetone to areas comprising 3% of the body surface (7.0 to 14.5 sq cm). Thirty six animals were treated at the initiation of each study.Groups of 3 animals were subsequently killed at 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hr after treatment. Skin from the treated area as well as blood, heart, liver, kidneys, remaining carcass, urine, and feces were analyzed for (14)C by scintillation counting techniques. Based on 14 counts, triadimefon was lost more rapidly from the skin of young animals (half-life, 20 to 25 hr) than from the skin of adult animals (half-life, 29 to 53 hr). Recovery studies indicated that adult males, adult females, young males, and young females, respectively, absorbed 53, 82, 57, and 52% of the dose. The rest of the dose based on material balance was presumably lost by evaporation. Approx 2.5 to 3.9% of the dose penetrated the skin in 1 hr and was available for absorption. The rate of entry triadimefon into blood was 2 to 2.5 times faster for young than that observed in adult animals. Elimination of it from blood was faster in the case of the young animals. Triadimefon was absorbed through the skins of the adult male, adult female, young male, and young female rat, respectively, at rates of 0.20, 0.50, 0.58, and 0.48 ug/hr/sq cm of skin.', 'For more Absorption, Distribution and Excretion (Complete) data for TRIADIMEFON (8 total), please visit the HSDB record page.']","['Metabolism of two triazole-containing antifungal azoles was studied using expressed human and rat cytochrome P450s (CYP) and liver microsomes. Substrate depletion methods were used due to the complex array of metabolites produced from myclobutanil and triadimefon. Myclobutanil was metabolized more rapidly than triadimefon, which is consistent with metabolism of the n-butyl side-chain in the former and the t-butyl group in the latter compound. Human and rat CYP2C and CYP3A enzymes were the most active. Metabolism was similar in microsomes prepared from livers of control and low-dose rats. High-dose (115 mg/kg/day of triadimefon or 150 mg/kg/day of myclobutanil) rats showed increased liver weight, induction of total CYP, and increased metabolism of the two triazoles, though the apparent Km appeared unchanged relative to the control. These data identify CYP enzymes important for the metabolization of these two triazoles. Estimated hepatic clearances suggest that CYP induction may have limited impact in vivo.', '/After/ non-radiolabeled triadimefon (97.6% purity, [phenyl-UL-14C] triadimefon (15.78 Ci/mmole, 99.3% radio-purity); single (5 or 50 mg/kg, 5 rats/sex/dose) and multiple oral dosing (5 mg/kg, pretreat 10 rats/sex daily with non-labeled triadimefon for 14 days prior to pulsing with a single dose of 14C-triadimefon; ... four major metabolites, KWG 0519 acid, KWG 1323-gluc, DeMe-KWG-1342-gluc and HO-DeMe-KWG 1342, were identified in urine and five major metabolites including KWG-0519 acid, KWG-1323, KWG-1342, KWG-1323-gluc were detected in feces; unmetabolized parent triadimefon was detected only in male rat feces and only in trace amounts (<1%).', 'Triadimefon was applied to cucumber, tomato, bean and wheat plants. Differences were primarily quantitative. Triadimenol, the 2-butenol analog, was formed in each case.', 'In plants, the carbonyl group is reduced to a hydroxyl group, with the formation of triadimenol.', 'For more Metabolism/Metabolites (Complete) data for TRIADIMEFON (6 total), please visit the HSDB record page.']","['Half-life in blood plasma is approx 2.5 hr.', '[(14)C] triadimefon in 50% aqueous ethanol was administered as a single gavage dose at 24.5-25.0 mg/kg to 12 Sprague Dawley rats/sex ... Plasma levels of radioactivity were highest 1-2 hours post-dose (2.5-3.2 ppm), and the half-life was approximately 4 hours.', '...Triadimefon was lost more rapidly from the skin of young animals (half-life, 20 to 25 hr) than from the skin of adult animals (half-life, 29 to 53 hr).']"
4691,39386,"3,5-Nonadien-7-yn-2-ol",CC#CC=CC=CC(C)O,,,,,,
4692,39387,"Magnesium, (2,2'-(dithio-kappaS)bis(pyridine) 1,1'-di(oxide-kappaO))(sulfato(2-)-kappaO)-, (T-4)-",C1=CC=[N+](C(=C1)SSC2=CC=CC=[N+]2[O-])[O-].[O-]S(=O)(=O)[O-].[Mg+2],,,,,,
4693,39388,"Benzaldehyde, ethenyl-",C=CC1=CC=C(C=C1)C=O.C=CC1=CC(=CC=C1)C=O.C=CC1=CC=CC=C1C=O,,,,,,
4694,39389,4-Vinylbenzaldehyde,C=CC1=CC=C(C=C1)C=O,,,,,,
4695,39390,3-Vinylbenzaldehyde,C=CC1=CC(=CC=C1)C=O,,,,,,
4696,39391,2-Vinylbenzaldehyde,C=CC1=CC=CC=C1C=O,,,,,,
4697,39392,"2-Oxazolidinone, 3-(4-carboxymethylphenyl)-5-(2-propynyloxymethyl)-",C#CCOCC1CN(C(=O)O1)C2=CC=C(C=C2)CC(=O)O,,,,,,
4698,39393,N-Benzyl-5-oxo-4-phenyltetrahydro-2-furamide,C1C(C(=O)OC1C(=O)NCC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4699,39394,CID 39394,CC12CCC(=O)C=C1C[C@H](C3C2CCC4(C3CC[C@]4(CCC(=O)[O-])O)C)C(=O)OC.[K+],,,,,,
4700,39395,"3-[(7R,17R)-17-hydroxy-7-methoxycarbonyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid",CC12CCC(=O)C=C1C[C@H](C3C2CCC4(C3CC[C@]4(CCC(=O)O)O)C)C(=O)OC,,,,,,
4701,39396,CID 39396,CC1=C2C=CC3=CC4=CC=CC=C4C=C3C2=CC=C1.CC1=C2C(=CC3=CC=CC=C13)C=CC4=CC=CC=C42,,,,,,
4702,39397,4-Methylbenz[a]anthracene,CC1=C2C=CC3=CC4=CC=CC=C4C=C3C2=CC=C1,,,,,,
4703,39398,Dichlorobutenedioic acid,C(=C(C(=O)O)Cl)(C(=O)O)Cl,,,,,,
4704,39399,"Dibenzo(b,f)thiepin-2-ol, 10,11-dihydro-11-(4-methyl-1-piperazinyl)-, dihydrochloride",CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)O.Cl.Cl,,,,,,
4705,39400,"5-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-3-ol",CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)O,,,,,,
4706,39401,3-(2-chlorophenyl)-N-(2-hydroxyethyl)prop-2-enamide,C1=CC=C(C(=C1)C=CC(=O)NCCO)Cl,,,,,,
4707,39402,3-(3-chlorophenyl)-N-(2-hydroxyethyl)prop-2-enamide,C1=CC(=CC(=C1)Cl)C=CC(=O)NCCO,,,,,,
4708,39403,N-(2-hydroxyethyl)-3-(2-methoxyphenyl)prop-2-enamide,COC1=CC=CC=C1C=CC(=O)NCCO,,,,,,
4709,39404,N-(2-hydroxyethyl)-3-(3-nitrophenyl)prop-2-enamide,C1=CC(=CC(=C1)[N+](=O)[O-])C=CC(=O)NCCO,,,,,,
4710,39405,N-(2-Hydroxyethyl)-3-(3-bromophenyl)propenamide,C1=CC(=CC(=C1)Br)C=CC(=O)NCCO,,,,,,
4711,39406,CID 39406,CC(=O)NC1=CC=C(C=C1)C=CC(=O)NCCO,,,,,,
4712,39407,N-(2-Hydroxyethyl)-3-(4-fluorophenyl)propenamide,C1=CC(=CC=C1C=CC(=O)NCCO)F,,,,,,
4713,39408,CID 39408,C1=CC(=CC(=C1)F)C=CC(=O)NCCO,,,,,,
4714,39409,N-(2-Hydroxyethyl)-3-(4-cyanophenyl)propenamide,C1=CC(=CC=C1C=CC(=O)NCCO)C#N,,,,,,
4715,39410,"3-(2,4-dichlorophenyl)-N-(2-hydroxyethyl)prop-2-enamide",C1=CC(=C(C=C1Cl)Cl)C=CC(=O)NCCO,,,,,,
4716,39411,"3-(3,4-dichlorophenyl)-N-(2-hydroxyethyl)prop-2-enamide",C1=CC(=C(C=C1C=CC(=O)NCCO)Cl)Cl,,,,,,
4717,39412,CID 39412,C1=CC=C(C=C1)C=CC(=O)NCCOC(=O)C=CC2=CC=CC=C2,,,,,,
4718,39413,3-(4-chlorophenyl)-N-(3-hydroxypropyl)prop-2-enamide,C1=CC(=CC=C1C=CC(=O)NCCCO)Cl,,,,,,
4719,39414,3-(3-chlorophenyl)-N-(2-hydroxyethyl)-N-methylprop-2-enamide,CN(CCO)C(=O)C=CC1=CC(=CC=C1)Cl,,,,,,
4720,39415,CID 39415,C1CCC(CC1)N(CCO)C(=O)C=CC2=CC=C(C=C2)Cl,,,,,,
4721,39416,3-(3-chlorophenyl)-N-cyclohexyl-N-(2-hydroxyethyl)prop-2-enamide,C1CCC(CC1)N(CCO)C(=O)C=CC2=CC(=CC=C2)Cl,,,,,,
4722,39417,CID 39417,C1CCC(CC1)N(CCO)C(=O)C=CC2=CC=CC=C2,,,,,,
4723,39418,CID 39418,CC(C)(C)N(CCO)C(=O)C=CC1=CC=CC=C1,,,,,,
4724,39419,Ethyl 2-(3-phenylprop-2-enoylamino)ethyl carbonate,CCOC(=O)OCCNC(=O)C=CC1=CC=CC=C1,,,,,,
4725,39420,"Nona-2,4-dien-6-yn-1-ol",CCC#CC=CC=CCO,,,,,,
4726,39421,6-Methylcholestan-3-ol,CC1CC2C3CCC(C3(CCC2C4(C1CC(CC4)O)C)C)C(C)CCCC(C)C,,,,,,
4727,39422,IA 3 methanesulfonate,CC[NH+](CC)CCN1C2=C3C(=C(C=C2)C)SC4=C(C3=N1)C=CC(=C4)Cl.CS(=O)(=O)[O-],,,,,,
4728,39423,6-Chloroindazolelucanthone,CCN(CC)CCN1C2=C3C(=C(C=C2)C)SC4=C(C3=N1)C=CC(=C4)Cl,,,,,,
4729,39424,Difenzoquat metilsulfate,CN1C(=CC(=[N+]1C)C2=CC=CC=C2)C3=CC=CC=C3.COS(=O)(=O)[O-],,,,,,
4730,39425,Difenzoquat,CN1C(=CC(=[N+]1C)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4731,39426,"2-Isoindolinebutyramide, 1,3-dioxo-N-ethyl-",CCNC(=O)CCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
4732,39427,"2-Isoindolinebutyramide, 1,3-dioxo-N-propyl-",CCCNC(=O)CCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
4733,39428,(Imino(methylamino)methyl)urea,CN=C(N)NC(=O)N,,,,,,
4734,39429,2-Chloroprop-2-enyl but-2-enoate,CC=CC(=O)OCC(=C)Cl,,,,,,
4735,39430,(2-Hydroxyethyl)trimethylammonium ester with methylphosphonofluoridate,C[N+](C)(C)CCOP(=O)(C)F,,,,,,
4736,39431,N-Nonylacetamide,CCCCCCCCCNC(=O)C,,,,,,
4737,39432,"Aziridine, 1-hexanoyl-",CCCCCC(=O)N1CC1,,,,,,
4738,39433,"4-Vinyl-1,2-dichlorocyclohexane",C=CC1CCC(C(C1)Cl)Cl,,,,,,
4739,39434,Ethenyl cyclopentaneacetate,C=COC(=O)CC1CCCC1,,,,,,
4740,39435,"3-Butyl-1,2,4-cyclopentanetrione",CCCCC1C(=O)CC(=O)C1=O,,,,,,
4741,39436,"GUANIDINE, (o-METHYLBENZYL)-",CC1=CC=CC=C1CN=C(N)N,,,,,,
4742,39437,"GUANIDINE, (o-IODOBENZYL)-",C1=CC=C(C(=C1)CN=C(N)N)I,,,,,,
4743,39438,"Guanidine, benzylamino-",C1=CC=C(C=C1)CNN=C(N)N,,,,,,
4744,39439,"GUANIDINE, (p-BROMOBENZYL)-",C1=CC(=CC=C1CN=C(N)N)Br,,,,,,
4745,39440,"GUANIDINE, (p-CHLOROBENZYL)-",C1=CC(=CC=C1CN=C(N)N)Cl,,,,,,
4746,39441,"Guanidine, (3,4-dichlorobenzyl)-",C1=CC(=C(C=C1CN=C(N)N)Cl)Cl,,,,,,
4747,39442,(2-(Phenylthio)ethyl)guanidine,C1=CC=C(C=C1)SCCN=C(N)N,,,,,,
4748,39443,"GUANIDINE, (o-CHLOROPHENETHYL)AMINO-",C1=CC=C(C(=C1)CCNN=C(N)N)Cl,,,,,,
4749,39444,"GUANIDINE, (2-(o-TOLYLOXY)ETHYL)-",CC1=CC=CC=C1OCCN=C(N)N,,,,,,
4750,39445,"GUANIDINE, (2-(o-CHLOROPHENOXY)ETHYL)-",C1=CC=C(C(=C1)OCCN=C(N)N)Cl,,,,,,
4751,39446,"GUANIDINE, (2-(m-TOLYLOXY)ETHYL)-",CC1=CC(=CC=C1)OCCN=C(N)N,,,,,,
4752,39447,(p-Chlorophenethyl)aminoguanidine,C1=CC(=CC=C1CCNN=C(N)N)Cl,,,,,,
4753,39448,(2-(p-Tolyloxy)ethyl)guanidine,CC1=CC=C(C=C1)OCCN=C(N)N,,,,,,
4754,39449,(2-(p-Chlorophenoxy)ethyl)guanidine,C1=CC(=CC=C1OCCN=C(N)N)Cl,,,,,,
4755,39450,"Indole, 3-((diethylamino)methyl)-",CCN(CC)CC1=CNC2=CC=CC=C21,,,,,,
4756,39451,"Guanidine, (2-(2,6-xylyl)ethyl)amino-",CC1=C(C(=CC=C1)C)CCNN=C(N)N,,,,,,
4757,39452,"Guanidine, (2-(2,6-xylyloxy)ethyl)-",CC1=C(C(=CC=C1)C)OCCN=C(N)N,,,,,,
4758,39453,"5H-DIBENZO(b,e)(1,4)DIAZEPINE, 1,2,3,4-TETRAHYDRO-, HYDRATE",C1CCC2=C(C1)C=NC3=CC=CC=C3N2.O,,,,,,
4759,39454,"8,9,10,11-tetrahydro-7H-benzo[b][1,4]benzodiazepine",C1CCC2=C(C1)C=NC3=CC=CC=C3N2,,,,,,
4760,39455,"Guanidine, (2-(N-methyl-2,6-xylidino)ethyl)-",CC1=C(C(=CC=C1)C)N(C)CCN=C(N)N,,,,,,
4761,39456,9-Chloro-10-methylacridinium,C[N+]1=C2C=CC=CC2=C(C3=CC=CC=C31)Cl,,,,,,
4762,39457,2-Ethoxy-N-isopropyl-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=NC(C)C)N,,,,,,
4763,39458,"(2-(2,6-Xylyloxy)propyl)guanidine",CC1=C(C(=CC=C1)C)OC(C)CN=C(N)N,,,,,,
4764,39459,"GUANIDINE, (2-(o-CUMENYLOXY)ETHYL)-",CC(C)C1=CC=CC=C1OCCN=C(N)N,,,,,,
4765,39460,"GUANIDINE, (2-(alpha-NAPHTHYLOXY)ETHYL)-",C1=CC=C2C(=C1)C=CC=C2OCCN=C(N)N,,,,,,
4766,39461,"GUANIDINE, (2-(beta-NAPHTHYLOXY)ETHYL)-",C1=CC=C2C=C(C=CC2=C1)OCCN=C(N)N,,,,,,
4767,39462,"Guanidine, (2-(2,6-diisopropylphenoxy)ethyl)-",CC(C)C1=C(C(=CC=C1)C(C)C)OCCN=C(N)N,,,,,,
4768,39463,Fluoridamid,CC1=C(C=C(C=C1)NC(=O)C)NS(=O)(=O)C(F)(F)F,,,,,,
4769,39464,N-Methyl-2-(alpha-methyl-m-trifluoromethylphenethylamino)acetamide,CC(CC1=CC(=CC=C1)C(F)(F)F)NCC(=O)NC,,,,,,
4770,39465,"Indole, 3-(2-(isoindolin-2-YL)ethyl)-",C1C2=CC=CC=C2CN1CCC3=CNC4=CC=CC=C43,,,,,,
4771,39466,Bis(o-chlorophenoxy)acetic acid,C1=CC=C(C(=C1)OC(C(=O)O)OC2=CC=CC=C2Cl)Cl,,,,,,
4772,39467,"Butyramide, 4-dimethylamino-2,2-diphenyl-",CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N,,,,,,
4773,39468,Levobunolol,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,['For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.'],"['Levobunolol is an ophthalmic beta-blocker, equally effective at &beta;(1)- and &beta;(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking agent, it can produce both systemic pulmonary and cardiovascular effects following topical application to the eye. These effects include adverse pulmonary effects (eg. bronchoconstriction, increased airway resistance), and a decrease in blood pressure and heart rate.']","['Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",['80%'],['Hepatic'],['20 hours']
4774,39469,CID 39469,CCN(CC)CCCN=C(C1=CC(=C(C=C1)OC)OC)S,,,,,,
4775,39470,"1,6-Hexanediamine, N,N'-dimethyl-N,N'-diphenyl-",CN(CCCCCCN(C)C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4776,39471,CID 39471,CCOC1=CC(=CC(=C1OCC)OCC)C(=NCCCN(C)C)S,,,,,,
4777,39472,"AZETIDINE, 3-(m-METHOXYPHENYL)-3-PENTYL-1-PHENETHYL-",CCCCCC1(CN(C1)CCC2=CC=CC=C2)C3=CC(=CC=C3)OC,,,,,,
4778,39473,"2-FURANPROPANETHIOL, TETRAHYDRO-beta-(1-NAPHTHYL)-S-(2-PYRROLIDINOETHYL)-",C1CCN(C1)CCSCC(CC2CCCO2)C3=CC=CC4=CC=CC=C43,,,,,,
4779,39474,"1-Naphthaleneethanethiol, S-(2-morpholinoethyl)-beta-(tetrahydrofurfuryl)-",C1CC(OC1)CC(CSCCN2CCOCC2)C3=CC=CC4=CC=CC=C43,,,,,,
4780,39475,N-(4-(2-Hydroxy-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)acetamide,CC(=O)NC1=CC=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
4781,39476,2-(alpha-Methyl-m-trifluoromethylphenethylamino)-N-(m-trifluoromethylphenyl)acetamide,CC(CC1=CC(=CC=C1)C(F)(F)F)NCC(=O)NC2=CC=CC(=C2)C(F)(F)F,,,,,,
4782,39477,N-(4-(2-Hydroxy-3-(4-(2-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)acetamide,CC(=O)NC1=CC=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3OC)O,,,,,,
4783,39478,4-((2-(Chlorophenoxy)-2-methyl-1-oxopropyl)amino)benzoic acid 2-(diethylamino)ethyl ester,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C(C)(C)OC2=CC=CC=C2Cl,,,,,,
4784,39479,"Borazine, 2,4,6-triallyl-1,3,5-triphenyl-",B1(N(B(N(B(N1CC=C)C2=CC=CC=C2)CC=C)C3=CC=CC=C3)CC=C)C4=CC=CC=C4,,,,,,
4785,39480,"(3-oxo-1H-2-benzofuran-1-yl) (5R,6R)-6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1(C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)OC4C5=CC=CC=C5C(=O)O4)C,,,,,,
4786,39481,Difenoximide,C1CC(=O)N(C1=O)OC(=O)C2(CCN(CC2)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
4787,39482,"Tetrasodium;5-amino-1-[[4-[4-[(5-amino-4-hydroxy-2,7-disulfonatonaphthalen-1-yl)diazenyl]-3-chlorophenyl]-2-chlorophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonate",C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C(C=C(C4=C3C=C(C=C4N)S(=O)(=O)[O-])O)S(=O)(=O)[O-])Cl)Cl)N=NC5=C(C=C(C6=C5C=C(C=C6N)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
4788,39483,"5-Amino-1-[[4-[4-[(5-amino-4-hydroxy-2,7-disulfonaphthalen-1-yl)diazenyl]-3-chlorophenyl]-2-chlorophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid",C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C(C=C(C4=C3C=C(C=C4N)S(=O)(=O)O)O)S(=O)(=O)O)Cl)Cl)N=NC5=C(C=C(C6=C5C=C(C=C6N)S(=O)(=O)O)O)S(=O)(=O)O,,,,,,
4789,39484,Cyperquat,C[N+]1=CC=C(C=C1)C2=CC=CC=C2,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,"['1-methyl-4-phenylpyridin-1-ium is a known human metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.']",
4790,39485,2-Phenoxyethyl acrylate,C=CC(=O)OCCOC1=CC=CC=C1,,,,,,
4791,39486,"Aziridine, 1-lauroyl-",CCCCCCCCCCCC(=O)N1CC1,,,,,,
4792,39487,CID 39487,CCCCC=CC=CC=CCCCCCCCC(=O)NNCC1=CC=CC=C1,,,,,,
4793,39488,CID 39488,CCCCC=CC=CC=CCCCCCCCC(=O)NNCCC1=CC=CC=C1,,,,,,
4794,39489,"BENZOFURO(3,2-c)PYRIDINE, 1,2,3,4-TETRAHYDRO-, HYDROCHLORIDE",C1CCC2=C(C1)C3=C(O2)C=C[NH+]=C3.[Cl-],,,,,,
4795,39490,"6,7,8,9-Tetrahydro-[1]benzofuro[3,2-c]pyridine",C1CCC2=C(C1)C3=C(O2)C=CN=C3,,,,,,
4796,39491,"Ethanol, 2-(1-phenylhydrazino)-",C1=CC=C(C=C1)N(CCO)N,,,,,,
4797,39492,"BARBITURIC ACID, 5-(p-METHOXYBENZYLIDENE)-",COC1=CC=C(C=C1)C=C2C(=O)NC(=O)NC2=O,,,,,,
4798,39493,"FURAZAN, 3-METHYL-4-NITRO-, 2(or 5)-OXIDE",CC1=[N+](ON=C1[N+](=O)[O-])[O-],,,,,,
4799,39494,"4-(2-(alpha-Methylphenethylamino)ethyl)-3-phenyl-1,2,4-oxadiazole monohydrochloride",CC(CC1=CC=CC=C1)[NH2+]CCN2CON=C2C3=CC=CC=C3.[Cl-],,,,,,
4800,39495,"1-phenyl-N-[2-(3-phenyl-5H-1,2,4-oxadiazol-4-yl)ethyl]propan-2-amine",CC(CC1=CC=CC=C1)NCCN2CON=C2C3=CC=CC=C3,,,,,,
4801,39496,"8-Amino-2,3-dimethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-ol",COC1=C(C(=C2CC(CCCC2=C1)N)O)OC,,,,,,
4802,39497,4-Cyanobenzenesulfonyl chloride,C1=CC(=CC=C1C#N)S(=O)(=O)Cl,,,,,,
4803,39498,"Adamantane, 1-(nitroamino)-",C1C2CC3CC1CC(C2)(C3)N[N+](=O)[O-],,,,,,
4804,39499,"3,3,4-Trimethyldecane",CCCCCCC(C)C(C)(C)CC,,,,,,
4805,39500,CID 39500,CCC=C[C@@H]1[C@@H](C1(C)C)C(=O)OCC2=COC(=C2)CC3=CC=CC=C3,,,,,,
4806,39501,CID 39501,CCNC1=NC(=O)N=C(N1)Cl,,,,,,
4807,39502,Nabitan hydrochloride,CCCCCC(C)C(C)C1=CC2=C(C3=C(CCN(C3)CC#C)C(O2)(C)C)C(=C1)OC(=O)CCCN4CCCCC4.Cl,,,,,,
4808,39503,Nabitan,CCCCCC(C)C(C)C1=CC2=C(C3=C(CCN(C3)CC#C)C(O2)(C)C)C(=C1)OC(=O)CCCN4CCCCC4,,,,,,
4809,39504,"1-Piperazineethanol, alpha-((o-(1-hydroxyethyl)phenoxy)methyl)-4-phenyl-",CC(C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3)O)O,,,,,,
4810,39505,4-Chloro-alpha-(methylimino)-o-cresol,CN=CC1=C(C=CC(=C1)Cl)O,,,,,,
4811,39506,Tribromodiphenyl ether,C1=CC=C(C(=C1)OC2=CC(=C(C=C2)Br)Br)Br,,,,,,
4812,39507,"(2R,13R,14S,15S,17S)-17-hydroxy-2,13,14,15-tetramethyl-14-propanoyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one",CCC(=O)[C@]1([C@@H](CC2[C@@]1(C[C@@H](C3C2CCC4=CC(=O)C=C[C@]34C)O)C)C)C,,,,,,
4813,39508,"5-Benzothiazoleacetic acid, 2-phenyl-, ethyl ester",CCOC(=O)CC1=CC2=C(C=C1)SC(=N2)C3=CC=CC=C3,,,,,,
4814,39509,"5-Benzothiazoleacetic acid, 2-(4-methoxyphenyl)-, ethyl ester",CCOC(=O)CC1=CC2=C(C=C1)SC(=N2)C3=CC=C(C=C3)OC,,,,,,
4815,39510,"Benzothiazole, 5-acetyl-2-(4-carbamoylphenyl)-",CC(=O)C1=CC2=C(C=C1)SC(=N2)C3=CC=C(C=C3)C(=O)N,,,,,,
4816,39511,"1-Hexadecanaminium, N,N,N-trimethyl-, ethyl sulfate",CCCCCCCCCCCCCCCC[N+](C)(C)C.CCOS(=O)(=O)[O-],,,,,,
4817,39512,"4,7-Dimethoxy-2,3-dimethyl-6-tetradecanoylbenzofuran",CCCCCCCCCCCCCC(=O)C1=CC(=C2C(=C(OC2=C1OC)C)C)OC,,,,,,
4818,39513,"4,7-Dimethoxy-2,3-dimethyl-6-hexadecanoylbenzofuran",CCCCCCCCCCCCCCCC(=O)C1=CC(=C2C(=C(OC2=C1OC)C)C)OC,,,,,,
4819,39514,"BENZOFURAN, 4,7-DIMETHOXY-2,3-DIMETHYL-6-(o-METHOXYBENZOYL)-",CC1=C(OC2=C(C(=CC(=C12)OC)C(=O)C3=CC=CC=C3OC)OC)C,,,,,,
4820,39515,"4,7-Benzofurandiol, 6-decanoyl-2,3-dimethyl-",CCCCCCCCCC(=O)C1=CC(=C2C(=C(OC2=C1O)C)C)O,,,,,,
4821,39516,CID 39516,CCCCCCCCCCC1=CC(C(=O)C=C1OC)OC,,,,,,
4822,39517,"4,7-Dimethoxy-2,3-dimethyl-6-benzofuranylamine hydrochloride",CC1=C(OC2=C(C(=CC(=C12)OC)[NH3+])OC)C.[Cl-],,,,,,
4823,39518,"4,7-Dimethoxy-2,3-dimethyl-1-benzofuran-6-amine",CC1=C(OC2=C(C(=CC(=C12)OC)N)OC)C,,,,,,
4824,39519,"1,4-Butanediamine, N-(3-aminopropyl)-, phosphate (2:3)",C(CC[NH2+]CCC[NH3+])C[NH3+].C(CC[NH2+]CCC[NH3+])C[NH3+].OP(=O)([O-])[O-].OP(=O)([O-])[O-].OP(=O)([O-])[O-],,,,,,
4825,39520,"11-Aza-7-azoniatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one;nitrate",C1C2CNCC1C3=CC=CC(=O)[NH+]3C2.[N+](=O)([O-])[O-],,,,,,
4826,39521,Amidantel,CC(=NC1=CC=C(C=C1)NC(=O)COC)N(C)C,,,,,,
4827,39522,5-Isopentylpicolinic acid,CC(C)CCC1=CN=C(C=C1)C(=O)O,,,,,,
4828,39523,"beta-ALANINE, N-(3-ACETAMIDO-5-METHYLCARBAMOYL-2,4,6-TRIIODOBENZOYL)-",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)NCCC(=O)O)I)C(=O)NC)I,,,,,,
4829,39524,"1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-",CC(C)(C)C(C=CC1=CC2=C(C=C1)OCO2)O,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
4830,39525,Azaclorzine hydrochloride,C1CC2CN(CCN2C1)CCC(=O)N3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl.Cl.Cl,,,,,,
4831,39526,Azaclorzine,C1CC2CN(CCN2C1)CCC(=O)N3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
4832,39527,Cadmium nitrilotriacetate,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Cd+2],,,,,,
4833,39528,Supidimide,C1CC(C(=O)NC1)N2C(=O)C3=CC=CC=C3S2(=O)=O,,,,,,
4834,39529,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N-isopropyl-5-methoxy-, hydrochloride, (S)-",CC(C)[NH2+][C@H]1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
4835,39530,"(1S)-8-chloro-5-methoxy-N-propan-2-yl-1,2,3,4-tetrahydronaphthalen-1-amine",CC(C)N[C@H]1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
4836,39531,2-Pyridylmethyl methoxydiphenylacetate hydrochloride,COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3=CC=CC=[NH+]3.[Cl-],,,,,,
4837,39532,"Pyridin-2-ylmethyl 2-methoxy-2,2-diphenylacetate",COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3=CC=CC=N3,,,,,,
4838,39533,CID 39533,CCOC=CC#CC(C)(C)O,,,,,,
4839,39534,"5-(3-Methoxyprop-2-enylidene)-2,2,4,4-tetramethyl-1,3-dioxolane",CC1(C(=CC=COC)OC(O1)(C)C)C,,,,,,
4840,39535,"Acetamide, N-(2-(4-morpholinyl)ethyl)-2-phenoxy-",C1COCCN1CCNC(=O)COC2=CC=CC=C2,,,,,,
4841,39536,"4,7-Benzofurandiol, 2,3-dimethyl-6-propionyl-",CCC(=O)C1=CC(=C2C(=C(OC2=C1O)C)C)O,,,,,,
4842,39537,"1H-Pyrrole, dimethyl-",CC1=C(NC=C1)C.CC1=CC(=CN1)C,,,,,,
4843,39538,"2,3-Dimethyl-1H-pyrrole",CC1=C(NC=C1)C,,,,,,
4844,39539,"2,4-Dimethyl-1H-pyrrole",CC1=CC(=CN1)C,,,,,,
4845,39540,3-Methyl-4-methylenebicyclo(3.2.1)oct-2-ene,CC1=CC2CCC(C2)C1=C,,,,,,
4846,39541,"2,3-Dimethylenebicyclo[3.2.1]octane",C=C1CC2CCC(C2)C1=C,,,,,,
4847,39542,"1-Heptanenitrile, 2-methyl-2-pentyl-",CCCCCC(C)(CCCCC)C#N,,,,,,
4848,39543,"4-Piperidinoacetyl-3,4-dihydro-2H-1,4-benzoxazine hydrochloride",C1CC[NH+](CC1)CC(=O)N2CCOC3=CC=CC=C32.[Cl-],,,,,,
4849,39544,"4-Piperidinoacetyl-3,4-dihydro-2H-1,4-benzoxazine",C1CCN(CC1)CC(=O)N2CCOC3=CC=CC=C32,,,,,,
4850,39545,"endo-2-(4-(Diethylamino)-2-butynyl)-1,3,3-trimethylbicyclo(2.2.1)heptan-2-ol",CCN(CC)CC#CCC1(C(C2CCC1(C2)C)(C)C)O,,,,,,
4851,39546,"endo-2-(4-(1-Piperidinyl)-2-butynyl)-1,3,3-trimethylbicyclo(2.2.1)heptan-2-ol",CC1(C2CCC(C2)(C1(CC#CCN3CCCCC3)O)C)C,,,,,,
4852,39547,"exo-2-(4-(Diethylamino)-2-butynyl)-1,7,7-trimethylbicyclo(2.2.1)heptan-2-ol",CCN(CC)CC#CCC1(CC2CCC1(C2(C)C)C)O,,,,,,
4853,39548,"exo-2-(4-(1-Piperidinyl)-2-butynyl)-1,7,7-trimethylbicyclo(2.2.1)heptan-2-ol",CC1(C2CCC1(C(C2)(CC#CCN3CCCCC3)O)C)C,,,,,,
4854,39549,"exo-2-(4-(1-Pyrrolidinyl)-2-butynyl)-1,7,7-trimethylbicyclo(2.2.1)heptan-2-ol",CC1(C2CCC1(C(C2)(CC#CCN3CCCC3)O)C)C,,,,,,
4855,39550,"3-(4-(Diethylamino)-2-butynyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane-2,4-dione",CCN(CC)CC#CCN1C(=O)C2CCC(C1=O)(C2(C)C)C,,,,,,
4856,39551,"3-(4-(1-Pyrrolidinyl)-2-butynyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane-2,4-dione",CC1(C2CCC1(C(=O)N(C2=O)CC#CCN3CCCC3)C)C,,,,,,
4857,39552,"3-(4-(1-Piperidinyl)-2-butynyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane-2,4-dione",CC1(C2CCC1(C(=O)N(C2=O)CC#CCN3CCCCC3)C)C,,,,,,
4858,39553,"3-(4-(1-Pyrrolidinyl)-2-butynyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane",CC1(C2CCC1(CN(C2)CC#CCN3CCCC3)C)C,,,,,,
4859,39554,"3-(4-(1-Piperidinyl)-2-butynyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane",CC1(C2CCC1(CN(C2)CC#CCN3CCCCC3)C)C,,,,,,
4860,39555,5-Ethyl-2-methyl-4-hepten-3-one,CCC(=CC(=O)C(C)C)CC,,,,,,
4861,39556,4-Nitrophenyl methylphenylcarbamic acid,CN(C1=CC=CC=C1)C(=O)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4862,39557,"5-Benzimidazolecarbamic acid, 1-amino-2-(4-thiazolyl)-, isopropyl ester",CC(C)OC(=O)NC1=CC2=C(C=C1)N(C(=N2)C3=CSC=N3)N,,,,,,
4863,39558,6-(Chloromethyl)benzo(a)pyrene,C1=CC=C2C(=C1)C3=C4C(=C2CCl)C=CC5=CC=CC(=C54)C=C3,,,,,,
4864,39559,6-Bromomethylbenzo(a)pyrene,C1=CC=C2C(=C1)C3=C4C(=C2CBr)C=CC5=CC=CC(=C54)C=C3,,,,,,
4865,39560,2-Ethoxy-2-(p-tolyl)acetamide oxime,CCOC(C1=CC=C(C=C1)C)C(=NO)N,,,,,,
4866,39561,2-(4-Chlorophenyl)-2-ethoxyacetamide oxime,CCOC(C1=CC=C(C=C1)Cl)C(=NO)N,,,,,,
4867,39562,Lonidamine,C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O,"['Investigated for use/treatment in benign prostatic hyperplasia, prostate disorders, and cancer/tumors (unspecified).']",,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)', 'Agents, either mechanical or chemical, which destroy spermatozoa in the male genitalia and block spermatogenesis. (See all compounds classified as Antispermatogenic Agents.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)']",,"['Lonidamine has known human metabolites that include (2S,3S,4S,5R)-6-[1-[(2,4-Dichlorophenyl)methyl]indazole-3-carbonyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
4868,39563,"(4-Nitrophenyl)methyl 2-(3-benzyl-7-oxo-4-thia-2,6-diazabicyclo[3.2.0]hept-2-en-6-yl)-3-methylbut-3-enoate",CC(=C)C(C(=O)OCC1=CC=C(C=C1)[N+](=O)[O-])N2C3C(C2=O)N=C(S3)CC4=CC=CC=C4,,,,,,
4869,39564,"5H-1,3-Dioxolo(4,5-f)pyrido(4,3-b)indole, 6,7,8,9-tetrahydro-5-(p-fluorobenzoyl)-8-methyl-, monohydrochloride",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)F)OCO4.[Cl-],,,,,,
4870,39565,"(4-Fluorophenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)F)OCO4,,,,,,
4871,39566,"5H-1,3-Dioxolo(4,5-f)pyrido(4,3-b)indole, 6,7,8,9-tetrahydro-5-(m-fluorobenzoyl)-8-methyl-, monohydrochloride",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)F)OCO4.[Cl-],,,,,,
4872,39567,"(3-Fluorophenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)F)OCO4,,,,,,
4873,39568,"5H-1,3-Dioxolo(4,5-f)pyrido(4,3-b)indole, 6,7,8,9-tetrahydro-5-(p-chlorobenzoyl)-8-methyl-, monohydrochloride",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)Cl)OCO4.[Cl-],,,,,,
4874,39569,"(4-Chlorophenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)Cl)OCO4,,,,,,
4875,39570,"5H-1,3-Dioxolo(4,5-f)pyrido(4,3-b)indole, 6,7,8,9-tetrahydro-5-(m-chlorobenzoyl)-8-methyl-, monohydrochloride",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)Cl)OCO4.[Cl-],,,,,,
4876,39571,"(3-Chlorophenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)Cl)OCO4,,,,,,
4877,39572,"6,7,8,9-Tetrahydro-5-(p-bromobenzoyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole HCl",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)Br)OCO4.[Cl-],,,,,,
4878,39573,"(4-Bromophenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)Br)OCO4,,,,,,
4879,39574,"6,7,8,9-Tetrahydro-5-(m-bromobenzoyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole HCl",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)Br)OCO4.[Cl-],,,,,,
4880,39575,"(3-Bromophenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)Br)OCO4,,,,,,
4881,39576,"6,7,8,9-Tetrahydro-5-(benzoyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole hydrochloride",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=CC=C5)OCO4.[Cl-],,,,,,
4882,39577,"(4-Methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)-phenylmethanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=CC=C5)OCO4,,,,,,
4883,39578,"6,7,8,9-Tetrahydro-5-(p-toluoyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole HCl",CC1=CC=C(C=C1)C(=O)N2C3=C(C[NH+](CC3)C)C4=CC5=C(C=C42)OCO5.[Cl-],,,,,,
4884,39579,"(4-Methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)-(4-methylphenyl)methanone",CC1=CC=C(C=C1)C(=O)N2C3=C(CN(CC3)C)C4=CC5=C(C=C42)OCO5,,,,,,
4885,39580,"6,7,8,9-Tetrahydro-5-(p-anisoyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole HCl",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)OC)OCO4.[Cl-],,,,,,
4886,39581,"(4-Methoxyphenyl)-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)methanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)OC)OCO4,,,,,,
4887,39582,"6,7,8,9-Tetrahydro-5-(2-thenoyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole HCl",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=CS5)OCO4.[Cl-],,,,,,
4888,39583,"(4-Methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)-thiophen-2-ylmethanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=CS5)OCO4,,,,,,
4889,39584,"6,7,8,9-Tetrahydro-5-(cyclopentylacetyl)-8-methyl-5H-1,3-dioxolo(4,5-f)pyrido(4,3-b)indole HCl",C[NH+]1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)CC5CCCC5)OCO4.[Cl-],,,,,,
4890,39585,"2-Cyclopentyl-1-(4-methyl-12,14-dioxa-4,8-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),9,11(15)-tetraen-8-yl)ethanone",CN1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)CC5CCCC5)OCO4,,,,,,
4891,39586,"Benzylamine, N-(2-chloroethyl)-N-(2-methoxyethyl)-",COCCN(CCCl)CC1=CC=CC=C1,,,,,,
4892,39587,Nitrosotriethylurea,CCN(CC)C(=O)N(CC)N=O,,,,,,
4893,39588,"N',N'-Dimethyl-N-ethyl-N-nitrosourea",CCN(C(=O)N(C)C)N=O,,,,,,
4894,39589,"1,1-Diethyl-3-methyl-3-nitrosourea",CCN(CC)C(=O)N(C)N=O,,,,,,
4895,39590,"Acetamide, 2-((5-bromopentyl)methylamino)-N-(2,6-dimethylphenyl)-, monohydrobromide",CC1=C(C(=CC=C1)C)NC(=O)C[NH+](C)CCCCCBr.[Br-],,,,,,
4896,39591,"2-[5-bromopentyl(methyl)amino]-N-(2,6-dimethylphenyl)acetamide",CC1=C(C(=CC=C1)C)NC(=O)CN(C)CCCCCBr,,,,,,
4897,39592,"Acetamide, N-(2,6-dimethylphenyl)-2-(ethylmethylamino)-, monohydrochloride (9CI)",CC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
4898,39593,Ethylmethylglycinexylidide,CCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
4899,39594,"Acetamide, N-(2,6-dimethylphenyl)-2-(methylpropylamino)-, monohydrochloride",CCC[NH+](C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
4900,39595,"Acetamide, N-(2,6-dimethylphenyl)-2-(methylpropylamino)-",CCCN(C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
4901,39596,"2-Butanone, 4-(6-methyl-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2-yl)-, (Z)-(+-)-",CC1C2=C(CC3N1CCN(C3)CCC(=O)C)C4=CC=CC=C4N2,,,,,,
4902,39597,5-Ethyl-1-(morpholinomethyl)-5-phenylbarbituric acid hydrochloride,CCC1(C(=O)NC(=O)N(C1=O)CN2CCOCC2)C3=CC=CC=C3.Cl,,,,,,
4903,39598,1-Morpholinomethylphenobarbital,CCC1(C(=O)NC(=O)N(C1=O)CN2CCOCC2)C3=CC=CC=C3,,,,,,
4904,39599,"Barbituric acid, 1,3-bis(2-isothioureidomethyl)-5-ethyl-5-phenyl-, dihydrobromide",CCC1(C(=O)N(C(=O)N(C1=O)CSC(=N)N)CSC(=N)N)C2=CC=CC=C2.Br.Br,,,,,,
4905,39600,"[3-(Carbamimidoylsulfanylmethyl)-5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl]methyl carbamimidothioate",CCC1(C(=O)N(C(=O)N(C1=O)CSC(=N)N)CSC(=N)N)C2=CC=CC=C2,,,,,,
4906,39601,"Barbituric acid, 1-((amidinothio)methyl)-5-ethyl-3-methyl-5-phenyl-, monohydrobromide",CCC1(C(=O)N(C(=O)N(C1=O)CSC(=N)N)C)C2=CC=CC=C2.Br,,,,,,
4907,39602,"(5-Ethyl-3-methyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)methyl carbamimidothioate",CCC1(C(=O)N(C(=O)N(C1=O)CSC(=N)N)C)C2=CC=CC=C2,,,,,,
4908,39603,"1-Naphthoic acid, 2-(dimethylamino)ethyl ester, hydrochloride",C[NH+](C)CCOC(=O)C1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
4909,39604,2-(Dimethylamino)ethyl naphthalene-1-carboxylate,CN(C)CCOC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
4910,39605,"2-Butene-1,2-diol",CC=C(CO)O,,,,,,
4911,39606,Dimethoxymethylium hexafluorophosphate,COC=[O+]C.F[P-](F)(F)(F)(F)F,,,,,,
4912,39607,Dimethoxymethylium,COC=[O+]C,,,,,,
4913,39608,Morazone HCl,CC1C(OCC[NH+]1CC2=C(N(N(C2=O)C3=CC=CC=C3)C)C)C4=CC=CC=C4.[Cl-],,,,,,
4914,39609,Morazone,CC1C(OCCN1CC2=C(N(N(C2=O)C3=CC=CC=C3)C)C)C4=CC=CC=C4,,,,,,
4915,39610,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(m-FLUOROBENZOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC(=CC=C4)F)OCO3)CC(=O)O,,,,,,
4916,39611,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(m-CHLOROBENZOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC(=CC=C4)Cl)OCO3)CC(=O)O,,,,,,
4917,39612,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(p-BROMOBENZOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=C(C=C4)Br)OCO3)CC(=O)O,,,,,,
4918,39613,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(m-BROMOBENZOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC(=CC=C4)Br)OCO3)CC(=O)O,,,,,,
4919,39614,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-BENZOYL-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=CC=C4)OCO3)CC(=O)O,,,,,,
4920,39615,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(p-ANISOYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=C(C=C4)OC)OCO3)CC(=O)O,,,,,,
4921,39616,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 6-METHYL-5-(3,4,5-TRIMETHOXYBENZOYL)-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC(=C(C(=C4)OC)OC)OC)OCO3)CC(=O)O,,,,,,
4922,39617,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(5-BROMO-2-FUROYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=C(O4)Br)OCO3)CC(=O)O,,,,,,
4923,39618,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 6-METHYL-5-(2-THENOYL)-",CC1=C(C2=CC3=C(C=C2N1C(=O)C4=CC=CS4)OCO3)CC(=O)O,,,,,,
4924,39619,"5-Acetyl-2-methyl-5H-1,3-dioxolo(4,5-f)indole-7-acetic acid",CC1OC2=C(O1)C=C3C(=C2)C(=CN3C(=O)C)CC(=O)O,,,,,,
4925,39620,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(4-CHLOROBUTYRYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)CCCCl)OCO3)CC(=O)O,,,,,,
4926,39621,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(p-FLUOROBENZOYL)-",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)F)OCO4,,,,,,
4927,39622,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(m-FLUOROBENZOYL)-",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)F)OCO4,,,,,,
4928,39623,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(p-CHLOROBENZOYL)-",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)Cl)OCO4,,,,,,
4929,39624,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(m-CHLOROBENZOYL)-",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC(=CC=C5)Cl)OCO4,,,,,,
4930,39625,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(p-BROMOBENZOYL)-",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=C(C=C5)Br)OCO4,,,,,,
4931,39626,"5-Benzoyl-6,7,8,9-tetrahydro-5H-1,3-dioxolo(4,5-b)carbazole",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=CC=C5)OCO4,,,,,,
4932,39627,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(p-TOLUOYL)-",CC1=CC=C(C=C1)C(=O)N2C3=C(CCCC3)C4=CC5=C(C=C42)OCO5,,,,,,
4933,39628,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(p-ANISOYL)-",COC1=CC=C(C=C1)C(=O)N2C3=C(CCCC3)C4=CC5=C(C=C42)OCO5,,,,,,
4934,39629,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(2-THENOYL)-",C1CCC2=C(C1)C3=CC4=C(C=C3N2C(=O)C5=CC=CS5)OCO4,,,,,,
4935,39630,"5H-1,3-DIOXOLO(4,5-b)CARBAZOLE, 6,7,8,9-TETRAHYDRO-5-(CYCLOPENTYLACETYL)-",C1CCC(C1)CC(=O)N2C3=C(CCCC3)C4=CC5=C(C=C42)OCO5,,,,,,
4936,39631,"5-(4-Fluorobenzoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC=C(C=C3)F)C4=CC5=C(C=C4N2)OCO5,,,,,,
4937,39632,"5-(3-Fluorobenzoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC(=CC=C3)F)C4=CC5=C(C=C4N2)OCO5,,,,,,
4938,39633,"5-(4-Chlorobenzoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC=C(C=C3)Cl)C4=CC5=C(C=C4N2)OCO5,,,,,,
4939,39634,"5-(3-Chlorobenzoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC(=CC=C3)Cl)C4=CC5=C(C=C4N2)OCO5,,,,,,
4940,39635,"5-(4-Bromobenzoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC=C(C=C3)Br)C4=CC5=C(C=C4N2)OCO5,,,,,,
4941,39636,"5-(3-Bromobenzoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC(=CC=C3)Br)C4=CC5=C(C=C4N2)OCO5,,,,,,
4942,39637,"5-Benzoyl-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC2=C(C(C1)C(=O)C3=CC=CC=C3)C4=CC5=C(C=C4N2)OCO5,,,,,,
4943,39638,"5-(p-Toluoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",CC1=CC=C(C=C1)C(=O)C2CCCCC3=C2C4=CC5=C(C=C4N3)OCO5,,,,,,
4944,39639,"5-(p-Anisoyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",COC1=CC=C(C=C1)C(=O)C2CCCCC3=C2C4=CC5=C(C=C4N3)OCO5,,,,,,
4945,39640,"CYCLOHEPTA(b)-1,3-DIOXOLO(4,5-f)INDOLE, 5,6,7,8,9,10-HEXAHYDRO-5-(2-THENOYL)-",C1CCC2=C(C(C1)C(=O)C3=CC=CS3)C4=CC5=C(C=C4N2)OCO5,,,,,,
4946,39641,"5-(Cyclopentylacetyl)-5,6,7,8,9,10-hexahydrocyclohepta(b)-1,3-dioxolo(4,5-f)indole",C1CCC(C1)CC(=O)C2CCCCC3=C2C4=CC5=C(C=C4N3)OCO5,,,,,,
4947,39642,"1-Naphthalenecarboxamide, N-(2-(dimethylamino)ethyl)-",CN(C)CCNC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
4948,39643,"1-Naphthalenecarboxamide, N-(2-(isopropylamino)ethyl)-",CC(C)NCCNC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
4949,39644,"1-Naphthalenecarboxamide, N-butyl-N-(2-(dimethylamino)ethyl)-",CCCCN(CCN(C)C)C(=O)C1=CC=CC2=CC=CC=C21,,,,,,
4950,39645,"1-Naphthalenecarboxamide, N-(2-(diethylamino)ethyl)-N-phenyl-",CCN(CC)CCN(C1=CC=CC=C1)C(=O)C2=CC=CC3=CC=CC=C32,,,,,,
4951,39646,"1-Naphthalenecarboxamide, N-butyl-6-chloro-N-(2-(diethylamino)ethyl)-",CCCCN(CCN(CC)CC)C(=O)C1=CC=CC2=C1C=CC(=C2)Cl,,,,,,
4952,39647,"2-Naphthalenecarboxamide, N-(2-(diethylamino)ethyl)-",CCN(CC)CCNC(=O)C1=CC2=CC=CC=C2C=C1,,,,,,
4953,39648,"2-Naphthalenecarboxamide, N-butyl-N-(2-(diethylamino)ethyl)-",CCCCN(CCN(CC)CC)C(=O)C1=CC2=CC=CC=C2C=C1,,,,,,
4954,39649,"2-Benzofurancarboxamide, N-(2-(diethylamino)ethyl)-",CCN(CC)CCNC(=O)C1=CC2=CC=CC=C2O1,,,,,,
4955,39650,N-Butyl-N-(2-(diethylamino)ethyl)-2-benzofurancarboxamide,CCCCN(CCN(CC)CC)C(=O)C1=CC2=CC=CC=C2O1,,,,,,
4956,39651,"1,2,3,4-Tetrahydro-N-(2-(dimethylamino)ethyl)-3-isoquinolinecarboxamide",CN(C)CCNC(=O)C1CC2=CC=CC=C2CN1,,,,,,
4957,39652,"1-Naphthalenecarboxamide, 6-chloro-N-(2-morpholinoethyl)-",C1COCCN1CCNC(=O)C2=CC=CC3=C2C=CC(=C3)Cl,,,,,,
4958,39653,"1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)C1C2=CC=CC=C2CCN1,,,,,,
4959,39654,Pentamidine dihydrochloride,C1=CC(=CC=C1C(=[NH2+])N)OCCCCCOC2=CC=C(C=C2)C(=[NH2+])N.[Cl-].[Cl-],,,,,,
4960,39655,"4-Methyl-1,3-dithiolane",CC1CSCS1,,,,,,
4961,39656,"2,3,6-Trichloroanisole",COC1=C(C=CC(=C1Cl)Cl)Cl,,,,,,
4962,39657,2-(Bis(4-fluorophenyl)methoxy)ethanamine hydrochloride,C1=CC(=CC=C1C(C2=CC=C(C=C2)F)OCC[NH3+])F.[Cl-],,,,,,
4963,39658,Flunamine,C1=CC(=CC=C1C(C2=CC=C(C=C2)F)OCCN)F,,,,,,
4964,39659,"Cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methylpropenyl)-, (5-benzyl-3-furyl)methyl ester, (-)-(Z)-",CC(=C[C@H]1[C@H](C1(C)C)C(=O)OCC2=CC=C(O2)CC3=CC=CC=C3)C,,,,,,
4965,39660,Methyl [(4-methylphenyl)sulfonyl]acetate,CC1=CC=C(C=C1)S(=O)(=O)CC(=O)OC,,,,,,
4966,39661,"5-Methyl-1,2,3-thiadiazole",CC1=CN=NS1,,,,,,
4967,39662,"4-(4,5-Dihydro-5,5-dimethyl-1-phenyl-1H-pyrazol-3-yl)-3-hydroxyfuran-2(5H)-one",CC1(CC(=C2COC(=O)C2=O)NN1C3=CC=CC=C3)C,,,,,,
4968,39663,"2-Amino-2'-chloro-6'-methylacetanilide, hydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH3+].[Cl-],,,,,,
4969,39664,2-amino-N-(2-chloro-6-methylphenyl)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CN,,,,,,
4970,39665,"5H-1,3-DIOXOLO(4,5-f)INDOLE-7-ACETIC ACID, 5-(CYCLOPENTYLACETYL)-6-METHYL-",CC1=C(C2=CC3=C(C=C2N1C(=O)CC4CCCC4)OCO3)CC(=O)O,,,,,,
4971,39666,CID 39666,CCOC1(C2=CC=CC=C2N(C1=O)CCC[NH+]3CCOCC3)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
4972,39667,3-Ethoxy-1-(3-morpholin-4-ylpropyl)-3-phenylindol-2-one,CCOC1(C2=CC=CC=C2N(C1=O)CCCN3CCOCC3)C4=CC=CC=C4,,,,,,
4973,39668,2-Hydroxy-3-methyl-5-(2-phenylbutanoyl)benzoic acid,CCC(C1=CC=CC=C1)C(=O)C2=CC(=C(C(=C2)C)O)C(=O)O,,,,,,
4974,39669,"Benzoic acid, 5-((4-fluorophenyl)acetyl)-2-hydroxy-3-methyl-(9CI)",CC1=CC(=CC(=C1O)C(=O)O)C(=O)CC2=CC=C(C=C2)F,,,,,,
4975,39670,2-amino-2-fluoro-3-(1H-imidazol-5-yl)propanoic acid,C1=C(NC=N1)CC(C(=O)O)(N)F,,,,,,
4976,39671,9-Methyl-9H-carbazole-3-carboxaldehyde 2-butylhydrazone,CCCCNN=CC1=CC2=C(C=C1)N(C3=CC=CC=C32)C,,,,,,
4977,39672,CID 39672,CCNN=CC1=CC2=C(C=C1)N(C3=CC=CC=C32)C,,,,,,
4978,39673,CID 39673,CN1C2=C(C=C(C=C2)C=NNC3=CC=C(C=C3)Cl)C4=CC=CC=C41,,,,,,
4979,39674,4-bromo-N-[(9-methylcarbazol-3-yl)methylideneamino]aniline,CN1C2=C(C=C(C=C2)C=NNC3=CC=C(C=C3)Br)C4=CC=CC=C41,,,,,,
4980,39675,"6,6-Dimethyl-2,5,10-undecanetrione",CC(=O)CCCC(C)(C)C(=O)CCC(=O)C,,,,,,
4981,39676,Vinclozolin,CC1(C(=O)N(C(=O)O1)C2=CC(=CC(=C2)Cl)Cl)C=C,,,"['Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)', 'Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","[""Vinclozolin (V) is a fungicide with antiandrogenic properties. To determine the pharmacokinetics and dosimetry of V, adult male rats were administered an oral dose of V (100 mg/kg) in corn oil and sacrificed over time after dosing. V and its metabolites were analyzed in serum and tissues by high performance liquid chromatography/diode array detector/mass spectrometer. V, 2-[[(3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid (M1), and 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide (M2), and five other metabolites were detected in serum and tissues. One metabolite was identified as 3',5'-dichloro-2,3,4-trihydroxy-2-methylbutylanilide (M5). The mean serum concentration data for V were fitted to a one-compartment model for kinetic analysis. At 2 hr, V serum concentration peaked; whereas only trace levels were detected at 24 hr (t(1/2 elim) = 3.6 hr). V was detected in all tissues and preferentially accumulated in fat. M1 serum levels increased until 8 hr, being at least 2-fold higher than those of V at this time, and then declined with a t(1/2) = 3.3 h. M5 was the main metabolite in serum and tissues. Serum M5 levels were 5-fold higher than V and 2-fold greater than M1 at all times. At 48 hr, M5 remained the main metabolite (t(1/2 elim) = 13.1 hr). Liver and kidney exhibited the highest levels of M5, V, and M1. M2 and 3,5-dichloroaniline had the lowest levels of V metabolites in serum and tissues. V is well absorbed, extensively metabolized and widely distributed. M5, the most abundant V metabolite, may be used as an exposure biomarker for pharmacokinetic modeling. These results may clarify the relationship between toxicity and tissue dose of V and its metabolites."", 'Male Wistar rats were dosed with 0.002, 0.02, 0.2, or 2 mg vinclozolin/sq m skin (nominal doses of 0.13, 1.3, 13, or 130 mg vinclozolin/kg b.w.) in CMC vehicle on shaved, unabraded skin of the back for up to 10 hr or until time of sacrifice (if earlier than 10 hr), at which time excess material was washed off with water. Rats were sacrificed at 0.5, 1, 2, 4, 10, or 72 hr after application. Total absorbed was defined as the sum of % of administered dose recovered in urine, cagewash, feces, and tissues plus remaining carcass. Percent absorption went down with increased dose, so that at 72 hr, total percent absorbed dose in 0.002, 0.02, 0.2, or 2 mg/sq m groups was 27, 20, 3, and 1%, respectively. In general, urine accounted for most of the label recovered. Feces generally contained about half as much label as urine for a given group. Most of the label was removed in the washing step in all groups, but the highest percentage recovery in washing was obtained from the higher dose animals.']","[""The mechanism of antiandrogenic activity of vinclozolin was investigated using recombinant human androgen receptor (AR). The two primary metabolites of vinclozolin in plants and mammals are M1 (2-[[3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid) and M2 (3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide). Both metabolites, in a dose-dependent manner, target androgen receptor to the nucleus and inhibit androgen-induced transactivation mediated by the mouse mammary tumor virus promoter. 3',5'-Dichloro-2-hydroxy-2-methylbut-3-enanilide is a 50-fold more potent inhibitor than (2-[[3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid) and only 2-fold less than hydroxyflutamide. In the presence of dihydrotestosterone (50 nM), 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide (0.2-10 uM) inhibits androgen-induced androgen receptor binding to androgen response element DNA. In the absence of dihydrotestosterone, concentrations of 10 uM 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide or hydroxyflutamide promote androgen receptor binding to androgen response element DNA and activation of transcription. Agonist activities of 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide and hydroxyflutamide occur at 10-fold lower concentrations with the mutant androgen receptor (Thr877 to Ala) endogenous to LNCaP human prostate cancer cells. The results indicate that androgen antagonists can act as agonists, depending on ligand binding affinity, concentration, and the presence of competing natural ligands."", ""Vinclozolin (V) is a fungicide used in agricultural settings. V administered to rats is hydrolyzed to 2-[[(3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid (M1) and 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide (M2). V, M1 and M2 have antiandrogenic properties by interacting with the androgen receptor ... Our objective was to characterize V metabolism by rat liver microsomes. V was incubated with non-treated adult male Long-Evans rat liver microsomes and NADPH. Several metabolites were detected following the extraction of incubate with acetonitrile and analysis by HPLC/DAD/MSD. One metabolite was identified as [3-(3,5-dichlorophenyl)-5-methyl-5-(1,2-dihydroxyethyl)-1,3-oxazolidine-2,4-dione] (M4), which was gradually converted to 3',5'-dichloro-2,3,4-trihydroxy-2-methylbutylanilide (M5). Both co-eluted in the same HPLC peak. Another metabolite ([M7]) was detected by UV but was unstable for mass spectral analysis. The K(M app) for co-eluted M4/M5 and [M7] was 53.7 and 135.4 ?M, the V(max app) was 0.812 and 0.669 nmoles/min/mg protein, and CL(int) was 15.1 and 4.9 mL/min/g protein, respectively. Pilocarpine, orphenadrine and proadifen and anti-rat cytochrome P450 (CYP)2A, 2B and 3A antibodies inhibited M4/M5 and [M7] formation. These results indicate that V is efficiently metabolized by CYP ..."", 'The major metabolite in urine, feces, and bile was N-(3,5-dichlorophenyl)-2-methyl-2,3,4-trihydroxybutyramide (in the case of urine and bile, this compound was conjugated as the glucuronide). The percentage of recovered label found in bile of cannulated rats was variable, but ranged as high as 71% of recovered radioactivity. Comparatively high tissue levels were found in liver and kidney. In either tissue, N-(3,5-dichlorophenyl)-2-methyl-2,3,4-trihydroxybutyramide was the major metabolite (not conjugated).', 'Metabolite is buteonic acid derivative and an enanilide metabolite', ""Vinclozolin (V) is a fungicide with antiandrogenic properties. To determine the pharmacokinetics and dosimetry of V, adult male rats were administered an oral dose of V (100 mg/kg) in corn oil and sacrificed over time after dosing. V and its metabolites were analyzed in serum and tissues by high performance liquid chromatography/diode array detector/mass spectrometer. V, 2-[[(3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid (M1), and 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide (M2), and five other metabolites were detected in serum and tissues. One metabolite was identified as 3',5'-dichloro-2,3,4-trihydroxy-2-methylbutylanilide (M5). The mean serum concentration data for V were fitted to a one-compartment model for kinetic analysis. At 2 hr, V serum concentration peaked; whereas only trace levels were detected at 24 hr (t(1/2 elim) = 3.6 hr). V was detected in all tissues and preferentially accumulated in fat. M1 serum levels increased until 8 hr, being at least 2-fold higher than those of V at this time, and then declined with a t(1/2) = 3.3 hr. M5 was the main metabolite in serum and tissues. Serum M5 levels were 5-fold higher than V and 2-fold greater than M1 at all times. At 48 hr, M5 remained the main metabolite (t(1/2 elim) = 13.1 hr). Liver and kidney exhibited the highest levels of M5, V, and M1. M2 and 3,5-dichloroaniline had the lowest levels of V metabolites in serum and tissues. V is well absorbed, extensively metabolized and widely distributed. M5, the most abundant V metabolite, may be used as an exposure biomarker for pharmacokinetic modeling ...""]","['... Plasma half-lives following single oral doses of 10 to 200 mg/kg/day vinclozolin were estimated at 23 and 36 hr for M and F, respectively. Similarly, half life after a 12-hr peak plateau following dietary administration was about 40 hr.', 'Vinclozolin (V) is a fungicide with antiandrogenic properties. To determine the pharmacokinetics and dosimetry of V, adult male rats were administered an oral dose of V (100 mg/kg) in corn oil and sacrificed over time after dosing. ...At 2 hr, V serum concentration peaked; whereas only trace levels were detected at 24 hr (t(1/2 elim) = 3.6 hr). V was detected in all tissues and preferentially accumulated in fat. M1 serum levels increased until 8 hr, being at least 2-fold higher than those of V at this time, and then declined with a t(1/2) = 3.3 hr. ... At 48 hr, M5 remained the main metabolite (t(1/2 elim) = 13.1 hr).']"
4982,39677,"4,5-Dimethylimidazo[5,1-f][1,2,4]triazine-2,7-diamine",CC1=C2C(=NC(=NN2C(=N1)N)N)C,,,,,,
4983,39678,"Carbamic acid, ((4-methoxyphenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SC3=CC=C(C=C3)OC)C,,,,,,
4984,39679,"Carbamic acid, (1,3-benzodioxol-5-ylthio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSC3=CC4=C(C=C3)OCO4)C,,,,,,
4985,39680,"3-Phenyl-1,2,4-thiadiazole",C1=CC=C(C=C1)C2=NSC=N2,,,,,,
4986,39681,Isoprothiolane,CC(C)OC(=O)C(=C1SCCS1)C(=O)OC(C)C,,,,,,
4987,39682,"Coumarin, 4-methylamino-3-nitro-",CNC1=C(C(=O)OC2=CC=CC=C21)[N+](=O)[O-],,,,,,
4988,39683,"Coumarin, 4-butylamino-3-nitro-",CCCCNC1=C(C(=O)OC2=CC=CC=C21)[N+](=O)[O-],,,,,,
4989,39684,4-Benzylamino-3-nitrocoumarin,C1=CC=C(C=C1)CNC2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
4990,39685,"Coumarin, 4-anilino-3-nitro-",C1=CC=C(C=C1)NC2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
4991,39686,"Coumarin, 4-diethylamino-3-nitro-",CCN(CC)C1=C(C(=O)OC2=CC=CC=C21)[N+](=O)[O-],,,,,,
4992,39687,4-Dipropylamino-3-nitrocoumarin,CCCN(CCC)C1=C(C(=O)OC2=CC=CC=C21)[N+](=O)[O-],,,,,,
4993,39688,"Coumarin, 4-morpholino-3-nitro-",C1COCCN1C2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
4994,39689,Xilobam,CC1=C(C(=CC=C1)C)NC(=O)N=C2CCCN2C,,,,,,
4995,39690,"Carbamic acid, methyl(phenylthio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SC3=CC=CC=C3)C,,,,,,
4996,39691,"Carbamic acid, methyl((4-methylphenyl)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=CC=C(C=C1)SN(C)C(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
4997,39692,"Carbamic acid, methyl((3-methylphenyl)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=CC(=CC=C1)SN(C)C(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
4998,39693,"Carbamic acid, ((2,4-dimethylphenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=CC(=C(C=C1)SCNC(=O)OC2=CC=CC3=C2OC(C3)(C)C)C,,,,,,
4999,39694,"Carbamic acid, ((p-tert-butylphenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSC3=CC=C(C=C3)C(C)(C)C)C,,,,,,
5000,39695,"Carbamic acid, ((4-(1,1-dimethylethyl)-2-methylphenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=C(C=CC(=C1)C(C)(C)C)SCNC(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
5001,39696,"Carbamic acid, methyl((2-(1-methylethyl)phenyl)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC(C)C1=CC=CC=C1SN(C)C(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
5002,39697,"Carbamic acid, ((4-chlorophenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSC3=CC=C(C=C3)Cl)C,,,,,,
5003,39698,"Carbamic acid, ((p-bromophenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSC3=CC=C(C=C3)Br)C,,,,,,
5004,39699,"Carbamic acid, ((4-bromo-2-methylphenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=C(C=CC(=C1)Br)SCNC(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
5005,39700,"Carbamic acid, methyl((pentachlorophenyl)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SC3=C(C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)C,,,,,,
5006,39701,"Carbamic acid, ((4-cyanophenyl)thio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSC3=CC=C(C=C3)C#N)C,,,,,,
5007,39702,"Carbamic acid, methyl(2-naphthalenylthio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SC3=CC4=CC=CC=C4C=C3)C,,,,,,
5008,39703,"Carbamic acid, (2-benzothiazolylthio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSC3=NC4=CC=CC=C4S3)C,,,,,,
5009,39704,"Carbamic acid, methyl(methylthio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SC)C,,,,,,
5010,39705,"Carbamic acid, (ethylthio)methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CCSN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
5011,39706,"CARBAMIC ACID, METHYL(PHENYLTHIO)-, o-ISOPROPOXYPHENYL ESTER",CC(C)OC1=CC=CC=C1OC(=O)N(C)SC2=CC=CC=C2,,,,,,
5012,39707,"Carbamic acid, methyl((4-methylphenyl)thio)-, 2-(1-methylethoxy)phenyl ester",CC1=CC=C(C=C1)SN(C)C(=O)OC2=CC=CC=C2OC(C)C,,,,,,
5013,39708,"Carbamic acid, methyl((3-methylphenyl)thio)-, 2-(1-methylethoxy)phenyl ester",CC1=CC(=CC=C1)SN(C)C(=O)OC2=CC=CC=C2OC(C)C,,,,,,
5014,39709,"Carbamic acid, methyl((2-methylphenyl)thio)-, o-isopropoxyphenyl ester",CC1=CC=CC=C1SN(C)C(=O)OC2=CC=CC=C2OC(C)C,,,,,,
5015,39710,"Carbamic acid, ((2,4-dimethylphenyl)thio)methyl-, 2-(1-methylethoxy)phenyl ester",CC1=CC(=C(C=C1)SCNC(=O)OC2=CC=CC=C2OC(C)C)C,,,,,,
5016,39711,CID 39711,CC(C)C1=CC=CC=C1SNC(=O)OC2=CC=CC=C2OC(C)C,,,,,,
5017,39712,N-(p-tert-Butylphenyl)thiomethylcarbamic acid o-isopropoxyphenyl ester,CC(C)OC1=CC=CC=C1OC(=O)NCSC2=CC=C(C=C2)C(C)(C)C,,,,,,
5018,39713,"Carbamic acid, ((4-bromophenyl)thio)methyl-, 2-(1-methylethoxy)phenyl ester",CC(C)OC1=CC=CC=C1OC(=O)NCSC2=CC=C(C=C2)Br,,,,,,
5019,39714,CID 39714,CC1=C(C=CC(=C1)Br)SCNC(=O)OC2=CC=CC=C2OC(C)C,,,,,,
5020,39715,"Carbamic acid, methyl(methylthio)-, 2-(1-methylethoxy)phenyl ester",CC(C)OC1=CC=CC=C1OC(=O)N(C)SC,,,,,,
5021,39716,"CARBAMIC ACID, METHYL(PHENYLTHIO)-, m-ISOPROPYLPHENYL ESTER",CC(C)C1=CC(=CC=C1)OC(=O)N(C)SC2=CC=CC=C2,,,,,,
5022,39717,N-(p-tert-Butylphenyl)thiomethylcarbamic acid m-isopropylphenyl ester,CC(C)C1=CC(=CC=C1)OC(=O)NCSC2=CC=C(C=C2)C(C)(C)C,,,,,,
5023,39718,CID 39718,CN1CC(=O)N=C1[NH3+].C1=CC(=C(C2=C1C(=CN2)CCN)O)O.OS(=O)(=O)[O-],,,,,,
5024,39719,"6,7-Dihydroxytryptamine",C1=CC(=C(C2=C1C(=CN2)CCN)O)O,,,,,,
5025,39720,"AMMONIUM, (p-CHLOROBENZYL)(10-(DIMETHYLDODECYLAMMONIO)DECYL)DIMETHYL-, DIBROMIDE",CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC1=CC=C(C=C1)Cl.[Br-].[Br-],,,,,,
5026,39721,(4-Chlorophenyl)methyl-[10-[dodecyl(dimethyl)azaniumyl]decyl]-dimethylazanium,CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC1=CC=C(C=C1)Cl,,,,,,
5027,39722,Dimethachlor,CC1=C(C(=CC=C1)C)N(CCOC)C(=O)CCl,,,,,,
5028,39723,Toluin,CC1=CC=CC=C1N(CCOC)C(=O)CCl,,,,,,
5029,39724,"Guanidine, N,N'-bis(4-ethoxyphenyl)-",CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OCC)N,,,,,,
5030,39725,"2,3-Dibromodibenzo-P-dioxin",C1=CC=C2C(=C1)OC3=CC(=C(C=C3O2)Br)Br,,,,,,
5031,39726,"2,3-Difluorodibenzo-P-dioxin",C1=CC=C2C(=C1)OC3=CC(=C(C=C3O2)F)F,,,,,,
5032,39727,"1,3-Dichlorodibenzo-P-dioxin",C1=CC=C2C(=C1)OC3=C(O2)C(=CC(=C3)Cl)Cl,,,,,,
5033,39728,"2,3-Dibromo-7,8-dichlorodibenzo-P-dioxin",C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Br)Br,,,,,,
5034,39729,"2,3,7,8-Tetrabromodibenzo-P-dioxin",C1=C2C(=CC(=C1Br)Br)OC3=CC(=C(C=C3O2)Br)Br,,,,,,
5035,39730,"2,3-Dichloro-7,8-difluorodibenzo-P-dioxin",C1=C2C(=CC(=C1F)F)OC3=CC(=C(C=C3O2)Cl)Cl,,,,,,
5036,39731,"2,3-Dibromo-7,8-difluorodibenzo-P-dioxin",C1=C2C(=CC(=C1F)F)OC3=CC(=C(C=C3O2)Br)Br,,,,,,
5037,39732,"1,3,7,8-Tetrachlorodibenzo-P-dioxin",C1=C(C=C(C2=C1OC3=CC(=C(C=C3O2)Cl)Cl)Cl)Cl,,,,,,
5038,39733,"Ammonium, (5-alpha-androstan-3-beta,17-beta-ylene)bis(dimethyl(2-hydroxyethyl)-, dibromide, diacetate",CC(=O)OCC[N+](C)(C)[C@@H]1CC[C@]2([C@H](C1)CC[C@@H]3C2CC[C@]4(C3CC[C@H]4[N+](C)(C)CCOC(=O)C)C)C.[Br-].[Br-],,,,,,
5039,39734,"2-acetyloxyethyl-[(3R,5S,8R,10S,13S,17R)-3-[2-acetyloxyethyl(dimethyl)azaniumyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-dimethylazanium",CC(=O)OCC[N+](C)(C)[C@@H]1CC[C@]2([C@H](C1)CC[C@@H]3C2CC[C@]4(C3CC[C@H]4[N+](C)(C)CCOC(=O)C)C)C,,,,,,
5040,39735,2-Piperidinoethyl phenylcarbamate,C1CC[NH+](CC1)CCOC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
5041,39736,Phenyl-carbamic acid 2-piperidin-1-yl-ethyl ester,C1CCN(CC1)CCOC(=O)NC2=CC=CC=C2,,,,,,
5042,39737,beta-EMGBL,CCC1(CC(=O)OC1)C,,,,,,
5043,39738,"3,5,5-Trimethyl-2(5H)-furanone",CC1=CC(OC1=O)(C)C,,,,,,
5044,39739,4-(Dimethylamino)-2-phenylbutyronitrile,CN(C)CCC(C#N)C1=CC=CC=C1,,,,,,
5045,39740,1-Chloroanthracene,C1=CC=C2C=C3C(=CC2=C1)C=CC=C3Cl,,,,,,
5046,39741,CID 39741,C(=N)([NH3+])SSC(=N)[NH3+].[Br-].[Br-],,,,,,
5047,39742,Butyl nonanoate,CCCCCCCCC(=O)OCCCC,,,,,,
5048,39743,CID 39743,CC(C)C(=CN=O)O,,,,,,
5049,39744,8-Chloro-6-oxooctanoic acid ethyl ester,CCOC(=O)CCCCC(=O)CCCl,,,,,,
5050,39745,"(6S,8S,9R,10S,11S,13S,16R,17R)-2-chloro-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",C[C@@H]1CC2[C@@H]3C[C@@H](C4=CC(=O)C(=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)Cl)F,,,,,,
5051,39746,CID 39746,CCCCC(CCC)C(=O)[O-].[Na+],,,,,,
5052,39747,"2,3-Dihydro-7-methoxy-N-(3-phenylpropyl)-2-benzofuranmethylamine hydrochloride",COC1=CC=CC2=C1OC(C2)C[NH2+]CCCC3=CC=CC=C3.[Cl-],,,,,,
5053,39748,"N-[(7-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]-3-phenylpropan-1-amine",COC1=CC=CC2=C1OC(C2)CNCCCC3=CC=CC=C3,,,,,,
5054,39749,"2-Hexen-1-ol, 2-ethyl-",CCCC=C(CC)CO,,,,,,
5055,39750,2-Methyl-5-undecanone,CCCCCCC(=O)CCC(C)C,,,,,,
5056,39751,But-2-enedioic acid;1-(4-methylsulfonylphenyl)-2-(4-phenylpiperazin-1-yl)ethanone,CS(=O)(=O)C1=CC=C(C=C1)C(=O)CN2CCN(CC2)C3=CC=CC=C3.C(=CC(=O)O)C(=O)O,,,,,,
5057,39752,1-(4-Methylsulfonylphenyl)-2-(4-phenylpiperazin-1-yl)ethanone,CS(=O)(=O)C1=CC=C(C=C1)C(=O)CN2CCN(CC2)C3=CC=CC=C3,,,,,,
5058,39753,"N-((2,4-Dichlorophenoxy)acetyl)-L-alanine",CC(C(=O)O)NC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
5059,39754,"Benzoic acid, 2-methoxy-, copper(2+) salt, hydrate",COC1=CC=CC=C1C(=O)[O-].COC1=CC=CC=C1C(=O)[O-].[Cu+2],,,,,,
5060,39755,"Carbamic acid, thiobis(methyl-, bis(2,3-dihydro-2,2-dimethyl-7-benzofuranyl) ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)NCSCNC(=O)OC3=CC=CC4=C3OC(C4)(C)C)C,,,,,,
5061,39756,"(3S,5S,10S,13R,17R)-3-hydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,3,4,5,6,7,9,11,12,16,17-dodecahydrocyclopenta[a]phenanthren-15-one",CC(C)CCCC(C)[C@H]1CC(=O)C2=C3CC[C@H]4C[C@H](CC[C@@]4(C3CC[C@]12C)C)O,,,,,,
5062,39757,CID 39757,CCOC(=O)CN1CCN(CC1)C(=O)C=CC2=CC(=C(C(=C2)OC)OC)OC.C(=CC(=O)O)C(=O)O,,,,,,
5063,39758,Ethyl cinepazate,CCOC(=O)CN1CCN(CC1)C(=O)C=CC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
5064,39759,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-3-((4-hydroxyphenyl)methyl)-5-phenyl-, (S)-",C1=CC=C(C=C1)C2=N[C@H](C(=O)NC3=C2C=C(C=C3)Cl)CC4=CC=C(C=C4)O,,,,,,
5065,39760,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-3-(1H-indol-3-ylmethyl)-5-phenyl-, (S)-",C1=CC=C(C=C1)C2=N[C@H](C(=O)NC3=C2C=C(C=C3)Cl)CC4=CNC5=CC=CC=C54,,,,,,
5066,39761,"(R-(R*,S*))-1,3-Dihydro-7-chloro-3-(1-hydroxyethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one",CC([C@@H]1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)O,,,,,,
5067,39762,"(S)-1,3-Dihydro-7-chloro-3-(1-methylethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one",CC(C)[C@H]1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,,,,,,
5068,39763,Acetimidoquinone,CC(=O)N=C1C=CC(=O)C=C1,,,,,['N-Acetyl-p-benzoquinone is a known human metabolite of acetaminophen.'],
5069,39764,Vecuronium bromide,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],,,"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",,,
5070,39765,Vecuronium,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,['Vecuronium is a muscle relaxing agent and is used as an adjunct in general anesthesia.'],['The principal pharmacologic effects demonstrated by vecuronium revolve around its competitive binding of cholinergic receptors located at motor end plates. This competitive binding results in muscle relaxant effects that are typically employed as an adjunct to general anesthesia.'],"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",['Fecal (40-75%) and renal (30% as unchanged drug and metabolites)'],['100%'],['5180 minutes']
5071,39766,M-Iodobenzenesulphonyl chloride,C1=CC(=CC(=C1)I)S(=O)(=O)Cl,,,,,,
5072,39767,"Benzoic acid, 3-(aminosulfonyl)-5-nitro-4-(2-phenylethyl)-",C1=CC=C(C=C1)CCC2=C(C=C(C=C2S(=O)(=O)N)C(=O)O)[N+](=O)[O-],,,,,,
5073,39768,"3,6-Diamino-9-ethylcarbazole",CCN1C2=C(C=C(C=C2)N)C3=C1C=CC(=C3)N,,,,,,
5074,39769,"Benzoic acid, 2-arsenoso-",C1=CC=C(C(=C1)C(=O)O)[As]=O,,,,,,
5075,39770,"Carbamic acid, methyl((2-methylphenyl)thio)-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=CC=CC=C1SN(C)C(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
5076,39771,"DIBENZO(b,e)THIEPIN-11-CARBOXAMIDE, 6,11-DIHYDRO-",C1C2=CC=CC=C2C(C3=CC=CC=C3S1)C(=O)N,,,,,,
5077,39772,N-(5-Bromo-3-adamantylmethylcarbonyl)anthranilic acid,C1C2CC3(CC1CC(C2)(C3)Br)CC(=O)NC4=CC=CC=C4C(=O)O,,,,,,
5078,39773,"Bicyclo[3.1.1]heptane, 2,6,6-trimethyl-3-(2-propenyl)-, (1alpha,2beta,3alpha,5alpha)-",CC1C(CC2CC1C2(C)C)CC=C,,,,,,
5079,39774,"1-Naphthaleneacetonitrile, alpha-(2-dimethylaminoethyl)-alpha-(3-methyl-2-butenyl)-, hydrochloride",CC(=CCC(CC[NH+](C)C)(C#N)C1=CC=CC2=CC=CC=C21)C.[Cl-],,,,,,
5080,39775,2-[2-(Dimethylamino)ethyl]-5-methyl-2-naphthalen-1-ylhex-4-enenitrile,CC(=CCC(CCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21)C,,,,,,
5081,39776,alpha-(2-Ethylmethylaminoethyl)-alpha-prenyl-1-naphthylacetonitrile hydrochloride,CC[NH+](C)CCC(CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
5082,39777,2-[2-[Ethyl(methyl)amino]ethyl]-5-methyl-2-naphthalen-1-ylhex-4-enenitrile,CCN(C)CCC(CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5083,39778,"1-Naphthaleneacetonitrile, alpha-(2-diethylaminoethyl)-alpha-(3-methyl-2-butenyl)-, hydrochloride",CC[NH+](CC)CCC(CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
5084,39779,2-[2-(Diethylamino)ethyl]-5-methyl-2-naphthalen-1-ylhex-4-enenitrile,CCN(CC)CCC(CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5085,39780,alpha-(2-Diprenylaminoethyl)-alpha-methyl-1-naphthylacetonitrile hydrochloride,CC(=CC[NH+](CCC(C)(C#N)C1=CC=CC2=CC=CC=C21)CC=C(C)C)C.[Cl-],,,,,,
5086,39781,4-[Bis(3-methylbut-2-enyl)amino]-2-methyl-2-naphthalen-1-ylbutanenitrile,CC(=CCN(CCC(C)(C#N)C1=CC=CC2=CC=CC=C21)CC=C(C)C)C,,,,,,
5087,39782,alpha-(2-Diprenylaminoethyl)-alpha-ethyl-1-naphthylacetonitrile hydrochloride,CCC(CC[NH+](CC=C(C)C)CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
5088,39783,4-[Bis(3-methylbut-2-enyl)amino]-2-ethyl-2-naphthalen-1-ylbutanenitrile,CCC(CCN(CC=C(C)C)CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5089,39784,alpha-Isopropyl-alpha-(2-diprenylaminoethyl)-1-naphthylacetonitrile hydrochloride,CC(C)C(CC[NH+](CC=C(C)C)CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
5090,39785,2-[2-[Bis(3-methylbut-2-enyl)amino]ethyl]-3-methyl-2-naphthalen-1-ylbutanenitrile,CC(C)C(CCN(CC=C(C)C)CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5091,39786,"1-Naphthaleneacetonitrile, alpha,alpha-bis(2-(bis(3-methyl-2-butenyl)amino)ethyl)-",CC(=CCN(CCC(CCN(CC=C(C)C)CC=C(C)C)(C#N)C1=CC=CC2=CC=CC=C21)CC=C(C)C)C,,,,,,
5092,39787,alpha-(2-Diprenylaminoethyl)-alpha-isopropyl-1-naphthylpropionitrile hydrochloride,CC(C)C(CC[NH+](CC=C(C)C)CC=C(C)C)(CC1=CC=CC2=CC=CC=C21)C#N.[Cl-],,,,,,
5093,39788,2-[2-[Bis(3-methylbut-2-enyl)amino]ethyl]-3-methyl-2-(naphthalen-1-ylmethyl)butanenitrile,CC(C)C(CCN(CC=C(C)C)CC=C(C)C)(CC1=CC=CC2=CC=CC=C21)C#N,,,,,,
5094,39789,alpha-(2-Dimethylaminoethyl)-alpha-prenyl-1-naphthylpropionitrile hydrochloride,CC(=CCC(CC[NH+](C)C)(CC1=CC=CC2=CC=CC=C21)C#N)C.[Cl-],,,,,,
5095,39790,2-[2-(Dimethylamino)ethyl]-5-methyl-2-(naphthalen-1-ylmethyl)hex-4-enenitrile,CC(=CCC(CCN(C)C)(CC1=CC=CC2=CC=CC=C21)C#N)C,,,,,,
5096,39791,alpha-(2-Dimethylaminoethyl)-alpha-prenyl-2-naphthylacetonitrile hydrochloride,CC(=CCC(CC[NH+](C)C)(C#N)C1=CC2=CC=CC=C2C=C1)C.[Cl-],,,,,,
5097,39792,2-[2-(Dimethylamino)ethyl]-5-methyl-2-naphthalen-2-ylhex-4-enenitrile,CC(=CCC(CCN(C)C)(C#N)C1=CC2=CC=CC=C2C=C1)C,,,,,,
5098,39793,O-Ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate,CCOP(=O)(C)SCCN(C(C)C)C(C)C,,,"['Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Chemicals that are used to cause the disturbance, disease, or death of humans during WARFARE. (See all compounds classified as Chemical Warfare Agents.)']","['The purpose of this study was to evaluate the efficacy of a novel barrier cream formulation at reducing the percutaneous toxicity of a 2xLD(50) liquid challenge of nerve agent (VX) ... in vitro and in vivo using the domestic pig. Pretreatment of the (inner ear skin) exposure site with barrier cream eliminated mortality, reduced cholinesterase inhibition and prevented any physiological or biochemical signs of intoxication. In contrast, untreated animals exposed to VX exhibited severe signs of intoxication, near total AChE inhibition and generally died within the (3 hr) exposure period (5/6 animals). Application of the barrier cream caused a significant decrease in the area of skin contaminated by VX. It was tentatively concluded that spreading was predominantly a surface phenomena (possibly mediated by capillary movement of the agent through the microrelief or between hair follicles) with little or no contribution from lateral diffusion within the stratum corneum. There was a disparity between the in vitro and in vivo skin absorption measurements that was ascribed to the absence of systemic clearance in vitro. However, both models indicated a substantial reservoir of VX within the skin ...', '... In order to obtain basic information on the toxicokinetics of (+/-)-VX, i.e., under conditions of 100% bioavailability, the blood levels of this agent were measured in hairless guinea pigs at iv doses corresponding with 1 and 2 x  LD50. The derived AUCs indicate a reasonable linearity of the toxicokinetics with dose. Also, the toxicokinetics in marmoset primates was studied at an absolute iv dose corresponding with 1 x  LD50 in the hairless guinea pig which led to approximately the same levels of (+/-)-VX in blood as observed at 2 x  LD50 in the hairless guinea pig. Finally, the toxicokinetics of (+/-)-VX were measured in hairless guinea pigs via the ...  percutaneous route at a dose corresponding with 1 x  LD50 (pc). Large variations were observed between individual animals in the rate of penetration of (+/-)-VX and in concomitant progression of AChE inhibition in blood of these animals. Blood levels of (+/-)-VX increased gradually over a 6-hr period of time. After a 7-hr penetration period, the total AUC corresponded with 2.5% bioavailability relative to iv administration. In contrast with the G-agents C(+/-)P(+/-)-soman and (+/-)-sarin, stereospecificity in the sequestration of the two enantiomers of (+/-)-VX is not a prominent phenomenon. It appears that (+/-)-VX is substantially more persistent in vivo than the two G-agents. This persistence may undermine the efficacy of pretreatment with carbamates of percutaneous intoxication in particular due to gradual replacement of carbamate on AChE by (+/-)-VX, whereas classical treatment of intoxication with oximes is hampered by the short persistence of oximes relative to the agent.', '... The purpose of the present study was to measure and compare the skin absorption kinetics of VX in vitro using pig, human and guinea pig skin to highlight any potential species differences in skin permeability. When undiluted VX was applied directly to the skin, the permeability of guinea pig skin was approximately 7-fold greater than human skin. There was no significant difference in the permeability of pig and human skin. When VX diluted with isopropyl alcohol was applied to the skin, the permeability of guinea pig skin was approximately 4-fold greater than human skin. There was no significant difference in the permeability of pig and human skin. From this data it may be inferred that dermatomed, abdominal pig skin is an appropriate model for the human skin absorption of VX.', 'Studies of the penetration of liquid VX through skin were conducted with Service volunteers in November 1960 ... . Drops of radioactively-tagged VX were placed on the skin in one of three locations: the back, the forearm, or the palm of the hand. The chosen area, excepting the palm, was shaved with an electric razor and a ring was attached to the skin. The rings used on the forearm and the palm were made of polythene with an internal diameter of 2.5 cm; those on the back were made of brass measuring 7 cm in diameter. VX was placed on the skin inside the ring in drops of 2 - 4 ug. Nylon film was stuck over the top of the ring. The assembly and VX were left in place for 6-10 hours, during which time a Geiger counter was used to take measurements. The assembly was then removed and the skin decontaminated, first by stripping with adhesive tape and then by washing with isopropanol and soapy water. ...  According to the volunteer records, 16 men took part in this study. ... ChE depressions observed were small, varying from 1.9% to 3.9%. After a brief delay the penetration of VX through the forearm and the back was ""regular and rapid"": on average, 8% of the VX dose penetrated through back skin and 15% through forearm skin in 8 hours.']",,
5099,39794,2-(p-(Dipropylamino)phenyl)-N-(alpha-methylphenethyl)acetamide,CCCN(CCC)C1=CC=C(C=C1)CC(=O)NC(C)CC2=CC=CC=C2,,,,,,
5100,39795,1-Hydroxy-3-adamantanecarboxylic acid nitrate,C1C2CC3(CC1CC(C2)(C3)O[N+](=O)[O-])C(=O)O,,,,,,
5101,39796,"BIGUANIDE, 1-p-AMINOPHENYL-, HYDROCHLORIDE",C1=CC(=CC=C1N)N=C(N)[NH+]=C(N)N.[Cl-],,,,,,
5102,39797,2-(4-Aminophenyl)-1-(diaminomethylidene)guanidine,C1=CC(=CC=C1N)N=C(N)N=C(N)N,,,,,,
5103,39798,"2-(Bis(2-chloroethyl)amino)-4-methyl-1,3,2-dioxaphospholane 2-oxide",CC1COP(=O)(O1)N(CCCl)CCCl,,,,,,
5104,39799,"Calcium, dichloro(5-chloro-2-methyl-3(2H)-isothiazolone-O)-, mixt. with dichloro(2-methyl-3(2H)-isothiazolone-O)calcium",CN1C(=O)C=CS1.CN1C(=O)C=C(S1)Cl.[Cl-].[Cl-].[Cl-].[Cl-].[Ca+2].[Ca+2],,,,,,
5105,39800,2-Methyl-4-isothiazolin-3-one,CN1C(=O)C=CS1,,,"['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)']",,,
5106,39801,9-Decenyl acetate,CC(=O)OCCCCCCCCC=C,,,,,,
5107,39802,"6-Carbomethoxyamino-2,3-dimethoxy-4-hydroxybenzocycloheptane",COC1=C(C(=C2CC(CCCC2=C1)NC(=O)OC)O)OC,,,,,,
5108,39803,"2,3-Dimethoxy-4-hydroxy-6-methylaminobenzocycloheptane",CNC1CCCC2=CC(=C(C(=C2C1)O)OC)OC,,,,,,
5109,39804,"N-(2,3,4-trimethoxy-5,7,8,9-tetrahydrobenzo[7]annulen-6-ylidene)hydroxylamine",COC1=C(C(=C2CC(=NO)CCCC2=C1)OC)OC,,,,,,
5110,39805,"6-Amino-2,3,4-trimethoxybenzocycloheptane hydrochloride",C[NH2+]C1=CC=CC2=C(C1)C(C(C(C2)OC)OC)OC.[Cl-],,,,,,
5111,39806,"2,3,4-trimethoxy-N-methyl-2,3,4,5-tetrahydro-1H-benzo[7]annulen-6-amine",CNC1=CC=CC2=C(C1)C(C(C(C2)OC)OC)OC,,,,,,
5112,39807,"(2,3,4-Trimethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)carbamic acid methyl ester",COC1=C(C(=C2CC(CCCC2=C1)NC(=O)OC)OC)OC,,,,,,
5113,39808,"5H-Benzocyclohepten-6-amine, 6,7,8,9-tetrahydro-N-methyl-2,3,4-trimethoxy-, oxalate (2:1)",C[NH2+]C1=CC=CC2=C(C1)C(C(C(C2)OC)OC)OC.C[NH2+]C1=CC=CC2=C(C1)C(C(C(C2)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
5114,39809,"NAPHTHO(2,3-d)-1,3-DIOXOLE-2-ACETIC ACID, 2-METHYL-",CC1(OC2=CC3=CC=CC=C3C=C2O1)CC(=O)O,,,,,,
5115,39810,"1,3-BENZODIOXOLE-2-PROPIONIC ACID, 2-(p-CHLOROPHENYL)-",C1=CC=C2C(=C1)OC(O2)(CCC(=O)O)C3=CC=C(C=C3)Cl,,,,,,
5116,39811,CID 39811,C1COCCN1CCOC(=O)CC2(OC3=CC=CC=C3O2)C4=CC=CC=C4.C(=CC(=O)O)C(=O)O,,,,,,
5117,39812,"2-Morpholin-4-ylethyl 2-(2-phenyl-1,3-benzodioxol-2-yl)acetate",C1COCCN1CCOC(=O)CC2(OC3=CC=CC=C3O2)C4=CC=CC=C4,,,,,,
5118,39813,"1,3-Benzodioxole-2-acetamide, N-(2-diethylaminoethyl)-2-methyl-5-nitro-, oxalate",CCN(CC)CCNC(=O)CC1(OC2=C(O1)C=C(C=C2)[N+](=O)[O-])C.C(=O)(C(=O)O)O,,,,,,
5119,39814,"N-(2-diethylaminoethyl)-2-(2-methyl-5-nitro-1,3-benzodioxol-2-yl)acetamide; oxalic acid",CCN(CC)CCNC(=O)CC1(OC2=C(O1)C=C(C=C2)[N+](=O)[O-])C,,,,,,
5120,39815,"1,3-Benzodioxole-2-acetic acid, 2-methyl-, 2-diethylaminoethyl ester, citrate",CCN(CC)CCOC(=O)CC1(OC2=CC=CC=C2O1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
5121,39816,"2-Diethylaminoethyl=2-methyl-1,3-benzodioxole-2-acetate",CCN(CC)CCOC(=O)CC1(OC2=CC=CC=C2O1)C,,,,,,
5122,39817,CID 39817,CCN(CC)CCOC(=O)CC1(OC2=CC=CC=C2O1)C3=CC=CC=C3.C(=CC(=O)O)C(=O)O,,,,,,
5123,39818,"2-(Diethylamino)ethyl 2-(2-phenyl-1,3-benzodioxol-2-yl)acetate",CCN(CC)CCOC(=O)CC1(OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
5124,39819,"1,3-Benzodioxole-2-acetic acid, 2-phenyl-, 2-(2-diethylaminoethoxy)ethyl ester, citrate",CCN(CC)CCOCCOC(=O)CC1(OC2=CC=CC=C2O1)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
5125,39820,"2-(2-Diethylaminoethoxy)ethyl=2-phenyl-1,3-benzodioxole-2-acetate",CCN(CC)CCOCCOC(=O)CC1(OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
5126,39821,"1,3-Benzodioxole-2-acetic acid, 2-phenyl-, (2-morpholinoethoxy)ethyl ester, oxalate",C1COCCN1CCOCCOC(=O)CC2(OC3=CC=CC=C3O2)C4=CC=CC=C4.C(=O)(C(=O)O)O,,,,,,
5127,39822,"2-(2-Morpholinoethoxy)ethyl=2-phenyl-1,3-benzodioxole-2-acetate",C1COCCN1CCOCCOC(=O)CC2(OC3=CC=CC=C3O2)C4=CC=CC=C4,,,,,,
5128,39823,"1,3-Benzodioxole-2-acetamide, N-(2-diethylaminoethyl)-2-methyl-, citrate",CCN(CC)CCNC(=O)CC1(OC2=CC=CC=C2O1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
5129,39824,"N-(2-Diethylaminoethyl)-2-methyl-1,3-benzodioxole-2-acetamide",CCN(CC)CCNC(=O)CC1(OC2=CC=CC=C2O1)C,,,,,,
5130,39825,"1,3-Benzodioxole-2-propionamide, N-(2-diethylaminoethyl)-2-methyl-",CCN(CC)CCNC(=O)CCC1(OC2=CC=CC=C2O1)C,,,,,,
5131,39826,"1,3-Benzodioxole-2-acetamide, N-(2-diethylaminoethyl)-2,5-dimethyl-, citrate",CCN(CC)CCNC(=O)CC1(OC2=C(O1)C=C(C=C2)C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
5132,39827,"N-(2-Diethylaminoethyl)-2,5-dimethyl-1,3-benzodioxole-2-acetamide",CCN(CC)CCNC(=O)CC1(OC2=C(O1)C=C(C=C2)C)C,,,,,,
5133,39828,"Acetic acid, p-chlorophenoxy-, 2-(2-methyl-4-oxo-3,4-dihydro-3-quinazolinyl)ethyl ester",CC1=NC2=CC=CC=C2C(=O)N1CCOC(=O)COC3=CC=C(C=C3)Cl,,,,,,
5134,39829,"Isonicotinic acid, 2-(2-methyl-4-oxo-3,4-dihydro-3-quinazolinyl)ethyl ester",CC1=NC2=CC=CC=C2C(=O)N1CCOC(=O)C3=CC=NC=C3,,,,,,
5135,39830,"Nicotinic acid, 2-(2-methyl-4-oxo-3,4-dihydro-3-quinazolinyl)ethyl ester",CC1=NC2=CC=CC=C2C(=O)N1CCOC(=O)C3=CN=CC=C3,,,,,,
5136,39831,Ethyl 3-(aziridin-1-yl)prop-2-enoate,CCOC(=O)C=CN1CC1,,,,,,
5137,39832,"Androst-5-en-3-one, 17-hydroxy-7-methyl-, (7alpha,17beta)-",C[C@@H]1C=C2CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)O)C,,,,,,
5138,39833,"Barbituric acid, 1-(butoxymethyl)-5-ethyl-5-phenyl-",CCCCOCN1C(=O)C(C(=O)NC1=O)(CC)C2=CC=CC=C2,,,,,,
5139,39834,"1-(Hydroxymethyl)indole-2,3-dione",C1=CC=C2C(=C1)C(=O)C(=O)N2CO,,,,,,
5140,39835,"2,2-Dichloropentanedioic acid",C(CC(C(=O)O)(Cl)Cl)C(=O)O,,,,,,
5141,39836,L-Name,COC(=O)[C@H](CCCN=C(N)N[N+](=O)[O-])N,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
5142,39837,alpha-(2-(Dimethylamino)ethyl)-4-biphenylmethanol hydrochloride,C[NH+](C)CCC(C1=CC=C(C=C1)C2=CC=CC=C2)O.[Cl-],,,,,,
5143,39838,3-(Dimethylamino)-1-(4-phenylphenyl)propan-1-ol,CN(C)CCC(C1=CC=C(C=C1)C2=CC=CC=C2)O,,,,,,
5144,39839,alpha-(2-(Diethylamino)ethyl)-4-biphenylmethanol hydrochloride,CC[NH+](CC)CCC(C1=CC=C(C=C1)C2=CC=CC=C2)O.[Cl-],,,,,,
5145,39840,3-(Diethylamino)-1-(4-phenylphenyl)propan-1-ol,CCN(CC)CCC(C1=CC=C(C=C1)C2=CC=CC=C2)O,,,,,,
5146,39841,alpha-(2-(Methylphenethylamino)ethyl)-4-biphenylmethanol hydrochloride,C[NH+](CCC1=CC=CC=C1)CCC(C2=CC=C(C=C2)C3=CC=CC=C3)O.[Cl-],,,,,,
5147,39842,3-[Methyl(2-phenylethyl)amino]-1-(4-phenylphenyl)propan-1-ol,CN(CCC1=CC=CC=C1)CCC(C2=CC=C(C=C2)C3=CC=CC=C3)O,,,,,,
5148,39843,4'-Chloro-alpha-(2-(dimethylamino)ethyl)-4-biphenylmethanol hydrochloride,C[NH+](C)CCC(C1=CC=C(C=C1)C2=CC=C(C=C2)Cl)O.[Cl-],,,,,,
5149,39844,1-[4-(4-Chlorophenyl)phenyl]-3-(dimethylamino)propan-1-ol,CN(C)CCC(C1=CC=C(C=C1)C2=CC=C(C=C2)Cl)O,,,,,,
5150,39845,"Ketone, 2-methyl-2-imidazolin-1-YL 3,4,5-trimethoxyphenyl-",CC1=NCCN1C(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
5151,39846,"Ketone, 2-isoxazolidinyl 3,4,5-triethoxyphenyl",CCOC1=CC(=CC(=C1OCC)OCC)C(=O)C2CCON2,,,,,,
5152,39847,"Ketone, 3-oxazolidinyl 3,4,5-triethoxyphenyl",CCOC1=CC(=CC(=C1OCC)OCC)C(=O)N2CCOC2,,,,,,
5153,39848,"Hexadeca-7,11-dienyl acetate",CCCCC=CCCC=CCCCCCCOC(=O)C,,,,,,
5154,39849,"1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)C2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C,,,,,,
5155,39850,"2-Propenoic acid, 3a,4,7,7a-tetrahydro-4,7-methano-1H-indenyl ester",C=CC(=O)OC1C=CC2C1C3CC2C=C3,,,,,,
5156,39851,Trilan,C1=C2C(=C(C(=C1Cl)Cl)Cl)NC(=O)O2,,,,,,
5157,39852,"Benzoic acid, 2-(((4-bromophenyl)sulfonyl)amino)-",C1=CC=C(C(=C1)C(=O)O)NS(=O)(=O)C2=CC=C(C=C2)Br,,,,,,
5158,39853,"Benzoic acid, 2-(((4-fluorophenyl)sulfonyl)amino)-",C1=CC=C(C(=C1)C(=O)O)NS(=O)(=O)C2=CC=C(C=C2)F,,,,,,
5159,39854,4-{[(4-Chlorophenyl)sulfonyl]amino}benzoic acid,C1=CC(=CC=C1C(=O)O)NS(=O)(=O)C2=CC=C(C=C2)Cl,,,,,,
5160,39855,N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulphonyl)benzamide monohydrochloride,CC[NH+](CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC.[Cl-],,,,,,
5161,39856,CID 39856,CC12CCC(=O)C=C1C3C[C@@H]3C4[C@@H]2CCC5(C4CC[C@]5(CCC(=O)[O-])O)C.[K+],,,,,,
5162,39857,CID 39857,CC12CCC(=O)C=C1C3C[C@@H]3C4C2CCC5(C4CC[C@]5(CCC(=O)O)O)C,,,,,,
5163,39858,"[2-[(2S,4R,8S,11S,12R)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] acetate",CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3C1(C[C@@H]([C@]4(C3CCC5=CC(=O)C=CC54C)F)O)C)OC6(O2)CCCC6,,,,,,
5164,39859,Albuterol sulfate,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.OS(=O)(=O)O,,,"['Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
5165,39860,Cesamet,CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)']",,,
5166,39861,CID 39861,CC1=NN(C2=NCCNC(=C12)C3=CC(=CC=C3)Cl)C,,,,,,
5167,39862,Butirosin sulfate,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)C(CCN)O)O)O[C@H]2[C@@H](C([C@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N.O.O.OS(=O)(=O)O.OS(=O)(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
5168,39863,CID 39863,C1[C@H](C([C@H](C([C@@H]1NC(=O)C(CCN)O)O)O[C@@H]2[C@@H](C([C@@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@H]([C@@H](O3)CN)O)O)N)N,,,,,,
5169,39864,"4,4,4-Trichlorobut-1-ene",C=CCC(Cl)(Cl)Cl,,,,,,
5170,39865,"Isoquinoline, 1,2,3,4-tetrahydro-5-(2-fluorobenzamido)-2-methyl-, hydrochloride",C[NH+]1CCC2=C(C1)C=CC=C2NC(=O)C3=CC=CC=C3F.[Cl-],,,,,,
5171,39866,"5-(2-Fluorobenzamido)-2-methyl-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=C(C1)C=CC=C2NC(=O)C3=CC=CC=C3F,,,,,,
5172,39867,CID 39867,CN(CO)C(=S)[S-].[K+],,,,,,
5173,39868,(Hydroxymethyl)methylcarbamodithioic acid,CN(CO)C(=S)S,,,,,,
5174,39869,"HYDANTOIN, 3-(o-CHLOROPHENYL)-5,5-DIMETHYL-",CC1(C(=O)N(C(=O)N1)C2=CC=CC=C2Cl)C,,,,,,
5175,39870,"3-Biphenylacetic acid, 5-methoxy-",COC1=CC(=CC(=C1)C2=CC=CC=C2)CC(=O)O,,,,,,
5176,39871,"Acetic acid, 3-isopropyl-5-methoxyphenyl-",CC(C)C1=CC(=CC(=C1)CC(=O)O)OC,,,,,,
5177,39872,"ACETIC ACID, (5-BUTOXY-m-TOLYL)-",CCCCOC1=CC(=CC(=C1)CC(=O)O)C,,,,,,
5178,39873,"ACETIC ACID, 5-ISOBUTOXY-m-TOLYL-",CC1=CC(=CC(=C1)OCC(C)C)CC(=O)O,,,,,,
5179,39874,"Acetic acid, 3-cyclohexyl-5-methoxyphenyl-",COC1=CC(=CC(=C1)C2CCCCC2)CC(=O)O,,,,,,
5180,39875,"3-Biphenylacetic acid, 2'-chloro-5-methoxy-",COC1=CC(=CC(=C1)C2=CC=CC=C2Cl)CC(=O)O,,,,,,
5181,39876,2-[3-(4-Chlorophenyl)-5-methoxyphenyl]acetic acid,COC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
5182,39877,"3-Biphenylacetic acid, 4',5-dimethoxy-",COC1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)OC,,,,,,
5183,39878,"3-Biphenylacetic acid, 5-methoxy-4'-methyl-",CC1=CC=C(C=C1)C2=CC(=CC(=C2)CC(=O)O)OC,,,,,,
5184,39879,"ACETIC ACID, 5-METHOXY-m-TOLYL-",CC1=CC(=CC(=C1)OC)CC(=O)O,,,,,,
5185,39880,6-Methyl-1-oxido-pyrazin-1-ium-2-carboxylic acid,CC1=CN=CC(=[N+]1[O-])C(=O)O,,,,,,
5186,39881,4'-Fluoro-2-hydroxy-4-(4-phenylpiperazin-1-yl)butyrophenone,C1CN(CCN1CCC(C(=O)C2=CC=C(C=C2)F)O)C3=CC=CC=C3,,,,,,
5187,39882,4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-2-hydroxybutyrophenone,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCC(C(=O)C3=CC=C(C=C3)F)O,,,,,,
5188,39883,4'-Fluoro-2-hydroxy-4-(4-(o-methoxyphenyl)-1-piperazinyl)butyrophenone,COC1=CC=CC=C1N2CCN(CC2)CCC(C(=O)C3=CC=C(C=C3)F)O,,,,,,
5189,39884,4'-Fluoro-2-hydroxy-4-(4-(2-pyridyl)-1-piperazinyl)butyrophenone,C1CN(CCN1CCC(C(=O)C2=CC=C(C=C2)F)O)C3=CC=CC=N3,,,,,,
5190,39885,"1-Butanone, 2-((dimethylcarbamoyl)oxy)-1-(4-fluorophenyl)-4-(4-phenyl-1-piperazinyl)-, dihydrochloride",CN(C)C(=O)OC(CCN1CCN(CC1)C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)F.Cl.Cl,,,,,,
5191,39886,"[1-(4-fluorophenyl)-1-oxo-4-(4-phenylpiperazin-1-yl)butan-2-yl] N,N-dimethylcarbamate",CN(C)C(=O)OC(CCN1CCN(CC1)C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)F,,,,,,
5192,39887,"N,N-Diethylaminoethyl indol-3-ylphenylacetate hydrochloride",CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)C2=CNC3=CC=CC=C32.[Cl-],,,,,,
5193,39888,2-(diethylamino)ethyl 2-(1H-indol-3-yl)-2-phenylacetate,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CNC3=CC=CC=C32,,,,,,
5194,39889,alpha-Phenylindole-3-acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)C2=CNC3=CC=CC=C32.[Cl-],,,,,,
5195,39890,2-(dimethylamino)ethyl 2-(1H-indol-3-yl)-2-phenylacetate,CN(C)CCOC(=O)C(C1=CC=CC=C1)C2=CNC3=CC=CC=C32,,,,,,
5196,39891,4-Isopropylbicyclophosphate,CC(C)C12COP(=O)(OC1)OC2,,,,,,
5197,39892,"N'-(2,6-Diethylphenyl)-N,N-dimethylformamidine",CCC1=C(C(=CC=C1)CC)N=CN(C)C,,,,,,
5198,39893,"4H-1-Benzopyran-2-carboxylic acid, 4-oxo-, butyl ester",CCCCOC(=O)C1=CC(=O)C2=CC=CC=C2O1,,,,,,
5199,39894,"Butanamide, N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-3-oxo-2-(phenylazo)-",CC(=O)C(C(=O)NC1=CC2=C(C=C1)NC(=O)N2)N=NC3=CC=CC=C3,,,,,,
5200,39895,CID 39895,CC(C)N=C(S)SC1=CC=CC=C1,,,,,,
5201,39896,"(1,1'-Biphenyl)-3-OL, 2,3',4,4'-tetrachloro-",C1=CC(=C(C=C1C2=C(C(=C(C=C2)Cl)O)Cl)Cl)Cl,,,,,,
5202,39897,"BENZO(c)PHENANTHRIDINIUM, 5-METHYL-2,3,8,9-TETRAMETHOXY-, METHYL SULFATE",C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC(=C(C=C4C=C3)OC)OC)OC)OC.COS(=O)(=O)[O-],,,,,,
5203,39898,O-Methylfagaronine,C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC(=C(C=C4C=C3)OC)OC)OC)OC,,,,,,
5204,39899,1-Bromo-3-methylpentane,CCC(C)CCBr,,,,,,
5205,39900,"N-Ethyl-1,2-bis(isobutylthiolcarbamoyl)ethane",CCN(CCNC(=O)SCC(C)C)C(=O)SCC(C)C,,,,,,
5206,39901,CID 39901,C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)[O-])O)O.[Na+],,,,,,
5207,39902,"2,2-Dimethyl-1,3-dioxane",CC1(OCCCO1)C,,,,,,
5208,39903,"Benzoic acid, 3,3'-(adipoyldiimino)bis(5-((2-oxo-1-pyrrolidinyl)methyl)-2,4,6-triiodo-",C1CC(=O)N(C1)CC2=C(C(=C(C(=C2I)NC(=O)CCCCC(=O)NC3=C(C(=C(C(=C3I)C(=O)O)I)CN4CCCC4=O)I)I)C(=O)O)I,,,,,,
5209,39904,"Benzoic acid, 3,3'-(ethylenebis(oxyethylenecarbonylimino))bis(2,4,6-triiodo-",C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,,,,
5210,39905,"Benzoic acid, 3,3'-(trimethylenebis(oxyethylenecarbonylimino))bis(2,4,6-triiodo-",C1=C(C(=C(C(=C1I)NC(=O)CCOCCCOCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,,,,
5211,39906,"Benzoic acid, 3,3'-(ethylenebis(oxyethylenecarbonylimino))bis(5-(propionamidomethyl)-2,4,6-triiodo-",CCC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)CNC(=O)CC)I)I)C(=O)O)I,,,,,,
5212,39907,"Benzoic acid, 3,3'-(ethylenebis(oxyethyleneoxyethylenecarbonylimino))bis(5-(propionamidomethyl)-2,4,6-triiodo-",CCC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)CNC(=O)CC)I)I)C(=O)O)I,,,,,,
5213,39908,"Benzoic acid, 3,3'-(oxybis(ethyleneoxyethylenecarbonylimino))bis(5-(butyramidomethyl)-2,4,6-triiodo-",CCCC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)CNC(=O)CCC)I)I)C(=O)O)I,,,,,,
5214,39909,"Benzoic acid, 3,3'-(ethylenebis(oxyethyleneoxyethylenecarbonylimino))bis (5-(butyramidomethyl)-2,4,6-triiodo-",CCCC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)CNC(=O)CCC)I)I)C(=O)O)I,,,,,,
5215,39910,"1,3-Benzodioxole-2-acetic acid, 2-methyl-, 2-(2-diethylaminoethoxy)ethyl ester, citrate",CCN(CC)CCOCCOC(=O)CC1(OC2=CC=CC=C2O1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
5216,39911,"2-(2-Diethylaminoethoxy)ethyl=2-methyl-1,3-benzodioxole-2-acetate",CCN(CC)CCOCCOC(=O)CC1(OC2=CC=CC=C2O1)C,,,,,,
5217,39912,Dexibuprofen,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,"['For more information, refer to [ibuprofen].']","['For more information, refer to [ibuprofen].']",,"['The time it take to reach peak plasma concentration is 2.25-5 hours post-administration of oral tablets containing 300mg of dexibuprofen. For more information, refer to [ibuprofen].', 'Mainly renal excretion. For more information, refer to [ibuprofen].', 'For more information, refer to [ibuprofen].', 'For more information, refer to [ibuprofen].']","['For more information, refer to [ibuprofen].', '(S)-(+)-ibuprofen has known human metabolites that include 2-Hydroxyibuprofen and 3-Hydroxyibuprofen.']","['Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours. For more information, refer to [ibuprofen].']"
5218,39913,1-Ethoxy-2-heptanone,CCCCCC(=O)COCC,,,,,,
5219,39914,Massoia lactone,CCCCCC1CC=CC(=O)O1,,,,,,
5220,39915,CID 39915,CCC[C@@H](C)C1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
5221,39916,CID 39916,CCC[C@H](C)C1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
5222,39917,CID 39917,CCC[C@@H](C)C1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
5223,39918,CID 39918,CCC[C@@H](C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
5224,39919,CID 39919,CCC[C@H](C)C1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
5225,39920,CID 39920,CCC[C@H](C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
5226,39921,CID 39921,CCC[C@@H](C)C1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
5227,39922,CID 39922,CCC[C@@H](C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
5228,39923,CID 39923,CCC[C@H](C)C1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
5229,39924,CID 39924,CCC[C@H](C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
5230,39925,"Butyrophenone, 4-(2-methylpiperidino)-, hydrochloride",CC1CCCC[NH+]1CCCC(=O)C2=CC=CC=C2.[Cl-],,,,,,
5231,39926,4-(2-Methylpiperidin-1-yl)-1-phenylbutan-1-one,CC1CCCCN1CCCC(=O)C2=CC=CC=C2,,,,,,
5232,39927,Silvex diethanolamine salt,CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl.C(CO)[NH2+]CCO,,,,,,
5233,39928,(-)-cis-Phenothrin,CC(=C[C@@H]1[C@@H](C1(C)C)C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C,,,,,,
5234,39929,"2,3,7,8-Tetrachlorodibenzofuran",C1=C2C3=CC(=C(C=C3OC2=CC(=C1Cl)Cl)Cl)Cl,,,"['Substances or energies, for example heat or light, which when introduced into the air, water, or land threaten life or health of individuals or ECOSYSTEMS. (See all compounds classified as Environmental Pollutants.)']","['Labeled tetrachlorodibenzofuran was admin orally and iv to male Fischer 344 rats at 0.1 and 1.0 mumole/kg. TCDF was completely absorbed. Within 3 days, <5% remained in liver or fat and <2% remained in skin, with no other tissues exhibiting significant amount of radioactivity. The liver was the main site of accumulation, with lesser amounts being present in adipose tissues and skin. It was excreted primarily by fecal route. More than 50% of the dose was excreted in feces within 48 hr and over 90% within 5 days. Approx 3% was eliminated in urine within 5 days. 5% of the radioactivity administered was excreted in bile within 4 hr as 1 or more metabolites of TCDF.', 'Tissue distribution of receptor protein for tetrachlorodibenzo-p-dioxin (TCDD) in male Sprague-Dawley rats was determined by isoelectric focusing in polyacrylamide gel of cytosol labeled With (3)H-TCDD. In order for the TCDD receptor to focus as a single sharp peak at pi (isoelectric point) of 5.2, partial proteolysis of the receptor was carried out. Radioactivity bound to this peak was completely displaced when labeling of cytosol was carried out in the presence of 100 fold unlabeled 2,3,7,8-tetrachlorodibenzofuran.', 'High absorption (90%) was... reported for 2,3,7,8-tetraCDF in male Fischer-344 rats administered a single gavage dose of the /chlorodibenzofuran/ in Emulphor/ethanol.', 'In /a 3-day period/..., 49% of a dose of 14C-2,3,7,8-tetraCDF was absorbed /from the clipped back skin of male Fischer-344 rats/.', 'For more Absorption, Distribution and Excretion (Complete) data for 2,3,7,8-TETRACHLORODIBENZOFURAN (13 total), please visit the HSDB record page.']","['A recent study... identified glucuronide and sulfate conjugates of 4-hydroxy-2,3,7,8-tetraCDF and 3-hydroxy-2,7,8-triCDF as the major biliary metabolites in rats dosed intravenously with 2,3,7,8-tetraCDF.', 'Thirteen chlorinated compounds were detected in bile collected for 48 hr from female Sprague Dawley rats given a single oral dose of 678 ug TCDF (79.4% pure)/kg bw. The four major metabolites considered to originate from TCDF were trichloromethoxy-dibenzofuran, two trichlorodimethoxy-dibenzofurans, and tetrachloromethoxydibenzofuran. The remaining nine metabolites, detected in minute amounts, originated most likely from contaminating PCDFs (1% triCDF, 8.4% tetraCDFs, 11.2% pentaCDFs).', 'Limited data suggest that autoinduction of metabolism and biliary excretion does occur for PCDFs, in contrast to PCDDs. Pretreatment of rats with 2,3,7,8-TCDF (1.0 umol/kg, 3 days earlier) significantly increased the biliary excretion of a subsequent dose of (14C)2,3,7,8-TCDF. The naive rats excreted 5.7 + or - 2.4% of the dose over the initial 8 hr, while the pretreated rats excreted 13.2 + or - 3.2% of the (14C)2,3,7,8-TCDF. Similarly, pretreatment of rats with 2,3,4,7,8-pentaCDF (500 ug/kg, /orally/, 3 days earlier) resulted in a two-fold increase in the biliary elimination of a subsequent dose of (14C)2,3,4,7,8-pentaCDF. These results suggest that pretreatment with 2,3,7,8-TCDF and 2,3,4,7,8-pentaCDF induces the metabolism of these congeners.', '...Isolated hepatocytes and liver slices in suspension culture and hepatic microsomes were used as in vitro models to assess the hepatic uptake and metabolism of [3H]- and [14C]TCDD and [3H]TCDF (0.01-1.0 uM) in control and induced (5 ug TCDD/kg, 3 days earlier) male Sprague-Dawley rats. TCDD pretreatment, with an increase in cytochromes P450 1A1 and 1A2 (CYP1A1, CYP1A2), produced an increase in the hepatic uptake of TCDD, while no increase in the hepatic uptake of TCDF was observed. ...The rates of metabolism of TCDD and TCDF were directly proportional to their concentrations. ...Very limited metabolism of TCDD and TCDF was observed in control rat liver (0.45 and 3.2 pmol/hr/g hepatocyte wet wt at 0.1 uM, respectively). TCDD induced its own rate of metabolism about two- to fivefold at 1.0 uM but no induction was observed at 0.01 and 0.1 uM. In contrast, TCDD markedly induced the rate of TCDF metabolism at all substrate concentrations.', '...Metabolism of all three compounds appears to be the rate-limiting step for excretion, which is primarily via the bile into the feces. Therefore, the biliary elimination of TCDF, TCDD, and TCB was examined as an indirect measure of metabolism. Male F344 rats were anesthetized with pentobarbital, the bile duct was cannulated, and 0.1 mumol [3H]TCDD, [14C]TCDF, or [14C]TCB/kg bw was administered iv. Bile was collected for 0-8 hr while the animals were kept under anesthesia. To determine if TCDF was able to induce its own metabolism in vivo, a single dose of 1.0 mumol TCDF/kg was administered to rats by oral gavage 3 days prior to iv injection of 0.1 or 0.3 mumol [14C]TCDF/kg. Biliary excretion and hepatic concentrations of [14C]TCDF were significantly increased in the pretreated animals. These results suggest an autoinduction of TCDF metabolism. Essentially all biliary [14C]TCDF radioactivity was attributable to metabolites. High-pressure liquid chromatography profiles of biliary radioactivity from 0-4 hr were qualitatively different between naive and pretreated rats. To determine if pretreatment with TCDD altered the metabolism of TCDF and vice versa, a single dose of 1.0 mumol TCDF/kg or 0.1 mumol TCDD/kg was administered by oral gavage 3 days prior to iv injection of 0.1 mumol [3H]TCDD or [14C]TCDF/kg, respectively.']","['In rhesus monkeys administered a single dose of 30.7 ug 14C-2,3,7,8-tetraCDF/kg iv the CDF was rapidly cleared from the blood. A two component exponential decay from blood was observed, with half-lives of 1.5 min and 1 hr, respectively. ...Half-lives for excretion in urine and feces were 6.2 and 10.3 days, respectively. ...Whole body half-life was /about/ 8 days.', 'TCDF has a short half-life /in rats and mice/ (2-4 days)... .', 'Elimination half-life /in young adult to adult humans/ (range of means): 1.5-3.2 years /from table/', '2,3,7,8-TCDF was also most persistent in the guinea pig /compared to other test species/, with a t1/2 of 20-40 days.']"
5235,39930,p-(9-Acridinylamino)benzoic acid methyl ester hydrochloride,COC(=O)C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
5236,39931,1-Dimethylamino-4-phenyl-4-benzoylaminobutane hydrochloride,C[NH+](C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC=CC=C2.[Cl-],,,,,,
5237,39932,N-[4-(dimethylamino)-1-phenylbutyl]benzamide,CN(C)CCCC(C1=CC=CC=C1)NC(=O)C2=CC=CC=C2,,,,,,
5238,39933,2-(Nitrosoamino)-3-mercaptopropionic acid,C(C(C(=O)O)NN=O)S,,,,,,
5239,39934,"Benzoic acid, 3,3'-(oxybis(ethyleneoxyethylenecarbonylimino))bis(5-(methylcarbamoyl)-2,4,6-triiodo-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
5240,39935,"Benzoic acid, 3,3'-(ethylenebis(oxyethyleneoxyethylenecarbonylimino))bis (5-(methylcarbamoyl)-2,4,6-triiodo-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
5241,39936,16-(Acetyloxy)-14-hydroxy-3-oxocard-20(22)-enolide,CC(=O)O[C@H]1C[C@@]2(C3CC[C@@H]4CC(=O)CC[C@@]4(C3CC[C@@]2(C1C5=CC(=O)OC5)C)C)O,,,,,,
5242,39937,"1,3-Dihydro-7-chloro-3-hydroxy-1-(2-hydroxyethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one",C1=CC=C(C=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCO)O,,,,,,
5243,39938,"7-chloro-5-(2-chlorophenyl)-1-(2-hydroxyethyl)-3H-1,4-benzodiazepin-2-one",C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3Cl)CCO,,,,,,
5244,39939,2-Phenyl-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3)C(=O)O,,,,,,
5245,39940,2-(4-Fluorophenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O,,,,,,
5246,39941,Benoxaprofen,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)']",,,
5247,39942,2-(3-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC(=CC=C3)Cl)C(=O)O,,,,,,
5248,39943,alpha-Methyl-2-(4-methylphenyl)-6-benzoxazoleacetic acid,CC1=CC=C(C=C1)C2=NC3=C(O2)C=C(C=C3)C(C)C(=O)O,,,,,,
5249,39944,2-(4-Acetylphenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)C(=O)C)C(=O)O,,,,,,
5250,39945,CID 39945,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Br)C(=O)[O-].[Na+],,,,,,
5251,39946,"2-[2-(4-Bromophenyl)-1,3-benzoxazol-5-yl]propanoic acid",CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Br)C(=O)O,,,,,,
5252,39947,Ethyl 2-(4-chlorophenyl)-alpha-methyl-5-benzoxazoleacetate,CCOC(=O)C(C)C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl,,,,,,
5253,39948,"6-Benzoxazoleacetic acid, 2-phenyl-, ethyl ester",CCOC(=O)CC1=CC2=C(C=C1)N=C(O2)C3=CC=CC=C3,,,,,,
5254,39949,beta-Methyl-2-phenyl-6-benzoxazoleethanol,CC(CO)C1=CC2=C(C=C1)N=C(O2)C3=CC=CC=C3,,,,,,
5255,39950,alpha-Methyl-2-phenyl-6-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)N=C(O2)C3=CC=CC=C3)C(=O)O,,,,,,
5256,39951,2-(4-Chlorophenyl)-alpha-methyl-6-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)N=C(O2)C3=CC=C(C=C3)Cl)C(=O)O,,,,,,
5257,39952,"alpha-Methyl-2-(3,4-methylenedioxyphenyl)-5-benzoxazoleacetic acid",CC(C1=CC2=C(C=C1)OC(=N2)C3=CC4=C(C=C3)OCO4)C(=O)O,,,,,,
5258,39953,"2-(3,4-Dichlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid",CC(C1=CC2=C(C=C1)OC(=N2)C3=CC(=C(C=C3)Cl)Cl)C(=O)O,,,,,,
5259,39954,"2-(2,4-Dichlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid",CC(C1=CC2=C(C=C1)OC(=N2)C3=C(C=C(C=C3)Cl)Cl)C(=O)O,,,,,,
5260,39955,alpha-Methyl-2-(3-trifluoromethylphenyl)-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC(=CC=C3)C(F)(F)F)C(=O)O,,,,,,
5261,39956,2-(2-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3Cl)C(=O)O,,,,,,
5262,39957,alpha-Methyl-2-(4-trifluoromethylphenyl)-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)C(F)(F)F)C(=O)O,,,,,,
5263,39958,2-(4-Iodophenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)I)C(=O)O,,,,,,
5264,39959,2-(3-Fluorophenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC(=CC=C3)F)C(=O)O,,,,,,
5265,39960,"2-(3,5-Dichlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid",CC(C1=CC2=C(C=C1)OC(=N2)C3=CC(=CC(=C3)Cl)Cl)C(=O)O,,,,,,
5266,39961,2-(2-Fluorophenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3F)C(=O)O,,,,,,
5267,39962,2-(2-Chlorophenyl)-alpha-methyl-6-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)N=C(O2)C3=CC=CC=C3Cl)C(=O)O,,,,,,
5268,39963,CID 39963,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)[O-].[Na+],,,,,,
5269,39964,alpha-Methyl-2-(4-nitrophenyl)-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)[N+](=O)[O-])C(=O)O,,,,,,
5270,39965,Hexazinone,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Orally administered hexazinone has not been demonstrated to accumulate preferentially in any tissue. /Dose not specified/', '... Hexazinone was given in the diet at 0, 1, 5, or 25 ppm to /dairy cows/ for 30 days. ... No detectable residues /were noted/ in milk, fat, liver, kidney or lean muscle.', '...Three groups of male and female Sprague Dawley rats were treated as follows: (1) Group A received a single intragastric low dose of (14)C-hexazinone (14 mg/kg) without preconditioning (treatment with non-radioactive hexazinone); (2) Group B received a single intragastric dose of (14)C-hexazinone (14 mg/kg) after three weeks of preconditioning with 100 ppm of non-radioactive hexazinone in the diet; and (3) Group C received a single intragastric high-dose of (14)C-hexazinone (1000 mg/kg) without preconditioning. Hexazinone was rapidly metabolized by hydroxylation and demethylation, and eliminated by the rats in urine and feces during the 3 to 6-day testing periods. About 77% and 20% (of the administered dose) of (14)C-hexazinone was excreted in urine and feces, respectively. Practically all radioactivity was recovered in the first 24 hours after treatment. Very low levels of radioactivity (about 0.2% of the administered dose) were detected in the G.I. tract, hide, organs (heart, lungs, liver, spleen, kidneys, brain, and testes or ovaries), muscle, fat and blood.', '/Male rats were/ ... administered 2,500 ppm (125 mg/kg) hexazinone in the diet ... for 17 days. This was followed by a single dose of 18.3 mg/300 g (61 mg/kg) (14)C-labeled hexazinone. The hexazinone was rapidly absorbed within 72 hours, with 61% detected in the urine and 32% in the feces. Trace amounts were found in the gastrointestinal tract (0.6%, tissues not specified) and expired air (0.08%).', 'For more Absorption, Distribution and Excretion (Complete) data for Hexazinone (8 total), please visit the HSDB record page.']","['Major urinary metabolites of hexazinone in rats /includes the following/: 3-(4-hydroxycyclohexyl)-6-(dimethylamino)-1-methyl-1,3,5-triazine- 2,4-(1H,3H)-dione (metabolite A); 3-cyclohexyl-6-(methylamino)-1-methyl- 1,3,5-triazine-2,4-(1H,3H)-dione (metabolite B); and 3-(4-hydroxycyclohexyl)-6- (methylamino)-1-methyl-1,3,5-triazine-2,4-(1H,3H)-dione (metabolite C). The percentages of these metabolites detected in the urine were 46.8, 11.5 and 39.3%, respectively. The major fecal metabolites ... were A (26.3%) and C (55.2%). Less than 1% unchanged hexazinone was detected in the urine or the feces.']",
5271,39966,Buminafos,CCCCNC1(CCCCC1)P(=O)(OCCCC)OCCCC,,,,,,
5272,39967,CID 39967,CCCCC(CC)CN1C(C(C(C(C1=O)C#N)C)N=NC2=CC=CC=C2[N+](=O)[O-])O,,,,,,
5273,39968,CID 39968,C(CCN=C(S)[S-])C[NH3+],,,,,,
5274,39969,CID 39969,C(CCN=C(S)S)CN,,,,,,
5275,39970,"Benzoic acid, 3,3'-(ethylenebis(oxyethylenecarbonylimino))bis(5-(butyramidomethyl)-2,4,6-triiodo-",CCCC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)CNC(=O)CCC)I)I)C(=O)O)I,,,,,,
5276,39971,"2,2',5,5'-Tetrachloro-4-biphenylol",C1=CC(=C(C=C1Cl)C2=CC(=C(C=C2Cl)O)Cl)Cl,,,,,,
5277,39972,DL-p-Chlorophenylalanine hydrochloride,C1=CC(=CC=C1CC(C(=O)O)[NH3+])Cl.[Cl-],,,,,,
5278,39973,Tiamenidine hydrochloride,CC1=CSC(=C1NC2=NCCN2)Cl.Cl,,,,,,
5279,39974,Tiamenidine,CC1=CSC(=C1NC2=NCCN2)Cl,,,,,,
5280,39975,Methyl 5-(2-chloro-4-fluorophenoxy)-2-nitrobenzoate,COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)F)Cl)[N+](=O)[O-],,,,,,
5281,39976,Denotivir,CC1=NSC(=C1C(=O)NC2=CC=C(C=C2)Cl)NC(=O)C3=CC=CC=C3,,,,,,
5282,39977,Perfluoromethyldecalin,C12(C(C(C(C(C1(C(F)(F)F)F)(F)F)(F)F)(F)F)(C(C(C(C2(F)F)(F)F)(F)F)(F)F)F)F,,,,,,
5283,39978,Buthiobate,CCCCSC(=NC1=CN=CC=C1)SCC2=CC=C(C=C2)C(C)(C)C,,,,,,
5284,39979,CID 39979,C[N+](C)(C)CC=CC(=O)OC.[O-]Cl(=O)(=O)=O,,,,,,
5285,39980,"2-Buten-1-aminium, 4-methoxy-N,N,N-trimethyl-4-oxo-",C[N+](C)(C)CC=CC(=O)OC,,,,,,
5286,39981,Sparfosic acid,C([C@@H](C(=O)O)NC(=O)CP(=O)(O)O)C(=O)O,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
5287,39982,CID 39982,BC#N.CN1CCOCC1,,,,,,
5288,39983,boranylformonitrile;N-methylmethanamine,BC#N.CNC,,,,,,
5289,39984,"Acetic acid, (4-(2,4-dichlorophenoxy)phenoxy)-",C1=CC(=CC=C1OCC(=O)O)OC2=C(C=C(C=C2)Cl)Cl,,,,,,
5290,39985,Diclofop-methyl,CC(C(=O)OC)OC1=CC=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl,,,,"['ESTERS NORMALLY EXHIBIT GREATER HERBICIDAL ACTIVITY THAN PARENT ACIDS, BECAUSE OF IMPROVED ABSORPTION BY TARGET PLANTS. /PHENOXYALKANOIC ACIDS/', 'The chlorophenoxy compounds are absorbed across the gut wall, lung, and skin. They are not significantly fat storable. Excretion occurs almost entirely by way of the urine. /Chlorphenoxy herbicides/']","['Diclofop-methyl undergoes extensive hydrolysis to its corresponding carboxylic acid in plants in soil. It is then decarboxylated to phenyl ethyl ether and transformed to the phenol in soil. The phenol may undergo complexing or binding to soil and/or be subjected to further degradative processes involving splitting of the ether linkage to give such products as m-dichlorobenzene or 2,4-dichlorophenol. Ring hydroxylation at the 5-position of the 2,4-dichlorophenol moiety was observed but not the other positions of the phenyl rings in plants and soil.', ""This herbicide was applied to wheat at the rate of 1 kg/ha. Analyses of plant material indicated the presence of unchanged herbicide in addition to a number of metabolites. The main metabolites were identified with GC-MS as the free acid, 5'-OH-analog, and 3'-OH- and 6'-OH-analogs of the free acid as plant conjugates. The breakdown of diclofop-methyl in moist nonsterile clays and sandy loam was investigated. Rapid hydrolysis to the acid occurred initially. This bound tightly to the soils. Subsequently, there was decarboxylation to the ethyl analog and cleavage of the ethyl moiety to produce 2,4-dichlorophenoxy-p-phenol. In soils, diclofop-methyl ester bond was rapidly hydrolyzed and the substituted propionic acid was aerobically oxidized to carbon dioxide. An intermediate was identified as 4-(2,4-dichlorophenoxy)phenol. Under anaerobic conditions, only a small degree of degradation occurred.""]",
5291,39986,CID 39986,CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4[C@@H](C3C)[C@@H](C5C4CC=C6C5(CCC(C6)O)C)O)C)NC1,,,,,,
5292,39987,(+)-cis-Tetramethrin,CC(=C[C@@H]1[C@@H](C1(C)C)C(=O)OCN2C(=O)C3=C(C2=O)CCCC3)C,,,,,,
5293,39988,Methyl 3-(2-(benzylmethylamino)ethyl)benzoate hydrochloride,C[NH+](CCC1=CC(=CC=C1)C(=O)OC)CC2=CC=CC=C2.[Cl-],,,,,,
5294,39989,Methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate,CN(CCC1=CC(=CC=C1)C(=O)OC)CC2=CC=CC=C2,,,,,,
5295,39990,"[2-Chloro-10,13-dimethyl-3-(4-nitrophenoxy)imino-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] acetate",CC(=O)OC1CCC2C1(CCC3C2CCC4C3(CC(C(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)Cl)C)C,,,,,,
5296,39991,CID 39991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C[C@H](C(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)Cl)C,,,,,,
5297,39992,CID 39992,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC[C@@H]4[C@@]3(C[C@H](C(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)Cl)C,,,,,,
5298,39993,CID 39993,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C[C@H](C(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)Br)C,,,,,,
5299,39994,CID 39994,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC[C@@H]4[C@@]3(C[C@H](C(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)Br)C,,,,,,
5300,39995,Diisodecyl phenyl phosphate,CC(C)CCCCCCCOP(=O)(OCCCCCCCC(C)C)OC1=CC=CC=C1,,,,,,
5301,39996,Phenylazoindole,C1=CC=C(C=C1)N=NC2=CNC3=CC=CC=C32,,,,,,
5302,39997,"(1R)-(+)-7-Hydroxy-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[C@@H]1C2=CC(=C(C=C2CC[NH2+]1)OC)O.[Cl-],,,,,,
5303,39998,"(1R)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol",C[C@@H]1C2=CC(=C(C=C2CCN1)OC)O,,,,,,
5304,39999,Isoamygdalin,C1=CC=C(C=C1)C(C#N)O[C@H]2C(C([C@@H](C(O2)CO[C@H]3C(C([C@@H](C(O3)CO)O)O)O)O)O)O,,,,,,
5305,40000,Dexbudesonide,CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,['Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).'],,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']","['/MILK/ Not known whether budesonide is distributed in milk.', 'When budesonide is administered intranasally, approximately 34% of a dose reaches systemic circulation. Mean peak plasma budesonide concentrations are achieved in about 0.7 hours.', 'Inhaled corticosteroids (ICS) are mainstay treatment of asthma and chronic obstructive pulmonary disease. However, highly lipophilic ICS accumulate in systemic tissues, which may lead to adverse systemic effects. The accumulation of a new, highly lipophilic ICS, ciclesonide and its active metabolite (des-CIC) has not yet been reported. Here, we have compared tissue accumulation of des-CIC and an ICS of a moderate lipophilicity, budesonide (BUD), after 14 days of once-daily treatment in mice. Single, three or 14 daily doses of [(3) H]-des-CIC or [(3) H]-BUD were administered subcutaneously to male CD1 albino mice, which were killed at 4 hrs, 24 hrs or 5 days after the last dose. Distribution of tissue concentration of radioactivity was studied by quantitative whole-body autoradiography. Pattern of radioactivity distribution across most tissues was similar for both corticosteroids after a single as well as after repeated dosing. However, tissue concentration of radioactivity differed between des-CIC and BUD. After a single dose, concentrations of radioactivity for both corticosteroids were low for most tissues but increased over 14 days of daily dosing. The tissue radioactivity of des-CIC at 24 hrs and 5 days after the 14th dose was 2-3 times higher than that of BUD in majority of tissues. Tissue accumulation, assessed as concentration of tissue radioactivity 5 days after the 14th versus 3rd dose, showed an average ratio of 5.2 for des-CIC and 2.7 for BUD (p < 0.0001). In conclusion, des-CIC accumulated significantly more than BUD. Systemic accumulation may lead to increased risk of adverse systemic side effects during long-term therapy.']","['Budesonide is metabolized in the liver by the cytochrome P-450 (CYP) isoenzyme 3A4; the 2 main metabolites have less than 1% of affinity for glucocorticoid receptors than the parent compound. Budesonide is excreted in urine and feces as metabolites.', 'Asthma is one of the most prevalent diseases in the world, for which the mainstay treatment has been inhaled glucocorticoids (GCs). Despite the widespread use of these drugs, approximately 30% of asthma sufferers exhibit some degree of steroid insensitivity or are refractory to inhaled GCs. One hypothesis to explain this phenomenon is interpatient variability in the clearance of these compounds. The objective of this research is to determine how metabolism of GCs by the CYP3A family of enzymes could affect their effectiveness in asthmatic patients. In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites. Both interenzyme and interdrug variability in rates of metabolism and metabolic fate were observed. CYP3A4 was the most efficient metabolic catalyst for all the compounds, and CYP3A7 had the slowest rates. CYP3A5, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and fluticasone propionate. In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or CYP3A7. Common metabolites included 6 Beta-hydroxylation and Delta (6)-dehydrogenation for triamcinolone acetonide, budesonide, and flunisolide. The structure of Delta (6)-flunisolide was unambiguously established by NMR analysis. Metabolism also occurred on the D-ring substituents, including the 21-carboxy metabolites for triamcinolone acetonide and flunisolide. The novel metabolite 21-nortriamcinolone acetonide was also identified by liquid chromatography-mass spectrometry and NMR analysis.']",
5306,40001,"3-Acetamido-alpha-ethyl-2,4,6-triiodohydrocinnamic acid",CCC(CC1=C(C(=C(C=C1I)I)NC(=O)C)I)C(=O)O,,,,,,
5307,40002,2-(Azepan-1-yl)ethanamine,C1CCCN(CC1)CCN,,,,,,
5308,40003,1'-Hydroxyestragole,COC1=CC=C(C=C1)C(C=C)O,,,,,,
5309,40004,2-[(4-Methoxyphenyl)methyl]oxirane,COC1=CC=C(C=C1)CC2CO2,,,,,,
5310,40005,CID 40005,CC[NH+](CC)CCCNC(=O)C(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].[Cl-],,,,,,
5311,40006,CID 40006,CCN(CC)CCCNC(=O)C(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
5312,40007,2-(2-Ethoxyethoxy)-2-methylpropane,CCOCCOC(C)(C)C,,,,,,
5313,40008,cis-1-Bromo-2-Chlorocyclohexane,C1CC[C@H]([C@H](C1)Cl)Br,,,,,,
5314,40009,Salsoline hydrochloride,C[C@@H]1C2=CC(=C(C=C2CC[NH2+]1)O)OC.[Cl-],,,"['Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)']",,,
5315,40010,(R)-salsoline,C[C@@H]1C2=CC(=C(C=C2CCN1)O)OC,,,"['Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)']",,,
5316,40011,"Benzoic acid, 4-(2-(octyloxy)benzamido)-, 2-(diethylamino)ethyl ester hydrochloride",CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
5317,40012,2-(Diethylamino)ethyl 4-(2-(octyloxy)benzamido)benzoate,CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCCN(CC)CC,,,,,,
5318,40013,Diethylmethyl(2-(4-(2-propoxybenzamido)benzoyloxy)ethyl)ammonium bromide,CCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-],,,,,,
5319,40014,Diethyl-methyl-[2-[4-[(2-propoxybenzoyl)amino]benzoyl]oxyethyl]azanium,CCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC,,,,,,
5320,40015,(2-(4-(2-Allyloxybenzamido)benzoyloxy)ethyl)diethylmethylammonium bromide,CC[N+](C)(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2OCC=C.[Br-],,,,,,
5321,40016,Diethyl-methyl-[2-[4-[(2-prop-2-enoxybenzoyl)amino]benzoyl]oxyethyl]azanium,CC[N+](C)(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2OCC=C,,,,,,
5322,40017,CID 40017,CN1C(CC2=CC(=C(C=C21)O)N=NC(=O)N)S(=O)(=O)[O-].[Na+],,,,,,
5323,40018,Carbazochrome sulfonic acid,CN1C(CC2=CC(=C(C=C21)O)N=NC(=O)N)S(=O)(=O)O,,,,,,
5324,40019,"Anthraquinone, 1,5-dinitro-2-methyl-",CC1=C(C2=C(C=C1)C(=O)C3=C(C2=O)C=CC=C3[N+](=O)[O-])[N+](=O)[O-],,,,,,
5325,40020,"N-(2,2-Dimethoxyethyl)-N'-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-N-methylurea",CC(C)(C)C1=NN=C(S1)NC(=O)N(C)CC(OC)OC,,,,,,
5326,40021,CID 40021,CC(C)CCCC(C(=O)C=CC1=CC(=C(C=C1)Cl)Cl)[NH+](C)C.[Cl-],,,,,,
5327,40022,CID 40022,CC(C)CCCC(C(=O)C=CC1=CC(=C(C=C1)Cl)Cl)N(C)C,,,,,,
5328,40023,2-Chloroethyl myristate,CCCCCCCCCCCCCC(=O)OCCCl,,,,,,
5329,40024,Deoxynivalenol,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3(C[C@H]([C@H]([C@@]34CO4)O2)O)C)CO,,,,"['Metabolic studies have been carried out on animals, principally with T-2 toxin, but a few with /deoxynivalenol/ (DON). These trichothecenes are rapidly absorbed from the alimentary tract... . The toxins are distributed fairly evenly without marked accumulation in any specific organ or tissue. Trichothecenes are metabolically transformed to less toxic metabolites by such reactions as hydrolysis, hydroxylation, de-epoxidation, and glucuronidation. Trichothecenes, such as T-2 toxin and DON, are rapidly eliminated in the feces and urine. ...In the rat, 25% of DON was eliminated in the urine and 65% in the feces, 96 hr after dosing.', 'Although deoxynivalenol appeared in the blood within 30 min after intake by sheep, the systemic bioavailability was only 7.5%. A single dose of 5 mg/kg bw of deoxynivalenol was administered by oral intubation to four 1-yr-old male sheep, and repeated blood samples were taken over 30 hr. Deoxynivalenol and the de-epoxy metabolite were determined by GC with electron capture detection (ECD). No deoxynivalenol or the de-epoxy metabolite could be detected in plasma within the 30-hr observation period. Three male sheep were given a single iv dose of deoxynivalenol at 0.5 mg/kg bw, with blood sampling and analysis as after oral dosing. Systemic bioavailability was calculated from the ratio of the integrated area under the concentration-time curve times the dose for both oral and iv administration. <0.3% of the oral dose and <2% of the iv dose was detected in plasma as the de-epoxy metabolite. Free deoxynivalenol accounted for an average of 24.8% of the absorbed dose measured in blood; the remainder was made up of the de-epoxy metabolite or the glucuronide conjugate of deoxynivalenol. The oral absorption rate of deoxynivalenol in sheep was approximately 7% on the basis of recovery rates from urine and bile collected over 36 hr from two sheep given 5 mg/kg bw of deoxynivalenol orally. Deoxynivalenol and the de-epoxy metabolite were analysed by GC/ECD. An average of 6.9% of the administered dose was recovered from urine and 0.11% from bile. Glucuronide-conjugated de-epoxy metabolite was the only form detected in bile (detection limit, 0.1 mg, corresponding to 0.04% of the administered dose). An average of 1.3% of the administered dose was recovered from urine as the de-epoxy metabolite or its conjugate, and 5.7% was recovered as deoxynivalenol or its conjugate.', 'In contrast to the low bioavailability seen in sheep and cows, relatively high bioavailability was observed in pigs. Blood, urine, bile, and feces were collected over 24 hr after an intragastric dose of 0.6 mg/kg bw of [(14)C]deoxynivalenol or an iv dose of 0.3 mg/kg bw. The proportions of radiolabel were assumed to represent those of administered deoxynivalenol, and the validity of this assumption was confirmed by GC/MS, which showed very little metabolism or conjugation. On the basis of measurements of the integrated area under the concentration-time curve for three animals treated intravenously and three treated intragastrically, the average systemic bioavailability of deoxynivalenol in pigs was estimated to be 55%. Approximately 95% of the administered dose was recovered as deoxynivalenol... .', 'Although the absolute bioavailability of deoxynivalenol has not been measured in rats, 25% of an oral dose of 10 mg/kg bw was recovered in urine at 96 hr, suggesting that the absorption rate in rats may be higher than in sheep or cows. HPLC and GC/MS analysis indicated that 25% of the radiolabel in 0-24 hr urine was associated with unchanged deoxynivalenol and 10% with the de-epoxy metabolite. Similarly, 4.5 and 4.4% of an orally administered dose of 6 mg/kg bw was recovered in the urine of Wistar rats as free deoxynivalenol and the de-epoxy metabolite, respectively, within 96 hr.', 'For more Absorption, Distribution and Excretion (Complete) data for DEOXYNIVALENOL (13 total), please visit the HSDB record page.']","['The minimum single emetic doses of deoxynivalenol and 15-acetyldeoxynivalenol in groups of three Yorkshire pigs weighing 10-15 kg were 0.050 and 0.075 mg/kg bw, respectively, when given either by gavage or ip. After gavage, 3 of 15 pigs given the 15-acetyl metabolite and 4 of 15 given deoxynivalenol showed emesis at all doses from 20-200 ug/kg bw. After ip administration, 9 of 15 pigs showed emesis at all doses. The NOELs were 0.025 mg/kg bw for deoxynivalenol and 0.050 mg/kg bw for the 15-acetyl metabolite after either oral intubation or ip injection...', 'Deoxynivalenol (DON) requires no activation for toxicity, though susceptibility may reflect individual variations in detoxification. This study reports the measurement of un-metabolised urinary DON (free DON) and DOM-1 in samples previously analyzed for the combined measure of free DON+DON-glucuronide (fD+DG), with a concentration >5 ng/mL, for 34 UK adults. Four consecutive daily urine samples were analyzed from twenty-two individuals, whilst from 12 individuals only a single sample was analyzed. The mean (median) concentration of urinary fD+DG in this sub-set was 17.8 ng/mL (13.8 ng/mL), range 5.0-78.2 ng/mL. In 23/34 (68%) individuals, free DON was detected, mean 2.4 ng/mL; range 0.5-9.3 ng/mL. Urinary DOM-1 was detected in 1/34 (3%) of individuals; present at /about/ 1% of urinary fD+DG concentration for that individual. The concentration of fD+DG combined was significantly correlated with urinary free DON (p<0.001, R(2)=0.65), but not with the percentage of free DON to fD+DG (p=0.615, R(2)=0.01), suggesting that the level of DON exposure did not affect the metabolism to DG within the range observed. In this survey most individuals had no detectable urinary DOM-1 and 68% did not detoxify all of the ingested DON to DON-glucuronide...', 'Deoxynivalenol-3-beta-D-glucoside (D3G), a plant phase II metabolite of the Fusarium mycotoxin deoxynivalenol (DON), occurs in naturally contaminated wheat, maize, oat, barley and products thereof. Although considered as a detoxification product in plants, the toxicity of this substance in mammals is currently unknown. A major concern is the possible hydrolysis of the D3G conjugate back to its toxic precursor mycotoxin DON during mammalian digestion. /The authors/ used in vitro model systems to investigate the stability of D3G to acidic conditions, hydrolytic enzymes and intestinal bacteria, mimicking different stages of digestion. D3G was found resistant to 0.2 M hydrochloric acid for at least 24 hr at 37 C, suggesting that it will not be hydrolyzed in the stomach of mammals. While human cytosolic beta-glucosidase also had no effect, fungal cellulase and cellobiase preparations could cleave a significant portion of D3G. Most importantly, several lactic acid bacteria such as Enterococcus durans, Enterococcus mundtii or Lactobacillus plantarum showed a high capability to hydrolyze D3G. Taken together these data indicate that D3G is of toxicological relevance and should be regarded as a masked mycotoxin.', 'Cultures of 20% w/w suspensions of rat cecal contents were incubated anaerobically with [(14)C]deoxynivalenol at a concentration of 35 ug/mL for up to 24 hr. A standard-co-elution method involving high-performance liquid chromatography (HPLC) was used to quantify the proportions of radiolabel associated with deoxynivalenol and with the de-epoxidated form. The latter represented 1.3% of the administered radiolabel immediately after addition of deoxynivalenol, 29% at 7 hr, and 90% at 24 hr; 60% co-eluted with deoxynivalenol at 7 hr and 2% at 24 hr. ...Deoxynivalenol was not converted to the de-epoxy metabolite in cultures of the contents of pig large intestine (including caecum, but not otherwise specified) in another study in which 1 mL of a 1-ug/mL solution of deoxynivalenol was added to 2 g of large intestinal contents and incubated anaerobically for 96 hr. Nearly complete recovery of intact deoxynivalenol was reported. The intestinal contents of chickens treated identically showed nearly complete conversion of deoxynivalenol to the de-epoxy metabolite after 96 hr. After 24 hr of incubation, the rate of conversion was 56% of an applied concentration of 0.014 ug/mL, 69% of 0.14 ug/mL, and 70% of 1.4 ug/mL. Similarly, 35% of the applied deoxynivalenol was metabolized to the de-epoxy metabolite in bovine rumenal fluid after 96 hr of incubation.', 'For more Metabolism/Metabolites (Complete) data for DEOXYNIVALENOL (8 total), please visit the HSDB record page.']","['/In pigs/ after oral intake, the peak concentration in plasma was reached within 15-30 min, remained elevated for about 9 hr and then declined with a half-time of 7.1 hr.', 'Following a single iv injection (1 mg/kg bw) of deoxynivalenol to swine, ... the elimination half-life was estimated at 3.9 hr.']"
5330,40025,CID 40025,CCCCCCN1CCN(CC1)C(=NCC(C)C)C2=CC=CC=C2.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5331,40026,Bucainide,CCCCCCN1CCN(CC1)C(=NCC(C)C)C2=CC=CC=C2,,,,,,
5332,40027,"(2S,5R,6R)-3,3-dimethyl-6-[[2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C,,,,,,
5333,40028,"Phosphoric acid--3-(1a,10b-dihydrodibenzo[a,e]cyclopropa[c][7]annulen-6(1H)-ylidene)-N-methylpropan-1-amine (1/1)",CNCCC=C1C2=CC=CC=C2C3CC3C4=CC=CC=C41.OP(=O)(O)O,,,,,,
5334,40029,Octriptyline,CNCCC=C1C2=CC=CC=C2C3CC3C4=CC=CC=C41,,,,,,
5335,40030,"1,3-Propanediol, 2-(hydroxymethyl)-2-isopropyl-, cyclic phosphite (1:1)",CC(C)C12COP(OC1)OC2,,,,,,
5336,40031,"4-Isopropyl-2,6,7-trioxa-1-phosphabicyclo(2.2.2)octane-1-sulfide",CC(C)C12COP(=S)(OC1)OC2,,,,,,
5337,40032,Cloethocarb,CNC(=O)OC1=CC=CC=C1OC(CCl)OC,,,,,,
5338,40033,"Benzamidine, 3,4-dimethoxy-, monohydrochloride",COC1=C(C=C(C=C1)C(=[NH2+])N)OC.[Cl-],,,,,,
5339,40034,"3,4-Dimethoxy-benzamidine",COC1=C(C=C(C=C1)C(=N)N)OC,,,,,,
5340,40035,"alpha-(6,7,8,9-Tetrahydro-5H-benzocyclohepten-2-yl)benzylamine hydrochloride",C1CCC2=C(CC1)C=C(C=C2)C(C3=CC=CC=C3)[NH3+].[Cl-],,,,,,
5341,40036,"phenyl(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)methanamine",C1CCC2=C(CC1)C=C(C=C2)C(C3=CC=CC=C3)N,,,,,,
5342,40037,"5H-Benzocycloheptene-2-methanamine, 6,7,8,9-tetrahydro-N,N-dimethyl-alpha-phenyl-, hydrochloride",C[NH+](C)C(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2.[Cl-],,,,,,
5343,40038,"N,N-dimethyl-1-phenyl-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)methanamine",CN(C)C(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2,,,,,,
5344,40039,CID 40039,C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5345,40040,"N,N-dimethyl-2-[phenyl(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)methoxy]ethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2,,,,,,
5346,40041,CID 40041,CC(C1=CC=CC=C1)(C2=CC3=C(CCCCC3)C=C2)OCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
5347,40042,"N,N-dimethyl-2-[1-phenyl-1-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl)ethoxy]ethanamine",CC(C1=CC=CC=C1)(C2=CC3=C(CCCCC3)C=C2)OCCN(C)C,,,,,,
5348,40043,CID 40043,C[NH+](C)CCC=C(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5349,40044,CID 40044,CN(C)CCC=C(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2,,,,,,
5350,40045,alpha-Methyl-3-biphenylacetic acid,CC(C1=CC=CC(=C1)C2=CC=CC=C2)C(=O)O,,,,,,
5351,40046,CID 40046,CN1CCN(CC1)CCCOC(=O)C2=CC=[N+](C=C2)[O-].C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5352,40047,3-(4-Methylpiperazin-1-yl)propyl 1-oxidopyridin-1-ium-4-carboxylate,CN1CCN(CC1)CCCOC(=O)C2=CC=[N+](C=C2)[O-],,,,,,
5353,40048,CID 40048,CN1CCN(CC1)CCOC(=O)C2=CC=[N+](C=C2)[O-].C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5354,40049,2-(4-Methylpiperazin-1-yl)ethyl 1-oxidopyridin-1-ium-4-carboxylate,CN1CCN(CC1)CCOC(=O)C2=CC=[N+](C=C2)[O-],,,,,,
5355,40050,CID 40050,CN1CCN(CC1)CCOC(=O)C2=C[N+](=CC=C2)[O-].C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5356,40051,2-(4-Methylpiperazin-1-yl)ethyl 1-oxidopyridin-1-ium-3-carboxylate,CN1CCN(CC1)CCOC(=O)C2=C[N+](=CC=C2)[O-],,,,,,
5357,40052,"2-((3-Pyridinylcarbonyl)oxy)-N,N,N-triethylethanaminium iodide N-oxide",CC[N+](CC)(CC)CCOC(=O)C1=C[N+](=CC=C1)[O-].[I-],,,,,,
5358,40053,Triethyl-[2-(1-oxidopyridin-1-ium-3-carbonyl)oxyethyl]azanium,CC[N+](CC)(CC)CCOC(=O)C1=C[N+](=CC=C1)[O-],,,,,,
5359,40054,CID 40054,CCC1C(C2C(O2)(C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)OC3C(C(CC(O3)C)N(C)C)O)CC=O)C)C)C,,,,,,
5360,40055,"Isobutyl 4-(2,4-dichlorophenoxy)butyrate",CC(C)COC(=O)CCCOC1=C(C=C(C=C1)Cl)Cl,,,,,,
5361,40056,Einecs 257-282-5,C(C(COCC(COCC(COCC(COCC(CO)O)O)O)O)O)O,,,,,,
5362,40057,Methyl isopropenyl ketone-methyl methacrylate copolymer,CC(=C)C(=O)C.CC(=C)C(=O)OC,,,,,,
5363,40058,"4,8-Dimethyl-7-nonenenitrile",CC(CCC=C(C)C)CCC#N,,,,,,
5364,40059,"alpha-Amino-4,6-dipropyl-o-cresol hydrochloride",CCCC1=CC(=C(C(=C1)C[NH3+])O)CCC.[Cl-],,,,,,
5365,40060,"2-(Aminomethyl)-4,6-dipropylphenol",CCCC1=CC(=C(C(=C1)CN)O)CCC,,,,,,
5366,40061,"Glycine, 2-phenyl-, butyl ester, hydrochloride, D,L-",CCCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
5367,40062,"Phenylglycine, butyl ester",CCCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
5368,40063,CID 40063,CC(C)(C)P(=O)(C1=CC=CC=C1)[SeH],,,,,,
5369,40064,Butyl(oxo)stannane,CCCC[SnH]=O,,,,,,
5370,40065,Iodo-gen,C1=CC=C(C=C1)C23C(N(C(=O)N2Cl)Cl)(N(C(=O)N3Cl)Cl)C4=CC=CC=C4,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
5371,40066,2H-chromene-3-carbaldehyde,C1C(=CC2=CC=CC=C2O1)C=O,,,,,,
5372,40067,1-(2H-chromen-3-yl)ethanone,CC(=O)C1=CC2=CC=CC=C2OC1,,,,,,
5373,40068,Mieshuan,C1=CC(=CN=C1)COC(=O)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
5374,40069,"Carbamic acid, (4-(methylthio)phenyl)-, 3-pyridinylmethyl ester",CSC1=CC=C(C=C1)NC(=O)OCC2=CN=CC=C2,,,,,,
5375,40070,Diheptylmercury,CCCCCCC[Hg]CCCCCCC,,,,,,
5376,40071,"beta,gamma-Dibromoadipic acid",C(C(C(CC(=O)O)Br)Br)C(=O)O,,,,,,
5377,40072,CID 40072,CC(C)(C)C(=CN=O)O,,,,,,
5378,40073,Cephatriazine,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)CSC4=NNN=C4,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
5379,40074,CID 40074,CC1=NN=C(S1)SCC2=CN3C(C(C3=O)NC(=O)C(C4=CC=C(C=C4)O)N)SC2,,,,,,
5380,40075,3-Phenoxyphenylacetonitrile,C1=CC=C(C=C1)OC2=CC=CC(=C2)CC#N,,,,,,
5381,40076,2-((3-Pyridinylcarbonyl)amino)benzoic acid methyl ester monohydrochloride,COC(=O)C1=CC=CC=C1NC(=O)C2=C[NH+]=CC=C2.[Cl-],,,,,,
5382,40077,Methyl 2-[(pyridin-3-ylcarbonyl)amino]benzoate,COC(=O)C1=CC=CC=C1NC(=O)C2=CN=CC=C2,,,,,,
5383,40078,2-((4-Pyridinylcarbonyl)amino)benzoic acid methyl ester monohydrochloride,COC(=O)C1=CC=CC=C1NC(=O)C2=CC=[NH+]C=C2.[Cl-],,,,,,
5384,40079,Methyl 2-(isonicotinoylamino)benzenecarboxylate,COC(=O)C1=CC=CC=C1NC(=O)C2=CC=NC=C2,,,,,,
5385,40080,"Benzothiazole, 6-methoxy-2-methylamino-",CNC1=NC2=C(S1)C=C(C=C2)OC,,,,,,
5386,40081,"Acetamide, N-(4-methyl-1-naphthyl)-",CC1=CC=C(C2=CC=CC=C12)NC(=O)C,,,,,,
5387,40082,2-{[Ethoxy(oxo)acetyl]amino}benzoic acid,CCOC(=O)C(=O)NC1=CC=CC=C1C(=O)O,,,,,,
5388,40083,"Coumarin, 4-(4-methyl-1-piperazinyl)-3-nitro-",CN1CCN(CC1)C2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
5389,40084,"Coumarin, 3-nitro-4-(4-phenyl-1-piperazinyl)-",C1CN(CCN1C2=CC=CC=C2)C3=C(C(=O)OC4=CC=CC=C43)[N+](=O)[O-],,,,,,
5390,40085,"Hexananilide, 4'-sulfanilyl-",CCCCCC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2,,,,,,
5391,40086,"BENZO(a)PYRENE-4,5-DIOL, 4,5-DIHYDRO-, cis-",C1=CC=C2C3=C4C(=CC2=C1)[C@@H]([C@@H](C5=CC=CC(=C54)C=C3)O)O,,,,,,
5392,40087,Thidiazuron,C1=CC=C(C=C1)NC(=O)NC2=CN=NS2,,,,"['[(14)C-aniline] thidiazuron was fed at a dose exaggeration of 1.9x to a lactating cow at a rate of 10 ppm for seven days. The animal was sacrificed within 24 hours of administration of the final dose. Parent equivalent radioactivity found was 0.05 ppm, 0.1 ppm, 1.5 ppm, and 1.0 ppm in fat, muscle, kidney and liver, respectively. Radioactivity reached a plateau in milk on the second day (0.2 ppm). Analysis was performed using HPLC and TLC.', '[(14)C-aniline] thidiazuron was fed once daily at a dose exaggeration of 100x to six hens for fourteen days at a rate of 8 ppm. Radioactivity did not plateau in eggs during this period. All tissues were first treated with protease and beta-glucuronidase prior to extraction. Parent equivalent radioactivity found was 0.02 ppm, 0.27 ppm, 1.11 ppm, 0.66 ppm, 0.10 ppm, 0.10 ppm and 0.34 ppm in fat, gastrointestinal tract, gastro-intestinal tract contents, liver, muscle, skin and blood, respectively.', 'In a metabolism study groups of male and female Sprague-Dawley CD rats were dosed with (14)C-thidiazuron [((14)C-aniline) thidiazuron or ((14)C-thiadizaole) thidiazuron (purity: >97% a.i.; batch No: 1695-3 and 1695-4)] at a single oral gavage dose (10 or 1000 mg/kg) or 14-day repeated oral doses of thidiazuron at 10 mg/kg followed by a single oral dose of (14)C-thidiazuron at 10 mg/kg ... The results of the pilot study showed that less than 0.2% of administered radioactivity was eliminated as (14)CO2 from administration of either ((14)C-aniline) thidiazuron or ((14)C-thiadizaole) thidiazuron. In addition, the study showed no significant differences in the percentages eliminated through urine or feces from administration of the two radiolabeled forms. Absorption of thidiazuron was rapid but incomplete at both doses, and appeared decreased at the high dose relative to the low dose. Elimination of thidiazuron was relatively rapid at the single low oral dose level. The major route of elimination was shown to be via urine. The single low, single high, and multiple low oral dose studies indicate that the total radioactivity recovered within 5 days after dosing in the urine and feces were 91-104% of administered dose. At the low dose, the radioactivity recovered in the urine and feces was 60-66% and 29-31% of the dose over a 5-day period, respectively. At the repeated low oral dose, the radioactivity recovered in the urine and feces was 73-75% and 26-28% of the dose over a 5-day period, respectively. At the high dose, the radioactivity recovered in the urine and feces was 41-47% and 56-60% of the dose over a 5-day period, respectively. Administration of a single high dose resulted in a decreased percentage of thidiazuron derived radioactivity eliminated in urine (approximately 20%), with concomitant rise in fecal elimination. This alteration is likely due to reduced absorption of test material at the high dose. Terminal tissue distribution data showed that highest concentrations of thidiazuron derived radioactivity at sacrifice were found in the liver, kidneys, thyroid, whole blood and adrenals at both low and high doses. Repeated oral dosing did not significantly affect distribution of thidiazuron derived radioactivity.', 'In a dermal penetration study Thidiazuron (99.9 %a.i., batch # OR 1844 (SEL/1098), [phenyl-U-(14)C]-thidiazuron) was administered to 5 male Sprague Dawley CD rats/dose to a 12 sq cm area of the back in a formulation and water dilution thereof at dose levels of 5.0, 0.04 and 0.004 mg/sq cm ... The mean total recoveries were in the range 88% and 99.54% dose for all groups. The amount in the stratum corneum was 0.73%, 10.68% and 8.14% at 24 hours for the high, middle and low dose groups respectively after a 24-hours exposure and 0.41%, 3.24% and 5.37% at 120 hours following 8-hours exposure for the high, middle and low dose groups respectively. However, the results showed that the majority of the radioactive material in the stratum corneum was lost by desquamation and upward renewal of the stratum corneum with time.', ""Thidiazuron (N-phenyl-N'-1,2,3-thiadiazol- 5-ylurea) cotton defoliant was administered for 10 consecutive days to lactating goats and laying hens. The vast majority of the radioactive material (> 70%) was eliminated in goat urine and feces; less than 1.5% of the administered radioactivity was in the milk. Hens excreted 72% of the total consumed radioactive material during the 10-day feeding period. In addition to the parent compound, which was present in low levels in goat milk and in chicken excreta, eggs, liver, and kidney, N-4-hydroxyphenyl- N'-1,2,3-thiol-5- ylurea or 4-hydroxyphenyl thidiazuron and phenylurea were detected. 4-Hydroxyphenyl thidiazuron was the major thidiazuron metabolite and was present in the free and/or conjugated form in goat and hen excreta, milk, eggs, and certain tissues. Phenylurea was detected only in goat urine. Other unidentified compounds also were present.""]","[""Thidiazuron (N-phenyl-N'-1,2,3-thiadiazol- 5-ylurea) cotton defoliant was administered for 10 consecutive days to lactating goats and laying hens. The vast majority of the radioactive material (> 70%) was eliminated in goat urine and feces; less than 1.5% of the administered radioactivity was in the milk. Hens excreted 72% of the total consumed radioactive material during the 10-day feeding period. In addition to the parent compound, which was present in low levels in goat milk and in chicken excreta, eggs, liver, and kidney, N-4-hydroxyphenyl- N'-1,2,3-thiol-5- ylurea or 4-hydroxyphenyl thidiazuron and phenylurea were detected. 4-Hydroxyphenyl thidiazuron was the major thidiazuron metabolite and was present in the free and/or conjugated form in goat and hen excreta, milk, eggs, and certain tissues. Phenylurea was detected only in goat urine. Other unidentified compounds also were present."", '/In/ an oral metabolism study in rats ... identification of urinary metabolites indicated the presence of oxidative metabolite (4-hydroxy thidiazuron) in urine and the presence of sulfate and glucuronide conjugates of 4-hydroxy thidiazuron. In feces, the major metabolites identified were 4-hydroxy thidiazuron at the low dose and unmetabolized thidiazuron at the high dose.']",
5393,40088,"6-Isoquinolinol, 1,2,3,4-tetrahydro-1,2-dimethyl-7-methoxy-, hydrochloride, (1R)-(-)-",C[C@@H]1C2=CC(=C(C=C2CC[NH+]1C)O)OC.[Cl-],,,,,,
5394,40089,"(1R)-7-methoxy-1,2-dimethyl-3,4-dihydro-1H-isoquinolin-6-ol",C[C@@H]1C2=CC(=C(C=C2CCN1C)O)OC,,,,,,
5395,40090,"(1R)-(-)-1,2-Dimethyl-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[C@@H]1C2=CC(=C(C=C2CC[NH+]1C)OC)O.[Cl-],,,,,,
5396,40091,"1,2-Dimethyl-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol",C[C@@H]1C2=CC(=C(C=C2CCN1C)OC)O,,,,,,
5397,40092,"7-Isoquinolinol, 1,2,3,4-tetrahydro-1,2-dimethyl-6-methoxy-, hydrochloride, (1S)-(+)-",CC1C2=CC(=C(C=C2CC[NH+]1C)OC)O.[Cl-],,,,,,
5398,40093,N-Methylisosalsoline,CC1C2=CC(=C(C=C2CCN1C)OC)O,,,,,,
5399,40094,N-Nitrosochlordiazepoxide,CN(C1=NC2=C(C=C(C=C2)Cl)C(=[N+](C1)[O-])C3=CC=CC=C3)N=O,,,,,,
5400,40095,"2-(1,3-Dithiolan-2-yl)cycloheptanone",C1CCC(C(=O)CC1)C2SCCS2,,,,,,
5401,40096,"8-(Dimethylsulfamoyl)-10-piperazino-10,11-dihydrodibenzo(b,f)thiepin dimethanesulfonate",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCNCC4.CS(=O)(=O)O.CS(=O)(=O)O,,,,,,
5402,40097,"N,N-dimethyl-5-piperazin-1-yl-5,6-dihydrobenzo[b][1]benzothiepine-3-sulfonamide",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCNCC4,,,,,,
5403,40098,"Dibenzo(b,f)thiepin-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-(4-(3-hydroxypropyl)-1-piperazinyl)-, methanesulfonate, hydrate (2:4:1)",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)CCCO.CS(=O)(=O)O.CS(=O)(=O)O,,,,,,
5404,40099,"5-[4-(3-hydroxypropyl)piperazin-1-yl]-N,N-dimethyl-5,6-dihydrobenzo[b][1]benzothiepine-3-sulfonamide",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)CCCO,,,,,,
5405,40100,"Dibenzo(b,f)thiepin-2-sulfonamide, N,N-dimethyl-11-(4-methyl-1-piperazinyl)-, monomethanesulfonate",C[NH+]1CCN(CC1)C2=CC3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)[O-],,,,,,
5406,40101,"N,N-dimethyl-5-(4-methylpiperazin-1-yl)benzo[b][1]benzothiepine-3-sulfonamide",CN1CCN(CC1)C2=CC3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,,,,,,
5407,40102,CID 40102,CN1CCN(CC1)C2CC3=C(N=CC=C3)SC4=C2C=C(C=C4)Cl.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5408,40103,"8-Chloro-6-(4-methylpiperazin-1-yl)-5,6-dihydro-[1]benzothiepino[2,3-b]pyridine",CN1CCN(CC1)C2CC3=C(N=CC=C3)SC4=C2C=C(C=C4)Cl,,,,,,
5409,40104,CID 40104,CC(C)C1=CC2=C(C=C1)SC3=C(CC2N4CCN(CC4)C)C=CC=N3.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5410,40105,"6-(4-Methylpiperazin-1-yl)-8-propan-2-yl-5,6-dihydro-[1]benzothiepino[2,3-b]pyridine",CC(C)C1=CC2=C(C=C1)SC3=C(CC2N4CCN(CC4)C)C=CC=N3,,,,,,
5411,40106,CID 40106,CC(C)C1=CC2=C(C=C1)SC3=C(C=CC=N3)C=C2N4CC[NH+](CC4)C.C(=CC(=O)[O-])C(=O)O,,,,,,
5412,40107,"8-Isopropyl-6-(4-methyl-1-piperazinyl)[1]benzothiepino[2,3-b]pyridine",CC(C)C1=CC2=C(C=C1)SC3=C(C=CC=N3)C=C2N4CCN(CC4)C,,,,,,
5413,40108,"Carbamic acid, (10,11-dihydro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)thiepin-2-yl)-, ethyl ester, dimethanesulfonate",CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C.CS(=O)(=O)O.CS(=O)(=O)O,,,,,,
5414,40109,"ethyl N-[5-(4-methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-3-yl]carbamate",CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C,,,,,,
5415,40110,CID 40110,CC(C(C1=CC=CC=C1)C2=CC=CC=C2)[NH2+]CCO.C(=CC(=O)[O-])C(=O)O,,,,,,
5416,40111,Aminosteroid,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)[NH3+])O)C.[Cl-],,,,,,
5417,40112,Amafolone,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)N)O)C,,,,,,
5418,40113,Phenazepam,C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=C3Cl,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Substances used for their pharmacological actions on GABAergic systems. GABAergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as GABA Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
5419,40114,CID 40114,CN1C(CNC2=C1C(=O)N=C(N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],,,,,,
5420,40115,"2-Naphthol, 7-amino-, hydrochloride",C1=CC2=C(C=C(C=C2)[NH3+])C(=C1)O.[Cl-],,,,,,
5421,40116,7-Amino-1-naphthol,C1=CC2=C(C=C(C=C2)N)C(=C1)O,,,,,,
5422,40117,"7-{[2-Amino-2-(cyclohexa-2,5-dien-1-yl)-1-hydroxyethylidene]amino}-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",COC1=C(N2[C@H]([C@H](C2=O)NC(=O)C(C3C=CCC=C3)N)SC1)C(=O)O,,,,,,
5423,40118,"9-Oxo-9H-thioxanthene-3-carboxylic acid 10,10-dioxide",C1=CC=C2C(=C1)C(=O)C3=C(S2(=O)=O)C=C(C=C3)C(=O)O,,,,,,
5424,40119,Doxantrazole,C1=CC=C2C(=C1)C(=O)C3=C(S2(=O)=O)C=C(C=C3)C4=NNN=N4,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
5425,40120,Cholovue; Endobil,CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,,,,
5426,40121,2-Phenyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxybenzofuran hydrochloride,CCOC(=O)C1=C(OC2=C1C(=C(C=C2)O)C[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
5427,40122,Ethyl 4-[(dimethylamino)methyl]-5-hydroxy-2-phenyl-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C(=C(C=C2)O)CN(C)C)C3=CC=CC=C3,,,,,,
5428,40123,"1-Naphthalenamine, N-[(1,1,3,3-tetramethylbutyl)phenyl]-",CC(C)(C)CC(C)(C)N(C1=CC=CC=C1)C2=CC=CC3=CC=CC=C32,,,,,,
5429,40124,"2-(N-(2-Chloroethyl)-N-ethylaminomethyl)-1,4-benzodioxan hydrochloride",CC[NH+](CCCl)CC1COC2=CC=CC=C2O1.[Cl-],,,,,,
5430,40125,"2-chloro-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-N-ethylethanamine",CCN(CCCl)CC1COC2=CC=CC=C2O1,,,,,,
5431,40126,Sonatox,C1C2C(C(C(C1(Cl)Cl)(C2(CCl)CCl)CCl)Cl)Cl,,,,,,
5432,40127,Carteolol hydrochloride,CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
5433,40128,"BENZ(c)ACRIDINE, 7,9,11-TRIMETHYL-",CC1=CC(=C2C(=C1)C(=C3C=CC4=CC=CC=C4C3=N2)C)C,,,,,,
5434,40129,"BENZ(a)ACRIDINE, 8,10,12-TRIMETHYL-",CC1=CC(=C2C(=C1)C(=C3C(=N2)C=CC4=CC=CC=C43)C)C,,,,,,
5435,40130,"1,4-Dioxa-8-azaspiro(4.5)decane-8-butanol, alpha,alpha-bis(4-fluorophenyl)-, hydrochloride",C1C[NH+](CCC12OCCO2)CCCC(C3=CC=C(C=C3)F)(C4=CC=C(C=C4)F)O.[Cl-],,,,,,
5436,40131,"4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-1,1-bis(4-fluorophenyl)butan-1-ol",C1CN(CCC12OCCO2)CCCC(C3=CC=C(C=C3)F)(C4=CC=C(C=C4)F)O,,,,,,
5437,40132,3-Hydroxy-3-(2-hydroxyiminopropyl)-1-methylindol-2-one,CC(=NO)CC1(C2=CC=CC=C2N(C1=O)C)O,,,,,,
5438,40133,"11-Methyl-4b,5,6,7,8,9,9a,10-octahydro-6,9-epiminobenzo[a]azulen-10-ol",CN1C2CCC1[C@@H]3[C@H](C2)C4=CC=CC=C4[C@@H]3O,,,,,,
5439,40134,"Benz(a)azulen-6,9-imin-10-ol, 4b,5,6,7,8,9,9a,10-octahydro-11-methyl-, acetate (ester), methanesulfonate (salt), (4bS-(4b-alpha,6-beta,9-beta,9a-alpha,10-beta))-",CC(=O)O[C@@H]1[C@H]2[C@H](CC3CCC2[NH+]3C)C4=CC=CC=C14.CS(=O)(=O)[O-],,,,,,
5440,40135,CID 40135,CC(=O)O[C@@H]1C2[C@H](CC3CCC2N3C)C4=CC=CC=C14,,,,,,
5441,40136,"(1,2,4)TRIAZOLO(1,5-a)PYRIMIDIN-7-AMINE, N-ETHYL-5-METHYL-",CCNC1=CC(=NC2=NC=NN12)C,,,,,,
5442,40137,"3,7-DIAZAADAMANTAN-9-ONE, 1,5-BIS(m-TOLYL)-",CC1=CC(=CC=C1)C23CN4CC(C2=O)(CN(C3)C4)C5=CC=CC(=C5)C,,,,,,
5443,40138,Quaternium-22,C[N+](C)(CCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)CCO.[Cl-],,,,,,
5444,40139,N-[3-[Dimethyl(2-hydroxyethyl)aminio]propyl]-D-gluconamide,C[N+](C)(CCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)CCO,,,,,,
5445,40140,"Acetamide, N-(2-(diethylamino)ethyl)-2-phenyl-",CCN(CC)CCNC(=O)CC1=CC=CC=C1,,,,,,
5446,40141,"(1R,3S,4aS,9as)-1,2,3,4,4a,9a-hexahydro-2-methyl-9H-1,3-ethanoindeno(2,1-c)pyridine",C[NH+]1C2CCC1[C@H]3CC4=CC=CC=C4[C@H]3C2.[Cl-],,,,,,
5447,40142,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a-octahydro-11-methyl-, (4bR-(4b-alpha,6-beta,9-beta,9a-alpha))-",CN1C2CCC1[C@H]3CC4=CC=CC=C4[C@H]3C2,,,,,,
5448,40143,"(2S,3S,10S)-15-methyl-15-azatetracyclo[10.2.1.02,10.04,9]pentadeca-4,6,8-trien-3-ol",CN1C2CCC1[C@@H]3[C@H](C2)C4=CC=CC=C4[C@H]3O,,,,,,
5449,40144,"N-(2-Picolyl)-3,5-dimethylbenzamide",CC1=CC(=CC(=C1)C(=O)NCC2=CC=CC=N2)C,,,,,,
5450,40145,"N-(3-Picolyl)-3,5-dimethylbenzamide",CC1=CC(=CC(=C1)C(=O)NCC2=CN=CC=C2)C,,,,,,
5451,40146,Picobenzide,CC1=CC(=CC(=C1)C(=O)NCC2=CC=NC=C2)C,,,,,,
5452,40147,L(-)-Karnitinaethylesterbromid [German],CCOC(=O)C[C@@H](C[N+](C)(C)C)O.[Br-],,,,,,
5453,40148,[(2S)-4-ethoxy-2-hydroxy-4-oxobutyl]-trimethylazanium,CCOC(=O)C[C@@H](C[N+](C)(C)C)O,,,,,,
5454,40149,"Aziridine, 1-((2-chlorophenoxy)acetyl)-",C1CN1C(=O)COC2=CC=CC=C2Cl,,,,,,
5455,40150,2-Acetyl-2-methylthiazolidine,CC(=O)C1(NCCS1)C,,,,,,
5456,40151,"Hydrazine, 1-(4-isopropylbenzyl)-",CC(C)C1=CC=C(C=C1)CNN,,,,,,
5457,40152,3-Propyl-2-hexanol,CCCC(CCC)C(C)O,,,,,,
5458,40153,Phthalyltetrathioacetic acid,C1=CC=C(C(=C1)C(SCC(=O)O)SCC(=O)O)C(SCC(=O)O)SCC(=O)O,,,,,,
5459,40154,Homocoralyne sulfopropionate,CCC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC.CCC(=O)OS(=O)(=O)[O-],,,,,,
5460,40155,"8-Ethyl-2,3,10,11-tetramethoxyisoquinolino[2,1-b]isoquinolin-7-ium",CCC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC,,,,,,
5461,40156,Propionyl sulfuric acid,CCC(=O)OS(=O)(=O)O,,,,,,
5462,40157,"Benz(a)azulen-6,9-imin-10(4bh)-one, 5,6,7,8,9,9a-hexahydro-11-methyl-, (4bR-(4b-alpha,6-beta,9-beta,9a-alpha))-",CN1C2CCC1[C@@H]3[C@H](C2)C4=CC=CC=C4C3=O,,,,,,
5463,40158,CID 40158,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CC(=O)[O-].[Na+],,,,,,
5464,40159,(-)-trans-Permethrin,CC1([C@H]([C@@H]1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C,,,,,,
5465,40160,"N,N-Dipropyl-1-(ethylsulfinyl)formamide",CCCN(CCC)C(=O)S(=O)CC,,,,,,
5466,40161,"Formamide, N,N-bis(2-methylpropyl)-1-(ethylsulfonyl)-",CCS(=O)(=O)C(=O)N(CC(C)C)CC(C)C,,,,,,
5467,40162,"Formamide, N,N-dipropyl-1-(ethylsulfonyl)-",CCCN(CCC)C(=O)S(=O)(=O)CC,,,,,,
5468,40163,"N,N-Bis(2-methylpropyl)-1-(ethylsulfinyl)formamide",CCS(=O)C(=O)N(CC(C)C)CC(C)C,,,,,,
5469,40164,CID 40164,CC(=O)NC1=CC=C(C=C1)C(=O)NC(=CC2=CC=C(C=C2)OC)C(=O)NC3CCCCC3,,,,,,
5470,40165,CID 40165,CC(=O)NC1=CC=C(C=C1)C(=O)NC(=CC2=CC=CC=C2Cl)C(=O)NC3CCCCC3,,,,,,
5471,40166,"N-(1-oxo-5-phenyl-1-piperidin-1-ylpenta-2,4-dien-2-yl)benzamide",C1CCN(CC1)C(=O)C(=CC=CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
5472,40167,CID 40167,CC(=O)NC1=CC=C(C=C1)C(=O)NC(=CC2=CC=C(C=C2)Cl)C(=O)N3CCCCC3,,,,,,
5473,40168,N-[1-(2-chlorophenyl)-3-morpholin-4-yl-3-oxoprop-1-en-2-yl]benzamide,C1COCCN1C(=O)C(=CC2=CC=CC=C2Cl)NC(=O)C3=CC=CC=C3,,,,,,
5474,40169,CID 40169,CC(=O)NC1=CC=C(C=C1)C(=O)NC(=CC2=CC=C(C=C2)OC)C(=O)N3CCOCC3,,,,,,
5475,40170,CID 40170,CC(=O)NC1=CC=C(C=C1)C(=O)NC(=CC2=CC=C(C=C2)N(C)C)C(=O)N3CCOCC3,,,,,,
5476,40171,N-[1-(furan-2-yl)-3-morpholin-4-yl-3-oxoprop-1-en-2-yl]benzamide,C1COCCN1C(=O)C(=CC2=CC=CO2)NC(=O)C3=CC=CC=C3,,,,,,
5477,40172,"2,2',3,4',5,5'-Hexachlorobiphenyl",C1=C(C=C(C(=C1C2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5478,40173,4-Chloro-1-butyne,C#CCCCl,,,,,,
5479,40174,"Alanine, 3-(3,4-dihydroxyphenyl)-N-methyl-, hydrochloride, L-",C[NH2+]C(CC1=CC(=C(C=C1)O)O)C(=O)O.[Cl-],,,,,,
5480,40175,"3-(3,4-Dihydroxyphenyl)-2-(methylamino)propanoic acid",CNC(CC1=CC(=C(C=C1)O)O)C(=O)O,,,,,,
5481,40176,"8,8'-Biquinoline",C1=CC2=C(C(=C1)C3=CC=CC4=C3N=CC=C4)N=CC=C2,,,,,,
5482,40177,"1-(Hydroxymethyl)-5,7-dimethyl-4-(phenylmethyl)-2,3-dithia-5,7-diazabicyclo(2.2.2)octane-6,8-dione",CN1C(=O)[C@]2(N(C(=O)C1(SS2)CC3=CC=CC=C3)C)CO,,,,,,
5483,40178,N-[3-(cyclohexylamino)-3-oxo-1-phenylprop-1-en-2-yl]benzamide,C1CCC(CC1)NC(=O)C(=CC2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
5484,40179,N-[1-[4-(dimethylamino)phenyl]-3-oxo-3-piperidin-1-ylprop-1-en-2-yl]benzamide,CN(C)C1=CC=C(C=C1)C=C(C(=O)N2CCCCC2)NC(=O)C3=CC=CC=C3,,,,,,
5485,40180,"2-Chlorobenzoic acid 2,3-dihydroxypropyl ester",C1=CC=C(C(=C1)C(=O)OCC(CO)O)Cl,,,,,,
5486,40181,"2-Iodobenzoic acid 2,3-dihydroxypropyl ester",C1=CC=C(C(=C1)C(=O)OCC(CO)O)I,,,,,,
5487,40182,"3-Nitrobenzoic acid 2,3-dihydroxypropyl ester",C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)OCC(CO)O,,,,,,
5488,40183,"Methyl 5-(2,4-dichloro-6-fluorophenoxy)-2-nitrobenzoate",COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Cl)Cl)F)[N+](=O)[O-],,,,,,
5489,40184,Propyl(4-hydroxybutyl)nitrosamine,CCCN(CCCCO)N=O,,,,,,
5490,40185,N-Methyl-N-(4-hydroxybutyl)nitrosamine,CN(CCCCO)N=O,,,,,,
5491,40186,"ISOCYANIC ACID, 4-(p-ISOCYANATOBENZYL)-m-PHENYLENE ESTER",C1=CC(=CC=C1CC2=C(C=C(C=C2)N=C=O)N=C=O)N=C=O,,,,,,
5492,40187,"Hepta-1,5-diene-3,4-diol",CC=CC(C(C=C)O)O,,,,,,
5493,40188,4A-Ethoxydecahydronaphthalene (cis),CCOC12CCCCC1CCCC2,,,,,,
5494,40189,"ARSINE, DICHLORO(p-NITROPHENYL)-",C1=CC(=CC=C1[N+](=O)[O-])[As](Cl)Cl,,,,,,
5495,40190,"1,2-Dichloro-4-(1,2-dichloroethyl)cyclohexane",C1CC(C(CC1C(CCl)Cl)Cl)Cl,,,,,,
5496,40191,"Carbamothioic acid, dipropyl-, S-ethyl ester, mixt. with 2,2-dichloro-N,N-di-2-propenylacetamide",CCCN(CCC)C(=O)SCC.C=CCN(CC=C)C(=O)C(Cl)Cl,,,,,,
5497,40192,3-(2-Aminopropyl)-2-(p-chlorophenyl)indole,CC(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)Cl)N,,,,,,
5498,40193,2-(4-Chlorophenyl)-alpha-ethyl-1H-indole-3-ethanamine,CCC(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)Cl)N,,,,,,
5499,40194,2-(4-Bromophenyl)-alpha-methyl-1H-indole-3-ethanamine,CC(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)Br)N,,,,,,
5500,40195,2-(4-Bromophenyl)-alpha-ethyl-1H-indole-3-ethanamine,CCC(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)Br)N,,,,,,
5501,40196,3-(2-Aminobutyl)-2-(p-methoxyphenyl)indole,CCC(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)OC)N,,,,,,
5502,40197,alpha-Ethyl-2-phenyl-1H-indole-3-ethanamine,CCC(CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3)N,,,,,,
5503,40198,3-(2-Aminopropyl)-2-(p-methoxyphenyl)indole,CC(CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)OC)N,,,,,,
5504,40199,alpha-Methyl-2-phenyl-1H-indole-3-ethanamine,CC(CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3)N,,,,,,
5505,40200,"4-Oxo-3-(1,3,6,8-tetrahydroxy-9,10-dioxo-9,10-dihydroanthracen-2-YL)butyl acetate",CC(=O)OCCC(C=O)C1=C(C=C2C(=C1O)C(=O)C3=C(C2=O)C=C(C=C3O)O)O,,,,,,
5506,40201,"2,2-Diphenylacetic acid (2-morpholinoethyl) ester hydrochloride",C1COCC[NH+]1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
5507,40202,"Acetic acid, 2,2-diphenyl-, 2-morpholinoethyl ester",C1COCCN1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5508,40203,N-(3-Propyl-2-hexyl)acetamide,CCCC(CCC)C(C)NC(=O)C,,,,,,
5509,40204,"3-Oxo-4-(2,3-dihydroxypropyl)-6-chloro-2,3-dihydro-1,4-benzoxazine",C1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(CO)O,,,,,,
5510,40205,"1H-NAPHTHO(2,1-b)PYRAN-1-ONE, 3-(ETHYLMETHYLAMINO)-",CCN(C)C1=CC(=O)C2=C(O1)C=CC3=CC=CC=C32,,,,,,
5511,40206,"Acetic acid, (6-isopropyl-2-methoxycarbonyl-3-methylphenoxy)-, 2-(dimethylamino)ethyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCN(C)C)C(=O)OC,,,,,,
5512,40207,"Acetic acid, (6-isopropyl-2-methoxycarbonyl-3-methylphenoxy)-, 2-piperidinoethyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCN2CCCCC2)C(=O)OC,,,,,,
5513,40208,"Acetic acid, (2-ethoxycarbonyl-6-isopropyl-3-methyl)phenoxy-, 2-(dimethylamino)ethyl ester",CCOC(=O)C1=C(C=CC(=C1OCC(=O)OCCN(C)C)C(C)C)C,,,,,,
5514,40209,"Acetic acid, (6-isopropyl-2-methoxycarbonyl-3-methylphenoxy)-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)COC1=C(C=CC(=C1C(=O)OC)C)C(C)C,,,,,,
5515,40210,"Acetic acid, (6-isopropyl-2-methoxycarbonyl-3-methylphenoxy)-, 2-morpholinoethyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCN2CCOCC2)C(=O)OC,,,,,,
5516,40211,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIMETHYLAMINO)ETHOXY)-, METHYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCN(C)C)C(=O)OC,,,,,,
5517,40212,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIMETHYLAMINO)ETHOXY)-, ETHYL ESTER",CCOC(=O)C1=C(C=CC(=C1OCCN(C)C)C(C)C)C,,,,,,
5518,40213,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIETHYLAMINO)ETHOXY)-, METHYL ESTER",CCN(CC)CCOC1=C(C=CC(=C1C(=O)OC)C)C(C)C,,,,,,
5519,40214,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIETHYLAMINO)ETHOXY)-, ETHYL ESTER",CCN(CC)CCOC1=C(C=CC(=C1C(=O)OCC)C)C(C)C,,,,,,
5520,40215,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-PIPERIDINOETHOXY)-, METHYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCN2CCCCC2)C(=O)OC,,,,,,
5521,40216,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-MORPHOLINOETHOXY)-, METHYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCN2CCOCC2)C(=O)OC,,,,,,
5522,40217,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-MORPHOLINOETHOXY)-, ETHYL ESTER",CCOC(=O)C1=C(C=CC(=C1OCCN2CCOCC2)C(C)C)C,,,,,,
5523,40218,"p-CYMENE-2-CARBOXYLIC ACID, 3-(3-(DIMETHYLAMINO)PROPOXY)-, METHYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCCN(C)C)C(=O)OC,,,,,,
5524,40219,Tricos-11-ene,CCCCCCCCCCCC=CCCCCCCCCCC,,,,,,
5525,40220,"cis-2,3-Dihydroxy-6-amino-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol hydrochloride",C1C[C@H]([C@H](C2=CC(=C(C=C2C1)O)O)O)[NH3+].[Cl-],,,,,,
5526,40221,"5H-BENZOCYCLOHEPTENE-2,3,5-TRIOL, 6,7,8,9-TETRAHYDRO-6-AMINO-, cis-",C1C[C@H]([C@H](C2=CC(=C(C=C2C1)O)O)O)N,,,,,,
5527,40222,Endobenzyline bromide,C[N+](C)(C)CCOC(=O)C(C1CC2CC1C=C2)(C3=CC=CC=C3)O.[Br-],,,,,,
5528,40223,Endobenzyline,C[N+](C)(C)CCOC(=O)C(C1CC2CC1C=C2)(C3=CC=CC=C3)O,,,,,,
5529,40224,7-Methyl-7H-benzo(c)fluorene,CC1C2=C(C3=CC=CC=C3C=C2)C4=CC=CC=C14,,,,,,
5530,40225,"Ketone, hydroxymethyl 2-indolyl-",C1=CC=C2C(=C1)C=C(N2)C(=O)CO,,,,,,
5531,40226,"Ketone, hydroxymethyl 1-methyl-2-indolyl-",CN1C2=CC=CC=C2C=C1C(=O)CO,,,,,,
5532,40227,"Ketone, hydroxymethyl 3-methyl-2-indolyl-",CC1=C(NC2=CC=CC=C12)C(=O)CO,,,,,,
5533,40228,"Ketone, 1-benzyl-2-indolyl hydroxymethyl-",C1=CC=C(C=C1)CN2C3=CC=CC=C3C=C2C(=O)CO,,,,,,
5534,40229,"Ketone, methoxymethyl 1-methyl-2-indolyl",CN1C2=CC=CC=C2C=C1C(=O)COC,,,,,,
5535,40230,"Ketone, methoxymethyl 3-methyl-2-indolyl-",CC1=C(NC2=CC=CC=C12)C(=O)COC,,,,,,
5536,40231,"Methyl 5-nitro-3,4-diphenylfuran-2-carboxylate",COC(=O)C1=C(C(=C(O1)[N+](=O)[O-])C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5537,40232,"3,4-Diphenyl-5-nitro-2-furoic acid",C1=CC=C(C=C1)C2=C(OC(=C2C3=CC=CC=C3)[N+](=O)[O-])C(=O)O,,,,,,
5538,40233,"17,20-Dithiahexatriacontane",CCCCCCCCCCCCCCCCSCCSCCCCCCCCCCCCCCCC,,,,,,
5539,40234,"2,2',3,4,5,5'-Hexachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
5540,40235,2-Amino-6-bromobenzoxazole,C1=CC2=C(C=C1Br)OC(=N2)N,,,,,,
5541,40236,"Benzoxazole, 2-amino-5,7-dibromo-",C1=C(C=C(C2=C1N=C(O2)N)Br)Br,,,,,,
5542,40237,2-Amino-6-chlorobenzoxazole,C1=CC2=C(C=C1Cl)OC(=N2)N,,,,,,
5543,40238,5-Allyl-5-(2-(cyclohexylamino)propyl)barbituric acid,CC(CC1(C(=O)NC(=O)NC1=O)CC=C)NC2CCCCC2,,,,,,
5544,40239,CID 40239,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CSC(F)(F)F)SC2)C(=O)[O-].[Na+],,,,,,
5545,40240,Cefazaflur,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CSC(F)(F)F)SC2)C(=O)O,,,,,,
5546,40241,"Ethanone, 1-(4-(dipropylamino)-3,5-dinitrophenyl)-",CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(=O)C)[N+](=O)[O-],,,,,,
5547,40242,CID 40242,C1=CC(=CC=C1C2=CC=C(O2)C=NN3C(C(=O)NC3=O)O)Cl,,,,,,
5548,40243,"1-[[5-(4-Aminophenyl)furan-2-yl]methylideneamino]-5-hydroxyimidazolidine-2,4-dione",C1=CC(=CC=C1C2=CC=C(O2)C=NN3C(C(=O)NC3=O)O)N,,,,,,
5549,40244,"4-[5-[[(5-Hydroxy-2,4-dioxo-1-imidazolidinyl)imino]methyl]-2-furanyl]benzonitrile",C1=CC(=CC=C1C#N)C2=CC=C(O2)C=NN3C(C(=O)NC3=O)O,,,,,,
5550,40245,"1-[[5-(3,4-Dichlorophenyl)furan-2-yl]methylideneamino]-5-hydroxyimidazolidine-2,4-dione",C1=CC(=C(C=C1C2=CC=C(O2)C=NN3C(C(=O)NC3=O)O)Cl)Cl,,,,,,
5551,40246,CID 40246,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N.[Na+],,,,,,
5552,40247,"(6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[(2-phenyl-2-sulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)S(=O)(=O)O)C(=O)O)C[N+]4=CC=C(C=C4)C(=O)N,,,,,,
5553,40248,"Benzoic acid, 2-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)-, butyl ester",CCCCOC(=O)C1=CC=CC=C1OC(=O)C(C)(C)OC2=CC=C(C=C2)Cl,,,,,,
5554,40249,"Benzoic acid, 4-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)-, ethyl ester",CCOC(=O)C1=CC=CC=C1OC(=O)C(C)(C)OC2=CC=C(C=C2)Cl,,,,,,
5555,40250,CID 40250,COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCOCC3)C(=O)C=CC4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
5556,40251,CID 40251,COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCOCC3)C(=O)C=CC4=CC=CC=C4,,,,,,
5557,40252,CID 40252,CC(C)OC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCC[NH+](C)C)OC)OC=C3)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
5558,40253,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(4-propan-2-yloxyphenyl)prop-2-en-1-one",CC(C)OC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCCN(C)C)OC)OC=C3)OC,,,,,,
5559,40254,CID 40254,CC(=O)[O-].C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=C(C=C3)OC)OC)OC)OC,,,,,,
5560,40255,CID 40255,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=C(C=C3)OC)OC)OC)OC,,,,,,
5561,40256,CID 40256,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
5562,40257,CID 40257,CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC,,,,,,
5563,40258,CID 40258,COC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCC[NH+]4CCCC4)OC)OC=C3)OC.C(=O)(C(=O)[O-])O,,,,,,
5564,40259,CID 40259,COC1=CC=C(C=C1)C=CC(=O)C2=C(C3=C(C(=C2OCCN4CCCC4)OC)OC=C3)OC,,,,,,
5565,40260,CID 40260,C[NH+](C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)O)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
5566,40261,"1-[6-[2-(Dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]-3-(4-hydroxyphenyl)prop-2-en-1-one",CN(C)CCOC1=C(C2=C(C=CO2)C(=C1C(=O)C=CC3=CC=C(C=C3)O)OC)OC,,,,,,
5567,40262,CID 40262,COC1=C(C(=C(C2=C1C=CO2)OC)OCC[NH+]3CCCC3)C(=O)C=CC4=CC=C(C=C4)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5568,40263,"1-[4,7-Dimethoxy-6-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-5-yl]-3-(4-hydroxyphenyl)prop-2-en-1-one",COC1=C(C(=C(C2=C1C=CO2)OC)OCCN3CCCC3)C(=O)C=CC4=CC=C(C=C4)O,,,,,,
5569,40264,"1,11-Dimethylchrysene",CC1=C2C=C(C3=C(C2=CC=C1)C=CC4=CC=CC=C43)C,,,,,,
5570,40265,"3,4-Dihydro-1,11-dimethylchrysene",CC1=CCCC2=C1C=C(C3=C2C=CC4=CC=CC=C43)C,,,,,,
5571,40266,"1,11-Dimethyl-1,2,3,4-tetrahydrochrysene",CC1CCCC2=C1C=C(C3=C2C=CC4=CC=CC=C43)C,,,,,,
5572,40267,"Acetonitrile, ((2-(((methylamino)carbonyl)oxy)phenyl)thio)-",CNC(=O)OC1=CC=CC=C1SCC#N,,,,,,
5573,40268,3-((2-(((Methylamino)carbonyl)oxy)phenyl)thio)butanenitrile,CC(CC#N)SC1=CC=CC=C1OC(=O)NC,,,,,,
5574,40269,"Acetamide, N,N-dimethyl-2-((2-(((methylamino)carbonyl)oxy)phenyl)thio)-",CNC(=O)OC1=CC=CC=C1SCC(=O)N(C)C,,,,,,
5575,40270,Phenoxyethyltriethylammonium bromide,CC[N+](CC)(CC)CCOC1=CC=CC=C1.[I-],,,,,,
5576,40271,Triethyl(2-phenoxyethyl)azanium,CC[N+](CC)(CC)CCOC1=CC=CC=C1,,,,,,
5577,40272,"Acetanilide, 2-indol-3-YL-",C1=CC=C(C=C1)NC(=O)CC2=CNC3=CC=CC=C32,,,,,,
5578,40273,"2-Chloro-1,4-diethoxybenzene",CCOC1=CC(=C(C=C1)OCC)Cl,,,,,,
5579,40274,"N-(1,1-Dimethylethyl)-1,3-propanediamine",CC(C)(C)NCCCN,,,,,,
5580,40275,"Carbanilic acid, N-ethyl-m-(pentyloxy)-, 1-methyl-2-piperidinoethyl ester, monohydrochloride",CCCCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
5581,40276,1-piperidin-1-ylpropan-2-yl N-ethyl-N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)CN2CCCCC2,,,,,,
5582,40277,"Carbanilic acid, N-ethyl-m-(hexyloxy)-, 1-methyl-2-piperidinoethyl ester, monohydrochloride",CCCCCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
5583,40278,1-piperidin-1-ylpropan-2-yl N-ethyl-N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)CN2CCCCC2,,,,,,
5584,40279,"Carbamic acid, (3-propoxyphenyl)-, 2-(1-piperidinyl)ethyl ester, monohydrochloride",CCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
5585,40280,2-(1-piperidyl)ethyl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
5586,40281,"Carbamic acid, (3-(pentyloxy)phenyl)-, 2-(1-piperidinyl)ethyl ester, monohydrochloride",CCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
5587,40282,2-(1-piperidyl)ethyl N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
5588,40283,"Carbamic acid, methyl(3-propoxyphenyl)-, 2-(1-piperidinyl)ethyl ester, monohydrochloride",CCCOC1=CC=CC(=C1)N(C)C(=O)OCCN2CCCCC2.Cl,,,,,,
5589,40284,2-piperidin-1-ylethyl N-methyl-N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)N(C)C(=O)OCCN2CCCCC2,,,,,,
5590,40285,"Carbamic acid, ethyl(3-propoxyphenyl)-, 2-(1-piperidinyl)ethyl ester, monohydrochloride",CCCOC1=CC=CC(=C1)N(CC)C(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
5591,40286,2-piperidin-1-ylethyl N-ethyl-N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)N(CC)C(=O)OCCN2CCCCC2,,,,,,
5592,40287,N-Ethyl-m-propoxycarbanilic acid 1-methyl-2-piperidinoethyl ester monohydrochloride,CCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
5593,40288,1-piperidin-1-ylpropan-2-yl N-ethyl-N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)CN2CCCCC2,,,,,,
5594,40289,m-Butoxy-N-ethylcarbanilic acid 1-methyl-2-piperidinoethyl ester monohydrochloride,CCCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)C[NH+]2CCCCC2.[Cl-],,,,,,
5595,40290,1-piperidin-1-ylpropan-2-yl N-(3-butoxyphenyl)-N-ethylcarbamate,CCCCOC1=CC=CC(=C1)N(CC)C(=O)OC(C)CN2CCCCC2,,,,,,
5596,40291,"disodium;[(17S)-3-[bis(2-chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] phosphate",CC12CCC3C(C1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+],,,,,,
5597,40292,"[(17S)-13-methyl-17-phosphonooxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate",CC12CCC3C(C1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,,,,,,
5598,40293,"Carbamic acid, methyl(3-(pentyloxy)phenyl)-, 2-(1-piperidinyl)ethyl ester, hydrochloride",CCCCCOC1=CC=CC(=C1)N(C)C(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
5599,40294,2-piperidin-1-ylethyl N-methyl-N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)N(C)C(=O)OCCN2CCCCC2,,,,,,
5600,40295,"Carbamic acid, ethyl(3-(pentyloxy)phenyl)-, 2-(1-piperidinyl)ethyl ester, monohydrochloride",CCCCCOC1=CC=CC(=C1)N(CC)C(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
5601,40296,2-piperidin-1-ylethyl N-ethyl-N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)N(CC)C(=O)OCCN2CCCCC2,,,,,,
5602,40297,"(1S)-(+)-1,2-Dimethyl-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CC1C2=CC(=C(C=C2CC[NH+]1C)O)OC.[Cl-],,,,,,
5603,40298,N-Methylsalsoline,CC1C2=CC(=C(C=C2CCN1C)O)OC,,,,,,
5604,40299,"1,2,4-Triazine-3,5(2H,4H)-dione, 6-(1,1-dimethylethyl)-",CC(C)(C)C1=NNC(=O)NC1=O,,,,,,
5605,40300,2-Ethylanthracene,CCC1=CC2=CC3=CC=CC=C3C=C2C=C1,,,,,,
5606,40301,2-Amino-4-phenylthiazole hydrobromide monohydrate,C1=CC=C(C=C1)C2=CSC(=N2)N.O.Br,,,,,,
5607,40302,2-Amino-4-phenylthiazole,C1=CC=C(C=C1)C2=CSC(=N2)N,,,,,,
5608,40303,"1-(Furan-3-yl)-7-hydroxy-4,8-dimethylnonane-1,6-dione",CC(C)C(C(=O)CC(C)CCC(=O)C1=COC=C1)O,,,,,,
5609,40304,Fagaronine chloride,C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC(=C(C=C4C=C3)O)OC)OC)OC.[Cl-],,,,,,
5610,40305,Fagaronine,C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC(=C(C=C4C=C3)O)OC)OC)OC,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
5611,40306,"4-Hydroxy-3,5-bis(3-methylbut-1-enyl)benzaldehyde",CC(C)C=CC1=CC(=CC(=C1O)C=CC(C)C)C=O,,,,,,
5612,40307,"17-Hydroxy-16,16-dimethylestr-4-en-3-one",CC1(CC2C3CCC4=CC(=O)CCC4C3CCC2(C1O)C)C,,,,,,
5613,40308,1-(Bromomethyl)-2-methoxybenzene,COC1=CC=CC=C1CBr,,,,,,
5614,40309,Tetrahydrofurfuryltrimethylammonium iodide,C[N+](C)(C)CC1CCCO1.[I-],,,,,,
5615,40310,"n,n,n-Trimethyl(tetrahydrofuran-2-yl)methanaminium",C[N+](C)(C)CC1CCCO1,,,,,,
5616,40311,"Isobutyl N,N-dimethylolcarbamate",CC(C)COC(=O)N(CO)CO,,,,,,
5617,40312,N-((2-Chloroethyl)nitrosocarbamoyl)alanine,CC(C(=O)O)NC(=O)N(CCCl)N=O,,,,,,
5618,40313,"Alanine, N-(((2-chloroethyl)nitrosoamino)carbonyl)-2-methyl-",CC(C)(C(=O)O)NC(=O)N(CCCl)N=O,,,,,,
5619,40314,3-Methyl-2-phenyl-5-benzothiazolineacetic acid,CN1C(SC2=C1C=C(C=C2)CC(=O)O)C3=CC=CC=C3,,,,,,
5620,40315,2-Phenyl-5-benzothiazolepropionic acid,C1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)CCC(=O)O,,,,,,
5621,40316,"5-BENZOTHIAZOLEACETIC ACID, alpha-METHYL-2-PHENYL-",CC(C1=CC2=C(C=C1)SC(=N2)C3=CC=CC=C3)C(=O)O,,,,,,
5622,40317,N-[1-(hydroxymethyl)propyl]-N-[2-[1-(hydroxymethyl)propyl-nitroso-amino]ethyl]nitrous amide,CCC(CO)N(CCN(C(CC)CO)N=O)N=O,,,,,,
5623,40318,"Alanine, N-(((2-chloroethyl)nitrosoamino)carbonyl)-3-phenyl-, DL-",C1=CC=C(C=C1)CC(C(=O)O)NC(=O)N(CCCl)N=O,,,,,,
5624,40319,"2,4,5-Trichlorodiphenyl ether",C1=CC=C(C=C1)OC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
5625,40320,2-Amino-5-benzoylbenzimidazole,C1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)N=C(N3)N,,,,,,
5626,40321,"BENZONITRILE, o-(2-OXAZOLO(5,4-b)PYRIDINYL)-",C1=CC=C(C(=C1)C#N)C2=NC3=C(O2)N=CC=C3,,,,,,
5627,40322,"2-(Oxazolo[4,5-b]pyridin-2-yl)benzonitrile",C1=CC=C(C(=C1)C#N)C2=NC3=C(O2)C=CC=N3,,,,,,
5628,40323,Triepoxy decane,C1C(O1)CCCC2C(O2)CC3CO3,,,,,,
5629,40324,"Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, (5-(phenylmethyl)-3-furanyl)methyl ester, trans-(+-)-",CC1([C@@H]([C@H]1C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C=C(Cl)Cl)C,,,,,,
5630,40325,"Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, (5-(phenylmethyl)-3-furanyl)methyl ester, cis-(+-)-",CC1([C@H]([C@H]1C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C=C(Cl)Cl)C,,,,,,
5631,40326,Permethrin,CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C,['For the treatment of infestation with <i>Sarcoptes scabiei</i> (scabies).'],"['Permethrin, a pyrethroid, is active against a broad range of pests including lice, ticks, fleas, mites, and other arthropods.']","['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']","['Poorly absorbed through the skin.', 'Permethrin is rapidly metabolized by ester hydrolysis to inactive metabolites which are excreted primarily in the urine.', 'Lactating cows (three/group) fed permethrin at dose levels of 0, 0.2, 1.0, 10, 50 mg/kg diet for 28 days showed no mortality, and growth and milk production were normal. Permethrin residues were observed in the milk within 3 days at the two highest dietary levels; levels appeared to reach a plateau rapidly and not to increase with time. Analysis of individual cis and trans isomers showed that the ratio of permethrin isomers in milk appeared to change during the course of the study with the cis isomer predominating. Permethrin residues were not found in the tissues of animals that received doses of 1 mg/kg or less. At dose levels of 10 or 50 mg/kg, residues were detected in the tissues, predominantly in the fat. Low levels were also present in the muscle and kidney at the highest dose level. Permethrin did not appear to accumulate in the fat but to reach a plateau rapidly.', '(14)C-cis-Permethrin was applied to the clipped skin of mice at a level of 1 mg/kg body weight in 0.1 mL of acetone. The mice were restrained until the solvent had evaporated and then placed in mouse metabolism cages. They were sacrificed at 1, 5, 15, 50, 480, and 2880 min after treatment and examined for absorption, distribution, and excretion of the insecticide. About 40% of the applied permethrin had moved from the site of application within 5 min and appeared to move rapidly to other parts of the body.', 'When ten consecutive oral doses of (14)C-trans- or (14)C-cis- permethrin (labelled in the acid or alcohol moieties) at 0.2-0.3 mg/kg bw/day were given to lactating goats, they excreted 72-79% and 25-36% of the trans and cis isomer doses, respectively, in urine & 12-15%, respectively, in the feces. The amounts of the radiocarbon appearing in the milk were <0.7% with any one of the four (14)C-labelled preparations. Concerning the tissue residues 24 hr after the last dose, detectable levels of radiocarbon were found in most tissue, but none was >0.04 mg/kg for the trans isomer or 0.25 mg/kg for the cis isomer.', 'Two human volunteers, who consumed about 2 and 4 mg of permethrin (25:75), respectively, excreted 18-37% and 32-39% of the administered dose, detected as the metabolite Cl2CA, after acid hydrolysis of their urine collected over 24 hr.', 'For more Absorption, Distribution and Excretion (Complete) data for PERMETHRIN (37 total), please visit the HSDB record page.']","['Rapidly metabolized by ester hydrolysis to inactive metabolites which are excreted primarily in the urine.', ""When the four (14)C-preparations of (IRS)-trans-, (IR)-trans- , (IRS)-cis, and (IR)-cis-permethrin labeled in the alcohol and acid moieties were administered orally to male rats at 1.6-4.8 mg/kg, the compounds were rapidly metabolized and the (14)C from the acid and alcohol moeity was almost completely eliminated from the body within a few days. ... The major metabolic reactions of both permethrin isomers /(trans and cis)/ were oxidation at the trans and cis portions of the gem-dimethyl group of the acid moiety and at the 2'- and 4'-positions of the alcohol moiety, ester cleavage, and the conjugation of the resulting carboxylic acids, alcohols, and phenols with glucuronic acid, glycine, and sulfuric acid. The cis isomer is more stable than the tans isomer, and the cis isomer yielded four fecal ester metabolites which resulted from hydroxylation  at the 2'- and 4'-positions of the phenoxy group, at the trans- methyl group, and at both of the two latter sites. The ester-cleaved metabolites were extensively excreted into the urine, whereas the metablites retaining ester linkage were found only in the feces. There were no significant differences in metabolism between the (IRS)-isomers and (IR)-isomers."", ""When White Leghorn hens were treated orally three consecutive days with one of four (14)C-trans- and cis-permethrin isomers labelled in the alcohol or acid at 10 mg/kg body weight, they showed no signs of poisoning. More than 87% of the radiocarbon from the four labelled perparations was found in the excreta 9 days after the initial dose, 0.7-4.7% of the dose was exhaled as (14)CO2, and 0.12-0.47% and 0.06-0.66% of the radiocarbon was recovered in egg yolk and fat (subcutaneous and visceral fat), respectively. Both the cis isomers labelled in the alcohol and acid moieties showed recoveries 3 to >10 times higher in the fat and egg yolk than those shown by the corresponding trans isomers. The excreta (0-72 hr) contained 1.7 times more cis-permethrin than trans-permethrin. Hydroxylated ester metabolites of trans-permethrin were not excreted, but four monohydroxy and dihydroxy esters (i.e. trans-OH-permethrin, 4'-OH-permethrin, 4'-OH, trans-OH-permethrin and trans-OH-permethrin sulfate) of cis-permethrin were found. Metabolites from the acid moieties of both isomers were the Cl2CA isomers in free, glucuronide, and taurine conjugate forms, trans-OH-Cl2CA, cis-OH-Cl2CA, cis-OH-Cl2CA lactone, and cis-OH-Cl2CA sulfate. trans-OH-Cl2CA was obtained from the cis isomer to larger extents than from the trans isomer, whereas the amounts of cis-OH-Cl2-CA were larger with the trans isomer than with the cis isomer. The metabolites from the alcohol moiety included PBalc, PBacid, their 4'-hydroxy-derivatives and the corresponding sulfate the glucuronide of PBalc, and a variety of unidentified conjugates of 4'-OH-PBalc and 4'-OH-PBacid. The taurine conjugate of PBacid was not detected. The metabolites produced in largest amounts were the unidentified conjugates of 4'-OH-PBalc (6-13% of the dose) and 4'-OH-PBacid (2-11%). The yolk of eggs 5 and 6 days after initial dosing contained 4.4 times cis-perethrin than trans-permethrin in unchanged form and the same ester metabolites of cis-permethrin as those found in the excreta. Other metabolites in the yolk were generally the same as those in the excreta. Overall, cis-permethrin appeared at higher levels than trans-permethrin in the egg yolk, fatty tissues, and excreta. Radiocarbon from cis-permethrin preparations also persisted longer in the blood than that from trans-permethrin preparations. It probably resulted from more rapid ester cleavage of the trans isomer than the cis isomer, based on the relative amounts of hydrolysis products form the two isomers in hen excreta."", 'Two human volunteers, who consumed about 2 and 4 mg of permethrin (25:75), respectively, excreted 18-37% and 32-39% of the administered dose, detected as the metabolite Cl2CA, after acid hydrolysis of their urine collected over 24 hr.', ""The permethrin metabolites in goats were formed through cleavage of the ester linkage, hydroxylation at the cis- or trans-methyl of the geminal dimethyl group, and hydroxylation at the 4'-position of the phenoxybenzyl moiety. Some of these metabolic products were further oxidized and/or conjugated with glycine, glutamic acid and glucuronic acid. The major compounds found in feces after dosing with cis-permethrin were unmetabolized parent compound 4'-OH-permethrin, trans-OH-permethrin, PBalc, cis-OH-cis-Cl2CA-lactone and eight unidentified ester metabolites. The feces of goats treated with the trans isomer contained large amounts of the parent compound (41-79% of the fecal (14)C and of PBalc (8-25%) and cis-OH-trans-Cl2CA-lactone. Also, three unidentified ester metabolites were found (8-23%). On the other hand, major urinary metabolites from the alcohol moiety of both isomers were PBacid-glycine (7-9% of the urinary (14)C) and r'-OH-PBacid-glycine (4-12%). PBalc, PBacid, 4'-OH-PBalc, 4'-OH-PBacid, PBacid-glutamic acid and 4'-OH-PBacid-glutamic acid were also identified as minor metabolites. The urine of goats treated with both isomers contained as major components, Cl2CA in the free form (2-4% of the urinary (14)C) and as a glucuronide (27-71%). Cl2CA-glucuronide was obtained to a larger extent with the trans isomer than with the cis isomer. Other major metabolites of the cis isomer were cis-OH-Cl2CA (33) (9-11%) and cis-OH-cis-Cl2CA-lactone (11-16%). trans-OH-Cl2CA was detected as a minor metabolite of both isomers. The milk of goats contained the parent compounds, PBacid-glycine, and 4'-OH-PBacide-glycine. On administration of the cis isomer, a large amount of the parent compund was excreted in the milk than in the case of the trans isomer. Comparatively, when the trans isomer was administered, PBacid-glycine was detected in the milk to a larger extent than with the cis isomer. Most of the radioactivity in the fat was attributed to the parent compound or ester metabolites such as trans-OH-permethrin and trans-OH-permethrin conjugate."", 'For more Metabolism/Metabolites (Complete) data for PERMETHRIN (25 total), please visit the HSDB record page.']","['The toxicokinetics of permethrin after single 460 mg/kg oral and 46 mg/kg intravenous doses were studied in male Sprague-Dawley rats. Serial blood samples after oral and intravenous dosage, and brain, medulla oblongata, sciatic nerve, and liver samples after oral administration were collected. Plasma, hypothalamus, cerebellum, frontal cortex, caudate putamen, hippocampus, medulla oblongata, sciatic nerve, and liver concentrations of permethrin and its metabolites, m-phenoxybenzyl alcohol and m-phenoxybenzoic acid, were determined by a high-performance liquid chromatographic assay. The permethrin plasma profile could be adequately described by a two-compartment open model. For permethrin, the elimination half-life (t1/2 beta) and the mean residence time from plasma were 8.67 and 11.19 hr after i.v. and 12.37 and 17.77 hr after /peroal/ administration. The total plasma clearance was not influenced by dose concentration or route and reached a value of 0.058 liter/hr. After the single oral dose, permethrin was absorbed slowly with a Tmax of 3.52 hr. The maximum plasma concentration was 49.46 micrograms/ml. The oral bioavailability of permethrin was found to be 60.69%. The plasma concentration-time data for permethrin metabolites as well as the tissue concentration-time data for permethrin and its metabolites after an oral dose of permethrin were found to fit a one-compartment open model. The elimination half-life (t1/2el) of permethrin was greater for the hippocampus, medulla oblongata, frontal cortex, and sciatic nerve (23.10, 22.36, 13.86, and 16.27 hr, respectively) than for plasma (t1/2 beta, 12.37 hr). The maximum amounts of permethrin in cerebellum, hippocampus, caudate putamen, frontal cortex, hypothalamus, and sciatic nerve were about 1.5, 2, 2, 2.7, 4.8, and 7.5 times higher than in plasma, respectively, indicating an accumulation of pyrethroid by nervous tissue itself. Nervous tissue accumulation of permethrin was also reflected by the area under the concentration curve ratios of tissue/plasma (1.16, 3.71, 1.57, 4.27, 3.48, and 8.77, respectively). The metabolites of permethrin, m-phenoxy-benzyl alcohol and m-phenoxybenzoic acid, were detected in plasma and in all selected tissues for 48 hr after dosing, suggesting that a combination of metabolism by the tissues and diffusion into it from the blood may be present.', 'In studies, the half-life of (+)-trans- and (+)-cis-permethrin applied to the leaf surface of bean plants was 7 and 9 days, respectively.']"
5632,40327,6-Methoxybenzo(a)pyrene,COC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C5=CC=CC=C51,,,,,,
5633,40328,Methyl octadec-6-enoate,CCCCCCCCCCCC=CCCCCC(=O)OC,,,,,,
5634,40329,"Naphtho(2,1-b)thiophene-4-methanol, alpha-((dibutylamino)methyl)-8-(trifluoromethyl)-, hydrochloride",CCCC[NH+](CCCC)CC(C1=C2C(=C3C=C(C=CC3=C1)C(F)(F)F)C=CS2)O.[Cl-],,,,,,
5635,40330,2-(Dibutylamino)-1-[8-(trifluoromethyl)benzo[e][1]benzothiol-4-yl]ethanol,CCCCN(CCCC)CC(C1=C2C(=C3C=C(C=CC3=C1)C(F)(F)F)C=CS2)O,,,,,,
5636,40331,"3-Naphthalenesulfonic acid, 1,2-dihydro-1-(dimethylamino)-4-phenyl-",CN(C)C1CC(=C(C2=CC=CC=C12)C3=CC=CC=C3)S(=O)(=O)O,,,,,,
5637,40332,"trans-1,2,3,4-Tetrahydro-N,N-dimethyl-4-phenyl-1-naphthylamine hydrochloride",C[NH+](C)[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC=CC=C3.[Cl-],,,,,,
5638,40333,CID 40333,CN(C)[C@H]1CCC(C2=CC=CC=C12)C3=CC=CC=C3,,,,,,
5639,40334,"1-Naphthonitrile, 1,2,3,4-tetrahydro-4-(dimethylamino)-1-phenyl-, hydrochloride, (E)-",C[NH+](C)[C@@H]1CC[C@](C2=CC=CC=C12)(C#N)C3=CC=CC=C3.[Cl-],,,,,,
5640,40335,"(1S,4R)-4-(dimethylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carbonitrile",CN(C)[C@@H]1CC[C@](C2=CC=CC=C12)(C#N)C3=CC=CC=C3,,,,,,
5641,40336,"1-Naphthamide, 1,2,3,4-tetrahydro-4-(dimethylamino)-N,N-dimethyl-1-phenyl-, hydrochloride, (E)-",C[NH+](C)[C@@H]1CCC(C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N(C)C.[Cl-],,,,,,
5642,40337,"4-(dimethylamino)-N,N-dimethyl-1-phenyl-3,4-dihydro-2H-naphthalene-1-carboxamide",CN(C)C1CCC(C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N(C)C,,,,,,
5643,40338,"cis-1,2,3,4-Tetrahydro-4-carbomethoxy-1-dimethylamino-4-phenylnaphthalene hydrochloride",C[NH+](C)[C@@H]1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)OC.[Cl-],,,,,,
5644,40339,"methyl (1R,4R)-4-(dimethylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carboxylate",CN(C)[C@@H]1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)OC,,,,,,
5645,40340,Methyl nonadec-11-enoate,CCCCCCCC=CCCCCCCCCCC(=O)OC,,,,,,
5646,40341,m-Iodohippuric acid,C1=CC(=CC(=C1)I)C(=O)NCC(=O)O,,,,,,
5647,40342,Dexclamol hydrochloride,CC(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O.Cl,,,,,,
5648,40343,CID 40343,CC(C)[C@]1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O,,,,,,
5649,40344,Flutemazepam,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3F,,,,,,
5650,40345,"2-(2-(Ethylamino)ethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC[NH2+]CCC1(OC2=CC=CC=C2O1)C.[Cl-],,,,,,
5651,40346,"N-ethyl-2-(2-methyl-1,3-benzodioxol-2-yl)ethanamine",CCNCCC1(OC2=CC=CC=C2O1)C,,,,,,
5652,40347,CID 40347,CC[NH+](CC)CC[NH2+]CCC1OC2=CC=CC=C2O1.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5653,40348,"N-[2-(1,3-benzodioxol-2-yl)ethyl]-N',N'-diethylethane-1,2-diamine",CCN(CC)CCNCCC1OC2=CC=CC=C2O1,,,,,,
5654,40349,CID 40349,CCC1(OC2=CC=CC=C2O1)CC[NH2+]CC[NH+](CC)CC.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5655,40350,"N',N'-diethyl-N-[2-(2-ethyl-1,3-benzodioxol-2-yl)ethyl]ethane-1,2-diamine",CCC1(OC2=CC=CC=C2O1)CCNCCN(CC)CC,,,,,,
5656,40351,"1,3-Benzodioxole, 2-(2-(2-(dimethylamino)ethylamino)ethyl)-2-methyl-, dihydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH2+]CC[NH+](C)C.[Cl-].[Cl-],,,,,,
5657,40352,"N',N'-dimethyl-N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]ethane-1,2-diamine",CC1(OC2=CC=CC=C2O1)CCNCCN(C)C,,,,,,
5658,40353,"2-Methyl-2-(2-morpholinoethyl)-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH+]3CCOCC3.[Cl-],,,,,,
5659,40354,"4-[2-(2-Methyl-1,3-benzodioxol-2-yl)ethyl]morpholine",CC1(OC2=CC=CC=C2O1)CCN3CCOCC3,,,,,,
5660,40355,CID 40355,CC(C)[NH2+]CCC1(OC2=CC=CC=C2O1)C.C(=CC(=O)[O-])C(=O)O,,,,,,
5661,40356,"N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]propan-2-amine",CC(C)NCCC1(OC2=CC=CC=C2O1)C,,,,,,
5662,40357,"4-Methyl-1-(2-(2-methyl-1,3-benzodioxol-2-yl)ethyl)piperazine hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH+]3CCN(CC3)C.[Cl-],,,,,,
5663,40358,"1-Methyl-4-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]piperazine",CC1(OC2=CC=CC=C2O1)CCN3CCN(CC3)C,,,,,,
5664,40359,"Ethanol, 2,2'-(2-(2-methyl-1,3-benzodioxol-2-YL)ethyl)iminodi-",CC1(OC2=CC=CC=C2O1)CCN(CCO)CCO,,,,,,
5665,40360,"2-(2-(Benzylamino)ethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH2+]CC3=CC=CC=C3.[Cl-],,,,,,
5666,40361,"N-benzyl-2-(2-methyl-1,3-benzodioxol-2-yl)ethanamine",CC1(OC2=CC=CC=C2O1)CCNCC3=CC=CC=C3,,,,,,
5667,40362,"1,3-Benzodioxole, 5-chloro-2-(2-(2-(diethylamino)ethylamino)ethyl)-2-methyl-, dihydrochloride",CC[NH+](CC)CC[NH2+]CCC1(OC2=C(O1)C=C(C=C2)Cl)C.[Cl-].[Cl-],,,,,,
5668,40363,"N-[2-(5-chloro-2-methyl-1,3-benzodioxol-2-yl)ethyl]-N',N'-diethylethane-1,2-diamine",CCN(CC)CCNCCC1(OC2=C(O1)C=C(C=C2)Cl)C,,,,,,
5669,40364,"2-Methyl-2-(2-morpholinoethyl)-5-nitro-1,3-benzodioxole hydrochloride",CC1(OC2=C(O1)C=C(C=C2)[N+](=O)[O-])CC[NH+]3CCOCC3.[Cl-],,,,,,
5670,40365,"4-[2-(2-Methyl-5-nitro-1,3-benzodioxol-2-yl)ethyl]morpholine",CC1(OC2=C(O1)C=C(C=C2)[N+](=O)[O-])CCN3CCOCC3,,,,,,
5671,40366,"1,3-Benzodioxole, 5,6-dibromo-2-(2-(2-(diethylamino)ethylamino)ethyl)-2-methyl-, dihydrochloride",CC[NH+](CC)CC[NH2+]CCC1(OC2=CC(=C(C=C2O1)Br)Br)C.[Cl-].[Cl-],,,,,,
5672,40367,"N-[2-(5,6-dibromo-2-methyl-1,3-benzodioxol-2-yl)ethyl]-N',N'-diethylethane-1,2-diamine",CCN(CC)CCNCCC1(OC2=CC(=C(C=C2O1)Br)Br)C,,,,,,
5673,40368,CID 40368,CC[NH+](CC)CC[NH2+]CC1(OC2=CC=CC=C2O1)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5674,40369,"N',N'-diethyl-N-[(2-methyl-1,3-benzodioxol-2-yl)methyl]ethane-1,2-diamine",CCN(CC)CCNCC1(OC2=CC=CC=C2O1)C,,,,,,
5675,40370,CID 40370,CC[NH+](CC)CC[NH2+]CCC1(OC2=CC=CC=C2O1)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5676,40371,"1,2-Ethanediamine, N,N-diethyl-N'-(2-(2-methyl-1,3-benzodioxol-2-yl)ethyl)-",CCN(CC)CCNCCC1(OC2=CC=CC=C2O1)C,,,,,,
5677,40372,"2-(2-(Dimethylamino)ethyl)-2-phenyl-1,3-benzodioxole hydrochloride",C[NH+](C)CCC1(OC2=CC=CC=C2O1)C3=CC=CC=C3.[Cl-],,,,,,
5678,40373,"N,N-dimethyl-2-(2-phenyl-1,3-benzodioxol-2-yl)ethanamine",CN(C)CCC1(OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
5679,40374,CID 40374,CC[NH+](CC)CC[NH2+]CCC1(OC2=C(O1)C=C(C=C2)C)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5680,40375,"N-[2-(2,5-dimethyl-1,3-benzodioxol-2-yl)ethyl]-N',N'-diethylethane-1,2-diamine",CCN(CC)CCNCCC1(OC2=C(O1)C=C(C=C2)C)C,,,,,,
5681,40376,"1,3-Benzodioxole, 5-amino-2-methyl-2-(2-morpholinoethyl)-, dihydrochloride, hemihydrate",CC1(OC2=C(O1)C=C(C=C2)[NH3+])CC[NH+]3CCOCC3.[Cl-].[Cl-],,,,,,
5682,40377,"2-Methyl-2-(2-morpholin-4-ylethyl)-1,3-benzodioxol-5-amine",CC1(OC2=C(O1)C=C(C=C2)N)CCN3CCOCC3,,,,,,
5683,40378,"BENZYL ALCOHOL, alpha,alpha-DIMETHYL-4-PIPERIDINO-",CC(C)(C1=CC=C(C=C1)N2CCCCC2)O,,,,,,
5684,40379,"Thiazole, 5-propyl-",CCCC1=CN=CS1,,,,,,
5685,40380,5-Ethyl-4-methylthiazole,CCC1=C(N=CS1)C,,,,,,
5686,40381,"4'-(3,3-Dimethyl-1-triazeno)acetophenone",CC(=O)C1=CC=C(C=C1)N=NN(C)C,,,,,,
5687,40382,CID 40382,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH3+].[Cl-],,,,,,
5688,40383,4-(6-Methyloctyl)phenol,CCC(C)CCCCCC1=CC=C(C=C1)O,,,,,,
5689,40384,Pectamol,CCC(CC)(C1=CC=CC=C1)C(=O)OCCOCC[NH+](CC)CC.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
5690,40385,"Anthranilic acid, N-(2-benzimidazolylmethyl)-",C1=CC=C(C(=C1)C(=O)O)NCC2=NC3=CC=CC=C3N2,,,,,,
5691,40386,CID 40386,C1=CC=C(C(=C1)C=CC(=O)OC2=C(C=CC3=C2N=CC=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
5692,40387,3-[4-(2-Fluorophenyl)phenyl]-2-methylpropanoic acid,CC(CC1=CC=C(C=C1)C2=CC=CC=C2F)C(=O)O,,,,,,
5693,40388,"cis-1,2,3,4-Tetrahydro-4-cyano-1-dimethylamino-4-phenylnaphthalene hydrochloride",C[NH+](C)[C@@H]1CC[C@@](C2=CC=CC=C12)(C#N)C3=CC=CC=C3.[Cl-],,,,,,
5694,40389,"(1R,4R)-4-(dimethylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carbonitrile",CN(C)[C@@H]1CC[C@@](C2=CC=CC=C12)(C#N)C3=CC=CC=C3,,,,,,
5695,40390,"NICOTINIC ACID, compd. with 2-(DIMETHYLAMINO)ETHANOL",CN(C)CCO.C1=CC(=CN=C1)C(=O)O,,,,,,
5696,40391,Pinazepam,C#CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
5697,40392,CID 40392,CC[NH+](CC)CC[NH+](C)CCC1(OC2=CC=CC=C2O1)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
5698,40393,"N',N'-diethyl-N-methyl-N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]ethane-1,2-diamine",CCN(CC)CCN(C)CCC1(OC2=CC=CC=C2O1)C,,,,,,
5699,40394,"1,3-Naphtho(2,3-d)dioxole, 2-(3-(2-(diethylamino)ethylamino)propyl)-2-methyl-, dihydrochloride",CC[NH+](CC)CC[NH2+]CCCC1(OC2=CC3=CC=CC=C3C=C2O1)C.[Cl-].[Cl-],,,,,,
5700,40395,"N',N'-diethyl-N-[3-(2-methylbenzo[f][1,3]benzodioxol-2-yl)propyl]ethane-1,2-diamine",CCN(CC)CCNCCCC1(OC2=CC3=CC=CC=C3C=C2O1)C,,,,,,
5701,40396,"2-(Aminoethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH3+].[Cl-],,,,,,
5702,40397,"2-Methyl-1,3-benzodioxole-2-ethanamine",CC1(OC2=CC=CC=C2O1)CCN,,,,,,
5703,40398,"3-(2,6-Dichlorophenyl)prop-2-enoyl chloride",C1=CC(=C(C(=C1)Cl)C=CC(=O)Cl)Cl,,,,,,
5704,40399,Exifone,C1=CC(=C(C(=C1C(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O,,,,,,
5705,40400,CID 40400,CC(C)(C)C(C)([C@H]1C[C@@]23CC[C@]1(C4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,,,,,,
5706,40401,Hydroxy(4-hydroxy-3-nitrophenyl)mercury sodium salt,C1=CC(=C(C=C1[Hg])[N+](=O)[O-])[O-].O.[Na+],,,,,,
5707,40402,(4-Hydroxy-3-nitrophenyl)mercury,C1=CC(=C(C=C1[Hg])[N+](=O)[O-])O,,,,,,
5708,40403,CID 40403,C[NH2+]CCC=C(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
5709,40404,CID 40404,CNCCC=C(C1=CC=CC=C1)C2=CC3=C(CCCCC3)C=C2,,,,,,
5710,40405,"Propanediamide, 2-(2-(diethylamino)ethyl)-N,N'-diphenyl-, monohydrochloride",CC[NH+](CC)CCC(C(=O)NC1=CC=CC=C1)C(=O)NC2=CC=CC=C2.OS(=O)(=O)[O-],,,,,,
5711,40406,"2-[2-(diethylamino)ethyl]-N,N'-diphenylpropanediamide",CCN(CC)CCC(C(=O)NC1=CC=CC=C1)C(=O)NC2=CC=CC=C2,,,,,,
5712,40407,2-Methylamino-2-phenylacetophenone hydrochloride,C[NH2+]C(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
5713,40408,"2-(Methylamino)-1,2-diphenylethanone",CNC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
5714,40409,"Ethyl 2-[(phenylacetyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate",CCOC(=O)C1=C(SC2=C1CCCC2)NC(=O)CC3=CC=CC=C3,,,,,,
5715,40410,CID 40410,CC1=NSC(=C1)[NH3+].[Cl-],,,,,,
5716,40411,2-[Bis(2-hydroxyethyl)amino]-5-nitrophenol,C1=CC(=C(C=C1[N+](=O)[O-])O)N(CCO)CCO,,,,,,
5717,40412,Strophanthidin-3-chloroacetate,C[C@]12CCC3C([C@]1(CCC2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)OC(=O)CCl)C=O)O,,,,,,
5718,40413,Naproanilide,CC(C(=O)NC1=CC=CC=C1)OC2=CC3=CC=CC=C3C=C2,,,,,,
5719,40414,"Adamantane, 1-(2-(1-pyrrolidinyl)ethyl)-, hydrochloride",C1CCN(C1)CCC23CC4CC(C2)CC(C4)C3.Cl,,,,,,
5720,40415,1-[2-(1-Adamantyl)ethyl]pyrrolidine,C1CCN(C1)CCC23CC4CC(C2)CC(C4)C3,,,,,,
5721,40416,"Adamantane, 1-(2-piperidinoethyl)-, hydrochloride",C1CCN(CC1)CCC23CC4CC(C2)CC(C4)C3.Cl,,,,,,
5722,40417,N-[2-(1-adamantyl)ethyl]piperidine,C1CCN(CC1)CCC23CC4CC(C2)CC(C4)C3,,,,,,
5723,40418,"Adamantane, 1-(2-(4-methylpiperazinyl)ethyl)-, dihydrochloride",CN1CCN(CC1)CCC23CC4CC(C2)CC(C4)C3.Cl.Cl,,,,,,
5724,40419,1-[2-(1-Adamantyl)ethyl]-4-methylpiperazine,CN1CCN(CC1)CCC23CC4CC(C2)CC(C4)C3,,,,,,
5725,40420,"Adamantane, 1-(2-morpholinoethyl)-, hydrochloride",C1COCCN1CCC23CC4CC(C2)CC(C4)C3.Cl,,,,,,
5726,40421,4-[2-(1-Adamantyl)ethyl]morpholine,C1COCCN1CCC23CC4CC(C2)CC(C4)C3,,,,,,
5727,40422,"Adamantane, 1-(3-ethylaminopropyl)-, hydrochloride",CCNCCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
5728,40423,3-(1-adamantyl)-N-ethylpropan-1-amine,CCNCCCC12CC3CC(C1)CC(C3)C2,,,,,,
5729,40424,"ADAMANTANE, 1-(3-tert-BUTYLAMINOPROPYL)-, HYDROCHLORIDE",CC(C)(C)NCCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
5730,40425,N-[3-(1-adamantyl)propyl]-2-methylpropan-2-amine,CC(C)(C)NCCCC12CC3CC(C1)CC(C3)C2,,,,,,
5731,40426,"Adamantane, 1-(3-(1-pyrrolidinyl)propyl)-, hydrochloride",C1CCN(C1)CCCC23CC4CC(C2)CC(C4)C3.Cl,,,,,,
5732,40427,N-[3-(1-adamantyl)propyl]pyrrolidine,C1CCN(C1)CCCC23CC4CC(C2)CC(C4)C3,,,,,,
5733,40428,"Adamantane, 1-(3-piperidinopropyl)-, hydrochloride",C1CCN(CC1)CCCC23CC4CC(C2)CC(C4)C3.Cl,,,,,,
5734,40429,1-[3-(1-Adamantyl)propyl]piperidine,C1CCN(CC1)CCCC23CC4CC(C2)CC(C4)C3,,,,,,
5735,40430,"Adamantane, 1-(4-methylaminobutyl)-, hydrochloride",CNCCCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
5736,40431,4-(1-adamantyl)-N-methylbutan-1-amine,CNCCCCC12CC3CC(C1)CC(C3)C2,,,,,,
5737,40432,"Adamantane, 1-(4-dimethylaminobutyl)-, hydrochloride",CN(C)CCCCC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
5738,40433,"4-(1-adamantyl)-N,N-dimethylbutan-1-amine",CN(C)CCCCC12CC3CC(C1)CC(C3)C2,,,,,,
5739,40434,"Adamantane, 1-(3-dimethylaminobutyl)-, hydrochloride",CC(CCC12CC3CC(C1)CC(C3)C2)N(C)C.Cl,,,,,,
5740,40435,"4-(1-adamantyl)-N,N-dimethylbutan-2-amine",CC(CCC12CC3CC(C1)CC(C3)C2)N(C)C,,,,,,
5741,40436,"1-Adamantaneethylamine, 2-chloro-N-methyl-, hydrochloride",CNCCC12CC3CC(C1)CC(C3)C2Cl.Cl,,,,,,
5742,40437,2-(2-chloro-1-adamantyl)-N-methylethanamine,CNCCC12CC3CC(C1)CC(C3)C2Cl,,,,,,
5743,40438,"Adamantane, 1-(2-methylaminoethyl)-2-phenyl-, hydrochloride",CNCCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4.Cl,,,,,,
5744,40439,N-methyl-2-(2-phenyl-1-adamantyl)ethanamine,CNCCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4,,,,,,
5745,40440,"Adamantane, 1-(2-(dimethylamino)ethyl)-2-phenyl-, hydrochloride",CN(C)CCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4.Cl,,,,,,
5746,40441,"N,N-dimethyl-2-(2-phenyl-1-adamantyl)ethanamine",CN(C)CCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4,,,,,,
5747,40442,"2-Bromo-N,N-dimethyl-1-adamantanepropanamine hydrochloride",CN(C)CCCC12CC3CC(C1)CC(C3)C2Br.Cl,,,,,,
5748,40443,"3-(2-bromo-1-adamantyl)-N,N-dimethylpropan-1-amine",CN(C)CCCC12CC3CC(C1)CC(C3)C2Br,,,,,,
5749,40444,"Adamantane, 1-(3-methylaminopropyl)-2-phenyl-, hydrochloride",CNCCCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4.Cl,,,,,,
5750,40445,N-methyl-3-(2-phenyl-1-adamantyl)propan-1-amine,CNCCCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4,,,,,,
5751,40446,"Adamantane, 1-(3-dimethylaminopropyl)-2-phenyl-, hydrochloride",CN(C)CCCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4.Cl,,,,,,
5752,40447,"N,N-dimethyl-3-(2-phenyl-1-adamantyl)propan-1-amine",CN(C)CCCC12CC3CC(C1)CC(C3)C2C4=CC=CC=C4,,,,,,
5753,40448,"Adamantane, 2-chloro-1-(2-methylaminopropyl)-3,5,7-trimethyl-, hydrochloride",CC(CC12CC3(CC(C1)(CC(C3)(C2Cl)C)C)C)NC.Cl,,,,,,
5754,40449,"1-(2-chloro-3,5,7-trimethyl-1-adamantyl)-N-methylpropan-2-amine",CC(CC12CC3(CC(C1)(CC(C3)(C2Cl)C)C)C)NC,,,,,,
5755,40450,"6,6-Dimethyl-3,4-undecadiene-2,10-dione",CC(=O)CCCC(C)(C)C=C=CC(=O)C,,,,,,
5756,40451,CID 40451,C1=C(C(=O)C1=O)[O-].[K+],,,,,,
5757,40452,Moniliformin,C1=C(C(=O)C1=O)O,,,,,,
5758,40453,"Phthalimide, N-(2,5-dioxo-1-phenyl-3-pyrrolidinyl)-",C1C(C(=O)N(C1=O)C2=CC=CC=C2)N3C(=O)C4=CC=CC=C4C3=O,,,,,,
5759,40454,CID 40454,CC1=C(C=C(C=C1)C(=O)NCC(=O)[O-])N(CCCl)CCCl.[Na+],,,,,,
5760,40455,2-[[3-[Bis(2-chloroethyl)amino]-4-methylbenzoyl]amino]acetic acid,CC1=C(C=C(C=C1)C(=O)NCC(=O)O)N(CCCl)CCCl,,,,,,
5761,40456,CID 40456,CC1=C(C=C(C=C1)C(=O)NC(C)C(=O)[O-])N(CCCl)CCCl.[Na+],,,,,,
5762,40457,2-[[3-[Bis(2-chloroethyl)amino]-4-methylbenzoyl]amino]propanoic acid,CC1=C(C=C(C=C1)C(=O)NC(C)C(=O)O)N(CCCl)CCCl,,,,,,
5763,40458,L-N-(3-(Bis(2-chloroethyl)amino)-4-methylbenzoyl)histidine dihydrochloride,CCC[NH+](CCC)C1=C(C=CC(=C1)C(=O)[NH+]2C=C(N=C2)CC(C(=O)O)N)C.[Cl-].[Cl-],,,,,,
5764,40459,2-Amino-3-[1-[3-(dipropylamino)-4-methylbenzoyl]imidazol-4-yl]propanoic acid,CCCN(CCC)C1=C(C=CC(=C1)C(=O)N2C=C(N=C2)CC(C(=O)O)N)C,,,,,,
5765,40460,Tioperidone,CCCSC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)C4=CC=CC=C4NC3=O,,,,,,
5766,40461,"Methyl 1-methyl-1,2,3,6-tetrahydroisonicotinate hydrochloride",C[NH+]1CCC(=CC1)C(=O)OC.[Cl-],,,,,,
5767,40462,"Methyl 1-methyl-1,2,3,6-tetrahydropyridine-4-carboxylate",CN1CCC(=CC1)C(=O)OC,,,,,,
5768,40463,cis-Permethrin,CC1([C@H]([C@H]1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
5769,40464,"5H-Benzo(a)phenoxazin-9-amine, 5-imino-N,N,10-trimethyl-, monoperchlorate",CC1=CC2=NC3=C(C=C(C4=CC=CC=C43)N)OC2=CC1=[N+](C)C.[O-]Cl(=O)(=O)=O,,,,,,
5770,40465,"3-[5-(2-Bromo-5-hydroxyphenyl)-5-methoxypentan-2-yl]-13-hydroxy-9-(1-hydroxyethyl)-4,14,16,16-tetramethyl-2,6,10,17-tetraoxatricyclo[11.3.1.11,5]octadecane-7,11-dione",CC1CC(C23CC(C(C(O2)C(C)CCC(C4=C(C=CC(=C4)O)Br)OC)C)OC(=O)CC(OC(=O)CC1(O3)O)C(C)O)(C)C,,,,,,
5771,40466,2-(4-Chlorophenyl)-1-nitroguanidine,C1=CC(=CC=C1N=C(N)N[N+](=O)[O-])Cl,,,,,,
5772,40467,"2,2',3,4-Tetrachlorobiphenyl",C1=CC=C(C(=C1)C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl,,,,,,
5773,40468,"2,2',3,3',6-Pentachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=C(C=CC(=C2Cl)Cl)Cl,,,,,,
5774,40469,"2,2',3,5,5'-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=C(C(=CC(=C2)Cl)Cl)Cl)Cl,,,,,,
5775,40470,Aroclor 1254,C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,,,['Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. (See all compounds classified as Antithyroid Agents.)'],"['Limited specific information is available on the oral absorption of Aroclor 1254. Pregnant ferrets that ingested a single oral dose of Aroclor 1254 (approx 0.06 mg/kg) absorbed approximately 85% of the initial amount. Studies predominately of individual chlorobiphenyl congeners indicate, in general, that PCBs are readily and extensively absorbed by animals. These studies have found oral absorption efficiency on the order of 75 to > 90% in rats, mice and monkeys. A study of a non-Aroclor 54% chlorine PCB mixture prepared by the investigators provides direct evidence of absorption of PCBs in humans after oral exposure, and indirect evidence of oral absorption of PCBs by humans is available from studies of ingestion of contaminated fish by the general population. There are no quantitative data regarding inhalation absorption of PCBs in humans but studies of workers exposed suggest that PCBs are well absorbed by the inhalation and dermal routes. PCBs distribute preferentially to adipose tissue and concentrate in human breast milk due to its high fat content.', 'When Aroclor 1254 was fed to pheasants either as a single dose of 50 mg or as 17 weekly doses of 12.5 or 50 mg, up to 82% was absorbed from the gastrointestinal tract and up to 50 mg/kg (wet weight) were found in their eggs.', 'In Sherman rats given doses of 10 or 50 mg/kg body weight/day Aroclor 1254 on days 7-15 of pregnancy, the average PCB concentrations in fetuses taken by Caesarean section on day 20 of pregnancy were 0.63 and 1.38 mg/kg, resp, compared with less than 0.12 mg/kg in controls.', 'In cows fed 200 mg/day Aroclor 1254 for 60 days, the average concn in milk fat was 60 mg/kg (measured between the 40th and 60th days of feeding).', 'For more Absorption, Distribution and Excretion (Complete) data for Aroclor 1254 (19 total), please visit the HSDB record page.']","[""The metabolism of PCBs in experimental animals has been extensively reviewed. Many substrates have been tested, and the PCBs were usually administered by the oral or parenteral routes. In general, these studies showed that the metabolism rate of PCBs depends on the number and position of chlorine atoms on the phenyl ring and on the animal species. In rats, the elimination half-lives of four PCBs with one, two, five, or six chlorines increased as the number of chlorines increased. The decreased excretion rate with increasing chlorination was directly related to the decreased rate of metabolism of the more highly chlorinated congeners. Sheep liver microsomes converted 2,2',5-triCB to at least 5 more polar metabolites within 1 min and at least 10 metabolites by 15 min; however, within the homologous series, 2,2',5,5'-tetraCB and 2,2',4,5,5'-pentaCB were oxidized to only 3 metabolites at rates 7- and 14-fold slower, respectively. Not only does the number of chlorines affect the rate of biotransformation, but the position of the chlorines on the phenyl rings is also critical. This was demonstrated in rats, which excreted four symmetrical hexachlorobiphenyls at different rates depending on the chlorine positions. As the number of unsubstituted meta positions or adjacent unsubstituted carbon atoms increases, the percentage of the dose excreted increases. The major hydroxylated PCB metabolite in rat plasma after administration of 25 mg/kg Aroclor 1254 in peanut oil by gavage is 4-hydroxy-2,3,3',4',5-pentaCB. From days 1 to 14 after exposure, this metabolite is found at concentrations 7-10 times the concentration of the major PCB 153."", ""The metabolism of PCBs following oral and parenteral administration in animals has been extensively studied and reviewed, but studies in animals following inhalation or dermal exposure are lacking. Information on metabolism of PCBs in humans is limited to occupationally exposed individuals whose intake is derived mainly from inhalation and dermal exposure. In general, metabolism of PCBs depends on the number and position of the chlorine atoms on the phenyl ring of the constituent congeners (i.e., congener profile of the PCB mixture) and animal species. Although only limited data are available on metabolism of PCBs following inhalation exposure, there is no reason to suspect that PCBs are metabolized differently by this route.  Data exist on the in vitro hepatic metabolism and in vivo metabolic clearance of 2,2',3,3',6,6'-hexachlorobiphenyl and 4,4'-dichlorobiphenyl congeners in humans, monkeys, dogs and rats. The hexachlorobiphenyl congener is a constituent of Aroclor 1254. For each congener, the Vmax values for metabolism in the monkey, dog and rat are consistent with the respective metabolic clearance values found in vivo. Thus, the kinetic constants for PCB metabolism obtained from the dog, monkey and rat hepatic microsomal preparations were good predictors of in vivo metabolism and clearance for these congeners. In investigations directed at determining which species most accurately predicts the metabolism and disposition of PCBs in humans, the in vitro metabolism of these congeners was also studied using human liver microsomes. Available data suggest that metabolism of PCBs in humans would most closely resemble that of the monkey and rat. For example, the in vitro apparent Km and Vmax are comparable between humans and monkeys. These studies show consistency between the in vitro and in vivo findings and collectively indicate that metabolism of the two congeners is similar in monkeys and humans."", '... To study the possible role of non-parenchymal cells in the metabolism of xenobiotics, populations of non-parenchymal and parenchymal cells (PC) were prepared from rats and various xenobiotic metabolizing enzyme activites investigated. The specific activity of every enzyme studied (ethoxyresorufin deethylase, benzphetamine demethylase, glutathione transferase, UDP glucuronosyltransferase, and microsomal epoxide hydrolase) was 12 to 1000% higher in the parenchymal than in the non-parenchymal populations ... The non-parenchymal cells demonstrated a more dramatic induction of enzyme activities in Aroclor 1254-pretreated animals than did the parenchymal. Moreover, despite the generally lower enzyme activities, even after induction, the non-parenchymal were damaged by biologically inert xenobiotics which can be metabolized to reactive intermediates ...', 'The distribution of aminopyrine N-demethylase (APND), ethoxyresorufin O-deethylase (ERRD), epoxide hydrolase (EH), and glutathione transferase (GST) activities in parenchymal (PC) and non-parenchymal (NPC) cell populations of control and Aroclor 1254-treated C57BL/6N and DBA/2N mice was determined. Furthermore, the metabolism of benzo(a)pyrene (BP) in parenchymal and non-parenchymal of both Aroclor 1254-treated mice strains was examined ... In non-parenchymal cells of both strains a low ratio of oxidative (epoxide aminopyrine N-demethylase and ethoxyresorufin O-deethylase) post-oxidative (epoxide hydrolase and glutathione transferase) enzyme activities was observed. ... Treatment with Aroclor 1254 enhanced all the enzyme activities measured in parenchymal and non-parenchymal of both mice strains with the exception of ethoxyresorufin O-deethylase in parenchymal and non-parenchymal of DBA/2N mice. This is due to the fact that the induction process of ethoxyresorufin O-deethylase by aromatic and halogenated aromatic compounds such as Aroclor 1254 depends upon the presence of a cytosolic receptor with a high affinity for this type of inducers and the DBA/2N mice have a very poor affinity receptor. After incubating benzo(a)pyrene with parenchymal or non-parenchymal or Aroclor 1254-treated C57BL/6N mice significant amounts of 9,10-dihydrodiol, 4,5-dihydrodiol, 7,8-dihydrodiol, quinone, 9-hydroxy, and 3-hydroxy derivatives of benzo(a)pyrene were detected.', 'Differences in aryl-hydrocarbon-hydroxylase (AHH) inducibility by sodium phenobarbital or Aroclor 1254 were investigated in four strains of Drosophila-melanogaster. Berlin-K, D-melanogaster-Oregon-K, D-melanogaster-Haag-79, and D-melanogaster-Hikone-R adults (2 days old) were transferred to vials containing labeled cytochrome P-450 inducer. Concentrations of the inducers were 6.67 ug 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 0.2 mg benzo(a)anthracene (BA), 0.15 mg Aroclor 1254, and 3.0 mg sodium-phenobarbital. After 3 days of feeding, two males and two females were combined and homogenized for the fluorometric assay of aryl-hydrocarbon-hydroxylase. Cytosolic samplers from D melanogaster adults were incubated with labeled 2,3,7,8-tetrachlorodibenzo-p-dioxin or benzo(a)anthracene for 1 hr at 4 C. High performance liquid chromatography was performed for the Ah receptor. Phenobarbital induced aryl-hydrocarbon-hydroxylase activity more than 10 fold in D-melanogaster-Berlin-K and D-melanogaster-Oregon-K and about 2 fold in D-melanogaster-Haag-79 and D-melanogaster-Hikone-R. Aroclor 1254 induced aryl-hydrocarbon-hydroxylase activity 2 to 4 fold in all the strains except D-melanogaster-Hikone-R. There was no significant aryl-hydrocarbon-hydroxylase induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin or benzo(a)anthracene in any of the four strains. In the presence of a 100 fold excess of nonlabeled benzo(a)anthracene competitor, no saturable high affinity low capacity benzo(a)anthracene binding moiety could be demonstrated in any of the four strains. High affinity 2,3,7,8-tetrachlorodibenzo-p-dioxin binding sites were observed by an excess of nonlabeled 2,3,7,8-tetrachlorodibenzo-p-dioxin ...']","['Serum: 1-3 years; [TDR, p. 1035]', 'In 1977 and 1985, serum polychlorinated biphenyl (PCB) concentrations were determined for 58 workers in a Bloomington, Indiana, factory that used polychlorinated biphenyls (PCBs) in capacitor manufacture until 1977. Less chlorinated PCBs were quantitated as Aroclor 1242, and more highly chlorinated PCBs were quantitated as Aroclor 1254. The median half-life was 2.6 yr for Aroclor 1242 and 4.8 y for Aroclor 1254. However, the half-life varied inversely with the initial serum concentration ...', 'A biological half-life of about 200 days was recorded in the fat of rats after feeding with Aroclor 1254.']"
5776,40471,"2,2',3,5,5',6-Hexachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
5777,40472,"2,2',3,3',5,6,6'-Heptachlorobiphenyl",C1=CC(=C(C(=C1Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5778,40473,"2,2',3,3',4,5'-Hexachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C(=CC(=C2)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5779,40474,"2,2',3,3',5,5',6-Heptachlorobiphenyl",C1=C(C=C(C(=C1C2=C(C(=CC(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5780,40475,"2,2',3,4',5,5',6-Heptachlorobiphenyl",C1=C(C(=CC(=C1Cl)Cl)Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl,,,,,,
5781,40476,"2,2',3,4,4',5',6-Heptachlorobiphenyl",C1=C(C(=CC(=C1Cl)Cl)Cl)C2=C(C(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
5782,40477,"2,2',3,3',4,5',6'-Heptachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C(=CC(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5783,40478,"2,2',3,3',4,4',6-Heptachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C(=C(C=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5784,40479,"2,3',4,4',5,5'-Hexachlorobiphenyl",C1=C(C=C(C(=C1Cl)Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,,,,"['DISPOSITION OF 37 PCB CONGENERS & ADIPOSE TISSUE-PLASMA PARTITION OF 28 PCB CONGENERS WERE STUDIED IN 26 PERSONS OCCUPATIONALLY EXPOSED TO VARIOUS PCBS (20-54% CL). CONCN OF PCBS IN ADIPOSE TISSUE & PLASMA WERE RELATED TO DURATION & INTENSITY OF EXPOSURE. PCB CONCN IN ADIPOSE TISSUE WAS PROPORTIONAL TO THAT IN PLASMA, WITH A PARTITION FOR TOTAL PCBS OF APPROX 190:1 INDICATED FROM REGRESSION ANALYSIS. PCB CONGENERS WITH CL IN BOTH 4-POSITIONS OF BIPHENYL RING WERE MAJOR COMPONENTS IN PLASMA & ADIPOSE TISSUE. CONGENERS WITH UNSUBSTITUTED 3,4-POSITIONS ON 1 OR BOTH OF BIPHENYL RINGS WERE OBSERVED AT LOWER CONCENTRATIONS. IN CONTRAST, THOSE COMPOUNDS WITH SUBSTITUENTS AT 2,4- & 3,4-POSITIONS ON BOTH RINGS WERE PRESENT IN MUCH HIGHER PROPORTIONS IN BLOOD OR ADIPOSE TISSUE THAN IN PCB MIXTURES USED. THESE COMPONENTS ALSO HAD HIGHER ADIPOSE TISSUE-PLASMA PARTITION THAN THOSE WITH UNSUBSTITUTED 3,4-POSITIONS, REGARDLESS OF DEGREE OF CHLORINATION.']","['A strain of Alcaligenes eutrophus, designated H850, that rapidly degrades a broad and unusual spectrum of polychlorinated biphenyls (PCBs) has been isolated and characterized. ... This strain was isolated from PCB-containing dredge spoils, grows well on biphenyl and 2-chlorobiphenyl but poorly on 3- and 4-chlorobiphenyl. Capillary gas-chromatographic analysis showed that biphenyl- grown resting cells of H850 degraded the components of 38 of the 41 largest peaks of Aroclor 1242 and 15 of the 44 largest peaks of Aroclor 1254, resulting in an overall reduction of PCBs by 81% for Aroclor 1242 (10 ppm) and 35% for Aroclor 1254 (10 ppm) in 2 days. H850 metabolized the predominantly ortho- substituted PCB congeners. ... The congener selectivity patterns indicate that a two-step process consisting of anaerobic dechlorination followed by oxidation by H850 can effectively degrade all of the congeners in Aroclor 1242 and possibly all those in Aroclor 1254.']","['BIOLOGICAL HALF-LIFE OF 31 DICHLORO- TO DECHLOROBIPHENYL CONGENERS WERE MONITORED FOR 105 DAYS IN ADULT RAINBOW TROUT THAT WERE EXPOSED TO A SINGLE ORAL DOSE. IN WHOLE FISH, HALF-LIFE INCR FROM 5 DAYS TO NO APPARENT ELIMINATION AS THE NUMBER OF CHLORINES ON THE BIPHENYL INCR. THIS STRUCTURE-ACTIVITY RELATION WAS NOT AS EVIDENT IN MUSCLE WHERE HALF-LIFE RANGED FROM LESS THAN 5 DAYS TO 127 DAYS. DECLINE IN MUSCLE PCB MAY BE RELATED TO THE DECR IN LIPID LEVELS & REDISTRIBUTION OF CONGENERS WITHIN THE FISH. FROM STRUCTURE-ACTIVITY ANALYSIS OF HALF-LIFE IN WHOLE FISH, ELIMINATION IS ENHANCED FOR THOSE CONGENERS WITH LOWER CHLORINE CONTENT, WITH NO CHLORINE SUBSTITUTIONS IN THE ORTHO POSITIONS, & THOSE WITH 2 UNSUBSTITUTED CARBONS THAT ARE ADJACENT (VICINAL) ON THE BIPHENYL. A SIGNIFICANT DECLINE IN TOTAL PCB CONTENT IN WHOLE FISH, EQUIV TO HALF-LIFE OF 219 DAYS, WAS PARTLY DUE TO DECOMP OF THE PCB MIXTURE ADMIN, & SELECTIVE ELIMINATION OF LOWER CHLORINATED BIPHENYLS.']"
5785,40480,"2,2',3,3',4,5,6,6'-Octachlorobiphenyl",C1=CC(=C(C(=C1Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5786,40481,"2,2',3,3',4,5,5'-Heptachlorobiphenyl",C1=C(C=C(C(=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5787,40482,"2,2',3,3',4,5,5',6'-Octachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl,,,,,,
5788,40483,"2,2',3,4,4',5,5',6-Octachlorobiphenyl",C1=C(C(=CC(=C1Cl)Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
5789,40484,"2,2',3,3',4,5,5',6,6'-Nonachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5790,40485,"2,2',3,3',4,4',5,6-Octachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5791,40486,Ionophore A23187,C[C@H]1CCC2([C@@H](C[C@H]([C@H](O2)C(C)C(=O)C3=CC=CN3)C)C)O[C@H]1CC4=NC5=C(O4)C=CC(=C5C(=O)O)NC,,,"['Chemical agents that increase the permeability of CELL MEMBRANES to CALCIUM ions. (See all compounds classified as Calcium Ionophores.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
5792,40487,Dibutyl methylphenylphosphoramidate,CCCCOP(=O)(N(C)C1=CC=CC=C1)OCCCC,,,,,,
5793,40488,"Adamantane, 1,3-bis(2-dimethylaminoethyl)-, dihydrochloride",CN(C)CCC12CC3CC(C1)CC(C3)(C2)CCN(C)C.Cl.Cl,,,,,,
5794,40489,"2-[3-[2-(dimethylamino)ethyl]-1-adamantyl]-N,N-dimethylethanamine",CN(C)CCC12CC3CC(C1)CC(C3)(C2)CCN(C)C,,,,,,
5795,40490,"1,3-Bis(2-dimethylaminopropyl)adamantane dihydrochloride",CC(CC12CC3CC(C1)CC(C3)(C2)CC(C)N(C)C)N(C)C.Cl.Cl,,,,,,
5796,40491,"1-[3-[2-(dimethylamino)propyl]-1-adamantyl]-N,N-dimethylpropan-2-amine",CC(CC12CC3CC(C1)CC(C3)(C2)CC(C)N(C)C)N(C)C,,,,,,
5797,40492,Acid Red 186,CC1=NN(C(=C1N=NC2=C(C=C(C3=CC=CC=C32)S(=O)(=O)[O-])[O-])[O-])C4=CC(=CC=C4)S(=O)(=O)[O-].[Na+].[Cr+3],,,,,,
5798,40493,Acid Red 186 free acid,CC1=C(C(=O)N(N1)C2=CC(=CC=C2)S(=O)(=O)O)N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)O)O,,,,,,
5799,40494,4-(Oxiran-2-yl)benzonitrile,C1C(O1)C2=CC=C(C=C2)C#N,,,,,,
5800,40495,"1,1,1-Trimethoxy-2-methylpropane",CC(C)C(OC)(OC)OC,,,,,,
5801,40496,"2,2',3,3',5,6-Hexachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl,,,,,,
5802,40497,"1-Butene, 1,1,2,3,4-pentachloro-",C(C(C(=C(Cl)Cl)Cl)Cl)Cl,,,,,,
5803,40498,"2-Amino-5-benzyl-10b-hydroxy-2-methyltetrahydro-2H-oxazolo(3,2-a)pyrrolo(2,1-C)pyrazine-3,6(5H,10bh)-dione, (2R,5S,10aS,10bS)-",C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)N,,,,,,
5804,40499,"6,7-Dichloro-2-isopropyl-1-oxo-5-indanyloxyacetic acid",CC(C)C1CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O,,,,,,
5805,40500,"2,2',3,4,5,5',6-Heptachlorobiphenyl",C1=CC(=C(C=C1Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5806,40501,CID 40501,C[C@H]1CC=C[C@H]2[C@@H](C(=C)[C@H]([C@@H]3C2(C(=O)CC([C@@](C1=O)(C)O)OC)C(=O)N[C@H]3CC4=CC=CC=C4)C)OC(=O)C,,,,,,
5807,40502,"Anthraquinone, 1-(dimethylamino)methyl-2-methoxy-",CN(C)CC1=C(C=CC2=C1C(=O)C3=CC=CC=C3C2=O)OC,,,,,,
5808,40503,"Anthraquinone, 1-(diethylamino)methyl-2-methoxy-",CCN(CC)CC1=C(C=CC2=C1C(=O)C3=CC=CC=C3C2=O)OC,,,,,,
5809,40504,"Anthraquinone, 2-methoxy-1-pyrrolidinylmethyl-",COC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)CN4CCCC4,,,,,,
5810,40505,1-(Dimethylamino)methyl-2-methoxyanthracene hydrochloride,C[NH+](C)CC1=C(C=CC2=CC3=CC=CC=C3C=C21)OC.[Cl-],,,,,,
5811,40506,"1-(2-methoxyanthracen-1-yl)-N,N-dimethylmethanamine",CN(C)CC1=C(C=CC2=CC3=CC=CC=C3C=C21)OC,,,,,,
5812,40507,1-(Diethylamino)methyl-2-methoxyanthracene hydrochloride,CC[NH+](CC)CC1=C(C=CC2=CC3=CC=CC=C3C=C21)OC.[Cl-],,,,,,
5813,40508,N-ethyl-N-[(2-methoxyanthracen-1-yl)methyl]ethanamine,CCN(CC)CC1=C(C=CC2=CC3=CC=CC=C3C=C21)OC,,,,,,
5814,40509,2-Methoxy-1-pyrrolidinylmethylanthracene hydrochloride,COC1=C(C2=CC3=CC=CC=C3C=C2C=C1)C[NH+]4CCCC4.[Cl-],,,,,,
5815,40510,1-[(2-Methoxyanthracen-1-yl)methyl]pyrrolidine,COC1=C(C2=CC3=CC=CC=C3C=C2C=C1)CN4CCCC4,,,,,,
5816,40511,1-[(2-Methoxyanthracen-1-yl)methyl]piperidine,COC1=C(C2=CC3=CC=CC=C3C=C2C=C1)CN4CCCCC4,,,,,,
5817,40512,"Acetic acid, 4-(butylnitrosamino)butyl ester",CCCCN(CCCCOC(=O)C)N=O,,,,,,
5818,40513,"Aminohydroxy-9,10-anthracenedione",C1=CC=C2C(=C1)C(=C3C=CC(=CC3=C2O)N=O)O,,,,,,
5819,40514,"DISULFIDE, p-CHLOROPHENYL TRICHLOROMETHYL",C1=CC(=CC=C1SSC(Cl)(Cl)Cl)Cl,,,,,,
5820,40515,"Disulfide, phenyl trichloromethyl",C1=CC=C(C=C1)SSC(Cl)(Cl)Cl,,,,,,
5821,40516,Calcium hydrogen arsorite,O[As]([O-])[O-].[Ca+2],,,,,,
5822,40517,"2,2',3,3',5,6'-Hexachlorobiphenyl",C1=CC(=C(C(=C1Cl)C2=C(C(=CC(=C2)Cl)Cl)Cl)Cl)Cl,,,,,,
5823,40518,"4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-13-ium-14-ol;iodide",C1CN2CC3=CCOC4CC(=[N+]5C6C4C3CC2C61C7=CC=CC=C75)O.[I-],,,,,,
5824,40519,"4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-13-ium-14-ol",C1CN2CC3=CCOC4CC(=[N+]5C6C4C3CC2C61C7=CC=CC=C75)O,,,,,,
5825,40520,Flamprop-isopropyl,CC(C)OC(=O)C(C)N(C1=CC(=C(C=C1)F)Cl)C(=O)C2=CC=CC=C2,,,,,,
5826,40521,Flamprop-methyl,CC(C(=O)OC)N(C1=CC(=C(C=C1)F)Cl)C(=O)C2=CC=CC=C2,,,,,,
5827,40522,1-Methyl-3-acetoxyhexahydroazepine,CC(=O)OC1CCCCN(C1)C,,,,,,
5828,40523,"2-Adamantanol, 1-(3-methylaminopropyl)-, hydrochloride",CNCCCC12CC3CC(C1)CC(C3)C2O.Cl,,,,,,
5829,40524,1-[3-(Methylamino)propyl]adamantan-2-ol,CNCCCC12CC3CC(C1)CC(C3)C2O,,,,,,
5830,40525,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, ethyl ester",CCOC(=O)C(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C,,,,,,
5831,40526,"4-(1,3-Benzoxathiol-2-yl)-alpha-methylbenzeneacetic acid",CC(C1=CC=C(C=C1)C2OC3=CC=CC=C3S2)C(=O)O,,,,,,
5832,40527,"Methanesulfonate;trimethyl-[4-[(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]phenyl]azanium",CC1(C2CCC1(C(=O)C2=CC3=CC=C(C=C3)[N+](C)(C)C)C)C.CS(=O)(=O)[O-],,,,,,
5833,40528,"N,N,N-Trimethyl-4-[(4,7,7-trimethyl-3-oxobicyclo[2.2.1]heptan-2-ylidene)methyl]anilinium",CC1(C2CCC1(C(=O)C2=CC3=CC=C(C=C3)[N+](C)(C)C)C)C,,,,,,
5834,40529,"(7S,9S)-9-acetyl-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4,6,9,11-tetrahydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride",C[C@H]1[C@H]([C@H](CC(O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(=O)C)O)N)O.Cl,,,,,,
5835,40530,Karminomitsin,C[C@H]1[C@H]([C@H](CC(O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(=O)C)O)N)O,,,,,,
5836,40531,2-Phenylpicolinium iodide,C[N+]1=CC=CC=C1C2=CC=CC=C2.[I-],,,,,,
5837,40532,1-Methyl-2-phenylpyridinium,C[N+]1=CC=CC=C1C2=CC=CC=C2,,,,,,
5838,40533,"(E)-2-(3,4-Dichlorophenyl)-3-(dimethylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC(=C(C=C3)Cl)Cl)CC2.[Cl-],,,,,,
5839,40534,"1-[(2R)-3-(3,4-dichlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@@H]1C2CCC(C1C3=CC(=C(C=C3)Cl)Cl)CC2,,,,,,
5840,40535,"(E)-2-(p-Chlorophenyl)-3-(dimethylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC=C(C=C3)Cl)CC2.[Cl-],,,,,,
5841,40536,"1-[(2R)-3-(4-chlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@@H]1C2CCC(C1C3=CC=C(C=C3)Cl)CC2,,,,,,
5842,40537,"Bicyclo(2.2.2)octane-2-methylamine, N,N-dimethyl-3-phenyl-, hydrochloride, (E)-",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC=CC=C3)CC2.[Cl-],,,,,,
5843,40538,Dimethyl-(3-phenyl-bicyclo[2.2.2]oct-2-ylmethyl)-amine,CN(C)CC1C2CCC(C1C3=CC=CC=C3)CC2,,,,,,
5844,40539,Quisqualic acid,C([C@@H](C(=O)O)N)N1C(=O)NC(=O)O1,,,['Drugs that bind to and activate excitatory amino acid receptors. (See all compounds classified as Excitatory Amino Acid Agonists.)'],,,
5845,40540,2-[2-(Tetrahydrofurfuryloxy)ethoxy]ethanol,C1CC(OC1)COCCOCCO,,,,,,
5846,40541,1-(6-Methoxy-2-benzofuranyl)ethanone,CC(=O)C1=CC2=C(O1)C=C(C=C2)OC,,,,,,
5847,40542,4-chloro-N-(nitromethylideneamino)aniline,C1=CC(=CC=C1NN=C[N+](=O)[O-])Cl,,,,,,
5848,40543,"Isopropyl N-(2,4,5-trichlorophenyl)carbamate",CC(C)OC(=O)NC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
5849,40544,Toxaphene toxicant C,C(C1(C2C(C(C1(C(C2(Cl)Cl)Cl)C(Cl)Cl)Cl)Cl)CCl)Cl,,,,,,
5850,40545,"6H-(1)BENZOTHIOPYRANO(4,3-b)QUINOLINE, 2-FLUORO-",C1C2=CC3=CC=CC=C3N=C2C4=C(S1)C=CC(=C4)F,,,,,,
5851,40546,"(1)BENZOTHIOPYRANO(4,3-b)INDOLE, 2-FLUORO-",C1=CC=C2C(=C1)C3=CSC4=C(C3=N2)C=C(C=C4)F,,,,,,
5852,40547,"3-Fluoro-6H-(1)benzothiopyrano(4,3-b)quinoline",C1C2=CC3=CC=CC=C3N=C2C4=C(S1)C=C(C=C4)F,,,,,,
5853,40548,"3-Fluoro-7-methyl-6H-(1)benzothiopyrano(4,3-b)quinoline",CC1=C2CSC3=C(C2=NC4=CC=CC=C14)C=CC(=C3)F,,,,,,
5854,40549,"(1)BENZOTHIOPYRANO(4,3-b)INDOLE, 3-FLUORO-",C1=CC=C2C(=C1)C3=CSC4=C(C3=N2)C=CC(=C4)F,,,,,,
5855,40550,"6H-(1)BENZOTHIOPYRANO(4,3-b)QUINOLINE, 4-FLUORO-",C1C2=CC3=CC=CC=C3N=C2C4=C(S1)C(=CC=C4)F,,,,,,
5856,40551,"6H-(1)BENZOTHIOPYRANO(4,3-b)QUINOLINE, 4-FLUORO-7-METHYL-",CC1=C2CSC3=C(C2=NC4=CC=CC=C14)C=CC=C3F,,,,,,
5857,40552,"(1)BENZOTHIOPYRANO(4,3-b)INDOLE, 4-FLUORO-",C1=CC=C2C(=C1)C3=CSC4=C(C3=N2)C=CC=C4F,,,,,,
5858,40553,"1,3-Dihydro-7-chloro-3-(dimethylamino)-5-phenyl-2H-1,4-benzodiazepin-2-one",CN(C)C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,,,,,,
5859,40554,N-Morpholinomethylbenzohydroxamic acid hydrochloride,C1COCC[NH+]1CN(C(=O)C2=CC=CC=C2)O.[Cl-],,,,,,
5860,40555,"1-Butene, 2-chloro-",CCC(=C)Cl,,,,,,
5861,40556,"Benzene, (2-bromo-1-propoxyethyl)-",CCCOC(CBr)C1=CC=CC=C1,,,,,,
5862,40557,"Acetic acid, ((methoxy(methylthio)phosphinyl)amino)oxo-, ethyl ester",CCOC(=O)C(=O)NP(=O)(OC)SC,,,,,,
5863,40558,"Mannitol, 1,6-diazido-, D-",C([C@H]([C@H]([C@@H]([C@@H](CN=[N+]=[N-])O)O)O)O)N=[N+]=[N-],,,,,,
5864,40559,"Mannitol, 1,6-dipiperidino-, D-, dihydrochloride",C1CC[NH+](CC1)CC(C(C(C(C[NH+]2CCCCC2)O)O)O)O.[Cl-].[Cl-],,,,,,
5865,40560,"1,6-Di(piperidin-1-yl)hexane-2,3,4,5-tetrol",C1CCN(CC1)CC(C(C(C(CN2CCCCC2)O)O)O)O,,,,,,
5866,40561,"Mannitol, 1,6-dimorpholino-, D-, dihydrochloride",C1COCC[NH+]1CC(C(C(C(C[NH+]2CCOCC2)O)O)O)O.[Cl-].[Cl-],,,,,,
5867,40562,"1,6-Dimorpholin-4-ylhexane-2,3,4,5-tetrol",C1COCCN1CC(C(C(C(CN2CCOCC2)O)O)O)O,,,,,,
5868,40563,"Mannitol, 1,6-bis(dimethylamino)-, D-, dihydrochloride",C[NH+](C)CC(C(C(C(C[NH+](C)C)O)O)O)O.[Cl-].[Cl-],,,,,,
5869,40564,"1,6-Bis(dimethylamino)hexane-2,3,4,5-tetrol",CN(C)CC(C(C(C(CN(C)C)O)O)O)O,,,,,,
5870,40565,"Mannitol, 1,6-bis(diethylamino)-, D-, dihydrochloride",CC[NH+](CC)CC(C(C(C(C[NH+](CC)CC)O)O)O)O.[Cl-].[Cl-],,,,,,
5871,40566,"1,6-Bis(diethylamino)hexane-2,3,4,5-tetrol",CCN(CC)CC(C(C(C(CN(CC)CC)O)O)O)O,,,,,,
5872,40567,"9,10-Anthracenedione, 1,4-bis((3-(dimethylamino)propyl)amino)-",CN(C)CCCNC1=C2C(=C(C=C1)NCCCN(C)C)C(=O)C3=CC=CC=C3C2=O,,,,,,
5873,40568,"2H-(1)Benzothiopyrano(4,3,2-cd)indazole-2-ethanamine, N,N-diethyl-5-methyl-, monomethanesulfonate",CC[NH+](CC)CCN1C2=C3C(=C(C=C2)C)SC4=CC=CC=C4C3=N1.CS(=O)(=O)[O-],,,,,,
5874,40569,"Benzophenone, 4-ethoxy-4'-methoxy-",CCOC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)OC,,,,,,
5875,40570,CID 40570,CC(=NO)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
5876,40571,CID 40571,CC[NH+](CC)CC(=C(C)O)N=O.[Cl-],,,,,,
5877,40572,CID 40572,CCN(CC)CC(=C(C)O)N=O,,,,,,
5878,40573,"1-Methoxycarbonyl-4-beta-methoxy-4-alpha-phenyl-3-alpha,5-alpha-propanopiperidine",COC(=O)N1CC2CCCC(C1)C2(C3=CC=CC=C3)OC,,,,,,
5879,40574,"1-Ethoxycarbonyl-4-beta-methoxy-4-alpha-phenyl-3-alpha,5-alpha-propanopiperidine",CCOC(=O)N1CC2CCCC(C1)C2(C3=CC=CC=C3)OC,,,,,,
5880,40575,"3-Azabicyclo(3.3.1)nonane-3-carboxylic acid, 9-methoxy-9-(3-methoxyphenyl)-, ethyl ester, syn-",CCOC(=O)N1CC2CCCC(C1)C2(C3=CC(=CC=C3)OC)OC,,,,,,
5881,40576,"Formamide, N-(9-methylcarbazol-3-YL)methyl-",CN1C2=C(C=C(C=C2)CNC=O)C3=CC=CC=C31,,,,,,
5882,40577,9-Ethyl-3-(1-(formylamino)ethyl)carbazole,CCN1C2=C(C=C(C=C2)C(C)NC=O)C3=CC=CC=C31,,,,,,
5883,40578,3-(1-(Formylamino)ethyl)-9-propylcarbazole,CCCN1C2=C(C=C(C=C2)C(C)NC=O)C3=CC=CC=C31,,,,,,
5884,40579,"Formamide, N-(1-(9-ethylcarbazol-3-YL)benzyl)-",CCN1C2=C(C=C(C=C2)C(C3=CC=CC=C3)NC=O)C4=CC=CC=C41,,,,,,
5885,40580,"Aniline, N-(2-adamantyl)-",C1C2CC3CC1CC(C2)C3NC4=CC=CC=C4,,,,,,
5886,40581,"2-Adamantanamine, N-benzyl-, hydrochloride",C1C2CC3CC1CC(C2)C3NCC4=CC=CC=C4.Cl,,,,,,
5887,40582,N-benzyladamantan-2-amine,C1C2CC3CC1CC(C2)C3NCC4=CC=CC=C4,,,,,,
5888,40583,CID 40583,C1C2CC3(CC1CC(C2)(C3)Cl)C(=O)C=[N+]=N,,,,,,
5889,40584,CID 40584,C1C2CC3(CC1CC(C2)(C3)Br)C(=O)C=[N+]=N,,,,,,
5890,40585,Deltamethrin,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['In rats, following oral administration, elimination occurs within 2-4 days. The phenyl ring is hydroxylated, the ester bond hydrolyzed, and the acid moiety is eliminated as the glucuronide and glycine conjugates.', 'Intravenous disposition kinetics /in a female black Bengal goat/ using a dose of 0.2 mg/kg showed that the maximum blood concentration of deltamethrin was recorded at 0.5 min, followed by rapid decline, and a minimum concentration was detected at 6 min after administration. The following values were obtained: Vdarea 0.148 (+ or -0.02) L/kg; t1/2 (a) 0.22 (+ or -0.02) min; t1/2 (beta) 2.17 (+ or -0.37) min; Kel 1.05 (+ or -0.24) /min; AUC 4.30(+ or -0.45)ug min/mL; ClB 0.05 (+ or -0.006) L/kg/min; T~B 1.93 (+ or -0.58); fc 0.40(+ or -0.05). After 10 min, liver retained the maximum residue, and heart, adrenal gland, kidney, spleen, fat and brain also held the insecticide; liver, fat, heart and spleen retained residue after 30 min, and bone, liver and fat retained residue after 60 min of iv administration. Oral absorption of deltamethrin was poor and inconsistent, and approximately 65% of administered dose was recovered from feces and gastrointestinal contents. The excretion of deltamethrin through urine was meager, and only 0.01 and 0.013% of the administered dose was recovered after 3 and 5 days of oral administration respectively. All the tissues retained the residue after 3 days; while fat, rumen, reticulum, omasum, abomasum, large and small intestine and bone retained the residue after 5 days of oral administration; and the percentage recoveries were 1.73 and 0.027 respectively. ...', 'Three young male human volunteers underwent a complete medical check-up one week prior to the morning of the study. Each of them received a single dose of 3 mg of (14)C deltamethrin mixed in 1 g glucose and diluted first in 10 mL polyethylene glycol300 and again in 150 mL water. Total radioactivity was 1.8 + or - 0.9 mBq. Samples of blood, urine, saliva, and feces were taken at intervals over 5 days. Clinical and biological examinations were performed every 12 hr during the trial and one week after its termination. Radioactivity in the biological samples was measured with a liquid scintillation spectrometer. The clinical and biological checks did not detect any abnormal findings. There were no signs of side effects ... either during or after the trial period. The maximum plasma radioactivity appeared between 1 and 2 hr after administration of the product, and remained over the detection limit (0.2 KBq/L) during the 48 hr. The apparent elimination half-life was between 10.0 and 11.5 hr. The radioactivity of blood cells, as well as the saliva, was extremely low. Urinary excretion was 51-50% of the initial radioactivity; 90% of this radioactivity was excreted during the 24 hr following absorption. The apparent half-life of urinary excretion was 10.0-13.5 hr, which is consistent with the plasma data. Fecal elimination at the end of the observation period represented 10-26% of the dose. The total fecal plus urine elimination was around 64-77% of the initial dose after 96 hr.', 'In a feeding study, deltamethrin was administered twice daily to lactating dairy cows in portions of their daily feed at the rate of 2 or 10 mg/kg diet for 28 consecutive days. The level of 2 mg/kg diet was the residue level found in a recently treated pasture, whereas 10 mg/kg diet was five times this level. Deltamethrin residues in the milk were dose-dependent and appeared to reach a plateau between 7 and 9 days after the start of treatment. At the high deltamethrin intake of 10 mg/kg diet, the deltamethrin residue in milk was about 0.025 mg/L. Deltamethrin residues in tissues were measured 1, 4, and 9 days after the last dose. At the 10 mg/kg diet intake, very small amounts of deltamethrin residues were found in the liver (<0.005 mg/kg), kidney )<0.002 mg/kg), and muscle (0.002-0.014 mg/kg). Residues in fat were about 0.04 mg/kg and 0.2 mg/kg for the 2 and 10 mg/kg intake, respectively. Depletion of deltamethrin in milk was very rapid (estimated half-life was about 1 day); while in fat (renal and subcutaneous) the half-life was 7-9 days. Br2CA (3-(2,2-dibromovinyl)-2,2-dimethylcyclopro-panecarboxylic acid) and PBacid (3-phenoxybenzoic acid) were the only metabolites detected in the milk and tissues of treated cows. In all cases, they were found at trace levels of < 0.0235 mg/L and < 0.034 mg/L, respectively. These two metabolites were also previously identified in rats and mice as the major degradation products of deltamethrin.', 'For more Absorption, Distribution and Excretion (Complete) data for DELTAMETHRIN (18 total), please visit the HSDB record page.']","[""Deltamethrin (1 ug) was incubated at 37 C for 30 min with each of the following mouse microsome preparations; a) tetraethyl pyrophosphate (TEPP)-treated microsomes (no esterase and oxidase activity); b) normal microsomes (esterase acivity); c) TEPP-treated microsomes plus NADPH (oxidase activity); and d)normal microsomes plus NADPH (esterase plus oxidase activity). Deltamethrin was more rapidly metabolized under the oxidase system than under the esterase system. The major site of ring hydroxylation was 4'-position and the secondary site was the 5-position. The trans methyl group was an important site of hydroxylation of the esters and cis methyl oxidation was evident in the metabolites of the cleaved acid moiety. The preferred sites of hydroxylation were as follows; trans of dimethyl group, 4'-position in the phenol group, and cis of the dimethyl group was equal to the 5-position in the phenoxy group. Cleavage of deltamethrin to cyanohydrin may result from both esterase and oxidase enzyme activities, since larger amounts of the cleaved products were evident in the oxidase system. ... However, at a much higher (approximately 35-fold) concentration of deltamethrin than that in the above study, it was not detectably hydrolysed. ... Deltamethrin was hydrolysed by esterases in the blood, brain, kidney, and stomach of mice yielding PBald and PBacid."", 'In a metabolic study, (14)C-deltamethrin was administered orally to lactating dairy cows at the rate of 10 mg/kg body weight per day for 3 consecutive days. It was poorly absorbed and mainly eliminated in the feces as unchanged deltamethrin. Only 4-6% of the administered (14)C was eliminated in the urine, and 0.42-1.62% was secreted in the milk. The radiocarbon contents of various tissues were generally very low with the exception of those of the liver, kidney, and fat, which were higher. Deltamethrin degradation occured by cleavage of the ester bond, as already reported in rats and mice. The enzymes responsible for the ester bond cleavage were located in cow liver homogenate, mainly in the microsomal fraction, as seen in an in vitro study. Metabolites resulting from ester bond cleavage further metabolized and/or conjugated, resulting in a large number of compounds excreted in the urine. In the milk, the major identifiable radiolabelled compound was deltamethrin.', ""The major metabolic pathways of deltamethrin in mice were similar to those in rats, though there were some differences. These included the presence of more unchanged deltamethrin in mouse feces than in rat feces. In mouse feces, there were 4 monohydroxy ester metabolites (2'-OH-, 4'-OH-, 5-OH-, and trans-OH-deltamethrin and one dihydroxy metabolite (4'-OH-trans-OH- deltamethrin) that were not found in mouse urine. Major metabolites from the acid moiety in mice were Br2CA, trans-OH-Br2CA, and their glucuronide and sulfate conjugates. Among them, trans-OH-Br2CA-sulfate was detected only in mice, but not in rats. Compared with rats, much larger amounts of trans-OH-Br2CA and its conjugates were formed in mice. A major metabolite of the alcohol moiety in mice was the taurine conjugate of PBacid in the urine, which was not detected in rats. Generally, mice produced smaller amounts of phenolic compounds compared with rats. Also, 3-phenoxybenzaldehyde (PBald), 3-phenoxybenzyl alcohol (PBalc), and its glucuronide, and glucuronides of 3-(4-hydroxyphenoxy)benzyl alcohol (4'-OH-PBalc) and 5-hydroxy-3-penoxybenzoic acid (5-OH-PBacid) were found in mice, but not in rats. When mice were given an ip dose of (14) C-deltamethrin with or without piperonyl butoxide (PBO) and/or S,S,S-tributylphosphorotrithioate (DEF), the same metabolites were obtained as with oral administration. However, DEF decreased the hydrolytic products relative to the controls, while PBO decreased the oxidation products."", ""Sulfate of 4'-OH-PBacid accounted for about 50% of the dose, together with small amounts of free (4%) and glucuronide forms (2%). The CN group was converted mainly to thiocyanate and, in small amounts, to ITCA. The trans-isomer of deltamethrin was also rapidly metabolized and yielded almost the same metabolties as deltamethrin, though 5-OH-derivative was found in the cis-isomer, but not in the trans-isomer."", 'For more Metabolism/Metabolites (Complete) data for DELTAMETHRIN (19 total), please visit the HSDB record page.', ""Deltamethrin has known human metabolites that include 4'-hydroxy-deltamethrin.""]","['Following intravenous administration, the distribution and elimination half-times were ... 1.39 and 33.0 hours for deltamethrin.', 'In rats administered deltamethrin and its metabolite (4-OH-deltamethrin) intravenously, elimination half-times were 33 and 25 hours, respectively.', 'Deltamethrin has a half-life in rat brain of 1-2 days, but it is rather more persistent in body fat, with a half-life of 5 days.', 'Three young male human volunteers underwent a complete medical check-up one week prior to the morning of the study. Each of them received a single dose of 3 mg of (14)C deltamethrin mixed in 1 g glucose and diluted first in 10 mL polyethylene glycol300 and again in 150 mL water. Total radioactivity was 1.8 + or - 0.9 mBq. ... The apparent elimination half-life was between 10.0 and 11.5 hr. ... The apparent half-life of urinary excretion was 10.0-13.5 hr, which is consistent with the plasma data. ...']"
5891,40586,Nanaomycin,CC1C2=C(CC(O1)CC(=O)O)C(=O)C3=C(C2=O)C(=CC=C3)O,,,,,,
5892,40587,Nanaomycin B,CC1[C@@]2(C(C[C@@H](O1)CC(=O)O)C(=O)C3=C(C2=O)C(=CC=C3)O)O,,,,,,
5893,40588,"4-Ethyl-1,6-heptadien-4-ol",CCC(CC=C)(CC=C)O,,,,,,
5894,40589,Etoperidone,CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl,"['Etoperidone has been studied for the treatment of depression, tremors in Parkinson, extrapyramidal symptoms and male impotence. It is not certain if it was ever approved and marketed but its current status is withdrawn.']","['Etoperidone has a biphasic effect on the central transmission of serotonin. It presents the capacity to inhibit serotonin receptor but also to inhibit the reuptake of serotonin, norepinephrine and dopamine. As part of its actions, etoperidone also inhibits the -adrenergic receptors which directly corresponds to the sedative and cardiovascular effects. The presence of both effects caused that the effective dose of etoperidone was poorly tolerated thus, efforts have been made to separate the serotonergic and adrenergic functions in order to generate etoperidone-derivatives like nefazodone.']",,"['The absorption and bioavailability is highly variable between individuals and can be as low as 12%. The lower bioavailability is explained due to its high metabolism. The mean time to peak plasma concentration is ranged from 1.4-4.8 hours.', 'The elimination of an oral dose of etoperidone presents a division of 78.8% found in urine and 9.6% found in faeces. On the elimination route, less than 0.01% of the etoperidone dose is represented by the unchanged drug while the rest is formed by 21 different metabolites.', 'The high protein binding presented in etoperidone modulates its volume of distribution to a range of 0.23 to 0.69 L/kg.', 'The apparent clearance of etoperidone was 1.01 ml/min.']","['Etoperidone is highly metabolized and it forms 21 different metabolites that can be found in plasma, urine and faeces. The metabolism of etoperidone is thought to be related to 5 different reaction pathways that are alkyl oxidation, piperazinyl oxidation, N-dealkylation, phenyl hydroxylation and conjugation.', 'Etoperidone has known human metabolites that include 1-(3-Chlorophenyl)piperazine, 2-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-4-ethyl-5-(1-hydroxyethyl)-1,2,4-triazol-3-one, 2-[3-[4-(3-chloro-4-hydroxyphenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one, and 4,5-diethyl-2-propyl-1,2,4-triazol-3-one.']",['After oral administration of etoperidone the terminal half-life was 21.7 hours.']
5895,40590,Diethyl 2-(ethoxymethylidene)-3-oxobutanedioate,CCOC=C(C(=O)C(=O)OCC)C(=O)OCC,,,,,,
5896,40591,CID 40591,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])C.[Na+],,,,,,
5897,40592,"Barbituric acid, 5-methyl-5-(1-methylbutyl)-",CCCC(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
5898,40593,5-(1-Methylbutyl)-5-propylbarbituric acid,CCCC(C)C1(C(=O)NC(=O)NC1=O)CCC,,,,,,
5899,40594,"5,5-Dimethyl-2-(alpha-ethoxybenzyl)-2-imidazoline",CCOC(C1=CC=CC=C1)C2=NCC(N2)(C)C,,,,,,
5900,40595,"2-(3,4-Dichloro-alpha-ethoxybenzyl)-5,5-dimethyl-2-imidazoline",CCOC(C1=CC(=C(C=C1)Cl)Cl)C2=NCC(N2)(C)C,,,,,,
5901,40596,"Antipyrine, 4-(9H-purin-6-ylamino)-",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC3=NC=NC4=C3NC=N4,,,,,,
5902,40597,N-(1-(Phenylmethyl)-4-piperidinyl)benzamide hydrochloride,C1C[NH+](CCC1NC(=O)C2=CC=CC=C2)CC3=CC=CC=C3.[Cl-],,,,,,
5903,40598,N-(1-benzylpiperidin-4-yl)benzamide,C1CN(CCC1NC(=O)C2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
5904,40599,"BENZO(b)THIOPHENE-3-ETHYLAMINE, N-METHYL-",CNCCC1=CSC2=CC=CC=C21,,,,,,
5905,40600,"Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-isothiocyanato-",C1=CC(=C(C=C1N=C=S)S(=O)(=O)O)C=CC2=C(C=C(C=C2)N=C=S)S(=O)(=O)O,,,,,,
5906,40601,"Benzenamine, tetranitro-",C1=C(C(=C(C(=C1[N+](=O)[O-])[N+](=O)[O-])N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
5907,40602,"2,4-Heptadiyne-1,7-diol, 1,1-diphenyl-",C1=CC=C(C=C1)C(C#CC#CCCO)(C2=CC=CC=C2)O,,,,,,
5908,40603,Phenmedipham-lenacil mixt,CC1=CC(=CC=C1)NC(=O)OC2=CC=CC(=C2)NC(=O)OC.C1CCC(CC1)N2C(=O)C3=C(CCC3)NC2=O,,,,,,
5909,40604,Austidiol,CC1=CC2=C(C(=O)[C@]([C@H](C2=CO1)O)(C)O)C=O,,,,,,
5910,40605,"Acetamide, N-(5-(9H-purin-6-ylthio)-1,3,4-thiadiazol-2-YL)-",CC(=O)NC1=NN=C(S1)SC2=NC=NC3=C2NC=N3,,,,,,
5911,40606,"3-Biphenylamine, 4'-nitro-",C1=CC(=CC(=C1)N)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
5912,40607,CID 40607,CC[C@H]1[C@]([C@@H]([C@@H](C(=NOC)[C@H](C[C@@]([C@@H](C([C@@H]([C@@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,,,,,,
5913,40608,CID 40608,COC1=C(C=C(C=C1)CCN2C(=O)CSC2=NN=CC3=CC=CC=C3)OC,,,,,,
5914,40609,"2-[(2-Chlorophenyl)methylidenehydrazinylidene]-3-[2-(3,4-dimethoxyphenyl)ethyl]-1,3-thiazolidin-4-one",COC1=C(C=C(C=C1)CCN2C(=O)CSC2=NN=CC3=CC=CC=C3Cl)OC,,,,,,
5915,40610,"2-[(4-Chlorophenyl)methylidenehydrazinylidene]-3-[2-(3,4-dimethoxyphenyl)ethyl]-1,3-thiazolidin-4-one",COC1=C(C=C(C=C1)CCN2C(=O)CSC2=NN=CC3=CC=C(C=C3)Cl)OC,,,,,,
5916,40611,CID 40611,COC1=CC=C(C=C1)C=NN=C2N(C(=O)CS2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
5917,40612,CID 40612,COC1=C(C=C(C=C1)CCN2C(=O)CSC2=NN=CC3=CC(=C(C=C3)OC)OC)OC,,,,,,
5918,40613,"3-[2-(3,4-Dimethoxyphenyl)ethyl]-2-[[4-(dimethylamino)phenyl]methylidenehydrazinylidene]-1,3-thiazolidin-4-one",CN(C)C1=CC=C(C=C1)C=NN=C2N(C(=O)CS2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
5919,40614,CID 40614,C=S(=O)CCCCCCCCCC(=O)N,,,,,,
5920,40615,"Dodecanoic acid, 1-oxo-2-(2,4,6-trimethylphenyl)-1H-inden-3-YL ester",CCCCCCCCCCCC(=O)OC1=C(C(=O)C2=CC=CC=C21)C3=C(C=C(C=C3C)C)C,,,,,,
5921,40616,"2-Cyclopenten-1-one, 3-chloro-",C1CC(=O)C=C1Cl,,,,,,
5922,40617,"Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, diethyl ester, butyrate",CCCC(=O)OC(C(Cl)(Cl)Cl)P(=O)(OCC)OCC,,,,,,
5923,40618,"Acetic acid, 6,7-dichloro-2,2-dimethyl-1-oxo-5-indanyloxy-",CC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C,,,,,,
5924,40619,(Hydrogen nitrilotriacetato)cobalt,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Co+2],,,,"['Rainbow trout (Oncorhynchus mykiss, 1-5 g) were exposed to approximately 7.5 uM Co in soft water for 2-3 hr at pH approximately 6.5. The water contained either complexing ligands such as nitrilotriacetic acid and natural dissolved organic matter (DOM) or competing cations such as Ca, Na, or H. After exposure, gills were excised and analyzed for total bound Co using a graphite furnace atomic absorption spectrophotometer. A Langmuir isotherm was used to calculate the conditional equilibrium binding constant (K) for Co binding to trout gills plus the concentrations of gill Co binding sites. The calculated binding constant for Co to trout gills was log KCo-gillCo = 5.1, with 88 nmol Co binding sites per g of wet gill tissue. Conditional equilibrium binding constants were also calculated for Ca, Na, and H binding to the gill Co sites and for Co binding to DOM. The experimentally determined binding constants were entered into an aquatic equilibrium chemistry program, MINEQL+, to predict Co binding by fish gills. Predicted and observed results indicate that Co would not accumulate on or in gills of trout held in a series of natural and 1:1 diluted natural waters supplemented with approximately 8.7 uM Co. Model analysis of the reasons for Co being kept off gills of trout held in natural waters indicated that Ca competition and DOM complexation were the most important factors in preventing Co binding by trout gills.']",,
5925,40620,"N-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[NH+]1CCC2=CC=CC=C2C1.[Cl-],,,,,,
5926,40621,Zinc(2+) NTA,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Zn+2],,,,"['Upon intravenous injection zinc is distributed to erythrocytes, plasma, and leukocytes; about 80% of the zinc present in the blood is found in the erythrocytes, 12-20% in the plasma, and about 3% in the leukocytes. ... There is a dynamic exchange of zinc between plasma and erythrocytes. Inhalation of dusts of zinc salts results in a transient accumulation in the lung before its absorption into the blood. There is little absorption of zinc or its salts through the skin. ... About 80% of parenterally administered zinc is excreted in the feces, suggesting an enterohepatic circulation for zinc. In humans, about 10% of the absorbed zinc is excreted in the urine, and in tropical climates about 2-3 mg zinc/day may be lost in sweat. /Soluble zinc compounds/']",,
5927,40622,Lead nitrilotriacetate,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Pb+2],,,,,,
5928,40623,Mercury(2+) NTA,C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Hg+2],,,,,,
5929,40624,"2-Hydroxyamino-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=CC(=C2O)N=O)O,,,,,,
5930,40625,"1,5-Bis(methylsulfonyl)naphthalene",CS(=O)(=O)C1=CC=CC2=C1C=CC=C2S(=O)(=O)C,,,,,,
5931,40626,5-(Methylthio)-1-naphthalenesulfonyl chloride,CSC1=CC=CC2=C1C=CC=C2S(=O)(=O)Cl,,,,,,
5932,40627,"3-Biphenylacetic acid, 4'-chloro-5-hydroxy-",C1=CC(=CC=C1C2=CC(=CC(=C2)CC(=O)O)O)Cl,,,,,,
5933,40628,5-Phenylfuran-2(5H)-one,C1=CC=C(C=C1)C2C=CC(=O)O2,,,,,,
5934,40629,CID 40629,C[C@](C1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O.Cl,,,,,,
5935,40630,"(1S,2S,6R,14R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol",C[C@](C1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O,,,,,,
5936,40631,3-Methylnon-2-enenitrile,CCCCCCC(=CC#N)C,,,,,,
5937,40632,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,['For the treatment of idiopathic pulmonary fibrosis (IPF).'],"['Pirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).']","['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']","['Rapidly absorbed following oral administration.', 'The steady-state volume of distribution following oral administration is approximately 70L.', 'Esbriet binds to human plasma proteins, primarily to serum albumin, in a concentration-independent manner over the range of concentrations observed in clinical trials. The overall mean binding was 58% at concentrations observed in clinical studies (1 to 10 ug/mL). Mean apparent oral volume of distribution is approximately 59 to 71 liters.', 'After single oral-dose administration of 801 mg Esbriet, the maximum observed plasma concentration (Cmax) was achieved between 30 minutes and 4 hours (median time of 0.5 hours). Food decreased the rate and extent of absorption. Median Tmax increased from 0.5 hours to 3 hours with food. Maximum plasma concentrations and AUC0-inf decreased by approximately 49% and 16% with food, respectively.', 'Pirfenidone is excreted predominantly as metabolite 5-carboxy-pirfenidone, mainly in the urine (approximately 80% of the dose). The majority of Esbriet was excreted as the 5-carboxy metabolite (approximately 99.6% of that recovered).', '/MILK/ A study with radio-labeled pirfenidone in rats has shown that pirfenidone or its metabolites are excreted in milk. It is not known whether Esbriet is excreted in human milk.', '... This study aimed to evaluate the pharmacokinetics and urinary excretion of pirfenidone and its major metabolite 5-carboxy-pirfenidone in healthy Chinese subjects under fed conditions. 20 healthy subjects of either sex were recruited in this randomized, single-center, and open-label, single ascending doses (200, 400, and 600 mg) and multiple doses (400 mg, 3 times daily) study. Safety was assessed by adverse events, ECGs, vital signs, and clinical laboratory parameters. Blood and urine samples were analyzed with a validated LC/MS method. Pirfenidone was safe and well tolerated. After single-dose administration, pirfenidone was rapidly absorbed with a mean Tmax of 1.8-2.2 hr and a mean half life of 2.1-2.4 hr. 5-carboxy-pirfenidone was rapidly formed with a mean Tmax of 1.5-2.2 hr and a mean half life of 2.1-2.6 hr. Cmax and AUC for both parent and metabolite were dose proportional over the 200-600 mg dose range. No gender effect was found. In the steady state, the accumulation index (R) estimated for the 3 dosing intervals ranged from 1.1 to 1.5 for both pirfenidone and 5-carboxy-pirfenidone, indicating that the exposure of pirfenidone and 5-carboxy-pirfenidone increased slightly with repeated dosing, but half life and CL/F remained unchanged. Metabolism is the primary mechanism of drug clearance of pirfenidone. About 87.76% of the administered pirfenidone was excreted in urine in the form of 5-carboxy-pirfenidone, while only 0.6159% of the administered pirfenidone was detected as the unchanged form in urine.']","['Pirfenidone is excreted predominantly as metabolite 5-carboxy-pirfenidone, mainly in the urine (approximately 80% of the dose). The majority of Esbriet was excreted as the 5-carboxy metabolite (approximately 99.6% of that recovered).', 'In vitro profiling studies in hepatocytes and liver microsomes have shown that Esbriet is primarily metabolized in the liver by CYP1A2 and multiple other CYPs (CYP2C9, 2C19, 2D6, and 2E1). Oral administration of Esbriet results in the formation of four metabolites. In humans, only pirfenidone and 5-carboxy-pirfenidone are present in plasma in significant quantities. The mean metabolite-to-parent ratio ranged from approximately 0.6 to 0.7. No formal radiolabeled studies have assessed the metabolism of pirfenidone in humans. In vitro data suggests that metabolites are not expected to be pharmacologically active at observed metabolite concentrations.']","['2-2.5 hours', 'The mean terminal half-life is approximately 3 hours in healthy subjects.', '... This study aimed to evaluate the pharmacokinetics and urinary excretion of pirfenidone and its major metabolite 5-carboxy-pirfenidone in healthy Chinese subjects under fed conditions. 20 healthy subjects of either sex were recruited in this randomized, single-center, and open-label, single ascending doses (200, 400, and 600 mg) and multiple doses (400 mg, 3 times daily) study. ... After single-dose administration, pirfenidone was rapidly absorbed with a mean ... half life of 2.1-2.4 hr. 5-carboxy-pirfenidone was rapidly formed with ... a mean half life of 2.1-2.6 hr. ...']"
5938,40633,"3-Biphenylacetic acid, 4'-chloro-5-methoxy-, methyl ester",COC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)OC,,,,,,
5939,40634,Trolox,CC1=C(C2=C(CCC(O2)(C)C(=O)O)C(=C1O)C)C,,,['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)'],,,
5940,40635,"ACETIC ACID, (tert-BUTYLNITROSAMINO)METHYL ESTER",CC(=O)OCN(C(C)(C)C)N=O,,,,,,
5941,40636,(1-Acetoxypropyl)propylnitrosamine,CCCN(C(CC)OC(=O)C)N=O,,,,,,
5942,40637,N-Nitroso(acetoxybenzyl)methylamine,CC(=O)OC(C1=CC=CC=C1)N(C)N=O,,,,,,
5943,40638,"1,2-Dimethyl-1H-indene",CC1C(=CC2=CC=CC=C12)C,,,,,,
5944,40639,CID 40639,CCCOC(=O)C1=C(C=CC(=C1OCCN(CC)CC)C(C)C)C,,,,,,
5945,40640,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIMETHYLAMINO)ETHOXY)-, ISOPROPYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCN(C)C)C(=O)OC(C)C,,,,,,
5946,40641,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIMETHYLAMINO)ETHOXY)-, ISOBUTYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCN(C)C)C(=O)OCC(C)C,,,,,,
5947,40642,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIMETHYLAMINO)ETHOXY)-, BENZYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCCN(C)C)C(=O)OCC2=CC=CC=C2,,,,,,
5948,40643,"Acetic acid, (2-isopropoxycarbonyl-6-isopropyl-3-methylphenoxy)-, 2-(dimethylamino)ethyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCN(C)C)C(=O)OC(C)C,,,,,,
5949,40644,"Acetic acid, (2-ethoxycarbonyl-6-isopropyl-3-methyl)phenoxy-, 2-piperidinoethyl ester",CCOC(=O)C1=C(C=CC(=C1OCC(=O)OCCN2CCCCC2)C(C)C)C,,,,,,
5950,40645,"Acetic acid, (2-isopropoxycarbonyl-6-isopropyl-3-methylphenoxy)-, 2-piperidinoethyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCN2CCCCC2)C(=O)OC(C)C,,,,,,
5951,40646,Methyl 3-(2-hydroxy-3-(isopropylamino)propoxy)-p-cymene-2-carboxylate,CC1=C(C(=C(C=C1)C(C)C)OCC(CNC(C)C)O)C(=O)OC,,,,,,
5952,40647,Methyl 3-(2-hydroxy-3-(2-propynylamino)propoxy)-p-cymene-2-carboxylate,CC1=C(C(=C(C=C1)C(C)C)OCC(CNCC#C)O)C(=O)OC,,,,,,
5953,40648,Methyl 3-(2-hydroxy-3-(dimethylamino)propoxy)-p-cymene-2-carboxylate,CC1=C(C(=C(C=C1)C(C)C)OCC(CN(C)C)O)C(=O)OC,,,,,,
5954,40649,Methyl 3-(2-hydroxy-3-(diethylamino)propoxy)-p-cymene-2-carboxylate,CCN(CC)CC(COC1=C(C=CC(=C1C(=O)OC)C)C(C)C)O,,,,,,
5955,40650,Methyl 3-(2-hydroxy-3-morpholinopropoxy)-p-cymene-2-carboxylate,CC1=C(C(=C(C=C1)C(C)C)OCC(CN2CCOCC2)O)C(=O)OC,,,,,,
5956,40651,Methyl 3-(2-hydroxy-3-(4-methyl-1-piperazinyl)propoxy)-p-cymene-2-carboxylate,CC1=C(C(=C(C=C1)C(C)C)OCC(CN2CCN(CC2)C)O)C(=O)OC,,,,,,
5957,40652,"Acetic acid, (6-isopropyl-2-methoxycarbonyl-3-methylphenoxy)-, (2-dimethylamino-1-methylethyl) ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OC(C)CN(C)C)C(=O)OC,,,,,,
5958,40653,"Acetic acid, (6-isopropyl-2-methoxycarbonyl-3-methylphenoxy)-, 3-(dimethylamino)propyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCCN(C)C)C(=O)OC,,,,,,
5959,40654,"p-CYMENE-2-CARBOXYLIC ACID, 3-CARBAMOYLMETHOXY-, METHYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)N)C(=O)OC,,,,,,
5960,40655,"p-CYMENE-2-CARBOXYLIC ACID, 3-DIETHYLAMINOCARBONYLMETHOXY-, METHYL ESTER",CCN(CC)C(=O)COC1=C(C=CC(=C1C(=O)OC)C)C(C)C,,,,,,
5961,40656,"p-Cymene-2-carboxylic acid, 3-(2-(dimethylamino)ethylcarbamoylmethoxy)-, methyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)NCCN(C)C)C(=O)OC,,,,,,
5962,40657,"p-Cymene-2-carboxylic acid, 3-(2-(diethylamino)ethylcarbamoylmethoxy)-, methyl ester",CCN(CC)CCNC(=O)COC1=C(C=CC(=C1C(=O)OC)C)C(C)C,,,,,,
5963,40658,"p-Cymene-2-carboxylic acid, 3-(3-(diethylamino)propylcarbamoylmethoxy)-, methyl ester",CCN(CC)CCCNC(=O)COC1=C(C=CC(=C1C(=O)OC)C)C(C)C,,,,,,
5964,40659,"Acetic acid, (2-isopropoxycarbonyl-6-isopropyl-3-methylphenoxy)-, 3-(dimethylamino)propyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)OCCCN(C)C)C(=O)OC(C)C,,,,,,
5965,40660,"p-CYMENE-2-CARBOXYLIC ACID, 3-PROPOXY-",CCCOC1=C(C=CC(=C1C(=O)O)C)C(C)C,,,,,,
5966,40661,"Ammonium, (2-acetamidoethyl)triethyl-, iodide",CC[N+](CC)(CC)CCNC(=O)C.[I-],,,,,,
5967,40662,2-Acetamidoethyl(triethyl)azanium,CC[N+](CC)(CC)CCNC(=O)C,,,,,,
5968,40663,CID 40663,CCC(C[NH+](C)C)C(=O)C1=CC=CC=C1.C(=CC(=O)[O-])C(=O)O,,,,,,
5969,40664,2-(Dimethylaminomethyl)-1-phenylbutan-1-one,CCC(CN(C)C)C(=O)C1=CC=CC=C1,,,,,,
5970,40665,"1-Propylamine, 3-hydroxy-3-(p-chlorophenyl)-N,N,2,2-tetramethyl-",CC(C)(CN(C)C)C(C1=CC=C(C=C1)Cl)O,,,,,,
5971,40666,"4-Cyclohexyl-alpha-((1,1-dimethyl-2-(dimethylamino))ethyl)benzyl alcohol",CC(C)(CN(C)C)C(C1=CC=C(C=C1)C2CCCCC2)O,,,,,,
5972,40667,CID 40667,CC1=C(N(C2=C(C1=O)C=CC(=C2)Cl)C)O,,,,,,
5973,40668,CID 40668,CC1=C(N(C2=C(C1=O)C=CC(=C2)OC)C)O,,,,,,
5974,40669,N-(2-Propyl)pentylbenzylamine hydrochloride,CCCC(CCC)C[NH2+]CC1=CC=CC=C1.[Cl-],,,,,,
5975,40670,N-benzyl-2-propylpentan-1-amine,CCCC(CCC)CNCC1=CC=CC=C1,,,,,,
5976,40671,"1,4-Dihydro-3,5-dicarboxy-1,2,6-trimethyl-4,4'-bipyridinium iodide diethyl ester",CCOC(=O)C1=C([NH+](C(=C(C1C2=CC=NC=C2)C(=O)OCC)C)C)C.[I-],,,,,,
5977,40672,"Diethyl 1,2,6-trimethyl-1,4-dihydro-4,4'-bipyridine-3,5-dicarboxylate",CCOC(=O)C1=C(N(C(=C(C1C2=CC=NC=C2)C(=O)OCC)C)C)C,,,,,,
5978,40673,N-(p-(Acridin-9-ylamino)phenyl)butanesulfonamide hydrochloride,CCCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC=CC3=[NH+]C4=CC=CC=C42.[Cl-],,,,,,
5979,40674,"Butanesulfonanilide, 4'-(9-acridinylamino)-",CCCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
5980,40675,"Acetamide, N-(9-((4-((ethylsulfonyl)amino)phenyl)amino)-3-acridinyl)-, methanesulfonate",CCS(=O)(=O)NC1=CC=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C.CS(O)(O)[O-],,,,,,
5981,40676,"Ethanesulfonanilide, 4'-(9-(3-acetamidoacridinyl)amino)-",CCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C,,,,,,
5982,40677,Trihydroxy(methyl)-lambda4-sulfane,CS(O)(O)O,,,,,,
5983,40678,"Acetamide, N-(9-((4-((propylsulfonyl)amino)phenyl)amino)-3-acridinyl)-, methanesulfonate",CCCS(=O)(=O)NC1=CC=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C.CS(=O)(=O)[O-],,,,,,
5984,40679,"Propanesulfonanilide, 4'-((3-acetamido-9-acridinyl)amino)-",CCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C,,,,,,
5985,40680,"Butanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-",CCCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C,,,,,,
5986,40681,"Acetamide, N-(9-(4-(butylsulfonamido)anilino)acridin-3-YL)-, methanesulfonate",CCCCS(=O)(=O)NC1=CC=C(C=C1)N=C2C3=C(C=C(C=C3)NC(=O)C)[NH2+]C4=CC=CC=C42.CS(=O)(=O)[O-],,,,,,
5987,40682,"Acetamide, N-(9-((4-((pentylsulfonyl)amino)phenyl)amino)-3-acridinyl)-, methanesulfonate",CCCCCS(=O)(=O)NC1=CC=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C.CS(=O)(=O)[O-],,,,,,
5988,40683,"Pentanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-",CCCCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C,,,,,,
5989,40684,"1-Hexanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-",CCCCCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C,,,,,,
5990,40685,N-(9-(4-(Hexylsulfonamido)anilino)acridin-3-yl)acetamide methanesulfonate,CCCCCCS(=O)(=O)NC1=CC=C(C=C1)[NH2+]C2=C3C=CC(=CC3=NC4=CC=CC=C42)NC(=O)C.CS(=O)(=O)[O-],,,,,,
5991,40686,"Acetamide, N-(9-((4-((methylsulfonyl)amino)phenyl)amino)-3-acridinyl)-, methanesulfonate",CC(=O)NC1=CC2=NC3=CC=CC=C3C(=C2C=C1)[NH2+]C4=CC=C(C=C4)NS(=O)(=O)C.CS(=O)(=O)[O-],,,,,,
5992,40687,"Methanesulfonanilide, 4'-(3-acetamido-9-acridinylamino)-",CC(=O)NC1=CC2=NC3=CC=CC=C3C(=C2C=C1)NC4=CC=C(C=C4)NS(=O)(=O)C,,,,,,
5993,40688,"12H-Dibenzo(B,H)floren-12-one",C1=CC=C2C=C3C(=CC2=C1)C4=CC5=CC=CC=C5C=C4C3=O,,,,,,
5994,40689,CID 40689,CC12CCC3C(C1CC[C@@H]2O)CCC4=CC(=NOC5=CC=CC=C5)CCC34,,,,,,
5995,40690,17-beta-Hydroxyandrost-4-en-3-one O-(2-pyridyl)oxime,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=NOC5=CC=CC=N5)CC[C@]34C,,,,,,
5996,40691,(1-Methylbutyl)oxirane,CCCC(C)C1CO1,,,,,,
5997,40692,Mefloquine hydrochloride,C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']","['Mefloquine is reasonably well absorbed from the gastrointestinal tract but there is marked interindividual variation in the time required to achieve peak plasma concentrations. ... Mefloquine undergoes enterohepatic recycling. It is approximately 98% bound to plasma proteins and is widely distributed throughout the body. The pharmacokinetics of mefloquine may be altered by malaria infection with reduced absorption and accelerated clearance. ... Mefloquine is excreted in small amounts in breast milk. It has a long elimination half-life of around 21 days, which is shortened in malaria to about 14 days, possibly because of interrupted enterohepatic cycling. Mefloquine is metabolized in the liver and excreted mainly in the bile and feces. Its pharmacokinetics show enantioselectivity after administration of the racemic mixture, with higher peak plasma concentrations and area under the curve values, and lower volume of distribution and total clearance of the SR enantiomer than its RS antipode.', 'The bioavailability of the tablet formulation compared with an oral solution was over 85%. The presence of food significantly enhances the rate and extent of absorption, leading to about a 40% increase in bioavailability. Plasma concentrations peak 6-24 hours (median, about 17 hours) after a single oral dose of mefloquine. Maximum plasma concentrations in ug/L are roughly equivalent to the dose in milligrams (for example, a single 1000 mg dose produces a maximum concentration of about 1000 ug/L). At a dose of 250 mg once weekly, maximum steady state plasma concentrations of 1000-2000 ug/L are reached after 7-10 weeks.', 'Distributed to blood, urine, CSF, and tissues; concentrated in erythrocytes...', 'In healthy adults, the apparent volume of distribution is approximately 20 L/kg, indicating extensive tissue distribution. Mefloquine may accumulate in parasitized erythrocytes at an erythrocyte-to-plasma concentration ratio of about 2. Protein binding is about 98%. Mefloquine blood concentrations of 620 ng/mL are considered necessary to achieve 95% prophylactic efficacy.', 'For more Absorption, Distribution and Excretion (Complete) data for MEFLOQUINE (12 total), please visit the HSDB record page.']","['Biotransformation: Hepatic (partial); metabolized primarily to the carboxylic acid metabolite.', 'Mefloquine is extensively metabolized in the liver by the cytochrome P450 system. In vitro and in vivo studies strongly suggested that CYP3A4 is the major isoform involved.  Two metabolites of mefloquine have been identified in humans. The main metabolite, 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid, is inactive in Plasmodium falciparum. In a study in healthy volunteers, the carboxylic acid metabolite appeared in plasma 2 to 4 hours after a single oral dose. Maximum plasma concentrations of the metabolite, which were about 50% higher than those of mefloquine, were reached after 2 weeks. Thereafter, plasma levels of the main metabolite and mefloquine declined at a similar rate. The area under the plasma concentration-time curve (AUC) of the main metabolite was 3 to 5 times larger than that of the parent drug. The other metabolite, an alcohol, was present in minute quantities only.']","['In healthy volunteers ... mefloquine /was/ absorbed with a half-life of 1 to 4 hours ... and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).', 'Half-life: Elimination - 13 to 33 days (median 20 days); may be shorter in seriously ill patients, such as patients with acute malaria.', 'The pharmacokinetics of mefloquine were studied in 10 healthy subjects and in 12 patients with severe acute Plasmodium falciparum malaria who received 750 mg oral mefloquine. Peak concn of mefloquine were achieved in both groups at 20-24 hr. The mean elimination half-life was 385 hr in normal subjects and was 493 hr in patients with malaria, a significant difference.', 'In several studies in healthy adults, the mean elimination half-life of mefloquine varied between 2 and 4 weeks, with an average of about 3 weeks.', 'For more Biological Half-Life (Complete) data for MEFLOQUINE (9 total), please visit the HSDB record page.']"
5998,40693,Ethyl 3-(2-hydroxy-3-(2-propynylamino)propoxy)-p-cymene-2-carboxylate,CCOC(=O)C1=C(C=CC(=C1OCC(CNCC#C)O)C(C)C)C,,,,,,
5999,40694,CID 40694,CCN(CC)CC(COC1=C(C=CC(=C1C(=O)OCC)C)C(C)C)O,,,,,,
6000,40695,"Acetic acid, (2-ethoxycarbonyl-6-isopropyl-3-methyl)phenoxy-, 3-(dimethylamino)propyl ester",CCOC(=O)C1=C(C=CC(=C1OCC(=O)OCCCN(C)C)C(C)C)C,,,,,,
6001,40696,Isopropyl 3-(2-hydroxy-3-(isopropylamino)propoxy)-p-cymene-2-carboxylate,CC1=C(C(=C(C=C1)C(C)C)OCC(CNC(C)C)O)C(=O)OC(C)C,,,,,,
6002,40697,"p-CYMENE-2-CARBOXYLIC ACID, 3-(2-(DIMETHYLAMINO)ETHOXY)-, BUTYL ESTER",CCCCOC(=O)C1=C(C=CC(=C1OCCN(C)C)C(C)C)C,,,,,,
6003,40698,Ethyl 3-(2-hydroxy-3-(methylamino)propoxy)-p-cymene-2-carboxylate,CCOC(=O)C1=C(C=CC(=C1OCC(CNC)O)C(C)C)C,,,,,,
6004,40699,Ethyl 3-(2-hydroxy-3-(isopropylamino)propoxy)-p-cymene-2-carboxylate,CCOC(=O)C1=C(C=CC(=C1OCC(CNC(C)C)O)C(C)C)C,,,,,,
6005,40700,"p-Cymene-2-carboxylic acid, 3-(3-(dimethylamino)propylcarbamoylmethoxy)-, methyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(=O)NCCCN(C)C)C(=O)OC,,,,,,
6006,40701,"Diethyl(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)methylammonium iodide",CC[N+](C)(CC)CCOCCC1CCC2CC1C2(C)C.[I-],,,,,,
6007,40702,"2-[2-(6,6-Dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl-diethyl-methylazanium",CC[N+](C)(CC)CCOCCC1CCC2CC1C2(C)C,,,,,,
6008,40703,Pinaverium bromide,CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.[Br-],,,"['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
6009,40704,Pinaverium,CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C,['Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.'],"['Pinaverium is a selective and specific voltage-dependent calcium channel blocker located on intestinal smooth muscle cells to inhibit calcium influx. It mediates various effects on the GI tract: it causes oesophageal, gastric and duodenal relaxation, relaxes the colon and intestines, inhibits colonic motility in response to food, hormonal or pharmacological stimuli, accelerates gastric emptying, and reduces contractions of the gallbladder and phasic contractions of sphincter of Oddi. At higher concentrations, pinaverium also exhibits very weak anticholinergic effects but is not shown to display vasodilatory or anti-arrythmic actions.']","['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']","['After oral administration, pinaverium is poorly absorbed (5-10%) followed by uptake by liver. Poor absorption is due to its highly polar quaternary ammonium group and high molecular weight, which limits extensive diffusion across all cell membranes and promotes its selectivity towards the gastrointestinal tracts []. Peak plasma concentration is reached within one hour after administration and the absolute oral bioavailability is reported to be less than 1%.', 'Pinaverium is predominantly eliminated into feces.', 'It is selectively distributed to the digestive tract due to poor absorption and marked hepatobiliary excretion.']","['Hepatic metabolism of pinaverium involves demethylation of one of the methoxy groups, hydroxylation of the norpinanyl ring and elimination of the benzyl group with subsequent opening of the morpholine ring.']",['The mean elimination half life is approximately 1.5 hours.']
6010,40705,N-[phenyl(thiophen-2-yl)methylidene]hydroxylamine,C1=CC=C(C=C1)C(=NO)C2=CC=CS2,,,,,,
6011,40706,Diethyl tert-butylmethylmalonate,CCOC(=O)C(C)(C(=O)OCC)C(C)(C)C,,,,,,
6012,40707,7-(1-Methylethylidene)bicyclo(4.1.0)heptane,CC(=C1C2C1CCCC2)C,,,,,,
6013,40708,CID 40708,CC12CCC3C(C1CC[C@@H]2O)CCC4=CC(=NOC5=CC=CC=N5)CCC34,,,,,,
6014,40709,(m-Methoxyphenyl)trimethylammonium iodide,C[N+](C)(C)C1=CC(=CC=C1)OC.[I-],,,,,,
6015,40710,3-Methoxyphenyltrimethylaminium,C[N+](C)(C)C1=CC(=CC=C1)OC,,,,,,
6016,40711,"5-IMIDIZOLIDINONE, 1-(o-CHLORO-p-SULFAMOYLPHENYL)-3-PHENYL-",C1C(=O)N(CN1C2=CC=CC=C2)C3=C(C=C(C=C3)S(=O)(=O)N)Cl,,,,,,
6017,40712,"5-IMIDAZOLIDINONE, 1-(o-BROMO-p-SULFAMOYLPHENYL)-3-PHENYL-",C1C(=O)N(CN1C2=CC=CC=C2)C3=C(C=C(C=C3)S(=O)(=O)N)Br,,,,,,
6018,40713,((2-Chloro-2-propenyl)oxy)benzene,C=C(COC1=CC=CC=C1)Cl,,,,,,
6019,40714,"2-Hexyn-1-OL, 6-(diethylamino)-",CCN(CC)CCCC#CCO,,,,,,
6020,40715,"6-Hydroxy-N,N,N-triethyl-4-hexyn-1-aminium iodide",CC[N+](CC)(CC)CCCC#CCO.[I-],,,,,,
6021,40716,"6-Hydroxy-N,N,N-triethyl-4-hexyn-1-aminium",CC[N+](CC)(CC)CCCC#CCO,,,,,,
6022,40717,"6-Hydroxy-6-methyl-N,N,N-triethyl-4-octyn-1-aminium iodide",CCC(C)(C#CCCC[N+](CC)(CC)CC)O.[I-],,,,,,
6023,40718,"6-Hydroxy-6-methyl-N,N,N-triethyl-4-octyn-1-aminium",CCC(C)(C#CCCC[N+](CC)(CC)CC)O,,,,,,
6024,40719,"6-Hydroxy-6-phenyl-N,N,N-triethyl-4-hexyn-1-aminium iodide",CC[N+](CC)(CC)CCCC#CC(C1=CC=CC=C1)O.[I-],,,,,,
6025,40720,"6-Hydroxy-6-phenyl-N,N,N-triethyl-4-hexyn-1-aminium",CC[N+](CC)(CC)CCCC#CC(C1=CC=CC=C1)O,,,,,,
6026,40721,6-(1-Piperidinyl)-2-hexyn-1-ol hydrochloride,C1CC[NH+](CC1)CCCC#CCO.[Cl-],,,,,,
6027,40722,6-(1-Piperidinyl)-2-hexyn-1-ol,C1CCN(CC1)CCCC#CCO,,,,,,
6028,40723,8-(Diethylamino)-3-methyl-4-octyn-3-ol hydrochloride,CCCC#CC(C)(CC[NH+](CC)CC)O.[Cl-],,,,,,
6029,40724,1-(Diethylamino)-3-methyloct-4-yn-3-ol,CCCC#CC(C)(CCN(CC)CC)O,,,,,,
6030,40725,3-Methyl-8-(1-piperidinyl)-4-octyn-3-ol hydrochloride,CCCC#CC(C)(CC[NH+]1CCCCC1)O.[Cl-],,,,,,
6031,40726,3-Methyl-1-piperidin-1-yloct-4-yn-3-ol,CCCC#CC(C)(CCN1CCCCC1)O,,,,,,
6032,40727,alpha-(5-(1-Piperidinyl)-1-pentynyl)benzyl alcohol hydrochloride,C1CC[NH+](CC1)CCCC#CC(C2=CC=CC=C2)O.[Cl-],,,,,,
6033,40728,1-Phenyl-6-piperidin-1-ylhex-2-yn-1-ol,C1CCN(CC1)CCCC#CC(C2=CC=CC=C2)O,,,,,,
6034,40729,m-Hydroxymandelonitrile,C1=CC(=CC(=C1)O)C(C#N)O,,,,,,
6035,40730,Cydrin,C(CCl)N(CCCl)NC(=O)[C@H](CSSC[C@@H](C(=O)NN(CCCl)CCCl)[NH3+])[NH3+].[Br-].[Br-],,,,,,
6036,40731,"(2R)-2-amino-3-[[(2R)-2-amino-3-[2,2-bis(2-chloroethyl)hydrazinyl]-3-oxopropyl]disulfanyl]-N',N'-bis(2-chloroethyl)propanehydrazide",C(CCl)N(CCCl)NC(=O)[C@H](CSSC[C@@H](C(=O)NN(CCCl)CCCl)N)N,,,,,,
6037,40732,1-(1H-indol-5-yl)ethanone,CC(=O)C1=CC2=C(C=C1)NC=C2,,,,,,
6038,40733,"p-Cymene-2-carboxylic acid, 3-(2-hydroxy-3-(4-(2-hydroxyethyl)-1-piperazinyl)propoxy)-, isopropyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(CN2CCN(CC2)CCO)O)C(=O)OC(C)C,,,,,,
6039,40734,"Benzoic acid, 2-(diethylamino)ethoxy-3-isopropyl-6-methyl-",CCN(CC)CCOC1=C(C=CC(=C1C(=O)O)C)C(C)C,,,,,,
6040,40735,"p-Cymene-2-carboxylic acid, 3-(2-hydroxy-3-(4-(2-hydroxyethyl)-1-piperazinyl)propoxy)-, methyl ester",CC1=C(C(=C(C=C1)C(C)C)OCC(CN2CCN(CC2)CCO)O)C(=O)OC,,,,,,
6041,40736,Nile Blue perchlorate,CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)N)OC2=C1)CC.[O-]Cl(=O)(=O)=O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
6042,40737,5-Chloro-3-ethyl-2-hydroxybenzyl alcohol,CCC1=C(C(=CC(=C1)Cl)CO)O,,,,,,
6043,40738,"o-CRESOL, 4-CHLORO-6-ETHYL-",CCC1=C(C(=CC(=C1)Cl)C)O,,,,,,
6044,40739,5-Chloro-3-ethyl-2-hydroxybenzoic acid,CCC1=C(C(=CC(=C1)Cl)C(=O)O)O,,,,,,
6045,40740,"Acetic acid, chloro-, 4-chloro-2-ethylphenyl ester",CCC1=C(C=CC(=C1)Cl)OC(=O)CCl,,,,,,
6046,40741,"Benzoic acid, 4-butylamino-2-ethoxy-, 2-(diethylamino)ethyl ester",CCCCNC1=CC(=C(C=C1)C(=O)OCCN(CC)CC)OCC,,,,,,
6047,40742,"2-(3,4-dihydroisoquinolin-2(1H)-yl)ethanamine",C1CN(CC2=CC=CC=C21)CCN,,,,,,
6048,40743,"Ammonium, (3-hydroxypropyl)trimethyl-, inner salt, O-(2,2,2-trichloroethyl)phosphate",C[N+](C)(C)CCCOP(=O)([O-])OCC(Cl)(Cl)Cl,,,,,,
6049,40744,"3-[Hydroxy(2,2,2-trichloroethoxy)phosphoryl]oxypropyl-trimethylazanium",C[N+](C)(C)CCCOP(=O)(O)OCC(Cl)(Cl)Cl,,,,,,
6050,40745,"Malonic acid, phenyl(piperidinomethyl)-, diethyl ester",CCOC(=O)C(CN1CCCCC1)(C2=CC=CC=C2)C(=O)OCC,,,,,,
6051,40746,1-Methyl-2-phenylimidazolidine,CN1CCNC1C2=CC=CC=C2,,,,,,
6052,40747,Menadiol dibutyrate,CCCC(=O)OC1=CC(=C(C2=CC=CC=C21)OC(=O)CCC)C,,,,,,
6053,40748,"8,9,10,11-Tetrahydro-3-methyl-1H,7H-cyclohepta(4,5-b)pyrrolo(1,2,3-de)quinoxalin-2(3H)-one",CC1C=CC2=NC3=C(CCCCC3)N4C2=C1C(=O)C4,,,,,,
6054,40749,Hex-2-en-1-yl propanoate,CCCC=CCOC(=O)CC,,,,,,
6055,40750,"Bis(1-hydroxypropan-2-yl)azanium;2-(2,4,5-trichlorophenoxy)propanoate",CC(CO)[NH2+]C(C)CO.CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6056,40751,"2,2'-Iminodipropanol",CC(CO)NC(C)CO,,,,,,
6057,40752,"2-Ethyl-4-methylpentyl 2-(2,4,5-trichlorophenoxy)propanoate",CCC(CC(C)C)COC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6058,40753,Silvex compd. with 1-amino-2-propanol,CC(CO)[NH3+].CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6059,40754,"1-Methylheptyl 2-(2,4,5-trichlorophenoxy)propionate",CCCCCCC(C)OC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6060,40755,Silvex oleylamine salt,CCCCCCCCC=CCCCCCCCC[NH3+].CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6061,40756,Silvex triethylamine salt,CC[NH+](CC)CC.CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6062,40757,"2-(2,4,5-Trichlorophenoxy)propanoate;tris(1-hydroxypropan-2-yl)azanium",CC(CO)[NH+](C(C)CO)C(C)CO.CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6063,40758,"2,2',2''-Nitrilotri(propan-1-ol)",CC(CO)N(C(C)CO)C(C)CO,,,,,,
6064,40759,"2-Ethylhexyl 2-(2,4,5-trichlorophenoxy)propionate",CCCCC(CC)COC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6065,40760,"2,4,5-T tridecylamine salt",CCCCCCCCCCCCC[NH3+].C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
6066,40761,Tridecylamine,CCCCCCCCCCCCCN,,,,,,
6067,40762,"Diethyl(2-hydroxyethyl)azanium; 2-(2,4,5-trichlorophenoxy)acetate",CC[NH+](CC)CCO.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
6068,40763,CID 40763,CCCCCCCCC=CCCCCCCCC[NH2+]CCCN.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
6069,40764,"N-(9-octadecenyl)-1,3-propylenediamine",CCCCCCCCC=CCCCCCCCCNCCCN,,,,,,
6070,40765,"2,4,5-T N,N-dimethyllinoleylamine salt",CCCCCC=CCC=CCCCCCCCC[NH+](C)C.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
6071,40766,"N,N-dimethyloctadeca-9,12-dien-1-amine",CCCCCC=CCC=CCCCCCCCCN(C)C,,,,,,
6072,40767,"Dimethyl(octadec-9-enyl)azanium;2-(2,4,5-trichlorophenoxy)acetate",CCCCCCCCC=CCCCCCCCC[NH+](C)C.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
6073,40768,"N,N-Dimethyl-9-octadecen-1-amine",CCCCCCCCC=CCCCCCCCCN(C)C,,,,,,
6074,40769,"2-(2,3-Dihydroxypropoxy)methylbenzoate",COC(=O)C1=CC=CC=C1OCC(CO)O,,,,,,
6075,40770,"Barbituric acid, 5,5-diallyl-1,3-dicyclohexyl-2-thio-",C=CCC1(C(=O)N(C(=S)N(C1=O)C2CCCCC2)C3CCCCC3)CC=C,,,,,,
6076,40771,"Barbituric acid, 1-cyclohexyl-5,5-diallyl-3-phenyl-",C=CCC1(C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3)CC=C,,,,,,
6077,40772,gamma-Carboxyglutamate,C(C(C(=O)O)C(=O)O)C(C(=O)O)N,,,,,,
6078,40773,(Trichloromethoxy)benzene,C1=CC=C(C=C1)OC(Cl)(Cl)Cl,,,,,,
6079,40774,"2,3,5,6-Tetrachloroanisole",COC1=C(C(=CC(=C1Cl)Cl)Cl)Cl,,,,,,
6080,40775,N-(3-Chloro-2-hydroxypropyl)-p-nitrobenzamide,C1=CC(=CC=C1C(=O)NCC(CCl)O)[N+](=O)[O-],,,,,,
6081,40776,"4-(Chloromethyl)-2-(o-nitrophenyl)-1,3-dioxolane",C1C(OC(O1)C2=CC=CC=C2[N+](=O)[O-])CCl,,,,,,
6082,40777,"Propanoic acid, 2-(2,4,5-trichlorophenoxy)-, ester with 1(or 2)-(2-methylpropoxy)propanol",CCC(C)OC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl.CC(CO)OC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6083,40778,"Butan-2-yl 2-(2,4,5-trichlorophenoxy)propanoate",CCC(C)OC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6084,40779,"1-Hydroxypropan-2-yl 2-(2,4,5-trichlorophenoxy)propanoate",CC(CO)OC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6085,40780,"2,4,5-T propylene glycol isobutyl ether ester",CCC(C)OC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl.CC(CO)OC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6086,40781,"Acetic acid, (2,4,5-trichlorophenoxy)-, 1-methylpropyl ester",CCC(C)OC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6087,40782,"1-Hydroxypropan-2-yl 2-(2,4,5-trichlorophenoxy)acetate",CC(CO)OC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6088,40783,N(sup 6)-(2-Mercaptoethyl)lysine dihydrochloride hydrate,C(CC[NH2+]CCS)CC(C(=O)O)[NH3+].[Cl-].[Cl-],,,,,,
6089,40784,2-Amino-6-(2-sulfanylethylamino)hexanoic acid,C(CCNCCS)CC(C(=O)O)N,,,,,,
6090,40785,Desbromoleptophos,COP(=S)(C1=CC=CC=C1)OC2=C(C=CC(=C2)Cl)Cl,,,,,,
6091,40786,Polyethylene glycol nono(4tert-nonylphenyl)ether,CCC(CC)(CC)CC1=CC=CC=C1,,,,,,
6092,40787,"2-Isopropyl-4,5-dimethylthiazole",CC1=C(SC(=N1)C(C)C)C,,,,,,
6093,40788,(o-Methoxyphenoxy)phenylacetic acid,COC1=CC=CC=C1OC(C2=CC=CC=C2)C(=O)O,,,,,,
6094,40789,Phenyl(o-tolyloxy)acetic acid,CC1=CC=CC=C1OC(C2=CC=CC=C2)C(=O)O,,,,,,
6095,40790,beta-Methylaminoethyl benzhydryl ether hydrochloride,C[NH2+]CCOC(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
6096,40791,2-(Diphenylmethoxy)-N-methylethylamine,CNCCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,"['N-Desmethyldiphenhydramine has known human metabolites that include N,N-Didesmethyldiphenhydramine.']",
6097,40792,N-Methyl-4'-(p-methylaminophenylazo)acetanilide,CC(=O)N(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)NC,,,,,,
6098,40793,CID 40793,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
6099,40794,CID 40794,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)[N+](=O)[O-])N=C2S,,,,,,
6100,40795,"1,4,5,6-Tetrahydro-1,2,4-trimethylpyrimidine",CC1CCN(C(=N1)C)C,,,,,,
6101,40796,CID 40796,CCCCC(=CN=O)O,,,,,,
6102,40797,CID 40797,CCCC(=C(C)N=O)O,,,,,,
6103,40798,CID 40798,CCC(=C(CC)O)N=O,,,,,,
6104,40799,"Isoquinoline, decahydro-8-(2-methoxybenzamido)-2-methyl-, (E)-",CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC=CC=C3OC,,,,,,
6105,40800,"Isoquinoline, decahydro-8-(4-methoxybenzamido)-2-methyl-, (E)-",CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC=C(C=C3)OC,,,,,,
6106,40801,"trans-Decahydro-8-(3,4-dimethoxybenzamido)-2-methylisoquinoline",CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC(=C(C=C3)OC)OC,,,,,,
6107,40802,"Isoquinoline, decahydro-2-methyl-8-(3,4,5-trimethoxybenzamido)-, (E)-",CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
6108,40803,trans-Decahydro-8-benzamido-2-methylisoquinoline,CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC=CC=C3,,,,,,
6109,40804,"Isoquinoline, decahydro-8-(4-chlorobenzamido)-2-methyl-, (E)-",CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
6110,40805,"Isoquinoline, decahydro-8-(3,4-dichlorobenzamido)-2-methyl-, (E)-",CN1CC[C@H]2CCCC([C@@H]2C1)NC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
6111,40806,"Phosphonic acid, P-ethenyl-, bis(2-chloroethyl) ester, polymer with dimethyl P-methylphosphonate",CCCCOP(=O)(C)OCCOP(=O)(C=C)OCCOP(=O)(C)OCCCC,,,,,,
6112,40807,"OXALIC ACID, (p-METHOXYPHENYLSULFONYL)HYDRAZIDE, PHENYLSULFONYLHYDRAZIDE",COC1=CC=C(C=C1)S(=O)(=O)NNC(=O)C(=O)NNS(=O)(=O)C2=CC=CC=C2,,,,,,
6113,40808,"1,4-Benzodioxan, 2-morpholinomethyl-, hydrochloride",C1COCC[NH+]1CC2COC3=CC=CC=C3O2.[Cl-],,,,,,
6114,40809,"Propanoic acid, 2-(2,4,5-trichlorophenoxy)-, methyl-2-(methyl-2-(2-methylpropoxy)ethoxy)ethyl ester",CCC(C)OCCOCCOC(=O)C(C)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6115,40810,Heptan-1-ol;heptan-2-ol;heptan-3-ol,CCCCCCCO.CCCCCC(C)O.CCCCC(CC)O,,,,,,
6116,40811,"1,2,3,8-Tetrachlorodibenzo-P-dioxin",C1=CC2=C(C=C1Cl)OC3=C(C(=C(C=C3O2)Cl)Cl)Cl,,,,,,
6117,40812,"BENZO(a)PYREN-6-OL, ACETATE",CC(=O)OC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C5=CC=CC=C51,,,,,,
6118,40813,Pyrinuron,C1=CC(=CN=C1)CNC(=O)NC2=CC=C(C=C2)[N+](=O)[O-],,,"['Substances used to destroy or inhibit the action of rats, mice, or other rodents. (See all compounds classified as Rodenticides.)']","['Rats tolerated, metabolized, & eliminated single or multiple sublethal dosages (5 mg/kg) but were less efficient than dogs in detoxifying dosages in excess of 20 mg/kg. It was concluded that the tolerance of dogs for the cmpd depended on their efficient hepatic extraction, metabolism, & excretion of it. The urine of poisoned rats & people contained the parent cmpd but the urine of dogs that had received it contained < 1%.', 'These studies compared the disposition of pyridyl- and nitrophenyl-1 [14C]RH-787 in tolerant and susceptible species. The compound was rapidly absorbed by rats, mice, and dogs after oral administration. Blood levels peaked in 1 to 6 hr, depending on species and label, and were higher after NP- than Py[14C] administration in each species. Doses of 30 mg/kg produced higher 14C levels in dogs than in rats-yet such dose levels are lethal to rats, but not dogs. G.I. transit of 14C was more rapid in dogs than in rats. Urinary and fecal excretion were of similar importance in all three species; NP label was more rapidly eliminated. Tissue distribution of two 14C labels varied, especially in dogs-suggesting more extensive metabolism. Liver contained more of the dose than any other single organ. Most hepatic 14C was located in the cytosol of each species, but rats and dogs differed in nuclear and microsomal fractions. Label differences in subcellular distribution were small when expressed as percentages of total liver 14C. Most 14C was reversibly bound to various organelle pellets. Rats tolerated, metabolized, and eliminated single or multiple sublethal RH-787 doses (5 mg/kg), but their metabolic systems were less efficient thant those of dogs for detoxifying larger doses (> 20 mg/kg). Pretreatment of rats with 3-MC enhanced their hepatic extraction of RH-787, increased biliary secretion of its metabolites, and protected rats against RH-787 toxicity. Thus, RH-787 tolerance in dogs seems to be related to effiicient hepatic extraction, followed by rapid metabolic degradation and excretion.']","['Several metabolites of pyriminil have been identified including aminopyriminil, acetamidopyriminil, p-aminophenyl urea, p-acetamidophenyl urea, p-nitroaniline, p-phenylenediamine, p-acetamidoaniline, nicotinic acid, nicotinuric acid & nicotenamide. Most of these metabolites were found in the urine of poisoned rats, dogs & people, but in different concentrations.', 'Repeated, sublethal doses of pyriminil incr the urinary & fecal excretion of latter dose of the cmpd tagged with (14)C; however, these same animals showed increased hexobarbital sleeping times & other evidence of inhibition of certain liver microsomal enzymes, especially p-nitro-anisole O-demethylase.', 'Analysis of liver from a human poisoning case demonstrated the presence of PNU & p-nitroaniline. It was suggested that p-nitroaniline was formed by amide hydrolysis of PNU.', ""Hepatic metabolism of the rodenticide RH-787 (N-3-pyridyl- methyl-N'- p-nitrophenyl urea) plays a key role in species sensitivity differences. 3-MC pretreatment of rats enhanced their hepatic extraction of 14C-787, increased biliary secretion of its metabolites and protected them against 787 toxicity. Dogs natively showed more efficient hepatic extraction of 787, leading to its rapid metabolic degradation. Rats tolerated chronic sublethal 787 levels, but most tissues showed 14C accumulation after multiple 14C-787 doses. Since this was more pronounced for pyridyl- than nitrophenyl-14C, metabolic cleavage products were suspected. Pretreatment of rats with multiple 787 doses enhanced urinary and fecal 14C excretion after pulse doses of 14C-787, but prolonged hexobarbital sleeping times and strongly inhibited hepatic p-nitroanisole O-demethylation in vitro; the latter was also inhibited by direct in vitro 787 addition. Antidotal levels of nicotinamide (NA) did not prevent MFO inhibition by 787, but altered 14C-787 disposition. Higher NA levels also inhibited the MFO. High affinity for microsomal enzymes may explain NAD-antagonism by 787 via glycohydrolase and make it useful as a model compound. Concentrates of urinary and biliary 787 metabolites and synthetic metabolites (amino-787, p-nitroaniline, p-nitrophenyl urea) were less toxic than 787."", ""Species selectivity of RH-787 (N-3-pyridylmethyl- N'-p-nitrophenyl urea) seems to depend on biotransformation. These studies compared fates of Py- and NP-14C-787 in rats and dogs. Human Vacor (pyriminil) metabolites were examined in poisoning cases. Although single oral 30 mg/kg doses of 787 were lethal to rats but not dogs, they produced higher blood levels in dogs. However, most 14C in rat blood was due to 787, while dog blood contained primarily p-nitrophenyl urea. Rat urine contained large amounts of 787 while dog urine had < 1%. Dog urine contained 40-60% unidentified polar material, but rat urine only 5-20%; this material from rats, but not dogs, was partially hydrolyzed by beta-glucuronidase to 787. Other identified metabolites include amino-787, acetamido-787, p-aminophenyl urea, p-acetamidophenyl urea, p-nitroaniline, p-phenylenediamine, p-acetamidoaniline, nicotinic acid, nicotinuric acid and nicotinamide. Most were found in all three species, but concentrations varied. The presence of parent compound in rat and human urine suggests that they may be more sensitive to Vacor because of inefficient metabolism. Tolerance in dogs is probably due to rapid detoxication.""]",
6119,40814,"1H-Indene, 2,3-dihydrodimethyl-",CC1CC2=CC=CC(=C2C1)C,,,,,,
6120,40815,"9H-Fluorene-9-carboxylic acid, 9-hydroxy-, butyl ester, mixt. with isooctyl (4-chloro-2-methylphenoxy)acetate",CCCCOC(=O)C1(C2=CC=CC=C2C3=CC=CC=C31)O.CC1=C(C=CC(=C1)Cl)OCC(=O)OCCCCCC(C)C,,,,,,
6121,40816,Flurenol-butyl,CCCCOC(=O)C1(C2=CC=CC=C2C3=CC=CC=C31)O,,,,,,
6122,40817,"NITROGLYCERIN mixed with ETHYLENE GLYCOL, DINITRATE (1:1)",C(CO[N+](=O)[O-])O[N+](=O)[O-].C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],,,,,,
6123,40818,Ethylene glycol dinitrate,C(CO[N+](=O)[O-])O[N+](=O)[O-],,,,"['In animals it is absorbed more rapidly through skin, lungs and gastrointestinal tract ... than nitroglycerin ...', '... The magnitude of the dose obtained by the cutaneous route relative to that by inhalation is variable and unknown; EGDN is known, however, to be absorbed with considerable ease through the intact skin.', 'Nitroglycerin and ethylene glycol dinitrate are absorbed through the lungs and the skin. Absorption through the skin is usually the major route of exposure for workers who have direct dermal contact with nitroglycerin or ethylene glycol dinitrate.', '... The rate of disappearance of ethylene glycol dinitrate from human blood in vitro /was determined/. Concentrations of ethylene glycol dinitrate were measured by gas chromatography with an electron-capture dectector. One-half the ethylene glycol dinitrate disappeared in 20 hr from a human blood sample that had originally contained 0.18 ppm ethylene glycol dinitrate, in 10 hr from a sample that had contained 0.08 ppm ethylene glycol dinitrate, and in about 2 hr from a sample that had contained 0.04 ppm ethylene glycol dinitrate. Since the rate of disappearance was more rapid when ethylene glycol dinitrate concentrations were lower, the authors suggested that ethylene glycol dinitrate concentrations in human urine and blood be measured as soon as possible after the samples are taken.', 'Inorganic nitrate levels in the blood peaked in about 3.5 hr, then returned to normal levels in 12 hr. During this period, sufficient inorganic nitrate was excreted in the urine to account for approximately 60 percent of the amount of ethylene glycol dinitrate administered. The fate of the other 40 percent of inorganic nitrate is not known.']","['Ethylene glycol dinitrate incubated with rat whole blood or with erythrocytes broke down into inorg nitrate and ethylene glycol mononitrate (EGMN). Free ethylene glycol dinitrate in the blood of rats which were injected subcutaneously with ethylene glycol dinitrate (65 mg ethylene glycol dinitrate/kg) reached a peak 30 min after injection and fell to zero at 8 hr. Inorg nitrate was major metabolite found in urine from degradation of ethylene glycol dinitrate.', 'Ethylene glycol dinitrate in vivo is metabolized mainly into ethylene glycol mononitrate, which in turn is converted into inorganic nitrates and ethylene glycol ...', '... When animals and humans are exposed to ethylene glycol dinitrate the material appears in the blood immediately, peaking in concn in about 30 min. Apparently it is rapidly metabolized, for it disappears in about 4 hr with very little found excreted in the urine. Blood analysis shows that inorganic nitrite, inorganic nitrate, and ethylene glycol mononitrate are the main metabolites.', 'Nitroglycol concn in the blood reached max 1 hr after its admin to mice. It decr rapidly, and only a trace amt was left at 6 hr. Sodium nitrate and ethylene glycol were metabolites of nitroglycol. The concn of sodium nitrate incr and peaked approx 3 hr after admin and remained almost constant thereafter. In contrast, the level of ethylene glycol reached a max at 2 hr after admin and declined thereafter.', 'For more Metabolism/Metabolites (Complete) data for Ethylene glycol dinitrate (6 total), please visit the HSDB record page.']",
6124,40819,C27 17A-Hopane (Tm),CC1(CCCC2(C1CCC3(C2CCC4C3(CCC5C4(CCC5)C)C)C)C)C,,,,,,
6125,40820,"(3R,3aS,5aR,5bR,7aS,11aS,11bR,13aR,13bS)-3-butan-2-yl-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysene",CCC(C)[C@H]1CC[C@]2([C@H]1CC[C@@]3([C@@H]2CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCCC5(C)C)C)C)C)C,,,,,,
6126,40821,Fendosal,C1CC2=C(C=C(N2C3=CC(=C(C=C3)O)C(=O)O)C4=CC=CC=C4)C5=CC=CC=C51,,,,,,
6127,40822,Plegatil,CC[N+](C)(CC)CC(C)OCC[N+](C)(C)C.[I-].[I-],,,,,,
6128,40823,"N,N-Diethyl-N-methyl-2-[2-(trimethylaminio)ethoxy]-1-propanaminium",CC[N+](C)(CC)CC(C)OCC[N+](C)(C)C,,,,,,
6129,40824,Bis(p-bromophenyl)iodonium chloride,C1=CC(=CC=C1Br)[I+]C2=CC=C(C=C2)Br.[Cl-],,,,,,
6130,40825,Bis(4-bromophenyl)iodonium,C1=CC(=CC=C1Br)[I+]C2=CC=C(C=C2)Br,,,,,,
6131,40826,"2-(4-Hydroxy-3,5-di-tert-butylphenylthio)-hexanoic acid",CCCCC(C(=O)O)SC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,,,,,,
6132,40827,2-Methoxy-5-nitrophenol acetate,CC(=O)OC1=C(C=CC(=C1)[N+](=O)[O-])OC,,,,,,
6133,40828,N-Nitrosobis(2-hydroxypropyl)amine,CC(CN(CC(C)O)N=O)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
6134,40829,"Benzimidazole, 4-bromo-5,6-dichloro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1Cl)Cl)Br)N=C(N2)C(F)(F)F,,,,,,
6135,40830,"Benzimidazole, 5-chloro-4,6-dibromo-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1Br)Cl)Br)N=C(N2)C(F)(F)F,,,,,,
6136,40831,"Benzofurazan, 4,7-bis((4-methylphenyl)sulfonyl)-, 1-oxide",CC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C3=[N+](ON=C23)[O-])S(=O)(=O)C4=CC=C(C=C4)C,,,,,,
6137,40832,"Benzofurazan, 4-(phenylsulfonyl)-7-(1-piperidinyl)-",C1CCN(CC1)C2=CC=C(C3=NON=C23)S(=O)(=O)C4=CC=CC=C4,,,,,,
6138,40833,5-Acetonyl-5-allyl-1-cyclohexylbarbituric acid,CC(=O)CC1(C(=O)NC(=O)N(C1=O)C2CCCCC2)CC=C,,,,,,
6139,40834,3-Thiophen-2-ylpropylazanium;chloride,C1=CSC(=C1)CCC[NH3+].[Cl-],,,,,,
6140,40835,3-(Thiophen-2-yl)propan-1-amine,C1=CSC(=C1)CCCN,,,,,,
6141,40836,"1-Chloro-1,3-dimethyl-1,3,3-triphenyldisiloxane",C[Si](C1=CC=CC=C1)(C2=CC=CC=C2)O[Si](C)(C3=CC=CC=C3)Cl,,,,,,
6142,40837,(alpha-Cyanobenzyl)ammonium chloride,C1=CC=C(C=C1)C(C#N)[NH3+].[Cl-],,,,,,
6143,40838,2-Amino-2-phenylacetonitrile,C1=CC=C(C=C1)C(C#N)N,,,,,,
6144,40839,Vindesine,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,,,"['Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
6145,40840,N-formyl-p-(methoxy)-styrylamine,COC1=CC=C(C=C1)C=CNC=O,,,,,,
6146,40841,"(1R,9S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol",C[C@]12CCCCC[C@H](C1N)CC3=C2C=C(C=C3)O,,,,,,
6147,40842,(2-Carboxy-6-nitrophenyl)mercury,C1=CC(=C(C(=C1)[N+](=O)[O-])[Hg])C(=O)O,,,,,,
6148,40843,"FORMAMIDINE, N,N-DIMETHYL-N'-(p-(DIMETHYLAMINO)PHENYL)-",CN(C)C=NC1=CC=C(C=C1)N(C)C,,,,,,
6149,40844,"N-(2,4-Dichlorophenyl)-N,N'-dimethylformamidine hydrochloride",CNC=[N+](C)C1=C(C=C(C=C1)Cl)Cl.[Cl-],,,,,,
6150,40845,"(2,4-Dichlorophenyl)-methyl-(methylaminomethylidene)azanium",CNC=[N+](C)C1=C(C=C(C=C1)Cl)Cl,,,,,,
6151,40846,"(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,5S)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid",C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)[C@@H](C)OC1[C@@H](C(O[C@H](C1NC(=O)C)O)CO)O,,,,,,
6152,40847,Butylmethoxycyclopenten-1-one,CCCCC1=C(CC(=O)C1)OC,,,,,,
6153,40848,CID 40848,CC(=O)C1=C(OC2=CC(=O)C=C(C2=C1)CO)O,,,,,,
6154,40849,L-alpha-Aminomethyltryptamine,C1=CC=C2C(=C1)C(=CN2)CC(CN)N,,,,,,
6155,40850,"(S)-3-(1H-Indol-3-YL)-N1-methylpropane-1,2-diamine",CNC[C@H](CC1=CNC2=CC=CC=C21)N,,,,,,
6156,40851,"Indole, 3-(2-amino-3-(diethylamino)propyl)-, (S)-",CCN(CC)C[C@H](CC1=CNC2=CC=CC=C21)N,,,,,,
6157,40852,Methyl 1-[1-(dimethylamino)propan-2-yl]-2-phenylcyclohexane-1-carboxylate--hydrogen chloride (1/1),CC(CN(C)C)C1(CCCCC1C2=CC=CC=C2)C(=O)OC.Cl,,,,,,
6158,40853,Methyl 1-[1-(dimethylamino)propan-2-yl]-2-phenylcyclohexane-1-carboxylate,CC(CN(C)C)C1(CCCCC1C2=CC=CC=C2)C(=O)OC,,,,,,
6159,40854,Oxfendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,,,"['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)', 'Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)']",,,
6160,40855,Lanadoxin,CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC([C@@H]5C6=CC(=O)OC6)OC=O)O)C)C)O)O,,,,,,
6161,40856,CID 40856,C1=CC2=C(C(=C1)OCC(COC3=CC=C(C=C3)C#N)O)C(=CC(=C4N=NN=N4)O2)[O-].[Na+],,,,,,
6162,40857,Cromitrile,C1=CC2=C(C(=C1)OCC(COC3=CC=C(C=C3)C#N)O)C(=O)C=C(O2)C4=NNN=N4,,,,,,
6163,40858,"3a,8a-Dihydrofuro(2,3-b)benzofuran",C1=CC=C2C(=C1)C3C=COC3O2,,,,,,
6164,40859,2-Methyl-4-(5-nitro-2-furyl)thiazole,CC1=NC(=CS1)C2=CC=C(O2)[N+](=O)[O-],,,,,,
6165,40860,N-(4-(2-(5-Nitro-2-furyl)vinyl)2-thiazolyl)-formamide,C1=C(OC(=C1)[N+](=O)[O-])C=CC2=CSC(=N2)NC=O,,,,,,
6166,40861,CID 40861,C1=CC=C(C=C1)C(=CC(=O)N)C2=CC=C(O2)[N+](=O)[O-],,,,,,
6167,40862,"cis-2,3,4,4a,9,9a-Hexahydro-2,9,9-trimethyl-1H-indeno(2,1-c)pyridine hydrochloride",CC1(C2C[NH+](CCC2C3=CC=CC=C31)C)C.[Cl-],,,,,,
6168,40863,"2,9,9-trimethyl-3,4,4a,9a-tetrahydro-1H-indeno[2,1-c]pyridine",CC1(C2CN(CCC2C3=CC=CC=C31)C)C,,,,,,
6169,40864,"Benz(a)azulen-6,9-imin-10(4bh)-one, 5,6,7,8,9,9a-hexahydro-3-methoxy-11-methyl-, hydrochloride, (4bs-(4b-alpha,6-beta,9-beta,9a-alpha))-",C[NH+]1C2CCC1[C@@H]3[C@H](C2)C4=C(C3=O)C=CC(=C4)OC.[Cl-],,,,,,
6170,40865,"(2S,10S)-7-methoxy-15-methyl-15-azatetracyclo[10.2.1.02,10.04,9]pentadeca-4(9),5,7-trien-3-one",CN1C2CCC1[C@@H]3[C@H](C2)C4=C(C3=O)C=CC(=C4)OC,,,,,,
6171,40866,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a,10-octahydro-3-methoxy-11-methyl-, (4bS-(4b-alpha,6-beta,9-beta,9a-alpha))-, sulfate (1:1)",C[NH+]1C2CCC1[C@H]3CC4=C([C@H]3C2)C=C(C=C4)OC.OS(=O)(=O)[O-],,,,,,
6172,40867,CID 40867,CN1C2CCC1[C@H]3CC4=C(C3C2)C=C(C=C4)OC,,,,,,
6173,40868,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a,10-octahydro-2-methoxy-11-methyl-, (4bS-(4b-alpha,6-beta,9-beta,9a-alpha))-, p-tolylsulfonate",CC1=CC=C(C=C1)S(=O)(=O)[O-].C[NH+]1C2CCC1[C@H]3CC4=C([C@H]3C2)C=CC(=C4)OC,,,,,,
6174,40869,"(2S,10S)-6-methoxy-15-methyl-15-azatetracyclo[10.2.1.02,10.04,9]pentadeca-4(9),5,7-triene",CN1C2CCC1[C@H]3CC4=C([C@H]3C2)C=CC(=C4)OC,,,,,,
6175,40870,"Benz(a)azulen-6,9-imin-10-ol, 4b,5,6,7,8,9,9a,10-octahydro-2-fluoro-11-methyl-, hydrochloride, (4bs-(4b-alpha,6-beta,9-beta,9a-alpha,10-beta))-",C[NH+]1C2CCC1[C@@H]3[C@H](C2)C4=C([C@H]3O)C=C(C=C4)F.[Cl-],,,,,,
6176,40871,CID 40871,CN1C2CCC1C3[C@H](C2)C4=C([C@H]3O)C=C(C=C4)F,,,,,,
6177,40872,"Benz(a)azulen-6,9-imin-3-ol, 4b,5,6,7,8,9,9a,10-octahydro-11-methyl-, hydrobromide, (4bs-(4b-alpha,6-beta,9-beta,9a-alpha))-",C[NH+]1C2CCC1[C@H]3CC4=C([C@H]3C2)C=C(C=C4)O.[Br-],,,,,,
6178,40873,CID 40873,CN1C2CCC1C3CC4=C([C@H]3C2)C=C(C=C4)O,,,,,,
6179,40874,"Benz(a)azulen-6,9-imin-10(4bh)-one, 5,6,7,8,9,9a-hexahydro-2-fluoro-11-methyl-, hydrochloride(4bS-(4b-alpha,6-beta,9-beta, 9a-alpha))-",C[NH+]1C2CCC1[C@@H]3[C@H](C2)C4=C(C3=O)C=C(C=C4)F.[Cl-],,,,,,
6180,40875,"(2S,10S)-6-fluoro-15-methyl-15-azatetracyclo[10.2.1.02,10.04,9]pentadeca-4(9),5,7-trien-3-one",CN1C2CCC1[C@@H]3[C@H](C2)C4=C(C3=O)C=C(C=C4)F,,,,,,
6181,40876,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a,10-octahydro-2-fluoro-11-methyl-, hydrochloride, (4bS-(4b-alpha,6-beta,9-beta,9a-alpha))-",C[NH+]1C2CCC1[C@H]3CC4=C([C@H]3C2)C=CC(=C4)F.[Cl-],,,,,,
6182,40877,CID 40877,CN1C2CCC1C3CC4=C([C@H]3C2)C=CC(=C4)F,,,,,,
6183,40878,"5H-Cyclohepta(b)naphthalen-6,9-imine, 5a,6,7,8,9,10,10a,11-octahydro-12-methyl-, hydrochloride, (5aS-(5a-alpha,6-beta,9-beta,10a-alpha))-",C[NH+]1C2CCC1[C@@H]3CC4=CC=CC=C4C[C@@H]3C2.[Cl-],,,,,,
6184,40879,"(2R,11R)-16-methyl-16-azatetracyclo[11.2.1.02,11.04,9]hexadeca-4,6,8-triene",CN1C2CCC1[C@@H]3CC4=CC=CC=C4C[C@@H]3C2,,,,,,
6185,40880,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a,10-octahydro-, hydrochloride, (4bs-(4b-alpha,6-beta,9-beta,9a-alpha))-",C1CC2[C@H]3CC4=CC=CC=C4[C@H]3CC1[NH2+]2.[Cl-],,,,,,
6186,40881,"15-Azatetracyclo[10.2.1.02,10.04,9]pentadeca-4,6,8-triene",C1CC2C3CC4=CC=CC=C4C3CC1N2,,,,,,
6187,40882,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a,10-octahydro-11-(cyclopropylmethyl)-, hydrochloride, (4bs-(4b-alpha,6-beta,9-beta,9a-alpha))-",C1CC1C[NH+]2C3CCC2[C@H]4CC5=CC=CC=C5[C@H]4C3.[Cl-],,,,,,
6188,40883,"15-(Cyclopropylmethyl)-15-azatetracyclo[10.2.1.02,10.04,9]pentadeca-4,6,8-triene",C1CC1CN2C3CCC2C4CC5=CC=CC=C5C4C3,,,,,,
6189,40884,"Benz(a)azulen-6,9-imine, 4b,5,6,7,8,9,9a,10-octahydro-11-benzyl-, (4-beta-S-(4b-alpha,6-beta,9-beta,9a-alpha))-, p-tolylsulfonate",CC1=CC=C(C=C1)S(=O)(=O)[O-].C1CC2[C@H]3CC4=CC=CC=C4[C@H]3CC1[NH+]2CC5=CC=CC=C5,,,,,,
6190,40885,CID 40885,C1CC2C3CC4=CC=CC=C4[C@H]3CC1N2CC5=CC=CC=C5,,,,,,
6191,40886,"Indole, 3-(2-amino-3-ethylaminopropyl)-, (S)-",CCNC[C@H](CC1=CNC2=CC=CC=C21)N,,,,,,
6192,40887,alpha-Phenylethyl-trimethylammonium iodide,CC(C1=CC=CC=C1)[N+](C)(C)C.[I-],,,,,,
6193,40888,alpha-Methylbenzyltrimethylaminium,CC(C1=CC=CC=C1)[N+](C)(C)C,,,,,,
6194,40889,CID 40889,C[C@H]1CC=C[C@H]2[C@@H](C(=C)[C@H]([C@@H]3C2([C@@H](C=C[C@@](C1)(C)O)OC(=O)C)C(=O)N[C@H]3CC4=CC=CC=C4)C)O,,,,,,
6195,40890,CID 40890,C[C@H]1CC=C[C@H]2[C@@H](C(=C)[C@H]([C@@H]3C2([C@@H](C=C[C@](C1)(C)O)O)C(=O)N[C@H]3CC4=CC=CC=C4)C)O,,,,,,
6196,40891,"BARBITURIC ACID, 5-tert-BUTYLPEROXY-5-(1-PHENETHYL)-",CC(C)(C)OOC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
6197,40892,"DIBUTYLAMINE, compd. with HEXAFLUOROPHOSPHATE",CCCCNCCCC.F[P-](F)(F)(F)(F)F,,,,,,
6198,40893,"2,3,4-Trimethyloxetane",CC1C(OC1C)C,,,,,,
6199,40894,2-Ethyl-3-methyloxetane,CCC1C(CO1)C,,,,,,
6200,40895,1-Methoxy-2-butanol,CCC(COC)O,,,,,,
6201,40896,Mefluidide,CC1=CC(=C(C=C1NC(=O)C)NS(=O)(=O)C(F)(F)F)C,,,,,,
6202,40897,"3,3-Dimethylcyclobutanecarbonitrile",CC1(CC(C1)C#N)C,,,,,,
6203,40898,Bicyclo[2.2.1]hept-2-en-7-ol,C1CC2C=CC1C2O,,,,,,
6204,40899,"3-Methoxy-1,3,4-hexatriene",CC=C=C(C=C)OC,,,,,,
6205,40900,"5H-1,4-DITHIINO(2,3-c)PYRROLE-5,7(6H)-DIONE, 2,3-DIHYDRO-6-(2-PYRIDINYL)-",C1CSC2=C(S1)C(=O)N(C2=O)C3=CC=CC=N3,,,,,,
6206,40901,"5H-Cyclohepta(b)naphthalen-6,9-imine, 5a,6,7,8,9,10,10a,11-octahydro-12-methyl-, hydrochloride, (5aR-(5a-alpha,6-alpha,9-alpha,10a-beta))-",C[NH+]1C2CCC1[C@@H]3CC4=CC=CC=C4C[C@H]3C2.[Cl-],,,,,,
6207,40902,"(2R,11S)-16-methyl-16-azatetracyclo[11.2.1.02,11.04,9]hexadeca-4,6,8-triene",CN1C2CCC1[C@@H]3CC4=CC=CC=C4C[C@H]3C2,,,,,,
6208,40903,Suriclone,CN1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
6209,40904,3-Methyl-5-(beta-diethylamino-o-ethoxyphenyl)isoxazole hydrochloride,CC[NH+](CC)CCOC1=CC=CC=C1C2=CC(=NO2)C.[Cl-],,,,,,
6210,40905,"N,N-diethyl-2-[2-(3-methyl-1,2-oxazol-5-yl)phenoxy]ethanamine",CCN(CC)CCOC1=CC=CC=C1C2=CC(=NO2)C,,,,,,
6211,40906,"[(3S)-6-methoxy-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide",C[N+]1(C2C[C@@H](CC1C(C2)OC)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)C.[Br-],,,,,,
6212,40907,"[(3S)-6-methoxy-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate",C[N+]1(C2C[C@@H](CC1C(C2)OC)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)C,,,,,,
6213,40908,6-Methoxybenzofuran-2-carbaldehyde,COC1=CC2=C(C=C1)C=C(O2)C=O,,,,,,
6214,40909,CID 40909,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6215,40910,CID 40910,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC(=CC=C3)[N+](=O)[O-])N=C2S,,,,,,
6216,40911,CID 40911,C1=CC(=CC(=C1)[N+](=O)[O-])C=C2C(=O)N(C(=N2)S)C3=CC(=CC=C3)Cl,,,,,,
6217,40912,CID 40912,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
6218,40913,beta-Estradiol-d2,[2H]C1=CC2=C(CCC3C2CCC4(C3CC[C@@H]4O)C)C(=C1O)[2H],,,,,,
6219,40914,"3-(3-Methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione",CC1(CC(=O)NC(=O)C1(CCCN(C)C)C2=CC(=CC=C2)OC)C,,,,,,
6220,40915,Lodoxamide ethyl,CCOC(=O)C(=O)NC1=CC(=CC(=C1Cl)NC(=O)C(=O)OCC)C#N,,,"['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']",,,
6221,40916,"Benzofurazan, 4,7-bis((4-methylphenyl)sulfonyl)-",CC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C3=NON=C23)S(=O)(=O)C4=CC=C(C=C4)C,,,,,,
6222,40917,3-Pyridylmethyl salicylate hydrochloride,C1=CC=C(C(=C1)C(=O)OCC2=C[NH+]=CC=C2)O.[Cl-],,,,,,
6223,40918,3-Pyridylmethylsalicylate,C1=CC=C(C(=C1)C(=O)OCC2=CN=CC=C2)O,,,,,,
6224,40919,4-Tert-butyl-2-methoxyphenol,CC(C)(C)C1=CC(=C(C=C1)O)OC,,,,,,
6225,40920,2-Ethyl-3-propyloxirane,CCCC1C(O1)CC,,,,,,
6226,40921,"Benzimidazole, 5-chloro-4-nitro-2-(trifluoromethyl)-",C1=CC(=C(C2=C1NC(=N2)C(F)(F)F)[N+](=O)[O-])Cl,,,,,,
6227,40922,"2,4,4-Trimethylpent-2-enal",CC(=CC(C)(C)C)C=O,,,,,,
6228,40923,7-Octen-4-OL,CCCC(CCC=C)O,,,,,,
6229,40924,"2-Ethyl-5-methyl-1,4-dioxane",CCC1COC(CO1)C,,,,,,
6230,40925,1-(1-Methylpropoxy)-2-propanol,CCC(C)OCC(C)O,,,,,,
6231,40926,CO-Vidarabine,C1[C@H](C2=C(NC=N1)N(C=N2)C3CC(C(O3)CO)O)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs that inhibit ADENOSINE DEAMINASE activity. (See all compounds classified as Adenosine Deaminase Inhibitors.)']",,,
6232,40927,"1H-Indole-2-carboxylic acid, 5-chloro-3-(diphenylmethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=C(NC4=C3C=C(C=C4)Cl)C(=O)O,,,,,,
6233,40928,"1H-Indole-2-carboxylic acid, 3-(diphenylmethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=C(NC4=CC=CC=C43)C(=O)O,,,,,,
6234,40929,"1H-Indole-2-carboxylic acid, 3-(diphenylmethyl)-5-hydroxy-",C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=C(NC4=C3C=C(C=C4)O)C(=O)O,,,,,,
6235,40930,3-((2-Methoxyphenyl)phenylmethyl)-1H-indole-5-carboxylic acid,COC1=CC=CC=C1C(C2=CC=CC=C2)C3=CNC4=C3C=C(C=C4)C(=O)O,,,,,,
6236,40931,"1H-Indole-2-carboxylic acid, 3-(diphenylmethyl)-5-(phenylmethoxy)-",C1=CC=C(C=C1)COC2=CC3=C(C=C2)NC(=C3C(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)O,,,,,,
6237,40932,"1H-Indole-1-acetic acid, 3-(bis(4-chlorophenyl)methyl)-",C1=CC=C2C(=C1)C(=CN2CC(=O)O)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl,,,,,,
6238,40933,3-((4-Chlorophenyl)phenylmethyl)-1H-indole-1-acetic acid,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)C3=CN(C4=CC=CC=C43)CC(=O)O,,,,,,
6239,40934,3-((4-Fluorophenyl)phenylmethyl)-1H-indole-1-acetic acid,C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)C3=CN(C4=CC=CC=C43)CC(=O)O,,,,,,
6240,40935,"1H-Indole-1-propionic acid, 3-(diphenylmethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CN(C4=CC=CC=C43)CCC(=O)O,,,,,,
6241,40936,"1H-Indole-1-acetic acid, 3-(9H-xanthen-9-YL)-",C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C4=CN(C5=CC=CC=C54)CC(=O)O,,,,,,
6242,40937,"2,3-Di-9H-xanthen-9-yl-1H-indole-1-acetic acid",C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C4=C(N(C5=CC=CC=C54)CC(=O)O)C6C7=CC=CC=C7OC8=CC=CC=C68,,,,,,
6243,40938,"3-(Phenyl(3,4,5-trimethoxyphenyl)methyl)-1H-indole-1-acetic acid",COC1=CC(=CC(=C1OC)OC)C(C2=CC=CC=C2)C3=CN(C4=CC=CC=C43)CC(=O)O,,,,,,
6244,40939,"1H-Indole-3-propionic acid, 2-(diphenylmethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=C(C4=CC=CC=C4N3)CCC(=O)O,,,,,,
6245,40940,2-((2-Methoxyphenyl)phenylmethyl)-1H-indole-3-acetic acid,COC1=CC=CC=C1C(C2=CC=CC=C2)C3=C(C4=CC=CC=C4N3)CC(=O)O,,,,,,
6246,40941,"1H-Indole-2-carboxylic acid, 3-((4'-carboxy(1,1'-biphenyl)-4-yl)methyl)-1-methyl-",CN1C2=CC=CC=C2C(=C1C(=O)O)CC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O,,,,,,
6247,40942,CID 40942,CC1=NC2=C(O1)CCC3=CC=CC=C3C2=CCC[NH+](C)C.[Cl-],,,,,,
6248,40943,"N,N-dimethyl-3-(5-methyl-6-oxa-4-azatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)propan-1-amine",CC1=NC2=C(O1)CCC3=CC=CC=C3C2=CCCN(C)C,,,,,,
6249,40944,CID 40944,CC1=NC2=C(S1)CCC3=CC=CC=C3C2=CCC[NH+](C)C.[Cl-],,,,,,
6250,40945,"N,N-dimethyl-3-(5-methyl-6-thia-4-azatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)propan-1-amine",CC1=NC2=C(S1)CCC3=CC=CC=C3C2=CCCN(C)C,,,,,,
6251,40946,CID 40946,CC1=NC2=C(S1)CCC3=CC=CC=C3C2=C4CC[NH+](CC4)C.C(=CC(=O)[O-])C(=O)O,,,,,,
6252,40947,"5-Methyl-2-(1-methylpiperidin-4-ylidene)-6-thia-4-azatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaene",CC1=NC2=C(S1)CCC3=CC=CC=C3C2=C4CCN(CC4)C,,,,,,
6253,40948,CID 40948,CC1=NC2=C(O1)CCC3=C(C2=C4CC[NH+](CC4)C)C=C(C=C3)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
6254,40949,"13-Chloro-5-methyl-2-(1-methylpiperidin-4-ylidene)-6-oxa-4-azatricyclo[8.4.0.03,7]tetradeca-1(10),3(7),4,11,13-pentaene",CC1=NC2=C(O1)CCC3=C(C2=C4CCN(CC4)C)C=C(C=C3)Cl,,,,,,
6255,40950,CID 40950,CC1=NC2=C([NH+]1C)CCC3=CC=CC=C3C2=C4CC[NH+](CC4)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
6256,40951,"5,6-Dimethyl-2-(1-methylpiperidin-4-ylidene)-4,6-diazatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaene",CC1=NC2=C(N1C)CCC3=CC=CC=C3C2=C4CCN(CC4)C,,,,,,
6257,40952,"Barbituric acid, 5-butyl-5-isopropyl-",CCCCC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
6258,40953,"Aniline, 2-isopropoxy-5-nitro-",CC(C)OC1=C(C=C(C=C1)[N+](=O)[O-])N,,,,,,
6259,40954,7-Bromotacrine,C1CCC2=NC3=C(C=C(C=C3)Br)C(=C2C1)N,,,,,,
6260,40955,Nibroxane,CC1OCC(CO1)([N+](=O)[O-])Br,,,,,,
6261,40956,"2H-1-Benzopyran-3-carboxylic acid, 2-oxo-, phenyl ester",C1=CC=C(C=C1)OC(=O)C2=CC3=CC=CC=C3OC2=O,,,,,,
6262,40957,7-Amino-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,C1C(=C(N2C(S1)C(C2=O)N)C(=O)O)Cl,,,,,,
6263,40958,"(6R-(6alpha,7beta))-7-(Aminophenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl,,,,,,
6264,40959,"Pyridine, 4,4'-(2,5-dihydro-1,3,4-thiadiazole-2,5-diyl)bis-",C1=CN=CC=C1C2N=NC(S2)C3=CC=NC=C3,,,,,,
6265,40960,1-Ethoxy-4-(1-(4-methylphenyl)-2-nitropropyl)benzene,CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)C(C)[N+](=O)[O-],,,,,,
6266,40961,CID 40961,CC1(COC(=N1)S)C,,,,,,
6267,40962,"Acetanilide, 4'-acetyl-2-diethylamino-",CCN(CC)CC(=O)NC1=CC=C(C=C1)C(=O)C,,,,,,
6268,40963,CID 40963,COC1=C(C=C(C=C1)C(=[NH+]OCC=C)C2=NC=CC3=CC(=C(C=C32)OC)OC)OC.[Cl-],,,,,,
6269,40964,CID 40964,COC1=C(C=C(C=C1)C(=NOCC=C)C2=NC=CC3=CC(=C(C=C32)OC)OC)OC,,,,,,
6270,40965,CID 40965,CC[NH+](CC)CCO[NH+]=C(C1=CC(=C(C=C1)OC)OC)C2=NC=CC3=CC(=C(C=C32)OC)OC.[Cl-].[Cl-],,,,,,
6271,40966,CID 40966,CCN(CC)CCON=C(C1=CC(=C(C=C1)OC)OC)C2=NC=CC3=CC(=C(C=C32)OC)OC,,,,,,
6272,40967,CID 40967,COC1=C(C=C(C=C1)C(=[NH+]OCC(=O)NCC[NH+]2CCOCC2)C3=NC=CC4=CC(=C(C=C43)OC)OC)OC.[Cl-].[Cl-],,,,,,
6273,40968,CID 40968,COC1=C(C=C(C=C1)C(=NOCC(=O)NCCN2CCOCC2)C3=NC=CC4=CC(=C(C=C43)OC)OC)OC,,,,,,
6274,40969,CID 40969,COC1=C(C=C(C=C1)C(=[NH+]OCC(=O)N(CC[NH+]2CCOCC2)C3=CC=CC=C3)C4=NC=CC5=CC(=C(C=C54)OC)OC)OC.[Cl-].[Cl-],,,,,,
6275,40970,CID 40970,COC1=C(C=C(C=C1)C(=NOCC(=O)N(CCN2CCOCC2)C3=CC=CC=C3)C4=NC=CC5=CC(=C(C=C54)OC)OC)OC,,,,,,
6276,40971,CID 40971,COC1=C(C=C(C=C1)C(=[NH+]OCCC(=O)NCC[NH+]2CCOCC2)C3=NC=CC4=CC(=C(C=C43)OC)OC)OC.[Cl-].[Cl-],,,,,,
6277,40972,CID 40972,COC1=C(C=C(C=C1)C(=NOCCC(=O)NCCN2CCOCC2)C3=NC=CC4=CC(=C(C=C43)OC)OC)OC,,,,,,
6278,40973,Desogestrel,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34,['Oral desogestrel is used in combination with [ethinylestradiol] as a contraceptive agent for the prevention of pregnancy.  Desogestrel is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulation.'],"['The effects of desogestrel are divided on reproductive including modification of luteinizing hormone and follicle stimulating hormone, declines on the onset of menstruation, and increases the viscosity of the vaginal fluid; and on metabolic that includes increase insulin secretion and resistance, increased lipase activity, and increased fat deposition. The effect of desogestrel on the lipids has been studied extensively and the results are contradictory.  Desogestrel main therapeutic effect due to its mechanism of action is known to be related to the inhibition of the ovulation in 97% of the cycles. This effect was proven in clinical trials in non-breastfeeding women from which the Pearl failure rate was reported to be of 0.17 per 100 women-years. This result indicated that desogestrel is more efficient when compared to other progestogen-only pills. All the therapeutic effect is produced by a transformation of the endometrium followed by an inhibition of the ovulation due to the suppression of other hormones.  Desogestrel has been widely confirmed to be related to an increase in the risk of venous thromboembolism due to the driven increased in blood coagulation factors, leading to a pronounced prothrombotic state. However, the effects of desogestrel are known to not impact significantly the level of total cholesterol remaining in the range of change of 10% which allows it to be a molecule that presents a favorable lipid profile.']","['Oral contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Oral, Hormonal.)', 'Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. (See all compounds classified as Progestins.)', 'Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)']","['After oral administration, desogestrel is rapidly absorbed and it reaches a peak concentration of 2 ng/ml after 1.5 hours. The bioavailability of desogestrel is reported to be in the range of 60-80% and the reported AUC is of 3000 ng.h/ml. Almost all the administered dose is modified to the active metabolite, [etonogestrel].', 'The elimination of desogestrel is found to be mainly renal corresponding to about 6 times the dose eliminated in the bile. The elimination of desogestrel is only done as the metabolites and not as the unchanged drug and about 85% of the administered dose can be excreted as metabolites after 6-8 days.', 'The apparent volume of distribution of desogestrel is of 1.5 L/kg.', 'The metabolic clearance rate of desogestrel is reported to be of about 2 ml/min/kg.', 'After oral dosing of Cerazette desogestrel (DSG) is rapidly absorbed and converted into etonogestrel (ENG). Under steady-state conditions, peak serum levels are reached 1.8 hours after tablet-intake and the absolute bioavailability of ENG is approximately 70%.', 'In the third cycle of use after a single desogestrel and ethinyl estradiol tablet, maximum concentrations of 3-keto-desogestrel of 2,805 +/- 1,203 pg/mL (mean+/-SD) are reached at 1.4+/-0.8 hours. The area under the curve (AUC) is 33,858+/-11,043 pg/mL (hr) after a single dose.', 'At steady state, attained from at least day 19 onwards, maximum concentrations of 5,840 +/-1,667 pg/mL are reached at 1.4+/-0.9 hours. The minimum plasma levels of 3-keto-desogestrel at steady state are 1,400+/-560 pg/mL. The AUC0-24 at steady state is 52,299+/-17,878 pg/mL (hr). The mean AUC0 for 3-keto-desogestrel at single dose is significantly lower than the mean AUC0-24 at steady state. This indicates that the kinetics of 3-keto-desogestrel are non-linear due to an increase in binding of 3-keto-desogestrel to sex hormone-binding globulin in the cycle, attributed to increased sex hormone-binding globulin levels which are induced by the daily administration of ethinyl estradiol. Sex hormone-binding globulin levels increased significantly in the third treatment cycle from day 1 (150+/-64 nmol/L) to day 21 (230+/-59 nmol/L).', 'Etonogestrel is 95.5-99% bound to serum proteins, predominantly to albumin and to a lesser extent to sex hormone-binding globulin (SHBG).', 'For more Absorption, Distribution and Excretion (Complete) data for DESOGESTREL (8 total), please visit the HSDB record page.']","['Desogestrel is rapidly metabolized in the intestinal mucosa and by first-pass hepatic metabolism to form the major metabolite of desogestrel is [etonogestrel] which is the biologically active metabolite. This modification is described by the hydroxylation in C3 of the desogestrel molecule. Later, etonogestrel is metabolized following the normal pathways of steroid metabolism. On the other hand, due to the 11-methylene side chain, desogestrel cannot be metabolized to other progestins.', 'In addition to 3-keto-desogestrel, other phase I metabolites are 3alpha-OH-desogestrel, 3beta-OH-desogestrel, and 3alpha-OH-5alpha-H-desogestrel. These other metabolites are not known to have any pharmacologic effects, and are further converted in part by conjugation (phase II metabolism) into polar metabolites, mainly sulfates and glucuronides.', 'Desogestrel is metabolized via hydroxylation and dehydrogenation to the active metabolite etonogestrel. Etonogestrel is metabolised via sulphate and glucuronide conjugation.', 'Desogestrel is metabolized rapidly and completely in the liver and gut wall. It is metabolized to 3-keto-desogestrel, which mediates its progestogenic effects, and it is not metabolized further to another progestogen. The serum concentrations of 3-keto-desogestrel reached maximum levels within 2-3 hours after oral administration of desogestrel and were subsequently cleared with a half-life of 12-24 hours.', 'The metabolism of desogestrel in microsomes from six hours livers in vitro /were studied/. The main metabolite formed was 3-keto-desogestrel; 3alpha-hydroxydesogestrel and 3beta-hydroxydesogestrel were also detected. The metabolism of desogestrel was inhibited by 50% by primaquine at a concentration of 30 umol/L, but not by levonorgestrel at 250 umol/L.', 'For more Metabolism/Metabolites (Complete) data for DESOGESTREL (7 total), please visit the HSDB record page.', 'Desogestrel has known human metabolites that include 3-alpha-hydroxydesogestrel, 3-beta-hydroxy-desogestrel, and Desogestrel 17-O-glucuronide.']","['The terminal half-life of desogestrel is determined to be of 30 hours.', 'Etonogestrel is eliminated with a mean half-life of approximately 30 hours, with no difference between single and multiple dosing.', 'The elimination half-life for 3-keto-desogestrel is approximately 38+/-20 hours at steady state. /3-Keto-desogestrel/']"
6279,40974,19-Nortestosterone nitrosocarbamate,CC12CCC3C(C1CC[C@@H]2OC(=O)N(CCCl)N=O)CCC4=CC(=O)CCC34,,,,,,
6280,40975,4-Hydroxy-3-(hydroxymethyl)benzaldehyde,C1=CC(=C(C=C1C=O)CO)O,,,,,,
6281,40976,"(17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CCC12CC(=C)C3C(C1CC[C@]2(C#C)O)CCC4=CC(=O)CCC34,,,,,,
6282,40977,2-(2-Methoxyethoxy)ethyl 8-(2-octylcyclopropyl)octanoate,CCCCCCCCC1CC1CCCCCCCC(=O)OCCOCCOC,,,,,,
6283,40978,"Benzoic acid, 4-(3,4,5-trimethoxybenzamido)-",COC1=CC(=CC(=C1OC)OC)C(=O)NC2=CC=C(C=C2)C(=O)O,,,,,,
6284,40979,C.I. Basic yellow 28,CC1(C2=CC=CC=C2[N+](=C1C=NN(C)C3=CC=C(C=C3)OC)C)C.COS(=O)(=O)[O-],,,,,,
6285,40980,Ctionic yellow X-GL,CC1(C2=CC=CC=C2[N+](=C1C=NN(C)C3=CC=C(C=C3)OC)C)C,,,,,,
6286,40981,"4,4,5-Trimethyl-1,3-dioxan-5-OL",CC1(C(COCO1)(C)O)C,,,,,,
6287,40982,CID 40982,CCOC=COCCOC,,,,,,
6288,40983,Amiterol,CCC(C)NCC(C1=CC=C(C=C1)N)O,,,,,,
6289,40984,Camiverine,CC(C)CCOC(=O)C(C1=CC=CC=C1)NCCN2CCCC2,,,,,,
6290,40985,"4'-(3-Oxo-1,2,3,4-tetrahydroisoquinolyl)-2-propylaminoacetanilide",CCCNCC(=O)NC1=CC=C(C=C1)C2C3=CC=CC=C3CC(=O)N2,,,,,,
6291,40986,"4'-(4-Isopropyl-3-oxo-1,2,3,4-tetrahydroisoquinolyl)-2-propylaminoacetanilide",CC(C)C1C2=CC=CC=C2C(NC1=O)C3=CC=C(C=C3)NC(=O)CNC(C)C,,,,,,
6292,40987,"2-Methylamino-4'-(3-oxo-1,2,3,4-tetrahydroisoquinolyl)acetanilide",CNCC(=O)NC1=CC=C(C=C1)C2C3=CC=CC=C3CC(=O)N2,,,,,,
6293,40988,"4'-(4,4-Dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinolyl)-2-morpholinoacetanilide",CC1(C2=CC=CC=C2C(NC1=O)C3=CC=C(C=C3)NC(=O)CN4CCOCC4)C,,,,,,
6294,40989,4-Bromophenyl chloromethyl sulfone,C1=CC(=CC=C1S(=O)(=O)CCl)Br,,,,,,
6295,40990,CID 40990,CC(=CCCC(=CC=NN=C(N)S)C)C,,,,,,
6296,40991,"Ammonium, (2-hydroxyethyl)triethyl-, iodide, 1-adamantaneacetate",CC[N+](CC)(CC)CCOC(=O)CC12CC3CC(C1)CC(C3)C2.[I-],,,,,,
6297,40992,2-[2-(1-Adamantyl)acetyl]oxyethyl-triethylazanium,CC[N+](CC)(CC)CCOC(=O)CC12CC3CC(C1)CC(C3)C2,,,,,,
6298,40993,"1-Adamantaneacetic acid, 3-(dimethylamino)propyl ester, ethyl iodide",CC[N+](C)(C)CC(C)OC(=O)CC12CC3CC(C1)CC(C3)C2.[I-],,,,,,
6299,40994,2-[2-(1-Adamantyl)acetyl]oxypropyl-ethyl-dimethylazanium,CC[N+](C)(C)CC(C)OC(=O)CC12CC3CC(C1)CC(C3)C2,,,,,,
6300,40995,2-(2-(Diethylamino)ethoxy)adamantane ethyl iodide,CC[N+](CC)(CC)CCOC1C2CC3CC(C2)CC1C3.[I-],,,,,,
6301,40996,2-(2-Adamantyloxy)ethyl-triethylazanium,CC[N+](CC)(CC)CCOC1C2CC3CC(C2)CC1C3,,,,,,
6302,40997,Undecylcyclohexane,CCCCCCCCCCCC1CCCCC1,,,,,,
6303,40998,"Benzoic acid, 3,4,5-trimethoxy-, 2-((4-chlorobutyl)ethylamino)ethyl ester, hydrochloride",CC[NH+](CCCCCl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[Cl-],,,,,,
6304,40999,"2-[4-Chlorobutyl(ethyl)amino]ethyl 3,4,5-trimethoxybenzoate",CCN(CCCCCl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
6305,41000,"Benzoic acid, 3,4,5-trimethoxy-, 2-((2-chloroethyl)ethylamino)ethyl ester, hydrochloride",CC[NH+](CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC)CCCl.[Cl-],,,,,,
6306,41001,"2-[2-Chloroethyl(ethyl)amino]ethyl 3,4,5-trimethoxybenzoate",CCN(CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC)CCCl,,,,,,
6307,41002,"Benzoic acid, 3,4,5-trimethoxy-, 2-((3-chloropropyl)ethylamino)ethyl ester, oxalate",CC[NH+](CCCCl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
6308,41003,"2-[3-Chloropropyl(ethyl)amino]ethyl 3,4,5-trimethoxybenzoate",CCN(CCCCl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
6309,41004,"Benzoic acid, 3,4,5-trimethoxy-, 2-((4-chloropentyl)ethylamino)ethyl ester, hydrochloride",CC[NH+](CCCC(C)Cl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[Cl-],,,,,,
6310,41005,"2-[4-Chloropentyl(ethyl)amino]ethyl 3,4,5-trimethoxybenzoate",CCN(CCCC(C)Cl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
6311,41006,"Benzoic acid, 3,4,5-trimethoxy-, 2-((5-chloropentyl)ethylamino)ethyl ester, oxalate",CC[NH+](CCCC(C)Cl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
6312,41007,"Benzoic acid, 3,4,5-trimethoxy-, 2-((5-bromopentyl)ethylamino)ethyl ester, oxalate",CC[NH+](CCCC(C)Br)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
6313,41008,"2-[4-Bromopentyl(ethyl)amino]ethyl 3,4,5-trimethoxybenzoate",CCN(CCCC(C)Br)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
6314,41009,"Benzoic acid, 3,4,5-trimethoxy-, 2-((6-chlorohexyl)ethylamino)ethyl ester, oxalate",CC[NH+](CCCCCCCl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.C(=O)(C(=O)[O-])O.Cl,,,,,,
6315,41010,"2-[6-Chlorohexyl(ethyl)amino]ethyl 3,4,5-trimethoxybenzoate",CCN(CCCCCCCl)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
6316,41011,"Guanidine, N,N'-bis(4-methylphenyl)-",CC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C)N,,,,,,
6317,41012,"Benzene, 1-ethyl-2,3,5-trimethyl-",CCC1=CC(=CC(=C1C)C)C,,,,,,
6318,41013,5-Methylisobenzofuran-1(3H)-one,CC1=CC2=C(C=C1)C(=O)OC2,,,,,,
6319,41014,"Carbazic acid, 3-(6-((2-hydroxyethyl)methylamino)pyridazin-3-YL)-, ethyl ester",CCOC(=O)NNC1=NN=C(C=C1)N(C)CCO,,,,,,
6320,41015,3-(2-Carbethoxyhydrazino)-6-(N-(2-hydroxypropyl)methylamino)pyridazine,CCOC(=O)NNC1=NN=C(C=C1)N(C)CC(C)O,,,,,,
6321,41016,3-(2-Carbethoxyhydrazino)-6-diallylaminopyridazine,CCOC(=O)NNC1=NN=C(C=C1)N(CC=C)CC=C,,,,,,
6322,41017,"2,3,4-Trichloroanisole",COC1=C(C(=C(C=C1)Cl)Cl)Cl,,,,,,
6323,41018,"Benzene, 1,2,5-trichloro-3-methoxy-",C1=C(C=C(C(=C1CO)Cl)Cl)Cl,,,,,,
6324,41019,"3,4,5-Trichloroanisole",COC1=CC(=C(C(=C1)Cl)Cl)Cl,,,,,,
6325,41020,"Acetic acid, phenoxy-, 1-(2-(4-morpholinyl)ethyl)-1-phenyl-3-butynyl ester, hydrochloride",C#CCC(CC[NH+]1CCOCC1)(C2=CC=CC=C2)OC(=O)COC3=CC=CC=C3.[Cl-],,,,,,
6326,41021,(1-Morpholin-4-yl-3-phenylhex-5-yn-3-yl) 2-phenoxyacetate,C#CCC(CCN1CCOCC1)(C2=CC=CC=C2)OC(=O)COC3=CC=CC=C3,,,,,,
6327,41022,Flecainide acetate,CC(=O)O.C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)']",,,
6328,41023,"Benzenamine, 2,4-dimethoxy-, hydrochloride",COC1=CC(=C(C=C1)[NH3+])OC.[Cl-],,,,,,
6329,41024,N-(1-Methyl-2-(1-piperidinyl)ethyl)-N-2-pyridinylbenzamide,CC(CN1CCCCC1)N(C2=CC=CC=N2)C(=O)C3=CC=CC=C3,,,,,,
6330,41025,N-(1-Methyl-2-(1-piperidinyl)ethyl)-N-2-pyridinylbutanamide,CCCC(=O)N(C1=CC=CC=N1)C(C)CN2CCCCC2,,,,,,
6331,41026,Dimethylcyclopropyl ketoxime,CC1CC1C(=NO)C2CC2C,,,,,,
6332,41027,"N,N-Dimethyl-alpha,alpha-diphenylthioacetamide",CN(C)C(=S)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
6333,41028,"6,7-Dichloro-2-ethyl-2-methyl-1-oxo-5-indanyloxyacetic acid",CCC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C,,,,,,
6334,41029,"6,7-Dichloro-2-isopropyl-2-methyl-1-oxo-5-indanyloxyacetic acid",CC(C)C1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C,,,,,,
6335,41030,"N-(3,4-Dimethylphenyl) isonicotinamide hydrochloride",CC1=C(C=C(C=C1)[NH2+]C(=O)C2=CC=NC=C2)C.[Cl-],,,,,,
6336,41031,"N-(3,4-dimethylphenyl)pyridine-4-carboxamide",CC1=C(C=C(C=C1)NC(=O)C2=CC=NC=C2)C,,,,,,
6337,41032,"N-(2,3-Dimethylphenyl)isonicotinamide hydrochloride",CC1=C(C(=CC=C1)[NH2+]C(=O)C2=CC=NC=C2)C.[Cl-],,,,,,
6338,41033,"N-(2,3-dimethylphenyl)isonicotinamide",CC1=C(C(=CC=C1)NC(=O)C2=CC=NC=C2)C,,,,,,
6339,41034,"Isonicotinamide, N-(3-difluoromethoxyphenyl)-, hydrochloride",C1=CC(=CC(=C1)OC(F)F)[NH2+]C(=O)C2=CC=NC=C2.[Cl-],,,,,,
6340,41035,N-[3-(difluoromethoxy)phenyl]pyridine-4-carboxamide,C1=CC(=CC(=C1)OC(F)F)NC(=O)C2=CC=NC=C2,,,,,,
6341,41036,"N-Chloroacetyl-2,6-dimethylanilinoacetaldehydediethyleneacetal",CC1=C(C(=CC=C1)C)N(C2COCCO2)C(=O)CCl,,,,,,
6342,41037,"Benzenemethanol, 4-amino-3-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)-5-(trifluoromethyl)-, monohydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)Cl)N)C(F)(F)F)O.[Cl-],,,,,,
6343,41038,Agn-PC-0jkru9,C[N+](C)(C)CCCl.C(CCl)P(=O)(O)O.[Cl-],,,,,,
6344,41039,"4-Butyl-1,3-cyclopentanedione",CCCCC1CC(=O)CC1=O,,,,,,
6345,41040,"4,5-Diethyl-2,3-dihydro-2,3-dimethylfuran",CCC1=C(OC(=C1C)C)CC,,,,,,
6346,41041,N-(1-Methyl-2-(1-piperidinyl)ethyl)-N-2-pyridinylformamide,CC(CN1CCCCC1)N(C=O)C2=CC=CC=N2,,,,,,
6347,41042,4-Ethylphenethyl alcohol,CCC1=CC=C(C=C1)CCO,,,,,,
6348,41043,"(1,4-oxathian-3-ylideneamino) N-methylcarbamate",CNC(=O)ON=C1COCCS1,,,,,,
6349,41044,"1,2,2,3-Tetrabromopropane",C(C(CBr)(Br)Br)Br,,,,,,
6350,41045,2-Methylheptanenitrile,CCCCCC(C)C#N,,,,,,
6351,41046,"2-Chloro-N,N-diethylpropionamide",CCN(CC)C(=O)C(C)Cl,,,,,,
6352,41047,CID 41047,CCN(CC)CCOC1=CC(=NC2=CC=CC=C21)C=CC3=CC=C(O3)[N+](=O)[O-],,,,,,
6353,41048,"N,N-Diethyl-2-[2-[2-(5-nitrofuran-2-yl)ethenyl]quinolin-8-yl]oxyethanamine",CCN(CC)CCOC1=CC=CC2=C1N=C(C=C2)C=CC3=CC=C(O3)[N+](=O)[O-],,,,,,
6354,41049,Meptazinol,CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
6355,41050,"[2-[(4-Acetyloxy-3-methoxybenzoyl)amino]-3,5-dibromophenyl]methyl-(cyclohexylmethyl)azanium;chloride",CC(=O)OC1=C(C=C(C=C1)C(=O)NC2=C(C=C(C=C2Br)Br)C[NH2+]CC3CCCCC3)OC.[Cl-],,,,,,
6356,41051,"[4-[[2,4-Dibromo-6-[(cyclohexylmethylamino)methyl]phenyl]carbamoyl]-2-methoxyphenyl] acetate",CC(=O)OC1=C(C=C(C=C1)C(=O)NC2=C(C=C(C=C2Br)Br)CNCC3CCCCC3)OC,,,,,,
6357,41052,"1,4,7-Trimethylindan",CC1CCC2=C(C=CC(=C12)C)C,,,,,,
6358,41053,"1-(1,3-Dimethylbutoxy)-2-propanol",CC(C)CC(C)OCC(C)O,,,,,,
6359,41054,"4-Hydroxy-3a,7a-dimethyl-3a,4,5,7a-tetrahydro-2-benzofuran-1(3H)-one",CC12COC(=O)C1(C=CCC2O)C,,,,,,
6360,41055,5-Methoxybenzo[d]thiazol-2-amine,COC1=CC2=C(C=C1)SC(=N2)N,,,,,,
6361,41056,CID 41056,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC(COC2=CC=CC=C2)O,,,,,,
6362,41057,"3A,7A-Dimethyloctahydro-4-isobenzofuranol",CC12CCCC(C1(COC2)C)O,,,,,,
6363,41058,l-alpha-Narcotine N-oxide,C[N+]1(CCC2=CC3=C(C(=C2[C@H]1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3)[O-],,,,,,
6364,41059,6-Ethyl-1-benzothiophene,CCC1=CC2=C(C=C1)C=CS2,,,,,,
6365,41060,"3a,4,7,7a-Tetrahydro-2-((2-oxopropoxy)phenyl)-1H-isoindole-1,3(2H)-dione",CC(=O)COC1=CC=C(C=C1)N2C(=O)C3CC=CCC3C2=O,,,,,,
6366,41061,"Benzoic acid, 4-(((4-chlorophenoxy)acetyl)amino)-, 2-(diethylamino)ethyl ester, mono(2-(4-chlorophenoxy)-2-methylpropanoate)",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)COC2=CC=C(C=C2)Cl.CC(C)(C(=O)[O-])OC1=CC=C(C=C1)Cl,,,,,,
6367,41062,2-(Diethylamino)ethyl 4-[[2-(4-chlorophenoxy)acetyl]amino]benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)COC2=CC=C(C=C2)Cl,,,,,,
6368,41063,"7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@@H]1[C@H]([C@H](CC(O1)O)O)CC=CCCCC(=O)O)O,,,,,,
6369,41064,"3a,4,7,7a-Tetrahydro-2-(2-propynyl)-1H-isoindole-1,3(2H)-dione",C#CCN1C(=O)C2CC=CCC2C1=O,,,,,,
6370,41065,p-Bromomethylbenzoylcholine iodide,C[N+](C)(C)CCOC(=O)C1=CC=C(C=C1)CBr.[I-],,,,,,
6371,41066,"2-[p-(Bromomethyl)benzoxy]-N,N,N-trimethylethanaminium",C[N+](C)(C)CCOC(=O)C1=CC=C(C=C1)CBr,,,,,,
6372,41067,4-(Trimethylammonio)butyramide chloride,C[N+](C)(C)CCCC(=O)N.[Cl-],,,,,,
6373,41068,(4-Amino-4-oxobutyl)-trimethylazanium,C[N+](C)(C)CCCC(=O)N,,,,,,
6374,41069,"Ethanone, 1-(4-(3-chlorophenyl)-4-piperidinyl)-, hydrochloride",CC(=O)C1(CC[NH2+]CC1)C2=CC(=CC=C2)Cl.[Cl-],,,,,,
6375,41070,1-[4-(3-Chlorophenyl)piperidin-4-yl]ethanone,CC(=O)C1(CCNCC1)C2=CC(=CC=C2)Cl,,,,,,
6376,41071,1-(4-(3-Chlorophenyl)-4-piperidinyl)-1-butanone hydrochloride,CCCC(=O)C1(CC[NH2+]CC1)C2=CC(=CC=C2)Cl.[Cl-],,,,,,
6377,41072,1-[4-(3-Chlorophenyl)piperidin-4-yl]butan-1-one,CCCC(=O)C1(CCNCC1)C2=CC(=CC=C2)Cl,,,,,,
6378,41073,"Cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-, 1-ethynyl-2-methyl-2-pentenyl ester",CCC=C(C)C(C#C)OC(=O)C1C(C1(C)C)C=C(C)C,,,,,,
6379,41074,1-Methyl-2-(1-ethylpropyl)benzene,CCC(CC)C1=CC=CC=C1C,,,,,,
6380,41075,2-Chloro(bromo)-2-butene,CC=C(CBr)Cl,,,,,,
6381,41076,4-Pentylcyclohexanol,CCCCCC1CCC(CC1)O,,,,,,
6382,41077,"4,6,8-Trimethyl-1-nonene",CC(C)CC(C)CC(C)CC=C,,,,,,
6383,41078,3-Methyldec-3-en-2-one,CCCCCCC=C(C)C(=O)C,,,,,,
6384,41079,(1-Chloroethyl)dimethylbenzene,CC1=CC(=CC(=C1)CCCl)C,,,,,,
6385,41080,CID 41080,CC(=O)OCC(C(C=O)OC(=O)C)OC(=O)C.C1=CC(=CC=C1N=N)N(O)O,,,,,,
6386,41081,"(2,3-Diacetyloxy-4-oxobutyl) acetate",CC(=O)OCC(C(C=O)OC(=O)C)OC(=O)C,,,,,,
6387,41082,CID 41082,CC(=O)O[C@@H]1CO[C@H]([C@H]([C@@H]1OC(=O)C)OC(=O)C)OC(=O)C.C1=CC(=C(C=C1N(O)O)[N+](=O)[O-])N=N,,,,,,
6388,41083,"[(3R,4R,5S,6S)-4,5,6-triacetyloxyoxan-3-yl] acetate",CC(=O)O[C@@H]1CO[C@H]([C@H]([C@@H]1OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
6389,41084,CID 41084,CC(=O)OC1COC(C(C1OC(=O)C)OC(=O)C)OC(=O)C.C1=CC(=C(C=C1N(O)O)[N+](=O)[O-])N=N,,,,,,
6390,41085,"Lyxopyranose, tetraacetate",CC(=O)OC1COC(C(C1OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
6391,41086,"7,8,9,10-Tetrahydro-3-(1-methyl-4-phenylbutyl)-6,6,9-trimethyl-6H-dibenzo(b,d)pyran-1-ol",CC1CCC2=C(C1)C3=C(C=C(C=C3OC2(C)C)C(C)CCCC4=CC=CC=C4)O,,,,,,
6392,41087,CID 41087,C1C([C@@H](C(C1O)CC=CCCCC(=O)O)C=C[C@H](C2OC3=CC=CC=C3O2)O)O,,,,,,
6393,41088,1-(2-Butoxyethoxy)ethanol,CCCCOCCOC(C)O,,,,,,
6394,41089,4-((2-(4-Chlorophenoxy)-1-oxopropyl)amino)benzoic acid 2-(diethylamino)ethyl ester citrate,CC[NH+](CC)CCOC(=O)C1=CC=CC=C1NC(=O)C(C)OC2=CC=C(C=C2)Cl.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
6395,41090,2-(Diethylamino)ethyl 2-[2-(4-chlorophenoxy)propanoylamino]benzoate,CCN(CC)CCOC(=O)C1=CC=CC=C1NC(=O)C(C)OC2=CC=C(C=C2)Cl,,,,,,
6396,41091,Copper ethylenediaminetetraacetate,C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Cu+2],,,,,,
6397,41092,"2,3,4,5-Tetramethyl-2-cyclopentenone",CC1C(C(=O)C(=C1C)C)C,,,,,,
6398,41093,Hexadecyl cyclopropanecarboxylate,CCCCCCCCCCCCCCCCOC(=O)C1CC1,,,,,,
6399,41094,"3,5-Dimethylbenzoic acid 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC(=CC(=C1)C)C.[Cl-],,,,,,
6400,41095,"2-(Diethylamino)ethyl 3,5-dimethylbenzoate",CCN(CC)CCOC(=O)C1=CC(=CC(=C1)C)C,,,,,,
6401,41096,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, diheptanoate, dihydrochloride",CCCCCCC(=O)OCCN1CCN(CC1)CCOC(=O)CCCCCC.Cl.Cl,,,,,,
6402,41097,2-[4-(2-Heptanoyloxyethyl)piperazin-1-yl]ethyl heptanoate,CCCCCCC(=O)OCCN1CCN(CC1)CCOC(=O)CCCCCC,,,,,,
6403,41098,Isopropylamino ethanol hydrochloride,CC(C)[NH2+]CCO.[Cl-],,,,,,
6404,41099,"2-Acetyl-1,1-dimethyl-1-(2-hydroxydodecyl)hydrazinium hydroxide inner salt",CCCCCCCCCCC(C[N+](C)(C)NC(=O)C)[O-],,,,,,
6405,41100,Acetamido-(2-hydroxydodecyl)-dimethylazanium,CCCCCCCCCCC(C[N+](C)(C)NC(=O)C)O,,,,,,
6406,41101,Acetic acid;(2-amino-5-nitrophenyl)mercury,CC(=O)O.C1=CC(=C(C=C1[N+](=O)[O-])[Hg])N,,,,,,
6407,41102,(2-Amino-5-nitrophenyl)mercury,C1=CC(=C(C=C1[N+](=O)[O-])[Hg])N,,,,,,
6408,41103,IA 4 N-Oxide,CCN(CC)CCN1C2=C3C(=C(C=C2)CO)SC4=C(C3=[N+]1[O-])C=CC(=C4)Cl,,,,,,
6409,41104,"2-(5-chloro-10-methyl-15-oxido-8-thia-14-aza-15-azoniatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-14-yl)-N,N-diethylethanamine",CCN(CC)CCN1C2=C3C(=C(C=C2)C)SC4=C(C3=[N+]1[O-])C=CC(=C4)Cl,,,,,,
6410,41105,(+-)-alpha-(1-(Benzylamino)ethyl)benzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1)O)[NH2+]CC2=CC=CC=C2.[Cl-],,,,,,
6411,41106,Benzyl(beta-hydroxy-alpha-methylphenethyl)amine,CC(C(C1=CC=CC=C1)O)NCC2=CC=CC=C2,,,,,,
6412,41107,alpha-(1-((p-(Dimethylamino)benzyl)amino)ethyl)benzyl alcohol dihydrochloride,CC(C(C1=CC=CC=C1)O)[NH2+]CC2=CC=C(C=C2)[NH+](C)C.[Cl-].[Cl-],,,,,,
6413,41108,2-[[4-(Dimethylamino)phenyl]methylamino]-1-phenylpropan-1-ol,CC(C(C1=CC=CC=C1)O)NCC2=CC=C(C=C2)N(C)C,,,,,,
6414,41109,Etofylline clofibrate,CC(C)(C(=O)OCCN1C=NC2=C1C(=O)N(C(=O)N2C)C)OC3=CC=C(C=C3)Cl,,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)', 'Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)']",,,
6415,41110,"1-(7-Theophyllinyl)-2,3-propylidene di(p-chlorophenoxyacetate)",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(COC(=O)COC3=CC=C(C=C3)Cl)OC(=O)COC4=CC=C(C=C4)Cl,,,,,,
6416,41111,16-Iodohexadecanoic acid,C(CCCCCCCC(=O)O)CCCCCCCI,,,,,,
6417,41112,Dibutoxymethanol,CCCCOC(O)OCCCC,,,,,,
6418,41113,1-(4-Isopropylphenyl)propan-1-ol,CCC(C1=CC=C(C=C1)C(C)C)O,,,,,,
6419,41114,Nicardipine hydrochloride,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC.Cl,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
6420,41115,"Nicotinic acid, 6-methyl-2-(3'-trifluoromethylanilino)-",CC1=NC(=C(C=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,,,,,,
6421,41116,"Indole, 5-acetyl-3-((dimethylamino)methyl)-",CC(=O)C1=CC2=C(C=C1)NC=C2CN(C)C,,,,,,
6422,41117,"1,2-Dichlorodibenzo-p-dioxin",C1=CC=C2C(=C1)OC3=C(O2)C(=C(C=C3)Cl)Cl,,,,,,
6423,41118,"1,4-Dichlorodibenzo-p-dioxin",C1=CC=C2C(=C1)OC3=C(C=CC(=C3O2)Cl)Cl,,,,,,
6424,41119,"6H-Dibenzo(b,d)pyran-1-ol, 7,8,9,10-tetrahydro-3-(5-(p-fluorophenyl)-1-methylpentyl)-6,6,9-trimethyl-",CC1CCC2=C(C1)C3=C(C=C(C=C3OC2(C)C)C(C)CCCCC4=CC=C(C=C4)F)O,,,,,,
6425,41120,"6H-Dibenzo(b,d)pyran-1-ol, 7,8,9,10-tetrahydro-3-(4-(p-fluorophenyl)-1,2-dimethylbutyl)-6,6,9-trimethyl-",CC1CCC2=C(C1)C3=C(C=C(C=C3OC2(C)C)C(C)C(C)CCC4=CC=C(C=C4)F)O,,,,,,
6426,41121,"6H-Dibenzo(b,d)pyran-1-ol, 7,8,9,10-tetrahydro-3-(5-(p-fluorophenyl)-1,2-dimethylpentyl)-6,6,9-trimethyl-",CC1CCC2=C(C1)C3=C(C=C(C=C3OC2(C)C)C(C)C(C)CCCC4=CC=C(C=C4)F)O,,,,,,
6427,41122,"Ethanone, 1-[4-(1-hydroxy-1-methylethyl)phenyl]-",CC(=O)C1=CC=C(C=C1)C(C)(C)O,,,,,,
6428,41123,"2-Ethyl-1,1-dimethylcyclopentane",CCC1CCCC1(C)C,,,,,,
6429,41124,2-Methyl-3-isopropylcyclopentanone,CC1C(CCC1=O)C(C)C,,,,,,
6430,41125,Diphenylpropoxyacetic acid 1-methyl-4-piperidyl ester hydrochloride,CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CC[NH+](CC3)C.[Cl-],,,,,,
6431,41126,"2,3,5-Trimethyl-2-cyclopentenone",CC1CC(=C(C1=O)C)C,,,,,,
6432,41127,"2(3H)-Benzoxazolone, 6-chloro-3-(1-piperidinylmethyl)-",C1CCN(CC1)CN2C3=C(C=C(C=C3)Cl)OC2=O,,,,,,
6433,41128,1-Methyl-3-((2-methylpropyl)thio)benzene,CC1=CC(=CC=C1)SCC(C)C,,,,,,
6434,41129,1-Methyl-4-((2-methylpropyl)thio)benzene,CC1=CC=C(C=C1)SCC(C)C,,,,,,
6435,41130,1-(Butylthio)-3-methylbenzene,CCCCSC1=CC=CC(=C1)C,,,,,,
6436,41131,"2,4,8-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C(=CC(=C3)Cl)Cl,,,,,,
6437,41132,2-Aminoacetic acid;azepan-2-one,C1CCC(=O)NCC1.C(C(=O)O)N,,,,,,
6438,41133,"2(1H)-Naphthalenone, octahydro-4a-methyl-7-(1-methylethyl)-. (4aalpha,7beta,8abeta)-",CC(C)C1CCC2(CCC(=O)CC2C1)C,,,,,,
6439,41134,CID 41134,CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
6440,41135,1-(Methylsulfonyl)-5-(methylthio)naphthalene,CSC1=CC=CC2=C1C=CC=C2S(=O)(=O)C,,,,,,
6441,41136,Unii-HJ1pbz6dve,C1=CC(=C(C=C1CC2=CC(=C(C=C2)Cl)[N+](=O)[O-])[N+](=O)[O-])Cl,,,,,,
6442,41137,"Benzaldehyde, 4-(2,3,5,7-tetrahydro-5,7-dioxo-6H-1,4-dithiino(2,3-c)pyrrol-6-yl)-",C1CSC2=C(S1)C(=O)N(C2=O)C3=CC=C(C=C3)C=O,,,,,,
6443,41138,"5H-1,4-DITHIINO(2,3-c)PYRROLE-5,7(6H)-DIONE, 2,3-DIHYDRO-6-(2-THIAZOLYL)-",C1CSC2=C(S1)C(=O)N(C2=O)C3=NC=CS3,,,,,,
6444,41139,"Benzoic acid, 4-(2,3,5,7-tetrahydro-5,7-dioxo-6H-1,4-dithiino(2,3-c)pyrrol-6-yl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)SCCS3.[Cl-],,,,,,
6445,41140,"2-(Diethylamino)ethyl 4-(5,7-dioxo-2,3-dihydro-[1,4]dithiino[2,3-c]pyrrol-6-yl)benzoate",CCN(CC)CCOC(=O)C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)SCCS3,,,,,,
6446,41141,"5H-1,4-Dithiino(2,3-c)pyrrole-5,7(6H)-dione, 2,3-dihydro-6-(4-(2-(diethylamino)ethoxy)phenyl)-, monohydrochloride",CC[NH+](CC)CCOC1=CC=C(C=C1)N2C(=O)C3=C(C2=O)SCCS3.[Cl-],,,,,,
6447,41142,"6-[4-[2-(Diethylamino)ethoxy]phenyl]-2,3-dihydro-[1,4]dithiino[2,3-c]pyrrole-5,7-dione",CCN(CC)CCOC1=CC=C(C=C1)N2C(=O)C3=C(C2=O)SCCS3,,,,,,
6448,41143,5-Methyl-2-heptanol,CCC(C)CCC(C)O,,,,,,
6449,41144,"2,4,6-Trimethylphenyl 2,2-dimethylpropanoate",CC1=CC(=C(C(=C1)C)OC(=O)C(C)(C)C)C,,,,,,
6450,41145,CID 41145,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3=CC=CC=C3OC)S,,,,,,
6451,41146,CID 41146,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3CCCCC3)S,,,,,,
6452,41147,CID 41147,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3=CC=CC=C3)S,,,,,,
6453,41148,CID 41148,CC1=CC=CC=C1N=C(NNC(=O)CC2=C(NC3=CC=CC=C32)C)S,,,,,,
6454,41149,CID 41149,CC1=CC(=CC=C1)N=C(NNC(=O)CC2=C(NC3=CC=CC=C32)C)S,,,,,,
6455,41150,CID 41150,CC1=CC=C(C=C1)N=C(NNC(=O)CC2=C(NC3=CC=CC=C32)C)S,,,,,,
6456,41151,CID 41151,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3=CC=C(C=C3)Cl)S,,,,,,
6457,41152,CID 41152,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3=CC=C(C=C3)Br)S,,,,,,
6458,41153,CID 41153,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3=CC=C(C=C3)I)S,,,,,,
6459,41154,CID 41154,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NCC=C)S,,,,,,
6460,41155,CID 41155,CCCCN=C(NNC(=O)CC1=C(NC2=CC=CC=C21)C)S,,,,,,
6461,41156,2-(5-Butylnonan-5-yloxy)ethanol,CCCCC(CCCC)(CCCC)OCCO,,,,,,
6462,41157,"diethyl-methyl-[2-[[2-(4-phenylsulfanylphenyl)-1H-1,5-benzodiazepin-4-yl]sulfanyl]ethyl]azanium;iodide",CC[N+](C)(CC)CCSC1=NC2=CC=CC=C2NC(=C1)C3=CC=C(C=C3)SC4=CC=CC=C4.[I-],,,,,,
6463,41158,"diethyl-methyl-[2-[[2-(4-phenylsulfanylphenyl)-1H-1,5-benzodiazepin-4-yl]sulfanyl]ethyl]azanium",CC[N+](C)(CC)CCSC1=NC2=CC=CC=C2NC(=C1)C3=CC=C(C=C3)SC4=CC=CC=C4,,,,,,
6464,41159,CID 41159,CC1=C(C2=CC=CC=C2N1)CC(=O)NNC(=NC3=CC=C(C=C3)OC)S,,,,,,
6465,41160,1-Methoxyindole,CON1C=CC2=CC=CC=C21,,,,,,
6466,41161,"Nonyl 3-oxo-1,3-dihydro-2-benzofuran-5-carboxylate",CCCCCCCCCOC(=O)C1=CC2=C(COC2=O)C=C1,,,,,,
6467,41162,3-(piperidin-2-yl)-1H-indole,C1CCNC(C1)C2=CNC3=CC=CC=C32,,,,,,
6468,41163,"Indole, 3-methyl-2-(piperidinyl)-",CC1=C(NC2=CC=CC=C12)N3CCCCC3,,,,,,
6469,41164,Hexahydro-1H-azepine-1-acetonitrile,C1CCCN(CC1)CC#N,,,,,,
6470,41165,"Anthracene, nitro-",C1=CC=C2C=C3C(=CC2=C1)C=CC=C3[N+](=O)[O-],,,,,,
6471,41166,"Cyano-(2-oxo-2,3-dihydro-1H-indol-3-yl)-acetic acid",C1=CC=C2C(=C1)C(C(=O)N2)C(C#N)C(=O)O,,,,,,
6472,41167,N-Allyl-N-nitroso-3-butenylamine,C=CCCN(CC=C)N=O,,,,,,
6473,41168,2-{[(2-Chloroethyl)(nitroso)carbamoyl]amino}-2-deoxyhexopyranose,C(CCl)N(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O,,,,,,
6474,41169,Nornuciferine,COC1=C(C2=C3[C@H](CC4=CC=CC=C42)NCCC3=C1)OC,,,,,,
6475,41170,5-Hexen-2-OL,CC(CCC=C)O,,,,,,
6476,41171,Tetrahydro-5-methylfuran-2-methanol,CC1CCC(O1)CO,,,,,,
6477,41172,2-Methyl-1-propylnaphthalene,CCCC1=C(C=CC2=CC=CC=C21)C,,,,,,
6478,41173,"Bicyclo(2.2.2)octane-1,4-diol, monoacetate",CC(=O)OC12CCC(CC1)(CC2)O,,,,,,
6479,41174,2-Phenyl-5-benzoxazoleethylamine monohydrochloride,C1=CC=C(C=C1)C2=NC3=C(O2)C=CC(=C3)CC[NH3+].[Cl-],,,,,,
6480,41175,2-(2-Phenylbenzo[d]oxazol-5-yl)ethan-1-amine,C1=CC=C(C=C1)C2=NC3=C(O2)C=CC(=C3)CCN,,,,,,
6481,41176,2-Phenyl-beta-methyl-5-benzoxazoleethylamine hydrogen succinate,CC(C[NH3+])C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3.C(CC(=O)[O-])C(=O)O,,,,,,
6482,41177,"2-(2-Phenyl-1,3-benzoxazol-5-yl)propan-1-amine",CC(CN)C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3,,,,,,
6483,41178,2-(4-Chlorophenyl)-5-(1-(5-tetrazolyl)ethyl)benzoxazole,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C4=NNN=N4,,,,,,
6484,41179,alpha-Methyl-2-(o-tolyl)-5-benzoxazoleacetic acid,CC1=CC=CC=C1C2=NC3=C(O2)C=CC(=C3)C(C)C(=O)O,,,,,,
6485,41180,2-(4-tert-Butylphenyl)-alpha-methyl-5-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)C(C)(C)C)C(=O)O,,,,,,
6486,41181,1-(1-Ethylpropyl)-2-propylbenzene,CCCC1=CC=CC=C1C(CC)CC,,,,,,
6487,41182,1-(Dichloromethyl)-4-ethylbenzene,CCC1=CC=C(C=C1)C(Cl)Cl,,,,,,
6488,41183,"1-(2,3,6-Trimethylphenyl)-3-buten-2-one",CC1=C(C(=C(C=C1)C)CC(=O)C=C)C,,,,,,
6489,41184,1-(2-(Diethylamino)ethyl)azulenecarboxamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=C2C=CC=CC=C2C=C1.[Cl-],,,,,,
6490,41185,N-[2-(Diethylamino)ethyl]-1-azulenecarboxamide,CCN(CC)CCNC(=O)C1=C2C=CC=CC=C2C=C1,,,,,,
6491,41186,1-(2-(Diethylamino)ethyl)-3-nitroazulenecarboxamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=CC(=C2C1=CC=CC=C2)[N+](=O)[O-].[Cl-],,,,,,
6492,41187,N-[2-(Diethylamino)ethyl]-3-nitro-1-azulenecarboxamide,CCN(CC)CCNC(=O)C1=CC(=C2C1=CC=CC=C2)[N+](=O)[O-],,,,,,
6493,41188,1-(2-(Diethylamino)ethyl)-3-acetamidoazulenecarboxamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=CC(=C2C1=CC=CC=C2)NC(=O)C.[Cl-],,,,,,
6494,41189,3-(Acetylamino)-N-[2-(diethylamino)ethyl]-1-azulenecarboxamide,CCN(CC)CCNC(=O)C1=CC(=C2C1=CC=CC=C2)NC(=O)C,,,,,,
6495,41190,"((Bis(2,2-dimethyl-1-aziridinyl)phosphinyl)oxy)carbamic acid ethyl ester",CCOC(=O)NOP(=O)(N1CC1(C)C)N2CC2(C)C,,,,,,
6496,41191,"Carbamic acid, acetoxy(bis(2,2-dimethyl-1-aziridinyl)phosphinyl)-, ethyl ester",CCOC(=O)N(OC(=O)C)P(=O)(N1CC1(C)C)N2CC2(C)C,,,,,,
6497,41192,"Carbamic acid, ((bis(1-aziridinyl)phosphinyl)oxy)-, ethyl ester",CCOC(=O)NOP(=O)(N1CC1)N2CC2,,,,,,
6498,41193,"Carbamic acid, acetoxy(bis(1-aziridinyl)phosphinyl)-, ethyl ester",CCOC(=O)N(OC(=O)C)P(=O)(N1CC1)N2CC2,,,,,,
6499,41194,Carboxyfenitrothion,COP(=S)(OC)OC1=CC(=C(C=C1)[N+](=O)[O-])C(=O)O,,,,,,
6500,41195,"Benzoic acid, 5-((dimethoxyphosphinyl)oxy)-2-nitro-",COP(=O)(OC)OC1=CC(=C(C=C1)[N+](=O)[O-])C(=O)O,,,,,,
6501,41196,"BENZOIC ACID, o-CHLORO-, 2-(p-CHLOROPHENYL)HYDRAZIDE",C1=CC=C(C(=C1)C(=O)NNC2=CC=C(C=C2)Cl)Cl,,,,,,
6502,41197,"5-tert-Butyl-1,3-benzodioxol-2-one",CC(C)(C)C1=CC2=C(C=C1)OC(=O)O2,,,,,,
6503,41198,"N,N-Diethyl-2,4-dimethylbenzamide",CCN(CC)C(=O)C1=C(C=C(C=C1)C)C,,,,,,
6504,41199,1-Methyl-2-(2-methylcyclohexyl)cyclohexane,CC1CCCCC1C2CCCCC2C,,,,,,
6505,41200,"3,3'-Dimethyl-1,1'-bi(cyclohexane)",CC1CCCC(C1)C2CCCC(C2)C,,,,,,
6506,41201,"1,1'-Bicyclohexyl, 4,4'-dimethyl-",CC1CCC(CC1)C2CCC(CC2)C,,,,,,
6507,41202,"4-[2-(Dimethylamino)ethyl]-7-nitrobenzo[de]isoquinoline-1,3-dione",CN(C)CCC1=C2C3=C(C=CC(=C3C=C1)[N+](=O)[O-])C(=O)NC2=O,,,,,,
6508,41203,"1H-Benz(de)isoquinoline-1,3(2H)-dione, 2-(2-(diethylamino)ethyl)-5-nitro-",CCN(CC)CCC1=C2C3=C(C=CC(=C3C=C1)[N+](=O)[O-])C(=O)NC2=O,,,,,,
6509,41204,CID 41204,C1CCN(CC1)CCC2=C3C4=C(C=CC(=C4C=C2)[N+](=O)[O-])C(=O)NC3=O,,,,,,
6510,41205,"7-Nitro-4-(2-pyrrolidin-1-ylethyl)benzo[de]isoquinoline-1,3-dione",C1CCN(C1)CCC2=C3C4=C(C=CC(=C4C=C2)[N+](=O)[O-])C(=O)NC3=O,,,,,,
6511,41206,"3,3',5,5'-Tetramethylbenzidine",CC1=CC(=CC(=C1N)C)C2=CC(=C(C(=C2)C)N)C,,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,"['Enteric bacterial and hepatic azoreductase enzymes are capable of reducing azo dyes to yield the constituent aromatic amines. Azo dyes based on benzidine and benzidine congeners have received particular attention because of their widespread use and the known carcinogenicity of benzidine to humans. Azo dyes based on beta-diketone coupling components exist preferentially as the tautomeric hydrazones. A series of hydrazone dyes based on benzidine and benzidine congeners was prepared and characterized by NMR and UV-visible spectroscopy. These dyes were tested for mutagenicity using a modified Ames assay and, unlike the true azo dyes, showed no significant mutagenic activity. The hydrazone dyes were resistant to enzymatic reduction by FMN-supplemented hamster-liver post-mitochondrial supernatant (S-9); under identical conditions, azo dyes such as trypan blue were rapidly reduced.', ""Benzidine and several derivatives are activated to mutagenic species in an H2O2-dependent Ames test system. Optical and electron paramagnetic resonance (EPR) spectroscopy are employed in studies of the H2O2-dependent oxidation of benzidine and 3,5,3',5'-tetramethylbenzidine (TMB) catalyzed by intact bacteria, and provide direct evidence for peroxidase activity in Salmonella typhimurium. The acetylase-proficient Ames tester strain TA98 and its acetylase-deficient derivative TA98/1,8-DNP6 are equally responsive to H2O2-dependent mutagenicity; enzymatic acetylation appears not to be involved in activation of benzidine, in this system. The H2O2-dependent mutagenicity of benzidine and oxidation of TMB are observed when the assays are carried out in acetate buffer (pH 5.5), but not in 2-[N-morpholino]ethane sulfonic acid (MES) buffer, at the same pH. This difference is interpreted in terms of the effects of these buffers on the intracellular pH of the bacteria. The H2O2-dependent mutagenicity of several benzidine congeners is also described."", 'Dichlorobenzidine can be peroxidatively activated in Salmonella typhimurium Ames tester strains. Mutagenicity is observed when an S. typhimurium strain which is sensitive to frame-shift mutagens is incubated with dichlorobenzidine and hydrogen peroxide. In this paper, we show that the bacterial enzyme, hydroperoxidase I, is responsible for much of this activation. We constructed isogenic tester strains which lack hydroperoxidase I or II, due to Tn10 insertions in the structural genes encoding these proteins. Hydrogen peroxide-dependent mutagenicity of dichlorobenzidine was measured in each strain. A tester strain lacking hydroperoxidase I activity was much less sensitive than was the parent strain. When hydroperoxidase I activity was restored in this strain, via a plasmid-borne copy of the gene encoding the Escherichia coli protein, sensitivity to peroxide-dependent dichlorobenzidine mutagenicity was enhanced.', 'An accumulation of insoluble, finely granular material has been observed under the pigmented surface of Xenopus eggs by a specialized ""dry fracture"" technique and scanning electron microscopy. Cortical granules and pigment granules can be recognized with the techniques and can be seen to be embedded in the material. Thin sections show that the region also contains mitochondria and membranous vesicles or reticula. Yolk platelets are largely excluded from the heaviest accumulations of the material. The substance is most dense just under the cortex and grades off gradually into the more diffuse, yolk-containing network of the endoplasm. The accumulation of material is much thicker in the animal hemisphere of the egg than in the vegetal hemisphere, and the pigment embedded in it defines the pigmented area of the animal hemisphere. In the pigmented area the material excludes yolk for a thickness of 3-7+ microns from the surface. In the vegetal hemisphere there is no such accumulation and yolk platelets can be found almost touching the plasmalemma. Cortical contractions have been experimentally induced in eggs. Their relative strength correlates with the relative thickness of the finely granular, subcortical material. During contraction the material accumulates to much greater thicknesses, excluding yolk from thicknesses of 15-30+ microns from the surface. The contracting entity is, or is in, the finely granular material. Injection of cytochalasins into the eggs inhibits cleavage furrow operation but does not inhibit the induced cortical contractions. The thus do not seem to be dependent on actin microfilamentogenesis as is the operation of the contractile ring of the cleavage furrow. The differential sensitivity to cytochalasins of the contractile ring and the system responding in the induced cortical contractions, suggests a two-component system for cortical contractions in the egg. A model is presented which accommodates the available data.', ""For more Metabolism/Metabolites (Complete) data for 3,3',5,5'-TETRAMETHYLBENZIDINE (6 total), please visit the HSDB record page.""]",
6512,41207,"1H-Indene, octahydro-2,2,4,4,7,7-hexamethyl-, trans-",CC1(CCC(C2C1CC(C2)(C)C)(C)C)C,,,,,,
6513,41208,10-Methylicosane,CCCCCCCCCCC(C)CCCCCCCCC,,,,,,
6514,41209,"2,6,10,15-Tetramethylheptadecane",CCC(C)CCCCC(C)CCCC(C)CCCC(C)C,,,,,,
6515,41210,CID 41210,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)(O)[O-])O)N.[Na+],,,,,,
6516,41211,3'-Adenylic acid,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)(O)O)O)N,,,,,,
6517,41212,(2-(Pentyloxy)ethyl)cyclohexane,CCCCCOCCC1CCCCC1,,,,,,
6518,41213,Disodium carboxymethylphosphonate,C(C(=O)[O-])P(=O)(O)[O-].[Na+].[Na+],,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']",,,
6519,41214,Meglitinide,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)C(=O)O,,,['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)'],,,
6520,41215,N-Salicyloyl-2-methyl-5-methoxy-3-indolylacetic acid,CC1=C(C2=C(N1C(=O)C3=CC=CC=C3O)C=CC(=C2)OC)CC(=O)O,,,,,,
6521,41216,CID 41216,C1=CC=C(C=C1)C[C@@H](C(=O)[O-])N=C(S)[S-].[Na+].[Na+],,,,,,
6522,41217,CID 41217,C1=CC=C(C=C1)C[C@@H](C(=O)O)N=C(S)S,,,,,,
6523,41218,"Acetanilide, 2-acetamido-2'-benzoyl-4'-chloro-N-methyl-",CC(=O)NCC(=O)N(C)C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
6524,41219,"BENZ(a)ANTHRACENE, 8-PROPYL",CCCC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
6525,41220,"P-(Tert-butyl)phenoxymethanol, acetate",CC(=O)OCOC1=CC=C(C=C1)C(C)(C)C,,,,,,
6526,41221,"6-Methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=C(C1)C=CC(=C2)OC,,,,,,
6527,41222,CID 41222,C1=CC=C(C=C1)CSC(=N)S,,,,,,
6528,41223,N-Ethyl-N-(4-hydroxybutyl)nitrosamine,CCN(CCCCO)N=O,,,,,,
6529,41224,N-Ethyl-N-(3-carboxypropyl)nitrosamine,CCN(CCCC(=O)O)N=O,,,,,,
6530,41225,6-Benzoylbenzoxazol-2(3H)-one,C1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)NC(=O)O3,,,,,,
6531,41226,"2(3H)-Benzoxazolone, 6-(2-thienylcarbonyl)-",C1=CSC(=C1)C(=O)C2=CC3=C(C=C2)NC(=O)O3,,,,,,
6532,41227,"2(3H)-Benzoxazolone, 6-(1-hydroxyethyl)-",CC(C1=CC2=C(C=C1)NC(=O)O2)O,,,,,,
6533,41228,6-(1-Hydroxypropyl)-2(3H)-benzoxazolone,CCC(C1=CC2=C(C=C1)NC(=O)O2)O,,,,,,
6534,41229,6-(Hydroxyphenylmethyl)-2(3H)-benzoxazolone,C1=CC=C(C=C1)C(C2=CC3=C(C=C2)NC(=O)O3)O,,,,,,
6535,41230,"2(3H)-Benzoxazolone, 6-(1-hydroxy-2-phenylethyl)-",C1=CC=C(C=C1)CC(C2=CC3=C(C=C2)NC(=O)O3)O,,,,,,
6536,41231,"2(3H)-Benzoxazolone, 6-acetyl-3-methyl-",CC(=O)C1=CC2=C(C=C1)N(C(=O)O2)C,,,,,,
6537,41232,"2-Furancarbamic acid, ethyl ester",CCOC(=O)NC1=CC=CO1,,,,,,
6538,41233,"3-(2-methyl-1,3-dithiolan-2-yl)-1H-indole",CC1(SCCS1)C2=CNC3=CC=CC=C32,,,,,,
6539,41234,"Phenol, 4-(2,2,3,3-tetramethylbutyl)-",CC(C)(C)C(C)(C)CC1=CC=C(C=C1)O,,,,,,
6540,41235,"Cyclopentane, 1,1'-(3-(2-cyclopentylethylidene)-1,5-pentanediyl)bis-",C1CCC(C1)CCC(=CCC2CCCC2)CCC3CCCC3,,,,,,
6541,41236,"Cyclohexane, 1-(cyclohexylmethyl)-2-ethyl-, cis-",CCC1CCCCC1CC2CCCCC2,,,,,,
6542,41237,Laxitex,CC1=C2C(=CC=C1)C(C(=O)N2)(C3=CC=C(C=C3)OS(=O)(=O)[O-])C4=CC=C(C=C4)OS(=O)(=O)[O-].[Na+].[Na+],,,,,,
6543,41238,Sulisatin,CC1=C2C(=CC=C1)C(C(=O)N2)(C3=CC=C(C=C3)OS(=O)(=O)O)C4=CC=C(C=C4)OS(=O)(=O)O,,,,,,
6544,41239,"Benzophenone, 4'-chloro-2-(2-imidazol-2-YL)-",C1=CC=C(C(=C1)C2=NC=CN2)C(=O)C3=CC=C(C=C3)Cl,,,,,,
6545,41240,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(2-(diisopropylamino)ethyl)-",CC(C)N(CCN1C(=O)CCCC2=CC=CC=C21)C(C)C,,,,,,
6546,41241,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(2-imidazolin-2-YL)methyl-",C1CC2=CC=CC=C2N(C(=O)C1)CC3=NCCN3,,,,,,
6547,41242,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(2-(1-pyrrolidinyl)ethyl)-",C1CCN(C1)CCN2C(=O)CCCC3=CC=CC=C32,,,,,,
6548,41243,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(3-(diisopropylamino)propyl)-",CC(C)N(CCCN1C(=O)CCCC2=CC=CC=C21)C(C)C,,,,,,
6549,41244,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(2-(dimethylamino)ethyl)-",CN(C)CCN1C(=O)CCCC2=CC=CC=C21,,,,,,
6550,41245,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(2-(diisopropylamino)ethyl)-7-methoxy-",CC(C)N(CCN1C(=O)CCCC2=C1C=CC(=C2)OC)C(C)C,,,,,,
6551,41246,"1H-1-Benzazepin-2-one, 2,3,4,5-tetrahydro-1-(2-(diisopropylamino)ethyl)-8-methoxy-",CC(C)N(CCN1C(=O)CCCC2=C1C=C(C=C2)OC)C(C)C,,,,,,
6552,41247,"3-(p-Chlorophenyl)-1-(2-imidazolin-2-yl)methyl-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one",C1CC2=CC=CC=C2N(C(=O)C1C3=CC=C(C=C3)Cl)CC4=NCCN4,,,,,,
6553,41248,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-1-(2-(1-pyrrolidinyl)ethyl)-",C1CCN(C2=CC=CC=C2C1)CCN3CCCC3,,,,,,
6554,41249,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-1-(2-(diisopropylamino)ethyl)-",CC(C)N(CCN1CCCCC2=CC=CC=C21)C(C)C,,,,,,
6555,41250,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-1-(3-(diisopropylamino)propyl)-",CC(C)N(CCCN1CCCCC2=CC=CC=C21)C(C)C,,,,,,
6556,41251,"2-[(5-Chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydroisochromene-7-carbonyl)amino]propanoic acid",CC1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(C)C(=O)O)Cl,,,,,,
6557,41252,CID 41252,CC(C(=O)O)N=C(C(=NC(C)C(=O)O)S)S,,,,,,
6558,41253,2-Bromo-2'-iodo-N-methyldiethylamine hydrochloride,C[NH+](CCBr)CCI.[Cl-],,,,,,
6559,41254,2-bromo-N-(2-iodoethyl)-N-methylethanamine,CN(CCBr)CCI,,,,,,
6560,41255,2-Fluoro-2'-iodo-N-methyldiethylamine hydrochloride,C[NH+](CCF)CCI.[Cl-],,,,,,
6561,41256,2-fluoro-N-(2-iodoethyl)-N-methylethanamine,CN(CCF)CCI,,,,,,
6562,41257,"9H-Fluorene, 2-methoxy-7-nitro-",COC1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)[N+](=O)[O-],,,,,,
6563,41258,"2,3,4a,5,8,8a-Hexahydro-1,4-naphthoquinone",C1CC(=O)C2CC=CCC2C1=O,,,,,,
6564,41259,"Plumbane, butyltrimethyl-",CCCC[Pb](C)(C)C,,,,,,
6565,41260,"Naphthalene, decahydro-1,4-dimethyl-5-octyl-",CCCCCCCCC1CCCC2C1C(CCC2C)C,,,,,,
6566,41261,"Silanamine, N-((4-methoxyphenyl)methyl)-1,1,1-trimethyl-",COC1=CC=C(C=C1)CN[Si](C)(C)C,,,,,,
6567,41262,4-Isopropyldicyclohexylmethane,CC(C)C1CCC(CC1)CC2CCCCC2,,,,,,
6568,41263,Ethyl 4-cyclobutyl-4-oxo-2-butanoate,CCOC(=O)C#CC(=O)C1CCC1,,,,,,
6569,41264,"5H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 6,7,9,10-tetrahydro-12,13-dimethoxy-7-methyl-6-oxo-, bromide",CC1C(=O)NC2=CC=CC=C2C3=[N+]1CCC4=CC(=C(C=C43)OC)OC.[Br-],,,,,,
6570,41265,"12,13-Dimethoxy-7-methyl-5,7,9,10-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepin-8-ium-6-one",CC1C(=O)NC2=CC=CC=C2C3=[N+]1CCC4=CC(=C(C=C43)OC)OC,,,,,,
6571,41266,"5H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 6,7,9,10-tetrahydro-12,13-dimethoxy-7-ethyl-6-oxo-, bromide",CCC1C(=O)NC2=CC=CC=C2C3=[N+]1CCC4=CC(=C(C=C43)OC)OC.[Br-],,,,,,
6572,41267,"7-Ethyl-12,13-dimethoxy-5,7,9,10-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepin-8-ium-6-one",CCC1C(=O)NC2=CC=CC=C2C3=[N+]1CCC4=CC(=C(C=C43)OC)OC,,,,,,
6573,41268,"Isoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one, 5,9,10,14b-tetrahydro-12,13-dimethoxy-7-ethyl-",CCC1C(=O)NC2=CC=CC=C2C3N1CCC4=CC(=C(C=C34)OC)OC,,,,,,
6574,41269,"5H-Isoquino(2,1-d)(1,4)benzodiazepin-6-one, 7,9,10,14b-tetrahydro-12,13-dimethoxy-7-phenyl-",COC1=C(C=C2C3C4=CC=CC=C4NC(=O)C(N3CCC2=C1)C5=CC=CC=C5)OC,,,,,,
6575,41270,"1,4-Dioxacyclohexadecane-5,16-dione",C1CCCCCC(=O)OCCOC(=O)CCCC1,,,,,,
6576,41271,"4-Methyl-1,2,3,4-tetrahydrobenzofuro(3,2-c)pyridine hydrochloride",CC1CCCC2=C1OC3=C2C=[NH+]C=C3.[Cl-],,,,,,
6577,41272,"6-Methyl-6,7,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridine",CC1CCCC2=C1OC3=C2C=NC=C3,,,,,,
6578,41273,"Benzofuro(3,2-c)pyridine, 1,2,3,4-tetrahydro-2-(3-(diethylamino)propionyl)-, hydrochloride",CC[NH+](CC)CCC(=O)C1CCC2=C(C1)C3=C(O2)C=CN=C3.[Cl-],,,,,,
6579,41274,"3-(Diethylamino)-1-(6,7,8,9-tetrahydro-[1]benzofuro[3,2-c]pyridin-8-yl)propan-1-one",CCN(CC)CCC(=O)C1CCC2=C(C1)C3=C(O2)C=CN=C3,,,,,,
6580,41275,"Butyrophenone, 4'-fluoro-4-(1,2,3,4-tetrahydrobenzofuro(3,2-c)pyridin-2-yl)-, hydrochloride",C1C[NH+](CC2=C1OC3=CC=CC=C23)CCCC(=O)C4=CC=C(C=C4)F.[Cl-],,,,,,
6581,41276,"4-(3,4-dihydro-1H-[1]benzofuro[3,2-c]pyridin-2-yl)-1-(4-fluorophenyl)butan-1-one",C1CN(CC2=C1OC3=CC=CC=C23)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
6582,41277,"Butyrophenone, 4'-fluoro-4-(4-methyl-1,2,3,4-tetrahydrobenzofuro(3,2-c)pyridin-2-yl)-, hydrochloride",CC1C[NH+](CC2=C1OC3=CC=CC=C23)CCCC(=O)C4=CC=C(C=C4)F.[Cl-],,,,,,
6583,41278,"1-(4-fluorophenyl)-4-(4-methyl-3,4-dihydro-1H-[1]benzofuro[3,2-c]pyridin-2-yl)butan-1-one",CC1CN(CC2=C1OC3=CC=CC=C23)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
6584,41279,"Benzamide, 4-amino-N-(2-(4-phenyl-1-piperazinyl)ethyl)-",C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)N)C3=CC=CC=C3,,,,,,
6585,41280,4-Amino-N-(1-methyl-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl)benzamide,CC(CN1CCN(CC1)C2=CC=CC=N2)NC(=O)C3=CC=C(C=C3)N,,,,,,
6586,41281,o-Nitrocinnamonitrile,C1=CC=C(C(=C1)C=CC#N)[N+](=O)[O-],,,,,,
6587,41282,"2,6,10-Trimethylhexadecane",CCCCCCC(C)CCCC(C)CCCC(C)C,,,,,,
6588,41283,"1,4-Dimethyl-5-octylnaphthalene",CCCCCCCCC1=C2C(=CC=C(C2=CC=C1)C)C,,,,,,
6589,41284,2-Chloro-1-(4-ethylphenyl)-2-methyl-1-propanone,CCC1=CC=C(C=C1)C(=O)C(C)(C)Cl,,,,,,
6590,41285,cis-3-Methyl-4-octanolide,CCCC[C@@H]1[C@@H](CC(=O)O1)C,,,,,,
6591,41286,(2-Hydroxyethyl)trimethylammonium bromide benzilate,C[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
6592,41287,Metacine,C[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
6593,41288,Dimethylethyl(2-hydroxyethyl)ammonium benzilate bromide,CC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
6594,41289,Butyldimethyl(2-hydroxyethyl)ammonium bromide benzilate,CCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
6595,41290,"2-(Hydroxydiphenylacetyloxy)-N-butyl-N,N-dimethylethanaminium",CCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
6596,41291,Dimethylhexyl(2-hydroxyethyl)ammonium bromide benzilate,CCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
6597,41292,"Hexyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]-dimethylazanium",CCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
6598,41293,Decyl-dimethyl(2-hydroxyethyl)ammonium bromide benzilate,CCCCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
6599,41294,"Decyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]-dimethylazanium",CCCCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
6600,41295,CID 41295,CCCC[NH+](C)CC(=O)C1=CC2=C(CCC2)C=C1.C(=CC(=O)[O-])C(=O)O,,,,,,
6601,41296,"2-[butyl(methyl)amino]-1-(2,3-dihydro-1H-inden-5-yl)ethanone",CCCCN(C)CC(=O)C1=CC2=C(CCC2)C=C1,,,,,,
6602,41297,CID 41297,C1CCC[NH+](CC1)CC(=O)C2=CC3=C(CCC3)C=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
6603,41298,"2-(azepan-1-yl)-1-(2,3-dihydro-1H-inden-5-yl)ethanone",C1CCCN(CC1)CC(=O)C2=CC3=C(CCC3)C=C2,,,,,,
6604,41299,CID 41299,C1CCC[NH+](CC1)CC(C2=CC3=C(CCC3)C=C2)O.C(=CC(=O)[O-])C(=O)O,,,,,,
6605,41300,"2-(azepan-1-yl)-1-(2,3-dihydro-1H-inden-5-yl)ethanol",C1CCCN(CC1)CC(C2=CC3=C(CCC3)C=C2)O,,,,,,
6606,41301,CID 41301,CN1CCN(CC1)CC(=O)C2=CC3=C(CCC3)C=C2.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
6607,41302,"1-(2,3-dihydro-1H-inden-5-yl)-2-(4-methylpiperazin-1-yl)ethanone",CN1CCN(CC1)CC(=O)C2=CC3=C(CCC3)C=C2,,,,,,
6608,41303,CID 41303,CCCCC[C@](C)(C=CC1[C@@H](CC(=O)[C@@H]1CC=CCCCC(=O)O)O)O,,,,,,
6609,41304,CID 41304,C1[C@H]([C@H](C([C@H]1O)C=C[C@@H](COC2=CC=CC(=C2)C(F)(F)F)O)CC=CCCCC(=O)[O-])O.[Na+],,,,,,
6610,41305,"7-[(1S,3S,5R)-3,5-dihydroxy-2-[(3S)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid",C1[C@H]([C@H](C([C@H]1O)C=C[C@@H](COC2=CC=CC(=C2)C(F)(F)F)O)CC=CCCCC(=O)O)O,,,,,,
6611,41306,"4,8-Dimethyltridecane",CCCCCC(C)CCCC(C)CCC,,,,,,
6612,41307,"1,2,3,4-Tetrahydro-4,9-dimethylacridine",CC1CCCC2=C(C3=CC=CC=C3N=C12)C,,,,,,
6613,41308,"1H-Indole-3-methanol, alpha-3-pyridinyl-",C1=CC=C2C(=C1)C(=CN2)C(C3=CN=CC=C3)O,,,,,,
6614,41309,"1,2-Dichloro-3,4-bis(dichloromethylene)cyclobutane",C1(C(C(=C(Cl)Cl)C1=C(Cl)Cl)Cl)Cl,,,,,,
6615,41310,5-Propyltridecane,CCCCCCCCC(CCC)CCCC,,,,,,
6616,41311,4-Ethyltetradecane,CCCCCCCCCCC(CC)CCC,,,,,,
6617,41312,3-(1-Pyrrolidinyl)propyl benzilate hydrochloride,C1CC[NH+](C1)CCCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
6618,41313,"3-Pyrrolidin-1-ylpropyl 2-hydroxy-2,2-diphenylacetate",C1CCN(C1)CCCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
6619,41314,"Cinchoninic acid, 2-(5-hexyl-2-hydroxyphenyl)-8-hydroxy-",CCCCCCC1=C(C(=CC=C1)O)C2=NC3=C(C=CC=C3O)C(=C2)C(=O)O,,,,,,
6620,41315,Abovis; Aclatonium napadisilate; TM 723,CC(C(=O)OCC[N+](C)(C)CC[N+](C)(C)CCOC(=O)C(C)OC(=O)C)OC(=O)C.C1=CC2=C(C=CC=C2S(=O)(=O)[O-])C(=C1)S(=O)(=O)[O-],,,,,,
6621,41316,2-(2-Acetyloxypropanoyloxy)ethyl-[2-[2-(2-acetyloxypropanoyloxy)ethyl-dimethylazaniumyl]ethyl]-dimethylazanium,CC(C(=O)OCC[N+](C)(C)CC[N+](C)(C)CCOC(=O)C(C)OC(=O)C)OC(=O)C,,,,,,
6622,41317,"9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC,,,,,,
6623,41318,N-(Fluoren-4-yl)acetohydroxamic acetate,CC(=O)N(C1=CC=CC2=C1C3=CC=CC=C3C2)OC(=O)C,,,,,,
6624,41319,"[(17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] N-(dimethylamino)carbamate",CC12CCC3C(C1CC[C@@H]2OC(=O)NN(C)C)CCC4=C3C=CC(=C4)O,,,,,,
6625,41320,"1-Dodecanamine, N-methyl-N-nitroso-",CCCCCCCCCCCCN(C)N=O,,,,,,
6626,41321,"(4S,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol",C=C1CC[C@]2([C@@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O,,,,,,
6627,41322,Benzo(a)pyrene diol epoxide,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C6C(O6)C(C5O)O)C=C2,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,"['Benzo(a)pyrene diol epoxide is a known human metabolite of 7,8-Dihydrobenzo[a]pyrene-7,8-diol.']",
6628,41323,"12-Hydroxy-6,6',7-trimethoxy-2,2,2',2'-tetramethylberbaman-2,2'-diium",C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CC[N+]6(C)C)OC)OC)O)OC)C,,,,,,
6629,41324,"2H-Cyclopentacycloocten-2-one, decahydro-3a-methyl-, trans-",CC12CCCCCCC1CC(=O)C2,,,,,,
6630,41325,"2(1H)-Benzocyclooctenone, decahydro-10a-methyl-, trans-",CC12CCCCCCC1CCC(=O)C2,,,,,,
6631,41326,Diethyl butylmethylmalonate,CCCCC(C)(C(=O)OCC)C(=O)OCC,,,,,,
6632,41327,CID 41327,CN1C(=CN=C1C=C2CCC3=C(C2=O)C=CC(=C3)OCC[NH+](C)C)[N+](=O)[O-].OS(=O)(=O)[O-],,,,,,
6633,41328,"6-[2-(Dimethylamino)ethoxy]-2-[(1-methyl-5-nitroimidazol-2-yl)methylidene]-3,4-dihydronaphthalen-1-one",CN1C(=CN=C1C=C2CCC3=C(C2=O)C=CC(=C3)OCCN(C)C)[N+](=O)[O-],,,,,,
6634,41329,"2,6,10,14-Tetramethylnonadecane",CCCCCC(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
6635,41330,CID 41330,CCOC(=O)C=CC(=O)[O-].[Na+],,,,,,
6636,41331,4-Ethoxy-4-oxobut-2-enoic acid,CCOC(=O)C=CC(=O)O,,,,,,
6637,41332,N-[2-hydroxy-2-(indol-3-yl)-2-(methylthio)ethyl]indole-3-carboxamide,CSC(CNC(=O)C1=CNC2=CC=CC=C21)(C3=CNC4=CC=CC=C43)O,,,,,,
6638,41333,3-Methyl-1-hexen-3-ol,CCCC(C)(C=C)O,,,,,,
6639,41334,CID 41334,CCOC(=O)C1=NC(=O)C2=CC3=CC(=C(C=C3NC2=N1)OC)OC,,,,,,
6640,41335,"N,N'-Dicyclohexylformamidinium acetate",CC(=O)[O-].C1CCC(CC1)NC=[NH+]C2CCCCC2,,,,,,
6641,41336,"N,N'-Dicyclohexylformamidine",C1CCC(CC1)NC=NC2CCCCC2,,,,,,
6642,41337,"4,5-Bis(aminomethyl)acridine dihydrochloride",C1=CC2=CC3=C(C(=CC=C3)C[NH3+])N=C2C(=C1)C[NH3+].[Cl-].[Cl-],,,,,,
6643,41338,"4,5-Bis(aminomethyl)acridine dihydrochloride salt",C1=CC2=CC3=C(C(=CC=C3)CN)N=C2C(=C1)CN,,,,,,
6644,41339,CID 41339,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)CN=C(C4=CC=NC=C4)N)C(=O)[O-])C.[Na+],,,,,,
6645,41340,"6-[[2-[[2-[[Amino(pyridin-4-yl)methylidene]amino]acetyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)CN=C(C4=CC=NC=C4)N)C(=O)O)C,,,,,,
6646,41341,"1,1-Dibromo-2-chloropropane",CC(C(Br)Br)Cl,,,,,,
6647,41342,2-Bromo-5-ethylnonane,CCCCC(CC)CCC(C)Br,,,,,,
6648,41343,Methyl 2-(4-chlorophenoxy)-2-methylpropanoate,CC(C)(C(=O)OC)OC1=CC=C(C=C1)Cl,,,,,,
6649,41344,"3,5,24-Trimethyltetracontane",CCCCCCCCCCCCCCCCC(C)CCCCCCCCCCCCCCCCCCC(C)CC(C)CC,,,,,,
6650,41345,"5H-Furo(3,2-g)(1)benzopyran-5-one, 9-(3-(benzylethylamino)-2-hydroxypropoxy)-4-hydroxy-7-methyl-, hydrochloride",CC[NH+](CC1=CC=CC=C1)CC(COC2=C3C(=C(C4=C2OC=CC4=O)O)C=C(O3)C)O.[Cl-],,,,,,
6651,41346,"9-[3-[Benzyl(ethyl)amino]-2-hydroxypropoxy]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CCN(CC1=CC=CC=C1)CC(COC2=C3C(=C(C4=C2OC=CC4=O)O)C=C(O3)C)O,,,,,,
6652,41347,"5H-Furo(3,2-g)(1)benzopyran-5-one, 4-(3-(benzylisopropylamino)-2-hydroxypropoxy)-9-methoxy-7-methyl-, hydrochloride",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OCC(C[NH+](CC4=CC=CC=C4)C(C)C)O)C2=O)OC.[Cl-],,,,,,
6653,41348,"5-[3-[Benzyl(propan-2-yl)amino]-2-hydroxypropoxy]-9-methoxy-2-methylfuro[3,2-g]chromen-4-one",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OCC(CN(CC4=CC=CC=C4)C(C)C)O)C2=O)OC,,,,,,
6654,41349,"5H-Furo(3,2-g)(1)benzopyran-5-one, 9-(3-ethylamino-2-hydroxypropoxy)-4-hydroxy-7-methyl-, hydrochloride",CC[NH2+]CC(COC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C)O.[Cl-],,,,,,
6655,41350,"9-[3-(Ethylamino)-2-hydroxypropoxy]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CCNCC(COC1=C2C(=C(C3=C1OC=CC3=O)O)C=C(O2)C)O,,,,,,
6656,41351,"5H-Furo(3,2-g)(1)benzopyran-5-one, 4-hydroxy-9-(2-hydroxy-3-isobutylaminopropoxy)-7-methyl-, hydrochloride",CC1=CC2=C(C3=C(C(=C2O1)OCC(C[NH2+]CC(C)C)O)OC=CC3=O)O.[Cl-],,,,,,
6657,41352,"4-Hydroxy-9-[2-hydroxy-3-(2-methylpropylamino)propoxy]-2-methylfuro[3,2-g]chromen-5-one",CC1=CC2=C(C3=C(C(=C2O1)OCC(CNCC(C)C)O)OC=CC3=O)O,,,,,,
6658,41353,"Tert-butyl-[2-hydroxy-3-(4-hydroxy-2-methyl-5-oxofuro[3,2-g]chromen-9-yl)oxypropyl]azanium;chloride",CC1=CC2=C(C3=C(C(=C2O1)OCC(C[NH2+]C(C)(C)C)O)OC=CC3=O)O.[Cl-],,,,,,
6659,41354,"9-[3-(Tert-butylamino)-2-hydroxypropoxy]-4-hydroxy-2-methylfuro[3,2-g]chromen-5-one",CC1=CC2=C(C3=C(C(=C2O1)OCC(CNC(C)(C)C)O)OC=CC3=O)O,,,,,,
6660,41355,"5H-Furo(3,2-g)(1)benzopyran-5-one, 4-(2-hydroxy-3-isopropylaminopropoxy)-9-methoxy-7-methyl-, hydrochloride",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OCC(C[NH2+]C(C)C)O)C2=O)OC.[Cl-],,,,,,
6661,41356,"5-[2-Hydroxy-3-(propan-2-ylamino)propoxy]-9-methoxy-2-methylfuro[3,2-g]chromen-4-one",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OCC(CNC(C)C)O)C2=O)OC,,,,,,
6662,41357,(m-Chlorobenzyl)guanidine,C1=CC(=CC(=C1)Cl)CN=C(N)N,,,,,,
6663,41358,"Octanoic acid, 2-tetradecyl ester",CCCCCCCCCCCCC(C)OC(=O)CCCCCCC,,,,,,
6664,41359,"20,29,30-Trinorlupane, (17alpha)-",CC1(CCCC2(C1CCC3(C2CCC4C3(CCC5(C4CCC5)C)C)C)C)C,,,,,,
6665,41360,"Indole-4,7-diol, 3-(2-aminoethyl)-",C1=CC(=C2C(=C1O)C(=CN2)CCN)O,,,,,,
6666,41361,"Indole-4,7-diol, 3-(2-aminopropyl)-",C1=CC(=C2C(=C1O)C(=CN2)CCCN)O,,,,,,
6667,41362,"2,2',3,4,6-Pentachlorobiphenyl",C1=CC=C(C(=C1)C2=C(C(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
6668,41363,"2,2',3,3',4,5-Hexachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
6669,41364,(trans)-2-Mercaptomethylcyclobutylamine hydrochloride,C1C[C@H]([C@@H]1CS)N.Cl,,,,,,
6670,41365,(2-Aminocyclobutyl)methanethiol,C1CC(C1CS)N,,,,,,
6671,41366,"5H-Furo(3,2-g)(1)benzopyran-5-one, 9-(2-hydroxy-3-isopropylaminopropoxy)-4-methoxy-7-methyl-, hydrochloride",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OC)C2=O)OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
6672,41367,"9-[2-Hydroxy-3-(propan-2-ylamino)propoxy]-5-methoxy-2-methylfuro[3,2-g]chromen-4-one",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OC)C2=O)OCC(CNC(C)C)O,,,,,,
6673,41368,Triadimenol,CC(C)(C)C(C(N1C=NC=N1)OC2=CC=C(C=C2)Cl)O,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['... 16 laying hens received [phenyl-(14)C]triadimefon at 28.7 ppm for three consecutive days in feed. Triadimefon was identified in fat and eggs (4-17% TRR) but was not detected in liver or muscle. Triadimenol and its related compounds were the major metabolites identified (totals of 41-49% TRR). The remainder of the radioactivity was identified as KWG 1342 and its related compounds (totals of 10-36% TRR), p-chlorophenol (liver and fat only at 2- 4% TRR), chlorophenoxytriazolyl acetic acid (muscle only at 3% TRR), and KWG 1323 (eggs and fat only at 3-5% TRR). /Triadimefon/', 'Single oral doses of 25 mg/kg /triadimenol/ were administered to rats. Label was fairly readily excreted (over 70% in a week). In males, label was distributed 30% in urine and 53% in feces: in females distribution was 40% and 35%, respectively. No activity was found in expired gases. The major identified band in urine and in feces was KWG 0519 acid (formed by oxidation of the isobutyl moiety of triadimenol]. KWG 0519 (two isomers are present) was more abundant in plasma and in liver than the original Bayleton. Prevalence of KWG 0519 isomers was particularly apparent in males.']","['... In studies conducted with rat hepatic microsomes, triadimenol was identified as the major metabolite (approximately 80%) of triadimefon metabolism, and reduction of the carbonyl group in triadimefon occurred stereoselectively with preferential formation of the less toxic triadimenol B diastereomer...', 'Triadimefon, triadimenol, and other triazole fungicides are metabolized in animals and plants to form compounds containing the triazole moiety, including 1,2,4-triazole (free triazole), triazole alanine, and triazole acetic acid, which are also considered in this decision ...', '... A lactating goat received [phenyl-(14)C]triadimefon at 86.4 ppm for three consecutive days in feed. Triadimefon was detected at low levels in milk and fat (<5% TRR) but was not detected in kidney, liver, or muscle. The major residue identified was KWG 1342 glucuronide (6-47% TRR). Triadimenol and its conjugates comprised a major portion of the residue in tissues and milk (totals of 9-42% TRR). The remainder of the radioactivity was identified as KWG 1323 glucuronide (19-22% TRR) and KWG 1342 (1-6% TRR) and its sulfate (1-15% TRR in tissues, 43% TRR in milk). /Triadimefon/', '... 16 laying hens received [phenyl-(14)C]triadimefon at 28.7 ppm for three consecutive days in feed. Triadimefon was identified in fat and eggs (4-17% TRR) but was not detected in liver or muscle. Triadimenol and its related compounds were the major metabolites identified (totals of 41-49% TRR). The remainder of the radioactivity was identified as KWG 1342 and its related compounds (totals of 10-36% TRR), p-chlorophenol (liver and fat only at 2- 4% TRR), chlorophenoxytriazolyl acetic acid (muscle only at 3% TRR), and KWG 1323 (eggs and fat only at 3-5% TRR). /Triadimefon/']",
6674,41369,"(1,1-Dimethylethyl)phenyl phosphinic fluoride",CC(C)(C)P(=O)(C1=CC=CC=C1)F,,,,,,
6675,41370,Triafungin,C1=CC=C(C=C1)CC2=NC3=C(C=CN=C3)N=N2,,,,,,
6676,41371,"Crotonic acid, 3-methyl-, ester with 2,3-dihydro-2-(1-hydroxy-1-methylethyl)-7H-furo(3,2-g)(1)benzopyran-7-one, (-)-, mixed with N-vinylpyrrolidone (14:86)",CC(COC(=O)C=C(C)C)C1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3.C=CN1CCCC1=O,,,,,,
6677,41372,"Hydantoin, 1,3-bis(methoxymethyl)-5,5-diphenyl-",COCN1C(=O)C(N(C1=O)COC)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6678,41373,3-Acetoxymethyl-5-ethyl-5-phenylhydantoin,CCC1(C(=O)N(C(=O)N1)COC(=O)C)C2=CC=CC=C2,,,,,,
6679,41374,"1,2,3,4-Tetrahydro-5,8-dimethyl-1-octylnaphthalene",CCCCCCCCC1CCCC2=C(C=CC(=C12)C)C,,,,,,
6680,41375,"(6R,7R)-3-(carbamoyloxymethyl)-7-[[2-(2-furanyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CC=CO1)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
6681,41376,Impromidine,CC1=C(N=CN1)CSCCNC(=NCCCC2=CN=CN2)N,,,['Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (See all compounds classified as Histamine Agonists.)'],,,
6682,41377,"3,3-Diphenylallylamine hydrochloride",C1=CC=C(C=C1)C(=CC[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
6683,41378,Diphenylpropenamine,C1=CC=C(C=C1)C(=CCN)C2=CC=CC=C2,,,,,,
6684,41379,"1,3,5-Trimethyl-2-octadecylcyclohexane",CCCCCCCCCCCCCCCCCCC1C(CC(CC1C)C)C,,,,,,
6685,41380,"Nona-3,8-diene-2-one",CC(=O)C=CCCCC=C,,,,,,
6686,41381,Ethalfluralin,CCN(CC(=C)C)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],,,,"['In the poultry metabolism study, laying hens were dosed with uniformly ring-labeled [14C]ethalfluralin at 10 ppm in the diet (about 200x the 14 maximum theoretical dietary burden) for ten consecutive days. The maximum total radioactive residues were 0.169 ppm in eggs, 0.697 ppm in liver, 0.070 ppm in muscle, and 0.194 ppm in skin. The parent compound, ethalfluralin, was the major compound identified in skin, but was a minor component in eggs, liver, and muscle. Four other metabolites, 2,6-dinitro-4-(trifluoromethyl)phenol, N-ethyl-2,6-dinitro-4- (trifluoromethyl)benzenamine, N-(2-methyl-2-propenyl)-2,6-dinitro-4- (trifluoromethyl)benzenamine, and 2,6-dinitro-4- (trifluoromethyl)benzenamine, were identified; each identified metabolite was present at >/=0.05 ppm.', 'A study with Rhesus monkeys indicated that 2.8% of a dermal dose was absorbed through the skin.', 'Fischer 344 rats were treated orally with a single low dose, a single high dose, or repeated low doses of radiolabeled ethalfluralin. Absorption of ethalfluralin was estimated at 79-87% of the dose for all dose levels. Ethalfluralin was rapidly and extensively metabolized, and 95% of the chemical was excreted in urine and feces by seven days. The major route of elimination for the radiolabel was in the feces, 50.9-63.2%, and the levels remaining in the tissues after 72 hours were negligible. ...']","['In the ruminant metabolism study, a lactating dairy cow was dosed with uniformly ring-labeled [14C]ethalfluralin at 10 ppm in the diet (about 14 200x the maximum theoretical dietary burden) for three consecutive days. The total radioactive residues were 0.011 ppm in fat, 0.050 ppm in kidney, 0.104 ppm in liver, 0.002 ppm in muscle, and up to 0.006 ppm in milk. Ethalfluralin was identified in milk and fat; neither parent nor metabolites were identified in kidney or liver.', 'In the poultry metabolism study, laying hens were dosed with uniformly ring-labeled [14C]ethalfluralin at 10 ppm in the diet (about 200x the 14 maximum theoretical dietary burden) for ten consecutive days. The maximum total radioactive residues were 0.169 ppm in eggs, 0.697 ppm in liver, 0.070 ppm in muscle, and 0.194 ppm in skin. The parent compound, ethalfluralin, was the major compound identified in skin, but was a minor component in eggs, liver, and muscle. Four other metabolites, 2,6-dinitro-4-(trifluoromethyl)phenol, N-ethyl-2,6-dinitro-4- (trifluoromethyl)benzenamine, N-(2-methyl-2-propenyl)-2,6-dinitro-4- (trifluoromethyl)benzenamine, and 2,6-dinitro-4- (trifluoromethyl)benzenamine, were identified; each identified metabolite was present at >/=0.05 ppm.']",
6687,41382,"Carbamic acid, N-(dimethylamino)thio-N-methyl-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SN(C)C)C,,,,,,
6688,41383,"2,3-Dihydro-2,2-dimethyl-7-benzofuranyl methyl(4-morpholinylthio)carbamate",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SN3CCOCC3)C,,,,,,
6689,41384,Carbosulfan,CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,"['Carbosulfan has known human metabolites that include (2,2-dimethyl-3H-1-benzofuran-7-yl) N-dibutylsulfinamoyl-N-methylcarbamate, Carbofuran, and dibutyl(sulfanyl)amine.']",
6690,41385,Dimethipin,CC1=C(S(=O)(=O)CCS1(=O)=O)C,,,,,,
6691,41386,Muzolimine,CC(C1=CC(=C(C=C1)Cl)Cl)N2C(=O)CC(=N2)N,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)']",,,
6692,41387,CID 41387,CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H](C23CC[C@H](C1([C@H]2C(=O)CC3)C)C)C)O)(C)C=C.C(=CC(=O)O)C(=O)O,,,,,,
6693,41388,"[(2R,3S,4S,6R,8S,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[2-(diethylamino)ethylsulfanyl]acetate",CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H](C23CC[C@H](C1([C@H]2C(=O)CC3)C)C)C)O)(C)C=C,,,,,,
6694,41389,Chlorohydroxybenzophenone,C1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)Cl)O,,,,,,
6695,41390,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylsilyl-",C[Si](C)(C)N1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
6696,41391,CID 41391,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C.C(=CC(=O)O)C(=O)O,,,,,,
6697,41392,"1-[5-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-3-yl]ethanone",CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C,,,,,,
6698,41393,CID 41393,CN1CC[NH+](CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)C=O.C(=CC(=O)[O-])C(=O)O,,,,,,
6699,41394,"5-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepine-3-carbaldehyde",CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)C=O,,,,,,
6700,41395,"Dibenzo(b,f)thiepin-2-carboxamide, 10,11-dihydro-11-(4-methyl-1-piperazinyl)-, methanesulfonate, hydrate (1:2:2)",CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)C(=O)N.CS(=O)(=O)O.CS(=O)(=O)O,,,,,,
6701,41396,"5-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepine-3-carboxamide",CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)C(=O)N,,,,,,
6702,41397,CID 41397,CC(=O)OCC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
6703,41398,"[5-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-3-yl]methyl acetate",CC(=O)OCC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C,,,,,,
6704,41399,CID 41399,CN1CCN(CC1)C2CC3C=CC=CC3SC4=C2C=C(C=C4)CO.C(=CC(=O)O)C(O)O.C(=CC(=O)O)C(=O)O,,,,,,
6705,41400,"[5-(4-Methylpiperazin-1-yl)-5,6,6a,10a-tetrahydrobenzo[b][1]benzothiepin-3-yl]methanol",CN1CCN(CC1)C2CC3C=CC=CC3SC4=C2C=C(C=C4)CO,,,,,,
6706,41401,"4,4-Dihydroxybut-2-enoic acid",C(=CC(=O)O)C(O)O,,,,,,
6707,41402,"2H-1,3-Benzoxazine, 3,4-dihydro-8-ethoxy-3-(2-phenylethyl)-",CCOC1=CC=CC2=C1OCN(C2)CCC3=CC=CC=C3,,,,,,
6708,41403,"N-((p-Chlorophenyl)thio)-N-methyl-N'-2,4-xylylformamidine",CC1=CC(=C(C=C1)N=CN(C)SC2=CC=C(C=C2)Cl)C,,,,,,
6709,41404,"2,2',3,4,5-Pentachlorobiphenyl",C1=CC=C(C(=C1)C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
6710,41405,CID 41405,CCC=CCC=CCC=CCCCCCCCC(=O)OCC(COC(=O)C)OC(=O)C,,,,,,
6711,41406,"5,5-Dimethylhexanal",CC(C)(C)CCCC=O,,,,,,
6712,41407,Tri(beta-isothioureido-S-ethyl)amine tetrahydrochloride,C(CSC(=[NH2+])N)[NH+](CCSC(=[NH2+])N)CCSC(=[NH2+])N.[Cl-].[Cl-].[Cl-].[Cl-],,,,,,
6713,41408,2-[2-[Bis(2-carbamimidoylsulfanylethyl)amino]ethyl]isothiourea,C(CSC(=N)N)N(CCSC(=N)N)CCSC(=N)N,,,,,,
6714,41409,CID 41409,C1=CC=C(C=C1)CC(=O)NC(CC2=CC=C(C=C2)Cl)C(=O)[O-].[Na+],,,,,,
6715,41410,"N-Phenylacetyl-p-chlorophenylalanine, DL-",C1=CC=C(C=C1)CC(=O)NC(CC2=CC=C(C=C2)Cl)C(=O)O,,,,,,
6716,41411,CID 41411,CC(C)COC(=O)NC(CC1=CC=C(C=C1)Cl)C(=O)[O-].[Na+],,,,,,
6717,41412,3-(4-Chlorophenyl)-2-(2-methylpropoxycarbonylamino)propanoic acid,CC(C)COC(=O)NC(CC1=CC=C(C=C1)Cl)C(=O)O,,,,,,
6718,41413,N-(3-Di-(2-chloroethyl)amino-4-methylbenzoyl)-DL-p-chlorophenylalanine,CC1=C(C=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)Cl)C(=O)O)N(CCCl)CCCl,,,,,,
6719,41414,CID 41414,C1=CC=C(C=C1)COC(=O)NC(CC2=CC=C(C=C2)Cl)C(=O)[O-].[Na+],,,,,,
6720,41415,Z-DL-Phe(4-CL)-OH,C1=CC=C(C=C1)COC(=O)NC(CC2=CC=C(C=C2)Cl)C(=O)O,,,,,,
6721,41416,N-(4-Di-(2-chloroethyl)aminophenylacetyl)-DL-p-chlorophenylalanine,C1=CC(=CC=C1CC(C(=O)O)NC(=O)CC2=CC=C(C=C2)N(CCCl)CCCl)Cl,,,,,,
6722,41417,N-(3-Bromo-1-oxopropyl)-4-chloro-DL-phenylalanine,C1=CC(=CC=C1CC(C(=O)O)NC(=O)CCBr)Cl,,,,,,
6723,41418,N-(Cyclopropylmethyl)-1H-indole-3-ethanamine hydrochloride,C1CC1C[NH2+]CCC2=CNC3=CC=CC=C32.[Cl-],,,,,,
6724,41419,N-cyclopropylmethyl-tryptamine,C1CC1CNCCC2=CNC3=CC=CC=C32,,,,,,
6725,41420,N-Cyclopropyltryptamine hydrochloride,C1CC1[NH2+]CCC2=CNC3=CC=CC=C32.[Cl-],,,,,,
6726,41421,N-[2-(1H-indol-3-yl)ethyl]cyclopropanamine,C1CC1NCCC2=CNC3=CC=CC=C32,,,,,,
6727,41422,5-Methoxy-N-cyclopropyltryptamine hydrochloride,COC1=CC2=C(C=C1)NC=C2CC[NH2+]C3CC3.[Cl-],,,,,,
6728,41423,N-[2-(5-methoxy-1H-indol-3-yl)ethyl]cyclopropanamine,COC1=CC2=C(C=C1)NC=C2CCNC3CC3,,,,,,
6729,41424,N-Cyclopropyl-7-methoxy-1H-indole-3-ethanamide hydrochloride,COC1=CC=CC2=C1NC=C2CC[NH2+]C3CC3.[Cl-],,,,,,
6730,41425,N-[2-(7-methoxy-1H-indol-3-yl)ethyl]cyclopropanamine,COC1=CC=CC2=C1NC=C2CCNC3CC3,,,,,,
6731,41426,"4a,5-Dimethyl-3-propan-2-yl-2,3,4,5,6,7,8,8a-octahydronaphthalen-1-one",CC1CCCC2C1(CC(CC2=O)C(C)C)C,,,,,,
6732,41427,"4a,5-Dimethyl-3-propan-2-yl-1,3,4,5,6,7,8,8a-octahydronaphthalen-2-one",CC1CCCC2C1(CC(C(=O)C2)C(C)C)C,,,,,,
6733,41428,Triclopyr,C1=C(C(=NC(=C1Cl)Cl)OCC(=O)O)Cl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","[""In the province of Quebec (Canada), the phytocide Garlon 4, whose active ingredient is triclopyr, is often used to prevent trees from reaching electrical conductors. The object of this paper is to assess the potential health risks in workers coming into contact with Garlon 4. Ten workers collected their urine during the 22 hr following the beginning of a work shift. Measured urinary amounts of triclopyr varied between 1 and 13 mg. The absorbed daily doses were estimated from the amounts of triclopyr in urine through the use of a kinetic model that links the rates of triclopyr elimination to absorbed doses. These estimated doses were compared with the no-observed-effect level (NOEL) observed in rats: 5 mg per kg of body weight. The upper-bound estimations of the worker's daily absorbed doses were found to be 13.3% or less of the rat NOEL."", 'Two herbicides, 2,4-D and triclopyr esters (application ratio 1.6:1 acid equivalents) were applied as a tank mix by a crew of 8 backpack sprayer applicators, a mixer/loader, and a field supervisor. The crew was employed in a conifer release program in northern California during the summer of 2002. Biomonitoring (urine, 24 hr) utilized 2,4-D and triclopyr (a.e.) as rapidly excreted exposure biomarkers. The absorbed dosages of 2,4-D and triclopyr were calculated based upon cotton whole body suits and biomonitoring. Dosages based upon accumulation of the herbicides on body suits averaged 42.6 ug (a.e.) 2,4-D/kg-d and 8.0 ug (a.e.) triclopyr/kg-d. Six consecutive days of concurrent urine collections showed that backpack applicators excreted an average of 11.0 ug (a.e.) 2,4-D/kg-d and 18.9 ug (a.e.) triclopyr/kg-d. Estimates based upon curve fitting were 17.1 and 29.3 ug (a.e.)/kg-d, respectively. Results suggest that passive dosimetry for 2,4-D consistently overestimated the dosage measured using biomonitoring by a factor of 2-3 fold, while for triclopyr, passive dosimetry underestimated the absorbed dose based on biomonitoring by a factor of 2-4 fold.', 'Disposition and metabolism of (14)C-triclopyr acid (98.8% a.i.) was investigated in male and female rats at a low oral dose (3 mg/kg), repeated low oral doses (3 mg/kg x 14 days), and a high dose (60 mg/kg). Comparison of disposition data in intravenously dosed and orally dosed rats demonstrated that triclopyr was well absorbed after oral administration. Excretion was relatively rapid at the low dose, with a majority of radioactivity eliminated in the urine by 24 hours. At 60 mg/kg, urinary elimination of (14)C-triclopyr derived radioactivity was decreased in male and female rats from 0-12 hours, due to apparent saturation of renal elimination mechanisms. Fecal elimination of (14)C-triclopyr derived radioactivity was a minor route of excretion, as was elimination via exhaled air. No significant effect was observed on metabolism or disposition of (14)C-triclopyr from repeated low oral dosing in male or female rats. Residual (14)C-triclopyr derived radioactivity was minimal in all dose groups, but measurable levels of tissue radioactivity were detected in perirenal fat of both sexes and ovaries of female rats which apparently increased with dose. Thus, potential accumulation of (14)C-triclopyr derived radioactivity may occur in these tissues. Urinary metabolites of (14)C-triclopyr were isolated and identified by HPLC and GC/MS. Unmetabolized parent chemical represented >90% of urinary radioactivity, with the remainder accounted for by the metabolite 3,5,6-trichloro-2-pyridinol (3,5,6-TCP), and possible glucuronide and/or sulfate conjugates of 3,5,6-TCP. Plasma elimination following intravenous administration of (14)C-triclopyr was consistent with a one-compartment model with an elimination half-life of 3.6 hr and zero-order kinetics from 0-12 hours at the 60 mg/kg dose. Kinetic parameters were optimized using SIMUSOLV modeling software. The model showed an apparent ""flip-flop"" phenomenon, in which absorption at the 3 mg/kg dose was rate limiting in elimination of (14)C-triclopyr derived radioactivity, but renal excretion was saturated and therefore limiting in elimination of (14)C-triclopyr derived radioactivity at the 60 mg/kg dose.', 'Blood levels and urinary excretion of triclopyr, the active ingredient in Garlon herbicides, were followed in six volunteers given single oral doses of 0.1 and 0.5 mg/kg body weight. Five of these volunteers later received dermal applications of Garlon 4 herbicide formulation equivalent to 3.7 mg triclopyr/kg body weight applied to the forearm. Following oral administration blood levels peaked at 2-3 hr and declined to undetectable levels within 48 hr; more than 80% of the dose was found as unchanged triclopyr in the urine. An average of 1.37% of the applied dose was recovered in the urine; when corrected for recovery after oral administration this was equivalent to an absorption of 1.65%. Triclopyr is slowly absorbed through skin and is rapidly eliminated. It has very low potential to accumulate in man or to be absorbed through the skin in acutely toxic amounts.']","['... 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) ... is the primary analyte found in /human/ urine as a result of exposure to ... triclopyr.', 'Disposition and metabolism of (14)C-triclopyr acid (98.8% a.i.) was investigated in male and female rats at a low oral dose (3 mg/kg), repeated low oral doses (3 mg/kg x 14 days), and a high dose (60 mg/kg). ... Urinary metabolites of (14)C-triclopyr were isolated and identified by HPLC and GC/MS. Unmetabolized parent chemical represented >90% of urinary radioactivity, with the remainder accounted for by the metabolite 3,5,6-trichloro-2-pyridinol (3,5,6-TCP), and possible glucuronide and/or sulfate conjugates of 3,5,6-TCP. ...']","['Disposition and metabolism of (14)C-triclopyr acid (98.8% a.i.) was investigated in male and female rats at a low oral dose (3 mg/kg), repeated low oral doses (3 mg/kg x 14 days), and a high dose (60 mg/kg). ... Plasma elimination following intravenous administration of (14)C-triclopyr was consistent with a one-compartment model with an elimination half-life of 3.6 hr ... .', 'A two-compartment pharmacokinetic model was used to describe the time-course of triclopyr clearance; half-lives for the rapid initial and slower terminal phases were 1.3 hr and 5.1 hr respectively, and were independent of dose. Due to the slow half-life for dermal absorption (t1/2 = 16.8 hr) the rapid initial elimination phase was obscured and the pharmacokinetics could be simplified by a one-compartment model.']"
6734,41429,3-Chloro-3-(4-fluorophenyl)prop-2-enal,C1=CC(=CC=C1C(=CC=O)Cl)F,,,,,,
6735,41430,1-Nitro-9H-fluoren-9-one,C1=CC=C2C(=C1)C3=C(C2=O)C(=CC=C3)[N+](=O)[O-],,,,,,
6736,41431,Methyl pentacosanoate,CCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
6737,41432,"2,6-Dimethyl-1,4-dinitrosopiperazine",CC1CN(CC(N1N=O)C)N=O,,,,,,
6738,41433,"1,4-Dithian-2-one, O-((methylamino)carbonyl)oxime",CNC(=O)ON=C1CSCCS1,,,,,,
6739,41434,N-Benzoyloxy-N-ethyl-4-aminoazobenzene,CCN(C1=CC=C(C=C1)N=NC2=CC=CC=C2)OC(=O)C3=CC=CC=C3,,,,,,
6740,41435,N-Benzoyloxy-4'-methyl-N-methyl-4-aminoazobenzene,CC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)OC(=O)C3=CC=CC=C3,,,,,,
6741,41436,N-Benzoyloxy-4'-ethyl-N-methyl-4-aminoazobenzene,CCC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)OC(=O)C3=CC=CC=C3,,,,,,
6742,41437,p-(4-Ethylphenylazo)-N-methylaniline,CCC1=CC=C(C=C1)N=NC2=CC=C(C=C2)NC,,,,,,
6743,41438,Dialkob,C=CCN(CCO)CCO.C=CCN(CCO)CCO.[Cl-].[Cl-].[Co+2],,,,,,
6744,41439,2-[Allyl(2-hydroxyethyl)amino]ethan-1-ol,C=CCN(CCO)CCO,,,,,,
6745,41440,11-Decyldocosane,CCCCCCCCCCCC(CCCCCCCCCC)CCCCCCCCCC,,,,,,
6746,41441,"5,5-Diethoxy-3-pentyn-2-one",CCOC(C#CC(=O)C)OCC,,,,,,
6747,41442,"2,2,7-Trimethyl-3-octyne",CC(C)CCC#CC(C)(C)C,,,,,,
6748,41443,3-Chloro-3-(4-iodophenyl)prop-2-enal,C1=CC(=CC=C1C(=CC=O)Cl)I,,,,,,
6749,41444,"Carbamic acid, hexamethylenedi-, bis(3-iodo-2-propynyl) ester",C(CCCNC(=O)OCC#CI)CCNC(=O)OCC#CI,,,,,,
6750,41445,Acodazole hydrochloride,CC1=CC(=C2C(=CC=C3C2=NC=N3)N1)NC4=CC=C(C=C4)N(C)C(=O)C.Cl,,,,,,
6751,41446,Acodazole,CC1=CC(=C2C(=CC=C3C2=NC=N3)N1)NC4=CC=C(C=C4)N(C)C(=O)C,,,,,,
6752,41447,"1,2-Epoxyoctahydropentalene",C1CC2CC3C(C2C1)O3,,,,,,
6753,41448,Isoxepac,C1C2=CC=CC=C2C(=O)C3=C(O1)C=CC(=C3)CC(=O)O,,,,,,
6754,41449,4'-(2-Hydroxy-3-(isopropylamino)propoxy)flavone,CC(C)NCC(COC1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2)O,,,,,,
6755,41450,4'-(3-(tert-Butylamino)-2-hydroxypropoxy)flavone,CC(C)(C)NCC(COC1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2)O,,,,,,
6756,41451,4'-(3-(Isopropylamino)-2-hydroxypropoxy)-3-methylflavanone,CC1=C(OC2=CC=CC=C2C1=O)C3=CC=C(C=C3)OCC(CNC(C)C)O,,,,,,
6757,41452,2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-2-methyl-3H-chromen-4-one,CC1(CC(=O)C2=CC=CC=C2O1)C3=CC=C(C=C3)OCC(CNC(C)(C)C)O,,,,,,
6758,41453,"2,2,4,15,17,17-Hexamethyl-7,12-bis(3,5,5-trimethylhexyl)octadecane",CC(CCC(CCCCC(CCC(C)CC(C)(C)C)CCC(C)CC(C)(C)C)CCC(C)CC(C)(C)C)CC(C)(C)C,,,,,,
6759,41454,"Benzamide, N-(4-chloro-6-(4-methyl-1-piperazinyl)-5-(methylthio)-2-pyrimidinyl)-N-methyl-, monohydrochloride",C[NH+]1CCN(CC1)C2=C(C(=NC(=N2)N(C)C(=O)C3=CC=CC=C3)Cl)SC.[Cl-],,,,,,
6760,41455,4-Chloro-2-(N-methylbenzoylamino)-6-(4-methylpiperazino)-5-(methylthio)pyrimidine,CN1CCN(CC1)C2=C(C(=NC(=N2)N(C)C(=O)C3=CC=CC=C3)Cl)SC,,,,,,
6761,41456,"Acetamide, N-(3-chlorophenyl)-2-(diethylamino)-, monohydrochloride",CC[NH+](CC)CC(=O)NC1=CC(=CC=C1)Cl.[Cl-],,,,,,
6762,41457,N-(3-Chlorophenyl)-2-(diethylamino)acetamide,CCN(CC)CC(=O)NC1=CC(=CC=C1)Cl,,,,,,
6763,41458,3-Methyl-3-piperidinooxindole,CC1(C2=CC=CC=C2NC1=O)N3CCCCC3,,,,,,
6764,41459,(9-Anthrylmethylene)malononitrile,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C=C(C#N)C#N,,,,,,
6765,41460,"1'H-Cholest-2-eno[3,2-b]indole, 5'-methoxy-, (5alpha)-",CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC4C3(CC5=C(C4)NC6=C5C=C(C=C6)OC)C)C,,,,,,
6766,41461,"2,2,3-Trimethylnonane",CCCCCCC(C)C(C)(C)C,,,,,,
6767,41462,Buthidazole,CC(C)(C)C1=NN=C(S1)N2C(CN(C2=O)C)O,,,,,,
6768,41463,Pyridate,CCCCCCCCSC(=O)OC1=CC(=NN=C1C2=CC=CC=C2)Cl,,,,,,
6769,41464,3-Methyl-2-(methylthio)benzo[d]thiazol-3-ium 4-methylbenzenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)[O-].C[N+]1=C(SC2=CC=CC=C21)SC,,,,,,
6770,41465,Methyl 2-methyltetradecanoate,CCCCCCCCCCCCC(C)C(=O)OC,,,,,,
6771,41466,N-Nitroso-3-hydroxypiperidine,C1CC(CN(C1)N=O)O,,,,,,
6772,41467,"2,5-Dimethyl-N-nitrosopyrrolidine",CC1CCC(N1N=O)C,,,,,,
6773,41468,"2,5-Dimethyldinitrosopiperazine",CC1CN(C(CN1N=O)C)N=O,,,,,,
6774,41469,Nitroso-4-piperidone,C1CN(CCC1=O)N=O,,,,,,
6775,41470,"N-Nitroso-1,2,3,6-tetrahydropyridine",C1CN(CC=C1)N=O,,,,,,
6776,41471,Nitrosopiperidinol,C1CN(CCC1O)N=O,,,,,,
6777,41472,"1,4-Dinitroso-2-methylpiperazine",CC1CN(CCN1N=O)N=O,,,,,,
6778,41473,Dinitrosohomopiperazine,C1CN(CCN(C1)N=O)N=O,,,,,,
6779,41474,N-Nitrosomethylphenidate,COC(=O)C(C1CCCCN1N=O)C2=CC=CC=C2,,,,,,
6780,41475,"4H-Pyran-4-one, 5-((trimethylsilyl)oxy)-2-(((trimethylsilyl)oxy)methyl)-",C[Si](C)(C)OCC1=CC(=O)C(=CO1)O[Si](C)(C)C,,,,,,
6781,41476,"[4-(Dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;naphthalene-2-sulfonic acid;hydrate",CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C.C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O.O,,,,,,
6782,41477,"S-[2-[(8S,9S,10R,11S,13S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanethioate",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4(C3CC[C@@]4(C(=O)CSC(=O)C(C)(C)C)O)C)O,,,,,,
6783,41478,Tetrakis(hydroxymethyl)phosphonium sulfate,C(O)[P+](CO)(CO)CO.C(O)[P+](CO)(CO)CO.[O-]S(=O)(=O)[O-],,,,,"['A metab study on rats has been conducted using 14C- radiolabelled THPS. THPS was not found in rat urine. However, three metabolites were present, identified as trihydroxymethyl phosphine oxide, bishydroxymethylphosphonic acid & possibly a formaldehyde adduct of the trihydroxy cmpd ... .']",
6784,41479,"HYDANTOIN, 5,5-BIS(p-CHLOROPHENYL)-1,3-DICHLORO-",C1=CC(=CC=C1C2(C(=O)N(C(=O)N2Cl)Cl)C3=CC=C(C=C3)Cl)Cl,,,,,,
6785,41480,"Ethyl 1,1-dimethylindan-4-carboxylate",CCOC(=O)C1=C2CCC(C2=CC=C1)(C)C,,,,,,
6786,41481,2-Amino-4-(carboxymethylsulfanyl)butanoic acid,C(CSCC(=O)O)C(C(=O)O)N,,,,,,
6787,41482,"beta-D-Mannopyranose, 1-ester with dolichol dihydrogen phosphate",CC(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CCOP(=O)(O)O[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
6788,41483,"Carbamic acid, ethylnitroso-, butyl ester",CCCCOC(=O)N(CC)N=O,,,,,,
6789,41484,"Dimethylammonium 2-(2,4,5-trichlorophenoxy)propionate",CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl.C[NH2+]C,,,,,,
6790,41485,N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-ethylsulfonylbenzamide hydrochloride,CC[NH+]1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)CC)OC.[Cl-],,,,,,
6791,41486,3-(2-Acetoxyphenyl)-2-propenoic Acid,CC(=O)OC1=CC=CC=C1C=CC(=O)O,,,,,,
6792,41487,"Pentanoic acid, 2,2-dimethyl-3-(6-methoxy-3,4-dihydro-2-naphthyl)-",CCC(C1=CC2=C(CC1)C=C(C=C2)OC)C(C)(C)C(=O)O,,,,,,
6793,41488,"2-Naphthalenepropionic acid, 3,4-dihydro-alpha,alpha-dimethyl-6-methoxy-beta-propyl-",CCCC(C1=CC2=C(CC1)C=C(C=C2)OC)C(C)(C)C(=O)O,,,,,,
6794,41489,"2,3-Diphenyl-1-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-1-butanone",CC(C1=CC=CC=C1)C(C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)OCCN4CCCC4,,,,,,
6795,41490,N-Butyl-N-(2-hydroxybutyl)nitrosamine,CCCCN(CC(CC)O)N=O,,,,,,
6796,41491,Adosterol (incomplete stereochemistry),CC(C)CCCC(C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H](C4=C3CC[C@@H](C4)O)CI)C,,,,,,
6797,41492,"8-(9,10-Dihydroxy-7-methoxy-3-methyl-1-oxo-3,4-dihydrobenzo[g]isochromen-8-yl)-10-hydroxy-7-methoxy-3-methyl-3,4-dihydrobenzo[g]isochromene-1,6,9-trione",CC1CC2=CC3=C(C(=C2C(=O)O1)O)C(=O)C(=C(C3=O)OC)C4=C(C5=C(C6=C(CC(OC6=O)C)C=C5C=C4OC)O)O,,,,,,
6798,41493,"1-(Furan-3-yl)-4-hydroxy-4,8-dimethylnonane-1,6-dione",CC(C)CC(=O)CC(C)(CCC(=O)C1=COC=C1)O,,,,,,
6799,41494,CID 41494,CCCC(=NOCC=C)C1=C(C(C(CC1=O)(C)C)C(=O)OC)[O-].[Na+],,,,,,
6800,41495,CID 41495,CCCC(=C1C(=O)CC(C(C1=O)C(=O)OC)(C)C)NOCC=C,,,,,,
6801,41496,1-((2-(1-Hydroxyethyl)benzofuran-7-yl)oxy)-3-(isopropylamino)propan-2-ol,CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(C)O)O,,,,,,
6802,41497,"2,2-Dimethyldeca-3,5-diene",CCCCC=CC=CC(C)(C)C,,,,,,
6803,41498,17beta-Bromoacetoxy-19-nortestosterone,CC12CCC3C(C1CC[C@@H]2OC(=O)CBr)CCC4=CC(=O)CCC34,,,,,,
6804,41499,"3-[4-(Dimethylamino)phenyl]-7,8-dihydro-1,2,3-benzotriazin-4-one",CN(C)C1=CC=C(C=C1)N2C(=O)C3=C(CCC=C3)N=N2,,,,,,
6805,41500,N-ethyl-2-(1H-indol-3-yl)-2-oxoacetamide,CCNC(=O)C(=O)C1=CNC2=CC=CC=C21,,,,,,
6806,41501,"Indole-3-glyoxylamide, N-isopropyl-1-methyl-",CC(C)NC(=O)C(=O)C1=CN(C2=CC=CC=C21)C,,,,,,
6807,41502,alpha-((Methylamino)methyl)-1-methylindole-3-methanol,CNCC(C1=CN(C2=CC=CC=C21)C)O,,,,,,
6808,41503,alpha-((Benzylamino)methyl)-1-methylindole-3-methanol,CN1C=C(C2=CC=CC=C21)C(CNCC3=CC=CC=C3)O,,,,,,
6809,41504,"Benzimidazole, 1-(2-aminoethyl)-",C1=CC=C2C(=C1)N=CN2CCN,,,,,,
6810,41505,4-Nitrophenyl-N-(2-chloroethyl)carbamate,C1=CC(=CC=C1[N+](=O)[O-])OC(=O)N(CCCl)N=O,,,,,,
6811,41506,"Cyclopropanecarboxylic acid, 3-(2,2-difluoroethenyl)-2,2-dimethyl-, (5-(phenylmethyl)-3-furanyl)methyl ester, (1R-cis)-",CC1([C@@H]([C@@H]1C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C=C(F)F)C,,,,,,
6812,41507,"cis-3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid",CC1([C@@H]([C@@H]1C(=O)O)C=C(Cl)Cl)C,,,,,,
6813,41508,"1-Isobutyl-2,5-dimethylbenzene",CC1=CC(=C(C=C1)C)CC(C)C,,,,,,
6814,41509,"2-Methylene-1-butanol, acetate",CCC(=C)COC(=O)C,,,,,,
6815,41510,"1,2,3,4,7,8,9-Heptachlorodibenzofuran",C1=C2C(=C(C(=C1Cl)Cl)Cl)C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
6816,41511,"3a,4,7,7a-Tetrahydro-2-(4-(2-propynyloxy)phenyl)-1H-isoindole-1,3(2H)-dione",C#CCOC1=CC=C(C=C1)N2C(=O)C3CC=CCC3C2=O,,,,,,
6817,41512,"3a,4,7,7a-Tetrahydro-2-(4-(1-piperidinyl)-2-butynyl)-1H-isoindole-1,3(2H)-dione hydrochloride",C1CC[NH+](CC1)CC#CCN2C(=O)C3CC=CCC3C2=O.[Cl-],,,,,,
6818,41513,"2-(4-Piperidin-1-ylbut-2-ynyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione",C1CCN(CC1)CC#CCN2C(=O)C3CC=CCC3C2=O,,,,,,
6819,41514,"2,2-Dimethyl-3,5-decadiyne",CCCCC#CC#CC(C)(C)C,,,,,,
6820,41515,"1,2-Dihydro-1,4,6-trimethylnaphthalene",CC1CC=C(C2=C1C=CC(=C2)C)C,,,,,,
6821,41516,"11,14,17-Eicosatrienoic acid-methyl ester",CCC=CCC=CCC=CCCCCCCCCCC(=O)OC,,,,,,
6822,41517,Methyl heptacosanoate,CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
6823,41518,Methyl octacosanoate,CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
6824,41519,"3-(2,3,5,6-Tetramethylphenyl)propanoic acid",CC1=CC(=C(C(=C1C)CCC(=O)O)C)C,,,,,,
6825,41520,"3,4,5-Trimethyl-2-cyclopenten-1-one",CC1C(C(=O)C=C1C)C,,,,,,
6826,41521,"2,3,3',4,4',5',6-Heptachlorodiphenyl ether",C1=C(C=C(C(=C1Cl)Cl)Cl)OC2=C(C(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
6827,41522,"1,2,3,4,8,9-Hexachlorodibenzofuran",C1=CC(=C(C2=C1OC3=C2C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
6828,41523,"Benzoic acid, 4-(2,4-diamino-5-pyrimidinylmethyl)-2,6-dimethoxy-, ethyl ester",CCOC(=O)C1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC,,,,,,
6829,41524,"Acetophenone, 4-(2,4-diamino-5-pyrimidinylmethyl)-2,6-dimethoxy-",CC(=O)C1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC,,,,,,
6830,41525,"4-(2,4-Diamino-5-pyrimidinylmethyl)-2,6-dimethoxy-alpha-methylbenzyl alcohol",CC(C1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC)O,,,,,,
6831,41526,"Benzyl alcohol, 4-(2,4-diamino-5-pyrimidinylmethyl)-2,6-dimethoxy-alpha,alpha-dimethyl-",CC(C)(C1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC)O,,,,,,
6832,41527,Heptabromonaphthalene,C1=C2C(=C(C(=C1Br)Br)Br)C(=C(C(=C2Br)Br)Br)Br,,,,,,
6833,41528,(+-)-alpha-(1-(Isopropylamino)ethyl)benzyl alcohol hydrochloride,CC(C)[NH2+]C(C)C(C1=CC=CC=C1)O.[Cl-],,,,,,
6834,41529,[1-Isopropylaminoethyl]-benzylalcohol,CC(C)NC(C)C(C1=CC=CC=C1)O,,,,,,
6835,41530,"Benzenemethanol, 3-hydroxy-alpha-(((1-methylethyl)amino)methyl)-, hydrochloride",CC(C)[NH2+]CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
6836,41531,Oxepinac,C1C2=CC=CC=C2C(=O)C3=C(O1)C=C(C=C3)CC(=O)O,,,,,,
6837,41532,"DIBENZ(b,e)OXEPIN-3-ACETIC ACID, 6,11-DIHYDRO-8-CHLORO-alpha-METHYL-11-OXO-",CC(C1=CC2=C(C=C1)C(=O)C3=C(CO2)C=C(C=C3)Cl)C(=O)O,,,,,,
6838,41533,"2-(6,11-Dihydro-11-oxodibenz(b,e)oxepin-3-yl)propionic acid",CC(C1=CC2=C(C=C1)C(=O)C3=CC=CC=C3CO2)C(=O)O,,,,,,
6839,41534,"3,4-Dinitrofluoranthene",C1=CC=C2C(=C1)C3=C4C2=CC=C(C4=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6840,41535,Cloroperone hydrochloride,C1CN(CCC1C(=O)C2=CC=C(C=C2)Cl)CCCC(=O)C3=CC=C(C=C3)F.Cl,,,,,,
6841,41536,Cloroperone,C1CN(CCC1C(=O)C2=CC=C(C=C2)Cl)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
6842,41537,"Cyclopropanecarboxylic acid, 3-(2,2-difluoroethenyl)-2,2-dimethyl-, (5-(phenylmethyl)-3-furanyl)methyl ester, (1R-trans)-",CC1([C@H]([C@@H]1C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C=C(F)F)C,,,,,,
6843,41538,"(3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dibromoethenyl)-2,2-dimethylcyclopropane-1-carboxylate",CC1([C@@H]([C@@H]1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,,,,,,
6844,41539,"(1S,3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid",CC1([C@H]([C@@H]1C(=O)O)C=C(Cl)Cl)C,,,,,,
6845,41540,"2,3,6-Trichlorobiphenyl",C1=CC=C(C=C1)C2=C(C=CC(=C2Cl)Cl)Cl,,,,,,
6846,41541,"2,3,4-Trichlorobiphenyl",C1=CC=C(C=C1)C2=C(C(=C(C=C2)Cl)Cl)Cl,,,,,,
6847,41542,3-Cyclohexyl-4-penten-2-one,CC(=O)C(C=C)C1CCCCC1,,,,,,
6848,41543,"1-Ethoxy-4,4-dimethylpent-2-ene",CCOCC=CC(C)(C)C,,,,,,
6849,41544,"Benzamide, N-methyl-2-(2-morpholinoacetamido)-N-phenyl-",CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2NC(=O)CN3CCOCC3,,,,,,
6850,41545,"Benzamide, 2-(N-methyl-2-morpholinoacetamido)-N-phenyl-",CN(C1=CC=CC=C1C(=O)NC2=CC=CC=C2)C(=O)CN3CCOCC3,,,,,,
6851,41546,"Benzamide, N-methyl-2-(N-methyl-2-morpholinoacetamido)-N-phenyl-",CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2N(C)C(=O)CN3CCOCC3,,,,,,
6852,41547,"BENZAMIDE, 2-(N-METHYL-2-PIPERIDINOACETAMIDO)-N-(p-TOLYL)-",CC1=CC=C(C=C1)NC(=O)C2=CC=CC=C2N(C)C(=O)CN3CCCCC3,,,,,,
6853,41548,N-Methyl-2-(N-methyl-2-piperidinoacetamido)-N-(p-tolyl)benzamide,CC1=CC=C(C=C1)N(C)C(=O)C2=CC=CC=C2N(C)C(=O)CN3CCCCC3,,,,,,
6854,41549,"N,N,4,4-Tetraethyl-4H-1,3-benzoxazine-2-methanamine hydrochloride",CCC1(C2=CC=CC=C2OC(=N1)C[NH+](CC)CC)CC.[Cl-],,,,,,
6855,41550,"N-[(4,4-diethyl-1,3-benzoxazin-2-yl)methyl]-N-ethylethanamine",CCC1(C2=CC=CC=C2OC(=N1)CN(CC)CC)CC,,,,,,
6856,41551,"2,3',4-Trichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=C(C=C(C=C2)Cl)Cl,,,,,,
6857,41552,2-Phenylethyl 2-methylbut-2-enoate,CC=C(C)C(=O)OCCC1=CC=CC=C1,,,,,,
6858,41553,2-(3-Amino-3-carboxyprop-1-enoxy)ethylazanium;chloride,C(COC=CC(C(=O)O)N)[NH3+].[Cl-],,,,,,
6859,41554,2-Amino-4-(2-aminoethoxy)but-3-enoic acid,C(COC=CC(C(=O)O)N)N,,,,,,
6860,41555,"2,3,5-Trichlorobiphenyl",C1=CC=C(C=C1)C2=C(C(=CC(=C2)Cl)Cl)Cl,,,,,,
6861,41556,"2,2',4,4',5,6'-Hexachlorodiphenyl ether",C1=C(C=C(C(=C1Cl)OC2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
6862,41557,CID 41557,CC(CC[C@H](C(C)(C)O)O)C1CCC2[C@@]1(CCCC2=CC=C3C[C@@H](CCC3=C)O)C,,,,,,
6863,41558,"1,2,6,7-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C=CC(=C3Cl)Cl)Cl)Cl,,,,,,
6864,41559,7-Methyl-7-heptadecanol,CCCCCCCCCCC(C)(CCCCCC)O,,,,,,
6865,41560,(3-Chloro-1-propynyl)cyclohexane,C1CCC(CC1)C#CCCl,,,,,,
6866,41561,5-Methoxy-2-methyl-2-pentanol,CC(C)(CCCOC)O,,,,,,
6867,41562,4-Butoxybutanoic acid,CCCCOCCCC(=O)O,,,,,,
6868,41563,1-beta-D-Arabinofuranosyl-N(sup 4)-lauroylcytosine,CCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
6869,41564,"CYTOSINE, 1-beta-D-ARABINOFURANOSYL-N(sup 4)-MYRISTOYL-",CCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
6870,41565,1-beta-D-Arabinofuranosyl-N(sup 4)-stearoylcytosine,CCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
6871,41566,1-beta-D-Arabinofuranosyl-N(sup 4)-palmitoylcytosine,CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
6872,41567,"Acetic acid, (4,6-dimethylpyrimidin-2-ylthio)-",CC1=CC(=NC(=N1)SCC(=O)O)C,,,,,,
6873,41568,3-(2-Methoxy-1-methylethoxy)-1-propanamine,CC(COC)OCCCN,,,,,,
6874,41569,"2,5-Dimethylfuran-3-thiol",CC1=CC(=C(O1)C)S,,,,,,
6875,41570,"2,5-Dimethyl-3-thioisovalerylfuran",CC1=CC(=C(O1)C)SC(=O)CC(C)C,,,,,,
6876,41571,"methyl-[2-[methyl-[(2R)-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azaniumyl]ethyl]-[(2R)-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azanium;dichloride",CC[C@H](COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)[NH+](C)CC[NH+](C)[C@H](CC)COC(=O)C2=CC(=C(C(=C2)OC)OC)OC.[Cl-].[Cl-],,,,,,
6877,41572,"[(2R)-2-[methyl-[2-[methyl-[(2R)-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]amino]ethyl]amino]butyl] 3,4,5-trimethoxybenzoate",CC[C@H](COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)N(C)CCN(C)[C@H](CC)COC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
6878,41573,Ethylpentachlorophenoxyacetate,CCOC(=O)COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
6879,41574,Arprinocid,C1=CC(=C(C(=C1)Cl)CN2C=NC3=C(N=CN=C32)N)F,,,"['Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)', 'Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)']",,,
6880,41575,p-Iodohippuric acid,C1=CC(=CC=C1C(=O)NCC(=O)O)I,,,,,,
6881,41576,"Hexananilide, 3'-hydroxy-",CCCCCC(=O)NC1=CC(=CC=C1)O,,,,,,
6882,41577,"3'-Hydroxy-2,2-dimethylbutyranilide",CCC(C)(C)C(=O)NC1=CC(=CC=C1)O,,,,,,
6883,41578,3'-Hydroxy-2-methylhexananilide,CCCCC(C)C(=O)NC1=CC(=CC=C1)O,,,,,,
6884,41579,3'-Hydroxy-3-methylcrotonanilide,CC(=CC(=O)NC1=CC(=CC=C1)O)C,,,,,,
6885,41580,(3-Methoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,COC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6886,41581,2-(1-piperidyl)ethyl N-(3-methoxyphenyl)carbamate,COC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6887,41582,(4-Methoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,COC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6888,41583,2-piperidin-1-ylethyl N-(4-methoxyphenyl)carbamate,COC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6889,41584,(2-Ethoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6890,41585,2-(1-piperidyl)ethyl N-(2-ethoxyphenyl)carbamate,CCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6891,41586,(3-Ethoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6892,41587,2-(1-piperidyl)ethyl N-(3-ethoxyphenyl)carbamate,CCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6893,41588,(4-Ethoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6894,41589,"Carbamic acid, (4-ethoxyphenyl)-, 2-(1-piperidinyl)ethyl ester",CCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6895,41590,(2-Propoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6896,41591,"Carbamic acid, (2-propoxyphenyl)-, 2-(1-piperidinyl)ethyl ester",CCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6897,41592,(4-Propoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6898,41593,1-[2-[[(4-Propoxyphenyl)amino]carbonyloxy]ethyl]piperidine,CCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6899,41594,(2-Butoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6900,41595,"Carbamic acid, (2-butoxyphenyl)-, 2-(1-piperidinyl)ethyl ester",CCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6901,41596,(3-Butoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6902,41597,"Carbamic acid, (3-butoxyphenyl)-, 2-(1-piperidinyl)ethyl ester",CCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6903,41598,(4-Butoxyphenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6904,41599,2-(1-piperidyl)ethyl N-(4-butoxyphenyl)carbamate,CCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6905,41600,N-(2-(2-Pentyloxyphenylcarbamoyloxy)ethyl)piperidinium chloride,CCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6906,41601,"Carbamic acid, [2-(pentyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6907,41602,(4-(Pentyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6908,41603,2-(1-piperidyl)ethyl N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6909,41604,(2-(Hexyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6910,41605,"Carbamic acid, [2-(hexyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6911,41606,(3-(Hexyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6912,41607,2-(1-piperidyl)ethyl N-(3-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6913,41608,(4-(Hexyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6914,41609,"Carbamic acid, [4-(hexyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6915,41610,Heptacaine,CCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
6916,41611,"Carbamic acid, (2-(heptyloxy)phenyl)-, 2-(1-piperidinyl)ethyl ester",CCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6917,41612,N-(2-(3-Heptyloxyphenylcarbamoyloxy)ethyl)piperidinium chloride,CCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6918,41613,"Carbamic acid, [3-(heptyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6919,41614,N-(2-(4-Heptyloxyphenylcarbamoyloxy)ethyl)piperidinium chloride,CCCCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6920,41615,2-Piperidinoethyl-4-heptyloxyphenylcarbamate,CCCCCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCC2,,,,,,
6921,41616,(2-(Octyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6922,41617,"Carbamic acid, [2-(octyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6923,41618,(3-(Octyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6924,41619,2-(1-piperidyl)ethyl N-(3-octoxyphenyl)carbamate,CCCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6925,41620,N-(2-(2-Nonyloxyphenylcarbamoyloxy)ethyl)piperidinium chloride,CCCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6926,41621,"Carbamic acid, [2-(nonyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6927,41622,(3-(Nonyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6928,41623,"Carbamic acid, [3-(nonyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6929,41624,(2-(Decyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6930,41625,2-(1-Piperidinyl)ethyl 2-(decyloxy)phenylcarbamate,CCCCCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCC2,,,,,,
6931,41626,(3-(Decyloxy)phenyl)carbamic acid 2-(1-piperidinyl)ethyl ester hydrochloride,CCCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
6932,41627,"Carbamic acid, [3-(decyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester",CCCCCCCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCC2,,,,,,
6933,41628,"Benzoic acid, 3,4,5-trimethoxy-, (1,4,5,6-tetrahydro-5,5-diethyl-4,6-dioxo-3-pyridinyl)methyl ester",CCC1(C(=O)C(=CNC1=O)COC(=O)C2=CC(=C(C(=C2)OC)OC)OC)CC,,,,,,
6934,41629,"Benzoic acid, 2-(acetyloxy)-, (1,4,5,6-tetrahydro-5,5-diethyl-4,6-dioxo-3-pyridinyl)methyl ester",CCC1(C(=O)C(=CNC1=O)COC(=O)C2=CC=CC=C2OC(=O)C)CC,,,,,,
6935,41630,"Benzoic acid, 2-hydroxy-, (1,4,5,6-tetrahydro-5,5-diethyl-4,6-dioxo-3-pyridinyl)methyl ester",CCC1(C(=O)C(=CNC1=O)COC(=O)C2=CC=CC=C2O)CC,,,,,,
6936,41631,Trinitronaphthalene,C1=CC2=C(C=C(C=C2C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6937,41632,Mepronil,CC1=CC=CC=C1C(=O)NC2=CC(=CC=C2)OC(C)C,,,,,,
6938,41633,"1-Propanone, 2,2-dimethyl-1-(4-phenoxyphenyl)-",CC(C)(C)C(=O)C1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
6939,41634,"beta-Alanine, N-(2-hydroxy-3,3-dimethyl-1-oxo-4-(phosphonoxy)butyl)-, calcium salt (1:1), (R)-",CC(C)(COP(=O)(O)[O-])[C@H](C(=O)NCCC(=O)[O-])O.[Ca+2],,,,,,
6940,41635,Phosphopantothenic acid,CC(C)(COP(=O)(O)O)[C@H](C(=O)NCCC(=O)O)O,,,,,,
6941,41636,"Indole, 5-hydroxy-3-(4-piperidylmethyl)-",C1CNCCC1CC2=CNC3=C2C=C(C=C3)O,,,,,,
6942,41637,[(2-Amino-3-hydroxypropanoyl)amino]-propan-2-ylazanium;chloride,CC(C)[NH2+]NC(=O)C(CO)N.[Cl-],,,,,,
6943,41638,Serine isopropylhydrazide,CC(C)NNC(=O)C(CO)N,,,,,,
6944,41639,"3-Benzofurancarboxylic acid, 4-chloro-6-(diethylaminomethyl)-5-hydroxy-2-methyl-, ethyl ester",CCN(CC)CC1=CC2=C(C(=C(O2)C)C(=O)OCC)C(=C1O)Cl,,,,,,
6945,41640,4-Chloro-5-hydroxy-2-methyl-6-(morpholinomethyl)-3-benzofurancarboxylic acid ethyl ester,CCOC(=O)C1=C(OC2=C1C(=C(C(=C2)CN3CCOCC3)O)Cl)C,,,,,,
6946,41641,"3-Benzofurancarboxylic acid, 4-chloro-5-hydroxy-2-methyl-6-((4-methyl-1-piperazinyl)methyl)-, ethyl ester",CCOC(=O)C1=C(OC2=C1C(=C(C(=C2)CN3CCN(CC3)C)O)Cl)C,,,,,,
6947,41642,"2,5-Cyclohexadiene-1,4-dione, compd. with 2-methylbenzene-1,4-diol",CC1=C(C=CC(=C1)O)O.C1=CC(=O)C=CC1=O,,,,,,
6948,41643,Butibufen,CCC(C1=CC=C(C=C1)CC(C)C)C(=O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
6949,41644,"Isoquinolinium, methoxycarbonylmethyl-, bromide",COC(=O)CC1=[NH+]C=CC2=CC=CC=C21.[Br-],,,,,,
6950,41645,Methyl 2-(isoquinolin-1-YL)acetate,COC(=O)CC1=NC=CC2=CC=CC=C21,,,,,,
6951,41646,"1-[4-(1,3-Benzodioxol-5-ylmethyl)piperazin-1-yl]-2-[[(6,7-dimethoxyisoquinolin-1-yl)-(3,4-dimethoxyphenyl)methylidene]amino]oxyethanone",COC1=C(C=C(C=C1)C(=NOCC(=O)N2CCN(CC2)CC3=CC4=C(C=C3)OCO4)C5=NC=CC6=CC(=C(C=C65)OC)OC)OC,,,,,,
6952,41647,2-chloro-N-(2-methoxyphenyl)acetamide,COC1=CC=CC=C1NC(=O)CCl,,,,,,
6953,41648,Isouron,CC(C)(C)C1=CC(=NO1)NC(=O)N(C)C,,,,,,
6954,41649,4-Chloro-6-dimethylaminomethyl-5-hydroxy-2-phenyl-3-benzofurancarboxylic acid ethyl ester,CCOC(=O)C1=C(OC2=C1C(=C(C(=C2)CN(C)C)O)Cl)C3=CC=CC=C3,,,,,,
6955,41650,Pentachlorobutadiene,C(=C(Cl)Cl)C(=C(Cl)Cl)Cl,,,,,,
6956,41651,(+-)-2-Amino-N-(1-methyl-2-phenylethyl)acetamide hydrochloride,CC(CC1=CC=CC=C1)NC(=O)C[NH3+].[Cl-],,,,,,
6957,41652,2-amino-N-(1-phenylpropan-2-yl)acetamide,CC(CC1=CC=CC=C1)NC(=O)CN,,,,,,
6958,41653,"[(4R,5S,6S,7R,9R,10R,16R)-10-acetyloxy-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4-acetyloxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate",CCC(=O)O[C@@H]1CC(=O)O[C@@H](CC=CC=C[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C,,,,,,
6959,41654,Diethyl methylpropylmalonate,CCCC(C)(C(=O)OCC)C(=O)OCC,,,,,,
6960,41655,CID 41655,CC(=O)NC1=CC=C(C=C1)C(=O)NN=CC2=C(C=CC(=C2)NC(=O)C)C(=O)OC3=CC=CC=C3,,,,,,
6961,41656,"Benzoic acid, 2-(acetyloxy)-2-(((4-(acetylamino)benzoyl)hydrazono)methyl)phenyl ester",CC(=O)NC1=CC=C(C=C1)C(=O)N=NCC2=CC=CC=C2OC(=O)C3=CC=CC=C3OC(=O)C,,,,,,
6962,41657,CID 41657,CC(=O)NC1=CC=C(C=C1)C(=O)NN=CC2=CC=CC=C2OC(=O)C3=CC(=CC=C3)[N+](=O)[O-],,,,,,
6963,41658,"Acetic acid, (2,3-dichloro-4-(3-thienylcarbonyl)phenoxy)-",C1=CC(=C(C(=C1C(=O)C2=CSC=C2)Cl)Cl)OCC(=O)O,,,,,,
6964,41659,"Acetic acid, (2,3-dichloro-4-(5-methyl-2-thenoyl)phenoxy)-",CC1=CC=C(S1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,,,,,,
6965,41660,"Acetic acid, (2,3-dichloro-4-(2-furoyl)phenoxy)-",C1=COC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,,,,,,
6966,41661,"Acetic acid, (2,3-dichloro-4-((2-thienyl)hydroxymethyl)phenoxy)-",C1=CSC(=C1)C(C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl)O,,,,,,
6967,41662,"Acetic acid, (2,3-dichloro-4-(2-thienylmethyl)phenoxy)-",C1=CSC(=C1)CC2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,,,,,,
6968,41663,4-(Bromomethyl)phenol,C1=CC(=CC=C1CBr)O,,,,,,
6969,41664,2-Nitro-4-phenylazophenol,C1=CC=C(C=C1)N=NC2=CC(=C(C=C2)O)[N+](=O)[O-],,,,,,
6970,41665,"Benzoic acid, p-((p-(benzoyloxymethylamino)phenyl)azo)-, methyl ester",CN(C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C(=O)OC)OC(=O)C3=CC=CC=C3,,,,,,
6971,41666,4'-Methoxycarbonyl-N-acetoxy-N-methyl-4-aminoazobenzene,CC(=O)ON(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C(=O)OC,,,,,,
6972,41667,"BENZOIC ACID, p-((p-(METHYLHYDROXYAMINO)PHENYL)AZO)-, METHYL ESTER",CN(C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C(=O)OC)O,,,,,,
6973,41668,CID 41668,C1=CC=C(C(=C1)C(=O)[O-])[Hg].O.[Na+],,,,,,
6974,41669,"Cyanamide, N-(4-acetamido-4-carbamoylbutyl)-N-nitroso-",CC(=O)NC(CCCN(C#N)N=O)C(=O)N,,,,,,
6975,41670,Sutan E,CCSC(=O)N(CC(C)C)CC(C)C.C=CCN(CC=C)C(=O)C(Cl)Cl,,,,,,
6976,41671,Methyl 2-methyltridecanoate,CCCCCCCCCCCC(C)C(=O)OC,,,,,,
6977,41672,2-[(Dimethylamino)methyl]-4-ethylbenzenol,CCC1=CC(=C(C=C1)O)CN(C)C,,,,,,
6978,41673,2-(2-Methoxy-1-methylethoxy)-2-propanol,CC(COC)OC(C)(C)O,,,,,,
6979,41674,"2-Propanol, 1-[1-methyl-2-(2-propenyloxy)ethoxy]-",CC(COC(C)COCC=C)O,,,,,,
6980,41675,CID 41675,CCCCC=CC(C)N(C)C,,,,,,
6981,41676,"4,5-Dimethyl-3-hydroxy-hept-2-ene",CCC(C)C(C)C(=CC)O,,,,,,
6982,41677,3-Prop-2-ynylcyclohexene,C#CCC1CCCC=C1,,,,,,
6983,41678,Sodium;1-methoxy-4-prop-1-enylbenzene;sulfite,CC=CC1=CC=C(C=C1)OC.[O-]S(=O)[O-].[Na+],,,,,,
6984,41679,Kathon 886,CN1C(=O)C=CS1.CN1C(=O)C=C(S1)Cl,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
6985,41680,Oxoglaucine methiodide,C[N+]1=C2C3=C(C4=CC(=C(C=C4C2=O)OC)OC)C(=C(C=C3C=C1)OC)OC.[I-],,,,,,
6986,41681,"4,5,15,16-Tetramethoxy-10-methyl-10-azoniatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2,4,6,9,11,13,15-octaen-8-one",C[N+]1=C2C3=C(C4=CC(=C(C=C4C2=O)OC)OC)C(=C(C=C3C=C1)OC)OC,,,,,,
6987,41682,CID 41682,CCCCC=CC(CCC)C#C,,,,,,
6988,41683,"Undeca-1,4-diene",CCCCCCC=CCC=C,,,,,,
6989,41684,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],"['For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>,  and for the treatment of diarrhea in children caused by the protozoan,  <i>Cryptosporidium parvum</i>.  Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency.']","['The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation.  Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, an essential reaction need for anaerobic energy metabolism of various microorganisms.  Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited, relieving symptoms of diahrrea. Interference with the PFOR enzyme-dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity.']",['Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)'],"['The relative bioavailability of the suspension compared to the tablet was 70%. When administered with food the AUC and C<sub>max</sub> increased by two-fold and 50%, respectively, for the tablet and 45 to 50% and &le; 10%, respectively, for the oral suspension.', 'Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately 2/3 of the oral dose of nitazoxanide is excreted in the faeces and 1/3 in the urine.', 'Nitazoxanide is cleared in the urine and feces. The metabolite, tizoxanide, is also found in the urine, plasma, and breastmilk.  The drug is not found unchanged in the urine.']","['The active metabolite of this drug is tizoxanide (desacetyl-nitazoxanide). The initial reaction in the metabolic pathway of Nitazoxanide is hydrolysis to tizoxanide,  followed by conjugation, primarily by glucuronidation to tizoxanide glucuronide.  The oral suspension bioavailability of this drug is not equivalent to that of the oral tablets. Compared to the to the tablet, the bioavailability of the suspension was 70%.  When administered with food, the AUCt of tizoxanide and tizoxanide glucuronide in plasma is increased to almost two-fold and the maximum concentration is increased by almost 50% compared to when ingested without food.  When the oral suspension was ingested with food, the AUC of tizoxanide and tizoxanide glucuronide increased by approximately 50% and the Cmax increased by less than 10%.']",['7.3h']
6990,41685,"[(3S)-3,7,11-trimethyldodeca-1,6,10-trien-3-yl] acetate",CC(=CCCC(=CCC[C@@](C)(C=C)OC(=O)C)C)C,,,,,,
6991,41686,"Glycine, N-nitro-N-(2,2,2-trinitroethyl)-, methyl ester",COC(=O)CN(CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6992,41687,"1-(1,5-Dimethylhexyl)-4-(4-methylpentyl)cyclohexane",CC(C)CCCC1CCC(CC1)C(C)CCCC(C)C,,,,,,
6993,41688,Methyl 2-methoxy-4-methylpent-2-enoate,CC(C)C=C(C(=O)OC)OC,,,,,,
6994,41689,3-(p-Chlorophenyl)-5-methylhydantoin,CC1C(=O)N(C(=O)N1)C2=CC=C(C=C2)Cl,,,,,,
6995,41690,4-Cyclohexylcyclohexanone,C1CCC(CC1)C2CCC(=O)CC2,,,,,,
6996,41691,"2,2'-Biphenyldiglyoxylaldehyde",C1=CC=C(C(=C1)C2=CC=CC=C2C(=O)C=O)C(=O)C=O,,,,,,
6997,41692,3-(3-Methylbut-1-enyl)cyclohexene,CC(C)C=CC1CCCC=C1,,,,,,
6998,41693,Sufentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC,"['The indications for this drug are as follows:  1. As an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated.  2. As a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.  3. For epidural administration as an analgesic combined with low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery   4. The sublingual form is indicated for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments.']","['**Effect on the Central Nervous System (CNS)**   In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary therapeutic actions are analgesia and sedation. Sufentanil may increase pain tolerance and decrease the perception of pain. This drug depresses the respiratory centers, depresses the cough reflex, and constricts the pupils,. When used in balanced general anesthesia, sufentanil has been reported to be as much as 10 times as potent as fentanyl. When administered intravenously as a primary anesthetic agent with 100% oxygen, sufentanil is approximately 5 to 7 times as potent as fentanyl. High doses of intravenous sufentanil have been shown to cause muscle rigidity, likely as a result of an effect on the substantia nigra and the striate nucleus in the brain. Sleep-inducing (hypnotic) activity can be demonstrated by EEG alterations.  **Effects on the Respiratory System**  Sufentanil may cause respiratory depression.  **Effects on the Cardiovascular System**  Sufentanil causes peripheral vasodilation which may result in orthostatic hypotension or syncope. Bradycardia may also occur. Clinical signs or symptoms of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension.  **Effects on the Gastrointestinal Tract**  Sufentanil causes a reduction in motility associated with an increase in smooth muscle tone in both the antrum of the stomach and duodenum. Digestion of food in the small intestine may be delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased and lead to spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of the sphincter of Oddi, as well as temporary elevations in serum amylase.']","['Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']","['Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.  After epidural administration of incremental doses totaling 5 to 40 mcg sufentanil during labor and delivery, maternal and neonatal sufentanil plasma concentrations were at or near the 0.05 to 0.1 ng/mL limit of detection, and were slightly higher in mothers than in their infants.', 'Approximately 80% of the administered dose is excreted within 24 hours and only 2% of the dose is eliminated as unchanged drug.', 'Sufentanil has a distribution time of 1.4 minutes and redistribution time of 17.1 minutes. The central volume of distribution after intravenous application of sufentanil is approximately 14 L and the volume of distribution at steady state is approximately 350 L.', 'The total plasma clearance after single intravenous administration is about 917 l/min.  The clearance of sufentanil in healthy neonates is approximately one-half that in adults and children. The clearance rate of sufentanil can be further reduced by up to a third in neonates with cardiovascular disease.', 'This randomized double-blind investigation was designed to study the placental transfer and neonatal effects of epidural sufentanil and fentanyl infused with bupivacaine for labor analgesia. Healthy parturient women (n = 36) received epidural bupivacaine alone (group B) or with fentanyl (group B-F) or sufentanil (group B-S). Group B received a 12-ml bolus of 0.25% bupivacaine followed by a 10 mL/hr infusion of 0.125% bupivacaine. Groups B-F and B-S received a 12-mL bolus of 0.125% bupivacaine with 75 ug fentanyl or 15 ug sufentanil, respectively, followed by 10 mL/hr of 0.125% bupivacaine with fentanyl 1.5 ug/mL or sufentanil 0.25 ug/mL. Maternal venous (MV) and umbilical arterial (UA) and umbilical venous (UV) bupivacaine and opioid plasma concentrations were determined. Neonatal assessment included Apgar scores, umbilical cord blood gas analyses, and neurobehavioral testing at delivery and at 2 and 24 hr of life using the Neurologic and Adaptive Capacity Score (NACS). The mean total dose of fentanyl was 136.6 +/- 13.1 micrograms (SEM), and of sufentanil, 23.8 +/- 1.8 micrograms. Although administered in a ratio of 5.7:1, fentanyl and sufentanil MV plasma concentrations were in the ratio of 27:1. UV/MV ratios were 0.37 for fentanyl and 0.81 for sufentanil. Fentanyl was detected in most UA samples, whereas sufentanil was present in only one sample. Neonatal condition was good and generally similar in all groups, with the exception of a lower NACS at 24 h in group B-F. Although the degree of placental transfer of sufentanil appeared greater than that of fentanyl, lower MV sufentanil concentrations resulted in less fetal exposure to sufentanil. The lower NACS at 24 hr in group B-F may reflect the continued presence of fentanyl in the neonate.', 'The effects of cirrhosis on the elimination kinetics and plasma protein binding of sufentanil were evaluated in 12 anesthetized patients with uncomplicated cirrhosis and these findings were compared with data from age-matched control anesthetized patients with normal hepatic and renal function. Sufentanil 3 ug/kg was given iv as a bolus injection and venous plasma concentrations were measured at intervals up to 10 hr. The average (+ or - standard deviation) elimination half life was 3.5 + or - 0.9 hr in controls and did not differ in cirrhotics: 4.1 + or - 0.6 hr. The plasma clearance did not differ between the two groups: 11.3 + or - 2.5 ml/min kg in controls and 10.8 + or - 4.6 ml/min kg in cirrhotic patients. The sufentanil free fraction was also similar in controls (8.3 + or - 1.5%) and in cirrhotic patients (9.6 + or - 1.8%). These data suggest that sufentanil in a single dose should have a similar duration of action in patients with uncomplicated cirrhosis and in normal patients.', 'The in vitro plasma protein binding and distribution in blood of fentanyl and three analogues were studied in rats, dogs and healthy volunteers. In human plasma, 84.4% of fentanyl was bound, 92.5% of sufentanil, 92.1% of alfentanil and 93.6% of lofentanil. Plasma protein binding of the four analgesics was independent of their concentration over the whole therapeutic range. Plasma protein binding of alfentanil was much less pH dependent than that of the three other analgesics. Attention was drawn to the possible contribution of the ""acute phase\' protein alpha 1-acid glycoprotein (alpha 1-AGP), of lipoproteins and of blood cells to the binding of fentanyl and its analogues in blood.', 'The aim of this study was to compare the pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. Six adult cats were used. Anesthesia was induced and maintained with isoflurane in oxygen. End-tidal isoflurane concentration was set at 2% and adjusted as required due to spontaneous movement. Fentanyl (10 ug/kg), alfentanil (100 ug/kg), or sufentanil (1 ug/kg) was administered intravenously as a bolus, on separate days. Blood samples were collected immediately before and for 8 hr following drug administration. Plasma drug concentration was determined using liquid chromatography/mass spectrometry. Compartment models were fitted to concentration-time data. A 3-compartment model best fitted the concentration-time data for all drugs, except for 1 cat in the sufentanil group (excluded from analysis). The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean +/- SEM (range)], the clearance (mL/min/kg) [harmonic mean +/- pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 +/- 0.04 (0.09-0.34), 2.18 +/- 0.16 (1.79-2.83), 18.6 +/- 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 +/- 0.01 (0.07-0.14), 0.89 +/- 0.16 (0.68-1.83), 11.6 +/- 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 +/- 0.01 (0.04-0.10), 0.77 +/- 0.07 (0.63-0.99), 17.6 +/- 4.3 (13.9-24.3), and 54 (46-76) for sufentanil. Differences in clearance and volume of distribution result in similar terminal half-lives for fentanyl and alfentanil, longer than for sufentanil.', 'For more Absorption, Distribution and Excretion (Complete) data for Sufentanil (18 total), please visit the HSDB record page.']","['The liver and small intestine are the major sites of biotransformation. Sufentanil is rapidly metabolized to a number of inactive metabolites, with oxidative N- and O-dealkylation being the major routes of elimination.', 'Although the metabolic fate of sufentanil in humans has not been fully characterized, the drug appears to be metabolized mainly in the liver and small intestine via N-dealkylation at the piperidine nitrogen and O-demethylation. The O-demethylated metabolite appears to have about 10% of the analgesic activity of the unchanged drug. The hepatic extraction ratio of the drug (EH) has been reported to be about 0.72 following IV administration of a single 5-mcg/kg dose.']","['The elimination half-life is 164 minutes in adults when administered intravenously (IV). The elimination half-life of sufentanil is shorter (e.g. 97 +/- 42 minutes) in infants and children, and longer in neonates (e.g. 434 +/- 160 minutes) compared to that of adolescents and adults.  After a single administration of a 15 microgram sufentanil sublingual tablet, mean terminal phase half-lives in the range of 6-10 hours have been observed. After multiple administrations, a longer average terminal half-life of up to 18 hours was measured, owing to the higher plasma concentrations of sufentanil achieved after repeated dosing and due to the possibility to quantify these concentrations over a longer time period.', 'In adults with normal renal and hepatic function, the plasma half-life in the initial (distribution) phase averages 0.72-1.2 minutes, the plasma half-life in the second (redistribution) phase averages 13.7-17 minutes, and the plasma half-life in the terminal (elimination) phase averages 140-158 minutes. The elimination half-life is longer (434 minutes) in neonates but shorter in infants and children (97 minutes), compared with adults and adolescents.']"
6999,41694,"Methanesulfonamide, N-[2-[ethyl(3-methyl-4-nitrosophenyl)amino]ethyl]-",CCN(CCNS(=O)(=O)C)C1=CC(=C(C=C1)N=O)C,,,,,,
7000,41695,Dibutyl 3-methylpentanedioate,CCCCOC(=O)CC(C)CC(=O)OCCCC,,,,,,
7001,41696,1-Methoxyhex-2-ene,CCCC=CCOC,,,,,,
7002,41697,2-Ethyl-3-propyloxirane (trans),CCC[C@H]1[C@@H](O1)CC,,,,,,
7003,41698,"1-(1,3-Dioxolan-2-yl)-4-propylhept-3-en-2-one",CCCC(=CC(=O)CC1OCCO1)CCC,,,,,,
7004,41699,"7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-(2,3-dihydroxypropoxy)-2H-1,4-benzodiazepin-2-one",C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)OCC(CO)O)Cl,,,,,,
7005,41700,"(1,1-Dipropylbutyl)ammonium chloride",CCCC(CCC)(CCC)[NH3+].[Cl-],,,,,,
7006,41701,Diprobutine,CCCC(CCC)(CCC)N,,,,,,
7007,41702,5-Butyl-5-nonanamine hydrochloride,CCCCC(CCCC)(CCCC)[NH3+].[Cl-],,,,,,
7008,41703,5-Butylnonan-5-amine,CCCCC(CCCC)(CCCC)N,,,,,,
7009,41704,2-Methyl-4-propyl-4-heptanamine hydrochloride,CCCC(CCC)(CC(C)C)[NH3+].[Cl-],,,,,,
7010,41705,2-Methyl-4-propylheptan-4-amine,CCCC(CCC)(CC(C)C)N,,,,,,
7011,41706,3-Ethyl-3-hexanamine hydrochloride,CCCC(CC)(CC)[NH3+].[Cl-],,,,,,
7012,41707,"3-Hexanamine, 3-ethyl-",CCCC(CC)(CC)N,,,,,,
7013,41708,4-Ethyl-4-heptanamine hydrochloride,CCCC(CC)(CCC)[NH3+].[Cl-],,,,,,
7014,41709,4-Ethylheptan-4-amine,CCCC(CC)(CCC)N,,,,,,
7015,41710,4-Ethyl-2-methyl-4-heptanamine hydrochloride,CCCC(CC)(CC(C)C)[NH3+].[Cl-],,,,,,
7016,41711,4-Ethyl-2-methylheptan-4-amine,CCCC(CC)(CC(C)C)N,,,,,,
7017,41712,"3,5-Dimethyl-3-octanamine hydrochloride",CCCC(C)CC(C)(CC)[NH3+].[Cl-],,,,,,
7018,41713,"3,5-Dimethyloctan-3-amine",CCCC(C)CC(C)(CC)N,,,,,,
7019,41714,4-Methyl-4-nonanamine hydrochloride,CCCCCC(C)(CCC)[NH3+].[Cl-],,,,,,
7020,41715,4-Methylnonan-4-amine,CCCCCC(C)(CCC)N,,,,,,
7021,41716,4-Ethyl-4-octanamine hydrochloride,CCCCC(CC)(CCC)[NH3+].[Cl-],,,,,,
7022,41717,1-Ethyl-1-n-propyl-n-pentylamine,CCCCC(CC)(CCC)N,,,,,,
7023,41718,Terbufos sulfone,CCOP(=S)(OCC)SCS(=O)(=O)C(C)(C)C,,,,,,
7024,41719,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7,8-dimethyl-4-(4-methyl-1-piperazinyl)-, dihydrochloride",CC1=CC2=C(C=C1C)OCCC(C2=O)N3CCN(CC3)C.Cl.Cl,,,,,,
7025,41720,"7,8-dimethyl-4-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1C)OCCC(C2=O)N3CCN(CC3)C,,,,,,
7026,41721,"1-Benzoxepin-5(2H)-one, 3,4-dihydro-7,8-dimethyl-4-piperidino-, hydrochloride",CC1=CC2=C(C=C1C)OCCC(C2=O)[NH+]3CCCCC3.[Cl-],,,,,,
7027,41722,"7,8-dimethyl-4-piperidin-1-yl-3,4-dihydro-2H-1-benzoxepin-5-one",CC1=CC2=C(C=C1C)OCCC(C2=O)N3CCCCC3,,,,,,
7028,41723,"cis-7,8-Dimethyl-4-piperidino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol hydrochloride",CC1=CC2=C(C=C1C)OCC[C@H]([C@H]2O)[NH+]3CCCCC3.[Cl-],,,,,,
7029,41724,CID 41724,CC1=CC2=C(C=C1C)OCCC([C@H]2O)N3CCCCC3,,,,,,
7030,41725,"trans-7,8-Dimethyl-4-(4-methyl-1-piperazinyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol",CC1=CC2=C(C=C1C)OCCC([C@H]2O)N3CCN(CC3)C,,,,,,
7031,41726,"trans-7,8-Dimethyl-4-piperidino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol hydrochloride",CC1=CC2=C(C=C1C)OCC[C@@H]([C@H]2O)[NH+]3CCCCC3.[Cl-],,,,,,
7032,41727,"7,8-Dimethyl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine hydrochloride",CC1=CC2=C(C=C1C)OCCCC2[NH3+].[Cl-],,,,,,
7033,41728,"7,8-Dimethyl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CC1=CC2=C(C=C1C)OCCCC2N,,,,,,
7034,41729,CID 41729,CC(C)[NH2+]C1CCCOC2=CC=CC=C12.C(=CC(=O)[O-])C(=O)O,,,,,,
7035,41730,"N-propan-2-yl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CC(C)NC1CCCOC2=CC=CC=C12,,,,,,
7036,41731,CID 41731,CC1=CC2=C(C=C1)OCCCC2[NH2+]C(C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
7037,41732,"7-methyl-N-propan-2-yl-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CC1=CC2=C(C=C1)OCCCC2NC(C)C,,,,,,
7038,41733,"7-Methyl-N-(p-methylphenethyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-amine hydrochloride",CC1=CC=C(C=C1)CC[NH2+]C2CCCOC3=C2C=C(C=C3)C.[Cl-],,,,,,
7039,41734,"7-methyl-N-[2-(4-methylphenyl)ethyl]-2,3,4,5-tetrahydro-1-benzoxepin-5-amine",CC1=CC=C(C=C1)CCNC2CCCOC3=C2C=C(C=C3)C,,,,,,
7040,41735,CID 41735,C1C(CC2=CC=CC=C2C1C3=C(OC4=CC=CC=C4C3=O)O)C5=CC=C(C=C5)C6=CC=CC=C6,,,,,,
7041,41736,CID 41736,C1C(CC2=CC=CC=C2C1C3=C(OC4=CC=CC=C4C3=O)O)C5=CC=C(C=C5)C6=CC=C(C=C6)Br,,,,,,
7042,41737,Ropitoin hydrochloride,COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CCCN3CCC(CC3)C4=CC=CC=C4)C5=CC=CC=C5.Cl,,,,,,
7043,41738,Ropitoin,COC1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)CCCN3CCC(CC3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
7044,41739,CID 41739,C[C@H](CCC(=O)O)C[C@H](C)C[C@@H](C)C(=O)C=C([C@H](C)C[C@H](C)CC=C[C@H](C)[C@H]([C@H](C)[C@@H](C[C@H]1CC[C@](O1)(C)[C@H]2CC[C@@](O2)(C)[C@H](C)O)O)O)O,,,,,,
7045,41740,"Dibenzo(b,f)thiepin-3-ol, 10,11-dihydro-8-chloro-10-(4-methyl-1-piperazinyl)-, monomethanesulfonate, hydrate",CN1CC[NH+](CC1)C2CC3=C(C=C(C=C3)O)SC4=C2C=C(C=C4)Cl.CS(=O)(=O)[O-],,,,,,
7046,41741,"3-Chloro-5-(4-methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-9-ol",CN1CCN(CC1)C2CC3=C(C=C(C=C3)O)SC4=C2C=C(C=C4)Cl,,,,,,
7047,41742,"3,7,9-Trimethyldeca-1,6-dien-3-ol",CC(C)CC(=CCCC(C)(C=C)O)C,,,,,,
7048,41743,4-Chloro-3-nitrobenzophenone,C1=CC=C(C=C1)C(=O)C2=CC(=C(C=C2)Cl)[N+](=O)[O-],,,,,,
7049,41744,N-Trifluoroacetyladriamycin-14-valerate,CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)C)O)NC(=O)C(F)(F)F)O,,,,,,
7050,41745,"N-Phenyldiethanolamine bis(2-methoxy-3,6-dichlorobenzoate)",COC1=C(C=CC(=C1C(=O)OCCN(CCOC(=O)C2=C(C(=CC(=C2)Cl)Cl)OC)C3=CC=CC=C3)Cl)Cl,,,,,,
7051,41746,CID 41746,C[C@H]1[C@H]2[C@@H](NC(=O)C23[C@@H](C=CCC(CC(C=C[C@H]3O)(C)O)C)C(C1=C)O)CC4=CC=CC=C4,,,,,,
7052,41747,2-Ethylindan,CCC1CC2=CC=CC=C2C1,,,,,,
7053,41748,4-Chloro-2-methylbenzenesulfonyl chloride,CC1=C(C=CC(=C1)Cl)S(=O)(=O)Cl,,,,,,
7054,41749,M-Hydroxybenzenesulphonyl chloride,C1=CC(=CC(=C1)S(=O)(=O)Cl)O,,,,,,
7055,41750,2-Methyl-2-nonanamine hydrochloride,CCCCCCCC(C)(C)[NH3+].[Cl-],,,,,,
7056,41751,2-Methylnonan-2-amine,CCCCCCCC(C)(C)N,,,,,,
7057,41752,CID 41752,CCCCC(C)(CC(C)C)[NH3+].CCCC(C)(CCC(C)C)[NH3+].C(=CC(=O)[O-])C(=O)[O-],,,,,,
7058,41753,"2,4-Dimethyloctan-4-amine",CCCCC(C)(CC(C)C)N,,,,,,
7059,41754,"4,7-Dimethyloctan-4-amine",CCCC(C)(CCC(C)C)N,,,,,,
7060,41755,2-((1-Methyltridecyl)amino)ethanol hydrochloride,CCCCCCCCCCCCC(C)[NH2+]CCO.[Cl-],,,,,,
7061,41756,2-(Tetradecan-2-ylamino)ethanol,CCCCCCCCCCCCC(C)NCCO,,,,,,
7062,41757,2-((1-Methylpentadecyl)amino)ethanol hydrochloride,CCCCCCCCCCCCCCC(C)[NH2+]CCO.[Cl-],,,,,,
7063,41758,2-(2-Hydroxyethyl)aminohexadecane,CCCCCCCCCCCCCCC(C)NCCO,,,,,,
7064,41759,"N,N-Bis(beta-hydroxyethyl)-2-aminododecane hydrochloride",CCCCCCCCCCC(C)[NH+](CCO)CCO.[Cl-],,,,,,
7065,41760,2-[Dodecan-2-yl(2-hydroxyethyl)amino]ethanol,CCCCCCCCCCC(C)N(CCO)CCO,,,,,,
7066,41761,2-((1-Methylundecyl)amino)ethanol hydrochloride,CCCCCCCCCCC(C)[NH2+]CCO.[Cl-],,,,,,
7067,41762,2-(Dodecan-2-ylamino)ethanol,CCCCCCCCCCC(C)NCCO,,,,,,
7068,41763,2-((1-Pentylheptyl)amino)ethanol hydrochloride,CCCCCCC(CCCCC)[NH2+]CCO.[Cl-],,,,,,
7069,41764,2-(Dodecan-6-ylamino)ethanol,CCCCCCC(CCCCC)NCCO,,,,,,
7070,41765,"N,N-Bis(beta-hydroxyethyl)-2-aminotetradecane hydrochloride",CCCCCCCCCCCCC(C)[NH+](CCO)CCO.[Cl-],,,,,,
7071,41766,"2,2'-(Tetradecan-2-ylazanediyl)diethanol",CCCCCCCCCCCCC(C)N(CCO)CCO,,,,,,
7072,41767,2-((1-Methylheptadecyl)amino)ethanol hydrochloride,CCCCCCCCCCCCCCCCC(C)[NH2+]CCO.[Cl-],,,,,,
7073,41768,2-(2-Hydroxyethyl)aminooctadecane,CCCCCCCCCCCCCCCCC(C)NCCO,,,,,,
7074,41769,"N,N-Bis(beta-hydroxyethyl)-2-aminooctadecane hydrochloride",CCCCCCCCCCCCCCCCC(C)[NH+](CCO)CCO.[Cl-],,,,,,
7075,41770,2-[2-Hydroxyethyl(octadecan-2-yl)amino]ethanol,CCCCCCCCCCCCCCCCC(C)N(CCO)CCO,,,,,,
7076,41771,"3,7-Dimethylocta-2,6-dienyl but-2-enoate",CC=CC(=O)OCC=C(C)CCC=C(C)C,,,,,,
7077,41772,Hydralazine acetone hydrazone,CC(=NNC1=NN=CC2=CC=CC=C21)C,,,,,,
7078,41773,"cis-7,8-Dimethyl-4-(4-methyl-1-piperazinyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol",CC1=CC2=C(C=C1C)OCC[C@H]([C@H]2O)N3CCN(CC3)C,,,,,,
7079,41774,Acarbose,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,,,['Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)'],"['In a study of 6 healthy men, less than 2% of an oral dose of acarbose was absorbed as active drug, while approximately 35% of total radioactivity from a 14C-labeled oral dose was absorbed. An average of 51% of an oral dose was excreted in the feces as unabsorbed drug-related radioactivity within 96 hours of ingestion. Because acarbose acts locally within the gastrointestinal tract, this low systemic bioavailability of parent compound is therapeutically desired.', 'Following oral dosing of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour. The delayed absorption of acarbose-related radioactivity reflects the absorption of metabolites that may be formed by either intestinal bacteria or intestinal enzymatic hydrolysis.', 'Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes. A fraction of these metabolites (approximately 34% of the dose) was absorbed and subsequently excreted in the urine.', 'The fraction of acarbose that is absorbed as intact drug is almost completely excreted by the kidneys. When acarbose was given intravenously, 89% of the dose was recovered in the urine as active drug within 48 hours. In contrast, less than 2% of an oral dose was recovered in the urine as active (i.e., parent compound and active metabolite) drug. This is consistent with the low bioavailability of the parent drug.', 'For more Absorption, Distribution and Excretion (Complete) data for Acarbose (6 total), please visit the HSDB record page.']","['Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes.  ... At least 13 metabolites have been separated chromatographically from urine specimens. The major metabolites have been identified as 4-methylpyrogallol derivatives (i.e., sulfate, methyl, and glucuronide conjugates). One metabolite (formed by cleavage of a glucose molecule from acarbose) also has alpha-glucosidase inhibitory activity. This metabolite, together with the parent compound, recovered from the urine, accounts for less than 2% of the total administered dose.']",['The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.']
7080,41775,"BENZ(a)ANTHRACENE, 5-METHOXY-",COC1=CC2=CC3=CC=CC=C3C=C2C4=CC=CC=C41,,,,,,
7081,41776,"CHRYSENE-5,6-DIOL, 5,6-DIHYDRO-, trans-",C1=CC=C2C(=C1)C=CC3=C2[C@H]([C@@H](C4=CC=CC=C34)O)O,,,,,,
7082,41777,N-[(4-chlorophenoxy)-(dimethylamino)phosphanyl]-N-methylmethanamine oxide,CN(C)P([N+](C)(C)[O-])OC1=CC=C(C=C1)Cl,,,,,,
7083,41778,Hexacyclen trisulfate,C1C[NH2+]CC[NH2+]CC[NH2+]CC[NH2+]CC[NH2+]CC[NH2+]1.[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-],,,,,,
7084,41779,"1,4,7,10,13,16-Hexaazacyclooctadecane",C1CNCCNCCNCCNCCNCCN1,,,,,,
7085,41780,"3,6-Dinitro-o-toluidine",CC1=C(C=CC(=C1N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
7086,41781,Torsemide,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,"['Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.  As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.']","['It is widely known that administration of torasemide can attenuate renal injury and reduce the severity of acute renal failure. This effect is obtained by increasing urine output and hence, facilitating fluid, acid-base and potassium control. This effect is obtained by the increase in the excretion of urinary sodium and chloride.  Several reports have indicated that torasemide presents a long-lasting diuresis and less potassium excretion which can be explained by the effect that torasemide has on the renin-angiotensin-aldosterone system. This effect is very similar to the effect observed with the administration of combination therapy with [furosemide] and [spironolactone] and it is characterized by a decrease in plasma brain natriuretic peptide and improved measurements of left ventricular function.   Above the aforementioned effect, torasemide presents a dual effect .in which the inhibition of aldosterone which donates torasemide with a potassium-sparing action.  Torasemide has been shown to reduce extracellular fluid volume and blood pressure in hypertensive patients suffering from chronic kidney disease. As well, some reports have indicated that torasemide can reduce myocardial fibrosis by reducing the collagen accumulation. This effect is suggested to be related to the decrease in aldosterone which in order has been shown to reduce the production of the enzyme procollagen type I carboxy-terminal proteinase which is known to be overexpressed in heart failure patients.']","['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA. (See all compounds classified as Sodium Potassium Chloride Symporter Inhibitors.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)']","['Torasemide is the diuretic with the highest oral bioavailability even in advanced stages of chronic kidney disease. This bioavailability tends to be higher than 80% regardless of the patient condition. The maximal serum concentration is reported to be of 1 hour and the absorption parameters are not affected by its use concomitantly with food.', 'Torasemide is mainly hepatically processed and excreted in the feces from which about 70-80% of the administered dose is excreted by this pathway. On the other hand, about 20-30% of the administered dose is found in the urine.', 'The volume of distribution of torasemide is 0.2 L/kg.', 'The clearance rate of torasemide is considerably reduced by the presence of renal disorders.']","['Torasemide is extensively metabolized in the liver and only 20% of the dose remains unchanged and it is recovered in the urine. Metabolized via the hepatic CYP2C8 and CYP2C9 mainly by reactions of hydroxylation, oxidation and reduction to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.', 'Torasemide has known human metabolites that include N-[(4-{[3-(hydroxymethyl)phenyl]imino}-1,4-dihydropyridin-3-yl)sulfonyl]propane-2-carbamimidic acid.']",['The average half-life of torasemide is 3.5 hours.']
7087,41782,Arildone,CCC(=O)C(CCCCCCOC1=C(C=C(C=C1)OC)Cl)C(=O)CC,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
7088,41783,CID 41783,CC=C(C)C(=O)OC1CC(=CC(=O)CC(=C(C2C1C(=C)C(=O)O2)O)C)C,,,,,,
7089,41784,N-(4-nitrobenzyl)acetamide,CC(=O)NCC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
7090,41785,"2-[(5-Chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydroisochromene-7-carbonyl)amino]butanedioic acid",CC1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC(=O)O)C(=O)O)Cl,,,,,,
7091,41786,"3,5-Dinitro-N-(beta-diethylaminoethyl)benzamide hydrochloride",CC[NH+](CC)CCNC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-].[Cl-],,,,,,
7092,41787,"N-(2-diethylaminoethyl)-3,5-dinitro-benzamide",CCN(CC)CCNC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
7093,41788,CID 41788,C[NH+]1C2=C(N=C1S)N(C(=O)N(C2=O)C)C.[Cl-],,,,,,
7094,41789,8-((3-Aminopropyl)thio)caffeine hydrochloride,C[NH+]1C2=C(N=C1SCCCN)N(C(=O)N(C2=O)C)C.[Cl-],,,,,,
7095,41790,"8-(3-Aminopropylsulfanyl)-1,3,7-trimethylpurine-2,6-dione",CN1C2=C(N=C1SCCCN)N(C(=O)N(C2=O)C)C,,,,,,
7096,41791,8-(beta-Hydroxyethylmercapto)caffeine hydrochloride,C[NH+]1C2=C(N=C1SCCO)N(C(=O)N(C2=O)C)C.[Cl-],,,,,,
7097,41792,"Caffeine, 8-((2-hydroxyethyl)thio)-",CN1C2=C(N=C1SCCO)N(C(=O)N(C2=O)C)C,,,,,,
7098,41793,"Aniline, N-(2-(diethylamino)ethyl)-2,4-dinitro-",CCN(CC)CCNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
7099,41794,"6-AZABICYCLO(3.2.1)OCTANE, 6,7-DIMETHYL-1-(m-METHOXYPHENYL)-, HYDROBROMIDE",CC1C2(CCCC(C2)[NH+]1C)C3=CC(=CC=C3)OC.[Br-],,,,,,
7100,41795,"1-(3-Methoxyphenyl)-6,7-dimethyl-6-azabicyclo[3,2,1]octane",CC1C2(CCCC(C2)N1C)C3=CC(=CC=C3)OC,,,,,,
7101,41796,1-(m-Methoxyphenyl)-6-methyl-6-azabicyclo(3.2.1)octane hydrobromide,C[NH+]1CC2(CCCC1C2)C3=CC(=CC=C3)OC.[Br-],,,,,,
7102,41797,1-(3-Methoxyphenyl)-6-methyl-6-azabicyclo[3.2.1]octane,CN1CC2(CCCC1C2)C3=CC(=CC=C3)OC,,,,,,
7103,41798,(+)-1-(m-Hydroxyphenyl)-6-methyl-6-azabicyclo(3.2.1)octane,CN1CC2(CCCC1C2)C3=CC(=CC=C3)O,,,,,,
7104,41799,CID 41799,C[NH+]1CC2(CCCC1C2)C3=CC(=CC=C3)O.[Br-],,,,,,
7105,41800,"6-Azabicyclo(3.2.1)octane, 6-cyclopropylmethyl-1-(m-hydroxyphenyl)-7-methyl-, hydrochloride",CC1C2(CCCC(C2)[NH+]1CC3CC3)C4=CC(=CC=C4)O.[Cl-],,,,,,
7106,41801,3-[6-(Cyclopropylmethyl)-7-methyl-6-azabicyclo[3.2.1]octan-1-yl]phenol,CC1C2(CCCC(C2)N1CC3CC3)C4=CC(=CC=C4)O,,,,,,
7107,41802,"6-Azabicyclo(3.2.1)octane, 1-(m-hydroxyphenyl)-7-methyl-6-phenethyl-, hydrochloride",CC1C2(CCCC(C2)[NH+]1CCC3=CC=CC=C3)C4=CC(=CC=C4)O.[Cl-],,,,,,
7108,41803,3-(7-Methyl-6-phenethyl-6-azabicyclo[3.2.1]octan-1-yl)phenol,CC1C2(CCCC(C2)N1CCC3=CC=CC=C3)C4=CC(=CC=C4)O,,,,,,
7109,41804,"6-Azabicyclo(3.2.1)octane, 6-(2-benzoylethyl)-1-(m-hydroxyphenyl)-, hydrochloride",C1CC2CC(C1)(C[NH+]2CCC(=O)C3=CC=CC=C3)C4=CC(=CC=C4)O.[Cl-],,,,,,
7110,41805,3-[1-(3-Hydroxyphenyl)-6-azabicyclo[3.2.1]octan-6-yl]-1-phenyl-1-propanone,C1CC2CC(C1)(CN2CCC(=O)C3=CC=CC=C3)C4=CC(=CC=C4)O,,,,,,
7111,41806,"[3-(6,7-Dimethyl-6-azoniabicyclo[3.2.1]octan-1-yl)phenyl] acetate;chloride",CC1C2(CCCC(C2)[NH+]1C)C3=CC(=CC=C3)OC(=O)C.[Cl-],,,,,,
7112,41807,"(+)-3-(6,7-Dimethyl-6-azabicyclo[3.2.1]octan-1-yl)phenol acetate",CC1C2(CCCC(C2)N1C)C3=CC(=CC=C3)OC(=O)C,,,,,,
7113,41808,"6-Azabicyclo(3.2.1)octane, 7-ethyl-1-(m-hydroxyphenyl)-6-methyl-, acetate (ester), hydrobromide",CCC1C2(CCCC(C2)[NH+]1C)C3=CC(=CC=C3)OC(=O)C.[Br-],,,,,,
7114,41809,3-(7-Ethyl-6-methyl-6-azabicyclo[3.2.1]octan-1-yl)phenol acetate,CCC1C2(CCCC(C2)N1C)C3=CC(=CC=C3)OC(=O)C,,,,,,
7115,41810,"6,7-Dimethyl-1-(m-hydroxyphenyl)-6-azabicyclo(3.2.1)octane propionate (ester) hydrobromide",CCC(=O)OC1=CC=CC(=C1)C23CCCC(C2)[NH+](C3C)C.[Br-],,,,,,
7116,41811,"3-(6,7-Dimethyl-6-azabicyclo[3.2.1]octan-1-yl)phenol propionate",CCC(=O)OC1=CC=CC(=C1)C23CCCC(C2)N(C3C)C,,,,,,
7117,41812,"6-Azabicyclo(3.2.1)octane, 6,7-dimethyl-1-(m-hydroxyphenyl)-, hexanoate (ester), hydrobromide",CCCCCC(=O)OC1=CC=CC(=C1)C23CCCC(C2)[NH+](C3C)C.[Br-],,,,,,
7118,41813,"3-(6,7-Dimethyl-6-azabicyclo[3.2.1]octan-1-yl)phenol hexanoate",CCCCCC(=O)OC1=CC=CC(=C1)C23CCCC(C2)N(C3C)C,,,,,,
7119,41814,"6-Azabicyclo(3.2.1)octane, 6,7-dimethyl-1-(m-hydroxyphenyl)-, benzoate (ester), hydrochloride",CC1C2CC([NH+]1C)CCC2C3=CC(=CC=C3)OC(=O)C4=CC=CC=C4.[Cl-],,,,,,
7120,41815,"[3-(6,7-Dimethyl-6-azabicyclo[3.2.1]octan-2-yl)phenyl] benzoate",CC1C2CC(N1C)CCC2C3=CC(=CC=C3)OC(=O)C4=CC=CC=C4,,,,,,
7121,41816,CID 41816,CON=C(C1=CC=CO1)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)[O-].[Na+],,,,,,
7122,41817,"(S)-2-Allyl-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline",CC1C2=CC(=C(C=C2CCN1CC=C)OC)OC,,,,,,
7123,41818,Antibiotic SS-228 Y,CC1=CC(=O)CC2(C1(C=CC3=C2C(=O)C4=C(C3=O)C(=CC=C4)O)O)O,,,,,,
7124,41819,"Benzene, 1,1'-(2-methylpropylidene)bis(4-ethoxy-",CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCC)C(C)C,,,,,,
7125,41820,"1,1'-(2-Chloropropylidene)bis(4-ethoxybenzene)",CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCC)C(C)Cl,,,,,,
7126,41821,"Benzene, 1,1'-(2,2-dichloropropylidene)bis(4-ethoxy-",CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCC)C(C)(Cl)Cl,,,,,,
7127,41822,"Benzene, 1,1'-(2-chloro-2-methylpropylidene)bis(4-ethoxy-",CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCC)C(C)(C)Cl,,,,,,
7128,41823,1-Ethoxy-4-(2-methyl-1-(4-methylphenyl)propyl)benzene,CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)C(C)C,,,,,,
7129,41824,1-(2-Chloro-1-(4-ethoxyphenyl)propyl)-4-methylbenzene,CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)C(C)Cl,,,,,,
7130,41825,"Acetanilide, 3'-((bis(2-bromoethyl)amino)methyl)-4'-ethoxy-",CCOC1=C(C=C(C=C1)NC(=O)C)CN(CCBr)CCBr,,,,,,
7131,41826,"Acetanilide, 3'-((2-bromoethylamino)methyl)-4'-ethoxy-",CCOC1=C(C=C(C=C1)NC(=O)C)CNCCBr,,,,,,
7132,41827,"N-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide",CCNC(=O)C=C(C)C=CC=C(C)C=CC1=C(C(=C(C=C1C)OC)C)C,,,,,,
7133,41828,"2-Methyl-5-chloro-2-(N,N-diethylaminoethoxyethyl)-1,3-benzodioxole",CCN(CC)CCOCCC1(OC2=C(O1)C=C(C=C2)Cl)C,,,,,,
7134,41829,"2-Methyl-2-(2-(2-morpholinoethoxy)ethyl)-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CCOCC[NH+]3CCOCC3.[Cl-],,,,,,
7135,41830,"2-Methyl-2-(beta-morpholinoethoxyethyl)-1,3-benzodioxole",CC1(OC2=CC=CC=C2O1)CCOCCN3CCOCC3,,,,,,
7136,41831,"1,3-Benzodioxole, 2-methyl-2-(2-(2-pyrrolidinoethoxy)ethyl)-",CC1(OC2=CC=CC=C2O1)CCOCCN3CCCC3,,,,,,
7137,41832,"2-(2-(3-(Dimethylamino)propoxy)ethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CCOCCC[NH+](C)C.[Cl-],,,,,,
7138,41833,"N,N-dimethyl-3-[2-(2-methyl-1,3-benzodioxol-2-yl)ethoxy]propan-1-amine",CC1(OC2=CC=CC=C2O1)CCOCCCN(C)C,,,,,,
7139,41834,"Acetanilide, 3'-((bis(2-chloroethyl)amino)methyl)-4'-methoxy-",CC(=O)NC1=CC(=C(C=C1)OC)CN(CCCl)CCCl,,,,,,
7140,41835,Medroxalol,CC(CCC1=CC2=C(C=C1)OCO2)NCC(C3=CC(=C(C=C3)O)C(=O)N)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)', 'Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
7141,41836,"2,5-Dimethyltetradecane",CCCCCCCCCC(C)CCC(C)C,,,,,,
7142,41837,"2,5-Dimethyldodecane",CCCCCCCC(C)CCC(C)C,,,,,,
7143,41838,"2,5-Dimethyltridecane",CCCCCCCCC(C)CCC(C)C,,,,,,
7144,41839,3-((2-Chlorophenyl)(ethylthio)methyl)-1-methyl-1H-indole-2-carboxylic acid,CCSC(C1=CC=CC=C1Cl)C2=C(N(C3=CC=CC=C32)C)C(=O)O,,,,,,
7145,41840,1-Ethyl-1-methylindan,CCC1(CCC2=CC=CC=C21)C,,,,,,
7146,41841,Satranidazole,CN1C(=CN=C1N2CCN(C2=O)S(=O)(=O)C)[N+](=O)[O-],,,,,,
7147,41842,Undec-5-en-4-one,CCCCCC=CC(=O)CCC,,,,,,
7148,41843,N-Propyl-N-(3-carboxypropyl)nitrosamine,CCCN(CCCC(=O)O)N=O,,,,,,
7149,41844,CID 41844,CC=C1CC[C@H]2[C@H]1CCCC2,,,,,,
7150,41845,"Benzyl alcohol, 4-amino-alpha-((tert-butylamino)methyl)-3-fluoro-5-iodo-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)I)N)F)O.[Cl-],,,,,,
7151,41846,1-(4'-Amino-3'-fluoro-5'-iodo-phenyl)-2-tert.butylamino-ethanol,CC(C)(C)NCC(C1=CC(=C(C(=C1)I)N)F)O,,,,,,
7152,41847,"Benzonitrile, 2-amino-5-(2-(tert-butylamino)-1-hydroxyethyl)-3-fluoro-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)F)N)C#N)O.[Cl-],,,,,,
7153,41848,1-(4'-Amino-3'-cyano-5'-fluoro-phenyl)-2-tert.butylamino-ethanol,CC(C)(C)NCC(C1=CC(=C(C(=C1)F)N)C#N)O,,,,,,
7154,41849,"Isophthalonitrile, 2-amino-5-(2-(tert-butylamino)-1-hydroxyethyl)-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)C#N)N)C#N)O.[Cl-],,,,,,
7155,41850,"1-(4'-Amino-3',5'-dicyano-phenyl)-2-tert.butylamino-ethanol",CC(C)(C)NCC(C1=CC(=C(C(=C1)C#N)N)C#N)O,,,,,,
7156,41851,"4,4'-Bipyridinium, 1,1'-dihexyl-, dichloride",CCCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCCCCC.[Cl-].[Cl-],,,,,,
7157,41852,"4,4'-Bipyridinium, 1,1'-dihexyl-",CCCCCC[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)CCCCCC,,,,,,
7158,41853,"3,3',4,4'-Tetrachlorodiphenyl ether",C1=CC(=C(C=C1OC2=CC(=C(C=C2)Cl)Cl)Cl)Cl,,,,,,
7159,41854,2-Cyano-1-aziridinecarboxamide,C1C(N1C(=O)N)C#N,,,,,,
7160,41855,N-Nitrosobutylamine,CCCCNN=O,,,,,,
7161,41856,Zindotrine,CC1=CC(=NN2C1=NN=C2)N3CCCCC3,,,,,,
7162,41857,5-Isobutyl-5-phenylbarbituric acid,CC(C)CC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
7163,41858,Octazamide,C1C2COCC2CN1C(=O)C3=CC=CC=C3,,,,,,
7164,41859,"(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol",CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)OC3C(CC=C(O3)CN)N)N,,,,"['Netilmicin is poorly absorbed from the intact GI tract following oral administration. The drug is rapidly and completely absorbed following IM administration.', 'Following absorption, netilmicin rapidly distributes into tissues, sputum, and pericardial, synovial, and peritoneal fluids. ...distributed principally in the extracellular fluid volume... The volume of distribution ...is approximately 20% of body weight. The drug is reportedly 0-30% protein bound.', 'Netilmicin crosses the placenta and has been detected in cord blood. Small amounts of the drug are distributed into milk.', '...is not metabolized and is excreted unchanged in urine mainly by glomerular filtration. In adults with normal renal function, 74% of a 2 mg/kg dose of netilmicin is excreted unchanged within 24 horus: in adults with creatinine clearances of 30-80 or 10-30 mL/min or in anephric adults, 55, 25, or 15% of the dose is excreted in urine within 24 hours, respectively.', 'Netilmicin is removed by hemodialysis. The drug is also removed by peritoneal dialysis but less readily than by hemodialysis.']",,"['The plasma elimination half-life on netilmicin is about 2-2.5 hr following IV or IM administration of a single dose in adults with normal renal function. The serum half-life is reported to be 18 hr in adults with creatinine clearances of 10-30 mL/min and more than 30 hr in anephric adults. The plasma elimination half-life of netilmicin in neonates is inversely related to birthweight and gestational and postnatal age and has been reported to be about 8 or 4.5 hr in neonates less than 7 days of age weighing 1.5-2 or 3-4 kg, respectively. The plasma elimination half-life for children 6 weeks of age and older is 1.5-2 hr.']"
7165,41860,Metoprolol tartaric acid,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
7166,41861,"N-(5,8-Dimethoxy-6-quinoxalinyl)acetamide",CC(=O)NC1=C(C2=NC=CN=C2C(=C1)OC)OC,,,,,,
7167,41862,CID 41862,C1=CC(=CC(=C1)[N+](=O)O)C(=N)N.[Cl-],,,,,,
7168,41863,CID 41863,C1=CC(=CC(=C1)[N+](=O)O)C(=N)N,,,,,,
7169,41864,"1,6-Hexanediamine, N,N'-dichloro-N,N'-dinitro-",C(CCCN([N+](=O)[O-])Cl)CCN([N+](=O)[O-])Cl,,,,,,
7170,41865,"Adamantane, 1-(chloronitroamino)-",C1C2CC3CC1CC(C2)(C3)N([N+](=O)[O-])Cl,,,,,,
7171,41866,"Barbituric acid, 5-phenyl-5-propyl-",CCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
7172,41867,Epirubicin,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,['For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.'],"['Epirubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Epirubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.']","['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']","['100%', 'Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion.', '21  2 L/kg [60 mg/m2 Dose]', '65 +/- 8 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 60 mg/m2]', ""... The plasma and tissue distribution of /anthracyline antibiotics/ doxorubicin (1), 4' epidoxorubicin (epirubicin; II) and daunorubicin (daunomycin; III) were studied in patients. Plasma levels of I and II and their 13 hydroxy metabolites were determined by LC, as were plasma levels of III. It was concluded that plasma kinetics for the 3 drugs were similar, and that tissue uptake for I and II were virtually the same. Tumor tissue concentrated the drugs to the greatest extent, while adipose tissue had the lowest concentrations."", '... The preparation and in vitro and in vivo evaluation of egg albumin microspheres containing epirubicin hydrochloride (I) are /detailed/, I pharmacokinetics were studied in rats following single intravenous doses and efficacy studies were carried out in mice with Ehrlich ascites carcinoma and in rats with Walker carcinoma. The kinetics of in vitro release of the drug complied partially with first order as well as with a diffusion model from a matrix. The pharmacokinetics in serum, heart and lungs of rats could be described by the equation of the 2 compartment open model. The pharmacokinetic parameters calculated suggest the possibility of improving the selective entrapment of I by the lungs. In the animal efficacy studies I increased the survival times in all treated groups. It was concluded that the data suggest the possibility of organ targeting of I microspheres.', '/MILK/ Epirubicin was excreted into the milk of rats treated with 0.50 mg/kg/day of epirubicin during peri- and postnatal periods. It is not known whether this drug is excreted in human milk.', 'Following intravenous administration, epirubicin is rapidly and widely distributed into the tissues. Binding of epirubicin to plasma proteins, predominantly albumin, is about 77% and is not affected by drug concentration. Epirubicin also appears to concentrate in red blood cells; whole blood concentrations are approximately twice those of plasma.', 'For more Absorption, Distribution and Excretion (Complete) data for EPIRUBICIN (11 total), please visit the HSDB record page.']","['Extensively and rapidly metabolized in the liver. Epirubicin is also metabolized by other organs and cells, including red blood cells. The four main metabolic routes are: (1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol exhibits in vitro cytoxic activity (~10% that of epirubicin), but it is unlikely to reach sufficient concentrations in vivo to produce cytotoxic effects.', 'Epirubicin is extensively and rapidly metabolized by the liver and is also metabolized by other organs and cells, including red blood cells. Four main metabolic routes have been identified:  (1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol has in vitro cytotoxic activity one-tenth that of epirubicin. As plasma levels of epirubicinol are lower than those of the unchanged drug, they are unlikely to reach in vivo concentrations sufficient for cytotoxicity. No significant activity or toxicity has been reported for the other metabolites.', 'Secondary alcohol metabolites have been proposed to mediate chronic cardiotoxicity induced by doxorubicin (DOX) and other anticancer anthracyclines. In this study, NADPH-supplemented human cardiac cytosol was found to reduce the carbonyl group in the side chain of the tetracyclic ring of doxorubicin, producing the secondary alcohol metabolite doxorubicinol (DOXol). A decrease in the level of alcohol metabolite formation was observed by replacing doxorubicin with epirubicin (EPI), a less cardiotoxic analogue characterized by an axial-to-equatorial epimerization of the hydroxyl group at C-4 in the amino sugar bound to the tetracyclic ring (daunosamine). A similar decrease was observed by replacing doxorubicin with MEN, a novel anthracycline with preclinical evidence of reduced cardiotoxicity. MEN is characterized by the lack of a methoxy group at C-4 in the tetracyclic ring and by intercalation of 2, 6-dideoxy-L-fucose between daunosamine and the aglycone. Multiple comparisons with methoxy- or 4-demethoxyaglycones, and a number of mono- or disaccharide 4-demethoxyanthracyclines, showed that both the lack of the methoxy group and the presence of a disaccharide moiety limited alcohol metabolite formation by MEN. Studies with enzymatically generated or purified anthracycline secondary alcohols also showed that the presence of a disaccharide moiety, but not the lack of a methoxy group, made the metabolite of MEN less reactive with the [4Fe-4S] cluster of cytoplasmic aconitase, as evidenced by its limited reoxidation to the parent carbonyl anthracycline and by a reduced level of delocalization of Fe(II) from the cluster. Collectively, these studies (i) characterize the different influence of methoxy and sugar substituents on the formation and [4Fe-4S] reactivity of anthracycline secondary alcohols, (ii) lend support to the role of alcohol metabolites in anthracycline-induced cardiotoxicity, as they demonstrate that the less cardiotoxic EPI and MEN 10755 share a reduction in the level of formation of such metabolites, and (iii) suggest that the cardiotoxicity of MEN might be further decreased by the reduced [4Fe-4S] reactivity of its alcohol metabolite.', 'Many antineoplastic drugs were found to have carcinogenic, mutagenic and teratogenic potential. The aim of this study was to carry out cytogenetic and internal dose monitoring of hospital pharmacy personnel regularly involved in the preparation of cytostatic agents, in order to test possible cytostatics-induced genotoxic effects due to occupational exposure under routine working conditions, and in cases of accidental contamination. ... Platinum in whole blood and anthracyclines in plasma were measured to assess internal exposure to cytostatics. The level of cytogenetic damage was determined in peripheral blood lymphocytes with the micronucleus test and the sister chromatid exchange assay. Five series of monitoring were performed over a period of 2 years. ... No significant differences in the mean frequencies of sister chromatid exchanges (SCE) and micronuclei (MN) were found between occupationally exposed probands and controls (9.9 +/- 1.4 vs 10.1 +/- 1.2 SCEs/cell and 21.2 +/- 7.2 vs 23.3 +/- 7.5 MN/2000 binucleated (BN) cells, n = 16). Significant elevations of SCE or MN were detected in seven out of 12 cases of accidental contamination at the workplace, whereas no increase in platinum in blood and anthracyclines in plasma was observed in these probands. Two cases of non-reported contamination were identified by measurement of epirubicin in plasma. Smoking was found to increase the SCE significantly. No correlation between individual SCE scores and MN scores was observed. ... /The authors/ findings support a transient increase in SCE or MN after relevant exposure to cytostatic drugs in cases of accidental contamination. The lack of significant differences in SCE and MN between hospital pharmacy personnel and unexposed controls, points to high standards of safety at the corresponding workplaces.', 'There is compelling in-vitro evidence that the evaluation of doxorubicin or epirubicin pharmacokinetics based solely on plasma concentration may not fully elucidate the differences between the two drugs. Both compounds bind to erythrocytes and their different binding to hemoglobin may influence their disposition in the body. The purpose of the present study was to compare the pharmacokinetics and metabolism of doxorubicin and epirubicin based on the plasma concentration, amount associated with blood cells and simultaneous monitoring of biliary and urinary elimination of unchanged drug and metabolites after single- and multiple-dose injections. The level of sarcoplasmic reticulum Ca2+ATPase in the heart was also measured as a biomarker of cardiotoxicity. Male Sprague-Dawley rats were treated in a parallel design with doxorubicin or epirubicin on a multiple-dosing basis (4 mg kg(-1) per week) or as a single dose injection (20 mg kg(-1)). Blood, urine and bile samples were collected periodically after each dose in the multiple-dosing regimen and the single dose injection, and at the end of each experiment the hearts were removed. The concentrations of each drug in plasma, blood cells, bile and urine samples were determined, and by simultaneous curve-fitting of plasma and bile data according to compartmental analysis, the pharmacokinetic parameters and constants were estimated. The concentration of drug associated with blood cells was analyzed according to non-compartmental analysis. The bile and urine samples provided the in-vivo metabolic data. The level of Ca2+ATPase in the heart, determined by Western blotting, was used as the toxicodynamic parameterto correlate with the kinetic data. Multiple-dosing regimens reduced the total plasma clearance and increased the area under the plasma concentration-time curve of both drugs. Also, the area under the curve of doxorubicin associated with blood cells increased with the weekly doses, and the related mean residence time (MRT) and apparent volume of distribution (Vdss) were steadily reduced. In contrast to doxorubicin, the mean residence time and Vdss of epirubicin increased significantly. Metabolic data indicated significant differences in the level of alcohol and aglycones metabolites. Doxorubicinol and doxorubicin aglycones were significantly greater than epirubicinol and epirubicin aglycone, whereas epirubicinol aglycone was greater than doxorubicinol aglycone. The area under the blood cells concentration-time curve correlated linearly with the changes in Ca2+ATPase net intensity. The results of this study demonstrate the importance of the kinetics of epirubicin and doxorubicin associated with blood cells. Linear correlation between the reduction of net intensity of the biomarker with the area under the curve of doxorubicin associated with blood cells confirms that the differences between the two compounds are related to their interaction with blood cells. This observation together with the observed differences in metabolism may underline a significant role for blood cells in distribution and metabolism of doxorubicin and epirubicin.', 'For more Metabolism/Metabolites (Complete) data for EPIRUBICIN (6 total), please visit the HSDB record page.']","['Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively', '... Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase. ...']"
7173,41868,"2-(6,11-Dihydro-11-oxodibenz(b,e)oxepin-2-yl)propionic acid",CC(C1=CC2=C(C=C1)OCC3=CC=CC=C3C2=O)C(=O)O,,,,,,
7174,41869,Bis(P-chlorobenzyl) ether,C1=CC(=CC=C1COCC2=CC=C(C=C2)Cl)Cl,,,,,,
7175,41870,Flumecinol,CCC(C1=CC=CC=C1)(C2=CC(=CC=C2)C(F)(F)F)O,,,,,,
7176,41871,9-(2-Pyridylmethyl)acridine dihydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)CC4=CC=CC=[NH+]4.[Cl-].[Cl-],,,,,,
7177,41872,9-(Pyridin-2-ylmethyl)acridine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)CC4=CC=CC=N4,,,,,,
7178,41873,9-(4-Pyridylmethyl)acridine dihydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)CC4=CC=[NH+]C=C4.[Cl-].[Cl-],,,,,,
7179,41874,9-(Pyridin-4-ylmethyl)acridine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)CC4=CC=NC=C4,,,,,,
7180,41875,"Acridine, 2-ethoxy-6-nitro-9-(4-quinolylmethyl)-",CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])N=C2C=C1)CC4=CC=NC5=CC=CC=C45,,,,,,
7181,41876,2-Ethoxy-6-nitro-9-(4-pyridylmethyl)acridine methyliodide,CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])[N+](=C2C=C1)C)CC4=CC=NC=C4.[I-],,,,,,
7182,41877,2-Ethoxy-10-methyl-6-nitro-9-(pyridin-4-ylmethyl)acridin-10-ium,CCOC1=CC2=C(C3=C(C=C(C=C3)[N+](=O)[O-])[N+](=C2C=C1)C)CC4=CC=NC=C4,,,,,,
7183,41878,"1,1-Dodecanediol, diacetate",CCCCCCCCCCCC(OC(=O)C)OC(=O)C,,,,,,
7184,41879,1-Dodecenyl acetate,CCCCCCCCCCC=COC(=O)C,,,,,,
7185,41880,"4-[(16-Methyl-2,5-dioxo-1-oxacyclohexadec-3-en-6-yl)oxy]-4-oxobutanoic acid",CC1CCCCCCCCCC(C(=O)C=CC(=O)O1)OC(=O)CCC(=O)O,,,,,,
7186,41881,Dicarboxidine dihydrochloride,C1=CC(=C(C=C1C2=CC(=C(C=C2)N)OCCCC(=O)O)OCCCC(=O)O)N.Cl.Cl,,,,,,
7187,41882,Dicarboxidine,C1=CC(=C(C=C1C2=CC(=C(C=C2)N)OCCCC(=O)O)OCCCC(=O)O)N,,,,,,
7188,41883,"Ethanone, 1-(4-amino-2-methyl-5-(4-methylphenyl)-1H-pyrrol-3-YL)-",CC1=CC=C(C=C1)C2=C(C(=C(N2)C)C(=O)C)N,,,,,,
7189,41884,"Ethanone, 1-(4-amino-5-(4-methoxyphenyl)-2-methyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1)C2=CC=C(C=C2)OC)N)C(=O)C,,,,,,
7190,41885,"Ethanone, 1-(4-amino-5-(4-fluorophenyl)-2-methyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1)C2=CC=C(C=C2)F)N)C(=O)C,,,,,,
7191,41886,"Ethanone, 1-(4-amino-2-methyl-5-(3-methylphenyl)-1H-pyrrol-3-YL)-",CC1=CC(=CC=C1)C2=C(C(=C(N2)C)C(=O)C)N,,,,,,
7192,41887,"ETHANONE, 1-(4-AMINO-5-(p-CHLOROPHENYL)-2-METHYL-1H-PYRROL-3-YL)-",CC1=C(C(=C(N1)C2=CC=C(C=C2)Cl)N)C(=O)C,,,,,,
7193,41888,"Ethanone, 1-(4-amino-2-methyl-5-(2-methylphenyl)-1H-pyrrol-3-YL)-",CC1=CC=CC=C1C2=C(C(=C(N2)C)C(=O)C)N,,,,,,
7194,41889,"Ethanone, 1-(4-(dimethylamino)-2-methyl-5-phenyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1)C2=CC=CC=C2)N(C)C)C(=O)C,,,,,,
7195,41890,"Ethanone, 1-(4-amino-1,2-dimethyl-5-phenyl-1H-pyrrol-3-YL)-",CC1=C(C(=C(N1C)C2=CC=CC=C2)N)C(=O)C,,,,,,
7196,41891,"Ethanone, 1-(4-amino-1-ethyl-2-methyl-5-phenyl-1H-pyrrol-3-YL)-",CCN1C(=C(C(=C1C2=CC=CC=C2)N)C(=O)C)C,,,,,,
7197,41892,"NAPHTHO(2,3-b)-p-DIOXIN-2-METHANOL, 2,3-DIHYDRO-",C1C(OC2=CC3=CC=CC=C3C=C2O1)CO,,,,,,
7198,41893,"Naphthalene, hexabromo-",C1=C2C(=CC(=C(C2=C(C(=C1Br)Br)Br)Br)Br)Br,,,,,,
7199,41894,"BENZO(a)PYRENE-9,10-DIOL, 9,10-DIHYDRO-(Z)-",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]([C@@H](C=C5)O)O)C=C2,,,,,,
7200,41895,"(+-)-6-Amino-6,7,8,9-tetrahydro-5H-benzocycloheptene hydrochloride",C1CC(CC2=CC=CC=C2C1)[NH3+].[Cl-],,,,,,
7201,41896,"6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-amine",C1CC(CC2=CC=CC=C2C1)N,,,,,,
7202,41897,"(+-)-6-Methylamino-6,7,8,9-tetrahydro-5H-benzocycloheptene hydrochloride",C[NH2+]C1CCCC2=CC=CC=C2C1.[Cl-],,,,,,
7203,41898,"N-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-amine",CNC1CCCC2=CC=CC=C2C1,,,,,,
7204,41899,"(+-)-6-Dimethylamino-6,7,8,9-tetrahydro-5H-benzocycloheptene hydrochloride",C[NH+](C)C1CCCC2=CC=CC=C2C1.[Cl-],,,,,,
7205,41900,"N,N-dimethyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-amine",CN(C)C1CCCC2=CC=CC=C2C1,,,,,,
7206,41901,"(+-)-6,7,8,9-Tetrahydro-6-methyl-5H-benzocyclohepten-6-amine hydrochloride",CC1(CCCC2=CC=CC=C2C1)[NH3+].[Cl-],,,,,,
7207,41902,"6-Methyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-amine",CC1(CCCC2=CC=CC=C2C1)N,,,,,,
7208,41903,"(+-)-6-Methylamino-6-methyl-6,7,8,9-tetrahydro-5H-benzocycloheptene hydrochloride",CC1(CCCC2=CC=CC=C2C1)[NH2+]C.[Cl-],,,,,,
7209,41904,"N,6-dimethyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-amine",CC1(CCCC2=CC=CC=C2C1)NC,,,,,,
7210,41905,"(+-)-6-Dimethylamino-6-methyl-6,7,8,9-tetrahydro-5H-benzocycloheptene hydrochloride",CC1(CCCC2=CC=CC=C2C1)[NH+](C)C.[Cl-],,,,,,
7211,41906,"N,N,6-trimethyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-amine",CC1(CCCC2=CC=CC=C2C1)N(C)C,,,,,,
7212,41907,Terbufibrol,CC(C)(C)C1=CC=C(C=C1)OCC(COC2=CC=C(C=C2)C(=O)O)O,,,,,,
7213,41908,"1H-Azepine, hexahydro-1-dodecyl-, 1-oxide",CCCCCCCCCCCC[N+]1(CCCCCC1)[O-],,,,,,
7214,41909,"1,2,4-Triazine-3,5(2H,4H)-dione, 4-amino-6-(1,1-dimethylethyl)-",CC(C)(C)C1=NNC(=O)N(C1=O)N,,,,,,
7215,41910,N-Nitroso-N-(phosphonomethyl)glycine,C(C(=O)O)N(CP(=O)(O)O)N=O,,,,,,
7216,41911,"3-(3,4-Dimethylphenyl)adamantane-1-carboxylic acid",CC1=C(C=C(C=C1)C23CC4CC(C2)CC(C4)(C3)C(=O)O)C,,,,,,
7217,41912,3-(4-Methylphenyl)adamantane-1-carboxylic acid,CC1=CC=C(C=C1)C23CC4CC(C2)CC(C4)(C3)C(=O)O,,,,,,
7218,41913,"Indoline, 1-piperidinoacetyl-",C1CCN(CC1)CC(=O)N2CCC3=CC=CC=C32,,,,,,
7219,41914,"Benzylamine, N,N-bis(2-bromoethyl)-2-methoxy-5-nitro-",COC1=C(C=C(C=C1)[N+](=O)[O-])CN(CCBr)CCBr,,,,,,
7220,41915,"Benzylamine, N-(2-chloroethyl)-2-methoxy-5-nitro-",COC1=C(C=C(C=C1)[N+](=O)[O-])CNCCCl,,,,,,
7221,41916,"Benzylamine, N-(2-chloroethyl)-2-ethoxy-5-nitro-",CCOC1=C(C=C(C=C1)[N+](=O)[O-])CNCCCl,,,,,,
7222,41917,"10H-Benzo(b)xanthene-7,10,12-trione, 6,11-dihydroxy-3,8-dimethoxy-1-methyl-, 6-benzoate",CC1=CC(=CC2=C1C(=O)C3=C(C4=C(C(=C3O2)OC(=O)C5=CC=CC=C5)C(=O)C(=CC4=O)OC)O)OC,,,,,,
7223,41918,CID 41918,COP(=S)(C)OC(=CCl)C1=C(C=CC(=C1)Cl)Cl,,,,,,
7224,41919,"Octadeca-9,17-dienal",C=CCCCCCCC=CCCCCCCCC=O,,,,,,
7225,41920,"1,1-Bis(dodecyloxy)hexadecane",CCCCCCCCCCCCCCCC(OCCCCCCCCCCCC)OCCCCCCCCCCCC,,,,,,
7226,41921,CID 41921,CC=CCC=CCC=CCCCCOS(=O)OC,,,,,,
7227,41922,17-Octadecenal,C=CCCCCCCCCCCCCCCCC=O,,,,,,
7228,41923,Octadec-2-enal,CCCCCCCCCCCCCCCC=CC=O,,,,,,
7229,41924,Octadec-4-enal,CCCCCCCCCCCCCC=CCCC=O,,,,,,
7230,41925,Octadec-3-enal,CCCCCCCCCCCCCCC=CCC=O,,,,,,
7231,41926,CID 41926,C[NH+](C)C=CC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.C(=CC(=O)[O-])C(=O)O,,,,,,
7232,41927,"N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)prop-1-en-1-amine",CN(C)C=CC=C1C2=CC=CC=C2C=CC3=CC=CC=C31,,,,,,
7233,41928,"2,3-Dihydro-2-methyl-1H-indene-1,2-diol (cis)",C[C@@]1(CC2=CC=CC=C2[C@H]1O)O,,,,,,
7234,41929,"9,10-Anthracenedione, 1-amino-4-chloro-2-(hydroxymethyl)-",C1=CC=C2C(=C1)C(=O)C3=C(C=C(C(=C3C2=O)N)CO)Cl,,,,,,
7235,41930,"(1-Amino-9,10-dihydro-9-chlorosulfurous acid",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)COS(=O)Cl)N,,,,,,
7236,41931,"9,10-Anthracenedione, 1-amino-4-chloro-2-(chloromethyl)-",C1=CC=C2C(=C1)C(=O)C3=C(C=C(C(=C3C2=O)N)CCl)Cl,,,,,,
7237,41932,"1-Amino-2-methoxymethyl-9,10-anthracenedione",COCC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
7238,41933,"1-Amino-2-ethoxymethyl-9,10-anthracenedione",CCOCC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
7239,41934,"1-Amino-2-propoxymethyl-9,10-anthracenedione",CCCOCC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
7240,41935,2-Ethyl-1-nitroanthraquinone,CCC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-],,,,,,
7241,41936,"N,2-dimethyl-3-phenylbut-2-enamide",CC(=C(C)C(=O)NC)C1=CC=CC=C1,,,,,,
7242,41937,N-ethyl-2-methyl-3-phenylbut-2-enamide,CCNC(=O)C(=C(C)C1=CC=CC=C1)C,,,,,,
7243,41938,N-cyclopropyl-2-methyl-3-phenylbut-2-enamide,CC(=C(C)C(=O)NC1CC1)C2=CC=CC=C2,,,,,,
7244,41939,2-methyl-3-phenyl-N-prop-2-enylbut-2-enamide,CC(=C(C)C(=O)NCC=C)C1=CC=CC=C1,,,,,,
7245,41940,2-methyl-3-phenyl-N-prop-2-ynylbut-2-enamide,CC(=C(C)C(=O)NCC#C)C1=CC=CC=C1,,,,,,
7246,41941,CID 41941,CC(=C(C)C(=O)N(C)C)C1=CC=CC=C1,,,,,,
7247,41942,2-methyl-3-phenyl-N-propylbut-2-enamide,CCCNC(=O)C(=C(C)C1=CC=CC=C1)C,,,,,,
7248,41943,N-butyl-2-methyl-3-phenylbut-2-enamide,CCCCNC(=O)C(=C(C)C1=CC=CC=C1)C,,,,,,
7249,41944,CID 41944,CC(C)NC(=O)C(=C(C)C1=CC=CC=C1)C,,,,,,
7250,41945,Spiromustine,C1CCC2(CC1)C(=O)N(C(=O)N2)CCN(CCCl)CCCl,,,,,,
7251,41946,Oxagrelate,CCOC(=O)C1=C(C2=C(C=C1C)C(=NNC2=O)CO)C,,,['Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)'],,,
7252,41947,"5,5-Dimethyl-2-phenyl-4-thiazolidinecarboxylic acid",CC1(C(NC(S1)C2=CC=CC=C2)C(=O)O)C,,,,,,
7253,41948,"3,9-Dihydroxybenzanthracene",C1=CC2=C(C=CC(=C2)O)C3=CC4=C(C=C31)C=C(C=C4)O,,,,,,
7254,41949,"Ethanone, 1-(4-(methylsulfonyl)phenyl)-2-(phenylamino)-",CS(=O)(=O)C1=CC=C(C=C1)C(=O)CNC2=CC=CC=C2,,,,,,
7255,41950,"Ethanone, 2-(4-(3-chlorophenyl)-1-piperazinyl)-1-(4-(methylsulfonyl)phenyl)-",CS(=O)(=O)C1=CC=C(C=C1)C(=O)CN2CCN(CC2)C3=CC(=CC=C3)Cl,,,,,,
7256,41951,"Ethanone, 2-(methyl(phenylmethyl)amino)-1-(4-(methylsulfonyl)phenyl)-, hydrochloride",C[NH+](CC1=CC=CC=C1)CC(=O)C2=CC=C(C=C2)S(=O)(=O)C.[Cl-],,,,,,
7257,41952,2-[Benzyl(methyl)amino]-1-(4-methylsulfonylphenyl)ethanone,CN(CC1=CC=CC=C1)CC(=O)C2=CC=C(C=C2)S(=O)(=O)C,,,,,,
7258,41953,CID 41953,CS(=O)(=O)C1=CC=C(C=C1)C(=O)C[NH+]2CCOCC2.C(=CC(=O)[O-])C(=O)O,,,,,,
7259,41954,1-(4-Methylsulfonylphenyl)-2-morpholin-4-ylethanone,CS(=O)(=O)C1=CC=C(C=C1)C(=O)CN2CCOCC2,,,,,,
7260,41955,"3,4-Bis(4-methoxyphenyl)but-3-en-2-one",CC(=O)C(=CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
7261,41956,"Anthracene-9,10-dione, 1-amino-2-(octoxymethyl)-",CCCCCCCCOCC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
7262,41957,CID 41957,CCCCOCC(=O)[O-].[Na+],,,,,,
7263,41958,Butoxyacetic acid,CCCCOCC(=O)O,,,,,,
7264,41959,CID 41959,CN1CCN(CC1)CC(=O)C2=CC=C(C=C2)S(=O)(=O)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
7265,41960,2-(4-Methylpiperazin-1-yl)-1-(4-methylsulfonylphenyl)ethanone,CN1CCN(CC1)CC(=O)C2=CC=C(C=C2)S(=O)(=O)C,,,,,,
7266,41961,Tetrahydro-2-(12-pentadecynyloxy)-2H-pyran,CCC#CCCCCCCCCCCCOC1CCCCO1,,,,,,
7267,41962,Hexamethylbiphenyl,CC1=C(C(=C(C=C1)C2=C(C(=C(C=C2)C)C)C)C)C,,,,,,
7268,41963,1-Phenyl-2-cyclopenten-1-OL,C1CC(C=C1)(C2=CC=CC=C2)O,,,,,,
7269,41964,"1,3,5-Tris(dichloromethyl)benzene",C1=C(C=C(C=C1C(Cl)Cl)C(Cl)Cl)C(Cl)Cl,,,,,,
7270,41965,"11-Hexadecen-1-ol, (11Z)-",CCCCC=CCCCCCCCCCCO,,,,,,
7271,41966,CID 41966,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC(COC2=CC(=CC=C2)Cl)O,,,,,,
7272,41967,Aliflurane,COC1(C(C1(F)Cl)(F)F)F,,,,,,
7273,41968,"16-Ethyl-4-hydroxy-5,9,13,15-tetramethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl 3,4,6-trideoxy-3-(dimethylamino)hexopyranoside",CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(CC(O2)C)N(C)C)O)CC=O)C)C)C,,,,,,
7274,41969,Canbisol,CCCCCCC(C)(C)C1=CC(=C2C3CC(CCC3C(OC2=C1)(C)C)O)O,,,,,,
7275,41970,"1,3-Dimethoxy-5-(3-methyloct-2-en-2-yl)benzene",CCCCCC(=C(C)C1=CC(=CC(=C1)OC)OC)C,,,,,,
7276,41971,Nonadiene,CCCCCC=CC=C,,,,,,
7277,41972,4-(3-Chlorophenoxy)aniline,C1=CC(=CC(=C1)Cl)OC2=CC=C(C=C2)N,,,,,,
7278,41973,4-(2-Chlorophenoxy)aniline,C1=CC=C(C(=C1)OC2=CC=C(C=C2)N)Cl,,,,,,
7279,41974,"5,5-Diallyl-N,1-dicyclohexyl-2,4,6-trioxonipecotamide",C=CCC1(C(=O)C(C(=O)N(C1=O)C2CCCCC2)C(=O)NC3CCCCC3)CC=C,,,,,,
7280,41975,"1,1'-Dicyclohexyl-5,5,5',5'-tetraallyl(3,3'-bipiperidine)-2,2',4,4',6,6'-hexone",C=CCC1(C(=O)C(C(=O)N(C1=O)C2CCCCC2)C3C(=O)C(C(=O)N(C3=O)C4CCCCC4)(CC=C)CC=C)CC=C,,,,,,
7281,41976,"3,4,5-Trimethyl-1-hexene",CC(C)C(C)C(C)C=C,,,,,,
7282,41977,"4,4-Diphenyl-2,5-cyclohexadien-1-amine hydrochloride",C1=CC=C(C=C1)C2(C=CC(C=C2)[NH3+])C3=CC=CC=C3.[Cl-],,,,,,
7283,41978,"4,4-Diphenylcyclohexa-2,5-dien-1-amine",C1=CC=C(C=C1)C2(C=CC(C=C2)N)C3=CC=CC=C3,,,,,,
7284,41979,"1-(1,3-Benzodioxol-5-yl)hex-1-en-3-one",CCCC(=O)C=CC1=CC2=C(C=C1)OCO2,,,,,,
7285,41980,"5-Methyl-1-(1,3-benzodioxol-5-yl)-1-hexen-3-one",CC(C)CC(=O)C=CC1=CC2=C(C=C1)OCO2,,,,,,
7286,41981,"1-(3,4-Methylenedioxyphenyl)-7-methyl-1,6-octadiene-3-one",CC(=CCCC(=O)C=CC1=CC2=C(C=C1)OCO2)C,,,,,,
7287,41982,"3,3-Diphenyl-7-azabicyclo(4.1.0)heptane",C1CC(CC2C1N2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
7288,41983,"3,3-Diphenyl-3-dimethylcarbamoyl-1-propyne",CN(C)C(=O)C(C#C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7289,41984,CID 41984,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)[O-].[Na+],,,,,,
7290,41985,Phenyl-P-pyridylketone,C1=CC=C(C=C1)C2(C3C=CC3C4C2C=C4)O,,,,,,
7291,41986,"3-Methyl-2,6-dioxohex-4-enoic acid",CC(C=CC=O)C(=O)C(=O)O,,,,,,
7292,41987,"3-(4-Bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-2-propen-1-amine",CN(C)CC=C(C1=CC=C(C=C1)Br)C2=CN=CC=C2,,,,,,
7293,41988,"1-Acetyl-3-acetoxy-5',5-diphenylhydantoin",CC(=O)N1C(=O)N(C(=O)C1(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C,,,,,,
7294,41989,3-Hydroxy-5-isopropyl hydantoin,CC(C)C1C(=O)N(C(=O)N1)O,,,,,,
7295,41990,3-Hydroxy-5-isobutyl hydantoin,CC(C)CC1C(=O)N(C(=O)N1)O,,,,,,
7296,41991,Tert-butyl-[2-(2-chlorophenyl)-2-hydroxyethyl]azanium;chloride,CC(C)(C)[NH2+]CC(C1=CC=CC=C1Cl)O.[Cl-],,,,,,
7297,41992,CID 41992,C1=CC=C(C=C1)C=CC2=C(C=C(C=C2)N3N=C4C=CC5=CC=CC=C5C4=N3)S(=O)(=O)[O-].[Na+],,,,,,
7298,41993,"5-(2H-Naphtho[1,2-d][1,2,3]triazol-2-yl)-2-(2-phenylethenyl)benzene-1-sulfonic acid",C1=CC=C(C=C1)C=CC2=C(C=C(C=C2)N3N=C4C=CC5=CC=CC=C5C4=N3)S(=O)(=O)O,,,,,,
7299,41994,CID 41994,CN(CCO)C1=NC(=NC(=N1)NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)NC4=NC(=NC(=N4)NC5=CC=CC=C5)N(C)CCO)S(=O)(=O)[O-])S(=O)(=O)[O-])C6=CC=CC=C6.[Na+].[Na+],,,,,,
7300,41995,CID 41995,CN(CCO)C1=NC(=NC(=N1)NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)NC4=NC(=NC(=N4)NC5=CC=CC=C5)N(C)CCO)S(=O)(=O)O)S(=O)(=O)O)C6=CC=CC=C6,,,,,,
7301,41996,4-Amino-alpha-((tert-butylamino)methyl)-3-fluorobenzyl alcohol hydrochloride,CC(C)(C)[NH2+]CC(C1=CC(=C(C=C1)N)F)O.[Cl-],,,,,,
7302,41997,1-(4'-Amino-3'-fluoro-phenyl)-2-tert.butylamino-ethanol,CC(C)(C)NCC(C1=CC(=C(C=C1)N)F)O,,,,,,
7303,41998,"Benzyl alcohol, 4-amino-alpha-((tert-butylamino)methyl)-3-chloro-5-fluoro-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)Cl)N)F)O.[Cl-],,,,,,
7304,41999,1-(4'-Amino-3'-chloro-5'-fluoro-phenyl)-2-tert.butylamino-ethanol,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)F)O,,,,,,
7305,42000,"Benzyl alcohol, 4-amino-3-bromo-alpha-((tert-butylamino)methyl)-5-fluoro-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)Br)N)F)O.[Cl-],,,,,,
7306,42001,1-(4'-Amino-3'-bromo-5'-fluoro-phenyl)-2-tert.butylamino-ethanol,CC(C)(C)NCC(C1=CC(=C(C(=C1)Br)N)F)O,,,,,,
7307,42002,"Benzonitrile, 2-amino-3-bromo-5-(2-(tert-butylamino)-1-hydroxyethyl)-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)Br)N)C#N)O.[Cl-],,,,,,
7308,42003,3-Bromo-5-[2-(tert-butylamino)-1-hydroxyethyl]anthranilonitrile,CC(C)(C)NCC(C1=CC(=C(C(=C1)Br)N)C#N)O,,,,,,
7309,42004,"Benzonitrile, 2-amino-5-(2-(tert-butylamino)-1-hydroxyethyl)-3-chloro-, hydrochloride",CC(C)(C)[NH2+]CC(C1=CC(=C(C(=C1)Cl)N)C#N)O.[Cl-],,,,,,
7310,42005,2-Amino-5-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorobenzonitrile,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)C#N)O,,,,,,
7311,42006,n-Propylhydrazine hydrochloride,CCCN[NH3+].[Cl-],,,,,,
7312,42007,Propylhydrazine,CCCNN,,,,,,
7313,42008,Cefmetazole,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,['For the treatment of infections caused by susceptible organisms.'],"['Cefmetazole is a second-generation cephalosporin. The cephalosporins are bactericidal drugs with both gram-positive and gram-negative activity. They inhibit bacterial cell wall synthesis in a way similar to the penicillins. Cefmetazole is more active than 1st-generation cephalosporins against indole-positive <i>Proteus</i>, <i>Serratia</i>, anaerobic gram-negative bacilli (including <i>B. fragilis</i>), and some <i>E. coli</i>, <i>Klebsiella</i>, and <i>P. mirabilis</i>, but is less active than cefoxitin or cefotetan against most gram-negative bacilli.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Bioavailability is approximately 100% following intramuscular injection.'],['No appreciable metabolism.'],['1.50 &plusmn;0.14 hours']
7314,42009,CID 42009,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)[O-].[Na+],,,,,,
7315,42010,Tetrasodium;hypochlorite;phosphate,[O-]P(=O)([O-])[O-].[O-]Cl.[Na+].[Na+].[Na+].[Na+],,,,,,
7316,42011,"3,6-Nonadien-1-ol",CCC=CCC=CCCO,,,,,,
7317,42012,"1,2-Butadiene, 1,1,3,4,4,4-hexachloro-",C(=C(C(Cl)(Cl)Cl)Cl)=C(Cl)Cl,,,,,,
7318,42013,"CARBANILIC ACID, o-HYDROXY-, METHYL ESTER, METHYLCARBAMATE",CNC(=O)OC1=CC=CC=C1NC(=O)OC,,,,,,
7319,42014,"2,4-Diphenylpyridine",C1=CC=C(C=C1)C2=CC(=NC=C2)C3=CC=CC=C3,,,,,,
7320,42015,"N-[(2,4-dichlorophenyl)methylidene]hydroxylamine",C1=CC(=C(C=C1Cl)Cl)C=NO,,,,,,
7321,42016,Methyl(acetoxymethyl)nitrosamine,CC(=O)OCN(C)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
7322,42017,"9,12-Octadecadienamide, N,N-bis(2-hydroxyethyl)-, (9Z,12Z)-",CCCCCC=CCC=CCCCCCCCC(=O)N(CCO)CCO,,,,,,
7323,42018,"Arsine, chlorobis(chloromethyl)-",C(Cl)[As](CCl)Cl,,,,,,
7324,42019,"KETONE, 1,3-DIMETHYL-5-(METHYLAMINO)-4-PYRAZOLYL o-FLUOROPHENYL",CC1=NN(C(=C1C(=O)C2=CC=CC=C2F)NC)C,,,,,,
7325,42020,"3-Benzofurancarboxylic acid, 2-((dimethylamino)methyl)-5-methoxy-, ethyl ester, hydrochloride",CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)C[NH+](C)C.[Cl-],,,,,,
7326,42021,Ethyl 2-[(dimethylamino)methyl]-5-methoxy-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)CN(C)C,,,,,,
7327,42022,5-Methoxy-2-(morpholinomethyl)-3-benzofurancarboxylic acid ethyl ester hydrochloride,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)C[NH+]3CCOCC3.[Cl-],,,,,,
7328,42023,5-Methoxy-2-morpholin-4-ylmethyl-benzofuran-3-carboxylic acid ethyl ester,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)CN3CCOCC3,,,,,,
7329,42024,"3-Benzofurancarboxylic acid, 6-chloro-4-(dimethylaminomethyl)-5-hydroxy-2-methyl-, ethyl ester",CCOC(=O)C1=C(OC2=CC(=C(C(=C21)CN(C)C)O)Cl)C,,,,,,
7330,42025,"Coumarin, 3-nitro-4-(1-pyrrolidinyl)-",C1CCN(C1)C2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
7331,42026,"Ethyl 2,4-dichlorobenzoate",CCOC(=O)C1=C(C=C(C=C1)Cl)Cl,,,,,,
7332,42027,2-Hydroxybenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC(=CC(=C54)C=C3)O,,,,,,
7333,42028,10-Hydroxybenzo(a)pyrene,C1=CC2=C3C(=C1)C=CC4=C5C(=CC(=C43)C=C2)C=CC=C5O,,,,,,
7334,42029,11-Hydroxybenzo[a]pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C(=CC5=CC=C4)O,,,,,,
7335,42030,12-Hydroxybenzo(a)pyrene,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C=C(C5=CC=C4)O,,,,,,
7336,42031,4-Chloro-2-ethyl-6-(hydroxyiminomethyl)phenol,CCC1=C(C(=CC(=C1)Cl)C=NO)O,,,,,,
7337,42032,4-Chloro-6-ethyl-alpha-(methylimino)-o-cresol,CCC1=C(C(=CC(=C1)Cl)C=NC)O,,,,,,
7338,42033,3-Ethyl-2-hydroxy-5-nitrobenzoic acid,CCC1=C(C(=CC(=C1)[N+](=O)[O-])C(=O)O)O,,,,,,
7339,42034,5-Chloro-3-ethyl-2-methoxybenzyl alcohol,CCC1=C(C(=CC(=C1)Cl)CO)OC,,,,,,
7340,42035,"Benzonitrile, 4-cyanoethylsulfonyl-2,3,5,6-tetrachloro-",C(CS(=O)(=O)C1=C(C(=C(C(=C1Cl)Cl)C#N)Cl)Cl)C#N,,,,,,
7341,42036,"4-(3-Phenylpropylsulfonyl)-2,3,5,6-tetrachlorobenzonitrile",C1=CC=C(C=C1)CCCS(=O)(=O)C2=C(C(=C(C(=C2Cl)Cl)C#N)Cl)Cl,,,,,,
7342,42037,"4-Pentylsulfonyl-2,3,5,6-tetrachlorobenzonitrile",CCCCCS(=O)(=O)C1=C(C(=C(C(=C1Cl)Cl)C#N)Cl)Cl,,,,,,
7343,42038,"Benzonitrile, 4-hexylsulfonyl-2,3,5,6-tetrachloro-",CCCCCCS(=O)(=O)C1=C(C(=C(C(=C1Cl)Cl)C#N)Cl)Cl,,,,,,
7344,42039,"4-Ethoxyethylsulfonyl-2,3,5,6-tetrachlorobenzonitrile",CCOCCS(=O)(=O)C1=C(C(=C(C(=C1Cl)Cl)C#N)Cl)Cl,,,,,,
7345,42040,Fluretofen,C#CC1=CC=C(C=C1)C2=CC=CC=C2F,,,,,,
7346,42041,2-(Butoxymethyl)furan,CCCCOCC1=CC=CO1,,,,,,
7347,42042,Dimethyl(2-hydroxyethyl)pentylammonium bromide benzilate,CCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
7348,42043,"2-(Hydroxydiphenylacetyloxy)-N,N-dimethyl-N-pentylethanaminium",CCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7349,42044,Dimethyl(2-hydroxyethyl)nonylammonium bromide benzilate,CCCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
7350,42045,"2-(2-Hydroxy-2,2-diphenylacetyl)oxyethyl-dimethyl-nonylazanium",CCCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7351,42046,Dimethyl(2-hydroxyethyl)undecylammonium bromide benzilate,CCCCCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
7352,42047,"2-(2-Hydroxy-2,2-diphenylacetyl)oxyethyl-dimethyl-undecylazanium",CCCCCCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7353,42048,Dimethylheptyl(2-hydroxyethyl)ammonium bromide benzilate,CCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
7354,42049,"Heptyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]-dimethylazanium",CCCCCCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7355,42050,"Benzenamine, 4-((chloromethyl)sulfonyl)-2-nitro-N-(4-((4-nitrophenyl)thio)phenyl)-",C1=CC(=CC=C1NC2=C(C=C(C=C2)S(=O)(=O)CCl)[N+](=O)[O-])SC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
7356,42051,4-((Chloromethyl)sulfonyl)-2-nitro-N-(4-((4-nitrophenyl)sulfinyl)phenyl)benzenamine,C1=CC(=CC=C1NC2=C(C=C(C=C2)S(=O)(=O)CCl)[N+](=O)[O-])S(=O)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
7357,42052,"Benzenamine, 4,4'-thiobis(N-(4-((chloromethyl)sulfonyl)-2-nitrophenyl)-",C1=CC(=CC=C1NC2=C(C=C(C=C2)S(=O)(=O)CCl)[N+](=O)[O-])SC3=CC=C(C=C3)NC4=C(C=C(C=C4)S(=O)(=O)CCl)[N+](=O)[O-],,,,,,
7358,42053,"4-Butylsulfonyl-2,3,5,6-tetrachlorobenzonitrile",CCCCS(=O)(=O)C1=C(C(=C(C(=C1Cl)Cl)C#N)Cl)Cl,,,,,,
7359,42054,"7-Chloro-10-(4-methylpiperazin-1-yl)tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,9,11,13-heptaen-2-one",CN1CCN(CC1)C2=CC3=C(C=CC=C3Cl)C(=O)C4=CC=CC=C42,,,,,,
7360,42055,"5H-DIBENZO(a,d)CYCLOHEPTEN-5-ONE, METHYL-10-(4-METHYL-1-PIPERAZINYL)-",CN1CCN(CC1)CC2=CC3=CC=CC=C3C(=O)C4=CC=CC=C42,,,,,,
7361,42056,"1,2-Bis(P-chlorophenyl) ethanol",C1=CC(=CC=C1CC(C2=CC=C(C=C2)Cl)O)Cl,,,,,"[""EVERY 24 HR UP TO 3 WK AFTER IM INJECTIONS FISH & WATER ANALYZED. P,P'-(14)C-DDOH APPARENTLY CONVERTED TO P,P'-DBP IN 1 EXPT."", ""GROUPS OF 5 OR 10 RAINBOW TROUT FRY (SALMO GAIRDNERII) WEIGHING APPROX 1 G INJECTED IM WITH (14)C-LABELED 2,2-BIS(P-CHLOROPHENYL) ETHANOL (P,P'-DDOH) AT INTERVALS OF 24 HR & 3 WK AFTER INJECTION, FISH & WATER EXAM. 2ND EXPOSURE DID NOT CONFIRM METABOLITES.""]",
7362,42057,"2,6-Dichloro-N,N-dimethylaniline",CN(C)C1=C(C=CC=C1Cl)Cl,,,,,,
7363,42058,4'-Bromo-3-methylbiphenyl,CC1=CC(=CC=C1)C2=CC=C(C=C2)Br,,,,,,
7364,42059,"Carbamic acid, ethylphenyl-, 1-methylethyl ester",CCN(C1=CC=CC=C1)C(=O)OC(C)C,,,,,,
7365,42060,Trichloropyrogallol,C1(=C(C(=C(C(=C1O)Cl)Cl)Cl)O)O,,,,,,
7366,42061,"4-Amino-3,5-dichlorobenzoic acid",C1=C(C=C(C(=C1Cl)N)Cl)C(=O)O,,,,,,
7367,42062,1-Chloro-2-(chlorophenylmethyl)benzene,C1=CC=C(C=C1)C(C2=CC=CC=C2Cl)Cl,,,,,,
7368,42063,BENZ(a)ANTHRACEN-8-AMINE,C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC=C(C4=C3)N,,,,,,
7369,42064,"BENZ(a)ANTHRACENE, 8-ETHYL-",CCC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
7370,42065,"BENZ(c)ACRIDINE, 9-ETHYL-7-METHYL-",CCC1=CC2=C(C=C1)N=C3C(=C2C)C=CC4=CC=CC=C43,,,,,,
7371,42066,"1-Bromo-2,3-dichlorobenzene",C1=CC(=C(C(=C1)Br)Cl)Cl,,,,,,
7372,42067,"Coumarin, 4-cyclohexylamino-3-nitro-",C1CCC(CC1)NC2=C(C(=O)OC3=CC=CC=C32)[N+](=O)[O-],,,,,,
7373,42068,"1,3,6-Cycloheptatriene-1-sulfonic acid, 4-hydroxy-5-oxo-, monoammonium salt",C1=CC(=O)C(=CC=C1S(=O)(=O)[O-])O.[NH4+],,,,,,
7374,42069,"4-Hydroxy-5-oxocyclohepta-1,3,6-triene-1-sulfonic acid",C1=CC(=O)C(=CC=C1S(=O)(=O)O)O,,,,,,
7375,42070,2-Methoxy-4-phenylaniline,COC1=C(C=CC(=C1)C2=CC=CC=C2)N,,,,,,
7376,42071,Heptamethonium bromide,C[N+](C)(C)CCCCCCC[N+](C)(C)C.[Br-].[Br-],,,,,,
7377,42072,Hexamethyloctamethylene bisammonium chloride,C[N+](C)(C)CCCCCCCC[N+](C)(C)C.[Cl-].[Cl-],,,,,,
7378,42073,"5H-DIBENZO(a,d)CYCLOHEPTEN-5-ONE, 10-(4-CYCLOPENTYL)-1-PIPERAZINYL-",C1CCC(C1)N2CCN(CC2)C3=CC4=CC=CC=C4C(=O)C5=CC=CC=C53,,,,,,
7379,42074,"10-(4-(Cyclopropylmethyl)-1-piperazinyl)-5H-dibenzo(a,d)cyclohepten-5-one",C1CC1CN2CCN(CC2)C3=CC4=CC=CC=C4C(=O)C5=CC=CC=C53,,,,,,
7380,42075,"10-(4-(2-(1-Piperidinyl)ethyl)-1-piperazinyl)-5H-dibenzo(a,d)cyclohepten-5-one",C1CCN(CC1)CCN2CCN(CC2)C3=CC4=CC=CC=C4C(=O)C5=CC=CC=C53,,,,,,
7381,42076,"10-(4-((2-Methylphenyl)methyl)-1-piperazinyl)-5H-dibenzo(a,d)cyclohepten-5-one",CC1=CC=CC=C1CN2CCN(CC2)C3=CC4=CC=CC=C4C(=O)C5=CC=CC=C53,,,,,,
7382,42077,"MALEIMIDE, 1,1'-(TETRAFLUORO-m-PHENYLENE)DI-",C1=CC(=O)N(C1=O)C2=C(C(=C(C(=C2F)F)F)N3C(=O)C=CC3=O)F,,,,,,
7383,42078,Adrevil,CCCC[NH+](CCCC)CCNC1=NC(=NO1)C2=CC=CC=C2.[Cl-],,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
7384,42079,"Acetanilide, 2-(diethylamino)-3'-ethyl-",CCC1=CC(=CC=C1)NC(=O)CN(CC)CC,,,,,,
7385,42080,CID 42080,CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C([NH3+])N.CS(=O)(=O)[O-],,,,,,
7386,42081,"18,19-Dinorcholestane, 5,14-dimethyl-, (5beta,8alpha,9beta,10alpha,14beta)-",CC(C)CCCC(C)C1CC[C@]2(C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCCC4)C)C,,,,,,
7387,42082,2-(2-Chlorophenyl)allophanic acid ethyl ester,CCOC(=O)N(C1=CC=CC=C1Cl)C(=O)N,,,,,,
7388,42083,"(6-Ethoxy-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl hydrogen carbonimidate",CCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
7389,42084,"(8a-Methoxy-5-methyl-4,7-dioxo-6-propoxy-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl hydrogen carbonimidate",CCCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
7390,42085,"[(7R,8S)-7-methoxy-12-methyl-10,13-dioxo-11-propan-2-yloxy-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)OC(C)C,,,,,,
7391,42086,"(6-Butoxy-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl hydrogen carbonimidate",CCCCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
7392,42087,"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-6-heptyloxy-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate",CCCCCCCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
7393,42088,"8-[[(Aminocarbonyl)oxy]methyl]-6-benzyloxy-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione",CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)OCC5=CC=CC=C5,,,,,,
7394,42089,"[(7R,8S)-7-methoxy-12-methyl-10,13-dioxo-11-pentoxy-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CCCCCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
7395,42090,"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-6-hexyloxy-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate",CCCCCCOC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
7396,42091,Furofenac,CCC1CC2=C(O1)C=CC(=C2)CC(=O)O,,,,,,
7397,42092,"4-(1,3-Benzodioxol-5-yl)but-3-en-2-ol",CC(C=CC1=CC2=C(C=C1)OCO2)O,,,,,,
7398,42093,CID 42093,CCCCC[C@@H](C=C[C@@H]1[C@@H]2C[C@@H](C1CC=CCCCC(=O)O)CO2)O,,,,,,
7399,42094,1-(Butylnitrosoamino)butyl acetate,CCCCN(C(CCC)OC(=O)C)N=O,,,,,,
7400,42095,N-Butyl-N-(acetoxymethyl)nitrosamine,CCCCN(COC(=O)C)N=O,,,,,,
7401,42096,sec-Butyl-acetoxymethyl-nitrosamine,CCC(C)N(COC(=O)C)N=O,,,,,,
7402,42097,CID 42097,CC1=CC=CC=C1N=C(NNC(=O)CC2=CC=CC3=CC=CC=C32)S,,,,,,
7403,42098,CID 42098,CC1=CC(=CC=C1)N=C(NNC(=O)CC2=CC=CC3=CC=CC=C32)S,,,,,,
7404,42099,CID 42099,CC1=CC(=C(C=C1)N=C(NNC(=O)CC2=CC=CC3=CC=CC=C32)S)C,,,,,,
7405,42100,CID 42100,CC1=C(C=C(C=C1)N=C(NNC(=O)CC2=CC=CC3=CC=CC=C32)S)C,,,,,,
7406,42101,"3-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-5-methoxy-1H-indole mononitrate",COC1=CC2=C(C=C1)NC=C2CC3=NCC[NH2+]3.[N+](=O)([O-])[O-],,,,,,
7407,42102,"3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-methoxy-1H-indole",COC1=CC2=C(C=C1)NC=C2CC3=NCCN3,,,,,,
7408,42103,"1H-Indole, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-5-methoxy-2-methyl-, mononitrate",CC1=C(C2=C(N1)C=CC(=C2)OC)CC3=NCC[NH2+]3.[N+](=O)([O-])[O-],,,,,,
7409,42104,"3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-methoxy-2-methyl-1H-indole",CC1=C(C2=C(N1)C=CC(=C2)OC)CC3=NCCN3,,,,,,
7410,42105,"Guanidine, N-(3,4-dichlorophenyl)-N'-(1-methylethyl)-",CC(C)N=C(N)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
7411,42106,Tiapamil hydrochloride,C[NH+](CCCC1(S(=O)(=O)CCCS1(=O)=O)C2=CC(=C(C=C2)OC)OC)CCC3=CC(=C(C=C3)OC)OC.[Cl-],,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
7412,42107,Tiapamil,CN(CCCC1(S(=O)(=O)CCCS1(=O)=O)C2=CC(=C(C=C2)OC)OC)CCC3=CC(=C(C=C3)OC)OC,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
7413,42108,"Methyl((2-methylphenyl)sulfinyl)carbamic acid 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester",CC1=CC=CC=C1S(=O)N(C)C(=O)OC2=CC=CC3=C2OC(C3)(C)C,,,,,,
7414,42109,CID 42109,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+](CCC(=O)O)C3CCCCC3.[Cl-],,,,,,
7415,42110,CID 42110,CC1=C2C=CC(=O)C(=C2OC(=C1)O)CN(CCC(=O)O)C3CCCCC3,,,,,,
7416,42111,"1H-Indole-2-carboxamide, N-(2-ethoxyphenyl)-3-(2-hydrazinoethoxy)-",CCOC1=CC=CC=C1NC(=O)C2=C(C3=CC=CC=C3N2)OCCNN,,,,,,
7417,42112,"1H-Indole-2-carboxamide, N-(4-ethoxyphenyl)-3-(2-hydrazinoethoxy)-",CCOC1=CC=C(C=C1)NC(=O)C2=C(C3=CC=CC=C3N2)OCCNN,,,,,,
7418,42113,Desflurane,C(C(F)(F)F)(OC(F)F)F,"['Desflurane is indicated for the induction and maintenance of anesthesia in adults, as well as the maintenance of anesthesia in pediatric patients.']","['Desflurane is a general inhalation anesthetic. It has a short duration of action as it is rapidly cleared. Patients should be counselled regarding the risks of malignant hyperthermia, perioperative hyperkalemia, respiratory adverse reactions in pediatric patients, QTc prolongation, hepatobiliary disorders, pediatric neurotoxicity, and postoperative agitation in children.']","['Gases or volatile liquids that vary in the rate at which they induce anesthesia; potency; the degree of circulation, respiratory, or neuromuscular depression they produce; and analgesic effects. Inhalation anesthetics have advantages over intravenous agents in that the depth of anesthesia can be changed rapidly by altering the inhaled concentration. Because of their rapid elimination, any postoperative respiratory depression is of relatively short duration. (From AMA Drug Evaluations Annual, 1994, p173) (See all compounds classified as Anesthetics, Inhalation.)']","['Data regarding the C<sub>max</sub>, T<sub>max</sub>, and AUC of desflurane are not readily available.', 'Initially, desflurane is rapidly eliminated from the lungs. A small amount of the metabolite trifluoroacetic acid is eliminated in the urine and only 0.02% of an inhaled dose is recovered as urinary metabolites.', 'Desflurane has a median volume of distribution of 612 mL/kg.', 'A 26 g dose of desflurane is 90% eliminated from the brain after 33 hours. The metabolite trifluoroacetic acid has a urinary clearance rate of 0.169  0.107 mol/L.', 'The concentrations of desflurane in milk are probably of no clinical importance 24 hours after anesthesia.', 'Due to the volatile nature of desflurane in plasma samples, the washin-washout profile of desflurane was used as a surrogate of plasma pharmacokinetics. Eight healthy male volunteers first breathed 70% N2O/30% O2 for 30 minutes and then a mixture of SUPRANE (desflurane, USP) 2.0%, isoflurane 0.4%, and halothane 0.2% for another 30 minutes. During this time, inspired and endtidal concentrations (FI and FA) were measured. The FA/FI (washin) value at 30 minutes for desflurane was 0.91, compared to 1.00 for N2O, 0.74 for isoflurane, and 0.58 for halothane. The washin rates for halothane and isoflurane were similar to literature values. The washin was faster for desflurane than for isoflurane and halothane at all time points. The FA/FAO (washout) value at 5 minutes was 0.12 for desflurane, 0.22 for isoflurane, and 0.25 for halothane. The washout for SUPRANE was more rapid than that for isoflurane and halothane at all elimination time points. By 5 days, the FA/FAO for desflurane is 1/20th of that for halothane or isoflurane.']","['Desflurane is minimally defluorinated by CYP2E1, to the extent that serum fluoride levels do not increase above baseline levels.', 'Renal and hepatic toxicity of the fluorinated ether volatile anesthetics is caused by biotransformation to toxic metabolites. Metabolism also contributes significantly to the elimination pharmacokinetics of some volatile agents. Although innumerable studies have explored anesthetic metabolism in animals, there is little information on human volatile anesthetic metabolism with respect to comparative rates or the identity of the enzymes responsible for defluorination. The first purpose of this investigation was to compare the metabolism of the fluorinated ether anesthetics by human liver microsomes. The second purpose was to test the hypothesis that cytochrome P450 2E1 is the specific P450 isoform responsible for volatile anesthetic defluorination in humans. Microsomes were prepared from human livers. Anesthetic metabolism in microsomal incubations was measured by fluoride production. The strategy for evaluating the role of P450 2E1 in anesthetic defluorination involved three approaches: for a series of 12 human livers, correlation of microsomal defluorination rate with microsomal P450 2E1 content (measured by Western blot analysis), correlation of defluorination rate with microsomal P450 2E1 catalytic activity using marker substrates (para-nitrophenol hydroxylation and chlorzoxazone 6-hydroxylation), and chemical inhibition by P450 isoform-selective inhibitors. The rank order of anesthetic metabolism, assessed by fluoride production at saturating substrate concentrations, was methoxyflurane > sevoflurane > enflurane > isoflurane > desflurane > 0. There was a significant linear correlation of sevoflurane and methoxyflurane defluorination with antigenic P450 2E1 content (r = 0.98 and r = 0.72, respectively), but not with either P450 1A2 or P450 3A3/4. Comparison of anesthetic defluorination with either para-nitrophenol or chlorzoxazone hydroxylation showed a significant correlation for sevoflurane (r = 0.93, r = 0.95) and methoxyflurane (r = 0.78, r = 0.66). Sevoflurane defluorination was also highly correlated with that of enflurane (r = 0.93), which is known to be metabolized by human P450 2E1. Diethyldithiocarbamate, a selective inhibitor of P450 2E1, produced a concentration-dependent inhibition of sevoflurane, methoxyflurane, and isoflurane defluorination. No other isoform-selective inhibitor diminished the defluorination of sevoflurane, whereas methoxyflurane defluorination was inhibited by the selective P450 inhibitors furafylline (P450 1A2), sulfaphenazole (P450 2C9/10), and quinidine (P450 2D6) but to a much lesser extent than by diethyldithiocarbamate. These results demonstrate that cytochrome P450 2E1 is the principal, if not sole human liver microsomal enzyme catalyzing the defluorination of sevoflurane. P450 2E1 is the principal, but not exclusive enzyme responsible for the metabolism of methoxyflurane, which also appears to be catalyzed by P450s 1A2, 2C9/10, and 2D6. The data also suggest that P450 2E1 is responsible for a significant fraction of isoflurane metabolism. Identification of P450 2E1 as the major anesthetic metabolizing enzyme in humans provides a mechanistic understanding of clinical fluorinated ether anesthetic metabolism and toxicity.', 'SUPRANE (desflurane, USP) is a volatile liquid inhalation anesthetic minimally biotransformed in the liver in humans.', 'Biotransformation and hepatotoxicity of desflurane were evaluated in the guinea pig liver slice culture system. Liver slices (250-300 microns) were prepared from 600-650-g male Hartley guinea pigs. The slices were incubated in sealed vials in a Krebs-Henseleit buffer at 37 degrees C under 95% O2. Desflurane was vaporized to produce media concentrations of 0.7-2.3 mM. After incubation (3-24 hr) viability of the slices was determined (K+ content; protein synthesis secretion) along with the biotransformation of desflurane (F-). Isoflurane (2.3 mM) was included in the studies for comparative purposes. Although desflurane caused a mild concentration-related reduction in slice K+ content (1.1-2.2 mM; 20%-40% of control), the effects were less than those produced by 2.3 mM isoflurane (50% of control). High concentrations of desflurane decreased protein synthesis at the first 9 hr of incubation, and isoflurane decreased protein synthesis throughout the incubation period. Neither anesthetic affected protein secretion. The biotransformation of desflurane was minimal with threefold less F- produced from desflurane than isoflurane.', 'The metabolism of desflurane has been assessed both in animals and humans by measuring the appearance of fluoride metabolites (fluoride ion, nonvolatile organic fluoride, trifluoroacetic acid) in blood and urine. Desflurane administered to rats (either pretreated or not pretreated with phenobarbital or ethanol) for 3.2 MAC-hours and to swine for 5.5 MAC-hours produced fluoride ion levels in blood that were almost indistinguishable from values measured in control animals. In contrast, a significant 17% increase in plasma fluoride ion concentration in swine was detected 4 hr after exposure to desflurane. In human studies, desflurane administered to patients (3.1 MAC-hours) and volunteers (7.35 MAC-hours) resulted in postanesthesia serum fluoride in concentrations that did not differ from background fluoride ion concentrations. Similarly, postanesthetic urinary excretion of fluoride ion and organic fluoride in volunteers was comparable to preanesthetic excretion rates. Small but statistically significant levels of trifluoroacetic acid were found in both serum and urine from volunteers after exposure to desflurane. Peak serum concentrations averaging 0.38 +/- 0.17 uM trifluoroacetic acid (mean +/- SD) and peak urinary excretion rates averaging 0.169 +/- 0.107 umol/hr were detected in volunteers 24 hr after desflurane exposure. Although these increases in trifluoroacetic acid after exposure to desflurane were statistically significant, they are approximately 10-fold less than levels seen after exposure to isoflurane. Desflurane strongly resists biodegradation, and only a small amount is metabolized in animals and humans.']",['Desflurane has a terminal elimination half life of 8.16  3.15 minutes.']
7419,42114,"1H-Indole-2-carboxylic acid, 3-((2-chlorophenyl)methyl)-1-methyl-",CN1C2=CC=CC=C2C(=C1C(=O)O)CC3=CC=CC=C3Cl,,,,,,
7420,42115,"3,4,5-Trichloroguaiacol",COC1=C(C(=C(C=C1O)Cl)Cl)Cl,,,,,,
7421,42116,N-((4-Chlorophenyl)methyl)acetamide,CC(=O)NCC1=CC=C(C=C1)Cl,,,,,,
7422,42117,"N,N-Dimethyl-N'-diphenylmethyl-acetamidine",CC(=NC(C1=CC=CC=C1)C2=CC=CC=C2)N(C)C,,,,,,
7423,42118,Isamoxole,CCCCN(C1=NC(=CO1)C)C(=O)C(C)C,,,,,,
7424,42119,CID 42119,C1=C[C@@H]([C@@H]([C@H]1NCC2=CN(C3=C2C(=O)N=C(N3)N)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
7425,42120,Diethylhymenovin,CCOC1CC2C(CC3C(CC2(C(O1)OCC)C)C(=C)C(=O)O3)C,,,,,,
7426,42121,"Acetic acid, 2-(4-(4-chlorobenzyl)phenoxy)-",C1=CC(=CC=C1CC2=CC=C(C=C2)Cl)OCC(=O)O,,,,,,
7427,42122,"Acetic acid, 2-(4-(4-chlorobenzyl)phenoxy)-, ethyl ester",CCOC(=O)COC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
7428,42123,"Acetic acid, 2-(4-(4-chlorobenzyl)phenoxy)-, 1-methyl-4-piperidyl ester, hydrochloride",C[NH+]1CCC(CC1)OC(=O)COC2=CC=C(C=C2)CC3=CC=C(C=C3)Cl.[Cl-],,,,,,
7429,42124,(1-Methylpiperidin-4-yl) 2-[4-[(4-chlorophenyl)methyl]phenoxy]acetate,CN1CCC(CC1)OC(=O)COC2=CC=C(C=C2)CC3=CC=C(C=C3)Cl,,,,,,
7430,42125,"Acetic acid, 2-(4-(4-chlorobenzyl)phenoxy)-, 3-pyridinylmethyl ester",C1=CC(=CN=C1)COC(=O)COC2=CC=C(C=C2)CC3=CC=C(C=C3)Cl,,,,,,
7431,42126,"Dipotassium;7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid;hydroxide",C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O.[OH-].[K+].[K+],,,,,,
7432,42127,CID 42127,CC(=NOC(=O)N(C)N=O)SC,,,,,,
7433,42128,"2,3,4,7,8-Pentachlorodibenzofuran",C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,,,,"['Male Fischer-344 rats received a single oral dose of 14C-2,3,4,7,8-pentaCDF at 34-338 ug/kg, and 3 days after dosing, CDF-derived radioactivity was most concentrated in the liver (>50%), followed by adipose (6%), skin (0.9%), and muscle (0.5%). When expressed as percentage of the dose per gram of tissue, the liver had 5.9% followed by adipose with 0.3%, and adrenal with 0.15%. Regardless of how the results were expressed, tissue distribution was not dose-related, and all other tissues and organs had only traces of radioactivity. .../About/ 30% of the CDF-derived radioactivity was excreted in the feces over a 3 day period, regardless of the dose. No radioactivity was detected in expired air, and urinary excretion accounted for <0.01% of the dose per day. Analysis of fecal samples 1 day after dosing suggested that >50% of the CDF-derived radioactivity was parent compound; however, 2 days later this fell to 20%. These results, when compared with those obtained with the tetra-substituted congener in rats, suggest that by adding a chlorine substitute to position four in the CDF ring, excretion rate is decreased by half. .../This/ is related to the metabolic handling of the two congeners. /2,3,4,7,8-Pentachlorodibenzofuran/', 'Young male Wistar rats absorbed approximately 6.8% of a single oral dose of 1.0 mg 2,3,4,7,8-pentaCDF/kg bw given in salad oil. The daily fecal excretion was about 0.1% of the administered dose/day, whereas no 2,3,4,7,8-pentaCDF was detected in urine. Four weeks after dosing the retention of 2,3,4,7,8-pentaCDF in the liver was 48.8% of the dose. The addition of 5% of activated charcoal beads to the diet, one week after dosing and throughout the study, increased the fecal elimination of 2,3,4,7,8-pentaCDF about 3-fold, but had no effect on urinary elimination. Both the liver and extrahepatic tissues, except the kidney, from rats on basal diet supplemented with activated charcoal beads had lower levels of 2,3,4,7,8-pentaCDF than rats on basal diet only. /2,3,4,7,8-Pentachlorodibenzofuran/', 'The oral bioavailability of 2,3,4,7,8-pentaCDF (2,3,4,7,8-pentachlorodibenzofuran) in corn oil is similar to that of TCDD. Furthermore, 2,3,4,7,8-pentaCDF absorption was independent of the dose (0.1, 0.5, or 1.0 umol/kg).', 'Studies in the rat, guinea pig, hamster, and mouse have found that essentially all of the TCDD-derived radioactivity excreted in the urine and bile corresponds to metabolites of TCDD. The apparent absence of TCDD metabolites in liver and fat suggests that once formed, the metabolites of TCDD are excreted readily. Thus, urinary and biliary elimination of TCDD depends on metabolism of the toxin. The more limited data for other compounds also suggest that this relationship may be true for ...1,2,3,7,8-pentaCDF, /and/ 2,3,4,7,8-pentaCDF... .', 'For more Absorption, Distribution and Excretion (Complete) data for 2,3,4,7,8-PENTACHLORODIBENZOFURAN (12 total), please visit the HSDB record page.']","['Among the pentaCDFs, the rate of transformation of 1,2,3,4,8-, 1,2,3,7,8-, and 2,3,4,7,8-pentaCDF was high, moderate, and low, respectively. The predominant metabolite (out of 7 compounds found) of 1,2,3,7,8-pentaCDF was a hydroxy-pentaCDF. According to investigators, formation of 6,7-dihydroxy-pentaCDF may also have occurred. Tetrachlorinated compounds were also identified. The major metabolite (out of 12 compounds found) of 1,2,3,7,8-pentaCDF was a dihydroxy-pentaCDF; other derivatives included monohydroxy-tetra- and pentaCDFs and a trichloro-dihydroxyCDF. Metabolism of 2,3,4,7,8-pentaCDF led to 2 major compounds (out of 10 compounds found), a methoxy-pentaCDF, and a dimethoxy-pentachlorobiphenyl, the latter formed by ether cleavage. A sulfur containing metabolite was also present. Unmetabolized pentaCDFs were also excreted in the bile. Only a small amount of a hydroxy-pentaCDF was identified from 1,2,3,6,7,8- hexaCDF, whereas no metabolites were detected from 1,2,3,4,6,7-heptaCDF. /Pentachlorodibenzofurans/', 'Limited data suggest that autoinduction of metabolism and biliary excretion does occur for PCDFs, in contrast to PCDDs. Pretreatment of rats with 2,3,7,8-TCDF (1.0 umol/kg, 3 days earlier) significantly increased the biliary excretion of a subsequent dose of (14C)2,3,7,8-TCDF. The naive rats excreted 5.7 + or - 2.4% of the dose over the initial 8 hr, while the pretreated rats excreted 13.2 + or - 3.2% of the (14C)2,3,7,8-TCDF. Similarly, pretreatment of rats with 2,3,4,7,8-pentaCDF (500 ug/kg, /orally/, 3 days earlier) resulted in a two-fold increase in the biliary elimination of a subsequent dose of (14C)2,3,4,7,8-pentaCDF. These results suggest that pretreatment with 2,3,7,8-TCDF and 2,3,4,7,8-pentaCDF induces the metabolism of these congeners.']","['... the half-life in the liver of the rat /is/ more than 100 days', 'Elimination half-life estimate for 2,3,4,7,8-pentaCDF in 5 German herbicide plant workers was 19.6 years, based on 2-3 serum samples taken in 6.3 year period. /from table/']"
7434,42129,"2,3,8-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=CC(=C(C=C3O2)Cl)Cl,,,,,,
7435,42130,"2,3,6-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=CC(=C(C=C23)Cl)Cl,,,,,,
7436,42131,"2,3,4-Trichlorodibenzofuran",C1=CC=C2C(=C1)C3=CC(=C(C(=C3O2)Cl)Cl)Cl,,,,,,
7437,42132,"1,3,7,8-Tetrachlorodibenzofuran",C1=C(C=C(C2=C1OC3=CC(=C(C=C32)Cl)Cl)Cl)Cl,,,,,,
7438,42133,"1,3,6,7-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C=C(C=C3Cl)Cl)Cl)Cl,,,,,,
7439,42134,"2,3,6,8-Tetrachlorodibenzofuran",C1=C(C=C(C2=C1C3=CC(=C(C=C3O2)Cl)Cl)Cl)Cl,,,,,,
7440,42135,"2,4,6,7-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
7441,42136,"2,3,6,7-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1C3=CC(=C(C=C3O2)Cl)Cl)Cl)Cl,,,,,,
7442,42137,"3,4,6,7-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(O2)C(=C(C=C3)Cl)Cl)Cl)Cl,,,,,,
7443,42138,"1,2,3,7,8-Pentachlorodibenzofuran",C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C(=C23)Cl)Cl)Cl,,,,,,
7444,42139,"1,2,3,6,7-Pentachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(C(=C(C=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
7445,42140,"1,2,3,6,7,8-Hexachlorodibenzofuran",C1=C2C3=C(C(=C(C=C3OC2=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7446,42141,"N,N-Didemethylchlordimeform",CC1=C(C=CC(=C1)Cl)N=CN,,,,,,
7447,42142,"Nipecotic acid, 1-methyl-4-phenyl-, methyl ester, hydrobromide, (E)-(+-)-",C[NH+]1CCC([C@@H](C1)C(=O)OC)C2=CC=CC=C2.[Br-],,,,,,
7448,42143,methyl (3S)-1-methyl-4-phenylpiperidine-3-carboxylate,CN1CCC([C@@H](C1)C(=O)OC)C2=CC=CC=C2,,,,,,
7449,42144,(+-)-cis-1-Methyl-4-phenylnipecotic acid methyl ester hydrobromide,C[NH+]1CC[C@@H]([C@@H](C1)C(=O)OC)C2=CC=CC=C2.[Br-],,,,,,
7450,42145,1-Methyl-4beta-phenylpiperidine-3beta-carboxylic acid methyl ester,CN1CC[C@@H]([C@@H](C1)C(=O)OC)C2=CC=CC=C2,,,,,,
7451,42146,"Nipecotic acid, 1-methyl-4-phenyl-, ethyl ester, hydrobromide, (Z)-(+)-",CCOC(=O)[C@@H]1C[NH+](CC[C@@H]1C2=CC=CC=C2)C.[Br-],,,,,,
7452,42147,"3-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester",CCOC(=O)C1CN(CCC1C2=CC=CC=C2)C,,,,,,
7453,42148,(+-)-trans-1-Methyl-4-phenylnipecotic acid ethyl ester hydrobromide,CCOC(=O)[C@@H]1C[NH+](CCC1C2=CC=CC=C2)C.[Br-],,,,,,
7454,42149,(+-)-1-Methyl-4-phenylnipecotic acid propyl ester hydrobromide,CCCOC(=O)[C@@H]1C[NH+](CC[C@@H]1C2=CC=CC=C2)C.[Br-],,,,,,
7455,42150,"propyl (3S,4S)-1-methyl-4-phenylpiperidine-3-carboxylate",CCCOC(=O)[C@@H]1CN(CC[C@@H]1C2=CC=CC=C2)C,,,,,,
7456,42151,"Methyl 2,5-octadecadiynoate",CCCCCCCCCCCCC#CCC#CC(=O)OC,,,,,,
7457,42152,Napactadine hydrochloride,C[NH2+]C(=NC)CC1=CC2=CC=CC=C2C=C1.[Cl-],,,,,,
7458,42153,Napactadine,CNC(=NC)CC1=CC2=CC=CC=C2C=C1,,,,,,
7459,42154,4-(3-Phenylpropoxy)aniline,C1=CC=C(C=C1)CCCOC2=CC=C(C=C2)N,,,,,,
7460,42155,(-)-cis-1-Methyl-4-phenylnipecotic acid ethyl ester hydrobromide,CCOC(=O)C1C[NH+](CCC1C2=CC=CC=C2)C.[Br-],,,,,,
7461,42156,"2-Methyl-1,2,3,4-tetrahydro-6-isoquinolinol hydrochloride",C[NH+]1CCC2=C(C1)C=CC(=C2)O.[Cl-],,,,,,
7462,42157,"1,2,3,4-Tetrahydro-2-methyl-4,6-isoquinolinediol hydrochloride",C[NH+]1CC(C2=C(C1)C=CC(=C2)O)O.[Cl-],,,,,,
7463,42158,"2-Methyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol",CN1CC(C2=C(C1)C=CC(=C2)O)O,,,,,,
7464,42159,"Isoquinoline, 6-methoxy-1,2,3,4-tetrahydro-, hydrochloride",COC1=CC2=C(C[NH2+]CC2)C=C1.[Cl-],,,,,,
7465,42160,"Dichloro(difluoro)methane;1,2-dichloro-1,1,2,2-tetrafluoroethane",C(C(F)(F)Cl)(F)(F)Cl.C(F)(F)(Cl)Cl,,,,,,
7466,42161,CID 42161,C#CC[NH+]1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.[Cl-],,,,,,
7467,42162,CID 42162,C#CCN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,,,,,,
7468,42163,Triclopyr triethylamine salt,CCN(CC)CC.C1=C(C(=NC(=C1Cl)Cl)OCC(=O)O)Cl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,,
7469,42164,"Acetanilide, 4-heptanoyl-",CCCCCCCC(=O)C1=CC=C(C=C1)NC(=O)C,,,,,,
7470,42165,O-(2-Diisopropylaminoethyl)-N-benzoyl-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C(C)C)C(C)C)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7471,42166,N-[3-[4-[2-[di(propan-2-yl)amino]ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C(C)C)C(C)C)NC(=O)C2=CC=CC=C2,,,,,,
7472,42167,O-(2-Di-n-propylaminoethyl)-N-benzoyl-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)CCOC1=CC=C(C=C1)CC(C(=O)N(CCC)CCC)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7473,42168,N-[1-(dipropylamino)-3-[4-[2-(dipropylamino)ethoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCCN(CCC)CCOC1=CC=C(C=C1)CC(C(=O)N(CCC)CCC)NC(=O)C2=CC=CC=C2,,,,,,
7474,42169,O-(4-Diethylaminobutyl)-N-benzoyl-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCCN(CC)CC)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7475,42170,N-[3-[4-[4-(diethylamino)butoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCCN(CC)CC)NC(=O)C2=CC=CC=C2,,,,,,
7476,42171,"(+-)-alpha-(Benzoylamino)-N,N-dipropyl-4-(2-(1-pyrrolidinyl)ethoxy)hydrocinnamamide oxalate",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=CC=C3.C(=O)(C(=O)O)O,,,,,,
7477,42172,N-[1-(dipropylamino)-1-oxo-3-[4-(2-pyrrolidin-1-ylethoxy)phenyl]propan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=CC=C3,,,,,,
7478,42173,"(+-)-alpha-(Benzoylamino)-N,N-dipropyl-4-(2-piperidinoethoxy)hydrocinnamamide oxalate",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCCCC2)NC(=O)C3=CC=CC=C3.C(=O)(C(=O)O)O,,,,,,
7479,42174,N-[1-(dipropylamino)-1-oxo-3-[4-(2-piperidin-1-ylethoxy)phenyl]propan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCCCC2)NC(=O)C3=CC=CC=C3,,,,,,
7480,42175,"Hydrocinnamamide, alpha-(benzoylamino)-4-(3-(4-benzyl-1-piperazinyl)propoxy)-N,N-dipropyl-, oxalate, (+-)-",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)CC3=CC=CC=C3)NC(=O)C4=CC=CC=C4.C(=O)(C(=O)O)O,,,,,,
7481,42176,N-[3-[4-[3-(4-benzylpiperazin-1-yl)propoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)CC3=CC=CC=C3)NC(=O)C4=CC=CC=C4,,,,,,
7482,42177,O-(2-Diethylaminoethyl)-N-benzoyl-DL-tyrosyl-dimethylamide oxalate,CCN(CC)CCOC1=CC=C(C=C1)CC(C(=O)N(C)C)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7483,42178,N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dimethylamino)-1-oxopropan-2-yl]benzamide,CCN(CC)CCOC1=CC=C(C=C1)CC(C(=O)N(C)C)NC(=O)C2=CC=CC=C2,,,,,,
7484,42179,O-(2-Dimethylaminoethyl)-N-benzoyl-DL-tyrosyl-ethylamide oxalate,CCNC(=O)C(CC1=CC=C(C=C1)OCCN(C)C)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7485,42180,N-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-(ethylamino)-1-oxopropan-2-yl]benzamide,CCNC(=O)C(CC1=CC=C(C=C1)OCCN(C)C)NC(=O)C2=CC=CC=C2,,,,,,
7486,42181,O-(2-Diisopropylaminoethyl)-N-benzoyl-DL-tyrosyl-ethylamide,CCNC(=O)C(CC1=CC=C(C=C1)OCCN(C(C)C)C(C)C)NC(=O)C2=CC=CC=C2,,,,,,
7487,42182,(+-)-alpha-(Benzoylamino)-N-propyl-4-(2-(1-pyrrolidinyl)ethoxy)hydrocinnamamide,CCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=CC=C3,,,,,,
7488,42183,O-(2-Diethylaminoethyl)-N-benzoyl-DL-tyrosyl-diethylamide oxalate,CCN(CC)CCOC1=CC=C(C=C1)CC(C(=O)N(CC)CC)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7489,42184,N-[1-(diethylamino)-3-[4-[2-(diethylamino)ethoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCN(CC)CCOC1=CC=C(C=C1)CC(C(=O)N(CC)CC)NC(=O)C2=CC=CC=C2,,,,,,
7490,42185,"Hydrocinnamamide, alpha-(benzoylamino)-N,N-diethyl-4-(2-(4-methyl-1-piperazinyl)ethoxy)-, (+-)-",CCN(CC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCN(CC2)C)NC(=O)C3=CC=CC=C3,,,,,,
7491,42186,(+-)-alpha-(Benzoylamino)-N-butyl-4-(2-(1-pyrrolidinyl)ethoxy)hydrocinnamamide oxalate,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=CC=C3.C(=O)(C(=O)O)O,,,,,,
7492,42187,N-[1-(butylamino)-1-oxo-3-[4-(2-pyrrolidin-1-ylethoxy)phenyl]propan-2-yl]benzamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=CC=C3,,,,,,
7493,42188,"Hydrocinnamamide, alpha-(benzoylamino)-N-butyl-4-(3-(4-methyl-1-piperazinyl)propoxy)-, oxalate, (+-)-",CCCCNC(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=CC=C3.C(=O)(C(=O)O)O,,,,,,
7494,42189,N-[1-(butylamino)-3-[4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=CC=C3,,,,,,
7495,42190,O-(2-Diethylaminoethyl)-N-benzoyl-DL-tyrosyl-n-butylamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=CC=C2,,,,,,
7496,42191,(+-)-alpha-(Benzoylamino)-N-hexyl-4-(2-(1-pyrrolidinyl)ethoxy)hydrocinnamamide,CCCCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=CC=C3,,,,,,
7497,42192,O-(2-Dimethylaminoethyl)-N-benzoyl-DL-tyrosylbenzylamide hydrochloride,CN(C)CCOC1=CC=C(C=C1)CC(C(=O)NCC2=CC=CC=C2)NC(=O)C3=CC=CC=C3.Cl,,,,,,
7498,42193,N-[1-(benzylamino)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-oxopropan-2-yl]benzamide,CN(C)CCOC1=CC=C(C=C1)CC(C(=O)NCC2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
7499,42194,O-(2-Dimethylaminoethyl)-N-toluoyl-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C)C)NC(=O)C2=CC=C(C=C2)C.C(=O)(C(=O)O)O,,,,,,
7500,42195,N-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]-4-methylbenzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C)C)NC(=O)C2=CC=C(C=C2)C,,,,,,
7501,42196,O-(2-Diethylaminoethyl)-N-toluoyl-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)C.C(=O)(C(=O)O)O,,,,,,
7502,42197,N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]-4-methylbenzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)C,,,,,,
7503,42198,"Hydrocinnamamide, N-butyl-4-(2-(1-pyrrolidinyl)ethoxy)-alpha-(p-toluoylamino)-, oxalate, (+-)-",CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=C(C=C3)C.C(=O)(C(=O)O)O,,,,,,
7504,42199,N-[1-(butylamino)-1-oxo-3-[4-(2-pyrrolidin-1-ylethoxy)phenyl]propan-2-yl]-4-methylbenzamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=C(C=C3)C,,,,,,
7505,42200,"Hydrocinnamamide, N-butyl-4-(3-(1-pyrrolidinyl)propoxy)-alpha-(p-toluoylamino)-, oxalate, (+-)-",CCCCNC(=O)C(CC1=CC=C(C=C1)OCCCN2CCCC2)NC(=O)C3=CC=C(C=C3)C.C(=O)(C(=O)O)O,,,,,,
7506,42201,N-[1-(butylamino)-1-oxo-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]propan-2-yl]-4-methylbenzamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCCN2CCCC2)NC(=O)C3=CC=C(C=C3)C,,,,,,
7507,42202,O-(2-Diisopropylaminoethyl)-N-toluoyl-DL-tyrosyl-n-butylamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN(C(C)C)C(C)C)NC(=O)C2=CC=C(C=C2)C,,,,,,
7508,42203,(+-)-N-Hexyl-4-(2-(1-pyrrolidinyl)ethoxy)-alpha-(p-toluoylamino)hydrocinnamamide,CCCCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=C(C=C3)C,,,,,,
7509,42204,"Hydrocinnamamide, alpha-((p-chlorobenzoyl)amino)-4-(2-(diethylamino)ethoxy)-N,N-dipropyl-, oxalate, (S)-",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)Cl.C(=O)(C(=O)O)O,,,,,,
7510,42205,4-chloro-N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)Cl,,,,,,
7511,42206,"Hydrocinnamamide, alpha-((p-chlorobenzoyl)amino)-N,N-dipropyl-4-(3-(4-methyl-1-piperazinyl)propoxy)-, citrate, (+-)-",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
7512,42207,4-chloro-N-[1-(dipropylamino)-3-[4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7513,42208,O-(2'-Diisopropylaminoethyl)-N-(p-chlorobenzoyl)-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C(C)C)C(C)C)NC(=O)C2=CC=C(C=C2)Cl.C(=O)(C(=O)O)O,,,,,,
7514,42209,4-chloro-N-[3-[4-[2-[di(propan-2-yl)amino]ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C(C)C)C(C)C)NC(=O)C2=CC=C(C=C2)Cl,,,,,,
7515,42210,"Hydrocinnamamide, alpha-((p-chlorobenzoyl)amino)-N,N-dipropyl-4-(2-(4-methyl-1-piperazinyl)ethoxy)-, citrate, (+-)-",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
7516,42211,4-chloro-N-[1-(dipropylamino)-3-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7517,42212,"Hydrocinnamamide, alpha-((p-chlorobenzoyl)amino)-N-ethyl-4-(3-(4-methyl-1-piperazinyl)propoxy)-, (+-)-",CCNC(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7518,42213,"Hydrocinnamamide, N-butyl-alpha-((p-chlorobenzoyl)amino)-4-(3-(4-methyl-1-piperazinyl)propoxy)-, (+-)-",CCCCNC(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7519,42214,O-(2-Diethylaminoethyl)-N-(p-chlorobenzoyl)-DL-tyrosyl-n-butylamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)Cl,,,,,,
7520,42215,"Hydrocinnamamide, N-butyl-alpha-((p-chlorobenzoyl)amino)-4-(2-(4-methyl-1-piperazinyl)ethoxy)-, (+-)-",CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCN(CC2)C)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7521,42216,(+-)-N-Butyl-alpha-((p-chlorobenzoyl)amino)-4-(2-(1-pyrrolidinyl)ethoxy)hydrocinnamamide,CCCCNC(=O)C(CC1=CC=C(C=C1)OCCN2CCCC2)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7522,42217,"Hydrocinnamamide, alpha-((o-chlorobenzoyl)amino)-N,N-dibutyl-4-(3-(4-methyl-1-piperazinyl)propoxy)-, citrate, (+-)-",CCCCN(CCCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=CC=C3Cl.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
7523,42218,2-chloro-N-[1-(dibutylamino)-3-[4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCCCN(CCCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)C)NC(=O)C3=CC=CC=C3Cl,,,,,,
7524,42219,O-(2-Diethylaminoethyl)-N-(p-bromobenzoyl)-DL-tyrosyl-di-n-propylamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)Br,,,,,,
7525,42220,O-(2-Dimethylaminoethyl)-N-(p-nitrobenzoyl)-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C)C)NC(=O)C2=CC=C(C=C2)[N+](=O)[O-].C(=O)(C(=O)O)O,,,,,,
7526,42221,N-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]-4-nitrobenzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(C)C)NC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
7527,42222,O-(2-Diethylaminoethyl)-N-(p-(trifluoromethyl)benzoyl)-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)C(F)(F)F.C(=O)(C(=O)O)O,,,,,,
7528,42223,N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]-4-(trifluoromethyl)benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=C(C=C2)C(F)(F)F,,,,,,
7529,42224,"O-(2-Diethylaminoethyl)-N-(3,4-dimethylbenzoyl)-DL-tyrosyl-di-n-propylamide oxalate",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC(=C(C=C2)C)C.C(=O)(C(=O)O)O,,,,,,
7530,42225,"N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]-3,4-dimethylbenzamide",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC(=C(C=C2)C)C,,,,,,
7531,42226,"Carbamic acid, (1-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-2-(dipropylamino)-2-oxoethyl)-, benzyl ester, oxalate, (S)-",CCCN(CCC)C(=O)[C@H](CC1=CC=C(C=C1)OCC[NH+](C)C)NC(=O)OCC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
7532,42227,benzyl N-[(2S)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]carbamate,CCCN(CCC)C(=O)[C@H](CC1=CC=C(C=C1)OCCN(C)C)NC(=O)OCC2=CC=CC=C2,,,,,,
7533,42228,O-(2-Diethylaminoethyl)-N-carbobenzoxy-L-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)[C@H](CC1=CC=C(C=C1)OCC[NH+](CC)CC)NC(=O)OCC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
7534,42229,benzyl N-[(2S)-3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]carbamate,CCCN(CCC)C(=O)[C@H](CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)OCC2=CC=CC=C2,,,,,,
7535,42230,"Carbamic acid, (1-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-2-(ethylamino)-2-oxoethyl)-, benzyl ester, oxalate, (S)-",CCNC(=O)[C@H](CC1=CC=C(C=C1)OCC[NH+](C)C)NC(=O)OCC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
7536,42231,benzyl N-[(2S)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-(ethylamino)-1-oxopropan-2-yl]carbamate,CCNC(=O)[C@H](CC1=CC=C(C=C1)OCCN(C)C)NC(=O)OCC2=CC=CC=C2,,,,,,
7537,42232,"Carbamic acid, (1-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-2-oxo-2-(benzylamino)ethyl)-, benzyl ester, hydrochloride, (S)-",C[NH+](C)CCOC1=CC=C(C=C1)C[C@@H](C(=O)NCC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3.[Cl-],,,,,,
7538,42233,benzyl N-[(2S)-1-(benzylamino)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-oxopropan-2-yl]carbamate,CN(C)CCOC1=CC=C(C=C1)C[C@@H](C(=O)NCC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
7539,42234,O-(2-Dimethylaminoethyl)-N-(p-nitrocarbobenzoxy)-L-tyrosyl-di-n-propylamide,CCCN(CCC)C(=O)[C@H](CC1=CC=C(C=C1)OCCN(C)C)NC(=O)OCC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
7540,42235,"Carbamic acid, (1-((4-(2-(diethylamino)ethoxy)phenyl)methyl)-2-(dipropylamino)-2-oxoethyl)-, benzyl ester, oxalate, (R)-",CCCN(CCC)C(=O)[C@@H](CC1=CC=C(C=C1)OCC[NH+](CC)CC)NC(=O)OCC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
7541,42236,benzyl N-[(2R)-3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]carbamate,CCCN(CCC)C(=O)[C@@H](CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)OCC2=CC=CC=C2,,,,,,
7542,42237,N-(9-Hydroxy-9H-fluoren-2-yl)acetamide,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2O,,,,,,
7543,42238,"2-Methyl-2-propyl-1,3-dithiolane",CCCC1(SCCS1)C,,,,,,
7544,42239,"2-Methyl-2-(2-phenylethenyl)-1,3-dithiolane",CC1(SCCS1)C=CC2=CC=CC=C2,,,,,,
7545,42240,4-Hydroxy-3-methoxyphenyl acetate,CC(=O)OC1=CC(=C(C=C1)O)OC,,,,,,
7546,42241,"Butyrophenone, 4-(4-(p-chloro-alpha-hydroxy-alpha-phenylbenzyl)piperidino)-4'-fluoro-, hydrochloride",C1C[NH+](CCC1C(C2=CC=CC=C2)(C3=CC=C(C=C3)Cl)O)CCCC(=O)C4=CC=C(C=C4)F.[Cl-],,,,,,
7547,42242,4-[4-[(4-Chlorophenyl)-hydroxy-phenylmethyl]piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,C1CN(CCC1C(C2=CC=CC=C2)(C3=CC=C(C=C3)Cl)O)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
7548,42243,3-Piperidyl benzilate,C1CC(CNC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
7549,42244,"3-Hydroxy-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=CC(=C3)O,,,,,,
7550,42245,"3-(Carboxyacetyl)-8-methyl-3,8-diazabicyclo(3.2.1)octane",CN1C2CCC1CN(C2)C(=O)CC(=O)O,,,,,,
7551,42246,"3-(p-Chlorobenzoyl)-8-methyl-3,8-diazabicyclo(3.2.1)octane",CN1C2CCC1CN(C2)C(=O)C3=CC=C(C=C3)Cl,,,,,,
7552,42247,"8-(Carboxyacetyl)-3-methyl-3,8-diazabicyclo(3.2.1)octane",CN1CC2CCC(C1)N2C(=O)CC(=O)O,,,,,,
7553,42248,CID 42248,CC1=CCC(C1(C)C)CC=CC(C)(CC(=O)[O-])O.[Na+],,,,,,
7554,42249,CID 42249,CC1=CCC(C1(C)C)CC=CC(C)(CC(=O)O)O,,,,,,
7555,42250,CID 42250,CC1=CCC(C1(C)C)C=CCC(C)(CC(=O)[O-])O.[Na+],,,,,,
7556,42251,CID 42251,CC1=CCC(C1(C)C)C=CCC(C)(CC(=O)O)O,,,,,,
7557,42252,But-2-enedioic acid;2-(4-methylpiperazin-1-yl)ethyl pyridine-3-carboxylate,CN1CCN(CC1)CCOC(=O)C2=CN=CC=C2.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
7558,42253,2-(4-Methylpiperazin-1-yl)ethyl pyridine-3-carboxylate,CN1CCN(CC1)CCOC(=O)C2=CN=CC=C2,,,,,,
7559,42254,But-2-enedioic acid;2-(4-methylpiperazin-1-yl)ethyl pyridine-4-carboxylate,CN1CCN(CC1)CCOC(=O)C2=CC=NC=C2.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
7560,42255,2-(4-Methylpiperazin-1-yl)ethyl pyridine-4-carboxylate,CN1CCN(CC1)CCOC(=O)C2=CC=NC=C2,,,,,,
7561,42256,CID 42256,C[NH+](C)CCOC(=O)C1=C[NH+]=CC=C1.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
7562,42257,Ethyl 15-methylheptadecanoate,CCC(C)CCCCCCCCCCCCCC(=O)OCC,,,,,,
7563,42258,4-(Cyclohexylamino)-1-(naphthalenyloxy)-2-butanol,C1CCC(CC1)NCCC(COC2=CC=CC3=CC=CC=C32)O,,,,,,
7564,42259,O-(2-Diethylaminoethyl)-N-carbobenzoxy-DL-tyrosyl-di-n-propylamide oxalate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCC[NH+](CC)CC)NC(=O)OCC2=CC=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
7565,42260,benzyl N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]carbamate,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)OCC2=CC=CC=C2,,,,,,
7566,42261,"(S)-alpha-(Benzoylamino)-4-(2-(diethylamino)ethoxy)-N,N-dipropylhydrocinnamamide oxalate",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=CC=C2.C(=O)(C(=O)O)O,,,,,,
7567,42262,Tiropramide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=CC=C2,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
7568,42263,2-Heptadecanol,CCCCCCCCCCCCCCCC(C)O,,,,,,
7569,42264,"2,6-Naphthalenedione, octahydro-1,1,8a-trimethyl-, cis-",CC1(C(=O)CCC2C1(CCC(=O)C2)C)C,,,,,,
7570,42265,2-Methyl-1-dodecanol,CCCCCCCCCCC(C)CO,,,,,,
7571,42266,Indacrinone,CC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3=CC=CC=C3,,,"['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma. (See all compounds classified as Uricosuric Agents.)']",,,
7572,42267,"Benzo(a)pyrene-7,8-diol",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(=C5O)O)C=C2,,,,,"['Benzo[a]pyrene-7,8-diol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(8-hydroxybenzo[a]pyren-7-yl)oxyoxane-2-carboxylic acid and 4-Oxahexacyclo[11.6.2.02,8.03,5.010,20.017,21]henicosa-1(20),2(8),3(5),6,9,11,13(21),14,16,18-decaene-6,7-diol.']",
7573,42268,"2,4,4'-Trichlorodiphenyl ether",C1=CC(=CC=C1OC2=C(C=C(C=C2)Cl)Cl)Cl,,,,,,
7574,42269,"Hydrocinnamamide, alpha-(benzoylamino)-N,N-dipropyl-4-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propoxy)-, oxalate, (+-)-",CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)CCO)NC(=O)C3=CC=CC=C3.C(=O)(C(=O)O)O,,,,,,
7575,42270,N-[1-(dipropylamino)-3-[4-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]phenyl]-1-oxopropan-2-yl]benzamide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCCN2CCN(CC2)CCO)NC(=O)C3=CC=CC=C3,,,,,,
7576,42271,"3-(p-Chlorobenzoyl)-6-chloro-alpha,2-dimethyl-1-indoleacetic acid",CC1=C(C2=C(N1C(C)C(=O)O)C=C(C=C2)Cl)C(=O)C3=CC=C(C=C3)Cl,,,,,,
7577,42272,Epofenonane,CCC1=CC=C(C=C1)OCCC(CC)CCC2C(O2)(C)CC,,,,,,
7578,42273,CID 42273,C[NH+]1CCN(CC1)C2=CC3=CC=CC=C3OC4=C2C=C(C=C4)F.C(=CC(=O)[O-])C(=O)O,,,,,,
7579,42274,"1-(8-Fluorodibenz(b,f)oxepin-10-yl)-4-methylpiperazine",CN1CCN(CC1)C2=CC3=CC=CC=C3OC4=C2C=C(C=C4)F,,,,,,
7580,42275,"Ammonium, diethyl(2-hydroxyethyl)methyl-, iodide, 3,3-diphenyl-3-hydroxypropionate",CC[N+](C)(CC)CCOC(=O)CC(C1=CC=CC=C1)(C2=CC=CC=C2)O.[I-],,,,,,
7581,42276,"Diethyl-[2-(3-hydroxy-3,3-diphenylpropanoyl)oxyethyl]-methylazanium",CC[N+](C)(CC)CCOC(=O)CC(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7582,42277,"Ammonium, (2-hydroxyethyl)triethyl-, iodide, 3,3-diphenyl-3-hydroxypropionate",CC[N+](CC)(CC)CCOC(=O)CC(C1=CC=CC=C1)(C2=CC=CC=C2)O.[I-],,,,,,
7583,42278,"Triethyl-[2-(3-hydroxy-3,3-diphenylpropanoyl)oxyethyl]azanium",CC[N+](CC)(CC)CCOC(=O)CC(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7584,42279,"Ammonium, (2-hydroxyethyl)triethyl-, bromide, 3,3-diphenyl-3-hydroxypropionate",CC[N+](CC)(CC)CCOC(=O)CC(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
7585,42280,"Podocarpa-8,11,13-trien-15-oic acid",CC12CCCC(C1CCC3=CC=CC=C23)(C)C(=O)O,,,,,,
7586,42281,"Acetamide, N,N'-trimethylenebis(iodo-",C(CNC(=O)CI)CNC(=O)CI,,,,,,
7587,42282,"8-Diethylaminomethyl-3,3',4',5,7-pentahydroxyflavanone, hydrochloride",CC[NH+](CC)CC1=C2C(=C(C=C1O)O)C(=O)C(C(O2)C3=CC(=C(C=C3)O)O)O.[Cl-],,,,,,
7588,42283,"8-(Diethylaminomethyl)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one",CCN(CC)CC1=C2C(=C(C=C1O)O)C(=O)C(C(O2)C3=CC(=C(C=C3)O)O)O,,,,,,
7589,42284,"3,3',4',5,7-Pentahydroxy-8-piperidinomethylflavanone, hydrochloride",C1CC[NH+](CC1)CC2=C3C(=C(C=C2O)O)C(=O)C(C(O3)C4=CC(=C(C=C4)O)O)O.[Cl-],,,,,,
7590,42285,"2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-8-(piperidin-1-ylmethyl)-2,3-dihydrochromen-4-one",C1CCN(CC1)CC2=C3C(=C(C=C2O)O)C(=O)C(C(O3)C4=CC(=C(C=C4)O)O)O,,,,,,
7591,42286,CID 42286,C[NH+](C)CC1=C2C(=C(C(=C(O2)C3=CC(=C(C=C3)O)O)O)O)C(=O)C=C1O.[Cl-],,,,,,
7592,42287,CID 42287,CN(C)CC1=C2C(=C(C(=C(O2)C3=CC(=C(C=C3)O)O)O)O)C(=O)C=C1O,,,,,,
7593,42288,CID 42288,C1CC[NH+](CC1)CC2=C3C(=C(C(=C(O3)C4=CC(=C(C=C4)O)O)O)O)C(=O)C=C2O.[Cl-],,,,,,
7594,42289,CID 42289,C1CCN(CC1)CC2=C3C(=C(C(=C(O3)C4=CC(=C(C=C4)O)O)O)O)C(=O)C=C2O,,,,,,
7595,42290,MordantBrown33,CC1C2=C(C=C(C=C2)C(F)(F)F)C(C3=CC=CC=C13)CCCN(C)C.Cl,,,,,,
7596,42291,Fluotracene,CC1C2=C(C=C(C=C2)C(F)(F)F)C(C3=CC=CC=C13)CCCN(C)C,,,,,,
7597,42292,"4,4'-Diethylbiphenyl",CCC1=CC=C(C=C1)C2=CC=C(C=C2)CC,,,,,,
7598,42293,5-Chloro-2-methyl-4-isothiazolin-3-one calcium chloride,CN1C(=O)C=C(S1)Cl.[Cl-].[Cl-].[Ca+2],,,,,,
7599,42294,2-Methyl-4-isothiazolin-3-one calcium chloride,CN1C(=O)C=CS1.[Cl-].[Cl-].[Ca+2],,,,,,
7600,42295,Hymenoxon,C[C@@H]1C[C@@H]2[C@H](C[C@]3([C@H]1C[C@@H](O[C@H]3O)O)C)C(=C)C(=O)O2,,,,,['THE SULFHYDRYL GROUP IS NOT THE PRIMARY REACTIVE SITE. HYMENOXON IS EXCRETED AS GLUCURONIDES VIA URINE AND BILE.'],
7601,42296,"2-Buten-1-one, 1-(2,6,6-trimethyl-3-cyclohexen-1-YL)-",CC=CC(=O)C1C(C=CCC1(C)C)C,,,,,,
7602,42297,"trans-9,10-Dihydroxy-9,10-dihydrobenzo[a]pyrene",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]([C@H](C=C5)O)O)C=C2,,,,,,
7603,42298,"2,5-Dihydro-4-methoxy-1-methyl-1H-pyrrole-2,3-dimethanol bis(ethylcarbamate)",CCNC(=O)OCC1C(=C(CN1C)OC)COC(=O)NCC,,,,,,
7604,42299,CID 42299,CC=CCOC(=O)C1=C[C@@H]([C@@H]([C@@H](C1=O)O)O)O,,,,,,
7605,42300,3-Iodobenzyl alcohol,C1=CC(=CC(=C1)I)CO,,,,,,
7606,42301,"5H-Cyclohepta(b)naphthalen-6,9-imin-5-ol, 5a,6,7,8,9,10,10a,11-octahydro-12-methyl-, (5R-(5-alpha,5a-alpha,6-alpha,9-alpha,10a-alpha))-",CN1[C@H]2CC[C@@H]1[C@H]3[C@@H](C2)CC4=CC=CC=C4[C@@H]3O,,,,,,
7607,42302,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(2-methylaminoethyl)-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC[NH2+]C.[Cl-],,,,,,
7608,42303,"6-Chloro-2-methyl-4-[2-(methylamino)ethyl]-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCNC,,,,,,
7609,42304,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-dimethylaminoethyl)-2-methyl-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC[NH+](C)C.[Cl-],,,,,,
7610,42305,"6-Chloro-4-[2-(dimethylamino)ethyl]-2-methyl-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCN(C)C,,,,,,
7611,42306,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-diethylaminoethyl)-2-methyl-, hydrochloride",CC[NH+](CC)CCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C.[Cl-],,,,,,
7612,42307,"6-Chloro-4-[2-(diethylamino)ethyl]-2-methyl-1,4-benzoxazin-3-one",CCN(CC)CCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C,,,,,,
7613,42308,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-diethylaminoethyl)-2-ethyl-, hydrochloride",CCC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC[NH+](CC)CC.[Cl-],,,,,,
7614,42309,"6-Chloro-4-[2-(diethylamino)ethyl]-2-ethyl-1,4-benzoxazin-3-one",CCC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCN(CC)CC,,,,,,
7615,42310,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-7,8-dichloro-4-(2-diethylaminoethyl)-2-methyl-, hydrochloride",CC[NH+](CC)CCN1C2=C(C(=C(C=C2)Cl)Cl)OC(C1=O)C.[Cl-],,,,,,
7616,42311,"7,8-Dichloro-4-[2-(diethylamino)ethyl]-2-methyl-1,4-benzoxazin-3-one",CCN(CC)CCN1C2=C(C(=C(C=C2)Cl)Cl)OC(C1=O)C,,,,,,
7617,42312,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-7-chloro-4-(2-diethylaminoethyl)-2-methyl-6-nitro-, hydrochloride",CC[NH+](CC)CCN1C2=CC(=C(C=C2OC(C1=O)C)Cl)[N+](=O)[O-].[Cl-],,,,,,
7618,42313,"7-Chloro-4-[2-(diethylamino)ethyl]-2-methyl-6-nitro-1,4-benzoxazin-3-one",CCN(CC)CCN1C2=CC(=C(C=C2OC(C1=O)C)Cl)[N+](=O)[O-],,,,,,
7619,42314,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-4-(2-diethylaminoethyl)-2,6-dimethyl-, hydrochloride",CC[NH+](CC)CCN1C2=C(C=CC(=C2)C)OC(C1=O)C.[Cl-],,,,,,
7620,42315,"4-[2-(Diethylamino)ethyl]-2,6-dimethyl-1,4-benzoxazin-3-one",CCN(CC)CCN1C2=C(C=CC(=C2)C)OC(C1=O)C,,,,,,
7621,42316,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-4-(2-diethylaminoethyl)-2-methyl-6-nitro-, hydrochloride",CC[NH+](CC)CCN1C2=C(C=CC(=C2)[N+](=O)[O-])OC(C1=O)C.[Cl-],,,,,,
7622,42317,"4-[2-(Diethylamino)ethyl]-2-methyl-6-nitro-1,4-benzoxazin-3-one",CCN(CC)CCN1C2=C(C=CC(=C2)[N+](=O)[O-])OC(C1=O)C,,,,,,
7623,42318,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(2-(1-pyrrolidinyl)ethyl)-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC[NH+]3CCCC3.[Cl-],,,,,,
7624,42319,"6-Chloro-2-methyl-4-(2-pyrrolidin-1-ylethyl)-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCN3CCCC3,,,,,,
7625,42320,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-dimethylaminoethyl)-2-phenyl-, hydrochloride",C[NH+](C)CCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C3=CC=CC=C3.[Cl-],,,,,,
7626,42321,"6-Chloro-4-[2-(dimethylamino)ethyl]-2-phenyl-1,4-benzoxazin-3-one",CN(C)CCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C3=CC=CC=C3,,,,,,
7627,42322,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-diethylaminoethyl)-2-phenyl-, hydrochloride",CC[NH+](CC)CCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C3=CC=CC=C3.[Cl-],,,,,,
7628,42323,"6-Chloro-4-[2-(diethylamino)ethyl]-2-phenyl-1,4-benzoxazin-3-one",CCN(CC)CCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C3=CC=CC=C3,,,,,,
7629,42324,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(3-methylaminopropyl)-, oxalate",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCC[NH2+]C.C(=O)(C(=O)[O-])O,,,,,,
7630,42325,"6-Chloro-2-methyl-4-[3-(methylamino)propyl]-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCCNC,,,,,,
7631,42326,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(3-dimethylaminopropyl)-2-methyl-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCC[NH+](C)C.Cl,,,,,,
7632,42327,"6-Chloro-4-[3-(dimethylamino)propyl]-2-methyl-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCCN(C)C,,,,,,
7633,42328,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(3-dimethylaminopropyl)-, hydrochloride",C[NH+](C)CCCN1C(=O)COC2=C1C=C(C=C2)Cl.[Cl-],,,,,,
7634,42329,"6-Chloro-4-[3-(dimethylamino)propyl]-1,4-benzoxazin-3-one",CN(C)CCCN1C(=O)COC2=C1C=C(C=C2)Cl,,,,,,
7635,42330,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(3-diethylaminopropyl)-2-methyl-, hydrochloride",CC[NH+](CC)CCCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C.[Cl-],,,,,,
7636,42331,"6-Chloro-4-[3-(diethylamino)propyl]-2-methyl-1,4-benzoxazin-3-one",CCN(CC)CCCN1C2=C(C=CC(=C2)Cl)OC(C1=O)C,,,,,,
7637,42332,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(3-(4-methylpiperazinyl)propyl)-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCC[NH+]3CCN(CC3)C.[Cl-],,,,,,
7638,42333,"6-Chloro-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CCCN3CCN(CC3)C,,,,,,
7639,42334,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-(dimethylamino)propyl)-2-methyl-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)[NH+](C)C.[Cl-],,,,,,
7640,42335,"6-Chloro-4-[2-(dimethylamino)propyl]-2-methyl-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)N(C)C,,,,,,
7641,42336,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-4-(2-(dimethylamino)propyl)-2-ethyl-, oxalate",CCC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)[NH+](C)C.C(=O)(C(=O)[O-])O,,,,,,
7642,42337,"6-Chloro-4-[2-(dimethylamino)propyl]-2-ethyl-1,4-benzoxazin-3-one",CCC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)N(C)C,,,,,,
7643,42338,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-2,6-dimethyl-4-(2-(dimethylamino)propyl)-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)C)CC(C)[NH+](C)C.[Cl-],,,,,,
7644,42339,"4-[2-(Dimethylamino)propyl]-2,6-dimethyl-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)C)CC(C)N(C)C,,,,,,
7645,42340,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-4-(2-(dimethylamino)propyl)-2-methyl-6-nitro-, hydrochloride",CC1C(=O)N(C2=C(O1)C=CC(=C2)[N+](=O)[O-])CC(C)[NH+](C)C.[Cl-],,,,,,
7646,42341,"4-[2-(Dimethylamino)propyl]-2-methyl-6-nitro-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)[N+](=O)[O-])CC(C)N(C)C,,,,,,
7647,42342,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-8-chloro-4-(2-(dimethylamino)propyl)-2-methyl-6-nitro-, hydrochloride",CC1C(=O)N(C2=C(O1)C(=CC(=C2)[N+](=O)[O-])Cl)CC(C)[NH+](C)C.[Cl-],,,,,,
7648,42343,"8-Chloro-4-[2-(dimethylamino)propyl]-2-methyl-6-nitro-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C(=CC(=C2)[N+](=O)[O-])Cl)CC(C)N(C)C,,,,,,
7649,42344,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(2-(1-pyrrolidinyl)propyl)-, oxalate",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)[NH+]3CCCC3.C(=O)(C(=O)[O-])O,,,,,,
7650,42345,"6-Chloro-2-methyl-4-(2-pyrrolidin-1-ylpropyl)-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)N3CCCC3,,,,,,
7651,42346,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-ethyl-4-(2-(1-pyrrolidinyl)propyl)-, oxalate",CCC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)[NH+]3CCCC3.C(=O)(C(=O)[O-])O,,,,,,
7652,42347,"6-Chloro-2-ethyl-4-(2-pyrrolidin-1-ylpropyl)-1,4-benzoxazin-3-one",CCC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)N3CCCC3,,,,,,
7653,42348,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(2-piperidinopropyl)-, oxalate",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)[NH+]3CCCCC3.C(=O)(C(=O)[O-])O,,,,,,
7654,42349,"6-Chloro-2-methyl-4-(2-piperidin-1-ylpropyl)-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)N3CCCCC3,,,,,,
7655,42350,"4H-1,4-Benzoxazin-3-one, 2,3-dihydro-6-chloro-2-methyl-4-(2-(methylamino)propyl)-, oxalate",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)[NH2+]C.C(=O)(C(=O)[O-])O,,,,,,
7656,42351,"6-Chloro-2-methyl-4-[2-(methylamino)propyl]-1,4-benzoxazin-3-one",CC1C(=O)N(C2=C(O1)C=CC(=C2)Cl)CC(C)NC,,,,,,
7657,42352,cis-6-Benzamido-2-methyldecahydroisoquinoline,CN1CC[C@H]2CC(CC[C@H]2C1)NC(=O)C3=CC=CC=C3,,,,,,
7658,42353,trans-6-Benzamido-2-methyldecahydroisoquinoline,CN1CC[C@@H]2CC(CC[C@H]2C1)NC(=O)C3=CC=CC=C3,,,,,,
7659,42354,"cis-2-Methyl-6-(3,4,5-trimethoxy-benzamido)decahydroisoquinoline",CN1CC[C@H]2CC(CC[C@H]2C1)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7660,42355,cis-6-(p-Chlorobenzamido)-2-methyldecahydroisoquinoline,CN1CC[C@H]2CC(CC[C@H]2C1)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7661,42356,"cis-6-(3,4-Dichlorobenzamido)-2-methyldecahydroisoquinoline",CN1CC[C@H]2CC(CC[C@H]2C1)NC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
7662,42357,"cis-2-Methyl-6-(3,4,5-trimethoxybenzoyloxy)decahydroisoquinoline hydrochloride",C[NH+]1CCC2C[C@H](CCC2C1)OC(=O)C3=CC(=C(C(=C3)OC)OC)OC.[Cl-],,,,,,
7663,42358,"[(6S)-2-methyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-6-yl] 3,4,5-trimethoxybenzoate",CN1CCC2C[C@H](CCC2C1)OC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7664,42359,"trans-2-Methyl-6-(3,4,5-trimethoxybenzoyloxy)decahydroisoquinoline hydrochloride",C[NH+]1CCC2CC(CCC2C1)OC(=O)C3=CC(=C(C(=C3)OC)OC)OC.[Cl-],,,,,,
7665,42360,"(2-methyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-6-yl) 3,4,5-trimethoxybenzoate",CN1CCC2CC(CCC2C1)OC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7666,42361,"cis-6-(3,4-Dichlorobenzoyloxy)-2-methyldecahydroisoquinoline",CN1CCC2C[C@H](CCC2C1)OC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
7667,42362,"trans-6-(3,4-Dichlorobenzoyloxy)-2-methyldecahydroisoquinoline",CN1CCC2CC(CCC2C1)OC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
7668,42363,"trans-6-(3,4-Dichlorobenzamido)-2-methyldecahydroisoquinoline",CN1CC[C@@H]2CC(CC[C@H]2C1)NC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
7669,42364,"1,2,3,4-Tetrahydro-2-propylisoquinoline hydrochloride",CCC[NH+]1CCC2=CC=CC=C2C1.[Cl-],,,,,,
7670,42365,"Isoquinoline, 1,2,3,4-tetrahydro-2-propyl-",CCCN1CCC2=CC=CC=C2C1,,,,,,
7671,42366,"DL-N-(3-Acetamido-5-methylcarbamoyl-2,4,6-triiodobenzoyl)alanine",CC(C(=O)O)NC(=O)C1=C(C(=C(C(=C1I)C(=O)NC)I)NC(=O)C)I,,,,,,
7672,42367,"beta-ALANINE, N-(3-CARBAMOYL-5-METHOXYACETAMIDO-2,4,6-TRIIODOBENZOYL)-",COCC(=O)NC1=C(C(=C(C(=C1I)C(=O)NCCC(=O)O)I)C(=O)N)I,,,,,,
7673,42368,CID 42368,CC(C)CC1=CC=C(C=C1)C(C)C(=O)[O-].C(CC[NH3+])C[C@@H](C(=O)O)N,,,,,,
7674,42369,[(2S)-2-(4-methylphenyl)-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]azanium;chloride,CC1=CC=C(C=C1)[C@@](C)(C(=O)OC(C)(C)C)[NH3+].[Cl-],,,,,,
7675,42370,tert-butyl (2S)-2-amino-2-(4-methylphenyl)propanoate,CC1=CC=C(C=C1)[C@@](C)(C(=O)OC(C)(C)C)N,,,,,,
7676,42371,"1,1-Dimethyl-2-phenylethyl 2-aminopropanoate hydrochloride",CC(C(=O)OC(C)(C)CC1=CC=CC=C1)[NH3+].[Cl-],,,,,,
7677,42372,(2-Methyl-1-phenylpropan-2-yl) 2-aminopropanoate,CC(C(=O)OC(C)(C)CC1=CC=CC=C1)N,,,,,,
7678,42373,Celiprolol hydrochloride,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)']",,,
7679,42374,"2-(3,4-Dichlorophenyl)-1,1-dimethylethyl 2-aminopropanoate hydrobromide",CC(C)(C)OC(=O)C(C)(C1=CC(=C(C=C1)Cl)Cl)[NH3+].[Br-],,,,,,
7680,42375,"Tert-butyl 2-amino-2-(3,4-dichlorophenyl)propanoate",CC(C)(C)OC(=O)C(C)(C1=CC(=C(C=C1)Cl)Cl)N,,,,,,
7681,42376,"trans-2-Methyl-6-(3,4,5-trimethoxy-benzamido)decahydroisoquinoline",CN1CC[C@@H]2CC(CC[C@H]2C1)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7682,42377,N-(3-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)propyl)acetamide,CC(C)NCC(COC1=CC=C(C=C1)CCCNC(=O)C)O,,,,,,
7683,42378,N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-N-methylacetamide,CC(C)NCC(COC1=CC=C(C=C1)N(C)C(=O)C)O,,,,,,
7684,42379,N-Hexyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzamide,CCCCCCNC(=O)C1=CC=C(C=C1)OCC(CNC(C)C)O,,,,,,
7685,42380,N-Cyclohexyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzamide,CC(C)NCC(COC1=CC=C(C=C1)C(=O)NC2CCCCC2)O,,,,,,
7686,42381,"N,N-Diethyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzamide",CCN(CC)C(=O)C1=CC=C(C=C1)OCC(CNC(C)C)O,,,,,,
7687,42382,CID 42382,C1=CC=C(C=C1)[NH+]=C2N=C(SS2)N.[Br-],,,,,,
7688,42383,"5-imino-N-phenyl-1,2,4-dithiazol-3-amine",C1=CC=C(C=C1)N=C2N=C(SS2)N,,,,,,
7689,42384,CID 42384,COC1=CC=C(C=C1)[NH+]=C2N=C(SS2)N.[Br-],,,,,,
7690,42385,"5-(4-Methoxyphenyl)imino-1,2,4-dithiazol-3-amine",COC1=CC=C(C=C1)N=C2N=C(SS2)N,,,,,,
7691,42386,CID 42386,COC1=CC=CC=C1[NH+]=C2N=C(SS2)N.[Br-],,,,,,
7692,42387,"5-(2-Methoxyphenyl)imino-1,2,4-dithiazol-3-amine",COC1=CC=CC=C1N=C2N=C(SS2)N,,,,,,
7693,42388,CID 42388,COC1=CC=CC=C1N=C(N=C(N)S)S,,,,,,
7694,42389,CID 42389,COC1=CC=C(C=C1)N=C(N=C(N)S)S,,,,,,
7695,42390,CID 42390,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)[O-].[Na+],,,,,,
7696,42391,"5H-Cyclohepta(b)naphthalen-6,9-imin-5-one, 5a,6,7,8,9,10,10a,11-octahydro-12-methyl-, hydrochloride, (5aR-(5a-alpha,6-alpha,9-alpha,10a-alpha))-",C[NH+]1[C@H]2CC[C@@H]1[C@H]3[C@@H](C2)CC4=CC=CC=C4C3=O.[Cl-],,,,,,
7697,42392,CID 42392,CN1[C@H]2CC[C@@H]1C3[C@@H](C2)CC4=CC=CC=C4C3=O,,,,,,
7698,42393,CID 42393,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].C(CCCCN=C([NH3+])N)CCC[NH2+]CCCCCCCCN=C([NH3+])N,,,,,,
7699,42394,"Ethanol, 2-((4-methoxy-2-nitrophenyl)amino)-",COC1=CC(=C(C=C1)NCCO)[N+](=O)[O-],,,,,,
7700,42395,"[(17R)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] pentanoate",CCCCC(=O)O[C@@]1(CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C)C(=O)CO,,,,,,
7701,42396,Prenalterol,CC(C)NC[C@@H](COC1=CC=C(C=C1)O)O,,,"['Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Agonists.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)']",,,
7702,42397,"INDOLO(1,7-ab)(1)BENZAZEPINE-1-ETHANAMINE, 6,7-DIHYDRO-N,N-DIMETHYL-",CN(C)CCC1=CC2=C3N1C4=CC=CC=C4CCC3=CC=C2,,,,,,
7703,42398,"6,7-Dihydro-N,N-dibenzyl-indolo(1,7-ab)(1)benzazepine-1-ethanamine hydrochloride",C1CC2=CC=CC3=C2N(C4=CC=CC=C41)C(=C3)CC[NH+](CC5=CC=CC=C5)CC6=CC=CC=C6.[Cl-],,,,,,
7704,42399,"2-(1-azatetracyclo[8.6.1.02,7.014,17]heptadeca-2,4,6,10,12,14(17),15-heptaen-16-yl)-N,N-dibenzylethanamine",C1CC2=CC=CC3=C2N(C4=CC=CC=C41)C(=C3)CCN(CC5=CC=CC=C5)CC6=CC=CC=C6,,,,,,
7705,42400,"6,7-Dihydro-N-methyl-indolo(1,7-ab)(1)benzazepine-1-ethanamine hydrochloride",C[NH2+]CCC1=CC2=C3N1C4=CC=CC=C4CCC3=CC=C2.[Cl-],,,,,,
7706,42401,"2-(1-azatetracyclo[8.6.1.02,7.014,17]heptadeca-2,4,6,10,12,14(17),15-heptaen-16-yl)-N-methylethanamine",CNCCC1=CC2=C3N1C4=CC=CC=C4CCC3=CC=C2,,,,,,
7707,42402,"INDOLO(1,7-ab)(1)BENZAZEPINE-1-ETHANAMINE, 6,7-DIHYDRO-N,N,2-TRIMETHYL-",CC1=C(N2C3=CC=CC=C3CCC4=C2C1=CC=C4)CCN(C)C,,,,,,
7708,42403,"6,7-Dihydro-N,2-dimethyl-indolo(1,7-ab)(1)benzazepine-1-ethanamine hydrochloride",CC1=C(N2C3=CC=CC=C3CCC4=C2C1=CC=C4)CC[NH2+]C.[Cl-],,,,,,
7709,42404,"6,7-Dihydro-2-methyl-1-(2-methylaminoethyl)-indolo[1,7-ab][1]benzazepine",CC1=C(N2C3=CC=CC=C3CCC4=C2C1=CC=C4)CCNC,,,,,,
7710,42405,"INDOLO(1,7-ab)(1)BENZAZEPINE-1-METHANAMINE, 6,7-DIHYDRO-N,N-DIMETHYL-",CN(C)CC1=CC2=C3N1C4=CC=CC=C4CCC3=CC=C2,,,,,,
7711,42406,"INDOLO(1,7-ab)(1)BENZAZEPINE-1-ETHANAMINE, 6,7-DIHYDRO-N,N-DIMETHYL-2-PHENYL-",CN(C)CCC1=C(C2=CC=CC3=C2N1C4=CC=CC=C4CC3)C5=CC=CC=C5,,,,,,
7712,42407,"INDOLO(1,7-ab)(1)BENZAZEPINE-2-METHANAMINE, 6,7-DIHYDRO-N,N,1-TRIMETHYL-",CC1=C(C2=CC=CC3=C2N1C4=CC=CC=C4CC3)CN(C)C,,,,,,
7713,42408,"INDOLO(1,7-ab)(1)BENZAZEPINE-2-METHANAMINE, 6,7-DIHYDRO-N,N-DIMETHYL-1-PHENYL-",CN(C)CC1=C(N2C3=CC=CC=C3CCC4=C2C1=CC=C4)C5=CC=CC=C5,,,,,,
7714,42409,2-Chloro-4-nitro-1H-imidazole,C1=C(NC(=N1)Cl)[N+](=O)[O-],,,,,,
7715,42410,CID 42410,C1=NC(=C(N1)Cl)[N+](=O)[O-],,,,,,
7716,42411,CID 42411,C1CCC2=C(C1)C=CC(=C2)N3CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F.C(=CC(=O)O)C(=O)O,,,,,,
7717,42412,"1-(4-Fluorophenyl)-4-[4-(5,6,7,8-tetrahydronaphthalen-2-yl)piperazin-1-yl]butan-1-one",C1CCC2=C(C1)C=CC(=C2)N3CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
7718,42413,"1-Benzyl-6,7-dimethoxyisoquinoline methanesulfonate",COC1=C(C=C2C(=C1)C=C[NH+]=C2CC3=CC=CC=C3)OC.CS(=O)(=O)[O-],,,,,,
7719,42414,"1-Benzyl-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=CN=C2CC3=CC=CC=C3)OC,,,,,,
7720,42415,"3,4-Dihydro-1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrobromide",COC1=C(C=C(C=C1)CC2=[NH+]CCC3=CC(=C(C=C32)OC)OC)OC.[Br-],,,,,,
7721,42416,"Isoquinoline, 3,4-dihydro-3-benzyl-6,7-dimethoxy-, hydrobromide",COC1=C(C=C2C=[NH+]C(CC2=C1)CC3=CC=CC=C3)OC.[Br-],,,,,,
7722,42417,"3-Benzyl-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C=NC(CC2=C1)CC3=CC=CC=C3)OC,,,,,,
7723,42418,"3-Benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrobromide",COC1=C(C=C2C[NH2+]C(CC2=C1)CC3=CC=CC=C3)OC.[Br-],,,,,,
7724,42419,"3-Benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CNC(CC2=C1)CC3=CC=CC=C3)OC,,,,,,
7725,42420,"ISOQUINOLINE, 3,4-DIHYDRO-3-(o-CHLOROBENZYL)-6,7-DIMETHOXY-, HYDROBROMIDE",COC1=C(C=C2C=[NH+]C(CC2=C1)CC3=CC=CC=C3Cl)OC.[Br-],,,,,,
7726,42421,"3-[(2-Chlorophenyl)methyl]-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C=NC(CC2=C1)CC3=CC=CC=C3Cl)OC,,,,,,
7727,42422,"ISOQUINOLINE, 3,4-DIHYDRO-3-(p-CHLOROBENZYL)-6,7-DIMETHOXY-, HYDROBROMIDE",COC1=C(C=C2C=[NH+]C(CC2=C1)CC3=CC=C(C=C3)Cl)OC.[Br-],,,,,,
7728,42423,"3-(4-Chlorobenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C=NC(CC2=C1)CC3=CC=C(C=C3)Cl)OC,,,,,,
7729,42424,"3,4-Dihydro-6,7-dimethoxy-3-(3,4-dimethoxybenzyl)isoquinoline hydrobromide",COC1=C(C=C(C=C1)CC2CC3=CC(=C(C=C3C=[NH+]2)OC)OC)OC.[Br-],,,,,,
7730,42425,"Isoquinoline, 3,4-dihydro-3-(o-chlorobenzyl)-6,7-dimethoxy-1-methyl-, hydrobromide",CC1=[NH+]C(CC2=CC(=C(C=C12)OC)OC)CC3=CC=CC=C3Cl.[Br-],,,,,,
7731,42426,"3-[(2-Chlorophenyl)methyl]-6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline",CC1=NC(CC2=CC(=C(C=C12)OC)OC)CC3=CC=CC=C3Cl,,,,,,
7732,42427,6-bromo-2H-chromene-3-carbaldehyde,C1C(=CC2=C(O1)C=CC(=C2)Br)C=O,,,,,,
7733,42428,8-methoxy-2H-chromene-3-carbaldehyde,COC1=CC=CC2=C1OCC(=C2)C=O,,,,,,
7734,42429,7-methoxy-2H-chromene-3-carbaldehyde,COC1=CC2=C(C=C1)C=C(CO2)C=O,,,,,,
7735,42430,6-Methoxy-2H-chromene-3-carbaldehyde,COC1=CC2=C(C=C1)OCC(=C2)C=O,,,,,,
7736,42431,2-methyl-2H-chromene-3-carbaldehyde,CC1C(=CC2=CC=CC=C2O1)C=O,,,,,,
7737,42432,8-Methoxy-2-methyl-2H-1-benzopyran-3-carboxaldehyde,CC1C(=CC2=C(O1)C(=CC=C2)OC)C=O,,,,,,
7738,42433,1-(8-methoxy-2H-chromen-3-yl)ethanone,CC(=O)C1=CC2=C(C(=CC=C2)OC)OC1,,,,,,
7739,42434,"2H-1-Benzopyran, 3-acetyl-7-methoxy-",CC(=O)C1=CC2=C(C=C(C=C2)OC)OC1,,,,,,
7740,42435,"2H-1-Benzopyran, 3-acetyl-6-methoxy-",CC(=O)C1=CC2=C(C=CC(=C2)OC)OC1,,,,,,
7741,42436,"2H-1-Benzopyran, 3-acetyl-5-methoxy-",CC(=O)C1=CC2=C(C=CC=C2OC)OC1,,,,,,
7742,42437,Ethyl 6-methoxy-2-methyl-2H-1-benzopyran-3-carboxylate,CCOC(=O)C1=CC2=C(C=CC(=C2)OC)OC1C,,,,,,
7743,42438,2H-chromene-3-carbonitrile,C1C(=CC2=CC=CC=C2O1)C#N,,,,,,
7744,42439,6-bromo-2H-chromene-3-carbonitrile,C1C(=CC2=C(O1)C=CC(=C2)Br)C#N,,,,,,
7745,42440,6-methoxy-2H-chromene-3-carbonitrile,COC1=CC2=C(C=C1)OCC(=C2)C#N,,,,,,
7746,42441,"2H-1-Benzopyran-3-carbonitrile, 5-methoxy-",COC1=CC=CC2=C1C=C(CO2)C#N,,,,,,
7747,42442,2-Methyl-2H-1-benzopyran-3-carbonitrile,CC1C(=CC2=CC=CC=C2O1)C#N,,,,,,
7748,42443,8-Methoxy-2-methyl-2H-1-benzopyran-3-carbonitrile,CC1C(=CC2=C(O1)C(=CC=C2)OC)C#N,,,,,,
7749,42444,6-Methoxy-2-methyl-2H-1-benzopyran-3-carbonitrile,CC1C(=CC2=C(O1)C=CC(=C2)OC)C#N,,,,,,
7750,42445,5-Methoxy-2-methyl-2H-1-benzopyran-3-carbonitrile,CC1C(=CC2=C(O1)C=CC=C2OC)C#N,,,,,,
7751,42446,6-Bromo-2-methyl-3-nitro-2H-1-benzopyran,CC1C(=CC2=C(O1)C=CC(=C2)Br)[N+](=O)[O-],,,,,,
7752,42447,8-Methoxy-2-methyl-3-nitro-2H-1-benzopyran,CC1C(=CC2=C(O1)C(=CC=C2)OC)[N+](=O)[O-],,,,,,
7753,42448,6-Methoxy-2-methyl-3-nitro-2H-1-benzopyran,CC1C(=CC2=C(O1)C=CC(=C2)OC)[N+](=O)[O-],,,,,,
7754,42449,"3-Nitro-2,6,7-trimethyl-2H-1-benzopyran",CC1C(=CC2=C(O1)C=C(C(=C2)C)C)[N+](=O)[O-],,,,,,
7755,42450,3-Nitro-2-phenyl-2H-chromene,C1=CC=C(C=C1)C2C(=CC3=CC=CC=C3O2)[N+](=O)[O-],,,,,,
7756,42451,6-Chloro-3-nitro-2-phenyl-2H-1-benzopyran,C1=CC=C(C=C1)C2C(=CC3=C(O2)C=CC(=C3)Cl)[N+](=O)[O-],,,,,,
7757,42452,6-Bromo-3-nitro-2-phenyl-2H-1-benzopyran,C1=CC=C(C=C1)C2C(=CC3=C(O2)C=CC(=C3)Br)[N+](=O)[O-],,,,,,
7758,42453,8-Methoxy-3-nitro-2-phenyl-2H-1-benzopyran,COC1=CC=CC2=C1OC(C(=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
7759,42454,6-Methoxy-3-nitro-2-phenyl-2H-1-benzopyran,COC1=CC2=C(C=C1)OC(C(=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
7760,42455,6-Bromo-8-methoxy-3-nitro-2-phenyl-2H-1-benzopyran,COC1=CC(=CC2=C1OC(C(=C2)[N+](=O)[O-])C3=CC=CC=C3)Br,,,,,,
7761,42456,6-Bromo-2-(2-methoxyphenyl)-3-nitro-2H-1-benzopyran,COC1=CC=CC=C1C2C(=CC3=C(O2)C=CC(=C3)Br)[N+](=O)[O-],,,,,,
7762,42457,6-Bromo-8-methoxy-2-(4-methoxyphenyl)-3-nitro-2H-1-benzopyran,COC1=CC=C(C=C1)C2C(=CC3=C(O2)C(=CC(=C3)Br)OC)[N+](=O)[O-],,,,,,
7763,42458,2-(2-Chlorophenyl)-6-methoxy-3-nitro-2H-1-benzopyran,COC1=CC2=C(C=C1)OC(C(=C2)[N+](=O)[O-])C3=CC=CC=C3Cl,,,,,,
7764,42459,6-Bromo-2-(4-chlorophenyl)-3-nitro-2H-1-benzopyran,C1=CC(=CC=C1C2C(=CC3=C(O2)C=CC(=C3)Br)[N+](=O)[O-])Cl,,,,,,
7765,42460,2-(4-Chlorophenyl)-8-methoxy-3-nitro-2H-1-benzopyran,COC1=CC=CC2=C1OC(C(=C2)[N+](=O)[O-])C3=CC=C(C=C3)Cl,,,,,,
7766,42461,2-(4-Chlorophenyl)-6-methoxy-3-nitro-2H-1-benzopyran,COC1=CC2=C(C=C1)OC(C(=C2)[N+](=O)[O-])C3=CC=C(C=C3)Cl,,,,,,
7767,42462,6-Bromo-2-(4-chlorophenyl)-8-methoxy-3-nitro-2H-1-benzopyran,COC1=CC(=CC2=C1OC(C(=C2)[N+](=O)[O-])C3=CC=C(C=C3)Cl)Br,,,,,,
7768,42463,"2,2-Dimethyl-3-nitro-2H-1-benzopyran",CC1(C(=CC2=CC=CC=C2O1)[N+](=O)[O-])C,,,,,,
7769,42464,"2H-1-Benzopyran, 2,2-dimethyl-6-methoxy-3-nitro-",CC1(C(=CC2=C(O1)C=CC(=C2)OC)[N+](=O)[O-])C,,,,,,
7770,42465,6-Chloro-2H-chromene-3-carbaldehyde,C1C(=CC2=C(O1)C=CC(=C2)Cl)C=O,,,,,,
7771,42466,"6,7-Dihydroxy-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolinium iodide",C[N+]1(CCC2=CC(=C(C=C2C1)O)O)C.[I-],,,,,,
7772,42467,"2,2-dimethyl-3,4-dihydro-1H-isoquinolin-2-ium-6,7-diol",C[N+]1(CCC2=CC(=C(C=C2C1)O)O)C,,,,,,
7773,42468,"3-Piperidinol, 1-ethyl-, O-ester with diphenylthioacetate, hydrochloride",CC[NH+]1CCCC(C1)OC(=S)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7774,42469,"O-(1-ethylpiperidin-3-yl) 2,2-diphenylethanethioate",CCN1CCCC(C1)OC(=S)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7775,42470,Secoverine,CCN(CCCC(=O)C1CCCCC1)C(C)CC2=CC=C(C=C2)OC,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
7776,42471,1-Cyclohexyl-4-(ethyl-(p-methoxy-alpha-methylphenethyl)amino)-1-butanone hydrochloride,CC[NH+](CCCC(=O)C1CCCCC1)C(C)CC2=CC=C(C=C2)OC.[Cl-],,,,,,
7777,42472,"Barbituric acid, 5-ethyl-1-methyl-5-(1-methylbutyl)-",CCCC(C)C1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
7778,42473,"1,5-Diethyl-5-(1-methylbutyl)barbituric acid",CCCC(C)C1(C(=O)NC(=O)N(C1=O)CC)CC,,,,,,
7779,42474,"methyl (1R,2R,4S)-4-[(2R,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate",CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5CC([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,,,,,,
7780,42475,"7-[(1S,3R,4S,5S)-3-[(3S)-3-hydroxyoct-1-enyl]-2,6-dioxabicyclo[3.1.1]heptan-4-yl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@@H]1[C@H]([C@@H]2C[C@@H](O2)O1)CC=CCCCC(=O)O)O,,,,,,
7781,42476,N-methyl-N-(pentylideneamino)formamide,CCCCC=NN(C)C=O,,,,,,
7782,42477,N-Methyl-N'-(3-methylbutylidene)formohydrazide,CC(C)CC=NN(C)C=O,,,,,,
7783,42478,CID 42478,CCCCCC=NN(C)C=O,,,,,,
7784,42479,"N-Acetyl-S-(2-bromo-2-chloro-1,1-difluoroethyl)-L-cysteine",CC(=O)NC(CSC(C(Cl)Br)(F)F)C(=O)O,,,,,,
7785,42480,"o-CRESOL, p-(o-TOLYLAZO)-",CC1=CC=CC=C1N=NC2=CC(=C(C=C2)O)C,,,,,,
7786,42481,"8-Chloro-(S)-10-((S)-3'-methylethylaminopyrrolidino)-10,11-dihydrodibenzo(b,f)thiepin",CCN(C)[C@H]1CCN(C1)[C@H]2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
7787,42482,CID 42482,CCN(C)[C@H]1CCN(C1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
7788,42483,"1-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-N-ethyl-N-methylpyrrolidin-3-amine",CCN(C)C1CCN(C1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
7789,42484,CID 42484,CCN(C)C1CCN(C1)[C@H]2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
7790,42485,"(4-Amino-4-carboxybutyl)-(diaminomethylidene)azanium;1,3-thiazolidine-2-carboxylate",C1CSC(N1)C(=O)[O-].C(CC(C(=O)O)N)C[NH+]=C(N)N,,,,,,
7791,42486,Thiazolidine-2-carboxylic acid,C1CSC(N1)C(=O)O,,,,,,
7792,42487,"Benzamide, N-(2-(diethylamino)ethyl)-4-((1-oxo-2-propenyl)amino)-",CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C=C,,,,,,
7793,42488,CID 42488,COC1=CC=C(C=C1)NC(=NC(=NC2=CC=C(C=C2)OC)S)S,,,,,,
7794,42489,5-Chloro-2-methoxy-N-(1-(phenylmethyl)-4-piperidinyl)-4-((trifluoroacetyl)amino)benzamide HCl,COC1=CC(=C(C=C1C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3)Cl)NC(=O)C(F)(F)F.[Cl-],,,,,,
7795,42490,"N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxy-4-[(2,2,2-trifluoroacetyl)amino]benzamide",COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)NC(=O)C(F)(F)F,,,,,,
7796,42491,"Benzamide, 5-chloro-4-((chloroacetyl)amino)-2-methoxy-N-(1-(phenylmethyl)-4-piperidinyl)-, monohydrochloride, hydrate",COC1=CC(=C(C=C1C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3)Cl)NC(=O)CCl.[Cl-],,,,,,
7797,42492,N-(1-benzylpiperidin-4-yl)-5-chloro-4-[(2-chloroacetyl)amino]-2-methoxybenzamide,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)NC(=O)CCl,,,,,,
7798,42493,5-Chloro-2-methoxy-N-(1-(phenylmethyl)-4-piperidinyl)benzamide hydrochloride,COC1=C(C=C(C=C1)Cl)C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3.[Cl-],,,,,,
7799,42494,N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide,COC1=C(C=C(C=C1)Cl)C(=O)NC2CCN(CC2)CC3=CC=CC=C3,,,,,,
7800,42495,"Benzamide, 4-amino-2-methoxy-N-(1-(phenylmethyl)-4-piperidinyl)-, dihydrochloride",COC1=C(C=CC(=C1)[NH3+])C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3.[Cl-].[Cl-],,,,,,
7801,42496,4-amino-N-(1-benzylpiperidin-4-yl)-2-methoxybenzamide,COC1=C(C=CC(=C1)N)C(=O)NC2CCN(CC2)CC3=CC=CC=C3,,,,,,
7802,42497,"Benzamide, 2-methoxy-4-(((methylamino)carbonyl)amino)-N-(1-(phenylmethyl)-4-piperidinyl)-, monohydrochloride",CNC(=O)NC1=CC(=C(C=C1)C(=O)N(CC2=CC=CC=C2)C3CC[NH2+]CC3)OC.[Cl-],,,,,,
7803,42498,N-benzyl-2-methoxy-4-(methylcarbamoylamino)-N-piperidin-4-ylbenzamide,CNC(=O)NC1=CC(=C(C=C1)C(=O)N(CC2=CC=CC=C2)C3CCNCC3)OC,,,,,,
7804,42499,4-Amino-5-chloro-2-methoxy-N-piperidin-4-YL-benzamide,COC1=CC(=C(C=C1C(=O)NC2CCNCC2)Cl)N,,,,,,
7805,42500,CID 42500,COC1=CC(=C(C=C1C(=O)NC2CC[NH+](CC2)CC=CC3=CC=CC=C3)Cl)N.[Cl-],,,,,,
7806,42501,CID 42501,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC=CC3=CC=CC=C3)Cl)N,,,,,,
7807,42502,CID 42502,COC1=CC(=C(C=C1C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3)Cl)N.C(=CC(=O)[O-])C(=O)O,,,,,,
7808,42503,Clebopride hydrogen malate,COC1=CC(=C(C=C1C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3)Cl)N.C(C(C(=O)[O-])O)C(=O)O,,,,,,
7809,42504,Furalaxyl,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)C2=CC=CO2,,,,,,
7810,42505,1-(Bis(2-(diethylamino)ethyl)amino)-3-phenylindole dihydrochloride,CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
7811,42506,"N'-[2-(diethylamino)ethyl]-N,N-diethyl-N'-(3-phenylindol-1-yl)ethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
7812,42507,"Indole, 1-((3-(dimethylamino)propyl)methylamino)-3-phenyl-, hydrochloride",C[NH+](C)CCCN(C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-],,,,,,
7813,42508,"N,N,N'-trimethyl-N'-(3-phenylindol-1-yl)propane-1,3-diamine",CN(C)CCCN(C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
7814,42509,Binedaline hydrochloride,C[NH+](C)CCN(C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-],,,,,,
7815,42510,Binedaline,CN(C)CCN(C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
7816,42511,"Indole, 1-((2-(diethylamino)ethyl)methylamino)-3-phenyl-, hydrochloride",CC[NH+](CC)CCN(C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3.[Cl-],,,,,,
7817,42512,"N',N'-diethyl-N-methyl-N-(3-phenylindol-1-yl)ethane-1,2-diamine",CCN(CC)CCN(C)N1C=C(C2=CC=CC=C21)C3=CC=CC=C3,,,,,,
7818,42513,"Indole, 5-chloro-1-((3-(dimethylamino)propyl)methylamino)-3-phenyl-, hydrochloride",C[NH+](C)CCCN(C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.[Cl-],,,,,,
7819,42514,"N'-(5-chloro-3-phenylindol-1-yl)-N,N,N'-trimethylpropane-1,3-diamine",CN(C)CCCN(C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
7820,42515,"Indole, 5-chloro-3-(p-chlorophenyl)-1-((3-(dimethylamino)propyl)methylamino)-, hydrochloride",C[NH+](C)CCCN(C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
7821,42516,"N'-[5-chloro-3-(4-chlorophenyl)indol-1-yl]-N,N,N'-trimethylpropane-1,3-diamine",CN(C)CCCN(C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
7822,42517,"Indole, 1-((2-(diethylamino)ethyl)methylamino)-5-fluoro-3-phenyl-, hydrochloride",CC[NH+](CC)CCN(C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=CC=C3.[Cl-],,,,,,
7823,42518,"N',N'-diethyl-N-(5-fluoro-3-phenylindol-1-yl)-N-methylethane-1,2-diamine",CCN(CC)CCN(C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=CC=C3,,,,,,
7824,42519,1-(Bis(3-(dimethylamino)propyl)amino)-5-chloro-3-phenylindole dihydrochloride,C[NH+](C)CCCN(CCC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
7825,42520,"N'-(5-chloro-3-phenylindol-1-yl)-N'-[3-(dimethylamino)propyl]-N,N-dimethylpropane-1,3-diamine",CN(C)CCCN(CCCN(C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
7826,42521,1-(Bis(2-(dimethylamino)ethyl)amino)-5-fluoro-3-phenylindole dihydrochloride,C[NH+](C)CCN(CC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
7827,42522,"N'-[2-(dimethylamino)ethyl]-N'-(5-fluoro-3-phenylindol-1-yl)-N,N-dimethylethane-1,2-diamine",CN(C)CCN(CCN(C)C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=CC=C3,,,,,,
7828,42523,1-(Bis(2-(diethylamino)ethyl)amino)-5-bromo-3-phenylindole dihydrochloride,CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)Br)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
7829,42524,"N'-(5-bromo-3-phenylindol-1-yl)-N'-[2-(diethylamino)ethyl]-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)Br)C3=CC=CC=C3,,,,,,
7830,42525,1-(Bis(2-(dimethylamino)ethyl)amino)-5-methyl-3-phenylindole dihydrochloride,CC1=CC2=C(C=C1)N(C=C2C3=CC=CC=C3)N(CC[NH+](C)C)CC[NH+](C)C.[Cl-].[Cl-],,,,,,
7831,42526,"N'-[2-(dimethylamino)ethyl]-N,N-dimethyl-N'-(5-methyl-3-phenylindol-1-yl)ethane-1,2-diamine",CC1=CC2=C(C=C1)N(C=C2C3=CC=CC=C3)N(CCN(C)C)CCN(C)C,,,,,,
7832,42527,"Indole, 1-(bis(2-(dimethylamino)ethyl)amino)-5-chloro-3-(p-chlorophenyl)-, dihydrochloride",C[NH+](C)CCN(CC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
7833,42528,"N'-[5-chloro-3-(4-chlorophenyl)indol-1-yl]-N'-[2-(dimethylamino)ethyl]-N,N-dimethylethane-1,2-diamine",CN(C)CCN(CCN(C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
7834,42529,"Indole, 1-(bis(3-(dimethylamino)propyl)amino)-5-chloro-3-(p-chlorophenyl)-, dihydrochloride",C[NH+](C)CCCN(CCC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
7835,42530,"N'-[5-chloro-3-(4-chlorophenyl)indol-1-yl]-N'-[3-(dimethylamino)propyl]-N,N-dimethylpropane-1,3-diamine",CN(C)CCCN(CCCN(C)C)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
7836,42531,"Indole, 1-(bis(2-(dimethylamino)ethyl)amino)-3-(p-chlorophenyl)-5-fluoro-, dihydrochloride",C[NH+](C)CCN(CC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
7837,42532,"N'-[3-(4-chlorophenyl)-5-fluoroindol-1-yl]-N'-[2-(dimethylamino)ethyl]-N,N-dimethylethane-1,2-diamine",CN(C)CCN(CCN(C)C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=C(C=C3)Cl,,,,,,
7838,42533,"Indole, 1-(bis(2-(diethylamino)ethyl)amino)-3-(p-chlorophenyl)-5-fluoro-, dihydrochloride",CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)F)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
7839,42534,"N'-[3-(4-chlorophenyl)-5-fluoroindol-1-yl]-N'-[2-(diethylamino)ethyl]-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)F)C3=CC=C(C=C3)Cl,,,,,,
7840,42535,"Indole, 1-(bis(3-(dimethylamino)propyl)amino)-3-(p-chlorophenyl)-5-fluoro-, dihydrochloride",C[NH+](C)CCCN(CCC[NH+](C)C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
7841,42536,"N'-[3-(4-chlorophenyl)-5-fluoroindol-1-yl]-N'-[3-(dimethylamino)propyl]-N,N-dimethylpropane-1,3-diamine",CN(C)CCCN(CCCN(C)C)N1C=C(C2=C1C=CC(=C2)F)C3=CC=C(C=C3)Cl,,,,,,
7842,42537,"Butyrophenone, 4'-fluoro-4-(4-(2-methylthiobenzimidazol-1-YL)piperidino)-",CSC1=NC2=CC=CC=C2N1C3CCN(CC3)CCCC(=O)C4=CC=C(C=C4)F,,,,,,
7843,42538,Oct-3-en-2-ol,CCCCC=CC(C)O,,,,,,
7844,42539,"4,5-Dihydrobenzo[a]pyrene",C1CC2=CC3=CC=CC=C3C4=C2C5=C(C=CC=C51)C=C4,,,,,,
7845,42540,"1,2,3,6,7,8-Hexachlorodibenzo-P-dioxin",C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,,,,"[""In the period 1980 to 1982, 19 cormorants (Phalacrocorax carbo), 3 herons (Ardea cinerea), and 1 great crested grebe (Podiceps crisatus) were collected in The Netherlands. The livers of these fish-eating birds were analyzed for polychlorinated dibenzo-p-dioxins and dibenzofurans. Only congeners with a 2,3,7,8-chlorine substitution pattern were found in the livers. The major component was 2,3,4,7,8-pentachlorodibenzofuran and 1,2,3,6,7,8-hexachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin, 1,2,3,7,8-pentachloridibenzo-p-dioxin were also present. Six pooled samples of the eel Anquilla anquilla showed the same congeneric pattern of chemicals as found in these bird species. In the eel, 2,3,4,7,8-pentachlorobenzofuran and 1,2,3,6,7,8-hexachlorodibenzo-p-dioxin were generally present in the 1-5 ng/kg range. Since the eel is the cormorant's major food, this indicates strong bioaccumulation for both congeners in the liver of the cormorant."", 'The polychlorinated dibenzo-p-dioxins and the polychlorinated dibenzofurans are predominantly stored in fat, but they are also excreted in milk and pass the placenta. They also appear in the blood and vital organs at lower concentrations. /Polychlorinated dibenzo-p-dioxins/', 'Human adipose tissue samples obtained during autopsies in 5 Canadian municipalities within the Great Lakes basin were analyzed for polychlorinated dibenzodioxins and dibenzofurans using GC-high resolution-MS. The mean congener values for male and female donors in each municipality are comparable with previously reported data. No significant differences in congener levels between male and female and between municipalities were detected. A positive correlation between congener level and age was observed for several congeners as well as for the total congener concn expressed as its 2,3,7,8-tetrachlorodibenzodioxin toxic equivalent.', 'The tissue distribution of 2,3,7,8-chlorine substituted dibenzo-p-dioxins was conducted in 11 patients who died of cancer. The concn of octachlorodibenzo-p-dioxin was the highest in each organ and tissue and heptachlorodibenzo-p-dioxin was also found at relatively high levels, second only to octachlorodibenzo-p-dioxin. The levels of 1,2,3,7,8-pentachlorodibenzo-p-dioxin and 1,2,3,6,7,8-hexachlorodibenzo-p-dioxin in the spleen were the highest, respectively. 2,3,7,8-Tetrachlorodibenzo-p-dioxin was also detected and its concentration was the highest in the gonad (0.8-3.2 pg/g-range). From the 2,3,7,8-tetrachlorodibenzodioxin toxic equivalent calculations, the highest equivalent value was obtained from a 54 yr old female who died of cancerous goiter. This individual had the highest concentration of 2,3,7,8-substituted penta- and hexachlorodibenzo-p-dioxins among the 11 patients.', 'For more Absorption, Distribution and Excretion (Complete) data for 1,2,3,6,7,8-HEXACHLORODIBENZO-P-DIOXIN (8 total), please visit the HSDB record page.']","['In rats, primary hydroxylation of dibenzo-p-dioxins takes place exclusively at 2, 3, 7, or 8 position.', 'The metabolism of seven polychlorodibenzofuran isomers were studied in female Sprague Dawley rats. Bile samples were taken from surgically implanted bile duct cannulas over a period of 3 to 7 days, beginning 2 hr after dosing with the appropriate polychlorodibenzofuran isomer. Doses were administered either intravenously or by oral gavage. Metabolites were isolated from bile and analyzed as hydroxylated cmpd by GS/MS. The tetrachlorodibenzofuran isomers underwent rapid biotransformation. No ring opened products were seen, and both isomers were metabolized to hydroxylated tetrachlorodibenzofurans and trichlorodibenzofurans, and dihydroxy-trichlorodibenzofurans. The metabolites of the pentachlorodibenzofuran isomers showed quantitative differences in distribution; 1,2,3,4,8-pentachlorodibenzofuran metabolized primarily to hydroxy-pentachlorodibenzofurans, 1,2,3,7,8-pentachlorodibenzofuran resulted in dihydroxy-pentachlorodibenzofurans, and 2,3,4,7,8-pentachlorodibenzofuran metabolites were varied and resulted from ether bond cleavage. Neither 1,2,3,6,7,8-hexachlorodibenzofuran nor 1,2,3,4,6,7,8-heptachlorodibenzofuran resulted in discernible metabolite concn. It was concluded that polychlorodibenzofuran metabolism in rat liver is primarily due to oxidation, or hydrolytic or reductive dechlorination, that ether bond cleavage is a relatively unimportant metabolic mechanism, that chlorine substitution patterns affect metabolism, and that metabolism of polychlorodibenzofurans decreases with more than two chlorines in each ring.']","['1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin /was calculated/ to be about 3.5 yr. The estimation was based on the analysis of fat tissue biopsies collected with an interval of 28 months from one 14 year old girl who for a period of about 2-3 years had been exposed to technical pentachlorophenol.', '/In a/... study of 48 workers at a German pesticide facility, elimination half times were estimated for several CDD congeners. The estimated half-/life was/... 13.1 years for 1,2,3,6,7,8-HxCDD... .']"
7846,42541,"Ethylamine, N,N-dimethyl-2-((methyldiphenylsilyl)oxy)-",CN(C)CCO[Si](C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7847,42542,"N,N-Diethyl-2-(diphenylmethylsiloxy)ethanamine",CCN(CC)CCO[SiH2]C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7848,42543,"Indole, 1-(bis(2-(diethylamino)ethyl)amino)-5-chloro-3-(p-chlorophenyl)-, dihydrochloride, hemihydrate",CC[NH+](CC)CCN(CC[NH+](CC)CC)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
7849,42544,"N'-[5-chloro-3-(4-chlorophenyl)indol-1-yl]-N'-[2-(diethylamino)ethyl]-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CCN(CC)CC)N1C=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
7850,42545,p-(Hexyloxy)aniline hydrochloride,CCCCCCOC1=CC=C(C=C1)[NH3+].[Cl-],,,,,,
7851,42546,Methyl 2-(aminosulfonyl)benzoate,COC(=O)C1=CC=CC=C1S(=O)(=O)N,,,,,,
7852,42547,N'-(2-phenylacetyl)but-2-enediamide,C1=CC=C(C=C1)CC(=O)NC(=O)C=CC(=O)N,,,,,,
7853,42548,Sitamaquine,CCN(CC)CCCCCCNC1=CC(=CC2=C(C=CN=C12)C)OC,['Investigated for use/treatment in infectious and parasitic disease (unspecified).'],,,,,
7854,42549,5-Tridecanone,CCCCCCCCC(=O)CCCC,,,,,,
7855,42550,"N-Methyl-N-(3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)-1,3-benzodioxole-5-methanamine",CC(=CCCC(=CCCC(=CCN(C)CC1=CC2=C(C=C1)OCO2)C)C)C,,,,,,
7856,42551,Nufenoxole,CC1=NN=C(O1)C(CCN2CC3CCC2CC3)(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
7857,42552,"3-Quinuclidinemethanol, alpha,alpha-di-o-tolyl-, hydrochloride",CC1=CC=CC=C1C(C2C[NH+]3CCC2CC3)(C4=CC=CC=C4C)O.[Cl-],,,,,,
7858,42553,Sequifenadine,CC1=CC=CC=C1C(C2CN3CCC2CC3)(C4=CC=CC=C4C)O,,,,,,
7859,42554,CID 42554,C1=CC(=C(C2=C(C=C(C=C21)S(=O)(=O)[O-])O)N=NC3=C(C=C(C=C3)Cl)C(F)(F)F)N.[Na+],,,,,,
7860,42555,"2-Naphthalenesulfonic acid, 6-amino-5-[[4-chloro-2-(trifluoromethyl)phenyl]azo]-4-hydroxy-",C1=CC(=C(C2=C(C=C(C=C21)S(=O)(=O)O)O)N=NC3=C(C=C(C=C3)Cl)C(F)(F)F)N,,,,,,
7861,42556,(2-Decoxy-2-oxoethyl)-diethyl-(3-methyl-4-phenylbut-2-enyl)azanium;chloride,CCCCCCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=CC=C1.[Cl-],,,,,,
7862,42557,(2-Decoxy-2-oxoethyl)-diethyl-(3-methyl-4-phenylbut-2-enyl)azanium,CCCCCCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=CC=C1,,,,,,
7863,42558,"Methane, dichlorodifluoro-mixed with trichlorotrifluoroethane",C(F)(F)(Cl)Cl.C(F)(Cl)(Cl)Cl,,,,,,
7864,42559,"Acridine, 9,9'-octamethylenedi(imino)bis-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
7865,42560,Forphenicine,C1=CC(=C(C=C1C(C(=O)O)N)O)C=O,,,,,,
7866,42561,"2H,8H-Benzo(1,2-b:3,4-b')dipyran-2-one, 9,10-dihydro-10-(2-(diethylamino)ethoxy)-8,8-dimethyl-9-hydroxy-, hydrate",CCN(CC)CCOC1=C2C(=CC3=C1C(C(CO3)(C)C)O)C=CC(=O)O2.O,,,,,,
7867,42562,"5-[2-(Diethylamino)ethoxy]-4-hydroxy-3,3-dimethyl-2,4-dihydropyrano[2,3-g]chromen-7-one",CCN(CC)CCOC1=C2C(=CC3=C1C(C(CO3)(C)C)O)C=CC(=O)O2,,,,,,
7868,42563,"2,6-Dichloroisonicotinohydrazide",C1=C(C=C(N=C1Cl)Cl)C(=O)NN,,,,,,
7869,42564,"Isonicotinic acid, 2,6-dichloro-, 1-methylhydrazide",CN(C(=O)C1=CC(=NC(=C1)Cl)Cl)N,,,,,,
7870,42565,"2,6-Dibutoxyisonicotinic acid hydrazide",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)NN,,,,,,
7871,42566,"Isonicotinic acid, 2,6-dibutoxy-, 1-methylhydrazide",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)N(C)N,,,,,,
7872,42567,"Isonicotinic acid, 2,6-dibutoxy-, 1,2-dimethylhydrazide",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)N(C)NC,,,,,,
7873,42568,"Isonicotinic acid, 2,6-dibutoxy-, 2,2-dimethylhydrazide, hydrochloride",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)N[NH+](C)C.[Cl-],,,,,,
7874,42569,"2,6-dibutoxy-N',N'-dimethylpyridine-4-carbohydrazide",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)NN(C)C,,,,,,
7875,42570,"Isonicotinic acid, 2,6-dibutoxy-, 2-methylhydrazide, hydrochloride",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)N[NH2+]C.[Cl-],,,,,,
7876,42571,"2,6-dibutoxy-N'-methylpyridine-4-carbohydrazide",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)NNC,,,,,,
7877,42572,"Isonicotinohydroxamic acid, 2,6-dichloro-",C1=C(C=C(N=C1Cl)Cl)C(=O)NO,,,,,,
7878,42573,"Isonicotinohydroxamic acid, 2,6-dibutoxy-",CCCCOC1=CC(=CC(=N1)OCCCC)C(=O)NO,,,,,,
7879,42574,Closantel,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,,,"['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
7880,42575,"DIBENZ(a,h)ANTHRACENE, 7,14-DIHYDRO-",C1C2=C(CC3=C1C4=CC=CC=C4C=C3)C5=CC=CC=C5C=C2,,,,,,
7881,42576,"[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,5R,9R,13R)-5,9-dimethyl-14-methylidene-13-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxytetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate",C[C@]12CCC[C@@](C1CC[C@@]34C2CC[C@@](C3)(C(=C)C4)OC5C(C(C(C(O5)COC6C(C(C(C(O6)CO)O)O)O)O)O)O)(C)C(=O)OC7C(C(C(C(O7)CO)O)O)O,,,,,,
7882,42577,"Hydrazinium, 2-acetyl-1,1-dimethyl-1-(2-hydroxytetradecyl)-, hydroxide, inner salt",CCCCCCCCCCCCC(C[N+](C)(C)NC(=O)C)[O-],,,,,,
7883,42578,Acetamido-(2-hydroxytetradecyl)-dimethylazanium,CCCCCCCCCCCCC(C[N+](C)(C)NC(=O)C)O,,,,,,
7884,42579,"Hydrazinium, 2-acetyl-1,1-dimethyl-1-(2-hydroxyoctadecyl)-, hydroxide, inner salt",CCCCCCCCCCCCCCCCC(C[N+](C)(C)NC(=O)C)[O-],,,,,,
7885,42580,Acetamido-(2-hydroxyoctadecyl)-dimethylazanium,CCCCCCCCCCCCCCCCC(C[N+](C)(C)NC(=O)C)O,,,,,,
7886,42581,"Hydrazinium, 1,1-dimethyl-1-(2-hydroxytetradecyl)-2-(2-methyl-1-oxo-2-propenyl)-, hydroxide, inner salt",CCCCCCCCCCCCC(C[N+](C)(C)NC(=O)C(=C)C)[O-],,,,,,
7887,42582,2-Hydroxytetradecyl-dimethyl-(2-methylprop-2-enoylamino)azanium,CCCCCCCCCCCCC(C[N+](C)(C)NC(=O)C(=C)C)O,,,,,,
7888,42583,"5H,6H-DIIMIDAZO(1,2-a;2',1'-c)PYRAZINE, 3-NITRO-",C1CN2C(=CN=C2C3=NC=CN31)[N+](=O)[O-],,,,,,
7889,42584,"5H,6H,7H-DIIMIDAZO(1,2-a;2',1'-c)(1,4)DIAZEPINE, 3-NITRO-",C1CN2C=CN=C2C3=NC=C(N3C1)[N+](=O)[O-],,,,,,
7890,42585,"6-Acetyloxy-3-nitro-5H,6H,7H-diimidazo(1,2-a;2',1'-c)(1,4)diazepine",CC(=O)OC1CCN2C(=CN=C2C3=NC=CN13)[N+](=O)[O-],,,,,,
7891,42586,Metalaxyl,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)COC,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['In a single dose study, male & female rats were administed 0.5 or 25 mg/kg of metalaxyl by  gavage. Over 60% of the low or high dose was excreted within 24 hr in urine or feces.  Negligible amounts were eliminated in expired air. Low tissue residues 6 days after treatment  indicated no appreciable bioaccumulation. Female rats eliminated the majority of the dose  (55-65%) in urine, & males eliminated most (60-70%) in feces. Although metabolites were not  identified, the chromatographic pattern was similar for both sexes & doses.']","['A recent comprehensive study evaluated metalaxyl pharmacokinetics with male & female  Sprague-Dawley rats following a single iv dose (1 mg/kg), single oral low dose (1 mg/kg),  single oral high dose (200 mg/kg), or repeated oral low doses (1 mg/kg/day for 14 days). The  absorption distribution, & elimination patterns were consistent with previous findings. No  major dose or sex differences were observed except that urine was th predominant elimination  route for females whereas feces was the major route for males. Metalaxyl was readily absorbed  (similar iv & oral elimination profiles), extensively metabolized (<1% parent compound in  excreta), & rapidly eliminated (70-80% in 24 hr). Ten metabolites were identified. The  majority of urinary metabolites were conjugated (glucuronide or sulfate) whereas fecal  metabolites were mostly unconjugated. The major metabolite in urine & feces was  N-(2,6-dimethylphenyl)-N-(hydroxyacetyl) alanine. Three major & one minor metabolic pathways  were proposed. One pathway involved hydrolysis of the ether, followed by oxidation of the  resulting alcohol, ester hydrolysis, or N-dealkylation of the ester chain. A second pathway  involved oxidation of an aromatic methyl to the benzylic acid or ester hydrolysis. The third  major pathway was ester hydrolysis, sometimes followed by benzylic acid formation. The minor  pathway involved hydroxylation at the meta position of the phenyl ring. Two major metabolited  in urine were not identified. ...', 'Metalaxyl has known human metabolites that include 2-[(2,6-Dimethyl-3-hydroxyphenyl)(methoxyacetyl)amino]propionic acid methyl ester, Metalaxyl acid, Methyl N-(2-(hydroxymethyl)-6-methylphenyl)-N-(methoxyacetyl)-DL-alanine, and demethylmetalaxyl.']",
7892,42587,"INDOLE-1,3-DIACETIC ACID, 5-METHOXY-2-METHYL-, 3-tert-BUTYL 1-ETHYL ESTER",CCOC(=O)CN1C(=C(C2=C1C=CC(=C2)OC)CC(=O)OC(C)(C)C)C,,,,,,
7893,42588,"Indole-3-acetic acid, 1-((N-hydroxycarbamoyl)methyl)-5-methoxy-2-methyl-, tert-butyl ester",CC1=C(C2=C(N1CC(=O)NO)C=CC(=C2)OC)CC(=O)OC(C)(C)C,,,,,,
7894,42589,"Malonic acid, ((1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl)acetyl)-, diethyl ester",CCOC(=O)C(C(=O)CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)C)C(=O)OCC,,,,,,
7895,42590,"Malonic acid, ((1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl)acetyl)-, dimethyl ester",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)C(C(=O)OC)C(=O)OC,,,,,,
7896,42591,"Butyric acid, 2-acetyl-4-(1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl)-3-oxo-, ethyl ester",CCOC(=O)C(C(=O)C)C(=O)CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)C,,,,,,
7897,42592,"Butyric acid, 4-(1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl)-2-cyano-3-oxo-, ethyl ester",CCOC(=O)C(C#N)C(=O)CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)C,,,,,,
7898,42593,"(7S,9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride",CC1C(C(CC(O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,,,,,,
7899,42594,"(7S,9S)-9-acetyl-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione",CC1C(C(CC(O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,,,,,,
7900,42595,(1-(2-Norbornyl)ethyl)hydrazine,CC(C1CC2CCC1C2)NN,,,,,,
7901,42596,"1,2-Dinitro-9,10-anthracenedione",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
7902,42597,Dimethyl(2-hydroxyethyl)propylammonium bromide benzilate,CCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
7903,42598,"2-(Hydroxydiphenylacetyloxy)-N,N-dimethyl-N-propylethanaminium",CCC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7904,42599,"7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-1-penten-1-yl)cyclopentyl]-5-heptenoic acid",C1C(C(C(C1O)C=CC(CCC2=CC=CC=C2)O)CC=CCCCC(=O)O)O,,,,,,
7905,42600,CID 42600,C(C[SeH])N=C(N)N,,,,,,
7906,42601,"(7-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran)-alpha-methyl-5-acetic acid",CC(C1=CC2=C(C(=C1)Cl)OC(C2)(C)C)C(=O)O,,,,,,
7907,42602,"3-Azabicyclo(3.3.1)nonane, hydrobromide",C1CC2CC(C1)C[NH2+]C2.[Br-],,,,,,
7908,42603,3-Azabicyclo[3.3.1]nonane,C1CC2CC(C1)CNC2,,,,,,
7909,42604,2-Chloroethyl-ethyl-[(2-methylphenyl)methyl]azanium;chloride,CC[NH+](CCCl)CC1=CC=CC=C1C.[Cl-],,,,,,
7910,42605,N-(alpha-Propargyloxyethyl)indole,CC(N1C=CC2=CC=CC=C21)OCC#C,,,,,,
7911,42606,"p-ACETANISIDIDE, 2-INDOL-3-YL-",COC1=CC=CC=C1NC(=O)CC2=CNC3=CC=CC=C32,,,,,,
7912,42607,"Acetanilide, 4'-ethoxy-2-indol-3-YL-",CCOC1=CC=C(C=C1)NC(=O)CC2=CNC3=CC=CC=C32,,,,,,
7913,42608,"Benzoic acid, 2-((1H-indol-3-ylacetyl)amino)-",C1=CC=C2C(=C1)C(=CN2)CC(=O)NC3=CC=CC=C3C(=O)O,,,,,,
7914,42609,"Carbamic acid, dimethyl-, vinyl ester",CN(C)C(=O)OC=C,,,,,,
7915,42610,"6-Methyl-8-{[(pyridin-2-yl)sulfanyl]methyl}-9,10-didehydroergoline",CN1CC(C=C2C1CC3=CNC4=CC=CC2=C34)CSC5=CC=CC=N5,,,,,,
7916,42611,Adinazolam mesylate,CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4.CS(=O)(=O)O,,,,,,
7917,42612,"2-Isopropylamino-1,4-naphthoquinone",CC(C)NC1=CC(=O)C2=CC=CC=C2C1=O,,,,,,
7918,42613,"9H-INDENO(2,1-b)PYRIDIN-9-ONE",C1=CC=C2C(=C1)C3=C(C2=O)N=CC=C3,,,,,,
7919,42614,Curzate,CCNC(=O)NC(=O)C(=NOC)C#N,,,,"['Cymoxanil is rapidly absorbed and maximum concentrations in the blood and plasma is reached within 4 hours after dosing. Rapid and almost complete elimination of the administered radioactive dose was observed in urine and feces within 48 hours. Excretion is primarily by urine (64 - 75%), fecal (16 - 24%) and expired air (< 5%) of the administered dose. There is no significant difference in residue profiles or elimination rates between sexes, dose levels, or single or multiple dosing. No evidence of bioaccumulation was detected. DPX-T3217 is metabolized extensively and only trace level of the administered (14)C-cymoxanil was detected in the urine and feces. ...', 'Five SD rats/sex with cannulated bile ducts were dosed orally with 2.5 mg/kg of (14)C-Cymoxanil (radiochemical purity = 98%; 14.09 uCi/mg) as a corn oil suspension. Urine, feces, and bile were collected over a 48 h period, after which the animals were terminated and whole blood, liver, kidneys, and residual carcass were collected for measurement of radiolabel. ...More than 85% of the test compound was eliminated in urine ( approximately 65%), feces (approximately 14%), and bile (approximately 7%) within 48 hr in both sexes, with most elimination occurring with the first 24 hr; polar amino acid conjugates comprised the major class of metabolites found in both urine (approximately 45-50%) and bile (approximately 4-6%); Metabolite A (unknown) and IN-W3595 /(2-cyano-2-methoxyimino acetic acid)/ were found at much lower concentrations (< 10%) in urine. IN-W3595 was found at higher concentrations in the urine of females (7.7%) as compared to males (2.8%); Metabolite A was not found in bile.', '/To study the absorption, distribution, metabolism, and excretion of 2-(14)C-DPX-T3217 in rats, doses of/ 2.5 & 120 mg/kg in corn oil /at/ 0.5 & 2 mL/animal, /were administered. Radioactivity amounted to/ ~10 & ~20 uCi/animal, respectively. /High dose/ set by expectation of slight toxicity. /With/ single gavage administration: 3/sex/dose - blood pharmacokinetics, 5/sex/dose - elimination/distribution, 8/sex/dose - tissue distribution; multiple administration (cold dosing at 2.5 mg/kg for 14 days followed by labeled dose): 5/sex; no significant differences between groups in blood/plasma and tissue residue profiles. Max. blood concentrations were attained by 4 hr; with the possible exception of a somewhat decreased relative fecal excretion at the high dose (both sexes) and at the multiple low dose (males only). No significant differences in excretion time or route were seen when comparing sexes, doses, or single vs. multiple dosing regimens. Including all dose groups, 57-65% of the administered dose (AD) recovered in urine & 5-17% in feces by 24 hr, 63-75% in urine & 16-24% in feces by 96 hr; at 96 hr <1% of AD remained in tissues (highest levels found in kidney, liver, & skin).', '(14)C-Cymoxanil was applied to either the root system or to the foliage of tomato plants and its uptake, translocation and degradation was followed using autoradiography, combustion and thin-layer chromatographic analyses of water or methanolic extracts. Cymoxanil was taken up by the root system within 1 hr and translocated to cotyledons, stem and leaves within 16 hr. The compound was degraded, mostly to glycine, within 16-44 h, in the root and all parts of the shoot. When applied to the surface of leaf 2 of five-leaf plants, enhanced uptake, translocation and degradation (mainly to glycine) of (14)C-cymoxanil was observed in plants treated with a mixture of oxadixyl and (14)C-cymoxanil, compared with plants treated with (14)C-cymoxanil alone. Root application data confirm that cymoxanil is a systemic compound with a short persistence in tomato plants. Foliage application data suggest that the well-documented synergistic interaction between cymoxanil, oxadixyl and mancozeb in controlling plant diseases caused by Peronosporales does not result from a delayed degradation of cymoxanil in the presence of the other fungicides; the mechanism of synergism has not yet been elucidated.']","['... In feces intact (14)C-cymoxanil (< 1%) and IN W3595 was detected, but the majority of radioactivity was (14)C-glycine (about 9 - 13%). Based on the data, the metabolic pathway involves hydrolysis of cymoxanil to IN W3595, which is then degraded to glycine, which in turn is incorporated into natural constituents or further metabolized.', '... IN-U3204 (1-ethyl-5,6-di-2,4(1H,3H) pyridinedione)  was detected in pooled 0-48 hr urine samples, both sexes, from animals treated with 120 mg/kg DPX-3217 and in pooled 0-24 hr samples, both sexes, from animals treated with 2.5 mg/kg in an ongoing low dose biliary fistula study. The latter group was included to ensure that the presence of IN-U3204 was not an artifact of storage; IN-U3204 was detected in both groups, though at apparently low levels.', '/2-(14)C-DPX-T3217/ was administered /to rats/  in corn oil to/ single dose groups: 2.5 & 120 mg/kg, 0.5 & 2 mL/animal (~10 & ~20 uCi/animal, groups D & E, respectively) and a multiple dose group: daily administration at 2.5 mg/kg for 14 days followed by labeled dose at 2.5 mg/kg (group F). /In a/ 5/sex/dose regimen, the primary metabolites detected by HPLC and TLC in excreta were IN-W3595 (2-cyano-2-methoxyimino acetic acid) and polar components (glycine and other amino acid conjugates); In group D males, 24 hr: 58% of /administered dose (AD)/ in urine (8.6% as IN-W3595, 46.5% as polars), 21.9% in feces (14% extractable, <1% IN-W3595, 13.1% polars). In /group D/ females, 64.2% of AD /appeared/ in urine (16.1% IN-W3595, 45.2% polars), 16.3% in feces (10.1% extractable, <1% IN-W3595, 8.7% polars). In group E males, 70.3% of AD /appeared/ in urine (26.3% IN-W3595, 40.3% polars), 16.1% in feces (11.3% extractable, <1% IN-W3595, 8.6% polars). /In group E/ females, 73% of AD in urine (33% IN-W3595, 36.7% polars), 17.1% in feces (11.5% extractable, <1% IN-W3595, 8.5% polars). In group F males, 66.2% of AD /appeared/ in urine (6.5% IN-W3595, 55% polars), 14.5% in feces (9% extractable, <1% IN-W3595, 8.9% polars). In group F females, 63.1% of AD /appeared/ in urine (11.1% IN-W3595, 46.6% polars), 19.4% in feces (12.3% extractable, <1% IN-W3595, 12.2% polars). /IN-W3595 metabolite/']",
7920,42615,68630-75-1 (Free base),CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,,,,,,
7921,42616,Diaziquone,CCOC(=O)NC1=C(C(=O)C(=C(C1=O)N2CC2)NC(=O)OCC)N3CC3,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)']",,,
7922,42617,"(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",C1[C@@H]2N(C1=O)[C@H](C(=CCO)O2)C(=O)O,,,,,,
7923,42618,"26,27-Dinorergost-5-EN-3-OL (3-beta)",CCCCC(C)(C)C1CCC2C1(CCC3C2C4(CCC(CC4=CC3)OC(=O)C5=CC=CC=C5)C)C,,,,,,
7924,42619,Pyrazolynate,CC1=CC=C(C=C1)S(=O)(=O)OC2=C(C(=NN2C)C)C(=O)C3=C(C=C(C=C3)Cl)Cl,,,,,,
7925,42620,"trans-9,10-Dihydroxy-9,10-dihydrobenzo(a)pyrene",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@@H](C=C5)O)O)C=C2,,,,,,
7926,42621,"2,3-Dihydro-5,6-diphenyl-1,4-oxathiin",C1CSC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7927,42622,3-(4-Hydroxy-3-methoxyphenyl)-2-nitroprop-2-enenitrile,COC1=C(C=CC(=C1)C=C(C#N)[N+](=O)[O-])O,,,,,,
7928,42623,"Carbamic acid, (4-(4-methoxyphenyl)-1H-imidazol-2-YL)-, methyl ester",COC1=CC=C(C=C1)C2=CN=C(N2)NC(=O)OC,,,,,,
7929,42624,"Carbamic acid, N-bis(2-chloroethyl)aminomethyl-, methyl ester",COC(=O)NCN(CCCl)CCCl,,,,,,
7930,42625,"Carbamic acid, N-bis(2-chloroethyl)aminomethyl-, ethyl ester",CCOC(=O)NCN(CCCl)CCCl,,,,,,
7931,42626,"Carbamic acid, N-bis(2-chloroethyl)aminomethyl-, isopropyl ester",CC(C)OC(=O)NCN(CCCl)CCCl,,,,,,
7932,42627,"Carbamic acid, N-bis(2-chloroethyl)aminomethyl-, isobutyl ester",CC(C)COC(=O)NCN(CCCl)CCCl,,,,,,
7933,42628,"Carbamic acid, N-bis(2-chloroethyl)aminomethyl-, benzyl ester",C1=CC=C(C=C1)COC(=O)NCN(CCCl)CCCl,,,,,,
7934,42629,Phenyl bis(2-chloroethyl)aminomethylcarbamate,C1=CC=C(C=C1)OC(=O)NCN(CCCl)CCCl,,,,,,
7935,42630,"Carbamic acid, N-(4-morpholinomethyl)-, ethyl ester",CCOC(=O)NCN1CCOCC1,,,,,,
7936,42631,Cysteine hydrazide,C([C@@H](C(=O)NN)N)S,,,,,,
7937,42632,Acomonine hydrochloride,CC[NH+]1CC2(CCC(C34[C@@H]2[C@@H](C([C@H]31)([C@]5(C[C@@H]([C@H]6C[C@@H]4C5(C6)OC)OC)O)O)OC)O)COC.[Cl-],,,,,,
7938,42633,"(2S,5S,6S,8S,10S,17R,18S)-11-ethyl-3,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-8,9,16-triol",CCN1CC2(CCC(C34[C@@H]2[C@@H](C([C@H]31)([C@]5(C[C@@H]([C@H]6C[C@@H]4C5(C6)OC)OC)O)O)OC)O)COC,,,,,,
7939,42634,"1H-Indole-2-carboxylic acid, 3,3'-((2-chlorophenyl)methylene)bis(1-methyl-",CN1C2=CC=CC=C2C(=C1C(=O)O)C(C3=CC=CC=C3Cl)C4=C(N(C5=CC=CC=C54)C)C(=O)O,,,,,,
7940,42635,"Ethanol, 2,2'-((7-nitrobenzofurazan-4-YL)imino)bis-",C1=C(C2=NON=C2C(=C1)[N+](=O)[O-])N(CCO)CCO,,,,,,
7941,42636,"Benzofurazan, 4-(4-methyl-1-piperazinyl)-7-nitro-",CN1CCN(CC1)C2=CC=C(C3=NON=C23)[N+](=O)[O-],,,,,,
7942,42637,"Benzofurazan, 4-((4-methylphenyl)sulfonyl)-7-(2-pyridinylthio)-, N-oxide",CC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C3=NON=C23)SC4=CC=CC=[N+]4[O-],,,,,,
7943,42638,"N,N-bis(2-hydroxyethyl)-7-nitro-2,1,3-benzoxadiazol-4-amine oxide",C1=C(C2=NON=C2C(=C1)[N+](CCO)(CCO)[O-])[N+](=O)[O-],,,,,,
7944,42639,"Benzofurazan, 4-(phenylsulfonyl)-7-(1-piperidinyl)-, 1-oxide",C1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])S(=O)(=O)C4=CC=CC=C4,,,,,,
7945,42640,"Benzofurazan, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide",CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-],,,,,,
7946,42641,"Benzofurazan, 4-((4-methylphenyl)sulfonyl)-7-(2-pyridinylthio)-, N,1-dioxide",CC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C3=[N+](ON=C23)[O-])SC4=CC=CC=[N+]4[O-],,,,,,
7947,42642,2-(1-Methylpropyl)phenyl methylnitrosocarbamate,CCC(C)C1=CC=CC=C1OC(=O)N(C)N=O,,,,,,
7948,42643,2-Isopropylphenyl methylnitrosocarbamate,CC(C)C1=CC=CC=C1OC(=O)N(C)N=O,,,,,,
7949,42644,"3,4-Dimethylphenyl methylnitrosocarbamate",CC1=C(C=C(C=C1)OC(=O)N(C)N=O)C,,,,,,
7950,42645,"3,5-Dimethylphenyl methylnitrosocarbamate",CC1=CC(=CC(=C1)OC(=O)N(C)N=O)C,,,,,,
7951,42646,3-Methylphenyl methylnitrosocarbamate,CC1=CC(=CC=C1)OC(=O)N(C)N=O,,,,,,
7952,42647,"Formamide, N-(4-(5-nitro-2-thienyl)-2-thiazolyl)-",C1=C(SC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,,,,,,
7953,42648,4-Bis(2-hydroxyethyl)amino-2-(2-thienyl)quinazoline,C1=CC=C2C(=C1)C(=NC(=N2)C3=CC=CS3)N(CCO)CCO,,,,,,
7954,42649,"Formamide, N-(4-(4-nitro-2-thienyl)-2-thiazolyl)-",C1=C(SC=C1[N+](=O)[O-])C2=CSC(=N2)NC=O,,,,,,
7955,42650,"Acetamide, N-(4-(4-nitro-2-thienyl)-2-thiazolyl)-",CC(=O)NC1=NC(=CS1)C2=CC(=CS2)[N+](=O)[O-],,,,,,
7956,42651,"Formamide, N-(4-(5-nitro-2-pyrrolyl)-2-thiazolyl)-",C1=C(NC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,,,,,,
7957,42652,"Formamide, N-(4-(4-nitro-2-pyrrolyl)-2-thiazolyl)-",C1=C(NC=C1[N+](=O)[O-])C2=CSC(=N2)NC=O,,,,,,
7958,42653,N-(4-(4-Nitro-1H-pyrrol-2-yl)-2-thiazolyl)acetamide,CC(=O)NC1=NC(=CS1)C2=CC(=CN2)[N+](=O)[O-],,,,,,
7959,42654,"2,2'-Diamino-4,4'-bithiazole",C1=C(N=C(S1)N)C2=CSC(=N2)N,,,,,,
7960,42655,"N,N'-bis(1,3-thiazol-4-yl)butanediamide",C1=C(N=CS1)NC(=O)CCC(=O)NC2=CSC=N2,,,,,,
7961,42656,"Isoquinoline, decahydro-8-benzamido-2-methyl-, (Z)-",CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC=CC=C3,,,,,,
7962,42657,cis-Decahydro-8-(2-methoxybenzamido)-2-methylisoquinoline,CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC=CC=C3OC,,,,,,
7963,42658,cis-Decahydro-8-(4-methoxybenzamido)-2-methylisoquinoline,CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC=C(C=C3)OC,,,,,,
7964,42659,"Isoquinoline, decahydro-8-(3,4-dimethoxybenzamido)-2-methyl-, (Z)-",CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC(=C(C=C3)OC)OC,,,,,,
7965,42660,"cis-Decahydro-2-methyl-8-(3,4,5-trimethoxybenzamido)isoquinoline",CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
7966,42661,cis-Decahydro-8-(4-chlorobenzamido)-2-methylisoquinoline,CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC=C(C=C3)Cl,,,,,,
7967,42662,"cis-Decahydro-8-(3,4-dichlorobenzamido)-2-methylisoquinoline",CN1CC[C@H]2CCCC([C@H]2C1)NC(=O)C3=CC(=C(C=C3)Cl)Cl,,,,,,
7968,42663,"cis-1-Benzyloxy-2-dimethylamino-1,2,3,4-tetrahydronaphthalene",CN(C)[C@H]1CCC2=CC=CC=C2[C@H]1OCC3=CC=CC=C3,,,,,,
7969,42664,"CARBAMIC ACID, METHYLNITROSO-, o-CHLOROPHENYL ESTER",CN(C(=O)OC1=CC=CC=C1Cl)N=O,,,,,,
7970,42665,"2,4,6-Tribromo-3,5-dimethylphenol",CC1=C(C(=C(C(=C1Br)O)Br)C)Br,,,,,,
7971,42666,"N-(5,5-Dimethyl-2-oxotetrahydro-3-furyl)benzamide",CC1(CC(C(=O)O1)NC(=O)C2=CC=CC=C2)C,,,,,,
7972,42667,Itanoxone,C=C(CC(=O)C1=CC=C(C=C1)C2=CC=CC=C2Cl)C(=O)O,,,,,,
7973,42668,"1,2,3,4,6,7-Hexachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7974,42669,"1,2,3,4,6,8-Hexachlorodibenzo-P-dioxin",C1=C(C=C(C2=C1OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7975,42670,"1,2,3,4,6,9-Hexachlorodibenzo-P-dioxin",C1=CC(=C2C(=C1Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
7976,42671,"1,2,3,6,8,9-Hexachlorodibenzo-P-dioxin",C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
7977,42672,"1,2,3,4,6,7,9-Heptachlorodibenzo-P-dioxin",C1=C(C2=C(C(=C1Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl)Cl,,,,,,
7978,42673,"Acetanilide, 2-chloro-N-(2-methoxyethyl)-",COCCN(C1=CC=CC=C1)C(=O)CCl,,,,,,
7979,42674,"2-Naphthalenecarboxaldehyde, 3-ethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-",CCC1=CC2=C(C=C1C=O)C(CCC2(C)C)(C)C,,,,,,
7980,42675,5-Hydroxy-1-(4-hydroxy-3-methoxycyclohexyl)decan-3-one,CCCCCC(CC(=O)CCC1CCC(C(C1)OC)O)O,,,,,,
7981,42676,"N,N'-Di-2-pentylethylenediamine dihydrobromide",CCCC(C)[NH2+]CC[NH2+]C(C)CCC.[Br-].[Br-],,,,,,
7982,42677,"N,N'-Bis(2-pentyl)-ethylenediamine",CCCC(C)NCCNC(C)CCC,,,,,,
7983,42678,"Bicyclo(2.2.1)heptan-2-ol, 1-((dimethylamino)methyl)-7,7-dimethyl-, exo-",CC1(C2CCC1(C(C2)O)CN(C)C)C,,,,,,
7984,42679,10-Pyrrolidinyl-bornan-2-exo-ol,CC1(C2CCC1(C(C2)O)CN3CCCC3)C,,,,,,
7985,42680,10-Piperidino-bornan-2-exo-ol,CC1(C2CCC1(C(C2)O)CN3CCCCC3)C,,,,,,
7986,42681,"Bicyclo(2.2.1)heptan-2-ol, 7,7-dimethyl-1-((4-phenyl-1-piperidinyl)methyl)-, exo-",CC1(C2CCC1(C(C2)O)CN3CCC(CC3)C4=CC=CC=C4)C,,,,,,
7987,42682,10-Dimethylamino-2-bornanone,CC1(C2CCC1(C(=O)C2)CN(C)C)C,,,,,,
7988,42683,"5,6,7,8-Tetrahydro-7-methyl-1,3-dioxolo(4,5-g)isoquinoline hydrochloride",CC1CC2=CC3=C(C=C2C[NH2+]1)OCO3.[Cl-],,,,,,
7989,42684,"7-Methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline",CC1CC2=CC3=C(C=C2CN1)OCO3,,,,,,
7990,42685,"Dichlorozinc-4,4-dimethyl-5-{[(methylcarbamoyl)oxy]imino}pentanenitrile (1:1)",CC(C)(CCC#N)C=NOC(=O)NC.[Cl-].[Cl-].[Zn+2],,,,,,
7991,42686,"[(4-cyano-2,2-dimethylbutylidene)amino] N-methylcarbamate",CC(C)(CCC#N)C=NOC(=O)NC,,,,,,
7992,42687,"BENZOIC ACID, p-(m-(BIS(2-CHLOROETHYL)AMINO)BENZENESULFONAMIDO)-",C1=CC(=CC(=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)O)N(CCCl)CCCl,,,,,,
7993,42688,"Benzoic acid, 3-(bis(2-chloroethyl)amino)-4-bromo-",C1=CC(=C(C=C1C(=O)O)N(CCCl)CCCl)Br,,,,,,
7994,42689,"(2,3,6,7-Tetrahydro-1H,5H-benzo(ij)quinolizin-9-ylmethylene)malononitrile",C1CC2=CCCN3C2=C(C1)C(=CC3)C=C(C#N)C#N,,,,,,
7995,42690,CID 42690,COCC(=O)NC1=C(C=CC(=C1)SC2=CC=CC=C2)NC(=NC(=O)OC)NC(=O)OC,,,,,,
7996,42691,"9-Acridanone, 4-(dimethylaminomethyl)-3-methoxy-",CN(C)CC1=C(C=CC2=C1NC3=CC=CC=C3C2=O)OC,,,,,,
7997,42692,"9-Acridanone, 4-(diethylaminomethyl)-3-methoxy-",CCN(CC)CC1=C(C=CC2=C1NC3=CC=CC=C3C2=O)OC,,,,,,
7998,42693,"9-Acridanone, 3-methoxy-4-(1-pyrrolidinyl)methyl-",COC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3N2)CN4CCCC4,,,,,,
7999,42694,"9-Acridanone, 3-methoxy-4-(piperidinomethyl)-",COC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3N2)CN4CCCCC4,,,,,,
8000,42695,"9-Acridanone, 3-methoxy-4-(morpholinomethyl)-",COC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3N2)CN4CCOCC4,,,,,,
8001,42696,3-Dimethylaminomethyl-4-methoxybenzophenone hydrochloride,C[NH+](C)CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)OC.[Cl-],,,,,,
8002,42697,[3-[(Dimethylamino)methyl]-4-methoxyphenyl]-phenylmethanone,CN(C)CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)OC,,,,,,
8003,42698,3-Diethylaminomethyl-4-methoxybenzophenone hydrochloride,CC[NH+](CC)CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)OC.[Cl-],,,,,,
8004,42699,[3-(Diethylaminomethyl)-4-methoxyphenyl]-phenylmethanone,CCN(CC)CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)OC,,,,,,
8005,42700,"Benzophenone, 4-methoxy-3-(1-pyrrolidinylmethyl)-, hydrochloride",COC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)C[NH+]3CCCC3.[Cl-],,,,,,
8006,42701,[4-Methoxy-3-(pyrrolidin-1-ylmethyl)phenyl]-phenylmethanone,COC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)CN3CCCC3,,,,,,
8007,42702,4-Methoxy-3-piperidinomethylbenzophenone hydrochloride,C.COC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)C[NH+]3CCCCC3.[Cl-],,,,,,
8008,42703,[4-Methoxy-3-(piperidin-1-ylmethyl)phenyl]-phenylmethanone,COC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)CN3CCCCC3,,,,,,
8009,42704,4-Methoxy-3-morpholinomethylbenzophenone hydrochloride,COC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)C[NH+]3CCOCC3.[Cl-],,,,,,
8010,42705,(4-Methoxy-3-morpholin-4-ylmethyl-phenyl)-phenyl-methanone,COC1=C(C=C(C=C1)C(=O)C2=CC=CC=C2)CN3CCOCC3,,,,,,
8011,42706,"2,4-Dimethoxy-3-dimethylaminomethylbenzophenone hydrochloride",C[NH+](C)CC1=C(C=CC(=C1OC)C(=O)C2=CC=CC=C2)OC.[Cl-],,,,,,
8012,42707,"[3-[(Dimethylamino)methyl]-2,4-dimethoxyphenyl]-phenylmethanone",CN(C)CC1=C(C=CC(=C1OC)C(=O)C2=CC=CC=C2)OC,,,,,,
8013,42708,"3-Diethylaminomethyl-2,4-dimethoxybenzophenone hydrochloride",CC[NH+](CC)CC1=C(C=CC(=C1OC)C(=O)C2=CC=CC=C2)OC.[Cl-],,,,,,
8014,42709,"[3-(Diethylaminomethyl)-2,4-dimethoxyphenyl]-phenylmethanone",CCN(CC)CC1=C(C=CC(=C1OC)C(=O)C2=CC=CC=C2)OC,,,,,,
8015,42710,"2,4-Dimethoxy-3-(1-pyrrolidinylmethyl)benzophenone hydrochloride",COC1=C(C(=C(C=C1)C(=O)C2=CC=CC=C2)OC)C[NH+]3CCCC3.[Cl-],,,,,,
8016,42711,"[2,4-Dimethoxy-3-(pyrrolidin-1-ylmethyl)phenyl]-phenylmethanone",COC1=C(C(=C(C=C1)C(=O)C2=CC=CC=C2)OC)CN3CCCC3,,,,,,
8017,42712,"2,4-Dimethoxy-3-piperidinomethylbenzophenone hydrochloride",COC1=C(C(=C(C=C1)C(=O)C2=CC=CC=C2)OC)C[NH+]3CCCCC3.[Cl-],,,,,,
8018,42713,"[2,4-Dimethoxy-3-(piperidin-1-ylmethyl)phenyl]-phenylmethanone",COC1=C(C(=C(C=C1)C(=O)C2=CC=CC=C2)OC)CN3CCCCC3,,,,,,
8019,42714,"2,4-Dimethoxy-3-morpholinomethylbenzophenone hydrochloride",COC1=C(C(=C(C=C1)C(=O)C2=CC=CC=C2)OC)C[NH+]3CCOCC3.[Cl-],,,,,,
8020,42715,"[2,4-Dimethoxy-3-(morpholin-4-ylmethyl)phenyl]-phenylmethanone",COC1=C(C(=C(C=C1)C(=O)C2=CC=CC=C2)OC)CN3CCOCC3,,,,,,
8021,42716,"3-Butyl-7-methyl-3,7-diazabicyclo(3.3.1)nonane hydrobromide",CCCCN1CC2CC(C1)C[NH+](C2)C.[Br-],,,,,,
8022,42717,"3-Butyl-7-methyl-3,7-diazabicyclo[3.3.1]nonane",CCCCN1CC2CC(C1)CN(C2)C,,,,,,
8023,42718,"5-(Chloromethyl)-1,3-oxathiolane",C1C(OCS1)CCl,,,,,,
8024,42719,"(2-Chlorophenoxy)acetic acid 3,3,5-trimethylcyclohexyl ester",CC1CC(CC(C1)(C)C)OC(=O)COC2=CC=CC=C2Cl,,,,,,
8025,42720,"(4-Fluorophenoxy)acetic acid 3,3,5-trimethylcyclohexyl ester",CC1CC(CC(C1)(C)C)OC(=O)COC2=CC=C(C=C2)F,,,,,,
8026,42721,"(4-Iodophenoxy)acetic acid 3,3,5-trimethylcyclohexyl ester",CC1CC(CC(C1)(C)C)OC(=O)COC2=CC=C(C=C2)I,,,,,,
8027,42722,Elliptinium acetate,CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C.CC(=O)[O-],,,"['Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
8028,42723,Elliptinium,CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)']",,,
8029,42724,N-Acetyl-S-(2-chloroethyl)-L-cysteine,CC(=O)N[C@@H](CSCCCl)C(=O)O,,,,,,
8030,42725,Dinaline,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)N,,,,,,
8031,42726,"1-(1,3-Benzodioxol-5-yl)-5,5-dimethylhex-1-en-3-one",CC(C)(C)CC(=O)C=CC1=CC2=C(C=C1)OCO2,,,,,,
8032,42727,"1-(1,3-Benzodioxol-5-yl)-6-methylhept-1-en-3-one",CC(C)CCC(=O)C=CC1=CC2=C(C=C1)OCO2,,,,,,
8033,42728,CID 42728,CCCC(C=CC1=CC2=C(C=C1)OCO2)O,,,,,,
8034,42729,"1-(1,3-Benzodioxol-5-yl)-6-methylhept-1-en-3-ol",CC(C)CCC(C=CC1=CC2=C(C=C1)OCO2)O,,,,,,
8035,42730,"1-(1,3-Benzodioxol-5-yl)-5,5-dimethylhex-1-en-3-ol",CC(C)(C)CC(C=CC1=CC2=C(C=C1)OCO2)O,,,,,,
8036,42731,"1-(1,3-Benzodioxol-5-yl)-5-methylhex-1-en-3-ol",CC(C)CC(C=CC1=CC2=C(C=C1)OCO2)O,,,,,,
8037,42732,"1-(6-Chloro-1,3-benzodioxol-5-yl)-6-methylhept-1-en-3-ol",CC(C)CCC(C=CC1=CC2=C(C=C1Cl)OCO2)O,,,,,,
8038,42733,"2-(Diethylamino)-2',6'-butyroxylidide hydrochloride",CCC(C(=O)NC1=C(C=CC=C1C)C)[NH+](CC)CC.[Cl-],,,,,,
8039,42734,"2-(diethylamino)-N-(2,6-dimethylphenyl)butanamide",CCC(C(=O)NC1=C(C=CC=C1C)C)N(CC)CC,,,,,,
8040,42735,"2-(Diethylamino)-2',6'-caproxylidide hydrochloride",CCCCC(C(=O)NC1=C(C=CC=C1C)C)[NH+](CC)CC.[Cl-],,,,,,
8041,42736,"2-(diethylamino)-N-(2,6-dimethylphenyl)hexanamide",CCCCC(C(=O)NC1=C(C=CC=C1C)C)N(CC)CC,,,,,,
8042,42737,4-Bromo-2-chloro-6-nitrophenol,C1=C(C=C(C(=C1[N+](=O)[O-])O)Cl)Br,,,,,,
8043,42738,Albaspidin,CCCC(=O)C1=C(C(=C(C(C1=O)(C)C)O)CC2=C(C(C(=O)C(=C2O)C(=O)CCC)(C)C)O)O,,,,,,
8044,42739,"1H-1,5-BENZODIAZEPINE, 2,3,4,5-TETRAHYDRO-2,4-DIMETHYL-, cis-",C[C@@H]1C[C@@H](NC2=CC=CC=C2N1)C,,,,,,
8045,42740,"2,2',2''-Nitrilotriethanol, cyclic ester with hydrogen phosphite, tetrafluoroborate (1-)",[B-](F)(F)(F)F.C1COP2OCC[NH+]1CCO2,,,,,,
8046,42741,"2,8,9-Trioxa-5-aza-1-phosphabicyclo[3.3.3]undecane",C1COP2OCCN1CCO2,,,,,,
8047,42742,"Benz(a)anthracene, 9,10-dimethyl-",CC1=CC2=C(C=C1C)C=C3C(=C2)C=CC4=CC=CC=C43,,,,,,
8048,42743,"BENZ(a)ANTHRACENE, 8,9-DIMETHYL-",CC1=C(C2=C(C=C1)C=C3C(=C2)C=CC4=CC=CC=C43)C,,,,,,
8049,42744,"BENZ(c)ACRIDINE, 7,9,10-TRIMETHYL-",CC1=CC2=C(C=C1C)N=C3C(=C2C)C=CC4=CC=CC=C43,,,,,,
8050,42745,"3,5,5-Trimethylhexyl acetate",CC(CCOC(=O)C)CC(C)(C)C,,,,,,
8051,42746,1-[Ethyl(nitroso)amino]ethyl acetate,CCN(C(C)OC(=O)C)N=O,,,,,,
8052,42747,Tilomisole,C1=CC=C2C(=C1)N=C3N2C(=C(S3)CC(=O)O)C4=CC=C(C=C4)Cl,,,,,,
8053,42748,2-(2-Isopropylphenyl)-1-propanol,CCC(C1=CC=CC=C1C(C)C)O,,,,,,
8054,42749,"[(6S,9S,10S,12R,13S,14S,16S,17R,19S,22S,23S,25R)-16-acetyloxy-17-carboxyoxy-10,12,14-trihydroxy-6,10,19,23-tetramethyl-13-(2-methylbutanoyloxy)-24-oxa-4-azoniaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 2-hydroxy-2-methylbutanoate;chloride",CCC(C)C(=O)O[C@H]1[C@@H](C2C(C[NH+]3C[C@H](CC[C@H]3[C@@]2(C)O)C)C4[C@@]1(C5[C@@H]([C@@H](C6[C@]7([C@]5(C4)O[C@@]6([C@H](CC7)OC(=O)C(C)(CC)O)C)C)OC(=O)O)OC(=O)C)O)O.[Cl-],,,,,,
8055,42750,"[(6S,9S,10S,12R,13S,14S,16S,17R,19S,22S,23S,25R)-16-acetyloxy-17-carboxyoxy-10,12,14-trihydroxy-6,10,19,23-tetramethyl-13-(2-methylbutanoyloxy)-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 2-hydroxy-2-methylbutanoate",CCC(C)C(=O)O[C@H]1[C@@H](C2C(CN3C[C@H](CC[C@H]3[C@@]2(C)O)C)C4[C@@]1(C5[C@@H]([C@@H](C6[C@]7([C@]5(C4)O[C@@]6([C@H](CC7)OC(=O)C(C)(CC)O)C)C)OC(=O)O)OC(=O)C)O)O,,,,,,
8056,42751,Diethyl isopropylmethylmalonate,CCOC(=O)C(C)(C(C)C)C(=O)OCC,,,,,,
8057,42752,Diethyl methyl(2-methylpropyl)propanedioate,CCOC(=O)C(C)(CC(C)C)C(=O)OCC,,,,,,
8058,42753,5-Chloro-2-(perfluoroethyl)-1H-benzo[d]imidazole,C1=CC2=C(C=C1Cl)NC(=N2)C(C(F)(F)F)(F)F,,,,,,
8059,42754,3-(3-bromophenyl)-N-ethylprop-2-enamide,CCNC(=O)C=CC1=CC(=CC=C1)Br,,,,,,
8060,42755,"Acridine, 9,9'-tetramethylenediiminobis-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
8061,42756,Spermidine diacridine,CCCC(NCCCNC1=C2C=CC=CC2=NC3=CC=CC=C31)NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
8062,42757,"6-Chloro-9-(2-(6-methyl-3-pyridyl)ethyl)-1,2,3,4-tetrahydrocarbazole-2-carboxylic acid",CC1=NC=C(C=C1)CC[NH+]2C3=C(CCC(C3)C(=O)O)C4=C2C=CC(=C4)Cl.[Cl-],,,,,,
8063,42758,"6-chloro-9-[2-(6-methylpyridin-3-yl)ethyl]-1,2,3,4-tetrahydrocarbazole-2-carboxylic Acid",CC1=NC=C(C=C1)CCN2C3=C(CCC(C3)C(=O)O)C4=C2C=CC(=C4)Cl,,,,,,
8064,42759,4-hydroxy-3-methoxy-N-octylbenzamide,CCCCCCCCNC(=O)C1=CC(=C(C=C1)O)OC,,,,,,
8065,42760,N-[(4-Hydroxy-3-methoxyphenyl)methyl]-9-octadecenamide,CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC,,,,,,
8066,42761,"16,17-Acetonide 21-propionate, procinonide",CCC(=O)OCC(=O)[C@@]12[C@@H](CC3C1(CC([C@]4(C3C[C@@H](C5=CC(=O)C=CC54C)F)F)O)C)OC(O2)(C)C,,,,,,
8067,42762,"Ethanimidamide, 2-(3,4-dichlorophenyl)-N,N'-diethyl-, hydrochloride",CCNC(=[NH+]CC)CC1=CC(=C(C=C1)Cl)Cl.[Cl-],,,,,,
8068,42763,"2-(3,4-dichlorophenyl)-N,N'-diethylethanimidamide",CCNC(=NCC)CC1=CC(=C(C=C1)Cl)Cl,,,,,,
8069,42764,Meobentine sulfate,CNC(=NC)NCC1=CC=C(C=C1)OC.CNC(=NC)NCC1=CC=C(C=C1)OC.OS(=O)(=O)O,,,,,,
8070,42765,Meobentine,CNC(=NC)NCC1=CC=C(C=C1)OC,,,,,,
8071,42766,"Isothiocyanic acid, butoxycarbonylmethyl ester",CCCCOC(=O)CN=C=S,,,,,,
8072,42767,"Acridine, 9,9'-dodecamethylenediiminobis-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCCCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
8073,42768,"[2-[(2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] cyclopropanecarboxylate",C[C@]12C[C@@H]([C@]3(C([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COC(=O)C5CC5)C[C@@H](C6=CC(=O)C=C[C@@]63C)F)F)O,,,,,,
8074,42769,"2,2'-((4-((2,6-Dichloro-4-nitrophenyl)azo)-3-methylphenyl)imino)bisethanol",CC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=C(C=C(C=C2Cl)[N+](=O)[O-])Cl,,,,,,
8075,42770,"7,7'-Methylenebis(2,3,4,5-tetrahydro-4-methyl-1H-1,5-benzodiazepine-2-carbonitrile)",CC1CC(NC2=C(N1)C=C(C=C2)CC3=CC4=C(C=C3)NC(CC(N4)C)C#N)C#N,,,,,,
8076,42771,"Benzimidazole, 1-(2-(ethylthio)-1-ethyl)-2-(2-(ethylthio)ethylthio)-",CCSCCN1C2=CC=CC=C2N=C1SCCSCC,,,,,,
8077,42772,1-Methylacenaphthylene,CC1=CC2=CC=CC3=C2C1=CC=C3,,,,,,
8078,42773,CID 42773,CCCCC[C@@](C)(C=CC1[C@H](C[C@H]([C@H]1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O,,,,,,
8079,42774,CID 42774,CCCCC[C@@](C)(C=CC1[C@H](C[C@H]([C@H]1CC=CCCCC(=O)O)O)O)O,,,,,,
8080,42775,"DL-2-Phenylglycine 4,4-dimethylpentyl ester hydrochloride",CC(C)(C)CCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
8081,42776,"4,4-Dimethylpentyl 2-amino-2-phenylacetate",CC(C)(C)CCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
8082,42777,DL-2-Phenylglycine 3-trimethylsilylpropyl ester hydrochloride,C[Si](C)(C)CCCOC(=O)C(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
8083,42778,3-Trimethylsilylpropyl 2-amino-2-phenylacetate,C[Si](C)(C)CCCOC(=O)C(C1=CC=CC=C1)N,,,,,,
8084,42779,"DL-2-Amino-6,6-dimethylheptanoic acid isopentyl ester hydrochloride",CC(C)CCOC(=O)C(CCCC(C)(C)C)[NH3+].[Cl-],,,,,,
8085,42780,"3-Methylbutyl 2-amino-6,6-dimethylheptanoate",CC(C)CCOC(=O)C(CCCC(C)(C)C)N,,,,,,
8086,42781,"5,5-Dimethylhexanoic acid 2-(diethylamino)ethyl ester citrate",CC[NH+](CC)C(CCC(C)(C)C)C(=O)OCC.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
8087,42782,"Ethyl 2-(diethylamino)-5,5-dimethylhexanoate",CCN(CC)C(CCC(C)(C)C)C(=O)OCC,,,,,,
8088,42783,"Butyric acid, 4-trimethylsilyl-, 2-(diethylamino)ethyl ester, citrate",CC[NH+](CC)CCOC(=O)CCC[Si](C)(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
8089,42784,2-(Diethylamino)ethyl 4-trimethylsilylbutanoate,CCN(CC)CCOC(=O)CCC[Si](C)(C)C,,,,,,
8090,42785,Metenkefalin,CSCCC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N,,,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']",,,
8091,42786,CID 42786,C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31.Cl,,,,,,
8092,42787,CID 42787,C(CCN=C([NH3+])N)CCN=C([NH3+])N.[Cl-].[Cl-],,,,,,
8093,42788,Audouine,C(CCN=C(N)N)CCN=C(N)N,,,,,,
8094,42789,CID 42789,CCOC(=O)CN=C(C(=NCC(=O)OCC)S)S,,,,,,
8095,42790,"Ammonium, (4,4'-biphenylylenebis(2-oxoethylene))bis((2-ethoxyethyl)dimethyl-, dibromide",CCOCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCOCC.[Br-].[Br-],,,,,,
8096,42791,2-Ethoxyethyl-[2-[4-[4-[2-[2-ethoxyethyl(dimethyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-dimethylazanium,CCOCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCOCC,,,,,,
8097,42792,"Ammonium, (4,4'-biphenylylenebis(2-oxoethylene))bis((4-oxopentyl)dimethyl-, dibromide",CC(=O)CCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCCC(=O)C.[Br-].[Br-],,,,,,
8098,42793,[2-[4-[4-[2-[Dimethyl(4-oxopentyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-dimethyl-(4-oxopentyl)azanium,CC(=O)CCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCCC(=O)C,,,,,,
8099,42794,Camphonium,CC1(C2CCC1(C[N+](C2)(C)CCC[N+](C)(C)C)C)C.[I-].[I-],,,,,,
8100,42795,"5-(2-(Dimethylamino)ethyl)-3-phenyl-1,2,4-oxadiazole hydrochloride",C[NH+](C)CCC1=NC(=NO1)C2=CC=CC=C2.[Cl-],,,,,,
8101,42796,"N,N-dimethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine",CN(C)CCC1=NC(=NO1)C2=CC=CC=C2,,,,,,
8102,42797,"Maleimide, N-4-biphenylyl-",C1=CC=C(C=C1)C2=CC=C(C=C2)N3C(=O)C=CC3=O,,,,,,
8103,42798,N-(1-Methyl-1-phenylethyl)urea,CC(C)(C1=CC=CC=C1)NC(=O)N,,,,,,
8104,42799,5-Acetyl-2-methylcoumaran,CC1CC2=C(O1)C=CC(=C2)C(=O)C,,,,,,
8105,42800,"3-Cyclopropylmethyl-5-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[d]azocin-1-one",CCC1CN(C2C(C1C3=C(C2=O)C=CC(=C3)O)C)CC4CC4,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
8106,42801,"1,3-Dioxa-6-aza-2-silacyclooctane-6-ethanol, 2,2-dimethyl-, diphenylacetate (ester)",C[Si]1(OCCN(CCO1)CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C,,,,,,
8107,42802,5-Methyl-2-octanone,CCCC(C)CCC(=O)C,,,,,,
8108,42803,4-(9-Acridinylamino)aniline,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)N,,,,,,
8109,42804,"Acetanilide, 3'-(9-acridinylamino)-",CC(=O)NC1=CC=CC(=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
8110,42805,"ACRIDINE, 9-(m-AMINOANILINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC(=C4)N,,,,,,
8111,42806,"Benzamide, 4-(9-acridinylamino)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)C(=O)N,,,,,,
8112,42807,Flamprop,CC(C(=O)O)N(C1=CC(=C(C=C1)F)Cl)C(=O)C2=CC=CC=C2,,,,,,
8113,42808,"1,1,4-Trichloro-1,2-butadiene",C(C=C=C(Cl)Cl)Cl,,,,,,
8114,42809,3-Methoxy-4-nitroazobenzene,COC1=C(C=CC(=C1)N=NC2=CC=CC=C2)[N+](=O)[O-],,,,,,
8115,42810,N-Cyclohexylglycine,C1CCC(CC1)NCC(=O)O,,,,,,
8116,42811,N-(1-Methylpropyl)glycine,CCC(C)NCC(=O)O,,,,,,
8117,42812,"2,3-Bis(carbomethoxymercapto)quinoxaline",COC(=O)SC1=NC2=CC=CC=C2N=C1SC(=O)OC,,,,,,
8118,42813,"Benzamide, 5-bromo-2-hydroxy-3-methyl-N-(1-methylethyl)-",CC1=CC(=CC(=C1O)C(=O)NC(C)C)Br,,,,,,
8119,42814,"Benzamide, 5-bromo-N-cyclopropyl-2-hydroxy-3-methyl-",CC1=CC(=CC(=C1O)C(=O)NC2CC2)Br,,,,,,
8120,42815,"Benzamide, 5-bromo-2-hydroxy-3-methyl-N-(3-(trifluoromethyl)phenyl)-",CC1=CC(=CC(=C1O)C(=O)NC2=CC=CC(=C2)C(F)(F)F)Br,,,,,,
8121,42816,"5-Bromo-2-hydroxy-3-methyl-N-(2,2,2-trichloro-1-hydroxyethyl)benzamide",CC1=CC(=CC(=C1O)C(=O)NC(C(Cl)(Cl)Cl)O)Br,,,,,,
8122,42817,5-Bromo-2-methoxy-3-methylbenzamide,CC1=CC(=CC(=C1OC)C(=O)N)Br,,,,,,
8123,42818,5-Bromo-3-methyl-2-(oxiranylmethoxy)benzamide,CC1=CC(=CC(=C1OCC2CO2)C(=O)N)Br,,,,,,
8124,42819,"Benzamide, 5-chloro-N-ethyl-2-hydroxy-3-methyl-",CCNC(=O)C1=C(C(=CC(=C1)Cl)C)O,,,,,,
8125,42820,"Benzamide, 5-chloro-N-ethyl-2-methoxy-3-methyl-",CCNC(=O)C1=C(C(=CC(=C1)Cl)C)OC,,,,,,
8126,42821,"Benzamide, 5-bromo-N-ethyl-2-methoxy-3-methyl-",CCNC(=O)C1=C(C(=CC(=C1)Br)C)OC,,,,,,
8127,42822,2-Methyl-6-trans-phenyl-6-cis-propionoxy-2-azabicyclo(2.2.2)octane,CCC(=O)OC1C2CCC(C1C3=CC=CC=C3)CN2C,,,,,,
8128,42823,"Benzamide, 5-chloro-N-ethyl-3-methyl-2-(2-propenyloxy)-",CCNC(=O)C1=C(C(=CC(=C1)Cl)C)OCC=C,,,,,,
8129,42824,"Dibenzo(b,f)thiepin-2-amine, 10,11-dihydro-10-(4-methyl-1-piperazinyl)-, trimethanesulfonate",C[NH+]1CC[NH+](CC1)C2CC3=C(C=CC(=C3)[NH3+])SC4=CC=CC=C24.CS(=O)(=O)[O-].CS(=O)(=O)[O-].CS(=O)(=O)[O-],,,,,,
8130,42825,"6-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-3-amine",CN1CCN(CC1)C2CC3=C(C=CC(=C3)N)SC4=CC=CC=C24,,,,,,
8131,42826,CID 42826,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3C(C2)N4CCN(CC4)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
8132,42827,"Ethanone, 1-[10,11-dihydro-10-(4-methyl-1-piperazinyl)dibenzo[b,f]thiepin-2-yl]-",CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3C(C2)N4CCN(CC4)C,,,,,,
8133,42828,4-Amino-1-naphthalenecarbonitrile,C1=CC=C2C(=C1)C(=CC=C2N)C#N,,,,,,
8134,42829,CID 42829,CC1([C@@H](C1C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C=C4CCSC4=O)C,,,,,,
8135,42830,epi-Deoxynegamycin,CN(CC(=O)O)NC(=O)C[C@H](CCCN)N.CN(CC(=O)O)NC(=O)C[C@H](CCCN)N.O,,,,,,
8136,42831,3-Epi-Deoxynegamycin,CN(CC(=O)O)NC(=O)C[C@H](CCCN)N,,,,,,
8137,42832,"trans-1-Benzoyloxy-2-dimethylamino-1,2,3,4-tetrahydronaphthalene hydrochloride",C[NH+](C)C1CCC2=CC=CC=C2[C@H]1OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
8138,42833,"[(1R)-2-(dimethylamino)-1,2,3,4-tetrahydronaphthalen-1-yl] benzoate",CN(C)C1CCC2=CC=CC=C2[C@H]1OC(=O)C3=CC=CC=C3,,,,,,
8139,42834,CID 42834,CC1([C@H](N2[C@@H](S1)[C@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CNC5=C(C4=O)N=CC=C5)C(=O)[O-])C.[Na+],,,,,,
8140,42835,"(2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(4-oxo-1H-1,5-naphthyridine-3-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@H](N2[C@@H](S1)[C@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CNC5=C(C4=O)N=CC=C5)C(=O)O)C,,,,,,
8141,42836,"1,2,4,7,8-Pentachlorodibenzo-P-dioxin",C1=C2C(=CC(=C1Cl)Cl)OC3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
8142,42837,"1,2,4,6,8,9-Hexachlorodibenzo-P-dioxin",C1=C(C2=C(C(=C1Cl)Cl)OC3=C(O2)C(=CC(=C3Cl)Cl)Cl)Cl,,,,,,
8143,42838,"2,4,6-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C=C(C=C3Cl)Cl,,,,,,
8144,42839,"1,2,4,7,8-Pentachlorodibenzofuran",C1=C2C(=CC(=C1Cl)Cl)OC3=C2C(=C(C=C3Cl)Cl)Cl,,,,,,
8145,42840,"1,3,4,7,8-Pentachlorodibenzofuran",C1=C2C(=CC(=C1Cl)Cl)OC3=C2C(=CC(=C3Cl)Cl)Cl,,,,,,
8146,42841,"2,3,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=CC(=C(C=C23)Cl)Cl,,,,,,
8147,42842,"1,7,8-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)C3=CC(=C(C=C3O2)Cl)Cl,,,,,,
8148,42843,"2,4,6,8-Tetrachlorodibenzofuran",C1=C(C=C(C2=C1C3=C(O2)C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
8149,42844,"1,2,7,8-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1OC3=CC(=C(C=C32)Cl)Cl)Cl)Cl,,,,,,
8150,42845,CID 42845,C1=CC2=C(C=C1Cl)OC3=C2C=CC(=C3)Cl.C1=CC2=C(C=C1Cl)OC3=C2C=CC(=C3)Cl.O,,,,,,
8151,42846,"3,7-Dichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C=CC(=C3)Cl,,,,,,
8152,42847,"Cobalt(2+), bis(2,2'-(propylimino)diethanol)-, dichloride",CCCN(CCO)CCO.CCCN(CCO)CCO.[Cl-].[Cl-].[Co+2],,,,,,
8153,42848,"Ethanol, 2,2'-(propylimino)bis-",CCCN(CCO)CCO,,,,,,
8154,42849,"Cobalt(2+), bis(2,2'-(propylimino)diethanol)-, dibromide",CCCN(CCO)CCO.CCCN(CCO)CCO.[Co+2].[Br-].[Br-],,,,,,
8155,42850,Ofurace,CC1=C(C(=CC=C1)C)N(C2CCOC2=O)C(=O)CCl,,,,,,
8156,42851,Octyl dimethyl 4-aminobenzoic acid,CCCCCCCCOC(=O)C1=CC=C(C=C1)N(C)C,,,,,,
8157,42852,Nonyltrimethylammonium chloride,CCCCCCCCC[N+](C)(C)C.[Cl-],,,,,,
8158,42853,Nithiazine,C1CNC(=C[N+](=O)[O-])SC1,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
8159,42854,"2-((2,3-Dimethylphenyl)thio)benzoic acid",CC1=C(C(=CC=C1)SC2=CC=CC=C2C(=O)O)C,,,,,,
8160,42855,2-((3-(Trifluoromethyl)phenyl)sulfinyl)benzoic acid,C1=CC=C(C(=C1)C(=O)O)S(=O)C2=CC=CC(=C2)C(F)(F)F,,,,,,
8161,42856,"BENZOIC ACID, o-(PHENYLSULFONYL)-",C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC=C2C(=O)O,,,,,,
8162,42857,2-((3-(Trifluoromethyl)phenyl)sulfonyl)benzoic acid,C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)C2=CC=CC(=C2)C(F)(F)F,,,,,,
8163,42858,"o-((2,3-Xylyl)sulfonyl)benzoic acid",CC1=C(C(=CC=C1)S(=O)(=O)C2=CC=CC=C2C(=O)O)C,,,,,,
8164,42859,"3-Bromodiimidazo[1,2-a:2',1'-c]pyrazine",C1=CN2C=CN3C(=CN=C3C2=N1)Br,,,,,,
8165,42860,"DIIMIDAZO(1,2-a;2',1'-c)PYRAZINE, 3,8-DIBROMO-",C1=CN2C(=CN=C2C3=NC=C(N31)Br)Br,,,,,,
8166,42861,2-(Diethylamino)ethyl 1-(4-cyclohexylphenyl)cyclopropane-1-carboxylate,CCN(CC)CCOC(=O)C1(CC1)C2=CC=C(C=C2)C3CCCCC3,,,,,,
8167,42862,1-(4-Cyclohexylphenyl)cyclopropanecarboxylic acid 2-(dimethylamino)ethyl ester,C[NH+](C)CCOC(=O)C1(CC1)C2=CC=C(C=C2)C3CCCCC3.[Cl-],,,,,,
8168,42863,2-(Dimethylamino)ethyl 1-(4-cyclohexylphenyl)cyclopropane-1-carboxylate,CN(C)CCOC(=O)C1(CC1)C2=CC=C(C=C2)C3CCCCC3,,,,,,
8169,42864,"Acetic acid, (3-chloro-4-isobutylphenyl)-",CC(C)CC1=C(C=C(C=C1)CC(=O)O)Cl,,,,,,
8170,42865,Roxadimate,CCOC(=O)C1=CC=C(C=C1)N(CC(C)O)CC(C)O,,,,,,
8171,42866,P-Nitrocresol,CC1=C(C=CC(=C1)[N+](=O)[O-])O.CC1=C(C=CC(=C1)O)[N+](=O)[O-],,,,,,
8172,42867,"Indolizine, 1,3-bis((4-(4-fluorophenyl)-1-piperazinyl)methyl)-2-phenyl-",C1CN(CCN1CC2=C3C=CC=CN3C(=C2C4=CC=CC=C4)CN5CCN(CC5)C6=CC=C(C=C6)F)C7=CC=C(C=C7)F,,,,,,
8173,42868,"Indolizine, 1,3-bis((4-(2-chlorophenyl)-1-piperazinyl)methyl)-2-phenyl-",C1CN(CCN1CC2=C3C=CC=CN3C(=C2C4=CC=CC=C4)CN5CCN(CC5)C6=CC=CC=C6Cl)C7=CC=CC=C7Cl,,,,,,
8174,42869,"Indolizine, 1,3-bis((4-(3-chlorophenyl)-1-piperazinyl)methyl)-2-phenyl-",C1CN(CCN1CC2=C3C=CC=CN3C(=C2C4=CC=CC=C4)CN5CCN(CC5)C6=CC(=CC=C6)Cl)C7=CC(=CC=C7)Cl,,,,,,
8175,42870,"Indolizine, 1,3-bis((4-(4-chlorophenyl)-1-piperazinyl)methyl)-2-phenyl-",C1CN(CCN1CC2=C3C=CC=CN3C(=C2C4=CC=CC=C4)CN5CCN(CC5)C6=CC=C(C=C6)Cl)C7=CC=C(C=C7)Cl,,,,,,
8176,42871,"Indolizine, 1,3-bis((4-phenyl-1-piperazinyl)methyl)-7-methyl-2-phenyl-",CC1=CC2=C(C(=C(N2C=C1)CN3CCN(CC3)C4=CC=CC=C4)C5=CC=CC=C5)CN6CCN(CC6)C7=CC=CC=C7,,,,,,
8177,42872,"Indolizine, 1,3-bis((4-phenyl-1-piperazinyl)methyl)-2-phenyl-",C1CN(CCN1CC2=C3C=CC=CN3C(=C2C4=CC=CC=C4)CN5CCN(CC5)C6=CC=CC=C6)C7=CC=CC=C7,,,,,,
8178,42873,"Indolizine, 1-methyl-2-phenyl-3-((4-phenyl-1-piperazinyl)methyl)-",CC1=C2C=CC=CN2C(=C1C3=CC=CC=C3)CN4CCN(CC4)C5=CC=CC=C5,,,,,,
8179,42874,2-(4-Chlorophenyl)-alpha-methyl-7-benzoxazoleacetic acid,CC(C1=C2C(=CC=C1)N=C(O2)C3=CC=C(C=C3)Cl)C(=O)O,,,,,,
8180,42875,"N,N'-Bis(9-acridinyl)-1,6-hexanediamine",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
8181,42876,"Acridine, 9,9'-ethylenediiminobis-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
8182,42877,"1,3-Propanediamine, N,N'-bis(9-acridinyl)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
8183,42878,"Indolizine, 3-methyl-2-phenyl-1-((4-phenyl-1-piperazinyl)methyl)-",CC1=C(C(=C2N1C=CC=C2)CN3CCN(CC3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
8184,42879,(-)-anti-BPDE,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]6[C@H](O6)[C@@H]([C@H]5O)O)C=C2,,,,,,
8185,42880,"Cobalt(2+), bis(2,2'-((2-methylallyl)imino)diethanol)-, dibromide",CC(=C)CN(CCO)CCO.CC(=C)CN(CCO)CCO.[Co+2].[Br-].[Br-],,,,,,
8186,42881,2-[2-Hydroxyethyl(2-methylprop-2-enyl)amino]ethanol,CC(=C)CN(CCO)CCO,,,,,,
8187,42882,"Cobalt(2+), bis(2,2'-((2-methylallyl)imino)diethanol)-, dichloride",CC(=C)CN(CCO)CCO.CC(=C)CN(CCO)CCO.[Cl-].[Cl-].[Co+2],,,,,,
8188,42883,Remivox,CC(C)[NH+]1CCC(CC1)N(C2=CC=C(C=C2)Cl)C(=O)CC3=CC=CC=C3.[Cl-],,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
8189,42884,Lorcainide,CC(C)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C(=O)CC3=CC=CC=C3,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
8190,42885,2-Chlorovinyl propyl ketone,CCCC(=O)C=CCl,,,,,,
8191,42886,3-Chloro-1-(4-ethylphenyl)prop-2-en-1-one,CCC1=CC=C(C=C1)C(=O)C=CCl,,,,,,
8192,42887,(2E)-1-biphenyl-4-yl-3-chloroprop-2-en-1-one,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C=CCl,,,,,,
8193,42888,"3-Chloro-1-(2,4-dimethylphenyl)prop-2-en-1-one",CC1=CC(=C(C=C1)C(=O)C=CCl)C,,,,,,
8194,42889,"3-Chloro-1-(2,5-dimethylphenyl)prop-2-en-1-one",CC1=CC(=C(C=C1)C)C(=O)C=CCl,,,,,,
8195,42890,Idarubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,['For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.'],"['Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.']","['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']","['The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.']",,['22 hours']
8196,42891,Isostearyl neopentanoate,CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C,,,,,,
8197,42892,CID 42892,CCCCCC(C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC(=O)CCCCC(=O)O)O)O)O,,,,,,
8198,42893,"9-Ethyl-1,2,3,4-tetrahydro-N,N,1-trimethylcarbazole-1-ethanamine hydrochloride",CCN1C2=CC=CC=C2C3=C1C(CCC3)(C)CC[NH+](C)C.[Cl-],,,,,,
8199,42894,"2-(9-ethyl-1-methyl-3,4-dihydro-2H-carbazol-1-yl)-N,N-dimethylethanamine",CCN1C2=CC=CC=C2C3=C1C(CCC3)(C)CCN(C)C,,,,,,
8200,42895,"1,9-Diethyl-N,N-dimethyl-1,2,3,4-tetrahydrocarbazole-1-ethanamine hydrochloride",CCC1(CCCC2=C1N(C3=CC=CC=C23)CC)CC[NH+](C)C.[Br-],,,,,,
8201,42896,"2-(1,9-diethyl-3,4-dihydro-2H-carbazol-1-yl)-N,N-dimethylethanamine",CCC1(CCCC2=C1N(C3=CC=CC=C23)CC)CCN(C)C,,,,,,
8202,42897,"Carbazole-1-ethylamine, 1,2,3,4-tetrahydro-N,N,1,9-tetramethyl-, hydrochloride",CC1(CCCC2=C1N(C3=CC=CC=C23)C)CC[NH+](C)C.[Cl-],,,,,,
8203,42898,"N,N,1,9-Tetramethyl-1,2,3,4-tetrahydrocarbazole-1-ethanamine",CC1(CCCC2=C1N(C3=CC=CC=C23)C)CCN(C)C,,,,,,
8204,42899,"9-Propyl-N,N,1-trimethyl-1,2,3,4-tetrahydrocarbazole-1-ethylamine hydrochloride",CCCN1C2=CC=CC=C2C3=C1C(CCC3)(C)CC[NH+](C)C.[Cl-],,,,,,
8205,42900,"N,N-dimethyl-2-(1-methyl-9-propyl-3,4-dihydro-2H-carbazol-1-yl)ethanamine",CCCN1C2=CC=CC=C2C3=C1C(CCC3)(C)CCN(C)C,,,,,,
8206,42901,"9-Ethyl-N,1-dimethyl-1,2,3,4-tetrahydrocarbazole-1-ethylamine hydrochloride",CCN1C2=CC=CC=C2C3=C1C(CCC3)(C)CC[NH2+]C.[Cl-],,,,,,
8207,42902,"9-Ethyl-1,2,3,4-tetrahydro-N,1-dimethylcarbazole-1-ethanamine",CCN1C2=CC=CC=C2C3=C1C(CCC3)(C)CCNC,,,,,,
8208,42903,"N,N,9-Trimethyl-1,2,3,4-tetrahydrocarbazole-1-ethanamine hydrochloride",CN1C2=CC=CC=C2C3=C1C(CCC3)CC[NH+](C)C.[Cl-],,,,,,
8209,42904,"N,N-dimethyl-2-(9-methyl-1,2,3,4-tetrahydrocarbazol-1-yl)ethanamine",CN1C2=CC=CC=C2C3=C1C(CCC3)CCN(C)C,,,,,,
8210,42905,"N-(2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-2-(dimethylamino)acetamide",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)CN(C)C,,,,,,
8211,42906,CID 42906,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC(=CC=C3)[N+](=O)[O-])N=C2S)[N+](=O)[O-],,,,,,
8212,42907,CID 42907,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S)[N+](=O)[O-],,,,,,
8213,42908,CID 42908,C1=CC=C(C(=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3[N+](=O)[O-])Cl,,,,,,
8214,42909,CID 42909,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S)[N+](=O)[O-],,,,,,
8215,42910,CID 42910,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2S)[N+](=O)[O-],,,,,,
8216,42911,CID 42911,CC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3[N+](=O)[O-],,,,,,
8217,42912,CID 42912,CC1=CC(=CC=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3[N+](=O)[O-],,,,,,
8218,42913,CID 42913,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3[N+](=O)[O-],,,,,,
8219,42914,CID 42914,COC1=CC=CC=C1C=C2C(=O)N(C(=N2)S)C3=CC=CC=C3[N+](=O)[O-],,,,,,
8220,42915,CID 42915,C1=CC=C(C(=C1)N2C(=O)C(=CC3=CC=C(C=C3)Br)N=C2S)[N+](=O)[O-],,,,,,
8221,42916,2-Methoxy-3-methyl-2-butenoic acid,CC(=C(C(=O)O)OC)C,,,,,,
8222,42917,"HYDROCINNAMIC ACID, 3,4-DIMETHOXY-alpha-PHENYL-, HYDRAZIDE",COC1=C(C=C(C=C1)C(CC(=O)NN)C2=CC=CC=C2)OC,,,,,,
8223,42918,"10-Ethyl-N,N,1-trimethyl-1,2,3,4,5,10-hexahydrocyclohept(b)indole-1-ethanamine hydrochloride",CCC1C=CC=CC2=C1C3=C(N2)CCCC3(C)CC[NH+](C)C.[Cl-],,,,,,
8224,42919,"2-(10-ethyl-1-methyl-3,4,5,10-tetrahydro-2H-cyclohepta[b]indol-1-yl)-N,N-dimethylethanamine",CCC1C=CC=CC2=C1C3=C(N2)CCCC3(C)CCN(C)C,,,,,,
8225,42920,CID 42920,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=NOC)CC=C4[C@@]3(CCC(C4)OCCN(C)C)C,,,,,,
8226,42921,Diphenprofos,CCCSP(=O)(OCC)OC1=CC=C(C=C1)SC2=CC=C(C=C2)Cl,,,,,,
8227,42922,"3-[(2-{[{3-[Acetyl(methyl)amino]-5-[hydroxy(methylimino)methyl]-2,4,6-triiodophenyl}(hydroxy)methylidene]amino}-1-hydroxyethylidene)amino]-5-{hydroxy[(2-hydroxyethyl)imino]methyl}-2,4,6-triiodobenzoic acid--1-deoxy-1-(methylamino)hexitol (1/1)",CC(=O)N(C)C1=C(C(=C(C(=C1I)C(=O)NCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NCCO)I)I)C(=O)NC)I.CNCC(C(C(C(CO)O)O)O)O,,,,,,
8228,42923,Nafazatrom,CC1=NN(C(=O)C1)CCOC2=CC3=CC=CC=C3C=C2,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)']",,,
8229,42924,"2,3-Bis(acetylsulfanyl)propyl acetate",CC(=O)OCC(CSC(=O)C)SC(=O)C,,,,,,
8230,42925,"BENZ(a)ANTHRACEN-5-OL, 7,12-DIMETHYL-",CC1=C2C=C(C3=CC=CC=C3C2=C(C4=CC=CC=C14)C)O,,,,,,
8231,42926,Methyl 2-cyano-2-[(3-methylphenyl)hydrazinylidene]acetate,CC1=CC(=CC=C1)NN=C(C#N)C(=O)OC,,,,,,
8232,42927,Methyl 2-cyano-2-[(4-methylphenyl)hydrazinylidene]acetate,CC1=CC=C(C=C1)NN=C(C#N)C(=O)OC,,,,,,
8233,42928,Methyl 2-[(4-chlorophenyl)hydrazinylidene]-2-cyanoacetate,COC(=O)C(=NNC1=CC=C(C=C1)Cl)C#N,,,,,,
8234,42929,CID 42929,CCOC(=O)C(=NNC1=CC(=C(C=C1)[N+](=O)[O-])Cl)C#N,,,,,,
8235,42930,CID 42930,CCCOC(=O)C(=NNC1=CC=C(C=C1)C)C#N,,,,,,
8236,42931,CID 42931,CCCOC(=O)C(=NNC1=CC(=CC=C1)Cl)C#N,,,,,,
8237,42932,CID 42932,CCCOC(=O)C(=NNC1=CC=C(C=C1)Cl)C#N,,,,,,
8238,42933,CID 42933,CCCOC(=O)C(=NNC1=CC(=C(C=C1)[N+](=O)[O-])Cl)C#N,,,,,,
8239,42934,CID 42934,CC(C)OC(=O)C(=NNC1=CC(=CC=C1)Cl)C#N,,,,,,
8240,42935,CID 42935,CC(C)OC(=O)C(=NNC1=CC=C(C=C1)Cl)C#N,,,,,,
8241,42936,CID 42936,CC(C)OC(=O)C(=NNC1=CC(=C(C=C1)[N+](=O)[O-])Cl)C#N,,,,,,
8242,42937,CID 42937,CCCCOC(=O)C(=NNC1=CC(=CC=C1)[N+](=O)[O-])C#N,,,,,,
8243,42938,Butyl 2-cyano-2-[(4-nitrophenyl)hydrazinylidene]acetate,CCCCOC(=O)C(=NNC1=CC=C(C=C1)[N+](=O)[O-])C#N,,,,,,
8244,42939,CID 42939,CCCCOC(=O)C(=NNC1=CC(=C(C=C1)[N+](=O)[O-])Cl)C#N,,,,,,
8245,42940,CID 42940,CC(C)COC(=O)C(=NNC1=CC(=CC=C1)[N+](=O)[O-])C#N,,,,,,
8246,42941,CID 42941,CC(C)COC(=O)C(=NNC1=CC=C(C=C1)[N+](=O)[O-])C#N,,,,,,
8247,42942,CID 42942,CCCCCOC(=O)C(=NNC1=CC(=CC=C1)[N+](=O)[O-])C#N,,,,,,
8248,42943,CID 42943,CCCCCOC(=O)C(=NNC1=CC=C(C=C1)[N+](=O)[O-])C#N,,,,,,
8249,42944,CID 42944,CC(C)CCOC(=O)C(=NNC1=CC=C(C=C1)[N+](=O)[O-])C#N,,,,,,
8250,42945,CID 42945,CCCOC(=O)C(=NNC1=CC=CC(=C1)C)C#N,,,,,,
8251,42946,CID 42946,CC1=CC=C(C=C1)OC(=O)C(C2=CSC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+],,,,,,
8252,42947,"3,3-Dimethyl-6-[[3-(4-methylphenoxy)-3-oxo-2-thiophen-3-ylpropanoyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1=CC=C(C=C1)OC(=O)C(C2=CSC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,,,,,,
8253,42948,"2,2',4,4',5,5'-Hexabromobiphenyl",C1=C(C(=CC(=C1Br)Br)Br)C2=CC(=C(C=C2Br)Br)Br,,,,"[""(14)C-labelled 2,2',4,4',5,5'-hexabromobiphenyl...administered to male rats was readily absorbed from intestine and distributed throughout body; it was stored principally in fat. Extrapolation of rate of excretion indicates that <10% of any dose would be excreted."", ""2,2',4,4',5,5'-Hexabromobiphenyl was most prevalent polybrominated biphenyl homolog in serum from Michigan chemical corp employees, serum from dairy farmers, and serum from rats exposed to Firemaster FF 1."", ""Timed-pregnant albino Hartley strain guinea pigs of approximately 65 days gestation or lactating animals within 6-12 hr of parturition received a single oral dose of Firemaster FF-1 (50 mg/kg bw). The pregnant animals and their fetuses were killed 2 days later at term while the lactating animals and their pups were killed at intervals of 2, 4, 7, 14, 28, 42, and 60 days. Tissues (liver, kidney, lung, perirenal fat) were /analyzed/ ...for 2,4,5,2',4',5'-hexabromobiphenyl (HBB)... content... . Transplacentally-acquired residues of the order of 45 ug HBB/g were found in both maternal and fetal adipose tissue and in fetal liver. HBB  residues in maternal kidney, lung and liver were of the order of 4-7 ug/g while, in the fetuses and pups, levels in the kidney and lung were of the order of 1-2 ug/g. Levels of HBB in breast milk 2 days after treatment averaged 22.4 +/- 7.8 ug/g (mean +/- S.D.)... . HBB levels in the pup kidney, lung and adipose tissue reflected redistribution or sequestration in the body fat. The biological half-life of HBB in tissues of both dams and pups appeared to be approximately 22 days. /Firemaster FF-1/"", ""In rats treated by gavage with one or four daily doses of 14C-2,2',4,4',5,5'-hexabromobiphenyl (BB 153), initial concentrations of radioactivity were highest in muscle, liver, and adipose tissue, but later redistribution to adipose tissue (4-7 days after the last dosing) resulted in lower concentrations in liver and muscle. In rats dosed daily with 14C-BB 153 over a 30-day period, tissue concentrations on day 31 were (in increasing order): blood, muscle, liver, skin, and adipose... ."", ""For more Absorption, Distribution and Excretion (Complete) data for 2,4,5,2',4',5'-HEXABROMOBIPHENYL (11 total), please visit the HSDB record page.""]","[""The in vitro metabolism of 2,2',4,4',5,5'-hexabromobiphenyl (BB 153) with liver microsomes of rats induced with either BB 153 or FireMaster BP-6 produced three major metabolic fractions: lipophilic ether soluble polar metabolites, trichloroacetic acid (TCA) soluble conjugates, and macromolecular adducts."", ""In contrast to the lower brominated congeners, no major metabolites were identified in the urine or feces of rats treated with a single ip dose of 2,2'4,4'5,5'-hexabromobiphenyl."", ""Feces of dogs fed BP-6 contained a metabolite identified as 6-hydroxy-2,4,5,2',4',5'-hexabromobiphenyl (hydroxy-HBB). MS analysis of synthetic hydroxy-HBB showed that, during GC on OV-101 columns at 230-260 C, it decomposes into two pentabromodibenzofurans (PDBF).""]","['Biological half-life in guinea pigs = 22 days; Estimated body burden t1/2 in man = 6.5 years; [HSDB]', ""Mathematical model was developed to describe pharmacokinetics of 2,2',4,4',5,5'-hexabromobiphenyl in rats and man. The estimated body burden t1/2 in man was 6.5 yr."", ""The biological half-life of HBB /(2,4,5,2',4',5'-hexabromobiphenyl)/ in tissues of both /lactating Hartley strain guinea pig / dams and /their/ pups appeared to be approximately 22 days.""]"
8254,42949,4-(4-Methylphenyl)pentanoic acid,CC1=CC=C(C=C1)C(C)CCC(=O)O,,,,,,
8255,42950,"Benzoic acid, 4-((trimethylsilyl)amino)-, ethyl ester",CCOC(=O)C1=CC=C(C=C1)N[Si](C)(C)C,,,,,,
8256,42951,"Nicotinic acid, 1,2,5,6-tetrahydro-1-methyl-, allyl ester",CN1CCC=C(C1)C(=O)OCC=C,,,,,,
8257,42952,"1,1-Dibromoheptane",CCCCCCC(Br)Br,,,,,,
8258,42953,Diglycerol,C(C(COCC(CO)O)O)O,,,,,,
8259,42954,"Phenanthrene, dichloro-",C1=CC=C2C(=C1)C=CC3=C2C=C(C=C3Cl)Cl,,,,,,
8260,42955,"7-[(1R,2R,3R)-3-hydroxy-2-(4-hydroxy-4-methyloct-1-enyl)-5-oxocyclopentyl]heptanoic acid methyl ester",CCCCC(C)(CC=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O,,,,,,
8261,42956,Hexadecyl 2-ethylhexanoate,CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC,,,,,,
8262,42957,1-(4-Amino-2-methyl-1H-pyrrol-3-yl)ethanone hydrochloride,CC1=C(C(=CN1)[NH3+])C(=O)C.[Cl-],,,,,,
8263,42958,1-(4-amino-2-methyl-1H-pyrrol-3-yl)ethanone,CC1=C(C(=CN1)N)C(=O)C,,,,,,
8264,42959,1-(4-Amino-2-methyl-5-phenyl-1H-pyrrol-3-yl)ethanone hydrochloride,CC1=C(C(=C(N1)C2=CC=CC=C2)[NH3+])C(=O)C.[Cl-],,,,,,
8265,42960,1-(4-Amino-2-methyl-5-phenyl-1h-pyrrol-3-yl)-ethanone,CC1=C(C(=C(N1)C2=CC=CC=C2)N)C(=O)C,,,,,,
8266,42961,Tetramethylammonium formate,C[N+](C)(C)C.C(=O)[O-],,,,,,
8267,42962,"Acetamide, N-phenyl-2-(phenylimino)-",C1=CC=C(C=C1)NC(=O)C=NC2=CC=CC=C2,,,,,,
8268,42963,Lidofenin,CC1=C(C(=CC=C1)C)NC(=O)CN(CC(=O)O)CC(=O)O,,,,,,
8269,42964,4-Bromo-1-methyl-5-nitro-1H-imidazole,CN1C=NC(=C1[N+](=O)[O-])Br,,,,,,
8270,42965,2-Chloro-N-methyl-1-adamantanemethanamine hydrochloride,CNCC12CC3CC(C1)CC(C3)C2Cl.Cl,,,,,,
8271,42966,1-(2-chloro-1-adamantyl)-N-methylmethanamine,CNCC12CC3CC(C1)CC(C3)C2Cl,,,,,,
8272,42967,CID 42967,CCN(C)C12CC3CC(C1)CC(C3)C2Br.C(=CC(=O)O)C(=O)O,,,,,,
8273,42968,2-bromo-N-ethyl-N-methyladamantan-1-amine,CCN(C)C12CC3CC(C1)CC(C3)C2Br,,,,,,
8274,42969,2-Bromo-1-(4-methyl-1-piperazinyl)methyladamantane dihydrobromide,CN1CCN(CC1)CC23CC4CC(C2)CC(C4)C3Br.Br.Br,,,,,,
8275,42970,1-[(2-Bromo-1-adamantyl)methyl]-4-methylpiperazine,CN1CCN(CC1)CC23CC4CC(C2)CC(C4)C3Br,,,,,,
8276,42971,1-[(4-Methylpiperazin-1-yl)methyl]adamantan-2-ol dihydrochloride,CN1CCN(CC1)CC23CC4CC(C2)CC(C4)C3O.Cl.Cl,,,,,,
8277,42972,1-[(4-Methylpiperazin-1-yl)methyl]adamantan-2-ol,CN1CCN(CC1)CC23CC4CC(C2)CC(C4)C3O,,,,,,
8278,42973,2-Bromo-N-methyl-1-adamantanemethanamine hydrochloride,CNCC12CC3CC(C1)CC(C3)C2Br.Cl,,,,,,
8279,42974,1-(2-bromo-1-adamantyl)-N-methylmethanamine,CNCC12CC3CC(C1)CC(C3)C2Br,,,,,,
8280,42975,"Acetanilide, 4'-chloro-2'-(o-chlorobenzoyl)-2-(2-(isopropylamino)acetamido)-N-methyl-, hydrochloride",CC(C)[NH2+]CC(=O)NCC(=O)N(C)C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl.[Cl-],,,,,,
8281,42976,N-[2-[4-chloro-2-(2-chlorobenzoyl)-N-methylanilino]-2-oxoethyl]-2-(propan-2-ylamino)acetamide,CC(C)NCC(=O)NCC(=O)N(C)C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl,,,,,,
8282,42977,Sodium cetostearyl sulfate,CCCCCCCCCCCCCCCCCCOS(=O)(=O)[O-].CCCCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+],,,,,,
8283,42978,Egomaketone,CC(=CCC(=O)C1=COC=C1)C,,,,,,
8284,42979,"2-BENZIMIDAZOLECARBAMIC ACID, 5-HYDROXY-, METHYL ESTER, BENZENESULFONATE (ester)",COC(=O)NC1=NC2=C(N1)C=C(C=C2)OS(=O)(=O)C3=CC=CC=C3,,,,,,
8285,42980,"Acetamide, N-(1,3-dioxo-2-ethyl-2-indanyl)-N-methyl-",CCC1(C(=O)C2=CC=CC=C2C1=O)N(C)C(=O)C,,,,,,
8286,42981,Laurocapram,CCCCCCCCCCCCN1CCCCCC1=O,,,,"['Azone (1-dodecylazacycloheptan-2-one) is an agent that has been shown to enhance percutaneous absorption of drugs. Azone is thought to act by partitioning into skin lipid bilayers and thereby disrupting the structure. An open-label study was done with nine volunteers (two males, seven females; aged 51-76 years) in which Azone cream (1.6%; 100 mg) was topically dosed on a 5 x 10-cm area of the ventral forearm for 21 consecutive days. On days 1, 8, and 15, the Azone cream contained 47 uCi of (14)C Azone. The skin application site was washed with soap and water after each 24-hr dosing. Percutaneous absorption was determined by urinary radioactivity excretion. The (14)C Azone was ring labeled [14C-2-cyclo-heptan]. Radiochemical purity was >98.6% and cold Azone purity was 99%. Percutaneous absorption of the first dose (day 1) was 1.84 +/- 1.56% (SD) of applied dose for 24-hr skin application time. Day 8 percutaneous absorption, after repeated application, increased significantly (p<0.002) to 2.76 +/- 1.91%. Day 15 percutaneous absorption, after continued repeated application, stayed the same at 2.72 +/- 1.21%. In humans, repeated application of Azone results in an initial self-absorption enhancement, probably due to its mechanism of action. However, steady-state percutaneous absorption of Azone is established after this initial change. Thus, Azone can enhance its own absorption as well as that of other compounds. This should be considered relevant for any pharmacological or toxicological evaluation. Washing the skin site of application with soap and water only recovered 1-2% of applied radioactivity. Previous published studies recovered the Azone dose with ethanol washes. Thus, there could potentially be an accumulation of Azone in skin.']",,
8287,42982,p-Chlorophenyl(diethylaminoethoxy)methylphenylsilane,CCN(CC)CCO[Si](C)(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,,,,,,
8288,42983,"BENZ(a)ANTHRACENE, 12-BROMOMETHYL-7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)CBr,,,,,,
8289,42984,"CYTOSINE, 1-beta-D-ARABINOFURANOSYL-N(sup 4)-PENTADECANOYL-",CCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8290,42985,"CYTOSINE, 1-beta-D-ARABINOFURANOSYL-N(sup 4)-MARGAROYL-",CCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8291,42986,"CYTOSINE, 1-beta-D-ARABINOFURANOSYL-N(sup 4)-NONADECANOYL-",CCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8292,42987,"Ethanamine, N,N-dimethyl-2-((2,2-dimethyl-4-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-1-benzopyran-7-yl)oxy)-, hydrochloride",CC1(CC(C2=C(O1)C=C(C=C2)OCCN(C)C)C3=CC(=CC=C3)C(F)(F)F)C.Cl,,,,,,
8293,42988,BRL-16644 free base,CC1(CC(C2=C(O1)C=C(C=C2)OCCN(C)C)C3=CC(=CC=C3)C(F)(F)F)C,,,,,,
8294,42989,"Ethanamine, N,N-dimethyl-2-((2,2-dimethyl-4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-1-benzopyran-7-yl)oxy)-, hydrochloride",CC1(CC(C2=C(O1)C=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)C(F)(F)F)C.Cl,,,,,,
8295,42990,BRL-16657 free base,CC1(CC(C2=C(O1)C=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)C(F)(F)F)C,,,,,,
8296,42991,"N,N''-Thiobis(N-methyl-N'-2,4-xylylformamidine)",CC1=CC(=C(C=C1)N=CN(C)SN(C)C=NC2=C(C=C(C=C2)C)C)C,,,,,,
8297,42992,"6,7-Dimethoxy-1-(2,3-dimethoxybenzyl)isoquinoline hydrochloride",COC1=CC=CC(=C1OC)CC2=[NH+]C=CC3=CC(=C(C=C32)OC)OC.[Cl-],,,,,,
8298,42993,"1-(2,3-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline",COC1=CC=CC(=C1OC)CC2=NC=CC3=CC(=C(C=C32)OC)OC,,,,,,
8299,42994,Lindleyin,CC(=O)CCC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C3=CC(=C(C(=C3)O)O)O)O)O)O,,,,,,
8300,42995,Triphenylguanidine hydrochloride,C1=CC=C(C=C1)[NH2+]C(=NC2=CC=CC=C2)NC3=CC=CC=C3.[Cl-],,,,,,
8301,42996,"3-[(3S,5R,10S,13R,14S,17R)-14-hydroxy-3-[(2R,5R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)OC)O,,,,,,
8302,42997,"Coumarin, 3-amino-4-methylamino-",CNC1=C(C(=O)OC2=CC=CC=C21)N,,,,,,
8303,42998,"Coumarin, 3-amino-4-butylamino-",CCCCNC1=C(C(=O)OC2=CC=CC=C21)N,,,,,,
8304,42999,3-Amino-4-benzylaminocoumarin,C1=CC=C(C=C1)CNC2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
8305,43000,"Coumarin, 3-amino-4-anilino-",C1=CC=C(C=C1)NC2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
8306,43001,"Coumarin, 3-amino-4-(1-pyrrolidinyl)-",C1CCN(C1)C2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
8307,43002,"Coumarin, 3-amino-4-morpholino-",C1COCCN1C2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
8308,43003,"Coumarin, 3-amino-4-(4-methyl-1-piperazinyl)-",CN1CCN(CC1)C2=C(C(=O)OC3=CC=CC=C32)N,,,,,,
8309,43004,"2,2',3,4,4',6'-Hexachlorobiphenyl",C1=CC(=C(C(=C1C2=C(C=C(C=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
8310,43005,"Ammonium, triethyl(((2,4,6-trimethylphenyl)carbamoyl)methyl)-",CC[N+](CC)(CC)CC(=O)NC1=C(C=C(C=C1C)C)C,,,,,,
8311,43006,"Benzimidazole, 1-(2-aminoethyl)-5-nitro-",C1=CC2=C(C=C1[N+](=O)[O-])N=CN2CCN,,,,,,
8312,43007,"Benzimidazole, 1-(2-aminoethyl)-6-nitro-",C1=CC2=C(C=C1[N+](=O)[O-])N(C=N2)CCN,,,,,,
8313,43008,Alizaprida,COC1=CC2=NNN=C2C=C1C(=O)NCC3CCCN3CC=C,,,,,,
8314,43009,"[(3,3-dimethyl-1,4-dithian-2-ylidene)amino] N-methylcarbamate",CC1(C(=NOC(=O)NC)SCCS1)C,,,,,,
8315,43010,"[(4-oxo-1,4-dithian-2-ylidene)amino] N-methylcarbamate",CNC(=O)ON=C1CS(=O)CCS1,,,,,,
8316,43011,"[(5,5-dimethyl-1,3-dithiolan-4-ylidene)amino] N-methylcarbamate",CC1(C(=NOC(=O)NC)SCS1)C,,,,,,
8317,43012,"(1,3-dithiolan-4-ylideneamino) N-methylcarbamate",CNC(=O)ON=C1CSCS1,,,,,,
8318,43013,"1,3-Dithiolan-4-one, 5-methyl-, O-((methylamino)carbonyl)oxime",CC1C(=NOC(=O)NC)SCS1,,,,,,
8319,43014,"1,3-Dithiolan-4-one, 2,2-dimethyl-, O-((methylamino)carbonyl)oxime",CC1(SCC(=NOC(=O)NC)S1)C,,,,,,
8320,43015,"(1,4-Dithian-2-ylideneamino) carbamate",C1CSC(=NOC(=O)N)CS1,,,,,,
8321,43016,"[(3-methyl-1,4-dithian-2-ylidene)amino] N-methylcarbamate",CC1C(=NOC(=O)NC)SCCS1,,,,,,
8322,43017,CID 43017,CC1CSC(=NOC(=O)NC)CS1,,,,,,
8323,43018,6-(3-(Dimethylamino)propionyl)-3-methyl-2-benzoxazolinone hydrochloride,CN1C2=C(C=C(C=C2)C(=O)CC[NH+](C)C)OC1=O.[Cl-],,,,,,
8324,43019,"6-[3-(Dimethylamino)propanoyl]-3-methyl-1,3-benzoxazol-2-one",CN1C2=C(C=C(C=C2)C(=O)CCN(C)C)OC1=O,,,,,,
8325,43020,3-Methyl-6-(3-piperidinopropionyl)-2-benzoxazolinone hydrochloride,CN1C2=C(C=C(C=C2)C(=O)CC[NH+]3CCCCC3)OC1=O.[Cl-],,,,,,
8326,43021,"3-Methyl-6-(3-piperidin-1-ylpropanoyl)-1,3-benzoxazol-2-one",CN1C2=C(C=C(C=C2)C(=O)CCN3CCCCC3)OC1=O,,,,,,
8327,43022,3-Methyl-6-(3-morpholinopropionyl)-2-benzoxazolinone hydrochloride,CN1C2=C(C=C(C=C2)C(=O)CC[NH+]3CCOCC3)OC1=O.[Cl-],,,,,,
8328,43023,3-Methyl-6-(3-morpholinopropionyl)benzoxazolinone,CN1C2=C(C=C(C=C2)C(=O)CCN3CCOCC3)OC1=O,,,,,,
8329,43024,"2-Benzoxazolinone, 3-methyl-6-(3-(4-methyl-1-piperazinyl)propionyl)-, dihydrochloride",CN1CCN(CC1)CCC(=O)C2=CC3=C(C=C2)N(C(=O)O3)C.Cl.Cl,,,,,,
8330,43025,"3-Methyl-6-[3-(4-methylpiperazin-1-yl)propanoyl]-1,3-benzoxazol-2-one",CN1CCN(CC1)CCC(=O)C2=CC3=C(C=C2)N(C(=O)O3)C,,,,,,
8331,43026,2-(4-Aminophenyl)propanoic acid,CC(C1=CC=C(C=C1)N)C(=O)O,,,,,,
8332,43027,"Ethyl 3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate",CCOC(=O)N1C2CCC1CN(C2)C,,,,,,
8333,43028,"3,4-Dihydro-1-((2-bromo-4,5-dimethoxy)benzyl)-6,7-dimethoxyisoquinoline hydrochloride",COC1=C(C=C2C(=C1)CC[NH+]=C2CC3=CC(=C(C=C3Br)OC)OC)OC.[Cl-],,,,,,
8334,43029,6'-Bromodihydropapaverine,COC1=C(C=C2C(=C1)CCN=C2CC3=CC(=C(C=C3Br)OC)OC)OC,,,,,,
8335,43030,C.I. Fluorescent Brightener 28,C1=CC=C(C=C1)NC2=NC(=NC(=N2)N(CCO)CCO)NC3=CC(=C(C=C3)C=CC4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC=CC=C6)N(CCO)CCO)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
8336,43031,"4,4'-bis[4-anilino-6-bis(2-hydroxyeth-yl)amino-S-triazin-2-ylamino]2,2'-stilbene disulphonic acid",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N(CCO)CCO)NC3=CC(=C(C=C3)C=CC4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC=CC=C6)N(CCO)CCO)S(=O)(=O)O)S(=O)(=O)O,,,,,,
8337,43032,Midazolam hydrochloride,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F.Cl,"['Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).']",,"['Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)', 'Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
8338,43033,"4-N,N-Bis(2-hydroxyethyl)aminobutyrophenone",CCCC(=O)C1=CC=C(C=C1)N(CCO)CCO,,,,,,
8339,43034,"1H-Indole-3-carboxylic acid, 2-(3-(dimethylamino)propyl)octahydro-1,3-dioxo-4,7-methano-1H-isoindol-5-yl ester, monohydrochloride, (3a-alpha,4-alpha,5-beta,7-alpha,7a-alpha)-(+-)-",C[NH+](C)CCCN1C(=O)C2[C@@H]3C[C@H](C2C1=O)C(C3)OC(=O)C4=CNC5=CC=CC=C54.[Cl-],,,,,,
8340,43035,"[(1R,7R)-4-[3-(dimethylamino)propyl]-3,5-dioxo-4-azatricyclo[5.2.1.02,6]decan-8-yl] 1H-indole-3-carboxylate",CN(C)CCCN1C(=O)C2[C@@H]3C[C@H](C2C1=O)C(C3)OC(=O)C4=CNC5=CC=CC=C54,,,,,,
8341,43036,2-(4-isobutylphenyl)-N-phenylpropanamide,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NC2=CC=CC=C2,,,,,,
8342,43037,7-Methoxy-2-methyl-2H-1-benzopyran-3-carbonitrile,CC1C(=CC2=C(O1)C=C(C=C2)OC)C#N,,,,,,
8343,43038,"6-Methoxy-2-(3,4-methylenedioxyphenyl)-3-nitro-2H-1-benzopyran",COC1=CC2=C(C=C1)OC(C(=C2)[N+](=O)[O-])C3=CC4=C(C=C3)OCO4,,,,,,
8344,43039,CID 43039,CC(C)(C)C(=O)OCC1=CCN2C1[C@H](CC2)OC(=O)C(C)(C)C,,,,,,
8345,43040,"7,9-Di-n-valerylheliotridine",CCCCC(=O)OCC1=CCN2C1[C@H](CC2)OC(=O)CCCC,,,,,,
8346,43041,Succinyldioxydiethylenebis(adamantyldimethylammonium) diiodide,C[N+](C)(CCOC(=O)CCC(=O)OCC[N+](C)(C)C1C2CC3CC(C2)CC1C3)C4C5CC6CC(C5)CC4C6.[I-].[I-],,,,,,
8347,43042,2-Adamantyl-[2-[4-[2-[2-adamantyl(dimethyl)azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl]-dimethylazanium,C[N+](C)(CCOC(=O)CCC(=O)OCC[N+](C)(C)C1C2CC3CC(C2)CC1C3)C4C5CC6CC(C5)CC4C6,,,,,,
8348,43043,"4-((5-(1,2-Dithiolan-3-yl)-1-oxopentyl)amino)butanoic acid",C1CSSC1CCCCC(=O)NCCCC(=O)O,,,,,,
8349,43044,5-Allyl-1-methyl-5-(1-methylbutyl)barbituric acid,CCCC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C,,,,,,
8350,43045,L-Menthyl acetoacetate,C[C@H]1CC[C@@H]([C@H](C1)OC(=O)CC(=O)C)C(C)C,,,,,,
8351,43046,p-Tolyl octanoate,CCCCCCCC(=O)OC1=CC=C(C=C1)C,,,,,,
8352,43047,"Benzamide, 2-(allyloxy)-5-amino-N-cyclohexyl-",C=CCOC1=C(C=C(C=C1)N)C(=O)NC2CCCCC2,,,,,,
8353,43048,CID 43048,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC2(OCCO2)COC3=CC=CC=C3,,,,,,
8354,43049,"7-[(2R)-3,5-dihydroxy-2-[2-[2-(phenoxymethyl)-1,3-dioxolan-2-yl]ethenyl]cyclopentyl]hept-5-enoic acid",C1COC(O1)(COC2=CC=CC=C2)C=C[C@H]3C(CC(C3CC=CCCCC(=O)O)O)O,,,,,,
8355,43050,"2-Chloro-3-ethoxy-1,4-naphthoquinone",CCOC1=C(C(=O)C2=CC=CC=C2C1=O)Cl,,,,,,
8356,43051,2-Propoxybenzamide,CCCOC1=CC=CC=C1C(=O)N,,,,,,
8357,43052,"2,5-Bis(3-methylphenyl)-1,3,4-oxadiazole",CC1=CC(=CC=C1)C2=NN=C(O2)C3=CC=CC(=C3)C,,,,,,
8358,43053,"DIBENZ(c,h)ACRIDINE, 7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=CC5=CC=CC=C54,,,,,,
8359,43054,CID 43054,CCCCCC(=NNC(=NN)S)C,,,,,,
8360,43055,"Alanine, 3-((2-aminoethyl)seleno)-, monohydrochloride",C(C[Se]CC(C(=O)O)N)[NH3+].[Cl-],,,,,,
8361,43056,2-Amino-3-(2-aminoethylselanyl)propanoic acid,C(C[Se]CC(C(=O)O)N)N,,,,,,
8362,43057,"Acetamide, N-(methylnitrosoaminomethyl)-",CC(=O)NCN(C)N=O,,,,,,
8363,43058,"Acetamide, N-((N-nitrosobenzylamino)methyl)-",CC(=O)NCN(CC1=CC=CC=C1)N=O,,,,,,
8364,43059,"BUTANEDIOIC ACID, MONO(4-HYDROXY-3-SULFOPHENYL)ESTER, compd. with PYRIDINE (1:1)",C1=CC=NC=C1.C1=CC(=C(C=C1OC(=O)CCC(=O)O)S(=O)(=O)O)O,,,,,,
8365,43060,4-(4-Hydroxy-3-sulfophenoxy)-4-oxobutanoic acid,C1=CC(=C(C=C1OC(=O)CCC(=O)O)S(=O)(=O)O)O,,,,,,
8366,43061,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N,N'-oxydiethylenedi-, ditartrate",CC[N+](C)(C)CCOCC[N+](CC)(CC)CC.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,,,,,,
8367,43062,Triethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]ethyl]azanium,CC[N+](C)(C)CCOCC[N+](CC)(CC)CC,,,,,,
8368,43063,"2-Ethyl-2-(alpha-hydroxybenzyl)butyric acid, ethyl ester",CCC(CC)(C(C1=CC=CC=C1)O)C(=O)OCC,,,,,,
8369,43064,CID 43064,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=N3.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
8370,43065,"2,2,4,4,6-Pentachloro-6-(2,2,3,3-tetrafluoropropoxy)-,3,5,2lambda5,4lambda5,6lambda5-triazatriphosphinine",C(C(C(F)F)(F)F)OP1(=NP(=NP(=N1)(Cl)Cl)(Cl)Cl)Cl,,,,,,
8371,43066,CID 43066,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@@H]3[C@H]4N(C3=O)[C@@H](C(S4)(C)C)C(=O)[O-].[Na+],,,,,,
8372,43067,"(2R,5S,6S)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@@H]3[C@H]4N(C3=O)[C@@H](C(S4)(C)C)C(=O)O,,,,,,
8373,43068,p-(3-Butyl-3-methyl-1-triazeno)benzamide,CCCCN(C)N=NC1=CC=C(C=C1)C(=O)N,,,,,,
8374,43069,p-(3-Benzyl-3-methyl-1-triazeno)benzamide,CN(CC1=CC=CC=C1)N=NC2=CC=C(C=C2)C(=O)N,,,,,,
8375,43070,"BENZAMIDE, p-(3-tert-BUTYL-3-METHYL-1-TRIAZENO)-",CC(C)(C)N(C)N=NC1=CC=C(C=C1)C(=O)N,,,,,,
8376,43071,Camostat monomethanesulfonate,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)[NH+]=C(N)N.CS(=O)(=O)[O-],,,"['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)', 'Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (See all compounds classified as Trypsin Inhibitors.)']",,,
8377,43072,CID 43072,C1COCC[NH+]1CCN2C(=O)CC3=CC=CC=C3C(=N2)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
8378,43073,"3-(2-morpholin-4-ylethyl)-1-phenyl-5H-2,3-benzodiazepin-4-one",C1COCCN1CCN2C(=O)CC3=CC=CC=C3C(=N2)C4=CC=CC=C4,,,,,,
8379,43074,CID 43074,C1COCC[NH+]1CCCN2C(=O)CC3=CC=CC=C3C(=N2)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
8380,43075,"3-(3-morpholin-4-ylpropyl)-1-phenyl-5H-2,3-benzodiazepin-4-one",C1COCCN1CCCN2C(=O)CC3=CC=CC=C3C(=N2)C4=CC=CC=C4,,,,,,
8381,43076,CID 43076,C1CC[NH+](C1)CCN2C(=O)CC3=CC=CC=C3C(=N2)C4=CC=CC=C4.C(=CC(=O)[O-])C(=O)O,,,,,,
8382,43077,"1-phenyl-3-(2-pyrrolidin-1-ylethyl)-5H-2,3-benzodiazepin-4-one",C1CCN(C1)CCN2C(=O)CC3=CC=CC=C3C(=N2)C4=CC=CC=C4,,,,,,
8383,43078,CID 43078,C1=CC=C(C=C1)NC(=O)CC(=N)S,,,,,,
8384,43079,Fluridone,CN1C=C(C(=O)C(=C1)C2=CC(=CC=C2)C(F)(F)F)C3=CC=CC=C3,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['/In a rat metabolism study/... Preliminary study: Group A, 2 male (M)/2 female (F) exposed to a single oral dose of [14C]fluridone (...radiopurity 99.8%; for test solutions [14C]fluridone was mixed w/[12C]fluridone, ...100% purity; test substance was suspended in 1% sodium carboxymethyl cellulose [CMC]) at ~10 mg/kg. Group B, 1M/1F exposed to a single oral dose at ~1000 mg/kg. Urine, feces and cage rinses were collected daily for 7 days (because expired (trapped) 14CO2 accounted for <1% of the dose after 24 hr, further 14CO2 measurements were discontinued). Definitive study: Group C, vehicle controls, 2M/2F exposed to a single oral dose of 1% CMC. Group D, 5M/5F exposed to a single oral dose at ~7.4 mg/kg. Group E, 7M/7F exposed to ~10 mg/kg unlabeled fluridone once daily for 14 days, then 5M/5F exposed on day 15 to ~10 mg/kg [14C]fluridone. Group F, 5M/5F exposed to a single oral dose at ~900 mg/kg. ...Clinical signs (lack of mobility, abnormal and rapid head movement, squinting, loss of balance and cage biting) occurred only at the HD (Groups B and F), clearing within 24 hr. Results, Group A: by 7 days, 12.52%/12.89% (M/F) was excreted in urine and 72.76%/81.79% in feces. Group B: by 7 days 4.83%/3.43% was excreted in urine and 86.43%/86.31% in feces. Group D: by 24 hr 11.14%/10.44% was excreted in urine and 72.46%/77.72% in feces. By 7 days 11.61%/10.93% was excreted in urine and 79.19%/84.62% in feces. Combined excretion (including cage rinse) by 7 days was 92.93%/98.74%. Group E: by 24 hr 9.54%/8.51% was excreted in urine and 70.69%/69.90% in feces. By 7 days 10.11%/9.14% was excreted in urine and 79.80%/81.79% in feces. Combined excretion (including cage rinse) by 7 days was 92.81%/94.21%. Group F: by 24 hr 2.40%/2.43% was excreted in urine and 27.16%/27.18% in feces (thus, a relative delay in fecal excretion at the HD). By 7 days 8.30%/8.07% was excreted in urine and 91.58%/90.09% in feces. Combined excretion (including cage rinse) by 7 days was 101.02%/99.62%. Total tissue residues were always <1% of the dose (Groups D-F). Under all conditions, highest tissue levels occurred in the liver. The major metabolites were a variety of polar and non-polar compounds resulting from aromatic hydroxylations and heteroaromatic N-demethylation. The parent compound was the primary fecal component over the 1st 72 hr.', 'In a metabolism study in rats, fluridone was rapidly and almost completely absorbed into the systemic circulation and eliminated in both the male and female rats within 3 days. The total radioactivity recovered within 3 days after dosing in the urine and feces were 78-90% and 87- 97% of administered dose in males and females, respectively. The majority (approximately 70%) of the radioactivity was eliminated via feces. No tissue accumulation was observed.', 'The rates of uptake of ... (14C) fluridone (1-methyl-3-phenyl-5-(3-trifluoromethylphenyl)-4-(1H)-pyridinone) from water by rainbow trout and Chironomus tentans (4th Instar) larvae were much lower than those for more hydrophobic compounds tested under similar conditions ...  Uptake and clearance of fluridone ... by chironomid larvae were more rapid than for rainbow trout. /BCF/ for chironomid larvae /was/ estimated to be 128 for fluridone ... Liver, intestine, and pyloric caeca of adult rainbow trout accumulated the highest residues of (14C)-fluridone ... Most of the radioactivity was found to be in the form of fluridone or 4-hydroxyfluridone (1-methyl-3-(4-hydroxyphenyl)-5-(3-trifluoromethyl phenyl)-4(1H)-pyridinone) ... in tissues of fish exposed to /fluridone/ ...']","['The major metabolites were a variety of polar and non-polar compounds resulting from aromatic hydroxylations and heteroaromatic N-demethylation. The parent compound was the primary fecal component over the 1st 72 hr.', 'Most of the radioactivity was found to be in the form of fluridone or 4-hydroxyfluridone (1-methyl-3-(4-hydroxyphenyl)-5-(3-trifluoromethyl phenyl)-4(1H)-pyridinone) ... in tissues of fish exposed to /fluridone/ ...']",
8385,43080,"DIBENZ(a,h)ANTHRACENE, 7,14-DIBENZYL-",C1=CC=C(C=C1)CC2=C3C=CC4=CC=CC=C4C3=C(C5=C2C6=CC=CC=C6C=C5)CC7=CC=CC=C7,,,,,,
8386,43081,1-[2-[1-(4-Chlorophenyl)-1-phenylethoxy]ethyl]azepan-1-ium;chloride,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[NH+]3CCCCCC3.[Cl-],,,,,,
8387,43082,Setastine,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN3CCCCCC3,,,,,,
8388,43083,"Benzamide, 4-amino-N-(2-(4-(4-methyl-2-pyridinyl)-1-piperazinyl)ethyl)-",CC1=CC(=NC=C1)N2CCN(CC2)CCNC(=O)C3=CC=C(C=C3)N,,,,,,
8389,43084,CID 43084,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)[O-])C.[Na+],,,,,,
8390,43085,"3,3-Dimethyl-6-[[2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
8391,43086,Tetrachlorocyclopentane,C1C(C(C(C1Cl)Cl)Cl)Cl,,,,,,
8392,43087,"1,4-Benzodioxan, 7-methyl-6-nitro-",CC1=CC2=C(C=C1[N+](=O)[O-])OCCO2,,,,,,
8393,43088,"1H-Indole-3-acetic acid, 1-((2-chloro-3-pyridinyl)carbonyl)-5-methoxy-2-methyl-",CC1=C(C2=C(N1C(=O)C3=C(N=CC=C3)Cl)C=CC(=C2)OC)CC(=O)O,,,,,,
8394,43089,"1H-Indole-3-acetic acid, 1-((6-chloro-3-pyridinyl)carbonyl)-5-methoxy-2-methyl-",CC1=C(C2=C(N1C(=O)C3=CN=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,,,,,,
8395,43090,"1H-Indole-3-acetic acid, 1-((4-chloro-2-pyridinyl)carbonyl)-5-methoxy-2-methyl-",CC1=C(C2=C(N1C(=O)C3=NC=CC(=C3)Cl)C=CC(=C2)OC)CC(=O)O,,,,,,
8396,43091,Procaterol hydrochloride,CC[C@@H]([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C.Cl,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)']",,,
8397,43092,CID 43092,CCC([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C,,,,,,
8398,43093,Propan-2-yl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate,CC(C)OC(=O)C=CC1=CC(=C(C=C1)O)OC,,,,,,
8399,43094,2-Methyl-1-piperidinoacetylindoline hydrochloride,CC1CC2=CC=CC=C2N1C(=O)C[NH+]3CCCCC3.[Cl-],,,,,,
8400,43095,2-Methyl-1-piperidinoacetylindoline,CC1CC2=CC=CC=C2N1C(=O)CN3CCCCC3,,,,,,
8401,43096,1-Piperidinoacetylindoline hydrochloride,C1CC[NH+](CC1)CC(=O)N2CCC3=CC=CC=C32.[Cl-],,,,,,
8402,43097,2-Methyl-1-(2-methylpiperidinoacetyl)indoline hydrochloride,CC1CCCC[NH+]1CC(=O)N2C(CC3=CC=CC=C32)C.[Cl-],,,,,,
8403,43098,"1-(2-Methyl-2,3-dihydroindol-1-yl)-2-(2-methylpiperidin-1-yl)ethanone",CC1CCCCN1CC(=O)N2C(CC3=CC=CC=C32)C,,,,,,
8404,43099,1-(Dipropylamino)acetylindoline hydrochloride,CCC[NH+](CCC)CC(=O)N1CCC2=CC=CC=C21.[Cl-],,,,,,
8405,43100,"Indoline, 1-(N,N-dipropylglycyl)-",CCCN(CCC)CC(=O)N1CCC2=CC=CC=C21,,,,,,
8406,43101,1-(Diisopropylamino)acetylindoline hydrochloride,CC(C)[NH+](CC(=O)N1CCC2=CC=CC=C21)C(C)C.[Cl-],,,,,,
8407,43102,"Indoline, 1-diisopropylglycyl-",CC(C)N(CC(=O)N1CCC2=CC=CC=C21)C(C)C,,,,,,
8408,43103,3-[(4-Methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine,CN1CCC(C(C1)COC2=CC=C(C=C2)OC)C3=CC=CC=C3,,,,,,
8409,43104,Cyclosporin AM 4N,CCC1C(=O)N(CC(=O)NC(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C,,,,,,
8410,43105,"3,4-Diacetyloxy-L-phenylalanyl-3,4-diacetyloxy-L-phenylalanine methyl ester hydrochloride",COC(=O)[C@H](CC1=CC(=C(C=C1)CC(=O)O)CC(=O)O)NC(=O)[C@H](CC2=CC(=C(C=C2)CC(=O)O)CC(=O)O)[NH3+].[Cl-],,,,,,
8411,43106,"2-[4-[(2S)-2-amino-3-[[(2S)-3-[3,4-bis(carboxymethyl)phenyl]-1-methoxy-1-oxopropan-2-yl]amino]-3-oxopropyl]-2-(carboxymethyl)phenyl]acetic acid",COC(=O)[C@H](CC1=CC(=C(C=C1)CC(=O)O)CC(=O)O)NC(=O)[C@H](CC2=CC(=C(C=C2)CC(=O)O)CC(=O)O)N,,,,,,
8412,43107,"1H-Imidazolium, 4-nitro-1,2,3-trimethyl-",CC1=[N+](C=C(N1C)[N+](=O)[O-])C,,,,,,
8413,43108,"1H-Imidazolium, 1,3-dimethyl-4-nitro-",CN1C=[N+](C=C1[N+](=O)[O-])C,,,,,,
8414,43109,"Diethyl 1,4-dihydroxynaphthalene-2,3-dicarboxylate",CCOC(=O)C1=C(C2=CC=CC=C2C(=C1C(=O)OCC)O)O,,,,,,
8415,43110,"Phenyl(2,4,6-trioxabicyclo[3.1.0]hexan-1-YL)methyl acetate",CC(=O)OC(C1=CC=CC=C1)C23C(O2)OCO3,,,,,,
8416,43111,"1'-Hydroxysafrole-2',3'-oxide",C1C(O1)C(C2=CC3=C(C=C2)OCO3)O,,,,,,
8417,43112,"2-p-Cumenyl-2-methyl-1,3-dioxolane-4-methanol",CC(C)C1=CC=C(C=C1)C2(OCC(O2)CO)C,,,,,,
8418,43113,"2-(p-Chlorophenyl)-2,4-dimethyl-1,3-dioxolane",CC1COC(O1)(C)C2=CC=C(C=C2)Cl,,,,,,
8419,43114,UNII-S7VK4KIN4B component LWRJZIPAGMGXQJ-DIJVWCDGSA-N,C1C=C[C@H]2CC3=C([C@@H]1[C@H]2N)C=CC(=C3)Cl.Cl,,,,,,
8420,43115,CID 43115,C1C=C[C@H]2CC3=C([C@@H]1C2N)C=CC(=C3)Cl,,,,,,
8421,43116,Vindesine sulfate,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O,,,"['Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
8422,43117,4'-Fluoro-4-(isopropyl)aminobutyrophenone hydrochloride,CC(C)[NH2+]CCCC(=O)C1=CC=C(C=C1)F.[Cl-],,,,,,
8423,43118,1-(4-Fluorophenyl)-4-(propan-2-ylamino)butan-1-one,CC(C)NCCCC(=O)C1=CC=C(C=C1)F,,,,,,
8424,43119,4-(Diallylamino)-4'-fluorobutyrophenone,C=CCN(CCCC(=O)C1=CC=C(C=C1)F)CC=C,,,,,,
8425,43120,"Butyrophenone, 4'-fluoro-4-(2-imidazolin-2-YL)amino-",C1CN=C(N1)NCCCC(=O)C2=CC=C(C=C2)F,,,,,,
8426,43121,4-(Cyclopentylamino)-4'-fluorobutyrophenone hydrochloride,C1CCC(C1)[NH2+]CCCC(=O)C2=CC=C(C=C2)F.[Cl-],,,,,,
8427,43122,4-(Cyclopentylamino)-1-(4-fluorophenyl)butan-1-one,C1CCC(C1)NCCCC(=O)C2=CC=C(C=C2)F,,,,,,
8428,43123,4-(Cyclohexylamino)-4'-fluorobutyrophenone hydrochloride,C1CCC(CC1)[NH2+]CCCC(=O)C2=CC=C(C=C2)F.[Cl-],,,,,,
8429,43124,4-(Cyclohexylamino)-1-(4-fluorophenyl)butan-1-one,C1CCC(CC1)NCCCC(=O)C2=CC=C(C=C2)F,,,,,,
8430,43125,"Butyrophenone, 4-(cyclohexylmethylamino)-4'-fluoro-, hydrochloride",C[NH+](CCCC(=O)C1=CC=C(C=C1)F)C2CCCCC2.[Cl-],,,,,,
8431,43126,4-[Cyclohexyl(methyl)amino]-1-(4-fluorophenyl)butan-1-one,CN(CCCC(=O)C1=CC=C(C=C1)F)C2CCCCC2,,,,,,
8432,43127,CID 43127,C1CC[NH+](C1)CCCC(=O)C2=CC=C(C=C2)F.C(=CC(=O)[O-])C(=O)O,,,,,,
8433,43128,1-(4-Fluorophenyl)-4-pyrrolidin-1-ylbutan-1-one,C1CCN(C1)CCCC(=O)C2=CC=C(C=C2)F,,,,,,
8434,43129,"Butyrophenone, 4'-fluoro-4-(2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-, hydrochloride",C1CCC[NH+](CC1)CCCC(=O)C2=CC=C(C=C2)F.[Cl-],,,,,,
8435,43130,4-(Azepan-1-yl)-1-(4-fluorophenyl)butan-1-one,C1CCCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,,,,,,
8436,43131,4-(Pyrrolidinyl)butyrophenone,C1CCN(C1)CCCC(=O)C2=CC=CC=C2,,,,,,
8437,43132,4'-Methyl-4-(pyrrolidinyl)butyrophenone,CC1=CC=C(C=C1)C(=O)CCCN2CCCC2,,,,,,
8438,43133,4'-Methylthio-4-(pyrrolidinyl)butyrophenone,CSC1=CC=C(C=C1)C(=O)CCCN2CCCC2,,,,,,
8439,43134,4'-Methylsulfonyl-4-(1-pyrrolidinyl)butyrophenone,CS(=O)(=O)C1=CC=C(C=C1)C(=O)CCCN2CCCC2,,,,,,
8440,43135,4'-Phenyl-4-(pyrrolidinyl)butyrophenone,C1CCN(C1)CCCC(=O)C2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
8441,43136,4-(Pyrrolidinyl)-2'-butyronaphthone hydrochloride,C1CC[NH+](C1)CCCC(=O)C2=CC3=CC=CC=C3C=C2.[Cl-],,,,,,
8442,43137,1-Naphthalen-2-yl-4-pyrrolidin-1-ylbutan-1-one,C1CCN(C1)CCCC(=O)C2=CC3=CC=CC=C3C=C2,,,,,,
8443,43138,CID 43138,C1CC[NH+](C1)CCCC(=O)C2=CC3=C(C=C2)OCCO3.C(=CC(=O)[O-])C(=O)O,,,,,,
8444,43139,"1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-4-pyrrolidin-1-ylbutan-1-one",C1CCN(C1)CCCC(=O)C2=CC3=C(C=C2)OCCO3,,,,,,
8445,43140,"1-Butanone, 1-(4-pyridyl)-4-(1-pyrrolidinyl)-, citrate",C1CC[NH+](C1)CCCC(=O)C2=CC=NC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
8446,43141,1-(4-Pyridinyl)-4-(1-pyrrolidinyl)-1-butanone,C1CCN(C1)CCCC(=O)C2=CC=NC=C2,,,,,,
8447,43142,"4-(2,5-Dimethylpyrrolidinyl)-4'-fluorobutyrophenone hydrochloride",CC1CCC([NH+]1CCCC(=O)C2=CC=C(C=C2)F)C.[Cl-],,,,,,
8448,43143,"4-(2,5-Dimethylpyrrolidin-1-yl)-1-(4-fluorophenyl)butan-1-one",CC1CCC(N1CCCC(=O)C2=CC=C(C=C2)F)C,,,,,,
8449,43144,4'-Fluoro-4-(2-oxo(1-pyrrolidinyl))butyrophenone,C1CC(=O)N(C1)CCCC(=O)C2=CC=C(C=C2)F,,,,,,
8450,43145,Diazinon mixt. with Methoxychlor,CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C.COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,,,,,,
8451,43146,"Butyramide, N-(2-fluorenyl)-",CCCC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
8452,43147,N-2-Fluorenylsuccinamic acid,C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)CCC(=O)O,,,,,,
8453,43148,"2H-1,2,4-Benzothiadiazine, 7-chloro-3-(4-methyl-1-piperazinyl)-, 1,1-dioxide",CN1CCN(CC1)C2=NS(=O)(=O)C3=C(N2)C=CC(=C3)Cl,,,,,,
8454,43149,Pamatolol sulfate,CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)OC)O.CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)OC)O.OS(=O)(=O)O,,,,,,
8455,43150,Pamatolol,CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)OC)O,,,,,,
8456,43151,"BENZO(c)PHENANTHRENE, 5-ETHYL-",CCC1=CC2=C(C3=CC=CC=C3C=C2)C4=CC=CC=C41,,,,,,
8457,43152,3-[4-(Dimethylaminodiazenyl)phenyl]prop-2-enoic acid,CN(C)N=NC1=CC=C(C=C1)C=CC(=O)O,,,,,,
8458,43153,"7-Oxabicyclo(2.2.1)hept-5-ene-2,3-dicarboxylic acid, dipotassium salt",C1=CC2C(C(C1O2)C(=O)[O-])C(=O)[O-].[K+].[K+],,,,,,
8459,43154,"7-Oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid",C1=CC2C(C(C1O2)C(=O)O)C(=O)O,,,,,,
8460,43155,N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)butanesulfonamide methanesulfonate,CCCCS(=O)(=O)NC1=CC(=C(C=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42)OC.CS(=O)(=O)[O-],,,,,,
8461,43156,N-[4-(9-Acridinylamino)-3-methoxyphenyl]-1-butanesulfonamide,CCCCS(=O)(=O)NC1=CC(=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42)OC,,,,,,
8462,43157,Eniluracil,C#CC1=CNC(=O)NC1=O,['For the treatment of cancer in combination with 5-fluorouracil.'],"['Eniluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU).']",['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
8463,43158,"(5R,6R)-3-(2-aminoethylsulfanyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",C[C@H]([C@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN)O,,,,,,
8464,43159,1-(2-Aminoethyl) 2-sulfohexadecanoate,CCCCCCCCCCCCCCC(C(=O)OCCN)S(=O)(=O)O,,,,,,
8465,43160,1-(2-(2-Aminoethoxy)ethyl) 2-sulfododecanoate,CCCCCCCCC(C(=O)OCCOCCN)S(=O)(=O)O,,,,,,
8466,43161,1-(2-(2-Aminoethoxy)ethyl) 2-sulfohexadecanoate,CCCCCCCCCCCCCCC(C(=O)OCCOCCN)S(=O)(=O)O,,,,,,
8467,43162,1-(2-(Methylamino)ethyl) 2-sulfododecanoate,CCCCCCCCCCC(C(=O)OCCNC)S(=O)(=O)O,,,,,,
8468,43163,1-(2-(Dimethylamino)ethyl) 2-sulfododecanoate,CCCCCCCCCCC(C(=O)OCCN(C)C)S(=O)(=O)O,,,,,,
8469,43164,1-(2-(Trimethylamino)ethyl) 2-sulfohexadecanoate,CCCCCCCCCCCCCCC(C(=O)OCC[N+](C)(C)C)S(=O)(=O)[O-],,,,,,
8470,43165,Trimethyl-[2-(2-sulfohexadecanoyloxy)ethyl]azanium,CCCCCCCCCCCCCCC(C(=O)OCC[N+](C)(C)C)S(=O)(=O)O,,,,,,
8471,43166,"3,8-Bis((diethylamino)methyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione",CCN(CC)CC1CC2(CC(OC2=O)CN(CC)CC)C(=O)O1,,,,,,
8472,43167,"3,8-Bis(1-piperidinylmethyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione",C1CCN(CC1)CC2CC3(CC(OC3=O)CN4CCCCC4)C(=O)O2,,,,,,
8473,43168,"3,8-Bis(4-morpholinylmethyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione",C1COCCN1CC2CC3(CC(OC3=O)CN4CCOCC4)C(=O)O2,,,,,,
8474,43169,"1,2-Bis(4-(2-chloroethyl)-1-piperazinyl)ethane tetrahydrochloride",C1CN(CCN1CCN2CCN(CC2)CCCl)CCCl.Cl.Cl.Cl.Cl,,,,,,
8475,43170,1-(2-Chloroethyl)-4-[2-[4-(2-chloroethyl)piperazin-1-yl]ethyl]piperazine,C1CN(CCN1CCN2CCN(CC2)CCCl)CCCl,,,,,,
8476,43171,"Ethanol, 2,2',2''-nitrilotri-, cyclic phosphorothioate (1:1)",C1COP2(=S)OCCN1CCO2,,,,,,
8477,43172,"N-(2,2,2-Trichloro-1-morpholinoethyl)formamide",C1COCCN1C(C(Cl)(Cl)Cl)NC=O,,,,,,
8478,43173,N-(2-Aminoethyl)-3-hydroxynaphthalene-2-carboxamide monohydrochloride,C1=CC=C2C=C(C(=CC2=C1)C(=O)NCC[NH3+])O.[Cl-],,,,,,
8479,43174,"2-Naphthalenecarboxamide, N-(2-aminoethyl)-3-hydroxy-",C1=CC=C2C=C(C(=CC2=C1)C(=O)NCCN)O,,,,,,
8480,43175,"Glycine, N,N-bis(carboxymethyl)-, calcium sodium salt (1:1:1)",C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Ca+2],,,,,,
8481,43176,2-Chloro-4-nonylphenol,CCCCCCCCCC1=CC(=C(C=C1)O)Cl,,,,,,
8482,43177,CID 43177,COC1=C(C=C(C=C1)C=C2C(=O)NC(=NC2=O)S)OC,,,,,,
8483,43178,Dimethyl(m-hydroxyphenyl)octylammonium iodide,CCCCCCCC[N+](C)(C)C1=CC(=CC=C1)O.[I-],,,,,,
8484,43179,(3-Hydroxyphenyl)-dimethyl-octylazanium,CCCCCCCC[N+](C)(C)C1=CC(=CC=C1)O,,,,,,
8485,43180,Dimethyl(m-hydroxyphenyl)octyloxymethylammonium chloride,CCCCCCCCOC[N+](C)(C)C1=CC(=CC=C1)O.[Cl-],,,,,,
8486,43181,(3-Hydroxyphenyl)-dimethyl-(octoxymethyl)azanium,CCCCCCCCOC[N+](C)(C)C1=CC(=CC=C1)O,,,,,,
8487,43182,"(2,1,3-Benzothia(S IV)diazol-4-yl)trimethylammonium iodide",C[N+](C)(C)C1=CC=CC2=NSN=C21.[I-],,,,,,
8488,43183,"2,1,3-Benzothiadiazol-4-yl(trimethyl)azanium",C[N+](C)(C)C1=CC=CC2=NSN=C21,,,,,,
8489,43184,"(2,1,3-Benzothia(S IV)diazol-5-yl)trimethylammonium iodide",C[N+](C)(C)C1=CC2=NSN=C2C=C1.[I-],,,,,,
8490,43185,"2,1,3-Benzothiadiazol-5-yl(trimethyl)azanium",C[N+](C)(C)C1=CC2=NSN=C2C=C1,,,,,,
8491,43186,"6-Amino-1-formyl-5-hydroxy-1,3-cyclohexadiene",C1=C[C@@H]([C@H](C(=C1)C=O)N)O,,,,,,
8492,43187,o-Chlorophenyl 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole acetate,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4=CC=CC=C4Cl,,,,,,
8493,43188,"1H-Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-, m-chlorophenyl ester",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4=CC(=CC=C4)Cl,,,,,,
8494,43189,"CARBONIC ACID, HEXYL p-IODOPHENYL ESTER",CCCCCCOC(=O)OC1=CC=C(C=C1)I,,,,,,
8495,43190,2-(p-Iodobenzyl)-1-butanol,CCC(CC1=CC=C(C=C1)I)CO,,,,,,
8496,43191,"Acetanilide, 3'-(hydroxymethyl)-2',4',6'-triiodo-",CC(=O)NC1=C(C=C(C(=C1I)CO)I)I,,,,,,
8497,43192,"CARBONIC ACID, p-IODOPHENYL OCTYL ESTER",CCCCCCCCOC(=O)OC1=CC=C(C=C1)I,,,,,,
8498,43193,"CARBONIC ACID, ETHYL p-IODOBENZYL ESTER",CCOC(=O)OCC1=CC=C(C=C1)I,,,,,,
8499,43194,"CARBONIC ACID, p-IODOBENZYL ISOBUTYL ESTER",CC(C)COC(=O)OCC1=CC=C(C=C1)I,,,,,,
8500,43195,(4-Iodophenyl)methyl 2-methoxyethyl carbonate,COCCOC(=O)OCC1=CC=C(C=C1)I,,,,,,
8501,43196,"CARBONIC ACID, p-IODOBENZYL PENTYL ESTER",CCCCCOC(=O)OCC1=CC=C(C=C1)I,,,,,,
8502,43197,"CARBONIC ACID, HEXYL p-IODOBENZYL ESTER",CCCCCCOC(=O)OCC1=CC=C(C=C1)I,,,,,,
8503,43198,"CARBONIC ACID, 1-ETHYLBUTYL p-IODOBENZYL ESTER",CCCC(CC)OC(=O)OCC1=CC=C(C=C1)I,,,,,,
8504,43199,"1,3-Dimethylbutyl p-iodobenzyl carbonate",CC(C)CC(C)OC(=O)OCC1=CC=C(C=C1)I,,,,,,
8505,43200,"Carbonic acid, 2-ethylhexyl (4-iodophenyl)methyl ester",CCCCC(CC)COC(=O)OCC1=CC=C(C=C1)I,,,,,,
8506,43201,Carbonic acid 2-ethoxycarbonyl-1-methylethyl 4-iodobenzyl ester,CCOC(=O)CC(C)OC(=O)OCC1=CC=C(C=C1)I,,,,,,
8507,43202,"CARBONIC ACID, ETHYL p-IODOPHENETHYL ESTER",CCOC(=O)OCCC1=CC=C(C=C1)I,,,,,,
8508,43203,"CARBONIC ACID, HEXYL p-IODOPHENETHYL ESTER",CCCCCCOC(=O)OCCC1=CC=C(C=C1)I,,,,,,
8509,43204,Ethyl 3-(4-iodophenyl)propyl carbonate,CCOC(=O)OCCCC1=CC=C(C=C1)I,,,,,,
8510,43205,"CARBONIC ACID, HEXYL 3-(p-IODOPHENYL)PROPYL ESTER",CCCCCCOC(=O)OCCCC1=CC=C(C=C1)I,,,,,,
8511,43206,3-(p-Iodophenyl)-1-butanol,CC(CCO)C1=CC=C(C=C1)I,,,,,,
8512,43207,Carbonic acid ethyl 3-(p-iodophenyl)butyl ester,CCOC(=O)OCCC(C)C1=CC=C(C=C1)I,,,,,,
8513,43208,Carbonic acid 3-(p-iodophenyl)-3-methylpropyl isopropyl ester,CC(C)OC(=O)OCCC(C)C1=CC=C(C=C1)I,,,,,,
8514,43209,"CARBONIC ACID, HEXYL 3-(p-IODOPHENYL)BUTYL ESTER",CCCCCCOC(=O)OCCC(C)C1=CC=C(C=C1)I,,,,,,
8515,43210,Ethyl 2-[(4-iodophenyl)methyl]butyl carbonate,CCC(CC1=CC=C(C=C1)I)COC(=O)OCC,,,,,,
8516,43211,"Carbonic acid, butyl 3-(p-iodophenyl)propyl ester",CCCCOC(=O)OCC(CC)CC1=CC=C(C=C1)I,,,,,,
8517,43212,"Carbonic acid, 3,5-diiodobenzyl hexyl ester",CCCCCCOC(=O)OCC1=CC(=CC(=C1)I)I,,,,,,
8518,43213,"2-(2,3-Dihydroxy-4-methylcyclopentyl)-1,3-thiazole-4-carboxamide",CC1CC(C(C1O)O)C2=NC(=CS2)C(=O)N,,,,,,
8519,43214,Clopipazan mesylate,CN1CCC(=C2C3=CC=CC=C3OC4=C2C=C(C=C4)Cl)CC1.CS(=O)(=O)O,,,,,,
8520,43215,Clopipazan,CN1CCC(=C2C3=CC=CC=C3OC4=C2C=C(C=C4)Cl)CC1,,,,,,
8521,43216,Dihydroalprenolol,CCCC1=CC=CC=C1OCC(CNC(C)C)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)']",,,
8522,43217,Cino-bufotoxin,CC(=O)O[C@@H]1[C@@H]([C@]2(CCC3C([C@@]24[C@@H]1O4)CC[C@H]5[C@@]3(CC[C@@H](C5)OC(=O)CCCCCCC(=O)NC(CCCN=C(N)N)C(=O)O)C)C)C6=CC(=O)OC=C6,,,,,,
8523,43218,"2,2',4,4',5-Pentachlorodiphenyl ether",C1=CC(=C(C=C1Cl)Cl)OC2=CC(=C(C=C2Cl)Cl)Cl,,,,,,
8524,43219,"2,3',4,4',5-Pentachlorodiphenyl ether",C1=CC(=C(C=C1OC2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl,,,,,,
8525,43220,"(4R,8S,12R,19S)-8-(2,2-dimethoxyacetyl)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC1(O[C@@H]2CC3C4C[C@@H](C5=CC(=O)C=CC5([C@]4(C(CC3([C@@]2(O1)C(=O)C(OC)OC)C)O)F)C)F)C,,,,,,
8526,43221,"1-(4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-isopropylpyrimidine-2,4(1H,3H)-dione",CC(C)C1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,,,,,,
8527,43222,"2,6-Dimethylheptanoic acid",CC(C)CCCC(C)C(=O)O,,,,,,
8528,43223,5-Methoxy-3-(4-piperidinyl)-1H-indole hydrochloride,COC1=CC2=C(C=C1)NC=C2C3CC[NH2+]CC3.[Cl-],,,,,,
8529,43224,5-methoxy-3-piperidin-4-yl-1H-indole,COC1=CC2=C(C=C1)NC=C2C3CCNCC3,,,,,,
8530,43225,"1,3-Dithiolane, 2,2'-ethylenebis(2-methyl-",CC1(SCCS1)CCC2(SCCS2)C,,,,,,
8531,43226,Fenarimol,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)(C3=CN=CN=C3)O)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']",,,
8532,43227,"Acetophenone, 2'-(2-piperidinoethoxy)-",CC(=O)C1=CC=CC=C1OCCN2CCCCC2,,,,,,
8533,43228,((p-Chlorophenyl)azo)cyanoacetic acid ethyl ester,CCOC(=O)C(C#N)N=NC1=CC=C(C=C1)Cl,,,,,,
8534,43229,CID 43229,CCC(COCCOC1=C(C=C(C(=C1I)NC(=O)C)I)I)C(=O)[O-].[Na+],,,,,,
8535,43230,((p-Chlorophenyl)azo)cyanoacetic acid methyl ester,COC(=O)C(C#N)N=NC1=CC=C(C=C1)Cl,,,,,,
8536,43231,Clorsulon,C1=C(C(=CC(=C1N)S(=O)(=O)N)S(=O)(=O)N)C(=C(Cl)Cl)Cl,,,"['Agents used to treat cestode, trematode, or other flatworm infestations in man or animals. (See all compounds classified as Antiplatyhelmintic Agents.)', 'Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)']",,,
8537,43232,"3-hydroxy-2-phenylpropanoic acid [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] ester",CC(C)[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,,,,,,
8538,43233,Azaconazole,C1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,,,,,,
8539,43234,Propiconazole,CCCC1COC(O1)(CN2C=NC=N2)C3=C(C=C(C=C3)Cl)Cl,,,,"['After oral administration to rats, propiconazole is rapidly absorbed and also rapidly and almost completely eliminated with urine and feces. Residues in tissues were generally low and there was no evidence for accumulation or retention of propiconazole or its metabolites.', 'Male and female mice were fed a diet containing 5, 100 and 2500 ppm propiconazole for 21 days, followed by a single oral dose of (14C)-phenyl propiconazole at a mean corresponding dose level (0.8/1.0, 16.8/21.5 and 434/475 mg/kg bw for males/females). Urinary excretion accounted for 45-81% of the administered dose after 96 hours and tended to be higher by males than by females. In the feces 22-43% was excreted. At the lowest dose level (5 ppm propiconazole) the residual radioactivity in blood, liver, kidneys, lungs and in the remaining carcass was below 0.02 mg/kg propiconazole equivalents and accordingly higher at the 100 and 2500 ppm dose level. Residues in female mice were higher than in male mice, except in the kidneys where the males showed higher or equal values. Independent of the dose level and sex of the animals, the highest residues were found in the liver, up to 2.3 and 3.0 mg/kg in males and females of the highest dose level, respectively.', 'Orally administered single doses (0.5 and 25 mg/kg bw) of triazole labelled (3,5-14C)-propiconazole to rats were rapidly excreted within 24 hours (74-84%). After 6 days, 0.04-0.15%, 28-46% and 53-67% had been recovered from expired air, feces and urine respectively. Only about 0.4% of the administered dose remained in the tissues. Highest tissue residues were found in liver, blood and kidneys. No unchanged propiconazole was excreted in the urine. Within 3 days after treatment of male rats with a single oral dose of about 32 mg/kg bw of triazole labelled (3,5-14C)-propiconazole or a phenyl-(U-14C) labelled propiconazole, more than 95% of the dose was excreted. Of this, 52% was found in the urine and 43-48% in the feces. The excretion pattern for both compounds was identical with no administered compound being found in the urine.', 'Single doses of triazole-14C-propiconazole (1.0 and 10.0 mg/kg bw) applied dermally to rats were absorbed through the skin following first order kinetics with half-lives averaging 24-31 hours for low and high dosed rats, respectively. Equal amounts of the dose were excreted within 72 hours in urine and feces. The amount of residual radioactivity on the skin averaged 20% of the applied dose.', 'Feed consumption, milk production or the general health of a lactating goat were not affected after the daily oral administration of 5 mg triazole-14C-propiconazole for 10 consecutive days (which would correspond to 4.5 ppm in the feed). Of the total dose, 89% was excreted within 24 hours after the last administration (68% and 21% in urine and feces, respectively). All tissues contained less than 0.02 mg/kg propiconazole equivalents, except liver (0.096 mg/kg) and kidney (0.029 mg/kg). The total radioactivity secreted with the milk reached a plateau at day three of 0.013-0.016 mg/kg, representing 0.18% of the total dose.']","['The metabolism of orally administered (14C)-phenyl propiconazole was studied in mice pretreated with unlabeled propiconazole followed by a single oral dose of (14C)-phenyl propiconazole at a corresponding dose level. The urinary metabolite pattern of propiconazole demonstrated a marked sex dependency. In male mice, 60% of the radioactivity in 0-24 hour urine was represented by one metabolite, this metabolite accounted for 30% in the 0-24 hour urine in female mice. This metabolite was identified by spectroscopy as the glucuronic acid conjugate of 1-(2,4-dichlorophenyl)-2-(1 H-1,2,4-triazol-1-yl) ethanol. This demonstrates that the major metabolic pathway in mice involves dioxolane ring cleavage.', 'The metabolism of propiconazole was investigated in male rats administered a single oral dose of 31.4 mg/kg triazole-(3,5-14C-propiconazole). Metabolites were isolated from first day urine and feces excretion representing 44.5% and 36.2% of the applied dose, respectively. A wide array of biotransformations occurred leading to numerous metabolites. The major site of enzymatic attack oxidation of the propyl side chain leading via alcohols and diols to carboxy acids and alpha-hydroxy carboxy acid or cleavage of the dioxolane ring. The majority of the alcoholic and phenolic metabolites are renally excreted as sulfuric acid and glucuronic acid conjugates. In the rat the main metabolite is the alpha hydroxyl carboxylic acid of propiconazole.', '/In rats/...the major sites of enzymic attack are the propyl side-chain and the cleavage of the dioxolane ring, together with some attack at the 2,4-dichlorophenyl and 1,2,4-triazole rings. In mice, the major metabolic pathway is via cleavage of the dioxolane ring.']",['Half-live averages 24-31 hours /in rats/.']
8540,43235,"Capramide, 2,6-diamino-n-hexadecyl-",CCCCCCCCCCCCCCCCNC(=O)C(CCCCN)N,,,,,,
8541,43236,"3,5-Dichlorobenzyl alcohol",C1=C(C=C(C=C1Cl)Cl)CO,,,,,,
8542,43237,"3,6,11,14-Tetramethoxydibenzo(g,p)chrysene",COC1=CC2=C3C4=C(C=CC(=C4)OC)C5=C(C3=C6C=C(C=CC6=C2C=C1)OC)C=C(C=C5)OC,,,,,,
8543,43238,"2,2',3,4',6'-Pentachlorobiphenyl",C1=CC(=C(C(=C1)Cl)Cl)C2=C(C=C(C=C2Cl)Cl)Cl,,,,,,
8544,43239,"(3,4-Dichloro-5-methylsulfanylphenoxy)-diethoxy-sulfanylidene-lambda5-phosphane",CCOP(=S)(OCC)OC1=CC(=C(C(=C1)Cl)Cl)SC,,,,,,
8545,43240,"(R*,R*)-N-(4-(1,2-Dihydroxy-2-phenylethyl)phenyl)acetamide",CC(=O)NC1=CC=C(C=C1)C(C(C2=CC=CC=C2)O)O,,,,,,
8546,43241,"Nonanoic acid, 9-chloro-8-oxo-",C(CCCC(=O)O)CCC(=O)CCl,,,,,,
8547,43242,5-Hydroxymebendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(C3=CC=CC=C3)O,,,,,,
8548,43243,"o-Mentha-1,4-diene",CC1=C(CC=CC1)C(C)C,,,,,,
8549,43244,"trans-Anti-benzo(A)pyrene-7,8-diol-9,10-oxide",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C6C(O6)[C@@H]([C@H]5O)O)C=C2,,,,,,
8550,43245,"trans-syn-Benzo(a)pyrene-7,8-diol-9,10-oxide",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C6C(O6)[C@H]([C@H]5O)O)C=C2,,,,,,
8551,43246,"Benzoic acid, 2-benzoyl-5-ethyl-",CCC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)C(=O)O,,,,,,
8552,43247,"N-Furfuryl-3,4,5-trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)NCC2=CC=CO2,,,,,,
8553,43248,"Sodium 5-nitro-9,10-dioxo-9,10-dihydroanthracene-1-sulfonate",C1=CC2=C(C(=C1)[N+](=O)[O-])C(=O)C3=C(C2=O)C(=CC=C3)S(=O)(=O)[O-].[Na+],,,,,,
8554,43249,"(17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one",CCC12CCC3C(C1C=C[C@]2(C#C)O)CCC4=CC(=O)CCC34,,,,,,
8555,43250,"3-sec-Butyl-5a,5b,8,8,11a,13b-hexamethyl-eicosahydro-cyclopenta[a]chrysene",CCC(C)C1CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C,,,,,,
8556,43251,CID 43251,CS(=O)(=O)NC(=O)CCCC=CC[C@@H]1[C@H]([C@@H](CC1=O)O)C=C[C@H](COC2=CC=CC=C2)O,,,,,,
8557,43252,N-(Phosphonoacetyl)-L-aspartic acid tetrasodium salt,C([C@@H](C(=O)[O-])NC(=O)CP(=O)([O-])[O-])C(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
8558,43253,"1,1-Bis(3,4-xylyl)-2,2,2-trichloroethane",CC1=C(C=C(C=C1)C(C2=CC(=C(C=C2)C)C)C(Cl)(Cl)Cl)C,,,,,,
8559,43254,"Dibenzo[b,k]fluoranthene",C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC5=C4C3=CC6=CC=CC=C56,,,,,,
8560,43255,"2,6-Dichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C=C(C=C3)Cl,,,,,,
8561,43256,Carboxymethylnitrosourea,C(C(=O)O)N(C(=O)N)N=O,,,,,,
8562,43257,"Ammonium, (3-(N-methylcarbamoyloxy)phenyl)diethylmethyl-, iodide",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)NC.[I-],,,,,,
8563,43258,"N,N-Diethyl-N-methyl-3-[[(methylamino)carbonyl]oxy]benzenaminium",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)NC,,,,,,
8564,43259,"beta-(2,5-Dimethoxyphenyl)-beta-hydroxyethylamine hydrochloride",COC1=CC(=C(C=C1)OC)C(C[NH3+])O.[Cl-],,,,,,
8565,43260,Desglymidodrine,COC1=CC(=C(C=C1)OC)C(CN)O,,,,,,
8566,43261,Amiprilose hydrochloride,CC1(O[C@@H]2[C@H]([C@H](O[C@@H]2O1)C(CO)O)OCCCN(C)C)C.Cl,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
8567,43262,Sdccgsbi-0050036.P004,CC1(O[C@@H]2[C@H]([C@H](O[C@@H]2O1)C(CO)O)OCCCN(C)C)C,,,,,,
8568,43263,2-Pentyl butyrate,CCCC(C)OC(=O)CCC,,,,,,
8569,43264,"2-Methoxy-5-(2',3',4'-trimethoxyphenyl)tropone",COC1=C(C(=C(C=C1)C2=CC=C(C(=O)C=C2)OC)OC)OC,,,['Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)'],,,
8570,43265,"2-Morpholino-1-methylethyl-3,4,5-trimethoxybenzoate",CC(CN1CCOCC1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
8571,43266,"Benzoic acid, 3,4,5-trimethoxy-, 1-methyl-3-morpholinopropyl ester",CC(CCN1CCOCC1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
8572,43267,"Benzoic acid, 3,4,5-trimethoxy-, 3-morpholinopropyl ester",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCN2CCOCC2,,,,,,
8573,43268,"3,5-Dichloro-N-cyclopropyl-4-(methylamino)benzamide",CNC1=C(C=C(C=C1Cl)C(=O)NC2CC2)Cl,,,,,,
8574,43269,"BENZAMIDE, o-BUTOXY-",CCCCOC1=CC=CC=C1C(=O)N,,,,,,
8575,43270,"Benzo(a)pyrene-11,12-epoxide",C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6C(C5=CC=C4)O6,,,,,,
8576,43271,(2-Butynyl)trimethylammonium iodide,CC#CC[N+](C)(C)C.[I-],,,,,,
8577,43272,But-2-ynyl(trimethyl)azanium,CC#CC[N+](C)(C)C,,,,,,
8578,43273,"Carbamic acid, isopentyl-, 2-chloroethyl ester",CC(C)CCNC(=O)OCCCl,,,,,,
8579,43274,"Carbamic acid, butyl-, 2-chloroethyl ester",CCCCNC(=O)OCCCl,,,,,,
8580,43275,"2-Hydroxy-3-methyl-2-phenylbutyric acid, 3-(dimethylamino)propyl ester hydrochloride",CC(C)C(C1=CC=CC=C1)(C(=O)OCCC[NH+](C)C)O.[Cl-],,,,,,
8581,43276,3-(Dimethylamino)propyl 2-hydroxy-3-methyl-2-phenylbutanoate,CC(C)C(C1=CC=CC=C1)(C(=O)OCCCN(C)C)O,,,,,,
8582,43277,CID 43277,CCCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C.C(=CC(=O)O)C(=O)O,,,,,,
8583,43278,CID 43278,CCCC(=NO)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C.Cl,,,,,,
8584,43279,CID 43279,CCCC(=NO)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C,,,,,,
8585,43280,"Carbamic acid, (4-nitrophenyl)-, 2-chloroethyl ester",C1=CC(=CC=C1NC(=O)OCCCl)[N+](=O)[O-],,,,,,
8586,43281,"Carbamic acid, (3-morpholinopropyl)-, 2-chloroethyl ester",C1COCCN1CCCNC(=O)OCCCl,,,,,,
8587,43282,"Carbamic acid, (3-isopropoxypropyl)-, 2-chloroethyl ester",CC(C)OCCCNC(=O)OCCCl,,,,,,
8588,43283,"1'-Ethyl-4'-(N-ethyl-2''-phenylethylamino)butyl-3,4,5-trimethoxybenzoate hydrochloride",CCC(CCC[NH+](CC)CCC1=CC=CC=C1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC.[Cl-],,,,,,
8589,43284,"3,4,5-Trimethoxybenzoic acid 4-[ethyl(phenethyl)amino]-1-ethylbutyl ester",CCC(CCCN(CC)CCC1=CC=CC=C1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
8590,43285,N-Ethyl-N-(4'-hydroxybutyl)-5-benzyloxytryptamine hydrochloride,CC[NH+](CCCCO)CCC1=CNC2=C1C=C(C=C2)OCC3=CC=CC=C3.[Cl-],,,,,,
8591,43286,4-[ethyl-[2-(5-phenylmethoxy-1H-indol-3-yl)ethyl]amino]butan-1-ol,CCN(CCCCO)CCC1=CNC2=C1C=C(C=C2)OCC3=CC=CC=C3,,,,,,
8592,43287,N-Ethyl-N-(4'-acetoxybutyl)-5-methoxytryptamine hydrochloride,CC[NH+](CCCCOC(=O)C)CCC1=CNC2=C1C=C(C=C2)OC.[Cl-],,,,,,
8593,43288,4-[ethyl-[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]butyl acetate,CCN(CCCCOC(=O)C)CCC1=CNC2=C1C=C(C=C2)OC,,,,,,
8594,43289,N-Ethyl-N-(4'-hydroxybutyl)-5-methoxytryptamine hydrochloride,CC[NH+](CCCCO)CCC1=CNC2=C1C=C(C=C2)OC.[Cl-],,,,,,
8595,43290,4-[ethyl-[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]butan-1-ol,CCN(CCCCO)CCC1=CNC2=C1C=C(C=C2)OC,,,,,,
8596,43291,CID 43291,[Li+].[B-]1(C2=CC=CC=C2C3=CC=CC=C3O1)(O)O,,,,,,
8597,43292,"9,9-Dihydroxy-8-oxa-9-boranuidatricyclo[8.4.0.02,7]tetradeca-1(14),2,4,6,10,12-hexaene",[B-]1(C2=CC=CC=C2C3=CC=CC=C3O1)(O)O,,,,,,
8598,43293,CID 43293,[B-]1(C2=CC=CC=C2C3=CC=CC=C3O1)(O)O.[K+],,,,,,
8599,43294,"Carbanilic acid, o-propoxy-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8600,43295,2-(azepan-1-yl)ethyl N-(2-propoxyphenyl)carbamate,CCCOC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
8601,43296,Dixyrazine dihydrochloride,CC(CN1CCN(CC1)CCOCCO)CN2C3=CC=CC=C3SC4=CC=CC=C42.Cl.Cl,,,,,,
8602,43297,Nitroindole,C1=CC=C2C(=C1)C=C(N2)[N+](=O)[O-],,,,,,
8603,43298,N-cyclopropyl-3-(4-fluorophenyl)-2-methylbut-2-enamide,CC(=C(C)C(=O)NC1CC1)C2=CC=C(C=C2)F,,,,,,
8604,43299,3-(4-chlorophenyl)-N-cyclopropyl-2-methylbut-2-enamide,CC(=C(C)C(=O)NC1CC1)C2=CC=C(C=C2)Cl,,,,,,
8605,43300,3-(4-bromophenyl)-N-cyclopropyl-2-methylbut-2-enamide,CC(=C(C)C(=O)NC1CC1)C2=CC=C(C=C2)Br,,,,,,
8606,43301,3-(4-fluorophenyl)-2-methyl-N-prop-2-enylbut-2-enamide,CC(=C(C)C(=O)NCC=C)C1=CC=C(C=C1)F,,,,,,
8607,43302,CID 43302,CC(=C(C)C(=O)NCC=C)C1=CC=C(C=C1)Cl,,,,,,
8608,43303,3-(4-bromophenyl)-2-methyl-N-prop-2-enylbut-2-enamide,CC(=C(C)C(=O)NCC=C)C1=CC=C(C=C1)Br,,,,,,
8609,43304,2-methyl-3-(4-methylphenyl)-N-prop-2-enylbut-2-enamide,CC1=CC=C(C=C1)C(=C(C)C(=O)NCC=C)C,,,,,,
8610,43305,CID 43305,CC(=C(C)C(=O)NCC=C)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
8611,43306,3-(4-fluorophenyl)-2-methyl-N-prop-2-ynylbut-2-enamide,CC(=C(C)C(=O)NCC#C)C1=CC=C(C=C1)F,,,,,,
8612,43307,CID 43307,CC(=C(C)C(=O)NCC#C)C1=CC=C(C=C1)Cl,,,,,,
8613,43308,CID 43308,CC(=C(C)C(=O)NCC#C)C1=CC=C(C=C1)Br,,,,,,
8614,43309,"2-methyl-N-prop-2-ynyl-3-(3,4,5-trimethoxyphenyl)but-2-enamide",CC(=C(C)C(=O)NCC#C)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
8615,43310,"2-Butenamide, N-cyclopropyl-3-(4-methoxyphenyl)-2-methyl-, (E)-",CC(=C(C)C(=O)NC1CC1)C2=CC=C(C=C2)OC,,,,,,
8616,43311,3-(4-methoxyphenyl)-2-methyl-N-prop-2-enylbut-2-enamide,CC(=C(C)C(=O)NCC=C)C1=CC=C(C=C1)OC,,,,,,
8617,43312,"Formamide, cyclobutyl-N-(2-fluorenyl)-",C1CC(C1)C(=O)NC2=CC3=C(C=C2)C4=CC=CC=C4C3,,,,,,
8618,43313,"Acetamide, N-(2-fluorenyl)-2,2,2-trichloro-",C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)C(Cl)(Cl)Cl,,,,,,
8619,43314,"Acetamide, N-(2-fluorenyl)-2-methoxy-",COCC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
8620,43315,"2-Fluorenecarbamic acid, methyl ester",COC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
8621,43316,"Carbamic acid, N-(2-fluorenyl)-, phenyl ester",C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)OC4=CC=CC=C4,,,,,,
8622,43317,N-(9H-fluoren-2-yl)cyclopropanecarboxamide,C1CC1C(=O)NC2=CC3=C(C=C2)C4=CC=CC=C4C3,,,,,,
8623,43318,"Acrylamide, N-(fluoren-2-YL)-",C=CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
8624,43319,"Acrylamide, N-(2-fluorenyl)-2-methyl-",CC(=C)C(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
8625,43320,N-(9H-fluoren-2-yl)but-2-enamide,CC=CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
8626,43321,N-(2-Fluorenyl)-4-biphenylcarboxamide,C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)C4=CC=C(C=C4)C5=CC=CC=C5,,,,,,
8627,43322,"Carbanilic acid, m-propoxy-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8628,43323,2-(azepan-1-yl)ethyl N-(3-propoxyphenyl)carbamate,CCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCCC2,,,,,,
8629,43324,"Carbanilic acid, p-propoxy-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8630,43325,2-(azepan-1-yl)ethyl N-(4-propoxyphenyl)carbamate,CCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCCC2,,,,,,
8631,43326,"Carbanilic acid, o-butoxy-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8632,43327,N-[2-Butoxyphenyl]carbamic acid 2-[(hexahydro-1H-azepin)-1-yl]ethyl ester,CCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
8633,43328,"Carbanilic acid, m-butoxy-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8634,43329,2-(azepan-1-yl)ethyl N-(3-butoxyphenyl)carbamate,CCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCCC2,,,,,,
8635,43330,"Carbanilic acid, p-butoxy-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8636,43331,N-[4-Butoxyphenyl]carbamic acid 2-[(hexahydro-1H-azepin)-1-yl]ethyl ester,CCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCCC2,,,,,,
8637,43332,"Carbanilic acid, o-(pentyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8638,43333,2-(azepan-1-yl)ethyl N-(2-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
8639,43334,"Carbanilic acid, m-(pentyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCOC1=CC=CC(=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8640,43335,2-(azepan-1-yl)ethyl N-(3-pentoxyphenyl)carbamate,CCCCCOC1=CC=CC(=C1)NC(=O)OCCN2CCCCCC2,,,,,,
8641,43336,"Carbanilic acid, p-(pentyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCOC1=CC=C(C=C1)NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8642,43337,2-(azepan-1-yl)ethyl N-(4-pentoxyphenyl)carbamate,CCCCCOC1=CC=C(C=C1)NC(=O)OCCN2CCCCCC2,,,,,,
8643,43338,"Carbanilic acid, o-(hexyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8644,43339,2-(azepan-1-yl)ethyl N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
8645,43340,"Carbanilic acid, o-(octyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8646,43341,N-[2-(Octyloxy)phenyl]carbamic acid 2-[(hexahydro-1H-azepin)-1-yl]ethyl ester,CCCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
8647,43342,"Carbanilic acid, o-(heptyloxy)-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCCCCC2.[Cl-],,,,,,
8648,43343,2-(azepan-1-yl)ethyl N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCCCCC2,,,,,,
8649,43344,N'-cyano-N-(3-pyridyl)-N''-(t-butyl)guanidine,CC(C)(C)N=C(NC#N)NC1=CN=CC=C1,,,,,,
8650,43345,"N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine",CCC(C)(C)N=C(NC#N)NC1=CN=CC=C1,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
8651,43346,"Guanidine, 2-cyano-1-(3-pentyl)-3-(3-pyridyl)-",CCC(CC)N=C(NC#N)NC1=CN=CC=C1,,,,,,
8652,43347,"2-Cyano-3-(3-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine",CC(C(C)(C)C)N=C(NC#N)NC1=CN=CC=C1,,,,,,
8653,43348,"GUANIDINE, 3-(5-BROMO-3-PYRIDYL)-1-tert-BUTYL-2-CYANO-",CC(C)(C)N=C(NC#N)NC1=CC(=CN=C1)Br,,,,,,
8654,43349,"GUANIDINE, 1-tert-BUTYL-2-CYANO-3-(6-METHOXY-3-PYRIDYL)-",CC(C)(C)N=C(NC#N)NC1=CN=C(C=C1)OC,,,,,,
8655,43350,"GUANIDINE, 1-tert-BUTYL-2-CYANO-3-(2-PYRIDYL)-",CC(C)(C)N=C(NC#N)NC1=CC=CC=N1,,,,,,
8656,43351,"Guanidine, 2-cyano-1-cyclopentyl-3-(3-pyridyl)-",C1CCC(C1)N=C(NC#N)NC2=CN=CC=C2,,,,,,
8657,43352,"Guanidine, 2-cyano-1-(2-methylallyl)-3-(3-pyridyl)-",CC(=C)CN=C(NC#N)NC1=CN=CC=C1,,,,,,
8658,43353,"GUANIDINE, 2-CYANO-1-tert-PENTYL-3-(4-PYRIDYL)-",CCC(C)(C)N=C(NC#N)NC1=CC=NC=C1,,,,,,
8659,43354,2-Cyano-1-(1-ethylpropyl)-3-(4-pyridyl)guanidine,CCC(CC)N=C(NC#N)NC1=CC=NC=C1,,,,,,
8660,43355,"Guanidine, 2-cyano-1-cyclooctyl-3-(4-pyridyl)-",C1CCCC(CCC1)N=C(NC#N)NC2=CC=NC=C2,,,,,,
8661,43356,"Guanidine, 1-benzyl-2-cyano-3-(4-pyridyl)-",C1=CC=C(C=C1)CN=C(NC#N)NC2=CC=NC=C2,,,,,,
8662,43357,"GUANIDINE, 2-CYANO-1-(tert-PENTYL)-3-(2,4,6-TRIMETHYL-3-PYRIDYL)-",CCC(C)(C)N=C(NC#N)NC1=C(N=C(C=C1C)C)C,,,,,,
8663,43358,2-Phenyl-N-(o-tolyl)glycine,CC1=CC=CC=C1NC(C2=CC=CC=C2)C(=O)O,,,,,,
8664,43359,Furmecyclox,CC1=CC(=C(O1)C)C(=O)N(C2CCCCC2)OC,,,,,,
8665,43360,1-Ethylpyrrolidin-3-yl cyclopentyl(hydroxy)phenylacetate hydrochloride,CC[NH+]1CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
8666,43361,(1-Ethylpyrrolidin-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate,CCN1CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
8667,43362,Ibotenic acid hydrate,C1=C(ONC1=O)C(C(=O)O)N.O,,,,,,
8668,43363,"3-(1,3-Dithiolan-2-yl)-1,7,7-trimethylbicyclo(2.2.1)heptan-2-one",CC1(C2CCC1(C(=O)C2C3SCCS3)C)C,,,,,,
8669,43364,"3,4-Dihydro-2-(1,3-dithiolan-2-yl)-1(2H)-naphthalenone",C1CC2=CC=CC=C2C(=O)C1C3SCCS3,,,,,,
8670,43365,Metoxadiazone,COC1=CC=CC=C1N2C(=O)OC(=N2)OC,,,,,,
8671,43366,"2,5,8-Trimethyl-4H-1-benzopyran-4-one",CC1=C2C(=O)C=C(OC2=C(C=C1)C)C,,,,,,
8672,43367,8-((2-Hydroxypropyl)amino)caffeine,CC(CNC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C)O,,,,,,
8673,43368,Trimethylhydrazine hydrochloride,CNN(C)C.Cl,,,,,,
8674,43369,Trimethylhydrazine,CNN(C)C,,,,,,
8675,43370,"2,5-Diamino-4-imino-1(4H)-naphthalenone",C1=CC2=C(C(=C1)N)C(=N)C=C(C2=O)N,,,,,,
8676,43371,N-Nitrosobis(2-oxopropyl)amine,CC(=O)CN(CC(=O)C)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
8677,43372,"Ether, bis(2-triethoxysilylethyl)",CCO[Si](CCOCC[Si](OCC)(OCC)OCC)(OCC)OCC,,,,,,
8678,43373,"(9S,14S,17S)-17-hydroxy-10,13-dimethyl-17-propyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CCC[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CCC4=CC(=O)CCC34C)C)O,,,,,,
8679,43374,"1,1,1,3,3,5,7,7,9,11,11,13,15,15,15-Pentadecamethyl-5,9,13-triphenyloctasiloxane",C[Si](C)(C)O[Si](C)(C)O[Si](C)(C1=CC=CC=C1)O[Si](C)(C)O[Si](C)(C2=CC=CC=C2)O[Si](C)(C)O[Si](C)(C3=CC=CC=C3)O[Si](C)(C)C,,,,,,
8680,43375,"Silane, (2-vinyloxyethyl)triethoxy-",CCO[Si](CCOC=C)(OCC)OCC,,,,,,
8681,43376,2-Bromo-4-hydroxy-5-methoxybenzaldehyde,COC1=C(C=C(C(=C1)C=O)Br)O,,,,,,
8682,43377,"ETHYLAMINE, beta-(o-BENZYL-p-CHLOROPHENOXY)-N,N-DIMETHYL-, HYDROCHLORIDE",C[NH+](C)CCOC1=C(C=C(C=C1)Cl)CC2=CC=CC=C2.[Cl-],,,,,,
8683,43378,"2-(2-benzyl-4-chlorophenoxy)-N,N-dimethylethanamine",CN(C)CCOC1=C(C=C(C=C1)Cl)CC2=CC=CC=C2,,,,,,
8684,43379,alpha-(Chloromethyl)phenethyl carbamate,C1=CC=C(C=C1)CC(CCl)OC(=O)N,,,,,,
8685,43380,"N-[4-(dimethylamino)phenyl]-3,4,5-trimethoxybenzamide",CN(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
8686,43381,"Cyclopropanecarboxamide, N-(4-acetyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-",CC(=O)C1(CCN(CC1)CCC2=CC=CC=C2)N(C3=CC=CC=C3)C(=O)C4CC4,,,,,,
8687,43382,Orpanoxin,C1=CC(=CC=C1C2=CC=C(O2)C(CC(=O)O)O)Cl,,,,,,
8688,43383,"cis-9,10-Dihydro-9,10-benzo(a)pyrenediol",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@H](C=C5)O)O)C=C2,,,,,,
8689,43384,"BENZO(a)PYRENE-11,12-DIONE",C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C(=O)C(=O)C5=CC=C4,,,,,,
8690,43385,"trans-Benzo(a)pyrene-11,12-dihydrodiol",C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2[C@H]([C@@H](C5=CC=C4)O)O,,,,,,
8691,43386,Pyridin-1-ium-3-ylmethyl 2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutanoate;chloride,CCC(C)(C(=O)OCC1=C[NH+]=CC=C1)OC2=CC=C(C=C2)CC3=CC=C(C=C3)Cl.[Cl-],,,,,,
8692,43387,Eniclobrate,CCC(C)(C(=O)OCC1=CN=CC=C1)OC2=CC=C(C=C2)CC3=CC=C(C=C3)Cl,,,,,,
8693,43388,CID 43388,CCOCC(OCC)OCC.CCOC1CCCO1,,,,,,
8694,43389,2-Ethoxytetrahydrofuran,CCOC1CCCO1,,,,,,
8695,43390,"1,1,2-Triethoxyethane",CCOCC(OCC)OCC,,,,,,
8696,43391,"2H-(1)Benzothiopyrano(4,3,2-cd)indazole-2-ethanamine, 8-chloro-N,N-diethyl-5-methyl-, N-oxide,monomethanesulfonate",CC[NH+](CC)CCN1C2=C3C(=C(C=C2)C)SC4=C(C3=[N+]1[O-])C=CC(=C4)Cl.CS(=O)(=O)[O-],,,,,,
8697,43392,"2H-(1)Benzothiopyrano(4,3,2-cd)indazole-5-methanol, 8-chloro-2-(2-(diethylamino)ethyl)-, N-oxide, monomethanesulfonate (salt)",CC[NH+](CC)CCN1C2=C3C(=C(C=C2)CO)SC4=C(C3=[N+]1[O-])C=CC(=C4)Cl.CS(=O)(=O)[O-],,,,,,
8698,43393,"(4,4-Dimethyl-3-oxopentyl)trimethylammonium iodide",CC(C)(C)C(=O)CC[N+](C)(C)C.[I-],,,,,,
8699,43394,"(4,4-Dimethyl-3-oxopentyl)-trimethylazanium",CC(C)(C)C(=O)CC[N+](C)(C)C,,,,,,
8700,43395,7-Ethyl-2-piperidinomethyl-1-oxotetrahydronaphthalene hydrochloride,CCC1=CC2=C(CCC(C2=O)C[NH+]3CCCCC3)C=C1.[Cl-],,,,,,
8701,43396,"7-ethyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CCC1=CC2=C(CCC(C2=O)CN3CCCCC3)C=C1,,,,,,
8702,43397,"4-amino-3,5-dichloro-N-cyclopropylbenzamide",C1CC1NC(=O)C2=CC(=C(C(=C2)Cl)N)Cl,,,,,,
8703,43398,"1,3-BENZODIOXOLE-5-ETHANAMINE, 7-METHOXY-alpha-METHYL-, HYDROCHLORIDE",CC(CC1=CC2=C(C(=C1)OC)OCO2)[NH3+].[Cl-],,,,,,
8704,43399,3-((2-Chlorophenyl)methyl)-1-methyl-1H-indole-2-methanamine monohydrochloride,CN1C2=CC=CC=C2C(=C1C[NH3+])CC3=CC=CC=C3Cl.[Cl-],,,,,,
8705,43400,[3-[(2-Chlorophenyl)methyl]-1-methylindol-2-yl]methanamine,CN1C2=CC=CC=C2C(=C1CN)CC3=CC=CC=C3Cl,,,,,,
8706,43401,CID 43401,C1=CC=C(C(=C1)N=NC=O)N(O)O,,,,,,
8707,43402,"(2,3-Dioxo-2,3-dihydro-indol-1-yl)-acetic acid",C1=CC=C2C(=C1)C(=O)C(=O)N2CC(=O)O,,,,,,
8708,43403,"Carbazole, 9-(1-methyl-2-piperidyl)methyl-",CN1CCCCC1CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
8709,43404,"Carbazole, 9-(1-methyl-4-piperidyl)methyl-",CN1CCC(CC1)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
8710,43405,9-(2-(1-Methyl-2-piperidyl)ethyl)carbazole,CN1CCCCC1CCN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
8711,43406,"Carbazole, 9-(1-methyl-3-piperidyl)methyl-",CN1CCCC(C1)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
8712,43407,"3,4,6-Trichloroguaiacol",COC1=C(C(=CC(=C1Cl)Cl)Cl)O,,,,,,
8713,43408,"1-Pivaloyl-1,2,4-triazole",CC(C)(C)C(=O)N1C=NC=N1,,,,,,
8714,43409,[2-(4-Chlorophenyl)-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]azanium;chloride,CC(C)(C)OC(=O)C(C)(C1=CC=C(C=C1)Cl)[NH3+].[Cl-],,,,,,
8715,43410,Tert-butyl 2-amino-2-(4-chlorophenyl)propanoate,CC(C)(C)OC(=O)C(C)(C1=CC=C(C=C1)Cl)N,,,,,,
8716,43411,"4H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 4a,8a-DIHYDRO-7-HYDROXY-4-OXO-, (Z)-",C1=CC(=C[C@H]2[C@@H]1C(=O)C=C(O2)C(=O)O)O,,,,,,
8717,43412,"4H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 4a,8a-DIHYDRO-7-HYDROXY-4-OXO-, (E)-",C1=CC(=C[C@H]2[C@H]1C(=O)C=C(O2)C(=O)O)O,,,,,,
8718,43413,"trans-7-Hydroxy-4-oxo-4a,8a-dihydro-4H-1-benzopyran-2-carboxylic acid acetate (ester)",CC(=O)OC1=C[C@H]2[C@H](C=C1)C(=O)C=C(O2)C(=O)O,,,,,,
8719,43414,"4H-1-Benzopyran-2-carboxylic acid, 2,3,4a,8a-tetrahydro-7-hydroxy-4-oxo-, acetate (ester)",C1C(OC2C=C(C=CC2C1=O)O)C(=O)OCC=O,,,,,,
8720,43415,"3,6-Dihydroxy-2-benzofuranacetic acid diacetate",CC(=O)OC1=CC2=C(C=C1)C(=C(O2)CC(=O)O)OC(=O)C,,,,,,
8721,43416,"2-Benzofuranacetamide, 3,6-dihydroxy-, diacetate",CC(=O)OC1=CC2=C(C=C1)C(=C(O2)CC(=O)N)OC(=O)C,,,,,,
8722,43417,"2-BENZOFURANACETAMIDE, 3,6-DIHYDROXY-N-(m-HYDROXYPHENYL)-, 3,6-DIACETATE",CC(=O)OC1=CC2=C(C=C1)C(=C(O2)CC(=O)NC3=CC(=CC=C3)O)OC(=O)C,,,,,,
8723,43418,"2-Benzofuranacetamide, N-(2,4-dichlorophenyl)-3,6-dihydroxy-, diacetate",CC(=O)OC1=CC2=C(C=C1)C(=C(O2)CC(=O)NC3=C(C=C(C=C3)Cl)Cl)OC(=O)C,,,,,,
8724,43419,"2-Benzofuranacetamide, N-cyclohexyl-3,6-dihydroxy-, diacetate",CC(=O)OC1=CC2=C(C=C1)C(=C(O2)CC(=O)NC3CCCCC3)OC(=O)C,,,,,,
8725,43420,"4-Benzoxazoleacetic acid, 2-phenyl-",C1=CC=C(C=C1)C2=NC3=C(C=CC=C3O2)CC(=O)O,,,,,,
8726,43421,"4-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-",C1=CC(=C2C(=C1)OC(=N2)C3=CC=C(C=C3)Cl)CC(=O)O,,,,,,
8727,43422,alpha-Methyl-2-phenyl-7-benzoxazoleacetic acid,CC(C1=C2C(=CC=C1)N=C(O2)C3=CC=CC=C3)C(=O)O,,,,,,
8728,43423,(4-(6-Chlorothymyloxy)butyl)dimethyl(5-nitro-2-furfuryl)ammonium bromide,CC1=CC(=C(C=C1Cl)C(C)C)OCCCC[N+](C)(C)CC2=CC=C(O2)[N+](=O)[O-].[Br-],,,,,,
8729,43424,4-(4-Chloro-5-methyl-2-propan-2-ylphenoxy)butyl-dimethyl-[(5-nitrofuran-2-yl)methyl]azanium,CC1=CC(=C(C=C1Cl)C(C)C)OCCCC[N+](C)(C)CC2=CC=C(O2)[N+](=O)[O-],,,,,,
8730,43425,"(4-(2,4,6-Tribromophenoxy)butyl)dimethyl(5-bromo-2-furfuryl)ammonium bromide",C[N+](C)(CCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)Br.[Br-],,,,,,
8731,43426,"(5-Bromofuran-2-yl)methyl-dimethyl-[4-(2,4,6-tribromophenoxy)butyl]azanium",C[N+](C)(CCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)Br,,,,,,
8732,43427,(4-(6-Chlorothymyloxy)butyl)dimethyl(5-bromo-2-furfuryl)ammonium bromide,CC1=C(C(=C(C=C1)C(C)C)OCCCC[N+](C)(C)CC2=CC=C(O2)Br)Cl.[Br-],,,,,,
8733,43428,(5-Bromofuran-2-yl)methyl-[4-(2-chloro-3-methyl-6-propan-2-ylphenoxy)butyl]-dimethylazanium,CC1=C(C(=C(C=C1)C(C)C)OCCCC[N+](C)(C)CC2=CC=C(O2)Br)Cl,,,,,,
8734,43429,(5-(6-Chlorothymyloxy)pentyl)dimethyl(5-nitro-2-furfuryl)ammonium bromide,CC1=CC(=C(C=C1Cl)C(C)C)OCCCCC[N+](C)(C)CC2=CC=C(O2)[N+](=O)[O-].[Br-],,,,,,
8735,43430,5-(4-Chloro-5-methyl-2-propan-2-ylphenoxy)pentyl-dimethyl-[(5-nitrofuran-2-yl)methyl]azanium,CC1=CC(=C(C=C1Cl)C(C)C)OCCCCC[N+](C)(C)CC2=CC=C(O2)[N+](=O)[O-],,,,,,
8736,43431,"Ammonium, (5-bromo-2-furfuryl)dimethyl(5-(2,4,6-tribromophenoxy)pentyl)-, bromide",C[N+](C)(CCCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)Br.[Br-],,,,,,
8737,43432,"(5-Bromofuran-2-yl)methyl-dimethyl-[5-(2,4,6-tribromophenoxy)pentyl]azanium",C[N+](C)(CCCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)Br,,,,,,
8738,43433,(5-(6-Chlorothymyloxy)pentyl)dimethyl(5-bromo-2-furfuryl)ammonium bromide,CC1=C(C(=C(C=C1)C(C)C)OCCCCC[N+](C)(C)CC2=CC=C(O2)Br)Cl.[Br-],,,,,,
8739,43434,(5-Bromofuran-2-yl)methyl-[5-(2-chloro-3-methyl-6-propan-2-ylphenoxy)pentyl]-dimethylazanium,CC1=C(C(=C(C=C1)C(C)C)OCCCCC[N+](C)(C)CC2=CC=C(O2)Br)Cl,,,,,,
8740,43435,"(6-(2,4,6-Tribromophenoxy)hexyl)dimethyl(5-nitro-2-furfuryl)ammonium bromide",C[N+](C)(CCCCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)[N+](=O)[O-].[Br-],,,,,,
8741,43436,"N,N-Dimethyl-N-(5-nitrofurfuryl)-6-(2,4,6-tribromophenoxy)-1-hexanaminium",C[N+](C)(CCCCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)[N+](=O)[O-],,,,,,
8742,43437,"(6-(2,4,6-Tribromophenoxy)hexyl)dimethyl(5-bromo-2-furfuryl)ammonium bromide",C[N+](C)(CCCCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)Br.[Br-],,,,,,
8743,43438,"(5-Bromofuran-2-yl)methyl-dimethyl-[6-(2,4,6-tribromophenoxy)hexyl]azanium",C[N+](C)(CCCCCCOC1=C(C=C(C=C1Br)Br)Br)CC2=CC=C(O2)Br,,,,,,
8744,43439,"Propylcarbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCCNC(=O)OC1C[NH+](C1)C(CC)(CC)C#C.[Cl-],,,,,,
8745,43440,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-propylcarbamate,CCCNC(=O)OC1CN(C1)C(CC)(CC)C#C,,,,,,
8746,43441,"1-Naphthalenylcarbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC2=CC=CC3=CC=CC=C32.[Cl-],,,,,,
8747,43442,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-naphthalen-1-ylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC2=CC=CC3=CC=CC=C32,,,,,,
8748,43443,"(3-Methylphenyl)carbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC2=CC=CC(=C2)C.[Cl-],,,,,,
8749,43444,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-(3-methylphenyl)carbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC2=CC=CC(=C2)C,,,,,,
8750,43445,"Butylcarbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCCCNC(=O)OC1C[NH+](C1)C(CC)(CC)C#C.[Cl-],,,,,,
8751,43446,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-butylcarbamate,CCCCNC(=O)OC1CN(C1)C(CC)(CC)C#C,,,,,,
8752,43447,"Propylcarbamic acid 1-(1,1-dimethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCCNC(=O)OC1C[NH+](C1)C(C)(C)C#C.[Cl-],,,,,,
8753,43448,[1-(2-methylbut-3-yn-2-yl)azetidin-3-yl] N-propylcarbamate,CCCNC(=O)OC1CN(C1)C(C)(C)C#C,,,,,,
8754,43449,"2-Propenylcarbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NCC=C.[Cl-],,,,,,
8755,43450,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-prop-2-enylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NCC=C,,,,,,
8756,43451,"Ethylcarbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NCC.[Cl-],,,,,,
8757,43452,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-ethylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NCC,,,,,,
8758,43453,"(1,1-Dimethylethyl)carbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC(C)(C)C.[Cl-],,,,,,
8759,43454,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-tert-butylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC(C)(C)C,,,,,,
8760,43455,"Carbamic acid, (1-methylethyl)-, 1-(1-ethynylcyclohexyl)-3-azetidinyl ester",CC(C)NC(=O)OC1CN(C1)C2(CCCCC2)C#C,,,,,,
8761,43456,1-(1-Ethynylcyclohexyl)-3-azetidinol methylcarbamate (ester) hydrochloride,CNC(=O)OC1C[NH+](C1)C2(CCCCC2)C#C.[Cl-],,,,,,
8762,43457,[1-(1-ethynylcyclohexyl)azetidin-3-yl] N-methylcarbamate,CNC(=O)OC1CN(C1)C2(CCCCC2)C#C,,,,,,
8763,43458,Propylcarbamic acid 1-(1-ethynylcyclohexyl)-3-azetidinyl ester hydrochloride,CCCNC(=O)OC1C[NH+](C1)C2(CCCCC2)C#C.[Cl-],,,,,,
8764,43459,[1-(1-ethynylcyclohexyl)azetidin-3-yl] N-propylcarbamate,CCCNC(=O)OC1CN(C1)C2(CCCCC2)C#C,,,,,,
8765,43460,"1-(1,1-Diethyl-2-propynyl)-3-azetidinol phenylcarbamate (ester) hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
8766,43461,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-phenylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC2=CC=CC=C2,,,,,,
8767,43462,"(1-Methylethyl)carbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC(C)C.[Cl-],,,,,,
8768,43463,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-propan-2-ylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC(C)C,,,,,,
8769,43464,"Cyclohexylcarbamic acid 1-(1,1-diethyl-2-propynyl)-3-azetidinyl ester hydrochloride",CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC2CCCCC2.[Cl-],,,,,,
8770,43465,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-cyclohexylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC2CCCCC2,,,,,,
8771,43466,1-(L-alpha-Glutamyl)-2-isopropylhydrazine,CC(C)NNC(=O)C(CCC(=O)O)N,,,,,,
8772,43467,Isopropyl diphenyl phosphate,CC(C)OP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
8773,43468,"5-Cyano-10,11-dihydro-5-(3-methylaminopropyl)-5H-dibenzo(a,d)cycloheptene hydrochloride",C[NH2+]CCCC1(C2=CC=CC=C2CCC3=CC=CC=C31)C#N.[Cl-],,,,,,
8774,43469,"2-[3-(Methylamino)propyl]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carbonitrile",CNCCCC1(C2=CC=CC=C2CCC3=CC=CC=C31)C#N,,,,,,
8775,43470,"2-(1,3-Dithiolan-2-yl)-4,6,6-trimethylbicyclo(3.1.1)heptan-3-one",CC1C2CC(C2(C)C)C(C1=O)C3SCCS3,,,,,,
8776,43471,"3-Amino-2,5-dimethylbenzoic acid",CC1=CC(=C(C(=C1)N)C)C(=O)O,,,,,,
8777,43472,CID 43472,CCCCCCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
8778,43473,5-Ethyl-5-heptylbarbituric acid,CCCCCCCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
8779,43474,"BENZ(a)ANTHRACENE, 1,7,12-TRIMETHYL-",CC1=C2C(=CC=C1)C=CC3=C(C4=CC=CC=C4C(=C32)C)C,,,,,,
8780,43475,"boranylformic acid;N,N-dimethylmethanamine",BC(=O)O.CN(C)C,,,,,,
8781,43476,Carboxyborane,BC(=O)O,,,,,,
8782,43477,CID 43477,BC(=O)NCC.CN(C)C,,,,,,
8783,43478,1-boranyl-N-ethylformamide,BC(=O)NCC,,,,,,
8784,43479,1-(alpha-Methylphenethyl)-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine,CC1=CC(=NO1)C(=O)NNC(C)CC2=CC=CC=C2,,,,,,
8785,43480,1-(2-Benzoylethyl)-4-phenylisonipecotic acid ethyl ester hydrochloride,CCOC(=O)C1(CC[NH+](CC1)CCC(=O)C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
8786,43481,Ethyl 1-(3-oxo-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CCC(=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8787,43482,"Ethanamine, 2-((2,2-dimethyl-6-pentyl-2H-1-benzopyran-7-yl)oxy)-N,N-dimethyl-, ethanedioate (2:1)",CCCCCC1=C(C=C2C(=C1)C=CC(O2)(C)C)OCC[NH+](C)C.C(=O)(C(=O)[O-])O,,,,,,
8788,43483,"2-(2,2-dimethyl-6-pentylchromen-7-yl)oxy-N,N-dimethylethanamine",CCCCCC1=C(C=C2C(=C1)C=CC(O2)(C)C)OCCN(C)C,,,,,,
8789,43484,"Ethanamine, 2-((2,2-dimethyl-6-pentyl-2H-1-benzopyran-7-yl)oxy)-N,N-diethyl-, ethanedioate (2:1)",CCCCCC1=C(C=C2C(=C1)C=CC(O2)(C)C)OCC[NH+](CC)CC.C(=O)(C(=O)[O-])O,,,,,,
8790,43485,"2-(2,2-dimethyl-6-pentylchromen-7-yl)oxy-N,N-diethylethanamine",CCCCCC1=C(C=C2C(=C1)C=CC(O2)(C)C)OCCN(CC)CC,,,,,,
8791,43486,"11,14-Dithiatetracosane",CCCCCCCCCCSCCSCCCCCCCCCC,,,,,,
8792,43487,"Dibenzo(b,f)(1,4)thiazepine, 8-chloro-10,11-dihydro-10-(3-methylaminopropyl)-, dihydrobromide, hydrate",C[NH2+]CCC[NH+]1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl.[Br-].[Br-],,,,,,
8793,43488,"3-(3-chloro-6H-benzo[b][1,4]benzothiazepin-5-yl)-N-methylpropan-1-amine",CNCCCN1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
8794,43489,4-Methyldibenzofuran,CC1=C2C(=CC=C1)C3=CC=CC=C3O2,,,,,,
8795,43490,3-(2-(Diethylpyrrolidino)ethoxy)-6-methoxy-2-phenylbenzofuran hydrochloride,CCC(CC)(COC1=C(OC2=C1C=CC(=C2)OC)C3=CC=CC=C3)[NH+]4CCCC4.[Cl-],,,,,,
8796,43491,1-[3-[(6-Methoxy-2-phenyl-1-benzofuran-3-yl)oxymethyl]pentan-3-yl]pyrrolidine,CCC(CC)(COC1=C(OC2=C1C=CC(=C2)OC)C3=CC=CC=C3)N4CCCC4,,,,,,
8797,43492,"2-Chloromethyl-3,3-dichloropropene",C=C(CCl)C(Cl)Cl,,,,,,
8798,43493,Ethyl (2Z)-2-methoxyimino-3-oxo-butanoate,CCOC(=O)C(=NOC)C(=O)C,,,,,,
8799,43494,"7H-Dibenz(DE,H)anthracen-7-one",C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC5=C4C(=CC=C5)C3=O,,,,,,
8800,43495,"2,3,4,6,7,8-Hexachlorodibenzofuran",C1=C2C3=CC(=C(C(=C3OC2=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
8801,43496,"N,N-Bis(2-chloroethyl)-1-naphthalenemethanamine hydrochloride",C1=CC=C2C(=C1)C=CC=C2C[NH+](CCCl)CCCl.[Cl-],,,,,,
8802,43497,2-chloro-N-(2-chloroethyl)-N-(naphthalen-1-ylmethyl)ethanamine,C1=CC=C2C(=C1)C=CC=C2CN(CCCl)CCCl,,,,,,
8803,43498,"4,4'-Biphenylenebis(2-oxoethylenebis(thiodimethyl)ammonium) dibromide",C[N+](C)(CCS)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCS.[Br-].[Br-],,,,,,
8804,43499,[2-[4-[4-[2-[Dimethyl(2-sulfanylethyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-dimethyl-(2-sulfanylethyl)azanium,C[N+](C)(CCS)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCS,,,,,,
8805,43500,"4,4'-Biphenylenebis(2-oxoethylenebis(2-acetylthioethyl)dimethylammonium) dibromide",CC(=O)SCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCSC(=O)C.[Br-].[Br-],,,,,,
8806,43501,2-Acetylsulfanylethyl-[2-[4-[4-[2-[2-acetylsulfanylethyl(dimethyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-dimethylazanium,CC(=O)SCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCSC(=O)C,,,,,,
8807,43502,"2(3H)-Isoxazolecarboxamide, N,N-dimethyl-3-oxo-",CN(C)C(=O)N1C(=O)C=CO1,,,,,,
8808,43503,"1,2-Hydrazinedicarboxylic acid, monoethyl ester",CCOC(=O)NNC(=O)O,,,,,,
8809,43504,Ammonium fluoroacetate,C(C(=O)[O-])F.[NH4+],,,,,,
8810,43505,"Ammonium, trimethyl(4-phenylbutyl)-, iodide",C[N+](C)(C)CCCCC1=CC=CC=C1.[I-],,,,,,
8811,43506,(4-Phenylbutyl)trimethylaminium,C[N+](C)(C)CCCCC1=CC=CC=C1,,,,,,
8812,43507,Ceforanide,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O,['For the treatment of infections caused by susceptible organisms.'],['Ceforanide is a semisynthetic second-generation cephalosporin. The cephalosporins are bactericidal drugs with both gram-positive and gram-negative activity. They inhibit bacterial cell wall synthesis in a way similar to the penicillins.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Rapidly absorbed following intramuscular injection.'],"['The major drug elimination route was urinary excretion with 85% of the dose being excreted unchanged in the urine within 12 hr, and no metabolites with antibiotic activity were observed in urine.']",['2.6 to 2.98 hours']
8813,43508,"1,3-Dihydroxyestra-1(10),2,4-trien-17-one",CC12CCC3C(C1CCC2=O)CCC4=C3C(=CC(=C4)O)O,,,,,,
8814,43509,"Benz(a)anthracene-1,2-diol, 1,2-dihydro-, trans-",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3[C@H]([C@@H](C=C4)O)O,,,,,,
8815,43510,"trans-3,4-Dihydro-3,4-dihydroxybenz(a)anthracene",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3C=C[C@H]([C@@H]4O)O,,,,,,
8816,43511,"BENZ(a)ANTHRACENE, 10,11-DIHYDRO-10,11-DIHYDROXY-, (E)-",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)[C@H]([C@@H](C=C4)O)O,,,,,,
8817,43512,"BENZ(a)ANTHRACENE, 3,4-DIHYDRO-",C1CC2=C(C=C1)C3=CC4=CC=CC=C4C=C3C=C2,,,,,,
8818,43513,"BENZ(a)ANTHRACENE, 1,2-DIHYDRO-",C1CC2=C(C=C1)C=CC3=CC4=CC=CC=C4C=C23,,,,,,
8819,43514,"Dibenzo(b,f)thiepin-2,3-diol, 10,11-dihydro-10-(4-methyl-1-piperazinyl)-, hydrobromide, hydrate (1:2:2)",CN1CCN(CC1)C2CC3=CC(=C(C=C3SC4=CC=CC=C24)O)O.Br.Br,,,,,,
8820,43515,"6-(4-Methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepine-2,3-diol",CN1CCN(CC1)C2CC3=CC(=C(C=C3SC4=CC=CC=C24)O)O,,,,,,
8821,43516,"Dibenzo(b,f)thiepin-10-amine, 10,11-dihydro-2,3-dimethoxy-N-methyl-, hydrochloride",C[NH2+]C1CC2=CC(=C(C=C2SC3=CC=CC=C13)OC)OC.[Cl-],,,,,,
8822,43517,"2,3-dimethoxy-N-methyl-5,6-dihydrobenzo[b][1]benzothiepin-6-amine",CNC1CC2=CC(=C(C=C2SC3=CC=CC=C13)OC)OC,,,,,,
8823,43518,"Ethanamine, N,N-dimethyl-2-((6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxy)-, hydrochloride",C[NH+](C)CCOC1=CC2=C(CCCCC2)C=C1.[Cl-],,,,,,
8824,43519,"N,N-dimethyl-2-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yloxy)ethanamine",CN(C)CCOC1=CC2=C(CCCCC2)C=C1,,,,,,
8825,43520,CID 43520,COC1=CC(=CC(=C1OC)OC)C(=N)S,,,,,,
8826,43521,"1-AZABICYCLO(2.2.2)OCT-2-ENE-3-METHANOL, alpha,alpha-DIPHENYL-",C1CN2CCC1C(=C2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
8827,43522,o-sec-Butylphenyl carbamate,CCC(C)C1=CC=CC=C1OC(=O)N,,,,,,
8828,43523,Fenapanil,CCCCC(CN1C=CN=C1)(C#N)C2=CC=CC=C2,,,,,,
8829,43524,"alpha,alpha-Dichlorophenylacetic acid",C1=CC=C(C=C1)C(C(=O)O)(Cl)Cl,,,,,,
8830,43525,C.I. Pigment yellow 151,CC(=O)C(C(=O)NC1=CC2=C(C=C1)NC(=O)N2)N=NC3=CC=CC=C3C(=O)O,,,,,,
8831,43526,D-(+)-Karnitinmethylesterbromid [German],C[N+](C)(C)C[C@@H](CC(=O)OC)O.[Br-],,,,,,
8832,43527,L(-)-Carnitine methyl ester,C[N+](C)(C)C[C@@H](CC(=O)OC)O,,,,,,
8833,43528,D(+)-Azetylkarnitinmethylesterbromid [German],CC(=O)O[C@H](CC(=O)OC)C[N+](C)(C)C.[Br-],,,,,,
8834,43529,[(2R)-2-acetyloxy-4-methoxy-4-oxobutyl]-trimethylazanium,CC(=O)O[C@H](CC(=O)OC)C[N+](C)(C)C,,,,,,
8835,43530,L(-)-Azetylkarnitinmethylesterbromid [German],CC(=O)O[C@@H](CC(=O)OC)C[N+](C)(C)C.[Br-],,,,,,
8836,43531,[(2S)-2-acetyloxy-4-methoxy-4-oxobutyl]-trimethylazanium,CC(=O)O[C@@H](CC(=O)OC)C[N+](C)(C)C,,,,,,
8837,43532,"1(3H)-Isobenzofuranone, 4,6-dimethoxy-5-hydroxy-",COC1=C(C(=C2COC(=O)C2=C1)OC)O,,,,,,
8838,43533,CID 43533,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O.CC(C)CC1=CC=C(C=C1)C(C)C(=O)O.O.[AlH3],,,,,,
8839,43534,"9H-Fluoren-2-amine, N-chloro-",C1C2=CC=CC=C2C3=C1C=C(C=C3)NCl,,,,,,
8840,43535,2-(Diethylamino)-4'-methyl-N-(2-(o-tolyloxy)ethyl)acetanilide hydrochloride,CC[NH+](CC)CC(=O)N(CCOC1=CC=CC=C1C)C2=CC=C(C=C2)C.[Cl-],,,,,,
8841,43536,2-(diethylamino)-N-[2-(2-methylphenoxy)ethyl]-N-(4-methylphenyl)acetamide,CCN(CC)CC(=O)N(CCOC1=CC=CC=C1C)C2=CC=C(C=C2)C,,,,,,
8842,43537,"Acetanilide, 2-(diethylamino)-2'-methyl-N-(2-(p-chlorophenoxy)ethyl)-, hydrochloride",CC[NH+](CC)CC(=O)N(CCOC1=CC=C(C=C1)Cl)C2=CC=CC=C2C.[Cl-],,,,,,
8843,43538,N-[2-(4-chlorophenoxy)ethyl]-2-(diethylamino)-N-(2-methylphenyl)acetamide,CCN(CC)CC(=O)N(CCOC1=CC=C(C=C1)Cl)C2=CC=CC=C2C,,,,,,
8844,43539,CID 43539,C1=CC=C(C=C1)P(=O)(OC2=CC=C(C=C2)C#N)S,,,,,,
8845,43540,"2-Imidazoline, 1-acetyl-2-allylthio-",CC(=O)N1CCN=C1SCC=C,,,,,,
8846,43541,"2-IMIDAZOLINE, 1-ACETYL-2-((p-FLUOROBENZYL)THIO)-",CC(=O)N1CCN=C1SCC2=CC=C(C=C2)F,,,,,,
8847,43542,"2-Imidazoline-1-carboxylic acid, 2-allylthio-, methyl ester",COC(=O)N1CCN=C1SCC=C,,,,,,
8848,43543,4-Anilino-1-benzylisonipecotic acid hydrochloride,C1CN(CCC1(C(=O)O)[NH2+]C2=CC=CC=C2)CC3=CC=CC=C3.[Cl-],,,,,,
8849,43544,1-Benzyl-4-(phenylamino)piperidine-4-carboxylic acid,C1CN(CCC1(C(=O)O)NC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
8850,43545,p-Cyanophenyl dimethyl phosphate,COP(=O)(OC)OC1=CC=C(C=C1)C#N,,,,,,
8851,43546,"1,2,3,4,5-Pentachloro-6-(2-chloroethenyl)benzene",C(=CCl)C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
8852,43547,1-Methoxyphenanthrene,COC1=CC=CC2=C1C=CC3=CC=CC=C32,,,,,,
8853,43548,"3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine;hydrate;dihydrochloride",CN(C)CC=C(C1=CC=C(C=C1)Br)C2=CN=CC=C2.O.Cl.Cl,,,,,,
8854,43549,"Acetic acid, (4-(3-(2-chloroethyl)-3-nitrosoureido)cyclohexyl)methyl ester, (E)-",CC(=O)OCC1CCC(CC1)NC(=O)N(CCCl)N=O,,,,,,
8855,43550,"Acetic acid, (4-(3-(2-fluoroethyl)-3-nitrosoureido)cyclohexyl)methyl ester, (E)-",CC(=O)OCC1CCC(CC1)NC(=O)N(CCF)N=O,,,,,,
8856,43551,"3,4-Diethylbiphenyl",CCC1=C(C=C(C=C1)C2=CC=CC=C2)CC,,,,,,
8857,43552,"1,2-Diethylcyclobutane",CCC1CCC1CC,,,,,,
8858,43553,CID 43553,CCC=C(CC)C(=C)C,,,,,,
8859,43554,"2,3-Dimethyltetrahydro-2-furanol (trans)",C[C@@H]1CCO[C@]1(C)O,,,,,,
8860,43555,"1H-ISOINDOLE-1,3(2H)-DIONE, 3a,4,7,7a-TETRAHYDRO-2-(PHENYLAMINO)-",C1C=CCC2C1C(=O)N(C2=O)NC3=CC=CC=C3,,,,,,
8861,43556,"3,4,5,6,12,12-Hexachloro-11-oxatetracyclo[6.2.1.13,6.02,7]dodec-4-ene",C1CC2C3C(C1O2)C4(C(=C(C3(C4(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
8862,43557,CID 43557,C(CCCCCCN=C([NH3+])N)CCCCCN=C([NH3+])N.[Cl-].[Cl-],,,,,,
8863,43558,1-(12-Guanidinododecyl)guanidine,C(CCCCCCN=C(N)N)CCCCCN=C(N)N,,,,,,
8864,43559,N-Acetyl-N'-(3-formyl-4-hydroxyphenyl)hydrazine,CC(=O)NNC1=CC(=C(C=C1)O)C=O,,,,,,
8865,43560,"7,8,9,10-Tetrahydro-7alpha,8beta,9beta-trihydroxy-benzo(a)pyrene",C1[C@@H]([C@@H]([C@H](C2=C1C3=C4C(=C2)C=CC5=C4C(=CC=C5)C=C3)O)O)O,,,,,,
8866,43561,CID 43561,C1[C@@H]2N(C1=O)[C@H](C(=CCO)O2)C(=O)[O-].[K+],,,,,,
8867,43562,4-(p-Chlorobenzyl)-7-methoxyisoquinoline methanesulfonate,COC1=CC=CC2=C1C=[NH+]C=C2CC3=CC=C(C=C3)Cl.CS(=O)(=O)[O-],,,,,,
8868,43563,4-[(4-Chlorophenyl)methyl]-8-methoxyisoquinoline,COC1=CC=CC2=C1C=NC=C2CC3=CC=C(C=C3)Cl,,,,,,
8869,43564,"Isoquinoline, 4-(2,6-dichlorobenzyl)-6,7-dimethoxy-, methanesulfonate",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=C(C=CC=C3Cl)Cl)OC.CS(=O)(=O)[O-],,,,,,
8870,43565,"Isoquinoline, 4-[(2,6-dichlorophenyl)methyl]-6,7-dimethoxy-",COC1=C(C=C2C(=C1)C=NC=C2CC3=C(C=CC=C3Cl)Cl)OC,,,,,,
8871,43566,"4-(3,4-Dichlorobenzyl)-6,7-dimethoxyisoquinoline methanesulfonate",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC(=C(C=C3)Cl)Cl)OC.CS(=O)(=O)[O-],,,,,,
8872,43567,"4-[(3,4-Dichlorophenyl)methyl]-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC(=C(C=C3)Cl)Cl)OC,,,,,,
8873,43568,"6,7-Dimethoxy-4-(p-methoxybenzyl)isoquinoline hydrobromide",COC1=CC=C(C=C1)CC2=C[NH+]=CC3=CC(=C(C=C32)OC)OC.[Br-],,,,,,
8874,43569,"6,7-Dimethoxy-4-(4-methoxybenzyl)isoquinoline",COC1=CC=C(C=C1)CC2=CN=CC3=CC(=C(C=C32)OC)OC,,,,,,
8875,43570,"6,7-Dimethoxy-4-(3,4-dimethoxybenzyl)isoquinoline methanesulfonate",COC1=C(C=C(C=C1)CC2=C[NH+]=CC3=CC(=C(C=C32)OC)OC)OC.CS(=O)(=O)[O-],,,,,,
8876,43571,"6,7-Dimethoxy-4-(3,4,5-trimethoxybenzyl)isoquinoline methanesulfonate",COC1=CC(=CC(=C1OC)OC)CC2=C[NH+]=CC3=CC(=C(C=C32)OC)OC.CS(=O)(=O)[O-],,,,,,
8877,43572,"6,7-Dimethoxy-4-[(3,4,5-trimethoxyphenyl)methyl]isoquinoline",COC1=CC(=CC(=C1OC)OC)CC2=CN=CC3=CC(=C(C=C32)OC)OC,,,,,,
8878,43573,"6,7-Dimethoxy-4-(3,4-methylenedioxybenzyl)isoquinoline methanesulfonate",COC1=C(C=C2C(=C1)C=[NH+]C=C2CC3=CC4=C(C=C3)OCO4)OC.CS(=O)(=O)[O-],,,,,,
8879,43574,"4-(1,3-Benzodioxol-5-ylmethyl)-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C=NC=C2CC3=CC4=C(C=C3)OCO4)OC,,,,,,
8880,43575,"4-(p-Chlorobenzyl)-5,6,7-trimethoxyisoquinoline hydrobromide",COC1=C(C(=C2C=[NH+]C=C(C2=C1)CC3=CC=C(C=C3)Cl)OC)OC.[Br-],,,,,,
8881,43576,"4-[(4-Chlorophenyl)methyl]-6,7,8-trimethoxyisoquinoline",COC1=C(C(=C2C=NC=C(C2=C1)CC3=CC=C(C=C3)Cl)OC)OC,,,,,,
8882,43577,"4-(p-Chlorobenzyl)-6,7-methylenedioxyisoquinoline methanesulfonate",CS(=O)(=O)[O-].C1OC2=C(O1)C3=C(C=C2)C(=C[NH+]=C3)CC4=CC=C(C=C4)Cl,,,,,,
8883,43578,"6-[(4-Chlorophenyl)methyl]-[1,3]dioxolo[4,5-h]isoquinoline",C1OC2=C(O1)C3=C(C=C2)C(=CN=C3)CC4=CC=C(C=C4)Cl,,,,,,
8884,43579,Propyl 2-methyl-3-furyl disulfide,CCCSSC1=C(OC=C1)C,,,,,,
8885,43580,Nitroacetate,C(C(=O)[O-])[N+](=O)[O-],,,,,,
8886,43581,Nitroacetic acid,C(C(=O)O)[N+](=O)[O-],,,,,,
8887,43582,"3-Buten-2-one, 3-bromo-",CC(=O)C(=C)Br,,,,,,
8888,43583,Pentadecylbenzenesulphonic acid,CCCCCCCCCCCCCCCC1=CC(=CC=C1)S(=O)(=O)O,,,,,,
8889,43584,Shell 52-RL-71,C12C(C3C4C(C1O3)O4)C5(C(=C(C2(C5(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
8890,43585,Tiopinac,C1C2=CC=CC=C2C(=O)C3=C(S1)C=C(C=C3)CC(=O)O,,,,,,
8891,43586,CID 43586,[B-]123OC4C(=O)OC5CC(C=CCC(C(C6CCC(C(O1)(O6)C(O2)C(=O)OC7CC(C=CCC(C(C8CCC(C4(O3)O8)C)(C)C)O)OC7C)C)(C)C)O)OC5C.[Na+],,,,,,
8892,43587,"12,32-Dihydroxy-6,13,13,17,26,33,33,37-octamethyl-4,7,19,21,24,27,38,39,41,42-decaoxa-20-boranuidaoctacyclo[18.17.1.11,34.12,20.15,8.114,18.125,28.018,22]tritetraconta-9,29-diene-3,23-dione",[B-]123OC4C(=O)OC5CC(C=CCC(C(C6CCC(C(O1)(O6)C(O2)C(=O)OC7CC(C=CCC(C(C8CCC(C4(O3)O8)C)(C)C)O)OC7C)C)(C)C)O)OC5C,,,,,,
8893,43588,N-{1-carboxy-1-[histidyl(methyl)amino]propan-2-yl}histidine,CC(C(C(=O)O)N(C)C(=O)C(CC1=CN=CN1)N)NC(CC2=CN=CN2)C(=O)O,,,,,,
8894,43589,Antibiotic A 32390A,CC(=C(C(=O)OCC(C(C(C(COC(=O)C(=C(C)C)[N+]#[C-])O)O)O)O)[N+]#[C-])C,,,,,,
8895,43590,Prenalterol hydrochloride,CC(C)NC[C@@H](COC1=CC=C(C=C1)O)O.Cl,,,"['Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Agonists.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)']",,,
8896,43591,"7-[(1R,2R,3R)-3-hydroxy-2-[(3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-methylidenecyclopentyl]hept-5-enoic acid",CCCCC(C)(C)[C@@H](C=C[C@H]1[C@@H](CC(=C)[C@@H]1CC=CCCCC(=O)O)O)O,,,,,,
8897,43592,"(6R,7R)-7-[(2-hydroxy-2-phenyl-acetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O,,,,,,
8898,43593,Cefonicid sodium,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)[O-])CSC4=NN=NN4CS(=O)(=O)[O-].[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
8899,43594,Cefonicid,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O,['For the treatment of bacterial infections caused by susceptible microorganisms.'],"['Cefonicid is a second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,['Not metabolized.'],['4.5 hours']
8900,43595,Deoxyschizandrin,CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1C)OC)OC)OC)OC)OC)OC,,,,,,
8901,43596,Bleomycin B4 hydrochloride,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCCN(CCCCN=C(N)N)C(=N)N)O.Cl,,,,,,
8902,43597,"[(2R,3S,4S,5R,6R)-2-[(2R,3S,4R,5S,6S)-2-[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[5-[[1-[2-[4-[4-[4-[carbamimidoyl-[4-(diaminomethylideneamino)butyl]amino]butylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate",CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCCN(CCCCN=C(N)N)C(=N)N)O,,,,,,
8903,43598,3-(2-Methyl-3-furylthio)-4-heptanone,CCCC(=O)C(CC)SC1=C(OC=C1)C,,,,,,
8904,43599,5-Bromo-2-thiazolamine hydrobromide,C1=C(SC(=N)[NH2+]1)Br.[Br-],,,,,,
8905,43600,5-Bromothiazol-2-amine,C1=C(SC(=N1)N)Br,,,,,,
8906,43601,"2-Propenenitrile, 3-ethoxy-",CCOC=CC#N,,,,,,
8907,43602,CID 43602,CC1=CC2=C(NC3=C(C=CC(=C3)F)N=C2S1)N4CCN(CC4)C,,,,,,
8908,43603,"1,2-Dichloro-4-(2-chlorophenoxy)benzene",C1=CC=C(C(=C1)OC2=CC(=C(C=C2)Cl)Cl)Cl,,,,,,
8909,43604,"2,4,4',5-Tetrachlorodiphenyl ether",C1=CC(=CC=C1OC2=CC(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
8910,43605,5-Ethyl-1-methyl-5-propylbarbituric acid,CCCC1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
8911,43606,"1,1-Difluorooctane",CCCCCCCC(F)F,,,,,,
8912,43607,"3a,4,7,7a-Tetrahydro-2-(2-(1-piperidinyl)ethyl)-1H-isoindole-1,3(2H)-dione hydrochloride",C1CC[NH+](CC1)CCN2C(=O)C3CC=CCC3C2=O.[Cl-],,,,,,
8913,43608,"2-(2-Piperidin-1-ylethyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione",C1CCN(CC1)CCN2C(=O)C3CC=CCC3C2=O,,,,,,
8914,43609,"1H-Isoindole-1,3(2H)-dione, 3a,4,7,7a-tetrahydro-2-(4-(2-(1-piperidinyl)ethoxy)phenyl)-, monohydrochloride",C1CC[NH+](CC1)CCOC2=CC=CC(=C2)N3C(=O)C4CC=CCC4C3=O.[Cl-],,,,,,
8915,43610,"2-[3-(2-Piperidin-1-ylethoxy)phenyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione",C1CCN(CC1)CCOC2=CC=CC(=C2)N3C(=O)C4CC=CCC4C3=O,,,,,,
8916,43611,"3a,4,7,7a-Tetrahydro-2-(2-(4-morpholinyl)ethyl)-1H-isoindole-1,3(2H)-dione hydrochloride",C1COCC[NH+]1CCN2C(=O)C3CC=CCC3C2=O.[Cl-],,,,,,
8917,43612,"2-(2-Morpholin-4-ylethyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione",C1COCCN1CCN2C(=O)C3CC=CCC3C2=O,,,,,,
8918,43613,"3a,4,7,7a-Tetrahydro-2-(4-(2-(1-pyrrolidinyl)ethoxy)cyclohexyl)-1H-isoindole-1,3(2H)-dione",C1CCN(C1)CCOC2CCC(CC2)N3C(=O)C4CC=CCC4C3=O,,,,,,
8919,43614,"1H-Isoindole-1,3(2H)-dione, 4,5,6,7-tetrahydro-2-(2-pyridinyl)-",C1CCC2=C(C1)C(=O)N(C2=O)C3=CC=CC=N3,,,,,,
8920,43615,"Benzamide, N,N-diethyl-4-(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-YL)-",CCN(CC)C(=O)C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)CCCC3,,,,,,
8921,43616,"Benzoic acid, 4-(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)CCCC3.[Cl-],,,,,,
8922,43617,"2-(Diethylamino)ethyl 4-(1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)benzoate",CCN(CC)CCOC(=O)C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)CCCC3,,,,,,
8923,43618,"Benzoic acid, 3-(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC(=CC=C1)N2C(=O)C3=C(C2=O)CCCC3.[Cl-],,,,,,
8924,43619,"2-(Diethylamino)ethyl 3-(1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)benzoate",CCN(CC)CCOC(=O)C1=CC(=CC=C1)N2C(=O)C3=C(C2=O)CCCC3,,,,,,
8925,43620,"1H-Isoindole-1,3(2H)-dione, 4,5,6,7-tetrahydro-2-(4-(2-(1-piperidinyl)ethoxy)phenyl)-",C1CCN(CC1)CCOC2=CC=CC(=C2)N3C(=O)C4=C(C3=O)CCCC4,,,,,,
8926,43621,"1H-Isoindole-1,3(2H)-dione, 4,5,6,7-tetrahydro-2-(4-(2-(4-morpholinyl)ethoxy)phenyl)-, monohydrochloride",C1CCC2=C(C1)C(=O)N(C2=O)C3=CC(=CC=C3)OCC[NH+]4CCOCC4.[Cl-],,,,,,
8927,43622,"2-[3-(2-Morpholin-4-ylethoxy)phenyl]-4,5,6,7-tetrahydroisoindole-1,3-dione",C1CCC2=C(C1)C(=O)N(C2=O)C3=CC(=CC=C3)OCCN4CCOCC4,,,,,,
8928,43623,"Benzylamine, N-(2-bromoethyl)-2-methoxy-5-nitro-",COC1=C(C=C(C=C1)[N+](=O)[O-])CNCCBr,,,,,,
8929,43624,"Benzylamine, N-(2-bromoethyl)-2-ethoxy-5-nitro-",CCOC1=C(C=C(C=C1)[N+](=O)[O-])CNCCBr,,,,,,
8930,43625,"Ethanol, 2-(((2-methoxy-5-nitrophenyl)methyl)amino)-",COC1=C(C=C(C=C1)[N+](=O)[O-])CNCCO,,,,,,
8931,43626,CID 43626,C[C@@H]1C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)C4CCCC4)C(=C5C(=C2O)C(=C(C6=C5C(=O)[C@](O6)(OC=C[C@@H]([C@@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
8932,43627,CID 43627,CC1=CC=CC=C1N2C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])N=C2S,,,,,,
8933,43628,CID 43628,CC1=CC(=CC=C1)N2C(=O)C(=CC3=CC(=CC=C3)Cl)N=C2S,,,,,,
8934,43629,CID 43629,CC1=CC(=CC=C1)N2C(=O)C(=CC3=CC=C(C=C3)Cl)N=C2S,,,,,,
8935,43630,CID 43630,CC1=CC=C(C=C1)C=C2C(=O)N(C(=N2)S)C3=CC=CC(=C3)C,,,,,,
8936,43631,"Diacetic acid 5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo[de,g]quinoline-10,11-diyl ester",CCCN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)OC(=O)C)OC(=O)C,,,,,,
8937,43632,"Aporphine-10,11-diyl methoxyacetate tartrate",CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)OC(=O)COC)OC(=O)COC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
8938,43633,"[(6aR)-11-(2-methoxyacetyl)oxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl] 2-methoxyacetate",CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)OC(=O)COC)OC(=O)COC,,,,,,
8939,43634,"10,11-Dihydroxy-6-propylaporphinium iodide",CCC[N+]1(CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O)C.[I-],,,,,,
8940,43635,"(6aS)-6-methyl-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-10,11-diol",CCC[N+]1(CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O)C,,,,,,
8941,43636,12-Fluoro-5-methylchrysene,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C(=C3)F,,,,,,
8942,43637,5-Methoxychrysene,COC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,,,,,,
8943,43638,1-((n-Dodecanoyloxy)methyl)-3-methylimidazolinium chloride,CCCCCCCCCCCC(=O)OCN1C=C[N+](=C1)C.[Cl-],,,,,,
8944,43639,(3-Methylimidazol-3-ium-1-yl)methyl dodecanoate,CCCCCCCCCCCC(=O)OCN1C=C[N+](=C1)C,,,,,,
8945,43640,"ACRIDINE, 9-(p-ANISIDINO)-",COC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
8946,43641,4-Hydroxybutyl-(2-propenyl)nitrosamine,C=CCN(CCCCO)N=O,,,,,,
8947,43642,2-(Hexylamino)-N-(2-methyl-4-phenoxyphenyl)acetamide hydrochloride,CCCCCC[NH2+]CC(=O)NC1=C(C=C(C=C1)OC2=CC=CC=C2)C.[Cl-],,,,,,
8948,43643,2-(hexylamino)-N-(2-methyl-4-phenoxyphenyl)acetamide,CCCCCCNCC(=O)NC1=C(C=C(C=C1)OC2=CC=CC=C2)C,,,,,,
8949,43644,"Acetamide, 2-(dipropylamino)-N-(2-methyl-4-(phenylmethoxy)phenyl)-, monohydrochloride",CCCN(CCC)CC(=O)NC1=C(C=C(C=C1)OCC2=CC=CC=C2)C.Cl,,,,,,
8950,43645,2-(dipropylamino)-N-(2-methyl-4-phenylmethoxyphenyl)acetamide,CCCN(CCC)CC(=O)NC1=C(C=C(C=C1)OCC2=CC=CC=C2)C,,,,,,
8951,43646,N-(2-Methyl-4-(phenylmethoxy)phenyl)-2-(propylamino)acetamide hydrochloride,CCC[NH2+]CC(=O)NC1=C(C=C(C=C1)COC2=CC=CC=C2)C.[Cl-],,,,,,
8952,43647,N-[2-methyl-4-(phenoxymethyl)phenyl]-2-(propylamino)acetamide,CCCNCC(=O)NC1=C(C=C(C=C1)COC2=CC=CC=C2)C,,,,,,
8953,43648,CID 43648,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=CC4=CC=CC=C43)N=C2S,,,,,,
8954,43649,CID 43649,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC=CC4=CC=CC=C43)N=C2S,,,,,,
8955,43650,CID 43650,C1=CC=C2C(=C1)C=CC=C2C=C3C(=O)N(C(=N3)S)C4=CC=C(C=C4)Cl,,,,,,
8956,43651,CID 43651,C1=CC=C(C=C1)N2C(=O)C(=CC3=CC4=CC=CC=C4C=C3)N=C2S,,,,,,
8957,43652,CID 43652,CC1=CC=C(C=C1)N2C(=O)C(=CC3=CC4=CC=CC=C4C=C3)N=C2S,,,,,,
8958,43653,CID 43653,C1=CC=C2C=C(C=CC2=C1)C=C3C(=O)N(C(=N3)S)C4=CC=C(C=C4)Cl,,,,,,
8959,43654,"Benzoic acid, 4-(2,8,9-trioxa-5-aza-1-silabicyclo(3.3.3)undec-1-yloxy)-, methyl ester",COC(=O)C1=CC=C(C=C1)O[Si]23OCCN(CCO2)CCO3,,,,,,
8960,43655,8-Hydroxyloxapine,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)O)OC4=C2C=C(C=C4)Cl,,,,,,
8961,43656,8-Hydroxyamoxapine,C1CN(CCN1)C2=NC3=C(C=CC(=C3)O)OC4=C2C=C(C=C4)Cl,,,,,,
8962,43657,"Heptanoic acid, (3Z)-3-hexenyl ester",CCCCCCC(=O)OCCC=CCC,,,,,,
8963,43658,Hex-3-enyl octanoate,CCCCCCCC(=O)OCCC=CCC,,,,,,
8964,43659,N-Nitroso-N-methyl-4-aminobutyric acid,CN(CCCC(=O)O)N=O,,,,,,
8965,43660,"AZETIDINE, 1-(10,11-DIHYDRO-5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-3-METHYLAMINO-",CNC1CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
8966,43661,"AZETIDINE, 1-(5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)-3-METHYLAMINO-",CNC1CN(C1)C2C3=CC=CC=C3C=CC4=CC=CC=C24,,,,,,
8967,43662,"Azetidine, 1-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-3-methyl-3-(methylamino)-",CC1(CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24)NC,,,,,,
8968,43663,"Azetidine, 1-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-3-(methylamino)methylene-",CNCC1CN(C1)C2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
8969,43664,"ACRIDINE, 9-(p-CHLOROANILINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)Cl,,,,,,
8970,43665,"2,3,6-Trichlorocumene",CC(C)C1=C(C=CC(=C1Cl)Cl)Cl,,,,,,
8971,43666,"1,3,4-Trichloro-2,5-dimethoxybenzene",COC1=CC(=C(C(=C1Cl)Cl)OC)Cl,,,,,,
8972,43667,"PYRIMIDO(3,4-a)INDOLE, 1,2,3,4-TETRAHYDRO-2,5,7-TRIMETHYL-",CC1=CC2=C(C=C1)N3CN(CCC3=C2C)C,,,,,,
8973,43668,"1,2,3,4-Tetrahydro-2,3,5-trimethylpyrimido(3,4-a)indole",CC1CC2=C(C3=CC=CC=C3N2CN1C)C,,,,,,
8974,43669,"Indole, 3,5-dimethyl-2-(2-dimethylaminoethyl)-",CC1=CC2=C(C=C1)NC(=C2C)CCN(C)C,,,,,,
8975,43670,(alpha-Methyl-m-trifluoromethylphenethylamino)acetic acid,CC(CC1=CC(=CC=C1)C(F)(F)F)NCC(=O)O,,,,,,
8976,43671,2-(beta-Methoxy-m-trifluoromethylphenethylamino)acetic acid,COC(CNCC(=O)O)C1=CC(=CC=C1)C(F)(F)F,,,,,,
8977,43672,Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,['For the treatment of polymicrobial infections.'],"['Piperacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name ""penicillin"" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Piperacillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Piperacillin results from the inhibition of cell wall synthesis and is mediated through Piperacillin binding to penicillin binding proteins (PBPs). Piperacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Not absorbed following oral administration.', 'As with other penicillins, PIPRACIL is eliminated primarily by glomerular filtration and tubular secretion; it is excreted rapidly as unchanged drug in high concentrations in the urine. Because PIPRACIL is excreted by the biliary route as well as by the renal route, it can be used safely in appropriate dosage in patients with severely restricted kidney function.', '101 mL/kg [intravenous administration of 50 mg/kg (5-minute infusion) in neonates]', '32\xa0-\xa041 mL/min/1.73\xa0m2']",['Largely not metabolized.'],['36-72 minutes']
8978,43673,"4-t-Butyl-1-oxo-1-phospha-2,6,7-trioxabicyclo(2.2.2)octane",CC(C)(C)C12COP(=O)(OC1)OC2,,,,,,
8979,43674,"7,8,9,10-Tetrahydroxytetrahydrobenzo(a)pyrene",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]([C@H]([C@@H]([C@H]5O)O)O)O)C=C2,,,,,,
8980,43675,(+)-cis-BPT,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@H]([C@H]([C@@H]5O)O)O)O)C=C2,,,,,,
8981,43676,Benzo(a)pyrenetetrol II 2,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]([C@@H]([C@H]([C@@H]5O)O)O)O)C=C2,,,,,,
8982,43677,N-Nitroso(2-hydroxypropyl)(2-oxopropyl)amine,CC(CN(CC(=O)C)N=O)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
8983,43678,Luprostiol,C1C(C(C(C1O)SCC(COC2=CC(=CC=C2)Cl)O)CC=CCCCC(=O)O)O,,,,,,
8984,43679,"4-Hydroxy-3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one",COC1=C(C=CC(=C1)C[C@H]2C(=O)OC[C@]2(CC3=CC(=C(C=C3)O)OC)O)O,,,,,,
8985,43680,CID 43680,CC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)CSC(=N[NH3+])N.[Br-],,,,,,
8986,43681,CID 43681,CC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)CSC(=NN)N,,,,,,
8987,43682,Tetramethylhydrazine hydrochloride,C[NH+](C)N(C)C.[Cl-],,,,,,
8988,43683,Tetramethylhydrazine,CN(C)N(C)C,,,,,,
8989,43684,"2,2'-Iminodiethanol dibutanesulfonate hydrochloride",CCCCS(=O)(=O)OCC[NH2+]CCOS(=O)(=O)CCCC.[Cl-],,,,,,
8990,43685,2-(2-Butylsulfonyloxyethylamino)ethyl butane-1-sulfonate,CCCCS(=O)(=O)OCCNCCOS(=O)(=O)CCCC,,,,,,
8991,43686,"2,2'-Iminodiethanol dipentanesulfonate hydrochloride",CCCCCS(=O)(=O)OCC[NH2+]CCOS(=O)(=O)CCCCC.[Cl-],,,,,,
8992,43687,2-(2-Pentylsulfonyloxyethylamino)ethyl pentane-1-sulfonate,CCCCCS(=O)(=O)OCCNCCOS(=O)(=O)CCCCC,,,,,,
8993,43688,6-((2-Hydroxyethyl)amino)-1-hexanol dimethanesulfonate hydrochloride,CS(=O)(=O)OCCCCCC[NH2+]CCOS(=O)(=O)C.[Cl-],,,,,,
8994,43689,6-(2-Methylsulfonyloxyethylamino)hexyl methanesulfonate,CS(=O)(=O)OCCCCCCNCCOS(=O)(=O)C,,,,,,
8995,43690,6-((2-Hydroxyethyl)amino)-1-hexanol diethanesulfonate hydrochloride,CCS(=O)(=O)OCCCCCC[NH2+]CCOS(=O)(=O)CC.[Cl-],,,,,,
8996,43691,6-(2-Ethylsulfonyloxyethylamino)hexyl ethanesulfonate,CCS(=O)(=O)OCCCCCCNCCOS(=O)(=O)CC,,,,,,
8997,43692,6-((2-Hydroxyethyl)amino)-1-hexanol dipropanesulfonate hydrochloride,CCCS(=O)(=O)OCCCCCC[NH2+]CCOS(=O)(=O)CCC.[Cl-],,,,,,
8998,43693,6-(2-Propylsulfonyloxyethylamino)hexyl propane-1-sulfonate,CCCS(=O)(=O)OCCCCCCNCCOS(=O)(=O)CCC,,,,,,
8999,43694,6-((2-Hydroxyethyl)amino)-1-hexanol dibutanesulfonate hydrochloride,CCCCS(=O)(=O)OCCCCCC[NH2+]CCOS(=O)(=O)CCCC.[Cl-],,,,,,
9000,43695,6-(2-Butylsulfonyloxyethylamino)hexyl butane-1-sulfonate,CCCCS(=O)(=O)OCCCCCCNCCOS(=O)(=O)CCCC,,,,,,
9001,43696,6-((3-Hydroxypropyl)amino)-1-hexanol dimethanesulfonate hydrochloride,CS(=O)(=O)OCCCCCC[NH2+]CCCOS(=O)(=O)C.[Cl-],,,,,,
9002,43697,6-(3-Methylsulfonyloxypropylamino)hexyl methanesulfonate,CS(=O)(=O)OCCCCCCNCCCOS(=O)(=O)C,,,,,,
9003,43698,6-((3-Hydroxypropyl)amino)-1-hexanol diethanesulfonate hydrochloride,CCS(=O)(=O)OCCCCCC[NH2+]CCCOS(=O)(=O)CC.[Cl-],,,,,,
9004,43699,6-(3-Ethylsulfonyloxypropylamino)hexyl ethanesulfonate,CCS(=O)(=O)OCCCCCCNCCCOS(=O)(=O)CC,,,,,,
9005,43700,6-((3-Hydroxypropyl)amino)-1-hexanol dipropanesulfonate hydrochloride,CCCS(=O)(=O)OCCCCCC[NH2+]CCCOS(=O)(=O)CCC.[Cl-],,,,,,
9006,43701,6-(3-Propylsulfonyloxypropylamino)hexyl propane-1-sulfonate,CCCS(=O)(=O)OCCCCCCNCCCOS(=O)(=O)CCC,,,,,,
9007,43702,"4-(5,5-Dimethyl-1-phenylpyrazolidin-3-ylidene)-5-methyloxolane-2,3-dione",CC1C(=C2CC(N(N2)C3=CC=CC=C3)(C)C)C(=O)C(=O)O1,,,,,,
9008,43703,Kumulan,CC(C)OC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)OC(C)C.S,,,,,,
9009,43704,Nitrothal-isopropyl,CC(C)OC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)OC(C)C,,,,,,
9010,43705,"OXALIC ACID, p-ACETAMIDOPHENYLSULFONYLHYDRAZIDE",CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NNC(=O)C(=O)O,,,,,,
9011,43706,"OXAMIDE, N-(p-AMINOBENZYLSULFONYL)-N'-(p-AMINOPHENYLSULFONYL)-",C1=CC(=CC=C1CS(=O)(=O)NC(=O)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N)N,,,,,,
9012,43707,Dinofenate,CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)OC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9013,43708,Cefotiam,CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O,['For treatment of severe infections caused by susceptible bacteria.'],['Cefotiam is a third generation beta-lactam cephalosporin antibiotic that works by inhibiting bacterial cell wall biosynthesis. It is a broad spectrum antibiotic that is effective against Gram positive and Gram negative bacteria.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection.'],,['Approximately 1 hour.']
9014,43709,4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)CCC(=O)O,,,,,,
9015,43710,"4-Acetoxy-4-androstene-3,17-dione",CC(=O)OC1=C2CC[C@H]3[C@@H]4CCC(=O)[C@]4(CC[C@@H]3[C@]2(CCC1=O)C)C,,,,,,
9016,43711,"Phenol, 4,5-dichloro-2-(2,4,5-trichlorophenoxy)-",C1=C(C(=CC(=C1Cl)Cl)OC2=CC(=C(C=C2Cl)Cl)Cl)O,,,,,,
9017,43712,"ACETAMIDE, N-(4-(3-PHENYLOXIRANYL)PHENYL)-, cis-",CC(=O)NC1=CC=C(C=C1)[C@@H]2[C@@H](O2)C3=CC=CC=C3,,,,,,
9018,43713,"ACETAMIDE, N-(4-(3-PHENYLOXIRANYL)PHENYL)-, trans-",CC(=O)NC1=CC=C(C=C1)[C@@H]2[C@H](O2)C3=CC=CC=C3,,,,,,
9019,43714,Cymiazole,CC1=CC(=C(C=C1)N=C2N(C=CS2)C)C,,,,,,
9020,43715,1'-Acetoxyestragole,CC(=O)OC(C=C)C1=CC=C(C=C1)OC,,,,,,
9021,43716,1'-Acetoxy-1-allyl-4-methoxynaphthalene,CC(=O)OC(C=C)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
9022,43717,6-Oxiranylbenzo(a)pyrene,C1C(O1)C2=C3C=CC4=CC=CC5=C4C3=C(C=C5)C6=CC=CC=C62,,,,,,
9023,43718,"BENZ(a)ANTHRACENE, 7-VINYL-",C=CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C41,,,,,,
9024,43719,7-Benzanthryloxirane,C1C(O1)C2=C3C=CC4=CC=CC=C4C3=CC5=CC=CC=C52,,,,,,
9025,43720,9-Anthryloxirane,C1C(O1)C2=C3C=CC=CC3=CC4=CC=CC=C42,,,,,,
9026,43721,7-Oxiranyl-12-methylbenz(a)anthracene,CC1=C2C(=C(C3=CC=CC=C13)C4CO4)C=CC5=CC=CC=C52,,,,,,
9027,43722,2-(p-Aminophenyl)-2-methoxy-2-phenylacetonitrile,COC(C#N)(C1=CC=CC=C1)C2=CC=C(C=C2)N,,,,,,
9028,43723,2-(p-Aminophenyl)-2-phenylbutyramide hydrochloride,CCC(C1=CC=CC=C1)(C2=CC=C(C=C2)[NH3+])C(=O)N.[Cl-],,,,,,
9029,43724,2-(4-Aminophenyl)-2-phenylbutanamide,CCC(C1=CC=CC=C1)(C2=CC=C(C=C2)N)C(=O)N,,,,,,
9030,43725,(E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O,,,,,,
9031,43726,"N,N'-Bis(9-acridinyl)-1,5-pentanediamine",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
9032,43727,"Acridine, 9,9'-heptamethylenediiminobis-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
9033,43728,CID 43728,CC[NH+](CC)CCON=CC1=CC=C(C=C1)[N+](=O)[O-].[Cl-],,,,,,
9034,43729,CID 43729,CCN(CC)CCON=CC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
9035,43730,CID 43730,CC[NH+](CC)CCON=CC1=CC=CC=C1Cl.[Cl-],,,,,,
9036,43731,CID 43731,CCN(CC)CCON=CC1=CC=CC=C1Cl,,,,,,
9037,43732,CID 43732,CC[NH+](CC)CCON=CC1=CC(=CC=C1)Cl.[Cl-],,,,,,
9038,43733,CID 43733,CCN(CC)CCON=CC1=CC(=CC=C1)Cl,,,,,,
9039,43734,CID 43734,CC[NH+](CC)CCON=CC1=CC=C(C=C1)Cl.[Cl-],,,,,,
9040,43735,"2-[(4-chlorophenyl)methylideneamino]oxy-N,N-diethylethanamine",CCN(CC)CCON=CC1=CC=C(C=C1)Cl,,,,,,
9041,43736,CID 43736,CC[NH+](CC)CCON=CC1=CC=C(C=C1)F.[Cl-],,,,,,
9042,43737,CID 43737,CCN(CC)CCON=CC1=CC=C(C=C1)F,,,,,,
9043,43738,CID 43738,CC[NH+](CC)CCON=CC1=CC=C(C=C1)Br.[Cl-],,,,,,
9044,43739,CID 43739,CCN(CC)CCON=CC1=CC=C(C=C1)Br,,,,,,
9045,43740,CID 43740,CC[NH+](CC)CCCON=CC1=CC=C(C=C1)Cl.[Cl-],,,,,,
9046,43741,CID 43741,CCN(CC)CCCON=CC1=CC=C(C=C1)Cl,,,,,,
9047,43742,CID 43742,CC[NH+](CC)C(C)CON=CC1=CC=C(C=C1)Cl.[Cl-],,,,,,
9048,43743,CID 43743,CCN(CC)C(C)CON=CC1=CC=C(C=C1)Cl,,,,,,
9049,43744,CID 43744,C1COCC[NH+]1CCON=CC2=CC(=CC=C2)[N+](=O)[O-].[Cl-],,,,,,
9050,43745,CID 43745,C1COCCN1CCON=CC2=CC(=CC=C2)[N+](=O)[O-],,,,,,
9051,43746,N-(2-morpholin-4-ium-4-ylethoxy)-1-(4-nitrophenyl)methanimine;chloride,C1COCC[NH+]1CCON=CC2=CC=C(C=C2)[N+](=O)[O-].[Cl-],,,,,,
9052,43747,N-(2-morpholin-4-ylethoxy)-1-(4-nitrophenyl)methanimine,C1COCCN1CCON=CC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
9053,43748,CID 43748,CC1=CC=C(C=C1)C=NOCC[NH+]2CCOCC2.[Cl-],,,,,,
9054,43749,CID 43749,CC1=CC=C(C=C1)C=NOCCN2CCOCC2,,,,,,
9055,43750,1-(4-fluorophenyl)-N-(2-morpholin-4-ium-4-ylethoxy)methanimine;chloride,C1COCC[NH+]1CCON=CC2=CC=C(C=C2)F.[Cl-],,,,,,
9056,43751,1-(4-fluorophenyl)-N-(2-morpholin-4-ylethoxy)methanimine,C1COCCN1CCON=CC2=CC=C(C=C2)F,,,,,,
9057,43752,CID 43752,C1COCC[NH+]1CCON=CC2=CC=C(C=C2)Cl.[Cl-],,,,,,
9058,43753,CID 43753,C1COCCN1CCON=CC2=CC=C(C=C2)Cl,,,,,,
9059,43754,1-(4-bromophenyl)-N-(2-morpholin-4-ium-4-ylethoxy)methanimine;chloride,C1COCC[NH+]1CCON=CC2=CC=C(C=C2)Br.[Cl-],,,,,,
9060,43755,1-(4-bromophenyl)-N-(2-morpholin-4-ylethoxy)methanimine,C1COCCN1CCON=CC2=CC=C(C=C2)Br,,,,,,
9061,43756,CID 43756,C1COCC[NH+]1CCCON=CC2=CC=C(C=C2)Cl.[Cl-],,,,,,
9062,43757,CID 43757,C1COCCN1CCCON=CC2=CC=C(C=C2)Cl,,,,,,
9063,43758,1-(4-chlorophenyl)-N-[2-(4-methylpiperazin-1-yl)ethoxy]methanimine;dihydrochloride,CN1CCN(CC1)CCON=CC2=CC=C(C=C2)Cl.Cl.Cl,,,,,,
9064,43759,1-(4-chlorophenyl)-N-[2-(4-methylpiperazin-1-yl)ethoxy]methanimine,CN1CCN(CC1)CCON=CC2=CC=C(C=C2)Cl,,,,,,
9065,43760,1-(4-chlorophenyl)-N-[2-[4-(2-phenylethyl)piperazin-1-yl]ethoxy]methanimine;dihydrochloride,C1CN(CCN1CCC2=CC=CC=C2)CCON=CC3=CC=C(C=C3)Cl.Cl.Cl,,,,,,
9066,43761,1-(4-chlorophenyl)-N-[2-[4-(2-phenylethyl)piperazin-1-yl]ethoxy]methanimine,C1CN(CCN1CCC2=CC=CC=C2)CCON=CC3=CC=C(C=C3)Cl,,,,,,
9067,43762,CID 43762,C1CN(CCN1CCO)CCON=CC2=CC=C(C=C2)Cl.Cl.Cl,,,,,,
9068,43763,CID 43763,C1CN(CCN1CCO)CCON=CC2=CC=C(C=C2)Cl,,,,,,
9069,43764,CID 43764,CC[NH+](CC)CCON=CC1=CC2=CC=CC=C2C=C1.[Cl-],,,,,,
9070,43765,CID 43765,CCN(CC)CCON=CC1=CC2=CC=CC=C2C=C1,,,,,,
9071,43766,N-Nitroso-N-pentyl-(4-hydroxybutyl)amine,CCCCCN(CCCCO)N=O,,,,,,
9072,43767,"1-Butanol, 4-((1,1-dimethylethyl)nitrosoamino)-",CC(C)(C)N(CCCCO)N=O,,,,,,
9073,43768,N-Butyl-N-(3-oxobutyl)nitrosamine,CCCCN(CCC(=O)C)N=O,,,,,,
9074,43769,"3-Butanone, 4-(butylnitrosamino)-",CCCCN(CC(=O)CC)N=O,,,,,,
9075,43770,"3-Fluorobenzo(a,i)pyrene",C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC6=C(C=CC(=C6)F)C(=C54)C=C3,,,,,,
9076,43771,"2,10-Difluorobenzo(a,i)pyrene",C1=CC(=CC2=C3C=CC4=C5C3=C(C=CC5=CC6=C4C=CC(=C6)F)C=C21)F,,,,,,
9077,43772,"Anthracene-1,5-disulfonic acid",C1=CC2=CC3=C(C=CC=C3S(=O)(=O)O)C=C2C(=C1)S(=O)(=O)O,,,,,,
9078,43773,"1,8-Anthracenedisulfonic acid",C1=CC2=CC3=C(C=C2C(=C1)S(=O)(=O)O)C(=CC=C3)S(=O)(=O)O,,,,,,
9079,43774,1-methoxy-N-nitrosodiethylamine,CCN(C(C)OC)N=O,,,,,,
9080,43775,"Ethylamine, N-(methoxymethyl)-N-nitroso-",CCN(COC)N=O,,,,,,
9081,43776,"Ethylamine, 1-methoxy-N-methyl-N-nitroso-",CC(N(C)N=O)OC,,,,,,
9082,43777,1-Fluoro-4-methylchrysene,CC1=C2C3=C(C=CC2=C(C=C1)F)C4=CC=CC=C4C=C3,,,,,,
9083,43778,N-(decylideneamino)-N-methylformamide,CCCCCCCCCC=NN(C)C=O,,,,,,
9084,43779,CID 43779,CC[NH+](CC)CCON=CC1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
9085,43780,CID 43780,CCN(CC)CCON=CC1=CC=CC2=CC=CC=C21,,,,,,
9086,43781,S-(Diisobutylcarbamoyl)cysteine,CC(C)CN(CC(C)C)C(=O)SC[C@@H](C(=O)O)N,,,,,,
9087,43782,"S-(N,N-Dipropylcarbamoyl)-N-acetylcysteine",CCCN(CCC)C(=O)SC[C@@H](C(=O)O)NC(=O)C,,,,,,
9088,43783,"L-CYSTEINE, N-ACETYL-, BIS(2-METHYLPROPYL)CARBAMATE (ester)",CC(C)CN(CC(C)C)C(=O)SC[C@@H](C(=O)O)NC(=O)C,,,,,,
9089,43784,N-Acetyl-L-cysteine (2-methylpropyl)carbamate (ester),CC(C)CNC(=O)SC[C@@H](C(=O)O)NC(=O)C,,,,,,
9090,43785,"Glycine, N-((((dipropylamino)carbonyl)thio)acetyl)-",CCCN(CCC)C(=O)SCC(=O)NCC(=O)O,,,,,,
9091,43786,"Glycine, N-((((bis(2-methylpropyl)amino)carbonyl)thio)acetyl)-",CC(C)CN(CC(C)C)C(=O)SCC(=O)NCC(=O)O,,,,,,
9092,43787,3-Phenoxybenzoyl cyanide,C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)C#N,,,,,,
9093,43788,"Benzofurazan, 4-nitro-7-(4-propyl-1-piperazinyl)-, 1-oxide",CCCN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-],,,,,,
9094,43789,"Benzofurazan, 7-(4-(2-hydroxyethyl)-1-piperazinyl)-4-nitro-, 1-oxide",C1CN(CCN1CCO)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-],,,,,,
9095,43790,"Benzofurazan, 4-(1-aziridinyl)-7-nitro-, 3-oxide",C1CN1C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-],,,,,,
9096,43791,"Benzofurazan, 4-nitro-7-(4-phenyl-1-piperazinyl)-, 1-oxide",C1CN(CCN1C2=CC=CC=C2)C3=CC=C(C4=NO[N+](=C34)[O-])[N+](=O)[O-],,,,,,
9097,43792,"Benzofurazan, 4-(4-(4-methoxyphenyl)-1-piperazinyl)-7-nitro-, 3-oxide",COC1=CC=C(C=C1)N2CCN(CC2)C3=CC=C(C4=NO[N+](=C34)[O-])[N+](=O)[O-],,,,,,
9098,43793,"Benzofurazan, 7-(4-(3-methoxyphenyl)-1-piperazinyl)-4-nitro-, 1-oxide",COC1=CC=CC(=C1)N2CCN(CC2)C3=CC=C(C4=NO[N+](=C34)[O-])[N+](=O)[O-],,,,,,
9099,43794,"Benzofurazan, 7-(4-(3-methylphenyl)-1-piperazinyl)-4-nitro-, 1-oxide",CC1=CC(=CC=C1)N2CCN(CC2)C3=CC=C(C4=NO[N+](=C34)[O-])[N+](=O)[O-],,,,,,
9100,43795,"Benzofurazan, 7-(4-benzyl-1-piperazinyl)-4-nitro-, 1-oxide",C1CN(CCN1CC2=CC=CC=C2)C3=CC=C(C4=NO[N+](=C34)[O-])[N+](=O)[O-],,,,,,
9101,43796,"Mercury, hydroxy(4-hydroxy-3-nitrophenyl)-",C1=CC(=C(C=C1[Hg])[N+](=O)[O-])O.O,,,,,,
9102,43797,3-Ethyl-4-heptyn-3-amine hydrochloride,CCC#CC(CC)(CC)[NH3+].[Cl-],,,,,,
9103,43798,"4-Heptyn-3-amine, 3-ethyl-",CCC#CC(CC)(CC)N,,,,,,
9104,43799,CID 43799,CCC=CC(CC)(CC)[NH3+].[Cl-],,,,,,
9105,43800,3-Ethylhept-4-en-3-amine,CCC=CC(CC)(CC)N,,,,,,
9106,43801,CID 43801,CCCC(C=CCC)(C(C)C)[NH3+].[Cl-],,,,,,
9107,43802,CID 43802,CCCC(C=CCC)(C(C)C)N,,,,,,
9108,43803,CID 43803,CCCC(CCC)(CC#C)[NH3+].CCCC(CCC)(CC#C)[NH3+].C(=CC(=O)[O-])C(=O)[O-],,,,,,
9109,43804,4-Propylhept-1-yn-4-amine,CCCC(CCC)(CC#C)N,,,,,,
9110,43805,Lipoxal,C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)[O-])[O-].[Pt+4],,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
9111,43806,"(1R,2R)-(-)-1,2-Diaminocyclohexane",C1CC[C@H]([C@@H](C1)N)N,,,,,,
9112,43807,1-Methyl-2-carboxy-3-(alpha-methoxybenzyl)indole,CN1C2=CC=CC=C2C(=C1C(=O)O)C(C3=CC=CC=C3)OC,,,,,,
9113,43808,1-Methyl-2-carboxy-3-(alpha-ethoxybenzyl)indole,CCOC(C1=CC=CC=C1)C2=C(N(C3=CC=CC=C32)C)C(=O)O,,,,,,
9114,43809,"2-Phenyl-4,5,6,7-tetrahydroisoindole",C1CCC2=CN(C=C2C1)C3=CC=CC=C3,,,,,,
9115,43810,"2,4-dinitro-N-[(2-phenyl-4,5,6,7-tetrahydroisoindol-1-yl)methylideneamino]aniline",C1CCC2=C(N(C=C2C1)C3=CC=CC=C3)C=NNC4=C(C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9116,43811,CID 43811,CC1CCC2=C(N(C=C2C1)C3=CC=CC=C3)C=NNC4=C(C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9117,43812,CID 43812,CC1=CCC2=C(N(C=C2C1)C3=CC=CC=C3)C=NNC4=C(C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9118,43813,"Glycine, N-butyl-N-nitroso-",CCCCN(CC(=O)O)N=O,,,,,,
9119,43814,Domiodol,C1C(OC(O1)CI)CO,,,,,,
9120,43815,Paroxetine,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,"['Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).']","['Paroxetine treats the symptoms of depression, various anxiety disorders, posttraumatic stress disorder, obsessive-compulsive disorder, and the vasomotor symptoms of menopause via the inhibition of serotonin reuptake. The onset of action of paroxetine is reported to be approximately 6 weeks.  Due its serotonergic activity, paroxetine, like other SSRI drugs, may potentiate serotonin syndrome. This risk is especially high when monoamine oxidase (MAO) inhibitors are given within 2 weeks of paroxetine administration. Upon cessation of MAO inhibitors, a 2-week interval before paroxetine administration is recommended. Do not coadminister these agents.']","['Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6. (See all compounds classified as Cytochrome P-450 CYP2D6 Inhibitors.)', 'Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)', 'A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)']","['Paroxetine is readily absorbed from the gastrointestinal tract. Due to the first-pass metabolism, the bioavailability ranges from 30-60%. Cmax is attained 2 to 8 hours after an oral dose. Mean Tmax is 4.3 hours in healthy patients.  The steady-state concentration of paroxetine is achieved within 7 to 14 days of oral therapy. In a pharmacokinetic study, AUC in healthy patients was 574 ngh/mL and 1053 ngh/mL in those with moderate renal impairment.', 'About 2/3 of a single paroxetine dose is found to be excreted in the urine and the remainder is found to be excreted in feces. Almost all of the dose is eliminated as metabolites; 3% is found to be excreted as unchanged paroxetine. About 64% of a 30 mg oral dose was found excreted in the urine, with 2% as the parent drug and 62% appearing as metabolites. Approximately 36% of the dose was found to be eliminated in the feces primarily as metabolites and less than 1% as the parent compound.', 'Paroxetine has a large volume of distribution and is found throughout the body, including in the central nervous system. Only 1%  of the drug is found in the plasma. Paroxetine is found in the breast milk at concentrations similar to the concentrations found in plasma.', 'The apparent oral clearance of paroxetine is 167 L/h. The clearance of paroxetine in patients with renal failure is significantly lower and dose adjustment may be required, despite the fact that it is mainly cleared by the liver. Dose adjustments may be required in hepatic impairment.', 'Paroxetine hydrochloride appears to be slowly but well absorbed from the GI tract following oral administration. Although the oral bioavailability of paroxetine hydrochloride in humans has not been fully elucidated to date, the manufacturer states that paroxetine is completely absorbed after oral dosing of a solution of the hydrochloride salt. However, the relative proportion of an oral dose that reaches systemic circulation unchanged appears to be relatively small because paroxetine undergoes extensive first-pass metabolism. The oral tablets and suspension of paroxetine hydrochloride reportedly are bioequivalent.', 'In steady-state dose proportionality studies involving elderly and nonelderly patients, at doses of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, again reflecting a saturable metabolic pathway. In comparison to Cmin values after 20 mg daily, values after 40 mg daily were only about 2 to 3 times greater than doubled.', 'Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL. Paroxetine does not alter the in vitro protein binding of phenytoin or warfarin.', 'Paroxetine distributes throughout the body, including the CNS, with only 1% remaining in the plasma.', 'For more Absorption, Distribution and Excretion (Complete) data for PAROXETINE (13 total), please visit the HSDB record page.']","['Paroxetine metabolism occurs in the liver and is largely mediated by cytochrome CYP2D6 with contributions from CYP3A4 and possibly other cytochrome enzymes.  Genetic polymorphisms of the CYP2D6 enzyme may alter the pharmacokinetics of this drug. Poor metabolizers may demonstrate increased adverse effects while rapid metabolizers may experience decreased therapeutic effects.   The majority of a paroxetine dose is oxidized to a catechol metabolite that is subsequently converted to both glucuronide and sulfate metabolites via methylation and conjugation. In rat synaptosomes, the glucuronide and sulfate conjugates have been shown to thousands of times less potent than paroxetine itself. The metabolites of paroxetine are considered inactive.', 'The exact metabolic fate of paroxetine has not been fully elucidated; however, paroxetine is extensively metabolized, probably in the liver. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared by the body. Conjugates with glucuronic acid and sulfate predominate, and the principal metabolites have been isolated and identified. The metabolites of paroxetine have been shown to possess no more than 2% of the potency of the parent compound as inhibitors of serotonin reuptake; therefore, they are essentially inactive.', 'Paroxetine is extensively metabolized after oral administration. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared. Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified. Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake. The metabolism of paroxetine is accomplished in part by CYP2D6. Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions', 'Paroxetine has known human metabolites that include 4-[[(3S,4R)-4-(4-Fluorophenyl)piperidin-3-yl]methoxy]benzene-1,2-diol.']","['The mean elimination half-life of paroxetine is about 21 hours. In healthy young subjects, mean elimination half-life was found to be 17.3 hours.', 'Paroxetine hydrochloride is completely absorbed after oral dosing of a solution of the hydrochloride salt. In a study in which normal male subjects (n = 15) received 30 mg tablets daily for 30 days, steady-state paroxetine concentrations were achieved by approximately 10 days for most subjects, although it may take substantially longer in an occasional patient. At steady state, mean ... half life was ... 21.0 hours (CV 32%) ... .', 'The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of Paxil.', 'The elimination half-life of paroxetine when administered as paroxetine hydrochloride averages approximately 21-24 hours, although there is wide interpatient variation with half-lives (ranging from 7-65 hours in one study). In healthy males receiving one 30-mg tablet of paroxetine (administered as paroxetine mesylate) once daily for 24 days, the mean paroxetine half-life was 33.2 hours. In geriatric individuals, elimination half-life of paroxetine (administered as paroxetine hydrochloride) may be increased (e.g., to about 36 hours).']"
9121,43816,"ISONICOTINAMIDE, N-(p-(1-ADAMANTYL)PHENYL)-, HYDROCHLORIDE",C1C2CC3CC1CC(C2)(C3)C4=CC=C(C=C4)NC(=O)C5=CC=NC=C5.Cl,,,,,,
9122,43817,N-[4-(1-adamantyl)phenyl]pyridine-4-carboxamide,C1C2CC3CC1CC(C2)(C3)C4=CC=C(C=C4)NC(=O)C5=CC=NC=C5,,,,,,
9123,43818,N-(1-(1-Adamantyl)ethyl)isonicotinamide hydrochloride,CC(C12CC3CC(C1)CC(C3)C2)NC(=O)C4=CC=NC=C4.Cl,,,,,,
9124,43819,"N-[1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethyl]pyridine-4-carboxamide",CC(C12CC3CC(C1)CC(C3)C2)NC(=O)C4=CC=NC=C4,,,,,,
9125,43820,N-(1-Adamantylmethyl)isonicotinamide hydrochloride,C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=CC=NC=C4.Cl,,,,,,
9126,43821,N-[(adamantan-1-yl)methyl]pyridine-4-carboxamide,C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=CC=NC=C4,,,,,,
9127,43822,N-(2-(1-Adamantyl)ethyl)isonicotinamide hydrochloride,C1C2CC3CC1CC(C2)(C3)CCNC(=O)C4=CC=NC=C4.Cl,,,,,,
9128,43823,N-[2-(1-adamantyl)ethyl]pyridine-4-carboxamide,C1C2CC3CC1CC(C2)(C3)CCNC(=O)C4=CC=NC=C4,,,,,,
9129,43824,"Isonicotinamide, N-(1-adamantyl)-, 1-oxide, hydrochloride",C1C2CC3CC1CC(C2)(C3)NC(=O)C4=CC=[N+](C=C4)[O-].Cl,,,,,,
9130,43825,N-(1-adamantyl)-1-oxidopyridin-1-ium-4-carboxamide,C1C2CC3CC1CC(C2)(C3)NC(=O)C4=CC=[N+](C=C4)[O-],,,,,,
9131,43826,N-(p-(1-Adamantyl)phenyl)isonicotinamide 1-oxide hydrochloride,C1C2CC3CC1CC(C2)(C3)C4=CC=C(C=C4)NC(=O)C5=CC=[N+](C=C5)[O-].Cl,,,,,,
9132,43827,4-{[4-(Adamantan-1-yl)phenyl]carbamoyl}pyridin-1-ium-1-olate,C1C2CC3CC1CC(C2)(C3)C4=CC=C(C=C4)NC(=O)C5=CC=[N+](C=C5)[O-],,,,,,
9133,43828,N-(1-(1-Adamantyl)ethyl)isonicotinamide 1-oxide hydrochloride,CC(C12CC3CC(C1)CC(C3)C2)NC(=O)C4=CC=[N+](C=C4)[O-].Cl,,,,,,
9134,43829,N-[1-(1-adamantyl)ethyl]-1-oxidopyridin-1-ium-4-carboxamide,CC(C12CC3CC(C1)CC(C3)C2)NC(=O)C4=CC=[N+](C=C4)[O-],,,,,,
9135,43830,N-(1-Adamantylmethyl)isonicotinamide 1-oxide hydrochloride,C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=CC=[N+](C=C4)[O-].Cl,,,,,,
9136,43831,N-(1-adamantylmethyl)-1-oxidopyridin-1-ium-4-carboxamide,C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=CC=[N+](C=C4)[O-],,,,,,
9137,43832,N-(2-(1-Adamantyl)ethyl)isonicotinamide 1-oxide hydrochloride,C1C2CC3CC1CC(C2)(C3)CCNC(=O)C4=CC=[N+](C=C4)[O-].Cl,,,,,,
9138,43833,N-[2-(1-adamantyl)ethyl]-1-oxidopyridin-1-ium-4-carboxamide,C1C2CC3CC1CC(C2)(C3)CCNC(=O)C4=CC=[N+](C=C4)[O-],,,,,,
9139,43834,"3-Biphenylacetic acid, 5-ethoxy-",CCOC1=CC(=CC(=C1)C2=CC=CC=C2)CC(=O)O,,,,,,
9140,43835,"3-Biphenylacetic acid, 5-propoxy-",CCCOC1=CC(=CC(=C1)C2=CC=CC=C2)CC(=O)O,,,,,,
9141,43836,"3-Biphenylacetic acid, 5-isobutoxy-",CC(C)COC1=CC(=CC(=C1)C2=CC=CC=C2)CC(=O)O,,,,,,
9142,43837,"3-Biphenylacetic acid, 5-pentoxy-",CCCCCOC1=CC(=CC(=C1)C2=CC=CC=C2)CC(=O)O,,,,,,
9143,43838,"3-Biphenylacetic acid, 4'-chloro-5-ethoxy-",CCOC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
9144,43839,"3-Biphenylacetic acid, 5-butoxy-4'-chloro-",CCCCOC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
9145,43840,"3-Biphenylacetic acid, 4'-chloro-5-isobutoxy-",CC(C)COC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
9146,43841,"3-Biphenylacetic acid, 4'-chloro-5-pentoxy-",CCCCCOC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
9147,43842,"3-Biphenylacetic acid, 2',4'-dichloro-5-methoxy-",COC1=CC(=CC(=C1)C2=C(C=C(C=C2)Cl)Cl)CC(=O)O,,,,,,
9148,43843,"3-Biphenylacetic acid, 4'-fluoro-5-methoxy-",COC1=CC(=CC(=C1)C2=CC=C(C=C2)F)CC(=O)O,,,,,,
9149,43844,"Biphenyl, 4'-chloro-3-(2-hydroxyethyl)-5-methoxy-",COC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CCO,,,,,,
9150,43845,"3-Biphenylpropionic acid, 4'-chloro-5-methoxy-",COC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CCC(=O)O,,,,,,
9151,43846,"3-Biphenylacetic acid, 4'-chloro-5-methoxy-, ethyl ester",CCOC(=O)CC1=CC(=CC(=C1)OC)C2=CC=C(C=C2)Cl,,,,,,
9152,43847,"3-Biphenylacetic acid, 4'-chloro-5-methylsulfonyloxy-, methyl ester",COC(=O)CC1=CC(=CC(=C1)OS(=O)(=O)C)C2=CC=C(C=C2)Cl,,,,,,
9153,43848,"3-Biphenylcarboxylic acid, 4'-chloro-5-methoxy-",COC1=CC(=CC(=C1)C(=O)O)C2=CC=C(C=C2)Cl,,,,,,
9154,43849,1-(2-(3-Methyl-5-benzyloxyindolyl)carbonyl)-2-isopropyl hydrazide,CC1=C(NC2=C1C=C(C=C2)OCC3=CC=CC=C3)C(=O)NNC(C)C,,,,,,
9155,43850,"3-Biphenylacetic acid, 4'-chloro-5-propoxy-",CCCOC1=CC(=CC(=C1)C2=CC=C(C=C2)Cl)CC(=O)O,,,,,,
9156,43851,"1,6-Nonadien-3-ol, 3,7-dimethyl-, 3-acetate",CCC(=CCCC(C)(C=C)OC(=O)C)C,,,,,,
9157,43852,CID 43852,C1=CC2=C(C=C(C=C2C=C1S(=O)(=O)O)S(=O)(=O)O)[O-].[Na+],,,,,,
9158,43853,"1-Naphthol-3,6-disulfonic acid",C1=CC2=C(C=C(C=C2C=C1S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
9159,43854,Yoronomycin,CC1(CC2(C=CC3=C(C2(C(=O)C1O)O)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O,,,,,,
9160,43855,CID 43855,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)[O-].[Na+],,,,,,
9161,43856,"FORMAMIDINE, N,N-DIMETHYL-N'-(alpha-METHYLPHENETHYL)-",CC(CC1=CC=CC=C1)N=CN(C)C,,,,,,
9162,43857,"N'-(3,4-Dimethoxyphenethyl)-N,N-dimethylformamidine",CN(C)C=NCCC1=CC(=C(C=C1)OC)OC,,,,,,
9163,43858,2-Methylhexan-1-ol,CCCCC(C)CO,,,,,,
9164,43859,trans-Permethrin,CC1([C@@H]([C@H]1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,['Trans-Permethrin has known human metabolites that include (3-Phenoxyphenyl)methanol.'],
9165,43860,Triciribine phosphate,CN1C2=NC=NC3=C2C(=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)C(=N1)N,,,,,,
9166,43861,CID 43861,C1=CC2=C(C=CC(=C2[O-])N=NC3=C(C=C(C=C3)[N+](=O)[O-])O)C(=C1)Cl.C1=CC2=C(C=CC(=NN=C3C=CC(=CC3=O)N(O)[O-])C2=O)C(=C1)Cl.[Co+2],,,,,,
9167,43862,CID 43862,C1=CC2=C(C=CC(=NN=C3C=CC(=CC3=O)N(O)O)C2=O)C(=C1)Cl,,,,,,
9168,43863,CID 43863,C1=CC2=C(C=CC(=NN=C3C=CC(=CC3=O)N(O)[O-])C2=O)C(=C1)Cl,,,,,,
9169,43864,3-Hydroxy-3-methoxy-2-butanone,CC(=O)C(C)(O)OC,,,,,,
9170,43865,"1,1-Diethoxy-2-(2-methoxyethoxy)ethane",CCOC(COCCOC)OCC,,,,,,
9171,43866,4-Methylcholest-8(14)-en-3-ol,CC1C2CCC3=C4CCC(C4(CCC3C2(CCC1O)C)C)C(C)CCCC(C)C,,,,,,
9172,43867,"2,3,7-Trimethyloctane",CC(C)CCCC(C)C(C)C,,,,,,
9173,43868,"Heptadecane, 1-chloro-",CCCCCCCCCCCCCCCCCCl,,,,,,
9174,43869,4-(Nitrosophenylamino)-1-butanol,C1=CC=C(C=C1)N(CCCCO)N=O,,,,,,
9175,43870,"1-Butanol, 4-((2-hydroxyethyl)nitrosoamino)-",C(CCO)CN(CCO)N=O,,,,,,
9176,43871,"1-Butanol, 4-(N-(3-hydroxypropyl)-N-nitrosoamino)-",C(CCO)CN(CCCO)N=O,,,,,,
9177,43872,"N-Butyl-N-(2,4-dihydroxybutyl)nitrosamine",CCCCN(CC(CCO)O)N=O,,,,,,
9178,43873,"beta-ALANINE, N-BUTYL-N-NITROSO-",CCCCN(CCC(=O)O)N=O,,,,,,
9179,43874,"Butanoic acid, 4-((1,1-dimethylethyl)nitrosoamino)-",CC(C)(C)N(CCCC(=O)O)N=O,,,,,,
9180,43875,"Butyric acid, 4-(N-nitrosopentylamino)-",CCCCCN(CCCC(=O)O)N=O,,,,,,
9181,43876,Duoperone,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(F)(F)F,,,,,,
9182,43877,"HYDANTOIN, 5,5-BIS(alpha,alpha,alpha-TRIFLUORO-p-TOLYL)-",C1=CC(=CC=C1C2(C(=O)NC(=O)N2)C3=CC=C(C=C3)C(F)(F)F)C(F)(F)F,,,,,,
9183,43878,CID 43878,COC1=CC=CC2=C1OC(C2)C[NH2+]CC=C.C(=CC(=O)[O-])C(=O)O,,,,,,
9184,43879,"N-[(7-methoxy-2,3-dihydro-1-benzofuran-2-yl)methyl]prop-2-en-1-amine",COC1=CC=CC2=C1OC(C2)CNCC=C,,,,,,
9185,43880,"2-[(2,4-Dichlorophenyl)methylidene]hydrazine-1-carboximidic acid",C1=CC(=C(C=C1Cl)Cl)C=NNC(=O)N,,,,,,
9186,43881,(1Z)-1-[2-(2-chloroethyl)benzylidene]-2-methylhydrazine,CNN=CC1=CC=CC=C1CCCl,,,,,,
9187,43882,"2,3-Dichlorobenzyl methylcarbamate",CNC(=O)OCC1=C(C(=CC=C1)Cl)Cl,,,,,,
9188,43883,"Ammonium, isophthaloylbis(iminoethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCNC(=O)C1=CC=CC=C1C(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9189,43884,Trimethyl-[2-[[2-[2-(trimethylazaniumyl)ethylcarbamoyl]benzoyl]amino]ethyl]azanium,C[N+](C)(C)CCNC(=O)C1=CC=CC=C1C(=O)NCC[N+](C)(C)C,,,,,,
9190,43885,"Ammonium, terephthaloylbis(iminoethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCNC(=O)C1=CC=C(C=C1)C(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9191,43886,Trimethyl-[2-[[4-[2-(trimethylazaniumyl)ethylcarbamoyl]benzoyl]amino]ethyl]azanium,C[N+](C)(C)CCNC(=O)C1=CC=C(C=C1)C(=O)NCC[N+](C)(C)C,,,,,,
9192,43887,"Ammonium, oxalylbis(iminoethylene)bis(triethyl-, diiodide",CC[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9193,43888,Triethyl-[2-[[2-oxo-2-[2-(triethylazaniumyl)ethylamino]acetyl]amino]ethyl]azanium,CC[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC,,,,,,
9194,43889,"Ammonium, oxalylbis(iminoethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCNC(=O)C(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9195,43890,Trimethyl-[2-[[2-oxo-2-[2-(trimethylazaniumyl)ethylamino]acetyl]amino]ethyl]azanium,C[N+](C)(C)CCNC(=O)C(=O)NCC[N+](C)(C)C,,,,,,
9196,43891,"Ammonium, malonylbis(iminoethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCNC(=O)CC(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9197,43892,"2,2'-(Malonylbisimino)bis(N,N,N-trimethylethanaminium)",C[N+](C)(C)CCNC(=O)CC(=O)NCC[N+](C)(C)C,,,,,,
9198,43893,CID 43893,C[N+](C)(C)CC=NC(CCCC(N=CC[N+](C)(C)C)O)O.[I-].[I-],,,,,,
9199,43894,CID 43894,C[N+](C)(C)CC=NC(CCCC(N=CC[N+](C)(C)C)O)O,,,,,,
9200,43895,"Ammonium, adipoylbis(iminoethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCNC(=O)CCCCC(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9201,43896,"N,N'-[Adipoylbis(imino-2,1-ethanediyl)]bis(N,N-dimethylmethanaminium)",C[N+](C)(C)CCNC(=O)CCCCC(=O)NCC[N+](C)(C)C,,,,,,
9202,43897,CID 43897,C[N+](C)(C)CCNC(=O)C=CC(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9203,43898,CID 43898,C[N+](C)(C)CCNC(=O)C=CC(=O)NCC[N+](C)(C)C,,,,,,
9204,43899,"Ammonium, succinylbis(iminoethylene)bis(triethyl-, diiodide",CC[N+](CC)(CC)CCNC(=O)CCC(=O)NCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9205,43900,Triethyl-[2-[[4-oxo-4-[2-(triethylazaniumyl)ethylamino]butanoyl]amino]ethyl]azanium,CC[N+](CC)(CC)CCNC(=O)CCC(=O)NCC[N+](CC)(CC)CC,,,,,,
9206,43901,CID 43901,CC[N+](CC)(CC)CC=NC(CCCC(N=CC[N+](CC)(CC)CC)O)O.[I-].[I-],,,,,,
9207,43902,CID 43902,CC[N+](CC)(CC)CC=NC(CCCC(N=CC[N+](CC)(CC)CC)O)O,,,,,,
9208,43903,"Ammonium, adipoylbis(iminoethylene)bis(triethyl-, diiodide",CC[N+](CC)(CC)CCNC(=O)CCCCC(=O)NCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9209,43904,"N,N'-[Adipoylbis(imino-2,1-ethanediyl)]bis(N,N-diethylethanaminium)",CC[N+](CC)(CC)CCNC(=O)CCCCC(=O)NCC[N+](CC)(CC)CC,,,,,,
9210,43905,N-(beta-Methoxy-m-trifluoromethylphenethyl)carbamic acid ethyl ester,CCOC(=O)NCC(C1=CC(=CC=C1)C(F)(F)F)OC,,,,,,
9211,43906,alpha-Aminomethyl-N-ethyl-p-fluorobenzyl alcohol hydrochloride,CC[NH2+]CC(C1=CC=C(C=C1)F)O.[Cl-],,,,,,
9212,43907,alpha-[(Ethylamino)methyl]-4-fluorobenzyl alcohol,CCNCC(C1=CC=C(C=C1)F)O,,,,,,
9213,43908,alpha-Aminomethyl-m-trifluoromethylbenzyl alcohol hydrochloride,C1=CC(=CC(=C1)C(F)(F)F)C(C[NH3+])O.[Cl-],,,,,,
9214,43909,"Benzenemethanol, alpha-((ethylamino)methyl)-3-(trifluoromethyl)-, hydrochloride",CC[NH2+]CC(C1=CC(=CC=C1)C(F)(F)F)O.[Cl-],,,,,,
9215,43910,alpha-[(Ethylamino)methyl]-3-(trifluoromethyl)benzyl alcohol,CCNCC(C1=CC(=CC=C1)C(F)(F)F)O,,,,,,
9216,43911,"Methanone, (4-hydroxy-3-methylphenyl)(3-methylphenyl)-",CC1=CC(=CC=C1)C(=O)C2=CC(=C(C=C2)O)C,,,,,,
9217,43912,"Ammonium, succinylbis(iminoethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCNC(=O)CCC(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
9218,43913,Trimethyl-[2-[[4-oxo-4-[2-(trimethylazaniumyl)ethylamino]butanoyl]amino]ethyl]azanium,C[N+](C)(C)CCNC(=O)CCC(=O)NCC[N+](C)(C)C,,,,,,
9219,43914,"Ammonium, malonylbis(iminoethylene)bis(triethyl-, diiodide",CC[N+](CC)(CC)CCNC(=O)CC(=O)NCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9220,43915,"2,2'-(Malonylbisimino)bis(N,N,N-triethylethanaminium)",CC[N+](CC)(CC)CCNC(=O)CC(=O)NCC[N+](CC)(CC)CC,,,,,,
9221,43916,"5,6-Dimethyl-2-aci-nitro-1,3-indandione sodium salt, monohydrate",CC1=CC2=C(C=C1C)C(=O)C(=[N+]([O-])[O-])C2=O.O.[Na+],,,,,,
9222,43917,CID 43917,CC1=CC2=C(C=C1C)C(=O)C(=[N+](O)[O-])C2=O,,,,,,
9223,43918,N-(4-(2-((2-(Diphenylmethoxy)ethyl)amino)propoxy)phenyl)acetamide hemioxalate,CC(COC1=CC=C(C=C1)NC(=O)C)NCCOC(C2=CC=CC=C2)C3=CC=CC=C3.CC(COC1=CC=C(C=C1)NC(=O)C)NCCOC(C2=CC=CC=C2)C3=CC=CC=C3.C(=O)(C(=O)O)O,,,,,,
9224,43919,N-[4-[2-(2-benzhydryloxyethylamino)propoxy]phenyl]acetamide,CC(COC1=CC=C(C=C1)NC(=O)C)NCCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9225,43920,Trimethyl(5-phenylpentyl)ammonium iodide,C[N+](C)(C)CCCCCC1=CC=CC=C1.[I-],,,,,,
9226,43921,"Benzenepentanaminium, N,N,N-trimethyl-",C[N+](C)(C)CCCCCC1=CC=CC=C1,,,,,,
9227,43922,6-Fluoromelatonin,CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)F,,,,,,
9228,43923,6-Ethyl-2-methyldecane,CCCCC(CC)CCCC(C)C,,,,,,
9229,43924,"2,6,7-Trimethyldecane",CCCC(C)C(C)CCCC(C)C,,,,,,
9230,43925,"4-Ethyl-2,2,6,6-tetramethylheptane",CCC(CC(C)(C)C)CC(C)(C)C,,,,,,
9231,43926,But-1-yn-1-yltrimethylsilane,CCC#C[Si](C)(C)C,,,,,,
9232,43927,CID 43927,C=CCN=C(S)SC1=CC=CC=C1,,,,,,
9233,43928,"1,1-Difluorononane",CCCCCCCCC(F)F,,,,,,
9234,43929,Ethyl alpha-cyano-4-(diethylamino)cinnamate,CCN(CC)C1=CC=C(C=C1)C=C(C#N)C(=O)OCC,,,,,,
9235,43930,(2-Cyclohexylethyl)(methyl)amine,CNCCC1CCCCC1,,,,,,
9236,43931,"6-Benzoxazoleacetic acid, 2-phenyl-",C1=CC=C(C=C1)C2=NC3=C(O2)C=C(C=C3)CC(=O)O,,,,,,
9237,43932,2-Phenyl-6-benzoxazoleethylamine hydrochloride,C1=CC=C(C=C1)C2=NC3=C(O2)C=C(C=C3)CC[NH3+].[Cl-],,,,,,
9238,43933,2-(2-Phenylbenzo[d]oxazol-6-yl)ethanamine,C1=CC=C(C=C1)C2=NC3=C(O2)C=C(C=C3)CCN,,,,,,
9239,43934,beta-Methyl-2-phenyl-6-benzoxazoleethylamine hemisuccinate,CC(C[NH3+])C1=CC2=C(C=C1)N=C(O2)C3=CC=CC=C3.C(CC(=O)[O-])C(=O)O,,,,,,
9240,43935,"2-(2-Phenyl-1,3-benzoxazol-6-yl)propan-1-amine",CC(CN)C1=CC2=C(C=C1)N=C(O2)C3=CC=CC=C3,,,,,,
9241,43936,"2-(2,4-Dichlorophenyl)-alpha-methyl-6-benzoxazoleacetic acid",CC(C1=CC2=C(C=C1)N=C(O2)C3=C(C=C(C=C3)Cl)Cl)C(=O)O,,,,,,
9242,43937,N-methyl-4-(3-methyl-2-nitroimidazol-4-yl)but-3-en-2-imine oxide,CC(=[N+](C)[O-])C=CC1=CN=C(N1C)[N+](=O)[O-],,,,,,
9243,43938,"1,5-Dihydro-5-methoxy-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one",CN1C2=C(C=C(C=C2)[N+](=O)[O-])C(N=CC1=O)(C3=CC=CC=C3)OC,,,,,,
9244,43939,"1,1-Dibromooctane",CCCCCCCC(Br)Br,,,,,,
9245,43940,"1,1-Dibromononane",CCCCCCCCC(Br)Br,,,,,,
9246,43941,"1,2,3,4,5,6-Hexachlorobenzene;1,2,3,4,5-pentachloro-6-nitrobenzene",C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-].C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
9247,43942,Dihydrocarminomycin,CC1C(C(CC(O1)OC2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(C)O)O)N)O,,,,,,
9248,43943,5-(1-Methylpropyl)nonane,CCCCC(CCCC)C(C)CC,,,,,,
9249,43944,2-Methoxy-N-(3-quinuclidinyl)-5-sulfamoylbenzamide,COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NC2CN3CCC2CC3,,,,,,
9250,43945,2-Methoxy-N-(2-(3-quinuclidinyl)ethyl)-5-sulfamoylbenzamide,COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NCCC2CN3CCC2CC3,,,,,,
9251,43946,"Benzamide, 2-methoxy-N-(4-quinuclidinyl)-5-sulfamoyl-, hemihydrate",COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NC23CCN(CC2)CC3.COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NC23CCN(CC2)CC3.O,,,,,,
9252,43947,2-Methoxy-N-(4-quinuclidinyl)-5-sulfamoylbenzamide,COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NC23CCN(CC2)CC3,,,,,,
9253,43948,2-Methoxy-N-(3-(3-quinuclidinyloxy)propyl)-5-sulfamoylbenzamide ethanol,CCO.COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NCCCOC2CN3CCC2CC3,,,,,,
9254,43949,2-Methoxy-N-[3-(3-quinuclidinyloxy)propyl]-5-sulfamoylbenzamide,COC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NCCCOC2CN3CCC2CC3,,,,,,
9255,43950,"2-Chloro-12,13-dimethoxy-6-phenyl-7,9,10,14-tetrahydroisoquino(2,1-d)(1,4)benzodiazepine",COC1=C(C=C2C3C4=C(C=CC(=C4)Cl)N=C(CN3CCC2=C1)C5=CC=CC=C5)OC,,,,,,
9256,43951,"6-(4-Biphenylyl)-2-chloro-12,13-dimethoxy-9,10-dihydro-7H-isoquino(2,1-d)(1,4)benzodiazepine",COC1=C(C=C2C3C4=C(C=CC(=C4)Cl)N=C(CN3CCC2=C1)C5=CC=C(C=C5)C6=CC=CC=C6)OC,,,,,,
9257,43952,"6-(4-Biphenylyl)-3-chloro-12,13-dimethoxy-9,10-dihydro-7H-isoquino(2,1-d)(1,4)benzodiazepine",COC1=C(C=C2C3C4=C(C=C(C=C4)Cl)N=C(CN3CCC2=C1)C5=CC=C(C=C5)C6=CC=CC=C6)OC,,,,,,
9258,43953,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-6-(p-bromophenyl)-2-chloro-12,13-dimethoxy-, bromide",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=CC(=C4)Cl)N=C(C3)C5=CC=C(C=C5)Br)OC.[Br-],,,,,,
9259,43954,"6-(4-bromophenyl)-2-chloro-12,13-dimethoxy-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=CC(=C4)Cl)N=C(C3)C5=CC=C(C=C5)Br)OC,,,,,,
9260,43955,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-6-(4-biphenylyl)-2-chloro-12,13-dimethoxy-, bromide",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=CC(=C4)Cl)N=C(C3)C5=CC=C(C=C5)C6=CC=CC=C6)OC.[Br-],,,,,,
9261,43956,"2-chloro-12,13-dimethoxy-6-(4-phenylphenyl)-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",COC1=C(C=C2C(=C1)CC[N+]3=C2C4=C(C=CC(=C4)Cl)N=C(C3)C5=CC=C(C=C5)C6=CC=CC=C6)OC,,,,,,
9262,43957,Fluomine dust,C1=CC(=C(C(=C1)F)C=NCCN=CC2=C(C=CC=C2F)[O-])[O-].[Co+2],,,,,,
9263,43958,3-Fluoro-2-[2-[(2-fluoro-6-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol,C1=CC(=C(C(=C1)F)C=NCCN=CC2=C(C=CC=C2F)O)O,,,,,,
9264,43959,"Oxamide, N,N'-dinitro-N,N'-dipropyl-",CCCN(C(=O)C(=O)N(CCC)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9265,43960,"Oxamide, N,N'-bis(2-hydroxyethyl)-N,N'-dinitro-, dinitrate",C(CO[N+](=O)[O-])N(C(=O)C(=O)N(CCO[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
9266,43961,Bipenamol,C1=CC=C(C(=C1)CN)SC2=CC=CC=C2CO,,,,,,
9267,43962,Alnert,C[NH2+]CCCCOC1=CC=CC=C1CC2=CC=CC=C2.[Cl-],,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
9268,43963,"2,2,7-Trimethyldecane",CCCC(C)CCCCC(C)(C)C,,,,,,
9269,43964,2-Butoxypentane,CCCCOC(C)CCC,,,,,,
9270,43965,"7H-Isoquino(2,1-d)(1,4)benzodiazepin-8-ium, 9,10-dihydro-2-chloro-12,13-dimethoxy-6-(p-methoxyphenyl)-, bromide",COC1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)Cl)C4=[N+](C2)CCC5=CC(=C(C=C54)OC)OC.[Br-],,,,,,
9271,43966,"2-chloro-12,13-dimethoxy-6-(4-methoxyphenyl)-9,10-dihydro-7H-isoquinolino[2,1-d][1,4]benzodiazepin-8-ium",COC1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)Cl)C4=[N+](C2)CCC5=CC(=C(C=C54)OC)OC,,,,,,
9272,43967,2-Methylhex-3-enoic acid,CCC=CC(C)C(=O)O,,,,,,
9273,43968,"4-[[2-chloroethyl(methyl)hydrazinylidene]methyl]-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)C=NN(C)CCCl,,,,,,
9274,43969,Ammonium (ethoxycarbonyl)(nitro)azanide,CCOC(=O)[N-][N+](=O)[O-].[NH4+],,,,,,
9275,43970,Ethyl N-nitrocarbamate,CCOC(=O)N[N+](=O)[O-],,,,,,
9276,43971,"3-((2-Chloro-3-benzothienyl)amino)butanol S,S,-dioxide",CC(CCO)NC1=C(S(=O)(=O)C2=CC=CC=C21)Cl,,,,,,
9277,43972,"2-Amino-4-((2-chloro-3-benzothienyl)amino)butanol S,S,-dioxide",C1=CC=C2C(=C1)C(=C(S2(=O)=O)Cl)NCCC(CO)N,,,,,,
9278,43973,"2-Chloro-3-((5-(diethylamino)-2-pentyl)amino)benzo(b)thiophene 1,1-dioxide",CCN(CC)CCCC(C)NC1=C(S(=O)(=O)C2=CC=CC=C21)Cl,,,,,,
9279,43974,"2-Chloro-3-(1-pyrrolidinyl)benzo(b)thiophene 1,1-dioxide",C1CCN(C1)C2=C(S(=O)(=O)C3=CC=CC=C32)Cl,,,,,,
9280,43975,"BENZO(b)THIOPHENE, 3-(1-AZIRIDINYL)-2-CHLORO-, 1,1-DIOXIDE",C1CN1C2=C(S(=O)(=O)C3=CC=CC=C32)Cl,,,,,,
9281,43976,"BENZO(b)THIOPHENE, 2-CHLORO-3-(2-(MORPHOLINO)ETHYLAMINO)-, 1,1-DIOXIDE",C1COCCN1CCNC2=C(S(=O)(=O)C3=CC=CC=C32)Cl,,,,,,
9282,43977,"Ethanone, 1-(4-(3-chlorophenyl)-1-(3-(1-piperidinyl)propyl)-4-piperidinyl)-, dihydrochloride",CC(=O)C1(CC[NH+](CC1)CCC[NH+]2CCCCC2)C3=CC(=CC=C3)Cl.[Cl-].[Cl-],,,,,,
9283,43978,1-[4-(3-Chlorophenyl)-1-(3-piperidin-1-ylpropyl)piperidin-4-yl]ethanone,CC(=O)C1(CCN(CC1)CCCN2CCCCC2)C3=CC(=CC=C3)Cl,,,,,,
9284,43979,"1-Butanone, 1-(4-(3-chlorophenyl)-1-(3-(1-piperidinyl)propyl)-4-piperidinyl)-, dihydrochloride",CCCC(=O)C1(CC[NH+](CC1)CCC[NH+]2CCCCC2)C3=CC(=CC=C3)Cl.[Cl-].[Cl-],,,,,,
9285,43980,1-[4-(3-Chlorophenyl)-1-(3-piperidin-1-ylpropyl)piperidin-4-yl]butan-1-one,CCCC(=O)C1(CCN(CC1)CCCN2CCCCC2)C3=CC(=CC=C3)Cl,,,,,,
9286,43981,"Ethanone, 1-(4-(3-chlorophenyl)-1-(3-(4-morpholinyl)propyl)-4-piperidinyl)-, dihydrochloride",CC(=O)C1(CC[NH+](CC1)CCC[NH+]2CCOCC2)C3=CC(=CC=C3)Cl.[Cl-].[Cl-],,,,,,
9287,43982,1-[4-(3-Chlorophenyl)-1-(3-morpholin-4-ylpropyl)piperidin-4-yl]ethanone,CC(=O)C1(CCN(CC1)CCCN2CCOCC2)C3=CC(=CC=C3)Cl,,,,,,
9288,43983,"1-Butanone, 1-(4-(3-chlorophenyl)-1-(3-(4-morpholinyl)propyl)-4-piperidinyl)-, dihydrochloride",CCCC(=O)C1(CC[NH+](CC1)CCC[NH+]2CCOCC2)C3=CC(=CC=C3)Cl.[Cl-].[Cl-],,,,,,
9289,43984,1-[4-(3-Chlorophenyl)-1-(3-morpholin-4-ylpropyl)piperidin-4-yl]butan-1-one,CCCC(=O)C1(CCN(CC1)CCCN2CCOCC2)C3=CC(=CC=C3)Cl,,,,,,
9290,43985,"Ethanone, 1-(4-(3-chlorophenyl)-1-(3-(4-methyl-1-piperazinyl)propyl)-4-piperidinyl)-, trihydrochloride",CC(=O)C1(CCN(CC1)CCCN2CCN(CC2)C)C3=CC(=CC=C3)Cl.Cl.Cl.Cl,,,,,,
9291,43986,1-[4-(3-Chlorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]piperidin-4-yl]ethanone,CC(=O)C1(CCN(CC1)CCCN2CCN(CC2)C)C3=CC(=CC=C3)Cl,,,,,,
9292,43987,"1-Butanone, 1-(4-(3-chlorophenyl)-1-(3-(4-methyl-1-piperazinyl)propyl)-4-piperidinyl)-, trihydrochloride",CCCC(=O)C1(CCN(CC1)CCCN2CCN(CC2)C)C3=CC(=CC=C3)Cl.Cl.Cl.Cl,,,,,,
9293,43988,1-[4-(3-Chlorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]piperidin-4-yl]butan-1-one,CCCC(=O)C1(CCN(CC1)CCCN2CCN(CC2)C)C3=CC(=CC=C3)Cl,,,,,,
9294,43989,2-(o-Tolyl)-2-(triethylsiloxy)acetic acid ethyl ester,CCOC(=O)C(C1=CC=CC=C1C)O[Si](CC)(CC)CC,,,,,,
9295,43990,"2-Benzoylhydrazono-1,3-dithiolane",C1CSC(=NNC(=O)C2=CC=CC=C2)S1,,,,,,
9296,43991,3-Methyl-4-((4-nitrophenyl)azo)benzenamine,CC1=C(C=CC(=C1)N)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
9297,43992,"N'-(o-Ethylphenyl)-N,N-dimethylformamidine",CCC1=CC=CC=C1N=CN(C)C,,,,,,
9298,43993,"Formamidine, N'-(1,3-benzodioxol-5-YL)-N,N-dimethyl-",CN(C)C=NC1=CC2=C(C=C1)OCO2,,,,,,
9299,43994,"N'-(5-Chloro-2,4-dimethoxyphenyl)-N,N-dimethylformamidine",CN(C)C=NC1=CC(=C(C=C1OC)OC)Cl,,,,,,
9300,43995,"4-(p-Chlorobenzyl)-6,7-dimethoxy-1-methylisoquinoline hydrobromide",CC1=[NH+]C=C(C2=CC(=C(C=C12)OC)OC)CC3=CC=C(C=C3)Cl.[Br-],,,,,,
9301,43996,"4-(4-Chlorobenzyl)-6,7-dimethoxy-1-methylisoquinoline",CC1=NC=C(C2=CC(=C(C=C12)OC)OC)CC3=CC=C(C=C3)Cl,,,,,,
9302,43997,"4-(p-Chlorobenzyl)-6,7-dimethoxy-1-ethylisoquinoline hydrobromide",CCC1=[NH+]C=C(C2=CC(=C(C=C21)OC)OC)CC3=CC=C(C=C3)Cl.[Br-],,,,,,
9303,43998,"4-(4-Chlorobenzyl)-1-ethyl-6,7-dimethoxyisoquinoline",CCC1=NC=C(C2=CC(=C(C=C21)OC)OC)CC3=CC=C(C=C3)Cl,,,,,,
9304,43999,"4-(p-Chlorobenzyl)-6,7-dimethoxy-1-isopropylisoquinoline hydrobromide",CC(C)C1=[NH+]C=C(C2=CC(=C(C=C21)OC)OC)CC3=CC=C(C=C3)Cl.[Br-],,,,,,
9305,44000,"4-[(4-Chlorophenyl)methyl]-6,7-dimethoxy-1-propan-2-ylisoquinoline",CC(C)C1=NC=C(C2=CC(=C(C=C21)OC)OC)CC3=CC=C(C=C3)Cl,,,,,,
9306,44001,"1-Benzyl-4-(p-chlorobenzyl)-6,7-dimethoxyisoquinoline hydrobromide",COC1=C(C=C2C(=C1)C(=C[NH+]=C2CC3=CC=CC=C3)CC4=CC=C(C=C4)Cl)OC.[Br-],,,,,,
9307,44002,"1-Benzyl-4-(4-chlorobenzyl)-6,7-dimethoxyisoquinoline",COC1=C(C=C2C(=C1)C(=CN=C2CC3=CC=CC=C3)CC4=CC=C(C=C4)Cl)OC,,,,,,
9308,44003,"4-(p-Chlorobenzyl)-6,7-dimethoxy-3-methylisoquinoline hydrobromide",CC1=C(C2=CC(=C(C=C2C=[NH+]1)OC)OC)CC3=CC=C(C=C3)Cl.[Br-],,,,,,
9309,44004,"4-(4-Chlorobenzyl)-6,7-dimethoxy-3-methylisoquinoline",CC1=C(C2=CC(=C(C=C2C=N1)OC)OC)CC3=CC=C(C=C3)Cl,,,,,,
9310,44005,CID 44005,CC=C1CCC(=C1)C,,,,,,
9311,44006,"3,3,8-Trimethyldecane",CCC(C)CCCCC(C)(C)CC,,,,,,
9312,44007,"Ethanone, 1-(4,5-diethyl-2-methyl-1-cyclopenten-1-yl)-",CCC1CC(=C(C1CC)C(=O)C)C,,,,,,
9313,44008,"Benzo(b)thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-(2-morpholinoacetamido)-, ethyl ester",CCOC(=O)C1=C(SC2=C1CCCC2)NC(=O)CN3CCOCC3,,,,,,
9314,44009,"(Z)-2-(2-Chlorophenyl)-3-(dimethylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=CC=C3Cl.[Cl-],,,,,,
9315,44010,"1-[(2R,3S)-3-(2-chlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=CC=C3Cl,,,,,,
9316,44011,cis-2-(m-Chlorophenyl)-3-dimethylaminomethylbicyclo(2.2.2)octane hydrochloride,C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC(=CC=C3)Cl.[Cl-],,,,,,
9317,44012,2alpha-(3-Chlorophenyl)-3alpha-(dimethylaminomethyl)bicyclo[2.2.2]octane,CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC(=CC=C3)Cl,,,,,,
9318,44013,"cis-3-(p-Fluorophenyl)-2-dimethylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)F.[Cl-],,,,,,
9319,44014,"1-[(2R,3S)-3-(4-fluorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)F,,,,,,
9320,44015,"cis-2-(p-Fluorophenyl)-3-methylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH2+]C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)F.[Cl-],,,,,,
9321,44016,CID 44016,CNCC1[C@H](C2CCC1CC2)C3=CC=C(C=C3)F,,,,,,
9322,44017,"cis-2-(3,4-Dichlorophenyl)-3-methylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH2+]C[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl.[Cl-],,,,,,
9323,44018,"1-[(2R,3S)-3-(3,4-dichlorophenyl)-2-bicyclo[2.2.2]octanyl]-N-methylmethanamine",CNC[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
9324,44019,"Bicyclo(2.2.2)octane-2-methylamine, N-methyl-3-phenyl-, hydrochloride, (Z)-",C[NH2+]C[C@H]1[C@H](C2CCC1CC2)C3=CC=CC=C3.[Cl-],,,,,,
9325,44020,CID 44020,CNC[C@@H]1C2CCC(C1C3=CC=CC=C3)CC2,,,,,,
9326,44021,"2-(Dimethylaminomethyl)-3-phenylbicyclo(2.2.2)oct-2-ene, hydrochloride",C[NH+](C)CC1=C(C2CCC1CC2)C3=CC=CC=C3.[Cl-],,,,,,
9327,44022,"N,N-dimethyl-1-(3-phenyl-2-bicyclo[2.2.2]oct-2-enyl)methanamine",CN(C)CC1=C(C2CCC1CC2)C3=CC=CC=C3,,,,,,
9328,44023,"(+)-cis-2-(3,4-Dichlorophenyl)-3-dimethylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl.[Cl-],,,,,,
9329,44024,"[(2R,3S)-3-(3,4-Dichloro-phenyl)-bicyclo[2.2.2]oct-2-ylmethyl]-dimethyl-amine",CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
9330,44025,"Bicyclo(2.2.2)oct-2-ene-2-methylamine, 3-(3,4-dichlorophenyl)-N-methyl-, hydrochloride",C[NH2+]CC1=C(C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl.[Cl-],,,,,,
9331,44026,"1-[3-(3,4-dichlorophenyl)-2-bicyclo[2.2.2]oct-2-enyl]-N-methylmethanamine",CNCC1=C(C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
9332,44027,"cis-2-(2,4-Dichlorophenyl)-3-methylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH2+]C[C@H]1[C@H](C2CCC1CC2)C3=C(C=C(C=C3)Cl)Cl.[Cl-],,,,,,
9333,44028,"1-[(2R,3S)-3-(2,4-dichlorophenyl)-2-bicyclo[2.2.2]octanyl]-N-methylmethanamine",CNC[C@H]1[C@H](C2CCC1CC2)C3=C(C=C(C=C3)Cl)Cl,,,,,,
9334,44029,cis-2-(p-Bromophenyl)-3-((dimethylamino)methyl)bicyclo(2.2.2)octane hydrochloride,C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)Br.[Cl-],,,,,,
9335,44030,"1-[(2R,3S)-3-(4-bromophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)Br,,,,,,
9336,44031,"cis-2-(p-Bromophenyl)-3-methylaminomethylbicyclo(2.2.2)octane, hydrochloride",C[NH2+]C[C@H]1[C@H](C2CCC1CC2)C3=CC=C(C=C3)Br.[Cl-],,,,,,
9337,44032,CID 44032,CNCC1[C@H](C2CCC1CC2)C3=CC=C(C=C3)Br,,,,,,
9338,44033,"Bicyclo(2.2.2)octane-2-methylamine, 3-(4-chloro-3-trifluoromethylphenyl)-N-methyl-, hydrochloride, (Z)-",C[NH2+]C[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)C(F)(F)F.[Cl-],,,,,,
9339,44034,"1-[(2R,3S)-3-[4-chloro-3-(trifluoromethyl)phenyl]-2-bicyclo[2.2.2]octanyl]-N-methylmethanamine",CNC[C@H]1[C@H](C2CCC1CC2)C3=CC(=C(C=C3)Cl)C(F)(F)F,,,,,,
9340,44035,"Bicyclo(2.2.2)oct-2-ene-2-methylamine, 3-(p-chlorophenyl)-N-methyl-, hydrochloride",C[NH2+]CC1=C(C2CCC1CC2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
9341,44036,1-[3-(4-chlorophenyl)-2-bicyclo[2.2.2]oct-2-enyl]-N-methylmethanamine,CNCC1=C(C2CCC1CC2)C3=CC=C(C=C3)Cl,,,,,,
9342,44037,"Bicyclo(2.2.2)oct-2-ene-2-methylamine, 3-(p-chlorophenyl)-N,N-dimethyl-, hydrochloride",C[NH+](C)CC1=C(C2CCC1CC2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
9343,44038,"1-[3-(4-chlorophenyl)-2-bicyclo[2.2.2]oct-2-enyl]-N,N-dimethylmethanamine",CN(C)CC1=C(C2CCC1CC2)C3=CC=C(C=C3)Cl,,,,,,
9344,44039,"(Z)-2-(Dimethylaminomethyl)-3-phenylbicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@H]1[C@H](C2CCC1CC2)C3=CC=CC=C3.[Cl-],,,,,,
9345,44040,CID 44040,CN(C)CC1[C@H](C2CCC1CC2)C3=CC=CC=C3,,,,,,
9346,44041,"Mercury, bis(3-hydroxy-1-propynyl)-",C(C#C[Hg]C#CCO)O,,,,,,
9347,44042,"ACRIDINE, 9-(p-FLUOROANILINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)F,,,,,,
9348,44043,"Ammonium, ((N-anthraquinon-2-YL)aminomethylene)dimethyl-, chloride",C[N+](=CNC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)C.[Cl-],,,,,,
9349,44044,"[(9,10-Dioxoanthracen-2-yl)amino]methylidene-dimethylazanium",C[N+](=CNC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)C,,,,,,
9350,44045,"Bicyclo(2.2.2)oct-2-ene-2-methylamine, 3-(3,4-dichlorophenyl)-N,N-dimethyl-, hydrochloride",C[NH+](C)CC1=C(C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl.[Cl-],,,,,,
9351,44046,"1-[3-(3,4-dichlorophenyl)-2-bicyclo[2.2.2]oct-2-enyl]-N,N-dimethylmethanamine",CN(C)CC1=C(C2CCC1CC2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
9352,44047,CID 44047,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](CC(=O)C2=CC=CC=C2)O,,,,,,
9353,44048,CID 44048,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](CC(=O)C2=CC=C(C=C2)Cl)O,,,,,,
9354,44049,CID 44049,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=C[C@H](CC(=O)C2=CC(=CC=C2)Cl)O,,,,,,
9355,44050,"cis-2-N-Benzyloxycyclopropyl-N,N,N-trimethylammonium iodide",CC(C[N+](C)(C)C)OC(=O)C1=CC=CC=C1.[I-],,,,,,
9356,44051,2-Benzoyloxypropyl(trimethyl)azanium,CC(C[N+](C)(C)C)OC(=O)C1=CC=CC=C1,,,,,,
9357,44052,"N-[2-chloro-5-(trifluoromethyl)phenyl]-3,5-dinitro-2-(trifluoromethyl)aniline",C1=CC(=C(C=C1C(F)(F)F)NC2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])C(F)(F)F)Cl,,,,,,
9358,44053,CID 44053,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)F)C(=O)CC[NH3+].[Cl-],,,,,,
9359,44054,"3-(3-Aminopropanoyl)-1-[[5-(4-fluorophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione",C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)F)C(=O)CCN,,,,,,
9360,44055,CID 44055,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)Cl)C(=O)CC[NH3+].[Cl-],,,,,,
9361,44056,"3-(3-Aminopropanoyl)-1-[[5-(4-chlorophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione",C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)Cl)C(=O)CCN,,,,,,
9362,44057,CID 44057,C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)C#N)C(=O)CC[NH3+].[Cl-],,,,,,
9363,44058,"4-[5-[[3-(3-Aminopropanoyl)-2,4-dioxoimidazolidin-1-yl]iminomethyl]furan-2-yl]benzonitrile",C1C(=O)N(C(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)C#N)C(=O)CCN,,,,,,
9364,44059,"N,N-Dimethyl-N-(3,3-diphenylpropyl)ethylenediamine dihydrochloride",C[NH+](C)CC[NH2+]CCC(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-].[Cl-],,,,,,
9365,44060,"N-(3,3-diphenylpropyl)-N',N'-dimethylethane-1,2-diamine",CN(C)CCNCCC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
9366,44061,"2-(2-((3,3-Diphenylpropyl)amino)ethyl)indole dihydrochloride",C1=CC=C(C=C1)C(CC[NH2+]CCC2=CC3=CC=CC=C3[NH2+]2)C4=CC=CC=C4.[Cl-].[Cl-],,,,,,
9367,44062,"N-[2-(1H-indol-2-yl)ethyl]-3,3-diphenylpropan-1-amine",C1=CC=C(C=C1)C(CCNCCC2=CC3=CC=CC=C3N2)C4=CC=CC=C4,,,,,,
9368,44063,"Ethylenediamine, N-(2-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylene)ethyl)-N',N'-dimethyl-, dihydrochloride",C[NH+](C)CC[NH2+]CC=C1C2=CC=CC=C2CCC3=CC=CC=C31.[Cl-].[Cl-],,,,,,
9369,44064,"N',N'-dimethyl-N-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]ethane-1,2-diamine",CN(C)CCNCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,,,,
9370,44065,"Ethylenediamine, N-(2-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylene)ethyl)-N',N'-diethyl-, dihydrochloride",CC[NH+](CC)CC[NH2+]CC=C1C2=CC=CC=C2CCC3=CC=CC=C31.[Cl-].[Cl-],,,,,,
9371,44066,"N',N'-diethyl-N-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]ethane-1,2-diamine",CCN(CC)CCNCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,,,,
9372,44067,"5H-Dibenzo(a,d)cyclohepten-delta(sup 5),beta-ethylamine, 10,11-dihydro-N-(2-(aminomethyl)cyclopentyl)-, dihydrochloride",C1CC(C(C1)[NH2+]CC=C2C3=CC=CC=C3CCC4=CC=CC=C42)C[NH3+].[Cl-].[Cl-],,,,,,
9373,44068,"2-(aminomethyl)-N-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]cyclopentan-1-amine",C1CC(C(C1)NCC=C2C3=CC=CC=C3CCC4=CC=CC=C42)CN,,,,,,
9374,44069,"1,3,7,9-Tetrachlorodibenzo-P-dioxin",C1=C(C=C(C2=C1OC3=C(O2)C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
9375,44070,"1,2,8,9-Tetrachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C(=C(C=C3)Cl)Cl)Cl)Cl,,,,,,
9376,44071,CID 44071,C[C@@](C=C[C@H]1C(CC(C1CC=CCCCC(=O)OC)O)O)(C#CC2=CC=CC=C2)O,,,,,,
9377,44072,Acifluorfen-sodium,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)[O-].[Na+],,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,"['Rapidly metabolized in plants to glucuronides, and homoglutathione and cysteine conjugates. /Acifluorfen/']",
9378,44073,Acifluorfen,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)O,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
9379,44074,"Glycine, N,N'-1,2-cyclopropanediylbis(N-(2-methoxy-2-oxoethyl)-, dimethyl ester, dihydrochloride, trans-",COC(=O)C[NH+](CC(=O)OC)[C@@H]1CC1[NH+](CC(=O)OC)CC(=O)OC.[Cl-].[Cl-],,,,,,
9380,44075,methyl 2-[[(1R)-2-[bis(2-methoxy-2-oxoethyl)amino]cyclopropyl]-(2-methoxy-2-oxoethyl)amino]acetate,COC(=O)CN(CC(=O)OC)[C@@H]1CC1N(CC(=O)OC)CC(=O)OC,,,,,,
9381,44076,"trans-N,N'-(1,2-Cyclopropanediyl)bis(N-carboxymethylglycine)",C1[C@H](C1N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,,,,
9382,44077,"3,4-Dihydro-2-(1-pyrrolidinylmethyl)-1(2H)-naphthalenone hydrochloride",C1CC[NH+](C1)CC2CCC3=CC=CC=C3C2=O.[Cl-],,,,,,
9383,44078,"3,4-Dihydro-2-(1-pyrrolidinylmethyl)-1(2H)-naphthalenone",C1CCN(C1)CC2CCC3=CC=CC=C3C2=O,,,,,,
9384,44079,"Ethanone, 1-(4,7,7-trimethylbicyclo[4.1.0]hept-4-en-3-yl)-",CC1=CC2C(C2(C)C)CC1C(=O)C,,,,,,
9385,44080,"Benzoic acid, fluoroacetylmethyl ester",C1=CC=C(C=C1)C(=O)OCC(=O)CF,,,,,,
9386,44081,"BENZOIC ACID, p-NITRO-, FLUOROACETYLMETHYL ESTER",C1=CC(=CC=C1C(=O)OCC(=O)CF)[N+](=O)[O-],,,,,,
9387,44082,"BENZOIC ACID, p-NITRO-, CHLOROACETYLMETHYL ESTER",C1=CC(=CC=C1C(=O)OCC(=O)CCl)[N+](=O)[O-],,,,,,
9388,44083,"Benzoic acid, 3,5-dinitro-, chloroacetylmethyl ester",C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(=O)OCC(=O)CCl,,,,,,
9389,44084,"Benzoic acid, 2,2-dimethoxy-3-fluoropropyl ester",COC(COC(=O)C1=CC=CC=C1)(CF)OC,,,,,,
9390,44085,"Acetic acid, fluoroacetylmethyl ester",CC(=O)OCC(=O)CF,,,,,,
9391,44086,1-Benzoyloxy-3-fluoropropan-2-ol,C1=CC=C(C=C1)C(=O)OCC(CF)O,,,,,,
9392,44087,1-Benzoyloxy-3-bromopropan-2-ol,C1=CC=C(C=C1)C(=O)OCC(CBr)O,,,,,,
9393,44088,CID 44088,COC(=O)C=CCC=CCC1[C@H](C(CC1O)O)C=C[C@H](COC2=CC=CC=C2)O,,,,,,
9394,44089,CID 44089,COC(=O)C=CCC=CCC1[C@H](C(CC1O)O)C=C[C@H](COC2=CC(=CC=C2)Cl)O,,,,,,
9395,44090,2-(4-Chlorophenyl)-3-oxopropanenitrile,C1=CC(=CC=C1C(C=O)C#N)Cl,,,,,,
9396,44091,CID 44091,COC(=O)C=CCC=CCC1[C@H](C(CC1O)O)C=C[C@H](COC2=CC=CC(=C2)C(F)(F)F)O,,,,,,
9397,44092,"2-((4-((2,4-Dinitrophenyl)azo)phenyl)ethylamino)ethanol",CCN(CCO)C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9398,44093,Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,"['For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, &beta;-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.']","['Captopril, an ACE inhibitor, antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain its effects by causing increased vasodilation and decreased blood pressure.']","['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant)', 'The drug /captopril/ is metabolized and renally excreted. More than 95% of a dose is excreted renally, both as unchanged (45-50%) drug and as metabolites.', 'In dogs, approximately 75% of an oral dose is absorbed but food in the GI tract reduces bioavailability by 30-40%. It is distributed to most tissues (not the CNS) and is 40% bound to plasma proteins in dogs.', 'Approximately 60-75% of an oral dose of captopril is rapidly absorbed from the GI tract in fasting healthy individuals or hypertensive patients. Food may decrease absorption of captopril by up to 25-40%, although there is some evidence that this effect is not clinically important. Following oral administration of a single 100-mg dose of captopril in fasting healthy individuals in one study, average peak blood drug concentrations of 800 ng/mL were attained in 1 hour.', '/MILK/ Concentrations of captopril in human milk are approximately one percent of those in maternal blood.', 'For more Absorption, Distribution and Excretion (Complete) data for Captopril (7 total), please visit the HSDB record page.']","['Hepatic. Major metabolites are captopril-cysteine disulfide and the disulfide dimer of captopril. Metabolites may undergo reversible interconversion.', 'About half the absorbed dose of captopril is rapidly metabolized, mainly to captopril-cysteine disulfide and the disulfide dimer of captopril. In vitro studies suggest that captopril and its metabolites may undergo reversible interconversions. It has been suggested that the drug may be more extensively metabolized in patients with renal impairment than in patients with normal renal function.']","['2 hours', 'A 43 year old patient with mild heart failure attempted suicide by ingesting between 5000 and 7500 mg of captopril. Blood pressure oscillated around 100-120/50-75 mm Hg and pulse rate showed no tendency to accelerate (75-100/min). ... The calculated half-life of captopril was 4.4 hr. ...', 'The half life of captopril is about 2.8 hours in dogs ... .', 'The elimination half-life of unchanged captopril appears to be less than 2 hours in patients with normal renal function. The elimination half-life of captopril and its metabolites is correlated with creatinine clearance and increases to about 20-40 hours in patients with creatinine clearances less than 20 mL/minute and as long as 6.5 days in anuric patients.']"
9399,44094,m-(3-Pentyl)phenyl N-methyl-N-nitrosocarbamate,CCC(CC)C1=CC(=CC=C1)OC(=O)N(C)N=O,,,,,,
9400,44095,"alpha,alpha-Dicyclopropyl-4-fluorobenzyl alcohol",C1CC1C(C2CC2)(C3=CC=C(C=C3)F)O,,,,,,
9401,44096,"4-Chloro-alpha,alpha-dicyclopropylbenzyl alcohol",C1CC1C(C2CC2)(C3=CC=C(C=C3)Cl)O,,,,,,
9402,44097,3-[(4-Carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[(2-phenyl-2-sulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
9403,44098,N-nitrosocarbofuran,CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)N=O)C,,,,,,
9404,44099,CID 44099,CNN=CC1=NC2=CC=CC=C2C(=C1)C(=O)O.O,,,,,,
9405,44100,CID 44100,CNN=CC1=NC2=CC=CC=C2C(=C1)C(=O)O,,,,,,
9406,44101,"2,3,4,6-Tetrachlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C(C(=C(C=C23)Cl)Cl)Cl,,,,,,
9407,44102,2-Amino-6-chloro-4-nitrophenol monohydrochloride,C1=C(C=C(C(=C1[NH3+])O)Cl)[N+](=O)[O-].[Cl-],,,,,,
9408,44103,Pirogliride tartrate,CN1CCCC1=NC(=NC2=CC=CC=C2)N3CCCC3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
9409,44104,Pirogliride,CN1CCCC1=NC(=NC2=CC=CC=C2)N3CCCC3,,,,,,
9410,44105,Ethyl N-2-hydroxyethylnitrosocarbamate,CCOC(=O)N(CCO)N=O,,,,,,
9411,44106,"1,2-Dihydro-1,2-dihydroxy-7-methylbenz(a)anthracene",CC1=C2C=CC3=C(C2=CC4=CC=CC=C14)C(C(C=C3)O)O,,,,,,
9412,44107,"7-Methylbenz(A)anthracene-3,4-diol",CC1=C2C=CC3=C(C2=CC4=CC=CC=C14)C=CC(C3O)O,,,,,,
9413,44108,"Benzoic acid, 4-(((4-(aminosulfonyl)phenyl)sulfonyl)amino)-",C1=CC(=CC=C1C(=O)O)NS(=O)(=O)C2=CC=C(C=C2)S(=O)(=O)N,,,,,,
9414,44109,4-((((4-(Aminosulfonyl)phenyl)methyl)amino)sulfonyl)benzoic acid,C1=CC(=CC=C1CNS(=O)(=O)C2=CC=C(C=C2)C(=O)O)S(=O)(=O)N,,,,,,
9415,44110,"Benzoic acid, 4-((2-((4-(aminosulfonyl)phenyl)sulfonyl)hydrazino)sulfonyl)-",C1=CC(=CC(=C1)S(=O)(=O)NNS(=O)(=O)C2=CC=C(C=C2)S(=O)(=O)N)C(=O)O,,,,,,
9416,44111,"1,4-Benzenediamine, ethanedioate (1:1)",C1=CC(=CC=C1N)N.C(=O)(C(=O)O)O,,,,,,
9417,44112,Bopindolol,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3,"['For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.']","['Bopindolol is a prodrug of pindolol. Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.']","['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
9418,44113,CID 44113,C1=CC(=CC=C1C(=NCCCC(=O)[O-])C2=C(C=CC(=C2)F)O)Cl.[Na+],,,,,,
9419,44114,Progabide acid,C1=CC(=CC=C1C(=NCCCC(=O)O)C2=C(C=CC(=C2)F)O)Cl,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
9420,44115,Progabide,C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl,['Indicated for the treatment of epilepsy.'],"['Progabide, a fatty acid derivative, is a GABA receptor agonist used to treat the symptoms of epilepsy.']","['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Endogenous compounds and drugs that bind to and activate GAMMA-AMINOBUTYRIC ACID receptors (RECEPTORS, GABA). (See all compounds classified as GABA Agonists.)', 'Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)']",['Well absorbed with a bioavailability of 60%'],['Hepatic'],['4 hours']
9421,44116,"2-Isopropylamino-1-(3,4,5-trichloro-2-thienyl)ethanol",CC(C)NCC(C1=C(C(=C(S1)Cl)Cl)Cl)O,,,,,,
9422,44117,"2-Isopropylamino-1-(3,4,5-tribromo-2-thienyl)ethanol",CC(C)NCC(C1=C(C(=C(S1)Br)Br)Br)O,,,,,,
9423,44118,2-((4-Chlorophenyl)thio)-alpha-(2-(dimethylamino)ethyl)benzeneacetamide hydrochloride,C[NH+](C)CCC(C1=CC=CC=C1SC2=CC=C(C=C2)Cl)C(=O)N.[Cl-],,,,,,
9424,44119,2-[(4-Chlorophenyl)thio]-alpha-[2-(dimethylamino)ethyl]benzeneacetamide,CN(C)CCC(C1=CC=CC=C1SC2=CC=C(C=C2)Cl)C(=O)N,,,,,,
9425,44120,2-(2-(4-Chlorophenylthio)phenyl)-5-dimethylaminovaleramide hydrochloride,C[NH+](C)CCCC(C1=CC=CC=C1SC2=CC=C(C=C2)Cl)C(=O)N.[Cl-],,,,,,
9426,44121,2-[(4-Chlorophenyl)thio]-alpha-[3-(dimethylamino)propyl]benzeneacetamide,CN(C)CCCC(C1=CC=CC=C1SC2=CC=C(C=C2)Cl)C(=O)N,,,,,,
9427,44122,"Dibenzo(b,f)thiepin-10(11H)-one, 8-chloro-11-(2-(dimethylamino)ethyl)-, hydrochloride",C[NH+](C)CCC1C2=CC=CC=C2SC3=C(C1=O)C=C(C=C3)Cl.[Cl-],,,,,,
9428,44123,3-chloro-6-[2-(dimethylamino)ethyl]-6H-benzo[b][1]benzothiepin-5-one,CN(C)CCC1C2=CC=CC=C2SC3=C(C1=O)C=C(C=C3)Cl,,,,,,
9429,44124,"Dibenzo(b,f)thiepin-10(11H)-one, 8-chloro-11-(3-(dimethylamino)propyl)-, hydrochloride",C[NH+](C)CCCC1C2=CC=CC=C2SC3=C(C1=O)C=C(C=C3)Cl.[Cl-],,,,,,
9430,44125,3-chloro-6-[3-(dimethylamino)propyl]-6H-benzo[b][1]benzothiepin-5-one,CN(C)CCCC1C2=CC=CC=C2SC3=C(C1=O)C=C(C=C3)Cl,,,,,,
9431,44126,"Dibenzo(b,f)thiepin-10(11H)-one, 8-chloro-11-(3-(dimethylamino)-2-methylpropyl)-, hydrochloride, hydrate (2:2:1)",CC(CC1C2=CC=CC=C2SC3=C(C1=O)C=C(C=C3)Cl)C[NH+](C)C.[Cl-],,,,,,
9432,44127,3-chloro-6-[3-(dimethylamino)-2-methylpropyl]-6H-benzo[b][1]benzothiepin-5-one,CC(CC1C2=CC=CC=C2SC3=C(C1=O)C=C(C=C3)Cl)CN(C)C,,,,,,
9433,44128,"cis-10,11-Dihydro-8-chloro-11-(2-(dimethylamino)ethyl)dibenzo(b,f)thiepin-10-ol hydrochloride",C[NH+](C)CC[C@@H]1[C@@H](C2=C(C=CC(=C2)Cl)SC3=CC=CC=C13)O.[Cl-],,,,,,
9434,44129,"(5S,6S)-3-chloro-6-[2-(dimethylamino)ethyl]-5,6-dihydrobenzo[b][1]benzothiepin-5-ol",CN(C)CC[C@@H]1[C@@H](C2=C(C=CC(=C2)Cl)SC3=CC=CC=C13)O,,,,,,
9435,44130,CID 44130,C[NH+](C)CCC[C@@H]1[C@@H](C2=C(C=CC(=C2)Cl)SC3=CC=CC=C13)O.C(=CC(=O)[O-])C(=O)O,,,,,,
9436,44131,"(5S,6S)-3-chloro-6-[3-(dimethylamino)propyl]-5,6-dihydrobenzo[b][1]benzothiepin-5-ol",CN(C)CCC[C@@H]1[C@@H](C2=C(C=CC(=C2)Cl)SC3=CC=CC=C13)O,,,,,,
9437,44132,"2-Chloro-N,N-dimethyldibenzo(b,f)thiepin-10-ethanamine hydrochloride",C[NH+](C)CCC1=CC2=C(C=CC(=C2)Cl)SC3=CC=CC=C31.[Cl-],,,,,,
9438,44133,"2-(2-chlorodibenzo[b,f]thiepin-10-yl)-N,N-dimethylethanamine",CN(C)CCC1=CC2=C(C=CC(=C2)Cl)SC3=CC=CC=C31,,,,,,
9439,44134,"2-Chloro-10-(3-dimethylaminopropyl)dibenzo(b,f)thiepin hydrochloride",C[NH+](C)CCCC1=CC2=C(C=CC(=C2)Cl)SC3=CC=CC=C31.[Cl-],,,,,,
9440,44135,"3-(3-chlorobenzo[b][1]benzothiepin-6-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1=CC2=C(C=CC(=C2)Cl)SC3=CC=CC=C31,,,,,,
9441,44136,"Dibenzo(2,3:6,7)thiepino(4,5-b)pyridinium, 1,2,3,4,4a,13b-hexahydro-12-chloro-1,1-dimethyl-, chloride, hydrate",C[N+]1(CCCC2C1C3=C(C=CC(=C3)Cl)SC4=CC=CC=C24)C.[Cl-],,,,,,
9442,44137,"12-Chloro-1,1-dimethyl-1,2,3,4,4a,13b-hexahydrodibenzo[2,3:6,7]thiepino[4,5-b]pyridin-1-ium",C[N+]1(CCCC2C1C3=C(C=CC(=C3)Cl)SC4=CC=CC=C24)C,,,,,,
9443,44138,Ethyl N-2-acetoxyethylnitrosocarbamate,CCOC(=O)N(CCOC(=O)C)N=O,,,,,,
9444,44139,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, methyl ester",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(=O)OC,,,,,,
9445,44140,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, propyl ester",CCCOC(=O)C(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C,,,,,,
9446,44141,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, 1-methylethyl ester",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(=O)OC(C)C,,,,,,
9447,44142,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, butyl ester",CCCCOC(=O)C(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C,,,,,,
9448,44143,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, 2-methylpropyl ester",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(=O)OCC(C)C,,,,,,
9449,44144,"Acetic acid, ((2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino)oxo-, phenylmethyl ester",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C(=O)OCC3=CC=CC=C3,,,,,,
9450,44145,"1H-Dibenzo(2,3:6,7)thiepino(4,5-b)pyrrolium, 2,3,3a,12b-tetrahydro-11-chloro-1,1-dimethyl-, chloride, hydrate",C[N+]1(CCC2C1C3=C(C=CC(=C3)Cl)SC4=CC=CC=C24)C.[Cl-],,,,,,
9451,44146,"11-chloro-1,1-dimethyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]thiepino[4,5-b]pyrrol-1-ium",C[N+]1(CCC2C1C3=C(C=CC(=C3)Cl)SC4=CC=CC=C24)C,,,,,,
9452,44147,"9H-Dibenzo(C,MN)phenanthren-9-one",C1=CC=C2C(=C1)C=C3C=CC=C4C3=C2C5=CC=CC=C5C4=O,,,,,,
9453,44148,"BENZIMIDAZOLE, 5-(2-IMIDAZOLINYL)-2-(p-(p-(2-IMIDAZOLINYL)PHENOXY)PHENYL)-",C1CN=C(N1)C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC5=CC=C(C=C5)C6NCC=N6,,,,,,
9454,44149,"8-Amino-1,2,3,5,6,7-hexahydrodicyclopenta(b,e)pyridine hydrate",C1CC2=C(C1)N=C3CCCC3=C2N.O,,,,,,
9455,44150,"1,2,3,5,6,7-Hexahydrodicyclopenta[b,e]pyridin-8-amine",C1CC2=C(C1)N=C3CCCC3=C2N,,,,,,
9456,44151,"1H-Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-, (benzoyloxy)methyl ester",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCOC(=O)C4=CC=CC=C4,,,,,,
9457,44152,"1H-Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-, ((3-methylbenzoyl)oxy)methyl ester",CC1=CC(=CC=C1)C(=O)OCOC(=O)CC2=C(N(C3=C2C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)Cl)C,,,,,,
9458,44153,"Biphenylene, 2,3,6,7-tetrabromo-",C1=C2C(=CC(=C1Br)Br)C3=CC(=C(C=C23)Br)Br,,,,,,
9459,44154,2-Methylquinolinium chloride,CC1=NC2=CC=CC=C2C=C1.Cl,,,,,,
9460,44155,Tilisolol HCl,CC(C)(C)[NH2+]CC(COC1=CN(C(=O)C2=CC=CC=C21)C)O.[Cl-],,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
9461,44156,CID 44156,CN(C)CCCN=C(C(=NCCCN(C)C)S)S,,,,,,
9462,44157,"DIBENZO-p-DIOXIN, 1-NITRO-2,3,7,8-TETRACHLORO-",C1=C2C(=CC(=C1Cl)Cl)OC3=C(C(=C(C=C3O2)Cl)Cl)[N+](=O)[O-],,,,,,
9463,44158,"1-Amino-2,3,7,8-tetrachlorodibenzo-p-dioxin",C1=C2C(=CC(=C1Cl)Cl)OC3=C(C(=C(C=C3O2)Cl)Cl)N,,,,,,
9464,44159,N-Methyl-N-nitroso-(2-methylphenyl)methylamine,CC1=CC=CC=C1CN(C)N=O,,,,,,
9465,44160,N-Nitroso-N-(3-methylbenzyl)methylamine,CC1=CC(=CC=C1)CN(C)N=O,,,,,,
9466,44161,N-Nitroso-N-(4-methylbenzyl)methylamine,CC1=CC=C(C=C1)CN(C)N=O,,,,,,
9467,44162,CID 44162,CCCCN1C(=O)C(=CC=CC=C2N(C3=CC=CC=C3O2)CCCS(=O)(=O)[O-])C(=O)N(C1=S)CCCC.[Na+],,,,,,
9468,44163,"2,2',4,6-Tetrachlorobiphenyl",C1=CC=C(C(=C1)C2=C(C=C(C=C2Cl)Cl)Cl)Cl,,,,,,
9469,44164,"(1R,2R)-cyclohexane-1,2-diamine;tetrachloroplatinum",C1CC[C@H]([C@@H](C1)N)N.Cl[Pt](Cl)(Cl)Cl,,,,,,
9470,44165,"Ketone, 10-(3-(4-hydroxypiperidino)propyl)phenothiazin-2-YL methyl",CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)O,,,,,,
9471,44166,N-(2-Carboxyphenyl)isonicotinamide 1-oxide,C1=CC=C(C(=C1)C(=O)O)NC(=O)C2=CC=[N+](C=C2)[O-],,,,,,
9472,44167,N-(3-Carboxyphenyl)nicotinamide 1-oxide,C1=CC(=CC(=C1)NC(=O)C2=C[N+](=CC=C2)[O-])C(=O)O,,,,,,
9473,44168,N-(4-Carboxyphenyl)isonicotinamide 1-oxide,C1=CC(=CC=C1C(=O)O)NC(=O)C2=CC=[N+](C=C2)[O-],,,,,,
9474,44169,N-(4-Carboxyphenyl)nicotinamide 1-oxide,C1=CC(=C[N+](=C1)[O-])C(=O)NC2=CC=C(C=C2)C(=O)O,,,,,,
9475,44170,CID 44170,CC1=CC=CC=C1N2C(=O)C(N=C2S)CC(=O)O,,,,,,
9476,44171,CID 44171,CC1=CC(=CC=C1)N2C(=O)C(N=C2S)CC(=O)O,,,,,,
9477,44172,CID 44172,CC1=CC=C(C=C1)N2C(=O)C(N=C2S)CC(=O)O.O,,,,,,
9478,44173,CID 44173,CC1=CC=C(C=C1)N2C(=O)C(N=C2S)CC(=O)O,,,,,,
9479,44174,CID 44174,C1=CC=C(C(=C1)N2C(=O)C(N=C2S)CC(=O)O)Cl,,,,,,
9480,44175,CID 44175,C1=CC(=CC(=C1)Cl)N2C(=O)C(N=C2S)CC(=O)O,,,,,,
9481,44176,CID 44176,C1=CC(=CC=C1N2C(=O)C(N=C2S)CC(=O)O)Cl.O,,,,,,
9482,44177,CID 44177,C1=CC(=CC=C1N2C(=O)C(N=C2S)CC(=O)O)Cl,,,,,,
9483,44178,Fenothiocarb,CN(C)C(=O)SCCCCOC1=CC=CC=C1,,,,,,
9484,44179,Zidometacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)N=[N+]=[N-])C=CC(=C2)OC)CC(=O)O,,,,,,
9485,44180,CID 44180,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)N[N+]#N)C=CC(=C2)OC)CC(=O)O,,,,,,
9486,44181,Cadmium zinc sulfide,[S-2].[S-2].[Zn+2].[Cd+2],,,,,,
9487,44182,alpha-(3-Methyl-1-butynyl)mandelic acid 3-quinuclidinyl ester,CC(C)C#CC(C1=CC=CC=C1)(C(=O)OC2CN3CCC2CC3)O,,,,,,
9488,44183,1-Methyl-4-piperidyl phenyl(3-methyl-but-1-yne-3-enyl)glycolate,CC(=C)C#CC(C1=CC=CC=C1)(C(=O)OC2CCN(CC2)C)O,,,,,,
9489,44184,"Benzofurazan, 4-(4-(2-methoxyphenyl)-1-piperazinyl)-7-nitro-, 3-oxide",COC1=CC=CC=C1N2CCN(CC2)C3=CC=C(C4=NO[N+](=C34)[O-])[N+](=O)[O-],,,,,,
9490,44185,"(6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O,,,,,,
9491,44186,CID 44186,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)[O-].[Na+],,,,,,
9492,44187,Cefoperazone,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O,"['Indicated for the treatment of following infections caused by susceptible bacteria:  1) Respiratory tract infections caused by _S. pneumoniae_, _H. influenzae_, _S. aureus_ (penicillinase and non-penicillinase producing strains), _S. pyogenes_ (Group A beta-hemolytic streptococci), _P. aeruginosa_, _Klebsiella pneumoniae_, _E. coli_, _Proteus mirabilis_, and Enterobacter species.  2) Peritonitis and other intra-abdominal infections caused by _E. coli_, _P. aeruginosa_, and anaerobic gram-negative bacilli (including _Bacteroides fragilis_).  3) Bacterial septicemia caused by _S. pneumoniae_, _S. agalactiae_, _S. aureus_, _Pseudomonas aeruginosa_, _E. coli_, _Klebsiella_ spp., _Klebsiella pneumoniae_, Proteus species (indole-positive and indole-negative), _Clostridium_ spp. and anaerobic gram-positive cocci.  4) Infections of the skin and skin structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa.  5) Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci.  6) Urinary tract infections caused by Escherichia coli and Pseudomonas aeruginosa.  7) Enterococcal Infections. Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, _in vitro_ susceptibility testing may not correlate directly with _in vivo_ results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.']",['Cefoperazone is a third generation cephalosporin antibiotic. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Cefoperazone is excreted mainly in the bile.'],['No significant quanitity of metabolites have been identified in urine.'],"['The mean serum half-life is approximately 2.0 hours, independent of the route of administration.']"
9493,44188,Tiflamizole,C1=CC(=CC=C1C2=C(N=C(N2)S(=O)(=O)C(C(F)F)(F)F)C3=CC=C(C=C3)F)F,,,,,,
9494,44189,"1,3-Benzodioxole-2-acetamide, N-(2-diethylaminoethyl)-alpha,2-dimethyl-, citrate",CCN(CC)CCNC(=O)C(C)C1(OC2=CC=CC=C2O1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
9495,44190,"N-(2-Diethylaminoethyl)-alpha,2-dimethyl-1,3-benzodioxole-2-acetamide",CCN(CC)CCNC(=O)C(C)C1(OC2=CC=CC=C2O1)C,,,,,,
9496,44191,"7-Chloro-1-methyl-5-(1-trifluoromethylethoxy)-3H-1,4-benzodiazepin-2(1H)-one",CC(C(F)(F)F)OC1=NCC(=O)N(C2=C1C=C(C=C2)Cl)C,,,,,,
9497,44192,"3H-1,4-Benzodiazepin-2(1H)-one, 7-chloro-1-methyl-5-(2-propynyloxy)-",CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)OCC#C,,,,,,
9498,44193,"3H-1,4-BENZODIAZEPIN-2(1H)-ONE, 7-CHLORO-5-(o-FLUOROPHENOXY)-1-METHYL-",CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)OC3=CC=CC=C3F,,,,,,
9499,44194,"3H-1,4-Benzodiazepin-2(1H)-one, 8-chloro-5-ethoxy-1-methyl-",CCOC1=NCC(=O)N(C2=C1C=CC(=C2)Cl)C,,,,,,
9500,44195,"3H-1,4-Benzodiazepin-2(1H)-one, 5-ethoxy-1-methyl-7-nitro-",CCOC1=NCC(=O)N(C2=C1C=C(C=C2)[N+](=O)[O-])C,,,,,,
9501,44196,"3H-1,4-Benzodiazepin-2(1H)-one, 1,7-dimethyl-5-ethoxy-",CCOC1=NCC(=O)N(C2=C1C=C(C=C2)C)C,,,,,,
9502,44197,"(N,N'-Pentamethylenedioxydiethylene)bis(dimethylethylammonium iodide)",CC[N+](C)(C)CCOCCCCCOCC[N+](C)(C)CC.[I-].[I-],,,,,,
9503,44198,Ethyl-[2-[5-[2-[ethyl(dimethyl)azaniumyl]ethoxy]pentoxy]ethyl]-dimethylazanium,CC[N+](C)(C)CCOCCCCCOCC[N+](C)(C)CC,,,,,,
9504,44199,"(N,N'-Pentamethylenedioxydiethylene)bis(triethylammonium iodide)",CC[N+](CC)(CC)CCOCCCCCOCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9505,44200,Triethyl-[2-[5-[2-(triethylazaniumyl)ethoxy]pentoxy]ethyl]azanium,CC[N+](CC)(CC)CCOCCCCCOCC[N+](CC)(CC)CC,,,,,,
9506,44201,"(N,N'-Oxydiethylenedioxydiethylene)bis(triethylammonium iodide)",CC[N+](CC)(CC)CCOCCOCCOCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
9507,44202,Triethyl-[2-[2-[2-[2-(triethylazaniumyl)ethoxy]ethoxy]ethoxy]ethyl]azanium,CC[N+](CC)(CC)CCOCCOCCOCC[N+](CC)(CC)CC,,,,,,
9508,44203,Mariptiline,C1C2C1C3=CC=CC=C3C(=NOCCN)C4=CC=CC=C24,,,,,,
9509,44204,N-(2-(Diethylamino)-1-((dimethylamino)methyl)ethyl)-alpha-phenylbenzeneacetamide,CCN(CC)CC(CN(C)C)NC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
9510,44205,N-(2-(Bis(1-methylethyl)amino)-1-((dimethylamino)methyl)ethyl)-alpha-phenylbenzeneacetamide,CC(C)N(CC(CN(C)C)NC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
9511,44206,"Benzeneacetamide, N-(2-(bis(1-methylethyl)amino)-1-((bis(1-methylethyl)amino)methyl)ethyl)-alpha-phenyl-",CC(C)N(CC(CN(C(C)C)C(C)C)NC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
9512,44207,N-(1-((Dimethylamino)methyl)-2-(4-morpholinyl)ethyl)-alpha-phenylbenzeneacetamide,CN(C)CC(CN1CCOCC1)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9513,44208,N-(1-((Diethylamino)methyl)-2-(4-morpholinyl)ethyl)-alpha-phenylbenzeneacetamide,CCN(CC)CC(CN1CCOCC1)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9514,44209,"Benzeneacetamide, N-(2-(4-morpholinyl)-1-(4-morpholinylmethyl)ethyl)-alpha-phenyl-",C1COCCN1CC(CN2CCOCC2)NC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9515,44210,N-(1-((Dimethylamino)methyl)-2-(1-piperidinyl)ethyl)-alpha-phenylbenzeneacetamide,CN(C)CC(CN1CCCCC1)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9516,44211,N-(1-((Diethylamino)methyl)-2-(1-piperidinyl)ethyl)-alpha-phenylbenzeneacetamide,CCN(CC)CC(CN1CCCCC1)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9517,44212,N-(1-((Bis(1-methylethyl)amino)methyl)-2-(1-piperidinyl)ethyl)-alpha-phenylbenzeneacetamide,CC(C)N(CC(CN1CCCCC1)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C(C)C,,,,,,
9518,44213,"Benzeneacetamide, alpha-phenyl-N-(2-(1-piperidinyl)-1-(1-piperidinylmethyl)ethyl)-",C1CCN(CC1)CC(CN2CCCCC2)NC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9519,44214,Dichlorodihydroxybis(isopropylamine)platinum,CC(C)N.CC(C)N.O.O.Cl[Pt]Cl,,,,,,
9520,44215,3-Chloro-4-hydroxy-5-methoxybenzoic acid,COC1=C(C(=CC(=C1)C(=O)O)Cl)O,,,,,,
9521,44216,2-Chloro-4-hydroxy-5-methoxybenzoic acid,COC1=C(C=C(C(=C1)C(=O)O)Cl)O,,,,,,
9522,44217,"1,4-Bis(1-adamantyl)piperazine dihydrochloride",C1CN(CCN1C23CC4CC(C2)CC(C4)C3)C56CC7CC(C5)CC(C7)C6.Cl.Cl,,,,,,
9523,44218,"1,4-Bis(1-adamantyl)piperazine",C1CN(CCN1C23CC4CC(C2)CC(C4)C3)C56CC7CC(C5)CC(C7)C6,,,,,,
9524,44219,Lysine acetylsalicylate,CC(=O)OC1=CC=CC=C1C(=O)[O-].C(CC[NH3+])CC(C(=O)O)N,,,"['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
9525,44220,"Benzeneacetamide, N-(2-(diethylamino)-1-((diethylamino)methyl)ethyl)-alpha-phenyl-",CCN(CC)CC(CN(CC)CC)NC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
9526,44221,CID 44221,CC1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)[O-].[Na+],,,,,,
9527,44222,4-[2-(4-Methylphenyl)diazenyl]benzenesulfonic acid,CC1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)O,,,,,,
9528,44223,CID 44223,CC1=CC(=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)[O-])C.[Na+],,,,,,
9529,44224,"4-[(2,4-Dimethylphenyl)diazenyl]benzenesulfonic acid",CC1=CC(=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)O)C,,,,,,
9530,44225,CID 44225,C1=CC(=CC=C1N=NC2=C(C=C(C=C2)Cl)Cl)S(=O)(=O)[O-].[Na+],,,,,,
9531,44226,"4-[(2,4-Dichlorophenyl)diazenyl]benzenesulfonic acid",C1=CC(=CC=C1N=NC2=C(C=C(C=C2)Cl)Cl)S(=O)(=O)O,,,,,,
9532,44227,(p-(p-Nitroanilino)phenyl)isocyanic acid,C1=CC(=CC=C1NC2=CC=C(C=C2)[N+](=O)[O-])N=C=O,,,,,,
9533,44228,"Butanoic acid, 4-(ethylamino)-4-oxo-, 2-phenylhydrazide",CCNC(=O)CCC(=O)NNC1=CC=CC=C1,,,,,,
9534,44229,"Butanoic acid, 4-oxo-4-(propylamino)-, 2-phenylhydrazide",CCCNC(=O)CCC(=O)NNC1=CC=CC=C1,,,,,,
9535,44230,"Butanoic acid, 4-((1-methylethyl)amino)-4-oxo-, 2-phenylhydrazide",CC(C)NC(=O)CCC(=O)NNC1=CC=CC=C1,,,,,,
9536,44231,"Butanoic acid, 4-(cyclohexylamino)-4-oxo-, 2-phenylhydrazide",C1CCC(CC1)NC(=O)CCC(=O)NNC2=CC=CC=C2,,,,,,
9537,44232,"Butanoic acid, 4-((2-cyanoethyl)amino)-4-oxo-, 2-phenylhydrazide",C1=CC=C(C=C1)NNC(=O)CCC(=O)NCCC#N,,,,,,
9538,44233,"Hexanoic acid, 6-oxo-6-(propylamino)-, 2-phenylhydrazide",CCCN=C(CCCCC(=O)O)NNC1=CC=CC=C1,,,,,,
9539,44234,alpha-Amino-9-acridinepropanoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)CC(C(=O)O)N,,,,,,
9540,44235,N-(2-Dimethylaminoethyl)-4-methylbenzamidine dihydrochloride,CC1=CC=C(C=C1)C(=[NH+]CC[NH+](C)C)N.[Cl-].[Cl-],,,,,,
9541,44236,N-[2-(Dimethylamino)ethyl]-4-methylbenzamidine,CC1=CC=C(C=C1)C(=NCCN(C)C)N,,,,,,
9542,44237,"Benzamidine, N-(2-diethylaminoethyl)-4-methyl-, dihydrochloride",CC[NH+](CC)CC[NH+]=C(C1=CC=C(C=C1)C)N.[Cl-].[Cl-],,,,,,
9543,44238,N-[2-(Diethylamino)ethyl]-4-methylbenzamidine,CCN(CC)CCN=C(C1=CC=C(C=C1)C)N,,,,,,
9544,44239,CID 44239,CC[NH+](CC)CC[NH+]=C(C1=CC=C(C=C1)[NH3+])N.[Cl-].[Cl-].[Cl-],,,,,,
9545,44240,4-Amino-N-[2-(diethylamino)ethyl]benzamidine,CCN(CC)CCN=C(C1=CC=C(C=C1)N)N,,,,,,
9546,44241,N-(2-Diethylaminoethyl)-4-ethoxybenzamidine dihydrochloride hydrate,CC[NH+](CC)CC[NH+]=C(C1=CC=C(C=C1)OCC)N.[Cl-].[Cl-],,,,,,
9547,44242,N'-[2-(diethylamino)ethyl]-4-ethoxybenzenecarboximidamide,CCN(CC)CCN=C(C1=CC=C(C=C1)OCC)N,,,,,,
9548,44243,N-(2-Diethylaminoethyl)-4-propoxybenzamidine dihydrochloride,CCCOC1=CC=C(C=C1)C(=[NH+]CC[NH+](CC)CC)N.[Cl-].[Cl-],,,,,,
9549,44244,N'-[2-(diethylamino)ethyl]-4-propoxybenzenecarboximidamide,CCCOC1=CC=C(C=C1)C(=NCCN(CC)CC)N,,,,,,
9550,44245,4-Propoxy-N-(2-pyrrolidinylethyl)benzamidine dihydrochloride,CCCOC1=CC=C(C=C1)C(=[NH+]CC[NH+]2CCCC2)N.[Cl-].[Cl-],,,,,,
9551,44246,4-propoxy-N'-(2-pyrrolidin-1-ylethyl)benzenecarboximidamide,CCCOC1=CC=C(C=C1)C(=NCCN2CCCC2)N,,,,,,
9552,44247,"Benzamidine, N-(2-diethylaminoethyl)-4-isopropoxy-",CCN(CC)CCN=C(C1=CC=C(C=C1)OC(C)C)N,,,,,,
9553,44248,4-Isopropoxy-N-(2-(1-pyrrolidinyl)ethyl)benzamidine dihydrochloride,CC(C)OC1=CC=C(C=C1)C(=[NH+]CC[NH+]2CCCC2)N.[Cl-].[Cl-],,,,,,
9554,44249,4-propan-2-yloxy-N'-(2-pyrrolidin-1-ylethyl)benzenecarboximidamide,CC(C)OC1=CC=C(C=C1)C(=NCCN2CCCC2)N,,,,,,
9555,44250,1-Chloro-1-butyne,CCC#CCl,,,,,,
9556,44251,CID 44251,CCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=CC=C1Br.[Cl-],,,,,,
9557,44252,CID 44252,CCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=CC=C1Br,,,,,,
9558,44253,CID 44253,CCCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=CC=C1Br.[Cl-],,,,,,
9559,44254,CID 44254,CCCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=CC=C1Br,,,,,,
9560,44255,CID 44255,CCCCCCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=C(C=C1)C.[Cl-],,,,,,
9561,44256,CID 44256,CCCCCCCCCCOC(=O)C[N+](CC)(CC)CC=C(C)CC1=CC=C(C=C1)C,,,,,,
9562,44257,CID 44257,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)N=C(N2)N)O)O,,,,,,
9563,44258,Etersalate,CC(=O)NC1=CC=C(C=C1)OCCOC(=O)C2=CC=CC=C2OC(=O)C,,,,,,
9564,44259,Staurosporine,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
9565,44260,1-Methyl-2-nitronaphthalene,CC1=C(C=CC2=CC=CC=C12)[N+](=O)[O-],,,,,,
9566,44261,"BENZ(a)ANTHRACEN-7-ACETIC ACID, METHYL ESTER",COC(=O)CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C41,,,,,,
9567,44262,"GLYCINE, N-(BENZ(a)ANTHRACEN-5-YLCARBAMOYL)-",C1=CC=C2C=C3C4=CC=CC=C4C(=CC3=CC2=C1)NC(=O)NCC(=O)O,,,,,,
9568,44263,"GLYCINE, N-(BENZ(a)ANTHRACEN-7-YLCARBAMOYL)-",C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)NC(=O)NCC(=O)O,,,,,,
9569,44264,"ISOCYANIC ACID, BENZ(a)ANTHRACEN-7-YL ESTER",C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)N=C=O,,,,,,
9570,44265,BENZ(a)ANTHRACENE-7-THIOL,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)S,,,,,,
9571,44266,BENZ(a)ANTHRACENE-7-METHANETHIOL,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)CS,,,,,,
9572,44267,"Benz(a)anthracene-7,12-dimethanol, diacetate",CC(=O)OCC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C41)COC(=O)C,,,,,,
9573,44268,"BENZ(a)ANTHRACENE, 8-BROMO-7,12-DIMETHYL-",CC1=C2C=CC=C(C2=C(C3=C1C4=CC=CC=C4C=C3)C)Br,,,,,,
9574,44269,"BENZ(a)ANTHRACENE, 8-BUTYL-",CCCCC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
9575,44270,"BENZ(a)ANTHRACENE, 8-CHLORO-7-METHYL-",CC1=C2C(=CC3=C1C=CC4=CC=CC=C43)C=CC=C2Cl,,,,,,
9576,44271,"BENZ(a)ANTHRACENE, 8-CYANO-7,12-DIMETHYL-",CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC(=C14)C#N)C,,,,,,
9577,44272,Benz[a]anthracene-7-acetonitrile,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)CC#N,,,,,,
9578,44273,"BENZ(a)ANTHRACENE-8-CARBONITRILE, 7-METHYL-",CC1=C2C(=CC3=C1C=CC4=CC=CC=C43)C=CC=C2C#N,,,,,,
9579,44274,"2,9,10-Trimethylanthracene",CC1=CC2=C(C3=CC=CC=C3C(=C2C=C1)C)C,,,,,,
9580,44275,"BENZO(c)PHENANTHRENE, 5-ACETYL-",CC(=O)C1=CC2=C(C3=CC=CC=C3C=C2)C4=CC=CC=C41,,,,,,
9581,44276,"BENZ(a)ANTHRACENE, 8-PENTYL-",CCCCCC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
9582,44277,"Benzylamine, N-cyclohexyl-N-pentyl-",CCCCCN(CC1=CC=CC=C1)C2CCCCC2,,,,,,
9583,44278,"N,N-Dimethyl-p-[2-(1-naphtyl)vinyl]aniline",CN(C)C1=CC=C(C=C1)C=CC2=CC=CC3=CC=CC=C32,,,,,,
9584,44279,"4,5-Dimethylchrysene",CC1=C2C(=CC=C1)C=CC3=C2C(=CC4=CC=CC=C34)C,,,,,,
9585,44280,"7,12-Dihydro-7,12-dimethyl-7,12-epoxybenz(a)anthracene",CC12C3=C(C4=CC=CC=C4C=C3)C(O1)(C5=CC=CC=C25)C,,,,,,
9586,44281,"BENZ(a)ANTHRACENE, 7-(ETHOXYMETHYL)-",CCOCC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C41,,,,,,
9587,44282,"BENZ(a)ANTHRACENE, 8-HEPTYL-",CCCCCCCC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
9588,44283,"BENZ(a)ANTHRACENE, 8-HEXYL-",CCCCCCC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
9589,44284,1-Hydroxychrysene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC=C4O,,,,,,
9590,44285,3-Hydroxychrysene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=C(C=C4)O,,,,,,
9591,44286,4-Hydroxychrysene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C(=CC=C4)O,,,,,,
9592,44287,CID 44287,CN(C)C1=CC=C(C=C1)[N+](=CC2=C3C=CC4=CC=CC=C4C3=NC5=CC=CC=C52)[O-],,,,,,
9593,44288,"BENZ(a)ACRIDINE, 9-CHLORO-8,12-DIMETHYL-",CC1=C2C=CC(=C(C2=NC3=C1C4=CC=CC=C4C=C3)C)Cl,,,,,,
9594,44289,"BENZ(c)ACRIDINE, 10-CHLORO-7-ETHYL-11-METHYL-",CCC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=CC(=C4C)Cl,,,,,,
9595,44290,"Aziridine, 1-diethylacetyl-",CCC(CC)C(=O)N1CC1,,,,,,
9596,44291,"4-(2-benzo[a]acridin-12-ylethenyl)-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)C=CC2=C3C(=NC4=CC=CC=C42)C=CC5=CC=CC=C53,,,,,,
9597,44292,"4-(2-benzo[c]acridin-7-ylethenyl)-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)C=CC2=C3C=CC4=CC=CC=C4C3=NC5=CC=CC=C52,,,,,,
9598,44293,N-1-Diacetamidofluorene,CC(=O)N(C1=CC=CC2=C1CC3=CC=CC=C32)C(=O)C,,,,,,
9599,44294,"Fluoren-2-amine, N-methyl-",CNC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
9600,44295,"BENZ(a)ANTHRACENE, 8-METHOXY-",COC1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
9601,44296,"BENZ(a)ANTHRACENE, 7,9,10,12-TETRAMETHYL-",CC1=CC2=C(C=C1C)C(=C3C(=C2C)C=CC4=CC=CC=C43)C,,,,,,
9602,44297,"DIBENZ(a,h)ANTHRACENE, 5-METHOXY-",COC1=CC2=C(C=C3C=CC4=CC=CC=C4C3=C2)C5=CC=CC=C51,,,,,,
9603,44298,6-Styrylbenzo[a]pyrene,C1=CC=C(C=C1)C=CC2=C3C=CC4=CC=CC5=C4C3=C(C=C5)C6=CC=CC=C62,,,,,,
9604,44299,7-((p-Nitrophenylazo)methyl)benz(c)acridine,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4N=C32)CN=NC5=CC=C(C=C5)[N+](=O)[O-],,,,,,
9605,44300,4-Amino-4'-nitro-3-biphenylol hydrochloride,C1=CC(=CC=C1C2=CC(=C(C=C2)[NH3+])O)[N+](=O)[O-].[Cl-],,,,,,
9606,44301,CID 44301,C1=CC(=CC=C1C2=CC(=O)C(=N)C=C2)N(O)O,,,,,,
9607,44302,"3-Biphenylol, 4-(dimethylamino)-",CN(C)C1=C(C=C(C=C1)C2=CC=CC=C2)O,,,,,,
9608,44303,3-Methyl-4-phenylaniline,CC1=C(C=CC(=C1)N)C2=CC=CC=C2,,,,,,
9609,44304,4-Amino-3-methylbiphenyl,CC1=C(C=CC(=C1)C2=CC=CC=C2)N,,,,,,
9610,44305,1-Methoxy-2-aminonaphthalene,COC1=C(C=CC2=CC=CC=C21)[NH3+].[Cl-],,,,,,
9611,44306,"BENZ(a)ANTHRACENE, 7-CYANO-12-METHYL-",CC1=C2C(=C(C3=CC=CC=C13)C#N)C=CC4=CC=CC=C42,,,,,,
9612,44307,"BENZ(a)ANTHRACENE, 7-ETHOXYMETHYL-12-METHYL-",CCOCC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C41)C,,,,,,
9613,44308,5-Propylbenzo[c]phenanthrene,CCCC1=CC2=C(C3=CC=CC=C3C=C2)C4=CC=CC=C41,,,,,,
9614,44309,"BENZ(a)ANTHRACENE, 7,12-DIMETHYL-8-PROPYL-",CCCC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,,,,,,
9615,44310,"BENZ(a)ANTHRACENE, 6-METHYL-1,2,3,4-TETRAHYDRO-",CC1=CC2=C(CCCC2)C3=CC4=CC=CC=C4C=C13,,,,,,
9616,44311,"BENZ(a)ANTHRACENE, 7,8,9,12-TETRAMETHYL-",CC1=C(C2=C(C=C1)C(=C3C(=C2C)C=CC4=CC=CC=C43)C)C,,,,,,
9617,44312,BENZ(a)ANTHRACENE-7-ETHANOL,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)CCO,,,,,,
9618,44313,"BENZ(a)ANTHRACENE, 8-ISOPROPYL-",CC(C)C1=CC=CC2=CC3=C(C=CC4=CC=CC=C43)C=C21,,,,,,
9619,44314,"BENZ(a)ANTHRACENE, 9-ISOPROPYL-",CC(C)C1=CC2=C(C=C1)C=C3C(=C2)C=CC4=CC=CC=C43,,,,,,
9620,44315,"BENZO(c)PHENANTHRENE, 5-ISOPROPYL-",CC(C)C1=CC2=C(C3=CC=CC=C3C=C2)C4=CC=CC=C41,,,,,,
9621,44316,7-Ethyl-5-methoxybenz(a)anthracene,CCC1=C2C=C(C3=CC=CC=C3C2=CC4=CC=CC=C41)OC,,,,,,
9622,44317,"BENZ(a)ANTHRACENE, 8-METHOXY-7-METHYL-",CC1=C2C(=CC3=C1C=CC4=CC=CC=C43)C=CC=C2OC,,,,,,
9623,44318,1-(Aziridin-1-yl)octadec-9-en-1-one,CCCCCCCCC=CCCCCCCCC(=O)N1CC1,,,,,,
9624,44319,"BENZ(c)ACRIDINE, 7-ETHYL-",CCC1=C2C=CC3=CC=CC=C3C2=NC4=CC=CC=C41,,,,,,
9625,44320,"DIBENZ(a,h)ACRIDINE, 1-ETHYL-",CCC1=CC=CC2=C1C3=C(C=C2)N=C4C(=C3)C=CC5=CC=CC=C54,,,,,,
9626,44321,"DIBENZ(a,j)ACRIDINE, 1-ETHYL-",CCC1=CC=CC2=C1C3=C(C=C2)N=C4C=CC5=CC=CC=C5C4=C3,,,,,,
9627,44322,"Aziridine, 1-(pentylsulfonyl)-",CCCCCS(=O)(=O)N1CC1,,,,,,
9628,44323,1-Myristoylaziridine,CCCCCCCCCCCCCC(=O)N1CC1,,,,,,
9629,44324,"Aziridine, 1-(2-naphthoyl)-",C1CN1C(=O)C2=CC3=CC=CC=C3C=C2,,,,,,
9630,44325,CID 44325,C1=CC=C2C(=C1)C=CC3=NC4=CC=CC=C4C(=C32)C=CC5=CC(=CC=C5)[N+](=O)[O-],,,,,,
9631,44326,12-[2-(2-Nitrophenyl)ethenyl]benzo[a]acridine,C1=CC=C2C(=C1)C=CC3=NC4=CC=CC=C4C(=C32)C=CC5=CC=CC=C5[N+](=O)[O-],,,,,,
9632,44327,7-[2-(3-Nitrophenyl)ethenyl]benzo[c]acridine,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4N=C32)C=CC5=CC(=CC=C5)[N+](=O)[O-],,,,,,
9633,44328,7-[2-(2-Nitrophenyl)ethenyl]benzo[c]acridine,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4N=C32)C=CC5=CC=CC=C5[N+](=O)[O-],,,,,,
9634,44329,7-[2-(4-Nitrophenyl)ethenyl]benzo[c]acridine,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4N=C32)C=CC5=CC=C(C=C5)[N+](=O)[O-],,,,,,
9635,44330,1-Nonanoylaziridine,CCCCCCCCC(=O)N1CC1,,,,,,
9636,44331,CID 44331,CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=CC=C2)[O-].CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=CC=C2)[O-].[Cu+2],,,,,,
9637,44332,CID 44332,CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=CC=C2)[O-],,,,,,
9638,44333,"DIBENZ(a,h)ANTHRACENE, OCTAHYDRO-",C1CC2=CC=CC=C2C3C1CC4C(C3)C=CC5=CC=CC=C45,,,,,,
9639,44334,1-Nitrochrysene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC=C4[N+](=O)[O-],,,,,,
9640,44335,5-Methylhexahydro-2-isoindolineethanol,CC1CCC2CN(CC2C1)CCO,,,,,,
9641,44336,"2,5-Dichloro-4'-isopropylbiphenyl",CC(C)C1=CC=C(C=C1)C2=C(C=CC(=C2)Cl)Cl,,,,,,
9642,44337,6-Carboxyvanillic acid,COC1=C(C=C(C(=C1)C(=O)O)C(=O)O)O,,,,,,
9643,44338,"Acetic acid, (7-hydroxy-1-naphthalenyl)oxy-",C1=CC2=C(C=C(C=C2)O)C(=C1)OCC(=O)O,,,,,,
9644,44339,"BENZ(c)ACRIDINE, 7-ETHYL-9-METHYL-",CCC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=C(C=C4)C,,,,,,
9645,44340,"BENZ(a)ACRIDINE, 3,8,12-TRIMETHYL-",CC1=CC2=C(C=C1)C3=C(C4=CC=CC(=C4N=C3C=C2)C)C,,,,,,
9646,44341,"BENZ(a)ACRIDINE, 9,10,12-TRIMETHYL-",CC1=CC2=C(C3=C(C=CC4=CC=CC=C43)N=C2C=C1C)C,,,,,,
9647,44342,"BENZ(c)ACRIDINE, 5,7,11-TRIMETHYL-",CC1=C2C(=CC=C1)C(=C3C=C(C4=CC=CC=C4C3=N2)C)C,,,,,,
9648,44343,"Acetohydroxamic acid, N-(4-quinolyl)-",CC(=O)N(C1=CC=NC2=CC=CC=C21)O,,,,,,
9649,44344,"3-Biphenylol, 4-amino-4'-methoxy-",COC1=CC=C(C=C1)C2=CC(=C(C=C2)N)O,,,,,,
9650,44345,4-Amino-4'-methoxy-3-biphenylol hydrochloride,COC1=CC=C(C=C1)C2=CC(=C(C=C2)[NH3+])O.[Cl-],,,,,,
9651,44346,3-Methyl-4-acetylaminobiphenyl,CC1=C(C=CC(=C1)C2=CC=CC=C2)NC(=O)C,,,,,,
9652,44347,"DIBENZ(a,h)ANTHRACENE, 5,6-DIMETHOXY-",COC1=C(C2=C(C=C3C=CC4=CC=CC=C4C3=C2)C5=CC=CC=C51)OC,,,,,,
9653,44348,BENZO(rst)PENTAPHENE-5-CARBOXALDEHYDE,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C6=CC=CC=C6C(=C54)C=C3)C=O,,,,,,
9654,44349,"DIBENZO(b,def)CHRYSENE-7-CARBOXALDEHYDE",C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C6=CC=CC=C56)C=O)C=C3,,,,,,
9655,44350,"BENZO(rst)PENTAPHENE-5-CARBOXALDEHYDE, 8-METHYL-",CC1=C2C=CC3=C(C4=CC=CC=C4C5=C3C2=C(C=C5)C6=CC=CC=C16)C=O,,,,,,
9656,44351,"14-Methyldibenzo(b,def)chrysene-7-carboxaldehyde",CC1=C2C=CC3=C4C2=C(C=CC4=C(C5=CC=CC=C35)C=O)C6=CC=CC=C16,,,,,,
9657,44352,4-((p-(Dimethylamino)phenyl)azo)isoquinoline,CN(C)C1=CC=C(C=C1)N=NC2=CN=CC3=CC=CC=C32,,,,,,
9658,44353,5-((p-(Dimethylamino)phenyl)azo)isoquinoline,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC3=C2C=CN=C3,,,,,,
9659,44354,7-((p-(Dimethylamino)phenyl)azo)isoquinoline,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC3=C2C=NC=C3,,,,,,
9660,44355,"DIPROPYLAMINE, 2,2'-BIS(2,3-EPOXYPROPOXY)-N-t-BUTYL-",CC(CN(CC(C)OCC1CO1)C(C)(C)C)OCC2CO2,,,,,,
9661,44356,"Heptanedioic acid, 4-oxo-, isonicotinoyl hydrazone",C1=CN=CC=C1C(=O)NN=C(CCC(=O)O)CCC(=O)O,,,,,,
9662,44357,"1-(Benz[a]anthracen-7-yl)-2,2,2-trichloroethanone",C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)C(=O)C(Cl)(Cl)Cl,,,,,,
9663,44358,"DIBENZ(a,h)ANTHRACENE, 7-AMINO-",C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC=CC=C5C4=C3N,,,,,,
9664,44359,"BENZO(a)PYRENE-7,8-DICARBOXYLIC ACID, POTASSIUM SALT",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(=C5C(=O)[O-])C(=O)[O-])C=C2.[K+].[K+],,,,,,
9665,44360,"Benzo[a]pyrene-7,8-dicarboxylic acid",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(=C5C(=O)O)C(=O)O)C=C2,,,,,,
9666,44361,"Sodium benzo(a)pyrene-7,8-dicarboxylic acid",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(=C5C(=O)[O-])C(=O)[O-])C=C2.[Na+].[Na+],,,,,,
9667,44362,"GLYCINE, N-(DIBENZ(a,h)ANTHRACEN-7-YLCARBAMOYL)-",C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC=CC=C5C4=C3NC(=O)NCC(=O)O,,,,,,
9668,44363,"13H-Dibenzo(A,G)fluoren-13-one",C1=CC=C2C(=C1)C=CC3=C2C(=O)C4=C3C5=CC=CC=C5C=C4,,,,,,
9669,44364,"DIBENZ(a,h)ANTHRACENE, 7,14-DIBUTYL-",CCCCC1=C2C=CC3=CC=CC=C3C2=C(C4=C1C5=CC=CC=C5C=C4)CCCC,,,,,,
9670,44365,"7,14-Dihydro-7,14-dipropyldibenz(a,h)anthracene-7,14-diol",CCCC1(C2=C(C3=CC=CC=C3C=C2)C(C4=C1C5=CC=CC=C5C=C4)(CCC)O)O,,,,,,
9671,44366,"DIBENZ(a,h)ANTHRACENE, 7-METHOXY-",COC1=C2C(=CC3=C1C=CC4=CC=CC=C43)C=CC5=CC=CC=C52,,,,,,
9672,44367,8-Methylbenzo[a]pyrene,CC1=CC2=C(C=C1)C3=C4C(=C2)C=CC5=C4C(=CC=C5)C=C3,,,,,,
9673,44368,7-Methylbenzo[a]pyrene,CC1=C2C=C3C=CC4=C5C3=C(C2=CC=C1)C=CC5=CC=C4,,,,,,
9674,44369,3-Methylcholanthrene compd. with picric acid (1:1),CC1=C2C(C(C3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1)O)O.C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9675,44370,"1,2-Dihydroxy-3-methylcholanthrene",CC1=C2C(C(C3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1)O)O,,,,,,
9676,44371,"DIBENZ(a,h)ANTHRACENE, 2-METHYL-",CC1=CC2=C(C=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,,,,,,
9677,44372,"DIBENZ(a,h)ANTHRACENE, 3-METHYL-",CC1=CC2=C(C=C1)C3=CC4=C(C=C3C=C2)C5=CC=CC=C5C=C4,,,,,,
9678,44373,"DIBENZ(a,h)ANTHRACENE, 6-METHYL-",CC1=CC2=CC=CC=C2C3=C1C=C4C(=C3)C=CC5=CC=CC=C54,,,,,,
9679,44374,6-Nitrobenzo[a]pyrene,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=CC=CC(=C54)C=C3,,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['The compounds 1-, 3-, and 6-nitrobenzo[a]pyrene (nitro-BaP) are environmental pollutants and have been shown to be potent bacterial mutagens. The anaerobic metabolism of these isomeric nitro-BaPs was investigated by the incubation of rat intestinal microflora with each isomer for 48 hr. Aliquots were removed at several time intervals, extracted, fractionated by high-pressure liquid chromatography (HPLC), and the radioactivity determined. Metabolites were identified by comparison of their chromatographic, ultraviolet-visible absorption, and mass spectral properties with those of authentic standards. The order of the extent of nitroreduction for these isomers was 3-nitro-BaP greater than 6-nitro-BaP greater than 1-nitro-BaP. After 48 hr of exposure, 84% of the added 3-nitro-BaP was present as 3-amino-BaP, 51% of the 6-nitro-BaP was metabolized to 6-amino-BaP, and 1-nitro-BaP was reduced to 1-amino-BaP (13%) and 1-nitroso-BaP (4%). The order of the extent of microbial nitroreduction for these nitro-BaP isomers is different from the predictions based on electronic and steric hindrance effects. These results suggest that intestinal microflora nitroreductases exhibit a markedly high degree of substrate specificity toward nitro-BaPs that affects the extent of nitroreduction.']",
9680,44375,"BENZ(e)ACEANTHRYLENE, 1,2,4,5,6,7-HEXAHYDRO-",C1CCC2=C(C1)C=C3CCC4=C3C2=CC5=CC=CC=C45,,,,,,
9681,44376,"DIBENZO(def,p)CHRYSENE, 8-METHYL-",CC1=CC2=C(C=C1)C3=C4C(=C2)C=CC5=C4C(=CC=C5)C6=CC=CC=C63,,,,,,
9682,44377,Methyl 4-(o-tolylazo)-o-tolyl carbonate,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)OC(=O)OC)C,,,,,,
9683,44378,Oxalyl-o-aminoazotoluene,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)NC(=O)C(=O)O)C,,,,,,
9684,44379,"(3-Butanoyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) benzoate",CCCC(=O)OC1=CC2=C(C=C1)C3CCC4(C(C3CC2)CCC4OC(=O)C5=CC=CC=C5)C,,,,,,
9685,44380,"3-Hydroxyestra-1(10),2,4-trien-17-yl octanoate",CCCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=C3C=CC(=C4)O)C,,,,,,
9686,44381,"BENZO(b)PHENANTHRO(3,2-d)THIOPHENE, 7,13-DIMETHYL-",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1SC5=CC=CC=C54)C,,,,,,
9687,44382,"BENZO(a)PYRENE, 3-METHOXY-",COC1=C2C=CC3=CC4=CC=CC=C4C5=C3C2=C(C=C5)C=C1,,,,,,
9688,44383,Terazosin hydrochloride,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.Cl,,,"['Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)']",,,
9689,44384,"2-Imidazoline, 2-((alpha,alpha,alpha-trifluoro-m-tolyloxy)methyl)-, hydrochloride",C1CN=C([NH2+]1)COC2=CC=CC(=C2)C(F)(F)F.[Cl-],,,,,,
9690,44385,"2-(3-Trifluoromethyl-phenoxymethyl)-4,5-dihydro-1h-imidazole",C1CN=C(N1)COC2=CC=CC(=C2)C(F)(F)F,,,,,,
9691,44386,N-Pentyl N-phenylcarbamate,CCCCCOC(=O)NC1=CC=CC=C1,,,,,,
9692,44387,"7H-DIBENZO(a,g)CARBAZOLE, 12,13-DIHYDRO-",C1CC2=C(C3=CC=CC=C31)NC4=C2C5=CC=CC=C5C=C4,,,,,,
9693,44388,CID 44388,C1=CC=C2C(=C1)C=CC(=C2OP(=O)([O-])OC3=C(C=CC4=CC=CC=C43)N)N.[Na+],,,,,,
9694,44389,Di-(2-amino-1-naphthyl)-hydrogen phosphate,C1=CC=C2C(=C1)C=CC(=C2OP(=O)(O)OC3=C(C=CC4=CC=CC=C43)N)N,,,,,,
9695,44390,"Malononitrile, (4-pyridylmethylene)-",C1=CN=CC=C1C=C(C#N)C#N,,,,,,
9696,44391,p-Hydroxyanilinium bisulfate,C1=CC(=CC=C1[NH3+])O.OS(=O)(=O)[O-],,,,,,
9697,44392,10-Methylbenzo(a)pyrene,CC1=C2C3=C4C(=CC2=CC=C1)C=CC5=C4C(=CC=C5)C=C3,,,,,,
9698,44393,"7,10-Dimethylbenzo[a]pyrene",CC1=C2C=C3C=CC4=C5C3=C(C2=C(C=C1)C)C=CC5=CC=C4,,,,,,
9699,44394,4-((Dimethylamino)methyl)-2-phenyl-5-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1C=C(O2)C3=CC=CC=C3)O.[Cl-],,,,,,
9700,44395,4-[(Dimethylamino)methyl]-2-phenyl-1-benzofuran-5-ol,CN(C)CC1=C(C=CC2=C1C=C(O2)C3=CC=CC=C3)O,,,,,,
9701,44396,4-((Dimethylamino)methyl)-3-phenyl-5-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1C(=CO2)C3=CC=CC=C3)O.[Cl-],,,,,,
9702,44397,4-[(Dimethylamino)methyl]-3-phenyl-1-benzofuran-5-ol,CN(C)CC1=C(C=CC2=C1C(=CO2)C3=CC=CC=C3)O,,,,,,
9703,44398,7-((Dimethylamino)methyl)-3-phenyl-6-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1OC=C2C3=CC=CC=C3)O.[Cl-],,,,,,
9704,44399,7-[(Dimethylamino)methyl]-3-phenyl-1-benzofuran-6-ol,CN(C)CC1=C(C=CC2=C1OC=C2C3=CC=CC=C3)O,,,,,,
9705,44400,4-((Dimethylamino)methyl)-6-nitro-2-phenyl-5-benzofuranol hydrochloride,C[NH+](C)CC1=C(C(=CC2=C1C=C(O2)C3=CC=CC=C3)[N+](=O)[O-])O.[Cl-],,,,,,
9706,44401,4-[(Dimethylamino)methyl]-6-nitro-2-phenyl-1-benzofuran-5-ol,CN(C)CC1=C(C(=CC2=C1C=C(O2)C3=CC=CC=C3)[N+](=O)[O-])O,,,,,,
9707,44402,3-Bromo-4-((dimethylamino)methyl)-2-phenyl-5-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1C(=C(O2)C3=CC=CC=C3)Br)O.[Cl-],,,,,,
9708,44403,3-Bromo-4-[(dimethylamino)methyl]-2-phenyl-1-benzofuran-5-ol,CN(C)CC1=C(C=CC2=C1C(=C(O2)C3=CC=CC=C3)Br)O,,,,,,
9709,44404,2-Bromo-4-((dimethylamino)methyl)-3-phenyl-5-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1C(=C(O2)Br)C3=CC=CC=C3)O.[Cl-],,,,,,
9710,44405,2-Bromo-4-[(dimethylamino)methyl]-3-phenyl-1-benzofuran-5-ol,CN(C)CC1=C(C=CC2=C1C(=C(O2)Br)C3=CC=CC=C3)O,,,,,,
9711,44406,2-Bromo-7-((dimethylamino)methyl)-3-phenyl-6-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1OC(=C2C3=CC=CC=C3)Br)O.[Cl-],,,,,,
9712,44407,2-Bromo-7-[(dimethylamino)methyl]-3-phenyl-1-benzofuran-6-ol,CN(C)CC1=C(C=CC2=C1OC(=C2C3=CC=CC=C3)Br)O,,,,,,
9713,44408,3-Chloro-4-((dimethylamino)methyl)-2-phenyl-5-benzofuranol hydrochloride,C[NH+](C)CC1=C(C=CC2=C1C(=C(O2)C3=CC=CC=C3)Cl)O.[Cl-],,,,,,
9714,44409,3-Chloro-4-[(dimethylamino)methyl]-2-phenyl-1-benzofuran-5-ol,CN(C)CC1=C(C=CC2=C1C(=C(O2)C3=CC=CC=C3)Cl)O,,,,,,
9715,44410,Anitrazafen,CC1=NC(=C(N=N1)C2=CC=C(C=C2)OC)C3=CC=C(C=C3)OC,,,,,,
9716,44411,"alpha-(2,2-Dimethylvinyl)-alpha-ethynyl-p-cresol",CC(=CC(C#C)C1=CC=C(C=C1)O)C,,,,,,
9717,44412,Dichloropropanol,CCC(O)(Cl)Cl,,,,,,
9718,44413,alpha-Methylbenzyl 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetate,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC(C)C4=CC=CC=C4,,,,,,
9719,44414,p-(((Dimethylamino)methylene)amino)benzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)N=CN(C)C,,,,,,
9720,44415,"4-Acridinecarboxamide, 9-(2-methoxy-4-(methylsulfonamido)anilino)-, hydrochloride",COC1=C(C=CC(=C1)NS(=O)(=O)C)[NH2+]C2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N.[Cl-],,,,,,
9721,44416,"Methanesulfonanilide, 4'-((4-carbamoyl-9-acridinyl)amino)-3'-methoxy-",COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=C(C3=NC4=CC=CC=C42)C(=O)N,,,,,,
9722,44417,N-(3-Indolylmethyl)isonicotinamide,C1=CC=C2C(=C1)C(=CN2)CNC(=O)C3=CC=NC=C3,,,,,,
9723,44418,N-(2-(2-Methyl-3-indolyl)ethyl)isonicotinamide,CC1=NC2=CC=CC=C2C1CCNC(=O)C3=CC=NC=C3,,,,,,
9724,44419,"Dibenzo(b,f)thiepin-2-ol, 10,11-dihydro-8-chloro-11-(4-methyl-1-piperazinyl)-, dihydrochloride",CN1CCN(CC1)C2CC3=C(C=CC(=C3)Cl)SC4=C2C=C(C=C4)O.Cl.Cl,,,,,,
9725,44420,"3-Chloro-6-(4-methylpiperazin-1-yl)-5,6-dihydrobenzo[b][1]benzothiepin-8-ol",CN1CCN(CC1)C2CC3=C(C=CC(=C3)Cl)SC4=C2C=C(C=C4)O,,,,,,
9726,44421,"6H-Indolo(2,3-c)quinolin-6-one, 5,7-dihydro-10-chloro-5-(2-(dimethylamino)ethyl)-, monohydrochloride",C[NH+](C)CCN1C2=CC=CC=C2C3=C(C1=O)NC4=C3C=C(C=C4)Cl.[Cl-],,,,,,
9727,44422,"10-Chloro-5-(2-dimethylaminoethyl)-7H-indolo(2,3-c)quinoline-6(5H)-one",CN(C)CCN1C2=CC=CC=C2C3=C(C1=O)NC4=C3C=C(C=C4)Cl,,,,,,
9728,44423,Phenoxyacetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=CC=C1.[Cl-],,,,,,
9729,44424,2-(Diethylamino)ethyl 2-phenoxyacetate,CCN(CC)CCOC(=O)COC1=CC=CC=C1,,,,,,
9730,44425,"3,4-Dihydro-7-ethyl-2-(morpholinomethyl)-1(2H)-naphthalenone hydrochloride",CCC1=CC2=C(CCC(C2=O)C[NH+]3CCOCC3)C=C1.[Cl-],,,,,,
9731,44426,"7-ethyl-2-(morpholin-4-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CCC1=CC2=C(CCC(C2=O)CN3CCOCC3)C=C1,,,,,,
9732,44427,"BENZO(c)PHENANTHRENE, 9,10-EPOXY-",C1=CC=C2C(=C1)C=CC3=C2C4=C(C=C3)C5=C(O5)C=C4,,,,,,
9733,44428,N-(2-Diethylaminoethyl)acetamide,CCN(CC)CCNC(=O)C,,,,,,
9734,44429,"Butyramide, N-(2-(diethylamino)ethyl)-",CCCC(=O)NCCN(CC)CC,,,,,,
9735,44430,"Acetamide, N-(2-(dimethylamino)ethyl)-2-phenyl-",CN(C)CCNC(=O)CC1=CC=CC=C1,,,,,,
9736,44431,"Butyramide, N-(2-(dimethylamino)ethyl)-4-phenyl-",CN(C)CCNC(=O)CCCC1=CC=CC=C1,,,,,,
9737,44432,N-(2-(Dimethylamino)ethyl)-3-phenylbutyramide,CC(CC(=O)NCCN(C)C)C1=CC=CC=C1,,,,,,
9738,44433,"Butyramide, N-(2-(diethylamino)ethyl)-4-phenyl-",CCN(CC)CCNC(=O)CCCC1=CC=CC=C1,,,,,,
9739,44434,N-(2-(Diethylamino)ethyl)-2-phenylbutyramide,CCC(C1=CC=CC=C1)C(=O)NCCN(CC)CC,,,,,,
9740,44435,N-(2-(Diethylamino)ethyl)-3-phenylbutyramide,CCN(CC)CCNC(=O)CC(C)C1=CC=CC=C1,,,,,,
9741,44436,CID 44436,C1=CC=C(C=C1)CN=C(NNC(=O)C2=CC=CO2)S,,,,,,
9742,44437,N-Myristoyloxy-N-acetyl-2-aminofluorene,CCCCCCCCCCCCCC(=O)ON(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)C,,,,,,
9743,44438,Sulfinalol hydrochloride,CC(CCC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)S(=O)C)O.Cl,,,,,,
9744,44439,Sulfinalol,CC(CCC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)S(=O)C)O,,,,,,
9745,44440,CID 44440,[Li+].C(CC(=O)[O-])CO,,,,,,
9746,44441,CID 44441,C1=CC=C(C=C1)OCC(C[NH2+]C(=N)[NH3+])O.[O-]S(=O)(=O)[O-],,,,,,
9747,44442,1-(2-Hydroxy-3-phenoxypropyl)guanidine,C1=CC=C(C=C1)OCC(CN=C(N)N)O,,,,,,
9748,44443,CID 44443,CC1=CC=CC=C1OCC(C[NH2+]C(=N)[NH3+])O.[O-]S(=O)(=O)[O-],,,,,,
9749,44444,N-[2-Hydroxy-3-(2-methylphenoxy)propyl]guanidine,CC1=CC=CC=C1OCC(CN=C(N)N)O,,,,,,
9750,44445,(+-)-(2-Hydroxy-3-(3-methylphenoxy)propyl)guanidine sulfate (2:1) (salt),CC1=CC(=CC=C1)OCC(C[NH2+]C(=[NH2+])N)O.[O-]S(=O)(=O)[O-],,,,,,
9751,44446,2-[2-Hydroxy-3-(3-methylphenoxy)propyl]guanidine,CC1=CC(=CC=C1)OCC(CN=C(N)N)O,,,,,,
9752,44447,(+-)-(2-Hydroxy-3-(4-methylphenoxy)propyl)guanidine sulfate (2:1) (salt),CC1=CC=C(C=C1)OCC(C[NH2+]C(=[NH2+])N)O.[O-]S(=O)(=O)[O-],,,,,,
9753,44448,2-[2-Hydroxy-3-(4-methylphenoxy)propyl]guanidine,CC1=CC=C(C=C1)OCC(CN=C(N)N)O,,,,,,
9754,44449,CID 44449,C1=CC=C(C=C1)OCOCC(C[NH2+]C(=N)[NH3+])O.[O-]S(=O)(=O)[O-],,,,,,
9755,44450,2-[2-Hydroxy-3-(phenoxymethoxy)propyl]guanidine,C1=CC=C(C=C1)OCOCC(CN=C(N)N)O,,,,,,
9756,44451,CID 44451,COC1=CC=C(C=C1)OCC(C[NH2+]C(=N)[NH3+])O.[O-]S(=O)(=O)[O-],,,,,,
9757,44452,2-[2-Hydroxy-3-(4-methoxyphenoxy)propyl]guanidine,COC1=CC=C(C=C1)OCC(CN=C(N)N)O,,,,,,
9758,44453,"Guanidine, (2-hydroxy-3-(3-methyl-4-(1-methylethyl)phenoxy)propyl)-, sulfate (2:1) (salt), (+-)-",CC1=C(C=CC(=C1)OCC(C[NH2+]C(=[NH2+])N)O)C(C)C.[O-]S(=O)(=O)[O-],,,,,,
9759,44454,2-[2-Hydroxy-3-(3-methyl-4-propan-2-ylphenoxy)propyl]guanidine,CC1=C(C=CC(=C1)OCC(CN=C(N)N)O)C(C)C,,,,,,
9760,44455,1-(alpha-Naphthoxy)-2-hydroxy-3-guanidinopropane sulfate,C1=CC=C2C(=C1)C=CC=C2OCC(C[NH2+]C(=[NH2+])N)O.[O-]S(=O)(=O)[O-],,,,,,
9761,44456,2-(2-Hydroxy-3-naphthalen-1-yloxypropyl)guanidine,C1=CC=C2C(=C1)C=CC=C2OCC(CN=C(N)N)O,,,,,,
9762,44457,"1,16-Hexadecanediamine, N,N'-bis(9-acridinyl)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCCCCCCCCCCCNC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
9763,44458,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl-, hydrochloride",CC1C2=CC(=C(C=C2CC[NH2+]1)OC)OC.[Cl-],,,,,,
9764,44459,"1,1-Dichloro-2-(1,3-dichloropropan-2-yloxy)propane",CC(C(Cl)Cl)OC(CCl)CCl,,,,,,
9765,44460,"Benzo(a)pyrene-7,8-dihydrodiol 9,10-epoxide, syn-(+)-",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@@H]([C@H]5O)O)C=C2,,,,,,
9766,44461,(+)-Anti-bpde,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,,,,,,
9767,44462,Ciramadol hydrochloride,CN(C)[C@H]([C@H]1CCCC[C@H]1O)C2=CC(=CC=C2)O.Cl,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
9768,44463,Ciramadol,CN(C)[C@H]([C@H]1CCCC[C@H]1O)C2=CC(=CC=C2)O,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
9769,44464,"Phenyltetrakis(2,2,2-trifluoroethoxy)phosphorane",C1=CC=C(C=C1)P(OCC(F)(F)F)(OCC(F)(F)F)(OCC(F)(F)F)OCC(F)(F)F,,,,,,
9770,44465,Bromethalin,CN(C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(F)(F)F)C2=C(C=C(C=C2Br)Br)Br,,,,"['A metabolism study was conducted in Fischer 344 rats following oral admin of (14)C-bromethalin at 1 mg/kg. Blood samples were taken from the orbital sinus at 0.25, 0.5, 1, 2, 4, and 24 hours, and at 2, 3, 4, 6, 8, 11, 14, 17, and 21 days after dosing. Based on radiolabeled material, the plasma half-life was 134 hours (5.6 days). The half-life of the distributive phase suggested distribution in total body water.']","['The major metabolite formed in the rat is desmethyl bromethalin.', 'The major route of metabolism in the rat is N-demethylation.']","['5.6 days (plasma);', 'The half life of bromethalin is 5.6 days /in Fischer 344 rats following oral admin of 1 mg/kg (14)C-bromethalin/.']"
9771,44466,CID 44466,OP(=O)O.OP(=O)O.[99Tc],,,,,,
9772,44467,"11,16-Dithiahexacosane",CCCCCCCCCCSCCCCSCCCCCCCCCC,,,,,,
9773,44468,"syn-(-)-Benzo(a)pyrene-7,8-diol-9,10-oxide",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]6[C@H](O6)[C@H]([C@@H]5O)O)C=C2,,,,,,
9774,44469,"1,3-Dioxa-9-azaspiro(5.5)undecane, 9-(3-(p-fluorobenzoyl)propyl)-, hydrochloride",C1C[NH+](CCC12CCOCO2)CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
9775,44470,"4-(1,3-Dioxa-9-azaspiro[5.5]undecan-9-yl)-1-(4-fluorophenyl)butan-1-one",C1CN(CCC12CCOCO2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
9776,44471,"1,3-Dioxa-9-azaspiro(5.5)undecane, 5-methyl-9-(3-(p-fluorobenzoyl)propyl)-, hydrochloride",CC1COCOC12CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
9777,44472,"1-(4-Fluorophenyl)-4-(5-methyl-1,3-dioxa-9-azaspiro[5.5]undecan-9-yl)butan-1-one",CC1COCOC12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
9778,44473,"Butyrophenone, 4-(5-ethyl-2-methyl-1,3-dioxa-9-azaspiro(5.5)undec-9-yl)-4'-fluoro-, oxalate",CCC1COC(OC12CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)C.C(=O)(C(=O)[O-])O,,,,,,
9779,44474,"4-(5-Ethyl-2-methyl-1,3-dioxa-9-azaspiro[5.5]undecan-9-yl)-1-(4-fluorophenyl)butan-1-one",CCC1COC(OC12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C,,,,,,
9780,44475,"1,3-Dioxa-9-azaspiro(5.5)undecane, 5-ethyl-9-(3-(p-fluorobenzoyl)propyl)-2-(p-fluorophenyl)-",CCC1COC(OC12CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.[Cl-],,,,,,
9781,44476,"4-[5-Ethyl-2-(4-fluorophenyl)-1,3-dioxa-9-azaspiro[5.5]undecan-9-yl]-1-(4-fluorophenyl)butan-1-one",CCC1COC(OC12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,,,,,,
9782,44477,3-Chlorobenzidine,C1=CC(=CC=C1C2=CC(=C(C=C2)N)Cl)N,,,,,,
9783,44478,"2-(Bis(2-chloroethyl)amino)-1,3,2-dioxaphosphorinane 2-oxide",C1COP(=O)(OC1)N(CCCl)CCCl,,,,,,
9784,44479,(+-)-alpha-((1-Ethylamino)ethyl)benzyl alcohol hydrochloride,CC[NH2+]C(C)C(C1=CC=CC=C1)O.[Cl-],,,,,,
9785,44480,2-Ethylamino-1-phenylpropanol,CCNC(C)C(C1=CC=CC=C1)O,,,,,,
9786,44481,N-[4-[2-(4-chlorophenyl)ethenyl]phenyl]-N-hydroxyacetamide,CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=C(C=C2)Cl)O,,,,,,
9787,44482,N-[4-[2-(4-fluorophenyl)ethenyl]phenyl]-N-hydroxyacetamide,CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=C(C=C2)F)O,,,,,,
9788,44483,N-[4-[2-(4-bromophenyl)ethenyl]phenyl]-N-hydroxyacetamide,CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=C(C=C2)Br)O,,,,,,
9789,44484,N-[4-[2-(4-fluorophenyl)ethenyl]phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)C=CC2=CC=C(C=C2)F,,,,,,
9790,44485,N-Hydroxy-1H-indole-2-carboxamide,C1=CC=C2C(=C1)C=C(N2)C(=O)NO,,,,,,
9791,44486,N-Methyl-N-nitrosobenzamide,CN(C(=O)C1=CC=CC=C1)N=O,,,,,,
9792,44487,CID 44487,C1=CC=C(C(=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])Cl,,,,,,
9793,44488,1-(4-Fluorophenyl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one,C1=CC(=CC=C1C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])F,,,,,,
9794,44489,CID 44489,C1=CC=C(C(=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])F,,,,,,
9795,44490,CID 44490,C1=CC=C(C(=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
9796,44491,3-(5-Nitrofuran-2-yl)-1-(3-nitrophenyl)prop-2-en-1-one,C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
9797,44492,1-(2-Hydroxy-phenyl)-3-(5-nitro-2furyl)-2-propen-1-one,C1=CC=C(C(=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])O,,,,,,
9798,44493,CID 44493,COC1=C(C=CC(=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])O,,,,,,
9799,44494,CID 44494,COC1=CC=CC(=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
9800,44495,CID 44495,COC1=C(C=C(C=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-])OC,,,,,,
9801,44496,CID 44496,COC1=CC(=CC(=C1OC)OC)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
9802,44497,"1-(3-Methyl-5,6,7-trimethoxybenzofuran-2-yl)carbonyl-4-methylpiperazine hydrochloride",CC1=C(OC2=C(C(=C(C=C12)OC)OC)OC)C(=O)N3CC[NH+](CC3)C.[Cl-],,,,,,
9803,44498,"(4-Methylpiperazin-1-yl)-(5,6,7-trimethoxy-3-methyl-1-benzofuran-2-yl)methanone",CC1=C(OC2=C(C(=C(C=C12)OC)OC)OC)C(=O)N3CCN(CC3)C,,,,,,
9804,44499,"(2-Diethylamino)ethyl 3-methyl-5,6,7-trimethoxy-2-benzofurancarboxylate hydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C2=CC(=C(C(=C2O1)OC)OC)OC)C.[Cl-],,,,,,
9805,44500,"2-(Diethylamino)ethyl 5,6,7-trimethoxy-3-methyl-1-benzofuran-2-carboxylate",CCN(CC)CCOC(=O)C1=C(C2=CC(=C(C(=C2O1)OC)OC)OC)C,,,,,,
9806,44501,"Coumarin, 7-(2-hydroxy-3-isobutylaminopropoxy)-6-methoxy-4-methyl-, hydrochloride",CC1=CC(=O)OC2=CC(=C(C=C12)OC)OCC(C[NH2+]CC(C)C)O.[Cl-],,,,,,
9807,44502,7-[2-Hydroxy-3-(2-methylpropylamino)propoxy]-6-methoxy-4-methylchromen-2-one,CC1=CC(=O)OC2=CC(=C(C=C12)OC)OCC(CNCC(C)C)O,,,,,,
9808,44503,"Coumarin, 6-(2-hydroxy-3-isobutylaminopropoxy)-7-methoxy-4-methyl-, hydrochloride",CC1=CC(=O)OC2=CC(=C(C=C12)OCC(C[NH2+]CC(C)C)O)OC.[Cl-],,,,,,
9809,44504,6-[2-Hydroxy-3-(2-methylpropylamino)propoxy]-7-methoxy-4-methylchromen-2-one,CC1=CC(=O)OC2=CC(=C(C=C12)OCC(CNCC(C)C)O)OC,,,,,,
9810,44505,"Coumarin, 7,8-dimethoxy-6-(2-hydroxy-3-isobutylaminopropoxy)-4-methyl-, hydrochloride",CC1=CC(=O)OC2=C(C(=C(C=C12)OCC(C[NH2+]CC(C)C)O)OC)OC.[Cl-],,,,,,
9811,44506,"6-[2-Hydroxy-3-(2-methylpropylamino)propoxy]-7,8-dimethoxy-4-methylchromen-2-one",CC1=CC(=O)OC2=C(C(=C(C=C12)OCC(CNCC(C)C)O)OC)OC,,,,,,
9812,44507,"Coumarin, 7,8-dimethoxy-6-(2-hydroxy-3-morpholinopropoxy)-4-methyl-, hydrochloride",CC1=CC(=O)OC2=C(C(=C(C=C12)OCC(C[NH+]3CCOCC3)O)OC)OC.[Cl-],,,,,,
9813,44508,"6-(2-Hydroxy-3-morpholin-4-ylpropoxy)-7,8-dimethoxy-4-methylchromen-2-one",CC1=CC(=O)OC2=C(C(=C(C=C12)OCC(CN3CCOCC3)O)OC)OC,,,,,,
9814,44509,"Coumarin, 6-(3-diethylamino-2-hydroxypropoxy)-7,8-dimethoxy-4-methyl-, hydrochloride",CC[NH+](CC)CC(COC1=C(C(=C2C(=C1)C(=CC(=O)O2)C)OC)OC)O.[Cl-],,,,,,
9815,44510,"6-[3-(Diethylamino)-2-hydroxypropoxy]-7,8-dimethoxy-4-methylchromen-2-one",CCN(CC)CC(COC1=C(C(=C2C(=C1)C(=CC(=O)O2)C)OC)OC)O,,,,,,
9816,44511,(4-(2-Furyl)butyl)trimethylammonium iodide,C[N+](C)(C)CCCCC1=CC=CO1.[I-],,,,,,
9817,44512,4-(Furan-2-yl)butyl-trimethylazanium,C[N+](C)(C)CCCCC1=CC=CO1,,,,,,
9818,44513,Benzyldimethyl(4-(2-furyl)butyl)ammonium iodide,C[N+](C)(CCCCC1=CC=CO1)CC2=CC=CC=C2.[I-],,,,,,
9819,44514,Benzyl-[4-(furan-2-yl)butyl]-dimethylazanium,C[N+](C)(CCCCC1=CC=CO1)CC2=CC=CC=C2,,,,,,
9820,44515,Dimethylethyl(5-(2-furyl)pentyl)ammonium iodide,CC[N+](C)(C)CCCCCC1=CC=CO1.[I-],,,,,,
9821,44516,Ethyl-[5-(furan-2-yl)pentyl]-dimethylazanium,CC[N+](C)(C)CCCCCC1=CC=CO1,,,,,,
9822,44517,(5-(2-Furyl)-1-methylpentyl)trimethylammonium iodide,CC(CCCCC1=CC=CO1)[N+](C)(C)C.[I-],,,,,,
9823,44518,6-(Furan-2-yl)hexan-2-yl-trimethylazanium,CC(CCCCC1=CC=CO1)[N+](C)(C)C,,,,,,
9824,44519,Dimethylethyl(5-(2-furyl)-1-methylpentyl)ammonium iodide,CC[N+](C)(C)C(C)CCCCC1=CC=CO1.[I-],,,,,,
9825,44520,Ethyl-[6-(furan-2-yl)hexan-2-yl]-dimethylazanium,CC[N+](C)(C)C(C)CCCCC1=CC=CO1,,,,,,
9826,44521,Benzyldimethyl(5-(2-furyl)-1-methylpentyl)ammonium iodide,CC(CCCCC1=CC=CO1)[N+](C)(C)CC2=CC=CC=C2.[I-],,,,,,
9827,44522,Benzyl-[6-(furan-2-yl)hexan-2-yl]-dimethylazanium,CC(CCCCC1=CC=CO1)[N+](C)(C)CC2=CC=CC=C2,,,,,,
9828,44523,"N,N-Dimethyl-2-furanbutylamine hydrochloride",C[NH+](C)CCCCC1=CC=CO1.[Cl-],,,,,,
9829,44524,"4-(furan-2-yl)-N,N-dimethylbutan-1-amine",CN(C)CCCCC1=CC=CO1,,,,,,
9830,44525,"N,N,alpha-Trimethyl-2-furanpentylamine hydrochloride",CC(CCCCC1=CC=CO1)[NH+](C)C.[Cl-],,,,,,
9831,44526,"6-(furan-2-yl)-N,N-dimethylhexan-2-amine",CC(CCCCC1=CC=CO1)N(C)C,,,,,,
9832,44527,"1-Butanaminium, N,N-dibutyl-N-ethyl-, hydroxide",CCCC[N+](CC)(CCCC)CCCC.[OH-],,,,,,
9833,44528,"1-Butanaminium, N,N-dibutyl-N-ethyl-",CCCC[N+](CC)(CCCC)CCCC,,,,,,
9834,44529,"Dodecanamide, N-(2-(diethylamino)ethyl)-",CCCCCCCCCCCC(=O)NCCN(CC)CC,,,,,,
9835,44530,2-((4-Bromophenyl)butylamino)ethanol,CCCCN(CCO)C1=CC=C(C=C1)Br,,,,,,
9836,44531,2-(2-(Butylphenylamino)ethoxy)ethanol,CCCCN(CCOCCO)C1=CC=CC=C1,,,,,,
9837,44532,"2-[3,3-Dimethyl-2-(2-oxoethylidene)indol-1-yl]acetaldehyde",CC1(C2=CC=CC=C2N(C1=CC=O)CC=O)C,,,,,,
9838,44533,3-Methoxy-5-methylaniline,CC1=CC(=CC(=C1)OC)N,,,,,,
9839,44534,"1-Bromo-3,5-dinitrobenzene",C1=C(C=C(C=C1[N+](=O)[O-])Br)[N+](=O)[O-],,,,,,
9840,44535,3-Bromo-5-nitroaniline,C1=C(C=C(C=C1[N+](=O)[O-])Br)N,,,,,,
9841,44536,"AR-Bromo-AR,AR-dinitrobenzenamine",C1=C(C=C(C(=C1N)[N+](=O)[O-])Br)[N+](=O)[O-],,,,,,
9842,44537,"Acetamide, N-(((2-cyanoethyl)ethylamino)ethoxyphenyl)-",CCN(CCC#N)C1=CC(=CC(=C1)NC(=O)C)OCC,,,,,,
9843,44538,"Aminobromohydroxy-9,10-anthracendione",C1=CC2=C(C=C1O)C(=O)C3=C(C=CC(=C3C2=O)N)Br,,,,,,
9844,44539,4-Acetamidophenyltrimethylammonium iodide,CC(=O)NC1=CC=C(C=C1)[N+](C)(C)C.[I-],,,,,,
9845,44540,"Benzenaminium, 4-(acetylamino)-N,N,N-trimethyl-",CC(=O)NC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
9846,44541,"1,4-Butanediol, 1,1,4,4-tetraphenyl-",C1=CC=C(C=C1)C(CCC(C2=CC=CC=C2)(C3=CC=CC=C3)O)(C4=CC=CC=C4)O,,,,,,
9847,44542,CID 44542,CCCOC1=CC(=C(C=C1)N(C)C(=NC(=O)OC)S)[N+](=O)[O-],,,,,,
9848,44543,7-(3-Diethylamino-2-hydroxypropoxy)-6-methoxy-4-methylcoumarin hydrochloride,CC[NH+](CC)CC(COC1=C(C=C2C(=CC(=O)OC2=C1)C)OC)O.[Cl-],,,,,,
9849,44544,7-[3-(Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-methylchromen-2-one,CCN(CC)CC(COC1=C(C=C2C(=CC(=O)OC2=C1)C)OC)O,,,,,,
9850,44545,Dimethylethyl(4-(2-furyl)butyl)ammonium iodide,CC[N+](C)(C)CCCCC1=CC=CO1.[I-],,,,,,
9851,44546,Ethyl-[4-(furan-2-yl)butyl]-dimethylazanium,CC[N+](C)(C)CCCCC1=CC=CO1,,,,,,
9852,44547,"2-(5-Methyl-1,3,4-thiadiazol-2-ylamino)ethanol hydrochloride",CC1=NN=C(S1)[NH2+]CCO.[Cl-],,,,,,
9853,44548,"2-((5-Methyl-1,3,4-thiadiazol-2-yl)amino)ethanol",CC1=NN=C(S1)NCCO,,,,,,
9854,44549,CID 44549,C(CO)NC1=NN=C(S1)S,,,,,,
9855,44550,"2-(5-Amino-1,3,4-thiadiazol-2-ylthio)ethylamine hydrochloride",C(CSC1=NN=C(S1)N)[NH3+].[Cl-],,,,,,
9856,44551,"5-(2-Aminoethylsulfanyl)-1,3,4-thiadiazol-2-amine",C(CSC1=NN=C(S1)N)N,,,,,,
9857,44552,N-(3-(2-Cyanoethyl(ethyl)amino)-5-methoxypheny))acetamide,CCN(CCC#N)C1=CC(=CC(=C1)NC(=O)C)OC,,,,,,
9858,44553,"(3-oxo-1,3-diphenylprop-1-enyl) N,N-diethylcarbamodithioate",CCN(CC)C(=S)SC(=CC(=O)C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
9859,44554,"(7R,9R)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",CC1CC(CC(O1)O[C@@H]2C[C@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N,,,,,,
9860,44555,"(6S,7S)-3-(acetyloxymethyl)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CC(=O)OCC1=C(N2[C@H]([C@H](C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,,,,,,
9861,44556,"3-[Acetyl(ethyl)amino]-5-[3-[3-[3-[acetyl(ethyl)amino]-5-carboxy-2,4,6-triiodoanilino]-3-oxopropyl]sulfonylpropanoylamino]-2,4,6-triiodobenzoic acid;6-(methylamino)hexane-1,2,3,4,5-pentol",CCN(C1=C(C(=C(C(=C1I)NC(=O)CCS(=O)(=O)CCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)N(CC)C(=O)C)I)I)C(=O)O)I)C(=O)C.CNCC(C(C(C(CO)O)O)O)O,,,,,,
9862,44557,Iosulamide,CCN(C1=C(C(=C(C(=C1I)NC(=O)CCS(=O)(=O)CCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)N(CC)C(=O)C)I)I)C(=O)O)I)C(=O)C,,,,,,
9863,44558,CID 44558,C1C=CC=CC1C(C2=CC=CC=C2)S(=O)CC(=O)NO,,,,,,
9864,44559,"Carbamic acid, bis(N,N-dimethyldithio-, 2-butynylene ester",CN(C)C(=S)SCC#CCSC(=S)N(C)C,,,,,,
9865,44560,"Carbamodithioic acid, dimethyl-, ((diethoxyphosphinothioyl)thio)methyl ester",CCOP(=S)(OCC)SCSC(=S)N(C)C,,,,,,
9866,44561,Foscarnet sodium,C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+],,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']",,,
9867,44562,(S)-Indobufen,CC[C@@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,,,,,,
9868,44563,"2,2'-[(2-Chloro-5-cyano-1,3-phenylene)diazanediyl]bis(oxoacetic acid)--2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)",C1=C(C=C(C(=C1NC(=O)C(=O)O)Cl)NC(=O)C(=O)O)C#N.C(C(CO)(CO)N)O,,,,,,
9869,44564,Lodoxamide,C1=C(C=C(C(=C1NC(=O)C(=O)O)Cl)NC(=O)C(=O)O)C#N,"['Indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.']",['Lodoxamide is a mast cell stabilizer that inhibits the in vivo Type 1 immediate hypersensitivity reaction. Lodoxamide therapy inhibits the increases in cutaneous vascular permeability that are associated with reagin or IgE and antigen-mediated reactions.'],"['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']","['In a study of twelve healthy adult volunteers, topical administration of lodoxamide tromethamine ophthalmic solution 0.1%, one drop in each eye four times per day for ten days, did not result in any measurable lodoxamide plasma levels at a detection limit of 2.5 ng/mL.', 'Urinary excretion is the major route of elimination.']",,['Elimination half-life was 8.5 hours in urine.']
9870,44565,3-nitro-N-phenylbenzenecarbohydrazonoyl chloride,C1=CC=C(C=C1)NN=C(C2=CC(=CC=C2)[N+](=O)[O-])Cl,,,,,,
9871,44566,"Colchicine, N-benzoyl-N-deacetyl-10-thio-",COC1=C(C(=C2C(=C1)CC[C@@H](C3=CC(=O)C(=CC=C32)SC)NC(=O)C4=CC=CC=C4)OC)OC,,,,,,
9872,44567,"Carbamic acid, (5,6,7,9-tetrahydro-10-(methylthio)-9-oxo-1,2,3-trimethoxybenzo(a)heptalen-7-yl)-, ethyl ester, (S)-",CCOC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC,,,,,,
9873,44568,Leuphasyl,CC(C)CC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)C(C)NC(=O)C(CC2=CC=C(C=C2)O)N,,,,,,
9874,44569,2-Chloro-1-methyl-4-nitro-1H-imidazole,CN1C=C(N=C1Cl)[N+](=O)[O-],,,,,,
9875,44570,Brofaromine hydrochloride,COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br.Cl,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
9876,44571,Brofaromine,COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,['Brofaromine has known human metabolites that include O-desmethyl-brofaromine.'],
9877,44572,4-Amino-5-chloro-2-methoxy-N-(1-methyl-4-piperidinyl)benzamide hydrochloride,C[NH+]1CCC(CC1)NC(=O)C2=CC(=C(C=C2OC)N)Cl.[Cl-],,,,,,
9878,44573,N-(1-Methylpiperidin-4-yl)-2-methoxy-4-amino-5-chlorobenzamide,CN1CCC(CC1)NC(=O)C2=CC(=C(C=C2OC)N)Cl,,,,,,
9879,44574,4-Amino-5-chloro-N-(1-ethyl-4-piperidinyl)-2-methoxybenzamide hydrochloride,CC[NH+]1CCC(CC1)NC(=O)C2=CC(=C(C=C2OC)N)Cl.[Cl-],,,,,,
9880,44575,4-amino-5-chloro-N-(1-ethylpiperidin-4-yl)-2-methoxybenzamide,CCN1CCC(CC1)NC(=O)C2=CC(=C(C=C2OC)N)Cl,,,,,,
9881,44576,4-Amino-5-chloro-2-methoxy-N-(1-(2-naphthalenylmethyl)-4-piperidinyl)benzamide hydrochloride,COC1=CC(=C(C=C1C(=O)NC2CC[NH+](CC2)CC3=CC4=CC=CC=C4C=C3)Cl)N.[Cl-],,,,,,
9882,44577,4-amino-5-chloro-2-methoxy-N-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]benzamide,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC4=CC=CC=C4C=C3)Cl)N,,,,,,
9883,44578,3-Chloro-N-(1-(phenylmethyl)-4-piperidinyl)benzamide hydrochloride,C1C[NH+](CCC1NC(=O)C2=CC(=CC=C2)Cl)CC3=CC=CC=C3.[Cl-],,,,,,
9884,44579,N-(1-benzylpiperidin-4-yl)-3-chlorobenzamide,C1CN(CCC1NC(=O)C2=CC(=CC=C2)Cl)CC3=CC=CC=C3,,,,,,
9885,44580,4-Amino-N-(1-(phenylmethyl)-4-piperidinyl)benzamide hydrochloride,C1C[NH+](CCC1NC(=O)C2=CC=C(C=C2)N)CC3=CC=CC=C3.[Cl-],,,,,,
9886,44581,4-amino-N-(1-benzylpiperidin-4-yl)benzamide,C1CN(CCC1NC(=O)C2=CC=C(C=C2)N)CC3=CC=CC=C3,,,,,,
9887,44582,2-Methoxy-N-(1-(phenylmethyl)-4-piperidinyl)benzamide hydrochloride,COC1=CC=CC=C1C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3.[Cl-],,,,,,
9888,44583,N-(1-benzylpiperidin-4-yl)-2-methoxybenzamide,COC1=CC=CC=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3,,,,,,
9889,44584,4-(Acetylamino)-2-methoxy-N-(1-(phenylmethyl)-4-piperidinyl)benzamide hydrochloride,CC(=O)NC1=CC(=C(C=C1)C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3)OC.[Cl-],,,,,,
9890,44585,4-acetamido-N-(1-benzylpiperidin-4-yl)-2-methoxybenzamide,CC(=O)NC1=CC(=C(C=C1)C(=O)NC2CCN(CC2)CC3=CC=CC=C3)OC,,,,,,
9891,44586,"N-(1-(Phenylmethyl)-4-piperidinyl)-3,4,5-trimethoxybenzamide hydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)NC2CC[NH+](CC2)CC3=CC=CC=C3.[Cl-],,,,,,
9892,44587,"N-(1-benzylpiperidin-4-yl)-3,4,5-trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCN(CC2)CC3=CC=CC=C3,,,,,,
9893,44588,"1(2H)-Chrysenone, 3,4-dihydro-",C1CC2=C(C=CC3=C2C=CC4=CC=CC=C43)C(=O)C1,,,,,,
9894,44589,"Glycine, N,N'-(2-hydroxy-1,3-propanediyl)bis(N-((2-hydroxyphenyl)methyl)-",C1=CC=C(C(=C1)CN(CC(CN(CC2=CC=CC=C2O)CC(=O)O)O)CC(=O)O)O,,,,,,
9895,44590,CID 44590,CC1=NC(=C(N1)Cl)[N+](=O)[O-],,,,,,
9896,44591,CID 44591,CC(=O)N[C@@H](CS)C(=O)[O-].[Na+],,,,,,
9897,44592,"Carbamic acid, dimethyl-, 8-quinolinyl ester, hydrochloride",CN(C)C(=O)OC1=CC=CC2=C1[NH+]=CC=C2.[Cl-],,,,,,
9898,44593,"quinolin-8-yl N,N-dimethylcarbamate",CN(C)C(=O)OC1=CC=CC2=C1N=CC=C2,,,,,,
9899,44594,2-Methyl-3-ethanol benzodioxane,CC1C(OC2=CC=CC=C2O1)CCO,,,,,,
9900,44595,"2-Hexylamine, N,2-dimethyl-",CCCCC(C)(C)NC,,,,,,
9901,44596,5-Methyl-2-hexyl-methylamine,CC(C)CCC(C)NC,,,,,,
9902,44597,"5-Methyl-7-phenyl-3H-1,2-dithiepin-3-thione",CC1=CC(=S)SSC(=C1)C2=CC=CC=C2,,,,,,
9903,44598,CID 44598,CC(C(=O)[O-])O.[Ca+2],,,,,,
9904,44599,(S)-Baclofen hydrochloride,C1=CC(=CC=C1[C@H](CC(=O)O)CN)Cl.Cl,,,,,,
9905,44600,(S)-Baclofen,C1=CC(=CC=C1[C@H](CC(=O)O)CN)Cl,,,,,,
9906,44601,Arbaclofen hydrochloride,C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl.Cl,,,,,,
9907,44602,Arbaclofen,C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl,"['Investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome.']",,,"['Unlike baclofen, absorption of arbaclofen is not limited to the upper small intestine. Arbaclofen can also be absorbed in the lower small intestine and the colon, allowing for the development of sustained release formulations.', '>80% of R-baclofen is renally eliminated unchanged.', 'Blood clearance of an IV bolus of R-baclofen in rats, monkeys, and dogs, resulted in a half life of 1.6-3.4hours, in one study. Total blood clearance was reported to be 0.510.13L/h/kg in rats, 0.310.11L/h/kg in monkeys, and 0.240.01L/h/kg in dogs. (2)']",,
9908,44603,"1,2,3-Trichloro-5-(2,4-dichlorophenoxy)-4-methoxybenzene",COC1=C(C(=C(C=C1OC2=C(C=C(C=C2)Cl)Cl)Cl)Cl)Cl,,,,,,
9909,44604,4-(1-Ethoxy-3-phenoxypropan-2-yl)oxy-4-oxobutanoic acid,CCOCC(COC1=CC=CC=C1)OC(=O)CCC(=O)O,,,,,,
9910,44605,3-(2'-Methylpiperidino)propyl phenylcarbamate,CC1CCCCN1CCCOC(=O)NC2=CC=CC=C2,,,,,,
9911,44606,"Thiocarbamic acid, p-hydroxyphenyl ester",C1=CC(=CC=C1O)SC(=O)N,,,,,,
9912,44607,3-(o-Tolyloxy)-2-propanol carbamate,CC1=CC=CC=C1OCC(C)OC(=O)N,,,,,,
9913,44608,"CARBAMIC ACID, 3-(o-TOLYLOXY)PROPYL ESTER",CC1=CC=CC=C1OCCCOC(=O)N,,,,,,
9914,44609,(propan-2-ylamino)methyl N-(3-chlorophenyl)carbamate,CC(C)NCOC(=O)NC1=CC(=CC=C1)Cl,,,,,,
9915,44610,(1-ethylpyrrolidin-3-yl) N-(2-chloro-5-methylphenyl)carbamate,CCN1CCC(C1)OC(=O)NC2=C(C=CC(=C2)C)Cl,,,,,,
9916,44611,"[2,6-Dimethyl-4-(methylcarbamoyloxy)phenyl]carbamic acid",CC1=CC(=CC(=C1NC(=O)O)C)OC(=O)NC,,,,,,
9917,44612,3-Amino-9-n-butylcarbazole hydrochloride,CCCCN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],,,,,,
9918,44613,9-Butyl-9h-carbazol-3-amine,CCCCN1C2=C(C=C(C=C2)N)C3=CC=CC=C31,,,,,,
9919,44614,"Carbazole, 5,6,7,8-tetrahydro-2-amino-3-ethoxy-, hydrochloride",CCOC1=C(C=C2C(=C1)C3=C([NH2+]2)CCCC3)N.[Cl-],,,,,,
9920,44615,"3-ethoxy-6,7,8,9-tetrahydro-5H-carbazol-2-amine",CCOC1=C(C=C2C(=C1)C3=C(N2)CCCC3)N,,,,,,
9921,44616,"Carbazole, 5,6,7,8-tetrahydro-3-amino-9-ethyl-, hydrochloride",CCN1C2=C(CCCC2)C3=C1C=CC(=C3)[NH3+].[Cl-],,,,,,
9922,44617,"9-Ethyl-2,3,4,9-tetrahydro-1h-carbazol-6-amine",CCN1C2=C(CCCC2)C3=C1C=CC(=C3)N,,,,,,
9923,44618,2-Aminocarbazole hydrochloride,C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)[NH3+].[Cl-],,,,,,
9924,44619,2-Aminocarbazole,C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)N,,,,,,
9925,44620,3-Aminocarbazole hydrochloride,C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)[NH3+].[Cl-],,,,,,
9926,44621,9H-Carbazol-3-amine,C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)N,,,,,,
9927,44622,"Carbazole, 5,6,7,8-tetrahydro-2-amino-9-methyl-, hydrochloride",CN1C2=C(CCCC2)C3=C1C=C(C=C3)[NH3+].[Cl-],,,,,,
9928,44623,"9-Methyl-5,6,7,8-tetrahydrocarbazol-2-amine",CN1C2=C(CCCC2)C3=C1C=C(C=C3)N,,,,,,
9929,44624,"1-Azoniabicyclo(2.2.2)octane, ((diphenylacetyl)oxy)-1-methyl-, bromide",C1C[N+]2(CCC1CC2)COC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4.[Br-],,,,,,
9930,44625,"1-Azoniabicyclo[2.2.2]octan-1-ylmethyl 2,2-diphenylacetate",C1C[N+]2(CCC1CC2)COC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9931,44626,"Quinine, n-amylchloride",CCCCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Cl-],,,,,,
9932,44627,(S)-[(2R)-5-ethenyl-1-pentyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CCCCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9933,44628,"Quinine, n-butylchloride",CCCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Cl-],,,,,,
9934,44629,(S)-[(2R)-1-butyl-5-ethenyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CCCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9935,44630,"Ethane, chloro-, compd. with (8alpha,9R)-6'-methoxycinchonan-9-ol (1:1)",CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Cl-],,,,,,
9936,44631,(S)-[(2R)-5-ethenyl-1-ethyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9937,44632,"Quinine, hexylbromide",CCCCCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Br-],,,,,,
9938,44633,(S)-[(2R)-5-ethenyl-1-hexyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CCCCCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9939,44634,"Quinine, isoamylbromide",CC(C)CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Br-],,,,,,
9940,44635,(S)-[(2R)-5-ethenyl-1-(3-methylbutyl)-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CC(C)CC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9941,44636,"Quinine, isopropylchloride",CC(C)[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Cl-],,,,,,
9942,44637,(S)-[(2R)-5-ethenyl-1-propan-2-yl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CC(C)[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9943,44638,"Quinine, methochloride",C[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Cl-],,,,,,
9944,44639,(S)-[(2R)-5-ethenyl-1-methyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,C[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9945,44640,"Quinine, n-propyl bromide",CCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Br-],,,,,,
9946,44641,(S)-[(2R)-5-ethenyl-1-propyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,CCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C,,,,,,
9947,44642,"Quinine, n-propyl chloride",CCC[N+]12CCC(C[C@@H]1[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O)C(C2)C=C.[Cl-],,,,,,
9948,44643,"Ammonium, oxydiethylenebis(benzyldimethyl-, dichloride",C[N+](C)(CCOCC[N+](C)(C)CC1=CC=CC=C1)CC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
9949,44644,Benzyl-[2-[2-[benzyl(dimethyl)azaniumyl]ethoxy]ethyl]-dimethylazanium,C[N+](C)(CCOCC[N+](C)(C)CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
9950,44645,"1,10-Bis(N-tetrahydroisoquinolyl)decane dihydrochloride",C1C[NH+](CC2=CC=CC=C21)CCCCCCCCCC[NH+]3CCC4=CC=CC=C4C3.[Cl-].[Cl-],,,,,,
9951,44646,"1,10-bis(3,4-dihydroisoquinolin-2(1H)-yl)decane",C1CN(CC2=CC=CC=C21)CCCCCCCCCCN3CCC4=CC=CC=C4C3,,,,,,
9952,44647,"1,7-Bis(N-tetrahydroisoquinolyl)heptane dihydrochloride",C1C[NH+](CC2=CC=CC=C21)CCCCCCC[NH+]3CCC4=CC=CC=C4C3.[Cl-].[Cl-],,,,,,
9953,44648,"2-[7-(3,4-dihydro-1H-isoquinolin-2-yl)heptyl]-3,4-dihydro-1H-isoquinoline",C1CN(CC2=CC=CC=C21)CCCCCCCN3CCC4=CC=CC=C4C3,,,,,,
9954,44649,Bromotrichloroethyl ethyl malonate,CCOC(=O)CC(=O)OC(C(Cl)(Cl)Cl)Br,,,,,,
9955,44650,"Butane, 2,3-bis(2-chloroethylthio)-",CC(C(C)SCCCl)SCCCl,,,,,,
9956,44651,1-Chloro-4-fluoro-1-nitrobutane,C(CC([N+](=O)[O-])Cl)CF,,,,,,
9957,44652,"N,N-Dimethyl-1,2-butanediamine",CCC(CN(C)C)N,,,,,,
9958,44653,"2-Propyl-1,3-butanediol dicarbamate",CCCC(COC(=O)N)C(C)OC(=O)N,,,,,,
9959,44654,CID 44654,CC(=C(CN(CC1=CC=CC=C1)CC2=CC=CC=C2)N=O)O,,,,,,
9960,44655,2-Phenyl-3-hydrazinobutane hydrochloride,CC(C1=CC=CC=C1)C(C)N[NH3+].[Cl-],,,,,,
9961,44656,3-Phenylbutan-2-ylhydrazine,CC(C1=CC=CC=C1)C(C)NN,,,,,,
9962,44657,Methyl gamma-fluoro-beta-hydroxythiolbutyrate,CSC(=O)CC(CF)O,,,,,,
9963,44658,"Butanethioic acid, 4-fluoro-, methyl ester",CSC(=O)CCCF,,,,,,
9964,44659,Guanidino-sec-butylthiol hydrogen sulfate (ester),CCC(C)(N=C(N)N)SS(=O)(=O)O,,,,,,
9965,44660,"1,2-Butanediol, 4-bromo-4,4-dinitro-1-phenyl-",C1=CC=C(C=C1)C(C(CC([N+](=O)[O-])([N+](=O)[O-])Br)O)O,,,,,,
9966,44661,CID 44661,C1=NC2=C(C(=N1)S)N=C[NH+]2C(CCO)CO.[Cl-],,,,,,
9967,44662,CID 44662,C1=NC2=C(C(=N1)S)N=CN2C(CCO)CO,,,,,,
9968,44663,"Carbazole, 5,6,7,8-tetrahydro-1-amino-9-ethyl-, hydrochloride",CC[NH+]1C2=C(CCCC2)C3=C1C(=CC=C3)N.[Cl-],,,,,,
9969,44664,"9-Ethyl-5,6,7,8-tetrahydrocarbazol-1-amine",CCN1C2=C(CCCC2)C3=C1C(=CC=C3)N,,,,,,
9970,44665,3-Amino-9-methylcarbazole hydrochloride,CN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],,,,,,
9971,44666,9-Methyl-9H-carbazol-3-amine,CN1C2=C(C=C(C=C2)N)C3=CC=CC=C31,,,,,,
9972,44667,6-Fluoro-2(3H)-benzothiazolone,C1=CC2=C(C=C1F)SC(=O)N2,,,,,,
9973,44668,Indalpine,C1CNCCC1CCC2=CNC3=CC=CC=C32,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)']",,,
9974,44669,"Butyramide, N-(2-(6-chloro-5-methoxy-3-indolyl)ethyl)-",CCCC(=O)NCCC1=C2C=C(C(=CC2=NC1)Cl)OC,,,,,,
9975,44670,2-Acetyl-3-oxohexanoic acid ethyl ester,CCCC(=O)C(C(=O)C)C(=O)OCC,,,,,,
9976,44671,Ethyl 5-fluorohexanoate,CCOC(=O)CCCC(C)F,,,,,,
9977,44672,"Hexanoic acid, 5-fluoro-, 2-fluoroethyl ester",CC(CCCC(=O)OCCF)F,,,,,,
9978,44673,2-Amino-2-methyl-3-hexanol,CCCC(C(C)(C)N)O,,,,,,
9979,44674,"3-Hexanol, 4-amino-2-methyl-",CCC(C(C(C)C)O)N,,,,,,
9980,44675,"6-Dimethylamino-4,4-diphenyl-5-methyl-3-hexanol hydrochloride",CCC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C)O.[Cl-],,,,,,
9981,44676,Isomethadol,CCC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C)O,,,,,,
9982,44677,"5-Acetoxy-N,N-dimethyl-4,4-diphenylheptylamine hydrochloride",CCC(C(CCC[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.[Cl-],,,,,,
9983,44678,"[7-(Dimethylamino)-4,4-diphenylheptan-3-yl] acetate",CCC(C(CCCN(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C,,,,,,
9984,44679,"3-Hexanol, 5-(N,N-dimethylamino)methyl-4,4-diphenyl-, propionate, hydrochloride",CCC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C)OC(=O)CC.[Cl-],,,,,,
9985,44680,"[6-(Dimethylamino)-5-methyl-4,4-diphenylhexan-3-yl] propanoate",CCC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C)OC(=O)CC,,,,,,
9986,44681,"3-Hexanol, 4,4-diphenyl-6-morpholino-, hydrochloride",CCC(C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)O.[Cl-],,,,,,
9987,44682,"6-Morpholin-4-yl-4,4-diphenylhexan-3-ol",CCC(C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)O,,,,,,
9988,44683,"3-Hexanone, 6-dimethylamino-4,4-diphenyl-5-methyl-, hydrobromide",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C.[Br-],,,,,,
9989,44684,"3-Hexanone, 5-(N,N-dimethylamino)methyl-4,4-diphenyl-, methylchloride",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[N+](C)(C)C.[Cl-],,,,,,
9990,44685,"Trimethyl-(2-methyl-4-oxo-3,3-diphenylhexyl)azanium",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[N+](C)(C)C,,,,,,
9991,44686,"4,4-Diphenyl-6-morpholino-3-hexanone",CCC(=O)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9992,44687,"4,4-Diphenyl-6-morpholino-3-hexanone hydrochloride",CCC(=O)C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
9993,44688,"4,4-Diphenyl-5-(pyrrolidinyl)methyl-3-hexanone",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN3CCCC3,,,,,,
9994,44689,N-(2-Nitroisobutyl)-2-ethylhexylamine,CCCCC(CC)CNCC(C)(C)[N+](=O)[O-],,,,,,
9995,44690,"Hexylamine, 5-methoxy-N,1,5-trimethyl-, hydrochloride",CC(CCCC(C)(C)OC)[NH2+]C.[Cl-],,,,,,
9996,44691,"6-methoxy-N,6-dimethylheptan-2-amine",CC(CCCC(C)(C)OC)NC,,,,,,
9997,44692,2-Phenylhexylamine hydrochloride,CCCCC(C[NH3+])C1=CC=CC=C1.[Cl-],,,,,,
9998,44693,beta-Butylbenzeneethanamine,CCCCC(CN)C1=CC=CC=C1,,,,,,
9999,44694,3-Propyl-2-hexylamine hydrochloride,CCCC(CCC)C(C)[NH3+].[Cl-],,,,,,
10000,44695,3-Propylhexan-2-amine,CCCC(CCC)C(C)N,,,,,,
10001,44696,"Hexylamine, N,1,5-trimethyl-, hydrochloride",CC(C)CCCC(C)[NH2+]C.[Cl-],,,,,,
10002,44697,CID 44697,CC1=C(C=C(C=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)[O-])N(CCCl)CCCl.[Na+],,,,,,
10003,44698,(2S)-2-[[3-[bis(2-chloroethyl)amino]-4-methylbenzoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid,CC1=C(C=C(C=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N(CCCl)CCCl,,,,,,
10004,44699,"Hydantoin, 3-(3-chloromethoxypropyl)-5,5-dimethyl-",CC1(C(=O)N(C(=O)N1)CCCOCCl)C,,,,,,
10005,44700,"Carbamic acid, ethylnaphthyl-, ethyl ester",CCN(C1=CC=CC2=CC=CC=C21)C(=O)OCC,,,,,,
10006,44701,"7,8-Naphthalenediol, 1-(methylamino)-1,2,3,4-tetrahydro-, hydroiodide",C[NH2+]C1CCCC2=C1C(=C(C=C2)O)O.[I-],,,,,,
10007,44702,"8-(Methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol",CNC1CCCC2=C1C(=C(C=C2)O)O,,,,,,
10008,44703,"Naphthaleneethylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-2-ethyl-7-methoxy-1-methyl-, hydrochloride",CCC1CCC2=C(C1(C)CC[NH+](C)C)C=C(C=C2)OC.[Cl-],,,,,,
10009,44704,"2-(2-ethyl-7-methoxy-1-methyl-3,4-dihydro-2H-naphthalen-1-yl)-N,N-dimethylethanamine",CCC1CCC2=C(C1(C)CCN(C)C)C=C(C=C2)OC,,,,,,
10010,44705,"1-Naphthaleneethylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-7-methoxy-1-propyl-, hydrochloride",CCCC1(CCCC2=C1C=C(C=C2)OC)CC[NH+](C)C.[Cl-],,,,,,
10011,44706,"2-(7-methoxy-1-propyl-3,4-dihydro-2H-naphthalen-1-yl)-N,N-dimethylethanamine",CCCC1(CCCC2=C1C=C(C=C2)OC)CCN(C)C,,,,,,
10012,44707,"1-Naphthaleneethylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-1-methyl-, hydrochloride",CC1(CCCC2=CC=CC=C21)CC[NH+](C)C.[Cl-],,,,,,
10013,44708,"1-(2-(Dimethylamino)ethyl)-1-methyl-1,2,3,4-tetrahydronaphthalene",CC1(CCCC2=CC=CC=C21)CCN(C)C,,,,,,
10014,44709,"1,2-Dimethyl-1-(2-dimethylaminoethyl)-7-methoxy-1,2,3,4-tetrahydronaphthalene hydrobromide",CC1CCC2=C(C1(C)CC[NH+](C)C)C=C(C=C2)OC.[Br-],,,,,,
10015,44710,"2-(7-methoxy-1,2-dimethyl-3,4-dihydro-2H-naphthalen-1-yl)-N,N-dimethylethanamine",CC1CCC2=C(C1(C)CCN(C)C)C=C(C=C2)OC,,,,,,
10016,44711,"1-Naphthaleneethylamine, 1,2,3,4-tetrahydro-N,N,1,2-tetramethyl-, hydrochloride",CC1CCC2=CC=CC=C2C1(C)CC[NH+](C)C.[Cl-],,,,,,
10017,44712,"1,2-Dimethyl-1-(2-dimethylaminoethyl)-1,2,3,4-tetrahydronaphthalene",CC1CCC2=CC=CC=C2C1(C)CCN(C)C,,,,,,
10018,44713,alpha-(Dimethylaminomethyl)-7-methoxy-1-naphthalenemethanol,CN(C)CC(C1=CC=CC2=C1C=C(C=C2)OC)O,,,,,,
10019,44714,7-Methoxy-alpha-(piperidinomethyl)-1-naphthalenemethanol,COC1=CC2=C(C=CC=C2C(CN3CCCCC3)O)C=C1,,,,,,
10020,44715,alpha-(Piperidinomethyl)-1-naphthalenemethanol,C1CCN(CC1)CC(C2=CC=CC3=CC=CC=C32)O,,,,,,
10021,44716,"1-Hydroxymethyl-5-methoxy-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride",COC1=CC=CC2=C1CCCC2C([NH3+])O.[Cl-],,,,,,
10022,44717,"Amino-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methanol",COC1=CC=CC2=C1CCCC2C(N)O,,,,,,
10023,44718,"1-Naphthalenemethanol, 1,2,3,4-tetrahydro-6-chloro-1-(dimethylamino)-5-methoxy-, hydrobromide",C[NH+](C)C(C1CCCC2=C1C=CC(=C2OC)Cl)O.[Br-],,,,,,
10024,44719,"(6-Chloro-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-(dimethylamino)methanol",CN(C)C(C1CCCC2=C1C=CC(=C2OC)Cl)O,,,,,,
10025,44720,"1-Naphthalenemethanol, 1,2,3,4-tetrahydro-1-(dimethylamino)-5-methoxy-, hydrochloride",C[NH+](C)C(C1CCCC2=C1C=CC=C2OC)O.[Cl-],,,,,,
10026,44721,"Dimethylamino-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methanol",CN(C)C(C1CCCC2=C1C=CC=C2OC)O,,,,,,
10027,44722,"Naphthalene-8-sulfonamide, 1,2,3,4-tetrahydro-N,N-dimethyl-5-methoxy-1-(1-pyrrolidinyl)-, hydrochloride",CN(C)S(=O)(=O)C1=C2C(CCCC2=C(C=C1)OC)[NH+]3CCCC3.[Cl-],,,,,,
10028,44723,"4-methoxy-N,N-dimethyl-8-pyrrolidin-1-yl-5,6,7,8-tetrahydronaphthalene-1-sulfonamide",CN(C)S(=O)(=O)C1=C2C(CCCC2=C(C=C1)OC)N3CCCC3,,,,,,
10029,44724,"2-Naphthalenesulfonic acid, 3,3'-methylenedi-, mercury salt",C1=CC=C2C=C(C(=CC2=C1)CC3=CC4=CC=CC=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-].[Hg+2],,,,,,
10030,44725,"Dipotassium 3,3'-methylenebisnaphthalene-2-sulphonate",C1=CC=C2C=C(C(=CC2=C1)CC3=CC4=CC=CC=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-].[K+].[K+],,,,,,
10031,44726,"cis-1,2,3,4-Tetrahydro-4-(dimethylamino)-N-methyl-1-phenyl-1-naphthamide hydrochloride",CNC(=O)[C@]1(CC[C@H](C2=CC=CC=C21)[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
10032,44727,"(1R,4R)-4-(dimethylamino)-N-methyl-1-phenyl-3,4-dihydro-2H-naphthalene-1-carboxamide",CNC(=O)[C@]1(CC[C@H](C2=CC=CC=C21)N(C)C)C3=CC=CC=C3,,,,,,
10033,44728,"cis-1,2,3,4-Tetrahydro-4-(dimethylamino)-1-phenyl-1-naphthamide hydrochloride",C[NH+](C)[C@@H]1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N.[Cl-],,,,,,
10034,44729,"(1R,4R)-4-(dimethylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carboxamide",CN(C)[C@@H]1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N,,,,,,
10035,44730,CID 44730,C[NH+](C)C1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N.C(=CC(=O)[O-])C(=O)O,,,,,,
10036,44731,"(1R)-4-(dimethylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carboxamide",CN(C)C1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N,,,,,,
10037,44732,N-Benzyl-N-ethyl-4-methoxy-1-naphthamidine hydrochloride,CC[NH+](CC1=CC=CC=C1)C(=N)C2=CC=C(C3=CC=CC=C32)OC.[Cl-],,,,,,
10038,44733,N-benzyl-N-ethyl-4-methoxynaphthalene-1-carboximidamide,CCN(CC1=CC=CC=C1)C(=N)C2=CC=C(C3=CC=CC=C32)OC,,,,,,
10039,44734,"N,N-Bis(sec-butyl)-4-ethoxy-1-naphthamidine hydrochloride",CCC(C)[NH+](C(C)CC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC.[Cl-],,,,,,
10040,44735,"N,N-di(butan-2-yl)-4-ethoxynaphthalene-1-carboximidamide",CCC(C)N(C(C)CC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC,,,,,,
10041,44736,"N,N-Bis(sec-butyl)-4-methoxy-1-naphthamidine hydrochloride",CCC(C)[NH+](C(C)CC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10042,44737,"N,N-di(butan-2-yl)-4-methoxynaphthalene-1-carboximidamide",CCC(C)N(C(C)CC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10043,44738,(4-Butoxynaphthalene-1-carboximidoyl)-dimethylazanium;chloride,CCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](C)C.[Cl-],,,,,,
10044,44739,"4-butoxy-N,N-dimethylnaphthalene-1-carboximidamide",CCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(C)C,,,,,,
10045,44740,"1-NAPHTHAMIDINE, N-BUTYL-4-METHOXY-N-(p-METHOXYPHENYL)-, HYDROCHLORIDE",CCCC[NH+](C1=CC=C(C=C1)OC)C(=N)C2=CC=C(C3=CC=CC=C32)OC.[Cl-],,,,,,
10046,44741,N-butyl-4-methoxy-N-(4-methoxyphenyl)naphthalene-1-carboximidamide,CCCCN(C1=CC=C(C=C1)OC)C(=N)C2=CC=C(C3=CC=CC=C32)OC,,,,,,
10047,44742,"N,N-Dibutyl-4-ethoxy-1-naphthamidine hydrochloride",CCCC[NH+](CCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC.[Cl-],,,,,,
10048,44743,"N,N-dibutyl-4-ethoxynaphthalene-1-carboximidamide",CCCCN(CCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC,,,,,,
10049,44744,"N,N-Dibutyl-4-methoxy-1-naphthamidine hydrochloride",CCCC[NH+](CCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10050,44745,"N,N-dibutyl-4-methoxynaphthalene-1-carboximidamide",CCCCN(CCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10051,44746,"N,N-Diethyl-4-methoxy-1-naphthamidine hydrochloride",CC[NH+](CC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10052,44747,"N,N-diethyl-4-methoxynaphthalene-1-carboximidamide",CCN(CC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10053,44748,"N,N-Dihexyl-4-methoxy-1-naphthamidine hydrochloride",CCCCCC[NH+](CCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10054,44749,"N,N-dihexyl-4-methoxynaphthalene-1-carboximidamide",CCCCCCN(CCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10055,44750,"N,N-Diisobutyl-4-ethoxy-1-naphthamidine hydrochloride",CCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CC(C)C)CC(C)C.[Cl-],,,,,,
10056,44751,"4-ethoxy-N,N-bis(2-methylpropyl)naphthalene-1-carboximidamide",CCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CC(C)C)CC(C)C,,,,,,
10057,44752,"N,N-Diisobutyl-4-methoxy-1-naphthamidine hydrochloride",CC(C)C[NH+](CC(C)C)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10058,44753,"4-methoxy-N,N-bis(2-methylpropyl)naphthalene-1-carboximidamide",CC(C)CN(CC(C)C)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10059,44754,"N,N-Diisopentyl-4-ethoxy-1-naphthamidine hydrochloride",CCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCC(C)C)CCC(C)C.[Cl-],,,,,,
10060,44755,"4-ethoxy-N,N-bis(3-methylbutyl)naphthalene-1-carboximidamide",CCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCC(C)C)CCC(C)C,,,,,,
10061,44756,"N,N-Diisopentyl-4-methoxy-1-naphthamidine hydrochloride",CC(C)CC[NH+](CCC(C)C)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10062,44757,"4-methoxy-N,N-bis(3-methylbutyl)naphthalene-1-carboximidamide",CC(C)CCN(CCC(C)C)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10063,44758,"N,N'-Diisopropyl-4-methoxy-1-naphthamidine hydrochloride",CC(C)[NH+](C(C)C)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
10064,44759,"4-methoxy-N,N-di(propan-2-yl)naphthalene-1-carboximidamide",CC(C)N(C(C)C)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
10065,44760,"Naphthalene-8-sulfonamide, 1,2,3,4-tetrahydro-N-benzyl-5-methoxy-N-methyl-1-(1-pyrrolidinyl)-, hydrochloride, hydrate",CN(CC1=CC=CC=C1)S(=O)(=O)C2=C3C(CCCC3=C(C=C2)OC)[NH+]4CCCC4.[Cl-],,,,,,
10066,44761,"N-benzyl-4-methoxy-N-methyl-8-pyrrolidin-1-yl-5,6,7,8-tetrahydronaphthalene-1-sulfonamide",CN(CC1=CC=CC=C1)S(=O)(=O)C2=C3C(CCCC3=C(C=C2)OC)N4CCCC4,,,,,,
10067,44762,"Disodium 8,8'-trithiobis(1-naphthalenesulfinate) dihydrate",C1=CC2=C(C=C(C=C2)S(=O)[O-])C(=C1)SSSC3=CC=CC4=C3C=C(C=C4)S(=O)[O-].[Na+].[Na+],,,,,,
10068,44763,8-[(7-Sulfinonaphthalen-1-yl)trisulfanyl]naphthalene-2-sulfinic acid,C1=CC2=C(C=C(C=C2)S(=O)O)C(=C1)SSSC3=CC=CC4=C3C=C(C=C4)S(=O)O,,,,,,
10069,44764,"1-Naphthamide, 1,2,3,4-tetrahydro-4-(dimethylamino)-N,N-dimethyl-1-phenyl-, hydrochloride, dihydrate, (Z)-",C[NH+](C)[C@@H]1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N(C)C.[Cl-],,,,,,
10070,44765,CID 44765,CN(C)C1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)N(C)C,,,,,,
10071,44766,"Benzilic acid, 2-(piperidinoamino)ethyl ester, hydrochloride",C1CC[NH+](CC1)NCCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
10072,44767,"2-(Piperidin-1-ylamino)ethyl 2-hydroxy-2,2-diphenylacetate",C1CCN(CC1)NCCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
10073,44768,"dl-2,3-Dichloro-1,4-butanediol",C(C(C(CO)Cl)Cl)O,,,,,,
10074,44769,"Pyrrolidine, 1-(1,2,3,4-tetrahydro-5-methoxy-8-methylsulfamoylnaphthyl)-, hydrochloride",CNS(=O)(=O)C1=C2C(CCCC2=C(C=C1)OC)[NH+]3CCCC3.[Cl-],,,,,,
10075,44770,"4-methoxy-N-methyl-8-pyrrolidin-1-yl-5,6,7,8-tetrahydronaphthalene-1-sulfonamide",CNS(=O)(=O)C1=C2C(CCCC2=C(C=C1)OC)N3CCCC3,,,,,,
10076,44771,"(E)-2-(m-Chlorophenyl)-3-(dimethylaminomethyl)bicyclo(2.2.2)octane, hydrochloride",C[NH+](C)C[C@@H]1C2CCC(C1C3=CC(=CC=C3)Cl)CC2.[Cl-],,,,,,
10077,44772,"1-[(2R)-3-(3-chlorophenyl)-2-bicyclo[2.2.2]octanyl]-N,N-dimethylmethanamine",CN(C)C[C@@H]1C2CCC(C1C3=CC(=CC=C3)Cl)CC2,,,,,,
10078,44773,"2,7-Naphthalenediamidine",C1=CC(=CC2=C1C=CC(=C2)C(=N)N)C(=N)N,,,,,,
10079,44774,"N,3-Dimethyl-3-hexylamine hydrochloride",CCCC(C)(CC)[NH2+]C.[Cl-],,,,,,
10080,44775,"N,3-dimethylhexan-3-amine",CCCC(C)(CC)NC,,,,,,
10081,44776,2-amino-3-(1H-imidazol-5-yl)propanethioic S-acid,C1=C(NC=N1)CC(C(=O)S)N,,,,,,
10082,44777,"dl-6-Dimethylamino-4,4-diphenyl-5-methyl-3-hexanone hydrochloride, monohydrate",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C.[Cl-],,,,,,
10083,44778,"FURFURYL ALCOHOL, alpha-(N-ETHYLCARBAMOYL)-",CCNC(=O)C(C1=CC=CO1)O,,,,,,
10084,44779,"N-(6-(Dimethylamino)-4,4-diphenyl-3-heptylidene)acetamide hydrochloride",CCC(=NC(=O)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,,,,,,
10085,44780,"N-[6-(dimethylamino)-4,4-diphenylheptan-3-ylidene]acetamide",CCC(=NC(=O)C)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
10086,44781,"3-Chloro-6-dimethylamino-4,4-diphenylheptane hydrochloride",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)Cl.[Cl-],,,,,,
10087,44782,"5-chloro-N,N-dimethyl-4,4-diphenylheptan-2-amine",CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)Cl,,,,,,
10088,44783,4-Acetyl-4-methylheptanedioic acid diallyl ester,CC(=O)C(C)(CCC(=O)OCC=C)CCC(=O)OCC=C,,,,,,
10089,44784,"2,4-Heptanediol, dicarbamate",CCCC(CC(C)OC(=O)N)OC(=O)N,,,,,,
10090,44785,N-(4-ethyl-5-hydroxyiminoheptan-3-ylidene)hydroxylamine,CCC(C(=NO)CC)C(=NO)CC,,,,,,
10091,44786,"2-Hydroxy-4,6,6-trimethylheptanenitrile",CC(CC(C#N)O)CC(C)(C)C,,,,,,
10092,44787,"Heptanethiol, 7-amino-",C(CCCN)CCCS,,,,,,
10093,44788,3-Ethyl-2-hydroxyheptanoic acid,CCCCC(CC)C(C(=O)O)O,,,,,,
10094,44789,"2-Heptanol, 2,4-dimethyl-6-methylamino-, hydrochloride",CC(CC(C)[NH2+]C)CC(C)(C)O.[Cl-],,,,,,
10095,44790,"2,4-Dimethyl-6-(methylamino)heptan-2-ol",CC(CC(C)NC)CC(C)(C)O,,,,,,
10096,44791,"2-Heptanol, 2,5-dimethyl-6-methylamino-, hydrochloride",CC(CCC(C)(C)O)C(C)[NH2+]C.[Cl-],,,,,,
10097,44792,"2,5-Dimethyl-6-(methylamino)heptan-2-ol",CC(CCC(C)(C)O)C(C)NC,,,,,,
10098,44793,"7-Dimethylamino-4,4-diphenyl-3-heptanone hydrochloride",CCC(=O)C(CCC[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
10099,44794,"7-(Dimethylamino)-4,4-diphenylheptan-3-one",CCC(=O)C(CCCN(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
10100,44795,"3-Heptanone, 6-dimethylamino-4,4-diphenyl-, methylchloride",CCC(=O)C(CC(C)[N+](C)(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
10101,44796,"Trimethyl-(5-oxo-4,4-diphenylheptan-2-yl)azanium",CCC(=O)C(CC(C)[N+](C)(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
10102,44797,"3-Heptanone, 4,4-diphenyl-7-pyrrolidinyl-",CCC(=O)C(CCCN1CCCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10103,44798,CID 44798,CCCCCCC(=O)C1=CC=C(C=C1)[NH3+].[Cl-],,,,,,
10104,44799,p-Amino enanthophenone,CCCCCCC(=O)C1=CC=C(C=C1)N,,,,,,
10105,44800,CID 44800,CC=CC(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
10106,44801,CID 44801,CC=CC(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
10107,44802,"N,N-Diethyl-4-heptylamine hydrochloride",CCCC(CCC)[NH+](CC)CC.[Cl-],,,,,,
10108,44803,"N,N-diethylheptan-4-amine",CCCC(CCC)N(CC)CC,,,,,,
10109,44804,"N,N-Dimethyl-4-heptylamine hydrochloride",CCCC(CCC)[NH+](C)C.[Cl-],,,,,,
10110,44805,"N,N-dimethyl-(4-heptylamine)",CCCC(CCC)N(C)C,,,,,,
10111,44806,"N,N-Dipropyl-4-heptylamine hydrochloride",CCCC(CCC)[NH+](CCC)CCC.[Cl-],,,,,,
10112,44807,"N,N-dipropylheptan-4-amine",CCCC(CCC)N(CCC)CCC,,,,,,
10113,44808,3-Heptylmethylamine,CCCCC(CC)NC,,,,,,
10114,44809,"N,N'-Bis(2,5-dimethylheptyl)-1,6-dimethyl-1,6-hexanediamine dihydrochloride",CCC(C)CCC(C)C[NH2+]C(C)CCCCC(C)[NH2+]CC(C)CCC(C)CC.[Cl-].[Cl-],,,,,,
10115,44810,"2-N,7-N-bis(2,5-dimethylheptyl)octane-2,7-diamine",CCC(C)CCC(C)CNC(C)CCCCC(C)NCC(C)CCC(C)CC,,,,,,
10116,44811,"3-Acetoxy-4,4-diphenyl-6-morpholinohexane hydrochloride",CCC(C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C.[Cl-],,,,,,
10117,44812,"(6-Morpholin-4-yl-4,4-diphenylhexan-3-yl) acetate",CCC(C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C,,,,,,
10118,44813,"Acetamide, N-(6-(dimethylamino)-4,4-diphenyl-5-methyl-3-hexylidene)-, hydrochloride",CCC(=NC(=O)C)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C.Cl,,,,,,
10119,44814,"N-[6-(dimethylamino)-5-methyl-4,4-diphenylhexan-3-ylidene]acetamide",CCC(=NC(=O)C)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C,,,,,,
10120,44815,"3-p-Aminobenzoxy-4,4-diphenyl-6-morpholinohexane hydrochloride",CCC(C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C4=CC=C(C=C4)N.[Cl-],,,,,,
10121,44816,"(6-Morpholin-4-yl-4,4-diphenylhexan-3-yl) 4-aminobenzoate",CCC(C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C4=CC=C(C=C4)N,,,,,,
10122,44817,CID 44817,CCCCCC(C1=CC=CC=C1)[NH3+].[Cl-],,,,,,
10123,44818,1-Phenylhexan-1-amine,CCCCCC(C1=CC=CC=C1)N,,,,,,
10124,44819,"1,6-HEXANEDIAMINE, N,N'-BIS(beta-MERCAPTOETHYL)-",C(CCCNCCS)CCNCCS,,,,,,
10125,44820,"N,N'-Di-9H-fluoren-9-yl-N,N'-dimethyl-1,6-hexanediamine dihydrobromide",C[NH+](CCCCCC[NH+](C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-],,,,,,
10126,44821,"N,N'-bis(9H-fluoren-9-yl)-N,N'-dimethylhexane-1,6-diamine",CN(CCCCCCN(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
10127,44822,"Hexane, 3-propionoxy-4,4-diphenyl-6-morpholino-, hydrochloride",CCCOC(CC)C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
10128,44823,"4-(3,3-Diphenyl-4-propoxyhexyl)morpholine",CCCOC(CC)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10129,44824,Methyl heptyl sulfide,CCCCCCCSC,,,,,,
10130,44825,Indol-3-yl piperidinomethyl ketone hydrochloride,C1CC[NH+](CC1)CC(=O)C2=CNC3=CC=CC=C32.[Cl-],,,,,,
10131,44826,"Ketone, 5-methoxy-1H-indol-3-YL 4-piperidylmethyl, monohydrochloride",COC1=CC2=C(C=C1)NC=C2C(=O)C[NH+]3CCCCC3.[Cl-],,,,,,
10132,44827,1-(5-methoxy-1H-indol-3-yl)-2-piperidin-1-ylethanone,COC1=CC2=C(C=C1)NC=C2C(=O)CN3CCCCC3,,,,,,
10133,44828,5-Chloro-1H-indol-3-yl 4-piperidinylmethyl ketone hydrochloride,C1C[NH2+]CCC1CC(=O)C2=CNC3=C2C=C(C=C3)Cl.[Cl-],,,,,,
10134,44829,1-(5-chloro-1H-indol-3-yl)-2-piperidin-4-ylethanone,C1CNCCC1CC(=O)C2=CNC3=C2C=C(C=C3)Cl,,,,,,
10135,44830,1-Methyl-3-(2-(4-piperidinyl)ethyl)-1H-indole hydrochloride,CN1C=C(C2=CC=CC=C21)CCC3CC[NH2+]CC3.[Cl-],,,,,,
10136,44831,1-Methyl-3-(2-piperidin-4-yl-ethyl)-1H-indole; hydrochloride,CN1C=C(C2=CC=CC=C21)CCC3CCNCC3,,,,,,
10137,44832,3-(2-(4-Piperidinyl)ethyl)-1H-indole hydrochloride,C1C[NH2+]CCC1CCC2=CNC3=CC=CC=C32.[Cl-],,,,,,
10138,44833,"3-Propionoxy-6-dimethylamino-4,4-diphenyl heptane hydrochloride",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)CC.[Cl-],,,,,,
10139,44834,"[6-(Dimethylamino)-4,4-diphenylheptan-3-yl] propanoate",CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)CC,,,,,,
10140,44835,"(1-alpha(R*),2-beta)-alpha-(2-Phenylcyclopropyl)benzyl alcohol",C1C(C1C(C2=CC=CC=C2)O)C3=CC=CC=C3,,,,,,
10141,44836,CID 44836,C1=CC(=C[NH+]=C1)COC(=O)C2=CN=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
10142,44837,Pyridin-3-ylmethyl Pyridine-3-carboxylate,C1=CC(=CN=C1)COC(=O)C2=CN=CC=C2,,,,,,
10143,44838,Trichloroisopropyl 2-ethylbutyrate,CCC(CC)C(=O)OC(C)C(Cl)(Cl)Cl,,,,,,
10144,44839,"Butyric acid, 2-bromo-2-ethyl-, 2,2,2-tribromoethyl ester",CCC(CC)(C(=O)OCC(Br)(Br)Br)Br,,,,,,
10145,44840,Methyl hexafluoro-2-bromobutyrate,COC(=O)C(C(C(F)(F)F)(F)F)(F)Br,,,,,,
10146,44841,"Butyric acid, 2-chloro-2-ethyl-, trichloroethyl ester",CCC(CC)(C(=O)OCC(Cl)(Cl)Cl)Cl,,,,,,
10147,44842,"BUTYRIC ACID, o-CHLOROPHENYL ESTER",CCCC(=O)OC1=CC=CC=C1Cl,,,,,,
10148,44843,"(4-Nitrophenyl)methyl 2,3-dibromo-3-((dimethoxyphosphinyl)oxy)butanoate",CC(C(C(=O)OCC1=CC=C(C=C1)[N+](=O)[O-])Br)(OP(=O)(OC)OC)Br,,,,,,
10149,44844,"Butyric acid, 4-(diethylamino)-",CCN(CC)CCCC(=O)O,,,,,,
10150,44845,"Butyric acid, 3-(N,N-dimethylamino)methyl-2,2-diphenyl-, ethyl ester, hydrochloride",CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C.[Cl-],,,,,,
10151,44846,"Ethyl 4-(dimethylamino)-3-methyl-2,2-diphenylbutanoate",CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C,,,,,,
10152,44847,"4,6-Dinitro-o-cresol butyrate",CCCC(=O)OC1=C(C=C(C=C1C)[N+](=O)[O-])[N+](=O)[O-],,,,,,
10153,44848,"Butyric acid, 2-ethyl-, 2,2,2-tribromoethyl ester",CCC(CC)C(=O)OCC(Br)(Br)Br,,,,,,
10154,44849,CID 44849,CC(C(C(=O)[O-])F)O.[Na+],,,,,,
10155,44850,2-Fluoro-3-hydroxybutanoic acid,CC(C(C(=O)O)F)O,,,,,,
10156,44851,CID 44851,CC(C(C(=O)[O-])O)F.[Na+],,,,,,
10157,44852,3-Fluoro-2-hydroxybutanoic acid,CC(C(C(=O)O)O)F,,,,,,
10158,44853,Isopropyl 2-fluorobutyrate,CCC(C(=O)OC(C)C)F,,,,,,
10159,44854,CID 44854,CCC(C(=O)[O-])F.[Na+],,,,,,
10160,44855,"Methyl-gamma-(2-methylpiperidino)butyrate, hydrochloride",CC1CCCC[NH+]1CCCC(=O)OC.[Cl-],,,,,,
10161,44856,Methyl 4-(2-methylpiperidin-1-yl)butanoate,CC1CCCCN1CCCC(=O)OC,,,,,,
10162,44857,"Methyl-gamma-morpholinobutyrate, hydrochloride",COC(=O)CCC[NH+]1CCOCC1.[Cl-],,,,,,
10163,44858,Methyl 4-morpholinobutanoate,COC(=O)CCCN1CCOCC1,,,,,,
10164,44859,3-(2'-Methylpiperidino)propyl 2-phenylbutyrate,CCC(C1=CC=CC=C1)C(=O)OCCCN2CCCCC2C,,,,,,
10165,44860,"4-Dimethylamino-2,2-diphenyl-3-methylbutyronitrile hydrochloride",CC(C[NH+](C)C)C(C#N)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
10166,44861,"4-(Dimethylamino)-3-methyl-2,2-diphenylbutanenitrile",CC(CN(C)C)C(C#N)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
10167,44862,"4-(Dimethylamino)-2-hydroxy-3,3-dimethylbutanenitrile",CC(C)(CN(C)C)C(C#N)O,,,,,,
10168,44863,4'-(2-Hydroxy-3-(4-phenylpiperazinyl)propoxy)butyrophenone,CCCC(=O)C1=CC=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
10169,44864,Di-p-tolyl oxalate,CC1=CC(=CC=C1)OC(=O)C(=O)OC2=CC=CC(=C2)C,,,,,,
10170,44865,CID 44865,CC(=O)OCCN=C(C(=NCCOC(=O)C)S)S,,,,,,
10171,44866,CID 44866,C(CCC(=O)O)CCN=C(C(=NCCCCCC(=O)O)S)S,,,,,,
10172,44867,CID 44867,CCC(C(=O)O)N=C(C(=NC(CC)C(=O)O)S)S,,,,,,
10173,44868,CID 44868,C1=CC=C(C(=C1)CN=C(C(=NCC2=CC=CC=C2Cl)S)S)Cl,,,,,,
10174,44869,CID 44869,C1=CC(=CC=C1CN=C(C(=NCC2=CC=C(C=C2)Cl)S)S)Cl,,,,,,
10175,44870,CID 44870,CCC(=O)CCC(=O)CCCN=C(C(=NCCCC(=O)CCC(=O)CC)S)S,,,,,,
10176,44871,CID 44871,CCCCCCCCCCCCC1=CC=C(C=C1)CN=C(C(=NCC2=CC=C(C=C2)CCCCCCCCCCCC)S)S,,,,,,
10177,44872,CID 44872,CCCCCCCCCCCCOC(=O)CN=C(C(=NCC(=O)OCCCCCCCCCCCC)S)S,,,,,,
10178,44873,CID 44873,CCCCCCCCC(CCCCCC)CCN=C(C(=NCCC(CCCCCC)CCCCCCCC)S)S,,,,,,
10179,44874,CID 44874,CCCCCCCCCCCCCCCCCCCN=C(C(=NCCCCCCCCCCCCCCCCCCC)S)S,,,,,,
10180,44875,CID 44875,CCCCCCCCN=C(C(=NCCCCCCCC)S)S,,,,,,
10181,44876,CID 44876,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)N=C(C(=NC(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)S)S,,,,,,
10182,44877,CID 44877,C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)N=C(C(=NC4C5=CC=CC=C5OC6=CC=CC=C46)S)S,,,,,,
10183,44878,"Oxamide, N,N,N',N'-tetradodecyldithio-",CCCCCCCCCCCCN(CCCCCCCCCCCC)C(=S)C(=S)N(CCCCCCCCCCCC)CCCCCCCCCCCC,,,,,,
10184,44879,CID 44879,C1=C(C=C(C(=O)C1=N)[N+](=O)[O-])N(O)[O-].C1=C(C=C(C(=O)C1=N)[N+](=O)[O-])N(O)[O-].C1=C(C=C(C(=O)C1=N)[N+](=O)O)N([O-])[O-].C1=C(C=C(C(=O)C1=N)[N+](=O)O)N([O-])[O-].[Zr+4],,,,,,
10185,44880,CID 44880,C1=C(C=C(C(=O)C1=N)[N+](=O)[O-])N(O)[O-],,,,,,
10186,44881,N-Hexylpilocarpinium iodide,CCCCCC[N+]1(C=NC=C1CC2COC(=O)C2CC)C.[I-],,,,,,
10187,44882,3-Ethyl-4-[(3-hexyl-3-methylimidazol-3-ium-4-yl)methyl]oxolan-2-one,CCCCCC[N+]1(C=NC=C1CC2COC(=O)C2CC)C,,,,,,
10188,44883,CID 44883,CCCCCCCOP(=O)OCCCCCCC.CC(=O)O.[Hg],,,,,,
10189,44884,Phosphonic acid diheptyl ester,CCCCCCCOP(=O)OCCCCCCC,,,,,,
10190,44885,CID 44885,CCCCCCOP(=O)OCCCCCC.CC(=O)O.[Hg],,,,,,
10191,44886,1-Hexoxyphosphonoyloxyhexane,CCCCCCOP(=O)OCCCCCC,,,,,,
10192,44887,CID 44887,CC(=O)O.C1=CC=C(C(=C1)[N+](=O)[O-])[Hg],,,,,,
10193,44888,(2-Nitrophenyl)mercury,C1=CC=C(C(=C1)[N+](=O)[O-])[Hg],,,,,,
10194,44889,Hydroxymercuripropanolamide of m-carboxyphenoxyacetic acid,COC1=CC=CC(=C1)C(=O)N(CC(C[Hg])O)C(=O)O.O,,,,,,
10195,44890,[3-[Carboxy-(3-methoxybenzoyl)amino]-2-hydroxypropyl]mercury,COC1=CC=CC(=C1)C(=O)N(CC(C[Hg])O)C(=O)O,,,,,,
10196,44891,Hydroxymercuripropanolamide of p-carboxyphenoxyacetic acid,COC1=CC=C(C=C1)C(=O)N(CC(C[Hg])O)C(=O)O.O,,,,,,
10197,44892,[3-[Carboxy-(4-methoxybenzoyl)amino]-2-hydroxypropyl]mercury,COC1=CC=C(C=C1)C(=O)N(CC(C[Hg])O)C(=O)O,,,,,,
10198,44893,CID 44893,CN1C2=C(C(=O)N(C1=O)C)NC=N2.COC1=CC=CC=C1C(=O)N(CC(C[Hg])OC)C(=O)[O-].O.[Na+],,,,,,
10199,44894,[3-[Carboxy-(2-methoxybenzoyl)amino]-2-methoxypropyl]mercury,COC1=CC=CC=C1C(=O)N(CC(C[Hg])OC)C(=O)O,,,,,,
10200,44895,"Mercury, chloro(dibutoxyphosphinyl)-",CCCCOP(=O)OCCCC.Cl[Hg],,,,,,
10201,44896,Dibutoxyphosphinylradical,CCCCOP(=O)OCCCC,,,,,,
10202,44897,"Mercury, chloro(diisopropoxyphosphinyl)-",CC(C)OP(=O)OC(C)C.Cl[Hg],,,,,,
10203,44898,(N'-cyanocarbamimidoyl)azanide;ethylmercury(1+),CC[Hg+].C(#N)N=C(N)[NH-],,,,,,
10204,44899,"Mercury, (2-hydroxyphenyl)hydroxy-",C1=CC=C(C(=C1)O)[Hg].O,,,,,,
10205,44900,(2-Hydroxyphenyl)mercury,C1=CC=C(C(=C1)O)[Hg],,,,,,
10206,44901,CID 44901,CC(=C)C=NONC(=O)C,,,,,,
10207,44902,"Methanearsonic acid, dimercury salt",C[As](=O)([O-])[O-].[Hg].[Hg],,,,,,
10208,44903,CID 44903,CCCCCCCCCCCCCCCCCCN1CC(N=C1S)(C)C,,,,,,
10209,44904,Diepoxydihydromyrcene,CC1(C(O1)CCC(=C)C2CO2)C,,,,,,
10210,44905,"Octanediamidine, dihydrochloride",C(CCCC[NH2+]C=N)CCC[NH2+]C=N.[Cl-].[Cl-],,,,,,
10211,44906,N'-[8-(aminomethylideneamino)octyl]methanimidamide,C(CCCCN=CN)CCCN=CN,,,,,,
10212,44907,"1,8-Dimethyl-octane-1,8-diamine dihydrochloride",CC(CCCCCCC(C)[NH3+])[NH3+].[Cl-].[Cl-],,,,,,
10213,44908,"Decane-2,9-diamine",CC(CCCCCCC(C)N)N,,,,,,
10214,44909,Methyl-gamma-diethylaminobutyrate hydrobromide,CC[NH+](CC)CCCC(=O)OC.[Br-],,,,,,
10215,44910,Methyl 4-(diethylamino)butanoate,CCN(CC)CCCC(=O)OC,,,,,,
10216,44911,3-(m-Toluoyloxy)phenyltrimethylammonium bromide,CC1=CC(=CC=C1)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-],,,,,,
10217,44912,Trimethyl-[3-(3-methylbenzoyl)oxyphenyl]azanium,CC1=CC(=CC=C1)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C,,,,,,
10218,44913,"2-Methyl-1,5-benzothiazepin-4(5H)-one",CC1=CC(=O)NC2=CC=CC=C2S1,,,,,,
10219,44914,CID 44914,CNC1CCC1CSC(=N)S,,,,,,
10220,44915,2-(Methylamino)cyclobutaneacetamide,CNC1CCC1CC(=O)N,,,,,,
10221,44916,1-(1-Aminobutyl)adamantane hydrochloride,CCCC(C12CC3CC(C1)CC(C3)C2)N.Cl,,,,,,
10222,44917,1-(1-Adamantyl)butan-1-amine,CCCC(C12CC3CC(C1)CC(C3)C2)N,,,,,,
10223,44918,1-(1-Aminopentyl)adamantane hydrochloride,CCCCC(C12CC3CC(C1)CC(C3)C2)N.Cl,,,,,,
10224,44919,"alpha-Butyltricyclo[3.3.1.13,7]decane-1-methanamine",CCCCC(C12CC3CC(C1)CC(C3)C2)N,,,,,,
10225,44920,"N,N-Diethylaminoethyl 6,11-dihydro-11-oxodibenz(b,e)oxepin-3-acetate hydrochloride",CC[NH+](CC)CCOC(=O)CC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3CO2.[Cl-],,,,,,
10226,44921,2-(diethylamino)ethyl 2-(11-oxo-6H-benzo[c][1]benzoxepin-3-yl)acetate,CCN(CC)CCOC(=O)CC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3CO2,,,,,,
10227,44922,"2,2-Dimethyl-1,3-dioxolan-4-ylmethyl 6,11-dihydro-11-oxodibenz(b,e)oxepin-3-acetate",CC1(OCC(O1)COC(=O)CC2=CC3=C(C=C2)C(=O)C4=CC=CC=C4CO3)C,,,,,,
10228,44923,"2,3-Dihydroxypropyl 6,11-dihydro-11-oxodibenz(b,e)oxepin-3-acetate",C1C2=CC=CC=C2C(=O)C3=C(O1)C=C(C=C3)CC(=O)OCC(CO)O,,,,,,
10229,44924,"(5-Hydroxycarvacryl)trimethylammonium iodide, (2-chloroethyl)ethylcarbamate",CCN(CCCl)C(=O)OC1=CC(=CC(=C1C)[N+](C)(C)C)C(C)C.[I-],,,,,,
10230,44925,[3-[2-Chloroethyl(ethyl)carbamoyl]oxy-2-methyl-5-propan-2-ylphenyl]-trimethylazanium,CCN(CCCl)C(=O)OC1=CC(=CC(=C1C)[N+](C)(C)C)C(C)C,,,,,,
10231,44926,1-Benziloyl-2-(alpha-methyl)phenethylhydrazine,CC(CC1=CC=CC=C1)NNC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
10232,44927,"HYDRAZINE, 1-(p-METHOXYPHENETHYL)-2-METHYL-, HYDROCHLORIDE",CN[NH2+]CCC1=CC=C(C=C1)OC.[Cl-],,,,,,
10233,44928,"Hydrazine,2-(p-methoxyphenethyl)-1-methyl-",CNNCCC1=CC=C(C=C1)OC,,,,,,
10234,44929,2-Methylcyclopropane-1-carbohydrazide,CC1CC1C(=O)NN,,,,,,
10235,44930,"Hydrazine, N-(3-(octylamino)propyl)-",CCCCCCCCNCCCNN,,,,,,
10236,44931,CID 44931,CC(C)NNCS(=O)(=O)[O-].[Na+],,,,,,
10237,44932,(2-Propan-2-ylhydrazinyl)methanesulfonic acid,CC(C)NNCS(=O)(=O)O,,,,,,
10238,44933,(o-Hydroxybenzyl)trimethylammonium iodide methylcarbamate,CNC(=O)OC1=CC=CC=C1C[N+](C)(C)C.[I-],,,,,,
10239,44934,Trimethyl-[[2-(methylcarbamoyloxy)phenyl]methyl]azanium,CNC(=O)OC1=CC=CC=C1C[N+](C)(C)C,,,,,,
10240,44935,Glycidyl dimethyldithiocarbamate,CN(C)C(=S)SCC1CO1,,,,,,
10241,44936,"3,5-Dimethyl-1-ethynylcyclohexyl carbamate",CC1CC(CC(C1)(C#C)OC(=O)N)C,,,,,,
10242,44937,"Carbamic acid, dimethyl-, 2-ethyl-2-(hydroxymethyl)butyl ester",CCC(CC)(CO)COC(=O)N(C)C,,,,,,
10243,44938,"Benzene, 1,2-bis(dimethylcarbamyloxy)-",CN(C)C(=O)OC1=CC=CC=C1OC(=O)N(C)C,,,,,,
10244,44939,"1,4-Bis(dimethylcarbamoyloxy)benzene",CN(C)C(=O)OC1=CC=C(C=C1)OC(=O)N(C)C,,,,,,
10245,44940,"Carbamic acid, diethyl-, 4-nitroso-3,5-xylyl ester",CCN(CC)C(=O)OC1=CC(=C(C(=C1)C)N=O)C,,,,,,
10246,44941,"Carbamic acid, (2,2-diethylpropanedioyl)DI-, diethyl ester",CCC(CC)(C(=O)NC(=O)OCC)C(=O)NC(=O)OCC,,,,,,
10247,44942,"Carbamic acid, (2,2-diethyl-1,3-propylene)DI-, diethyl ester",CCC(CC)(CNC(=O)OCC)CNC(=O)OCC,,,,,,
10248,44943,CID 44943,CN(C)N=C(S)SCC1=CC=C(C=C1)Cl,,,,,,
10249,44944,"Benzene, 1,2-bis(dimethylcarbamyloxy)-4-amino-",CN(C)C(=O)OC1=C(C=C(C=C1)N)OC(=O)N(C)C,,,,,,
10250,44945,Ammonium dimethylcarbamate,CN(C)C(=O)[O-].[NH4+],,,,,,
10251,44946,Dimethylcarbamic acid,CN(C)C(=O)O,,,,,,
10252,44947,"Benzene, 1,2,3-tris(dimethylcarbamyloxy)-",CN(C)C(=O)OC1=C(C(=CC=C1)OC(=O)N(C)C)OC(=O)N(C)C,,,,,,
10253,44948,"Carbamic acid, dimethyl-, (alpha-(diethylamino))-o-tolyl ester, hydrochloride",CC[NH+](CC)CC1=CC=CC=C1OC(=O)N(C)C.[Cl-],,,,,,
10254,44949,"[2-(diethylaminomethyl)phenyl] N,N-dimethylcarbamate",CCN(CC)CC1=CC=CC=C1OC(=O)N(C)C,,,,,,
10255,44950,"Carbamic acid, dimethyl-, (2-(dimethylamino)-4-ethylphenyl) ester, hydrochloride",CCC1=CC(=C(C=C1)OC(=O)N(C)C)[NH+](C)C.[Cl-],,,,,,
10256,44951,"[2-(dimethylamino)-4-ethylphenyl] N,N-dimethylcarbamate",CCC1=CC(=C(C=C1)OC(=O)N(C)C)N(C)C,,,,,,
10257,44952,"Carbamic acid, N,N-dimethyl-, 4-dimethylamino-3-ethylphenyl ester, hydrochloride",CCC1=C(C=CC(=C1)OC(=O)N(C)C)[NH+](C)C.[Cl-],,,,,,
10258,44953,"[4-(dimethylamino)-3-ethylphenyl] N,N-dimethylcarbamate",CCC1=C(C=CC(=C1)OC(=O)N(C)C)N(C)C,,,,,,
10259,44954,"Phenethylamine, N,N-dimethyl-p-(N',N'-dimethylcarbamoyloxy)-, hydrochloride",C[NH+](C)CCC1=CC=C(C=C1)OC(=O)N(C)C.[Cl-],,,,,,
10260,44955,"[4-[2-(dimethylamino)ethyl]phenyl] N,N-dimethylcarbamate",CN(C)CCC1=CC=C(C=C1)OC(=O)N(C)C,,,,,,
10261,44956,"Carbamic acid, N,N-dimethyl-, 3-(dimethylamino)phenyl ester, tartrate",CN(C)C1=CC(=CC=C1)OC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
10262,44957,3-(Dimethylamino)phenyl dimethylcarbamate,CN(C)C1=CC(=CC=C1)OC(=O)N(C)C,,,,,,
10263,44958,"Carbamic acid, dimethyl-, 6-(dimethylamino)thymyl ester, hydrochloride",CC1=C(C(=C(C=C1)C(C)C)OC(=O)N(C)C)[NH+](C)C.[Cl-],,,,,,
10264,44959,"[2-(dimethylamino)-3-methyl-6-propan-2-ylphenyl] N,N-dimethylcarbamate",CC1=C(C(=C(C=C1)C(C)C)OC(=O)N(C)C)N(C)C,,,,,,
10265,44960,"CARBAMIC ACID, DIMETHYL-, 4-(DIMETHYLAMINO)-m-TOLYL ESTER, HYDROCHLORIDE",CC1=C(C=CC(=C1)OC(=O)N(C)C)[NH+](C)C.[Cl-],,,,,,
10266,44961,"[4-(dimethylamino)-3-methylphenyl] N,N-dimethylcarbamate",CC1=C(C=CC(=C1)OC(=O)N(C)C)N(C)C,,,,,,
10267,44962,"CARBAMIC ACID, DIMETHYL-, 2-(DIMETHYLAMINO)-p-TOLYL ESTER, HYDROCHLORIDE",CC1=CC(=C(C=C1)OC(=O)N(C)C)[NH+](C)C.[Cl-],,,,,,
10268,44963,"[2-(dimethylamino)-4-methylphenyl] N,N-dimethylcarbamate",CC1=CC(=C(C=C1)OC(=O)N(C)C)N(C)C,,,,,,
10269,44964,CID 44964,CCC(C)(C)C(C)CC=NN=C(N)S,,,,,,
10270,44965,4'-Aminooctanophenone,CCCCCCCC(=O)C1=CC=C(C=C1)N,,,,,,
10271,44966,"CARBAMIC ACID, N-(p-ACETAMIDOBENZYLSULFONYL)ETHYL-, ETHYL ESTER",CCOC(=O)NCCS(=O)(=O)CC1=CC=C(C=C1)NC(=O)C,,,,,,
10272,44967,"CARBAMIC ACID, ALLYL-, m-(DIMETHYLAMINO)PHENYL ESTER, HYDROCHLORIDE",C[NH+](C)C1=CC(=CC=C1)OC(=O)NCC=C.[Cl-],,,,,,
10273,44968,[3-(dimethylamino)phenyl] N-prop-2-enylcarbamate,CN(C)C1=CC(=CC=C1)OC(=O)NCC=C,,,,,,
10274,44969,"Aniline, 3-(N'-benzylcarbamoyloxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)C1=CC(=CC=C1)OC(=O)NCC2=CC=CC=C2.[Cl-],,,,,,
10275,44970,[3-(dimethylamino)phenyl] N-benzylcarbamate,CN(C)C1=CC(=CC=C1)OC(=O)NCC2=CC=CC=C2,,,,,,
10276,44971,"Carbamic acid, bis(2-chloroethyl)-, 4-nitroso-3,5-xylyl ester",CC1=CC(=CC(=C1N=O)C)OC(=O)N(CCCl)CCCl,,,,,,
10277,44972,"CARBAMIC ACID, 4-tert-BUTYL-1-ETHYNYLCYCLOHEXYL ESTER",CC(C)(C)C1CCC(CC1)(C#C)OC(=O)N,,,,,,
10278,44973,CID 44973,CCCCCOC(=NS(=O)(=O)CCCC)[O-].[Na+],,,,,,
10279,44974,N-(Butylsulfonyl)carbamic acid pentyl ester,CCCCCOC(=O)NS(=O)(=O)CCCC,,,,,,
10280,44975,CID 44975,C1=CC=C(C=C1)CSC(=NCCCC(=O)O)S,,,,,,
10281,44976,"Carbamic acid, N-(2-chloroethyl)-N-ethyl-, 4-nitroso-3,5-xylyl ester",CCN(CCCl)C(=O)OC1=CC(=C(C(=C1)C)N=O)C,,,,,,
10282,44977,"Carbamic acid, (2-chloroethyl)nitroso-, 2-fluoroethyl ester",C(CCl)N(C(=O)OCCF)N=O,,,,,,
10283,44978,"Acetohydroxamic acid, 2-(4-butoxy-3-ethylphenyl)-",CCCCOC1=C(C=C(C=C1)CC(=O)NO)CC,,,,,,
10284,44979,(p-tert-Pentyl)phenylacetohydroxamic acid,CC(C)(C)CC1=CC=C(C=C1)CC(=O)NO,,,,,,
10285,44980,"ACETOHYDROXAMIC ACID, (p-PENTYLTHIO)PHENYL-",CCCCCSC1=CC=C(C=C1)CC(=O)NO,,,,,,
10286,44981,1-Butoxy-1-(cyanomethoxy)ethane,CCCCOC(C)OCC#N,,,,,,
10287,44982,Diethylaminoacetonitrile hydrochloride,CC[NH+](CC)CC#N.[Cl-],,,,,,
10288,44983,Diethylaminoacetonitrile,CCN(CC)CC#N,,,,,,
10289,44984,2-(1-Ethoxyethoxy)pent-4-enenitrile,CCOC(C)OC(CC=C)C#N,,,,,,
10290,44985,CID 44985,C1=CC=[N+](C=C1)N(C(=N)[NH3+])[N+]2=CC=CC=C2.[Cl-].[Cl-].[Cl-],,,,,,
10291,44986,"1,1-Di(pyridin-1-ium-1-yl)guanidine",C1=CC=[N+](C=C1)N(C(=N)N)[N+]2=CC=CC=C2,,,,,,
10292,44987,"Guanidine, 1,3-bis(2-pyridyl)-2-(2-dimethylaminoethyl)-, trichloride",C[NH+](C)CC[NH+]=C(NC1=CC=CC=[NH+]1)NC2=CC=CC=N2.[Cl-].[Cl-].[Cl-],,,,,,
10293,44988,"2-[2-(Dimethylamino)ethyl]-1,3-dipyridin-2-ylguanidine",CN(C)CCN=C(NC1=CC=CC=N1)NC2=CC=CC=N2,,,,,,
10294,44989,"Guanidine, 1,3-bis(3-pyridyl)-2-(2-hydroxyethyl)-",C1=CC(=CN=C1)NC(=NCCO)NC2=CN=CC=C2,,,,,,
10295,44990,CID 44990,C(CCCCCCCCN=C([NH3+])N)CCCCCCCN=C([NH3+])N.[Cl-].[Cl-],,,,,,
10296,44991,"N,N'''-(1,16-Hexadecanediyl)bis(guanidine)",C(CCCCCCCCN=C(N)N)CCCCCCCN=C(N)N,,,,,,
10297,44992,CID 44992,C(CO)N=C([NH3+])N.[Cl-],,,,,,
10298,44993,1-(2-Hydroxyethyl)guanidine,C(CO)N=C(N)N,,,,,,
10299,44994,"1,5-Diguanidinonaphthalene",C1=CC2=C(C=CC=C2N=C(N)N)C(=C1)N=C(N)N,,,,,,
10300,44995,CID 44995,CCCCCCCCCN=C([NH3+])N.[I-],,,,,,
10301,44996,Nonylguanidine,CCCCCCCCCN=C(N)N,,,,,,
10302,44997,CID 44997,C(CCCCCCCCCN=C([NH3+])N)CCCCCCCCN=C([NH3+])N.[Cl-].[Cl-],,,,,,
10303,44998,"N,N'''-(1,18-Octadecanediyl)bis(guanidine)",C(CCCCCCCCCN=C(N)N)CCCCCCCCN=C(N)N,,,,,,
10304,44999,CID 44999,C(CCCCCCCN=C([NH3+])N)CCCCCCN=C([NH3+])N.[Cl-].[Cl-],,,,,,
10305,45000,"N,N'''-(1,14-Tetradecanediyl)bis(guanidine)",C(CCCCCCCN=C(N)N)CCCCCCN=C(N)N,,,,,,
10306,45001,"GUANIDINE, 1,1,3-TRIS(p-NITROPHENYL)-",C1=CC(=CC=C1N=C(N)N(C2=CC=C(C=C2)[N+](=O)[O-])C3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
10307,45002,CID 45002,C1=CC=C(C=C1)C(=O)N=C(NC2=CC(=CC=C2)NC(=NC(=O)C3=CC=CC=C3)S)S,,,,,,
10308,45003,"Benzamide, N-cyclopropyl-3,5-dichloro-4-nitro-",C1CC1NC(=O)C2=CC(=C(C(=C2)Cl)[N+](=O)[O-])Cl,,,,,,
10309,45004,o-(beta-Diethylamino)ethoxybenzamide hydrochloride,CC[NH+](CC)CCOC1=CC=CC=C1C(=O)N.[Cl-],,,,,,
10310,45005,2-[2-(Diethylamino)ethoxy]benzamide,CCN(CC)CCOC1=CC=CC=C1C(=O)N,,,,,,
10311,45006,"BENZAMIDE, N,N-DIETHYL-o-(beta-HYDROXYETHOXY)-",CCN(CC)C(=O)C1=CC=CC=C1OCCO,,,,,,
10312,45007,"Benzamide, N,N-diisopropyl-3,4,5-trimethoxy-",CC(C)N(C(C)C)C(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
10313,45008,1-(Benzamidomethyl)cyclohexyldimethylamine,CN(C)C(C1CCCCC1)NC(=O)C2=CC=CC=C2,,,,,,
10314,45009,"BENZAMIDE, N,N-DIMETHYL-o-(beta-HYDROXYETHOXY)-",CN(C)C(=O)C1=CC=CC=C1OCCO,,,,,,
10315,45010,"Benzamide, N,N-bis(2-hydroxyethyl)-3,4,5-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)N(CCO)CCO,,,,,,
10316,45011,"Benzamide, N,N-bis(2-methoxyethyl)-3,4,5-trimethoxy-",COCCN(CCOC)C(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
10317,45012,"BENZAMIDE, 5-BROMO-2-(beta-DIPROPYLAMINOETHOXY)-3-PHENYL-",CCCN(CCC)CCOC1=C(C=C(C=C1C(=O)N)Br)C2=CC=CC=C2,,,,,,
10318,45013,"BENZAMIDE, 5-BROMO-2-(beta-HYDROXYETHOXY)-",C1=CC(=C(C=C1Br)C(=O)N)OCCO,,,,,,
10319,45014,"BENZAMIDE, 5-BROMO-2-(beta-HYDROXYETHOXY)-N-(beta-HYDROXYETHYL)-3-PHENYL-",C1=CC=C(C=C1)C2=C(C(=CC(=C2)Br)C(=O)NCCO)OCCO,,,,,,
10320,45015,5-Bromo-2-(beta-hydroxyethoxy)-N-methylbenzamide,CNC(=O)C1=C(C=CC(=C1)Br)OCCO,,,,,,
10321,45016,"BENZAMIDE, 5-BROMO-2-(beta-HYDROXYPROPOXY)-",C1=CC(=C(C=C1Br)C(=O)N)OCCCO,,,,,,
10322,45017,5-Bromo-2-methoxy-N-methyl-3-phenylbenzamide,CNC(=O)C1=CC(=CC(=C1OC)C2=CC=CC=C2)Br,,,,,,
10323,45018,CID 45018,CCCCOC1=C(C=CC=C1OC)C(=O)NCCO[NH+]=C(C)CC.C(=O)(C(=O)[O-])O,,,,,,
10324,45019,CID 45019,CCCCOC1=C(C=CC=C1OC)C(=O)NCCON=C(C)CC,,,,,,
10325,45020,N-(2-Pentylideneaminoethyl)-2-butoxy-3-methoxybenzamide oxalate,CCCCOC1=C(C=CC=C1OC)C(=O)NCC[NH+]=C(C)CCC.C(=O)(C(=O)[O-])O,,,,,,
10326,45021,2-butoxy-3-methoxy-N-[2-(pentan-2-ylideneamino)ethyl]benzamide,CCCCOC1=C(C=CC=C1OC)C(=O)NCCN=C(C)CCC,,,,,,
10327,45022,CID 45022,CCC(=[NH+]OCCNC(=O)C1=C(C(=CC=C1)OC)OCC)C.C(=O)(C(=O)[O-])O,,,,,,
10328,45023,CID 45023,CCC(=NOCCNC(=O)C1=C(C(=CC=C1)OC)OCC)C,,,,,,
10329,45024,CID 45024,CCCOC1=C(C=CC=C1OC)C(=O)NCCO[NH+]=C(C)CC.C(=O)(C(=O)[O-])O,,,,,,
10330,45025,CID 45025,CCCOC1=C(C=CC=C1OC)C(=O)NCCON=C(C)CC,,,,,,
10331,45026,"N-Cyclohexyl-o-(2,3-dihydroxy)propoxybenzamide",C1CCC(CC1)NC(=O)C2=CC=CC=C2OCC(CO)O,,,,,,
10332,45027,"2,6-Dichloro-N-cyclopropylbenzamide",C1CC1NC(=O)C2=C(C=CC=C2Cl)Cl,,,,,,
10333,45028,"3,5-Dichloro-N-cyclopropylbenzamide",C1CC1NC(=O)C2=CC(=CC(=C2)Cl)Cl,,,,,,
10334,45029,"BENZAMIDE, o-ALLYLOXY-N-(beta-HYDROXYETHYL)-",C=CCOC1=CC=CC=C1C(=O)NCCO,,,,,,
10335,45030,"Benzamide, 2-allyloxy-3-phenyl-",C=CCOC1=C(C=CC=C1C(=O)N)C2=CC=CC=C2,,,,,,
10336,45031,CID 45031,C1=CC=C2C(=C1)[NH2+]C(=N2)NC(=O)C3=CC=C(C=C3)[NH3+].[Cl-].[Cl-],,,,,,
10337,45032,4-amino-N-(1H-benzimidazol-2-yl)benzamide,C1=CC=C2C(=C1)NC(=N2)NC(=O)C3=CC=C(C=C3)N,,,,,,
10338,45033,2-Amino-4-chloro-N-cyclopropylbenzamide,C1CC1NC(=O)C2=C(C=C(C=C2)Cl)N,,,,,,
10339,45034,3-Amino-4-chloro-N-cyclopropylbenzamide,C1CC1NC(=O)C2=CC(=C(C=C2)Cl)N,,,,,,
10340,45035,"Benzamide, 4-amino-N-cyclobutyl-3,5-dichloro-",C1CC(C1)NC(=O)C2=CC(=C(C(=C2)Cl)N)Cl,,,,,,
10341,45036,"Benzamide, 4-amino-N-cyclopropyl-3,5-dibromo-",C1CC1NC(=O)C2=CC(=C(C(=C2)Br)N)Br,,,,,,
10342,45037,"2-Amino-3,5-dichloro-N-cyclopropylbenzamide",C1CC1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)N,,,,,,
10343,45038,"3-Amino-2,5-dichloro-N-cyclopropylbenzamide",C1CC1NC(=O)C2=C(C(=CC(=C2)Cl)N)Cl,,,,,,
10344,45039,"4-Amino-3,5-dichlorobenzamide",C1=C(C=C(C(=C1Cl)N)Cl)C(=O)N,,,,,,
10345,45040,"BENZAMIDE, 4-AMINO-3,5-DICHLORO-N-(tert-BUTYL)-",CC(C)(C)NC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10346,45041,"Benzamide, 4-amino-3,5-dichloro-N-ethyl-",CCNC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10347,45042,"Benzamide, 4-amino-3,5-dichloro-N-isopropyl-",CC(C)NC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10348,45043,"4-amino-3,5-dichloro-N-methylbenzamide",CNC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10349,45044,"Benzamide, 4-amino-3,5-dichloro-N-(2-propenyl)-",C=CCNC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10350,45045,"N-Propyl-4-amino-3,5-dichlorobenzamide",CCCNC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10351,45046,"N-(2-Propynyl)-4-amino-3,5-dichlorobenzamide",C#CCNC(=O)C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
10352,45047,p-Amino-N-(2-diethylaminoethyl)benzamide sulfate,CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)N.OS(=O)(=O)[O-],,,,,,
10353,45048,(+-)-alpha-(1-(Propylamino)ethyl)benzaldehyde hydrochloride,CCC[NH2+]C(C)C(=O)C1=CC=CC=C1.[Cl-],,,,,,
10354,45049,1-Phenyl-2-(propylamino)propan-1-one,CCCNC(C)C(=O)C1=CC=CC=C1,,,,,,
10355,45050,2-Acetoxy-3-phenylbenzamide,CC(=O)OC1=C(C=CC=C1C(=O)N)C2=CC=CC=C2,,,,,,
10356,45051,"BENZAMIDE, o-ALLYLOXY-N-CYCLOHEXYL-",C=CCOC1=CC=CC=C1C(=O)NC2CCCCC2,,,,,,
10357,45052,"BENZAMIDE, o-ALLYLOXY-N,N-DIETHYL-",CCN(CC)C(=O)C1=CC=CC=C1OCC=C,,,,,,
10358,45053,"BENZAMIDE, o-ALLYLOXY-N,N-DIMETHYL-",CN(C)C(=O)C1=CC=CC=C1OCC=C,,,,,,
10359,45054,"BENZAMIDE, o-ALLYLOXY-N-ETHYL-",CCNC(=O)C1=CC=CC=C1OCC=C,,,,,,
10360,45055,1-(2-Aminophenyl)-2-nitroethanone,C1=CC=C(C(=C1)C(=O)C[N+](=O)[O-])N,,,,,,
10361,45056,(+)-Isomenthol,C[C@@H]1CC[C@@H]([C@H](C1)O)C(C)C,,,,,,
10362,45057,"Acetohydroxamic acid, N-fluoren-2-YL-, iron(3+) complex",CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)[O-].CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)[O-].CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)[O-].[Fe+3],,,,,,
10363,45058,"Acetic acid, (dimethylphenoxy)-, 2-(2-butoxyethoxy)ethyl ester",CCCCOCCOCCOC(=O)C(C)(C)OC1=CC=CC=C1,,,,,,
10364,45059,Xylyloxyacetate 2-(xylyloxy)ethyl ester,CC1=CC(=CC(=C1)OCCOC(=O)COC2=CC(=CC(=C2)C)C)C,,,,,,
10365,45060,N-(1-Methylethyl)benzothiazolesulfonamide,CC(C)NS(=O)(=O)C1=NC2=CC=CC=C2S1,,,,,,
10366,45061,CID 45061,C(CC(=O)O)CN=C(C(=NCCCC(=O)O)S)S,,,,,,
10367,45062,Ethyl gamma-fluorobutyrate,CCOC(=O)CCCF,,,,,,
10368,45063,"Butyric acid, 4-fluoro-, isopropyl ester",CC(C)OC(=O)CCCF,,,,,,
10369,45064,Methyl 4-fluoro-2-hydroxybutanoate,COC(=O)C(CCF)O,,,,,,
10370,45065,2-Chloroethyl gamma-fluoro-beta-hydroxybutyrate,C(CF)C(C(=O)OCCCl)O,,,,,,
10371,45066,CID 45066,CN(C)CCN=C(C(=NCCN(C)C)S)S,,,,,,
10372,45067,CID 45067,C1=CC=NC(=C1)CN=C(C(=NCC2=CC=CC=N2)S)S,,,,,,
10373,45068,"2'-(2,3-Dihydroxypropoxy)acetanilide",CC(=O)NC1=CC=CC=C1OCC(CO)O,,,,,,
10374,45069,CID 45069,CC(=CCN1C=NC(=C2C1=NC=N2)[NH3+])C.[Cl-],,,,,,
10375,45070,CID 45070,CC(=CCN1C=NC(=C2C1=NC=N2)N)C,,,,,,
10376,45071,Bis(cyclohex-3-enylmethyl) adipate,C1CC(CC=C1)COC(=O)CCCCC(=O)OCC2CCC=CC2,,,,,,
10377,45072,"alpha,beta-Dibromoadipic acid",C(CC(=O)O)C(C(C(=O)O)Br)Br,,,,,,
10378,45073,S-2-Aminoethyl cysteine dihydrochloride,C(CSCC(C(=O)O)[NH3+])[NH3+].[Cl-].[Cl-],,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
10379,45074,"DL-N-(2,4-Dichloro-phenoxyacetyl)-3-phenylalanine",C1=CC=C(C=C1)CC(C(=O)O)NC(=O)COC2=C(C=C(C=C2)Cl)Cl,,,,,,
10380,45075,"Allylamine, 2-(allyloxy)-N,N-dimethyl-",CN(C)CC(=C)OCC=C,,,,,,
10381,45076,CID 45076,CN(C)CC=COCC=C,,,,,,
10382,45077,"Allylamine, N,N-bis(2-chloroethyl)-",C=CCN(CCCl)CCCl,,,,,,
10383,45078,2-Chloroallyl-bis(2-chloroethyl)amine hydrochloride,C=C(C[NH+](CCCl)CCCl)Cl.[Cl-],,,,,,
10384,45079,"2-Propen-1-amine, 2-chloro-N,N-bis(2-chloroethyl)-",C=C(CN(CCCl)CCCl)Cl,,,,,,
10385,45080,Allyl-bis(beta-chloroethyl)amine hydrochloride,C=CC[NH+](CCCl)CCCl.[Cl-],,,,,,
10386,45081,CID 45081,CCCCCCCCCCCCSC=CCN(C)C,,,,,,
10387,45082,CID 45082,CN(C)CC=CSC1=CC=CC=C1,,,,,,
10388,45083,CID 45083,CC1=CC=C(C=C1)SC=CCN(C)C,,,,,,
10389,45084,"Isoindolinium, 2-(4'-(diethylmethylammonio)butyl)-2-methyl-4,5,6,7-tetrachloro-, diiodide",CC[N+](C)(CC)CCCC[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)C.[I-].[I-],,,,,,
10390,45085,"Diethyl-methyl-[4-(4,5,6,7-tetrachloro-2-methyl-1,3-dihydroisoindol-2-ium-2-yl)butyl]azanium",CC[N+](C)(CC)CCCC[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)C,,,,,,
10391,45086,"Ammonium, (5-(2-methyl-4,5,6,7-tetrachloroisoindolinio)pentyl)diethylmethyl-, diiodide",CC[N+](C)(CC)CCCCC[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)C.[I-].[I-],,,,,,
10392,45087,"Diethyl-methyl-[5-(4,5,6,7-tetrachloro-2-methyl-1,3-dihydroisoindol-2-ium-2-yl)pentyl]azanium",CC[N+](C)(CC)CCCCC[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)C,,,,,,
10393,45088,CID 45088,C1=CN=CC=C1C(=NCN=C(C2=CC=NC=C2)S)S.O,,,,,,
10394,45089,CID 45089,C1=CN=CC=C1C(=NCN=C(C2=CC=NC=C2)S)S,,,,,,
10395,45090,"2,6-Dimethylisonicotinoyl azide",CC1=CC(=CC(=N1)C)C(=O)N=[N+]=[N-],,,,,,
10396,45091,CID 45091,CC1=CC(=CC(=N1)C)C(=O)N[N+]#N,,,,,,
10397,45092,4-Ethoxycarbonyl-1-(2-hydroxy-3-phenoxypropyl) 4-phenylpiperidine hydrochloride,CCOC(=O)C1(CC[NH+](CC1)CC(COC2=CC=CC=C2)O)C3=CC=CC=C3.[Cl-],,,,,,
10398,45093,Ethyl 1-(2-hydroxy-3-phenoxypropyl)-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CC(COC2=CC=CC=C2)O)C3=CC=CC=C3,,,,,,
10399,45094,4-Ethoxycarbonyl-1-(2-hydroxy-3-phenoxypropyl) 4-phenylpiperidine hypophosphite,CCOC(=O)C1(CC[NH+](CC1)CC(COC2=CC=CC=C2)O)C3=CC=CC=C3.[O-]P=O,,,,,,
10400,45095,"Isoleucine, N-(2,4-dichlorophenoxyacetyl)-, DL-",CCC(C)C(C(=O)O)NC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
10401,45096,"Isopropylamine, 2-furyl-, sulfate",CC(C)(C1=CC=CO1)[NH3+].OS(=O)(=O)[O-],,,,,,
10402,45097,2-(Furan-2-yl)propan-2-amine,CC(C)(C1=CC=CO1)N,,,,,,
10403,45098,"Isopropylamine, 2-thienyl-, sulfate",CC(C)(C1=CC=CS1)[NH3+].OS(=O)(=O)[O-],,,,,,
10404,45099,2-(Thiophen-2-yl)propan-2-amine,CC(C)(C1=CC=CS1)N,,,,,,
10405,45100,"1-Isopropyl-2-(2-furyl)-4,4-dimethylimidazolidine",CC(C)N1CC(NC1C2=CC=CO2)(C)C,,,,,,
10406,45101,"3-Biphenylol, 4-isopropyl-",CC(C)C1=C(C=C(C=C1)C2=CC=CC=C2)O,,,,,,
10407,45102,CID 45102,COC1=C(C=C(C=C1)CC2=NC(=CC3=CC(=C(C=C32)OC)OC)C(=O)[O-])OC.[Na+],,,,,,
10408,45103,"1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline-3-carboxylic acid",COC1=C(C=C(C=C1)CC2=NC(=CC3=CC(=C(C=C32)OC)OC)C(=O)O)OC,,,,,,
10409,45104,"Isoquinoline, 6,7-diethoxy-1,2,3,4-tetrahydro-, hydrochloride",CCOC1=C(C=C2C[NH2+]CCC2=C1)OCC.[Cl-],,,,,,
10410,45105,"6,7-Diethoxy-1,2,3,4-tetrahydroisoquinoline",CCOC1=C(C=C2CNCCC2=C1)OCC,,,,,,
10411,45106,"5,6-Dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C1C[NH2+]CC2=CC(=C(C=C21)O)O.[Cl-],,,,,,
10412,45107,"Isoquinoline, 5,6-dimethoxy-1,2,3,4-tetrahydro-, hydrochloride",COC1=C(C2=C(C[NH2+]CC2)C=C1)OC.[Cl-],,,,,,
10413,45108,"5,6-Dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C2=C(CNCC2)C=C1)OC,,,,,,
10414,45109,"6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-2-methyl-, diacetate (ester), hydrogen oxalate",CC(=O)OC1=C(C=C2C([NH+](CCC2=C1)C)CCC3=CC=C(C=C3)Cl)OC(=O)C.C(=O)(C(=O)[O-])O,,,,,,
10415,45110,"[7-acetyloxy-1-[2-(4-chlorophenyl)ethyl]-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl] acetate",CC(=O)OC1=C(C=C2C(N(CCC2=C1)C)CCC3=CC=C(C=C3)Cl)OC(=O)C,,,,,,
10416,45111,"6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-2-methyl-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)O)O.[Cl-],,,,,,
10417,45112,"1-[2-(4-chlorophenyl)ethyl]-2-methyl-3,4-dihydro-1H-isoquinoline-6,7-diol",CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)O)O,,,,,,
10418,45113,"5-Ethoxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=C(C=CC2=C1CC[NH2+]C2)OC.[Cl-],,,,,,
10419,45114,"5-Ethoxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline",CCOC1=C(C=CC2=C1CCNC2)OC,,,,,,
10420,45115,"Isoquinoline, 6-ethoxy-1,2,3,4-tetrahydro-, hydrochloride",CCOC1=CC2=C(C[NH2+]CC2)C=C1.[Cl-],,,,,,
10421,45116,"6-Ethoxy-1,2,3,4-tetrahydroisoquinoline",CCOC1=CC2=C(CNCC2)C=C1,,,,,,
10422,45117,"Isoquinoline, 6-hydroxy-1,2,3,4-tetrahydro-, hydrochloride",C1C[NH2+]CC2=C1C=C(C=C2)O.[Cl-],,,,,,
10423,45118,"6-Methoxy-7-ethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=C(C=C2CC[NH2+]CC2=C1)OC.[Cl-],,,,,,
10424,45119,"7-Ethoxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline",CCOC1=C(C=C2CCNCC2=C1)OC,,,,,,
10425,45120,"ACETIC ACID, DI-n-HEPTYL-, ETHYL ESTER",CCCCCCCC(CCCCCCC)C(=O)OCC,,,,,,
10426,45121,"1-Acetoxy-3-dimethylamino-1,1-diphenyl-2-methylpropane hydrochloride",CC(C[NH+](C)C)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC(=O)C.[Cl-],,,,,,
10427,45122,"[3-(Dimethylamino)-2-methyl-1,1-diphenylpropyl] acetate",CC(CN(C)C)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC(=O)C,,,,,,
10428,45123,"1-Naphthaleneacetic acid, alpha-(1-naphthyl)-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C(C1=CC=CC2=CC=CC=C21)C3=CC=CC4=CC=CC=C43.[Cl-],,,,,,
10429,45124,"2-(Diethylamino)ethyl 2,2-dinaphthalen-1-ylacetate",CCN(CC)CCOC(=O)C(C1=CC=CC2=CC=CC=C21)C3=CC=CC4=CC=CC=C43,,,,,,
10430,45125,"2-Naphthaleneacetic acid, alpha-(2-naphthyl)-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C(C1=CC2=CC=CC=C2C=C1)C3=CC4=CC=CC=C4C=C3.[Cl-],,,,,,
10431,45126,"2-(Diethylamino)ethyl 2,2-dinaphthalen-2-ylacetate",CCN(CC)CCOC(=O)C(C1=CC2=CC=CC=C2C=C1)C3=CC4=CC=CC=C4C=C3,,,,,,
10432,45127,"((2,5-Dioxo-3-cyclohexen-1-yl)thio)acetic acid",C1C(C(=O)C=CC1=O)SCC(=O)O,,,,,,
10433,45128,"Diphenylacetic acid, 4-n-butylpiperidyl ester hydrochloride",CCCC[NH+]1CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
10434,45129,"(1-Butylpiperidin-4-yl) 2,2-diphenylacetate",CCCCN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10435,45130,3-(2'-Methylpiperidino)propyl diphenylacetate,CC1CCCCN1CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10436,45131,"Diphenylacetic acid 1,2,6-trimethyl-4-piperidyl ester hydrochloride",CC1CC(CC([NH+]1C)C)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
10437,45132,"(1,2,6-Trimethylpiperidin-4-yl) 2,2-diphenylacetate",CC1CC(CC(N1C)C)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10438,45133,Aluminum fluoroacetate,C(C(=O)[O-])F.C(C(=O)[O-])F.C(C(=O)[O-])F.[Al+3],,,,,,
10439,45134,"Acetic acid, fluoro-, calcium salt",C(C(=O)[O-])F.C(C(=O)[O-])F.[Ca+2],,,,,,
10440,45135,2-Ethylamyl fluoroacetate,CCCC(CC)COC(=O)CF,,,,,,
10441,45136,Magnesium fluoroacetate,C(C(=O)[O-])F.C(C(=O)[O-])F.[Mg+2],,,,,,
10442,45137,Mercury (II) fluoroacetate,C(C(=O)[O-])F.C(C(=O)[O-])F.[Hg+2],,,,,,
10443,45138,"Acetic acid, fluoro-, thallium(I) salt",C(C(=O)[O-])F.[Tl+],,,,,,
10444,45139,CID 45139,COC1=CC=C(C=C1)C(=N)CC(=O)S,,,,,,
10445,45140,2-Dimethylaminoethyl (1H-indol-3-yl)acetate hydrochloride,C[NH+](C)CCOC(=O)CC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10446,45141,2-(dimethylamino)ethyl 2-(1H-indol-3-yl)acetate,CN(C)CCOC(=O)CC1=CNC2=CC=CC=C21,,,,,,
10447,45142,"Acetic acid, iodo-, 2-hydroxyethyl ester",C(COC(=O)CI)O,,,,,,
10448,45143,"Acetic acid, isonicotinamido guanylmercapto-",C1=CN=CC=C1C(=O)NC(C(=O)O)SC(=N)N,,,,,,
10449,45144,"Acetic acid, mercapto-, 2-chloroethyl ester",C(CCl)OC(=O)CS,,,,,,
10450,45145,Ethyl ((methyl(propylthio)phosphinothioyl)thio)acetate,CCCSP(=S)(C)SCC(=O)OCC,,,,,,
10451,45146,"ACETIC ACID, 2-MERCAPTO-, p-XYLYL ESTER",CC1=CC=C(C=C1)COC(=O)CS,,,,,,
10452,45147,CID 45147,CNC(=O)C1=C(C=CC=C1OCC(=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
10453,45148,2-[2-(Methylcarbamoyl)-3-phenylphenoxy]acetic acid,CNC(=O)C1=C(C=CC=C1OCC(=O)O)C2=CC=CC=C2,,,,,,
10454,45149,2-Dimethylaminoethyl 1-naphthyloxyacetate hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
10455,45150,2-(Dimethylamino)ethyl 2-naphthalen-1-yloxyacetate,CN(C)CCOC(=O)COC1=CC=CC2=CC=CC=C21,,,,,,
10456,45151,2-Dimethylaminoethyl 2-naphthyloxyacetate hydrochloride,C[NH+](C)CCOC(=O)COC1=CC2=CC=CC=C2C=C1.[Cl-],,,,,,
10457,45152,2-(Dimethylamino)ethyl 2-naphthalen-2-yloxyacetate,CN(C)CCOC(=O)COC1=CC2=CC=CC=C2C=C1,,,,,,
10458,45153,Phenoxyacetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=CC=C1.[Cl-],,,,,,
10459,45154,2-(Dimethylamino)ethyl phenoxyacetate,CN(C)CCOC(=O)COC1=CC=CC=C1,,,,,,
10460,45155,3-(2'-Methylpiperidino)propyl phenoxyacetate,CC1CCCCN1CCCOC(=O)COC2=CC=CC=C2,,,,,,
10461,45156,3-(2'-Methylpiperidino)propyl phenylacetate,CC1CCCCN1CCCOC(=O)CC2=CC=CC=C2,,,,,,
10462,45157,2-Phenyl-2-(o-xylylamino)acetic acid,CC1=CC=CC=C1CNC(C2=CC=CC=C2)C(=O)O,,,,,,
10463,45158,Butyl selenocyanoacetate,CCCCOC(=O)C[Se]C#N,,,,,,
10464,45159,CID 45159,C(C(=O)[O-])[Se]C#N.[K+],,,,,,
10465,45160,Selenocyanatoacetic acid,C(C(=O)O)[Se]C#N,,,,,,
10466,45161,Thiocyanatoacetate bicyclo(2.2.1)hept-5-en-2-ylmethyl ester,C1C2CC(C1C=C2)COC(=O)CSC#N,,,,,,
10467,45162,CID 45162,C(C(=O)[O-])SC#N.[Na+],,,,,,
10468,45163,Thiocyanatoacetic acid,C(C(=O)O)SC#N,,,,,,
10469,45164,S-(2-ethylphenyl) ethanethioate,CCC1=CC=CC=C1SC(=O)C,,,,,,
10470,45165,N-(2-Pentylideneaminoethyl)-2-ethoxy-3-methoxybenzamide oxalate,CCCCC=[NH+]CCNC(=O)C1=C(C(=CC=C1)OC)OCC.C(=O)(C(=O)[O-])O,,,,,,
10471,45166,2-ethoxy-3-methoxy-N-[2-(pentylideneamino)ethyl]benzamide,CCCCC=NCCNC(=O)C1=C(C(=CC=C1)OC)OCC,,,,,,
10472,45167,2-(2-Hydroxyethoxy)benzamide,C1=CC=C(C(=C1)C(=O)N)OCCO,,,,,,
10473,45168,"BENZAMIDE, 2-(beta-HYDROXYETHOXY)-N-METHYL-4-PHENYL-",CNC(=O)C1=C(C=C(C=C1)C2=CC=CC=C2)OCCO,,,,,,
10474,45169,"BENZAMIDE, 2-(beta-HYDROXYETHOXY)-N-METHYL-5-PHENYL-",CNC(=O)C1=C(C=CC(=C1)C2=CC=CC=C2)OCCO,,,,,,
10475,45170,"BENZAMIDE, 2-(beta-HYDROXYETHOXY)-3-PHENYL-",C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)N)OCCO,,,,,,
10476,45171,2-Methoxy-N-methyl-3-phenylbenzamide,CNC(=O)C1=CC=CC(=C1OC)C2=CC=CC=C2,,,,,,
10477,45172,N-(2-Pentylideneaminoethyl)-2-propoxy-3-methoxybenzamide oxalate,CCCCC=[NH+]CCNC(=O)C1=C(C(=CC=C1)OC)OCCC.C(=O)(C(=O)[O-])O,,,,,,
10478,45173,3-methoxy-N-[2-(pentylideneamino)ethyl]-2-propoxybenzamide,CCCCC=NCCNC(=O)C1=C(C(=CC=C1)OC)OCCC,,,,,,
10479,45174,2-Methoxy-3-phenylbenzamide,COC1=C(C=CC=C1C(=O)N)C2=CC=CC=C2,,,,,,
10480,45175,"Benzamide, N,N'-(1,2-phenylenebis(thio)bis-",C1=CC=C(C=C1)C(=O)NSC2=CC=CC=C2SNC(=O)C3=CC=CC=C3,,,,,,
10481,45176,Digammacaine,C1CC[NH+](CC1)CCC(C2=CC=CC=C2)NC(=O)C3=CC=CC=C3.[Cl-],,,,,,
10482,45177,N-[1-phenyl-3-piperidinopropyl]benzamide,C1CCN(CC1)CCC(C2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
10483,45178,"Octadecanediamine, dihydrochloride",C(CCCCCCCCC[NH3+])CCCCCCCC[NH3+].[Cl-].[Cl-],,,,,,
10484,45179,"1,18-Octadecanediamine",C(CCCCCCCCCN)CCCCCCCCN,,,,,,
10485,45180,CID 45180,C(CCCC(=N)[NH3+])CCCC(=N)[NH3+].[Cl-].[Cl-],,,,,,
10486,45181,Nonanediimidamide,C(CCCC(=N)N)CCCC(=N)N,,,,,,
10487,45182,"NONANOIC ACID, ESTER with ALLYL LACTATE",CCCCCCCCC(=O)OC(=O)C(C)OCC=C,,,,,,
10488,45183,2-Chloro-2-nitro-3-nonanol,CCCCCCC(C(C)([N+](=O)[O-])Cl)O,,,,,,
10489,45184,CID 45184,C1CC1C[NH+]2CCC3=C4C2CC5=C(C4=CC=C3)C(=C(C=C5)O)O.[Cl-],,,,,,
10490,45185,CID 45185,C1CC1CN2CCC3=C4C2CC5=C(C4=CC=C3)C(=C(C=C5)O)O,,,,,,
10491,45186,"2-Norbornanamine, N,2-dimethyl-",CC1(CC2CCC1C2)NC,,,,,,
10492,45187,"2-Norbornanamine, 2,3-dimethyl-",CC1C2CCC(C2)C1(C)N,,,,,,
10493,45188,"2-Norbornanamine, 2-ethyl-N-methyl-",CCC1(CC2CCC1C2)NC,,,,,,
10494,45189,CID 45189,C(CCCCCCCCC(=O)[O-])CCCCCCCCF.[Na+],,,,,,
10495,45190,"2,3-Epoxy-2-ethylhexyl 9,10-epoxyoctadecanoate",CCCCCCCCC1C(O1)CCCCCCCC(=O)OCC2(C(O2)CCC)CC,,,,,,
10496,45191,CID 45191,CC1(CN(C(=N1)S)C(C)(C)CO)C,,,,,,
10497,45192,"Imidazoline, heptadecyl-, hydrochloride",CCCCCCCCCCCCCCCCCC1=NCC[NH2+]1.[Cl-],,,,,,
10498,45193,CID 45193,C1=CC(=CC=C1CC(C[Hg])O)OCC(=O)[O-].O.[Na+],,,,,,
10499,45194,[3-[4-(Carboxymethoxy)phenyl]-2-hydroxypropyl]mercury,C1=CC(=CC=C1CC(C[Hg])O)OCC(=O)O,,,,,,
10500,45195,"Acetic acid, (o-((3-(hydroxymercuri)-2-(2-methoxyethoxy)propyl)carbamoyl)phenoxy)-, compd. with procaine",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)N.COCCOC(CNC(=O)C1=CC=CC=C1OCC(=O)[O-])C[Hg].O,,,,,,
10501,45196,[3-[[2-(Carboxymethoxy)benzoyl]amino]-2-(2-methoxyethoxy)propyl]mercury,COCCOC(CNC(=O)C1=CC=CC=C1OCC(=O)O)C[Hg],,,,,,
10502,45197,"Nitrogen oxide (NO), mixt. with nitrogen oxide (N2O4)",N=O.[N+](=O)([N+](=O)[O-])[O-],,,,,,
10503,45198,CID 45198,C[NH+](CCSC(=N)[NH3+])CCSC(=N)[NH3+].[Cl-].[Cl-].[Cl-],,,,,,
10504,45199,2-[2-Carbamimidoylsulfanylethyl(methyl)amino]ethyl carbamimidothioate,CN(CCSC(=N)N)CCSC(=N)N,,,,,,
10505,45200,Methylbis(beta-chloroethylthioethyl)amine hydrochloride,C[NH+](CCSCCCl)CCSCCCl.[Cl-],,,,,,
10506,45201,Methylbis(beta-chloroethylthioethyl)amine,CN(CCSCCCl)CCSCCCl,,,,,,
10507,45202,"Diethylamine, 2,2'-bis(cyanodithio)-N-methyl-, hydrochloride",CN(CCSSC#N)CCSSC#N,,,,,,
10508,45203,Ethyl-di-(beta-chloroethyl)ammonium picrate,CC[NH+](CCCl)CCCl.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
10509,45204,Bis-(beta-chloroethyl)-nitrosoamine hydrochloride,C(CCl)[NH+](CCCl)N=O.[Cl-],,,,,,
10510,45205,Nitrosobis(2-chloroethyl)amine,C(CCl)N(CCCl)N=O,,,,,,
10511,45206,beta-(beta-Morpholinoethylamino)ethyl benzhydryl ether dihydrochloride,C1COCC[NH+]1CC[NH2+]CCOC(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
10512,45207,N-(2-benzhydryloxyethyl)-2-morpholin-4-ylethanamine,C1COCCN1CCNCCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10513,45208,Bis-(beta-chloroethyl)chloroamine,C(CCl)N(CCCl)Cl,,,,,,
10514,45209,CID 45209,C1C2=CC=CC=C2C(=CCC[NH3+])C3=CC=CC=C3O1.[Cl-],,,,,,
10515,45210,"N-(2-Chloroethyl)-4,4'-methyldibenzylamine hydrochloride",CC1=CC=C(C=C1)C[NH+](CCCl)CC2=CC=C(C=C2)C.[Cl-],,,,,,
10516,45211,"2-chloro-N,N-bis[(4-methylphenyl)methyl]ethanamine",CC1=CC=C(C=C1)CN(CCCl)CC2=CC=C(C=C2)C,,,,,,
10517,45212,N-(2-Chloro-2-methylpropyl)dibenzylamine hydrochloride,CC(C)(C[NH+](CC1=CC=CC=C1)CC2=CC=CC=C2)Cl.[Cl-],,,,,,
10518,45213,"N,N-dibenzyl-2-chloro-2-methylpropan-1-amine",CC(C)(CN(CC1=CC=CC=C1)CC2=CC=CC=C2)Cl,,,,,,
10519,45214,"Benzyl-2,4-dichlorobenzylamine hydrochloride",C1=CC=C(C=C1)C[NH2+]CC2=C(C=C(C=C2)Cl)Cl.[Cl-],,,,,,
10520,45215,"N-benzyl-1-(2,4-dichlorophenyl)methanamine",C1=CC=C(C=C1)CNCC2=C(C=C(C=C2)Cl)Cl,,,,,,
10521,45216,"Benzyl-3,4-dichlorobenzylamine hydrochloride",C1=CC=C(C=C1)C[NH2+]CC2=CC(=C(C=C2)Cl)Cl.[Cl-],,,,,,
10522,45217,"Benzyl-(3,4-dichlorobenzyl)amine",C1=CC=C(C=C1)CNCC2=CC(=C(C=C2)Cl)Cl,,,,,,
10523,45218,N-Diethylaminoethyldibenzylamine hydrochloride,CC[NH+](CC)CCN(CC1=CC=CC=C1)CC2=CC=CC=C2.[Cl-],,,,,,
10524,45219,"N',N'-dibenzyl-N,N-diethylethane-1,2-diamine",CCN(CC)CCN(CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
10525,45220,"11H-Dibenzo(b,e)(1,4)diazepin-11-one, 5,10-dihydro-5-(3-(methylamino)propyl)-, monohydrochloride, hydrate",C[NH2+]CCCN1C2=CC=CC=C2C(=O)NC3=CC=CC=C31.[Cl-],,,,,,
10526,45221,Methylaminopropyldibenzodiazepinone,CNCCCN1C2=CC=CC=C2C(=O)NC3=CC=CC=C31,,,,,,
10527,45222,2-(2-(Diethylamino)-1-oxoethyl)dibenzofuran hydrochloride,CC[NH+](CC)CC(=O)C1=CC2=C(C=C1)OC3=CC=CC=C32.[Cl-],,,,,,
10528,45223,1-Dibenzofuran-2-yl-2-(diethylamino)ethanone,CCN(CC)CC(=O)C1=CC2=C(C=C1)OC3=CC=CC=C32,,,,,,
10529,45224,"Trimethylamine, dibenzofuran-2-ylcarbonyl-, hydrochloride",C[NH+](C)CC(=O)C1=CC2=C(C=C1)OC3=CC=CC=C32.[Cl-],,,,,,
10530,45225,1-Dibenzofuran-2-yl-2-(dimethylamino)ethanone,CN(C)CC(=O)C1=CC2=C(C=C1)OC3=CC=CC=C32,,,,,,
10531,45226,CID 45226,C1CCN(CC1)C2=CC=C(C=C2)C=NN=C(N)S,,,,,,
10532,45227,3-(2'-Methylpiperidino)propyl p-bromobenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)Br,,,,,,
10533,45228,CID 45228,CCCCOC1=C(C=CC=C1OC)C(=O)OCCO[NH+]=CCCC.[Cl-],,,,,,
10534,45229,CID 45229,CCCCOC1=C(C=CC=C1OC)C(=O)OCCON=CCCC,,,,,,
10535,45230,3-(2-Methylpiperidin-1-yl)propyl 4-butoxybenzoate,CCCCOC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
10536,45231,3-(2'-Methylpiperidino)propyl p-sec-butoxybenzoate,CCC(C)OC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
10537,45232,cis-Decahydro-2-methylisoquinolin-8-yl benzoate hydrochloride,C[NH+]1CC[C@@H]2CCCC([C@@H]2C1)OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
10538,45233,"[(4aS,8aS)-2-methyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-8-yl] benzoate",CN1CC[C@@H]2CCCC([C@@H]2C1)OC(=O)C3=CC=CC=C3,,,,,,
10539,45234,"Benzoic acid, 6-dimethylamino-4,4-diphenyl-3-heptyl ester, hydrochloride",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
10540,45235,"[6-(Dimethylamino)-4,4-diphenylheptan-3-yl] benzoate",CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3,,,,,,
10541,45236,"3-Benzooxy-6-dimethylamino-4,4-diphenyl-5-methylhexane hydrochloride",CCC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C)OC(=O)C3=CC=CC=C3.[Cl-],,,,,,
10542,45237,"[6-(Dimethylamino)-5-methyl-4,4-diphenylhexan-3-yl] benzoate",CCC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C)OC(=O)C3=CC=CC=C3,,,,,,
10543,45238,"1,2-Dimethyl-3-(4'-methylpiperidino)propyl benzoate",CC1CCN(CC1)CC(C)C(C)OC(=O)C2=CC=CC=C2,,,,,,
10544,45239,"Benzoic acid, 2,2-dimethyl-3-(4'-methylpiperidino)propyl ester",CC1CCN(CC1)CC(C)(C)COC(=O)C2=CC=CC=C2,,,,,,
10545,45240,3-(2'-Methylpiperidino)propyl p-ethoxybenzoate,CCOC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
10546,45241,2-Diethylaminoethyl 4-fluoro-3-iodobenzoate hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC(=C(C=C1)F)I.[Cl-],,,,,,
10547,45242,2-(Diethylamino)ethyl 4-fluoro-3-iodobenzoate,CCN(CC)CCOC(=O)C1=CC(=C(C=C1)F)I,,,,,,
10548,45243,"Benzoic acid, 4-fluoro-3-iodo-, 3-(4-morpholino)propyl ester, hydrochloride",C1COCC[NH+]1CCCOC(=O)C2=CC(=C(C=C2)F)I.[Cl-],,,,,,
10549,45244,3-Morpholin-4-ylpropyl 4-fluoro-3-iodobenzoate,C1COCCN1CCCOC(=O)C2=CC(=C(C=C2)F)I,,,,,,
10550,45245,3-(2'-Methylpiperidino)propyl p-hexoxybenzoate,CCCCCCOC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
10551,45246,3-(2'-Hexylpiperidino)propyl benzoate,CCCCCCC1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
10552,45247,3-(2'-Methylpiperidino)propyl m-hydroxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC(=CC=C2)O,,,,,,
10553,45248,3-(2'-Methylpiperidino)propyl o-hydroxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2O,,,,,,
10554,45249,3-(2'-Methylpiperidino)propyl p-hydroxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)O,,,,,,
10555,45250,3-(2'-Methylpiperidino)propyl o-iodobenzoate,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2I,,,,,,
10556,45251,3-(2'-Methylpiperidino)propyl p-iodobenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)I,,,,,,
10557,45252,3-(2'-Methylpiperidino)propyl p-isobutoxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OCC(C)C,,,,,,
10558,45253,3-(2'-Methylpiperidino)propyl p-isopentylbenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)CCC(C)C,,,,,,
10559,45254,3-(2'-Methylpiperidino)propyl p-isopropoxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OC(C)C,,,,,,
10560,45255,3-(2'-Methylpiperidino)propyl p-isopropylbenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)C(C)C,,,,,,
10561,45256,3-(2'-Isopropylpiperidino)propyl benzoate,CC(C)C1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
10562,45257,3-(2'-Methylpiperidino)propyl p-methoxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OC,,,,,,
10563,45258,Bis(2-chloroethyl) 2-chlorobut-2-enedioate,C(CCl)OC(=O)C=C(C(=O)OCCCl)Cl,,,,,,
10564,45259,CID 45259,CCOP(=S)(OCC)SC(=CC(=O)OC)C(=O)OC,,,,,,
10565,45260,Methylene bisfluoroacetate,C(C(=O)OCF)C(=O)OCF,,,,,,
10566,45261,"Malonic acid, diethyl-, ethyl isobutyl ester",CCC(C)OC(=O)C(CC)(CC)C(=O)OCC,,,,,,
10567,45262,"Malononitrile, (ethoxyethylidene)-",CCOCC=C(C#N)C#N,,,,,,
10568,45263,Ethoxypropylidene malononitrile,CCOCCC=C(C#N)C#N,,,,,,
10569,45264,"MANDELIC ACID, alpha-CYCLOHEXYL-, 1-ETHYL-3-PIPERIDYL ESTER",CCN1CCCC(C1)OC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O,,,,,,
10570,45265,CID 45265,C1CCC(CC1)[NH2+]C2CCCCC2.C1=CC(=CC=C1C(C(=O)[O-])O)N(CCCl)CCCl,,,,,,
10571,45266,2-[4-[Bis(2-chloroethyl)amino]phenyl]-2-hydroxyacetic acid,C1=CC(=CC=C1C(C(=O)O)O)N(CCCl)CCCl,,,,,,
10572,45267,"4-(Di-2'-chloroethylamino)mandelic acid, piperidine salt",C1CC[NH2+]CC1.C1=CC(=CC=C1C(C(=O)[O-])O)N(CCCl)CCCl,,,,,,
10573,45268,"MANDELIC ACID, alpha-PROPYL-, 1-ETHYL-3-PIPERIDYL ESTER",CCCC(C1=CC=CC=C1)(C(=O)OC2CCCN(C2)CC)O,,,,,,
10574,45269,"Diethylaminoacetyl 2,3,6-trimethylaniline hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=CC(=C1C)C)C.[Cl-],,,,,,
10575,45270,"Acetamide, 2-(diethylamino)-N-(2,3,6-trimethylphenyl)-",CCN(CC)CC(=O)NC1=C(C=CC(=C1C)C)C,,,,,,
10576,45271,"Dimethylamine, N-(3,4-bis(dimethylcarbamyloxy)benzyl)-, hydrochloride",C[NH+](C)CC1=CC(=C(C=C1)OC(=O)N(C)C)OC(=O)N(C)C.[Cl-],,,,,,
10577,45272,"[4-[(dimethylamino)methyl]-2-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate",CN(C)CC1=CC(=C(C=C1)OC(=O)N(C)C)OC(=O)N(C)C,,,,,,
10578,45273,"Dimethylaminoacetyl 2,4-dimethylaniline hydrochloride",CC1=CC(=C(C=C1)NC(=O)C[NH+](C)C)C.[Cl-],,,,,,
10579,45274,"2-(dimethylamino)-N-(2,4-dimethylphenyl)acetamide",CC1=CC(=C(C=C1)NC(=O)CN(C)C)C,,,,,,
10580,45275,"Dimethylaminoacetyl 2,4,6-trimethylaniline hydrochloride",CC1=CC(=C(C(=C1)C)NC(=O)C[NH+](C)C)C.[Cl-],,,,,,
10581,45276,"2-(dimethylamino)-N-(2,4,6-trimethylphenyl)acetamide",CC1=CC(=C(C(=C1)C)NC(=O)CN(C)C)C,,,,,,
10582,45277,"Dimethylaminoacetyl 3,4,6-trimethylaniline hydrochloride",CC1=CC(=C(C=C1C)NC(=O)C[NH+](C)C)C.[Cl-],,,,,,
10583,45278,"2-(dimethylamino)-N-(2,4,5-trimethylphenyl)acetamide",CC1=CC(=C(C=C1C)NC(=O)CN(C)C)C,,,,,,
10584,45279,"3,6,9,12,15,18,21,24,27-Nonathianonacosane-1-thiol, 29-(2,2-dimethylhydrazino)-",CN(C)NCCSCCSCCSCCSCCSCCSCCSCCSCCSCCS,,,,,,
10585,45280,"6-Methyl-1,4-dioxaspiro(4.5)decane-3-methanol",CC1CCCCC12OCC(O2)OC,,,,,,
10586,45281,"7-Methyl-1,4-dioxaspiro(4.5)decane-3-methanol",CC1CCCC2(C1)OCC(O2)OC,,,,,,
10587,45282,"8-Methyl-1,4-dioxaspiro(4.5)decane-3-methanol",CC1CCC2(CC1)OCC(O2)OC,,,,,,
10588,45283,"6-Methyl-1,4-dioxaspiro(4.4)nonane-2-methanol",CC1CCCC12OCC(O2)CO,,,,,,
10589,45284,"2-(2-(Tetrahydro-2-furyl)ethyl)-1,6-dioxaspiro(4.4)nonane",C1CC(OC1)CCC2CCC3(O2)CCCO3,,,,,,
10590,45285,Dioxamate,CCCCCCCCCC1(OCC(O1)COC(=O)N)C,,,,,,
10591,45286,"2-Methyl-2-pentyl-1,3-dioxolane-4-methanol acetate",CCCCCC1(OCC(O1)COC(=O)C)C,,,,,,
10592,45287,CID 45287,C[NH+](C)CCOC1C2=C(CCC3=C1C=C(C=C3)OC)N=CC=C2.C(=CC(=O)[O-])C(=O)O,,,,,,
10593,45288,"2-[(14-methoxy-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)oxy]-N,N-dimethylethanamine",CN(C)CCOC1C2=C(CCC3=C1C=C(C=C3)OC)N=CC=C2,,,,,,
10594,45289,"2(3H)-Benzofuranone, 3-cyclohexyl-3-(2-(diethylamino)ethyl)-, hydrochloride",CC[NH+](CC)CCC1(C2=CC=CC=C2OC1=O)C3CCCCC3.[Cl-],,,,,,
10595,45290,3-Cyclohexyl-3-[2-(diethylamino)ethyl]-1-benzofuran-2-one,CCN(CC)CCC1(C2=CC=CC=C2OC1=O)C3CCCCC3,,,,,,
10596,45291,"2(3H)-Benzofuranone, 3-(2-(dibutylamino)ethyl)-3-phenyl-, hydrochloride",CCCC[NH+](CCCC)CCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10597,45292,3-[2-(Dibutylamino)ethyl]-3-phenyl-1-benzofuran-2-one,CCCCN(CCCC)CCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10598,45293,"2(3H)-Benzofuranone, 3-(3-(dibutylamino)propyl)-3-phenyl-, hydrochloride",CCCC[NH+](CCCC)CCCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10599,45294,3-[3-(Dibutylamino)propyl]-3-phenyl-1-benzofuran-2-one,CCCCN(CCCC)CCCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10600,45295,"2(3H)-Benzofuranone, 3-(2-(diethylamino)ethyl)-5-methyl-3-phenyl-, hydrochloride",CC[NH+](CC)CCC1(C2=C(C=CC(=C2)C)OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10601,45296,3-[2-(Diethylamino)ethyl]-5-methyl-3-phenyl-1-benzofuran-2-one,CCN(CC)CCC1(C2=C(C=CC(=C2)C)OC1=O)C3=CC=CC=C3,,,,,,
10602,45297,"2(3H)-Benzofuranone, 3-((2-diethylamino-1-methyl)ethyl)-3-phenyl-, hydrochloride",CC[NH+](CC)CC(C)C1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10603,45298,3-[1-(Diethylamino)propan-2-yl]-3-phenyl-1-benzofuran-2-one,CCN(CC)CC(C)C1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10604,45299,"2(3H)-Benzofuranone, 3-((2-diethylamino-2-methyl)ethyl)-3-phenyl-, hydrochloride",CC[NH+](CC)C(C)CC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10605,45300,3-[2-(Diethylamino)propyl]-3-phenyl-1-benzofuran-2-one,CCN(CC)C(C)CC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10606,45301,3-(3-(Diethylamino)propyl)-3-phenyl-2(3H)-benzofuranone hydrochloride,CC[NH+](CC)CCCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10607,45302,3-[3-(Diethylamino)propyl]-3-phenyl-1-benzofuran-2-one,CCN(CC)CCCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10608,45303,3-(11-(Diethylamino)undecyl)-3-phenyl-2(3H)-benzofuranone hydrochloride,CC[NH+](CC)CCCCCCCCCCCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10609,45304,3-[11-(Diethylamino)undecyl]-3-phenyl-1-benzofuran-2-one,CCN(CC)CCCCCCCCCCCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10610,45305,"2(3H)-Benzofuranone, 3-(2-(dimethylamino)ethyl)-3-phenyl-, hydrochloride",C[NH+](C)CCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
10611,45306,3-[2-(Dimethylamino)ethyl]-3-phenyl-1-benzofuran-2-one,CN(C)CCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3,,,,,,
10612,45307,"2(3H)-Benzofuranone, 3-(2-morpholinoethyl)-3-phenyl-, hydrochloride",C1COCC[NH+]1CCC2(C3=CC=CC=C3OC2=O)C4=CC=CC=C4.[Cl-],,,,,,
10613,45308,3-(Beta-morpholinoethyl)-3-phenyl-2-benzofuranone,C1COCCN1CCC2(C3=CC=CC=C3OC2=O)C4=CC=CC=C4,,,,,,
10614,45309,"2(3H)-Benzofuranone, 3-(3-morpholinopropyl)-3-phenyl-, hydrochloride",C1COCC[NH+]1CCCC2(C3=CC=CC=C3OC2=O)C4=CC=CC=C4.[Cl-],,,,,,
10615,45310,3-(3-Morpholin-4-ylpropyl)-3-phenyl-1-benzofuran-2-one,C1COCCN1CCCC2(C3=CC=CC=C3OC2=O)C4=CC=CC=C4,,,,,,
10616,45311,"2(3H)-Benzofuranone, 3-(2-piperidinoethyl)-3-phenyl-, hydrochloride",C1CC[NH+](CC1)CCC2(C3=CC=CC=C3OC2=O)C4=CC=CC=C4.[Cl-],,,,,,
10617,45312,3-Phenyl-3-(2-piperidin-1-ylethyl)-1-benzofuran-2-one,C1CCN(CC1)CCC2(C3=CC=CC=C3OC2=O)C4=CC=CC=C4,,,,,,
10618,45313,"Benzo(a)heptalen-9(5H)-one, 7-acetamido-6,7-dihydro-10-ethylamino-1,2,3-trimethoxy-",CCNC1=CC=C2C(=CC1=O)C(CCC3=CC(=C(C(=C32)OC)OC)OC)NC(=O)C,,,,,,
10619,45314,N-Methylcolchiceinamide,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)NC)OC)OC)OC,,,,,,
10620,45315,Ethyldesacetylcolchaminone,CCNC1=CC=C2C(=CC1=O)C(CCC3=CC(=C(C(=C32)OC)OC)OC)N,,,,,,
10621,45316,Methyldesacetylcolchaminone [French],CNC1=CC=C2C(=CC1=O)C(CCC3=CC(=C(C(=C32)OC)OC)OC)N,,,,,,
10622,45317,3-(2'-Methylpiperidino)propyl p-allyloxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OCC=C,,,,,,
10623,45318,"BENZOIC ACID, p-AMINO-, 3-(beta-(DIBUTYLAMINO)ETHOXY)PROPYL ESTER",CCCCN(CCCC)CCOCCCOC(=O)C1=CC=C(C=C1)N,,,,,,
10624,45319,"BENZOIC ACID, p-AMINO-, 3-(beta-(DIETHYLAMINO)ETHOXY)PROPYL ESTER",CCN(CC)CCOCCCOC(=O)C1=CC=C(C=C1)N,,,,,,
10625,45320,"BENZOIC ACID, p-AMINO-, 3-(beta-(DIMETHYLAMINO)ETHOXY)PROPYL ESTER",CN(C)CCOCCCOC(=O)C1=CC=C(C=C1)N,,,,,,
10626,45321,"BENZOIC ACID, p-AMINO-, 3-(beta-(DIPROPYLAMINO)ETHOXY)PROPYL ESTER",CCCN(CCC)CCOCCCOC(=O)C1=CC=C(C=C1)N,,,,,,
10627,45322,4-Amino-2-methylbenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=C(C=C(C=C1)N)C.[Cl-],,,,,,
10628,45323,2-Diethylaminoethyl 4-amino-2-methylbenzoate,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)C,,,,,,
10629,45324,"BENZOIC ACID, p-AMINOTHIO-, 3-(DIBUTYLAMINO)PROPYL ESTER",CCCCN(CCCC)CCCOC(=S)C1=CC=C(C=C1)N,,,,,,
10630,45325,3-(2'-Methylpiperidino)propyl p-benzyloxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OCC3=CC=CC=C3,,,,,,
10631,45326,Bis-(o-tolyloxyethyl)ethylamine hydrochloride,CC1=CC=CC=C1OCCC(CCOC2=CC=CC=C2C)C[NH3+].[Cl-],,,,,,
10632,45327,4-(2-Methylphenoxy)-2-[2-(2-methylphenoxy)ethyl]butan-1-amine,CC1=CC=CC=C1OCCC(CCOC2=CC=CC=C2C)CN,,,,,,
10633,45328,2-(p-Bromodiphenylmethoxy)-N-pyrrolidinylethylamine hydrochloride,C1CCN(C1)[NH2+]CCOC(C2=CC=CC=C2)C3=CC=C(C=C3)Br.[Cl-],,,,,,
10634,45329,N-[2-[(4-bromophenyl)-phenylmethoxy]ethyl]pyrrolidin-1-amine,C1CCN(C1)NCCOC(C2=CC=CC=C2)C3=CC=C(C=C3)Br,,,,,,
10635,45330,"2-(p-Bromophenyl-(p'-tolyl)methoxy)-N,N-dimethylethylamine hydrochloride",CC1=CC=C(C=C1)C(C2=CC=C(C=C2)Br)OCC[NH+](C)C.[Cl-],,,,,,
10636,45331,"2-[(4-bromophenyl)-(4-methylphenyl)methoxy]-N,N-dimethylethanamine",CC1=CC=C(C=C1)C(C2=CC=C(C=C2)Br)OCCN(C)C,,,,,,
10637,45332,2-Chloro-bis-N-(2-methoxyphenoxyethyl)ethylamine hydrochloride,COC1=CC=CC=C1OCC[NH+](CCOC2=CC=CC=C2OC)CCCl.[Cl-],,,,,,
10638,45333,N-(2-chloroethyl)-2-(2-methoxyphenoxy)-N-[2-(2-methoxyphenoxy)ethyl]ethanamine,COC1=CC=CC=C1OCCN(CCOC2=CC=CC=C2OC)CCCl,,,,,,
10639,45334,2-Chloro-bis-N-(4-methylphenoxyethyl)ethylamine hydrochloride,CC1=CC=C(C=C1)OCC[NH+](CCOC2=CC=C(C=C2)C)CCCl.[Cl-],,,,,,
10640,45335,"2-Chloro-N,N-bis[2-(4-methylphenoxy)ethyl]ethan-1-amine",CC1=CC=C(C=C1)OCCN(CCOC2=CC=C(C=C2)C)CCCl,,,,,,
10641,45336,"2-(m-Chlorodiphenylmethoxy)-N,N-dimethylethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC(=CC=C2)Cl.[Cl-],,,,,,
10642,45337,"2-[(3-chlorophenyl)-phenylmethoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC(=CC=C2)Cl,,,,,,
10643,45338,2-Isopropylphenoxyethyl ethyl-beta-chloroethylamine hydrochloride,CC[NH+](CCOC1=CC=CC=C1C(C)C)CCCl.[Cl-],,,,,,
10644,45339,N-(2-chloroethyl)-N-ethyl-2-(2-propan-2-ylphenoxy)ethanamine,CCN(CCOC1=CC=CC=C1C(C)C)CCCl,,,,,,
10645,45340,"Ethylamine, N-(2-chloroethyl)-N-(2-ethylphenoxyethyl)-, hydrochloride",CCC1=CC(=CC=C1)OCC[NH+](CC)CCCl.[Cl-],,,,,,
10646,45341,N-(2-chloroethyl)-N-ethyl-2-(3-ethylphenoxy)ethanamine,CCC1=CC(=CC=C1)OCCN(CC)CCCl,,,,,,
10647,45342,2-Methoxyphenoxyethyl-beta-chloroethyl ethylamine hydrochloride,CC[NH+](CCOC1=CC=CC=C1OC)CCCl.[Cl-],,,,,,
10648,45343,N-(2-chloroethyl)-N-ethyl-2-(2-methoxyphenoxy)ethanamine,CCN(CCOC1=CC=CC=C1OC)CCCl,,,,,,
10649,45344,2-Methoxy-4-propylenephenoxyethylethyl-beta-chloroethylamine hydrochloride,CC[NH+](CCOC1=C(C=C(C=C1)CC=C)OC)CCCl.[Cl-],,,,,,
10650,45345,N-(2-chloroethyl)-N-ethyl-2-(2-methoxy-4-prop-2-enylphenoxy)ethanamine,CCN(CCOC1=C(C=C(C=C1)CC=C)OC)CCCl,,,,,,
10651,45346,"Ethylamine, N-(2-chloroethyl)-N-(2-methylphenoxyethoxyethyl)-, hydrochloride",CC[NH+](CCOCCOC1=CC=CC=C1C)CCCl.[Cl-],,,,,,
10652,45347,N-(2-chloroethyl)-N-ethyl-2-[2-(2-methylphenoxy)ethoxy]ethanamine,CCN(CCOCCOC1=CC=CC=C1C)CCCl,,,,,,
10653,45348,4-Methylphenoxyethyl-beta-chloroethylethylamine hydrochloride,CC[NH+](CCOC1=CC=C(C=C1)C)CCCl.[Cl-],,,,,,
10654,45349,N-(2-chloroethyl)-N-ethyl-2-(4-methylphenoxy)ethanamine,CCN(CCOC1=CC=C(C=C1)C)CCCl,,,,,,
10655,45350,1-Naphthyloxyethylethyl-beta-chloroethylamine hydrochloride,CC[NH+](CCOC1=CC=CC2=CC=CC=C21)CCCl.[Cl-],,,,,,
10656,45351,N-(2-chloroethyl)-N-ethyl-2-naphthalen-1-yloxyethanamine,CCN(CCOC1=CC=CC2=CC=CC=C21)CCCl,,,,,,
10657,45352,2-Naphthyloxyethylethyl-beta-chloroethylamine hydrochloride,CC[NH+](CCOC1=CC2=CC=CC=C2C=C1)CCCl.[Cl-],,,,,,
10658,45353,N-(2-chloroethyl)-N-ethyl-2-naphthalen-2-yloxyethanamine,CCN(CCOC1=CC2=CC=CC=C2C=C1)CCCl,,,,,,
10659,45354,2-Pentylphenoxyethyl ethyl-beta-chloroethylamine hydrochloride,CCCCCC1=CC=CC=C1OCC[NH+](CC)CCCl.[Cl-],,,,,,
10660,45355,2-Amylphenoxyethylethyl-beta-chloroethylamine,CCCCCC1=CC=CC=C1OCCN(CC)CCCl,,,,,,
10661,45356,"N-(2-Chloroethyl)-N-(3,4-xylyloxyethyl)ethylamine hydrochloride",CC[NH+](CCOC1=CC(=C(C=C1)C)C)CCCl.[Cl-],,,,,,
10662,45357,"N-(2-chloroethyl)-2-(3,4-dimethylphenoxy)-N-ethylethanamine",CCN(CCOC1=CC(=C(C=C1)C)C)CCCl,,,,,,
10663,45358,2-Methylphenylthioethyl-beta-chloroethylamine hydrochloride,CC1=CC=CC=C1SCC[NH2+]CCCl.[Cl-],,,,,,
10664,45359,N-(2-chloroethyl)-2-(2-methylphenyl)sulfanylethanamine,CC1=CC=CC=C1SCCNCCCl,,,,,,
10665,45360,"ETHYLAMINE, 2-(o-CHLOROPHENYL)THIO-N,N-DIETHYL-",CCN(CC)CCSC1=CC=CC=C1Cl,,,,,,
10666,45361,"2-(p-Cyclohexyldiphenylmethoxy)-N,N-dimethylethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)C3CCCCC3.[Cl-],,,,,,
10667,45362,"2-[(4-cyclohexylphenyl)-phenylmethoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)C3CCCCC3,,,,,,
10668,45363,"2-(m,p-Dichlorodiphenylmethoxy)-N,N-dimethylethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=C(C=C1)Cl)C2=CC(=CC=C2)Cl.[Cl-],,,,,,
10669,45364,"2-[(3-chlorophenyl)-(4-chlorophenyl)methoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC(=CC=C2)Cl,,,,,,
10670,45365,"2-(o,p'-Dichlorodiphenylmethoxy)-N,N-dimethylethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=C2Cl.[Cl-],,,,,,
10671,45366,"2-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=C2Cl,,,,,,
10672,45367,"Ethylamine, 3,4-diethoxy-5-methoxyphenyl-",CCOC1=CC(=CC(=C1OCC)OC)CCN,,,,,,
10673,45368,"ETHYLAMINE, N,N-DIETHYL-2-(o-TOLYLTHIO)-",CCN(CC)CCSC1=CC=CC=C1C,,,,,,
10674,45369,"N,N-Diethyl-beta-(p-tolylthio)ethylamine hydrochloride",CC[NH+](CC)CCSC1=CC=C(C=C1)C.[Cl-],,,,,,
10675,45370,"N,N-diethyl-2-(4-methylphenyl)sulfanylethanamine",CCN(CC)CCSC1=CC=C(C=C1)C,,,,,,
10676,45371,"2-(Di-(9-fluorenyl)methoxy)-N,N-dimethylethylamine hydrochloride",C[NH+](C)CCOC(C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Cl-],,,,,,
10677,45372,"2-[bis(9H-fluoren-9-yl)methoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
10678,45373,"N,N-Dimethyl-2-(di-(o,m'-tolyl)methoxy)ethylamine hydrochloride",CC1=CC(=CC=C1)C(C2=CC=CC=C2C)OCC[NH+](C)C.[Cl-],,,,,,
10679,45374,"N,N-dimethyl-2-[(2-methylphenyl)-(3-methylphenyl)methoxy]ethanamine",CC1=CC(=CC=C1)C(C2=CC=CC=C2C)OCCN(C)C,,,,,,
10680,45375,"N,N-Dimethyl-2-(di-(o,p'-tolyl)methoxy)ethylamine hydrochloride",CC1=CC=C(C=C1)C(C2=CC=CC=C2C)OCC[NH+](C)C.[Cl-],,,,,,
10681,45376,"N,N-dimethyl-2-[(2-methylphenyl)-(4-methylphenyl)methoxy]ethanamine",CC1=CC=C(C=C1)C(C2=CC=CC=C2C)OCCN(C)C,,,,,,
10682,45377,"N,N-Dimethyl-2-(mesityl(phenyl)methoxy)ethylamine hydrochloride",CC1=CC(=C(C(=C1)C)C(C2=CC=CC=C2)OCC[NH+](C)C)C.[Cl-],,,,,,
10683,45378,"N,N-dimethyl-2-[phenyl-(2,4,6-trimethylphenyl)methoxy]ethanamine",CC1=CC(=C(C(=C1)C)C(C2=CC=CC=C2)OCCN(C)C)C,,,,,,
10684,45379,"N,N-Dimethyl-2-(1-naphthyl(phenyl)methoxy)ethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC3=CC=CC=C32.[Cl-],,,,,,
10685,45380,"N,N-dimethyl-2-[naphthalen-1-yl(phenyl)methoxy]ethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC3=CC=CC=C32,,,,,,
10686,45381,"N,N-Dimethyl-2-(phenyl-(2'-thienyl)methoxy)ethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CS2.[Cl-],,,,,,
10687,45382,"N,N-dimethyl-2-[phenyl(thiophen-2-yl)methoxy]ethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC=CS2,,,,,,
10688,45383,"N,N-Dimethyl-2-(p-propyldiphenylmethoxy)ethylamine hydrochloride",CCCC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[NH+](C)C.[Cl-],,,,,,
10689,45384,"N,N-dimethyl-2-[phenyl-(4-propylphenyl)methoxy]ethanamine",CCCC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN(C)C,,,,,,
10690,45385,beta-Isopropylaminoethyl benzhydryl ether hydrochloride,CC(C)[NH2+]CCOC(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
10691,45386,N-(2-benzhydryloxyethyl)propan-2-amine,CC(C)NCCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
10692,45387,2-(Diphenylmethoxy)-N-morpholinoethylamine hydrochloride,C1COCCN1[NH2+]CCOC(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
10693,45388,N-(2-benzhydryloxyethyl)morpholin-4-amine,C1COCCN1NCCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10694,45389,2-Methylphenoxyethyl-beta-hydroxyethylamine hydrochloride,CC1=CC=CC=C1OCC[NH2+]CCO.[Cl-],,,,,,
10695,45390,2-{[2-(2-Methylphenoxy)ethyl]amino}ethan-1-ol,CC1=CC=CC=C1OCCNCCO,,,,,,
10696,45391,"2-(p-Iododiphenylmethoxy)-N,N-dimethylethylamine hydrochloride",C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)I.[Cl-],,,,,,
10697,45392,"2-[(4-iodophenyl)-phenylmethoxy]-N,N-dimethylethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)I,,,,,,
10698,45393,"2-(p-Isopropyldiphenylmethoxy)-N,N-dimethylethylamine hydrochloride",CC(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[NH+](C)C.[Cl-],,,,,,
10699,45394,"N,N-dimethyl-2-[phenyl-(4-propan-2-ylphenyl)methoxy]ethanamine",CC(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN(C)C,,,,,,
10700,45395,N-Morpholino-2-(phenyl-(p-tolyl)methoxy)ethylamine hydrochloride,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[NH2+]N3CCOCC3.[Cl-],,,,,,
10701,45396,N-[2-[(4-methylphenyl)-phenylmethoxy]ethyl]morpholin-4-amine,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCNN3CCOCC3,,,,,,
10702,45397,2-(Phenyl-(p-tolyl)methoxy)-N-piperidinoethylamine hydrochloride,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN[NH+]3CCCCC3.[Cl-],,,,,,
10703,45398,N-[2-[(4-methylphenyl)-phenylmethoxy]ethyl]piperidin-1-amine,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCNN3CCCCC3,,,,,,
10704,45399,2-(Phenyl-(p-tolyl)methoxy)-N-pyrrolidinylethylamine hydrochloride,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN[NH+]3CCCC3.[Cl-],,,,,,
10705,45400,N-[2-[(4-methylphenyl)-phenylmethoxy]ethyl]pyrrolidin-1-amine,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCNN3CCCC3,,,,,,
10706,45401,CID 45401,C1CC[NH+](CC1)C(CN)C2=CC=CS2.C(=CC(=O)[O-])C(=O)O,,,,,,
10707,45402,2-(Piperidin-1-yl)-2-(thiophen-2-yl)ethan-1-amine,C1CCN(CC1)C(CN)C2=CC=CS2,,,,,,
10708,45403,"ETHYLAMINE, beta-o-TOLYLOXY-N-(o-TOLYLOXYETHYL)-, HYDROCHLORIDE",CC1=CC=CC=C1OCC[NH2+]CCOC2=CC=CC=C2C.[Cl-],,,,,,
10709,45404,2-(2-methylphenoxy)-N-[2-(2-methylphenoxy)ethyl]ethanamine,CC1=CC=CC=C1OCCNCCOC2=CC=CC=C2C,,,,,,
10710,45405,"2,2,2-Triphenylethylazanium;chloride",C1=CC=C(C=C1)C(C[NH3+])(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
10711,45406,"2,2,2-Triphenylethanamine",C1=CC=C(C=C1)C(CN)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
10712,45407,"Butyric acid, 4-diethylamino-, ethyl ester",CCN(CC)CCCC(=O)OCC,,,,,,
10713,45408,Bis(2-amino-2-phenylethyl)disulfide dihydrochloride,C1=CC=C(C=C1)C(CSSCC(C2=CC=CC=C2)[NH3+])[NH3+].[Cl-].[Cl-],,,,,,
10714,45409,2-[(2-Amino-2-phenylethyl)disulfanyl]-1-phenylethanamine,C1=CC=C(C=C1)C(CSSCC(C2=CC=CC=C2)N)N,,,,,,
10715,45410,"Ethylenediamine, N,N'-bis(2-chloroethyl)-N-(2-chloroethylaminoethyl)-, trihydrochloride",C(C[NH+](CC[NH2+]CCCl)CCCl)[NH2+]CCCl.[Cl-].[Cl-].[Cl-],,,,,,
10716,45411,"N,N'-bis(2-chloroethyl)-N'-[2-(2-chloroethylamino)ethyl]ethane-1,2-diamine",C(CN(CCNCCCl)CCCl)NCCCl,,,,,,
10717,45412,"N,N'-Bis(2-chloroethyl)-N,N'-diethylethylenediamine dihydrochloride",CC[NH+](CC[NH+](CC)CCCl)CCCl.[Cl-].[Cl-],,,,,,
10718,45413,"N,N'-Bis(2-chloroethyl)-N,N'-diethylethylenediamine",CCN(CCN(CC)CCCl)CCCl,,,,,,
10719,45414,Ethylcholine aziridinium,CC[N+]1(CC1)CCO,,,"['Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc. (See all compounds classified as Neuromuscular Blocking Agents.)']",,,
10720,45415,"Aziridinium, 1-ethyl-1-(2-hydroxyethyl)-, 2,4,6-trinitrobenzenesulfonate",CC[N+]1(CC1)CCO.C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
10721,45416,2-(Diethylamino)ethyl 9-fluoreneacetate hydrochloride,CC[NH+](CC)CCOC(=O)CC1C2=CC=CC=C2C3=CC=CC=C13.[Cl-],,,,,,
10722,45417,2-(diethylamino)ethyl 2-(9H-fluoren-9-yl)acetate,CCN(CC)CCOC(=O)CC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
10723,45418,CID 45418,CC[NH+](CC)CCOC(=O)C=CC1C2=CC=CC=C2C3=CC=CC=C13.[Cl-],,,,,,
10724,45419,CID 45419,CCN(CC)CCOC(=O)C=CC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
10725,45420,2-Aminofluorene-9-carboxylic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1C2=CC=CC=C2C3=C1C=C(C=C3)N.[Cl-],,,,,,
10726,45421,2-(diethylamino)ethyl 2-amino-9H-fluorene-9-carboxylate,CCN(CC)CCOC(=O)C1C2=CC=CC=C2C3=C1C=C(C=C3)N,,,,,,
10727,45422,2-(Di-n-butylamino)propyl 9-fluorenecarboxylate hydrochloride,CCCC[NH+](CCCC)CCCOC(=O)C1C2=CC=CC=C2C3=CC=CC=C13.[Cl-],,,,,,
10728,45423,3-(dibutylamino)propyl 9H-fluorene-9-carboxylate,CCCCN(CCCC)CCCOC(=O)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
10729,45424,2-(Diethylamino)propyl 9-fluorenecarboxylate hydrochloride,CC[NH+](CC)C(C)COC(=O)C1C2=CC=CC=C2C3=CC=CC=C13.[Cl-],,,,,,
10730,45425,2-(diethylamino)propyl 9H-fluorene-9-carboxylate,CCN(CC)C(C)COC(=O)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
10731,45426,"N'-[(4-chlorophenyl)-phenylmethyl]-N-prop-1-enylethane-1,2-diamine",CC=CNCCNC(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,,,,,,
10732,45427,"Ethylenediamine, N,N,N',N'-tetrakis(2-chloroethyl)-, dihydrochloride",C(C[NH+](CCCl)CCCl)[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
10733,45428,"Ethylenediamine, N,N,N',N'-tetrakis(2-chloroethyl)-",C(CN(CCCl)CCCl)N(CCCl)CCCl,,,,,,
10734,45429,"1-Chloro-1,2-diethoxyethene",CCOC=C(OCC)Cl,,,,,,
10735,45430,"1,2-Dichloro-1,2-diethoxyethene",CCOC(=C(OCC)Cl)Cl,,,,,,
10736,45431,"Aziridinium, 1-(2-chloroethyl)-1-ethyl-",CC[N+]1(CC1)CCCl,,,,,,
10737,45432,Ethyl-beta-chloroethyl-ethylenimonium picrylsulfonate,CCC1C[NH+]1CCCl.C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
10738,45433,1-(2-Chloroethyl)-2-ethylaziridine,CCC1CN1CCCl,,,,,,
10739,45434,"7H-DIBENZO(a,g)CARBAZOLE, 2-METHYL-",CC1=CC2=C(C=C1)C=CC3=C2C4=C(N3)C5=CC=CC=C5C=C4,,,,,,
10740,45435,CID 45435,C[NH+](C)CCOC1C=CC2=C(CCC=C2)CC3=CC=CC=C13.C(=CC(=O)[O-])C(=O)O,,,,,,
10741,45436,CID 45436,CN(C)CCOC1C=CC2=C(CCC=C2)CC3=CC=CC=C13,,,,,,
10742,45437,"Tricyclo[10.4.0.03,8]hexadeca-1(12),3,5,7,10,13-hexaen-9-ol",C1CC2=C(C=C1)C=CC(C3=CC=CC=C3C2)O,,,,,,
10743,45438,"5H-Dibenzo(b,e)(1,4)diazepine, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-",CN(C)CCCN1C2=CC=CC=C2NCC3=C1C=C(C=C3)Cl,,,,,,
10744,45439,"5H-DIBENZO(b,e)(1,4)DIAZEPINE, 10,11-DIHYDRO-5-(2-(DIETHYLAMINO)ETHYL)-",CCN(CC)CCN1C2=CC=CC=C2CNC3=CC=CC=C31,,,,,,
10745,45440,"5H-DIBENZ(c,e)AZEPINE, 6-ALLYL-6,7-DIHYDRO-3,9-DICHLORO-",C=CCN1CC2=C(C=CC(=C2)Cl)C3=C(C1)C=C(C=C3)Cl,,,,,,
10746,45441,"1-Fluoro-4-(1,2,2,2-tetrachloroethoxy)butane",C(CCF)COC(C(Cl)(Cl)Cl)Cl,,,,,,
10747,45442,Isoamyl pentachlorophenyl ether,CC(C)CCOC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
10748,45443,"ETHYLAMINE, 2-(o-ANISYLTHIO)-N,N-DIETHYL-, HYDROCHLORIDE",CC[NH+](CC)CCSC1=CC=CC=C1OC.[Cl-],,,,,,
10749,45444,"N,N-diethyl-2-(2-methoxyphenyl)sulfanylethanamine",CCN(CC)CCSC1=CC=CC=C1OC,,,,,,
10750,45445,"4-[2-(13-azapentacyclo[12.8.0.03,12.04,9.017,22]docosa-1,3(12),4,6,8,10,13,15,17,19,21-undecaen-2-yl)ethenyl]-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)C=CC2=C3C(=NC4=C2C5=CC=CC=C5C=C4)C=CC6=CC=CC=C63,,,,,,
10751,45446,2-(alpha-Methylphenethyl)aminoethanol,CC(CC1=CC=CC=C1)NCCO,,,,,,
10752,45447,3-(2-Piperidino-1-hydroxyethyl)phenanthrene hydrochloride,C1CC[NH+](CC1)CC(C2=CC3=C(C=CC4=CC=CC=C43)C=C2)O.[Cl-],,,,,,
10753,45448,1-Phenanthren-3-yl-2-piperidin-1-ylethanol,C1CCN(CC1)CC(C2=CC3=C(C=CC4=CC=CC=C43)C=C2)O,,,,,,
10754,45449,1-Phenyl-2-hydrazinoethanol hydrochloride,C1=CC=C(C=C1)C(CNN)O.Cl,,,,,,
10755,45450,1-Phenyl-2-hydrazinoethanol,C1=CC=C(C=C1)C(CNN)O,,,,,,
10756,45451,"Ethanol, 2-propoxy-, phosphate (3:1)",CCCOCCOP(=O)(OCCOCCC)OCCOCCC,,,,,,
10757,45452,O-Mustard,C(CSCCCl)OCCSCCCl,,,,,,
10758,45453,2-Hexyloxy-2-ethoxyethyl ether,CCCCCCOC(COCC(OCC)OCCCCCC)OCC,,,,,,
10759,45454,"Ether, bis(isothiocyanomethyl)",C(N=C=S)OCN=C=S,,,,,,
10760,45455,"Ether, bis(2-naphthylethyl)",C1=CC=C2C=C(C=CC2=C1)CCOCCC3=CC4=CC=CC=C4C=C3,,,,,,
10761,45456,4-Nonylphenyl-beta-dimethylaminoethyl ether,CCCCCCCCCC1=CC=C(C=C1)OCCN(C)C,,,,,,
10762,45457,3-(2'-Methylpiperidino)propyl p-sec-hexoxybenzoate,CCCCC(C)OC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
10763,45458,Glycidylphenyl glycidyl ether,C1C(O1)CC2=CC=C(C=C2)OCC3CO3,,,,,,
10764,45459,"2-[Difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane",COC(C(C(F)(F)F)C(F)(F)F)(F)F,,,,,,
10765,45460,"2,2',3,3',4,4',5,5',6-Nonachlorodiphenyl ether",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
10766,45461,"Ethylamine, 2-(biphenylyl(phenyl)methoxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)C3=CC=CC=C3.[Cl-],,,,,,
10767,45462,"N,N-dimethyl-2-[phenyl-(4-phenylphenyl)methoxy]ethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
10768,45463,alpha-(6-Methoxyquinol-4-yl)isoquinolineethanol dihydrochloride,COC1=CC2=C(C=C[NH+]=C2C=C1)C(CC3=[NH+]C=CC4=CC=CC=C43)O.[Cl-].[Cl-],,,,,,
10769,45464,2-Isoquinolin-1-yl-1-(6-methoxyquinolin-4-yl)ethanol,COC1=CC2=C(C=CN=C2C=C1)C(CC3=NC=CC4=CC=CC=C43)O,,,,,,
10770,45465,CID 45465,C1CN(C(=S)N1CCO)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
10771,45466,CID 45466,C1=C[N+](=CC=C1C(=N)S)[O-],,,,,,
10772,45467,Sodium salt of hydroxymercuripropanol phenyl malonic acid,C1=CC=C(C=C1)C(CC(C[Hg])O)(C(=O)[O-])C(=O)[O-].O.[Na+].[Na+],,,,,,
10773,45468,"(4,4-Dicarboxy-2-hydroxy-4-phenylbutyl)mercury",C1=CC=C(C=C1)C(CC(C[Hg])O)(C(=O)O)C(=O)O,,,,,,
10774,45469,Sodium nitroprussiate,[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Na+].[Na+].[Na+].[Na+].[Fe+3],,,,,,
10775,45470,4-(N-(2-Hydroxypropyl)-N-nitrosoamino)-2-butanol,CC(CCN(CC(C)O)N=O)O,,,,,,
10776,45471,4-(N-(2-Hydroxypropyl)-N-nitrosoamino)-1-butanol,CC(CN(CCCCO)N=O)O,,,,,,
10777,45472,Nonabromodiphenyl ether,C1=C(C(=C(C(=C1Br)Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,,,,,,
10778,45473,Mercury gluconate,C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Hg+],,,,,,
10779,45474,Protoverine hydrochloride,C[C@H]1CC[C@H]2[C@@](C3[C@H]([C@@H]([C@@]4(C(C3C[NH+]2C1)C[C@@]56C4[C@@H]([C@@H](C7[C@@]5(CC[C@@H]([C@]7(O6)O)O)C)O)O)O)O)O)(C)O.[Cl-],,,,,,
10780,45475,CID 45475,C1CN(CCN1CC(COC2=CC=C(C=C2)C=CC(=O)C3=CC=CC=C3)O)C4=CC=CC=C4,,,,,,
10781,45476,Butyl 2-butoxycyclopropane-1-carboxylate,CCCCOC1CC1C(=O)OCCCC,,,,,,
10782,45477,"Isoquinoline, 1,2,3,4-tetrahydro-2,3-dimethyl-6-nitro-4-phenyl-, hydrochloride, (E)-",C[C@H]1C(C2=C(C[NH+]1C)C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3.[Cl-],,,,,,
10783,45478,"(3S)-2,3-dimethyl-6-nitro-4-phenyl-3,4-dihydro-1H-isoquinoline",C[C@H]1C(C2=C(CN1C)C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
10784,45479,"1-(4-Nitrophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=C(C1CCC3=CC=C(C=C3)[N+](=O)[O-])C=CC(=C2)OC,,,,,,
10785,45480,"Isoquinoline, 1,2,3,4-tetrahydro-2-methyl-6,7-methylenedioxy-1-(4-nitrophenethyl)-",CN1CCC2=CC3=C(C=C2C1CCC4=CC=C(C=C4)[N+](=O)[O-])OCO3,,,,,,
10786,45481,"Isoquinoline, 1,2,3,4-tetrahydro-2-octanoyl-",CCCCCCCC(=O)N1CCC2=CC=CC=C2C1,,,,,,
10787,45482,"1-[2-(3,5-dichloro-2-methoxyphenyl)ethyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=C(C(=CC(=C3)Cl)Cl)OC)OC)OC,,,,,,
10788,45483,"1-(2,3-Dichlorophenethyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=C(C(=CC=C3)Cl)Cl)OC)OC,,,,,,
10789,45484,"1-(2,6-Dichlorophenethyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=C(C=CC=C3Cl)Cl)OC)OC,,,,,,
10790,45485,"Isoquinoline, 1,2,3,4-tetrahydro-1-(3,4-dichlorophenethyl)-2-methyl-6,7-methylenedioxy-, hydrochloride",C[NH+]1CCC2=CC3=C(C=C2C1CCC4=CC(=C(C=C4)Cl)Cl)OCO3.[Cl-],,,,,,
10791,45486,"5-[2-(3,4-dichlorophenyl)ethyl]-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline",CN1CCC2=CC3=C(C=C2C1CCC4=CC(=C(C=C4)Cl)Cl)OCO3,,,,,,
10792,45487,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(alpha-methyl-4-nitro)phenethyl-, hydrogen sulfosalicylate",CC(CC1=CC=C(C=C1)[N+](=O)[O-])C2C3=CC(=C(C=C3CC[NH+]2C)OC)OC.C1=CC(=C(C=C1S(=O)(=O)[O-])C(=O)O)O,,,,,,
10793,45488,"6,7-dimethoxy-2-methyl-1-[1-(4-nitrophenyl)propan-2-yl]-3,4-dihydro-1H-isoquinoline",CC(CC1=CC=C(C=C1)[N+](=O)[O-])C2C3=CC(=C(C=C3CCN2C)OC)OC,,,,,,
10794,45489,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(4-nitrobenzyl)-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)[N+](=O)[O-])OC)OC.[Cl-],,,,,,
10795,45490,"6,7-dimethoxy-2-methyl-1-[(4-nitrophenyl)methyl]-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)[N+](=O)[O-])OC)OC,,,,,,
10796,45491,"1-(2-Nitrophenethyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=CC=CC=C3[N+](=O)[O-])OC)OC,,,,,,
10797,45492,4'-Nitromethopholine,CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)[N+](=O)[O-])OC)OC,,,,,,
10798,45493,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3-nitrophenethyl)-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC(=CC=C3)[N+](=O)[O-])OC)OC.[Cl-],,,,,,
10799,45494,"6,7-dimethoxy-2-methyl-1-[2-(3-nitrophenyl)ethyl]-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=CC(=CC=C3)[N+](=O)[O-])OC)OC,,,,,,
10800,45495,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(4-nitrophenethyl)methyl-, hydrobromide",C[NH+]1CCC2=CC(=C(C=C2C1CCCC3=CC=C(C=C3)[N+](=O)[O-])OC)OC.[Br-],,,,,,
10801,45496,"6,7-dimethoxy-2-methyl-1-[3-(4-nitrophenyl)propyl]-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCCC3=CC=C(C=C3)[N+](=O)[O-])OC)OC,,,,,,
10802,45497,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(phenethylmethyl)-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCCC3=CC=CC=C3)OC)OC.[Cl-],,,,,,
10803,45498,"6,7-dimethoxy-2-methyl-1-(3-phenylpropyl)-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCCC3=CC=CC=C3)OC)OC,,,,,,
10804,45499,"1-(2,3,4-Trichlorophenethyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=C(C(=C(C=C3)Cl)Cl)Cl)OC)OC,,,,,,
10805,45500,"1-(2,4,5-Trichlorophenethyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=CC(=C(C=C3Cl)Cl)Cl)OC)OC,,,,,,
10806,45501,"Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trichlorophenethyl)-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC(=C(C(=C3)Cl)Cl)Cl)OC)OC.[Cl-],,,,,,
10807,45502,"6,7-dimethoxy-2-methyl-1-[2-(3,4,5-trichlorophenyl)ethyl]-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=CC(=C(C(=C3)Cl)Cl)Cl)OC)OC,,,,,,
10808,45503,"Isoquinoline, 1,2,3,4-tetrahydro-1-(3-dimethylaminopropyl)-1-phenyl-",CN(C)CCCC1(C2=CC=CC=C2CCN1)C3=CC=CC=C3,,,,,,
10809,45504,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorobenzyl)-6,7-dimethoxy-2-methyl-, hydrobromide",C[NH+]1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)Cl)OC)OC.[Br-],,,,,,
10810,45505,"1-[(4-chlorophenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)Cl)OC)OC,,,,,,
10811,45506,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chloro-alpha-methyl)phenethyl-6,7-dimethoxy-2-methyl-, hydrobromide",CC(CC1=CC=C(C=C1)Cl)C2C3=CC(=C(C=C3CC[NH+]2C)OC)OC.[Br-],,,,,,
10812,45507,"1-[1-(4-chlorophenyl)propan-2-yl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CC(CC1=CC=C(C=C1)Cl)C2C3=CC(=C(C=C3CCN2C)OC)OC,,,,,,
10813,45508,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-6,7-diethoxy-2-methyl-, hydrogen oxalate",CCOC1=C(C=C2C([NH+](CCC2=C1)C)CCC3=CC=C(C=C3)Cl)OCC.C(=O)(C(=O)[O-])O,,,,,,
10814,45509,"1-[2-(4-chlorophenyl)ethyl]-6,7-diethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CCOC1=C(C=C2C(N(CCC2=C1)C)CCC3=CC=C(C=C3)Cl)OCC,,,,,,
10815,45510,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-2-(2-(diethylamino)ethyl)-6,7-dimethoxy-, hydrobromide",CC[NH+](CC)CCN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)OC.[Br-],,,,,,
10816,45511,"2-[1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-N,N-diethylethanamine",CCN(CC)CCN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
10817,45512,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-6,7-dimethoxy-2,3-dimethyl-, hydrobromide",CC1CC2=CC(=C(C=C2C([NH+]1C)CCC3=CC=C(C=C3)Cl)OC)OC.[Br-],,,,,,
10818,45513,"1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-2,3-dimethyl-3,4-dihydro-1H-isoquinoline",CC1CC2=CC(=C(C=C2C(N1C)CCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
10819,45514,"1-(4-Chlorophenethyl)-6,7-dimethoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline",CCN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
10820,45515,"1-(4-Chlorophenethyl)-6,7-dimethoxy-2-(3-methylbut-2-enyl)-1,2,3,4-tetrahydroisoquinoline",CC(=CCN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)OC)C,,,,,,
10821,45516,"Isoquinoline, 1,2,3,4-tetrahydro-1-(2-chlorophenethyl)-6,7-dimethoxy-2-methyl-, hydrobromide",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC=CC=C3Cl)OC)OC.[Br-],,,,,,
10822,45517,"1-[2-(2-chlorophenyl)ethyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=CC=CC=C3Cl)OC)OC,,,,,,
10823,45518,"Isoquinoline, 1,2,3,4-tetrahydro-1-(3-chlorophenethyl)-6,7-dimethoxy-2-methyl-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC(=CC=C3)Cl)OC)OC.[Cl-],,,,,,
10824,45519,"1-[2-(3-chlorophenyl)ethyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCC3=CC(=CC=C3)Cl)OC)OC,,,,,,
10825,45520,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-5,6-dimethoxy-2-methyl-, hydrochloride",C[NH+]1CCC2=C(C1CCC3=CC=C(C=C3)Cl)C=CC(=C2OC)OC.[Cl-],,,,,,
10826,45521,"1-[2-(4-chlorophenyl)ethyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=C(C1CCC3=CC=C(C=C3)Cl)C=CC(=C2OC)OC,,,,,,
10827,45522,"1-(4-Chlorophenethyl)-6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline oxalate",COC1=C(C=C2C([NH+](CCC2=C1)CCC3=CC=CC=C3)CCC4=CC=C(C=C4)Cl)OC.C(=O)(C(=O)[O-])O,,,,,,
10828,45523,"1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-2-(2-phenylethyl)-3,4-dihydro-1H-isoquinoline",COC1=C(C=C2C(N(CCC2=C1)CCC3=CC=CC=C3)CCC4=CC=C(C=C4)Cl)OC,,,,,,
10829,45524,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-6,7-dimethyl-2-methyl-, hydrobromide",CC1=CC2=C(C=C1C)C([NH+](CC2)C)CCC3=CC=C(C=C3)Cl.[Br-],,,,,,
10830,45525,"1-[2-(4-chlorophenyl)ethyl]-2,6,7-trimethyl-3,4-dihydro-1H-isoquinoline",CC1=CC2=C(C=C1C)C(N(CC2)C)CCC3=CC=C(C=C3)Cl,,,,,,
10831,45526,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-6-methoxy-2-methyl-, hydrochloride",C[NH+]1CCC2=C(C1CCC3=CC=C(C=C3)Cl)C=CC(=C2)OC.[Cl-],,,,,,
10832,45527,"1-[2-(4-chlorophenyl)ethyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=C(C1CCC3=CC=C(C=C3)Cl)C=CC(=C2)OC,,,,,,
10833,45528,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)methyl-6,7-dimethoxy-2-methyl-, hydrobromide",C[NH+]1CCC2=CC(=C(C=C2C1CCCC3=CC=C(C=C3)Cl)OC)OC.[Br-],,,,,,
10834,45529,"1-[3-(4-chlorophenyl)propyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C=C2C1CCCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
10835,45530,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-2-methyl-6,7,8-trimethoxy-, hydrobromide",C[NH+]1CCC2=CC(=C(C(=C2C1CCC3=CC=C(C=C3)Cl)OC)OC)OC.[Br-],,,,,,
10836,45531,"1-[2-(4-chlorophenyl)ethyl]-6,7,8-trimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CN1CCC2=CC(=C(C(=C2C1CCC3=CC=C(C=C3)Cl)OC)OC)OC,,,,,,
10837,45532,"Isoquinoline, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-2,3,6,7-tetramethyl-, hydrochloride",CC1CC2=C(C=C(C(=C2)C)C)C([NH+]1C)CCC3=CC=C(C=C3)Cl.[Cl-],,,,,,
10838,45533,"1-[2-(4-chlorophenyl)ethyl]-2,3,6,7-tetramethyl-3,4-dihydro-1H-isoquinoline",CC1CC2=C(C=C(C(=C2)C)C)C(N1C)CCC3=CC=C(C=C3)Cl,,,,,,
10839,45534,CID 45534,COC1=C(C=C2C[NH+](CCC2=C1)CCCC3=CC=C(C=C3)Cl)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
10840,45535,"2-[3-(4-chlorophenyl)propyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline",COC1=C(C=C2CN(CCC2=C1)CCCC3=CC=C(C=C3)Cl)OC,,,,,,
10841,45536,"N-Methyl-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=C(C=C2C[NH+](CCC2=C1)C)OCC.[Cl-],,,,,,
10842,45537,"6,7-diethoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CCOC1=C(C=C2CN(CCC2=C1)C)OCC,,,,,,
10843,45538,"2-Methyl-1,2,3,4-tetrahydroisoquinoline-5,6-diol hydrochloride",C[NH+]1CCC2=C(C1)C=CC(=C2O)O.[Cl-],,,,,,
10844,45539,"2-methyl-3,4-dihydro-1H-isoquinoline-5,6-diol",CN1CCC2=C(C1)C=CC(=C2O)O,,,,,,
10845,45540,"N-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1)O)O.[Cl-],,,,,,
10846,45541,"N-Methyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[NH+]1CCC2=C(C1)C=CC(=C2OC)OC.[Cl-],,,,,,
10847,45542,"5,6-Dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=C(C1)C=CC(=C2OC)OC,,,,,,
10848,45543,"N-Methyl-5-ethoxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=C(C=CC2=C1CC[NH+](C2)C)OC.[Cl-],,,,,,
10849,45544,"5-ethoxy-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CCOC1=C(C=CC2=C1CCN(C2)C)OC,,,,,,
10850,45545,"N-Methyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=CC2=C(C[NH+](CC2)C)C=C1.[Cl-],,,,,,
10851,45546,"2-Methyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline",CCOC1=CC2=C(CN(CC2)C)C=C1,,,,,,
10852,45547,"N-Methyl-6-methoxy-7-ethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=C(C=C2CC[NH+](CC2=C1)C)OC.[Cl-],,,,,,
10853,45548,"7-ethoxy-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CCOC1=C(C=C2CCN(CC2=C1)C)OC,,,,,,
10854,45549,"N-Methyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[NH+]1CCC2=C(C1)C=CC(=C2)OC.[Cl-],,,,,,
10855,45550,"N-Methyl-7,8-methylenedioxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",C[NH+]1CCC2=C(C1)C3=C(C=C2)OCO3.[Cl-],,,,,,
10856,45551,"8-methyl-7,9-dihydro-6H-[1,3]dioxolo[4,5-h]isoquinoline",CN1CCC2=C(C1)C3=C(C=C2)OCO3,,,,,,
10857,45552,"1-(4-Chlorophenethyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline",CN1CCC2=C(C1CCC3=CC=C(C=C3)Cl)CCCC2,,,,,,
10858,45553,"1-(2-Nitrophenethyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline",CN1CCC2=C(C1CCC3=CC=CC=C3[N+](=O)[O-])CCCC2,,,,,,
10859,45554,"1-(3-Nitrophenethyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline",CN1CCC2=C(C1CCC3=CC(=CC=C3)[N+](=O)[O-])CCCC2,,,,,,
10860,45555,"1-(4-Nitrophenethyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline",CN1CCC2=C(C1CCC3=CC=C(C=C3)[N+](=O)[O-])CCCC2,,,,,,
10861,45556,"Isoquinoline, 1,2,3,4-tetrahydro-1-(beta-acetoxy-4-chloro)phenethyl-6,7-dimethoxy-2-methyl-, hydrochloride",CC(=O)OC(CC1C2=CC(=C(C=C2CC[NH+]1C)OC)OC)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
10862,45557,"[1-(4-chlorophenyl)-2-(6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl)ethyl] acetate",CC(=O)OC(CC1C2=CC(=C(C=C2CCN1C)OC)OC)C3=CC=C(C=C3)Cl,,,,,,
10863,45558,"1-(4-Chlorophenethyl)-2-allyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",COC1=C(C=C2C([NH+](CCC2=C1)CC=C)CCC3=CC=C(C=C3)Cl)OC.[Cl-],,,,,,
10864,45559,"1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-2-prop-2-enyl-3,4-dihydro-1H-isoquinoline",COC1=C(C=C2C(N(CCC2=C1)CC=C)CCC3=CC=C(C=C3)Cl)OC,,,,,,
10865,45560,"1-(4-Nitrophenethyl)-2-allyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",COC1=C(C=C2C([NH+](CCC2=C1)CC=C)CCC3=CC=C(C=C3)[N+](=O)[O-])OC.[Cl-],,,,,,
10866,45561,"6,7-dimethoxy-1-[2-(4-nitrophenyl)ethyl]-2-prop-2-enyl-3,4-dihydro-1H-isoquinoline",COC1=C(C=C2C(N(CCC2=C1)CC=C)CCC3=CC=C(C=C3)[N+](=O)[O-])OC,,,,,,
10867,45562,CID 45562,CC1CCCCN1CCCOC(=O)C=CC2=CC=CC=C2,,,,,,
10868,45563,CID 45563,C1=CC=C(C=C1)C=CC(=O)[O-].C1=CC=C(C=C1)C=CC(=O)[O-].[Ni+2],,,,,,
10869,45564,Benzyl-(2-chloroethyl)-[3-(2-methylphenyl)prop-2-enyl]azanium;chloride,CC1=CC=CC=C1C=CC[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
10870,45565,N-benzyl-N-(2-chloroethyl)-3-(2-methylphenyl)prop-2-en-1-amine,CC1=CC=CC=C1C=CCN(CCCl)CC2=CC=CC=C2,,,,,,
10871,45566,Yttrium citrate,C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O.[Y+3],,,,,,
10872,45567,"4H-1-Benzopyran-4-one, 7-methoxy-2,3-dimethyl-8-(4-morpholinylmethyl)-, hydrochloride",CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCOCC3)OC)C.[Cl-],,,,,,
10873,45568,CID 45568,CCCCCC(=CC1=CC=CC=C1)C(=O)NCCN(CC)CC,,,,,,
10874,45569,3-(2-Chlorophenyl)-3-cyanoprop-2-enamide,C1=CC=C(C(=C1)C(=CC(=O)N)C#N)Cl,,,,,,
10875,45570,"Erythramine, hydrobromide",CO[C@H]1CC=C2CC[NH+]3C2(C1)C4=CC5=C(C=C4CC3)OCO5.[Br-],,,,,,
10876,45571,"(19S)-19-methoxy-5,7-dioxa-13-azapentacyclo[11.7.0.01,16.02,10.04,8]icosa-2,4(8),9,16-tetraene",CO[C@H]1CC=C2CCN3C2(C1)C4=CC5=C(C=C4CC3)OCO5,,,,,,
10877,45572,"1,2-Bis(2-bromoethylthio)ethane",C(CSCCBr)SCCBr,,,,,,
10878,45573,"ETHANE, 2,2-BIS(m-CHLORO-p-TOLYL)-1,1,1-TRICHLORO-",CC1=C(C=C(C=C1)C(C2=CC(=C(C=C2)C)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
10879,45574,"Ethane, 1,2-bis(2-fluoroethoxy)-",C(COCCF)OCCF,,,,,,
10880,45575,"ETHANE, 1,2-BIS(beta-(beta-NAPHTHOXY)ETHYLTHIO)-",C1=CC=C2C=C(C=CC2=C1)OCCSCCSCCOC3=CC4=CC=CC=C4C=C3,,,,,,
10881,45576,"ETHANE, 1,2-BIS(beta-(PHTHALIMIDO)ETHYLTHIO)-",C1=CC=C2C(=C1)C(=O)N(C2=O)CCSCCSCCN3C(=O)C4=CC=CC=C4C3=O,,,,,,
10882,45577,"Ethane, 2,2-bis(5,6,7,8-tetrahydronaphthyl)-1,1,1-trichloro-",C1CCC2=C(C1)C=CC=C2C(C3=CC=CC4=C3CCCC4)C(Cl)(Cl)Cl,,,,,,
10883,45578,Trisodium-2-(hydroxycyclohexyl)ethylenediamine triacetate,C1CCC(C(C1)N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Na+].[Na+].[Na+],,,,,,
10884,45579,2-[Carboxymethyl-[2-[carboxymethyl-(2-hydroxycyclohexyl)amino]ethyl]amino]acetic acid,C1CCC(C(C1)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O)O,,,,,,
10885,45580,CID 45580,CCOC(=O)CNC(=O)C=C(C)OP(=O)(OC)OC,,,,,,
10886,45581,N-Butyltryptamine hydrochloride,CCCC[NH2+]CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10887,45582,N-n-butyl-tryptamine,CCCCNCCC1=CNC2=CC=CC=C21,,,,,,
10888,45583,"N,N-Dibenzyltryptamine hydrochloride",C1=CC=C(C=C1)C[NH+](CCC2=CNC3=CC=CC=C32)CC4=CC=CC=C4.[Cl-],,,,,,
10889,45584,"1H-Indole-3-ethanamine, N,N-bis(phenylmethyl)-",C1=CC=C(C=C1)CN(CCC2=CNC3=CC=CC=C32)CC4=CC=CC=C4,,,,,,
10890,45585,3-(2-(2-Isobutylamino)ethyl)indole monohydrochloride,CC(C)C[NH2+]CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10891,45586,N-isobutyl-tryptamine,CC(C)CNCCC1=CNC2=CC=CC=C21,,,,,,
10892,45587,1-Methyl-3-(2-pyrrolidinyl)indole hydrochloride,CN1C=C(C2=CC=CC=C21)C3CCC[NH2+]3.[Cl-],,,,,,
10893,45588,1-Methyl-3-(pyrrolidin-2-yl)-1h-indole,CN1C=C(C2=CC=CC=C21)C3CCCN3,,,,,,
10894,45589,3-(2-(Isopropylamino)ethyl)indole monohydrochloride,CC(C)[NH2+]CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10895,45590,N-[2-(1H-indol-3-yl)ethyl]propan-2-amine,CC(C)NCCC1=CNC2=CC=CC=C21,,,,,,
10896,45591,N-Benzyltryptamine hydrochloride,C1=CC=C(C=C1)C[NH2+]CCC2=CNC3=CC=CC=C32.[Cl-],,,,,,
10897,45592,N-Benzyl-1H-indole-3-ethylamine,C1=CC=C(C=C1)CNCCC2=CNC3=CC=CC=C32,,,,,,
10898,45593,3-(2-(4-Chlorobenzylamino)ethyl)indole monohydrochloride,C1=CC=C2C(=C1)C(=CN2)CC[NH2+]CC3=CC=C(C=C3)Cl.[Cl-],,,,,,
10899,45594,N-[(4-chlorophenyl)methyl]-2-(1H-indol-3-yl)ethanamine,C1=CC=C2C(=C1)C(=CN2)CCNCC3=CC=C(C=C3)Cl,,,,,,
10900,45595,Diethyltryptamine hydrochloride,CC[NH+](CC)CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10901,45596,3-(2-(Diisobutylamino)ethyl)indole monohydrochloride,CC(C)C[NH+](CCC1=CNC2=CC=CC=C21)CC(C)C.[Cl-],,,,,,
10902,45597,"N,N-Diisobutyl-1H-indole-3-ethaneamine",CC(C)CN(CCC1=CNC2=CC=CC=C21)CC(C)C,,,,,,
10903,45598,"Indole, 2,4-dimethyl-5-methoxy-3-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-, dihydrochloride, hemihydrate",CC1=C(C=CC2=C1C(=C(N2)C)CCN3CCN(CC3)C4=CC=CC=C4OC)OC.Cl.Cl,,,,,,
10904,45599,"5-methoxy-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-2,4-dimethyl-1H-indole",CC1=C(C=CC2=C1C(=C(N2)C)CCN3CCN(CC3)C4=CC=CC=C4OC)OC,,,,,,
10905,45600,"Indole, 2,4-dimethyl-5-methoxy-3-(2-(3-pyrrolinyl)ethyl)-",CC1=C(C=CC2=C1C(=C(N2)C)CCC3CCNC3)OC,,,,,,
10906,45601,N-Ethyltryptamine hydrochloride,CC[NH2+]CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10907,45602,3-(2-(alpha-Methylbenzylamino)ethyl)indole monohydrochloride,CC(C1=CC=CC=C1)[NH2+]CCC2=CNC3=CC=CC=C32.[Cl-],,,,,,
10908,45603,N-[2-(1H-indol-3-yl)ethyl]-1-phenylethanamine,CC(C1=CC=CC=C1)NCCC2=CNC3=CC=CC=C32,,,,,,
10909,45604,3-(2-(n-Propylamino)ethyl)indole monohydrochloride,CCC[NH2+]CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
10910,45605,N-[2-(1H-indol-3-yl)ethyl]propan-1-amine,CCCNCCC1=CNC2=CC=CC=C21,,,,,,
10911,45606,Bis(2-bromo-4-chlorophenyl)iodonium chloride,C1=CC(=C(C=C1Cl)Br)[I+]C2=C(C=C(C=C2)Cl)Br.[Cl-],,,,,,
10912,45607,Bis(2-bromo-4-chlorophenyl)iodanium,C1=CC(=C(C=C1Cl)Br)[I+]C2=C(C=C(C=C2)Cl)Br,,,,,,
10913,45608,"IODONIUM, BIS(p-BROMOPHENYL)-, SULFATE",C1=CC(=CC=C1Br)[I+]C2=CC=C(C=C2)Br.C1=CC(=CC=C1Br)[I+]C2=CC=C(C=C2)Br.[O-]S(=O)(=O)[O-],,,,,,
10914,45609,"IODONIUM, BIS(p-IODOPHENYL)-, SULFATE",C1=CC(=CC=C1I)[I+]C2=CC=C(C=C2)I.C1=CC(=CC=C1I)[I+]C2=CC=C(C=C2)I.[O-]S(=O)(=O)[O-],,,,,,
10915,45610,Bis(4-iodophenyl)iodonium,C1=CC(=CC=C1I)[I+]C2=CC=C(C=C2)I,,,,,,
10916,45611,2-Ethoxy-3-methoxybenzoic acid 2-piperidinoethyl ester hydrochloride,CCOC1=C(C=CC=C1OC)C(=O)OCC[NH+]2CCCCC2.[Cl-],,,,,,
10917,45612,2-Piperidin-1-ylethyl 2-ethoxy-3-methoxybenzoate,CCOC1=C(C=CC=C1OC)C(=O)OCCN2CCCCC2,,,,,,
10918,45613,"2(3H)-Benzofuranone, 3-(2-(diethylamino)ethyl)-5-methyl-3-propyl-, hydrochloride",CCCC1(C2=C(C=CC(=C2)C)OC1=O)CC[NH+](CC)CC.[Cl-],,,,,,
10919,45614,3-[2-(Diethylamino)ethyl]-5-methyl-3-propyl-1-benzofuran-2-one,CCCC1(C2=C(C=CC(=C2)C)OC1=O)CCN(CC)CC,,,,,,
10920,45615,2-Methylphenoxyethyl-beta-chloroethylamine hydrochloride,CC1=CC=CC=C1OCC[NH2+]CCCl.[Cl-],,,,,,
10921,45616,N-(2-chloroethyl)-2-(2-methylphenoxy)ethanamine,CC1=CC=CC=C1OCCNCCCl,,,,,,
10922,45617,"2-(p,p'-Dichlorodiphenylmethoxy)-N-morpholinoethylamine hydrochloride",C1COCCN1[NH2+]CCOC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
10923,45618,N-[2-[bis(4-chlorophenyl)methoxy]ethyl]morpholin-4-amine,C1COCCN1NCCOC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
10924,45619,"N,N,N',N'-Tetrakis(2-dihydroxyboroxypropyl)ethylenediamine",B(O)(O)OC(C)CN(CCN(CC(C)OB(O)O)CC(C)OB(O)O)CC(C)OB(O)O,,,,,,
10925,45620,N-(2-(Diethylamino)ethyl)-fluorene-9-carboxamide hydrochloride,CC[NH+](CC)CCNC(=O)C1C2=CC=CC=C2C3=CC=CC=C13.[Cl-],,,,,,
10926,45621,N-[2-(diethylamino)ethyl]-9H-fluorene-9-carboxamide,CCN(CC)CCNC(=O)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
10927,45622,"Carbonic acid, trithio-, bis(2-chloroethyl)ester",C(CCl)SC(=S)SCCCl,,,,,,
10928,45623,CID 45623,C1=CC=C(C(=C1)O)SCC(=O)O.O.O.[SbH3],,,,,,
10929,45624,CID 45624,C[NH+](C)C1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)O.[Cl-].[Cl-],,,,,,
10930,45625,CID 45625,CN(C)C1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)O,,,,,,
10931,45626,"Acridine, 9,10-dihydro-10-(4-methoxybenzoyl)-",COC1=CC=C(C=C1)C(=O)N2C3=CC=CC=C3CC4=CC=CC=C42,,,,,,
10932,45627,CID 45627,CC(C(=O)[O-])NC(=O)C1=CC=C(C=C1)NCC2=NC3=CN=C(N=C3[N+](=C2)N)N.[Na+],,,,,,
10933,45628,"2-[[4-[(2,8-Diaminopteridin-8-ium-6-yl)methylamino]benzoyl]amino]propanoic acid",CC(C(=O)O)NC(=O)C1=CC=C(C=C1)NCC2=NC3=CN=C(N=C3[N+](=C2)N)N,,,,,,
10934,45629,"ACETAMIDE, N-(beta-MERCAPTOETHYL)-N-METHYL-",CC(=O)N(C)CCS,,,,,,
10935,45630,Acetic acid;(2-amino-3-mercurio-5-nitrophenyl)mercury,CC(=O)O.CC(=O)O.C1=C(C=C(C(=C1[Hg])N)[Hg])[N+](=O)[O-],,,,,,
10936,45631,(2-Amino-3-mercurio-5-nitrophenyl)mercury,C1=C(C=C(C(=C1[Hg])N)[Hg])[N+](=O)[O-],,,,,,
10937,45632,Phenyl-bis(2-chloroethyl-mercaptoethyl)amine hydrochloride,C1=CC=C(C=C1)[NH+](CCSCCCl)CCSCCCl.[Cl-],,,,,,
10938,45633,"Benzenamine, N,N-bis(2-((2-chloroethyl)thio)ethyl)-",C1=CC=C(C=C1)N(CCSCCCl)CCSCCCl,,,,,,
10939,45634,"N,N-Bis(2-(2,3-epoxypropoxy)ethoxy)aniline",C1C(O1)COCCON(C2=CC=CC=C2)OCCOCC3CO3,,,,,,
10940,45635,"2,6-Bis(hydroxymercuri)-4-nitroaniline",C1=C(C=C(C(=C1[Hg])N)[Hg])[N+](=O)[O-].O.O,,,,,,
10941,45636,N-(2-Chloroethyl)-N-ethylaniline hydrochloride,CC[NH+](CCCl)C1=CC=CC=C1.[Cl-],,,,,,
10942,45637,3'-Chloro-4'-methyl-4-dimethylaminoazobenzene,CC1=C(C=C(C=C1)N=NC2=CC=C(C=C2)N(C)C)Cl,,,,,,
10943,45638,Diethylaminoethyl ethylaniline,CC[NH+](CC)CCN(CC)C1=CC=CC=C1.[Cl-],,,,,,
10944,45639,"1,2-Ethanediamine, N'-phenyl-N,N,N'-triethyl-",CCN(CC)CCN(CC)C1=CC=CC=C1,,,,,,
10945,45640,"AMMONIUM, (6-(p-TRIETHYLAMMONIOPHENYL)HEXYL)TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CCCCCCC1=CC=C(C=C1)[N+](CC)(CC)CC.[I-].[I-],,,,,,
10946,45641,Triethyl-[4-[6-(triethylazaniumyl)hexyl]phenyl]azanium,CC[N+](CC)(CC)CCCCCCC1=CC=C(C=C1)[N+](CC)(CC)CC,,,,,,
10947,45642,"AMMONIUM, (5-(p-TRIETHYLAMMONIOPHENYL)PENTYL)TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CCCCCC1=CC=C(C=C1)[N+](CC)(CC)CC.[I-].[I-],,,,,,
10948,45643,Triethyl-[4-[5-(triethylazaniumyl)pentyl]phenyl]azanium,CC[N+](CC)(CC)CCCCCC1=CC=C(C=C1)[N+](CC)(CC)CC,,,,,,
10949,45644,"AMMONIUM, (3-(p-TRIETHYLAMMONIOPHENYL)PROPYL)TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CCCC1=CC=C(C=C1)[N+](CC)(CC)CC.[I-].[I-],,,,,,
10950,45645,Triethyl-[3-[4-(triethylazaniumyl)phenyl]propyl]azanium,CC[N+](CC)(CC)CCCC1=CC=C(C=C1)[N+](CC)(CC)CC,,,,,,
10951,45646,"Ammonium, N,N,N'-triethyl-N,N',N'-trimethyl-N,N'-oxydiethylenedi-, dibromide",CC[N+](C)(C)CCOCC[N+](C)(CC)CC.[Br-].[Br-],,,,,,
10952,45647,Diethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]ethyl]-methylazanium,CC[N+](C)(C)CCOCC[N+](C)(CC)CC,,,,,,
10953,45648,"AMMONIUM, (p-TRIMETHYLAMMONIO)BENZYLTRIMETHYL-, DIIODIDE",C[N+](C)(C)CC1=CC=C(C=C1)[N+](C)(C)C.[I-].[I-],,,,,,
10954,45649,Trimethyl-[4-[(trimethylazaniumyl)methyl]phenyl]azanium,C[N+](C)(C)CC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
10955,45650,"AMMONIUM, (4-(p-TRIMETHYLAMMONIOPHENYL)BUTYL)TRIMETHYL-, DIIODIDE",C[N+](C)(C)CCCCC1=CC=C(C=C1)[N+](C)(C)C.[I-].[I-],,,,,,
10956,45651,Trimethyl-[4-[4-(trimethylazaniumyl)butyl]phenyl]azanium,C[N+](C)(C)CCCCC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
10957,45652,"AMMONIUM, (6-(p-TRIMETHYLAMMONIOPHENYL)HEXYL)TRIMETHYL-, DIIODIDE",C[N+](C)(C)CCCCCCC1=CC=C(C=C1)[N+](C)(C)C.[I-].[I-],,,,,,
10958,45653,Trimethyl-[4-[6-(trimethylazaniumyl)hexyl]phenyl]azanium,C[N+](C)(C)CCCCCCC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
10959,45654,"AMMONIUM, (5-(p-TRIMETHYLAMINONIOPHENYL)PENTYL)TRIMETHYL-, DIIODIDE",C[N+](C)(C)CCCCCC1=CC=C(C=C1)[N+](C)(C)C.[I-].[I-],,,,,,
10960,45655,Trimethyl-[4-[5-(trimethylazaniumyl)pentyl]phenyl]azanium,C[N+](C)(C)CCCCCC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
10961,45656,"AMMONIUM, (3-(p-TRIMETHYLAMMONIOPHENYL)PROPYL)TRIMETHYL-, DIIODIDE",C[N+](C)(C)CCCC1=CC=C(C=C1)[N+](C)(C)C.[I-].[I-],,,,,,
10962,45657,Trimethyl-[3-[4-(trimethylazaniumyl)phenyl]propyl]azanium,C[N+](C)(C)CCCC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
10963,45658,Butyltrimethylammonium hydroxide,CCCC[N+](C)(C)C.[OH-],,,,,,
10964,45659,"Ammonium, trimethylenebis(fluoren-9-yldimethyl-, dibromide",C[N+](C)(CCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-],,,,,,
10965,45660,9H-fluoren-9-yl-[3-[9H-fluoren-9-yl(dimethyl)azaniumyl]propyl]-dimethylazanium,C[N+](C)(CCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
10966,45661,3-Ureidophenyltrimethylammonium iodide,C[N+](C)(C)C1=CC=CC(=C1)NC(=O)N.[I-],,,,,,
10967,45662,[3-(Carbamoylamino)phenyl]-trimethylazanium,C[N+](C)(C)C1=CC=CC(=C1)NC(=O)N,,,,,,
10968,45663,Trimethyl(p-ureidophenyl)ammonium iodide,C[N+](C)(C)C1=CC=C(C=C1)NC(=O)N.[I-],,,,,,
10969,45664,[4-(Carbamoylamino)phenyl]-trimethylazanium,C[N+](C)(C)C1=CC=C(C=C1)NC(=O)N,,,,,,
10970,45665,"Ammonium, sulfinyldiethylenebis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCS(=O)CC[N+](C)(CC)CC.[I-].[I-],,,,,,
10971,45666,2-[2-[Diethyl(methyl)azaniumyl]ethylsulfinyl]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCS(=O)CC[N+](C)(CC)CC,,,,,,
10972,45667,"Ammonium, sulfinyldiethylenebis(ethyldimethyl-, dibromide",CC[N+](C)(C)CCS(=O)CC[N+](C)(C)CC.[Br-].[Br-],,,,,,
10973,45668,Ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethylsulfinyl]ethyl]-dimethylazanium,CC[N+](C)(C)CCS(=O)CC[N+](C)(C)CC,,,,,,
10974,45669,"Ammonium, sulfinyldiethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCS(=O)CC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
10975,45670,Triethyl-[2-[2-(triethylazaniumyl)ethylsulfinyl]ethyl]azanium,CC[N+](CC)(CC)CCS(=O)CC[N+](CC)(CC)CC,,,,,,
10976,45671,"Ammonium, sulfinyldiethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCS(=O)CC[N+](C)(C)C.[I-].[I-],,,,,,
10977,45672,Trimethyl-[2-[2-(trimethylazaniumyl)ethylsulfinyl]ethyl]azanium,C[N+](C)(C)CCS(=O)CC[N+](C)(C)C,,,,,,
10978,45673,Hexamethyltetradecamethylene bisammonium chloride,C[N+](C)(C)CCCCCCCCCCCCCC[N+](C)(C)C.[Cl-].[Cl-],,,,,,
10979,45674,"n,n,n,n',n',n'-Hexamethyltetradecane-1,14-diaminium",C[N+](C)(C)CCCCCCCCCCCCCC[N+](C)(C)C,,,,,,
10980,45675,"Ammonium, (1,2,3,4-tetrahydro-5-hydroxynaphthyl)trimethyl-, iodide, methylcarbamate",CNC(=O)OC1=CC=CC2=C1CCCC2[N+](C)(C)C.[I-],,,,,,
10981,45676,"Trimethyl-[5-(methylcarbamoyloxy)-1,2,3,4-tetrahydronaphthalen-1-yl]azanium",CNC(=O)OC1=CC=CC2=C1CCCC2[N+](C)(C)C,,,,,,
10982,45677,"Ammonium, ((5,6,7,8-tetrahydro-4-hydroxy)naphthyl)trimethyl-, iodide, methylcarbamate",CNC(=O)OC1=C2CCCCC2=C(C=C1)[N+](C)(C)C.[I-],,,,,,
10983,45678,"Trimethyl-[4-(methylcarbamoyloxy)-5,6,7,8-tetrahydronaphthalen-1-yl]azanium",CNC(=O)OC1=C2CCCCC2=C(C=C1)[N+](C)(C)C,,,,,,
10984,45679,"Ammonium, tetramethylenebis(diethylmethyl-, dibromide",CC[N+](C)(CC)CCCC[N+](C)(CC)CC.[Br-].[Br-],,,,,,
10985,45680,"N,N,N',N'-Tetraethyl-N,N'-dimethyl-1,4-butanediaminium",CC[N+](C)(CC)CCCC[N+](C)(CC)CC,,,,,,
10986,45681,"Ammonium, thiodiethylenebis(ethyldimethyl-, dibromide",CC[N+](C)(C)CCSCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
10987,45682,"Ammonium, thiodiethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCSCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
10988,45683,Triethyl-[2-[2-(triethylazaniumyl)ethylsulfanyl]ethyl]azanium,CC[N+](CC)(CC)CCSCC[N+](CC)(CC)CC,,,,,,
10989,45684,3-(p-Toluoyloxy)phenyltrimethylammonium bromide,CC1=CC=C(C=C1)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-],,,,,,
10990,45685,Trimethyl-[3-(4-methylbenzoyl)oxyphenyl]azanium,CC1=CC=C(C=C1)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C,,,,,,
10991,45686,"AMMONIUM, ((p-TRIETHYLAMMONIO)PHENETHYL)TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CCC1=CC=C(C=C1)[N+](CC)(CC)CC.[I-].[I-],,,,,,
10992,45687,Triethyl-[4-[2-(triethylazaniumyl)ethyl]phenyl]azanium,CC[N+](CC)(CC)CCC1=CC=C(C=C1)[N+](CC)(CC)CC,,,,,,
10993,45688,"AMMONIUM, (4-(p-TRIETHYLAMMONIOPHENYL)BUTYL)TRIETHYL-, DIIODIDE",CC[N+](CC)(CC)CCCCC1=CC=C(C=C1)[N+](CC)(CC)CC.[I-].[I-],,,,,,
10994,45689,Triethyl-[4-[4-(triethylazaniumyl)butyl]phenyl]azanium,CC[N+](CC)(CC)CCCCC1=CC=C(C=C1)[N+](CC)(CC)CC,,,,,,
10995,45690,O-Deacetylgerminaline,CCC(C)C(=O)O[C@H]1CC[C@]2(C3[C@@]1(O[C@@]24CC5C6CN7C[C@H](CC[C@H]7[C@@](C6[C@H](C([C@]5(C4[C@@H](C3)O)O)OC(=O)C(C)(CC)O)O)(C)O)C)O)C,,,,,,
10996,45691,CID 45691,CC(C)CCOC(=O)C(C1=CC=CC=C1)[NH2+]CC[NH+]2CCCC2.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
10997,45692,"2-FURAMIDE, 5-tert-BUTYL-",CC(C)(C)C1=CC=C(O1)C(=O)N,,,,,,
10998,45693,tert-Amyl 2-furylcarbamate,CC(C)(C)COC(=O)NC1=CC=CO1,,,,,,
10999,45694,"2-Furancarbamic acid, propyl ester",CCCOC(=O)NC1=CC=CO1,,,,,,
11000,45695,"FURFURYLAMINE, alpha-METHYL-N-(2-OXAZOLINYL)-",CC(C1=CC=CO1)NC2=NCCO2,,,,,,
11001,45696,"Furfurylamine, tetrahydro-N,N-bis(2-chloroethyl)-",C1CC(OC1)CN(CCCl)CCCl,,,,,,
11002,45697,"5H-Furo(3,2-g)(1)benzopyran, 2,3,6,7-tetrahydro-9-(3-(tert-butylamino)-2-hydroxypropoxy)-4-hydroxy-7-methyl-, hydrochloride",CC1CC2=C(O1)C(=C3C(=C(CCO3)O)C2)OCC(C[NH2+]C(C)(C)C)O.[Cl-],,,,,,
11003,45698,"9-[3-(tert-butylamino)-2-hydroxypropoxy]-2-methyl-3,4,6,7-tetrahydro-2H-furo[3,2-g]chromen-5-ol",CC1CC2=C(O1)C(=C3C(=C(CCO3)O)C2)OCC(CNC(C)(C)C)O,,,,,,
11004,45699,"5H-Furo(3,2-g)(1)benzopyran, 2,3,6,7-tetrahydro-4-hydroxy-9-(3-isopropylamino-2-hydroxypropoxy)-7-methyl-, hydrochloride",CC1CC2=C(O1)C(=C3C(=C(CCO3)O)C2)OCC(C[NH2+]C(C)C)O.[Cl-],,,,,,
11005,45700,"9-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2-methyl-3,4,6,7-tetrahydro-2H-furo[3,2-g]chromen-5-ol",CC1CC2=C(O1)C(=C3C(=C(CCO3)O)C2)OCC(CNC(C)C)O,,,,,,
11006,45701,"5H-Furo(3,2-g)(1)benzopyran-5-one, 4-(3-(benzylisopropylamino)-2-hydroxypropoxy)-9-methoxy-7-methyl-, citrate",CC1=CC2=C(O1)C(=C3C(=C(C=CO3)OCC(C[NH+](CC4=CC=CC=C4)C(C)C)O)C2=O)OC.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
11007,45702,CID 45702,CC(C(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])N2CCN(CC2)C.O.O,,,,,,
11008,45703,CID 45703,CC(C(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])N2CCN(CC2)C,,,,,,
11009,45704,CID 45704,C1CC[NH+](CC1)NCC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-].[Cl-],,,,,,
11010,45705,CID 45705,C1CCN(CC1)NCC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
11011,45706,"Fluorene-9-carboxylic acid, 2-(isobutylamino)ethyl ester, hydrochloride",CCC(C)[NH2+]CCOC(=O)C1C2=CC=CC=C2C3=CC=CC=C13.[Cl-],,,,,,
11012,45707,2-(butan-2-ylamino)ethyl 9H-fluorene-9-carboxylate,CCC(C)NCCOC(=O)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
11013,45708,4-(N-Methylpiperidyl)-9-fluorenecarboxylate hydrochloride,C[NH+]1CCC(CC1)OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24.[Cl-],,,,,,
11014,45709,9H-Fluorene-9-carboxylic acid 1-methyl-4-piperidinyl ester,CN1CCC(CC1)OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
11015,45710,4-(N-Phenethylpiperidyl)-9-fluorenecarboxylate hydrochloride,C1C[NH+](CCC1OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24)CCC5=CC=CC=C5.[Cl-],,,,,,
11016,45711,[1-(2-phenylethyl)piperidin-4-yl] 9H-fluorene-9-carboxylate,C1CN(CCC1OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24)CCC5=CC=CC=C5,,,,,,
11017,45712,"1,2,6-Trimethyl-4-piperidyl 9-fluorenecarboxylate hydrochloride",CC1CC(CC([NH+]1C)C)OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24.[Cl-],,,,,,
11018,45713,"(1,2,6-trimethylpiperidin-4-yl) 9H-fluorene-9-carboxylate",CC1CC(CC(N1C)C)OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
11019,45714,"FORMAMIDE, N-(tert-BUTYL)-N-METHYL-",CC(C)(C)N(C)C=O,,,,,,
11020,45715,CID 45715,C(COC(=O)C=CC(=O)OCCOCCCl)OCCCl,,,,,,
11021,45716,CID 45716,CC[NH+](CC)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-].[Cl-],,,,,,
11022,45717,CID 45717,CCN(CC)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
11023,45718,"Ammonium, triethylbutyl-, hydroxide",CCCC[N+](CC)(CC)CC.[OH-],,,,,,
11024,45719,"1-Butanaminium, N,N,N-triethyl-",CCCC[N+](CC)(CC)CC,,,,,,
11025,45720,"Aniline, arsenate",C1=CC=C(C=C1)[NH3+].C1=CC=C(C=C1)[NH3+].C1=CC=C(C=C1)[NH3+].[O-][As](=O)([O-])[O-],,,,,,
11026,45721,CID 45721,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C=CC2=CC=CC=C2.[Br-],,,,,,
11027,45722,CID 45722,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C=CC2=CC=CC=C2,,,,,,
11028,45723,Decamethylenebis(diethyl-(9-fluorenyl)ammonium) dibromide hemihydrate,CC[N+](CC)(CCCCCCCCCC[N+](CC)(CC)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-],,,,,,
11029,45724,10-[diethyl(9H-fluoren-9-yl)azaniumyl]decyl-diethyl-(9H-fluoren-9-yl)azanium,CC[N+](CC)(CCCCCCCCCC[N+](CC)(CC)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
11030,45725,Decamethylenebis(dimethyl-(9-fluorenyl)ammonium) dibromide ethanolate,C[N+](C)(CCCCCCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-],,,,,,
11031,45726,9H-fluoren-9-yl-[10-[9H-fluoren-9-yl(dimethyl)azaniumyl]decyl]-dimethylazanium,C[N+](C)(CCCCCCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
11032,45727,"N,N-Dibenzyl-5-(dibenzylamino)penta-2,4-dien-1-iminium chloride",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C=CC=CC=[N+](CC3=CC=CC=C3)CC4=CC=CC=C4.[Cl-],,,,,,
11033,45728,"Dibenzyl-[5-(dibenzylamino)penta-2,4-dienylidene]azanium",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C=CC=CC=[N+](CC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
11034,45729,"AMMONIUM, DIETHYLDI-n-BUTYL-, HYDROXIDE",CCCC[N+](CC)(CC)CCCC.[OH-],,,,,,
11035,45730,Dibutyldiethylaminium,CCCC[N+](CC)(CC)CCCC,,,,,,
11036,45731,"Ammonium, N,N-diethyl-N',N'-dimethyl-N'-ethyl-N-propyl-N,N'-oxydiethylenedi-, dibromide",CCC[N+](CC)(CC)CCOCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
11037,45732,Diethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]ethyl]-propylazanium,CCC[N+](CC)(CC)CCOCC[N+](C)(C)CC,,,,,,
11038,45733,"Ammonium, N,N-diethyl-N',N'-dimethyl-N,N'-oxydiethylenebis(butyl-, dibromide",CCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCC.[Br-].[Br-],,,,,,
11039,45734,Butyl-[2-[2-[butyl(diethyl)azaniumyl]ethoxy]ethyl]-dimethylazanium,CCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCC,,,,,,
11040,45735,"Ammonium, N,N-diethyl-N',N'-dimethyl-N,N'-oxydiethylenebis(heptyl-, dibromide",CCCCCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCCCCC.[Br-].[Br-],,,,,,
11041,45736,Diethyl-heptyl-[2-[2-[heptyl(dimethyl)azaniumyl]ethoxy]ethyl]azanium,CCCCCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCCCCC,,,,,,
11042,45737,"Ammonium, N,N-diethyl-N'.N'-dimethyl-N,N'-oxydiethylenebis(hexyl-, dibromide",CCCCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCCCC.[Br-].[Br-],,,,,,
11043,45738,Diethyl-hexyl-[2-[2-[hexyl(dimethyl)azaniumyl]ethoxy]ethyl]azanium,CCCCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCCCC,,,,,,
11044,45739,"Ammonium, N,N-diethyl-N',N'-dimethyl-N,N'-oxydiethylenebis(beta-hydroxyethyl-, dibromide",CC[N+](CC)(CCO)CCOCC[N+](C)(C)CCO.[Br-].[Br-],,,,,,
11045,45740,Diethyl-(2-hydroxyethyl)-[2-[2-[2-hydroxyethyl(dimethyl)azaniumyl]ethoxy]ethyl]azanium,CC[N+](CC)(CCO)CCOCC[N+](C)(C)CCO,,,,,,
11046,45741,"Ammonium, N,N-diethyl-N',N'-dimethyl-N,N'-oxydiethylenebis(pentyl-, dibromide",CCCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCCC.[Br-].[Br-],,,,,,
11047,45742,2-[2-[Diethyl(pentyl)azaniumyl]ethoxy]ethyl-dimethyl-pentylazanium,CCCCC[N+](C)(C)CCOCC[N+](CC)(CC)CCCCC,,,,,,
11048,45743,Banthine chloride,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13.[Cl-],,,,,,
11049,45744,"AMMONIUM, DIETHYL(m-HYDROXYPHENYL)METHYL-, METHYL SULFATE, METHYLCARBAMATE",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)NC.COS(=O)(=O)[O-],,,,,,
11050,45745,N-(2-Acetoxyethyl)-N-[(1-methyl-2-nitro-1H-imidazol-5-yl)methylene]amine oxide,CC(=O)OCC[N+](=CC1=CN=C(N1C)[N+](=O)[O-])[O-],,,,,,
11051,45746,"4,5-Dihydroxyphthalic acid",C1=C(C(=CC(=C1O)O)C(=O)O)C(=O)O,,,,,,
11052,45747,1-Chloro-3-phenoxy-2-propyl butylcarbamate,CCCCNC(=O)OC(COC1=CC=CC=C1)CCl,,,,,,
11053,45748,Dehydroindapamide,CC1=CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,,,,,,
11054,45749,Kassinin,CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(CC(=O)O)N,,,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']",,,
11055,45750,N-Hydroxy-N-(4-hydroxyphenyl)acetamide,CC(=O)N(C1=CC=C(C=C1)O)O,,,,,,
11056,45751,"Iridium, triamminetrichloro-",[NH2-].[NH2-].[NH2-].Cl[Ir](Cl)Cl,,,,,,
11057,45752,"Ammonium, N,N-dimethyl-N,N',N'N'-tetraethyl-N,N'-oxydiethylenedi-, diiodide",CC[N+](C)(C)CCOCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
11058,45753,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N,N'-oxyethylenetrimethylenedi-dibromide",CC[N+](C)(C)CCOCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11059,45754,Triethyl-[3-[2-[ethyl(dimethyl)azaniumyl]ethoxy]propyl]azanium,CC[N+](C)(C)CCOCCC[N+](CC)(CC)CC,,,,,,
11060,45755,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N',N'-oxyethylenetrimethylenedi-, dibromide",CC[N+](C)(C)CCCOCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11061,45756,Triethyl-[2-[3-[ethyl(dimethyl)azaniumyl]propoxy]ethyl]azanium,CC[N+](C)(C)CCCOCC[N+](CC)(CC)CC,,,,,,
11062,45757,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N,N'-sulfinyldiethylenedi-, dibromide",CC[N+](C)(C)CCS(=O)CC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11063,45758,Triethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethylsulfinyl]ethyl]azanium,CC[N+](C)(C)CCS(=O)CC[N+](CC)(CC)CC,,,,,,
11064,45759,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N,N'-thiodiethylenedi-, dibromide",CC[N+](C)(C)CCSCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11065,45760,Triethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethylsulfanyl]ethyl]azanium,CC[N+](C)(C)CCSCC[N+](CC)(CC)CC,,,,,,
11066,45761,"Ammonium, dithiodiethylenebis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCSSCC[N+](C)(CC)CC.[I-].[I-],,,,,,
11067,45762,2-[2-[Diethyl(methyl)azaniumyl]ethyldisulfanyl]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCSSCC[N+](C)(CC)CC,,,,,,
11068,45763,"Ammonium, dithiodiethylenebis(ethyldimethyl-, dibromide",CC[N+](C)(C)CCSSCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
11069,45764,Ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethyldisulfanyl]ethyl]-dimethylazanium,CC[N+](C)(C)CCSSCC[N+](C)(C)CC,,,,,,
11070,45765,3-Ethylcarboxyphenyl trimethylammonium iodide,CCOC(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[I-],,,,,,
11071,45766,(3-Ethoxycarbonyloxyphenyl)-trimethylazanium,CCOC(=O)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
11072,45767,"AMMONIUM, (2-(p-ETHOXYPHENOXY)ETHYL)TRIETHYL-, IODIDE",CC[N+](CC)(CC)CCOC1=CC=C(C=C1)OCC.[I-],,,,,,
11073,45768,2-(4-Ethoxyphenoxy)ethyl-triethylazanium,CC[N+](CC)(CC)CCOC1=CC=C(C=C1)OCC,,,,,,
11074,45769,"1,10-Dimethyl-decane-1,10-diamine dihydrochloride",C[NH+](C)CCCCCCCC[NH+](C)C.[Cl-].[Cl-],,,,,,
11075,45770,"N,N,N',N'-tetramethyloctane-1,8-diamine",CN(C)CCCCCCCCN(C)C,,,,,,
11076,45771,Ethyl 9-fluorodecanoate,CCOC(=O)CCCCCCCC(C)F,,,,,,
11077,45772,CID 45772,C(CCCCC(=O)[O-])CCCCF.[Na+],,,,,,
11078,45773,"Ammonium, N,N-diethyl-N,N',N',N'-tetramethyl-N,N'-oxyethylenetrimethylenedi-, diiodide",CC[N+](C)(CC)CCOCCC[N+](C)(C)C.[Br-].[Br-],,,,,,
11079,45774,Diethyl-methyl-[2-[3-(trimethylazaniumyl)propoxy]ethyl]azanium,CC[N+](C)(CC)CCOCCC[N+](C)(C)C,,,,,,
11080,45775,"Ammonium, N,N-diethyl-N,N',N',N'-tetramethyl-N',N-oxyethylenetrimethylenedi-, diiodide",CC[N+](C)(CC)CCOCCC[N+](C)(C)C.[I-].[I-],,,,,,
11081,45776,"Ammonium, N,N-diethyl-N,N',N',N'-tetramethyl-N,N'-sulfinyldiethylenedi-, diiodide",CC[N+](C)(CC)CCS(=O)CC[N+](C)(C)C.[I-].[I-],,,,,,
11082,45777,Diethyl-methyl-[2-[2-(trimethylazaniumyl)ethylsulfinyl]ethyl]azanium,CC[N+](C)(CC)CCS(=O)CC[N+](C)(C)C,,,,,,
11083,45778,"Ammonium, N,N-diethyl-N,N',N',N'-tetramethyl-N,N'-thiodiethylenedi-, diiodide",CC[N+](C)(CC)CCSCC[N+](C)(C)C.[I-].[I-],,,,,,
11084,45779,Diethyl-methyl-[2-[2-(trimethylazaniumyl)ethylsulfanyl]ethyl]azanium,CC[N+](C)(CC)CCSCC[N+](C)(C)C,,,,,,
11085,45780,"2,5-Dihydroxyphenyltrimethylammonium bromide",C[N+](C)(C)C1=C(C=CC(=C1)O)O.[Br-],,,,,,
11086,45781,"(2,5-Dihydroxyphenyl)-trimethylazanium",C[N+](C)(C)C1=C(C=CC(=C1)O)O,,,,,,
11087,45782,"(2,5-Dimethoxy-beta-hydroxy-beta-methylphenethyl)trimethylammonium chloride",CC(C[N+](C)(C)C)(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
11088,45783,"[2-(2,5-Dimethoxyphenyl)-2-hydroxypropyl]-trimethylazanium",CC(C[N+](C)(C)C)(C1=C(C=CC(=C1)OC)OC)O,,,,,,
11089,45784,"(2,5-Dimethoxy-beta-hydroxyphenethyl)trimethylammonium chloride",C[N+](C)(C)CC(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
11090,45785,"[2-(2,5-Dimethoxyphenyl)-2-hydroxyethyl]-trimethylazanium",C[N+](C)(C)CC(C1=C(C=CC(=C1)OC)OC)O,,,,,,
11091,45786,"AMMONIUM, (2,5-DIMETHOXY-beta-HYDROXY-alpha-METHYLPHENETHYL)TRIMETHYL-, CHLORIDE",CC(C(C1=C(C=CC(=C1)OC)OC)O)[N+](C)(C)C.[Cl-],,,,,,
11092,45787,"[1-(2,5-Dimethoxyphenyl)-1-hydroxypropan-2-yl]-trimethylazanium",CC(C(C1=C(C=CC(=C1)OC)OC)O)[N+](C)(C)C,,,,,,
11093,45788,"AMMONIUM, (2,5-DIMETHOXY-alpha-METHYLPHENETHYL)TRIMETHYL-, CHLORIDE",CC(CC1=C(C=CC(=C1)OC)OC)[N+](C)(C)C.[Cl-],,,,,,
11094,45789,"1-(2,5-Dimethoxyphenyl)propan-2-yl-trimethylazanium",CC(CC1=C(C=CC(=C1)OC)OC)[N+](C)(C)C,,,,,,
11095,45790,Bis(2-chloroethyl)dimethylammonium chloride,C[N+](C)(CCCl)CCCl.[Cl-],,,,,,
11096,45791,Bis(2-chloroethyl)-dimethylazanium,C[N+](C)(CCCl)CCCl,,,,,,
11097,45792,"Carbamic acid, dimethyldithio-, p-(trimethylammonio)phenyl ester, iodide",CN(C)C(=S)SC1=CC=C(C=C1)[N+](C)(C)C.[I-],,,,,,
11098,45793,[4-(Dimethylcarbamothioylsulfanyl)phenyl]-trimethylazanium,CN(C)C(=S)SC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
11099,45794,(3-Hydroxyphenyl)isopropyldimethylammonium iodide,CC(C)[N+](C)(C)C1=CC(=CC=C1)O.[I-],,,,,,
11100,45795,(3-Hydroxyphenyl)-dimethyl-propan-2-ylazanium,CC(C)[N+](C)(C)C1=CC(=CC=C1)O,,,,,,
11101,45796,"(2,4-Dimethyl-5-hydroxyphenyl)trimethylammonium bromide",CC1=CC(=C(C=C1[N+](C)(C)C)O)C.[Br-],,,,,,
11102,45797,"(5-Hydroxy-2,4-dimethylphenyl)-trimethylazanium",CC1=CC(=C(C=C1[N+](C)(C)C)O)C,,,,,,
11103,45798,"(2,4-Dimethyl-3-hydroxyphenyl)trimethylammonium bromide",CC1=C(C(=C(C=C1)[N+](C)(C)C)C)O.[Br-],,,,,,
11104,45799,"(3-Hydroxy-2,4-dimethylphenyl)-trimethylazanium",CC1=C(C(=C(C=C1)[N+](C)(C)C)C)O,,,,,,
11105,45800,"(3,4-Dimethyl-5-methoxyphenyl)trimethylammonium iodide",CC1=CC(=CC(=C1C)OC)[N+](C)(C)C.[I-],,,,,,
11106,45801,"(3-Methoxy-4,5-dimethylphenyl)-trimethylazanium",CC1=CC(=CC(=C1C)OC)[N+](C)(C)C,,,,,,
11107,45802,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N,N'-oxybis(trimethylene)di-, dibromide",CC[N+](C)(C)CCCOCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11108,45803,Triethyl-[3-[3-[ethyl(dimethyl)azaniumyl]propoxy]propyl]azanium,CC[N+](C)(C)CCCOCCC[N+](CC)(CC)CC,,,,,,
11109,45804,"Ammonium, N,N-dimethyl-N,N',N',N'-tetraethyl-N,N'-oxydiethylenedi-, dibromide",CC[N+](C)(C)CCOCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11110,45805,"AMMONIUM, ((p-DIETHYLMETHYLAMMONIO)PHENETHYL)DIETHYLMETHYL-, DIIODIDE",CC[N+](C)(CC)CCC1=CC=C(C=C1)[N+](C)(CC)CC.[I-].[I-],,,,,,
11111,45806,[4-[2-[Diethyl(methyl)azaniumyl]ethyl]phenyl]-diethyl-methylazanium,CC[N+](C)(CC)CCC1=CC=C(C=C1)[N+](C)(CC)CC,,,,,,
11112,45807,"AMMONIUM, (4-(p-DIETHYLMETHYLAMMONIOPHENYL)BUTYL)DIETHYLMETHYL-, DIIODIDE",CC[N+](C)(CC)CCCCC1=CC=C(C=C1)[N+](C)(CC)CC.[I-].[I-],,,,,,
11113,45808,[4-[4-[Diethyl(methyl)azaniumyl]butyl]phenyl]-diethyl-methylazanium,CC[N+](C)(CC)CCCCC1=CC=C(C=C1)[N+](C)(CC)CC,,,,,,
11114,45809,"AMMONIUM, (3-(p-DIETHYLMETHYLAMMONIOPHENYL)PROPYL)DIETHYLMETHYL-, DIIODIDE",CC[N+](C)(CC)CCCC1=CC=C(C=C1)[N+](C)(CC)CC.[I-].[I-],,,,,,
11115,45810,3-[4-[Diethyl(methyl)azaniumyl]phenyl]propyl-diethyl-methylazanium,CC[N+](C)(CC)CCCC1=CC=C(C=C1)[N+](C)(CC)CC,,,,,,
11116,45811,Diethylmethyl(4-methyl-2-oxo-2H-1-benzopyran-7-yl)ammonium iodide,CC[N+](C)(CC)C1=CC2=C(C=C1)C(=CC(=O)O2)C.[I-],,,,,,
11117,45812,Diethyl-methyl-(4-methyl-2-oxochromen-7-yl)azanium,CC[N+](C)(CC)C1=CC2=C(C=C1)C(=CC(=O)O2)C,,,,,,
11118,45813,Diethylmethylphenylammonium bromide,CC[N+](C)(CC)C1=CC=CC=C1.[Br-],,,,,,
11119,45814,Diethylmethylphenylammonium,CC[N+](C)(CC)C1=CC=CC=C1,,,,,,
11120,45815,CID 45815,CC[N+](C)(CC)CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2.[I-],,,,,,
11121,45816,CID 45816,CC[N+](C)(CC)CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
11122,45817,"Ammonium, N,N-diethyl-N,N',N',N'-tetramethyl-N,N'-oxybis(trimethylene)di-, diiodide",CC[N+](C)(CC)CCCOCCC[N+](C)(C)C.[I-].[I-],,,,,,
11123,45818,Diethyl-methyl-[3-[3-(trimethylazaniumyl)propoxy]propyl]azanium,CC[N+](C)(CC)CCCOCCC[N+](C)(C)C,,,,,,
11124,45819,"Ammonium, N,N-diethyl-N,N',N',N'-tetramethyl-N,N'-oxydiethylenedi-, diiodide",CC[N+](C)(CC)CCOCC[N+](C)(C)C.[I-].[I-],,,,,,
11125,45820,Diethyl-methyl-[2-[2-(trimethylazaniumyl)ethoxy]ethyl]azanium,CC[N+](C)(CC)CCOCC[N+](C)(C)C,,,,,,
11126,45821,"3-[(4-Chlorophenyl)-phenylmethyl]-8-methyl-3,8-diazabicyclo[3.2.1]octane",CN1C2CCC1CN(C2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
11127,45822,"3-(2-Chloroethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CCCl,,,,,,
11128,45823,"1-(8-Methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-3-phenylprop-2-en-1-one",CN1C2CCC1CN(C2)C(=O)C=CC3=CC=CC=C3,,,,,,
11129,45824,CID 45824,CN1C2CCC1C[NH+](C2)CC=CC3=CC=CC=C3,,,,,,
11130,45825,"8-Methyl-3-(3-phenylprop-2-enyl)-3,8-diazabicyclo[3.2.1]octane",CN1C2CCC1CN(C2)CC=CC3=CC=CC=C3,,,,,,
11131,45826,"1-[3-(4-Phenylbut-3-enyl)-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one",CCC(=O)N1C2CCC1CN(C2)CCC=CC3=CC=CC=C3,,,,,,
11132,45827,"2-Cyclohexyl-3-hydroxy-1-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-phenylpropan-1-one",CN1C2CCC1CN(C2)C(=O)C(CO)(C3CCCCC3)C4=CC=CC=C4,,,,,,
11133,45828,"2-Cyclohexyl-3-hydroxy-1-(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)-2-phenylpropan-1-one",CN1CC2CCC(C1)N2C(=O)C(CO)(C3CCCCC3)C4=CC=CC=C4,,,,,,
11134,45829,"3-(2-(Cyclopentyl)ethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CCC3CCCC3,,,,,,
11135,45830,"3-(Cyclopentylmethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CC3CCCC3,,,,,,
11136,45831,CID 45831,CCC(=O)N1C2CCC1CN(C2)CC=CC3=C(C=CC(=C3)Cl)Cl,,,,,,
11137,45832,"3-[Bis(4-chlorophenyl)methyl]-8-methyl-3,8-diazabicyclo[3.2.1]octane",CN1C2CCC1CN(C2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl,,,,,,
11138,45833,CID 45833,CCC(=O)C1C2CNCC1CN(C2)CC=CC3=CC=CC=C3,,,,,,
11139,45834,"1-(3-Methyl-3,9-diazabicyclo[3.3.1]nonan-9-yl)propan-1-one",CCC(=O)N1C2CCCC1CN(C2)C,,,,,,
11140,45835,"8-Acetyl-3-methyl-3,8-diazabicyclo(3.2.1)octane",CC(=O)N1C2CCC1CN(C2)C,,,,,,
11141,45836,"2-(3-Methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)ethyl 4-aminobenzoate",CN1CC2CCC(C1)N2CCOC(=O)C3=CC=C(C=C3)N,,,,,,
11142,45837,"3-(2-(Phenylamino)ethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CCNC3=CC=CC=C3,,,,,,
11143,45838,"3-(Phenacylmethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CCC(=O)C3=CC=CC=C3,,,,,,
11144,45839,"3-Benzyl-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CC3=CC=CC=C3,,,,,,
11145,45840,"4-(3-Methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)butanal",CN1CC2CCC(C1)N2CCCC=O,,,,,,
11146,45841,"8-(p-Chlorobenzoyl)-3-methyl-3,8-diazabicyclo(3.2.1)octane",CN1CC2CCC(C1)N2C(=O)C3=CC=C(C=C3)Cl,,,,,,
11147,45842,CID 45842,CN1C2CCC1CN(C2)CC=CC3=CC=CC=C3Cl,,,,,,
11148,45843,CID 45843,CN1CC2CCC(C1)N2CC=CC3=CC=CC=C3Cl,,,,,,
11149,45844,"8-(o-Chlorodiphenyl)methyl-3-methyl-3,8-diazabicyclo(3.2.1)octane",CN1CC2CCC(C1)N2C(C3=CC=CC=C3)C4=CC=CC=C4Cl,,,,,,
11150,45845,"1-Naphthylamine, 1,2,3,4-tetrahydro-6-chloro-N,N-dimethyl-5-methoxy-, hydrochloride",C[NH+](C)C1CCCC2=C1C=CC(=C2OC)Cl.[Cl-],,,,,,
11151,45846,"6-chloro-5-methoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C1C=CC(=C2OC)Cl,,,,,,
11152,45847,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-(4-methylbenzyloxy)-, hydrochloride",CC1=CC=C(C=C1)COC2=C3CCCC(C3=C(C=C2)Cl)[NH+](C)C.[Cl-],,,,,,
11153,45848,"8-chloro-N,N-dimethyl-5-[(4-methylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-amine",CC1=CC=C(C=C1)COC2=C3CCCC(C3=C(C=C2)Cl)N(C)C,,,,,,
11154,45849,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-propoxy-, hydrochloride",CCCOC1=C2CCCC(C2=C(C=C1)Cl)[NH+](C)C.[Cl-],,,,,,
11155,45850,"8-chloro-N,N-dimethyl-5-propoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CCCOC1=C2CCCC(C2=C(C=C1)Cl)N(C)C,,,,,,
11156,45851,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-(2-propynyloxy)-, hydrochloride",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OCC#C.[Cl-],,,,,,
11157,45852,"8-chloro-N,N-dimethyl-5-prop-2-ynoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)Cl)OCC#C,,,,,,
11158,45853,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-(3-trifluoromethylbenzyloxy)-, hydrobromide",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC(=CC=C3)C(F)(F)F.[Br-],,,,,,
11159,45854,"8-chloro-N,N-dimethyl-5-[[3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC(=CC=C3)C(F)(F)F,,,,,,
11160,45855,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N-ethyl-5-methoxy-N-(2-propynyl)-, hydrochloride",CC[NH+](CC#C)C1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
11161,45856,"8-chloro-N-ethyl-5-methoxy-N-prop-2-ynyl-1,2,3,4-tetrahydronaphthalen-1-amine",CCN(CC#C)C1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
11162,45857,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N-isopropyl-5-methoxy-, hydrochloride",CC(C)[NH2+]C1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
11163,45858,"8-chloro-5-methoxy-N-propan-2-yl-1,2,3,4-tetrahydronaphthalen-1-amine",CC(C)NC1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
11164,45859,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N-isopropyl-5-methoxy-N-methyl-, hydrobromide",CC(C)[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OC.[Br-],,,,,,
11165,45860,"8-chloro-5-methoxy-N-methyl-N-propan-2-yl-1,2,3,4-tetrahydronaphthalen-1-amine",CC(C)N(C)C1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
11166,45861,"5-Naphthol, 8-chloro-1-(dimethylamino)-1,2,3,4-tetrahydro-, hydroiodide",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)O.[I-],,,,,,
11167,45862,"4-Chloro-5-(dimethylamino)-5,6,7,8-tetrahydronaphthalen-1-ol",CN(C)C1CCCC2=C(C=CC(=C12)Cl)O,,,,,,
11168,45863,"1-Naphthylamine, 1,2,3,4-tetrahydro-6-chloro-N,N-dimethyl-5-hydroxy-, hydroiodide",C[NH+](C)C1CCCC2=C1C=CC(=C2O)Cl.[I-],,,,,,
11169,45864,"2-Chloro-5-(dimethylamino)-5,6,7,8-tetrahydronaphthalen-1-ol",CN(C)C1CCCC2=C1C=CC(=C2O)Cl,,,,,,
11170,45865,"1-Naphthol, 2,4,5-trinitro-",C1=CC2=C(C(=C1)[N+](=O)[O-])C(=CC(=C2O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
11171,45866,"trans-1,2,3,4-Tetrahydro-4-cyano-1-methylamino-4-phenylnaphthalene hydrochloride",C[NH2+]C1CC[C@@](C2=CC=CC=C12)(C#N)C3=CC=CC=C3.[Cl-],,,,,,
11172,45867,"(1R)-4-(methylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carbonitrile",CNC1CC[C@@](C2=CC=CC=C12)(C#N)C3=CC=CC=C3,,,,,,
11173,45868,"1,4-Naphthoquinone, 2-(DI-2'-chloroethylamino)-",C1=CC=C2C(=C1)C(=O)C=C(C2=O)N(CCCl)CCCl,,,,,,
11174,45869,"1-NAPHTHALENOL, 4-((p-(BIS(2-CHLOROETHYL)AMINO)PHENYL)AMINO)-",C1=CC=C2C(=C1)C(=CC=C2O)NC3=CC=C(C=C3)N(CCCl)CCCl,,,,,,
11175,45870,4-(1-Naphthylazo)-2-naphthylamine,C1=CC=C2C(=C1)C=CC=C2N=NC3=CC(=CC4=CC=CC=C43)N,,,,,,
11176,45871,1-Phenyl-2-naphthylaminopropane,CC(CC1=CC=CC=C1)NC2=CC3=CC=CC=C3C=C2,,,,,,
11177,45872,"1-Naphthylamine, 8-acetamido-N,N-dimethyl-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",CC(=O)NC1=C2C(CCCC2=C(C=C1)OC)[NH+](C)C.[Cl-],,,,,,
11178,45873,"N-[8-(dimethylamino)-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl]acetamide",CC(=O)NC1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11179,45874,"1-Naphthylamine, 8-acetyl-N,N-dimethyl-5-methoxy-1,2,3,4-tetrahydro-",CC(=O)C1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11180,45875,"1-Naphthylamine, 5-allyloxy-8-chloro-N,N-dimethyl-1,2,3,4-tetrahydro-, hydrochloride",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OCC=C.[Cl-],,,,,,
11181,45876,"8-chloro-N,N-dimethyl-5-prop-2-enoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)Cl)OCC=C,,,,,,
11182,45877,"5-Benzyloxy-8-chloro-N,N-dimethyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC=CC=C3.[Cl-],,,,,,
11183,45878,"8-chloro-N,N-dimethyl-5-phenylmethoxy-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC=CC=C3,,,,,,
11184,45879,"1-Naphthylamine, 8-bromo-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",COC1=C2CCCC(C2=C(C=C1)Br)[NH3+].[Cl-],,,,,,
11185,45880,"8-Bromo-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=C2CCCC(C2=C(C=C1)Br)N,,,,,,
11186,45881,"1-Naphthylamine, 1,2,3,4-tetrahydro-5-butoxy-8-chloro-N,N-dimethyl-, hydrochloride",CCCCOC1=C2CCCC(C2=C(C=C1)Cl)[NH+](C)C.[Cl-],,,,,,
11187,45882,"5-butoxy-8-chloro-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CCCCOC1=C2CCCC(C2=C(C=C1)Cl)N(C)C,,,,,,
11188,45883,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-butyryl-N,N-dimethyl-5-methoxy-",CCCC(=O)C1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11189,45884,"1-Naphthylamine, 8-chloro-5-(3-chlorobenzyl)-N,N-dimethyl-1,2,3,4-tetrahydro-, hydrobromide",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC(=CC=C3)Cl.[Br-],,,,,,
11190,45885,"8-chloro-5-[(3-chlorophenyl)methoxy]-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC(=CC=C3)Cl,,,,,,
11191,45886,"1-Naphthylamine, 1,2,3,4-tetrahydro-5-chloro-7,8-dimethoxy-N,N-dimethyl-, hydrochloride",C[NH+](C)C1CCCC2=C(C=C(C(=C12)OC)OC)Cl.[Cl-],,,,,,
11192,45887,"5-chloro-7,8-dimethoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=C(C(=C12)OC)OC)Cl,,,,,,
11193,45888,"1-Naphthylamine, 1,2,3,4-tetrahydro-5-chloro-7,8-dimethoxy-N-methyl-, hydrochloride",C[NH2+]C1CCCC2=C(C=C(C(=C12)OC)OC)Cl.[Cl-],,,,,,
11194,45889,"5-chloro-7,8-dimethoxy-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",CNC1CCCC2=C(C=C(C(=C12)OC)OC)Cl,,,,,,
11195,45890,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-dodecyloxy-, hydrochloride",CCCCCCCCCCCCOC1=C2CCCC(C2=C(C=C1)Cl)[NH+](C)C.[Cl-],,,,,,
11196,45891,"8-chloro-5-dodecoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CCCCCCCCCCCCOC1=C2CCCC(C2=C(C=C1)Cl)N(C)C,,,,,,
11197,45892,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-ethoxy-, hydrochloride",CCOC1=C2CCCC(C2=C(C=C1)Cl)[NH+](C)C.[Cl-],,,,,,
11198,45893,"8-chloro-5-ethoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CCOC1=C2CCCC(C2=C(C=C1)Cl)N(C)C,,,,,,
11199,45894,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-N,N-dimethyl-5-isopropoxy-, hydrochloride",CC(C)OC1=C2CCCC(C2=C(C=C1)Cl)[NH+](C)C.[Cl-],,,,,,
11200,45895,"8-chloro-N,N-dimethyl-5-propan-2-yloxy-1,2,3,4-tetrahydronaphthalen-1-amine",CC(C)OC1=C2CCCC(C2=C(C=C1)Cl)N(C)C,,,,,,
11201,45896,"N,N-Dipentyl-4-ethoxy-1-naphthamidine hydrochloride",CCCCC[NH+](CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC.[Cl-],,,,,,
11202,45897,"4-ethoxy-N,N-dipentylnaphthalene-1-carboximidamide",CCCCCN(CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCC,,,,,,
11203,45898,"N,N-Dipentyl-4-methoxy-1-naphthamidine hydrochloride",CCCCC[NH+](CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
11204,45899,"4-methoxy-N,N-dipentylnaphthalene-1-carboximidamide",CCCCCN(CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
11205,45900,"N,N-Dipropyl-4-methoxy-1-naphthamidine hydrochloride",CCC[NH+](CCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
11206,45901,"4-methoxy-N,N-dipropylnaphthalene-1-carboximidamide",CCCN(CCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
11207,45902,N-Ethyl-4-methoxy-N-(o-tolyl)-1-naphthamidine hydrochloride,CC[NH+](C1=CC=CC=C1C)C(=N)C2=CC=C(C3=CC=CC=C32)OC.[Cl-],,,,,,
11208,45903,N-ethyl-4-methoxy-N-(2-methylphenyl)naphthalene-1-carboximidamide,CCN(C1=CC=CC=C1C)C(=N)C2=CC=C(C3=CC=CC=C32)OC,,,,,,
11209,45904,4-(p-Bis(2-chloroethyl)aminophenyl)imino-1(4H)-naphthalenone,C1=CC=C2C(=O)C=CC(=NC3=CC=C(C=C3)N(CCCl)CCCl)C2=C1,,,,,,
11210,45905,CID 45905,C1CCC2=CC3=C(C=C2C1)N=C(S3)[NH3+].[Cl-],,,,,,
11211,45906,"2-Amino-6,7,8,9-tetrahydronaphtho(2,1-D)thiazole",C1CCC2=CC3=C(C=C2C1)N=C(S3)N,,,,,,
11212,45907,"1-Naphthoic acid, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
11213,45908,"1-Naphthoic acid, 2-diethylaminoethyl ester",CCN(CC)CCOC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
11214,45909,Tetrahydropamaquin naphthoate,CCN(CC)CCCC(C)NC1=CC(=CC2=C1NCCC2)OC.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,,,,
11215,45910,"1-N,1-N-diethyl-4-N-(6-methoxy-1,2,3,4-tetrahydroquinolin-8-yl)pentane-1,4-diamine",CCN(CC)CCCC(C)NC1=CC(=CC2=C1NCCC2)OC,,,,,,
11216,45911,"2-Naphthoic acid, 1-methyl-4-oxo-1,2,3,4-tetrahydro-",CC1C(CC(=O)C2=CC=CC=C12)C(=O)O,,,,,,
11217,45912,"1-Naphthoic acid, 1,2,3,4-tetrahydro-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1CCCC2=CC=CC=C12.[Cl-],,,,,,
11218,45913,"2-(Diethylamino)ethyl 1,2,3,4-tetrahydronaphthalene-1-carboxylate",CCN(CC)CCOC(=O)C1CCCC2=CC=CC=C12,,,,,,
11219,45914,"trans-1,2,3,4-Tetrahydro-4-carbomethoxy-1-dimethylamino-4-phenylnaphthalene hydrochloride",C[NH+](C)C1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)OC.[Cl-],,,,,,
11220,45915,"methyl (1R)-4-(dimethylamino)-1-phenyl-3,4-dihydro-2H-naphthalene-1-carboxylate",CN(C)C1CC[C@](C2=CC=CC=C12)(C3=CC=CC=C3)C(=O)OC,,,,,,
11221,45916,"1-NAPHTHOL, 2-(beta-HYDROXYETHOXY)-",C1=CC=C2C(=C1)C=CC(=C2O)OCCO,,,,,,
11222,45917,"2-t-Butyl-2-methyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)C(C)(C)C,,,,,,
11223,45918,"2-Chloromethyl-2-methyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)CCl,,,,,,
11224,45919,"2-Methyl-2-s-pentyl-1,3-dioxolane-4-methanol",CCC(CC)C1(OCC(O1)CO)C,,,,,,
11225,45920,"2-Methyl-6,7-methylenedioxy-1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)isoquinoline",CN1CCC2=CC3=C(C=C2C1C4=CC(=C(C(=C4)OC)OC)OC)OCO3,,,,,,
11226,45921,Di(beta-p-methoxyphenylethyl)amine hydrochloride,COC1=CC=C(C=C1)CC[NH2+]CCC2=CC=C(C=C2)OC.[Cl-],,,,,,
11227,45922,2-(4-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]ethanamine,COC1=CC=C(C=C1)CCNCCC2=CC=C(C=C2)OC,,,,,,
11228,45923,"Diphenylamine, 4'-(bis(2''-chloroethyl)amino)-4-hydroxy-",C1=CC(=CC=C1NC2=CC=C(C=C2)O)N(CCCl)CCCl,,,,,,
11229,45924,"4-[4-[Bis(2-chloroethyl)amino]anilino]-2,6-dimethylphenol",CC1=CC(=CC(=C1O)C)NC2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
11230,45925,"Diphenylamine, 4'-(bis(2-chloroethyl)amino)-4-hydroxy-3-methyl-",CC1=C(C=CC(=C1)NC2=CC=C(C=C2)N(CCCl)CCCl)O,,,,,,
11231,45926,N-(gamma-Dimethylaminopropyl)-2-methyl thiodiphenylamine hydrochloride,C[NH+](C)CCCN(C1=CC=CC=C1)C2=CC=CC=C2SC.[Cl-],,,,,,
11232,45927,"N,N-dimethyl-N'-(2-methylsulfanylphenyl)-N'-phenylpropane-1,3-diamine",CN(C)CCCN(C1=CC=CC=C1)C2=CC=CC=C2SC,,,,,,
11233,45928,"Dodecanamide, N-(tris(hydroxymethyl)methyl)-",CCCCCCCCCCCC(=O)NC(CO)(CO)CO,,,,,,
11234,45929,CID 45929,C(CCCCCC(=N)[NH3+])CCCCC(=N)[NH3+].[Cl-].[Cl-],,,,,,
11235,45930,"1,7-Diimino-1,7-dodecanediamine",C(CCCCCC(=N)N)CCCCC(=N)N,,,,,,
11236,45931,alpha-Acetyloxypropionyl-k-strophanthidin,CC(C(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4(C(CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O)OC(=O)C,,,,,,
11237,45932,n-Butyl-k-strophanthidin,CCCC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
11238,45933,3-Diethylaminoacetyl strophantidin,CCN(CC)CC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
11239,45934,"5,14-Dihydroxy-3-[(2-methylpropanoyl)oxy]-19-oxocard-20(22)-enolide",CC(C)C(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
11240,45935,"k-Strophanthidin, phenylacetyl-",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)OC(=O)CC6=CC=CC=C6)C=O)O,,,,,,
11241,45936,n-Valeryl-k-strophanthidin,CCCCC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
11242,45937,i-Valeryl-k-strophanthidin,CC(C)CC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
11243,45938,alpha-i-Valeryloxypropionyl-k-strophanthidin,CC(C)CC(=O)OC(C)C(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=CC(=O)OC5)C)C=O,,,,,,
11244,45939,"Formamide, N-2-azabicyclo(2.2.2)oct-2-YL-N-((4-methylphenyl)sulfonyl)-",CC1=CC=C(C=C1)S(=O)(=O)N(C=O)N2CC3CCC2CC3,,,,,,
11245,45940,"2-Naphthol, 1-((4-tolylazo)tolylazo)-",CC1=CC=C(C=C1)N=NC2=CC(=C(C=C2)N=NC3=C(C=CC4=CC=CC=C43)O)C,,,,,,
11246,45941,"1,3,4-Trichloronaphthalen-2-ol",C1=CC=C2C(=C1)C(=C(C(=C2Cl)Cl)O)Cl,,,,,,
11247,45942,"2-Naphthol, tetrabromo-",C1=CC2=C(C(=C1)Br)C(=C(C(=C2Br)O)Br)Br,,,,,,
11248,45943,3-Bromo-2-naphthol,C1=CC=C2C=C(C(=CC2=C1)O)Br,,,,,,
11249,45944,"2-Naphthol, chloro-",C1=CC=C2C=C(C(=CC2=C1)O)Cl,,,,,,
11250,45945,"2-Naphthol, dibromo-",C1=CC2=C(C(=C1)Br)C(=C(C=C2)O)Br,,,,,,
11251,45946,"2-Naphthol, dichloro-",C1=CC2=C(C=CC(=C2Cl)O)C=C1Cl,,,,,,
11252,45947,"2-Methyl-2-(methylpentyl)-1,3-dioxolane-4-methanol",CCCCC(C)C1(OCC(O1)CO)C,,,,,,
11253,45948,alpha-((Diethylamino)methyl)-2-dibenzofuranmethanol hydrochloride,CC[NH+](CC)CC(C1=CC2=C(C=C1)OC3=CC=CC=C32)O.[Cl-],,,,,,
11254,45949,1-Dibenzofuran-2-yl-2-(diethylamino)ethanol,CCN(CC)CC(C1=CC2=C(C=C1)OC3=CC=CC=C32)O,,,,,,
11255,45950,"Ethanol, 2-fluoro-, phosphite (3:1)",C(CF)OP(OCCF)OCCF,,,,,,
11256,45951,"Ethanol, 2-(2-(1-isobutyl-3-methylbutoxy)ethoxy)-",CC(C)CC(CC(C)C)OCCOCCO,,,,,,
11257,45952,2-Hydroxy-N-(2-methyl-5-nitrophenyl)-3-nitrobenzamide,CC1=C(C=C(C=C1)[N+](=O)[O-])NC(=O)C2=C(C(=CC=C2)[N+](=O)[O-])O,,,,,,
11258,45953,"N-(2,5-Dimethylphenyl)-2-hydroxy-3-nitrobenzamide",CC1=CC(=C(C=C1)C)NC(=O)C2=C(C(=CC=C2)[N+](=O)[O-])O,,,,,,
11259,45954,"N-(2,6-Dimethylphenyl)-2-hydroxy-3-nitrobenzamide",CC1=C(C(=CC=C1)C)NC(=O)C2=C(C(=CC=C2)[N+](=O)[O-])O,,,,,,
11260,45955,"Carbamic acid, allyl-, 2-(trimethylammonio)ethyl ester, chloride",C[N+](C)(C)CCOC(=O)NCC=C.[Cl-],,,,,,
11261,45956,Trimethyl-[2-(prop-2-enylcarbamoyloxy)ethyl]azanium,C[N+](C)(C)CCOC(=O)NCC=C,,,,,,
11262,45957,"Carbamic acid, diethyl-, 2-(trimethylammonio)ethyl ester, iodide",CCN(CC)C(=O)OCC[N+](C)(C)C.[I-],,,,,,
11263,45958,"N,N,N-Trimethyl-2-[(diethylamino)carbonyloxy]ethanaminium",CCN(CC)C(=O)OCC[N+](C)(C)C,,,,,,
11264,45959,"Carbamic acid, dimethyl-, ((p-trimethylammonio)-o-isopropyl)phenyl ester, iodide",CC(C)C1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
11265,45960,[4-(Dimethylcarbamoyloxy)-3-propan-2-ylphenyl]-trimethylazanium,CC(C)C1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
11266,45961,"Carbamic acid, dimethyl-, ((4-trimethylammonio)-3-isopropyl)phenyl ester, iodide",CC(C)C1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11267,45962,[4-(Dimethylcarbamoyloxy)-2-propan-2-ylphenyl]-trimethylazanium,CC(C)C1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11268,45963,"Carbamic acid, methyl-, (5-(trimethylammonio)-o-cumenyl) ester, iodide",CC(C)C1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)NC.[I-],,,,,,
11269,45964,"4-Isopropyl-3-[[(methylamino)carbonyl]oxy]-N,N,N-trimethylbenzenaminium",CC(C)C1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)NC,,,,,,
11270,45965,"Ammonium, (4-methylcarbamoyloxy-m-tolyl)trimethyl-, iodide",CC(C)C1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)NC.[I-],,,,,,
11271,45966,Trimethyl-[4-(methylcarbamoyloxy)-3-propan-2-ylphenyl]azanium,CC(C)C1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)NC,,,,,,
11272,45967,"Carbamic acid, phenyl-, 4-(trimethylammonio)-m-cumenyl ester, iodide",CC(C)C1=C(C=CC(=C1)OC(=O)NC2=CC=CC=C2)[N+](C)(C)C.[I-],,,,,,
11273,45968,Trimethyl-[4-(phenylcarbamoyloxy)-2-propan-2-ylphenyl]azanium,CC(C)C1=C(C=CC(=C1)OC(=O)NC2=CC=CC=C2)[N+](C)(C)C,,,,,,
11274,45969,"1-Piperidinecarboxylic acid, 4-(trimethylammonio)-m-cumenyl ester, iodide",CC(C)C1=C(C=CC(=C1)OC(=O)N2CCCCC2)[N+](C)(C)C.[I-],,,,,,
11275,45970,Trimethyl-[4-(piperidine-1-carbonyloxy)-2-propan-2-ylphenyl]azanium,CC(C)C1=C(C=CC(=C1)OC(=O)N2CCCCC2)[N+](C)(C)C,,,,,,
11276,45971,"Carbamic acid, methyl-, (2-cyclohexyl-5-(trimethylammonio)phenyl) ester, iodide",CNC(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)C2CCCCC2.[I-],,,,,,
11277,45972,"N-[4-Cyclohexyl-3-(methylaminocarbonyloxy)phenyl]-N,N-dimethylmethanaminium",CNC(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)C2CCCCC2,,,,,,
11278,45973,"Ammonium, ((4-(N,N-dimethylcarbamoyloxy)-2-cyclopentyl)phenyl)trimethyl-, iodide",CN(C)C(=O)OC1=CC(=C(C=C1)[N+](C)(C)C)C2CCCC2.[I-],,,,,,
11279,45974,[2-Cyclopentyl-4-(dimethylcarbamoyloxy)phenyl]-trimethylazanium,CN(C)C(=O)OC1=CC(=C(C=C1)[N+](C)(C)C)C2CCCC2,,,,,,
11280,45975,"Ammonium, ((4-hydroxy-2-cyclopentyl)phenyl)trimethyl-, iodide, methylcarbamate",CNC(=O)OC1=CC(=C(C=C1)[N+](C)(C)C)C2CCCC2.[I-],,,,,,
11281,45976,[2-Cyclopentyl-4-(methylcarbamoyloxy)phenyl]-trimethylazanium,CNC(=O)OC1=CC(=C(C=C1)[N+](C)(C)C)C2CCCC2,,,,,,
11282,45977,"Carbamic acid, 10-(trimethylammonio)decyl ester, chloride",C[N+](C)(C)CCCCCCCCCCOC(=O)N.[Cl-],,,,,,
11283,45978,10-Carbamoyloxydecyl(trimethyl)azanium,C[N+](C)(C)CCCCCCCCCCOC(=O)N,,,,,,
11284,45979,"Ammonium, ((4-hydroxy-3,5-diisopropyl)phenyl)trimethyl-, iodide, methylcarbamate",CC(C)C1=CC(=CC(=C1OC(=O)NC)C(C)C)[N+](C)(C)C.[I-],,,,,,
11285,45980,"Trimethyl-[4-(methylcarbamoyloxy)-3,5-di(propan-2-yl)phenyl]azanium",CC(C)C1=CC(=CC(=C1OC(=O)NC)C(C)C)[N+](C)(C)C,,,,,,
11286,45981,"Ammonium, (1-(2-hydroxy-5-methylphenyl)ethyl)trimethyl-, iodide, methylcarbamate",CC1=CC(=C(C=C1)OC(=O)NC)C(C)[N+](C)(C)C.[I-],,,,,,
11287,45982,Trimethyl-[1-[5-methyl-2-(methylcarbamoyloxy)phenyl]ethyl]azanium,CC1=CC(=C(C=C1)OC(=O)NC)C(C)[N+](C)(C)C,,,,,,
11288,45983,"2-Hydroxy-3,5-dimethylphenyl trimethylammonium bromide",CC1=CC(=C(C(=C1)[N+](C)(C)C)O)C.[Br-],,,,,,
11289,45984,"(2-Hydroxy-3,5-dimethylphenyl)-trimethylazanium",CC1=CC(=C(C(=C1)[N+](C)(C)C)O)C,,,,,,
11290,45985,"Carbamic acid, methyl-, 3-(alpha-trimethylammoniopropyl)phenyl ester, iodide",CCC(C1=CC(=CC=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11291,45986,Trimethyl-[1-[3-(methylcarbamoyloxy)phenyl]propyl]azanium,CCC(C1=CC(=CC=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11292,45987,"Carbamic acid, dimethyl-, (4-ethyl-2-(trimethylammonio)phenyl) ester, iodide",CCC1=CC(=C(C=C1)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
11293,45988,[2-(Dimethylcarbamoyloxy)-4-ethylphenyl]-trimethylazanium,CCC1=CC(=C(C=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
11294,45989,"Carbamic acid, dimethyl-, ((4-trimethylammonio)-3-ethyl)phenyl ester, iodide",CCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11295,45990,[4-(Dimethylcarbamoyloxy)-2-ethylphenyl]-trimethylazanium,CCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11296,45991,"Carbamic acid, methyl-, (2-ethyl-5-(trimethylammonio)phenyl) ester, iodide",CCC1=CC(=C(C=C1)[N+](C)(C)C)OC(=O)NC.[I-],,,,,,
11297,45992,[4-Ethyl-2-(methylcarbamoyloxy)phenyl]-trimethylazanium,CCC1=CC(=C(C=C1)[N+](C)(C)C)OC(=O)NC,,,,,,
11298,45993,"Ammonium, ((2-ethyl-4-methylcarbamoyloxy)phenyl)trimethyl-, iodide",CCC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11299,45994,[2-Ethyl-4-(methylcarbamoyloxy)phenyl]-trimethylazanium,CCC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11300,45995,"Ammonium, ((2-ethyl-5-methylcarbamoyloxy)phenyl)trimethyl-, iodide",CCC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11301,45996,"2-Ethyl-5-[[(methylamino)carbonyl]oxy]-N,N,N-trimethylbenzenaminium",CCC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11302,45997,"1-Piperidinecarboxylic acid, (4-(trimethylammonio)-3-ethyl)phenyl ester, iodide",CCC1=C(C=CC(=C1)OC(=O)N2CCCCC2)[N+](C)(C)C.[I-],,,,,,
11303,45998,[2-Ethyl-4-(piperidine-1-carbonyloxy)phenyl]-trimethylazanium,CCC1=C(C=CC(=C1)OC(=O)N2CCCCC2)[N+](C)(C)C,,,,,,
11304,45999,Hexamethylenebis((beta-phenothiazin-10-yl)dimethylammonium bromide),C[N+](C)(CCCCCC[N+](C)(C)CCN1C2=CC=CC=C2SC3=CC=CC=C31)CCN4C5=CC=CC=C5SC6=CC=CC=C64.[Br-].[Br-],,,,,,
11305,46000,6-[Dimethyl(2-phenothiazin-10-ylethyl)azaniumyl]hexyl-dimethyl-(2-phenothiazin-10-ylethyl)azanium,C[N+](C)(CCCCCC[N+](C)(C)CCN1C2=CC=CC=C2SC3=CC=CC=C31)CCN4C5=CC=CC=C5SC6=CC=CC=C64,,,,,,
11306,46001,"AMMONIUM, (o-HYDROXYBENZYL)DIETHYLMETHYL-, IODIDE, DIMETHYLCARBAMATE",CC[N+](C)(CC)CC1=CC=CC=C1OC(=O)N(C)C.[I-],,,,,,
11307,46002,[2-(Dimethylcarbamoyloxy)phenyl]methyl-diethyl-methylazanium,CC[N+](C)(CC)CC1=CC=CC=C1OC(=O)N(C)C,,,,,,
11308,46003,2-Hydroxybenzyltrimethylammonium bromide,C[N+](C)(C)CC1=CC=CC=C1O.[Br-],,,,,,
11309,46004,2-Hydroxybenzyltrimethylaminium,C[N+](C)(C)CC1=CC=CC=C1O,,,,,,
11310,46005,"Carbamic acid, methyl-, alpha-(trimethylammonio)-m-tolyl ester, iodide",CNC(=O)OC1=CC=CC(=C1)C[N+](C)(C)C.[I-],,,,,,
11311,46006,Trimethyl-[[3-(methylcarbamoyloxy)phenyl]methyl]azanium,CNC(=O)OC1=CC=CC(=C1)C[N+](C)(C)C,,,,,,
11312,46007,"Carbamic acid, N-methyl-N-(methylcarbamyl)-, 2-(trimethylammonio)methylphenyl ester, iodide",CNC(=O)N(C)C(=O)OC1=CC=CC=C1C[N+](C)(C)C.[I-],,,,,,
11313,46008,Trimethyl-[[2-[methyl(methylcarbamoyl)carbamoyl]oxyphenyl]methyl]azanium,CNC(=O)N(C)C(=O)OC1=CC=CC=C1C[N+](C)(C)C,,,,,,
11314,46009,"Ammonium, ((4-(N,N-dimethylcarbamoyloxy)-2-butyl)phenyl)trimethyl-, iodide",CCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11315,46010,[2-Butyl-4-(dimethylcarbamoyloxy)phenyl]-trimethylazanium,CCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11316,46011,"Ammonium, (5-tert-butyl-2-(dimethylcarbamoyloxy)phenyl)trimethyl-, iodide",CC(C)(C)C1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11317,46012,[5-Tert-butyl-2-(dimethylcarbamoyloxy)phenyl]-trimethylazanium,CC(C)(C)C1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11318,46013,"Ammonium, ((4-hydroxy-2-butyl)phenyl)trimethyl-, iodide, methylcarbamate",CCCCC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11319,46014,[2-Butyl-4-(methylcarbamoyloxy)phenyl]-trimethylazanium,CCCCC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11320,46015,"Carbamic acid, 4-(trimethylammonio)butyl ester, chloride",C[N+](C)(C)CCCCOC(=O)N.[Cl-],,,,,,
11321,46016,4-Carbamoyloxybutyl(trimethyl)azanium,C[N+](C)(C)CCCCOC(=O)N,,,,,,
11322,46017,"Carbamic acid, bis(2-chloroethyl)-, 6-(trimethylammonio)thymyl ester, chloride",CC1=C(C=C(C=C1OC(=O)N(CCCl)CCCl)C(C)C)[N+](C)(C)C.[Cl-],,,,,,
11323,46018,[3-[Bis(2-chloroethyl)carbamoyloxy]-2-methyl-5-propan-2-ylphenyl]-trimethylazanium,CC1=C(C=C(C=C1OC(=O)N(CCCl)CCCl)C(C)C)[N+](C)(C)C,,,,,,
11324,46019,"(5-Hydroxycarvacryl)trimethylammonium iodide, dimethylcarbamate",CC1=C(C=C(C=C1OC(=O)N(C)C)C(C)C)[N+](C)(C)C.[I-],,,,,,
11325,46020,[3-(Dimethylcarbamoyloxy)-2-methyl-5-propan-2-ylphenyl]-trimethylazanium,CC1=C(C=C(C=C1OC(=O)N(C)C)C(C)C)[N+](C)(C)C,,,,,,
11326,46021,"Carbamic acid, methyl-, (2-chloro-5-(trimethylammonio)phenyl) ester, iodide",CNC(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)Cl.[I-],,,,,,
11327,46022,"4-Chloro-3-(methylaminocarbonyloxy)-N,N,N-trimethylbenzenaminium",CNC(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)Cl,,,,,,
11328,46023,"Ammonium, (4-methylcarbamoyloxy-o-cumenyl)allyldimethyl-, bromide",CC(C)C1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)CC=C.[Br-],,,,,,
11329,46024,Dimethyl-[4-(methylcarbamoyloxy)-2-propan-2-ylphenyl]-prop-2-enylazanium,CC(C)C1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)CC=C,,,,,,
11330,46025,"Carbamic acid, dimethyl-, ((4-dimethylethylammonio)-3-isopropyl)phenyl ester, iodide",CC[N+](C)(C)C1=C(C=C(C=C1)OC(=O)N(C)C)C(C)C.[I-],,,,,,
11331,46026,[4-(Dimethylcarbamoyloxy)-2-propan-2-ylphenyl]-ethyl-dimethylazanium,CC[N+](C)(C)C1=C(C=C(C=C1)OC(=O)N(C)C)C(C)C,,,,,,
11332,46027,"Carbamic acid, dimethyl-, ((4-trimethylammonio)-3-isopropyl)phenyl ester, chloride",CC(C)C1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[Cl-],,,,,,
11333,46028,"Ammonium, (4-methylcarbamoyloxy-o-cumenyl)trimethyl-, chloride",CC(C)C1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C.[Cl-],,,,,,
11334,46029,Trimethyl[4-[[(methylamino)carbonyl]oxy]-2-isopropylphenyl]aminium,CC(C)C1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11335,46030,"AMMONIUM, (4-HYDROXY-o-CUMENYL)TRIMETHYL-, IODIDE",CC(C)C1=C(C=CC(=C1)O)[N+](C)(C)C.[I-],,,,,,
11336,46031,(4-Hydroxy-2-propan-2-ylphenyl)-trimethylazanium,CC(C)C1=C(C=CC(=C1)O)[N+](C)(C)C,,,,,,
11337,46032,"AMMONIUM, (4-(p-ETHYLDIMETHYLAMMONIOPHENYL)BUTYL)ETHYLDIMETHYL-, DIIODIDE",CC[N+](C)(C)CCCCC1=CC=C(C=C1)[N+](C)(C)CC.[I-].[I-],,,,,,
11338,46033,Ethyl-[4-[4-[ethyl(dimethyl)azaniumyl]butyl]phenyl]-dimethylazanium,CC[N+](C)(C)CCCCC1=CC=C(C=C1)[N+](C)(C)CC,,,,,,
11339,46034,"AMMONIUM, (3-(p-ETHYLDIMETHYLAMMONIOPHENYL)PROPYL)ETHYLDIMETHYL-, DIIODIDE",CC[N+](C)(C)CCCC1=CC=C(C=C1)[N+](C)(C)CC.[I-].[I-],,,,,,
11340,46035,Ethyl-[3-[4-[ethyl(dimethyl)azaniumyl]phenyl]propyl]-dimethylazanium,CC[N+](C)(C)CCCC1=CC=C(C=C1)[N+](C)(C)CC,,,,,,
11341,46036,Suxethonium bromide,CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
11342,46037,Suxethonium,CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC,,,,,,
11343,46038,"AMMONIUM, (m-HYDROXYPHENYL)DIMETHYLETHYL-, IODIDE, METHYLCARBAMATE",CC[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC.[I-],,,,,,
11344,46039,"N-Ethyl-N,N-dimethyl-3-[[(methylamino)carbonyl]oxy]benzenaminium",CC[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC,,,,,,
11345,46040,"Ammonium, N-ethyl-N,N,N',N',N'-pentamethyl-N,N'-oxydiethylenedi-, diiodide",CC[N+](C)(C)CCOCC[N+](C)(C)C.[I-].[I-],,,,,,
11346,46041,Ethyl-dimethyl-[2-[2-(trimethylazaniumyl)ethoxy]ethyl]azanium,CC[N+](C)(C)CCOCC[N+](C)(C)C,,,,,,
11347,46042,"Ammonium, N-ethyl-N-propyl-N,N',N',N'-tetramethyl-N,N'-oxydiethylenedi-, diiodide",CCC[N+](C)(CC)CCOCC[N+](C)(C)C.[I-].[I-],,,,,,
11348,46043,Ethyl-methyl-propyl-[2-[2-(trimethylazaniumyl)ethoxy]ethyl]azanium,CCC[N+](C)(CC)CCOCC[N+](C)(C)C,,,,,,
11349,46044,"Ammonium, ((2-fluoroethoxycarbonyl)methyl)trimethyl-, chloride",C[N+](C)(C)CC(=O)OCCF.[Cl-],,,,,,
11350,46045,[2-(2-Fluoroethoxy)-2-oxoethyl]-trimethylazanium,C[N+](C)(C)CC(=O)OCCF,,,,,,
11351,46046,3-Formylphenyltrimethylammonium iodide,C[N+](C)(C)C1=CC=CC(=C1)C=O.[I-],,,,,,
11352,46047,"3-Formyl-N,N,N-trimethylbenzenaminium",C[N+](C)(C)C1=CC=CC(=C1)C=O,,,,,,
11353,46048,"1-Heptadecanaminium, N,N,N-trimethyl-, methyl sulfate",CCCCCCCCCCCCCCCCC[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
11354,46049,Trimethylheptadecylaminium,CCCCCCCCCCCCCCCCC[N+](C)(C)C,,,,,,
11355,46050,"Ammonium, heptamethylenebis(diethylmethyl-, dibromide",CC[N+](C)(CC)CCCCCCC[N+](C)(CC)CC.[Br-].[Br-],,,,,,
11356,46051,7-[Diethyl(methyl)azaniumyl]heptyl-diethyl-methylazanium,CC[N+](C)(CC)CCCCCCC[N+](C)(CC)CC,,,,,,
11357,46052,"Ammonium, heptamethylenebis(ethyldimethyl-, dibromide",CC[N+](C)(C)CCCCCCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
11358,46053,Ethyl-[7-[ethyl(dimethyl)azaniumyl]heptyl]-dimethylazanium,CC[N+](C)(C)CCCCCCC[N+](C)(C)CC,,,,,,
11359,46054,"Ammonium, heptamethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCCCCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
11360,46055,Heptamethylenebis(triethylaminium),CC[N+](CC)(CC)CCCCCCC[N+](CC)(CC)CC,,,,,,
11361,46056,"Ammonium, hexamethylenebis(fluoren-9-yldiethyl-, dibromide",CC[N+](CC)(CCCCCC[N+](CC)(CC)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-],,,,,,
11362,46057,6-[diethyl(9H-fluoren-9-yl)azaniumyl]hexyl-diethyl-(9H-fluoren-9-yl)azanium,CC[N+](CC)(CCCCCC[N+](CC)(CC)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
11363,46058,"Ammonium, hexamethylenebis(diethylmethyl-, dibromide",CC[N+](C)(CC)CCCCCC[N+](C)(CC)CC.[Br-].[Br-],,,,,,
11364,46059,6-[Diethyl(methyl)azaniumyl]hexyl-diethyl-methylazanium,CC[N+](C)(CC)CCCCCC[N+](C)(CC)CC,,,,,,
11365,46060,"Ammonium, hexamethylenebis((beta-9,10-dihydroanthracen-9-ylethyl)dimethyl-, dibromide",C[N+](C)(CCCCCC[N+](C)(C)CCC1C2=CC=CC=C2CC3=CC=CC=C13)CCC4C5=CC=CC=C5CC6=CC=CC=C46.[Br-].[Br-],,,,,,
11366,46061,"2-(9,10-Dihydroanthracen-9-yl)ethyl-[6-[2-(9,10-dihydroanthracen-9-yl)ethyl-dimethylazaniumyl]hexyl]-dimethylazanium",C[N+](C)(CCCCCC[N+](C)(C)CCC1C2=CC=CC=C2CC3=CC=CC=C13)CCC4C5=CC=CC=C5CC6=CC=CC=C46,,,,,,
11367,46062,"Methylcarbamic acid 9-methyl-9H-pyrido(3,4-b)indol-7-yl ester hydrochloride",CNC(=O)OC1=CC2=C(C=C1)C3=C([NH+]2C)C=NC=C3.[Cl-],,,,,,
11368,46063,"(9-methylpyrido[3,4-b]indol-7-yl) N-methylcarbamate",CNC(=O)OC1=CC2=C(C=C1)C3=C(N2C)C=NC=C3,,,,,,
11369,46064,"Carbamic acid, N-methyl-N-nitroso-, 2-chloroethyl ester",CN(C(=O)OCCCl)N=O,,,,,,
11370,46065,2-Fluoroethyl N-methyl-N-nitrosocarbamate,CN(C(=O)OCCF)N=O,,,,,,
11371,46066,"Carbamic acid, methyl-, 8-quinolinyl ester, hydrochloride",CNC(=O)OC1=CC=CC2=C1[NH+]=CC=C2.[Cl-],,,,,,
11372,46067,8-Quinolyl methylcarbamate,CNC(=O)OC1=CC=CC2=C1N=CC=C2,,,,,,
11373,46068,"Carbamic acid, methyl-, (5,6,7,8-tetrahydro-5-dimethylamino)-2-naphthyl ester, hydrobromide",CNC(=O)OC1=CC2=C(C=C1)C(CCC2)[NH+](C)C.[Br-],,,,,,
11374,46069,"[5-(dimethylamino)-5,6,7,8-tetrahydronaphthalen-2-yl] N-methylcarbamate",CNC(=O)OC1=CC2=C(C=C1)C(CCC2)N(C)C,,,,,,
11375,46070,"Isoquinoline, 2-methyl-1,2,3,4-tetrahydro-5,6-bis-(N-methylcarbamyloxy) hydrochloride",CNC(=O)OC1=C(C2=C(C[NH+](CC2)C)C=C1)OC(=O)NC.[Cl-],,,,,,
11376,46071,"[2-methyl-5-(methylcarbamoyloxy)-3,4-dihydro-1H-isoquinolin-6-yl] N-methylcarbamate",CNC(=O)OC1=C(C2=C(CN(CC2)C)C=C1)OC(=O)NC,,,,,,
11377,46072,"Isoquinoline, 2-methyl-1,2,3,4-tetrahydro-6,7-bis(N-methylcarbamyloxy) hydrochloride",CNC(=O)OC1=C(C=C2C[NH+](CCC2=C1)C)OC(=O)NC.[Cl-],,,,,,
11378,46073,"[2-methyl-7-(methylcarbamoyloxy)-3,4-dihydro-1H-isoquinolin-6-yl] N-methylcarbamate",CNC(=O)OC1=C(C=C2CN(CCC2=C1)C)OC(=O)NC,,,,,,
11379,46074,"Carbamic acid, N-methyl-, 1-methyl-1,2,3,4-tetrahydro-7-quinolinyl ester, hydrochloride",CNC(=O)OC1=CC2=C(CCC[NH+]2C)C=C1.[Cl-],,,,,,
11380,46075,"(1-methyl-3,4-dihydro-2H-quinolin-7-yl) N-methylcarbamate",CNC(=O)OC1=CC2=C(CCCN2C)C=C1,,,,,,
11381,46076,3-(2'-Methylpiperidino)propyl alpha-naphthylcarbamate,CC1CCCCN1CCCOC(=O)NC2=CC=CC3=CC=CC=C32,,,,,,
11382,46077,"Carbamic acid, octylsulfonyl-, ethyl ester",CCCCCCCCS(=O)(=O)NC(=O)OCC,,,,,,
11383,46078,"Carbamic acid, phenethyl-, isopropyl ester",CC(C)OC(=O)NCCC1=CC=CC=C1,,,,,,
11384,46079,"Aniline, N,N-dimethyl-3-(N-phenylcarbamoyloxy)-, hydrochloride",C[NH+](C)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
11385,46080,3-(Dimethylamino)phenyl phenylcarbamate,CN(C)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,,,,,,
11386,46081,"Ammonium, ethylbis(2-hydroxyethyl)methyl-, chloride",CC[N+](C)(CCO)CCO.[Cl-],,,,,,
11387,46082,"N,N-Bis(2-hydroxyethyl)-N-methylethaneaminium",CC[N+](C)(CCO)CCO,,,,,,
11388,46083,"Ammonium, ((2-(2-(ethyldimethylammonio)ethoxy)-2-methyl)ethyl)ethyldimethyl-, dibromide",CC[N+](C)(C)CCOC(C)C[N+](C)(C)CC.[Br-].[Br-],,,,,,
11389,46084,Ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]propyl]-dimethylazanium,CC[N+](C)(C)CCOC(C)C[N+](C)(C)CC,,,,,,
11390,46085,"Ammonium, ((2-(2-(ethyldimethylammonio)ethoxy)-2-methyl)ethyl)ethyldimethyl-, diiodide",CC[N+](C)(C)CCOC(C)C[N+](C)(C)CC.[I-].[I-],,,,,,
11391,46086,"Ammonium, ((1-methyl-2-(triethylammonio)ethoxy)ethyl)dimethylethyl-, diiodide",CC[N+](C)(C)CCOC(C)C[N+](CC)(CC)CC.[I-].[I-],,,,,,
11392,46087,Triethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]propyl]azanium,CC[N+](C)(C)CCOC(C)C[N+](CC)(CC)CC,,,,,,
11393,46088,"AMMONIUM, ((p-ETHYLDIMETHYLAMMONIO)PHENETHYL)ETHYLDIMETHYL-, DIIODIDE",CC[N+](C)(C)CCC1=CC=C(C=C1)[N+](C)(C)CC.[I-].[I-],,,,,,
11394,46089,Ethyl-[4-[2-[ethyl(dimethyl)azaniumyl]ethyl]phenyl]-dimethylazanium,CC[N+](C)(C)CCC1=CC=C(C=C1)[N+](C)(C)CC,,,,,,
11395,46090,"Carbamic acid, N-methyl-, 3-(alpha-dimethylaminoethyl)-6-methoxyphenyl ester, hydrochloride",CC(C1=CC(=C(C=C1)OC)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
11396,46091,[5-[1-(dimethylamino)ethyl]-2-methoxyphenyl] N-methylcarbamate,CC(C1=CC(=C(C=C1)OC)OC(=O)NC)N(C)C,,,,,,
11397,46092,"Carbamic acid, N-methyl-, m-(alpha-dimethylaminoethyl)phenyl ester, hydrochloride",CC(C1=CC(=CC=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
11398,46093,Miotine,CC(C1=CC(=CC=C1)OC(=O)NC)N(C)C,,,,,,
11399,46094,"Carbamic acid, methyl-, 3-(2-(dimethylamino)ethyl)phenyl ester, hydrochloride",CNC(=O)OC1=CC=CC(=C1)CC[NH+](C)C.[Cl-],,,,,,
11400,46095,[3-[2-(dimethylamino)ethyl]phenyl] N-methylcarbamate,CNC(=O)OC1=CC=CC(=C1)CCN(C)C,,,,,,
11401,46096,"Carbamic acid, methyl-, 4-(2-dimethylaminoethyl)phenyl ester, hydrochloride",CNC(=O)OC1=CC=C(C=C1)CC[NH+](C)C.[Cl-],,,,,,
11402,46097,[4-[2-(dimethylamino)ethyl]phenyl] N-methylcarbamate,CNC(=O)OC1=CC=C(C=C1)CCN(C)C,,,,,,
11403,46098,"Carbamic acid, methyl-, 2-(alpha-(dimethylamino)ethyl)-p-tolyl ester, hydrochloride",CC1=CC(=C(C=C1)OC(=O)NC)C(C)[NH+](C)C.[Cl-],,,,,,
11404,46099,[2-[1-(dimethylamino)ethyl]-4-methylphenyl] N-methylcarbamate,CC1=CC(=C(C=C1)OC(=O)NC)C(C)N(C)C,,,,,,
11405,46100,"Carbamic acid, methyl-, (alpha-(dimethylamino)-5-methyl)-o-tolyl ester, hydrochloride",CC1=CC(=C(C=C1)C[NH+](C)C)OC(=O)NC.[Cl-],,,,,,
11406,46101,[2-[(dimethylamino)methyl]-5-methylphenyl] N-methylcarbamate,CC1=CC(=C(C=C1)CN(C)C)OC(=O)NC,,,,,,
11407,46102,"CARBAMIC ACID, METHYL-, 2-(DIMETHYLAMINOMETHYL)-p-TOLYL ESTER, HYDROCHLORIDE",CC1=CC(=C(C=C1)OC(=O)NC)C[NH+](C)C.[Cl-],,,,,,
11408,46103,[2-[(dimethylamino)methyl]-4-methylphenyl] N-methylcarbamate,CC1=CC(=C(C=C1)OC(=O)NC)CN(C)C,,,,,,
11409,46104,"Carbamic acid, methyl-, alpha-dimethylamino-alpha-methyl-p-tolyl ester, hydrochloride",CC(C1=CC=C(C=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
11410,46105,[4-[1-(dimethylamino)ethyl]phenyl] N-methylcarbamate,CC(C1=CC=C(C=C1)OC(=O)NC)N(C)C,,,,,,
11411,46106,"Carbamic acid, N-methyl-, 3-(dimethylamino)phenyl ester, hydrochloride",CNC(=O)OC1=CC=CC(=C1)[NH+](C)C.[Cl-],,,,,,
11412,46107,"Phenol, 3-(dimethylamino)-, methylcarbamate (ester)",CNC(=O)OC1=CC=CC(=C1)N(C)C,,,,,,
11413,46108,"Carbamic acid, methyl-, 2-(1-(dimethylamino)propyl)phenyl ester, hydrochloride",CCC(C1=CC=CC=C1OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
11414,46109,[2-[1-(dimethylamino)propyl]phenyl] N-methylcarbamate,CCC(C1=CC=CC=C1OC(=O)NC)N(C)C,,,,,,
11415,46110,"Carbamic acid, methyl-, 3-(1-(dimethylamino)propyl)phenyl ester, hydrochloride",CCC(C1=CC(=CC=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
11416,46111,[3-[1-(dimethylamino)propyl]phenyl] N-methylcarbamate,CCC(C1=CC(=CC=C1)OC(=O)NC)N(C)C,,,,,,
11417,46112,"Carbamic acid, methyl-, 4-(3-dimethylaminopropyl)phenyl ester, hydrochloride",CNC(=O)OC1=CC=C(C=C1)CCC[NH+](C)C.[Cl-],,,,,,
11418,46113,[4-[3-(dimethylamino)propyl]phenyl] N-methylcarbamate,CNC(=O)OC1=CC=C(C=C1)CCCN(C)C,,,,,,
11419,46114,"Carbamic acid, methyl-, 3-(dimethylaminomethyl)phenyl ester, hydrochloride",CNC(=O)OC1=CC=CC(=C1)C[NH+](C)C.[Cl-],,,,,,
11420,46115,[3-[(dimethylamino)methyl]phenyl] N-methylcarbamate,CNC(=O)OC1=CC=CC(=C1)CN(C)C,,,,,,
11421,46116,"Carbamic acid, N-methyl-, 4-(dimethylaminomethyl)phenyl ester, hydrochloride",CNC(=O)OC1=CC=C(C=C1)C[NH+](C)C.[Cl-],,,,,,
11422,46117,[4-[(dimethylamino)methyl]phenyl] N-methylcarbamate,CNC(=O)OC1=CC=C(C=C1)CN(C)C,,,,,,
11423,46118,"Carbamic acid, N-methyl-, 3-dimethylamino-4-methylphenyl ester, hydrochloride",CC1=C(C=C(C=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
11424,46119,"Carbamic acid, N-methyl-, 2-dimethylaminomethyl-6-methylphenyl ester, hydrochloride",CC1=C(C(=CC=C1)C[NH+](C)C)OC(=O)NC.[Cl-],,,,,,
11425,46120,[2-[(dimethylamino)methyl]-6-methylphenyl] N-methylcarbamate,CC1=C(C(=CC=C1)CN(C)C)OC(=O)NC,,,,,,
11426,46121,"Carbamic acid, N-methyl-, 2,4-dimethyl-5-dimethylaminophenyl ester, hydrochloride",CC1=CC(=C(C=C1[NH+](C)C)OC(=O)NC)C.[Cl-],,,,,,
11427,46122,"[5-(dimethylamino)-2,4-dimethylphenyl] N-methylcarbamate",CC1=CC(=C(C=C1N(C)C)OC(=O)NC)C,,,,,,
11428,46123,"Carbamic acid, N-methyl-, 1,6-dinitro-2-naphthyl ester",CNC(=O)OC1=C(C2=C(C=C1)C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
11429,46124,"Carbamic acid, methyl-, 2,4-dinitro-1-naphthyl ester",CNC(=O)OC1=C(C=C(C2=CC=CC=C21)[N+](=O)[O-])[N+](=O)[O-],,,,,,
11430,46125,"Benzene, 1,4-bis(methylcarbamyloxy)-2-isopropyl-5-methyl-",CC1=CC(=C(C=C1OC(=O)NC)C(C)C)OC(=O)NC,,,,,,
11431,46126,Dibutyl(3-hydroxyphenyl)methylammonium iodide methylcarbamate,CCCC[N+](C)(CCCC)C1=CC(=CC=C1)OC(=O)NC.[I-],,,,,,
11432,46127,Dibutyl-methyl-[3-(methylcarbamoyloxy)phenyl]azanium,CCCC[N+](C)(CCCC)C1=CC(=CC=C1)OC(=O)NC,,,,,,
11433,46128,"Ammonium, butyltripropyl-, hydroxide",CCCC[N+](CCC)(CCC)CCC.[OH-],,,,,,
11434,46129,"Carbanilic acid, 2-methyl-4-propoxy-, 2-(dimethylamino)ethyl ester",CCCOC1=CC(=C(C=C1)NC(=O)OCCN(C)C)C,,,,,,
11435,46130,"Carbanilic acid, 4-butoxy-2-methyl-, 2-(dimethylamino)ethyl ester",CCCCOC1=CC(=C(C=C1)NC(=O)OCCN(C)C)C,,,,,,
11436,46131,"Carbanilic acid, 4-(hexyloxy)-2-methyl-, 2-(dimethylamino)ethyl ester",CCCCCCOC1=CC(=C(C=C1)NC(=O)OCCN(C)C)C,,,,,,
11437,46132,"Carbanilic acid, 2-methyl-4-propoxy-, 2-(diethylamino)ethyl ester",CCCOC1=CC(=C(C=C1)NC(=O)OCCN(CC)CC)C,,,,,,
11438,46133,"Carbanilic acid, 4-butoxy-2-methyl-, 2-(diethylamino)ethyl ester",CCCCOC1=CC(=C(C=C1)NC(=O)OCCN(CC)CC)C,,,,,,
11439,46134,"Carbanilic acid, 2-methyl-4-(pentyloxy)-, 2-(diethylamino)ethyl ester",CCCCCOC1=CC(=C(C=C1)NC(=O)OCCN(CC)CC)C,,,,,,
11440,46135,CID 46135,CCCCCCOC1=CC(=C(C=C1)NC(=O)OCC[NH+](CC)CC)C.[Cl-],,,,,,
11441,46136,"Carbanilic acid, 4-(hexyloxy)-2-methyl-, 2-(diethylamino)ethyl ester",CCCCCCOC1=CC(=C(C=C1)NC(=O)OCCN(CC)CC)C,,,,,,
11442,46137,"Carbanilic acid, 2-methyl-4-propoxy-, 2-piperidinoethyl ester",CCCOC1=CC(=C(C=C1)NC(=O)OCCN2CCCCC2)C,,,,,,
11443,46138,"Carbanilic acid, 4-butoxy-2-methyl-, 2-piperidinoethyl ester",CCCCOC1=CC(=C(C=C1)NC(=O)OCCN2CCCCC2)C,,,,,,
11444,46139,"Carbanilic acid, 2-methyl-4-(pentyloxy)-, 2-piperidinoethyl ester",CCCCCOC1=CC(=C(C=C1)NC(=O)OCCN2CCCCC2)C,,,,,,
11445,46140,"Carbanilic acid, 4-(hexyloxy)-2-methyl-, 2-piperidinoethyl ester",CCCCCCOC1=CC(=C(C=C1)NC(=O)OCCN2CCCCC2)C,,,,,,
11446,46141,"Carbanilic acid, 2-methyl-4-propoxy-, 2-(dibutylamino)ethyl ester",CCCCN(CCCC)CCOC(=O)NC1=C(C=C(C=C1)OCCC)C,,,,,,
11447,46142,"Carbanilic acid, 2-methyl-4-propoxy-, 2-morpholinoethyl ester",CCCOC1=CC(=C(C=C1)NC(=O)OCCN2CCOCC2)C,,,,,,
11448,46143,"Carbanilic acid, 2-methyl-4-(pentyloxy)-, 2-morpholinoethyl ester",CCCCCOC1=CC(=C(C=C1)NC(=O)OCCN2CCOCC2)C,,,,,,
11449,46144,1-((Diethylamino)methyl)ethyl 4-butoxy-2-methylcarbanilate,CCCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN(CC)CC)C,,,,,,
11450,46145,2-Methyl-4-(pentyloxy)carbanilic acid 1-((diethylamino)methyl)ethyl ester,CCCCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN(CC)CC)C,,,,,,
11451,46146,1-((Diethylamino)methyl)ethyl 4-(hexyloxy)-2-methylcarbanilate,CCCCCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN(CC)CC)C,,,,,,
11452,46147,2-Methyl-4-propoxycarbanilic acid 1-(piperidinomethyl)ethyl ester,CCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN2CCCCC2)C,,,,,,
11453,46148,1-(Piperidinomethyl)ethyl 4-butoxy-2-methylcarbanilate,CCCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN2CCCCC2)C,,,,,,
11454,46149,2-Methyl-4-(pentyloxy)carbanilic acid 1-(piperidinomethyl)ethyl ester,CCCCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN2CCCCC2)C,,,,,,
11455,46150,1-(Piperidinomethyl)ethyl 4-(hexyloxy)-2-methylcarbanilate,CCCCCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN2CCCCC2)C,,,,,,
11456,46151,"Benzamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)-",COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)OC)OC)NC(=O)C4=CC=CC=C4,,,,,,
11457,46152,"Coumarin, 6-amino-, hydrochloride",C1=CC2=C(C=CC(=O)O2)C=C1[NH3+].[Cl-],,,,,,
11458,46153,6-Amino-2H-chromen-2-one,C1=CC2=C(C=CC(=O)O2)C=C1N,,,['Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)'],,,
11459,46154,"m-Cresol, 6-decyl-",CCCCCCCCCCC1=C(C=C(C=C1)C)O,,,,,,
11460,46155,"o-CRESOL, alpha,alpha'-(4,6-DIMETHYL-m-PHENYLENE)-BIS(4-CHLORO-",CC1=CC(=C(C=C1CC2=C(C=CC(=C2)Cl)O)CC3=C(C=CC(=C3)Cl)O)C,,,,,,
11461,46156,"3,5-Dinitro-p-cresol",CC1=C(C=C(C=C1[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
11462,46157,"o-CRESOL, 4,6-DINITRO-, BARIUM DERIVATIVE",CC1=CC(=CC(=C1[O-])[N+](=O)[O-])[N+](=O)[O-].CC1=CC(=CC(=C1[O-])[N+](=O)[O-])[N+](=O)[O-].[Ba+2],,,,,,
11463,46158,"4,6-Dinitro-o-cresol methylamine (1:1)",CC1=CC(=CC(=C1[O-])[N+](=O)[O-])[N+](=O)[O-].C[NH3+],,,,,,
11464,46159,"4,6-Dinitro-o-cresol morpholine (1:1)",CC1=CC(=CC(=C1[O-])[N+](=O)[O-])[N+](=O)[O-].C1COCC[NH2+]1,,,,,,
11465,46160,"m-Cresol, 6-heptyl-",CCCCCCCC1=C(C=C(C=C1)C)O,,,,,,
11466,46161,4'-(2-Hydroxy-3-(4-phenylpiperazinyl)propoxy)acetophenone,CC(=O)C1=CC=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
11467,46162,1-(4-Acetyl-2-methylphenoxy)-3-(4-phenylpiperazinyl)propan-2-ol,CC1=C(C=CC(=C1)C(=O)C)OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
11468,46163,3'-((2-Hydroxy-3-piperidino)propoxy)acetophenone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCCCC2)O,,,,,,
11469,46164,3'-((2-Hydroxy-3-(p-tolylpiperazinyl))propoxy)acetophenone,CC1=CC=C(C=C1)N2CCN(CC2)CC(COC3=CC=CC(=C3)C(=O)C)O,,,,,,
11470,46165,"Acetophenone, 2'-((2-hydroxy-3-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazinyl))propoxy)-",CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)O,,,,,,
11471,46166,"Acetophenone, 3'-((2-hydroxy-3-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazinyl))propoxy)-, dihydrochloride",CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)O.Cl.Cl,,,,,,
11472,46167,1-[3-[2-Hydroxy-3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propoxy]phenyl]ethanone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC=CC(=C3)C(F)(F)F)O,,,,,,
11473,46168,"Acetophenone, 2'-((2-hydroxy-3-(4-(4-o-xylyl)piperazinyl))propoxy)-, dihydrochloride, acetate",CC1=CC(=C(C=C1)N2CCN(CC2)CC(COC3=CC=CC=C3C(=O)C)OC(=O)C)C.Cl.Cl,,,,,,
11474,46169,"[1-(2-Acetylphenoxy)-3-[4-(2,4-dimethylphenyl)piperazin-1-yl]propan-2-yl] acetate",CC1=CC(=C(C=C1)N2CCN(CC2)CC(COC3=CC=CC=C3C(=O)C)OC(=O)C)C,,,,,,
11475,46170,"o-ACETOTOLUIDIDE, alpha, alpha'-DISELENOBIS-",CC(=O)NC1=CC=CC=C1[Se][Se]C2=CC=CC=C2NC(=O)C,,,,,,
11476,46171,"Acetyl chloride, (2,4-bis(1-methylbutyl)phenoxy)-",CCCC(C)C1=CC(=C(C=C1)OCC(=O)Cl)C(C)CCC,,,,,,
11477,46172,Chloracetylcholin bromide,C[N+](C)(C)CCOC(=O)CCl.[Br-],,,,,,
11478,46173,"Ethanaminium, 2-[(chloroacetyl)oxy]-N,N,N-trimethyl-",C[N+](C)(C)CCOC(=O)CCl,,,,,,
11479,46174,"Acetylene, bis(2-methoxyethylmercuri)-",COCC[Hg]C#C[Hg]CCOC,,,,,,
11480,46175,2'-((3-(4-(o-Chlorophenyl)piperazinyl)-2-hydroxy)propoxy)acetophenone,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3Cl)O,,,,,,
11481,46176,"Acetophenone, 3',5'-dibromo-2',4',6'-trihydroxy-",CC(=O)C1=C(C(=C(C(=C1O)Br)O)Br)O,,,,,,
11482,46177,CID 46177,CC1=CC(N=C(N1C2=CC=C(C=C2)C(=O)C)S)(C)C,,,,,,
11483,46178,2'-((3-Diisopropylamino-2-hydroxy)propoxy)acetophenone hydrochloride,CC(C)[NH+](CC(COC1=CC=CC=C1C(=O)C)O)C(C)C.[Cl-],,,,,,
11484,46179,1-[2-[3-[Di(propan-2-yl)amino]-2-hydroxypropoxy]phenyl]ethanone,CC(C)N(CC(COC1=CC=CC=C1C(=O)C)O)C(C)C,,,,,,
11485,46180,3'-((3-Diisopropylamino-2-hydroxy)propoxy)acetophenone hydrochloride,CC(C)[NH+](CC(COC1=CC=CC(=C1)C(=O)C)O)C(C)C.[Cl-],,,,,,
11486,46181,1-[3-[3-[Di(propan-2-yl)amino]-2-hydroxypropoxy]phenyl]ethanone,CC(C)N(CC(COC1=CC=CC(=C1)C(=O)C)O)C(C)C,,,,,,
11487,46182,"Acetophenone, 3'-((3-(4-(3,4-dimethoxyphenyl)piperazinyl)-2-hydroxy)propoxy)-, dihydrochloride",CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC(=C(C=C3)OC)OC)O.Cl.Cl,,,,,,
11488,46183,"1-[3-[3-[4-(3,4-Dimethoxyphenyl)piperazin-1-yl]-2-hydroxypropoxy]phenyl]ethanone",CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC(=C(C=C3)OC)OC)O,,,,,,
11489,46184,3'-((2-Hydroxy-3-(4-hydroxy-4-phenylpiperidino))propoxy)acetophenone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O,,,,,,
11490,46185,"Acetophenone, 2'-((2-hydroxy-3-(4-hydroxy-4-phenylpiperidino))propoxy)-, hydrochloride",CC(=O)C1=CC=CC=C1OCC(C[NH+]2CCC(CC2)(C3=CC=CC=C3)O)O.[Cl-],,,,,,
11491,46186,2'-[2-Hydroxy-3-(4-hydroxy-4-phenylpiperidino)propoxy]acetophenone,CC(=O)C1=CC=CC=C1OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O,,,,,,
11492,46187,2'-((2-Hydroxy-3-(4-(o-methoxyphenyl)piperazinyl))propoxy)acetophenone,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3OC)O,,,,,,
11493,46188,3'-((2-Hydroxy-3-(4-(o-methoxyphenyl)piperazinyl))propoxy)acetophenone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3OC)O,,,,,,
11494,46189,1-(o-Acetylphenoxy)-2-acetoxy-3-(N(sup 4)-(o-methoxyphenyl)piperazinyl)propane,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3OC)OC(=O)C,,,,,,
11495,46190,"Acetophenone, 2'-((2-hydroxy-3-(4-(m-methoxyphenyl)piperazinyl))propoxy)-, dihydrochloride",CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC(=CC=C3)OC)O.Cl.Cl,,,,,,
11496,46191,1-[2-[2-Hydroxy-3-[4-(3-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]ethanone,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC(=CC=C3)OC)O,,,,,,
11497,46192,"Acetophenone, 2'-((2-hydroxy-3-(4-(o-methoxyphenyl)piperazinyl))propoxy)-, dihydrochloride",CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3OC)O.Cl.Cl,,,,,,
11498,46193,"ACETOPHENONE, m-HYDROXYMETHYLAMINO-, HYDROCHLORIDE",CC(=O)C1=CC(=CC=C1)[NH+](C)O.[Cl-],,,,,,
11499,46194,1-[3-[Hydroxy(methyl)amino]phenyl]ethanone,CC(=O)C1=CC(=CC=C1)N(C)O,,,,,,
11500,46195,2'-((2-Hydroxy-3-(4-methylpiperazinyl))propoxy)acetophenone dihydrochloride,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C)O.Cl.Cl,,,,,,
11501,46196,1-{2-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]phenyl}ethanone,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C)O,,,,,,
11502,46197,3'-((2-Hydroxy-3-(4-methylpiperazinyl))propoxy)acetophenone dihydrochloride,CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C)O.Cl.Cl,,,,,,
11503,46198,1-[3-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]phenyl]ethanone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C)O,,,,,,
11504,46199,3'-((2-Hydroxy-3-morpholino)propoxy)acetophenone,CC(=O)C1=CC(=CC=C1)OCC(CN2CCOCC2)O,,,,,,
11505,46200,3'-((2-Hydroxy-3-phenethylamino)propoxy)acetophenone hydrochloride,CC(=O)C1=CC(=CC=C1)OCC(C[NH2+]CCC2=CC=CC=C2)O.[Cl-],,,,,,
11506,46201,1-[3-[2-Hydroxy-3-(2-phenylethylamino)propoxy]phenyl]ethanone,CC(=O)C1=CC(=CC=C1)OCC(CNCCC2=CC=CC=C2)O,,,,,,
11507,46202,Lobeline hydrochloride,CN1C(CCCC1CC(=O)C2=CC=CC=C2)CC(C3=CC=CC=C3)O.Cl,,,,,,
11508,46203,2'-((2-Hydroxy-3-(4-phenylpiperazinyl))propoxy)acetophenone,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
11509,46204,"Acetophenone, 2'-((2-hydroxy-3-(4-phenylpiperazinyl))propoxy)-, dihydrochloride, acetate",CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3)OC(=O)C.Cl.Cl,,,,,,
11510,46205,[1-(2-Acetylphenoxy)-3-(4-phenylpiperazin-1-yl)propan-2-yl] acetate,CC(=O)C1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC=CC=C3)OC(=O)C,,,,,,
11511,46206,CID 46206,CC(=NO)C1=CC(=CC=C1)OCC(C[NH+]2CCN(CC2)C3=CC=CC=C3)O.[Cl-],,,,,,
11512,46207,CID 46207,CC(=NO)C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
11513,46208,Beryllium;dihypofluorite,[Be+2].[O-]F.[O-]F,,,,,,
11514,46209,Hypofluorite,[O-]F,,,,,,
11515,46210,alpha-Cyclohexyl-alpha-(3-pyridyl)benzyl alcohol hydrochloride,C1CCC(CC1)C(C2=CC=CC=C2)(C3=C[NH+]=CC=C3)O.[Cl-],,,,,,
11516,46211,alpha-Cyclohexyl-alpha-phenyl-3-pyridinemethanol,C1CCC(CC1)C(C2=CC=CC=C2)(C3=CN=CC=C3)O,,,,,,
11517,46212,"Bicyclo(2.2.2)octane, 1,4-bis(1,2,3,4-tetrahydroisoquinolylmethyl)-",C1CNC(C2=CC=CC=C21)CC34CCC(CC3)(CC4)CC5C6=CC=CC=C6CCN5,,,,,,
11518,46213,(+-)-alpha-(1-(Pentylamino)ethyl)benzyl alcohol hydrochloride,CCCCC[NH2+]C(C)C(C1=CC=CC=C1)O.[Cl-],,,,,,
11519,46214,2-(Pentylamino)-1-phenylpropan-1-ol,CCCCCNC(C)C(C1=CC=CC=C1)O,,,,,,
11520,46215,(+-)-alpha-(1-(n-Propylamino)ethyl)benzyl alcohol hydrochloride,CCC[NH2+]C(C)C(C1=CC=CC=C1)O.[Cl-],,,,,,
11521,46216,CID 46216,CCCNC(C)C(C1=CC=CC=C1)O,,,,,,
11522,46217,"BENZYLAMINE, N-(2-AMINOETHYLAMINO)-p-CHLORO-N-METHYL-, DIHYDROCHLORIDE",C[NH+](CC1=CC=C(C=C1)Cl)NCC[NH3+].[Cl-].[Cl-],,,,,,
11523,46218,2-[2-[(4-Chlorophenyl)methyl]-2-methylhydrazinyl]ethanamine,CN(CC1=CC=C(C=C1)Cl)NCCN,,,,,,
11524,46219,N-3-(1-Butynyl)-benzylamine,CC(C#C)NCC1=CC=CC=C1,,,,,,
11525,46220,"BENZYLAMINE, m-CHLORO-N-(2-CHLOROETHYL)-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CCCl)CC1=CC(=CC=C1)Cl.[Cl-],,,,,,
11526,46221,2-chloro-N-[(3-chlorophenyl)methyl]-N-ethylethanamine,CCN(CCCl)CC1=CC(=CC=C1)Cl,,,,,,
11527,46222,"BENZYLAMINE, p-CHLORO-N-(2-CHLOROETHYL)-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CCCl)CC1=CC=C(C=C1)Cl.[Cl-],,,,,,
11528,46223,"BENZYLAMINE, p-CHLORO-N-(2-CHLOROETHYL)-N-ETHYL-",CCN(CCCl)CC1=CC=C(C=C1)Cl,,,,,,
11529,46224,2-Isopropylphenoxyisopropylbenzyl-beta-chloroethylamine hydrochloride,CC(C)C1=CC=CC=C1OCC(C)[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
11530,46225,N-benzyl-N-(2-chloroethyl)-1-(2-propan-2-ylphenoxy)propan-2-amine,CC(C)C1=CC=CC=C1OCC(C)N(CCCl)CC2=CC=CC=C2,,,,,,
11531,46226,2-Chloro-N-(p-ethylbenzyl)diethylamine hydrochloride,CCC1=CC=C(C=C1)C[NH+](CC)CCCl.[Cl-],,,,,,
11532,46227,2-chloro-N-ethyl-N-[(4-ethylphenyl)methyl]ethanamine,CCC1=CC=C(C=C1)CN(CC)CCCl,,,,,,
11533,46228,"Benzylamine, N-(2-chloroethyl)-N-(2-ethylphenoxyethyl)-, hydrochloride",CCC1=CC=CC=C1OCC[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
11534,46229,N-benzyl-N-(2-chloroethyl)-2-(2-ethylphenoxy)ethanamine,CCC1=CC=CC=C1OCCN(CCCl)CC2=CC=CC=C2,,,,,,
11535,46230,"BENZYLAMINE, N-(2-CHLOROETHYL)-p-METHOXY-N-METHYL-, HYDROCHLORIDE",C[NH+](CCCl)CC1=CC=C(C=C1)OC.[Cl-],,,,,,
11536,46231,2-chloro-N-[(4-methoxyphenyl)methyl]-N-methylethanamine,CN(CCCl)CC1=CC=C(C=C1)OC,,,,,,
11537,46232,2-Methoxyphenoxyethylbenzyl-beta-chloroethylamine hydrochloride,COC1=CC=CC=C1OCC[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
11538,46233,N-benzyl-N-(2-chloroethyl)-2-(2-methoxyphenoxy)ethanamine,COC1=CC=CC=C1OCCN(CCCl)CC2=CC=CC=C2,,,,,,
11539,46234,"Benzylamine, N-(2-chloroethyl)-N-(4-methoxyphenoxyethyl)-, hydrochloride",COC1=CC=C(C=C1)OCC[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
11540,46235,N-benzyl-N-(2-chloroethyl)-2-(4-methoxyphenoxy)ethanamine,COC1=CC=C(C=C1)OCCN(CCCl)CC2=CC=CC=C2,,,,,,
11541,46236,"N,N-Diethyl-alpha-methyl-p-phenoxybenzylamine",CCN(CC)C(C)C1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
11542,46237,"alpha-(1-Aminoethyl)-2,4-dimethoxybenzyl alcohol hydrochloride",CC(C(C1=C(C=C(C=C1)OC)OC)O)[NH3+].[Cl-],,,,,,
11543,46238,"2-Amino-1-(2,4-dimethoxyphenyl)propan-1-ol",CC(C(C1=C(C=C(C=C1)OC)OC)O)N,,,,,,
11544,46239,"2,5-Dimethoxy-alpha-(1-dimethylaminoethyl)benzyl alcohol hydrochloride",CC(C(C1=C(C=CC(=C1)OC)OC)O)[NH+](C)C.[Cl-],,,,,,
11545,46240,"1-(2,5-Dimethoxyphenyl)-2-(dimethylamino)propan-1-ol",CC(C(C1=C(C=CC(=C1)OC)OC)O)N(C)C,,,,,,
11546,46241,"2,5-Dimethoxy-alpha-(dimethylaminomethyl)benzyl alcohol hydrochloride",C[NH+](C)CC(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
11547,46242,"alpha-[(Dimethylamino)methyl]-2,5-dimethoxybenzenemethanol",CN(C)CC(C1=C(C=CC(=C1)OC)OC)O,,,,,,
11548,46243,"beta-(2,5-Dimethoxyphenyl)-beta-hydroxyethylmethylamine hydrochloride",C[NH2+]CC(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
11549,46244,"1-(2,5-Dimethoxyphenyl)-2-(methylamino)ethanol",CNCC(C1=C(C=CC(=C1)OC)OC)O,,,,,,
11550,46245,"Benzyl alcohol, alpha-(aminomethyl)-2,5-dimethoxy-alpha-methyl-, hydrochloride",CC(C[NH3+])(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
11551,46246,"1-Amino-2-(2,5-dimethoxyphenyl)propan-2-ol",CC(CN)(C1=C(C=CC(=C1)OC)OC)O,,,,,,
11552,46247,1-(4-Hexylphenyl)-2-piperidin-1-ylethanol,CCCCCCC1=CC=C(C=C1)C(CN2CCCCC2)O,,,,,,
11553,46248,Einecs 264-595-0,CC(C(C1=CC=CC=C1)O)[NH2+]CCO.[Cl-],,,,,,
11554,46249,alpha-[1-[(2-Hydroxyethyl)amino]ethyl]benzenemethanol,CC(C(C1=CC=CC=C1)O)NCCO,,,,,,
11555,46250,"BENZYL ALCOHOL, m-HYDROXY-alpha-((METHYLAMINO)ETHYL)-, HYDROCHLORIDE, (-)-",CC(C(C1=CC(=CC=C1)O)O)[NH2+]C.[Cl-],,,,,,
11556,46251,"BENZYL ALCOHOL, m-HYDROXY-alpha-((METHYLAMINO)METHYL)-, DIACETATE",CC(=O)OC1=CC=CC(=C1)C(CNC)OC(=O)C,,,,,,
11557,46252,alpha-(1-Aminoethyl)-4-methoxybenzyl alcohol hydrochloride,CC(C(C1=CC=C(C=C1)OC)O)[NH3+].[Cl-],,,,,,
11558,46253,2-Amino-1-(4-methoxyphenyl)propan-1-ol,CC(C(C1=CC=C(C=C1)OC)O)N,,,,,,
11559,46254,(+-)-alpha-(1-(Methylamino)butyl)benzyl alcohol hydrochloride,CCCC(C(C1=CC=CC=C1)O)[NH2+]C.[Cl-],,,,,,
11560,46255,2-(Methylamino)-1-phenylpentan-1-ol,CCCC(C(C1=CC=CC=C1)O)NC,,,,,,
11561,46256,alpha-(1-(Methylamino)ethyl)benzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1)O)[NH2+]C.[Cl-],,,,,,
11562,46257,"1-Propanol, 1-(m-tolyl)-2-amino-, hydrochloride",CC1=CC(=CC=C1)C(C(C)[NH3+])O.[Cl-],,,,,,
11563,46258,2-Amino-1-(3-methylphenyl)propan-1-ol,CC1=CC(=CC=C1)C(C(C)N)O,,,,,,
11564,46259,(+-)-alpha-(1-(Methylamino)propyl)benzyl alcohol hydrochloride,CCC(C(C1=CC=CC=C1)O)[NH2+]C.[Cl-],,,,,,
11565,46260,2-(Methylamino)-1-phenylbutan-1-ol,CCC(C(C1=CC=CC=C1)O)NC,,,,,,
11566,46261,"Benzyl alcohol, alpha-methyl-3-((2-hydroxy-3-(4-phenylpiperazinyl))propoxy)-, hydrochloride",CC(C1=CC(=CC=C1)OCC(C[NH+]2CCN(CC2)C3=CC=CC=C3)O)O.[Cl-],,,,,,
11567,46262,1-[3-(1-Hydroxyethyl)phenoxy]-3-(4-phenylpiperazin-1-yl)propan-2-ol,CC(C1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O)O,,,,,,
11568,46263,(+-)-alpha-(1-(Dibutylamino)propyl)benzyl alcohol hydrochloride,CCCC[NH+](CCCC)C(CC)C(C1=CC=CC=C1)O.[Cl-],,,,,,
11569,46264,2-(Dibutylamino)-1-phenylbutan-1-ol,CCCCN(CCCC)C(CC)C(C1=CC=CC=C1)O,,,,,,
11570,46265,alpha-(1-Aminoethyl)-3-hydroxy-4-methylbenzyl alcohol hydrochloride,CC1=C(C=C(C=C1)C(C(C)[NH3+])O)O.[Cl-],,,,,,
11571,46266,5-(2-Amino-1-hydroxypropyl)-2-methylphenol,CC1=C(C=C(C=C1)C(C(C)N)O)O,,,,,,
11572,46267,"BENZYL ALCOHOL, alpha-(1-AMINOHEPTYL)-, HYDROCHLORIDE",CCCCCCC(C(C1=CC=CC=C1)O)[NH3+].[Cl-],,,,,,
11573,46268,2-Amino-1-phenyloctan-1-ol,CCCCCCC(C(C1=CC=CC=C1)O)N,,,,,,
11574,46269,"Benzyl alcohol, 3,4-bis(dimethylcarbamyloxy)-",CN(C)C(=O)OC1=C(C=C(C=C1)CO)OC(=O)N(C)C,,,,,,
11575,46270,(+-)-alpha-(1-(n-Butylamino)ethyl)benzyl alcohol hydrochloride,CCCC[NH2+]C(C)C(C1=CC=CC=C1)O.[Cl-],,,,,,
11576,46271,2-(Butylamino)-1-phenyl-1-propanol,CCCCNC(C)C(C1=CC=CC=C1)O,,,,,,
11577,46272,"BENZYL ALCOHOL, alpha-BUTYLAMINOMETHYL, HYDROCHLORIDE, (+-)-",CCCC[NH2+]CC(C1=CC=CC=C1)O.[Cl-],,,,,,
11578,46273,2-(Butylamino)-1-phenylethanol,CCCCNCC(C1=CC=CC=C1)O,,,,,,
11579,46274,4-Butyl-alpha-ethyl-alpha-(piperidinomethyl)benzyl alcohol,CCCCC1=CC=C(C=C1)C(CC)(CN2CCCCC2)O,,,,,,
11580,46275,2-(4-Butylphenyl)-1-piperidin-1-ylpropan-2-ol,CCCCC1=CC=C(C=C1)C(C)(CN2CCCCC2)O,,,,,,
11581,46276,1-(4-Butylphenyl)-2-piperidin-1-ylethanol,CCCCC1=CC=C(C=C1)C(CN2CCCCC2)O,,,,,,
11582,46277,"Benzilic acid, 1,2,2,6,6-pentamethyl-3-piperidyl ester",CC1(CCC(C(N1C)(C)C)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C,,,,,,
11583,46278,"Benzilic acid, 1,2,2,6-tetramethyl-4-piperidinyl ester, hydrochloride",CC1CC(CC([NH+]1C)(C)C)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
11584,46279,"(1,2,2,6-Tetramethylpiperidin-4-yl) 2-hydroxy-2,2-diphenylacetate",CC1CC(CC(N1C)(C)C)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
11585,46280,CID 46280,C1=CC(=CC(=C1)[NH3+])C2=[NH+]C3=C(N2)C=C(C=C3)N.[Cl-].[Cl-],,,,,,
11586,46281,2-(3-Aminophenyl)-1H-benzo[d]imidazol-6-amine,C1=CC(=CC(=C1)N)C2=NC3=C(N2)C=C(C=C3)N,,,,,,
11587,46282,CID 46282,C1=CC(=CC=C1C2=[NH+]C3=C(N2)C=C(C=C3)[NH3+])N.[Cl-].[Cl-],,,,,,
11588,46283,2-(2-(Dimethylamino)ethylthio)benzimidazole dihydrochloride,C[NH+](C)CCSC1=[NH+]C2=CC=CC=C2N1.[Cl-].[Cl-],,,,,,
11589,46284,"Benzimidazole, 2-(3-(dimethylamino)propylthio)-",CN(C)CCCSC1=NC2=CC=CC=C2N1,,,,,,
11590,46285,"BENZYLAMINE, p-(2,3-EPOXYPROPOXY)-N-PHENYL-",C1C(O1)COC2=CC=C(C=C2)CNC3=CC=CC=C3,,,,,,
11591,46286,"Benzylamine, N-ethyl-N-phenoxyethyl-, hydrochloride",CC[NH+](CCOC1=CC=CC=C1)CC2=CC=CC=C2.[Cl-],,,,,,
11592,46287,N-benzyl-N-ethyl-2-phenoxyethanamine,CCN(CCOC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
11593,46288,p-Isopropylbenzylheptylamine sulfate,CCCCCCC[NH2+]CC1=CC=C(C=C1)C(C)C.OS(=O)(=O)[O-],,,,,,
11594,46289,N-[(4-propan-2-ylphenyl)methyl]heptan-1-amine,CCCCCCCNCC1=CC=C(C=C1)C(C)C,,,,,,
11595,46290,"1,6-Bis(p-methylaminomethylphenoxy)hexane dihydrochloride",C[NH2+]CC1=CC=C(C=C1)OCCCCCCOC2=CC=C(C=C2)C[NH2+]C.[Cl-].[Cl-],,,,,,
11596,46291,N-methyl-1-[4-[6-[4-(methylaminomethyl)phenoxy]hexoxy]phenyl]methanamine,CNCC1=CC=C(C=C1)OCCCCCCOC2=CC=C(C=C2)CNC,,,,,,
11597,46292,p-Isopropylbenzylhexylamine sulfate,CCCCCC[NH2+]CC1=CC=C(C=C1)C(C)C.OS(=O)(=O)[O-],,,,,,
11598,46293,N-[(4-propan-2-ylphenyl)methyl]hexan-1-amine,CCCCCCNCC1=CC=C(C=C1)C(C)C,,,,,,
11599,46294,"BENZYLAMINE, p-ISOPROPYL-N-OCTYL-",CCCCCCCCNCC1=CC=C(C=C1)C(C)C,,,,,,
11600,46295,"Benzylamine, N-methyl-N-octyl-",CCCCCCCCN(C)CC1=CC=CC=C1,,,,,,
11601,46296,"3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-N-(phenylmethyl)-, 4-oxide",CN(CC1=CC=CC=C1)C2=NC3=C(C=C(C=C3)Cl)C(=[N+](C2)[O-])C4=CC=CC=C4,,,,,,
11602,46297,2-Methyldiacetylbenzidine,CC1=C(C=CC(=C1)C2=CC=C(C=C2)NC(=O)C)NC(=O)C,,,,,,
11603,46298,1-Phenyl-1-hydrazinopropane hydrochloride,CCC(C1=CC=CC=C1)N[NH3+].[Cl-],,,,,,
11604,46299,(1-Phenylpropyl)hydrazine,CCC(C1=CC=CC=C1)NN,,,,,,
11605,46300,alpha-(p-Phenoxyphenyl)ethyldimethylamine,CC(C1=CC=C(C=C1)OC2=CC=CC=C2)N(C)C,,,,,,
11606,46301,"3-Butyl-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCCCN1CC2CCC(C1)N2C(=O)CC,,,,,,
11607,46302,"3-(o-Chlorodiphenylmethyl)-8-methyl-3,8-diazabicyclo(3.2.1)octane",CN1C2CCC1CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4Cl,,,,,,
11608,46303,"AMMONIUM, HEXAMETHYLENEBIS(DIETHYL-(beta-(10-PHENOTHIAZINYL)ETHYL)-, DIBROMIDE",CC[N+](CC)(CCCCCC[N+](CC)(CC)CCN1C2=CC=CC=C2SC3=CC=CC=C31)CCN4C5=CC=CC=C5SC6=CC=CC=C64.[Br-].[Br-],,,,,,
11609,46304,6-[Diethyl(2-phenothiazin-10-ylethyl)azaniumyl]hexyl-diethyl-(2-phenothiazin-10-ylethyl)azanium,CC[N+](CC)(CCCCCC[N+](CC)(CC)CCN1C2=CC=CC=C2SC3=CC=CC=C31)CCN4C5=CC=CC=C5SC6=CC=CC=C64,,,,,,
11610,46305,CID 46305,CC(=O)NCCSSC1=C(C=CC(=C1)Cl)C2=C(C=C(C=C2)Cl)S(=O)[O-].[Na+],,,,,,
11611,46306,2-[2-(2-Acetamidoethyldisulfanyl)-4-chlorophenyl]-5-chlorobenzenesulfinic acid,CC(=O)NCCSSC1=C(C=CC(=C1)Cl)C2=C(C=C(C=C2)Cl)S(=O)O,,,,,,
11612,46307,[N'-[N'-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]-propan-2-ylazanium;acetate,CC(C)[NH2+]C(=NC(=NC1=CC=C(C=C1)Cl)N)N.CC(=O)[O-],,,,,,
11613,46308,"2,2'-BIPHENYLDIOL, 4,4'-DI-tert-BUTYL-",CC(C)(C)C1=CC(=C(C=C1)C2=C(C=C(C=C2)C(C)(C)C)O)O,,,,,,
11614,46309,"4,4'-Biphenyldiol, 2,2'-dipropyl-",CCCC1=C(C=CC(=C1)O)C2=C(C=C(C=C2)O)CCC,,,,,,
11615,46310,"2-Biphenylacetic acid, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)CC1=CC=CC=C1C2=CC=CC=C2.[Cl-],,,,,,
11616,46311,2-(Diethylamino)ethyl 2-(2-phenylphenyl)acetate,CCN(CC)CCOC(=O)CC1=CC=CC=C1C2=CC=CC=C2,,,,,,
11617,46312,"1,1'-Biphenyl, 2-arsenoso-",C1=CC=C(C=C1)C2=CC=CC=C2[As]=O,,,,,,
11618,46313,"Arsonic acid, (1,1'-biphenyl)-2-YL-, disodium salt",C1=CC=C(C=C1)C2=CC=CC=C2[As](=O)([O-])[O-].[Na+].[Na+],,,,,,
11619,46314,CID 46314,C1=CC=C(C=C1)C2=CC=CC=C2[As](=O)(O)[O-].[Na+],,,,,,
11620,46315,beta-Diethylaminoethyl-4-amino-4'-biphenylcarboxylate hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)N.[Cl-],,,,,,
11621,46316,2-(Diethylamino)ethyl 4-(4-aminophenyl)benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)N,,,,,,
11622,46317,"Di-(beta-diethylaminoethyl)-2,2'-diamino-5,5'-biphenylcarboxylate hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC(=C(C=C1)N)C2=C(C=CC(=C2)C(=O)OCCN(CC)CC)N.[Cl-],,,,,,
11623,46318,2-(Diethylamino)ethyl 4-amino-3-[2-amino-5-[2-(diethylamino)ethoxycarbonyl]phenyl]benzoate,CCN(CC)CCOC(=O)C1=CC(=C(C=C1)N)C2=C(C=CC(=C2)C(=O)OCCN(CC)CC)N,,,,,,
11624,46319,"4,4'-Biphenyldiol, 2,2'-diallyl-",C=CCC1=C(C=CC(=C1)O)C2=C(C=C(C=C2)O)CC=C,,,,,,
11625,46320,"alpha-(Piperidinomethyl)-1,1'-biphenyl-4-methanol",C1CCN(CC1)CC(C2=CC=C(C=C2)C3=CC=CC=C3)O,,,,,,
11626,46321,CID 46321,C1=CC=C(C=C1)C2=C(C=CC=C2Cl)[O-].[Na+],,,,,,
11627,46322,3-Chloro-2-phenylphenol,C1=CC=C(C=C1)C2=C(C=CC=C2Cl)O,,,,,,
11628,46323,"m-Cresol, 6-nonyl-",CCCCCCCCCC1=C(C=C(C=C1)C)O,,,,,,
11629,46324,"m-Cresol, 6-octyl-",CCCCCCCCC1=C(C=C(C=C1)C)O,,,,,,
11630,46325,"2-bromo-N,N-diethylbut-2-enamide",CCN(CC)C(=O)C(=CC)Br,,,,,,
11631,46326,CID 46326,CCN(CC)CCCNC(=O)C(=CC)Br,,,,,,
11632,46327,"N,N-Dimethyl-2-bromo-2-butenamide",CC=C(C(=O)N(C)C)Br,,,,,,
11633,46328,CID 46328,CCC(C)NC1=CC=C(C=C1)N(C(C)CC)C(=O)C=CC,,,,,,
11634,46329,CID 46329,CC[NH+](CC)CCOC(=O)C=CC(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
11635,46330,CID 46330,CCN(CC)CCOC(=O)C=CC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
11636,46331,CID 46331,C(C=CC(=O)[O-])F.[Na+],,,,,,
11637,46332,4-Fluorobut-2-enoic acid,C(C=CC(=O)O)F,,,,,,
11638,46333,CID 46333,CCOP(=O)(OCC)OC(=CC(=O)OCC1=CC=CC=C1)C,,,,,,
11639,46334,3-(Methoxyphenoxyphosphinyloxy)-2-butenoic acid benzyl ester,CC(=CC(=O)OCC1=CC=CC=C1)OP(=O)(OC)OC2=CC=CC=C2,,,,,,
11640,46335,N-Amyl-N-nitrosourethane,CCCCCN(C(=O)OCC)N=O,,,,,,
11641,46336,"2-Nitro-2-methyl-1,3-propanediol-bis(N-phenylcarbamate)",CC(COC(=O)NC1=CC=CC=C1)(COC(=O)NC2=CC=CC=C2)[N+](=O)[O-],,,,,,
11642,46337,"1,6-Hexanediaminium, N,N'-bis(2-(9H-fluoren-9-yl)ethyl)-N,N,N',N'-tetramethyl-, dibromide",C[N+](C)(CCCCCC[N+](C)(C)CCC1C2=CC=CC=C2C3=CC=CC=C13)CCC4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-],,,,,,
11643,46338,2-(9H-fluoren-9-yl)ethyl-[6-[2-(9H-fluoren-9-yl)ethyl-dimethylazaniumyl]hexyl]-dimethylazanium,C[N+](C)(CCCCCC[N+](C)(C)CCC1C2=CC=CC=C2C3=CC=CC=C13)CCC4C5=CC=CC=C5C6=CC=CC=C46,,,,,,
11644,46339,"Diisodecyl-1,2-cyclobutanedicarboxylate",CC(C)CCCCCCCOC(=O)C1CCC1C(=O)OCCCCCCCC(C)C,,,,,,
11645,46340,5-Cyclohexylbutyl-5-(2-thienyl)hydantoin,C1CCC(CC1)CCCCC2(C(=O)NC(=O)N2)C3=CC=CS3,,,,,,
11646,46341,5-Cyclohexylethyl-5-(2-thienyl) hydantoin,C1CCC(CC1)CCC2(C(=O)NC(=O)N2)C3=CC=CS3,,,,,,
11647,46342,1-Methyl-p-aminoethylthioazocyclohexane,CC1CCC(CC1)N=NSCCN,,,,,,
11648,46343,"Cyclobutane-1,2-dicarboxylic acid, diisopropyl ester, (E)-",CC(C)OC(=O)[C@H]1CC[C@@H]1C(=O)OC(C)C,,,,,,
11649,46344,"Cyclobutane-1,2-dicarboxylic acid, diisopropyl ester, (Z)-",CC(C)OC(=O)[C@@H]1CC[C@@H]1C(=O)OC(C)C,,,,,,
11650,46345,(2-Chlorophenyl)methyl 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OCC1=CC=CC=C1Cl)OP(=O)(OC)OC,,,,,,
11651,46346,(4-Chlorophenyl) 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OC1=CC=C(C=C1)Cl)OP(=O)(OC)OC,,,,,,
11652,46347,Cyclohexyl 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OC1CCCCC1)OP(=O)(OC)OC,,,,,,
11653,46348,3-(Dimethoxyphosphinyloxy)-2-butenoic acid cyclohexylmethyl ester,CC(=CC(=O)OCC1CCCCC1)OP(=O)(OC)OC,,,,,,
11654,46349,Decyl 3-dimethoxyphosphoryloxybut-2-enoate,CCCCCCCCCCOC(=O)C=C(C)OP(=O)(OC)OC,,,,,,
11655,46350,"3-(Dimethoxyphosphinyloxy)-2-butenoic acid 3,4-dimethylbenzyl ester",CC1=C(C=C(C=C1)COC(=O)C=C(C)OP(=O)(OC)OC)C,,,,,,
11656,46351,(4-Methoxyphenyl) 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OC1=CC=C(C=C1)OC)OP(=O)(OC)OC,,,,,,
11657,46352,CID 46352,CC(C)OP(=O)(OCC(CCl)Cl)OC(=CC(=O)OC)C,,,,,,
11658,46353,1-(3-Nitrophenyl)ethyl 3-dimethoxyphosphoryloxybut-2-enoate,CC(C1=CC(=CC=C1)[N+](=O)[O-])OC(=O)C=C(C)OP(=O)(OC)OC,,,,,,
11659,46354,3-(Dimethoxyphosphinyloxy)-2-butenoic acid 2-methyl-5-nitrobenzyl ester,CC1=C(C=C(C=C1)[N+](=O)[O-])COC(=O)C=C(C)OP(=O)(OC)OC,,,,,,
11660,46355,(4-Methylphenyl) 3-dimethoxyphosphoryloxybut-2-enoate,CC1=CC=C(C=C1)OC(=O)C=C(C)OP(=O)(OC)OC,,,,,,
11661,46356,CID 46356,CCNC1=CC=CC(=C1)CC(=O)C=CC,,,,,,
11662,46357,"3-Acridinecarbonitrile, 9-chloro-7-methyl-",CC1=CC2=C(C3=C(C=C(C=C3)C#N)N=C2C=C1)Cl,,,,,,
11663,46358,"2-[2-(2-Amino-1,1-dicyanoethyl)cyclobutyl]-2-(aminomethyl)propanedinitrile",C1CC(C1C(CN)(C#N)C#N)C(CN)(C#N)C#N,,,,,,
11664,46359,"1,2-Bis(beta-mercaptoethylaminomethyl) cyclobutane",C1CC(C1CNCCS)CNCCS,,,,,,
11665,46360,"Cyclobutane-1,2-bis(methylamine), phosphate",C[NH2+]C1CCC1NC.OP(=O)(O)[O-],,,,,,
11666,46361,"1-N,2-N-dimethylcyclobutane-1,2-diamine",CNC1CCC1NC,,,,,,
11667,46362,"trans-1,2-Bis(aminoethyl)cyclobutane",C1C[C@H]([C@@H]1CCN)CCN,,,,,,
11668,46363,"CYCLOBUTANE-1,2-DICARBOXAMIDE, N,N'-DI-tert-BUTYL-",CC(C)(C)NC(=O)C1CCC1C(=O)NC(C)(C)C,,,,,,
11669,46364,"Cyclobutane-1,2-dicarboxamide, N,N'-dinaphthyl-",C1CC(C1C(=O)NC2=CC=CC3=CC=CC=C32)C(=O)NC4=CC=CC5=CC=CC=C54,,,,,,
11670,46365,"N,N'-Bis(1,1,3,3-tetramethylbutyl)-1,1-cyclobutanedicarboxamide",CC(C)(C)CC(C)(C)NC(=O)C1CCC1C(=O)NC(C)(C)CC(C)(C)C,,,,,,
11671,46366,"Bis(2,4,5-trichlorophenyl) cyclobutane-1,2-dicarboxylate",C1CC(C1C(=O)OC2=CC(=C(C=C2Cl)Cl)Cl)C(=O)OC3=CC(=C(C=C3Cl)Cl)Cl,,,,,,
11672,46367,"BENZYLAMINE, N-(2-CHLOROETHYL)-o-METHOXY-N-METHYL-, HYDROCHLORIDE",C[NH+](CCCl)CC1=CC=CC=C1OC.[Cl-],,,,,,
11673,46368,2-chloro-N-[(2-methoxyphenyl)methyl]-N-methylethanamine,CN(CCCl)CC1=CC=CC=C1OC,,,,,,
11674,46369,2-Methyl-4-propoxycarbanilic acid 1-((diethylamino)methyl)ethyl ester,CCCOC1=CC(=C(C=C1)NC(=O)OC(C)CN(CC)CC)C,,,,,,
11675,46370,"Ethyl 2-(1,3-benzothiazol-2-ylsulfanyl)acetate",CCOC(=O)CSC1=NC2=CC=CC=C2S1,,,,,,
11676,46371,"BENZO(b)THIOPHENE, CHLORO-",C1=CC=C2C(=C1)C=C(S2)Cl,,,,,,
11677,46372,"4,6-Dimethyl-1,3-benzothiazol-2-amine",CC1=CC(=C2C(=C1)SC(=N2)N)C,,,,,,
11678,46373,CID 46373,CC1=C2C(=CC=C1)SC(=N2)[NH3+].[Cl-],,,,,,
11679,46374,"Benzothiazole, 4,6-dichloro-7-(2-diethylaminoethyl)amino-, dihydrochloride",CC[NH+](CC)CCNC1=C(C=C(C2=C1SC=[NH+]2)Cl)Cl.[Cl-].[Cl-],,,,,,
11680,46375,"N-(4,6-dichloro-1,3-benzothiazol-7-yl)-N',N'-diethylethane-1,2-diamine",CCN(CC)CCNC1=C(C=C(C2=C1SC=N2)Cl)Cl,,,,,,
11681,46376,"BENZOTHIAZOLE, 6-NITRO-2-(p-NITROBENZOYLAMINO)-",C1=CC(=CC=C1C(=O)NC2=NC3=C(S2)C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
11682,46377,CID 46377,CC1(CN(C(=N1)S)C(C)(C)CC(C)(C)C)C,,,,,,
11683,46378,alpha-Methyl-2-(m-tolyl)-5-benzoxazoleacetic acid,CC1=CC(=CC=C1)C2=NC3=C(O2)C=CC(=C3)C(C)C(=O)O,,,,,,
11684,46379,alpha-Methyl-2-(p-tolyl)-5-benzoxazoleacetic acid,CC1=CC=C(C=C1)C2=NC3=C(O2)C=CC(=C3)C(C)C(=O)O,,,,,,
11685,46380,5-Bromobenzo[d]oxazol-2-amine,C1=CC2=C(C=C1Br)N=C(O2)N,,,,,,
11686,46381,"Benzoxazole, 2-amino-6-bromo-5-chloro-",C1=C2C(=CC(=C1Cl)Br)OC(=N2)N,,,,,,
11687,46382,"Benzoxazole, 2-amino-5-bromo-6-chloro-",C1=C2C(=CC(=C1Br)Cl)OC(=N2)N,,,,,,
11688,46383,4-Chlorobenzo[d]oxazol-2-amine,C1=CC2=C(C(=C1)Cl)N=C(O2)N,,,,,,
11689,46384,"2-Benzoxazolamine, 7-chloro-",C1=CC2=C(C(=C1)Cl)OC(=N2)N,,,,,,
11690,46385,"Benzoxazole, 2-amino-5,6-dichloro-",C1=C2C(=CC(=C1Cl)Cl)OC(=N2)N,,,,,,
11691,46386,"2-Benzoxazolamine, 5-iodo-",C1=CC2=C(C=C1I)N=C(O2)N,,,,,,
11692,46387,2-Amino-5-methoxybenzoxazole,COC1=CC2=C(C=C1)OC(=N2)N,,,,,,
11693,46388,"5-Methyl-1,3-benzoxazol-2-amine",CC1=CC2=C(C=C1)OC(=N2)N,,,,,,
11694,46389,5-Nitrobenzo[d]oxazol-2-amine,C1=CC2=C(C=C1[N+](=O)[O-])N=C(O2)N,,,,,,
11695,46390,"Benzoxazole, 2-(2-carboxy)anilino-",C1=CC=C(C(=C1)C(=O)O)NC2=NC3=CC=CC=C3O2,,,,,,
11696,46391,"Benzoxazole, 5-chloro-2-(2-chloroacetamido)-",C1=CC2=C(C=C1Cl)N=C(O2)NC(=O)CCl,,,,,,
11697,46392,"Benzoxazole, 5-chloro-2-(2,2-dimethylacetatamido)-",CC(C)C(=O)NC1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
11698,46393,"Benzoxazole, 5-chloro-2-dimethylamino-",CN(C)C1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
11699,46394,"Benzoxazole, 5-chloro-2-(3-(dimethylamino)propyl)amino-",CN(C)CCCNC1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
11700,46395,"Benzoxazole, 5-chloro-2-hydrazino-",C1=CC2=C(C=C1Cl)N=C(O2)NN,,,,,,
11701,46396,"Benzoxazoline, 5-chloro-2-imino-3-methyl-",CN1C2=C(C=CC(=C2)Cl)OC1=N,,,,,,
11702,46397,"Benzoxazole, 5-chloro-2-methylamino-",CNC1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
11703,46398,"5-Chloro-2-(methylthio)-1,3-benzoxazole",CSC1=NC2=C(O1)C=CC(=C2)Cl,,,,,,
11704,46399,"2,5-Diaminobenzoxazole",C1=CC2=C(C=C1N)N=C(O2)N,,,,,,
11705,46400,2-Phenyl-beta-methyl-5-benzoxazoleethanol hydrate,CC(CO)C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3.CC(CO)C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3.CC(CO)C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3.CC(CO)C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3.O,,,,,,
11706,46401,"2-(2-Phenyl-1,3-benzoxazol-5-yl)propan-1-ol",CC(CO)C1=CC2=C(C=C1)OC(=N2)C3=CC=CC=C3,,,,,,
11707,46402,"3(2H)-Benzoxazolepropanoic acid, 2-imino-, ethyl ester",CCOC(=O)CCN1C2=CC=CC=C2OC1=N,,,,,,
11708,46403,"Benzoxazole-7-sulfonic acid, 2-amino-5-chloro-",C1=C(C=C(C2=C1N=C(O2)N)S(=O)(=O)O)Cl,,,,,,
11709,46404,"2-Benzoxazolinone, 6-amino-5-chloro-",C1=C(C(=CC2=C1OC(=O)N2)Cl)N,,,,,,
11710,46405,"2-Benzoxazolinone, 4,5,7-trichloro-",C1=C(C2=C(C(=C1Cl)Cl)NC(=O)O2)Cl,,,,,,
11711,46406,alpha-Phenyl-beta-aminopentanol,CCCC(C(C1=CC=CC=C1)O)[NH3+].[Cl-],,,,,,
11712,46407,2-Amino-1-phenylpentan-1-ol,CCCC(C(C1=CC=CC=C1)O)N,,,,,,
11713,46408,"BENZYL ALCOHOL, alpha-(1-AMINOETHYL)-4-HYDROXY-3-METHYL-, HYDROCHLORIDE",CC1=C(C=CC(=C1)C(C(C)[NH3+])O)O.[Cl-],,,,,,
11714,46409,4-(2-Amino-1-hydroxypropyl)-2-methylphenol,CC1=C(C=CC(=C1)C(C(C)N)O)O,,,,,,
11715,46410,Tris(2-chloro-2-nitro-1-butyl) phosphate,CCC(COP(=O)(OCC(CC)([N+](=O)[O-])Cl)OCC(CC)([N+](=O)[O-])Cl)([N+](=O)[O-])Cl,,,,,,
11716,46411,"1-Butanol, 2-(diethoxymethyl)-2-ethyl-",CCC(CC)(CO)C(OCC)OCC,,,,,,
11717,46412,"4,4-Difluoro-2-butanol",CC(CC(F)F)O,,,,,,
11718,46413,"1-(3,4-Dihydroxyphenyl)-2-methylamino-1-butanol hydrochloride",CCC(C(C1=CC(=C(C=C1)O)O)O)[NH2+]C.[Cl-],,,,,,
11719,46414,"3,4-Dihydroxy-alpha-[1-(methylamino)propyl]benzenemethanol",CCC(C(C1=CC(=C(C=C1)O)O)O)NC,,,,,,
11720,46415,3-(N-Methylisopropylamino)-3-methyl-2-butanol hydrochloride,CC(C)[NH+](C)C(C)(C)C(C)O.[Cl-],,,,,,
11721,46416,3-Methyl-3-[(isopropyl)methylamino]-2-butanol,CC(C)N(C)C(C)(C)C(C)O,,,,,,
11722,46417,"2-Butanone, 4-(bis(2-chloroethylamino)-, hydrobromide",CC(=O)CC[NH+](CCCl)CCCl.[Br-],,,,,,
11723,46418,"2-Butanone, 4-(bis(2-chloroethyl)amino)-",CC(=O)CCN(CCCl)CCCl,,,,,,
11724,46419,3-(N-Methylisopropylamino)-3-methyl-2-butanone hydrochloride,CC(C)[NH+](C)C(C)(C)C(=O)C.[Cl-],,,,,,
11725,46420,3-[(Isopropyl)methylamino]-3-methyl-2-butanone,CC(C)N(C)C(C)(C)C(=O)C,,,,,,
11726,46421,CID 46421,CC(=C(C)N=O)NC1=CC=CC=C1NC(=C(C)N=O)C,,,,,,
11727,46422,"N,N,N',N'-tetramethyl-2-phenylsulfanylbut-2-ene-1,4-diamine",CN(C)CC=C(CN(C)C)SC1=CC=CC=C1,,,,,,
11728,46423,Ethylmethylthiambutene hydrochloride,CC[NH+](C)C(C)C=C(C1=CC=CS1)C2=CC=CS2.[Cl-],,,,,,
11729,46424,Ethylmethylthiambutene,CCN(C)C(C)C=C(C1=CC=CS1)C2=CC=CS2,,,,,,
11730,46425,CID 46425,CC(C=CCl)Br,,,,,,
11731,46426,4-(4-Morpholin-4-yl-2-phenylsulfanylbut-2-enyl)morpholine,C1COCCN1CC=C(CN2CCOCC2)SC3=CC=CC=C3,,,,,,
11732,46427,CID 46427,CCCCN1CC(N=C1S)(C)C,,,,,,
11733,46428,2-Allylthio-2-ethylbutyramide,CCC(CC)(C(=O)N)SCC=C,,,,,,
11734,46429,3-Dimethylaminobutyramide hydrochloride,CC(CC(=O)N)[NH+](C)C.[Cl-],,,,,,
11735,46430,3-(Dimethylamino)butanamide,CC(CC(=O)N)N(C)C,,,,,,
11736,46431,"Butyramide, 2-ethyl-2-methylthio-",CCC(CC)(C(=O)N)SC,,,,,,
11737,46432,"Butyramide, 2-ethyl-2-(2-propynyl)thio-",CCC(CC)(C(=O)N)SCC#C,,,,,,
11738,46433,N-(alpha-Hydroxy-beta-trichloro)ethyl-2-isopropylbutyramide,CCC(C(C)C)C(=O)NC(C(Cl)(Cl)Cl)O,,,,,,
11739,46434,2-Isopropylbutyramide,CCC(C(C)C)C(=O)N,,,,,,
11740,46435,"Butyramide, 2-isopropyl-4-morpholino-2-phenyl-",CC(C)C(CCN1CCOCC1)(C2=CC=CC=C2)C(=O)N,,,,,,
11741,46436,N-Methyl-4-(trimethylammonio)butyramide iodide,CNC(=O)CCC[N+](C)(C)C.[I-],,,,,,
11742,46437,Trimethyl-[4-(methylamino)-4-oxobutyl]azanium,CNC(=O)CCC[N+](C)(C)C,,,,,,
11743,46438,Methyl 4-bromo-5-oxohexanoate,CC(=O)C(CCC(=O)OC)Br,,,,,,
11744,46439,Methyl 4-chloro-5-oxohexanoate,CC(=O)C(CCC(=O)OC)Cl,,,,,,
11745,46440,CID 46440,CCC(C(=O)O)SC(=N)[NH3+].[Br-],,,,,,
11746,46441,2-Carbamimidoylsulfanylbutanoic acid,CCC(C(=O)O)SC(=N)N,,,,,,
11747,46442,"4-(Amidinothio)butyric acid, monohydrobromide",C(CC(=O)O)CSC(=[NH2+])N.[Br-],,,,,,
11748,46443,4-Carbamimidoylsulfanylbutanoic acid,C(CC(=O)O)CSC(=N)N,,,,,,
11749,46444,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-N-phenethyl-, hydrochloride",COC1=C2CCCC(C2=C(C=C1)Cl)[NH2+]CCC3=CC=CC=C3.[Cl-],,,,,,
11750,46445,"8-chloro-5-methoxy-N-(2-phenylethyl)-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=C2CCCC(C2=C(C=C1)Cl)NCCC3=CC=CC=C3,,,,,,
11751,46446,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-N-methyl-N-(2-propynyl)-, hydrochloride",C[NH+](CC#C)C1CCCC2=C(C=CC(=C12)Cl)OC.[Cl-],,,,,,
11752,46447,"8-chloro-5-methoxy-N-methyl-N-prop-2-ynyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(CC#C)C1CCCC2=C(C=CC(=C12)Cl)OC,,,,,,
11753,46448,"1-Naphthylamine, 1,2,3,4-tetrahydro-5,8-dimethoxy-, hydrochloride, hemihydrate",COC1=C2CCCC(C2=C(C=C1)OC)[NH3+].[Cl-],,,,,,
11754,46449,"1,2,3,4-Tetrahydro-5,8-dimethoxynaphthalen-1-amine",COC1=C2CCCC(C2=C(C=C1)OC)N,,,,,,
11755,46450,"1-Naphthylamine, 1,2,3,4-tetrahydro-7,8-dimethoxy-N-methyl-, hydrochloride",C[NH2+]C1CCCC2=C1C(=C(C=C2)OC)OC.[Cl-],,,,,,
11756,46451,"7,8-dimethoxy-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",CNC1CCCC2=C1C(=C(C=C2)OC)OC,,,,,,
11757,46452,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6,8-dinitro-5-methoxy-, hydrochloride",C[NH+](C)C1CCCC2=C1C(=CC(=C2OC)[N+](=O)[O-])[N+](=O)[O-].[Cl-],,,,,,
11758,46453,"5-methoxy-N,N-dimethyl-6,8-dinitro-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C1C(=CC(=C2OC)[N+](=O)[O-])[N+](=O)[O-],,,,,,
11759,46454,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-8-fluoro-5-methoxy-, hydrochloride",C[NH+](C)C1CCCC2=C(C=CC(=C12)F)OC.[Cl-],,,,,,
11760,46455,"8-fluoro-5-methoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)F)OC,,,,,,
11761,46456,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride",C[NH+](C)C1CCCC2=CC=CC=C12.[Cl-],,,,,,
11762,46457,Dimethylaminotetra-hydronaphthalene,CN(C)C1CCCC2=CC=CC=C12,,,,,,
11763,46458,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-8-isobutyryl-5-methoxy-",CC(C)C(=O)C1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11764,46459,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-8-isovaleryl-5-methoxy-, hydrochloride",CC(C)CC(=O)C1=C2C(CCCC2=C(C=C1)OC)[NH+](C)C.[Cl-],,,,,,
11765,46460,"1-[8-(Dimethylamino)-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl]-3-methylbutan-1-one",CC(C)CC(=O)C1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11766,46461,"1-Naphthylamine, N,N-dimethyl-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",C[NH+](C)C1CCCC2=C1C=CC=C2OC.[Cl-],,,,,,
11767,46462,"N-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)-N,N-dimethylamine",CN(C)C1CCCC2=C1C=CC=C2OC,,,,,,
11768,46463,"1-Naphthylamine, N,1-dimethyl-5-methoxy-1,2,3,4-tetrahydro-, hydrochloride",CC1(CCCC2=C1C=CC=C2OC)[NH2+]C.[Cl-],,,,,,
11769,46464,"5-methoxy-N,1-dimethyl-3,4-dihydro-2H-naphthalen-1-amine",CC1(CCCC2=C1C=CC=C2OC)NC,,,,,,
11770,46465,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-5-methoxy-6-nitro-, hydrochloride",C[NH+](C)C1CCCC2=C1C=CC(=C2OC)[N+](=O)[O-].[Cl-],,,,,,
11771,46466,"5-methoxy-N,N-dimethyl-6-nitro-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C1C=CC(=C2OC)[N+](=O)[O-],,,,,,
11772,46467,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-5-methoxy-8-nitro-, hydrochloride",C[NH+](C)C1CCCC2=C(C=CC(=C12)[N+](=O)[O-])OC.[Cl-],,,,,,
11773,46468,"5-methoxy-N,N-dimethyl-8-nitro-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)[N+](=O)[O-])OC,,,,,,
11774,46469,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-5-methoxy-8-propionyl-",CCC(=O)C1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11775,46470,"1-Naphthylamine, 1,2,3,4-tetrahydro-N,N-dimethyl-5-methoxy-8-valeryl-, hydrochloride",CCCCC(=O)C1=C2C(CCCC2=C(C=C1)OC)[NH+](C)C.[Cl-],,,,,,
11776,46471,"1-[8-(Dimethylamino)-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl]pentan-1-one",CCCCC(=O)C1=C2C(CCCC2=C(C=C1)OC)N(C)C,,,,,,
11777,46472,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-fluoro-5-methoxy-, hydrochloride",COC1=C2CCCC(C2=C(C=C1)F)[NH3+].[Cl-],,,,,,
11778,46473,"8-Fluoro-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=C2CCCC(C2=C(C=C1)F)N,,,,,,
11779,46474,"1-Naphthylamine, N-methyl-1,2,3,4-tetrahydro-, hydrochloride",C[NH2+]C1CCCC2=CC=CC=C12.[Cl-],,,,,,
11780,46475,"N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",CNC1CCCC2=CC=CC=C12,,,,,,
11781,46476,"3-(1-Naphthalenyl)-3-azabicyclo(3.2.0)heptane-2,4-dione",C1CC2C1C(=O)N(C2=O)C3=CC=CC4=CC=CC=C43,,,,,,
11782,46477,"3-(2-Naphthalenyl)-3-azabicyclo(3.2.0)heptane-2,4-dione",C1CC2C1C(=O)N(C2=O)C3=CC4=CC=CC=C4C=C3,,,,,,
11783,46478,"Nicotinic acid, 3-(2'-methylpiperidino)propyl ester",CC1CCCCN1CCCOC(=O)C2=CN=CC=C2,,,,,,
11784,46479,"1,4,6-Trimethyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile",CC1=CC(=C(C(=O)N1C)C#N)C,,,,,,
11785,46480,CID 46480,CCCN1C(=O)C(C(=O)N=C1[O-])(CC)CC.[Na+],,,,,,
11786,46481,"1-Propyl-5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione",CCCN1C(=O)C(C(=O)NC1=O)(CC)CC,,,,,,
11787,46482,CID 46482,CCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
11788,46483,CID 46483,C1=CC=C(C=C1)C2(C(=O)NC(=NC2=O)[O-])C3=CC=CC=C3.[Na+],,,,,,
11789,46484,"5,5-Diphenylbarbituric acid",C1=CC=C(C=C1)C2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3,,,,,,
11790,46485,"Barbituric acid, 1-(3-ethoxy-2-hydroxypropyl)-5-ethyl-5-phenyl-, carbamate (ester)",CCC1(C(=O)NC(=O)N(C1=O)CC(COCC)OC(=O)N)C2=CC=CC=C2,,,,,,
11791,46486,5-(p-Aminophenyl)-5-ethyl-1-methylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=C(C=C2)N,,,,,,
11792,46487,CID 46487,CCCCCCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
11793,46488,CID 46488,CCCCCCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
11794,46489,"Barbituric acid, 5-ethyl-1-(2-hydroxy-3-isobutoxypropyl)-5-phenyl-, carbamate (ester)",CCC1(C(=O)NC(=O)N(C1=O)CC(COCC(C)C)OC(=O)N)C2=CC=CC=C2,,,,,,
11795,46490,"Barbituric acid, 5-ethyl-1-(2-hydroxy-3-isopropoxypropyl)-5-phenyl-, carbamate (ester)",CCC1(C(=O)NC(=O)N(C1=O)CC(COC(C)C)OC(=O)N)C2=CC=CC=C2,,,,,,
11796,46491,"Barbituric acid, 5-ethyl-1-(2-hydroxy-3-methoxypropyl)-5-phenyl-, carbamate (ester)",CCC1(C(=O)NC(=O)N(C1=O)CC(COC)OC(=O)N)C2=CC=CC=C2,,,,,,
11797,46492,"Barbituric acid, 5-ethyl-1-(2-hydroxy-3-propoxypropyl)-5-phenyl-, carbamate (ester)",CCCOCC(CN1C(=O)C(C(=O)NC1=O)(CC)C2=CC=CC=C2)OC(=O)N,,,,,,
11798,46493,CID 46493,CCC1(C(=O)N=C(N(C1=O)C)[O-])CCC(C)C.[Na+],,,,,,
11799,46494,"Barbituric acid, 5-ethyl-5-isopentyl-1-methyl-",CCC1(C(=O)NC(=O)N(C1=O)C)CCC(C)C,,,,,,
11800,46495,CID 46495,CCCN1C(=O)C(C(=O)N=C1[O-])(CC)CCC(C)C.[Na+],,,,,,
11801,46496,"5-Ethyl-5-(3-methylbutyl)-1-propyl-1,3-diazinane-2,4,6-trione",CCCN1C(=O)C(C(=O)NC1=O)(CC)CCC(C)C,,,,,,
11802,46497,CID 46497,CCC1(C(=NC(=S)N(C1=O)C)[O-])C(C)C.[Na+],,,,,,
11803,46498,CID 46498,CCC1(C(=O)N=C(N(C1=O)C)S)C(C)C,,,,,,
11804,46499,CID 46499,CCC1(C(=O)NC(=NC1=O)[O-])C(C)CC=C.[Na+],,,,,,
11805,46500,"5-Ethyl-5-pent-4-en-2-yl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)CC=C,,,,,,
11806,46501,CID 46501,CCC=CCC1(C(=O)N=C(N(C1=O)C)[O-])CC.[Na+],,,,,,
11807,46502,"5-Ethyl-1-methyl-5-pent-2-enyl-1,3-diazinane-2,4,6-trione",CCC=CCC1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
11808,46503,CID 46503,CCC=CCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
11809,46504,"5-Ethyl-5-pent-2-enyl-1,3-diazinane-2,4,6-trione",CCC=CCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
11810,46505,CID 46505,CCC=CCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
11811,46506,CID 46506,CCC=CCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
11812,46507,CID 46507,CCC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
11813,46508,"5-Ethyl-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
11814,46509,CID 46509,CCC1(C(=NC(=NC1=O)S)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
11815,46510,CID 46510,CCC1(C(=O)NC(=NC1=O)S)CCC2=CC=CC=C2,,,,,,
11816,46511,CID 46511,CCC1(C(=NC(=NC1=O)S)[O-])C2=CC=CC=C2.[Na+],,,,,,
11817,46512,CID 46512,CCC1(C(=O)NC(=NC1=O)S)C2=CC=CC=C2,,,,,,
11818,46513,CID 46513,CCC(=CC)C1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
11819,46514,"5-Pent-2-en-3-yl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCC(=CC)C1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
11820,46515,CID 46515,CCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
11821,46516,"5-Ethyl-5-propylpyrimidine-2,4,6(1H,3H,5H)-trione",CCCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
11822,46517,CID 46517,CCCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
11823,46518,CID 46518,CCCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
11824,46519,CID 46519,CCC=C(C)C1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
11825,46520,"5-Pent-2-en-2-yl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCC=C(C)C1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
11826,46521,CID 46521,CC(C)C=CC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
11827,46522,"5-(3-Methylbut-1-enyl)-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CC(C)C=CC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
11828,46523,CID 46523,CCC=CCC1(C(=O)N=C(N(C1=O)C)[O-])C(C)C.[Na+],,,,,,
11829,46524,"1-Methyl-5-pent-2-enyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCC=CCC1(C(=O)NC(=O)N(C1=O)C)C(C)C,,,,,,
11830,46525,CID 46525,CCCC=CC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
11831,46526,"5-Pent-1-enyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCCC=CC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
11832,46527,CID 46527,CCC=CCC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
11833,46528,CID 46528,CCC=CCC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
11834,46529,"BENZ(c)ACRIDINE, 10-CHLORO-7,11-DIMETHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=CC(=C4C)Cl,,,,,,
11835,46530,"BENZ(a)ACRIDINE, 9,12-DIMETHYL-10-FLUORO-",CC1=CC2=NC3=C(C(=C2C=C1F)C)C4=CC=CC=C4C=C3,,,,,,
11836,46531,"BENZ(c)ACRIDINE, 7,8,11-TRIMETHYL-",CC1=C2C(=C3C=CC4=CC=CC=C4C3=NC2=C(C=C1)C)C,,,,,,
11837,46532,CID 46532,C1=CC=C(C(=C1)C=O)OCC(=O)[O-].[Na+],,,,,,
11838,46533,2-(2-Formylphenoxy)acetic acid,C1=CC=C(C(=C1)C=O)OCC(=O)O,,,,,,
11839,46534,"Imidazolidine, 2,2-bis(trifluoromethyl)-, hydrate",C1CNC(N1)(C(F)(F)F)C(F)(F)F.O,,,,,,
11840,46535,"2,2-Bis(trifluoro-methyl)imidazolidine",C1CNC(N1)(C(F)(F)F)C(F)(F)F,,,,,,
11841,46536,"2,2-Bis(trifluoromethyl)-4-methylimidazolidine hydrate",CC1CNC(N1)(C(F)(F)F)C(F)(F)F.O,,,,,,
11842,46537,"4-Methyl-2,2-bis(trifluoromethyl)imidazolidine",CC1CNC(N1)(C(F)(F)F)C(F)(F)F,,,,,,
11843,46538,"Imidazolidine, 4,4-dimethyl-1-isopropyl-",CC(C)N1CC(NC1)(C)C,,,,,,
11844,46539,"Imidazolidine, 4,4-dimethyl-1-phenyl-",CC1(CN(CN1)C2=CC=CC=C2)C,,,,,,
11845,46540,CID 46540,C1CCN(CC1)CCC(C2=CC=CC3=CC=CC=C32)C(=O)[O-].[K+],,,,,,
11846,46541,2-Naphthalen-1-yl-4-piperidin-1-ylbutanoic acid,C1CCN(CC1)CCC(C2=CC=CC3=CC=CC=C32)C(=O)O,,,,,,
11847,46542,CID 46542,C1=CC=C2C(=C1)C=CC=C2C(CC3C=CC=CO3)C(=O)[O-].[Na+],,,,,,
11848,46543,2-naphthalen-1-yl-3-(2H-pyran-2-yl)propanoic acid,C1=CC=C2C(=C1)C=CC=C2C(CC3C=CC=CO3)C(=O)O,,,,,,
11849,46544,CID 46544,C1CCN(C1)CCC(C2=CC=CC3=CC=CC=C32)C(=O)[O-].[K+],,,,,,
11850,46545,2-Naphthalen-1-yl-4-pyrrolidin-1-ylbutanoic acid,C1CCN(C1)CCC(C2=CC=CC3=CC=CC=C32)C(=O)O,,,,,,
11851,46546,o-Hydroxy-alpha-(1-(methylamino)ethyl)benzyl alcohol,CC(C(C1=CC=CC=C1O)O)NC,,,,,,
11852,46547,CID 46547,C1COCCN1C2=CC=C(C=C2)C=NN=C(N)S,,,,,,
11853,46548,"Hydroxylamine, N-(2-methoxy-4-(phenylazo)phenyl)-, hydrochloride",COC1=C(C=CC(=C1)NNC2=CC=CC=C2)N=O.Cl,,,,,,
11854,46549,N-Hydroxy-2-methoxy-4-(phenylazo)-benzenamine,COC1=C(C=CC(=C1)NNC2=CC=CC=C2)N=O,,,,,,
11855,46550,"Benzenamine, N-hydroxy-3-methoxy-4-(phenylazo)-, monohydrochloride",COC1=C(C=CC(=C1)[NH2+]O)N=NC2=CC=CC=C2.[Cl-],,,,,,
11856,46551,N-(3-Methoxy-4-(phenylazo)phenyl)hydroxylamine,COC1=C(C=CC(=C1)N=O)NNC2=CC=CC=C2,,,,,,
11857,46552,2-Methoxy-4-nitroazobenzene,COC1=C(C=CC(=C1)[N+](=O)[O-])N=NC2=CC=CC=C2,,,,,,
11858,46553,(1-Hydroxy-1-phenylpropan-2-yl)-methyl-(3-phenylprop-2-enyl)azanium;chloride,CC(C(C1=CC=CC=C1)O)[NH+](C)CC=CC2=CC=CC=C2.[Cl-],,,,,,
11859,46554,2-[Methyl(3-phenylprop-2-en-1-yl)amino]-1-phenylpropan-1-ol,CC(C(C1=CC=CC=C1)O)N(C)CC=CC2=CC=CC=C2,,,,,,
11860,46555,"Carbamic acid, 5-(trimethylammonio)pentyl ester, chloride",C[N+](C)(C)CCCCCOC(=O)N.[Cl-],,,,,,
11861,46556,5-Carbamoyloxypentyl(trimethyl)azanium,C[N+](C)(C)CCCCCOC(=O)N,,,,,,
11862,46557,"Carbamic acid, methyl-, 3-(beta-(trimethylammonio)ethyl)phenyl ester, iodide",CNC(=O)OC1=CC=CC(=C1)CC[N+](C)(C)C.[I-],,,,,,
11863,46558,Trimethyl-[2-[3-(methylcarbamoyloxy)phenyl]ethyl]azanium,CNC(=O)OC1=CC=CC(=C1)CC[N+](C)(C)C,,,,,,
11864,46559,"Carbamic acid, methyl-, 4-(3-(trimethylammonio)butyl)phenyl ester, iodide",CC(CCC1=CC=C(C=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11865,46560,Trimethyl-[4-[4-(methylcarbamoyloxy)phenyl]butan-2-yl]azanium,CC(CCC1=CC=C(C=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11866,46561,"Carbamic acid, N,N-dimethyl-, p-(beta-(trimethylammonio)ethyl)phenyl ester, iodide",CN(C)C(=O)OC1=CC=C(C=C1)CC[N+](C)(C)C.[I-],,,,,,
11867,46562,2-[4-(Dimethylcarbamoyloxy)phenyl]ethyl-trimethylazanium,CN(C)C(=O)OC1=CC=C(C=C1)CC[N+](C)(C)C,,,,,,
11868,46563,"AMMONIUM, (p-HYDROXYPHENYL)ALLYLDIETHYL-, IODIDE, METHYLCARBAMATE",CC[N+](CC)(CC=C)C1=CC=C(C=C1)OC(=O)NC.[I-],,,,,,
11869,46564,Diethyl-[4-(methylcarbamoyloxy)phenyl]-prop-2-enylazanium,CC[N+](CC)(CC=C)C1=CC=C(C=C1)OC(=O)NC,,,,,,
11870,46565,"Ammonium, (3-(N-methylcarbamoyloxy)phenyl)allyldimethyl-, bromide",CNC(=O)OC1=CC=CC(=C1)[N+](C)(C)CC=C.[Br-],,,,,,
11871,46566,Dimethyl-[3-(methylcarbamoyloxy)phenyl]-prop-2-enylazanium,CNC(=O)OC1=CC=CC(=C1)[N+](C)(C)CC=C,,,,,,
11872,46567,"Carbamic acid, dimethyl-, (p-allyldimethylammonio)phenyl ester, iodide",CN(C)C(=O)OC1=CC=C(C=C1)[N+](C)(C)CC=C.[I-],,,,,,
11873,46568,[4-(Dimethylcarbamoyloxy)phenyl]-dimethyl-prop-2-enylazanium,CN(C)C(=O)OC1=CC=C(C=C1)[N+](C)(C)CC=C,,,,,,
11874,46569,"AMMONIUM, (p-HYDROXYPHENYL)ALLYLDIMETHYL-, IODIDE, METHYLCARBAMATE",CNC(=O)OC1=CC=C(C=C1)[N+](C)(C)CC=C.[I-],,,,,,
11875,46570,Dimethyl-[4-(methylcarbamoyloxy)phenyl]-prop-2-enylazanium,CNC(=O)OC1=CC=C(C=C1)[N+](C)(C)CC=C,,,,,,
11876,46571,"Carbamic acid, methyl-, 3-(3-(trimethylammonio)butyl)phenyl ester, iodide",CC(CCC1=CC(=CC=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11877,46572,Trimethyl-[4-[3-(methylcarbamoyloxy)phenyl]butan-2-yl]azanium,CC(CCC1=CC(=CC=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11878,46573,"Carbamic acid, dimethyl-, m-(diethylmethylammonio)phenyl ester, chloride",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)N(C)C.[Cl-],,,,,,
11879,46574,"Carbamic acid, methyl-, m-(diethylmethylammonio)phenyl ester, chloride",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)NC.[Cl-],,,,,,
11880,46575,"Carbamic acid, ethyl-, m-(diethylmethylammonio)phenyl ester, iodide",CCNC(=O)OC1=CC=CC(=C1)[N+](C)(CC)CC.[I-],,,,,,
11881,46576,Diethyl-[3-(ethylcarbamoyloxy)phenyl]-methylazanium,CCNC(=O)OC1=CC=CC(=C1)[N+](C)(CC)CC,,,,,,
11882,46577,"AMMONIUM, (p-HYDROXYPHENYL)DIETHYLMETHYL-, IODIDE, METHYLCARBAMATE",CC[N+](C)(CC)C1=CC=C(C=C1)OC(=O)NC.[I-],,,,,,
11883,46578,Diethyl-methyl-[4-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(CC)C1=CC=C(C=C1)OC(=O)NC,,,,,,
11884,46579,"1-Piperidinecarboxylic acid, m-(diethylmethylammonio)phenyl ester, iodide",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)N2CCCCC2.[I-],,,,,,
11885,46580,Diethyl-methyl-[3-(piperidine-1-carbonyloxy)phenyl]azanium,CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)N2CCCCC2,,,,,,
11886,46581,"AMMONIUM, (m-HYDROXYPHENYL)DIMETHYLETHYL-, BROMIDE, METHYLCARBAMATE",CC[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC.[Br-],,,,,,
11887,46582,"Ammonium, ((p-dimethylcarbamoyloxy)phenyl)dimethylethyl-, iodide",CC[N+](C)(C)C1=CC=C(C=C1)OC(=O)N(C)C.[I-],,,,,,
11888,46583,[4-(Dimethylcarbamoyloxy)phenyl]-ethyl-dimethylazanium,CC[N+](C)(C)C1=CC=C(C=C1)OC(=O)N(C)C,,,,,,
11889,46584,"AMMONIUM, (p-HYDROXYPHENYL)DIMETHYLETHYL-, IODIDE, METHYLCARBAMATE",CC[N+](C)(C)C1=CC=C(C=C1)OC(=O)NC.[I-],,,,,,
11890,46585,Ethyl-dimethyl-[4-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(C)C1=CC=C(C=C1)OC(=O)NC,,,,,,
11891,46586,"Carbamic acid, dimethyl-, p-(N,N-dimethyl-N-(2-hydroxyethyl)ammonio)phenyl ester, bromide",CN(C)C(=O)OC1=CC=C(C=C1)[N+](C)(C)CCO.[Br-],,,,,,
11892,46587,[4-(Dimethylcarbamoyloxy)phenyl]-(2-hydroxyethyl)-dimethylazanium,CN(C)C(=O)OC1=CC=C(C=C1)[N+](C)(C)CCO,,,,,,
11893,46588,"Ammonium, (3-(N-methylcarbamoyloxy)phenyl)dimethylpropyl-, bromide",CCC[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC.[Br-],,,,,,
11894,46589,Dimethyl-[3-(methylcarbamoyloxy)phenyl]-propylazanium,CCC[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC,,,,,,
11895,46590,"1-Piperidinecarboxylic acid, 2-(trimethylammonio)ethyl ester, iodide",C[N+](C)(C)CCOC(=O)N1CCCCC1.[I-],,,,,,
11896,46591,"N,N,N-Trimethyl-2-[piperidinocarbonyloxy]ethanaminium",C[N+](C)(C)CCOC(=O)N1CCCCC1,,,,,,
11897,46592,"Ammonium, ((4-(N,N-dimethylcarbamoyloxy)-2-heptyl)phenyl)trimethyl-, iodide",CCCCCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11898,46593,[4-(Dimethylcarbamoyloxy)-2-heptylphenyl]-trimethylazanium,CCCCCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11899,46594,"Ammonium, ((4-hydroxy-3-hexyl)phenyl)trimethyl-, iodide, methylcarbamate",CCCCCCC1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)NC.[I-],,,,,,
11900,46595,[3-Hexyl-4-(methylcarbamoyloxy)phenyl]-trimethylazanium,CCCCCCC1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)NC,,,,,,
11901,46596,"Carbamic acid, dimethyl-, (4-isopropyl-2-(trimethylammonio)phenyl) ester, iodide",CC(C)C1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11902,46597,[2-(Dimethylcarbamoyloxy)-5-propan-2-ylphenyl]-trimethylazanium,CC(C)C1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11903,46598,"Ammonium, (4-methylcarbamoyloxy-o-cumenyl)trimethyl-, iodide",CC(C)C1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11904,46599,"Benzenemethanaminium, 4-methoxy-N,N,N,alpha-tetramethyl-3-(methylamino)carbonyloxy-, iodide",CC(C1=CC(=C(C=C1)OC)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11905,46600,1-[4-Methoxy-3-(methylcarbamoyloxy)phenyl]ethyl-trimethylazanium,CC(C1=CC(=C(C=C1)OC)OC(=O)NC)[N+](C)(C)C,,,,,,
11906,46601,"Carbamic acid, N-methyl-, 4-(methyl(beta-diethylaminoethyl)amino)phenyl ester, monomethiodide",CC[N+](C)(CC)CCN(C)C1=CC=C(C=C1)OC(=O)NC.[I-],,,,,,
11907,46602,diethyl-methyl-[2-[N-methyl-4-(methylcarbamoyloxy)anilino]ethyl]azanium,CC[N+](C)(CC)CCN(C)C1=CC=C(C=C1)OC(=O)NC,,,,,,
11908,46603,"Carbamic acid, methyl-, 2-(trimethylammoniomethyl)-p-tolyl ester, iodide",CC1=CC(=C(C=C1)OC(=O)NC)C[N+](C)(C)C.[I-],,,,,,
11909,46604,Trimethyl-[[5-methyl-2-(methylcarbamoyloxy)phenyl]methyl]azanium,CC1=CC(=C(C=C1)OC(=O)NC)C[N+](C)(C)C,,,,,,
11910,46605,"Carbamic acid, methyl-, 3-(2-(trimethylammonio)propyl)phenyl ester, iodide",CC(CC1=CC(=CC=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11911,46606,Trimethyl-[1-[3-(methylcarbamoyloxy)phenyl]propan-2-yl]azanium,CC(CC1=CC(=CC=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11912,46607,"Carbamic acid, methyl-, 3-(allyldimethylammonio)-p-tolyl ester, bromide",CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)CC=C.[Br-],,,,,,
11913,46608,Dimethyl-[2-methyl-5-(methylcarbamoyloxy)phenyl]-prop-2-enylazanium,CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)CC=C,,,,,,
11914,46609,"Carbamic acid, methyl-, 3-(benzyldimethylammonio)-p-tolyl ester, bromide",CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)CC2=CC=CC=C2.[Br-],,,,,,
11915,46610,Benzyl-dimethyl-[2-methyl-5-(methylcarbamoyloxy)phenyl]azanium,CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)CC2=CC=CC=C2,,,,,,
11916,46611,3-Hydroxy-4-methylphenyltrimethylammonium bromide,CC1=C(C=C(C=C1)[N+](C)(C)C)O.[Br-],,,,,,
11917,46612,(3-Hydroxy-4-methyl-phenyl)-trimethyl-ammonium,CC1=C(C=C(C=C1)[N+](C)(C)C)O,,,,,,
11918,46613,"Carbamic acid, dimethyl-, (3-trimethylammonio-p-tolyl) ester, iodide",CC1=C(C=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11919,46614,[5-(Dimethylcarbamoyloxy)-2-methylphenyl]-trimethylazanium,CC1=C(C=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11920,46615,"Carbamic acid, methyl-, 3-(trimethylammonio)-p-tolyl ester, iodide",CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11921,46616,"5-[[(Methylamino)carbonyl]oxy]-N,N,N,2-tetramethylbenzenaminium",CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11922,46617,"1-Piperidinecarboxylic acid, 3-(trimethylammonio)-p-tolyl ester, iodide",CC1=C(C=C(C=C1)OC(=O)N2CCCCC2)[N+](C)(C)C.[I-],,,,,,
11923,46618,Trimethyl-[2-methyl-5-(piperidine-1-carbonyloxy)phenyl]azanium,CC1=C(C=C(C=C1)OC(=O)N2CCCCC2)[N+](C)(C)C,,,,,,
11924,46619,"Carbamic acid, methyl-, 3-(trimethylammonio)-p-tolyl ester, methylsulfate",CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
11925,46620,"Ammonium, ((4-(N,N-dimethylcarbamoyloxy)-2-pentyl)phenyl)trimethyl-, iodide",CCCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
11926,46621,[4-(Dimethylcarbamoyloxy)-2-pentylphenyl]-trimethylazanium,CCCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
11927,46622,"Ammonium, ((4-methylcarbamoyloxy-2-pentyl)phenyl)trimethyl-, iodide",CCCCCC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
11928,46623,Trimethyl-[4-(methylcarbamoyloxy)-2-pentylphenyl]azanium,CCCCCC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
11929,46624,"ACETIC ACID, (o-CARBAMOYL)PHENOXY-, CALCIUM SALT (2:1)",C1=CC=C(C(=C1)NC=O)OCC(=O)[O-].C1=CC=C(C(=C1)NC=O)OCC(=O)[O-].[Ca+2],,,,,,
11930,46625,2-(2-Formamidophenoxy)acetic acid,C1=CC=C(C(=C1)NC=O)OCC(=O)O,,,,,,
11931,46626,"[4-(3-Chlorobenzo[b]thiophen-2-yl)-2,3-dichlorophenoxy]acetic acid",C1=CC=C2C(=C1)C(=C(S2)C3=C(C(=C(C=C3)OCC(=O)O)Cl)Cl)Cl,,,,,,
11932,46627,"N,N-Bis-(2-(chloroacetoxy)ethyl)-N-methyl amine hydrochloride",C[NH+](CCOC(=O)CCl)CCOC(=O)CCl.[Cl-],,,,,,
11933,46628,2-[2-(2-Chloroacetyl)oxyethyl-methylamino]ethyl 2-chloroacetate,CN(CCOC(=O)CCl)CCOC(=O)CCl,,,,,,
11934,46629,"Acetic acid, (4-((5-chloro-2-furyl)carbonyl)-2,3-dichloro)phenoxy-",C1=CC(=C(C(=C1C(=O)C2=CC=C(O2)Cl)Cl)Cl)OCC(=O)O,,,,,,
11935,46630,"Acetic acid, chloro-, 4-isopropylcyclohexyl ester",CC(C)C1CCC(CC1)OC(=O)CCl,,,,,,
11936,46631,1-Methoxyisopropyl chloroacetate,CC(C)(OC)OC(=O)CCl,,,,,,
11937,46632,"Acetic acid, chloro-, 3-phenylpropyl ester",C1=CC=C(C=C1)CCCOC(=O)CCl,,,,,,
11938,46633,(4-Chloro-o-tolyloxy)acetic acid 2-dimethylaminoethyl ester hydrochloride,CC1=C(C=CC(=C1)Cl)OCC(=O)OCC[NH+](C)C.[Cl-],,,,,,
11939,46634,2-(Dimethylamino)ethyl 2-(4-chloro-2-methylphenoxy)acetate,CC1=C(C=CC(=C1)Cl)OCC(=O)OCCN(C)C,,,,,,
11940,46635,Ethyl 2-cyano-3-ethoxybut-2-enoate,CCOC(=C(C#N)C(=O)OCC)C,,,,,,
11941,46636,3-(2-Methylpiperidin-1-yl)propyl 2-cyclohexylacetate,CC1CCCCN1CCCOC(=O)CC2CCCCC2,,,,,,
11942,46637,"2,4-Dichlorophenoxyacetic acid 2-dimethylaminoethyl ester hydrochloride",C[NH+](C)CCOC(=O)COC1=C(C=C(C=C1)Cl)Cl.[Cl-],,,,,,
11943,46638,"2-(Dimethylamino)ethyl 2-(2,4-dichlorophenoxy)acetate",CN(C)CCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
11944,46639,"Acetanilide, 2-(diethylamino)-4'-phenoxy-, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)OC2=CC=CC=C2.[Cl-],,,,,,
11945,46640,2-(diethylamino)-N-(4-phenoxyphenyl)acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
11946,46641,"Acetanilide, 2-(diethylamino)-2'-phenoxy-, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=CC=C1OC2=CC=CC=C2.[Cl-],,,,,,
11947,46642,2-(diethylamino)-N-(2-phenoxyphenyl)acetamide,CCN(CC)CC(=O)NC1=CC=CC=C1OC2=CC=CC=C2,,,,,,
11948,46643,"Acetanilide, 2-(diethylamino)-3'-phenoxy-, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC(=CC=C1)OC2=CC=CC=C2.[Cl-],,,,,,
11949,46644,2-(diethylamino)-N-(3-phenoxyphenyl)acetamide,CCN(CC)CC(=O)NC1=CC(=CC=C1)OC2=CC=CC=C2,,,,,,
11950,46645,"Acetamide, 2,2'-diselenobis(N-phenyl-",C1=CC=C(C=C1)NC(=O)C[Se][Se]CC(=O)NC2=CC=CC=C2,,,,,,
11951,46646,p-Ethoxyfluoroacetanilide,CCOC1=CC=C(C=C1)NC(=O)CF,,,,,,
11952,46647,"Acetanilide, alpha-mercapto-, carbamate",C1=CC=C(C=C1)NC(=O)C(OC(=O)N)S,,,,,,
11953,46648,m-Tolylazoacetanilide,CC1=CC(=CC=C1)N=NCC(=O)NC2=CC=CC=C2,,,,,,
11954,46649,3-Prop-2-enoxyprop-2-enyl acetate,CC(=O)OCC=COCC=C,,,,,,
11955,46650,Butyl 2-aminooxyacetate hydrochloride,CCCCOC(=O)CO[NH3+].[Cl-],,,,,,
11956,46651,Butyl 2-aminooxyacetate,CCCCOC(=O)CON,,,,,,
11957,46652,Dodecyl 2-aminooxyacetate hydrochloride,CCCCCCCCCCCCOC(=O)CO[NH3+].[Cl-],,,,,,
11958,46653,Dodecyl 2-aminooxyacetate,CCCCCCCCCCCCOC(=O)CON,,,,,,
11959,46654,Propyl 2-aminooxyacetate hydrochloride,CCCOC(=O)CO[NH3+].[Cl-],,,,,,
11960,46655,Propyl 2-aminooxyacetate,CCCOC(=O)CON,,,,,,
11961,46656,2-(Carboxymethyldiazenyl)acetic acid,C(C(=O)O)N=NCC(=O)O,,,,,,
11962,46657,"Acetic acid, 2-(4-biphenylyl)-2-methyl-, 2-piperidinoethyl ester",CC(C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)OCCC3CCCCN3,,,,,,
11963,46658,"Acetic acid, bromo-, 1-methoxyisopropyl ester",CC(C)(OC)OC(=O)CBr,,,,,,
11964,46659,"Arsine, amyldicyano-",CCCCC[As](C#N)C#N,,,,,,
11965,46660,Bis(2-chloroethenyl)-phenylarsane,C1=CC=C(C=C1)[As](C=CCl)C=CCl,,,,,,
11966,46661,"Acridine, 9-amino-2-cyano-",C1=CC=C2C(=C1)C(=C3C=C(C=CC3=N2)C#N)N,,,,,,
11967,46662,"Acridine, 7-amino-3-dimethylamino-",CN(C)C1=CC2=NC3=C(C=C2C=C1)C=C(C=C3)N,,,,,,
11968,46663,"2-Acridinecarboxylic acid, 9-amino-, methyl ester",COC(=O)C1=CC2=C(C3=CC=CC=C3N=C2C=C1)N,,,,,,
11969,46664,"2-Acridinecarboxylic acid, 9-amino-",C1=CC=C2C(=C1)C(=C3C=C(C=CC3=N2)C(=O)O)N,,,,,,
11970,46665,2-(Diethylamino)ethyl 9-acridinecarboxylate hydrochloride,CC[NH+](CC)CCOC(=O)C1=C2C=CC=CC2=NC3=CC=CC=C31.[Cl-],,,,,,
11971,46666,2-(Diethylamino)ethyl acridine-9-carboxylate,CCN(CC)CCOC(=O)C1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
11972,46667,"Acridine, 2-chloro-5-((4-dimethylamino-1-methylbutyl)amino)-7-methoxy-",CC(CCCN(C)C)NC1=C2C(=CC(=C1)OC)C=C3C=C(C=CC3=N2)Cl,,,,,,
11973,46668,"Acridine, 9-cyclohexylamino-",C1CCC(CC1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
11974,46669,CID 46669,C1=CC2=NC3=C(C=C(C=C3)N)C=C2C=C1[NH3+].[Cl-],,,,,,
11975,46670,"7-Acridinesulfonamide, 3-amino-",C1=CC(=CC2=NC3=C(C=C21)C=C(C=C3)S(=O)(=O)N)N,,,,,,
11976,46671,"7-Acridinesulfonic acid, 3-amino-",C1=CC(=CC2=NC3=C(C=C21)C=C(C=C3)S(=O)(=O)O)N,,,,,,
11977,46672,"Acridinium, 3-amino-10-methyl-, bromide",C[N+]1=C2C=C(C=CC2=CC3=CC=CC=C31)N.[Br-],,,,,,
11978,46673,"Acridinium, 9-amino-10-methyl-, bromide",C[N+]1=C2C=CC=CC2=C(C3=CC=CC=C31)N.[Br-],,,,,,
11979,46674,CID 46674,C1=CC(=CC=C1NC(=O)C=CC2=CC=C(O2)[N+](=O)[O-])SCCCl,,,,,,
11980,46675,2-(Diethylamino)ethyl anthracene-10-carboxylate hydrochloride,CC[NH+](CC)CCOC(=O)C1=C2C=CC=CC2=CC3=CC=CC=C31.[Cl-],,,,,,
11981,46676,2-(Diethylamino)ethyl anthracene-9-carboxylate,CCN(CC)CCOC(=O)C1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
11982,46677,"Anthraquinone, 1-amino-2-benzylthio-4-hydroxy-",C1=CC=C(C=C1)CSC2=C(C3=C(C(=C2)O)C(=O)C4=CC=CC=C4C3=O)N,,,,,,
11983,46678,"ANTIMONY, BIS(TRICHLORO-, compd. with 1 mol. of OCTAMETHYL PYROPHOSPHORAMIDE",CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C.Cl[Sb](Cl)Cl.Cl[Sb](Cl)Cl,,,,,,
11984,46679,CID 46679,CC=C1C[NH+]2CCC1CC2C(C3=C4C=C(C=CC4=[NH+]C=C3)O)O.[Cl-].[Cl-],,,,,,
11985,46680,4-[(5-Ethylidene-1-azabicyclo[2.2.2]octan-2-yl)-hydroxymethyl]quinolin-6-ol,CC=C1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)O)O,,,,,,
11986,46681,"m-ARSANILIC ACID, N-ACETYL-4-HYDROXY-, CALCIUM SALT",CC(=O)NC1=C(C=CC(=C1)[As](=O)([O-])[O-])O.[Ca+2],,,,,,
11987,46682,CID 46682,C1=CC(=CC=C1NCCC(=O)N)[As](=O)(O)[O-].[Na+],,,,,,
11988,46683,[4-[(3-Amino-3-oxopropyl)amino]phenyl]arsonic acid,C1=CC(=CC=C1NCCC(=O)N)[As](=O)(O)O,,,,,,
11989,46684,"Arsanilic acid, N-((1-carbamoyl-1-methyl)ethyl)-",CC(C)(C(=O)N)NC1=CC=C(C=C1)[As](=O)(O)O,,,,,,
11990,46685,"Arsanilic acid, N-(1-carbamoylpropyl)-",CCC(C(=O)N)NC1=CC=C(C=C1)[As](=O)(O)O,,,,,,
11991,46686,"Arsanilic acid, N-3-phenoselenazinyl-",C1=CC=C2C(=C1)NC3=C([Se]2)C=C(C=C3)NC4=CC=C(C=C4)[As](=O)(O)O,,,,,,
11992,46687,"Arsine, allyldichloro-",C=CC[As](Cl)Cl,,,,,,
11993,46688,"Arsine, pentyldibromo-",CCCCC[As](Br)Br,,,,,,
11994,46689,"Acetanilide, 2-(ethoxycarbonylphenyl)-",CCOC(=O)C1=CC=C(C=C1)CC(=O)NC2=CC=CC=C2,,,,,,
11995,46690,CID 46690,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(=O)[O-])Cl.[Na+],,,,,,
11996,46691,"Acetic acid, dichlorophenoxy-, butyl ester",CCCCOC(=O)C(OC1=CC=CC=C1)(Cl)Cl,,,,,,
11997,46692,"6-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-7-methoxy-2-methyl-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)O.[Cl-],,,,,,
11998,46693,"1-[2-(4-chlorophenyl)ethyl]-7-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-6-ol",CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)O,,,,,,
11999,46694,"(1S)-(-)-6-Hydroxy-7-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",CC1C2=CC(=C(C=C2CC[NH2+]1)O)OC.[Cl-],,,,,,
12000,46695,Salsoline,CC1C2=CC(=C(C=C2CCN1)O)OC,,,"['Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)']",,,
12001,46696,"(1S)-(-)-7-Hydroxy-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",C.CC1C2=CC(=C(C=C2CC[NH2+]1)OC)O.[Cl-],,,,,,
12002,46697,"6-Methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol",CC1C2=CC(=C(C=C2CCN1)OC)O,,,,,,
12003,46698,p-Dodecyloxyphenylisothiocyanate,CCCCCCCCCCCCOC1=CC=C(C=C1)N=C=S,,,,,,
12004,46699,4-isothiocyanato-N-pyrimidin-2-ylbenzenesulfonamide,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N=C=S,,,,,,
12005,46700,Tribromoethyl 2-bromoisovalerate,CC(C)C(C(=O)OCC(Br)(Br)Br)Br,,,,,,
12006,46701,Trichloroethyl 2-bromoisovalerate,CC(C)C(C(=O)OCC(Cl)(Cl)Cl)Br,,,,,,
12007,46702,"ISOXAZOLE, 5-AMINO-4-(p-CHLOROPHENYL)-",C1=CC(=CC=C1C2=C(ON=C2)N)Cl,,,,,,
12008,46703,"3-Methylisoxazoledione-4,5 o-chlorophenylhydrazone",CC1=NOC(=C1O)N=NC2=CC=CC=C2Cl,,,,,,
12009,46704,"Acetic acid--3-hydroxy-17,23-epoxyveratraman-11-one (1/1)",CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4C5CC=C6CC(CCC6(C5C(=O)C4=C3C)C)O)C)NC1.CC(=O)O,,,,,,
12010,46705,"(3'aS,7'aR,9R)-3-hydroxy-3',6',10,11b-tetramethylspiro[1,2,3,4,6,6a,6b,7,8,11a-decahydrobenzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-11-one",CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4C5CC=C6CC(CCC6(C5C(=O)C4=C3C)C)O)C)NC1,,,,,,
12011,46706,"KETONE, AZIRIDINYL 3-(BIS(2-CHLOROETHYL)AMINO)-p-TOLYL, HYDRATE",CC1=C(C=C(C=C1)C(=O)N2CC2)N(CCCl)CCCl.O,,,,,,
12012,46707,"Isoquinolinium, 4-acetamido-2-(3-(trimethylammonio)propyl)-, dibromide",CC(=O)NC1=C[N+](=CC2=CC=CC=C21)CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12013,46708,3-(4-Acetamidoisoquinolin-2-ium-2-yl)propyl-trimethylazanium,CC(=O)NC1=C[N+](=CC2=CC=CC=C21)CCC[N+](C)(C)C,,,,,,
12014,46709,"Isoquinolinium, 6,7-dimethoxy-2-(3-(trimethylammonio)propyl)-, dibromide",C[N+](C)(C)CCC[N+]1=CC2=CC(=C(C=C2C=C1)OC)OC.[Br-].[Br-],,,,,,
12015,46710,"3-(6,7-Dimethoxyisoquinolin-2-ium-2-yl)propyl-trimethylazanium",C[N+](C)(C)CCC[N+]1=CC2=CC(=C(C=C2C=C1)OC)OC,,,,,,
12016,46711,"Isoquinolinium, 2-(4-(1-methylpyrrolidinio)butyl)-, dibromide",C[N+]1(CCCC1)CCCC[N+]2=CC3=CC=CC=C3C=C2.[Br-].[Br-],,,,,,
12017,46712,2-[4-(1-Methylpyrrolidin-1-ium-1-yl)butyl]isoquinolin-2-ium,C[N+]1(CCCC1)CCCC[N+]2=CC3=CC=CC=C3C=C2,,,,,,
12018,46713,"Isoquinolinium, 2-(3-(1-methylpyrrolidinio)propyl)-, dibromide",C[N+]1(CCCC1)CCC[N+]2=CC3=CC=CC=C3C=C2.[Br-].[Br-],,,,,,
12019,46714,2-[3-(1-Methylpyrrolidin-1-ium-1-yl)propyl]isoquinolin-2-ium,C[N+]1(CCCC1)CCC[N+]2=CC3=CC=CC=C3C=C2,,,,,,
12020,46715,Trimethyl-[3-(1-methylisoquinolin-2-ium-2-yl)propyl]azanium dibromide,CC1=[N+](C=CC2=CC=CC=C12)CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12021,46716,Trimethyl-[3-(1-methylisoquinolin-2-ium-2-yl)propyl]azanium,CC1=[N+](C=CC2=CC=CC=C12)CCC[N+](C)(C)C,,,,,,
12022,46717,"Isoquinolinium, 3-methyl-2-(3-(trimethylammonio)propyl)-, dibromide",CC1=CC2=CC=CC=C2C=[N+]1CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12023,46718,Trimethyl-[3-(3-methylisoquinolin-2-ium-2-yl)propyl]azanium,CC1=CC2=CC=CC=C2C=[N+]1CCC[N+](C)(C)C,,,,,,
12024,46719,"Isoquinolinium, 2-(3-(pyridinio)propyl)-, dibromide",C1=CC=[N+](C=C1)CCC[N+]2=CC3=CC=CC=C3C=C2.[Br-].[Br-],,,,,,
12025,46720,2-(3-Pyridin-1-ium-1-ylpropyl)isoquinolin-2-ium,C1=CC=[N+](C=C1)CCC[N+]2=CC3=CC=CC=C3C=C2,,,,,,
12026,46721,"Isoquinolinium, 1,2,3,4-tetrahydro-2,2-dimethyl-5,6-bis(methylcarbamoyloxy)-, iodide",CNC(=O)OC1=C(C2=C(C[N+](CC2)(C)C)C=C1)OC(=O)NC.[I-],,,,,,
12027,46722,"[2,2-dimethyl-5-(methylcarbamoyloxy)-3,4-dihydro-1H-isoquinolin-2-ium-6-yl] N-methylcarbamate",CNC(=O)OC1=C(C2=C(C[N+](CC2)(C)C)C=C1)OC(=O)NC,,,,,,
12028,46723,"Isoquinolinium, 1,2,3,4-tetrahydro-1,2-dimethyl-2-(3-(trimethylammonio)propyl)-, dibromide",CC1C2=CC=CC=C2CC[N+]1(C)CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12029,46724,"3-(1,2-dimethyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl)propyl-trimethylazanium",CC1C2=CC=CC=C2CC[N+]1(C)CCC[N+](C)(C)C,,,,,,
12030,46725,"Ammonium, (3-(2-ethyl-1,2,3,4-tetrahydroisoquinolinio)propyl)trimethyl-, dibromide",CC[N+]1(CCC2=CC=CC=C2C1)CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12031,46726,"3-(2-ethyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl)propyl-trimethylazanium",CC[N+]1(CCC2=CC=CC=C2C1)CCC[N+](C)(C)C,,,,,,
12032,46727,"Isoquinolinium, 1,2,3,4-tetrahydro-2-methyl-2-(3-(1-methylpyrrolidinio)propyl)-, dibromide",C[N+]1(CCCC1)CCC[N+]2(CCC3=CC=CC=C3C2)C.[Br-].[Br-],,,,,,
12033,46728,"2-methyl-2-[3-(1-methylpyrrolidin-1-ium-1-yl)propyl]-3,4-dihydro-1H-isoquinolin-2-ium",C[N+]1(CCCC1)CCC[N+]2(CCC3=CC=CC=C3C2)C,,,,,,
12034,46729,"Ammonium, (3-(2-methyl-1,2,3,4-tetrahydroisoquinolinio)propyl)trimethyl-, dibromide",C[N+]1(CCC2=CC=CC=C2C1)CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12035,46730,"trimethyl-[3-(2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl)propyl]azanium",C[N+]1(CCC2=CC=CC=C2C1)CCC[N+](C)(C)C,,,,,,
12036,46731,"Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-(trimethylammonio)propyl)-, dibromide",C[N+](C)(C)CCC[NH+]1CCC2=CC=CC=C2C1.[Br-].[Br-],,,,,,
12037,46732,"3-(3,4-dihydro-1H-isoquinolin-2-yl)propyl-trimethylazanium",C[N+](C)(C)CCCN1CCC2=CC=CC=C2C1,,,,,,
12038,46733,"Isoquinolinium, 2-(3-(triethylammonio)propyl)-, dibromide",CC[N+](CC)(CC)CCC[N+]1=CC2=CC=CC=C2C=C1.[Br-].[Br-],,,,,,
12039,46734,Triethyl(3-isoquinolin-2-ium-2-ylpropyl)azanium,CC[N+](CC)(CC)CCC[N+]1=CC2=CC=CC=C2C=C1,,,,,,
12040,46735,"Isoquinolinium, 2-(5-(trimethylammonio)pentyl)-, dibromide",C[N+](C)(C)CCCCC[N+]1=CC2=CC=CC=C2C=C1.[Br-].[Br-],,,,,,
12041,46736,5-Isoquinolin-2-ium-2-ylpentyl(trimethyl)azanium,C[N+](C)(C)CCCCC[N+]1=CC2=CC=CC=C2C=C1,,,,,,
12042,46737,"1-(4-Chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-5-ol oxalate",C[NH+]1CCC2=C(C1CCC3=CC=C(C=C3)Cl)C=CC(=C2O)OC.C(=O)(C(=O)[O-])O,,,,,,
12043,46738,"1-[2-(4-chlorophenyl)ethyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-5-ol",CN1CCC2=C(C1CCC3=CC=C(C=C3)Cl)C=CC(=C2O)OC,,,,,,
12044,46739,"7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-chlorophenethyl)-6-methoxy-2-methyl-, hydrochloride",C[NH+]1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)O)OC.[Cl-],,,,,,
12045,46740,"1-[2-(4-chlorophenyl)ethyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol",CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)O)OC,,,,,,
12046,46741,"Phenol, 2,4-dichloro-6-nitro-, sodium salt",C1=C(C=C(C(=C1[N+](=O)[O-])[O-])Cl)Cl.[Na+],,,,,,
12047,46742,CID 46742,CCCC[Hg].C(C(=O)O)[S-].[Na+],,,,,,
12048,46743,Butylmercury,CCCC[Hg],,,,,,
12049,46744,CID 46744,CC[Hg].C(C(=O)O)[S-].[K+],,,,,,
12050,46745,CID 46745,C[Hg].C(C(=O)O)[S-].[Na+],,,,,,
12051,46746,Acetic acid;(5-mercuriothiophen-2-yl)mercury;hydrate,CC(=O)O.C1=C(SC(=C1)[Hg])[Hg].O,,,,,,
12052,46747,(5-Mercuriothiophen-2-yl)mercury,C1=C(SC(=C1)[Hg])[Hg],,,,,,
12053,46748,"trans-N-(2-n-Butoxycyclopropyl)-N,N,N-trimethylammonium iodide",CCCCO[C@H]1C[C@@H]1[N+](C)(C)C.[I-],,,,,,
12054,46749,"[(1S,2S)-2-butoxycyclopropyl]-trimethylazanium",CCCCO[C@H]1C[C@@H]1[N+](C)(C)C,,,,,,
12055,46750,"Ammonium, N-butyl-N-ethyl-N,N',N',N'-tetramethyl-N,N'-oxydiethylenedi-, diiodide",CCCC[N+](C)(CC)CCOCC[N+](C)(C)C.[I-].[I-],,,,,,
12056,46751,Butyl-ethyl-methyl-[2-[2-(trimethylazaniumyl)ethoxy]ethyl]azanium,CCCC[N+](C)(CC)CCOCC[N+](C)(C)C,,,,,,
12057,46752,"Ammonium, 3,3'-carbonyldioxybis(phenyltrimethyl-dimethylsulfate",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)OC2=CC=CC(=C2)[N+](C)(C)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-],,,,,,
12058,46753,Trimethyl-[3-[3-(trimethylazaniumyl)phenoxy]carbonyloxyphenyl]azanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)OC2=CC=CC(=C2)[N+](C)(C)C,,,,,,
12059,46754,3-(p-Chlorobenzoyloxy)phenyltrimethylammonium bromide,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC=C(C=C2)Cl.[Br-],,,,,,
12060,46755,[3-(4-Chlorobenzoyl)oxyphenyl]-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC=C(C=C2)Cl,,,,,,
12061,46756,3-(m-Chlorobenzoyloxy)phenyltrimethylammonium bromide,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC(=CC=C2)Cl.[Br-],,,,,,
12062,46757,[3-(3-Chlorobenzoyl)oxyphenyl]-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC(=CC=C2)Cl,,,,,,
12063,46758,"Ammonium, (2-chloroethyl)dibenzylmethyl-, methylsulfate",C[N+](CCCl)(CC1=CC=CC=C1)CC2=CC=CC=C2.COS(=O)(=O)[O-],,,,,,
12064,46759,Dibenzyl-(2-chloroethyl)-methylazanium,C[N+](CCCl)(CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
12065,46760,"Ammonium, (2-(N-(2-chloroethyl)-N-ethylamino)ethyl)bis(2-hydroxyethyl)methyl-, chloride, hydrochloride",CC[NH+](CC[N+](C)(CCO)CCO)CCCl.[Cl-].[Cl-],,,,,,
12066,46761,2-[2-Chloroethyl(ethyl)amino]ethyl-bis(2-hydroxyethyl)-methylazanium,CCN(CC[N+](C)(CCO)CCO)CCCl,,,,,,
12067,46762,Benzilyloxyethyldimethylisopropylammonium chloride,CC(C)[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
12068,46763,"2-(2-Hydroxy-2,2-diphenylacetyl)oxyethyl-dimethyl-propan-2-ylazanium",CC(C)[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
12069,46764,Benzilyloxypropyldiethylmethylammonium chloride,CC[N+](C)(CC)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
12070,46765,"Diethyl-[3-(2-hydroxy-2,2-diphenylacetyl)oxypropyl]-methylazanium",CC[N+](C)(CC)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
12071,46766,Benzilyloxypropyldimethylethylammonium chloride,CC[N+](C)(C)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
12072,46767,"Ethyl-[3-(2-hydroxy-2,2-diphenylacetyl)oxypropyl]-dimethylazanium",CC[N+](C)(C)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
12073,46768,3-Benzoyloxyphenyldiethylmethylammonium bromide,CC[N+](C)(CC)C1=CC=CC(=C1)C(=O)OC2=CC=CC=C2.[Br-],,,,,,
12074,46769,Diethyl-methyl-(3-phenoxycarbonylphenyl)azanium,CC[N+](C)(CC)C1=CC=CC(=C1)C(=O)OC2=CC=CC=C2,,,,,,
12075,46770,2-Benzoyloxyphenyltrimethylammonium bromide,C[N+](C)(C)C1=CC=CC=C1OC(=O)C2=CC=CC=C2.[Br-],,,,,,
12076,46771,(2-Benzoyloxyphenyl)-trimethylazanium,C[N+](C)(C)C1=CC=CC=C1OC(=O)C2=CC=CC=C2,,,,,,
12077,46772,4-Benzoyloxyphenyltrimethylammonium bromide,C[N+](C)(C)C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2.[Br-],,,,,,
12078,46773,"Benzenaminium, 4-(benzoyloxy)-N,N,N-trimethyl-",C[N+](C)(C)C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2,,,,,,
12079,46774,2-Benzoyloxybenzyltrimethylammonium bromide,C[N+](C)(C)CC1=CC=CC=C1OC(=O)C2=CC=CC=C2.[Br-],,,,,,
12080,46775,(2-Benzoyloxyphenyl)methyl-trimethylazanium,C[N+](C)(C)CC1=CC=CC=C1OC(=O)C2=CC=CC=C2,,,,,,
12081,46776,3-Benzoyloxyphenyltrimethylammonium bromide,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC=CC=C2.[Br-],,,,,,
12082,46777,(3-Benzoyloxyphenyl)-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC=CC=C2,,,,,,
12083,46778,Benzyl-diethyl-[2-[4-(2-phenylethenyl)phenoxy]ethyl]azanium;bromide,CC[N+](CC)(CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2)CC3=CC=CC=C3.[Br-],,,,,,
12084,46779,Benzyl-diethyl-[2-[4-(2-phenylethenyl)phenoxy]ethyl]azanium,CC[N+](CC)(CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
12085,46780,(3-Hydroxyphenyl)benzyldimethylammonium bromide,C[N+](C)(CC1=CC=CC=C1)C2=CC(=CC=C2)O.[Br-],,,,,,
12086,46781,Dimethylbenzyl(3-hydroxyphenyl)aminium,C[N+](C)(CC1=CC=CC=C1)C2=CC(=CC=C2)O,,,,,,
12087,46782,"Ammonium, benzyldimethyl(2-(2-(p-1,1,3,3-tetramethylbutylphenoxy)ethoxy)ethyl)-, thiocyanate",CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.C(#N)[S-],,,,,,
12088,46783,Diethyl(2-hydroxyethyl)methylammonium iodide 4-biphenylylacetate,CC[N+](C)(CC)CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2.[I-],,,,,,
12089,46784,Diethyl-methyl-[2-[2-(4-phenylphenyl)acetyl]oxyethyl]azanium,CC[N+](C)(CC)CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
12090,46785,(2-Hydroxyethyl)triethylammonium iodide 4-biphenylylacetate,CC[N+](CC)(CC)CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2.[I-],,,,,,
12091,46786,Triethyl-[2-[2-(4-phenylphenyl)acetyl]oxyethyl]azanium,CC[N+](CC)(CC)CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
12092,46787,(2-(Biphenylyloxy)ethyl)diethylmethylammonium iodide,CC[N+](C)(CC)CCOC1=CC=CC=C1C2=CC=CC=C2.[I-],,,,,,
12093,46788,Diethyl-methyl-[2-(2-phenylphenoxy)ethyl]azanium,CC[N+](C)(CC)CCOC1=CC=CC=C1C2=CC=CC=C2,,,,,,
12094,46789,"Ammonium, (4,4'-biphenylylenebis(carbamoylmethylene))bis((2-hydroxyethyl)dimethyl-, dibromide",C[N+](C)(CCO)CNC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NC[N+](C)(C)CCO.[Br-].[Br-],,,,,,
12095,46790,2-Hydroxyethyl-[[[4-[4-[[2-hydroxyethyl(dimethyl)azaniumyl]methylcarbamoyl]phenyl]benzoyl]amino]methyl]-dimethylazanium,C[N+](C)(CCO)CNC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NC[N+](C)(C)CCO,,,,,,
12096,46791,Agn-PC-0jkviq,CC[N+](CC)(CC)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](CC)(CC)CC.[I-].[I-],,,,,,
12097,46792,Triethyl-[2-[4-[4-[2-oxo-2-(triethylazaniumyl)ethyl]phenyl]phenyl]acetyl]azanium,CC[N+](CC)(CC)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](CC)(CC)CC,,,,,,
12098,46793,3-Amino-1-(5-phenyl-1H-indol-3-yl)-1-butanone monohydrochloride,CC(CC(=O)C1=CNC2=C1C=C(C=C2)C3=CC=CC=C3)[NH3+].[Cl-],,,,,,
12099,46794,3-amino-1-(5-phenyl-1H-indol-3-yl)butan-1-one,CC(CC(=O)C1=CNC2=C1C=C(C=C2)C3=CC=CC=C3)N,,,,,,
12100,46795,"(2-Acetoxy-3,5-dimethyl)phenyltrimethylammonium bromide",CC1=CC(=C(C(=C1)[N+](C)(C)C)OC(=O)C)C.[Br-],,,,,,
12101,46796,"(2-Acetyloxy-3,5-dimethylphenyl)-trimethylazanium",CC1=CC(=C(C(=C1)[N+](C)(C)C)OC(=O)C)C,,,,,,
12102,46797,Adipic acid ester of formocholine,C[N+](C)(C)COC(=O)CCCCC(=O)OC[N+](C)(C)C.[I-].[I-],,,,,,
12103,46798,"N,N'-[Adipoylbis(oxymethylene)]bis(N,N-dimethylmethanaminium)",C[N+](C)(C)COC(=O)CCCCC(=O)OC[N+](C)(C)C,,,,,,
12104,46799,3-(p-Aminobenzoyloxy)phenyltrimethylammonium bromide,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC=C(C=C2)N.[Br-],,,,,,
12105,46800,[3-(4-Aminobenzoyl)oxyphenyl]-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)C2=CC=C(C=C2)N,,,,,,
12106,46801,3-Aminophenyltrimethylammonium iodide,C[N+](C)(C)C1=CC=CC(=C1)N.[I-],,,,,,
12107,46802,"3-Azabicyclo(3.3.1)nonane, 3-(4-(trimethylammonio)butyl)-, iodide",C[N+](C)(C)CCCCN1CC2CCCC(C2)C1.[I-],,,,,,
12108,46803,4-(3-Azabicyclo[3.3.1]nonan-3-yl)butyl-trimethylazanium,C[N+](C)(C)CCCCN1CC2CCCC(C2)C1,,,,,,
12109,46804,"3-Azabicyclo(3.3.1)nonane, 3-(2-(trimethylammonio)ethyl)-, iodide",C[N+](C)(C)CCN1CC2CCCC(C2)C1.[I-],,,,,,
12110,46805,2-(3-Azabicyclo[3.3.1]nonan-3-yl)ethyl-trimethylazanium,C[N+](C)(C)CCN1CC2CCCC(C2)C1,,,,,,
12111,46806,"3-Azabicyclo(3.3.1)nonane, 3-(3-(trimethylammonio)propyl)-, iodide",C[N+](C)(C)CCCN1CC2CCCC(C2)C1.[I-],,,,,,
12112,46807,3-(3-Azabicyclo[3.3.1]nonan-3-yl)propyl-trimethylazanium,C[N+](C)(C)CCCN1CC2CCCC(C2)C1,,,,,,
12113,46808,3-Tropanyl 4'-bromoatropate hydrochloride,C[NH+]1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)Br.[Cl-],,,,,,
12114,46809,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-bromophenyl)prop-2-enoate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)Br,,,,,,
12115,46810,3-Tropanyl 4'-tert-butylatropate hydrochloride hemihydrate,CC(C)(C)C1=CC=C(C=C1)C(=C)C(=O)OC2CC3CCC(C2)[NH+]3C.[Cl-],,,,,,
12116,46811,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-tert-butylphenyl)prop-2-enoate,CC(C)(C)C1=CC=C(C=C1)C(=C)C(=O)OC2CC3CCC(C2)N3C,,,,,,
12117,46812,"2'-Chloroatropic acid, 3-tropanyl ester, hydrochloride",C[NH+]1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=CC=C3Cl.[Cl-],,,,,,
12118,46813,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(2-chlorophenyl)prop-2-enoate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=CC=C3Cl,,,,,,
12119,46814,"3'-Chloroatropic acid, 3-tropanyl ester, hydrochloride",C[NH+]1C2CCC1CC(C2)OC(=O)C(=C)C3=CC(=CC=C3)Cl.[Cl-],,,,,,
12120,46815,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(3-chlorophenyl)prop-2-enoate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC(=CC=C3)Cl,,,,,,
12121,46816,"3-Tropanyl 2',6'-dichloroatropate hydrochloride",C[NH+]1C2CCC1CC(C2)OC(=O)C(=C)C3=C(C=CC=C3Cl)Cl.[Cl-],,,,,,
12122,46817,"3-Tropanyl 2-[2,6-dichlorophenyl]acrylate",CN1C2CCC1CC(C2)OC(=O)C(=C)C3=C(C=CC=C3Cl)Cl,,,,,,
12123,46818,2-(Diethylamino)ethyl ester alpha-phenylacrylic acid hydrochloride,CC[NH+](CC)CCOC(=O)C(=C)C1=CC=CC=C1.[Cl-],,,,,,
12124,46819,2-(Diethylamino)ethyl 2-phenylprop-2-enoate,CCN(CC)CCOC(=O)C(=C)C1=CC=CC=C1,,,,,,
12125,46820,3-Tropanyl 4'-methoxyatropate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)OC,,,,,,
12126,46821,1-Methyl-4-piperidyl alpha-phenylacrylate hydrochloride,C[NH+]1CCC(CC1)OC(=O)C(=C)C2=CC=CC=C2.[Cl-],,,,,,
12127,46822,(1-Methylpiperidin-4-yl) 2-phenylprop-2-enoate,CN1CCC(CC1)OC(=O)C(=C)C2=CC=CC=C2,,,,,,
12128,46823,3-Tropanyl 4'-(trifluoromethyl)atropate quarterhydrate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)C(F)(F)F.CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)C(F)(F)F.CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)C(F)(F)F.CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)C(F)(F)F.O,,,,,,
12129,46824,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-[4-(trifluoromethyl)phenyl]prop-2-enoate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)C(F)(F)F,,,,,,
12130,46825,1-(o-Chlorobenzyl)azabicyclo(3.2.2)nonane dihydrochloride,C1CC2CC[N+](C1)(CC2)CC3=CC=CC=C3Cl.[Cl-],,,,,,
12131,46826,1-[(2-Chlorophenyl)methyl]-1-azoniabicyclo[3.2.2]nonane,C1CC2CC[N+](C1)(CC2)CC3=CC=CC=C3Cl,,,,,,
12132,46827,1-Cyclohexylmethylazabicyclo(3.2.2)nonane dihydrochloride,C1CCC(CC1)C[N+]23CCCC(CC2)CC3.[Cl-],,,,,,
12133,46828,1-(Cyclohexylmethyl)-1-azoniabicyclo[3.2.2]nonane,C1CCC(CC1)C[N+]23CCCC(CC2)CC3,,,,,,
12134,46829,"3-Azabicyclo(3.2.1)octane, 2-ethyl-N-methyl-",CCC1C2CCC(C2)CN1C,,,,,,
12135,46830,"2-Azabicyclo(3.2.1)octane, 2,3,4,4-tetramethyl-",CC1C(C2CCC(C2)N1C)(C)C,,,,,,
12136,46831,"2,3,4-Trimethyl-3-azabicyclo[3.2.1]octane",CC1C2CCC(C2)C(N1C)C,,,,,,
12137,46832,"3-Azabicyclo(3.2.1)octane, 2,2,4-trimethyl-",CC1C2CCC(C2)C(N1)(C)C,,,,,,
12138,46833,"2-Azabicyclo(3.2.1)octane, 3,4,4-trimethyl-",CC1C(C2CCC(C2)N1)(C)C,,,,,,
12139,46834,"Arsonium, (3-(dimethylcarbamoyloxy)phenyl)trimethyl-, iodide",CN(C)C(=O)OC1=CC(=CC=C1)[As+](C)(C)C.[I-],,,,,,
12140,46835,[3-(Dimethylcarbamoyloxy)phenyl]-trimethylarsanium,CN(C)C(=O)OC1=CC(=CC=C1)[As+](C)(C)C,,,,,,
12141,46836,Dichloro(pent-4-enyl)arsane,C=CCCC[As](Cl)Cl,,,,,,
12142,46837,Dichloro(m-trifluoromethylphenyl)arsine,C1=CC(=CC(=C1)[As](Cl)Cl)C(F)(F)F,,,,,,
12143,46838,"Arsine, ethylidipropoxy-",CCCO[As](CC)OCCC,,,,,,
12144,46839,"Arsine oxide, (3-amino-4-(2-hydroxyethoxy)phenyl)-",C1=CC(=C(C=C1[As]=O)N)OCCO,,,,,,
12145,46840,"Arsine oxide, diphenylhydroxy-, nitrate",C1=CC=C(C=C1)[As](=O)(C2=CC=CC=C2)O[N+](=O)[O-],,,,,,
12146,46841,"Arsine, tri-2-furyl-",C1=COC(=C1)[As](C2=CC=CO2)C3=CC=CO3,,,,,,
12147,46842,"Arsine, trioctyl-",CCCCCCCC[As](CCCCCCCC)CCCCCCCC,,,,,,
12148,46843,"Tris(3,3,5-trimethylcyclohexyl)arsine",CC1CC(CC(C1)(C)C)[As](C2CC(CC(C2)(C)C)C)C3CC(CC(C3)(C)C)C,,,,,,
12149,46844,"ARSONIUM, DIETHYL(m-HYDROXYPHENYL)METHYL-, IODIDE",CC[As+](C)(CC)C1=CC=CC(=C1)O.[I-],,,,,,
12150,46845,Diethyl-(3-hydroxyphenyl)-methylarsanium,CC[As+](C)(CC)C1=CC=CC(=C1)O,,,,,,
12151,46846,"Arsonium, (3-(N-methylcarbamoyloxy)phenyl)trimethyl-, iodide",CC[As+](C)(CC)C1=CC=CC(=C1)OC(=O)NC.[I-],,,,,,
12152,46847,Diethyl-methyl-[3-(methylcarbamoyloxy)phenyl]arsanium,CC[As+](C)(CC)C1=CC=CC(=C1)OC(=O)NC,,,,,,
12153,46848,"Arsonium, (2-(N-methylcarbamoyloxy)phenyl)trimethyl-, iodide",CNC(=O)OC1=CC=CC=C1[As+](C)(C)C.[I-],,,,,,
12154,46849,Trimethyl-[2-(methylcarbamoyloxy)phenyl]arsanium,CNC(=O)OC1=CC=CC=C1[As+](C)(C)C,,,,,,
12155,46850,Iodomethyltrimethylarsonium iodide,C[As+](C)(C)CI.[I-],,,,,,
12156,46851,Iodomethyl(trimethyl)arsanium,C[As+](C)(C)CI,,,,,,
12157,46852,"Arsonium, tetra(4-aminophenyl)-, chloride",C1=CC(=CC=C1N)[As+](C2=CC=C(C=C2)N)(C3=CC=C(C=C3)N)C4=CC=C(C=C4)N.[Cl-],,,,,,
12158,46853,Tetrakis(4-aminophenyl)arsanium,C1=CC(=CC=C1N)[As+](C2=CC=C(C=C2)N)(C3=CC=C(C=C3)N)C4=CC=C(C=C4)N,,,,,,
12159,46854,CID 46854,C1=CC(=CC=C1C(=O)NC(CC(=O)O)C(=O)[O-])NCC2=CN=C3C(=N2)C(=NC(=N3)N)N.[Na+],,,,,,
12160,46855,Aminoanfol,C1=CC(=CC=C1C(=O)NC(CC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,,,,,,
12161,46856,"Arsine, butylchloroethyl-",CCCC[As](CC)Cl,,,,,,
12162,46857,"Arsine, butylcyanoethyl-",CCCC[As](CC)C#N,,,,,,
12163,46858,Chloro-(2-chloroethenyl)-phenylarsane,C1=CC=C(C=C1)[As](C=CCl)Cl,,,,,,
12164,46859,"Arsine, chlorodi(2-furyl)-",C1=COC(=C1)[As](C2=CC=CO2)Cl,,,,,,
12165,46860,"Arsine, (2-chloroethylthio)dimethyl-",C[As](C)SCCCl,,,,,,
12166,46861,Bis(methylthio)(2-chlorovinyl)arsine,CS[As](C=CCl)SC,,,,,,
12167,46862,2-Chloroethenyl(dimethoxy)arsane,CO[As](C=CCl)OC,,,,,,
12168,46863,"Arsine, cyanodi(2-furyl)-",C1=COC(=C1)[As](C#N)C2=CC=CO2,,,,,,
12169,46864,CID 46864,CCCC(=C[As](Cl)Cl)Cl,,,,,,
12170,46865,"Arsine, dichloro(4-ethoxy-3,5-dinitrophenyl)-",CCOC1=C(C=C(C=C1[N+](=O)[O-])[As](Cl)Cl)[N+](=O)[O-],,,,,,
12171,46866,"Arsine, dichloro(2-ethoxyethyl)-",CCOCC[As](Cl)Cl,,,,,,
12172,46867,"Arsine, dichloroheptyl-",CCCCCCC[As](Cl)Cl,,,,,,
12173,46868,"Arsine, dichlorohexyl-",CCCCCC[As](Cl)Cl,,,,,,
12174,46869,"Arsine, dichloroisopentyl-",CC(C)CC[As](Cl)Cl,,,,,,
12175,46870,"Arsine, dichloro(2-methoxyethyl)-",COCC[As](Cl)Cl,,,,,,
12176,46871,(2-Methylbutyl)dichloroarsine,CCC(C)C[As](Cl)Cl,,,,,,
12177,46872,2-(Hydroxymercuri)-4-nitroaniline,C1=CC(=C(C=C1[N+](=O)[O-])[Hg])N.O,,,,,,
12178,46873,"4,4'-Methylene-bis(2-chloroaniline) hydrochloride",C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)[NH3+].[Cl-],,,,,,
12179,46874,"Aniline, 4-taurylsulfamoyl-",C1=CC(=CC=C1N)S(=O)(=O)NS(=O)(=O)CCN,,,,,,
12180,46875,"Acetamide, N,N'-(2-hydroxy-1,3-propylene)bis(chloro-",C(C(CNC(=O)CCl)O)NC(=O)CCl,,,,,,
12181,46876,"Acetamide, N,N'-(2-hydroxy-1,3-propylene)bis(iodo-",C(C(CNC(=O)CI)O)NC(=O)CI,,,,,,
12182,46877,3-Acetamino-9-methylcarbazole hydrochloride,CC(=O)NC1=CC=CC2=C1[NH+](C3=CC=CC=C23)C.[Cl-],,,,,,
12183,46878,N-(9-methylcarbazol-1-yl)acetamide,CC(=O)NC1=CC=CC2=C1N(C3=CC=CC=C23)C,,,,,,
12184,46879,"Ammonium, (1,4-phenylenebis(oxyethylene))bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCOC1=CC=C(C=C1)OCC[N+](C)(CC)CC.[I-].[I-],,,,,,
12185,46880,2-[4-[2-[Diethyl(methyl)azaniumyl]ethoxy]phenoxy]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCOC1=CC=C(C=C1)OCC[N+](C)(CC)CC,,,,,,
12186,46881,"Ammonium, (1,4-phenylenebis(oxyethylene))bis(trimethyl-, diiodide",C[N+](C)(C)CCOC1=CC=C(C=C1)OCC[N+](C)(C)C.[I-].[I-],,,,,,
12187,46882,Trimethyl-[2-[4-[2-(trimethylazaniumyl)ethoxy]phenoxy]ethyl]azanium,C[N+](C)(C)CCOC1=CC=C(C=C1)OCC[N+](C)(C)C,,,,,,
12188,46883,beta-Phenylethyltriethylammonium iodide,CC[N+](CC)(CC)CCC1=CC=CC=C1.[I-],,,,,,
12189,46884,"Benzeneethanaminium, N,N,N-triethyl-",CC[N+](CC)(CC)CCC1=CC=CC=C1,,,,,,
12190,46885,"AMMONIUM, OCTADECYLTRIMETHYL-, p-FLUOROBENZENESULFONATE",CCCCCCCCCCCCCCCCCC[N+](C)(C)C.C1=CC(=CC=C1F)S(=O)(=O)[O-],,,,,,
12191,46886,4-Fluorobenzenesulphonic acid,C1=CC(=CC=C1F)S(=O)(=O)O,,,,,,
12192,46887,"Ammonium, (oxybis(p-phenylylene)bis(2-oxoethylene))bis((2-hydroxyethyl)dimethyl-, dibromide",C[N+](C)(CCO)CC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C[N+](C)(C)CCO.[Br-].[Br-],,,,,,
12193,46888,2-Hydroxyethyl-[2-[4-[4-[2-[2-hydroxyethyl(dimethyl)azaniumyl]acetyl]phenoxy]phenyl]-2-oxoethyl]-dimethylazanium,C[N+](C)(CCO)CC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C[N+](C)(C)CCO,,,,,,
12194,46889,"Ammonium, oxybis(1,2-propylene)bis(ethyldimethyl-, dibromide",CC[N+](C)(C)CC(C)OC(C)C[N+](C)(C)CC.[Br-].[Br-],,,,,,
12195,46890,Ethyl-[2-[1-[ethyl(dimethyl)azaniumyl]propan-2-yloxy]propyl]-dimethylazanium,CC[N+](C)(C)CC(C)OC(C)C[N+](C)(C)CC,,,,,,
12196,46891,"Ammonium, oxybis(1,2-propylene)bis(trimethyl-, diiodide",CC(C[N+](C)(C)C)OC(C)C[N+](C)(C)C.[I-].[I-],,,,,,
12197,46892,Trimethyl-[2-[1-(trimethylazaniumyl)propan-2-yloxy]propyl]azanium,CC(C[N+](C)(C)C)OC(C)C[N+](C)(C)C,,,,,,
12198,46893,"Ammonium, oxybis(trimethylene)bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCCOCCC[N+](C)(CC)CC.[I-].[I-],,,,,,
12199,46894,3-[3-[Diethyl(methyl)azaniumyl]propoxy]propyl-diethyl-methylazanium,CC[N+](C)(CC)CCCOCCC[N+](C)(CC)CC,,,,,,
12200,46895,"Ammonium, oxybis(trimethylene)bis(ethyldimethyl-, dibromide",CC[N+](C)(C)CCCOCCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
12201,46896,Ethyl-[3-[3-[ethyl(dimethyl)azaniumyl]propoxy]propyl]-dimethylazanium,CC[N+](C)(C)CCCOCCC[N+](C)(C)CC,,,,,,
12202,46897,"Ammonium, oxybis(trimethylene)bis(triethyl-, dibromide",CC[N+](CC)(CC)CCCOCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
12203,46898,Triethyl-[3-[3-(triethylazaniumyl)propoxy]propyl]azanium,CC[N+](CC)(CC)CCCOCCC[N+](CC)(CC)CC,,,,,,
12204,46899,"Ammonium, oxybis(trimethylene)bis(trimethyl-, diiodide",C[N+](C)(C)CCCOCCC[N+](C)(C)C.[I-].[I-],,,,,,
12205,46900,Trimethyl-[3-[3-(trimethylazaniumyl)propoxy]propyl]azanium,C[N+](C)(C)CCCOCCC[N+](C)(C)C,,,,,,
12206,46901,"Ammonium, oxydiethylenebis(allyldimethyl-, dibromide",C[N+](C)(CCOCC[N+](C)(C)CC=C)CC=C.[Br-].[Br-],,,,,,
12207,46902,2-[2-[Dimethyl(prop-2-enyl)azaniumyl]ethoxy]ethyl-dimethyl-prop-2-enylazanium,C[N+](C)(CCOCC[N+](C)(C)CC=C)CC=C,,,,,,
12208,46903,"Ammonium, oxydiethylenebis(butyldimethyl-, dibromide",CCCC[N+](C)(C)CCOCC[N+](C)(C)CCCC.[Br-].[Br-],,,,,,
12209,46904,Butyl-[2-[2-[butyl(dimethyl)azaniumyl]ethoxy]ethyl]-dimethylazanium,CCCC[N+](C)(C)CCOCC[N+](C)(C)CCCC,,,,,,
12210,46905,"Ammonium, oxydiethylenebis(dimethylethoxycarbonylethyl-, dichloride",CCOC(=O)CC[N+](C)(C)CCOCC[N+](C)(C)CCC(=O)OCC.[Cl-].[Cl-],,,,,,
12211,46906,(3-Ethoxy-3-oxopropyl)-[2-[2-[(3-ethoxy-3-oxopropyl)-dimethylazaniumyl]ethoxy]ethyl]-dimethylazanium,CCOC(=O)CC[N+](C)(C)CCOCC[N+](C)(C)CCC(=O)OCC,,,,,,
12212,46907,"Ammonium, oxydiethylenebis(dimethylethyl-, dibromide",CC[N+](C)(C)CCOCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
12213,46908,Ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]ethyl]-dimethylazanium,CC[N+](C)(C)CCOCC[N+](C)(C)CC,,,,,,
12214,46909,"Ammonium, oxydiethylenebis(dimethyloctyl-, dibromide",CCCCCCCC[N+](C)(C)CCOCC[N+](C)(C)CCCCCCCC.[Br-].[Br-],,,,,,
12215,46910,2-[2-[Dimethyl(octyl)azaniumyl]ethoxy]ethyl-dimethyl-octylazanium,CCCCCCCC[N+](C)(C)CCOCC[N+](C)(C)CCCCCCCC,,,,,,
12216,46911,"Ammonium, oxydiethylenebis(dimethylpropyl-, dibromide",CCC[N+](C)(C)CCOCC[N+](C)(C)CCC.[Br-].[Br-],,,,,,
12217,46912,2-[2-[Dimethyl(propyl)azaniumyl]ethoxy]ethyl-dimethyl-propylazanium,CCC[N+](C)(C)CCOCC[N+](C)(C)CCC,,,,,,
12218,46913,"Ammonium, oxydiethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCOCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
12219,46914,Triethyl-[2-[2-(triethylazaniumyl)ethoxy]ethyl]azanium,CC[N+](CC)(CC)CCOCC[N+](CC)(CC)CC,,,,,,
12220,46915,(3-Phenylacetoxy)phenyltrimethylammonium bromide,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)CC2=CC=CC=C2.[Br-],,,,,,
12221,46916,Trimethyl-[3-(2-phenylacetyl)oxyphenyl]azanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)CC2=CC=CC=C2,,,,,,
12222,46917,(Phenylcyanomethyl)-triethylammonium bromide,CC[N+](CC)(CC)C(C#N)C1=CC=CC=C1.[Br-],,,,,,
12223,46918,[Cyano(phenyl)methyl]-triethylazanium,CC[N+](CC)(CC)C(C#N)C1=CC=CC=C1,,,,,,
12224,46919,"Carbamic acid, methyl-, 5-trimethylammonio-2,4-xylyl ester, iodide",CC1=CC(=C(C=C1[N+](C)(C)C)OC(=O)NC)C.[I-],,,,,,
12225,46920,"5-[[(Methylamino)carbonyl]oxy]-N,N,N,2,4-pentamethylbenzenaminium",CC1=CC(=C(C=C1[N+](C)(C)C)OC(=O)NC)C,,,,,,
12226,46921,"(2-Methoxy-4,6-dimethyl-m-xylene)bis(benzyldimethylammonium chloride)",CC1=CC(=C(C(=C1C[N+](C)(C)CC2=CC=CC=C2)OC)C[N+](C)(C)CC3=CC=CC=C3)C.[Cl-].[Cl-],,,,,,
12227,46922,"Benzyl-[[3-[[benzyl(dimethyl)azaniumyl]methyl]-2-methoxy-4,6-dimethylphenyl]methyl]-dimethylazanium",CC1=CC(=C(C(=C1C[N+](C)(C)CC2=CC=CC=C2)OC)C[N+](C)(C)CC3=CC=CC=C3)C,,,,,,
12228,46923,"Carbamic acid, (p-methoxyphenyl)-, m-(trimethylammonio)phenyl ester, iodide",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC2=CC=C(C=C2)OC.[I-],,,,,,
12229,46924,[3-[(4-Methoxyphenyl)carbamoyloxy]phenyl]-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC2=CC=C(C=C2)OC,,,,,,
12230,46925,Ciba derivative 9646,CN(CCC[N+](C)(C)C)CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
12231,46926,Trimethyl-[3-[methyl-[3-(trimethylazaniumyl)propyl]amino]propyl]azanium,CN(CCC[N+](C)(C)C)CCC[N+](C)(C)C,,,,,,
12232,46927,"AMMONIUM, (m-(N-METHYLCARBAMOYLMETHOXY)PHENYL)TRIMETHYL-, METHYLSULFATE",CNC(=O)COC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
12233,46928,Trimethyl-[3-[2-(methylamino)-2-oxoethoxy]phenyl]azanium,CNC(=O)COC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
12234,46929,"Ammonium, (methylenebis(p-phenylene)bis(2-oxoethylene))bis((2-hydroxyethyl)dimethyl-, dibromide",C[N+](C)(CCO)C(=O)CC1=CC=C(C=C1)CC2=CC=C(C=C2)CC(=O)[N+](C)(C)CCO.[Br-].[Br-],,,,,,
12235,46930,2-Hydroxyethyl-[2-[4-[[4-[2-[2-hydroxyethyl(dimethyl)azaniumyl]-2-oxoethyl]phenyl]methyl]phenyl]acetyl]-dimethylazanium,C[N+](C)(CCO)C(=O)CC1=CC=C(C=C1)CC2=CC=C(C=C2)CC(=O)[N+](C)(C)CCO,,,,,,
12236,46931,"Ammonium, methyliminodiethylenebis(bis(2-hydroxyethyl)methyl-, dichloride",CN(CC[N+](C)(CCO)CCO)CC[N+](C)(CCO)CCO.[Cl-].[Cl-],,,,,,
12237,46932,2-[2-[Bis(2-hydroxyethyl)-methylazaniumyl]ethyl-methylamino]ethyl-bis(2-hydroxyethyl)-methylazanium,CN(CC[N+](C)(CCO)CCO)CC[N+](C)(CCO)CCO,,,,,,
12238,46933,"Ammonium, N-methyl-N,N,N',N',N'-pentaethyl-N,N'-oxydiethylenedi-, dibromide",CC[N+](C)(CC)CCOCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
12239,46934,Diethyl-methyl-[2-[2-(triethylazaniumyl)ethoxy]ethyl]azanium,CC[N+](C)(CC)CCOCC[N+](CC)(CC)CC,,,,,,
12240,46935,Methyl-(phenylcyanomethyl)-diethylammonium iodide,CC[N+](C)(CC)C(C#N)C1=CC=CC=C1.[I-],,,,,,
12241,46936,[Cyano(phenyl)methyl]-diethyl-methylazanium,CC[N+](C)(CC)C(C#N)C1=CC=CC=C1,,,,,,
12242,46937,"Ammonium, (2-methyl-2-(2-(triethylammonio)ethoxy)ethyl)ethyldimethyl-, dibromide",CC[N+](C)(C)CC(C)OCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
12243,46938,Triethyl-[2-[1-[ethyl(dimethyl)azaniumyl]propan-2-yloxy]ethyl]azanium,CC[N+](C)(C)CC(C)OCC[N+](CC)(CC)CC,,,,,,
12244,46939,"Ammonium, ((1-methyl-2-(triethylammonio)ethoxy)ethyl)triethyl-, diiodide",CC[N+](CC)(CC)CCOC(C)C[N+](CC)(CC)CC.[I-].[I-],,,,,,
12245,46940,Triethyl-[2-[2-(triethylazaniumyl)ethoxy]propyl]azanium,CC[N+](CC)(CC)CCOC(C)C[N+](CC)(CC)CC,,,,,,
12246,46941,"Ammonium, ((1-methyl-2-(trimethylammonio)ethoxy)ethyl)trimethyl-, diiodide",CC(C[N+](C)(C)C)OCC[N+](C)(C)C.[I-].[I-],,,,,,
12247,46942,Trimethyl-[2-[2-(trimethylazaniumyl)ethoxy]propyl]azanium,CC(C[N+](C)(C)C)OCC[N+](C)(C)C,,,,,,
12248,46943,"Carbamic acid, methyl-, (5-(benzyldimethylammonio)-o-tolyl) ester, chloride",CC1=C(C=C(C=C1)[N+](C)(C)CC2=CC=CC=C2)OC(=O)NC.[Cl-],,,,,,
12249,46944,Benzyl-dimethyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]azanium,CC1=C(C=C(C=C1)[N+](C)(C)CC2=CC=CC=C2)OC(=O)NC,,,,,,
12250,46945,"Ammonium, (3-dimethylcarbamoyloxy-p-tolyl)diethylmethyl-, iodide",CC[N+](C)(CC)C1=CC(=C(C=C1)C)OC(=O)N(C)C.[I-],,,,,,
12251,46946,[3-(Dimethylcarbamoyloxy)-4-methylphenyl]-diethyl-methylazanium,CC[N+](C)(CC)C1=CC(=C(C=C1)C)OC(=O)N(C)C,,,,,,
12252,46947,"Carbamic acid, dimethyl-, p-(diethylmethylammonio)-m-tolyl ester, iodide",CC[N+](C)(CC)C1=C(C=C(C=C1)OC(=O)N(C)C)C.[I-],,,,,,
12253,46948,[4-(Dimethylcarbamoyloxy)-2-methylphenyl]-diethyl-methylazanium,CC[N+](C)(CC)C1=C(C=C(C=C1)OC(=O)N(C)C)C,,,,,,
12254,46949,"Carbamic acid, methyl-, (5-(diethylmethylammonio)-o-tolyl) ester, iodide",CC[N+](C)(CC)C1=CC(=C(C=C1)C)OC(=O)NC.[I-],,,,,,
12255,46950,Diethyl-methyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(CC)C1=CC(=C(C=C1)C)OC(=O)NC,,,,,,
12256,46951,"Ammonium, (4-methylcarbamoyloxy-o-tolyl)diethylmethyl-, iodide",CC[N+](C)(CC)C1=C(C=C(C=C1)OC(=O)NC)C.[I-],,,,,,
12257,46952,Diethyl-methyl-[2-methyl-4-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(CC)C1=C(C=C(C=C1)OC(=O)NC)C,,,,,,
12258,46953,"Ammonium, (3-(methylcarbamoyloxy)-p-tolyl)dimethyl(ethoxycarbonylmethyl)-, chloride",CCOC(=O)C[N+](C)(C)C1=CC(=C(C=C1)C)OC(=O)NC.[Cl-],,,,,,
12259,46954,(2-Ethoxy-2-oxoethyl)-dimethyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]azanium,CCOC(=O)C[N+](C)(C)C1=CC(=C(C=C1)C)OC(=O)NC,,,,,,
12260,46955,"Carbamic acid, methyl-, (5-(dimethylethylammonio)-o-tolyl) ester, chloride",CC[N+](C)(C)C1=CC(=C(C=C1)C)OC(=O)NC.[Cl-],,,,,,
12261,46956,"Carbamic acid, dimethyl-, p-(dimethylethylammonio)-m-tolyl ester, iodide",CC[N+](C)(C)C1=C(C=C(C=C1)OC(=O)N(C)C)C.[I-],,,,,,
12262,46957,[4-(Dimethylcarbamoyloxy)-2-methylphenyl]-ethyl-dimethylazanium,CC[N+](C)(C)C1=C(C=C(C=C1)OC(=O)N(C)C)C,,,,,,
12263,46958,"Ammonium, (4-methylcarbamoyloxy-o-tolyl)dimethylethyl-, iodide",CC[N+](C)(C)C1=C(C=C(C=C1)OC(=O)NC)C.[I-],,,,,,
12264,46959,Ethyl-dimethyl-[2-methyl-4-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(C)C1=C(C=C(C=C1)OC(=O)NC)C,,,,,,
12265,46960,"Ammonium, (3-(methylcarbamoyloxy)-p-tolyl)dimethyl(2-hydroxyethyl)-, iodide",CC1=C(C=C(C=C1)[N+](C)(C)CCO)OC(=O)NC.[I-],,,,,,
12266,46961,2-Hydroxyethyl-dimethyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]azanium,CC1=C(C=C(C=C1)[N+](C)(C)CCO)OC(=O)NC,,,,,,
12267,46962,"AMMONIUM, (3-HYDROXY-p-TOLYL)TRIMETHYL-, BISULFATE, METHYLCARBAMATE",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)NC.OS(=O)(=O)[O-],,,,,,
12268,46963,"Carbamic acid, methyl-, 4-(trimethylammonio)benzyl ester, chloride",CNC(=O)OCC1=CC=C(C=C1)[N+](C)(C)C.[Cl-],,,,,,
12269,46964,Trimethyl-[4-(methylcarbamoyloxymethyl)phenyl]azanium,CNC(=O)OCC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
12270,46965,"Carbamic acid, methyl-, 5-(trimethylammonio)-o-tolyl ester, chloride",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)NC.[Cl-],,,,,,
12271,46966,4-Hydroxymethylphenyltrimethylammonium iodide,C[N+](C)(C)C1=CC=C(C=C1)CO.[I-],,,,,,
12272,46967,[4-(Hydroxymethyl)phenyl]-trimethylazanium,C[N+](C)(C)C1=CC=C(C=C1)CO,,,,,,
12273,46968,"Ammonium, (m-carbamoyloxyphenyl)trimethyl-, iodide",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N.[I-],,,,,,
12274,46969,(3-Carbamoyloxy-4-methylphenyl)-trimethylazanium,CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N,,,,,,
12275,46970,"Ammonium, (2-(dimethylcarbamoyloxy)-3-tolyl)trimethyl-, iodide",CC1=C(C(=CC=C1)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
12276,46971,[2-(Dimethylcarbamoyloxy)-3-methylphenyl]-trimethylazanium,CC1=C(C(=CC=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
12277,46972,"Ammonium, (3-dimethylcarbamoyloxy-p-tolyl)trimethyl-, iodide",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
12278,46973,[3-(Dimethylcarbamoyloxy)-4-methylphenyl]-trimethylazanium,CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
12279,46974,"Carbamic acid, dimethyl-, p-(trimethylammonio)-o-tolyl ester, iodide",CC1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
12280,46975,[4-(Dimethylcarbamoyloxy)-3-methylphenyl]-trimethylazanium,CC1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
12281,46976,"Carbamic acid, dimethyl-, p-(trimethylammonio)-m-tolyl ester, iodide",CC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
12282,46977,[4-(Dimethylcarbamoyloxy)-2-methylphenyl]-trimethylazanium,CC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
12283,46978,"AMMONIUM, (3-HYDROXY-p-TOLYL)TRIMETHYL-, IODIDE, N-METHOXY-N-METHYLCARBAMATE",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N(C)OC.[I-],,,,,,
12284,46979,[3-[Methoxy(methyl)carbamoyl]oxy-4-methylphenyl]-trimethylazanium,CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N(C)OC,,,,,,
12285,46980,"Ammonium, (3-methylcarbamoyloxy-m-tolyl)trimethyl-, iodide",CC1=CC(=CC(=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
12286,46981,"3-[[(Methylamino)carbonyl]oxy]-N,N,N,5-tetramethylbenzenaminium",CC1=CC(=CC(=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
12287,46982,"AMMONIUM, (4-HYDROXY-o-TOLYL)TRIMETHYL-, IODIDE, METHYLCARBAMATE",CC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
12288,46983,Trimethyl-[2-methyl-4-(methylcarbamoyloxy)phenyl]azanium,CC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
12289,46984,"Ammonium, (3-piperidinocarbonyloxy-p-tolyl)trimethyl-, iodide",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N2CCCCC2.[I-],,,,,,
12290,46985,Trimethyl-[4-methyl-3-(piperidine-1-carbonyloxy)phenyl]azanium,CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)N2CCCCC2,,,,,,
12291,46986,"Ammonium, (4-methylcarbamoyloxy-2,5-xylyl)dimethylethyl-, iodide",CC[N+](C)(C)C1=C(C=C(C(=C1)C)OC(=O)NC)C.[I-],,,,,,
12292,46987,"[2,5-Dimethyl-4-(methylcarbamoyloxy)phenyl]-ethyl-dimethylazanium",CC[N+](C)(C)C1=C(C=C(C(=C1)C)OC(=O)NC)C,,,,,,
12293,46988,Ethoxypropylacrylate,CCOCCCOC(=O)C=C,,,,,,
12294,46989,Ethyl 3-(phenylthio)acrylate,CCOC(=O)C=CSC1=CC=CC=C1,,,,,,
12295,46990,"Adamantane, 5,7-dimethyl-1-(2-methylaminopropyl)-2-phenyl-, hydrochloride",CC(CC12CC3(CC(C1C4=CC=CC=C4)CC(C3)(C2)C)C)NC.Cl,,,,,,
12296,46991,"1-(5,7-dimethyl-2-phenyl-1-adamantyl)-N-methylpropan-2-amine",CC(CC12CC3(CC(C1C4=CC=CC=C4)CC(C3)(C2)C)C)NC,,,,,,
12297,46992,"Adamantane, 1-(2-(4-hydroxypiperazinyl)propyl)-, dihydrochloride",CC(CC12CC3CC(C1)CC(C3)C2)N4CCN(CC4)O.Cl.Cl,,,,,,
12298,46993,1-[1-(1-Adamantyl)propan-2-yl]-4-hydroxypiperazine,CC(CC12CC3CC(C1)CC(C3)C2)N4CCN(CC4)O,,,,,,
12299,46994,CID 46994,CC1=C2C(=C(C=C1)C)[AsH]C3=C(N2Cl)C4=CC=CC=C4C=C3,,,,,,
12300,46995,1-(4-Benzoylphenoxy)-3-(4-phenylpiperazinyl)propan-2-ol dihydrochloride,C1CN(CCN1CC(COC2=CC=CC(=C2O)C(=O)C3=CC=CC=C3)O)C4=CC=CC=C4.Cl.Cl,,,,,,
12301,46996,[2-Hydroxy-3-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]phenyl]-phenylmethanone,C1CN(CCN1CC(COC2=CC=CC(=C2O)C(=O)C3=CC=CC=C3)O)C4=CC=CC=C4,,,,,,
12302,46997,12H-benzo[b]phenoselenazine,C1=CC=C2C=C3C(=CC2=C1)NC4=CC=CC=C4[Se]3,,,,,,
12303,46998,1-Methyl-2-(2'-methylpiperidino)ethyl benzoate,CC1CCCCN1CC(C)OC(=O)C2=CC=CC=C2,,,,,,
12304,46999,3-Methyl-3-(4'-methylpiperidino)propyl benzoate,CC1CCN(CC1)C(C)CCOC(=O)C2=CC=CC=C2,,,,,,
12305,47000,4-(2'-Methylpiperidino)butyl benzoate,CC1CCCCN1CCCCOC(=O)C2=CC=CC=C2,,,,,,
12306,47001,2-(2'-(2''-Methylpiperidino)ethoxy)ethyl benzoate,CC1CCCCN1CCOCCOC(=O)C2=CC=CC=C2,,,,,,
12307,47002,6-(2'-Methylpiperidino)hexyl benzoate,CC1CCCCN1CCCCCCOC(=O)C2=CC=CC=C2,,,,,,
12308,47003,5-(2'-Methylpiperidino)pentyl benzoate,CC1CCCCN1CCCCCOC(=O)C2=CC=CC=C2,,,,,,
12309,47004,CID 47004,CC=CCCC1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
12310,47005,3-(2'-Methylpiperidino)propyl p-pentoxybenzoate,CCCCCOC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
12311,47006,3-(2-Pentylpiperidin-1-yl)propyl benzoate,CCCCCC1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
12312,47007,3-(2'-Methylpiperidino)propyl p-phenethyloxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OCCC3=CC=CC=C3,,,,,,
12313,47008,3-(2-Methylpiperidin-1-yl)propyl 4-phenoxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3,,,,,,
12314,47009,3-(2-Methylpiperidin-1-yl)propyl 4-phenylbenzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
12315,47010,CID 47010,C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)NC3=CC=C(C=C3)C(=O)[O-])O.[Na+],,,,,,
12316,47011,4-[(2-Hydroxy-3-phenylbenzoyl)amino]benzoic acid,C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)O,,,,,,
12317,47012,3-(2-Methylpiperidin-1-yl)propyl 4-propoxybenzoate,CCCOC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
12318,47013,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, ETHYLMETHYLCARBAMATE",CCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
12319,47014,[3-[Ethyl(methyl)carbamoyl]oxyphenyl]-trimethylazanium,CCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
12320,47015,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, METHYLCARBAMATE",CNC(=O)OC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
12321,47016,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, METHYLPHENYLCARBAMATE",CN(C1=CC=CC=C1)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
12322,47017,Trimethyl-[3-[methyl(phenyl)carbamoyl]oxyphenyl]azanium,CN(C1=CC=CC=C1)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C,,,,,,
12323,47018,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, PENTAMETHYLENECARBAMATE",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N2CCCCC2.COS(=O)(=O)[O-],,,,,,
12324,47019,Trimethyl-[3-(piperidine-1-carbonyloxy)phenyl]azanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N2CCCCC2,,,,,,
12325,47020,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, PHENYLCARBAMATE",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2.COS(=O)(=O)[O-],,,,,,
12326,47021,"N,N,N-trimethyl-3-(phenylcarbamoyloxy)benzenaminium methyl sulfate",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,,,,,,
12327,47022,"Carbamic acid, dimethyl-, ((4-trimethylammonio)-3-propyl)phenyl ester, iodide",CCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
12328,47023,[4-(Dimethylcarbamoyloxy)-2-propylphenyl]-trimethylazanium,CCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
12329,47024,"Carbamic acid, methyl-, ((3-propyl-4-trimethylammonio)phenyl) ester, iodide",CCCC1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)NC.[I-],,,,,,
12330,47025,Trimethyl-[4-(methylcarbamoyloxy)-3-propylphenyl]azanium,CCCC1=C(C=CC(=C1)[N+](C)(C)C)OC(=O)NC,,,,,,
12331,47026,"Ammonium, (2-hydroxypropyl)trimethyl-, chloride, ethyl ether",CCOC(C)C[N+](C)(C)C.[Cl-],,,,,,
12332,47027,2-Ethoxypropyl(trimethyl)azanium,CCOC(C)C[N+](C)(C)C,,,,,,
12333,47028,"Carbamic acid, 3-(trimethylammonio)propyl ester, iodide",C[N+](C)(C)CCCOC(=O)N.[I-],,,,,,
12334,47029,3-Carbamoyloxypropyl(trimethyl)azanium,C[N+](C)(C)CCCOC(=O)N,,,,,,
12335,47030,"Carbamic acid, methyl-, (5-dimethylethylammonio)carvacryl ester, iodide",CC[N+](C)(C)C1=C(C=CC(=C1OC(=O)NC)C)C(C)C.[I-],,,,,,
12336,47031,Ethyl-dimethyl-[3-methyl-2-(methylcarbamoyloxy)-6-propan-2-ylphenyl]azanium,CC[N+](C)(C)C1=C(C=CC(=C1OC(=O)NC)C)C(C)C,,,,,,
12337,47032,"Carbamic acid, dimethyl-, (5-trimethylammonio)carvacryl ester, iodide",CC1=C(C(=C(C=C1)C(C)C)[N+](C)(C)C)OC(=O)N(C)C.[I-],,,,,,
12338,47033,[2-(Dimethylcarbamoyloxy)-3-methyl-6-propan-2-ylphenyl]-trimethylazanium,CC1=C(C(=C(C=C1)C(C)C)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
12339,47034,"4-Morpholinecarboxylic acid, 5-(trimethylammonio)carvacryl ester, iodide",CC1=C(C(=C(C=C1)C(C)C)[N+](C)(C)C)OC(=O)N2CCOCC2.[I-],,,,,,
12340,47035,Trimethyl-[3-methyl-2-(morpholine-4-carbonyloxy)-6-propan-2-ylphenyl]azanium,CC1=C(C(=C(C=C1)C(C)C)[N+](C)(C)C)OC(=O)N2CCOCC2,,,,,,
12341,47036,"1-Piperidinecarboxylic acid, 5-(trimethylammonio)carvacryl ester, iodide",CC1=C(C(=C(C=C1)C(C)C)[N+](C)(C)C)OC(=O)N2CCCCC2.[I-],,,,,,
12342,47037,Trimethyl-[3-methyl-2-(piperidine-1-carbonyloxy)-6-propan-2-ylphenyl]azanium,CC1=C(C(=C(C=C1)C(C)C)[N+](C)(C)C)OC(=O)N2CCCCC2,,,,,,
12343,47038,"Carbamic acid, methyl-, (5-(acetonyldimethylammonio)-o-tolyl) ester, chloride",CC1=C(C=C(C=C1)[N+](C)(C)CC(=O)C)OC(=O)NC.[Cl-],,,,,,
12344,47039,Dimethyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]-(2-oxopropyl)azanium,CC1=C(C=C(C=C1)[N+](C)(C)CC(=O)C)OC(=O)NC,,,,,,
12345,47040,"Carbamic acid, methyl-, (5-(allyldimethylammonio)-o-tolyl) ester, chloride",CC1=C(C=C(C=C1)[N+](C)(C)CC=C)OC(=O)NC.[Cl-],,,,,,
12346,47041,Dimethyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]-prop-2-enylazanium,CC1=C(C=C(C=C1)[N+](C)(C)CC=C)OC(=O)NC,,,,,,
12347,47042,"Ammonium, (4-methylcarbamoyloxy-o-tolyl)allyldimethyl-, iodide",CC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)CC=C.[I-],,,,,,
12348,47043,Dimethyl-[2-methyl-4-(methylcarbamoyloxy)phenyl]-prop-2-enylazanium,CC1=C(C=CC(=C1)OC(=O)NC)[N+](C)(C)CC=C,,,,,,
12349,47044,"AMMONIUM, 5-HYDROXY-m-PHENYLENEBIS(TRIMETHYL-, DICHLORIDE",C[N+](C)(C)C1=CC(=CC(=C1)O)[N+](C)(C)C.[Cl-].[Cl-],,,,,,
12350,47045,[3-Hydroxy-5-(trimethylazaniumyl)phenyl]-trimethylazanium,C[N+](C)(C)C1=CC(=CC(=C1)O)[N+](C)(C)C,,,,,,
12351,47046,"Ammonium, 2-hydroxy-1,4-phenylenebis(trimethyl-, diiodide, methylcarbamate",CNC(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)[N+](C)(C)C.[I-].[I-],,,,,,
12352,47047,"N,N,N,N',N',N'-Hexamethyl-2-[[(methylamino)carbonyl]oxy]-1,4-benzenediaminium",CNC(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)[N+](C)(C)C,,,,,,
12353,47048,"Carbamic acid, methyl-, 2-(1-(trimethylammonio)propyl)phenyl ester, iodide",CCC(C1=CC=CC=C1OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
12354,47049,Trimethyl-[1-[2-(methylcarbamoyloxy)phenyl]propyl]azanium,CCC(C1=CC=CC=C1OC(=O)NC)[N+](C)(C)C,,,,,,
12355,47050,"Ammonium, (1-(4-hydroxyphenyl)propyl)trimethyl-, iodide, methylcarbamate",CCC(C1=CC=C(C=C1)OC(=O)NC)[N+](C)(C)C.[I-],,,,,,
12356,47051,Trimethyl-[1-[4-(methylcarbamoyloxy)phenyl]propyl]azanium,CCC(C1=CC=C(C=C1)OC(=O)NC)[N+](C)(C)C,,,,,,
12357,47052,"Carbamic acid, methyl-, 4-(3-(trimethylammonio)propyl)phenyl ester, iodide",CNC(=O)OC1=CC=C(C=C1)CCC[N+](C)(C)C.[I-],,,,,,
12358,47053,Trimethyl-[3-[4-(methylcarbamoyloxy)phenyl]propyl]azanium,CNC(=O)OC1=CC=C(C=C1)CCC[N+](C)(C)C,,,,,,
12359,47054,"Carbamic acid, methyl-, m-(triethylammonio)phenyl ester, iodide",CC[N+](CC)(CC)C1=CC(=CC=C1)OC(=O)NC.[Br-],,,,,,
12360,47055,Triethyl-[3-(methylcarbamoyloxy)phenyl]azanium,CC[N+](CC)(CC)C1=CC(=CC=C1)OC(=O)NC,,,,,,
12361,47056,(2-Hydroxyphenyl)trimethylammonium bromide,C[N+](C)(C)C1=CC=CC=C1O.[Br-],,,,,,
12362,47057,(4-Hydroxyphenyl)trimethylammonium bromide,C[N+](C)(C)C1=CC=C(C=C1)O.[Br-],,,,,,
12363,47058,"Ammonium, (3-(methylcarbamoyloxy)phenyl)trimethyl-, chloride",CNC(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Cl-],,,,,,
12364,47059,"Ammonium, (3-(benzylcarbamoyloxy)phenyl)trimethyl-, iodide",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NCC2=CC=CC=C2.[I-],,,,,,
12365,47060,"3-[[(Benzylamino)carbonyl]oxy]-N,N,N-trimethylbenzenaminium",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NCC2=CC=CC=C2,,,,,,
12366,47061,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, IODIDE, CARBAMATE",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N.[I-],,,,,,
12367,47062,(3-Carbamoyloxyphenyl)-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N,,,,,,
12368,47063,"Carbamic acid, N,N-diallyl-, 3-(trimethylammonio)phenyl ester, iodide",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N(CC=C)CC=C.[I-],,,,,,
12369,47064,[3-[Bis(prop-2-enyl)carbamoyloxy]phenyl]-trimethylazanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N(CC=C)CC=C,,,,,,
12370,47065,"1-Piperidinecarboxylic acid, m-(trimethylammonio)phenyl ester, iodide",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N2CCCCC2.[I-],,,,,,
12371,47066,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, ACETATE",CC(=O)OC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
12372,47067,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, ALLYLCARBAMATE",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NCC=C.COS(=O)(=O)[O-],,,,,,
12373,47068,Trimethyl-[3-(prop-2-enylcarbamoyloxy)phenyl]azanium,C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NCC=C,,,,,,
12374,47069,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, BENZYLCARBAMATE",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)NCC2=CC=CC=C2.COS(=O)(=O)[O-],,,,,,
12375,47070,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, CARBAMATE",C[N+](C)(C)C1=CC(=CC=C1)OC(=O)N.COS(=O)(=O)[O-],,,,,,
12376,47071,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, ETHYLCARBAMATE",CCNC(=O)OC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
12377,47072,[3-(Ethylcarbamoyloxy)phenyl]-trimethylazanium,CCNC(=O)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
12378,47073,N-(2-Chloroethyl)-N-nitrosoacetamide,CC(=O)N(CCCl)N=O,,,,,,
12379,47074,"N-(2-(Diethylamino)ethyl)-2,2-diphenylacetamide hydrochloride",CC[NH+](CC)CCNC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
12380,47075,"Acetamide, N-(2-dimethylaminoethyl)-2-ethoxy-N-methyl-2,2-diphenyl-, hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(C)CC[NH+](C)C.[Cl-],,,,,,
12381,47076,"N-[2-(dimethylamino)ethyl]-2-ethoxy-N-methyl-2,2-diphenylacetamide",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(C)CCN(C)C,,,,,,
12382,47077,"Acetamide, 2,2'-dithiodi-",C(C(=O)N)SSCC(=O)N,,,,,,
12383,47078,"ACETAMIDE, N-(4-ETHYL-5-(5-NITRO-2-FURYL)-s-TRIAZOL-3-YL)-",CCN1C(=NN=C1NC(=O)C)C2=CC=C(O2)[N+](=O)[O-],,,,,,
12384,47079,Trichloromethyl allyl perthioxanthate,C=CCSC(=S)SC(Cl)(Cl)Cl,,,,,,
12385,47080,"Carbonic acid, bis(1,3-diisopropoxyisopropyl)ester",CC(C)OCC(COC(C)C)OC(=O)OC(COC(C)C)COC(C)C,,,,,,
12386,47081,Bis(3-dimethylaminophenyl) carbonate dihydrochloride,C[NH+](C)C1=CC(=CC=C1)OC(=O)OC2=CC=CC(=C2)[NH+](C)C.[Cl-].[Cl-],,,,,,
12387,47082,Bis[3-(dimethylamino)phenyl] carbonate,CN(C)C1=CC(=CC=C1)OC(=O)OC2=CC=CC(=C2)N(C)C,,,,,,
12388,47083,Bis(2-methylallyl) carbonate,CC(=C)COC(=O)OCC(=C)C,,,,,,
12389,47084,2-Fluoroethyl xanthate,CCSC(=S)OCCF,,,,,,
12390,47085,3-Ethylcarboxydimethylaminophenol hydrochloride,CCOC(=O)OC1=CC=CC(=C1)[NH+](C)C.[Cl-],,,,,,
12391,47086,[3-(Dimethylamino)phenyl] ethyl carbonate,CCOC(=O)OC1=CC=CC(=C1)N(C)C,,,,,,
12392,47087,Carbomethoxymethyl benzylmethyl dithiocarbamate,CN(CC1=CC=CC=C1)C(=S)SCC(=O)OC,,,,,,
12393,47088,"Carbazole, 3-amino-9-methyl-5,6,7,8-tetrahydro-, hydrochloride",CN1C2=C(CCCC2)C3=C1C=CC(=C3)[NH3+].[Cl-],,,,,,
12394,47089,"9-Methyl-2,3,4,9-tetrahydro-1h-carbazol-6-amine",CN1C2=C(CCCC2)C3=C1C=CC(=C3)N,,,,,,
12395,47090,3-Amino-9-n-propylcarbazole hydrochloride,CCC[NH+]1C2=C(C=C(C=C2)N)C3=CC=CC=C31.[Cl-],,,,,,
12396,47091,9-Propyl-9h-carbazol-3-amine,CCCN1C2=C(C=C(C=C2)N)C3=CC=CC=C31,,,,,,
12397,47092,"Carbazole, 1-amino-5,6,7,8-tetrahydro-, hydrochloride",C1CCC2=C(C1)C3=C(N2)C(=CC=C3)[NH3+].[Cl-],,,,,,
12398,47093,"2,3,4,9-Tetrahydro-1h-carbazol-8-amine",C1CCC2=C(C1)C3=C(N2)C(=CC=C3)N,,,,,,
12399,47094,"Carbazole, 5,6,7,8-tetrahydro-2-amino-, hydrochloride",C1CCC2=C(C1)C3=C(N2)C=C(C=C3)[NH3+].[Cl-],,,,,,
12400,47095,"1,2,3,4-Tetrahydro-9H-carbazole-7-amine",C1CCC2=C(C1)C3=C(N2)C=C(C=C3)N,,,,,,
12401,47096,3-Aminocarbazole-9-carboxylic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)N1C2=C(C=C(C=C2)N)C3=CC=CC=C31.[Cl-],,,,,,
12402,47097,2-(Diethylamino)ethyl 3-aminocarbazole-9-carboxylate,CCN(CC)CCOC(=O)N1C2=C(C=C(C=C2)N)C3=CC=CC=C31,,,,,,
12403,47098,"Carbazole-9-carboxylic acid, 2-(diethylamino)ethyl ester, citrate",CC[NH+](CC)CCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31.C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
12404,47099,2-(Diethylamino)ethyl carbazole-9-carboxylate,CCN(CC)CCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
12405,47100,"Carbazole-9-carboxylic acid, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31.[Cl-],,,,,,
12406,47101,"Carbazole-9-carboxylic acid, 3-(diethylamino)propyl ester, hydrochloride",CC[NH+](CC)CCCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31.[Cl-],,,,,,
12407,47102,3-(Diethylamino)propyl carbazole-9-carboxylate,CCN(CC)CCCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
12408,47103,"Carbazole-9-carboxylic acid, 2-(dimethylamino)ethyl ester, hydrochloride",C[NH+](C)CCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31.[Cl-],,,,,,
12409,47104,2-(Dimethylamino)ethyl carbazole-9-carboxylate,CN(C)CCOC(=O)N1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
12410,47105,Piperidinoethyl carbazol-N-carboxylate hydrochloride,C1CC[NH+](CC1)CCOC(=O)N2C3=CC=CC=C3C4=CC=CC=C42.[Cl-],,,,,,
12411,47106,2-Piperidin-1-ylethyl carbazole-9-carboxylate,C1CCN(CC1)CCOC(=O)N2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
12412,47107,"3,6-Diaminocarbazole dihydrochloride",C1=CC2=C(C=C1[NH3+])C3=C(N2)C=CC(=C3)[NH3+].[Cl-].[Cl-],,,,,,
12413,47108,"9H-Carbazole-3,6-diamine",C1=CC2=C(C=C1N)C3=C(N2)C=CC(=C3)N,,,,,,
12414,47109,CID 47109,CCCCC1(C(=O)N=C(N(C1=O)C)[O-])CC.[Na+],,,,,,
12415,47110,CID 47110,CCCCC1(C(=O)N=C(N(C1=O)CCC)[O-])CC.[Na+],,,,,,
12416,47111,"5-Butyl-5-ethyl-1-propyl-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)N(C1=O)CCC)CC,,,,,,
12417,47112,CID 47112,CCCCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
12418,47113,CID 47113,CCCCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
12419,47114,CID 47114,CCC=CCC1(C(=O)NC(=NC1=O)[O-])C(C)CC.[Na+],,,,,,
12420,47115,"5-Butan-2-yl-5-pent-2-enyl-1,3-diazinane-2,4,6-trione",CCC=CCC1(C(=O)NC(=O)NC1=O)C(C)CC,,,,,,
12421,47116,CID 47116,C=CCC1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
12422,47117,CID 47117,C=CCC1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
12423,47118,"3-Azoniabicyclo(3.3.1)nonane, 3-methyl-3-(2-(trimethylammonio)ethyl)-, diiodide",C[N+]1(CC2CCCC(C2)C1)CC[N+](C)(C)C.[I-].[I-],,,,,,
12424,47119,3-Methyl-3-[2-(trimethylaminio)ethyl]-3-azoniabicyclo[3.3.1]nonane,C[N+]1(CC2CCCC(C2)C1)CC[N+](C)(C)C,,,,,,
12425,47120,"3-Azoniabicyclo(3.3.1)nonane, 3-methyl-3-(3-(trimethylammonio)propyl)-, diiodide",C[N+]1(CC2CCCC(C2)C1)CCC[N+](C)(C)C.[I-].[I-],,,,,,
12426,47121,3-Methyl-3-[3-(trimethylaminio)propyl]-3-azoniabicyclo[3.3.1]nonane,C[N+]1(CC2CCCC(C2)C1)CCC[N+](C)(C)C,,,,,,
12427,47122,"Morpholinium, 4-methyl-4-(3-(3-methyl-3-azoniabicyclo(3.3.1)non-3-yl)propyl)-, diiodide",C[N+]1(CCOCC1)CCC[N+]2(CC3CCCC(C3)C2)C.[I-].[I-],,,,,,
12428,47123,4-Methyl-4-[3-[3-methyl-3-azoniabicyclo[3.3.1]nonan-3-yl]propyl]morpholinium,C[N+]1(CCOCC1)CCC[N+]2(CC3CCCC(C3)C2)C,,,,,,
12429,47124,"3-Azoniabicyclo(3.3.1)nonane, 3-methyl-3-(4-(1-methylpyrrolidinio)butyl)-, diiodide",C[N+]1(CCCC1)CCCC[N+]2(CC3CCCC(C3)C2)C.[I-].[I-],,,,,,
12430,47125,1-Methyl-1-[4-[3-methyl-3-azoniabicyclo[3.3.1]nonan-3-yl]butyl]pyrrolidinium,C[N+]1(CCCC1)CCCC[N+]2(CC3CCCC(C3)C2)C,,,,,,
12431,47126,"3-Azoniabicyclo(3.3.1)nonane, 3-methyl-3-(2-(1-methylpyrrolidinio)ethyl)-, diiodide",C[N+]1(CCCC1)CC[N+]2(CC3CCCC(C3)C2)C.[I-].[I-],,,,,,
12432,47127,3-Methyl-3-[2-[(1-methylpyrrolidinium)-1-yl]ethyl]-3-azoniabicyclo[3.3.1]nonane,C[N+]1(CCCC1)CC[N+]2(CC3CCCC(C3)C2)C,,,,,,
12433,47128,"3-Azoniabicyclo(3.3.1)nonane, 3-methyl-3-(3-(1-methylpyrrolidinio)propyl)-, diiodide",C[N+]1(CCCC1)CCC[N+]2(CC3CCCC(C3)C2)C.[I-].[I-],,,,,,
12434,47129,3-Methyl-3-[3-[(1-methylpyrrolidinium)-1-yl]propyl]-3-azoniabicyclo[3.3.1]nonane,C[N+]1(CCCC1)CCC[N+]2(CC3CCCC(C3)C2)C,,,,,,
12435,47130,"3-Azoniabicyclo(3.3.1)nonane, 3-methyl-3-(4-(trimethylammonio)butyl)-, diiodide",C[N+]1(CC2CCCC(C2)C1)CCCC[N+](C)(C)C.[I-].[I-],,,,,,
12436,47131,3-Methyl-3-[4-(trimethylaminio)butyl]-3-azoniabicyclo[3.3.1]nonane,C[N+]1(CC2CCCC(C2)C1)CCCC[N+](C)(C)C,,,,,,
12437,47132,CID 47132,C=CCC1(C(=NC(=NC1=O)S)[O-])CC2=CC=CC=C2.[Na+],,,,,,
12438,47133,CID 47133,C=CCC1(C(=O)NC(=NC1=O)S)CC2=CC=CC=C2,,,,,,
12439,47134,CID 47134,CCC(C)C1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
12440,47135,CID 47135,CC(C)C1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
12441,47136,CID 47136,CC(C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
12442,47137,CID 47137,CCCC(C)C1(C(=N)N=C(N=C1[O-])S)CC=C.[Na+],,,,,,
12443,47138,CID 47138,CCCC(C)C1(C(=NC(=NC1=O)S)N)CC=C,,,,,,
12444,47139,"Barbituric acid, 1-(3-allyloxy-2-hydroxypropyl)-5-ethyl-5-phenyl-, carbamate (ester)",CCC1(C(=O)NC(=O)N(C1=O)CC(COCC=C)OC(=O)N)C2=CC=CC=C2,,,,,,
12445,47140,CID 47140,CCCCC1(C(=NC(=NC1=O)S)[O-])CC2=CC=CC=C2.[Na+],,,,,,
12446,47141,CID 47141,CCCCC1(C(=O)NC(=NC1=O)S)CC2=CC=CC=C2,,,,,,
12447,47142,CID 47142,CCCCN1C(=O)C(C(=O)N=C1[O-])(CC)CC.[Na+],,,,,,
12448,47143,N-n-Butylbarbital,CCCCN1C(=O)C(C(=O)NC1=O)(CC)CC,,,,,,
12449,47144,CID 47144,CCCCN1C(=O)C(C(=O)N=C1[O-])(CC)CCC(C)C.[Na+],,,,,,
12450,47145,"1-Butyl-5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione",CCCCN1C(=O)C(C(=O)NC1=O)(CC)CCC(C)C,,,,,,
12451,47146,"2H-Azepin-7-amine, 3,4,5,6-tetrahydro-2-imino-",C1CCC(=N)N=C(C1)N,,,,,,
12452,47147,1-(2-Ethoxy-2-phenyl-N-propylacetimidoyl)hexahydro-1H-azepine,CCCN=C(C(C1=CC=CC=C1)OCC)N2CCCCCC2,,,,,,
12453,47148,Hexahydro-1-(2-methoxy-2-phenyl-N-propylacetimidoyl)-1H-azepine,CCCN=C(C(C1=CC=CC=C1)OC)N2CCCCCC2,,,,,,
12454,47149,"1-[5-(Azepan-1-ium-1-ylidene)-4-methylpenta-1,3-dienyl]azepane;chloride",CC(=CC=CN1CCCCCC1)C=[N+]2CCCCCC2.[Cl-],,,,,,
12455,47150,"Hexahydro-1-[5-[(hexahydro-1H-azepin)-1-yl]-2-methyl-2,4-pentadien-1-ylidene]-1H-azepin-1-ium",CC(=CC=CN1CCCCCC1)C=[N+]2CCCCCC2,,,,,,
12456,47151,"Aziridinium, 1,1-bis(2-chloroethyl)-, chloride",C1C[N+]1(CCCl)CCCl.[Cl-],,,,,,
12457,47152,"1,1-Bis(2-chloroethyl)aziridinium",C1C[N+]1(CCCl)CCCl,,,,,,
12458,47153,"N,N-Bis(2-hydroxyethyl)aziridinium chloride",C1C[N+]1(CCO)CCO.[Cl-],,,,,,
12459,47154,"1,1-Bis(2-hydroxyethyl)aziridinium",C1C[N+]1(CCO)CCO,,,,,,
12460,47155,"Aziridinium, 1-(2-chloroethyl)-1-(2-hydroxyethyl)-, chloride",C1C[N+]1(CCO)CCCl.[Cl-],,,,,,
12461,47156,1-(2-Chloroethyl)-1-(2-hydroxyethyl)aziridinium,C1C[N+]1(CCO)CCCl,,,,,,
12462,47157,Azobenzen [Czech],C1CN1C(=O)NC2=CC=C(C=C2)N=NC3=CC=CC=C3,,,,,,
12463,47158,"1-[5-(Azocan-1-yl)penta-2,4-dien-1-ylidene]azocan-1-ium chloride",C1CCCN(CCC1)C=CC=CC=[N+]2CCCCCCC2.[Cl-],,,,,,
12464,47159,"1-[5-[(3,4,5,6,7,8-Hexahydroazocin)-1(2H)-yl]-2,4-pentadienylidene]octahydroazocin-1-ium",C1CCCN(CCC1)C=CC=CC=[N+]2CCCCCCC2,,,,,,
12465,47160,CID 47160,C1=CC(=CN=C1)C(=NO)C(F)(F)F.O,,,,,,
12466,47161,"N-(2,2,2-trifluoro-1-pyridin-3-ylethylidene)hydroxylamine",C1=CC(=CN=C1)C(=NO)C(F)(F)F,,,,,,
12467,47162,"N-(2,2,2-trifluoro-1-pyridin-4-ylethylidene)hydroxylamine;hydrate",C1=CN=CC=C1C(=NO)C(F)(F)F.O,,,,,,
12468,47163,"N-(2,2,2-trifluoro-1-pyridin-4-ylethylidene)hydroxylamine",C1=CN=CC=C1C(=NO)C(F)(F)F,,,,,,
12469,47164,CID 47164,CC(=NO)C1=C2C(=CC=C1)SC3=CC=CC=C3N2CCCN(C)C,,,,,,
12470,47165,CID 47165,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3C2=CCC[NH+](C)C.[Cl-],,,,,,
12471,47166,CID 47166,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3C2=CCCN(C)C,,,,,,
12472,47167,Phantolide,CC1C(C2=C(C1(C)C)C=C(C(=C2)C)C(=O)C)(C)C,,,,,,
12473,47168,1-[4-(3-Hydroxyphenyl)-1-methylpiperidin-4-yl]ethanone,CC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O,,,,,,
12474,47169,"Ketone, 2-pyridyl trifluoromethyl, oxime, hydrate",C1=CC=NC(=C1)C(=NO)C(F)(F)F.O,,,,,,
12475,47170,"N-(2,2,2-trifluoro-1-pyridin-2-ylethylidene)hydroxylamine",C1=CC=NC(=C1)C(=NO)C(F)(F)F,,,,,,
12476,47171,"1-Naphthylamine, 1,2,3,4-tetrahydro-6,8-dichloro-N,N-dimethyl-5-methoxy-, hydrobromide",C[NH+](C)C1CCCC2=C1C(=CC(=C2OC)Cl)Cl.[Br-],,,,,,
12477,47172,"6,8-dichloro-5-methoxy-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C1C(=CC(=C2OC)Cl)Cl,,,,,,
12478,47173,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-methoxy-N-methyl-N-phenethyl-, hydrobromide",C[NH+](CCC1=CC=CC=C1)C2CCCC3=C(C=CC(=C23)Cl)OC.[Br-],,,,,,
12479,47174,"8-chloro-5-methoxy-N-methyl-N-(2-phenylethyl)-1,2,3,4-tetrahydronaphthalen-1-amine",CN(CCC1=CC=CC=C1)C2CCCC3=C(C=CC(=C23)Cl)OC,,,,,,
12480,47175,CID 47175,CC=C(C)CC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
12481,47176,"5-(2-Methylbut-2-enyl)-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CC=C(C)CC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
12482,47177,"1H-1-Benzazepine, 2,3,4,5-tetrahydro-3-(p-chlorophenyl)-1-(3-(diisopropylamino)propyl)-",CC(C)N(CCCN1CC(CCC2=CC=CC=C21)C3=CC=C(C=C3)Cl)C(C)C,,,,,,
12483,47178,"3-(p-Chlorophenyl)-1-(3-(diisopropylamino)propyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one",CC(C)N(CCCN1C2=CC=CC=C2CCC(C1=O)C3=CC=C(C=C3)Cl)C(C)C,,,,,,
12484,47179,CID 47179,CC(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])[Hg].CC(=O)O,,,,,,
12485,47180,(2-Acetamido-5-nitrophenyl)mercury,CC(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])[Hg],,,,,,
12486,47181,"Acetanilide, 2'-benzyloxy-2-diethylamino-, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=CC=C1OCC2=CC=CC=C2.[Cl-],,,,,,
12487,47182,2-(diethylamino)-N-(2-phenylmethoxyphenyl)acetamide,CCN(CC)CC(=O)NC1=CC=CC=C1OCC2=CC=CC=C2,,,,,,
12488,47183,2-(Diethylamino)-2'-phenethyloxyacetanilide hydrochloride,CC[NH+](CC)CC(=O)NC1=CC=CC=C1OCCC2=CC=CC=C2.[Cl-],,,,,,
12489,47184,2-(diethylamino)-N-[2-(2-phenylethoxy)phenyl]acetamide,CCN(CC)CC(=O)NC1=CC=CC=C1OCCC2=CC=CC=C2,,,,,,
12490,47185,2-(Diethylamino)-3'-phenethyloxyacetanilide hydrochloride,CC[NH+](CC)CC(=O)NC1=CC(=CC=C1)OCCC2=CC=CC=C2.[Cl-],,,,,,
12491,47186,2-(diethylamino)-N-[3-(2-phenylethoxy)phenyl]acetamide,CCN(CC)CC(=O)NC1=CC(=CC=C1)OCCC2=CC=CC=C2,,,,,,
12492,47187,2-(Diethylamino)-4'-phenethyloxyacetanilide hydrochloride,CC[NH+](CC)CC(=O)NC1=CC=C(C=C1)OCCC2=CC=CC=C2.[Cl-],,,,,,
12493,47188,2-(diethylamino)-N-[4-(2-phenylethoxy)phenyl]acetamide,CCN(CC)CC(=O)NC1=CC=C(C=C1)OCCC2=CC=CC=C2,,,,,,
12494,47189,2-Ethoxy-N-hexyl-2-phenylacetamidine,CCCCCCN=C(C(C1=CC=CC=C1)OCC)N,,,,,,
12495,47190,2-Ethoxy-N-isobutyl-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=NCC(C)C)N,,,,,,
12496,47191,2-Ethoxy-N-(3-methoxypropyl)-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=NCCCOC)N,,,,,,
12497,47192,2-Ethoxy-N-(2-phenethyl)-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=NCCC2=CC=CC=C2)N,,,,,,
12498,47193,2-Ethoxy-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=N)N,,,,,,
12499,47194,2-Ethoxy-2-phenyl-N-propylacetamidine,CCCN=C(C(C1=CC=CC=C1)OCC)N,,,,,,
12500,47195,"Acetamide, N,N'-pentamethylenebis(iodo-",C(CCNC(=O)CI)CCNC(=O)CI,,,,,,
12501,47196,CID 47196,CC(=O)NC1=CC=CC2=C1N(C3=C2CCCC3)C,,,,,,
12502,47197,2-(m-Tolyloxy)acetamidine hydrochloride,CC1=CC(=CC=C1)OCC(=[NH2+])N.[Cl-],,,,,,
12503,47198,2-(3-Methylphenoxy)ethanimidamide,CC1=CC(=CC=C1)OCC(=N)N,,,,,,
12504,47199,N-Benzyl-2-ethoxy-2-phenylacetamidine,CCOC(C1=CC=CC=C1)C(=NCC2=CC=CC=C2)N,,,,,,
12505,47200,N-Butyl-2-ethoxy-2-phenylacetamidine,CCCCN=C(C(C1=CC=CC=C1)OCC)N,,,,,,
12506,47201,"2-(p-Chlorophenyl)-N,N'-dibutyl-2-ethoxyacetamidine",CCCCNC(=NCCCC)C(C1=CC=C(C=C1)Cl)OCC,,,,,,
12507,47202,"2-(p-Chlorophenyl)-N,N'-dipropyl-2-ethoxyacetamidine",CCCNC(=NCCC)C(C1=CC=C(C=C1)Cl)OCC,,,,,,
12508,47203,"2-ethoxy-2-phenyl-N,N'-dipropylethanimidamide",CCCNC(=NCCC)C(C1=CC=CC=C1)OCC,,,,,,
12509,47204,2-(Diethylamino)ethyl diphenylmethylcarbamate hydrochloride,CC[NH+](CC)CCOC(=O)NC(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
12510,47205,2-(diethylamino)ethyl N-benzhydrylcarbamate,CCN(CC)CCOC(=O)NC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
12511,47206,"Carbamic acid, N-methyl-N-(methylthio)dithio-, 2-nitrophenyl ester",CN(C(=S)SC1=CC=CC=C1[N+](=O)[O-])SC,,,,,,
12512,47207,"Carbamic acid, 1-ethylcyclohexyl ester",CCC1(CCCCC1)OC(=O)N,,,,,,
12513,47208,CID 47208,C(CN=C(S)SCC(=O)O)N=C(S)SCC(=O)O,,,,,,
12514,47209,"CARBAMIC ACID, N-ETHYL-N-(p-NITROPHENYL)SULFONYL-, ETHYL ESTER",CCN(C(=O)OCC)S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
12515,47210,"CARBAMIC ACID, N-ETHYL-N-(o-TOLYLSULFONYL)-, ETHYL ESTER",CCN(C(=O)OCC)S(=O)(=O)C1=CC=CC=C1C,,,,,,
12516,47211,1-Isopropoxy-3-(o-tolyloxy)-2-propanol carbamate,CC1=CC=CC=C1OCC(COC(C)C)OC(=O)N,,,,,,
12517,47212,"CARBAMIC ACID, METHYL-, p-AMINOPHENYL ESTER, HYDROCHLORIDE",CNC(=O)OC1=CC=C(C=C1)[NH3+].[Cl-],,,,,,
12518,47213,"Carbamic acid, methyl-, 2,4-bis(dimethylamino)phenyl ester, dihydrochloride",CNC(=O)OC1=C(C=C(C=C1)[NH+](C)C)[NH+](C)C.[Cl-].[Cl-],,,,,,
12519,47214,"[2,4-bis(dimethylamino)phenyl] N-methylcarbamate",CNC(=O)OC1=C(C=C(C=C1)N(C)C)N(C)C,,,,,,
12520,47215,"Carbamic acid, methyl-, 2,5-bis(dimethylamino)phenyl ester, dihydrochloride",CNC(=O)OC1=C(C=CC(=C1)[NH+](C)C)[NH+](C)C.[Cl-].[Cl-],,,,,,
12521,47216,"[2,5-bis(dimethylamino)phenyl] N-methylcarbamate",CNC(=O)OC1=C(C=CC(=C1)N(C)C)N(C)C,,,,,,
12522,47217,"Carbamic acid, N-methyl-, 2-chloro-5-dimethylaminophenyl ester, hydrochloride",CNC(=O)OC1=C(C=CC(=C1)[NH+](C)C)Cl.[Cl-],,,,,,
12523,47218,[2-chloro-5-(dimethylamino)phenyl] N-methylcarbamate,CNC(=O)OC1=C(C=CC(=C1)N(C)C)Cl,,,,,,
12524,47219,4-Diallylaminophenyl methylcarbamate,CNC(=O)OC1=CC=C(C=C1)N(CC=C)CC=C,,,,,,
12525,47220,"Carbamic acid, methyl-, m-(N-(2-(diethylamino)ethyl)-N-methylamino)phenyl ester, hydrochloride",CC[NH+](CC)CCN(C)C1=CC(=CC=C1)OC(=O)NC.[Cl-],,,,,,
12526,47221,[3-[2-(diethylamino)ethyl-methylamino]phenyl] N-methylcarbamate,CCN(CC)CCN(C)C1=CC(=CC=C1)OC(=O)NC,,,,,,
12527,47222,"Carbamic acid, methyl-, p-(N-(2-(diethylamino)ethyl)-N-methylamino)phenyl ester, hydrochloride",CC[NH+](CC)CCN(C)C1=CC=C(C=C1)OC(=O)NC.[Cl-],,,,,,
12528,47223,[4-[2-(diethylamino)ethyl-methylamino]phenyl] N-methylcarbamate,CCN(CC)CCN(C)C1=CC=C(C=C1)OC(=O)NC,,,,,,
12529,47224,diethyl-[2-[N-methyl-4-(methylcarbamoyloxy)anilino]ethyl]azanium;bromide,CC[NH+](CC)CCN(C)C1=CC=C(C=C1)OC(=O)NC.[Br-],,,,,,
12530,47225,"CARBAMIC ACID, METHYL-, m-(DIETHYLAMINO)PHENYL ESTER, HYDROCHLORIDE",CC[NH+](CC)C1=CC(=CC=C1)OC(=O)NC.[Cl-],,,,,,
12531,47226,"Carbamic acid, methyl-, 3-(3-(dimethylamino)butyl)phenyl ester, hydrochloride",CC(CCC1=CC(=CC=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
12532,47227,[3-[3-(dimethylamino)butyl]phenyl] N-methylcarbamate,CC(CCC1=CC(=CC=C1)OC(=O)NC)N(C)C,,,,,,
12533,47228,"Carbamic acid, methyl-, 4-(3-(dimethylamino)butyl)phenyl ester, hydrochloride",CC(CCC1=CC=C(C=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
12534,47229,[4-[3-(dimethylamino)butyl]phenyl] N-methylcarbamate,CC(CCC1=CC=C(C=C1)OC(=O)NC)N(C)C,,,,,,
12535,47230,N-Methylcarbamic acid 4-(dimethylamino)carvacryl ester hydrochloride,CC1=CC(=C(C=C1OC(=O)NC)C(C)C)[NH+](C)C.[Cl-],,,,,,
12536,47231,4-(Dimethylamino)-2-methyl-5-(propan-2-yl)phenyl methylcarbamate,CC1=CC(=C(C=C1OC(=O)NC)C(C)C)N(C)C,,,,,,
12537,47232,"CARBAMIC ACID, METHYL-, 3-(DIMETHYLAMINO)-p-CUMENYL ESTER, HYDROCHLORIDE",CC(C)C1=C(C=C(C=C1)OC(=O)NC)[NH+](C)C.[Cl-],,,,,,
12538,47233,"Carbamic acid, methyl-, 3-(dimethylamino)-4-isopropylphenyl ester, hydrochloride",CC(C)C1=C(C=C(C=C1)OC(=O)NC)N(C)C,,,,,,
12539,47234,"Carbamic acid, methyl-, (5-dimethylamino-2-dimethylaminomethyl)phenyl ester, dihydrochloride",CNC(=O)OC1=C(C=CC(=C1)[NH+](C)C)C[NH+](C)C.[Cl-].[Cl-],,,,,,
12540,47235,[5-(dimethylamino)-2-[(dimethylamino)methyl]phenyl] N-methylcarbamate,CNC(=O)OC1=C(C=CC(=C1)N(C)C)CN(C)C,,,,,,
12541,47236,"Hydrazine, (thienyl)-",C1=CSC(=C1)NN,,,,,,
12542,47237,Azulenecarboxylic acid,C1=CC=C2C=CC(=C2C=C1)C(=O)O,,,,,,
12543,47238,Trichloroisopropyl 2-bromoisovalerate,CC(C)C(C(=O)OC(C)C(Cl)(Cl)Cl)Br,,,,,,
12544,47239,CID 47239,CCC=CCC1(C(=NC(=NC1=O)S)[O-])C(C)C.[Na+],,,,,,
12545,47240,CID 47240,CCC=CCC1(C(=O)NC(=NC1=O)S)C(C)C,,,,,,
12546,47241,"Ammonium, N-butyl-N',N'-dimethyl-N,N,N'-triethyl-N,N'-oxydiethylenedi-, dibromide",CCCC[N+](CC)(CC)CCOCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
12547,47242,Butyl-diethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethoxy]ethyl]azanium,CCCC[N+](CC)(CC)CCOCC[N+](C)(C)CC,,,,,,
12548,47243,"Ammonium, (2-methyl-2-(2-(triethylammonio)ethoxy)ethyl)ethyldimethyl-, diiodide",CC[N+](C)(C)CC(C)OCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
12549,47244,"Acetic acid, 2-(8-chloromethyl-1-naphthylthio)-",C1=CC2=C(C(=C1)CCl)C(=CC=C2)SCC(=O)O,,,,,,
12550,47245,"Isoquinolinium, 2-(6-(trimethylammonio)hexyl)-, dibromide",C[N+](C)(C)CCCCCC[N+]1=CC2=CC=CC=C2C=C1.[Br-].[Br-],,,,,,
12551,47246,2-[6-(Trimethylaminio)hexyl]isoquinolinium,C[N+](C)(C)CCCCCC[N+]1=CC2=CC=CC=C2C=C1,,,,,,
12552,47247,"Isoquinolinium, 2-(3-(4-methylmorpholino)propyl)-, dibromide",C[N+]1(CCOCC1)CCC[N+]2=CC3=CC=CC=C3C=C2.[Br-].[Br-],,,,,,
12553,47248,4-(3-Isoquinolin-2-ium-2-ylpropyl)-4-methylmorpholin-4-ium,C[N+]1(CCOCC1)CCC[N+]2=CC3=CC=CC=C3C=C2,,,,,,
12554,47249,"Isoquinolinium, 2-(3-(dimethylamino)propyl)-, bromide, hydrochloride",C[NH+](C)CCC[N+]1=CC2=CC=CC=C2C=C1.[Cl-].[Br-],,,,,,
12555,47250,"3-isoquinolin-2-ium-2-yl-N,N-dimethylpropan-1-amine",CN(C)CCC[N+]1=CC2=CC=CC=C2C=C1,,,,,,
12556,47251,"Isoquinolinium, 4-bromo-2-(3-(trimethylammonio)propyl)-, dibromide",C[N+](C)(C)CCC[N+]1=CC2=CC=CC=C2C(=C1)Br.[Br-].[Br-],,,,,,
12557,47252,3-(4-Bromoisoquinolin-2-ium-2-yl)propyl-trimethylazanium,C[N+](C)(C)CCC[N+]1=CC2=CC=CC=C2C(=C1)Br,,,,,,
12558,47253,"Ammonium, (p-phenylenebis(carbonylmethyl))bis(dimethyl-2-hydroxyethyl-, dibromide",C[N+](C)(CCO)CC(=O)C1=CC=C(C=C1)C(=O)C[N+](C)(C)CCO.[Br-].[Br-],,,,,,
12559,47254,2-Hydroxyethyl-[2-[4-[2-[2-hydroxyethyl(dimethyl)azaniumyl]acetyl]phenyl]-2-oxoethyl]-dimethylazanium,C[N+](C)(CCO)CC(=O)C1=CC=C(C=C1)C(=O)C[N+](C)(C)CCO,,,,,,
12560,47255,"3-Azabicyclo(3.2.1)octane, 2,2,3,4-tetramethyl-",CC1C2CCC(C2)C(N1C)(C)C,,,,,,
12561,47256,"3-Azabicyclo(3.2.1)octane, N,2-dimethyl-",CC1C2CCC(C2)CN1C,,,,,,
12562,47257,"BENZYL ALCOHOL, alpha-(n-AMINOPENTYL)-, HYDROCHLORIDE",CCCCC(C(C1=CC=CC=C1)O)[NH3+].[Cl-],,,,,,
12563,47258,2-Amino-1-phenylhexan-1-ol,CCCCC(C(C1=CC=CC=C1)O)N,,,,,,
12564,47259,"Dimethyl-(2-methyl-4-oxo-3,3-diphenylhexan-2-yl)azanium;chloride",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)(C)[NH+](C)C.[Cl-],,,,,,
12565,47260,"5-(Dimethylamino)-5-methyl-4,4-diphenylhexan-3-one",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)(C)N(C)C,,,,,,
12566,47261,CID 47261,CCCCCN=C(C(=NCCCCC)S)S,,,,,,
12567,47262,CID 47262,CCCCCCCCCCCCCCCCNC1=CC=C(C=C1)C(=O)[O-].[Na+],,,,,,
12568,47263,Cetaben,CCCCCCCCCCCCCCCCNC1=CC=C(C=C1)C(=O)O,,,,,,
12569,47264,Picotrin,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CN=C(C=C4)C(=O)O,,,,,,
12570,47265,"4-Amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid",C1CC(C(OC1CN)OC2C(CC(C(C2O)OC3C(C(C(C(O3)CO)O)N)O)N)N)N.OS(=O)(=O)O,,,,,,
12571,47266,"Carbamic acid, methyl-, 3-(trimethylammonio)-p-tolyl ester, chloride",CC1=C(C=C(C=C1)OC(=O)NC)[N+](C)(C)C.[Cl-],,,,,,
12572,47267,"Ammonium, ((4-(N,N-dimethylcarbamoyloxy)-2-hexyl)phenyl)trimethyl-, iodide",CCCCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
12573,47268,[4-(Dimethylcarbamoyloxy)-2-hexylphenyl]-trimethylazanium,CCCCCCC1=C(C=CC(=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
12574,47269,"Carbamic acid, methyl-, 3-(dimethylethylammonio)-p-tolyl ester, iodide",CC[N+](C)(C)C1=C(C=CC(=C1)OC(=O)NC)C.[I-],,,,,,
12575,47270,Ethyl-dimethyl-[2-methyl-5-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(C)C1=C(C=CC(=C1)OC(=O)NC)C,,,,,,
12576,47271,"Carbamic acid, dimethyl-, (4-tert-pentyl-2-(trimethylammonio)phenyl) ester, iodide",CCCCCC1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C.[I-],,,,,,
12577,47272,[2-(Dimethylcarbamoyloxy)-5-pentylphenyl]-trimethylazanium,CCCCCC1=CC(=C(C=C1)OC(=O)N(C)C)[N+](C)(C)C,,,,,,
12578,47273,"AMMONIUM, (2-(o-ACETAMIDOPHENYLTHIO)ETHYL)DIETHYLMETHYL-, IODIDE",CC[N+](C)(CC)CCSC1=CC=CC=C1NC(=O)C.[I-],,,,,,
12579,47274,2-(2-Acetamidophenyl)sulfanylethyl-diethyl-methylazanium,CC[N+](C)(CC)CCSC1=CC=CC=C1NC(=O)C,,,,,,
12580,47275,Trisodium arsenate,[O-][As](=O)([O-])[O-].[Na+].[Na+].[Na+],,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
12581,47276,"Ammonium, 4-acetamido-4,4-diphenyl-2-butyltrimethyl-, iodide",CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)C)[N+](C)(C)C.[I-],,,,,,
12582,47277,"(4-Acetamido-4,4-diphenylbutan-2-yl)-trimethylazanium",CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)C)[N+](C)(C)C,,,,,,
12583,47278,CID 47278,CCCCC[C@@H](C=C[C@@H]1C(C(CC1=O)O)CC=CCCCCCC(=O)O)O,,,,,,
12584,47279,4-(p-Chlorophenyl)-N-(2-methoxyphenyl)-4-oxobutyramide,COC1=CC=CC=C1NC(=O)CCC(=O)C2=CC=C(C=C2)Cl,,,,,,
12585,47280,CID 47280,[Li+].[Si-]#[Fe],,,,,,
12586,47281,Silanidylidyneiron,[Si-]#[Fe],,,,,,
12587,47282,"Bipyridinium, N-(2-bromoethyl)-, bromide",C1=CC=NC(=C1)C2=CC=CC=[N+]2CCBr.[Br-],,,,,,
12588,47283,1-(2-Bromoethyl)-2-pyridin-2-ylpyridin-1-ium,C1=CC=NC(=C1)C2=CC=CC=[N+]2CCBr,,,,,,
12589,47284,CID 47284,CCCC1(C(=O)NC(=NC1=O)[O-])CC=CCC.[Na+],,,,,,
12590,47285,"5-Pent-2-enyl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)CC=CCC,,,,,,
12591,47286,CID 47286,CCCC(CC1(C(=O)NC(=NC1=O)[O-])CC=C)O.[Na+],,,,,,
12592,47287,"5-(2-Hydroxypentyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CCCC(CC1(C(=O)NC(=O)NC1=O)CC=C)O,,,,,,
12593,47288,"BENZ(a)ANTHRACEN-8-YL CARBAMIDE, 7-METHYL-",CC1=C2C(=CC3=C1C=CC4=CC=CC=C43)C=CC=C2C(=O)N,,,,,,
12594,47289,4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone,CN(CCCC(=O)C1=CN=CC=C1)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['Extensive studies have examined the metabolism of NNK and the formation of DNA adducts by NNK and its metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in humans and laboratory animals; the metabolic pathways and structures of DNA adducts have been characterized comprehensively. NNK and NNAL have been detected in the saliva of smokeless tobacco users, and NNAL and another metabolite of NNK, NNAL-glucuronide, have been quantified in human urine. The presence of these metabolites, which are specific to exposure to tobacco products (e.g. in smokers, users of smokeless tobacco and nonsmokers exposed to secondhand tobacco smoke), signals human uptake and metabolism of NNK, and their quantification allows an estimation of the dose of NNK absorbed. Dose calculations show that the total amounts of NNK taken up by people who used tobacco products for a period of 30 years or more approximate the total amounts that induce tumors in rats.', 'Absorption of NNK in smokeless tobacco users was demonstrated by the detection of its metabolites, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and NNAL-glucuronide (Gluc), in plasma and urine and of NNAL-N-oxide in urine. Similar results have been obtained in smokers, although only NNAL has been reported in plasma. NNAL-N-Gluc comprised 50 +/- 25% of total NNAL-Gluc in the urine of smokers and 24 +/- 12% in snuff-dippers. Toombak users excreted exceptionally high levels of NNAL and NNAL-Gluc (0.12 to 0.14 mg per day), which demonstrated a higher uptake of NNK by humans than of any other non-occupational carcinogen.', '4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), but not NNAL-Gluc, was detected in the amniotic fluid of mothers who smoked. Both NNAL and NNAL-Gluc were detected in the urine of neonates born to mothers who smoked, but not in the urine of newborns of nonsmoking mothers. These results indicate that NNK is converted to NNAL in the mother, and that NNAL crosses the placental barrier and is absorbed and metabolized to NNAL-Gluc in the late stages of fetal development. /NNAL/', '4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and NNAL-Gluc are excreted in the urine more slowly than would be expected, based on their structures, after cessation of smoking or smokeless tobacco use. One week after smoking cessation, 34.5% of baseline NNAL plus NNALGluc was detected in urine, whereas the corresponding values for the structurally related compounds cotinine and nicotine were 1.1 and 0.5%, respectively. Even 6 weeks after cessation, 7.6% of the original levels of NNAL plus NNAL-Gluc remained. The distribution half-life of NNAL and NNAL-Gluc was 3 to 4 days, while the elimination half-life was 40 to 45 days. Total body clearance of NNAL was estimated to be 61.4 +/- 35.4 mL/min, and the volume of distribution in the beta-phase was estimated to be 3800 +/- 2100 L, which indicates substantial distribution into tissues. After cessation of smokeless tobacco use, the distribution half-lives of NNAL (1.32 +/- 0.85 versus 3.35 +/- 1.86 days) and NNAL-Gluc (1.53 +/- 1.22 versus 3.89 +/- 2.43 days) were significantly shorter than those in smokers. There were no significant differences in the terminal half-lives. /NNAL/', 'For more Absorption, Distribution and Excretion (Complete) data for 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (10 total), please visit the HSDB record page.']","['NNK uptake by measurement of the urinary metabolites 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL) has been reported in many studies, but there are no data in the literature on the percentage of the NNK dose that is converted to NNAL in smokeless tobacco users. ... 15 male subjects abstained from tobacco use for 3 weeks before placing 2 g smokeless tobacco between their cheeks and gums for 30 min. They then continued abstinence and collected three consecutive 24-hr urine samples. The amount of NNK in the tobacco before and after use was determined along with the amount in expectorated saliva. The NNK dose thus calculated was compared with the amount of total NNAL excreted in the next 72 hr. These data, taken together with previous pharmacokinetic data, show that the percent conversion of NNK to total NNAL in smokeless tobacco users is approximately 14% to 17%. This figure can be used to calculate daily exposure to NNK in smokeless tobacco users ( approximately 6 ug). The results of this study also indicate that metabolic activation of NNK to intermediates that can react with DNA is its major pathway of metabolism in smokeless tobacco users.', 'NNK can be converted to the pyridine oxidation products 4-(methylnitrosamino)-1-[3- (6-hydroxypyridyl)]-1-butanone (6-HONNK) and NNK-N-oxide. Denitrosation of NNK followed by oxidation produces myosmine. NNK can replace nicotinamide in NADP+ or NADPH, to yield NNK adenosine dinucleotide phosphate ((NNK)ADP+) and (NNK)ADPH (reduced form). Carbonyl reduction of NNK produces NNAL which can be conjugated by glucuronidation giving four diastereomers of NNAL-Gluc: two isomers of 4- (methylnitrosamino)-1-(3-pyridyl)-1-(O-beta-D-glucopyranuronosyl)butane (NNAL-O-Gluc) and two isomers of 4-(methylnitrosamino)-1-(3-pyridyl-N-beta-D-glucopyranuronosyl)-1- butanolonium inner salt (NNAL-N-Gluc). NNAL is also converted to NNAL-N-oxide and NNAL(ADP+).', 'Alpha-Hydroxylation of NNK and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) leads to DNA and hemoglobin adducts. Hydroxylation of the NNK methyl group gives 4-(hydroxymethylnitrosamino)-1-(3-pyridyl)-1-butanone (alpha-HOMeNNK) which can be conjugated as a glucuronide, alpha-HOMeNNK-Gluc. -HOMeNNK spontaneously decomposes to 4-oxo-4-(3-pyridyl)-1-butanediazohydroxide (POB-DZH) and formaldehyde. POB-DZH reacts with water to give 4-hydroxy-1-(3-pyridyl)- 1-butanone (HPB) which can be conjugated as its glucuronide, HPB-Gluc. POB-DZH also reacts with DNA and haemoglobin to produce a series of adducts. Alpha-Hydroxylation of the NNK methylene group produces 4-(methylnitrosamino)-1-(3-pyridyl)- 1-(4-hydroxy)butanone (alpha-HOMethyleneNNK). This metabolite spontaneously decomposes to 4-(3-pyridyl)-4-oxobutanal (keto aldehyde) and methanediazohydroxide (Me- DZH). Keto aldehyde is further metabolized to 4-(3-pyridyl)-4-oxobutanoic acid (keto acid) which in turn can be converted to 4-hydroxy-4-(3-pyridyl)butanoic acid (hydroxy acid). Me-DZH reacts with water to yield methanol and with DNA to produce methyl adducts as shown in Figures 2 and 5. NNAL similarly undergoes alpha-hydroxylation at its methylene group to yield 4-(methylnitrosamino)-1-(3-pyridyl)-1-(4-hydroxy)butanol (alpha-HOMethyleneNNAL) and at its methyl group to yield 4-(hydroxymethylnitrosamino)-1-(3-pyridyl)- 1-butanol (alpha-HOMeNNAL). Alpha-HOMethyleneNNAL spontaneously decomposes to Me- DZH and 5-(3-pyridyl)-2-hydroxytetrahydrofuran (lactol), which can be converted to hydroxy acid. Alpha-HOMeNNAL spontaneously decomposes to 4-hydroxy-4-(3-pyridyl)-1- butanediazohydroxide (PHB-DZH) and formaldehyde. PHB-DZH reacts with water to yield 4-(3-pyridyl)butane-1,4-diol (diol), cyclizes to 2-(3-pyridyl)tetrahydrofuran (pyridylTHF) and reacts with DNA and hemoglobin to produce adducts.', 'CYPs are the major catalysts of NNK alpha-hydroxylation in humans and rodents. ... The relative efficiencies in NNK metabolism by human CYP are (from greatest catalyst to least): 2A13 > 2B6 > 2A6 > 1A2 ~ 1A1 > 2D6 ~ 2E1 ~ 3A4. ... The actual involvement of these enzymes in NNK metabolism in vivo depends on many factors that include relative expression levels, the amount of CYP oxido-reductase expressed in a given tissue, tissue localization and inducibility of individual CYPs, and the concentration of NNK in human tissues. Among hepatic CYPs, 2B6 has the highest affinity for NNK. However, low levels of this enzyme are present in most liver samples. CYP2A6 is also present at relatively low levels, and accounts for < 1% to 4% of the total CYP content. Levels of CYP1A2 are four- to 20-fold higher than those of CYP2A6. Therefore, despite its somewhat higher Km and lower Vmax/Km, CYP1A2 is most probably as important a catalyst of NNK alpha-hydroxylation in human liver as CYP2A6. CYP3A4 may also play a role in hepatic NNK alpha-hydroxylation, since it is often present at concentrations that are 10 to 50 times greater than those of CYP2A6. It is not possible to rule out completely the presence of CYP2A13, the best known human catalyst of NNK metabolism, in the liver. However, the very low hepatic mRNA levels of CYP2A13 relative to CYP2A6 suggest that, if this enzyme is present, it is so at very low levels. Results to date do not identify that any single CYP in the liver is a key player in NNK activation. Several enzymes, including CYP1A2, CYP2A6, CYP2B6 and CYP3A4, clearly play a role. The relative contribution of any one of these CYPs varies among individuals, and their relative abundance and catalytic efficiencies suggest that rarely, if ever, is one of them the dominant catalyst.', 'For more Metabolism/Metabolites (Complete) data for 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (19 total), please visit the HSDB record page.', '4-(Methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) has known thirdhand smoke metabolites that include 1-(3-Pyridinyl)-1,4-butanediol (1,4-Diol), 1-(Methylnitrosoamino)-4-(3-pyridinyl)-1,4-butanediol, 2-Hydroxy-1-pyridin-3-ylpropan-1-one, 3-(Oxolan-2-yl)pyridine, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-Hydroxy-1-(3-pyridyl)-1-butanone (HPB), 4-Hydroxy-4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone, 4-Hydroxy-4-pyridin-3-ylbutanal, 4-Oxo-4-(3-pyridyl)-butanoic acid (OPBA), 4-Oxo-4-(pyridin-3-yl)butanal, 4-Oxo-4-pyridin-3-ylbutane-1-diazonium, 4-[(Hydroxymethyl)nitrosoamino]-1-(3-pyridinyl)-1-butanone, 4-hydroxy-4-(3-pyridyl)-butanoic acid (HPBA), 5-(3-Pyridyl))-2-hydroxytetrahydrofuran (lactol), 5-(3-Pyridyl)-tetrahydro-furan-2-one(lactone), NNAL-N-Oxide, NNAL-N-glucoronide, NNAL-O-glucoronide, NNK-N-Oxide, alpha-[3-[(Hydroxymethyl)nitrosoamino]propyl]-3-pyridinemethanol, and iso-NNAL.', 'NNK has known human metabolites that include 4-[(Hydroxymethyl)nitrosoamino]-1-(3-pyridinyl)-1-butanone.']",
12595,47290,CID 47290,CC1=C(N(C(=C1)CC(=O)[O-])C)C(=O)C2=CC=C(C=C2)Cl.[Na+],,,,,,
12596,47291,"1-(p-Aminophenyl)-1,2,3,4-tetrahydroisoquinolin-3-one hydrochloride",C1C2=CC=CC=C2C([NH2+]C1=O)C3=CC=C(C=C3)N.[Cl-],,,,,,
12597,47292,"3(2H)-Isoquinolinone, 1-(4-aminophenyl)-1,4-dihydro-",C1C2=CC=CC=C2C(NC1=O)C3=CC=C(C=C3)N,,,,,,
12598,47293,"(11S,17S)-11-ethyl-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",CC[C@H]1CC2([C@H](CCC2C3C1C4=C(CC3)C=C(C=C4)O)O)C,,,,,,
12599,47294,Azimexon,CC(C)(N1CC1C#N)N2CC2C(=O)N,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']",,,
12600,47295,"GLYCINE, N-(4,6-BIS(DIMETHYLAMINO)-s-TRIAZIN-2-YL)-N-METHYL-",CN(C)C1=NC(=NC(=N1)N(C)CC(=O)O)N(C)C,,,,,,
12601,47296,"Butanedioic acid, mono(2-((4,6-bis(dimethylamino)-1,3,5-triazin-2-yl)methylamino)ethyl)ester",CN(C)C1=NC(=NC(=N1)CNCCOC(=O)CCC(=O)O)N(C)C,,,,,,
12602,47297,"3-((4,6-Bis(dimethylamino)-s-triazin-2-yl)thio)alanine",CN(C)C1=NC(=NC(=N1)SCC(C(=O)O)N)N(C)C,,,,,,
12603,47298,"1,2-Dichlorodibenzofuran",C1=CC=C2C(=C1)C3=C(O2)C=CC(=C3Cl)Cl,,,,,,
12604,47299,"2,3-Dichlorodibenzofuran",C1=CC=C2C(=C1)C3=CC(=C(C=C3O2)Cl)Cl,,,,,,
12605,47300,"1,2,4,8-Tetrachlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C(=CC(=C3Cl)Cl)Cl,,,,,,
12606,47301,"Isonicotinic acid, 1-adamantyl ester",C1C2CC3CC1CC(C2)(C3)OC(=O)C4=CC=NC=C4,,,,,,
12607,47302,"Isonicotinic acid, 1-adamantylmethyl ester",C1C2CC3CC1CC(C2)(C3)COC(=O)C4=CC=NC=C4,,,,,,
12608,47303,"Isonicotinic acid, 2-(1-adamantyl)ethyl ester",C1C2CC3CC1CC(C2)(C3)CCOC(=O)C4=CC=NC=C4,,,,,,
12609,47304,"Indoline, 1-(3-piperidinopropionyl)-",C1CCN(CC1)CCC(=O)N2CCC3=CC=CC=C32,,,,,,
12610,47305,"Acetic acid, ((5-phenyl-1,3,4-thiadiazol-2-YL)thio)-",C1=CC=C(C=C1)C2=NN=C(S2)SCC(=O)O,,,,,,
12611,47306,"Acetic acid, ((5-phenyl-1,3,4-thiadiazol-2-YL)thio)-, ethyl ester",CCOC(=O)CSC1=NN=C(S1)C2=CC=CC=C2,,,,,,
12612,47307,"Acetic acid, ((5-phenyl-1,3,4-thiadiazol-2-YL)sulfonyl)-, ethyl ester",CCOC(=O)CS(=O)(=O)C1=NN=C(S1)C2=CC=CC=C2,,,,,,
12613,47308,"ALANINE, 3-(p-HYDROXYPHENYL)-N-(p-TOLYLSULFONYL)-, CYANOMETHYL ESTER, L-",CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)OCC#N,,,,,,
12614,47309,N-Carbobenzoxyglycine vinyl ester,C=COC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
12615,47310,"N-Carbobenzoxyglycine 1,2-dibromoethyl ester",C1=CC=C(C=C1)COC(=O)NCC(=O)OC(CBr)Br,,,,,,
12616,47311,"N-Carbobenzoxy-L-phenylalanine 1,2-dibromoethyl ester",C1=CC=C(C=C1)C[C@@H](C(=O)OC(CBr)Br)NC(=O)OCC2=CC=CC=C2,,,,,,
12617,47312,L-3-Phenyl-N-(p-tolylsulfonyl)alanine cyanomethyl ester,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CC2=CC=CC=C2)C(=O)OCC#N,,,,,,
12618,47313,"Alanine, N-benzoyl-3-phenyl-, cyanomethyl ester, L-",C1=CC=C(C=C1)C[C@@H](C(=O)OCC#N)NC(=O)C2=CC=CC=C2,,,,,,
12619,47314,"Acetamide, 2-chloro-N-(2-methoxyethyl)-N-(2-methoxyphenyl)-",COCCN(C1=CC=CC=C1OC)C(=O)CCl,,,,,,
12620,47315,CID 47315,CC=CC(=O)OC1=C(C=C(C=C1Cl)[N+](=O)[O-])Cl,,,,,,
12621,47316,"1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine;nitric acid",C1=CC(=C(C=C1Cl)Cl)CON=C(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-],,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
12622,47317,"(5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1S)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",C[C@@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O,,,,,,
12623,47318,Oltipraz,CC1=C(SSC1=S)C2=NC=CN=C2,,,"['Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)', 'Agents that act systemically to kill adult schistosomes. (See all compounds classified as Schistosomicides.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
12624,47319,Atracurium,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,,,"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",,,
12625,47320,Atracurium besylate,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-],"['For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.']","['Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.']","['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",,,['The elimination half-life is approximately 20 minutes.']
12626,47321,"1-Butanol, 4-dimethylamino-1,1-bis((3,4-(methylenedioxy)phenoxy)methyl)-, acetate, citrate",CC(=O)OC(CCC[NH+](C)C)(COC1=CC2=C(C=C1)OCO2)COC3=CC4=C(C=C3)OCO4.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
12627,47322,"4-(Dimethylamino)-1,1-bis[[3,4-(methylenedioxy)phenoxy]methyl]-1-butanol acetate",CC(=O)OC(CCCN(C)C)(COC1=CC2=C(C=C1)OCO2)COC3=CC4=C(C=C3)OCO4,,,,,,
12628,47323,"1-Butanol, 4-dimethylamino-1,1-bis((3,4-(methylenedioxy)phenoxy)methyl)-, methylcarbamate (ester), citrate",CNC(=O)OC(CCC[NH+](C)C)(COC1=CC2=C(C=C1)OCO2)COC3=CC4=C(C=C3)OCO4.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
12629,47324,"[1-(1,3-benzodioxol-5-yloxy)-2-(1,3-benzodioxol-5-yloxymethyl)-5-(dimethylamino)pentan-2-yl] N-methylcarbamate",CNC(=O)OC(CCCN(C)C)(COC1=CC2=C(C=C1)OCO2)COC3=CC4=C(C=C3)OCO4,,,,,,
12630,47325,"N,N-Bis(2-chloroethyl)-p-(phenylazo)aniline",C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
12631,47326,Fenpropathrin,CC1(C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,,,,"['/PYRETHROIDS/ READILY PENETRATE INSECT CUTICLE AS SHOWN BY TOPICAL LD50 TO PERIPLANETA (COCKROACH) ... /PYRETHROIDS/', 'WHEN RADIOACTIVE PYRETHROID IS ADMIN ORALLY TO MAMMALS, IT IS ABSORBED FROM INTESTINAL TRACT OF THE ANIMALS & DISTRIBUTED IN EVERY TISSUE EXAMINED. EXCRETION OF RADIOACTIVITY IN RATS ADMIN TRANS-ISOMER: DOSAGE: 500 MG/KG; INTERVAL 20 DAYS; URINE 36%; FECES 64%; TOTAL 100%. /PYRETHROIDS/', 'Pyrethrins are absorbed through intact skin when applied topically. When animals were exposed to aerosols of pyrethrins with piperonyl butoxide being released into the air, little or none of the combination was systemically absorbed. /Pyrethrins/', 'Although limited absorption may account for the low toxicity of some pyrethroids, rapid biodegradation by mammalian liver enzymes (ester hydrolysis and oxidation) is probably the major factor responsible. Most pyrethroid metabolites are promptly excreted, at least in part, by the kidney. /Pyrethroids/']","['Metabolism of fenproponate in rats involves rapid oxidase catalyzed ester cleavage followed by hydroxylation.', 'The metabolic pathways for the breakdown of the pyrethroids vary little between mammalian species but vary somewhat with structure. ... Essentially, pyrethrum & allethrin are broken down mainly by oxidation of the isobutenyl side chain of the acid moiety & of the unsaturated side chain of the alcohol moiety with ester hydrolysis playing & important part, whereas for the other pyrethroids ester hydrolysis predominates. /Pyrethrum and pyrethroids/', 'The relative resistance of mammals to the pyrethroids is almost wholly attributable to their ability to hydrolyze the pyrethroids rapidly to their inactive acid & alcohol components, since direct injection into the mammalian CNS leads to a susceptibility similar to that seen in insects. Some additional resistance of homeothermic organisms can also be attributed to the negative temperature coefficient of action of the pyrethroids, which are thus less toxic at mammalian body temperatures, but the major effect is metabolic. Metabolic disposal of the pyrethroids is very rapid, which means that toxicity is high by the iv route, moderate by slower oral absorption, & often unmeasureably low by dermal absorption. /Pyrethroids/', 'FASTEST BREAKDOWN IS SEEN WITH PRIMARY ALCOHOL ESTERS OF TRANS-SUBSTITUTED ACIDS SINCE THEY UNDERGO RAPID HYDROLYTIC & OXIDATIVE ATTACK. FOR ALL SECONDARY ALCOHOL ESTERS & FOR PRIMARY ALCOHOL CIS-SUBSTITUTED CYCLOPROPANECARBOXYLATES, OXIDATIVE ATTACK IS PREDOMINANT. /PYRETHROIDS/', 'For more Metabolism/Metabolites (Complete) data for FENPROPATHRIN (7 total), please visit the HSDB record page.']",
12632,47327,"BENZO(a)PYRENE-11,12-DIOL, 11,12-DIHYDRO-, cis-",C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2[C@@H]([C@@H](C5=CC=C4)O)O,,,,,,
12633,47328,D-N-Benzyloxycarbonyl-3-phenylalanine vinyl ester,C=COC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2,,,,,,
12634,47329,N-Carbobenzoxy-L-phenylalanine vinyl ester,C=COC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2,,,,,,
12635,47330,D-N-Benzyloxycarbonyl-3-phenylalanine cyanomethyl ester,C1=CC=C(C=C1)C[C@H](C(=O)OCC#N)NC(=O)OCC2=CC=CC=C2,,,,,,
12636,47331,"N-Carbobenzoxy-L-phenylalanine 1,2-dichloroethyl ester",C1=CC=C(C=C1)C[C@@H](C(=O)OC(CCl)Cl)NC(=O)OCC2=CC=CC=C2,,,,,,
12637,47332,"Alanine, N-benzyloxycarbonyl-3-phenyl-, 1,2-dibromoethyl ester, D-",C1=CC=C(C=C1)C[C@H](C(=O)OC(CBr)Br)NC(=O)OCC2=CC=CC=C2,,,,,,
12638,47333,"(+)-2-Ethyl-1,5-dimesyloxypentane",CCC(CCCS(=O)(=O)C)CS(=O)(=O)C,,,,,,
12639,47334,"3,7-Dimethyl-2-isopropyl-3,7-diazabicyclo(3.3.1)nonane dihydrochloride",CC(C)C1C2CC(C[NH+](C2)C)C[NH+]1C.[Cl-].[Cl-],,,,,,
12640,47335,"3,7-Dimethyl-2-propan-2-yl-3,7-diazabicyclo[3.3.1]nonane",CC(C)C1C2CC(CN(C2)C)CN1C,,,,,,
12641,47336,"3,7-Dibutyl-3,7-diazabicyclo(3.3.1)nonane hydrochloride",CCCC[NH+]1CC2CC(C1)CN(C2)CCCC.[Cl-],,,,,,
12642,47337,"3,7-Dibutyl-3,7-diazabicyclo[3.3.1]nonane",CCCCN1CC2CC(C1)CN(C2)CCCC,,,,,,
12643,47338,"3-Benzyl-7-butyl-3,7-diazabicyclo(3.3.1)nonane hydrochloride",CCCC[NH+]1CC2CC(C1)CN(C2)CC3=CC=CC=C3.[Cl-],,,,,,
12644,47339,"3-Benzyl-7-butyl-3,7-diazabicyclo[3.3.1]nonane",CCCCN1CC2CC(C1)CN(C2)CC3=CC=CC=C3,,,,,,
12645,47340,"3,7-Dibenzyl-3,7-diazabicyclo(3.3.1)nonane hydrochloride",C1C2C[NH+](CC1CN(C2)CC3=CC=CC=C3)CC4=CC=CC=C4.[Cl-],,,,,,
12646,47341,"3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane",C1C2CN(CC1CN(C2)CC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
12647,47342,"3-Diphenylmethyl-7-methyl-3,7-diazabicyclo(3.3.1)nonane hydrochloride",C[NH+]1CC2CC(C1)CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
12648,47343,"3-Benzhydryl-7-methyl-3,7-diazabicyclo[3.3.1]nonane",CN1CC2CC(C1)CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
12649,47344,(1R)-trans-(alphaR)-cyphenothrin,CC(=C[C@@H]1[C@H](C1(C)C)C(=O)O[C@@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,,,,,,
12650,47345,"[cyano-(3-phenoxyphenyl)methyl] (1S,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate",CC(=C[C@@H]1[C@@H](C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,,,,,,
12651,47346,N-(13-Methyltetradecyl)acetamide,CC(C)CCCCCCCCCCCCNC(=O)C,,,,,,
12652,47347,"methyl 7-[(1S,2S,3S)-3-hydroxy-2-[(3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate",CCCCC(C)(C)[C@@H](C=C[C@@H]1[C@H](CC(=O)[C@H]1CCCCC=CC(=O)OC)O)O,,,,,,
12653,47348,Aflatoxicol M1,COC1=C2C3=C(C(CC3)O)C(=O)OC2=C4C(=C1)O[C@H]5[C@@]4(C=CO5)O,,,,,,
12654,47349,(2S)-2-[[2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoic acid,CCC(C)[C@@H](C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)N,,,,,,
12655,47350,1-Bromo-3-buten-2-OL,C=CC(CBr)O,,,,,,
12656,47351,Butyltriethylplumbane,CCCC[Pb](CC)(CC)CC,,,,,,
12657,47352,4-Butyl-2'-fluorobenzophenone,CCCCC1=CC=C(C=C1)C(=O)C2=CC=CC=C2F,,,,,,
12658,47353,Cyclohexyl(diethylaminoethoxy)methylphenylsilane,CCN(CC)CCO[Si](C)(C1CCCCC1)C2=CC=CC=C2,,,,,,
12659,47354,trans-Deltamethrin,CC1([C@H]([C@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,,,,,,
12660,47355,N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide,C1CC1NC(=O)C=CC2=CC(=CC=C2)F,,,,,,
12661,47356,N-cyclopropyl-3-[3-(trifluoromethyl)phenyl]prop-2-enamide,C1CC1NC(=O)C=CC2=CC(=CC=C2)C(F)(F)F,,,,,,
12662,47357,3-[3-(Trifluoromethyl)phenyl]prop-2-enamide,C1=CC(=CC(=C1)C(F)(F)F)C=CC(=O)N,,,,,,
12663,47358,"7-Isochromancarboxylic acid, 5-chloro-3-methyl-1-oxo-",CC1CC2=C(C=C(C=C2Cl)C(=O)O)C(=O)O1,,,,,,
12664,47359,N-(5-Nitrothiazol-2-yl)benzamide,C1=CC=C(C=C1)C(=O)NC2=NC=C(S2)[N+](=O)[O-],,,,,,
12665,47360,"ANILINE, p-CHLORO-N-(2,3-EPOXYPROPYL)-",C1C(O1)CNC2=CC=C(C=C2)Cl,,,,,,
12666,47361,CID 47361,C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)O.C1=CC=C(C(=C1)C(=O)[O-])O.[Mg+2],,,,,,
12667,47362,"Aziridine, 1-((4-(1-aziridinyl)-3,5-dinitrophenyl)sulfonyl)-",C1CN1C2=C(C=C(C=C2[N+](=O)[O-])S(=O)(=O)N3CC3)[N+](=O)[O-],,,,,,
12668,47363,"6-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-1H-indole",C1CN=C(N1)C2=CC=C(C=C2)C3=CC4=C(N3)C=C(C=C4)C5=NCCN5,,,,,,
12669,47364,Arsenobetaine,C[As+](C)(C)CC(=O)[O-],,,,,,
12670,47365,Carboxymethyl(trimethyl)arsanium,C[As+](C)(C)CC(=O)O,,,,,,
12671,47366,"Ether, cyclohexyl pentachlorophenyl",C1CCC(CC1)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
12672,47367,"1,2,3,6,7,9-Hexachlorodibenzo-P-dioxin",C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C=C3Cl)Cl)Cl,,,,,,
12673,47368,"5-(2,4-Dichlorophenyl)-5-methylimidazolidine-2,4-dione",CC1(C(=O)NC(=O)N1)C2=C(C=C(C=C2)Cl)Cl,,,,,,
12674,47369,"4,7-Dimethoxy-2-benzofuranyl methyl ketone",CC(=O)C1=COC2=C(C=CC(=C12)OC)OC,,,,,,
12675,47370,"6,7-Dimethoxy-2-benzofuranyl methyl ketone",CC(=O)C1=COC2=C1C=CC(=C2OC)OC,,,,,,
12676,47371,"1-(5,8-Dimethoxy-2H-1-benzopyran-3-yl)ethanone",CC(=O)C1=CC2=C(C=CC(=C2OC1)OC)OC,,,,,,
12677,47372,"1-(7,8-Dimethoxy-2H-1-benzopyran-3-yl)ethanone",CC(=O)C1=CC2=C(C(=C(C=C2)OC)OC)OC1,,,,,,
12678,47373,4-(1-Methylethyl)-4-heptanamine hydrochloride,CCCC(CCC)(C(C)C)[NH3+].[Cl-],,,,,,
12679,47374,4-Propan-2-ylheptan-4-amine,CCCC(CCC)(C(C)C)N,,,,,,
12680,47375,4-Ethyl-5-octyn-4-amine hydrochloride,CCCC(CC)(C#CCC)[NH3+].[Cl-],,,,,,
12681,47376,4-Ethyloct-5-yn-4-amine,CCCC(CC)(C#CCC)N,,,,,,
12682,47377,N-Methyl-4-propyl-4-heptanamine hydrochloride,CCCC(CCC)(CCC)[NH2+]C.[Cl-],,,,,,
12683,47378,N-methyl-4-propylheptan-4-amine,CCCC(CCC)(CCC)NC,,,,,,
12684,47379,"N,N-Dimethyl-4-propyl-4-heptanamine hydrochloride",CCCC(CCC)(CCC)[NH+](C)C.[Cl-],,,,,,
12685,47380,"(1,1-Dipropyl-butyl)-dimethyl-amine",CCCC(CCC)(CCC)N(C)C,,,,,,
12686,47381,N-Ethyl-4-propyl-4-heptanamine hydrochloride,CCCC(CCC)(CCC)[NH2+]CC.[Cl-],,,,,,
12687,47382,"N-Ethyl-1,1-di-n-propyl-n-butylamine",CCCC(CCC)(CCC)NCC,,,,,,
12688,47383,"N,N-Di-2-propynyl-4-propyl-4-heptanamine hydrochloride",CCCC(CCC)(CCC)[NH+](C#CC)C#CC.[Cl-],,,,,,
12689,47384,"4-propyl-N,N-bis(prop-1-ynyl)heptan-4-amine",CCCC(CCC)(CCC)N(C#CC)C#CC,,,,,,
12690,47385,"N,4-Dipropyl-4-heptanamine hydrochloride",CCCC(CCC)(CCC)[NH2+]CCC.[Cl-],,,,,,
12691,47386,"N,4-dipropylheptan-4-amine",CCCC(CCC)(CCC)NCCC,,,,,,
12692,47387,N-Ethyl-N-methyl-4-propyl-4-heptanamine hydrochloride,CCCC(CCC)(CCC)[NH+](C)CC.[Cl-],,,,,,
12693,47388,N-ethyl-N-methyl-4-propylheptan-4-amine,CCCC(CCC)(CCC)N(C)CC,,,,,,
12694,47389,"1-(1,1-Dipropylbutyl)azetidine hydrochloride",CCCC(CCC)(CCC)[NH+]1CCC1.[Cl-],,,,,,
12695,47390,1-(4-Propylheptan-4-yl)azetidine,CCCC(CCC)(CCC)N1CCC1,,,,,,
12696,47391,"N,2-Dimethyl-4-propyl-4-heptanamine hydrochloride",CCCC(CCC)(CC(C)C)[NH2+]C.[Cl-],,,,,,
12697,47392,"N,2-dimethyl-4-propylheptan-4-amine",CCCC(CCC)(CC(C)C)NC,,,,,,
12698,47393,"4-Propyl-N,N,2-trimethyl-4-heptanamine hydrochloride",CCCC(CCC)(CC(C)C)[NH+](C)C.[Cl-],,,,,,
12699,47394,"N,N,2-trimethyl-4-propylheptan-4-amine",CCCC(CCC)(CC(C)C)N(C)C,,,,,,
12700,47395,CID 47395,CCCC(CCC)(CC=C)[NH2+]C.C(=CC(=O)[O-])C(=O)O,,,,,,
12701,47396,N-methyl-4-propylhept-1-en-4-amine,CCCC(CCC)(CC=C)NC,,,,,,
12702,47397,N-Ethylidene-4-propyl-4-heptanamine,CCCC(CCC)(CCC)N=CC,,,,,,
12703,47398,L(+)-2-alpha-Tropanyl phenyl(isopropenyl)glycolate,CC(=C)[C@](C1=CC=CC=C1)(C(=O)OC2CCC3CCC2N3C)O,,,,,,
12704,47399,CID 47399,CC(=O)OCC1=C(N2[C@H]([C@H](C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)[O-].[Na+],,,,,,
12705,47400,CID 47400,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)[O-].[Na+],,,,,,
12706,47401,CID 47401,CCOC1=NC(=NS1)C(Cl)(Cl)Cl.COC(=O)N=C(NC1=CC=CC=C1NC(=NC(=O)OC)S)S,,,,,,
12707,47402,N-(1-Methylethyl)-4-propyl-4-heptanamine hydrochloride,CCCC(CCC)(CCC)[NH2+]C(C)C.[Cl-],,,,,,
12708,47403,N-propan-2-yl-4-propylheptan-4-amine,CCCC(CCC)(CCC)NC(C)C,,,,,,
12709,47404,2-(2-Phenylsuccinimido)acetic acid ethyl ester,CCOC(=O)CN1C(=O)CC(C1=O)C2=CC=CC=C2,,,,,,
12710,47405,N-(3-(2-Hydroxy-3-(4-(3-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)acetamide,CC(=O)NC1=CC(=CC=C1)OCC(CN2CCN(CC2)C3=CC(=CC=C3)OC)O,,,,,,
12711,47406,N-(4-(2-Hydroxy-3-(4-phenyl-1-piperidinyl)propoxy)phenyl)acetamide,CC(=O)NC1=CC=C(C=C1)OCC(CN2CCC(CC2)C3=CC=CC=C3)O,,,,,,
12712,47407,N-(4-(2-Hydroxy-3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)acetamide,CC(=O)NC1=CC=C(C=C1)OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O,,,,,,
12713,47408,N-(3-(2-Hydroxy-3-(4-hydroxy-4-phenyl-1-piperidinyl)propoxy)phenyl)acetamide,CC(=O)NC1=CC(=CC=C1)OCC(CN2CCC(CC2)(C3=CC=CC=C3)O)O,,,,,,
12714,47409,1-(1-(2-Hydroxy-3-(3-nitrophenoxy)propyl)-4-phenyl-4-piperidinyl)ethanone,CC(=O)C1(CCN(CC1)CC(COC2=CC=CC(=C2)[N+](=O)[O-])O)C3=CC=CC=C3,,,,,,
12715,47410,"Glycine, N-(cyclopropylcarbonyl)-",C1CC1C(=O)NCC(=O)O,,,,,,
12716,47411,Nitrosolandrin,CC1=CC(=C(C(=C1)OC(=O)N(C)N=O)C)C,,,,,,
12717,47412,"BENZ(a)ANTHRACENE, 1,2-DIHYDRO-1,2-DIHYDROXY-7-METHYL-, (E)-",CC1=C2C=CC3=C(C2=CC4=CC=CC=C14)[C@H]([C@@H](C=C3)O)O,,,,,,
12718,47413,"BENZ(a)ANTHRACENE, 3,4-DIHYDRO-3,4-DIHYDROXY-7-METHYL-, trans-",CC1=C2C=CC3=C(C2=CC4=CC=CC=C14)C=C[C@H]([C@@H]3O)O,,,,,,
12719,47414,"trans-7-Methylbenz(a)anthracene-8,9-dihydrodiol",CC1=C2[C@H]([C@@H](C=CC2=CC3=C1C=CC4=CC=CC=C43)O)O,,,,,,
12720,47415,"1,2-Epoxy-1,2,3,4-tetrahydrobenz(a)anthracene",C1CC2=C(C3C1O3)C4=CC5=CC=CC=C5C=C4C=C2,,,,,,
12721,47416,"1,2,3,4-Tetrahydro-3,4-epoxybenz[a]anthracene",C1CC2=C(C=CC3=CC4=CC=CC=C4C=C23)C5C1O5,,,,,,
12722,47417,4-Nonylphenyl diphenyl phosphate,CCCCCCCCCC1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
12723,47418,CID 47418,CC1=C2C(=CC(=C1C(=O)[O-])O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)[C@H]4[C@H]([C@@H]([C@@H](C(O4)CO)O)O)O)O.[Na+],,,,,,
12724,47419,CID 47419,CC(OC(=O)C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Following oral administration of cefuroxime axetil in pediatric patients with acute otitis media with effusion or with chronic or recurrent otitis media with effusion, cefuroxime is distributed into middle ear effusions. In a study in pediatric patients 1-4 years of age with acute otitis media with effusion who received a single 15 mg/kg dose of cefuroxime as cefuroxime axetil oral suspension, cefuroxime concentrations in middle ear effusions 2-5 hours after a dose ranged from 0.2-3.6 ug/mL; concurrent serum concentrations were 2.8-7.3 ug/mL.', 'In pharmacokinetic studies of cefuroxime axetil oral suspension in children, the drug was administered postprandially or with food; no data are available regarding absorption of the suspension in fasting children. Following oral administration to children 3 months to 12 years of age (mean age: 23 months) of a single 10-, 15-, or 20-mg/kg dose of commercially available cefuroxime axetil oral suspension concomitantly with milk or milk products, peak serum cefuroxime concentrations are attained approximately 3.6, 2.7, or 3.1 hours after the dose, respectively, and average 3.3, 5.1, or 7 mcg/mL, respectively.', 'Results of a study in healthy adults indicate that cefuroxime axetil oral suspensions containing 125 mg/5 mL or 250 mg/5 mL are bioequivalent. In healthy adults who received a 250-mg dose of cefuroxime axetil given as a suspension containing 125 mg/5 mL or 250 mg/5 mL with food, peak plasma concentrations of cefuroxime were 2.4 or 2.2 aug/mL, respectively, and were attained 3 hours after the dose.', 'Following oral administration in adults of a single 125-mg, 250-mg, 500-mg, or 1-g dose of commercially available cefuroxime axetil tablets immediately following a meal, peak serum cefuroxime concentrations are attained approximately 2-3 hours after the dose and average 2.1, 4.1, 7, or 13.6 ug/mL, respectively; serum concentrations 6 hours after the dose average 0.3, 0.7, 2.2, or 3.4 ug/mL, respectively. AUC of the drug in these individuals averaged 6.7, 12.9, 27.4, or 50 mcg-h/mL, respectively.', 'For more Absorption, Distribution and Excretion (Complete) data for Cefuroxime axetil (13 total), please visit the HSDB record page.']","['Following oral administration, cefuroxime axetil is rapidly hydrolyzed to cefuroxime by nonspecific esterases in the intestinal mucosa and blood; the axetil moiety is metabolized to acetaldehyde and acetic acid. Cefuroxime is not metabolized and is excreted unchanged principally in urine by both glomerular filtration and tubular secretion.']","['In neonates and children, the serum half-life of cefuroxime is inversely proportional to age.6 25 30 Following oral administration of cefuroxime axetil oral suspension in children 3 months to 12 years of age, the serum half-life of cefuroxime averages 1.4-1.9 hours.', 'In adults, the serum or plasma half-life of cefuroxime following oral administration of commercially available cefuroxime axetil tablets or oral suspension ranges from 1.2-1.6 hours.', 'Because cefuroxime is renally excreted, the serum half-life is prolonged in patients with reduced renal function. In a study of 20 elderly patients (mean age = 83.9 years) having a mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life was 3.5 hours.']"
12725,47420,"BA 10,11-Diol-8,9-epoxide l",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)[C@H]([C@@H]([C@@H]5[C@H]4O5)O)O,,,,,,
12726,47421,"anti-(+/-)-Benz(a)anthracene-3,4-diol-1,2-oxide",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3[C@H]5C(O5)[C@@H]([C@@H]4O)O,,,,,,
12727,47422,"3-Hydroxy-28-methyl-17,23-epoxyveratraman-11-one",CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4C5CC=C6CC(CCC6(C5C(=O)C4=C3C)C)O)C)N(C1)C,,,,,,
12728,47423,"1,9-Dichlorodibenzo-p-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(O2)C=CC=C3Cl,,,,,,
12729,47424,"1,4,8-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(C=CC(=C3O2)Cl)Cl,,,,,,
12730,47425,"1,2,6-Trichlorodibenzofuran",C1=CC2=C(C(=C1)Cl)OC3=C2C(=C(C=C3)Cl)Cl,,,,,,
12731,47426,"1,3,7-Trichlorodibenzofuran",C1=CC2=C(C=C1Cl)OC3=C2C(=CC(=C3)Cl)Cl,,,,,,
12732,47427,"1,3,7,9-Tetrachlorodibenzofuran",C1=C(C=C(C2=C1OC3=C2C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
12733,47428,CID 47428,CCCC(CCC)(CCC)[NH2+]C=CC.[Cl-],,,,,,
12734,47429,CID 47429,CCCC(CCC)(CCC)NC=CC,,,,,,
12735,47430,CID 47430,CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=NOC5=CC=C(C=C5)[N+](=O)[O-])C4)C)C,,,,,,
12736,47431,CID 47431,C[C@]12CCC(=NOC3=CC=C(C=C3)[N+](=O)[O-])C[C@@H]1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@@H]5O[N+](=O)[O-])C,,,,,,
12737,47432,CID 47432,C[C@]12CCC(=NOC3=CC=C(C=C3)[N+](=O)[O-])C[C@@H]1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@]5(C)O)C,,,,,,
12738,47433,"4-[[(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ylidene]amino]oxybenzonitrile",C[C@]12CCC(=NOC3=CC=C(C=C3)C#N)C[C@@H]1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@@H]5O)C,,,,,,
12739,47434,CID 47434,CC1=C(C=CC(=C1)ON=C2CC[C@]3([C@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@H]4CC[C@@H]5O)C)C)[N+](=O)[O-],,,,,,
12740,47435,CID 47435,C[C@]12CCC(=NOCC3=CC=CC=C3)C[C@@H]1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@@H]5O)C,,,,,,
12741,47436,CID 47436,C[C@]12CCC(=NOC3=CC=C(C=C3)[N+](=O)[O-])C[C@H]1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@@H]5O)C,,,,,,
12742,47437,CID 47437,C[C@]12CCC(=NOC3=CC=CC=C3)C[C@H]1CC[C@@H]4[C@@H]2CC[C@]5([C@H]4CC[C@@H]5O)C,,,,,,
12743,47438,CID 47438,CC12CCC3C(C1CC[C@@H]2O)CCC4C3CCC(=NOC5=C(C=C(C=C5)[N+](=O)[O-])[N+](=O)[O-])C4,,,,,,
12744,47439,CID 47439,CC12CCC3C(C1CC[C@@H]2O)CCC4=CC(=NOC5=CC=CC=C5[N+](=O)[O-])CCC34,,,,,,
12745,47440,"17-beta-Hydroxyandrost-4-en-3-one O-(alpha,alpha,alpha-trifluoro-p-tolyl)oxime",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=NOC5=CC=C(C=C5)C(F)(F)F)CC[C@]34C,,,,,,
12746,47441,"(+-)-(1R,2S,3R,4R)-3,4-Dihydro-3,4-dihydroxy-1,2-epoxybenz(a)anthracene",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3[C@H]5C(O5)[C@@H]([C@H]4O)O,,,,,,
12747,47442,"anti-8,9,10,11-Tetrahydro-8,9-dihydroxy-10,11-epoxybenz(a)anthracene",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)[C@H]5[C@H](O5)[C@H]([C@@H]4O)O,,,,,,
12748,47443,"8,9-Dihydroxy-10,11-epoxy-8,9,10,11-tetrahydrobenz(a)anthracene",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O,,,,,,
12749,47444,CID 47444,C[C@]12CCC(=NOC)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,,,,,,
12750,47445,Triflumuron,C1=CC=C(C(=C1)C(=O)NC(=O)NC2=CC=C(C=C2)OC(F)(F)F)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Compounds that cause reproductive sterility in organisms. They are sometimes used to control pest populations by sterilizing males within the population. (See all compounds classified as Chemosterilants.)']",,,
12751,47446,"2,3,4-Trichloro-6-(2,4-dichlorophenoxy)aniline",C1=CC(=C(C=C1Cl)Cl)OC2=CC(=C(C(=C2N)Cl)Cl)Cl,,,,,,
12752,47447,"2,3,4,5-Tetrachloro-6-(2,4-dichlorophenoxy)aniline",C1=CC(=C(C=C1Cl)Cl)OC2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)N,,,,,,
12753,47448,CID 47448,C1=CC=C2C(=C1)C(=NN=C2Cl)CNN=CC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
12754,47449,CID 47449,C1=CC=C(C=C1)C=NNCC2=NNC(=O)C3=CC=CC=C32,,,,,,
12755,47450,CID 47450,C1=CC=C2C(=C1)C(=NNC2=O)CNN=CC3=CC=C(C=C3)O,,,,,,
12756,47451,CID 47451,C1=CC=C2C(=C1)C(=NNC2=O)CNN=CC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
12757,47452,"N-Allyl-3,4-(methylenedioxy)benzamide",C=CCNC(=O)C1=CC2=C(C=C1)OCO2,,,,,,
12758,47453,"4-{[(Pyridin-2-yl)carbamoyl]amino}benzene-1,3-disulfonyl diazide",C1=CC=NC(=C1)NC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N=[N+]=[N-])S(=O)(=O)N=[N+]=[N-],,,,,,
12759,47454,CID 47454,CC(=O)N=C1C=C(C=CC1=O)NC2=CC=C(C=C2)N(C)C,,,,,,
12760,47455,Triclopyr-butotyl,CCCCOCCOC(=O)COC1=NC(=C(C=C1Cl)Cl)Cl,,,,,,
12761,47456,"Carbamic acid, N-((diethylamino)thio)-N-methyl-, o-isopropoxyphenyl ester",CCN(CC)SN(C)C(=O)OC1=CC=CC=C1OC(C)C,,,,,,
12762,47457,2-Azaspiro[4.5]decan-3-one,C1CCC2(CC1)CC(=O)NC2,,,,,,
12763,47458,Quinuclium bromide,C[N+]12CCC(CC1)(C(=O)C2)C3=CC=CC=C3.[Br-],,,,,,
12764,47459,Quinuclium,C[N+]12CCC(CC1)(C(=O)C2)C3=CC=CC=C3,,,,,,
12765,47460,CID 47460,CN1C(=NN=CC2=CC=C(C=C2)[N+](=O)[O-])C3=CC=CC=C3C=N1,,,,,,
12766,47461,CID 47461,COC(=O)CC=CC=CCC1[C@H](C(CC1O)O)C=C[C@H](COC2=CC(=CC=C2)Cl)O,,,,,,
12767,47462,Lobenzarit sodium,C1=CC=C(C(=C1)C(=O)[O-])NC2=C(C=CC(=C2)Cl)C(=O)[O-].[Na+].[Na+],,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
12768,47463,5-Allyl-5-(2-cyclopentenyl)-1-methylbarbituric acid,CN1C(=O)C(C(=O)NC1=O)(CC=C)C2CCC=C2,,,,,,
12769,47464,CID 47464,COC(=O)CC=CC=CCC1[C@H](C(CC1O)O)C=C[C@H](COC2=CC=CC=C2)O,,,,,,
12770,47465,"1,7,8-Anthracenetriol, 9-myristoyl-",CCCCCCCCCCCCCC(=O)C1=C2C(=CC3=C1C(=C(C=C3)O)O)C=CC=C2O,,,,,,
12771,47466,Ethylacridine,CCC1=CC=CC2=NC3=CC=CC=C3C=C21,,,,,,
12772,47467,5-Methyl-2-phenylpyridine,CC1=CN=C(C=C1)C2=CC=CC=C2,,,,,,
12773,47468,"1,2,3,4-Tetrahydro-3alpha,4alpha-epoxybenz[a]anthracene-1beta,2alpha-diol",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3[C@H]([C@@H]([C@H]5[C@@H]4O5)O)O,,,,,,
12774,47469,"1H-Indole, methylphenyl-",CC1=CC(=CC2=C1C=CN2)C3=CC=CC=C3,,,,,,
12775,47470,Damme,CC(C(=O)NCC(=O)N(C)C(CC1=CC=CC=C1)C(=O)NC(CCS(=O)C)CO)NC(=O)C(CC2=CC=C(C=C2)O)N,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
12776,47471,Butoconazole nitrate,C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl.[N+](=O)(O)[O-],,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
12777,47472,Butoconazole,C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl,['For the local treatment of vulvovaginal candidiasis (infections caused by Candida)'],['Butoconazole is an imidazole derivative that has fungicidal activity <i>in vitro</i> against <i>Candida</i> spp. and has been demonstrated to be clinically effective against vaginal infections due to <i>Candida albicans</i>. <i>Candida albicans</i> has been identified as the predominant species responsible for vulvovaginal candidasis.'],"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']","['Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average.']",,
12778,47473,"(R*,S*)-1-Methyl-alpha-phenyl-2-aziridinemethanol",CN1C[C@@H]1[C@@H](C2=CC=CC=C2)O,,,,,,
12779,47474,"2-AZIRIDINEMETHANOL, 1-METHYL-alpha-PHENYL-, (R*,R*)-",CN1C[C@H]1[C@@H](C2=CC=CC=C2)O,,,,,,
12780,47475,N-Propylpentanamine,CCCCCNCCC,,,,,,
12781,47476,CID 47476,CC(=O)NC1=CC=C(C=C1)C2=CC=C(O2)C=NN3C(C(=O)NC3=O)O,,,,,,
12782,47477,"Acetamide, N-(2-chloro-6-methylphenyl)-2-((1,1-dimethylethyl)amino)-, monohydrochloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[NH2+]C(C)(C)C.[Cl-],,,,,,
12783,47478,2-(tert-butylamino)-N-(2-chloro-6-methylphenyl)acetamide,CC1=C(C(=CC=C1)Cl)NC(=O)CNC(C)(C)C,,,,,,
12784,47479,"BENZOIC ACID, p-(9-ACRIDINYLAMINO)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)C(=O)O,,,,,,
12785,47480,"ACETIC ACID, p-(9-ACRIDINYLAMINO)PHENYL-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CC(=O)O,,,,,,
12786,47481,3-[p-(9-Acridinylamino)phenyl]propenoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)C=CC(=O)O,,,,,,
12787,47482,2-(p-(9-Acridinylamino)phenyl)acetamide methanesulfonate,CS(=O)(=O)[O-].C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)CC(=O)N,,,,,,
12788,47483,2-[p-[(Acridin-9-yl)amino]phenyl]acetamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CC(=O)N,,,,,,
12789,47484,Acridin-9-yl-(4-nitro-phenyl)-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)[N+](=O)[O-],,,,,,
12790,47485,"3,3-Diphenylcyclobutylamine hydrochloride",C1C(CC1(C2=CC=CC=C2)C3=CC=CC=C3)[NH3+].[Cl-],,,,,,
12791,47486,"3,3-Diphenylcyclobutanamine",C1C(CC1(C2=CC=CC=C2)C3=CC=CC=C3)N,,,,,,
12792,47487,"N-Methyl-3,3-diphenylcyclobutylamine hydrochloride",C[NH2+]C1CC(C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
12793,47488,"N-methyl-3,3-diphenylcyclobutan-1-amine",CNC1CC(C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
12794,47489,"N,N-Dimethyl-3,3-diphenylcyclobutylamine",C[NH+](C)C1CC(C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
12795,47490,"N,N-dimethyl-3,3-diphenylcyclobutanamine",CN(C)C1CC(C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
12796,47491,Chlorsulfuron,CC1=NC(=NC(=N1)OC)NC(=O)NS(=O)(=O)C2=CC=CC=C2Cl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Absorbed by foliage and roots of both resistant and susceptible species, with acropetal and basipetal translocation.']",,
12797,47492,CID 47492,C1=CC(=CC(=C1)N)C(=O)C=CC2=CN=CC=C2,,,,,,
12798,47493,1-(3-Amino-phenyl)-3-pyridin-4-YL-propenone,C1=CC(=CC(=C1)N)C(=O)C=CC2=CC=NC=C2,,,,,,
12799,47494,1-(4-Aminophenyl)-3-pyridin-3-ylprop-2-en-1-one,C1=CC(=CN=C1)C=CC(=O)C2=CC=C(C=C2)N,,,,,,
12800,47495,"1-Butanesulfonamide, N-cyclohexyl-",CCCCS(=O)(=O)NC1CCCCC1,,,,,,
12801,47496,2-Chloroethyl laurate,CCCCCCCCCCCC(=O)OCCCl,,,,,,
12802,47497,"(1R,2R)-1,2-dihydrochrysene-1,2-diol",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=C[C@H]([C@@H]4O)O,,,,,,
12803,47498,"trans-3,4-Dihydroxy-3,4-dihydrochrysene",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@H]([C@@H](C=C4)O)O,,,,,,
12804,47499,Latamoxef,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O,"['Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef  is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.']",['Latamoxef works by inhibiting bacterial cell wall biosynthesis.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Rapidly absorbed after oral administration.', 'Renal Excretion accounts for 75 %', '8.51 L']",,['1.6 hours']
12805,47500,Latamoxef sodium,CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[Na+].[Na+],,,,,,
12806,47501,"Phenylalanine, 4-(bis(2-chloroethyl)amino)-alpha-methyl-",CC(CC1=CC=C(C=C1)N(CCCl)CCCl)(C(=O)O)N,,,,,,
12807,47502,1-Fluoro-5-methylchrysene,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)C(=CC=C4)F,,,,,,
12808,47503,3-Fluoro-5-methylchrysene,CC1=CC2=CC=CC=C2C3=C1C4=C(C=CC(=C4)F)C=C3,,,,,,
12809,47504,6-Fluoro-5-methylchrysene,CC1=C(C2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3)F,,,,,,
12810,47505,"Chrysene, 7-fluoro-5-methyl-",CC1=CC2=C(C=CC=C2F)C3=C1C4=CC=CC=C4C=C3,,,,,,
12811,47506,9-Fluoro-5-methylchrysene,CC1=CC2=C(C=C(C=C2)F)C3=C1C4=CC=CC=C4C=C3,,,,,,
12812,47507,11-Fluoro-5-methylchrysene,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3F,,,,,,
12813,47508,"Acetanilide, 4'-(9-acridinylamino)-",CC(=O)NC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
12814,47509,Lidamidine hydrochloride,CC1=C(C(=CC=C1)C)NC(=O)NC(=NC)N.Cl,,,"['Drugs that bind to and activate adrenergic receptors. (See all compounds classified as Adrenergic Agonists.)', 'Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition. (See all compounds classified as Antidiarrheals.)']",,,
12815,47510,Lidamidine,CC1=C(C(=CC=C1)C)NC(=O)NC(=NC)N,,,"['Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition. (See all compounds classified as Antidiarrheals.)', 'Drugs that bind to and activate adrenergic receptors. (See all compounds classified as Adrenergic Agonists.)']",,,
12816,47511,"N-(2,6-Diethylphenyl)-N'-(imino(methylamino)methyl)urea hydrochloride",CCC1=C(C(=CC=C1)CC)NC(=O)NC(=NC)N.Cl,,,,,,
12817,47512,"N-(2,6-diethylphenyl)-N'-(N-methylcarbamimidoyl)urea",CCC1=C(C(=CC=C1)CC)NC(=O)NC(=NC)N,,,,,,
12818,47513,CID 47513,[B-](F)(F)(F)F.C1COP2(OCC[NH+]1CCO2)C(C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
12819,47514,CID 47514,C1COP2(OCCN1CCO2)C(C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
12820,47515,5-Methyl-2-phenylhexahydroisoindoline,CC1CCC2CN(CC2C1)C3=CC=CC=C3,,,,,,
12821,47516,2-Cyclohexyl-5-methylhexahydroisoindoline,CC1CCC2CN(CC2C1)C3CCCCC3,,,,,,
12822,47517,Indeloxazine hydrochloride,C1COC(CN1)COC2=CC=CC3=C2CC=C3.Cl,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']",,,
12823,47518,CID 47518,COCC(OC)OC.COC1CCCO1,,,,,,
12824,47519,2-Methoxytetrahydrofuran,COC1CCCO1,,,,,,
12825,47520,"1,1,2-Trimethoxyethane",COCC(OC)OC,,,,,,
12826,47521,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,,,,,,
12827,47522,"Benzoic acid, 3-((3-pyridinylcarbonyl)amino)-, methyl ester, N-oxide",COC(=O)C1=CC(=CC=C1)NC(=O)C2=C[N+](=CC=C2)[O-],,,,,,
12828,47523,"Benzoic acid, 3-((4-pyridinylcarbonyl)amino)-, methyl ester, N-oxide",COC(=O)C1=CC(=CC=C1)NC(=O)C2=CC=[N+](C=C2)[O-],,,,,,
12829,47524,Butyldiethylmethylplumbane,CCCC[Pb](C)(CC)CC,,,,,,
12830,47525,Butylethyldimethylplumbane,CCCC[Pb](C)(C)CC,,,,,,
12831,47526,"1,4-Dichloro-4-ethenylcyclohexene",C=CC1(CCC(=CC1)Cl)Cl,,,,,,
12832,47527,"N-(4-(2-Chloro-4,6-dinitrophenylazo)-3-methylphenyl)diethanolamine",CC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=C(C=C(C=C2Cl)[N+](=O)[O-])[N+](=O)[O-],,,,,,
12833,47528,Nicorandil,C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-],['Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.'],"['Nicorandil is a potassium channel opener with nitrovasodilator (NO donor) actions, making it both an arterial and a venous dilator. It causes sustained dilation of both the arterial resistance and conductive vessels that increases coronary blood flow, however the effect of the drug on coronary arteries does not involve the coronary steal phenomenon. Activation of potassium channels lead to hyperpolarization of the smooth muscle cells, followed by arterial dilation and afterload reduction. Nicorandil is shown to increase pooling in the capacitance vessels with a decrease in preload through relaxing the venous vascular system. Overall, improved blood flow and reduced infarct size are achieved through reduction of end-diastolix pressure and decreased extravascular component of vascular resistance. Open studies showed the effectiveness of nicorandil treatment on various types of angina pectoris.']","['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']","['Following oral administration, nicorandil is well absorbed from the gastrointestinal tract with the oral bioavailability of 75% with the maximum peak plasma concentration (Cmax) reached within 30-60 minutes. The mean Cmax is Cmax then is approximately 300 ng/ml. Steady-state plasma concentrations of nicorandil usually are reached within approximately 96-120 h after twice daily dosing (10 or 20mg).', 'The main route of elimination is the kidney with more than 60% of the administered dose was eliminated in the urine 24 hours after dosing. Only approximately 1% of nicorandil is excreted unchanged in the urine, and the remaining compounds are mainly the denitrated metabolite (9%) and its derivatives (e.g. nicotinuric acid 6%, nicotinamide 1%, N-methylnicotinamide < 1% and nicotinic acid < 1%). Less than 2% of administered dose is excreted through the biliary system.', 'After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0-1.4 L/kg body weight.', 'The total body clearance is approximately 1.15 L/min.']","['Nicorandil undergoes extensive hepatic metabolism. The main biotransformation pathways of nicorandil are denitration, followed by subsequent nicotinamide metabolism. The main pharmacologically inactive denitrated metabolite 2-nicotinamidoethanol can be detected in the urine. The derivatives formed from the nicotinamide metabolism of denitrated products are nicotinuric acid, nicotinamide, N-methylnicotinamide and nicotinic acid.']",['The elimination half life is approximately 1 hour.']
12834,47529,"Plumbane, tributylethyl-",CCCC[Pb](CC)(CCCC)CCCC,,,,,,
12835,47530,Tropesin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(C4=CC=CC=C4)C(=O)O,,,,,,
12836,47531,"(1'R,2R,3S,4'S,6S,8'R,12'S,13'S,20'R,21'R,24'S)-2-[(2S)-Butan-2-yl]-21',24'-dihydroxy-12'-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one",CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)C,,,,,,
12837,47532,CID 47532,CCC(=CN1CCN(CC1)C2=CC=CC=C2)C(=O)C3=CC=C(C=C3)F,,,,,,
12838,47533,"2-(2-(Cyclohexylamino)ethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH2+]C3CCCCC3.[Cl-],,,,,,
12839,47534,"N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]cyclohexanamine",CC1(OC2=CC=CC=C2O1)CCNC3CCCCC3,,,,,,
12840,47535,"2-Methyl-2-(2-(phenethylamino)ethyl)-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH2+]CCC3=CC=CC=C3.[Cl-],,,,,,
12841,47536,"N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]-2-phenylethanamine",CC1(OC2=CC=CC=C2O1)CCNCCC3=CC=CC=C3,,,,,,
12842,47537,"2-(2-(Dimethylamino)ethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH+](C)C.[Cl-],,,,,,
12843,47538,"N,N-dimethyl-2-(2-methyl-1,3-benzodioxol-2-yl)ethanamine",CC1(OC2=CC=CC=C2O1)CCN(C)C,,,,,,
12844,47539,"2-(2-(Diethylamino)ethyl)-2-methyl-1,3-benzodioxole hydrochloride",CC[NH+](CC)CCC1(OC2=CC=CC=C2O1)C.[Cl-],,,,,,
12845,47540,"N,N-diethyl-2-(2-methyl-1,3-benzodioxol-2-yl)ethanamine",CCN(CC)CCC1(OC2=CC=CC=C2O1)C,,,,,,
12846,47541,"1,3-Benzodioxole, 2-methyl-2-(2-(N-methyl-N-phenethylamino)ethyl)-, hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH+](C)CCC3=CC=CC=C3.[Cl-],,,,,,
12847,47542,"N-methyl-N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]-2-phenylethanamine",CC1(OC2=CC=CC=C2O1)CCN(C)CCC3=CC=CC=C3,,,,,,
12848,47543,"2-Methyl-2-(2-piperidinoethyl)-1,3-benzodioxole hydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH+]3CCCCC3.[Cl-],,,,,,
12849,47544,"1-[2-(2-Methyl-1,3-benzodioxol-2-yl)ethyl]piperidine",CC1(OC2=CC=CC=C2O1)CCN3CCCCC3,,,,,,
12850,47545,"1,3-Benzodioxole, 2-methyl-2-(2-piperidinoethyl)-5-(piperidinomethyl)-, dihydrochloride, hemihydrate",CC1(OC2=C(O1)C=C(C=C2)C[NH+]3CCCCC3)CC[NH+]4CCCCC4.[Cl-].[Cl-],,,,,,
12851,47546,"1-[[2-Methyl-2-(2-piperidin-1-ylethyl)-1,3-benzodioxol-5-yl]methyl]piperidine",CC1(OC2=C(O1)C=C(C=C2)CN3CCCCC3)CCN4CCCCC4,,,,,,
12852,47547,"2-(2-(Aminoethylamino)ethyl)-2-methyl-1,3-benzodioxole dihydrochloride",CC1(OC2=CC=CC=C2O1)CC[NH2+]CC[NH3+].[Cl-].[Cl-],,,,,,
12853,47548,"N'-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]ethane-1,2-diamine",CC1(OC2=CC=CC=C2O1)CCNCCN,,,,,,
12854,47549,"1,3-Benzodioxole, 2-(2-(3-(diethylamino)propylamino)ethyl)-2-methyl-, dihydrochloride",CC[NH+](CC)CCC[NH2+]CCC1(OC2=CC=CC=C2O1)C.[Cl-].[Cl-],,,,,,
12855,47550,"N',N'-diethyl-N-[2-(2-methyl-1,3-benzodioxol-2-yl)ethyl]propane-1,3-diamine",CCN(CC)CCCNCCC1(OC2=CC=CC=C2O1)C,,,,,,
12856,47551,N-(Cyanoethyl)diethylenetriamine,C(CN(CCN)CCN)C#N,,,,,,
12857,47552,"Furazan, 3-methyl-4-morpholinocarbonyl-",CC1=NON=C1C(=O)N2CCOCC2,,,,,,
12858,47553,"Furazan, 3-methyl-4-pyrrolidinocarbonyl-",CC1=NON=C1C(=O)N2CCCC2,,,,,,
12859,47554,"Furazan, 3-acetylamino-4-methyl-",CC1=NON=C1NC(=O)C,,,,,,
12860,47555,CID 47555,CCC(CC)(C#C)[NH+]1CC(C1)OC(=O)NC.C(=CC(=O)[O-])C(=O)O,,,,,,
12861,47556,[1-(3-ethylpent-1-yn-3-yl)azetidin-3-yl] N-methylcarbamate,CCC(CC)(C#C)N1CC(C1)OC(=O)NC,,,,,,
12862,47557,1-Naphthalenylcarbamic acid 1-(1-ethynylcyclohexyl)-3-azetidinyl ester hydrochloride,C#CC1(CCCCC1)[NH+]2CC(C2)OC(=O)NC3=CC=CC4=CC=CC=C43.[Cl-],,,,,,
12863,47558,[1-(1-ethynylcyclohexyl)azetidin-3-yl] N-naphthalen-1-ylcarbamate,C#CC1(CCCCC1)N2CC(C2)OC(=O)NC3=CC=CC4=CC=CC=C43,,,,,,
12864,47559,"Butanol, 2,2'-(ethylenebis(nitrosoimino))bis-",C(CCO)CN(CCN(CCCCO)N=O)N=O,,,,,,
12865,47560,"9,10-Anthracenedione, 1,8-diamino-2-bromo-4,5-dihydroxy-",C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=CC(=C3N)Br)O)O,,,,,,
12866,47561,"Carbamic acid, ethyl-, ((10H-phenothiazin-10-ylcarbonyl)imino)di-2,1-ethanediyl ester",CCNC(=O)OCCN(CCOC(=O)NCC)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
12867,47562,"Carbamic acid, (1-methylethyl)-, ((10H-phenothiazin-10-ylcarbonyl)imino)di-2,1-ethanediyl ester",CC(C)NC(=O)OCCN(CCOC(=O)NC(C)C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
12868,47563,"Carbamic acid, butyl-, ((10H-phenothiazin-10-ylcarbonyl)imino)di-2,1-ethanediyl ester",CCCCNC(=O)OCCN(CCOC(=O)NCCCC)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
12869,47564,"Carbamic acid, ethyl-, (((2-chloro-10H-phenothiazin-10-yl)carbonyl)imino)di-2,1-ethanediyl ester",CCNC(=O)OCCN(CCOC(=O)NCC)C(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
12870,47565,"Carbamic acid, (1-methylethyl)-, (((2-chloro-10H-phenothiazin-10-yl)carbonyl)imino)di-2,1-ethanediyl ester",CC(C)NC(=O)OCCN(CCOC(=O)NC(C)C)C(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
12871,47566,"Carbamic acid, butyl-, (((2-chloro-10H-phenothiazin-10-yl)carbonyl)imino)di-2,1-ethanediyl ester",CCCCNC(=O)OCCN(CCOC(=O)NCCCC)C(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
12872,47567,"Carbamic acid, ethyl-, (((2-methoxy-10H-phenothiazin-10-yl)carbonyl)imino)di-2,1-ethanediyl ester",CCNC(=O)OCCN(CCOC(=O)NCC)C(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)OC,,,,,,
12873,47568,"Carbamic acid, (1-methylethyl)-, (((2-methoxy-10H-phenothiazin-10-yl)carbonyl)imino)di-2,1-ethanediyl ester",CC(C)NC(=O)OCCN(CCOC(=O)NC(C)C)C(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)OC,,,,,,
12874,47569,"Carbamic acid, butyl-, (((2-methoxy-10H-phenothiazin-10-yl)carbonyl)imino)di-2,1-ethanediyl ester",CCCCNC(=O)OCCN(CCOC(=O)NCCCC)C(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)OC,,,,,,
12875,47570,"2-Imidazoline, 2-benzyl-1-methyl-",CN1CCN=C1CC2=CC=CC=C2,,,,,,
12876,47571,"1,3,5-Triphenylfluoranthene",C1=CC=C(C=C1)C2=CC3=C4C(=C2)C5=CC=CC=C5C4=C(C=C3C6=CC=CC=C6)C7=CC=CC=C7,,,,,,
12877,47572,Tribenzoperylene,C1=CC=C(C=C1)C2=C3C=CC=C4C3=C(C=C2)C5=C(C=CC6=CC(=CC4=C65)C7=CC=CC=C7)C8=CC=CC=C8,,,,,,
12878,47573,"Dibenzo[a,f]perylene",C1=CC=C2C(=C1)C=C3C=C4C=CC=CC4=C5C3=C2C6=CC=CC7=C6C5=CC=C7,,,,,,
12879,47574,CID 47574,CC[NH+](CC)CC[NH2+]CCCC1(OC2=CC=CC=C2O1)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
12880,47575,"N',N'-diethyl-N-[3-(2-methyl-1,3-benzodioxol-2-yl)propyl]ethane-1,2-diamine",CCN(CC)CCNCCCC1(OC2=CC=CC=C2O1)C,,,,,,
12881,47576,Nizoral,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,['Investigated for use/treatment in diabetes mellitus type 2.'],,"['Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. (See all compounds classified as 14-alpha Demethylase Inhibitors.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']","['Ketoconazole is rapidly absorbed from the GI tract. Following oral administration, ketoconazole is dissolved in gastric secretions and converted to the hydrochloride salt prior to absorption from the stomach.', 'The effect of food on the rate and extent of GI absorption of ketoconazole has not been clearly determined. Some clinicians have reported that administration of ketoconazole to fasting individuals results in higher plasma concentrations of the drug than does administration with food. However, the manufacturer states that administration of ketoconazole with food increases the extent of absorption and results in more consistent plasma concentrations of the drug. The manufacturer suggests that food increases absorption of ketoconazole by increasing the rate and/or extent of dissolution of ketoconazole (e.g., by increasing bile secretions) or by delaying stomach emptying.', 'Ketoconazole is a weak dibasic agent and thus requires acidity for dissolution and absorption.', 'The bioavailability of oral ketoconazole depends on the pH of the gastric contents in the stomach; an increase in the pH results in decreased absorption of the drug. Decreased bioavailability of ketoconazole has been reported in patients with acquired immunodeficiency syndrome (AIDS), probably because of gastric hypochlorhydria associated with this condition; concomitant administration of dilute hydrochloric acid solution normalized absorption of the drug in these patients.198 Concomitant administration of an acidic beverage may increase bioavailability of oral ketoconazole in some individuals with achlorhydria.', 'For more Absorption, Distribution and Excretion (Complete) data for KETOCONAZOLE (19 total), please visit the HSDB record page.']","['Ketoconazole is partially metabolized, in the liver, to several inactive metabolites by oxidation and degradation of the imidazole and piperazine rings, by oxidative O-dealkylation, and by aromatic hydroxylation.']","['Plasma concentrations of ketoconazole appear to decline in a biphasic manner with a half-life of approximately 2 hours in the initial phase and approximately 8 hours in the terminal phase.', 'Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.']"
12882,47577,CID 47577,C1=CC=C(C=C1)CC(=O)N(CC(=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
12883,47578,CID 47578,C1=CC=C(C=C1)C[C@@H](C(=O)[O-])NC(=O)CC2=CC=CC=C2.[K+],,,,,,
12884,47579,N-Phenylacetylphenylalanine,C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)CC2=CC=CC=C2,,,,,,
12885,47580,CID 47580,C1=CC=C(C=C1)C[C@H](C(=O)[O-])NC(=O)CC2=CC=CC=C2.[K+],,,,,,
12886,47581,n-(Phenylacetyl)-d-phenylalanine,C1=CC=C(C=C1)C[C@H](C(=O)O)NC(=O)CC2=CC=CC=C2,,,,,,
12887,47582,CID 47582,C1=CC=C(C=C1)CC(C(=O)[O-])NC(=O)CC2=CC=CC=C2.[K+],,,,,,
12888,47583,3-Phenyl-2-(2-phenylacetamido)propanoic acid,C1=CC=C(C=C1)CC(C(=O)O)NC(=O)CC2=CC=CC=C2,,,,,,
12889,47584,CID 47584,C1=CC=C(C=C1)CC(=O)NC(CSCC2=CC=CC=C2)C(=O)[O-].[K+],,,,,,
12890,47585,CID 47585,C1=CC=C(C=C1)CC(=O)N[C@@H](CC2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)[O-].[Na+],,,,,,
12891,47586,(2S)-2-[(2-phenylacetyl)amino]-3-(4-phenylmethoxyphenyl)propanoic acid,C1=CC=C(C=C1)CC(=O)N[C@@H](CC2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)O,,,,,,
12892,47587,CID 47587,C1=CC=C(C=C1)CCC(=O)NC(C2=CC=CC=C2)C(=O)[O-].[Na+],,,,,,
12893,47588,2-Phenyl-2-(3-phenylpropanamido)acetic acid,C1=CC=C(C=C1)CCC(=O)NC(C2=CC=CC=C2)C(=O)O,,,,,,
12894,47589,CID 47589,C1=CC=C(C=C1)CCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[O-].[K+],,,,,,
12895,47590,beta-Phenylpropionyl-L-phenylalanine,C1=CC=C(C=C1)CCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O,,,,,,
12896,47591,CID 47591,C1=CC=C(C=C1)CCC(=O)N[C@H](CC2=CC=CC=C2)C(=O)[O-].[K+],,,,,,
12897,47592,(2R)-3-phenyl-2-(3-phenylpropanamido)propanoic acid,C1=CC=C(C=C1)CCC(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,,,,,,
12898,47593,CID 47593,C1=CC=C(C=C1)CCC(=O)NC(COCC2=CC=CC=C2)C(=O)[O-].[Na+],,,,,,
12899,47594,3-Phenylmethoxy-2-(3-phenylpropanoylamino)propanoic acid,C1=CC=C(C=C1)CCC(=O)NC(COCC2=CC=CC=C2)C(=O)O,,,,,,
12900,47595,CID 47595,C1=CC=C(C=C1)CCC(=O)NC(CSCC2=CC=CC=C2)C(=O)[O-].[K+],,,,,,
12901,47596,3-Benzylsulfanyl-2-(3-phenylpropanoylamino)propanoic acid,C1=CC=C(C=C1)CCC(=O)NC(CSCC2=CC=CC=C2)C(=O)O,,,,,,
12902,47597,CID 47597,C1=CC=C(C=C1)CCC(=O)N[C@@H](CC2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)[O-].[Na+],,,,,,
12903,47598,(2S)-3-(4-phenylmethoxyphenyl)-2-(3-phenylpropanoylamino)propanoic acid,C1=CC=C(C=C1)CCC(=O)N[C@@H](CC2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)O,,,,,,
12904,47599,CID 47599,C1=CC=C(C=C1)COC2=CC=C(C=C2)C[C@@H](C(=O)[O-])NC(=O)OCC3=CC=CC=C3.[Na+],,,,,,
12905,47600,Z-Tyr(Bzl)-OH,C1=CC=C(C=C1)COC2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)OCC3=CC=CC=C3,,,,,,
12906,47601,CID 47601,C1=CC=C(C=C1)COC(=O)C[C@@H](C(=O)[O-])NC(=O)OCC2=CC=CC=C2.[K+],,,,,,
12907,47602,Z-Asp(OBzl)-OH,C1=CC=C(C=C1)COC(=O)C[C@@H](C(=O)O)NC(=O)OCC2=CC=CC=C2,,,,,,
12908,47603,CID 47603,C1=CC=C(C=C1)COC(=O)C[C@H](C(=O)[O-])NC(=O)OCC2=CC=CC=C2.[K+],,,,,,
12909,47604,Z-D-Asp(obzl)-OH,C1=CC=C(C=C1)COC(=O)C[C@H](C(=O)O)NC(=O)OCC2=CC=CC=C2,,,,,,
12910,47605,CID 47605,CC1=C(C=CC(=C1)Cl)OCC(=O)[O-].C1=CC2=C(C(=C1)Cl)N(C(=O)S2)CC(=O)O.[Na+],,,,,,
12911,47606,"12,14-Dichlorodehydroabietic acid",CC(C)C1=C(C=C2C(=C1Cl)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)Cl,,,,,,
12912,47607,Endralazine mesylate,CS(=O)(=O)O.C1CN(CC2=CC(=NN=C21)NN)C(=O)C3=CC=CC=C3,,,,,,
12913,47608,Endralazine,C1CN(CC2=CC(=NN=C21)NN)C(=O)C3=CC=CC=C3,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
12914,47609,Bis(diisopropylaminoethyl)disulfide,CC(C)N(CCSSCCN(C(C)C)C(C)C)C(C)C,,,,,,
12915,47610,"2-Methoxy-5,7,3',4'-tetrahydroxyflavan",COC1CC2=C(C=C(C=C2OC1C3=CC(=C(C=C3)O)O)O)O,,,"['Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
12916,47611,"Benzeneacetic acid, 4-bromo-alpha-(1-cyclopropyl)-, cyano(3-phenoxyphenyl)methyl ester",C1CC1C(C2=CC=C(C=C2)Br)C(=O)OC(C#N)C3=CC(=CC=C3)OC4=CC=CC=C4,,,,,,
12917,47612,"Cystine, N,N'-bis(hydrocinnamoyl)-, dipotassium salt, L-",C1=CC=C(C=C1)CCC(=O)N[C@@H](CSSC[C@@H](C(=O)[O-])NC(=O)CCC2=CC=CC=C2)C(=O)[O-].[K+].[K+],,,,,,
12918,47613,CID 47613,C1=CC=C(C=C1)CCC(=O)NC(CSSCC(C(=O)O)NC(=O)CCC2=CC=CC=C2)C(=O)O,,,,,,
12919,47614,CID 47614,CN1CCSC1NCNC(=O)C2=CC=CC=C2,,,,,,
12920,47615,3-Carboxy-N-(3-methyl-2-thiazolidinylidene)propionamide,CN1CCSC1=NC(=O)CCC(=O)O,,,,,,
12921,47616,"3-Hexen-1-ol, 1-(2-aminobenzoate), (3Z)-",CCC=CCCOC(=O)C1=CC=CC=C1N,,,,,,
12922,47617,CID 47617,C1=CC=C(C=C1)CC(=O)NCCCC[C@@H](C(=O)[O-])NC(=O)CC2=CC=CC=C2.[K+],,,,,,
12923,47618,"N(sup 2),N(sup 6)-Bis(phenylacetyl)-DL-lysine",C1=CC=C(C=C1)CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)CC2=CC=CC=C2,,,,,,
12924,47619,CID 47619,C1=CC=C(C=C1)CC(=O)NCCCCC(C(=O)[O-])NC(=O)CC2=CC=CC=C2.[K+],,,,,,
12925,47620,"(2S)-2,6-bis[(2-phenylacetyl)amino]hexanoic acid",C1=CC=C(C=C1)CC(=O)NCCCCC(C(=O)O)NC(=O)CC2=CC=CC=C2,,,,,,
12926,47621,CID 47621,C1=CC=C(C=C1)CCC(=O)NCCCCC(C(=O)[O-])NC(=O)CCC2=CC=CC=C2.[K+],,,,,,
12927,47622,"2,6-Bis(3-phenylpropanoylamino)hexanoic acid",C1=CC=C(C=C1)CCC(=O)NCCCCC(C(=O)O)NC(=O)CCC2=CC=CC=C2,,,,,,
12928,47623,"2-Diethylamino-4-(2,5-dimethoxyphenyl)-4-octanol hydrochloride",CCCCC(CC(C)[NH+](CC)CC)(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
12929,47624,"2-(Diethylamino)-4-(2,5-dimethoxyphenyl)octan-4-ol",CCCCC(CC(C)N(CC)CC)(C1=C(C=CC(=C1)OC)OC)O,,,,,,
12930,47625,"2,4,6-Cycloheptatrien-1-one, 2-hydroxy-3-methoxy-",COC1=CC(=O)C(=CC=C1)O,,,,,,
12931,47626,2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-6-carboximidamide,C1=CC(=CC=C1C2=CC3=C(N2)C=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N,,,,,,
12932,47627,"2,2'-Vinylenedi-1-benzofuran-5-carboxamidine",C1=CC2=C(C=C1C(=N)N)C=C(O2)C=CC3=CC4=C(O3)C=CC(=C4)C(=N)N,,,,,,
12933,47628,"Benzofurazan, 4-((2-morpholinoethyl)amino)-7-nitro-",C1COCCN1CCNC2=CC=C(C3=NON=C23)[N+](=O)[O-],,,,,,
12934,47629,"Benzofurazan, 4-(4-(3-methoxyphenyl)-1-piperazinyl)-7-nitro-",COC1=CC=CC(=C1)N2CCN(CC2)C3=CC=C(C4=NON=C34)[N+](=O)[O-],,,,,,
12935,47630,"Benzofurazan, 4-(4-(3-methylphenyl)-1-piperazinyl)-7-nitro-",CC1=CC(=CC=C1)N2CCN(CC2)C3=CC=C(C4=NON=C34)[N+](=O)[O-],,,,,,
12936,47631,"Benzofurazan, 5-(4-(2-hydroxyethyl)-1-piperazinyl)-4-nitro-, 1-oxide",C1CN(CCN1CCO)C2=C(C3=NO[N+](=C3C=C2)[O-])[N+](=O)[O-],,,,,,
12937,47632,"Benzofurazan, 5-(3-(diethylamino)propylamino)-4-nitro-, 1-oxide",CCN(CC)CCCNC1=C(C2=NO[N+](=C2C=C1)[O-])[N+](=O)[O-],,,,,,
12938,47633,"Benzofurazan, 5-(2-dimethylaminoethyl)amino-4-nitro-",CN(C)CCNC1=C(C2=NON=C2C=C1)[N+](=O)[O-],,,,,,
12939,47634,"Benzofurazan, 5-(4-(3-methoxyphenyl)-1-piperazinyl)-4-nitro-",COC1=CC=CC(=C1)N2CCN(CC2)C3=C(C4=NON=C4C=C3)[N+](=O)[O-],,,,,,
12940,47635,"Benzofurazan, 5-(4-(3-methylphenyl)-1-piperazinyl)-4-nitro-",CC1=CC(=CC=C1)N2CCN(CC2)C3=C(C4=NON=C4C=C3)[N+](=O)[O-],,,,,,
12941,47636,"Benzofurazan, 4-nitro-5-(4-phenyl-1-piperazinyl)-",C1CN(CCN1C2=CC=CC=C2)C3=C(C4=NON=C4C=C3)[N+](=O)[O-],,,,,,
12942,47637,"Benzofurazan, 4-nitro-5-(4-phenyl-1-piperazinyl)-, 1-oxide",C1CN(CCN1C2=CC=CC=C2)C3=C(C4=NO[N+](=C4C=C3)[O-])[N+](=O)[O-],,,,,,
12943,47638,"Phenol, 2,3,4-tribromo-6-methyl-",CC1=CC(=C(C(=C1O)Br)Br)Br,,,,,,
12944,47639,CID 47639,C(CN(CC(=O)[O-])CC(=O)[O-])N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[NaH].[Tc].[Tc],,,,,,
12945,47640,N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine;hydrochloride,CN(CC=CC1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32.Cl,,,,,,
12946,47641,Naftifine,CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
12947,47642,Indomethacin salicylate,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4=CC=CC=C4C(=O)O,,,,,,
12948,47643,"2,7-Dibromodibenzofuran",C1=CC2=C(C=C1Br)OC3=C2C=C(C=C3)Br,,,,,,
12949,47644,"(S)-1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methyl-2-(phenylsulfonyl)isoquinoline",CC1C2=CC(=C(C=C2CCN1S(=O)(=O)C3=CC=CC=C3)OC)OC,,,,,,
12950,47645,"1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methyl-2-phenyl-isoquinoline",CC1C2=CC(=C(C=C2CCN1C3=CC=CC=C3)OC)OC,,,,,,
12951,47646,"(S)-1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methyl-2-(1-methylethyl)isoquinoline",CC1C2=CC(=C(C=C2CCN1C(C)C)OC)OC,,,,,,
12952,47647,"(S)-4-(3,4-Dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)benzenamide",C[C@H]1C2=CC(=C(C=C2CCN1C3=CC=C(C=C3)N)OC)OC,,,,,,
12953,47648,"(S)-1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methyl-2-(4-nitrophenyl)isoquinoline",CC1C2=CC(=C(C=C2CCN1C3=CC=C(C=C3)[N+](=O)[O-])OC)OC,,,,,,
12954,47649,Methyl 2-methyl-3-furyl disulfide,CC1=C(C=CO1)SSC,,,,,,
12955,47650,"2,3',4,4',5'-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=CC(=C(C(=C2)Cl)Cl)Cl,,,,,,
12956,47651,"2,2',3,4,4'-Pentachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,,,,,,
12957,47652,Nantradol hydrochloride,C[C@H]1[C@@H]2CC[C@H](C[C@H]2C3=C(N1)C=C(C=C3OC(=O)C)OC(C)CCCC4=CC=CC=C4)O.Cl,,,"['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
12958,47653,Nantradol,C[C@H]1[C@@H]2CC[C@H](C[C@H]2C3=C(N1)C=C(C=C3OC(=O)C)OC(C)CCCC4=CC=CC=C4)O,,,"['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
12959,47654,"Phenylalanine, 2,4,5-trihydroxy-alpha-methyl-",CC(CC1=CC(=C(C=C1O)O)O)(C(=O)O)N,,,,,,
12960,47655,CID 47655,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)OCCCS(=O)(=O)[O-])O.[Na+],,,,,,
12961,47656,"1-Hydroxy-2-(3-sulfopropoxy)-9,10-anthraquinone",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)OCCCS(=O)(=O)O)O,,,,,,
12962,47657,CID 47657,CCCCCCCC(C(=O)OC)S(=O)(=O)[O-].[Na+],,,,,,
12963,47658,1-Methoxy-1-oxononane-2-sulfonic acid,CCCCCCCC(C(=O)OC)S(=O)(=O)O,,,,,,
12964,47659,"Ethanaminium, N,N,N-trimethyl-2-((1-oxo-2-sufododecyl)oxy)-, inner salt",CCCCCCCCCCC(C(=O)OCC[N+](C)(C)C)S(=O)(=O)[O-],,,,,,
12965,47660,Trimethyl-[2-(2-sulfododecanoyloxy)ethyl]azanium,CCCCCCCCCCC(C(=O)OCC[N+](C)(C)C)S(=O)(=O)O,,,,,,
12966,47661,"Dodecanoic acid, 2-sulfo-, 1-(2-((2-hydroxyethyl)amino)ethyl) ester",CCCCCCCCCCC(C(=O)OCCNCCO)S(=O)(=O)O,,,,,,
12967,47662,"Dodecanoic acid, 2-sulfo-, compd. with 2-(2-aminoethoxy)ethanol (1:1)",CCCCCCCCCCC(C(=O)O)S(=O)(=O)O.C(COCCO)N,,,,,,
12968,47663,"Benzylamine, N-(2-oxazolinyl)-",C1COC(=N1)NCC2=CC=CC=C2,,,,,,
12969,47664,p-(3-(p-Chlorobenzyl)-3-methyl-1-triazeno)benzoic acid,CN(CC1=CC=C(C=C1)Cl)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12970,47665,p-(3-Methyl-3-(p-nitrobenzyl)-1-triazeno)benzoic acid,CN(CC1=CC=C(C=C1)[N+](=O)[O-])N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12971,47666,p-(3-(p-Cyanobenzyl)-3-methyl-1-triazeno)benzoic acid,CN(CC1=CC=C(C=C1)C#N)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12972,47667,p-(3-(p-Methylbenzyl)-3-methyl-1-triazeno)benzoic acid,CC1=CC=C(C=C1)CN(C)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12973,47668,p-(3-(p-Methoxybenzyl)-3-methyl-1-triazeno)benzoic acid,CN(CC1=CC=C(C=C1)OC)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12974,47669,p-(3-(p-Acetamidobenzyl)-3-methyl-1-triazeno)benzoic acid,CC(=O)NC1=CC=C(C=C1)CN(C)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12975,47670,p-(3-(p-tert-Butylbenzyl)-3-methyl-1-triazeno)benzoic acid,CC(C)(C)C1=CC=C(C=C1)CN(C)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12976,47671,p-(3-Benzyl-3-methyl-1-triazeno)benzonitrile,CN(CC1=CC=CC=C1)N=NC2=CC=C(C=C2)C#N,,,,,,
12977,47672,p-(3-(p-Chlorobenzyl)-3-methyl-1-triazeno)benzonitrile,CN(CC1=CC=C(C=C1)Cl)N=NC2=CC=C(C=C2)C#N,,,,,,
12978,47673,"Indolizine, 3-(3-aminopropyl)-2-methyl-",CC1=C(N2C=CC=CC2=C1)CCCN,,,,,,
12979,47674,"Indolizine, 3-(3-(methylamino)propyl)-2-methyl-",CC1=C(N2C=CC=CC2=C1)CCCNC,,,,,,
12980,47675,"Indolizine, 3-(3-(dimethylamino)propyl)-2-methyl-",CC1=C(N2C=CC=CC2=C1)CCCN(C)C,,,,,,
12981,47676,"Indolizine, 3-(3-(ethylamino)propyl)-2-methyl-",CCNCCCC1=C(C=C2N1C=CC=C2)C,,,,,,
12982,47677,"Indolizine, 5,6,7,8-tetrahydro-3-(3-aminopropyl)-2-methyl-",CC1=C(N2CCCCC2=C1)CCCN,,,,,,
12983,47678,"Indolizine, 5,6,7,8-tetrahydro-3-(3-(ethylamino)propyl)-2-methyl-",CCNCCCC1=C(C=C2N1CCCC2)C,,,,,,
12984,47679,"Indolizine, 5,6,7,8-tetrahydro-3-(3-(diethylamino)propyl)-2-methyl-",CCN(CC)CCCC1=C(C=C2N1CCCC2)C,,,,,,
12985,47680,"Indolizine, 5,6,7,8-tetrahydro-3-(3-(dimethylamino)propyl)-2-methyl-",CC1=C(N2CCCCC2=C1)CCCN(C)C,,,,,,
12986,47681,"Indolizine, 3-(3-(diethylamino)propyl)-2-methyl-",CCN(CC)CCCC1=C(C=C2N1C=CC=C2)C,,,,,,
12987,47682,"3',4'-Dihydroxy-2'-nitroso-2-(methylamino)acetophenone",CNCC(=O)C1=C(C(=C(C=C1)O)O)N=O,,,,,,
12988,47683,CID 47683,C1=CC(=C(C=C1C(=CN=O)NO)O)O,,,,,,
12989,47684,p-(3-Benzyl-3-methyl-1-triazeno)benzoic acid,CN(CC1=CC=CC=C1)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
12990,47685,"2,2,4,4-Tetrachloro-6,6-bis(2,2,3,3-tetrafluoropropoxy)-1,3,5,2,4,6-triazatriphosphorine",C(C(C(F)F)(F)F)OP1(=NP(=NP(=N1)(Cl)Cl)(Cl)Cl)OCC(C(F)F)(F)F,,,,,,
12991,47686,"2,4,4-Trichloro-2,6,6-tris(2,2,3,3-tetrafluoropropoxy)-1,3,5,2,4,6-triazatriphosphorine",C(C(C(F)F)(F)F)OP1(=NP(=NP(=N1)(Cl)Cl)(OCC(C(F)F)(F)F)Cl)OCC(C(F)F)(F)F,,,,,,
12992,47687,"2,2,6,6-Tetrakis(2,2,3,3-tetrafluoropropoxy)-4,4-dichloro-1,3,5,2,4,6-triazatriphosphorine",C(C(C(F)F)(F)F)OP1(=NP(=NP(=N1)(Cl)Cl)(OCC(C(F)F)(F)F)OCC(C(F)F)(F)F)OCC(C(F)F)(F)F,,,,,,
12993,47688,"5-IMIDIZOLIDINONE, 1-(o-CHLORO-p-SULFAMOYLPHENYL)-3-(o-FLUOROPHENYL)-",C1C(=O)N(CN1C2=CC=CC=C2F)C3=C(C=C(C=C3)S(=O)(=O)N)Cl,,,,,,
12994,47689,"A'-Neo-28,30-dinorgammacerane, (17alpha)-",CCC1CCC2C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C,,,,,,
12995,47690,"5H-1,4-Benzodiazepin-5-one, 1,2,3,4-tetrahydro-4-(2-dimethylaminoethyl)-1-phenyl-",CN(C)CCN1CCN(C2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
12996,47691,"5H-1,4-Benzodiazepin-5-one, 1,2,3,4-tetrahydro-4-(3-dimethylaminopropyl)-1-phenyl-",CN(C)CCCN1CCN(C2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
12997,47692,"5H-1,4-Benzodiazepin-5-one, 1,2,3,4-tetrahydro-4-(2-(dimethylamino)-1-methylethyl)-1-phenyl-",CC(CN(C)C)N1CCN(C2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
12998,47693,"5H-1,4-Benzodiazepin-5-one, 1,2,3,4-tetrahydro-4-(2-diethylaminoethyl)-1-phenyl-",CCN(CC)CCN1CCN(C2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
12999,47694,"5H-1,4-Benzodiazepin-5-one, 1,2,3,4-tetrahydro-1-phenyl-4-(2-pyrrolidin-1-ylethyl)-",C1CCN(C1)CCN2CCN(C3=CC=CC=C3C2=O)C4=CC=CC=C4,,,,,,
13000,47695,"4-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-1,4-benzodiazepin-5-one",C1CCN(CC1)CCN2CCNC3=CC=CC=C3C2=O,,,,,,
13001,47696,"Phosphoric acid, bis[(1,1-dimethylethyl)phenyl] phenyl ester",CC(C)(C)C1=CC=CC=C1OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3C(C)(C)C,,,,,,
13002,47697,"ACETOHYDROXAMIC ACID, 2-(p-METHOXYBENZAMIDO)-",COC1=CC=C(C=C1)C(=O)NCC(=O)NO,,,,,,
13003,47698,2-Methoxyhippurohydroxamic acid,COC1=CC=CC(=C1)C(=O)NCC(=O)NO,,,,,,
13004,47699,"ACETOHYDROXAMIC ACID, 2-(m-ACETAMIDOBENZAMIDO)-",CC(=O)NC1=CC=CC(=C1)C(=O)NCC(=O)NO,,,,,,
13005,47700,"Acetohydroxamic acid, 2-(2-furamido)-",C1=COC(=C1)C(=O)NCC(=O)NO,,,,,,
13006,47701,CID 47701,C1=CSC(=C1)CC(=O)NCC(=O)NO,,,,,,
13007,47702,"Acetohydroxamic acid, 2-((1,3-benzodioxol-5-YL)carboxamido)-",C1OC2=C(O1)C=C(C=C2)C(=O)NCC(=O)NO,,,,,,
13008,47703,"BENZYLAMINE, o-(3-(DIMETHYLAMINO)PROPOXY)-N-PHENYL-",CN(C)CCCOC1=CC=CC=C1CNC2=CC=CC=C2,,,,,,
13009,47704,"Ethanol, 2-((7-nitro-4-benzofurazanyl)amino)-",C1=C(C2=NON=C2C(=C1)[N+](=O)[O-])NCCO,,,,,,
13010,47705,"Carbamic acid, (2-(hexyloxy)phenyl)-, 3-(1-piperidinyl)propyl ester, hydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
13011,47706,(2-(Hexyloxy)phenyl)carbamic acid 3-piperidinopropyl ester,CCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCC2,,,,,,
13012,47707,"Carbamic acid, (2-(heptyloxy)phenyl)-, 3-(1-piperidinyl)propyl ester, hydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
13013,47708,"Carbamic acid, (2-(heptyloxy)phenyl)-, 3-(1-piperidinyl)propyl ester",CCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCC2,,,,,,
13014,47709,"Carbamic acid, (2-(octyloxy)phenyl)-, 3-(1-piperidinyl)propyl ester, hydrochloride",CCCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCC2.[Cl-],,,,,,
13015,47710,(2-(Octyloxy)phenyl)carbamic acid 3-piperidinopropyl ester,CCCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCC2,,,,,,
13016,47711,"Carbamic acid, (2-(hexyloxy)phenyl)-, 3-(hexahydro-1H-azepin-1-yl)propyl ester hydrochloride",CCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCCC2.[Cl-],,,,,,
13017,47712,3-(azepan-1-yl)propyl N-(2-hexoxyphenyl)carbamate,CCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCCC2,,,,,,
13018,47713,"Carbamic acid, (2-(heptyloxy)phenyl)-, 3-(hexahydro-1H-azepin-1-yl)propyl ester hydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCCC2.[Cl-],,,,,,
13019,47714,3-(azepan-1-yl)propyl N-(2-heptoxyphenyl)carbamate,CCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCCC2,,,,,,
13020,47715,"Carbamic acid, (2-(octyloxy)phenyl)-, 3-(hexahydro-1H-azepin-1-yl)propyl ester hydrochloride",CCCCCCCCOC1=CC=CC=C1NC(=O)OCCC[NH+]2CCCCCC2.[Cl-],,,,,,
13021,47716,3-(azepan-1-yl)propyl N-(2-octoxyphenyl)carbamate,CCCCCCCCOC1=CC=CC=C1NC(=O)OCCCN2CCCCCC2,,,,,,
13022,47717,"Carbanilic acid, o-(heptyloxy)-, 2-(2,4-dimethylpiperidino)ethyl ester, hydrochloride",CCCCCCCOC1=CC=CC=C1NC(=O)OCC[NH+]2CCC(CC2C)C.[Cl-],,,,,,
13023,47718,"2-(2,4-dimethylpiperidin-1-yl)ethyl N-(2-heptoxyphenyl)carbamate",CCCCCCCOC1=CC=CC=C1NC(=O)OCCN2CCC(CC2C)C,,,,,,
13024,47719,4-Isopropylbenzyl bromide,CC(C)C1=CC=C(C=C1)CBr,,,,,,
13025,47720,Dichloro-P-cymene,CC1=C(C=C(C=C1Cl)C(C)C)Cl,,,,,,
13026,47721,"3,3,7-Trimethyl-1,2,3,4-tetrahydrochrysene",CC1=C2C=CC3=C(C2=CC=C1)C=CC4=C3CC(CC4)(C)C,,,,,,
13027,47722,"Dimethylbenz(a)anthracene-8,9-diol-10,11-epoxide",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1[C@H]([C@@H](C5[C@H]4O5)O)O)C,,,,,,
13028,47723,"trans-8,9-Dihydro-8,9-dihydroxy-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1[C@H]([C@@H](C=C4)O)O)C,,,,,,
13029,47724,2-(1-Adamantyl)-2-hydroxyiminoethanol,C1C2CC3CC1CC(C2)(C3)C(=NO)CO,,,,,,
13030,47725,Goserelinacetate,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,,,,,,
13031,47726,1-Amino-7-nitrofluorene,C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C(=CC=C3)N,,,,,,
13032,47727,"[1,6-Dihydroxy-5-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-propan-2-ylazanium;chloride",CC(C)[NH2+]C1CCC2=C(C1O)C=CC(=C2CO)O.[Cl-],,,,,,
13033,47728,"5-Hydroxymethyl-6-hydroxy-2-isopropylamino-1,2,3,4-tetrahydronaphthalene-1-ol",CC(C)NC1CCC2=C(C1O)C=CC(=C2CO)O,,,,,,
13034,47729,"N-(2-Morpholinoethyl)-3,4,5-trimethoxyphenoxyacetamide hydrochloride hemihydrate",COC1=CC(=CC(=C1OC)OC)OCC(=O)NCC[NH+]2CCOCC2.[Cl-],,,,,,
13035,47730,"N-(2-morpholin-4-ylethyl)-2-(3,4,5-trimethoxyphenoxy)acetamide",COC1=CC(=CC(=C1OC)OC)OCC(=O)NCCN2CCOCC2,,,,,,
13036,47731,"N-(3-(4-Morpholinyl)propyl)-2-(3,4,5-trimethoxyphenoxy)acetamide hydrochloride",COC1=CC(=CC(=C1OC)OC)OCC(=O)NCCC[NH+]2CCOCC2.[Cl-],,,,,,
13037,47732,"N-(3-morpholin-4-ylpropyl)-2-(3,4,5-trimethoxyphenoxy)acetamide",COC1=CC(=CC(=C1OC)OC)OCC(=O)NCCCN2CCOCC2,,,,,,
13038,47733,"Acetamide, N-(3-(4-methyl-1-piperazinyl)propyl)-2-(3,4,5-trimethoxyphenoxy)-, dihydrochloride",CN1CCN(CC1)CCCNC(=O)COC2=CC(=C(C(=C2)OC)OC)OC.Cl.Cl,,,,,,
13039,47734,"N-[3-(4-methylpiperazin-1-yl)propyl]-2-(3,4,5-trimethoxyphenoxy)acetamide",CN1CCN(CC1)CCCNC(=O)COC2=CC(=C(C(=C2)OC)OC)OC,,,,,,
13040,47735,"Acetamide, N-(3-(4-phenyl-1-piperazinyl)propyl)-2-(3,4,5-trimethoxyphenoxy)-, dihydrochloride",COC1=CC(=CC(=C1OC)OC)OCC(=O)NCCCN2CCN(CC2)C3=CC=CC=C3.Cl.Cl,,,,,,
13041,47736,"N-[3-(4-phenylpiperazin-1-yl)propyl]-2-(3,4,5-trimethoxyphenoxy)acetamide",COC1=CC(=CC(=C1OC)OC)OCC(=O)NCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
13042,47737,"Acetamide, N-(3-(4-(2-methylphenyl)-1-piperazinyl)propyl)-2-(3,4,5-trimethoxyphenoxy)-, dihydrochloride",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=CC(=C(C(=C3)OC)OC)OC.Cl.Cl,,,,,,
13043,47738,"N-[3-[4-(2-methylphenyl)piperazin-1-yl]propyl]-2-(3,4,5-trimethoxyphenoxy)acetamide",CC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)COC3=CC(=C(C(=C3)OC)OC)OC,,,,,,
13044,47739,CID 47739,CC[NH+](CC)CCOC(=O)COC1=CC(=C(C(=C1)OC)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
13045,47740,"2-(Diethylamino)ethyl 2-(3,4,5-trimethoxyphenoxy)acetate",CCN(CC)CCOC(=O)COC1=CC(=C(C(=C1)OC)OC)OC,,,,,,
13046,47741,"2,4-Diamino-6-methylphenol hydrochloride",CC1=CC(=CC(=C1O)N)N.Cl,,,,,,
13047,47742,N-Acetyl-N-methylpentanamide,CCCCC(=O)N(C)C(=O)C,,,,,,
13048,47743,N-Acetyl-N-propylpentanamide,CCCCC(=O)N(CCC)C(=O)C,,,,,,
13049,47744,"N-Acetyl-N-(1,1-dimethylethyl) acetamide",CC(=O)N(C(=O)C)C(C)(C)C,,,,,,
13050,47745,N-Acetylhexadecanamide,CCCCCCCCCCCCCCCC(=O)NC(=O)C,,,,,,
13051,47746,N-Acetyloctadecanamide,CCCCCCCCCCCCCCCCCC(=O)NC(=O)C,,,,,,
13052,47747,"7-Methyl-N,N-dimethyltryptamine",CC1=C2C(=CC=C1)C(=CN2)CCN(C)C,,,,,,
13053,47748,CID 47748,C1=CC=C2C(=C1)N(C(=CN=NC(=O)CC#N)C=[N+]2[O-])O,,,,,,
13054,47749,"1,3,5-Triazine-2,4,6-triamine, N''-methyl-N,N,N',N'-tetraethyl-",CCN(CC)C1=NC(=NC(=N1)NC)N(CC)CC,,,,,,
13055,47750,Hexakis(trideuteriomethyl)melamine,[2H]C([2H])([2H])N(C1=NC(=NC(=N1)N(C([2H])([2H])[2H])C([2H])([2H])[2H])N(C([2H])([2H])[2H])C([2H])([2H])[2H])C([2H])([2H])[2H],,,,,,
13056,47751,Fazarabine,C1=NC(=NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)N,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
13057,47752,"Benzamide, N-(1-amino-2-anthraquinonyl)-",C1=CC=C(C=C1)C(=O)NC2=C(C3=C(C=C2)C(=O)C4=CC=CC=C4C3=O)N,,,,,,
13058,47753,"2-Anthracenesulfonic acid, 9,10-dihydro-1-amino-4-benzoyl-9,10-dioxo-",C1=CC=C(C=C1)C(=O)C2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O,,,,,,
13059,47754,2-Bromo-4-nitro-1H-imidazole,C1=C(NC(=N1)Br)[N+](=O)[O-],,,,,,
13060,47755,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-methoxycarbonylaminothio)-N-methylcarbamoyloxy)-",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)SN(C)C(=O)OC)C,,,,,,
13061,47756,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-ethoxycarbonylaminothio)-N-methylcarbamoyloxy)-",CCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13062,47757,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-propoxycarbonylaminothio)-N-methylcarbamoyloxy)-",CCCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13063,47758,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-isopropoxycarbonylaminothio)-N-methylcarbamoyloxy)-",CC(C)OC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13064,47759,Furathiocarb,CCCCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,"['Little information is available on the distribution of carbamates in the various organs and tissues in mammals following exposure by inhalation or the oral route.  The organs in which residues have been reported are the liver, kidneys, brain, fat, and muscle.The half-life in the rat is of the order of 3 - 8 hr. It seems that the excretion of carbamates via urine is also rapid in man, and that the metabolic pathways in man are the same as those in the rat. /Carbamate pesticides/', 'The pharmacokinetics of furathiocarb were studied in vivo in male Sprague-Dawley rats following dermal treatment. HPLC and post-column derivatization were used for the analysis of furathiocarb and its metabolites (carbofuran, 3-hydroxycarbofuran and 3-ketocarbofuran). Carbofuran and 3-hydroxycarbofuran were detected in plasma and urine rather than furathiocarb. 3-Ketocarbofuran, another potential metabolite, was not observed in any sample. The concentration of carbofuran was higher than that of 3-hydroxycarbofuran in plasma, but the reverse was the case in urine. The corresponding area under the plasma concentration-time curve, Tmax, and Cmax values of carbofuran and 3-hydroxycarbofuran for 1,500 mg/kg doses were 2.4-8.0 mg equiv/ml, 12 hr and 0.1-0.4 mg equiv/ml, respectively. T1/2 was calculated only for 3-hydroxycarbofuran (28 hr). Two metabolites were excreted in a dose-dependent manner without saturation.']","['Metabolic transformation in rats proceeds via rapid and complete hydrolysis, followed by oxidation and conjugation. Excretion occurs mainly via kidney.', 'The first step in the metabolism of carbamates is hydrolysis to carbamic acid, which decomposes to carbon dioxide (CO2) and the corresponding amine. The mechanism of hydrolysis is different for  N -methyl and  N-dimethyl derivatives.  The  N-methyl carbamates pass through an isocyanate intermediate, whereas in the hydrolysis of  N-dimethylcarbamates, an addition product with a hydroxyl ion is formed yielding the alcohol and  N-dimethyl substituted acid.  The rate of hydrolysis by esterases is faster in mammals than in plants and insects. Apart from hydrolysis, oxidation also takes place including: hydroxylation of the aromatic ring,  O-dealkylation,  N -methyl hydroxylation,  N-dealkylation, oxidation of aliphatic side chains, and sulfoxidation to the corresponding sulfone. Oxidation is associated with the mixed-function oxidase (MFO) enzymes. Conjugation leads to the formation of  O- and  N- glucuronides, sulfates, and mercapturic acid derivatives in mammals.  Glycosides and phosphates are conjugation products more common in plants. /Carbamate Pesticides/', 'The pharmacokinetics of furathiocarb were studied in vivo in male Sprague-Dawley rats following dermal treatment. HPLC and post-column derivatization were used for the analysis of furathiocarb and its metabolites (carbofuran, 3-hydroxycarbofuran and 3-ketocarbofuran). Carbofuran and 3-hydroxycarbofuran were detected in plasma and urine rather than furathiocarb. 3-Ketocarbofuran, another potential metabolite, was not observed in any sample. ...']",['The half-life in the rat is of the order of 3-8 hr. /Carbamate pesticides/']
13065,47760,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-pentoxycarbonylaminothio)-N-methylcarbamoyloxy)-",CCCCCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13066,47761,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-heptyloxycarbonylaminothio)-N-methylcarbamoyloxy)-",CCCCCCCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13067,47762,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-octyloxycarbonylaminothio)-N-methylcarbamoyloxy)-",CCCCCCCCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13068,47763,"Benzofuran, 2,3-dihydro-2,2-dimethyl-7-(N-(N-methyl-N-decyloxycarbonylaminothio)-N-methylcarbamoyloxy)-",CCCCCCCCCCOC(=O)N(C)SN(C)C(=O)OC1=CC=CC2=C1OC(C2)(C)C,,,,,,
13069,47764,"Carbamic acid, thiobis(N-methyl-, naphthyl octyl ester",CCCCCCCCOC(=O)NCSCNC(=O)OC1=CC=CC2=CC=CC=C21,,,,,,
13070,47765,"Carbamic acid, thiobis(N-methyl-, 3-isopropylphenyl methyl ester",CC(C)C1=CC(=CC=C1)OC(=O)NCSCNC(=O)OC,,,,,,
13071,47766,"Carbamic acid, thiobis(N-methyl-, 3-isopropylphenyl propyl ester",CCCOC(=O)NCSCNC(=O)OC1=CC=CC(=C1)C(C)C,,,,,,
13072,47767,"Carbamic acid, thiobis(N-methyl-, butyl 3-isopropylphenyl ester",CCCCOC(=O)NCSCNC(=O)OC1=CC=CC(=C1)C(C)C,,,,,,
13073,47768,"3-Benzofurancarboxylic acid, 6-bromo-5-hydroxy-2-methyl-4-((4-methyl-1-piperazinyl)methyl)-, ethyl ester, hydrochloride",CCOC(=O)C1=C(OC2=CC(=C(C(=C21)CN3CC[NH+](CC3)C)O)Br)C.[Cl-],,,,,,
13074,47769,"3-Benzofurancarboxylic acid, 6-bromo-5-hydroxy-2-methyl-4-((4-methyl-1-piperazinyl)methyl)-, ethyl ester",CCOC(=O)C1=C(OC2=CC(=C(C(=C21)CN3CCN(CC3)C)O)Br)C,,,,,,
13075,47770,CID 47770,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)C[NH2+]C(=N)S.[Br-],,,,,,
13076,47771,CID 47771,CCOC(=O)C1=C(OC2=C1C=C(C=C2)OC)CN=C(N)S,,,,,,
13077,47772,5-Hydroxy-2-(piperidinomethyl)-3-benzofurancarboxylic acid ethyl ester hydrochloride,CCOC(=O)C1=C(OC2=C1C=C(C=C2)O)C[NH+]3CCCCC3.[Cl-],,,,,,
13078,47773,Ethyl 5-hydroxy-2-(piperidin-1-ylmethyl)-1-benzofuran-3-carboxylate,CCOC(=O)C1=C(OC2=C1C=C(C=C2)O)CN3CCCCC3,,,,,,
13079,47774,5-Hydroxy-2-(morpholinomethyl)-3-benzofurancarboxylic acid ethyl ester hydrochloride,CCOC(=O)C1=C(OC2=C1C=C(C=C2)O)C[NH+]3CCOCC3.[Cl-],,,,,,
13080,47775,5-Hydroxy-2-morpholin-4-ylmethyl-benzofuran-3-carboxylic acid ethyl ester,CCOC(=O)C1=C(OC2=C1C=C(C=C2)O)CN3CCOCC3,,,,,,
13081,47776,"2-Benzofurancarboxylic acid, 4-bromo-6-((dimethylamino)methyl)-5-hydroxy-, ethyl ester, hydrochloride",CCOC(=O)C1=CC2=C(O1)C=C(C(=C2Br)O)C[NH+](C)C.[Cl-],,,,,,
13082,47777,Ethyl 4-bromo-6-[(dimethylamino)methyl]-5-hydroxy-1-benzofuran-2-carboxylate,CCOC(=O)C1=CC2=C(O1)C=C(C(=C2Br)O)CN(C)C,,,,,,
13083,47778,4-((Dimethylamino)methyl)-5-hydroxy-2-benzofurancarboxylic acid ethyl ester hydrochloride,CCOC(=O)C1=CC2=C(O1)C=CC(=C2C[NH+](C)C)O.[Cl-],,,,,,
13084,47779,Ethyl 4-[(dimethylamino)methyl]-5-hydroxy-1-benzofuran-2-carboxylate,CCOC(=O)C1=CC2=C(O1)C=CC(=C2CN(C)C)O,,,,,,
13085,47780,"Nicotinic acid, 2-(6-((2-hydroxypropyl)methylamino)-3-pyridazinyl)hydrazide",CC(CN(C)C1=NN=C(C=C1)NNC(=O)C2=CN=CC=C2)O,,,,,,
13086,47781,"3-Furancarboxamide, N,N-diethyltetrahydro-5-oxo-3-phenyl-",CCN(CC)C(=O)C1(CC(=O)OC1)C2=CC=CC=C2,,,,,,
13087,47782,2-Hydroxychrysene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC(=C4)O,,,,,,
13088,47783,CID 47783,C1=CC2=C3C=C(NN3C(=O)N=C2C=C1)CO,,,,,,
13089,47784,CID 47784,CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CCC5C6=CC(=O)OC6)O)C)C)O)O)[NH3+].[Cl-],,,,,,
13090,47785,CID 47785,CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CCC5C6=CC(=O)OC6)O)C)C)O)O)N,,,,,,
13091,47786,"Acetophenone, 3'-(3-(4-phenyl-1-piperazinyl)propoxy)-",CC(=O)C1=CC(=CC=C1)OCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
13092,47787,"Acrylophenone, 4'-(3-(4-phenyl-1-piperazinyl)propoxy)-, dihydrochloride",C=CC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3.Cl.Cl,,,,,,
13093,47788,1-[4-[3-(4-Phenylpiperazin-1-yl)propoxy]phenyl]prop-2-en-1-one,C=CC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
13094,47789,1-(p-alpha-Hydroxypropylphenoxy)-3-(N-phenylpiperazinyl)propane,CCC(C1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3)O,,,,,,
13095,47790,1-(p-alpha-Acetoxypropylphenoxy)-3-(N-phenylpiperazinyl)propane,CCC(C1=CC=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3)OC(=O)C,,,,,,
13096,47791,Zinc pantothenate,CC(C)(CO)C(C(=O)NCCC(=O)[O-])O.CC(C)(CO)C(C(=O)NCCC(=O)[O-])O.[Zn+2],,,"['A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
13097,47792,"Ethylamine, 1-acetoxy-N-methyl-N-nitroso-",CC(N(C)N=O)OC(=O)C,,,,,,
13098,47793,N-Ethyl-N-(acetoxymethyl)nitrosamine,CCN(COC(=O)C)N=O,,,,,,
13099,47794,CID 47794,COC1=C(C=C(C=C1)CCN2C(=O)CSC2=NN=CC3=CC=CO3)OC,,,,,,
13100,47795,"4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine",C1CN(N=C1N)C2=CC=CC(=C2)C(F)(F)F,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)', 'Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)']",,,
13101,47796,3-Ethylcyclobutanecarboxylic acid,CCC1CC(C1)C(=O)O,,,,,,
13102,47797,"Cyclobutanecarboxylic acid, 3-propyl-",CCCC1CC(C1)C(=O)O,,,,,,
13103,47798,"Cyclobutanecarboxylic acid, 3-butyl-",CCCCC1CC(C1)C(=O)O,,,,,,
13104,47799,3-Pentyl-cyclobutanecarboxylic acid,CCCCCC1CC(C1)C(=O)O,,,,,,
13105,47800,"Cyclobutanecarboxylic acid, 3-cyclopentyl-",C1CCC(C1)C2CC(C2)C(=O)O,,,,,,
13106,47801,3-Benzylcyclobutanecarboxylic acid,C1C(CC1C(=O)O)CC2=CC=CC=C2,,,,,,
13107,47802,"Cyclobutanecarboxylic acid, 3-cycloheptyl-",C1CCCC(CC1)C2CC(C2)C(=O)O,,,,,,
13108,47803,"Cyclobutanecarboxylic acid, 3-ethyl-3-methyl-",CCC1(CC(C1)C(=O)O)C,,,,,,
13109,47804,"Cyclobutanecarboxylic acid, 3,3-diethyl-",CCC1(CC(C1)C(=O)O)CC,,,,,,
13110,47805,"CYCLOBUTANECARBOXYLIC ACID, 3-tert-BUTYL-",CC(C)(C)C1CC(C1)C(=O)O,,,,,,
13111,47806,3-Phenylcyclobutanecarboxylic acid,C1C(CC1C(=O)O)C2=CC=CC=C2,,,,,,
13112,47807,N-Propyl-N-(acetoxymethyl)nitrosamine,CCCN(COC(=O)C)N=O,,,,,,
13113,47808,3-Methyl-2-benzofurancarboxylic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=C(C2=CC=CC=C2O1)C.[Cl-],,,,,,
13114,47809,2-(Diethylamino)ethyl 3-methyl-1-benzofuran-2-carboxylate,CCN(CC)CCOC(=O)C1=C(C2=CC=CC=C2O1)C,,,,,,
13115,47810,"Carbamic acid, (3-methyl-2-benzofuranyl)-, 2-(1-piperidinyl)ethyl ester",CC1=C(OC2=CC=CC=C12)NC(=O)OCCN3CCCCC3,,,,,,
13116,47811,Pergolide,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,"[""Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.""]","['Pergolide stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D<sub>1</sub> and D<sub>5</sub> subreceptors and are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> subreceptors and has been associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D<sub>2</sub> and D<sub>3</sub> receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D<sub>2</sub>- and D<sub>3</sub>-receptors. It also exhibits agonist activity on dopamine D<sub>4</sub>, D<sub>1</sub>, and D<sub>5</sub>, 5-hydroxytryptamine (5-HT)<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, &alpha;<sub>2A</sub>-, &alpha;<sub>2B</sub>-, &alpha;<sub>2C</sub>-, &alpha;<sub>1A</sub>-, &alpha;<sub>1B</sub>-, and &alpha;<sub>1D</sub>-adrenergic receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT<sub>2A</sub> agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion. Pergolide also causes transient increases in somatotropin (growth hormone) secretion and decreases in luteinizing hormone (LH) concentrations.']",['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],"['Significant amount may be absorbed (evidence on bioavailability still lacking).', 'The major route of excretion is the kidney.']",['Extensively hepatic.'],['27 hours']
13117,47812,Pergolide mesylate,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
13118,47813,"(6aR,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline",CCCN1CC(C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,,,,,,
13119,47814,CID 47814,[Be+2].[Be+2].[Be+2].C(=O)([O-])[O-].C(=O)([O-])[O-].[OH-].[OH-],,,,,,
13120,47815,"2,2-Bis(bromomethyl)-3-chloropropyl bis(2-chloro-1-(chloromethyl)ethyl) phosphate",C(C(CCl)OP(=O)(OCC(CCl)(CBr)CBr)OC(CCl)CCl)Cl,,,,,,
13121,47816,"4-[[2-[2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid",CC(C(C(=O)NC(CCC(=O)O)C(=O)N)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)O)CO)O)O,,,,,,
13122,47817,CID 47817,C1=CC(=C2C(=C1Cl)C(=O)C3=C(C2=O)C(=[N+](O)[O-])C=CC3=N)Cl,,,,,,
13123,47818,"Ethanol, 2-((3-hydrazino-6-pyridazinyl)amino)-, dihydrochloride",C1=CC(=NN=C1NCCO)NN.Cl.Cl,,,,,,
13124,47819,2-[(6-Hydrazinylpyridazin-3-yl)amino]ethanol,C1=CC(=NN=C1NCCO)NN,,,,,,
13125,47820,"4-(p-(9-Acridinylamino)phenyl)butyric acid, hydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)NC4=CC=C(C=C4)CCCC(=O)O.[Cl-],,,,,,
13126,47821,4-[4-(Acridin-9-ylamino)phenyl]butanoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCC(=O)O,,,,,,
13127,47822,"6-(p-(9-Acridinylamino)phenyl)hexanoic acid, hydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)NC4=CC=C(C=C4)CCCCCC(=O)O.[Cl-],,,,,,
13128,47823,6-[4-(Acridin-9-ylamino)phenyl]hexanoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCC(=O)O,,,,,,
13129,47824,"HEPTANOIC ACID, 7-(p-(9-ACRIDINYLAMINO)PHENYL)-",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCCC(=O)O,,,,,,
13130,47825,"8-(p-(9-Acridinylamino)phenyl)octanoic acid, hydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)CCCCCCCC(=O)O.[Cl-],,,,,,
13131,47826,8-[4-(Acridin-9-ylamino)phenyl]octanoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCCCC(=O)O,,,,,,
13132,47827,9-(p-(9-Acridinylamino)phenyl)nonanoic acid hydrochloride,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)CCCCCCCCC(=O)O.[Cl-],,,,,,
13133,47828,9-[4-(Acridin-9-ylamino)phenyl]nonanoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCCCCC(=O)O,,,,,,
13134,47829,"4-(p-(9-Acridinylamino)phenoxy)butyric acid, hydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)NC4=CC=C(C=C4)OCCCC(=O)O.[Cl-],,,,,,
13135,47830,4-[4-(Acridin-9-ylamino)phenoxy]butanoic acid,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)OCCCC(=O)O,,,,,,
13136,47831,"2-(p-(9-Acridinylamino)phenyl)butyric acid, hydrochloride",CCC(C1=CC=C(C=C1)NC2=C3C=CC=CC3=[NH+]C4=CC=CC=C42)C(=O)O.[Cl-],,,,,,
13137,47832,2-[4-(Acridin-9-ylamino)phenyl]butanoic acid,CCC(C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42)C(=O)O,,,,,,
13138,47833,"HEXANAMIDE, 6-(p-(9-ACRIDINYLAMINO)PHENYL)-, METHANESULFONATE",CS(=O)(=O)O.C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCC(=O)N,,,,,,
13139,47834,6-[4-(Acridin-9-ylamino)phenyl]hexanamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCC(=O)N,,,,,,
13140,47835,"8-(p-(9-Acridinylamino)phenyl)octanamide, methanesulfonate",CS(=O)(=O)[O-].C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=C(C=C4)CCCCCCCC(=O)N,,,,,,
13141,47836,8-[4-(Acridin-9-ylamino)phenyl]octanamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)CCCCCCCC(=O)N,,,,,,
13142,47837,N-(p-(Acridin-9-ylamino)phenyl)hexanesulfonamide hydrochloride,CCCCCCS(=O)(=O)NC1=CC=C(C=C1)[NH2+]C2=C3C=CC=CC3=NC4=CC=CC=C42.[Cl-],,,,,,
13143,47838,"Hexanesulfonanilide, 4'-(9-acridinylamino)-",CCCCCCS(=O)(=O)NC1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
13144,47839,[(2R)-2-(4-chlorophenyl)-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]azanium;chloride,C[C@@](C1=CC=C(C=C1)Cl)(C(=O)OC(C)(C)C)[NH3+].[Cl-],,,,,,
13145,47840,tert-butyl (2R)-2-amino-2-(4-chlorophenyl)propanoate,C[C@@](C1=CC=C(C=C1)Cl)(C(=O)OC(C)(C)C)N,,,,,,
13146,47841,"2-(3-Chlorophenyl)-1,1-dimethylethyl 2-aminopropanoate hydrochloride",CC(C)(C)OC(=O)C(C)(C1=CC(=CC=C1)Cl)[NH3+].[Cl-],,,,,,
13147,47842,Tert-butyl 2-amino-2-(3-chlorophenyl)propanoate,CC(C)(C)OC(=O)C(C)(C1=CC(=CC=C1)Cl)N,,,,,,
13148,47843,"1,1-Dimethyl-2-(4-methylphenyl)ethyl 2-aminopropanoate hydrobromide",CC1=CC=C(C=C1)CC(C)(C)OC(=O)C(C)[NH3+].[Br-],,,,,,
13149,47844,[2-Methyl-1-(4-methylphenyl)propan-2-yl] 2-aminopropanoate,CC1=CC=C(C=C1)CC(C)(C)OC(=O)C(C)N,,,,,,
13150,47845,Verofylline,CCC(C)CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C,,,,,,
13151,47846,CID 47846,CCCCOC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC2(OCCO2)COC3=CC=CC=C3,,,,,,
13152,47847,CID 47847,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)CCC2(OCCO2)COC3=CC=CC=C3,,,,,,
13153,47848,CID 47848,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC2(OCCO2)CCC3=CC=CC=C3,,,,,,
13154,47849,CID 47849,COC(=O)CCCC=CCC1C(CC(C1C=CC2OCC(O2)C3=CC=C(C=C3)Cl)O)O,,,,,,
13155,47850,CID 47850,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC2OCC(O2)COC3=CC=C(C=C3)F,,,,,,
13156,47851,CID 47851,COC(=O)CCCC=CCC1[C@H](C(CC1O)O)C=CC2(OCCO2)COC3=CC=CC(=C3)C(F)(F)F,,,,,,
13157,47852,CID 47852,CC1=CC(=CC=C1)OCC2=NN=C(O2)S,,,,,,
13158,47853,"Acetamide, N-(4,7-dimethoxy-6-(2-(1-pyrrolidinyl)ethoxy)-5-benzofuranyl)-, methanesulfonate",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCCC3)OC)OC=C2)OC.CS(=O)(=O)O,,,,,,
13159,47854,"N-[4,7-dimethoxy-6-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-5-yl]acetamide",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCCC3)OC)OC=C2)OC,,,,,,
13160,47855,"Acetamide, N-(4,7-dimethoxy-6-(2-(diethylamino)ethoxy)-5-benzofuranyl)-, methanesulfonate, hydrate",CCN(CC)CCOC1=C(C2=C(C=CO2)C(=C1NC(=O)C)OC)OC.CS(=O)(=O)O,,,,,,
13161,47856,"N-[6-[2-(diethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]acetamide",CCN(CC)CCOC1=C(C2=C(C=CO2)C(=C1NC(=O)C)OC)OC,,,,,,
13162,47857,"Acetamide, N-(4,7-dimethoxy-6-(3-piperidinopropoxy)-5-benzofuranyl)-, methanesulfonate",CC(=O)NC1=C(C2=C(C(=C1OCCCN3CCCCC3)OC)OC=C2)OC.CS(=O)(=O)O,,,,,,
13163,47858,"N-[4,7-dimethoxy-6-(3-piperidin-1-ylpropoxy)-1-benzofuran-5-yl]acetamide",CC(=O)NC1=C(C2=C(C(=C1OCCCN3CCCCC3)OC)OC=C2)OC,,,,,,
13164,47859,"4,7-Dimethoxy-6-(2-piperidinoethoxy)-5-benzofuranamine dihydrochloride",COC1=C(C(=C(C2=C1C=CO2)OC)OCCC3CCCC[NH2+]3)[NH3+].[Cl-].[Cl-],,,,,,
13165,47860,"4,7-Dimethoxy-6-(2-piperidin-2-ylethoxy)-1-benzofuran-5-amine",COC1=C(C(=C(C2=C1C=CO2)OC)OCCC3CCCCN3)N,,,,,,
13166,47861,"N-(4,7-Dimethoxy-6-(2-piperidinoethoxy)-5-benzofuranyl)acetamide hydrochloride",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCCCC3)OC)OC=C2)OC.Cl,,,,,,
13167,47862,"5-Acetamido 4,7-dimethoxy 6-piperidinoethoxy benzofuran",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCCCC3)OC)OC=C2)OC,,,,,,
13168,47863,"Acetamide, N-(4,7-dimethoxy-6-(2-(4-methyl-1-piperazinyl)ethoxy)-5-benzofuranyl)-, hydrochloride, hydrate (1:2:2.5)",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCN(CC3)C)OC)OC=C2)OC.Cl.Cl,,,,,,
13169,47864,"5-Acetamido 4,7-dimethoxy 6-(4-methyl piperazino ethoxy) benzofuran",CC(=O)NC1=C(C2=C(C(=C1OCCN3CCN(CC3)C)OC)OC=C2)OC,,,,,,
13170,47865,"Benzo(a)pyrene-9,10-diol-7,8-epoxide, syn",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@@H]([C@@H]6[C@H]5O6)O)O)C=C2,,,,,,
13171,47866,Cyromazine,C1CC1NC2=NC(=NC(=N2)N)N,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Dermal Absorption /in rats/ ... at 10 hrs = 13 %. Cyromazine /was/ apparently rapidly absorbed into the skin in an inverse dose related manner. The absorption into the skin is followed by a slower release into the body. The main route of excretion is apparently by the urine. There is no evidence that the compound is sequestered in the skin. Mean absorption based on blood, urinary/ fecal excretion, and carcass, ranged from 0.6 to 7% for animals sacrificed at the end of the exposure periods. For animals exposed for 10 and 24 hours and followed for 48 hours post-exposure, mean absorption ranged from 8 to 14.5%. Total radioactivity absorbed generally decreased as dose increased indicating saturation of absorption with increasing dose. Amounts remaining in/on the skin at termination ranged from 4.5% (10 mg dose/2 hr exposure) to 24% ( 0.1 mg dose/24 hr exposure). The majority of the absorbed radioactivity was found in the urine and carcass. Most of the unabsorbed radioactivity was found in the skin washes from each dose/ duration. /In another portion of the same study in rats/ absorption at 10 hrs = 10%. Mean total recoveries of applied radioactivity from all dose groups ranged from 85 to 101%. Mean absorption based on blood, urinary/ fecal excretion, and carcass, ranged from 2% to 11%. Total radioactivity absorbed generally increased with increasing exposure time but decreased with increasing dose indicating saturation of penetration with increasing dose. The majority of the absorbed radioactivity was found in the urine and carcass. Most of the unabsorbed radioactivity was found in the skin washes from each dose/duration (35-90%). However, based on measurements of skin absorption, a significant amount of radioactive dose was also found in the skin itself (9-40%). Mean absorption with inclusion of radioactivity in dissolved skin ranged from 10 to 45%. The ratio of the amount of radioactive dose in the skin wash to the radioactivity in the skin itself decreased with time indicating penetration into the subsurface of the skin with time after treatment.', 'Cyromazine was well absorbed after oral administration /to rats/. Excretion was rapid at the dose (3 mg/kg), but an apparent delay in excretion occurred at the high dose (300 mg/kg). Fecal elimination was equivalent among dose groups except the high dose males, where a greater percentage was eliminated by this route. The origin of fecal radioactivity was via biliary elimination. Residual radioactivity in tissues was minimal in all dose groups. Urinary and fecal metabolites of 14C-cyromazine were isolated and identified by TLC, HPLC, and GC/MS. The major compounds were the N-dealkylated product melamine, hydroxycyromazine, and unmetabolized cyromazine identified', 'A single dose of 0.5 mg/kg bw of 14C-cyromazine (uniformly triazine ring labeled) was given orally to two male and one female Charles River white rats (not further identified). By 72 hours after dosing, 95% of the administered dose had been excreted in urine, essentially all within the first 24 hours. About 3% was excreted in feces, again predominantly in the first 24 hours. Negligible amounts were excreted as volatiles or CO2 in another two males and one female given the same dose. Tissue residues were below the level of detection except in liver; however, liver levels were too low to permit accurate quantitation (about 0.007 ppm).', 'Two chickens (strain not indicated) were given daily oral doses of 14C-cyromazine (uniformly triazine ring labeled) of 0.75 mg/hen/day by capsule for seven days. By 24 hours after the last dose 99.1% of the administered radioactivity had been recovered in the excreta with essentially none in volatiles and CO2. Both egg whites and egg yolks contained about 0.12-0.15 ppm consistently. Tissue levels were: byproducts (i.e. head and feet) 0.047 ppm test material equivalents; reproductive tract 0.047 ppm; liver 0.032 ppm; all other tissues 0.008-0.019 ppm.', 'For more Absorption, Distribution and Excretion (Complete) data for CYROMAZINE (10 total), please visit the HSDB record page.']","['Cyromazine was well absorbed after oral administration /to rats/. ... Urinary and fecal metabolites of 14C-cyromazine were isolated and identified by TLC, HPLC, and GC/MS. The major compounds were the N-dealkylated product melamine, hydroxycyromazine, and unmetabolized cyromazine identified.', 'Urine from a female rat given a single oral dose of 14C-cyromazine (uniformly triazine ring labeled) of 0.5 mg/kg bw was analyzed using TLC and a cation exchange column chromatography system. With both systems the majority of the urinary radioactivity was determined to be in the form of unchanged parent compound. Unchanged parent compound in urine accounted for about 80% of the administered dose. Three metabolites were detected with each system and were presumed to be the same compounds. These metabolites accounted for 2.2-3.2%, 3.0-5.5%, and 4.6-5.3% of the administered dose, respectively, but no identification was made. Fecal material from a male rat given the same dose as the above female was found to contain little unchanged parent compound: <0.1% of the administered dose. The same three metabolites as observed in urine were found and represented 0.1, 0.1 and 4.1% of the administered dose, respectively.', 'One male and one female albino Sprague-Dawley rats were given diet containing 3000 ppm of 14C-cyromazine for 10 days. In the male the liver was found to contain 31.3 ppm cyromazine and 0.96 ppm melamine and the kidney 62.4 ppm cyromazine and 1.3 ppm melamine. In the female liver residues were 13.2 ppm and 0.51 ppm and kidney residues 22.2 and 0.68 ppm of cyromazine and melamine, respectively. This study indicated that there was some conversion of cyromazine to melamine in vivo.', 'Urine from male and female monkeys (Macaca fasicicula) given single oral doses of 14C-cyromazine (uniformly triazine ring labeled) of 0.05 or 0.5 mg/kg bw by capsule was found to have the majority of the radioactivity present in the form of unchanged parent compound. Regardless of dose 93.6-96.1% of the urinary radioactivity was present as unchanged cyromazine. Additionally, 2.9-6.4% of the radioactivity as identified as melamine ... In a second study with the same strain of monkey given the same dose levels, urine collected during the first 24 hours after dosing had 95-100% of the recovered radioactivity in the form of unchanged cyromazine. In one male dosed at 0.05 mg/kg bw, no melamine was detected in the urine. In one female at 0.05 mg/kg bw and one monkey of each sex given 0.5 mg/kg bw 3.0-3.9% of the urinary radioactivity was in the form of melamine.', 'For more Metabolism/Metabolites (Complete) data for CYROMAZINE (9 total), please visit the HSDB record page.']",
13172,47867,"3-((Diethylamino)methyl)-8-methyl-2,7-dioxaspiro(4.4)nonane-1,6-dione",CCN(CC)CC1CC2(CC(OC2=O)C)C(=O)O1,,,,,,
13173,47868,"3-Methyl-8-(4-morpholinylmethyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione hemihydrate",CC1CC2(CC(OC2=O)CN3CCOCC3)C(=O)O1.CC1CC2(CC(OC2=O)CN3CCOCC3)C(=O)O1.O,,,,,,
13174,47869,"8-Methyl-3-(morpholin-4-ylmethyl)-2,7-dioxaspiro[4.4]nonane-1,6-dione",CC1CC2(CC(OC2=O)CN3CCOCC3)C(=O)O1,,,,,,
13175,47870,"3-Methyl-8-(1-piperidinylmethyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione",CC1CC2(CC(OC2=O)CN3CCCCC3)C(=O)O1,,,,,,
13176,47871,"3-Methyl-8-((4-methyl-1-piperazinyl)methyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione",CC1CC2(CC(OC2=O)CN3CCN(CC3)C)C(=O)O1,,,,,,
13177,47872,"3-Methyl-8-((phenylamino)methyl)-2,7-dioxaspiro(4.4)nonane-1,6-dione",CC1CC2(CC(OC2=O)CNC3=CC=CC=C3)C(=O)O1,,,,,,
13178,47873,"1,6-Dioxo-N,N,N,8-tetramethyl-2,7-dioxaspiro(4.4)nonane-3-methanaminium bromide",CC1CC2(CC(OC2=O)C[N+](C)(C)C)C(=O)O1.[Br-],,,,,,
13179,47874,"Trimethyl-[(8-methyl-1,6-dioxo-2,7-dioxaspiro[4.4]nonan-3-yl)methyl]azanium",CC1CC2(CC(OC2=O)C[N+](C)(C)C)C(=O)O1,,,,,,
13180,47875,Propyl-3-tert-butylphenoxyacetate,CCCOC(=O)COC1=CC=CC(=C1)C(C)(C)C,,,,,,
13181,47876,Fenvalerate beta,CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)O[C@@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,,,,,,
13182,47877,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, butyl ester",CCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13183,47878,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, undecyl ester",CCCCCCCCCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13184,47879,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, dodecyl ester",CCCCCCCCCCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13185,47880,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, tetradecyl ester",CCCCCCCCCCCCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13186,47881,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, hexadecyl ester",CCCCCCCCCCCCCCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13187,47882,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, octadecyl ester",CCCCCCCCCCCCCCCCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13188,47883,"Acetamide, N-(4,7-dimethoxy-6-(2-(dimethylamino)ethoxy)-5-benzofuranyl)-, hydrochloride, hydrate",CC(=O)NC1=C(C2=C(C(=C1OCCN(C)C)OC)OC=C2)OC.O.Cl,,,,,,
13189,47884,"N-[6-[2-(dimethylamino)ethoxy]-4,7-dimethoxy-1-benzofuran-5-yl]acetamide",CC(=O)NC1=C(C2=C(C(=C1OCCN(C)C)OC)OC=C2)OC,,,,,,
13190,47885,"BENZ(a)ANTHRACEN-2-OL, 7,12-DIMETHYL-",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C(C=C3)O,,,,,"['BENZ(a)ANTHRACEN-2-OL, 7,12-DIMETHYL- is a known human metabolite of 7,12 Dimethylbenzanthracene.']",
13191,47886,"trans-1,2-Dihydro-1,2-dihydroxydibenz(a,h)anthracene",C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=C(C4=C3)[C@@H]([C@H](C=C5)O)O,,,,,,
13192,47887,"(3R,4R)-3,4-dihydronaphtho[1,2-b]phenanthrene-3,4-diol",C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=C(C4=C3)C=C[C@H]([C@@H]5O)O,,,,,,
13193,47888,"Acetic acid, 2-(N,N-bis(2-chloroethyl)aminophenyl)-, decyl ester",CCCCCCCCCCOC(=O)CC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
13194,47889,"4-Amino-3,5-dichloropyridine-2-carboxylic acid",C1=C(C(=C(C(=N1)C(=O)O)Cl)N)Cl,,,,,,
13195,47890,"Dodecahydro-4,7-methano-2,3,8-methenocyclopent[a]indene",C1CC2CC1C3C2C4C5C3C6C4C6C5,,,,,,
13196,47891,N-[(1-heptylpyridin-1-ium-3-yl)methylidene]hydroxylamine;iodide,CCCCCCC[N+]1=CC=CC(=C1)C=NO.[I-],,,,,,
13197,47892,N-[(1-heptylpyridin-1-ium-3-yl)methylidene]hydroxylamine,CCCCCCC[N+]1=CC=CC(=C1)C=NO,,,,,,
13198,47893,Cyclopropanecarboxaldehyde oxime,C1CC1C=NO,,,,,,
13199,47894,Butilfenin,CCCCC1=CC=C(C=C1)NC(=O)CN(CC(=O)O)CC(=O)O,,,,,,
13200,47895,Iprofenin,CC(C)C1=CC=C(C=C1)NC(=O)CN(CC(=O)O)CC(=O)O,,,,,,
13201,47896,Cefotiam hydrochloride,CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O.Cl.Cl,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
13202,47897,"Acetic acid, (ethylenedinitrilo)tetra-, calcium copper complex",C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Ca+2].[Cu+2],,,,,,
13203,47898,Flutolanil,CC(C)OC1=CC=CC(=C1)NC(=O)C2=CC=CC=C2C(F)(F)F,,,,"['In a study performed in 1992, [aniline ring-U-14C]flutolanil (specific activity; 20 mCi/mmol; radiochemical purity, >99%) suspended in a vehicle consisting of 1% Tween 80 and 0.5% carboxymethyl cellulose was given orally to groups of three male and three female CD (Sprague-Dawley-derived) rats. Unlabelled flutolanil (purity, 99.9% or 97.6%) was also used in preparation of the solutions. The animals received either a single dose of 20 mg/kg bw [14C]flutolanil; consecutive doses of 20 mg/kg bw per day of unlabelled flutolanil for 14 days followed by single dose of [14C]flutolanil on day 15; or a single dose of 1000 mg/kg [14C]flutolanil. After administration, urine was collected three times on day 1, then daily; and feces and cage wash were collected daily. After sample collection on day 7, the animals were killed, and blood and 12 tissue samples were obtained. The radioactivity in the samples was determined by liquid scintillation counting after appropriate processing. Volatile 14C production was not determined as an earlier study showed that <0.1% of the dose had been exhaled. The total recovery was acceptable at the lower dose but was <90% at the higher dose. Most of the radioactivity was excreted within 24 hr, approximately half the urinary excretion occurring within 12 hr, indicating relatively rapid absorption. The extent of absorption, as determined by urinary excretion, varied with dose and repeated dosing, indicating saturation of absorption by large doses. There was evidence of induction of flutolanil metabolism by repeated dosing. Similar results were found in the two sexes. The concentration and distribution of radioactivity in blood and tissues at 7 days was minimal, representing <0.2% of that administered to any animal, indicating no significant potential for bioaccumulation. The tissue concentrations varied considerably between animals in the same group. The only tissue in which consistent concentrations were found was the liver, in which the mean was about 10 times those in blood. The amount of radioactivity in the livers was higher in females in all groups than in males (2.4 +/- 1.1 versus 0.68 +/- 0.38 ug/g at 1000 mg/kg bw; 0.23 +/- 0.04 versus 0.12 +/- 0.01 ug/g after repeated doses).', 'In a study in which flutolanil was given in the diet to Sprague-Dawley rats for 4 weeks, analyses of brain, liver, blood, kidney and fat showed low concentrations in animals receiving >2000 ppm. The highest concentrations of residues were found in adipose tissue and liver. There was minimal retention of flutolanil. The lowest dose of 400 ppm was equal to 36 mg/kg bw per day in males and 41 mg/kg bw per day in females. Comparison of the results at 400 ppm with those at 20 mg/kg bw in /another study/ indicated that flutolanil that has no significant propensity to accumulate. The increase in residue concentration with increasing dose indicated that the saturation of absorption seen after administration by gavage does not occur after dietary intake.', 'An analysis of tissue samples from the study in rats given repeated doses showed that flutolanil was present only in fat and at low concentrations: 0.2 ppm at 2,000 ppm and 0.6 ppm at 10,000 ppm, which are similar to those found after a single dose. As the analytical method was only for the parent compound, any metabolites that might have contributed to the residues after a single dose would not have been detected. However, as the metabolites formed from flutolanil are relatively polar and are excreted primarily in urine, the findings from the study with repeated doses indicate that flutolanil has little if any potential to bioaccumulate.']",,
13204,47899,"1H-Indole, 2-phenyl-3-(1H-tetrazol-5-ylthio)-",C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)SC4=NNN=N4,,,,,,
13205,47900,"1H-Indole, 2-phenyl-3-((1H-tetrazol-5-ylmethyl)thio)-",C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)SCC4=NNN=N4,,,,,,
13206,47901,"1H-Indole, 1-(4-chlorobenzoyl)-2-phenyl-3-((1H-tetrazol-5-ylmethyl)thio)-",C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2C(=O)C4=CC=C(C=C4)Cl)SCC5=NNN=N5,,,,,,
13207,47902,"1H-Indole, 5-chloro-2-phenyl-3-((1H-tetrazol-5-ylmethyl)thio)-",C1=CC=C(C=C1)C2=C(C3=C(N2)C=CC(=C3)Cl)SCC4N=NN=N4,,,,,,
13208,47903,"1H-Indole, 6-chloro-2-phenyl-3-((1H-tetrazol-5-ylmethyl)thio)-",C1=CC=C(C=C1)C2=C(C3=C(N2)C=C(C=C3)Cl)SCC4N=NN=N4,,,,,,
13209,47904,"1H-Indole, 6-methoxy-2-phenyl-3-((1H-tetrazol-5-ylmethyl)thio)-",COC1=CC2=C(C=C1)C(=C(N2)C3=CC=CC=C3)SCC4=NNN=N4,,,,,,
13210,47905,"1H-Indole, 2-(4-methoxyphenyl)-3-((1H-tetrazol-5-ylmethyl)thio)-",COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)SCC4=NNN=N4,,,,,,
13211,47906,"1H-Indole, 2-(2,4-dimethylphenyl)-3-((1H-tetrazol-5-ylmethyl)thio)-",CC1=CC(=C(C=C1)C2=C(C3=CC=CC=C3N2)SCC4=NNN=N4)C,,,,,,
13212,47907,"1H-Indole, 5-methoxy-2-(4-methoxyphenyl)-3-((1H-tetrazol-5-ylmethyl)thio)-",COC1=CC=C(C=C1)C2=C(C3=C(N2)C=CC(=C3)OC)SCC4=NNN=N4,,,,,,
13213,47908,2-Phenyl-3-((1-(1H-tetrazol-5-yl)ethyl)thio)-1H-indole,CC(C1=NNN=N1)SC2=C(NC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
13214,47909,Ranitidine hydrochloride,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.Cl,,,"['Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)', 'Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)']",,,
13215,47910,Enpiroline phosphate,C1CCN[C@H](C1)[C@@H](C2=CC(=NC(=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)O.OP(=O)(O)O,,,,,,
13216,47911,CID 47911,C1CCN[C@H](C1)C(C2=CC(=NC(=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)O,,,,,,
13217,47912,N-(2-bicyclo[3.1.0]hexanylidene)hydroxylamine,C1CC(=NO)C2C1C2,,,,,,
13218,47913,2-(3-Chloro-1-adamantyl)-2-hydroxyiminoethanol,C1C2CC3(CC1CC(C2)(C3)Cl)C(=NO)CO,,,,,,
13219,47914,2-(3-Bromo-1-adamantyl)-2-hydroxyiminoethanol,C1C2CC3(CC1CC(C2)(C3)Br)C(=NO)CO,,,,,,
13220,47915,N-[6-(hydroxyimino)bicyclo[3.3.1]nonan-2-ylidene]hydroxylamine,C1CC(=NO)C2CCC(=NO)C1C2,,,,,,
13221,47916,N-[4-(hydroxyimino)adamantan-2-ylidene]hydroxylamine,C1C2CC3CC1C(=NO)C(C2)C3=NO,,,,,,
13222,47917,"4,8-Adamantanedione, dioxime",C1C2CC3CC(C2=NO)CC1C3=NO,,,,,,
13223,47918,"1,3-Dinitrosoadamantane",C1C2CC3(CC1CC(C2)(C3)N=O)N=O,,,,,,
13224,47919,N-Nitrosomethyl-(2-tosyloxyethyl) amine,CC1=CC=C(C=C1)S(=O)(=O)OCCN(C)N=O,,,,,,
13225,47920,"1H-Indole, 1-(4-chlorobenzoyl)-2-phenyl-3-(1H-tetrazol-5-ylthio)-",C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2C(=O)C4=CC=C(C=C4)Cl)SC5=NNN=N5,,,,,,
13226,47921,"1H-Indole, 5-methoxy-2-phenyl-3-((1H-tetrazol-5-ylmethyl)thio)-",COC1=CC2=C(C=C1)NC(=C2SCC3=NNN=N3)C4=CC=CC=C4,,,,,,
13227,47922,"2-(2,6-Dimethylhepta-1,5-dienyl)-1,3-dioxolane",CC(=CCCC(=CC1OCCO1)C)C,,,,,,
13228,47923,CID 47923,CCCCN1CC(C[C@@H]2[C@@H]1C([C@]3(O2)CCC4[C@@H](C3C)C(=O)C5C4CC=C6C5(CCC(C6)OC(=O)C)C)C)C,,,,,,
13229,47924,"3-Hydroxy-11-oxo-17,23-epoxyveratraman-28-carbaldehyde",CC1C[C@@H]2[C@H](C([C@]3(O2)CCC4C5CC=C6CC(CCC6(C5C(=O)C4=C3C)C)O)C)N(C1)C=O,,,,,,
13230,47925,"Card-20(22)-enolide, 2,3-((6,10-dihydroxy-9-methyl-8-oxa-1-thia-4-azaspiro(4.5)dec-3-ene-6,7-diyl)bis(oxy))-14-hydroxy-, (2-alpha(7S,9R),3-beta,5-alpha)-",C[C@@H]1C(C2(C3([C@@H](O1)O[C@@H]4C[C@H]5CCC6C([C@]5(C[C@H]4O3)C)CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)N=CCS2)O,,,,,,
13231,47926,"Card-20(22)-enolide, 14-hydroxy-2,3-((tetrahydro-3,5-dihydroxy-6-methyl-4-oxo-2H-pyran-3,2-diyl)bis(oxy))-, (2-alpha(2S,6R),3-beta,5-alpha)-",C[C@@H]1C(C(=O)C2([C@@H](O1)O[C@@H]3C[C@]4([C@@H](CCC5C4CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)C[C@H]3O2)C)O)O,,,,,,
13232,47927,"Card-20(22)-enolide, 14-hydroxy-2,3-((tetrahydro-3,4,5-trihydroxy-6-methyl-2H-pyran-3,2-diyl)bis(oxy))-, (2-alpha(2S,6R),3-beta,5-alpha)-",C[C@@H]1C(C(C2([C@@H](O1)O[C@@H]3C[C@]4([C@@H](CCC5C4CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)C[C@H]3O2)C)O)O)O,,,,,,
13233,47928,CID 47928,CC[NH+](CC)CCON=C(C)C1=CC=C(C=C1)Br.[Cl-],,,,,,
13234,47929,CID 47929,CCN(CC)CCON=C(C)C1=CC=C(C=C1)Br,,,,,,
13235,47930,CID 47930,CC[NH+](CC)CCON=C(C)C1=CC=C(C=C1)C.[Cl-],,,,,,
13236,47931,CID 47931,CCN(CC)CCON=C(C)C1=CC=C(C=C1)C,,,,,,
13237,47932,"2-(2,4-Diaminophenoxy)ethanol dihydrochloride",C1=CC(=C(C=C1N)N)OCCO.Cl.Cl,,,['Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)'],"['THE CUTANEOUS PENETRATION OF THE OXIDATION DYESTUFF 2,4-DIAMINOPHENOXYETHANOL EITHER ALONE OR WHEN FORMULATED WITH OTHER DYESTUFFS, & UNDER EXPERIMENTAL CONDITIONS, HAS BEEN EVALUATED IN THE HAIRLESS RAT USING (14)C-LABELED MOLECULES. NO FIXATION OF THE DYESTUFFS INVESTIGATED WHICH DO PASS THROUGH THE CUTANEOUS BARRIER IS FOUND IN EITHER LIVER OR THYROID OF THE EXPERIMENTAL ANIMALS, 4 DAYS AFTER THEIR TOPICAL APPLICATION.']",,
13238,47933,"2-(2,4-Diaminophenoxy)ethanol",C1=CC(=C(C=C1N)N)OCCO,,,,,,
13239,47934,2-Acetamidoethyldimethylethylammonium iodide,CC[N+](C)(C)CCNC(=O)C.[I-],,,,,,
13240,47935,2-Acetamidoethyl-ethyl-dimethylazanium,CC[N+](C)(C)CCNC(=O)C,,,,,,
13241,47936,Forskolin,CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
13242,47937,"Ethyl 2-{3-[(6-chloro-1,3-benzothiazol-2-YL)oxy]phenoxy}propanoate",CCOC(=O)C(C)OC1=CC=CC(=C1)OC2=NC3=C(S2)C=C(C=C3)Cl,,,,,,
13243,47938,Fenoxaprop-ethyl,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,['Chronic angina and Coronary Artery Disease'],,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Dermal absorption of the (14)C ring-labelled herbicide fenoxaprop-ethyl was examined after topical applications of the herbicide in either acetone or in field formulation (Excel) to the shaved backs of rats (n= 6) according to standard in vivo procedure. The total percentage dermal absorption was determined from the mean percentage recoveries of (14)C in the urine after correction for incomplete urinary excretion using the recovery figures obtained from im dose studies (49:17.7% recovery). The mean percentage dermal absorption of fenoxaprop-ethyl applied in acetone at a dose of 1.8 ug/sq cm was 32:6.8% and was significantly greater than that obtained at the same dose of fenoxaprop-ethyl applied in the Excel formulation (18:4.5%). Increasing the applied dose of fenoxaprop-ethyl had no effect on dermal absorption within the dose range 1.8 to 100 ug/sq cm; when doses of 10 and 100 ug/sq cm were applied in Excel, 20:6.7% and 21:4.5% was absorbed, respectively. Mass balance studies with the total percentage recovery in urine (im corrected) added to recovery from foam patches covering the dose site, and from gauze swabs moistened with soapy water taken of dosed skin 24 hr after treatment, demonstrated only 56:3.7%, 54:3.8%, 56:5.4% and 53:3.9% total recovery for the acetone 1.8 ug/sq cm and Excel 1.8, 10 and 100 ug/sq cm treatments, respectively. Significantly less residual (14)C activity was detected in the skin swabs taken for the acetone (8:3.5%) than for the Excel treatments (21:6.0%, 27:4.0% and 25:5.8% for the 1.8, 10 and 100 ug/sq cm dose rates, respectively). Comparative studies conducted at a dose rate of 1.4 ug/sq cm with automated in vitro dermal absorption procedure demonstrated no significantly different total percentage dermal absorption in dermatomed skin taken from the same rats tested in vivo at a dose rate of 1.8 ug/sq cm. There was no significant difference between the total percentage dermal absorption obtained for automated in vitro dermal absorption analysis of fresh rat skin (27:9.3%; n= 20) compared with that for rat skin frozen for 7 days in liquid nitrogen (25:7.6%; n= 19).']",,
13244,47939,CID 47939,CC1=CC(=CC=C1)C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC=CC=C4,,,,,,
13245,47940,CID 47940,CC1=CC=C(C=C1)C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC=CC=C4,,,,,,
13246,47941,CID 47941,COC1=CC=CC=C1C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC=CC=C4,,,,,,
13247,47942,CID 47942,COC1=CC=CC=C1C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC(=CC=C4)N,,,,,,
13248,47943,CID 47943,CC1=CC(=CC=C1)C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC(=CC=C4)N,,,,,,
13249,47944,CID 47944,CC1=CC=C(C=C1)C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC(=CC=C4)N,,,,,,
13250,47945,Dihydro-7-hydroxymyoporone,CC(C)C(C(CC(C)CCC(=O)C1=COC=C1)O)O,,,,,,
13251,47946,Selenoaspirine,CC(=O)[Se]C1=CC=CC=C1C(=O)O,,,,,,
13252,47947,(5-Hydroxymethylfurfuryl)trimethylammonium iodide,C[N+](C)(C)CC1=CC=C(O1)CO.[I-],,,,,,
13253,47948,"N,N,N-Trimethyl[5-(hydroxymethyl)-2-furyl]methanaminium",C[N+](C)(C)CC1=CC=C(O1)CO,,,,,,
13254,47949,(5-Chloromethylfurfuryl)trimethylammonium iodide,C[N+](C)(C)CC1=CC=C(O1)CCl.[I-],,,,,,
13255,47950,"N,N,N-Trimethyl[5-(chloromethyl)-2-furyl]methanaminium",C[N+](C)(C)CC1=CC=C(O1)CCl,,,,,,
13256,47951,"Mercury, bis(4-hydroxy-3-nitrophenyl)-",C1=CC(=C(C=C1[Hg]C2=CC(=C(C=C2)O)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
13257,47952,Bicifadine hydrochloride,CC1=CC=C(C=C1)C23CC2CNC3.Cl,,,,,,
13258,47953,Bicifadine,CC1=CC=C(C=C1)C23CC2CNC3,['For the treatment of pain.'],"['Bicifadine is a chemically distinct molecule with a unique profile of pharmacological activity. Its primary pharmacological action is to enhance and prolong the actions of norepinephrine and serotonin by inhibiting the transport proteins that terminate the physiological actions of the two biogenic amines. Bicifadine is not a narcotic and is well-tolerated and, in preclinical studies, has been shown not to act at any opiate receptor. Bicifadine does not exhibit any anti-inflammatory activity and does not inhibit prostaglandin synthetase in vitro.']",,,['The primary enzymes responsible for the primary metabolism of bicifadine in humans are MAO-B and CYP2D6.'],
13259,47954,"2,3,9,10-Tetramethylanthracene",CC1=CC2=C(C3=CC=CC=C3C(=C2C=C1C)C)C,,,,,,
13260,47955,"2-Ethyl-1,3-butanediol",CCC(CO)C(C)O,,,,,,
13261,47956,"1,2,3-trimethoxy-10-methylsulfanyl-7-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-9-one",COC1=C(C(=C2C(=C1)CCC(C3=CC(=O)C(=CC=C32)SC)NC4C(C(C(C(O4)CO)O)O)O)OC)OC,,,,,,
13262,47957,"Benzo(a)heptalen-9(5H)-one, 6,7-dihydro-1,2,3-trimethoxy-10-(methylthio)-7-((2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)amino)-, (S)-",CC(=O)OCC1C(C(C(C(O1)NC2CCC3=CC(=C(C(=C3C4=CC=C(C(=O)C=C24)SC)OC)OC)OC)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
13263,47958,Disodium;2-[(2-phosphonatoacetyl)amino]butanedioic acid,C(C(C(=O)O)NC(=O)CP(=O)([O-])[O-])C(=O)O.[Na+].[Na+],,,,,,
13264,47959,"2-Ethyl-2H-1,3-benzoxazin-4(3H)-one",CCC1NC(=O)C2=CC=CC=C2O1,,,,,,
13265,47960,"o-Hydroxybenzoic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CC1CCCC([NH+]1CCCOC(=O)C2=CC=CC=C2O)C.[Cl-],,,,,,
13266,47961,"3-(2,6-Dimethylpiperidin-1-yl)propyl 2-hydroxybenzoate",CC1CCCC(N1CCCOC(=O)C2=CC=CC=C2O)C,,,,,,
13267,47962,"o-Mercaptobenzoic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CC1CCCC([NH+]1CCCOC(=O)C2=CC=CC=C2S)C.[Cl-],,,,,,
13268,47963,"3-(2,6-Dimethylpiperidin-1-yl)propyl 2-sulfanylbenzoate",CC1CCCC(N1CCCOC(=O)C2=CC=CC=C2S)C,,,,,,
13269,47964,Cefadroxil monohydrate,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
13270,47965,Cefadroxil,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O,"['For the treatment of the following infections (skin, UTI, ENT) caused by; <i>S. pneumoniae, H. influenzae, staphylococci, S. pyogenes</i> (group A beta-hemolytic streptococci), <i>E. coli, P. mirabilis, Klebsiella</i> sp, coagulase-negative staphylococci and <i>Streptococcus pyogenes</i>']","['Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption.', 'Over 90% of the drug is excreted unchanged in the urine within 24 hours. Cefadroxil was detected in the placenta and breast milk.']",,['1.5 hours']
13271,47966,4-Chlorophenyl-bis(2-hydroxy-1-naphthyl)methane,C1=CC=C2C(=C1)C=CC(=C2C(C3=CC=C(C=C3)Cl)C4=C(C=CC5=CC=CC=C54)O)O,,,,,,
13272,47967,"1-(3,4-Methylenedioxyphenyl)-4-morpholino-1-butene-3-one",C1COCCN1CC(=O)C=CC2=CC3=C(C=C2)OCO3,,,,,,
13273,47968,CID 47968,CCCCC(C=CC1=CC(=C(C(=C1)OC)OC)OC)O,,,,,,
13274,47969,CID 47969,CC(C)CC(C=CC1=CC(=C(C(=C1)OC)OC)OC)O,,,,,,
13275,47970,"1-(1,3-Benzodioxol-5-yl)-7-methylocta-1,6-dien-3-ol",CC(=CCCC(C=CC1=CC2=C(C=C1)OCO2)O)C,,,,,,
13276,47971,"1-(3,4-Methylenedioxyphenyl)-4-morpholino-1-butene-3-ol",C1COCCN1CC(C=CC2=CC3=C(C=C2)OCO3)O,,,,,,
13277,47972,"Acetamide, N,N'-(thiodi-4,1-phenylene)bis(2-chloro-",C1=CC=C(C=C1)SC2=C(C=CC(=C2)NC(=O)CCl)NC(=O)CCl,,,,,,
13278,47973,Boranylformonitrile;pyridine,BC#N.C1=CC=NC=C1,,,,,,
13279,47974,"BENZOIC ACID, 2-HYDROXY-, compd. with 3-PYRIDINECARBOXAMIDE (1:1)",C1=CC=C(C(=C1)C(=O)O)O.C1=CC(=CN=C1)C(=O)N,,,,,,
13280,47975,Anirolac,COC1=CC=C(C=C1)C(=O)C2=CC=C3N2CCC3C(=O)O,,,,,,
13281,47976,"5-Benzofurancarboximidamide, 2-(4-aminophenyl)-",C1=CC(=CC=C1C2=CC3=C(O2)C=CC(=C3)C(=N)N)N,,,,,,
13282,47977,2-[2-(6-carbamimidoyl-1H-benzimidazol-2-yl)ethenyl]-3H-benzimidazole-5-carboximidamide,C1=CC2=C(C=C1C(=N)N)NC(=N2)C=CC3=NC4=C(N3)C=C(C=C4)C(=N)N,,,,,,
13283,47978,"1,2-Di(5-amidino-2-benzofuranyl)ethane",C1=CC2=C(C=C1C(=N)N)C=C(O2)CCC3=CC4=C(O3)C=CC(=C4)C(=N)N,,,,,,
13284,47979,Veralipride,COC1=CC(=CC(=C1OC)C(=O)NCC2CCCN2CC=C)S(=O)(=O)N,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
13285,47980,"3,5,6-Trichloropyridine",C1=C(C(=NC(=C1Cl)Cl)SP(=O)(O)O)Cl,,,,,,
13286,47981,CID 47981,CC(C)[NH+](CCON=C1CCCCCC1=CC2=CC=CC=C2)C(C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
13287,47982,"(1E,2Z)-2-benzylidenecycloheptanone O-2-(diisopropylamino)ethyl oxime",CC(C)N(CCON=C1CCCCCC1=CC2=CC=CC=C2)C(C)C,,,,,,
13288,47983,[2-[7-[2-(diethylazaniumyl)acetyl]-9H-fluoren-2-yl]-2-oxoethyl]-diethylazanium;dichloride,CC[NH+](CC)CC(=O)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)C(=O)C[NH+](CC)CC.[Cl-].[Cl-],,,,,,
13289,47984,2-(diethylamino)-1-[7-[2-(diethylamino)acetyl]-9H-fluoren-2-yl]ethanone,CCN(CC)CC(=O)C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)C(=O)CN(CC)CC,,,,,,
13290,47985,"9,9'-Ethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13291,47986,N-[2-[2-[2-(acridin-9-ylamino)phenoxy]ethoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13292,47987,"9,9'-Trimethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13293,47988,N-[2-[3-[2-(acridin-9-ylamino)phenoxy]propoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13294,47989,"9,9'-Tetramethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13295,47990,N-[2-[4-[2-(acridin-9-ylamino)phenoxy]butoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13296,47991,"9,9'-Pentamethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13297,47992,N-[2-[5-[2-(acridin-9-ylamino)phenoxy]pentoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13298,47993,"9,9'-Hexamethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13299,47994,N-[2-[6-[2-(acridin-9-ylamino)phenoxy]hexoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13300,47995,"9,9'-Heptamethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13301,47996,N-[2-[7-[2-(acridin-9-ylamino)phenoxy]heptoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13302,47997,"9,9'-Octamethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13303,47998,N-[2-[8-[2-(acridin-9-ylamino)phenoxy]octoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13304,47999,"9,9'-Nonamethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCCCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13305,48000,N-[2-[9-[2-(acridin-9-ylamino)phenoxy]nonoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCCCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13306,48001,"9,9'-Decamethylenedioxybis(o-phenyleneimino)bisacridine dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]C4=CC=CC=C4OCCCCCCCCCCOC5=CC=CC=C5[NH2+]C6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13307,48002,N-[2-[10-[2-(acridin-9-ylamino)phenoxy]decoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=CC=C4OCCCCCCCCCCOC5=CC=CC=C5NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13308,48003,"4-Acridinecarboxamide, 9,9'-tetramethylenedioxybis(4-methylsulfonamido-o-phenyleneimino)bis-, dihydrochloride, dihydrate",CS(=O)(=O)NC1=CC(=C(C=C1)OCCCCOC2=C(C=C(C=C2)NS(=O)(=O)C)[NH2+]C3=C4C=CC=C(C4=NC5=CC=CC=C53)C(=O)N)[NH2+]C6=C7C=CC=C(C7=NC8=CC=CC=C86)C(=O)N.[Cl-].[Cl-],,,,,,
13309,48004,9-[2-[4-[2-[(4-Carbamoylacridin-9-yl)amino]-4-(methanesulfonamido)phenoxy]butoxy]-5-(methanesulfonamido)anilino]acridine-4-carboxamide,CS(=O)(=O)NC1=CC(=C(C=C1)OCCCCOC2=C(C=C(C=C2)NS(=O)(=O)C)NC3=C4C=CC=C(C4=NC5=CC=CC=C53)C(=O)N)NC6=C7C=CC=C(C7=NC8=CC=CC=C86)C(=O)N,,,,,,
13310,48005,"Acridine, 9-(o-(4-(4-quinolinylamino)butoxy)anilino)-, dihydrochloride, dihydrate",C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCOC3=CC=CC=C3[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Cl-].[Cl-],,,,,,
13311,48006,N-[2-[4-(quinolin-4-ylamino)butoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=CC=N2)NCCCCOC3=CC=CC=C3NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13312,48007,"Acridine, 9-(o-(5-(4-quinolinylamino)pentyloxy)anilino)-, dihydrochloride, hydrate",C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCCOC3=CC=CC=C3[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Cl-].[Cl-],,,,,,
13313,48008,N-[2-[5-(quinolin-4-ylamino)pentoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=CC=N2)NCCCCCOC3=CC=CC=C3NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13314,48009,"Acridine, 9-(o-(6-(4-quinolinylamino)hexyloxy)anilino)-, dihydrochloride, hemihydrate",C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCCCOC3=CC=CC=C3[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Cl-].[Cl-],,,,,,
13315,48010,N-[2-[6-(quinolin-4-ylamino)hexoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=CC=N2)NCCCCCCOC3=CC=CC=C3NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13316,48011,"Acridine, 9-(o-(7-(4-quinolinylamino)heptyloxy)anilino)-, dihydrochloride, hemihydrate",C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCCCCOC3=CC=CC=C3[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Cl-].[Cl-],,,,,,
13317,48012,N-[2-[7-(quinolin-4-ylamino)heptoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=CC=N2)NCCCCCCCOC3=CC=CC=C3NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13318,48013,9-(o-(8-(4-Quinolinylamino)octyloxy)anilino)acridine dihydrochloride,C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCCCCCOC3=CC=CC=C3[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Cl-].[Cl-],,,,,,
13319,48014,N-[2-[8-(quinolin-4-ylamino)octoxy]phenyl]acridin-9-amine,C1=CC=C2C(=C1)C(=CC=N2)NCCCCCCCCOC3=CC=CC=C3NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13320,48015,"Butanesulfonanilide, 4'-(9-acridinylamino)-4-(4-quinolinylamino)-, dihydrobromide",C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCS(=O)(=O)NC3=CC=C(C=C3)[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Br-].[Br-],,,,,,
13321,48016,N-[4-(9-Acridinylamino)phenyl]-4-(4-quinolylamino)-1-butanesulfonamide,C1=CC=C2C(=C1)C(=CC=N2)NCCCCS(=O)(=O)NC3=CC=C(C=C3)NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13322,48017,"Hexanesulfonanilide, 4'-(9-acridinylamino)-6-(4-quinolinylamino)-, dihydrobromide, sesquihydrate",C1=CC=C2C(=C1)C(=CC=N2)[NH2+]CCCCCCS(=O)(=O)NC3=CC=C(C=C3)[NH2+]C4=C5C=CC=CC5=NC6=CC=CC=C64.[Br-].[Br-],,,,,,
13323,48018,N-[4-(9-Acridinylamino)phenyl]-6-(4-quinolinylamino)-1-hexanesulfonamide,C1=CC=C2C(=C1)C(=CC=N2)NCCCCCCS(=O)(=O)NC3=CC=C(C=C3)NC4=C5C=CC=CC5=NC6=CC=CC=C64,,,,,,
13324,48019,"4,4'-Bis(9-acridinylamino)butanesulfonanilide dihydrochloride trihydrate",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]CCCCS(=O)(=O)NC4=CC=C(C=C4)[NH2+]C5=C6C=CC=CC6=NC7=CC=CC=C75.[Cl-].[Cl-],,,,,,
13325,48020,4-(9-Acridinylamino)-N-[4-(9-acridinylamino)phenyl]-1-butanesulfonamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCS(=O)(=O)NC4=CC=C(C=C4)NC5=C6C=CC=CC6=NC7=CC=CC=C75,,,,,,
13326,48021,"4',6-Bis(9-acridinylamino)hexanesulfonanilide dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)[NH2+]CCCCCCS(=O)(=O)NC4=CC=C(C=C4)[NH2+]C5=C6C=CC=CC6=NC7=CC=CC=C75.[Cl-].[Cl-],,,,,,
13327,48022,6-(acridin-9-ylamino)-N-[4-(acridin-9-ylamino)phenyl]hexane-1-sulfonamide,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NCCCCCCS(=O)(=O)NC4=CC=C(C=C4)NC5=C6C=CC=CC6=NC7=CC=CC=C75,,,,,,
13328,48023,"4',4''-Bis(9-acridinylamino)-1,4-butanesulfonanilide dihydrochloride",C1=CC=C2C(=C1)C(=C3C=CC=CC3=[NH+]2)NC4=CC=C(C=C4)NS(=O)(=O)CCCCS(=O)(=O)NC5=CC=C(C=C5)NC6=C7C=CC=CC7=[NH+]C8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13329,48024,"N,N'-Bis[4-(9-acridinylamino)phenyl]-1,4-butanedisulfonamide",C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC=C(C=C4)NS(=O)(=O)CCCCS(=O)(=O)NC5=CC=C(C=C5)NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13330,48025,"N,N'-Bis(4-(9-acridinylamino)-3-methoxyphenyl)-1,4-butanedisulfonamide",COC1=C(C=CC(=C1)NS(=O)(=O)CCCCS(=O)(=O)NC2=CC(=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53)OC)NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13331,48026,"BENZO(b)THIOPHENE, 2-CHLORO-3-(2-(4-PIPERIDYL)ETHYLAMINO)-, 1,1-DIOXIDE",C1CCN(CC1)CCNC2=C(S(=O)(=O)C3=CC=CC=C32)Cl,,,,,,
13332,48027,"[2-[(7R,14S,16R,17R)-7-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate",CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2C1(CC(C3C2[C@@H](CC4=CC(=O)C=CC34C)Cl)O)C)C)OC(=O)CC,,,,,,
13333,48028,Diethyl(2-mercaptoethyl)methylammonium iodide,CC[N+](C)(CC)CCS.[I-],,,,,,
13334,48029,Diethyl-methyl-(2-sulfanylethyl)azanium,CC[N+](C)(CC)CCS,,,,,,
13335,48030,"1,6-Hexanedisulfon-m-anisidide, 4',4''-bis(9-acridinylamino)-, dihydrochloride, tetrahydrate",COC1=C(C=CC(=C1)[NH2+]S(=O)(=O)CCCCCCS(=O)(=O)[NH2+]C2=CC(=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53)OC)NC6=C7C=CC=CC7=NC8=CC=CC=C86.[Cl-].[Cl-],,,,,,
13336,48031,"N,N'-bis[4-(acridin-9-ylamino)-3-methoxyphenyl]hexane-1,6-disulfonamide",COC1=C(C=CC(=C1)NS(=O)(=O)CCCCCCS(=O)(=O)NC2=CC(=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53)OC)NC6=C7C=CC=CC7=NC8=CC=CC=C86,,,,,,
13337,48032,"4-N-(2-chloro-6-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine",CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)OC)Cl,,,,,,
13338,48033,4-methoxy-N-[2-(1-piperidin-1-ylpropan-2-yl)phenyl]benzamide,CC(CN1CCCCC1)C2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC,,,,,,
13339,48034,"BENZO(e)PYRENE, 9,10-DIHYDRO-",C1CC2=C(C=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,,,,,,
13340,48035,"trans-9,10-Dihydroxy-9,10-dihydrobenzo(e)pyrene",C1=CC2=C3C(=C1)C4=C([C@H]([C@@H](C=C4)O)O)C5=CC=CC(=C53)C=C2,,,,,,
13341,48036,CID 48036,C[C@@H](C(C1=CC=CC=C1)O)[NH2+]CC=C(C2=CSC=C2)C3=CSC=C3.[Cl-],,,,,,
13342,48037,Tinofedrine,CC(C(C1=CC=CC=C1)O)NCC=C(C2=CSC=C2)C3=CSC=C3,,,,,,
13343,48038,"1-Heptanamine, N-ethyl-",CCCCCCCNCC,,,,,,
13344,48039,"1,4,6,7-Tetrachlorodibenzofuran",C1=CC(=C(C2=C1C3=C(C=CC(=C3O2)Cl)Cl)Cl)Cl,,,,,,
13345,48040,Encainide hydrochloride,CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)']",,,
13346,48041,Encainide,CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC,"['Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.']","['Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainide decreases the rate of rise of the action potential without markedly affecting its duration.']","['A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",['A radiolabeled dose of encainide is excreted in approximately equal amounts in the urine and feces.'],['Encainide has known human metabolites that include N-demethylencainide and O-demethylencainide.'],['1-2 hours']
13347,48042,"1,4-Butanedisulfon-m-anisidide, 4',4''-bis(4-quinolylamino)-, dihydrochloride, hydrate",COC1=C(C=CC(=C1)NS(=O)(=O)CCCCS(=O)(=O)NC2=CC(=C(C=C2)[NH2+]C3=CC=NC4=CC=CC=C43)OC)[NH2+]C5=CC=NC6=CC=CC=C65.[Cl-].[Cl-],,,,,,
13348,48043,"N,N'-Bis[3-methoxy-4-(4-quinolylamino)phenyl]-1,4-butanedisulfonamide",COC1=C(C=CC(=C1)NS(=O)(=O)CCCCS(=O)(=O)NC2=CC(=C(C=C2)NC3=CC=NC4=CC=CC=C43)OC)NC5=CC=NC6=CC=CC=C65,,,,,,
13349,48044,Ethyl 3-(4-chlorophenyl)sulfonylprop-2-enoate,CCOC(=O)C=CS(=O)(=O)C1=CC=C(C=C1)Cl,,,,,,
13350,48045,"2-Methoxy-2-(1-methylethyl)-1,3-dioxolane",CC(C)C1(OCCO1)OC,,,,,,
13351,48046,"Ammonium, pentamethylenebis(1-methyl-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)propyl)bis(dimethyl-, dibromide, sesquihydrate",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
13352,48047,"5-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]pentyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C,,,,,,
13353,48048,"Ammonium, pentamethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13354,48049,"5-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]pentyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13355,48050,"Ammonium, (p-phenylene)dimethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(C)CC2=CC=C(C=C2)C[N+](C)(C)C(C)CCC3C(CCCC3(C)C)C)(C)C.[Br-].[Br-],,,,,,
13356,48051,"[4-[[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]methyl]phenyl]methyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CC2=CC=C(C=C2)C[N+](C)(C)C(C)CCC3C(CCCC3(C)C)C)(C)C,,,,,,
13357,48052,"AMMONIUM, (2-(10H-PYRIDO(3,2-b)(1,4)BENZOTHIAZIN-10-YL)ETHYL)TRIMETHYL-, IODIDE",C[N+](C)(C)CCN1C2=CC=CC=C2SC3=C1N=CC=C3.[I-],,,,,,
13358,48053,"Trimethyl(2-pyrido[3,2-b][1,4]benzothiazin-10-ylethyl)azanium",C[N+](C)(C)CCN1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
13359,48054,"Ammonium, (2-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)ethyl)trimethyl-, methyl sulfate",C[N+](C)(C)CCN1C2=CC=CC=C2SC3=C1N=CC=C3.COS(=O)(=O)[O-],,,,,,
13360,48055,"Ammonium, (2-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethyl-, benzenesulfonate",CC(C[N+](C)(C)C)N1C2=CC=CC=C2SC3=C1N=CC=C3.C1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
13361,48056,"Trimethyl(2-pyrido[3,2-b][1,4]benzothiazin-10-ylpropyl)azanium",CC(C[N+](C)(C)C)N1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
13362,48057,"(2-(10H-Pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethylammonium bromide",CC(C[N+](C)(C)C)N1C2=CC=CC=C2SC3=C1N=CC=C3.[Br-],,,,,,
13363,48058,"Ammonium, (2-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethyl-, methyl sulfate",CC(C[N+](C)(C)C)N1C2=CC=CC=C2SC3=C1N=CC=C3.COS(=O)(=O)[O-],,,,,,
13364,48059,"Ammonium, (3-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethyl-, methyl sulfate",C[N+](C)(C)CCCN1C2=CC=CC=C2SC3=C1N=CC=C3.COS(=O)(=O)[O-],,,,,,
13365,48060,"Trimethyl(3-pyrido[3,2-b][1,4]benzothiazin-10-ylpropyl)azanium",C[N+](C)(C)CCCN1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
13366,48061,"Ammonium, (2-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethyl-, p-toluenesulfonate",CC1=CC=C(C=C1)S(=O)(=O)[O-].CC(C[N+](C)(C)C)N1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
13367,48062,"Ammonium, (3-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethyl-, p-toluenesulfonate",CC1=CC=C(C=C1)S(=O)(=O)[O-].C[N+](C)(C)CCCN1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
13368,48063,"Tetradecamethylenebis(dimethyl(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)ammonium bromide)",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13369,48064,"14-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]tetradecyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13370,48065,"AMMONIUM, TETRAMETHYL-, CHLORIDE with SODIUM FLUOROACETATE",C[N+](C)(C)C.C(C(=O)[O-])F.[Na+].[Cl-],,,,,,
13371,48066,"Ammonium, tetramethylenebis(2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)butyl)bis(dimethyl-, bis(p-toluenesulfonate), sesquihydrate",CC1=C(C(CCC1)(C)C)CCC(C)C[N+](C)(C)CCCC[N+](C)(C)CC(C)CCC2=C(CCCC2(C)C)C.CC1=CC=C(C=C1)S(=O)(=O)[O-].CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
13372,48067,"4-[Dimethyl-[2-methyl-4-(2,6,6-trimethylcyclohexen-1-yl)butyl]azaniumyl]butyl-dimethyl-[2-methyl-4-(2,6,6-trimethylcyclohexen-1-yl)butyl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)C[N+](C)(C)CCCC[N+](C)(C)CC(C)CCC2=C(CCCC2(C)C)C,,,,,,
13373,48068,"Ammonium, tetramethylenebis(1-methyl-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)propyl)bis(dimethyl-, dibromide, hemihydrate",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
13374,48069,"4-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]butyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C,,,,,,
13375,48070,"Ammonium, tetramethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride",CC1CCCC(C1CCC(C)[N+](C)(C)CCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
13376,48071,"4-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]butyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13377,48072,Thiodiethylenebis(diethylmethylammonium) dichloride,CC[N+](C)(CC)CCSCC[N+](C)(CC)CC.[Cl-].[Cl-],,,,,,
13378,48073,"Ammonium, trimethylenebis(1-methyl-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)propyl)bis(dimethyl-, dibromide, dihydrate",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
13379,48074,"3-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]propyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C,,,,,,
13380,48075,"Ammonium, trimethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(C)CCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13381,48076,"3-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]propyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13382,48077,"2-Chloro-2,2-diphenylacetic acid (2-morpholinoethyl) ester hydrochloride",C1COCC[NH+]1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)Cl.[Cl-],,,,,,
13383,48078,"2-Morpholin-4-ylethyl 2-chloro-2,2-diphenylacetate",C1COCCN1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)Cl,,,,,,
13384,48079,"Acetic acid, 2-(3-(2-chloroethyl)-3-nitrosoureido)-2-cyclohexyl-",C1CCC(CC1)C(C(=O)O)NC(=O)N(CCCl)N=O,,,,,,
13385,48080,"ACETIC ACID, 2-(p-CHLOROPHENYL)-2-ISOPROPYL-, CYANO(p-PHENOXYPHENYL)METHYL ESTER",CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC=C(C=C2)OC3=CC=CC=C3,,,,,,
13386,48081,"2-Cyclohexyl-2-phenylacetic acid (2,2-dimethyl-3-morpholinopropyl) ester hydrochloride",CC(C)(C[NH+]1CCOCC1)COC(=O)C(C2CCCCC2)C3=CC=CC=C3.[Cl-],,,,,,
13387,48082,"(2,2-Dimethyl-3-morpholin-4-ylpropyl) 2-cyclohexyl-2-phenylacetate",CC(C)(CN1CCOCC1)COC(=O)C(C2CCCCC2)C3=CC=CC=C3,,,,,,
13388,48083,2-Cyclohexyl-2-phenylacetic acid (2-morpholinoethyl) ester hydrochloride,C1CCC(CC1)C(C2=CC=CC=C2)C(=O)OCC[NH+]3CCOCC3.[Cl-],,,,,,
13389,48084,2-Morpholin-4-ylethyl 2-cyclohexyl-2-phenylacetate,C1CCC(CC1)C(C2=CC=CC=C2)C(=O)OCCN3CCOCC3,,,,,,
13390,48085,"2,2-Diphenylacetic acid (2,2-dimethyl-3-morpholinopropyl) ester hydrochloride",CC(C)(C[NH+]1CCOCC1)COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13391,48086,"(2,2-Dimethyl-3-morpholin-4-ylpropyl) 2,2-diphenylacetate",CC(C)(CN1CCOCC1)COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13392,48087,N-Phenethyl-N-(2-phenoxyethyl)acetamide,CC(=O)N(CCC1=CC=CC=C1)CCOC2=CC=CC=C2,,,,,,
13393,48088,"2-Acetoxy-2,2-diphenylacetic acid (2-morpholinoethyl) ester hydrochloride",CC(=O)OC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+]3CCOCC3.[Cl-],,,,,,
13394,48089,"2-Morpholin-4-ylethyl 2-acetyloxy-2,2-diphenylacetate",CC(=O)OC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN3CCOCC3,,,,,,
13395,48090,"Acetic acid, 2-allyl-2-cyclohexyl-, 3-(diethylamino)-2,2-dimethylpropyl ester, hydrochloride",CC[NH+](CC)CC(C)(C)COC(=O)C(CC=C)C1CCCCC1.[Cl-],,,,,,
13396,48091,"[3-(Diethylamino)-2,2-dimethylpropyl] 2-cyclohexylpent-4-enoate",CCN(CC)CC(C)(C)COC(=O)C(CC=C)C1CCCCC1,,,,,,
13397,48092,"Acetic acid, 2-(2-bromoallyl)-2-phenyl-, 3-(diethylamino)-2,2-dimethylpropyl ester",CCN(CC)CC(C)(C)COC(=O)C(CC(=C)Br)C1=CC=CC=C1,,,,,,
13398,48093,p-Butoxyphenylacetic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCCOC1=CC=C(C=C1)CC(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
13399,48094,3-(2-Methylpiperidin-1-yl)propyl 2-(4-butoxyphenyl)acetate,CCCCOC1=CC=C(C=C1)CC(=O)OCCCN2CCCCC2C,,,,,,
13400,48095,2-Cyclohexyl-N-(2-morpholinoethyl)-2-phenylacetamide hydrochloride,C1CCC(CC1)C(C2=CC=CC=C2)C(=O)NCC[NH+]3CCOCC3.[Cl-],,,,,,
13401,48096,2-cyclohexyl-N-(2-morpholin-4-ylethyl)-2-phenylacetamide,C1CCC(CC1)C(C2=CC=CC=C2)C(=O)NCCN3CCOCC3,,,,,,
13402,48097,"N-(4,4-Diphenyl-6-morpholino-3-hexylidene)acetamide",CCC(=NC(=O)C)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13403,48098,"N-(4,4-Diphenyl-6-piperidino-3-hexylidene)acetamide hydrochloride",CCC(=NC(=O)C)C(CCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,,,,
13404,48099,"N-(4,4-diphenyl-6-piperidin-1-ylhexan-3-ylidene)acetamide",CCC(=NC(=O)C)C(CCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13405,48100,N-(2-Ethoxyethyl)-N-phenethylacetamide,CCOCCN(CCC1=CC=CC=C1)C(=O)C,,,,,,
13406,48101,"Acetamide, N-ethyl-N-(3-phenoxypropyl)-",CCN(CCCOC1=CC=CC=C1)C(=O)C,,,,,,
13407,48102,N-Ethyl-N-(1-phenylethyl)acetamide,CCN(C(C)C1=CC=CC=C1)C(=O)C,,,,,,
13408,48103,"alpha-7-Chloro-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",C1CC[NH2+]C(C1)C2COC3(O2)CCCC(C3)Cl.[Cl-],,,,,,
13409,48104,"2-(7-Chloro-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",C1CCNC(C1)C2COC3(O2)CCCC(C3)Cl,,,,,,
13410,48105,"beta-8-Chloro-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",C1CC[NH2+]C(C1)C2COC3(O2)CCC(CC3)Cl.[Cl-],,,,,,
13411,48106,"2-(8-Chloro-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",C1CCNC(C1)C2COC3(O2)CCC(CC3)Cl,,,,,,
13412,48107,"Undecamethylenebis(dimethyl(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)ammonium bromide)",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13413,48108,"11-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]undecyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13414,48109,beta-Anisoyloxy-beta-phenylethyl dimethylamine,CN(C)CC(C1=CC=CC=C1)OC(=O)C2=CC=C(C=C2)OC,,,,,,
13415,48110,"o-ANISIC ACID, 3-(2-METHYLPIPERIDINO)PROPYL ESTER, HYDROCHLORIDE",CC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2OC.[Cl-],,,,,,
13416,48111,3-(2-Methylpiperidin-1-yl)propyl 2-methoxybenzoate,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2OC,,,,,,
13417,48112,"p-ANISIC ACID, 3-(2-METHYLPIPERIDINO)PROPYL ESTER, HYDROCHLORIDE",CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OC.[Cl-],,,,,,
13418,48113,"10-Anthracenecarboxamide, 9,10-dihydro-",C1C2=CC=CC=C2C(C3=CC=CC=C31)C(=O)N,,,,,,
13419,48114,"10-Anthracenecarboxamide, 9,10-dihydro-9,9-dimethyl-",CC1(C2=CC=CC=C2C(C3=CC=CC=C31)C(=O)N)C,,,,,,
13420,48115,"9,10-Dihydro-9-anthroic acid 2-(dibutylamino)ethyl ester hydrochloride",CCCC[NH+](CCCC)CCOC(=O)C1C2=CC=CC=C2CC3=CC=CC=C13.[Cl-],,,,,,
13421,48116,"2-(Dibutylamino)ethyl 9,10-dihydroanthracene-9-carboxylate",CCCCN(CCCC)CCOC(=O)C1C2=CC=CC=C2CC3=CC=CC=C13,,,,,,
13422,48117,"9,10-Dihydro-9-anthroic acid 3-(diethylamino)propyl ester hydrochloride",CC[NH+](CC)CCCOC(=O)C1C2=CC=CC=C2CC3=CC=CC=C13.[Cl-],,,,,,
13423,48118,"3-(Diethylamino)propyl 9,10-dihydroanthracene-9-carboxylate",CCN(CC)CCCOC(=O)C1C2=CC=CC=C2CC3=CC=CC=C13,,,,,,
13424,48119,"9-Anthroic acid, 9,10-dihydro-9-methyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1(C2=CC=CC=C2CC3=CC=CC=C31)C.[Cl-],,,,,,
13425,48120,2-(diethylamino)ethyl 9-methyl-10H-anthracene-9-carboxylate,CCN(CC)CCOC(=O)C1(C2=CC=CC=C2CC3=CC=CC=C31)C,,,,,,
13426,48121,"9-Anthroic acid, 9,10-dihydro-10-methyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1C2=CC=CC=C2C(C3=CC=CC=C13)C.[Cl-],,,,,,
13427,48122,"2-(Diethylamino)ethyl 10-methyl-9,10-dihydroanthracene-9-carboxylate",CCN(CC)CCOC(=O)C1C2=CC=CC=C2C(C3=CC=CC=C13)C,,,,,,
13428,48123,"9,10-Dihydro-9-anthroic acid (2-morpholinoethyl) ester, hydrochloride",C1COCC[NH+]1CCOC(=O)C2C3=CC=CC=C3CC4=CC=CC=C24.[Cl-],,,,,,
13429,48124,"2-Morpholin-4-ylethyl 9,10-dihydroanthracene-9-carboxylate",C1COCCN1CCOC(=O)C2C3=CC=CC=C3CC4=CC=CC=C24,,,,,,
13430,48125,"cis-2-(Dimethylamino)-3,5,5-trimethyl-1,2-oxaphospholan-3-ol 2-oxide",CC1(CC(P(=O)(O1)N(C)C)(C)O)C,,,,,,
13431,48126,Cianopramine,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)C#N,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
13432,48127,3-Pyrrolidinomethyl-4-hydroxybiphenyl,C1CCN(C1)CC2=C(C=CC(=C2)C3=CC=CC=C3)O,,,,,,
13433,48128,"(1,1'-Biphenyl)-4-OL, 3-(1-piperidinylmethyl)-",C1CCN(CC1)CC2=C(C=CC(=C2)C3=CC=CC=C3)O,,,,,,
13434,48129,"(1,1'-Biphenyl)-4-OL, 3-((diethylamino)methyl)-",CCN(CC)CC1=C(C=CC(=C1)C2=CC=CC=C2)O,,,,,,
13435,48130,"Carbamic acid, 2-(dimethylamino)ethyl ester, monohydrochloride",C[NH+](C)CCOC(=O)N.[Cl-],,,,,,
13436,48131,2-(Dimethylamino)ethyl carbamate,CN(C)CCOC(=O)N,,,,,,
13437,48132,Tralomethrin,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C(C(Br)(Br)Br)Br)C,,,,"['When radioactive pyrethroid is administered orally to mammals, it is absorbed from intestinal tract of the animals and distributed in every tissue examined. Excretion of radioactivity in rats admin trans-isomer: dosage: 500 mg/kg; interval 20 days; urine 36%; feces 64%; total 100%. /Pyrethroids/', 'Although limited absorption may account for the low toxicity of some pyrethroids, rapid biodegradation by mammalian liver enzymes (ester hydrolysis and oxidation) is probably the major factor responsible for this phenomenon ... Most pyrethroid metabolites are promptly excreted, at least in part, by the kidneys. /Pyrethroids/']","['The relative resistance of mammals to the pyrethroids is almost wholly attributable to their ability to hydrolyze the pyrethroids rapidly to their inactive acid and alcohol components, since direct injection into the mammalian CNS leads to a susceptibility similar to that seen in insects. Some additional resistance of homeothermic organisms can also be attributed to the negative temperature coefficient of action of the pyrethroids, which are thus less toxic at mammalian body temperatures, but the major effect is metabolic. Metabolic disposal of the pyrethroids is very rapid, which means that toxicity is high by the intravenous route, moderate by slower oral absorption, and often unmeasureably low by dermal absorption. /Pyrethroids/', 'Synthetic pyrethroids are generally metabolized in mammals through ester hydrolysis, oxidation, and conjugation, and there is no tendency to accumulate in tissues. In the environment, synthetic pyrethroids are fairly rapidly degraded in soil and in plants. Ester hydrolysis and oxidation at various sites on the molecule are the major degradation processes. /Pyrethroids/']",
13438,48133,6-Chrysenyloxirane,C1C(O1)C2=CC3=C(C=CC4=CC=CC=C43)C5=CC=CC=C52,,,,,,
13439,48134,9-Methyl-10-anthryloxirane,CC1=C2C=CC=CC2=C(C3=CC=CC=C13)C4CO4,,,,,,
13440,48135,N-(2-Chloroethyl)diphenethylamine hydrochloride,C1=CC=C(C=C1)CC[NH+](CCC2=CC=CC=C2)CCCl.[Cl-],,,,,,
13441,48136,N-(2-chloroethyl)-2-phenyl-N-(2-phenylethyl)ethanamine,C1=CC=C(C=C1)CCN(CCC2=CC=CC=C2)CCCl,,,,,,
13442,48137,"N-(2-Chloroethyl)-3,3'-diphenyldipropylamine hydrochloride",C1=CC=C(C=C1)CCC[NH+](CCCC2=CC=CC=C2)CCCl.[Cl-],,,,,,
13443,48138,N-(2-chloroethyl)-3-phenyl-N-(3-phenylpropyl)propan-1-amine,C1=CC=C(C=C1)CCCN(CCCC2=CC=CC=C2)CCCl,,,,,,
13444,48139,"N,3,7,11-tetramethyl-N-prop-2-enyldodeca-2,6,10-trien-1-amine",CC(=CCCC(=CCCC(=CCN(C)CC=C)C)C)C,,,,,,
13445,48140,CID 48140,CC(=CCCC(=CCCC(=CCN(C)CC1=CC=CC2=CC=CC=C21)C)C)C,,,,,,
13446,48141,"N,3,7,11-tetramethyl-N-(3-phenylprop-2-ynyl)dodeca-2,6,10-trien-1-amine",CC(=CCCC(=CCCC(=CCN(C)CC#CC1=CC=CC=C1)C)C)C,,,,,,
13447,48142,N-(2-Diethylaminoethyl)-4-methoxybenzamidine dihydrochloride,CC[NH+](CC)CC[NH+]=C(C1=CC=C(C=C1)OC)N.[Cl-].[Cl-],,,,,,
13448,48143,N-[2-(Diethylamino)ethyl]-4-methoxybenzamidine,CCN(CC)CCN=C(C1=CC=C(C=C1)OC)N,,,,,,
13449,48144,N-(2-Dimethylaminoethyl)-4-isopropoxybenzamidine dihydrochloride,CC(C)OC1=CC=C(C=C1)C(=[NH+]CC[NH+](C)C)N.[Cl-].[Cl-],,,,,,
13450,48145,N-[2-(Dimethylamino)ethyl]-4-isopropoxybenzamidine,CC(C)OC1=CC=C(C=C1)C(=NCCN(C)C)N,,,,,,
13451,48146,"Benzaldehyde,4-chloro-, O-[2-(4-morpholinyl)propyl]oxime, monohydrochloride, (E)-(9CI)",CC(CON=CC1=CC=C(C=C1)Cl)[NH+]2CCOCC2.[Cl-],,,,,,
13452,48147,1-(4-chlorophenyl)-N-(2-morpholin-4-ylpropoxy)methanimine,CC(CON=CC1=CC=C(C=C1)Cl)N2CCOCC2,,,,,,
13453,48148,"5-(Hydroxyiminomethyl)-3-methoxybenzene-1,2-diol",COC1=CC(=CC(=C1O)O)C=NO,,,,,,
13454,48149,"Barbituric acid, 5-(3-methyl-2-butenyl)-5-propyl-",CCCC1(C(=O)NC(=O)NC1=O)CC=C(C)C,,,,,,
13455,48150,CID 48150,CCCC1(C(=O)NC(=NC1=O)[O-])C(=CCC)C.[Na+],,,,,,
13456,48151,"5-Pent-2-en-2-yl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C(=CCC)C,,,,,,
13457,48152,CID 48152,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CSC.[Na+],,,,,,
13458,48153,"5-(Methylsulfanylmethyl)-5-pentan-2-yl-1,3-diazinane-2,4,6-trione",CCCC(C)C1(C(=O)NC(=O)NC1=O)CSC,,,,,,
13459,48154,"Barbituric acid, 5-(2-methylbutyl)-5-propyl-",CCCC1(C(=O)NC(=O)NC1=O)CC(C)CC,,,,,,
13460,48155,CID 48155,CCC=C(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13461,48156,"Barbituric acid, 5-methyl-5-(3-methyl-2-butenyl)-",CC(=CCC1(C(=O)NC(=O)NC1=O)C)C,,,,,,
13462,48157,"1-Methyl-5-pent-2-en-2-yl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)N(C1=O)C)C(=CCC)C,,,,,,
13463,48158,"5-Hept-2-en-2-yl-5-methyl-1,3-diazinane-2,4,6-trione",CCCCC=C(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13464,48159,5-Methyl-5-(1-methyl-1-pentenyl)-barbituric acid,CCCC=C(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13465,48160,5-Methyl-5-(1-methylpentyl)barbituric acid,CCCCC(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13466,48161,"5-But-2-en-2-yl-5-methyl-1,3-diazinane-2,4,6-trione",CC=C(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13467,48162,CID 48162,CCCC1(C(=O)NC(=NC1=O)S)C(=CC)C,,,,,,
13468,48163,CID 48163,CCCC1(C(=NC(=NC1=O)S)[O-])C(C)SCC(C)C.[Na+],,,,,,
13469,48164,CID 48164,CCCC1(C(=O)NC(=NC1=O)S)C(C)SCC(C)C,,,,,,
13470,48165,5-Pentyl-5-phenylbarbituric acid,CCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
13471,48166,CID 48166,C1=CC=C(C=C1)CCC2(C(=O)NC(=NC2=O)[O-])CCOC3=CC=CC=C3.[Na+],,,,,,
13472,48167,"5-(2-Phenoxyethyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",C1=CC=C(C=C1)CCC2(C(=O)NC(=O)NC2=O)CCOC3=CC=CC=C3,,,,,,
13473,48168,CID 48168,C1=CC=C(C=C1)CCC2(C(=O)NC(=NC2=O)[O-])CCCOC3=CC=CC=C3.[Na+],,,,,,
13474,48169,"5-(3-Phenoxypropyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",C1=CC=C(C=C1)CCC2(C(=O)NC(=O)NC2=O)CCCOC3=CC=CC=C3,,,,,,
13475,48170,CID 48170,CCCC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
13476,48171,"5-(2-Phenylethyl)-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
13477,48172,CID 48172,CCCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
13478,48173,"5-Prop-1-enyl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C=CC,,,,,,
13479,48174,"1,5,5-Triallylbarbituric acid",C=CCC1(C(=O)NC(=O)N(C1=O)CC=C)CC=C,,,,,,
13480,48175,"[(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate",CCC(=O)O[C@@]1([C@H](CC2C1(CC([C@]3(C2C[C@@H](C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)CCl,,,,,,
13481,48176,"Ammonium, (4,4'-biphenylylenebis(2-oxoethylene))bis((1-pentyl)dimethyl-, dibromide",CCCCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCCCC.[Br-].[Br-],,,,,,
13482,48177,[2-[4-[4-[2-[Dimethyl(pentyl)azaniumyl]-2-oxoethyl]phenyl]phenyl]acetyl]-dimethyl-pentylazanium,CCCCC[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)CCCCC,,,,,,
13483,48178,"Ammonium, (2-(10H-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)trimethyl-, ethyl sulfate",CCOS(=O)(=O)[O-].CC(C[N+](C)(C)C)N1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
13484,48179,"Acetic acid, 2,2-diphenyl-, (2,2-dimethyl-3-morpholinopropyl) ester, hydrogen sulfate (2:1)",CC(C)(C[NH+]1CCOCC1)COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.OS(=O)(=O)[O-],,,,,,
13485,48180,"1-Benzyl-2-(2,2-diphenyl-1,3-dioxolan-4-yl)-1-hydroxypiperidin-1-ium chloride",C1CC[N+](C(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4)(CC5=CC=CC=C5)O.[Cl-],,,,,,
13486,48181,"1-Benzyl-2-(2,2-diphenyl-1,3-dioxolan-4-yl)-1-hydroxypiperidin-1-ium",C1CC[N+](C(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4)(CC5=CC=CC=C5)O,,,,,,
13487,48182,"Ethyl 4-amino-2-(3,4-methylenedioxyphenyl)butyrate hydrochloride",CCOC(=O)C(CC[NH3+])C1=CC2=C(C=C1)OCO2.[Cl-],,,,,,
13488,48183,"Ethyl 4-amino-2-(1,3-benzodioxol-5-yl)butanoate",CCOC(=O)C(CCN)C1=CC2=C(C=C1)OCO2,,,,,,
13489,48184,"4-Amino-2-(3,4-methylenedioxyphenyl)butyric acid hydrochloride",C1OC2=C(O1)C=C(C=C2)C(CC[NH3+])C(=O)O.[Cl-],,,,,,
13490,48185,"4-Amino-2-(1,3-benzodioxol-5-yl)butanoic acid",C1OC2=C(O1)C=C(C=C2)C(CCN)C(=O)O,,,,,,
13491,48186,"Butyric acid, 4-amino-3-methyl-2-phenyl-, hydrochloride",CC(C[NH3+])C(C1=CC=CC=C1)C(=O)O.[Cl-],,,,,,
13492,48187,4-Amino-3-methyl-2-phenylbutanoic acid,CC(CN)C(C1=CC=CC=C1)C(=O)O,,,,,,
13493,48188,Ethyl(4-amino-2-phenyl)butyrate hydrochloride,CCOC(=O)C(CC[NH3+])C1=CC=CC=C1.[Cl-],,,,,,
13494,48189,Ethyl 4-amino-2-phenylbutanoate,CCOC(=O)C(CCN)C1=CC=CC=C1,,,,,,
13495,48190,"Butyric acid, 4-amino-2-phenyl-, hydrochloride",C1=CC=C(C=C1)C(CC[NH3+])C(=O)O.[Cl-],,,,,,
13496,48191,"3,3-Dimethylbutyric acid (2-morpholinoethyl) ester hydrochloride",CC(C)(C)CC(=O)OCC[NH+]1CCOCC1.[Cl-],,,,,,
13497,48192,"2-Morpholin-4-ylethyl 3,3-dimethylbutanoate",CC(C)(C)CC(=O)OCCN1CCOCC1,,,,,,
13498,48193,"2,2-Diphenyl-4-morpholinobutyric acid ethyl ester hydrochloride",CCOC(=O)C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13499,48194,Dioxaphetyl butyrate,CCOC(=O)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13500,48195,2-Phenylbutyric acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCC(C1=CC=CC=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
13501,48196,2-But-2-enylsulfanyl-2-ethylbutanamide,CCC(CC)(C(=O)N)SCC=CC,,,,,,
13502,48197,2-but-2-enylsulfanyl-2-ethyl-N-methylbutanamide,CCC(CC)(C(=O)NC)SCC=CC,,,,,,
13503,48198,"Butyramide, 2-butylthio-2-ethyl-",CCCCSC(CC)(CC)C(=O)N,,,,,,
13504,48199,"Butyramide, 2-butylthio-2-ethyl-N-methyl-",CCCCSC(CC)(CC)C(=O)NC,,,,,,
13505,48200,"Butyramide, N-cyclohexyl-2-ethyl-2-ethylthio-",CCC(CC)(C(=O)NC1CCCCC1)SCC,,,,,,
13506,48201,"Butyramide, 2-ethyl-2-(ethylsulfonyl)-",CCC(CC)(C(=O)N)S(=O)(=O)CC,,,,,,
13507,48202,"Butyramide, 2-ethyl-2-ethylthio-",CCC(CC)(C(=O)N)SCC,,,,,,
13508,48203,"Butyramide, 2-ethyl-2-ethylthio-N-methyl-",CCC(CC)(C(=O)NC)SCC,,,,,,
13509,48204,"Butyramide, 2-ethyl-N-methyl-2-methylthio-",CCC(CC)(C(=O)NC)SC,,,,,,
13510,48205,"Butyramide, 2-ethyl-N-methyl-2-(2-propynylthio)-",CCC(CC)(C(=O)NC)SCC#C,,,,,,
13511,48206,"Butyramide, 2-ethyl-2-(propylsulfonyl)-",CCCS(=O)(=O)C(CC)(CC)C(=O)N,,,,,,
13512,48207,"Butyramide, 2-ethyl-2-propylthio-",CCCSC(CC)(CC)C(=O)N,,,,,,
13513,48208,"Butyramide, 2-(ethylsulfonyl)-N,N,2-triethyl-",CCC(CC)(C(=O)N(CC)CC)S(=O)(=O)CC,,,,,,
13514,48209,"Butyric acid, 3-acetoxy-2-benzyl-, 3-(diethylamino)-2,2-dimethylpropyl ester, hydrochloride",CC[NH+](CC)CC(C)(C)COC(=O)C(CC1=CC=CC=C1)C(C)OC(=O)C.[Cl-],,,,,,
13515,48210,"[3-(Diethylamino)-2,2-dimethylpropyl] 3-acetyloxy-2-benzylbutanoate",CCN(CC)CC(C)(C)COC(=O)C(CC1=CC=CC=C1)C(C)OC(=O)C,,,,,,
13516,48211,Ethyl 4-amino-2-(p-chlorophenyl)butyrate hydrochloride,CCOC(=O)C(CC[NH3+])C1=CC=C(C=C1)Cl.[Cl-],,,,,,
13517,48212,Ethyl 4-amino-2-(4-chlorophenyl)butanoate,CCOC(=O)C(CCN)C1=CC=C(C=C1)Cl,,,,,,
13518,48213,4-Amino-2-(p-chlorophenyl)butyric acid hydrochloride,C1=CC(=CC=C1C(CC[NH3+])C(=O)O)Cl.[Cl-],,,,,,
13519,48214,4-Amino-2-(4-chlorophenyl)butanoic acid,C1=CC(=CC=C1C(CCN)C(=O)O)Cl,,,,,,
13520,48215,Ethyl 4-amino-2-(p-methoxyphenyl)butyrate hydrochloride,CCOC(=O)C(CC[NH3+])C1=CC=C(C=C1)OC.[Cl-],,,,,,
13521,48216,Ethyl 4-amino-2-(4-methoxyphenyl)butanoate,CCOC(=O)C(CCN)C1=CC=C(C=C1)OC,,,,,,
13522,48217,"1-Butanol, 2,2-diphenyl-4-morpholino-",C1COCCN1CCC(CO)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13523,48218,"1-Butanol, 4-(N-ethyl-N-phenethylamino)-",CCN(CCCCO)CCC1=CC=CC=C1,,,,,,
13524,48219,N-[4-[4-(dimethylamino)phenyl]butan-2-ylidene]hydroxylamine,CC(=NO)CCC1=CC=C(C=C1)N(C)C,,,,,,
13525,48220,"Butyramide, N-allyl-2-allylthio-2-ethyl-",CCC(CC)(C(=O)NCC=C)SCC=C,,,,,,
13526,48221,"Butyramide, N-allyl-2-ethyl-2-ethylthio-",CCC(CC)(C(=O)NCC=C)SCC,,,,,,
13527,48222,2-[2-[2-(2-Oxoazepan-3-ylidene)hydrazinyl]phenyl]acetic acid,C1CCNC(=O)C(=NNC2=CC=CC=C2CC(=O)O)C1,,,,,,
13528,48223,"Indole-7-acetic acid, 3-(3-aminopropyl)-2-carboxy-",C1=CC(=C2C(=C1)C(=C(N2)C(=O)O)CCCN)CC(=O)O,,,,,,
13529,48224,"Indole-7-acetic acid, 3-(2-aminoethyl)-2-carboxy-",C1=CC(=C2C(=C1)C(=C(N2)C(=O)O)CCN)CC(=O)O,,,,,,
13530,48225,CID 48225,BC#N.BC#N.BC#N.BC#N.BC#N.BC#N.N.N.N.N.N.N.[Na+].[I-],,,,,,
13531,48226,"Coumarin, 3-ethyl-",CCC1=CC2=CC=CC=C2OC1=O,,,,,,
13532,48227,"Coumarin, 3-propyl-",CCCC1=CC2=CC=CC=C2OC1=O,,,,,,
13533,48228,"Coumarin, 3-butyl-",CCCCC1=CC2=CC=CC=C2OC1=O,,,,,,
13534,48229,Talniflumate,C1=CC=C2C(=C1)C(OC2=O)OC(=O)C3=C(N=CC=C3)NC4=CC=CC(=C4)C(F)(F)F,"['Talnifumate is a phthalidyl ester of nifumic acid, which has potent analgesic and anti-inflammatory effects and is widely used to treat inflammatory disorders, such as rheumatoid arthritis and osteoarthritis, and has also been studied for the management of cystic fibrosis.']","['Talniflumate is metabolized to its prodrug, niflumic acid, which has several pharmacodynamic effects. Firstly, it blocks synthesis of mucin. Secondly, talniflumate blocks prostaglandin synthesis by cyclooxygenases, which aids in pain and inflammation management.']",,"['In 12 subjects after a single oral administration,  total plasma clearance of the main metabolite, niflumic acid, averaged 45 ml/min giving a distribution volume of 0.12 l/kg on average.', 'This drug undergoes extensive first pass effect.']",['Extensive liver metabolism.'],['Approximately 2h in 12 subjects']
13535,48230,"1(3-Phenylpropyl)-2-methyl-6,7-methylenedioxy-8-methoxy-1,2,3,4-tetrahydroisoquinoline HCl",C[NH+]1CC2=C(C3=C(C=C2CC1CCCC4=CC=CC=C4)OCO3)OC.[Cl-],,,,,,
13536,48231,"4-methoxy-6-methyl-7-(3-phenylpropyl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline",CN1CC2=C(C3=C(C=C2CC1CCCC4=CC=CC=C4)OCO3)OC,,,,,,
13537,48232,N-(2-Dimethylaminoethyl)-4-ethoxybenzamidine dihydrochloride,CCOC1=CC=C(C=C1)C(=[NH+]CC[NH+](C)C)N.[Cl-].[Cl-],,,,,,
13538,48233,N-[2-(Dimethylamino)ethyl]-4-ethoxybenzamidine,CCOC1=CC=C(C=C1)C(=NCCN(C)C)N,,,,,,
13539,48234,"Acetic acid, (2,2-diphenyl-1-ethyl-4-morpholino)pentyl ester, hydrochloride",CCC(C(CC(C)[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C.[Cl-],,,,,,
13540,48235,"(6-Morpholin-4-yl-4,4-diphenylheptan-3-yl) acetate",CCC(C(CC(C)N1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)OC(=O)C,,,,,,
13541,48236,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(dimethylamino)ethyl) ester, hydrochloride",C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
13542,48237,"2-(Dimethylamino)ethyl 2-methoxy-2,2-diphenylacetate",CN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
13543,48238,"2,2-Diphenyl-2-methylacetic acid (2-morpholinoethyl) ester hydrochloride",CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+]3CCOCC3.[Cl-],,,,,,
13544,48239,"2-Morpholin-4-ylethyl 2,2-diphenylpropanoate",CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN3CCOCC3,,,,,,
13545,48240,"2,2-Diphenylacetic acid (2-methyl-2-morpholinopropyl) ester hydrochloride",CC(C)(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)[NH+]3CCOCC3.[Cl-],,,,,,
13546,48241,"(2-Methyl-2-morpholin-4-ylpropyl) 2,2-diphenylacetate",CC(C)(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)N3CCOCC3,,,,,,
13547,48242,"Acetic acid, diphenyl-, 1-methyl-2-(1-methyl-2-piperidyl)ethyl ester, hydrochloride",CC(CC1CCCC[NH+]1C)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13548,48243,"1-(1-Methylpiperidin-2-yl)propan-2-yl 2,2-diphenylacetate",CC(CC1CCCCN1C)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13549,48244,Diphenylacetic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13550,48245,Diphenylacetic acid 2-(1-methyl-2-piperidyl)ethyl ester hydrochloride,C[NH+]1CCCCC1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13551,48246,"2-(1-Methylpiperidin-2-yl)ethyl 2,2-diphenylacetate",CN1CCCCC1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13552,48247,"2,2-Diphenylacetic acid (4-morpholinobutyl) ester hydrochloride",C1COCC[NH+]1CCCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13553,48248,"4-Morpholin-4-ylbutyl 2,2-diphenylacetate",C1COCCN1CCCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13554,48249,Diphenylacetic acid 2-(1-methyl-4-piperidyl)ethyl ester hydrochloride,C[NH+]1CCC(CC1)CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13555,48250,"2-(1-Methylpiperidin-4-yl)ethyl 2,2-diphenylacetate",CN1CCC(CC1)CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13556,48251,"2,2-Diphenylacetic acid (2-morpholinoethyl) ester hydrobromide",C1COCC[NH+]1CCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
13557,48252,Diphenylacetic acid 3-(1-methyl-2-piperidyl)propyl ester hydrochloride,C[NH+]1CCCCC1CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13558,48253,"3-(1-Methylpiperidin-2-yl)propyl 2,2-diphenylacetate",CN1CCCCC1CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13559,48254,Diphenylacetic acid 3-(1-methyl-4-piperidyl)propyl ester hydrochloride,C[NH+]1CCC(CC1)CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13560,48255,"3-(1-Methylpiperidin-4-yl)propyl 2,2-diphenylacetate",CN1CCC(CC1)CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13561,48256,"2,2-Diphenylacetic acid (6-morpholinohexyl) ester hydrochloride",C1COCC[NH+]1CCCCCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13562,48257,"6-Morpholin-4-ylhexyl 2,2-diphenylacetate",C1COCCN1CCCCCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13563,48258,Diphenylacetic acid 1-methyl-2-(2-pyridyl)ethyl ester hydrochloride,CC(CC1=CC=CC=[NH+]1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13564,48259,"1-Pyridin-2-ylpropan-2-yl 2,2-diphenylacetate",CC(CC1=CC=CC=N1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13565,48260,"2,2-Diphenylacetic acid (3-morpholinopropyl) ester hydrochloride",C1COCC[NH+]1CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
13566,48261,"3-Morpholin-4-ylpropyl 2,2-diphenylacetate",C1COCCN1CCCOC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13567,48262,Diphenylacetic acid 2-(2-pyridyl)ethyl ester hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCC3=CC=CC=[NH+]3.[Cl-],,,,,,
13568,48263,"2-Pyridin-2-ylethyl 2,2-diphenylacetate",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCC3=CC=CC=N3,,,,,,
13569,48264,Diphenylacetic acid 3-(2-pyridyl)propyl ester hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCCC3=CC=CC=[NH+]3.[Cl-],,,,,,
13570,48265,"3-Pyridin-2-ylpropyl 2,2-diphenylacetate",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCCC3=CC=CC=N3,,,,,,
13571,48266,Diphenylacetic acid 3-(4-pyridyl)propyl ester hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCCC3=CC=[NH+]C=C3.[Cl-],,,,,,
13572,48267,"3-Pyridin-4-ylpropyl 2,2-diphenylacetate",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCCC3=CC=NC=C3,,,,,,
13573,48268,p-Hydroxyphenylacetic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)CC2=CC=C(C=C2)O.[Cl-],,,,,,
13574,48269,3-(2-Methylpiperidin-1-yl)propyl 2-(4-hydroxyphenyl)acetate,CC1CCCCN1CCCOC(=O)CC2=CC=C(C=C2)O,,,,,,
13575,48270,"p-Methoxyphenylacetic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CC1CCCC([NH+]1CCCOC(=O)CC2=CC=C(C=C2)OC)C.[Cl-],,,,,,
13576,48271,"3-(2,6-Dimethylpiperidin-1-yl)propyl 2-(4-methoxyphenyl)acetate",CC1CCCC(N1CCCOC(=O)CC2=CC=C(C=C2)OC)C,,,,,,
13577,48272,p-Methoxyphenylacetic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)CC2=CC=C(C=C2)OC.[Cl-],,,,,,
13578,48273,3-(2-Methylpiperidin-1-yl)propyl 2-(4-methoxyphenyl)acetate,CC1CCCCN1CCCOC(=O)CC2=CC=C(C=C2)OC,,,,,,
13579,48274,Phenoxyacetic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)COC2=CC=CC=C2.[Cl-],,,,,,
13580,48275,beta-Phenylacetyloxy-beta-phenylethyl dimethylamine,CN(C)CC(C1=CC=CC=C1)OC(=O)CC2=CC=CC=C2,,,,,,
13581,48276,"Phenylacetic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CC1CCCC([NH+]1CCCOC(=O)CC2=CC=CC=C2)C.[Cl-],,,,,,
13582,48277,"3-(2,6-Dimethylpiperidin-1-yl)propyl 2-phenylacetate",CC1CCCC(N1CCCOC(=O)CC2=CC=CC=C2)C,,,,,,
13583,48278,Phenylacetic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)CC2=CC=CC=C2.[Cl-],,,,,,
13584,48279,3-(4-(Bis(2-chloroethyl)amino)-3-methoxyphenyl)alanine,COC1=C(C=CC(=C1)CC(C(=O)O)N)N(CCCl)CCCl,,,,,,
13585,48280,CID 48280,C1=C(NC(=NC1=O)SCC(=O)O)N,,,,,,
13586,48281,"Ammonium, (acetylimino)diethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride, dihydrate",CC1CCCC(C1CCC(C)CC[N+](C)(C)N(C(=O)C)[N+](C)(C)CCC(C)CCC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
13587,48282,"[Acetyl-[dimethyl-[3-methyl-5-(2,2,6-trimethylcyclohexyl)pentyl]azaniumyl]amino]-dimethyl-[3-methyl-5-(2,2,6-trimethylcyclohexyl)pentyl]azanium",CC1CCCC(C1CCC(C)CC[N+](C)(C)N(C(=O)C)[N+](C)(C)CCC(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13588,48283,(2-(3-Acetyl-2-methyl-1-indolizinyl)-2-methylethyl)dimethylhexylammonium bromide,CCCCCC[N+](C)(C)CC(C)C1=C2C=CC=CN2C(=C1C)C(=O)C.[Br-],,,,,,
13589,48284,2-(3-Acetyl-2-methylindolizin-1-yl)propyl-hexyl-dimethylazanium,CCCCCC[N+](C)(C)CC(C)C1=C2C=CC=CN2C(=C1C)C(=O)C,,,,,,
13590,48285,(2-(3-Acetyl-2-methyl-1-indolizinyl)-2-methylethyl)dimethylpentylammonium bromide,CCCCC[N+](C)(C)CC(C)C1=C2C=CC=CN2C(=C1C)C(=O)C.[Br-],,,,,,
13591,48286,2-(3-Acetyl-2-methylindolizin-1-yl)propyl-dimethyl-pentylazanium,CCCCC[N+](C)(C)CC(C)C1=C2C=CC=CN2C(=C1C)C(=O)C,,,,,,
13592,48287,"Ammonium, allyldimethyl(2-(3-acetyl-2-methyl-1-indolizinyl)-2-methylethyl)-, bromide",CC1=C(N2C=CC=CC2=C1C(C)C[N+](C)(C)CC=C)C(=O)C.[Br-],,,,,,
13593,48288,2-(3-Acetyl-2-methylindolizin-1-yl)propyl-dimethyl-prop-2-enylazanium,CC1=C(N2C=CC=CC2=C1C(C)C[N+](C)(C)CC=C)C(=O)C,,,,,,
13594,48289,Benzyl(2-chloroethyl)ethylmethylammonium methyl sulfate,CC[N+](C)(CCCl)CC1=CC=CC=C1.COS(=O)(=O)[O-],,,,,,
13595,48290,Benzyl-(2-chloroethyl)-ethyl-methylazanium,CC[N+](C)(CCCl)CC1=CC=CC=C1,,,,,,
13596,48291,Benzyldimethyl(2-(3-acetyl-2-methyl-1-indolizinyl)-2-methylethyl)ammonium chloride,CC1=C(N2C=CC=CC2=C1C(C)C[N+](C)(C)CC3=CC=CC=C3)C(=O)C.[Cl-],,,,,,
13597,48292,2-(3-Acetyl-2-methylindolizin-1-yl)propyl-benzyl-dimethylazanium,CC1=C(N2C=CC=CC2=C1C(C)C[N+](C)(C)CC3=CC=CC=C3)C(=O)C,,,,,,
13598,48293,Benzyldimethyl(2-hydroxy-1-naphthyl)methylammonium bromide dimethylcarbamate (ester),CN(C)C(=O)OC1=C(C2=CC=CC=C2C=C1)C[N+](C)(C)CC3=CC=CC=C3.[Br-],,,,,,
13599,48294,Benzyl-[[2-(dimethylcarbamoyloxy)naphthalen-1-yl]methyl]-dimethylazanium,CN(C)C(=O)OC1=C(C2=CC=CC=C2C=C1)C[N+](C)(C)CC3=CC=CC=C3,,,,,,
13600,48295,CID 48295,CC1CCCC(C1C(CC(C)CC=CCC(C)CC(C2C(CCCC2(C)C)C)[NH+](C)C)[NH+](C)C)(C)C.[Cl-].[Cl-],,,,,,
13601,48296,CID 48296,CC1CCCC(C1C(CC(C)CC=CCC(C)CC(C2C(CCCC2(C)C)C)N(C)C)N(C)C)(C)C,,,,,,
13602,48297,"Ammonium, butyldimethyl(2-(3-acetyl-2-methyl-1-indolizinyl)-2-methylethyl)-, iodide",CCCC[N+](C)(C)CC(C)C1=C2C=CC=CN2C(=C1C)C(=O)C.[I-],,,,,,
13603,48298,2-(3-Acetyl-2-methylindolizin-1-yl)propyl-butyl-dimethylazanium,CCCC[N+](C)(C)CC(C)C1=C2C=CC=CN2C(=C1C)C(=O)C,,,,,,
13604,48299,(5-tert-Butyl-2-hydroxybenzyl)trimethylammonium bromide dimethylcarbamate (ester),CC(C)(C)C1=CC(=C(C=C1)OC(=O)N(C)C)C[N+](C)(C)C.[Br-],,,,,,
13605,48300,[5-Tert-butyl-2-(dimethylcarbamoyloxy)phenyl]methyl-trimethylazanium,CC(C)(C)C1=CC(=C(C=C1)OC(=O)N(C)C)C[N+](C)(C)C,,,,,,
13606,48301,"Ammonium, 2-butynylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride, dihydrate",CC1CCCC(C1CCC(C)[N+](C)(C)CC#CC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
13607,48302,"4-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]but-2-ynyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CC#CC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13608,48303,"Ammonium, (p-chlorobenzyl)(2-(2-(6-chloro-2,4-bis(1-ethylpropyl)phenoxy)ethoxy)ethyl)dimethyl-, chloride",CCC(CC)C1=CC(=C(C(=C1)Cl)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl)C(CC)CC.[Cl-],,,,,,
13609,48304,"2-[2-[2-Chloro-4,6-di(pentan-3-yl)phenoxy]ethoxy]ethyl-[(4-chlorophenyl)methyl]-dimethylazanium",CCC(CC)C1=CC(=C(C(=C1)Cl)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl)C(CC)CC,,,,,,
13610,48305,"Ammonium, (p-chlorobenzyl)(2-(2-(4-chloro-3,5-dimethylphenoxy)ethoxy)ethyl)dimethyl-, chloride",CC1=CC(=CC(=C1Cl)C)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl.[Cl-],,,,,,
13611,48306,"2-[2-(4-Chloro-3,5-dimethylphenoxy)ethoxy]ethyl-[(4-chlorophenyl)methyl]-dimethylazanium",CC1=CC(=CC(=C1Cl)C)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl,,,,,,
13612,48307,((4-(2-Methyl-2-butyl)-2-chlorophenoxy)ethoxyethyl)(4-chlorobenzyl)dimethylammonium chloride,CCC(C)(C)C1=CC(=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl)Cl.[Cl-],,,,,,
13613,48308,2-[2-[2-Chloro-4-(2-methylbutan-2-yl)phenoxy]ethoxy]ethyl-[(4-chlorophenyl)methyl]-dimethylazanium,CCC(C)(C)C1=CC(=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl)Cl,,,,,,
13614,48309,"Ammonium, (p-chlorobenzyl)(2-(2-(4-chloro-2-isopropyl-5-methylphenoxy)ethoxy)ethyl)dimethyl-, chloride",CC1=CC(=C(C=C1Cl)C(C)C)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl.[Cl-],,,,,,
13615,48310,2-[2-(4-Chloro-5-methyl-2-propan-2-ylphenoxy)ethoxy]ethyl-[(4-chlorophenyl)methyl]-dimethylazanium,CC1=CC(=C(C=C1Cl)C(C)C)OCCOCC[N+](C)(C)CC2=CC=C(C=C2)Cl,,,,,,
13616,48311,trans-(Cyclopropylenediethyl)bis(trimethylammonium) diiodide,C[N+](C)(C)CC[C@@H]1C[C@H]1CC[N+](C)(C)C.[I-].[I-],,,,,,
13617,48312,"trimethyl-[2-[(1S,2S)-2-[2-(trimethylazaniumyl)ethyl]cyclopropyl]ethyl]azanium",C[N+](C)(C)CC[C@@H]1C[C@H]1CC[N+](C)(C)C,,,,,,
13618,48313,"10-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]decyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium dibromide",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCCCCCCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
13619,48314,"10-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]decyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCCCCCCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C,,,,,,
13620,48315,"Ammonium, decamethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13621,48316,"10-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]decyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13622,48317,Dibenzyl((3-hydroxy-2-pyridyl)methyl)methylammonium bromide dimethylcarbamate (ester),CN(C)C(=O)OC1=C(N=CC=C1)C[N+](C)(CC2=CC=CC=C2)CC3=CC=CC=C3.[Br-],,,,,,
13623,48318,Dibenzyl-[[3-(dimethylcarbamoyloxy)pyridin-2-yl]methyl]-methylazanium,CN(C)C(=O)OC1=C(N=CC=C1)C[N+](C)(CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
13624,48319,Dibutyl((3-hydroxy-2-pyridyl)methyl)methylammonium bromide dimethylcarbamate (ester),CCCC[N+](C)(CCCC)CC1=C(C=CC=N1)OC(=O)N(C)C.[Br-],,,,,,
13625,48320,Dibutyl-[[3-(dimethylcarbamoyloxy)pyridin-2-yl]methyl]-methylazanium,CCCC[N+](C)(CCCC)CC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
13626,48321,"Ammonium, (2,4-dichlorobenzyl)dimethyl(2-(3-acetyl-2-methyl-1-indolizinyl)-2-methylethyl)-, chloride",CC1=C(N2C=CC=CC2=C1C(C)C[N+](C)(C)CC3=C(C=C(C=C3)Cl)Cl)C(=O)C.[Cl-],,,,,,
13627,48322,"2-(3-Acetyl-2-methylindolizin-1-yl)propyl-[(2,4-dichlorophenyl)methyl]-dimethylazanium",CC1=C(N2C=CC=CC2=C1C(C)C[N+](C)(C)CC3=C(C=C(C=C3)Cl)Cl)C(=O)C,,,,,,
13628,48323,"Ammonium, diethyl(2,2-dimethyl-3-hydroxypropyl)methyl-, methyl sulfate, benzilate (ester)",CC[N+](C)(CC)CC(C)(C)COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.COS(=O)(=O)[O-],,,,,,
13629,48324,"Diethyl-[3-(2-hydroxy-2,2-diphenylacetyl)oxy-2,2-dimethylpropyl]-methylazanium",CC[N+](C)(CC)CC(C)(C)COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
13630,48325,"Ammonium, diethyl(2-dimethyl-3-hydroxypropyl)methyl-, methyl sulfate, 2-(2-bromoallyl)-2-phenylacetate (ester)",CC[N+](C)(CC)CC(C)(C)COC(=O)C(CC(=C)Br)C1=CC=CC=C1.COS(=O)(=O)[O-],,,,,,
13631,48326,"[3-(4-Bromo-2-phenylpent-4-enoyl)oxy-2,2-dimethylpropyl]-diethyl-methylazanium",CC[N+](C)(CC)CC(C)(C)COC(=O)C(CC(=C)Br)C1=CC=CC=C1,,,,,,
13632,48327,1-Phenylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester methiodide,CC[N+](C)(CC)CCOC(=O)C1(CCCCC1)C2=CC=CC=C2.[I-],,,,,,
13633,48328,Diethyl-methyl-[2-(1-phenylcyclohexanecarbonyl)oxyethyl]azanium,CC[N+](C)(CC)CCOC(=O)C1(CCCCC1)C2=CC=CC=C2,,,,,,
13634,48329,"Ammonium, diethyl(3-(2-(alpha-hydroxy-alpha-phenylbenzyl)phenoxy)propyl)methyl-, toluenesulfonate, hydrate (4:7)",CC[N+](C)(CC)CCCOC1=CC=CC=C1C(C2=CC=CC=C2)(C3=CC=CC=C3)O.CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
13635,48330,Diethyl-[3-[2-[hydroxy(diphenyl)methyl]phenoxy]propyl]-methylazanium,CC[N+](C)(CC)CCCOC1=CC=CC=C1C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
13636,48331,Diethyl(3-hydroxy-2-pyridylmethyl)methylammonium bromide dimethylcarbamate (ester),CC[N+](C)(CC)CC1=C(C=CC=N1)OC(=O)N(C)C.[Br-],,,,,,
13637,48332,[3-(Dimethylcarbamoyloxy)pyridin-2-yl]methyl-diethyl-methylazanium,CC[N+](C)(CC)CC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
13638,48333,"Ammonium, (m-(1,4-dihydro-3,5-diethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)trimethyl-, iodide",CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](C)(C)C)C(=O)OCC)C)C.[I-],,,,,,
13639,48334,"[3-[3,5-Bis(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl]phenyl]-trimethylazanium",CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](C)(C)C)C(=O)OCC)C)C,,,,,,
13640,48335,"Benzyl alcohol, alpha-(2-(4-(m-methoxyphenyl)piperazinyl)ethyl)-3,4,5-trimethoxy-, dihydrochloride",COC1=CC=CC(=C1)N2CCN(CC2)CCC(C3=CC(=C(C(=C3)OC)OC)OC)O.Cl.Cl,,,,,,
13641,48336,"3-[4-(3-Methoxyphenyl)piperazin-1-yl]-1-(3,4,5-trimethoxyphenyl)propan-1-ol",COC1=CC=CC(=C1)N2CCN(CC2)CCC(C3=CC(=C(C(=C3)OC)OC)OC)O,,,,,,
13642,48337,"Benzylamine, N-allyl-N-(2-chloroethyl)-, hydrochloride",C=CC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13643,48338,N-benzyl-N-(2-chloroethyl)prop-2-en-1-amine,C=CCN(CCCl)CC1=CC=CC=C1,,,,,,
13644,48339,"Benzylamine, N-benzoylmethyl-N-(2-chloroethyl)-, hydrochloride",C1=CC=C(C=C1)C[NH+](CCCl)CC(=O)C2=CC=CC=C2.[Cl-],,,,,,
13645,48340,2-[Benzyl(2-chloroethyl)amino]-1-phenylethanone,C1=CC=C(C=C1)CN(CCCl)CC(=O)C2=CC=CC=C2,,,,,,
13646,48341,"Benzylamine, N-(2-bromoallyl)-N-methyl-, hydrochloride",C[NH+](CC1=CC=CC=C1)CC(=C)Br.[Cl-],,,,,,
13647,48342,N-benzyl-2-bromo-N-methylprop-2-en-1-amine,CN(CC1=CC=CC=C1)CC(=C)Br,,,,,,
13648,48343,"BENZYLAMINE, 2-tert-BUTYL-N-(2-CHLOROETHYL)-4,6-DIMETHYL-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CCCl)CC1=C(C=C(C=C1C(C)(C)C)C)C.[Cl-],,,,,,
13649,48344,"N-[(2-tert-butyl-4,6-dimethylphenyl)methyl]-2-chloro-N-ethylethanamine",CCN(CCCl)CC1=C(C=C(C=C1C(C)(C)C)C)C,,,,,,
13650,48345,"Benzylamine, N-butyl-N-(2-chloroethyl)-, hydrochloride",CCCC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13651,48346,N-benzyl-N-(2-chloroethyl)butan-1-amine,CCCCN(CCCl)CC1=CC=CC=C1,,,,,,
13652,48347,"Benzylamine, N-(2-chloroethyl)-N-dodecyl-, hydrochloride",CCCCCCCCCCCC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13653,48348,N-benzyl-N-(2-chloroethyl)dodecan-1-amine,CCCCCCCCCCCCN(CCCl)CC1=CC=CC=C1,,,,,,
13654,48349,N-(2-Chloroethyl)-N-ethyl-4-isopropylbenzylamine hydrochloride,CC[NH+](CCCl)CC1=CC=C(C=C1)C(C)C.[Cl-],,,,,,
13655,48350,2-chloro-N-ethyl-N-[(4-propan-2-ylphenyl)methyl]ethanamine,CCN(CCCl)CC1=CC=C(C=C1)C(C)C,,,,,,
13656,48351,"Benzylamine, N-(2-chloroethyl)-N-ethyl-3,4-methylenedioxy-, hydrochloride",CC[NH+](CCCl)CC1=CC2=C(C=C1)OCO2.[Cl-],,,,,,
13657,48352,"N-(1,3-benzodioxol-5-ylmethyl)-2-chloro-N-ethylethanamine",CCN(CCCl)CC1=CC2=C(C=C1)OCO2,,,,,,
13658,48353,N-(2-Chloroethyl)-N-ethyl-alpha-methylbenzylamine hydrochloride,CC[NH+](CCCl)C(C)C1=CC=CC=C1.[Cl-],,,,,,
13659,48354,N-(2-chloroethyl)-N-ethyl-1-phenylethanamine,CCN(CCCl)C(C)C1=CC=CC=C1,,,,,,
13660,48355,"Benzylamine, N-(2-chloroethyl)-N-heptyl-, hydrochloride",CCCCCCC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13661,48356,N-benzyl-N-(2-chloroethyl)heptan-1-amine,CCCCCCCN(CCCl)CC1=CC=CC=C1,,,,,,
13662,48357,"Benzylamine, N-(2-chloroethyl)-N-isopropyl-, hydrochloride",CC(C)[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13663,48358,N-benzyl-N-(2-chloroethyl)propan-2-amine,CC(C)N(CCCl)CC1=CC=CC=C1,,,,,,
13664,48359,"Benzylamine, N-(2-chloroethyl)-N-(2-(2-methoxyethoxy)ethyl)-, hydrochloride",COCCOCC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13665,48360,N-benzyl-N-(2-chloroethyl)-2-(2-methoxyethoxy)ethanamine,COCCOCCN(CCCl)CC1=CC=CC=C1,,,,,,
13666,48361,"Benzylamine, N-(2-chloroethyl)-N-propyl-, hydrochloride",CCC[NH+](CCCl)CC1=CC=CC=C1.[Cl-],,,,,,
13667,48362,N-benzyl-N-(2-chloroethyl)propan-1-amine,CCCN(CCCl)CC1=CC=CC=C1,,,,,,
13668,48363,"Benzoic acid, 3,4,5-trimethoxy-, 4-(N-benzyl-N-ethylamino)butyl ester",CCN(CCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC)CC2=CC=CC=C2,,,,,,
13669,48364,"N-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3,7,11-trimethyldodeca-2,6,10-trien-1-amine",CCN(CC=C(C)CCC=C(C)CCC=C(C)C)CC1=CC2=C(C=C1)OCO2,,,,,,
13670,48365,CID 48365,CC(C)CN(CC=C(C)CCC=C(C)CCC=C(C)C)CC1=CC2=C(C=C1)OCO2,,,,,,
13671,48366,"2-Biphenylol, 4,6-dinitro-",C1=CC=C(C=C1)C2=C(C=C(C=C2O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
13672,48367,"Biuret, 1-benzyl-",C1=CC=C(C=C1)CNC(=O)NC(=O)N,,,,,,
13673,48368,"4-((3,4-Dimethoxy-2-(1-pyrrolidinylcarbonyl)benzylidene)amino)antipyrine",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=CC3=C(C(=C(C=C3)OC)OC)C(=O)N4CCCC4,,,,,,
13674,48369,CID 48369,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=CC3=CC=CC=C3C(=O)[O-].[Na+],,,,,,
13675,48370,"2-[(1,5-Dimethyl-3-oxo-2-phenylpyrazol-4-yl)iminomethyl]benzoic acid",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=CC3=CC=CC=C3C(=O)O,,,,,,
13676,48371,"p-ACETOPHENETIDIDE, N-ETHYL-",CCN(C1=CC=C(C=C1)OCC)C(=O)C,,,,,,
13677,48372,"Acetophenone, 4-allyloxy-3,5-dimethoxy-",CC(=O)C1=CC(=C(C(=C1)OC)OCC=C)OC,,,,,,
13678,48373,"Acetophenone, 5-methoxy-3,4-methylenedioxy-",CC(=O)C1=CC2=C(C(=C1)OC)OCO2,,,,,,
13679,48374,"3'-Methoxy-2,2,4'-trihydroxyacetophenone",COC1=C(C=CC(=C1)C(=O)C(O)O)O,,,,,,
13680,48375,"Acetophenone, 2-(4-(2-pyrimidyl)piperazinyl)-3',4',5'-trimethoxy-, dihydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)CN2CCN(CC2)C3=NC=CC=N3.Cl.Cl,,,,,,
13681,48376,"2-(4-Pyrimidin-2-ylpiperazin-1-yl)-1-(3,4,5-trimethoxyphenyl)ethanone",COC1=CC(=CC(=C1OC)OC)C(=O)CN2CCN(CC2)C3=NC=CC=N3,,,,,,
13682,48377,Brilliantphosphine-imino,CC1=CC2=CC3=C(C=C(C(=C3)C)NC)[N+](=C2C=C1NC)C.[N+](=O)([O-])[O-],,,,,,
13683,48378,"3-N,6-N,2,7,10-pentamethylacridin-10-ium-3,6-diamine",CC1=CC2=CC3=C(C=C(C(=C3)C)NC)[N+](=C2C=C1NC)C,,,,,,
13684,48379,CID 48379,CC[NH+](CC)CCOC(=O)C(=CC1=CC=CO1)C2=CC=CC=C2.[Cl-],,,,,,
13685,48380,CID 48380,CCN(CC)CCOC(=O)C(=CC1=CC=CO1)C2=CC=CC=C2,,,,,,
13686,48381,"Adamantane, 1,3-bis(2-methylaminopropyl)-",CC(CC12CC3CC(C1)CC(C3)(C2)CC(C)NC)NC.Cl.Cl,,,,,,
13687,48382,N-methyl-1-[3-[2-(methylamino)propyl]-1-adamantyl]propan-2-amine,CC(CC12CC3CC(C1)CC(C3)(C2)CC(C)NC)NC,,,,,,
13688,48383,Antimony sodium propylene diamine tetraacetic acid dihydrate,CC(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Sb+3],,,,,,
13689,48384,"Ethyl 4-amino-2-(3,4-xylyl)butyrate hydrochloride",CCOC(=O)C(CC[NH3+])C1=CC(=C(C=C1)C)C.[Cl-],,,,,,
13690,48385,"Ethyl 4-amino-2-(3,4-dimethylphenyl)butanoate",CCOC(=O)C(CCN)C1=CC(=C(C=C1)C)C,,,,,,
13691,48386,"Butyramide, 2-allylthio-2-ethyl-N-methyl-",CCC(CC)(C(=O)NC)SCC=C,,,,,,
13692,48387,1-Methylhexahydro-2-azepinylmethyl diphenylacetate,CN1CCCCCC1COC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13693,48388,CID 48388,C.C[NH+](C)CCON=C(C1=CC=CC=C1)C2=CN=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
13694,48389,CID 48389,CN(C)CCON=C(C1=CC=CC=C1)C2=CN=CC=C2,,,,,,
13695,48390,CID 48390,C[NH+](C)CCON=C(C1=CC=CC=C1)C2=CN=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
13696,48391,CID 48391,CC[NH+](CC)CCON=C(C1=CC=CC=C1)C2=CN=CC=C2.C(=O)(C(=O)[O-])O,,,,,,
13697,48392,CID 48392,CCN(CC)CCON=C(C1=CC=CC=C1)C2=CN=CC=C2,,,,,,
13698,48393,"BARBITURIC ACID, 1-(p-CHLOROPHENYL)-5,5-DIETHYL-",CCC1(C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)Cl)CC,,,,,,
13699,48394,CID 48394,CCC1(C(=O)NC(=NC1=O)[O-])CC=CC2=CC=CC=C2.[Na+],,,,,,
13700,48395,"5-Ethyl-5-(3-phenylprop-2-enyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CC=CC2=CC=CC=C2,,,,,,
13701,48396,CID 48396,CC1(C(=NC(=S)N(C1=O)C)[O-])C2=CCCCC2.[Na+],,,,,,
13702,48397,CID 48397,CC1(C(=O)N=C(N(C1=O)C)S)C2=CCCCC2,,,,,,
13703,48398,CID 48398,CCC1(C(=O)NC(=NC1=O)[O-])CCC2CCCCC2.[Na+],,,,,,
13704,48399,"5-(2-Cyclohexylethyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCC2CCCCC2,,,,,,
13705,48400,CID 48400,C1CCC(CC1)CCC2(C(=O)NC(=NC2=O)[O-])CCC3=CC=CC=C3.[Na+],,,,,,
13706,48401,"5-(2-Cyclohexylethyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",C1CCC(CC1)CCC2(C(=O)NC(=O)NC2=O)CCC3=CC=CC=C3,,,,,,
13707,48402,5-(2-Cyclohexylideneethyl)-5-ethyl-1-methylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C)CC=C2CCCCC2,,,,,,
13708,48403,"Barbituric acid, 5-(2-cyclohexylideneethyl)-5-methyl-",CC1(C(=O)NC(=O)NC1=O)CC=C2CCCCC2,,,,,,
13709,48404,"Barbituric acid, 5-(cyclohexylideneethyl)-5-phenyl-",C1CCC(=CCC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3)CC1,,,,,,
13710,48405,"Barbituric acid, 5-cyclohexyl-5-(3-methyl-2-butenyl)-",CC(=CCC1(C(=O)NC(=O)NC1=O)C2CCCCC2)C,,,,,,
13711,48406,5-(2-Cyclopentenyl)-5-ethyl-1-methylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C)C2CCC=C2,,,,,,
13712,48407,CID 48407,CCC1(C(=O)NC(=NC1=O)S)C2CCC=C2,,,,,,
13713,48408,5-(2-Cyclopentenyl)-5-isobutylbarbituric acid,CC(C)CC1(C(=O)NC(=O)NC1=O)C2CCC=C2,,,,,,
13714,48409,5-(2-Cyclopentenyl)-5-isobutyl-1-methylbarbituric acid,CC(C)CC1(C(=O)NC(=O)N(C1=O)C)C2CCC=C2,,,,,,
13715,48410,CID 48410,CC(C)CC1(C(=O)NC(=NC1=O)S)C2CCC=C2,,,,,,
13716,48411,5-(2-Cyclopentenyl)-5-(2-methylallyl)barbituric acid,CC(=C)CC1(C(=O)NC(=O)NC1=O)C2CCC=C2,,,,,,
13717,48412,CID 48412,CC(=C)CC1(C(=O)NC(=NC1=O)S)C2CCC=C2,,,,,,
13718,48413,5-(2-Cyclopentenyl)-1-methyl-5-(1-methylvinyl)barbituric acid,CC(=C)C1(C(=O)NC(=O)N(C1=O)C)C2CCC=C2,,,,,,
13719,48414,CID 48414,CC(=C)C1(C(=O)NC(=NC1=O)S)C2CCC=C2,,,,,,
13720,48415,CID 48415,CC=CC1(C(=O)NC(=O)NC1=O)C2CCC=C2,,,,,,
13721,48416,CID 48416,CCCC1(C(=O)NC(=NC1=O)S)C2CCC=C2,,,,,,
13722,48417,"5-cyclopentyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione",CCC1(C(=O)NC(=O)NC1=O)C2CCCC2,,,,,,
13723,48418,CID 48418,C1CCC(C1)CCC2(C(=O)NC(=NC2=O)[O-])CCC3=CC=CC=C3.[Na+],,,,,,
13724,48419,"5-(2-cyclopentylethyl)-5-(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione",C1CCC(C1)CCC2(C(=O)NC(=O)NC2=O)CCC3=CC=CC=C3,,,,,,
13725,48420,"Barbituric acid, 5-(2-cyclopentylideneethyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)CC=C2CCCC2,,,,,,
13726,48421,"5-Cyclopentyl-5-(2-methylprop-2-enyl)-1,3-diazinane-2,4,6-trione",CC(=C)CC1(C(=O)NC(=O)NC1=O)C2CCCC2,,,,,,
13727,48422,"Barbituric acid, 5,5-diallyl-1-(N,N-diethylcarbamoylmethyl)-",CCN(CC)C(=O)CN1C(=O)C(C(=O)NC1=O)(CC=C)CC=C,,,,,,
13728,48423,"Barbituric acid, 5,5-diallyl-1-heptyl-",CCCCCCCN1C(=O)C(C(=O)NC1=O)(CC=C)CC=C,,,,,,
13729,48424,CID 48424,CCCCC1(C(=O)NC(=NC1=O)[O-])CCCC.[Na+],,,,,,
13730,48425,"Barbituric acid, 5,5-diethyl-1-(2,3-dimethoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=C(C(=CC=C2)OC)OC)CC,,,,,,
13731,48426,"Barbituric acid, 5,5-diethyl-1-(2,4-dimethoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=C(C=C(C=C2)OC)OC)CC,,,,,,
13732,48427,"Barbituric acid, 5,5-diethyl-1-(2,5-dimethoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=C(C=CC(=C2)OC)OC)CC,,,,,,
13733,48428,"Barbituric acid, 5,5-diethyl-1-(3,4-dimethoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=CC(=C(C=C2)OC)OC)CC,,,,,,
13734,48429,"Barbituric acid, 5,5-diethyl-1-(1,1-dimethylpropyl)-",CCC1(C(=O)NC(=O)N(C1=O)C(C)(C)CC)CC,,,,,,
13735,48430,"Barbituric acid, 5,5-diethyl-1-(2,2-dimethylpropyl)-",CCC1(C(=O)NC(=O)N(C1=O)CC(C)(C)C)CC,,,,,,
13736,48431,"d,l-5,5-Diethyl-1-(1,2-dimethylpropyl)barbituric acid",CCC1(C(=O)NC(=O)N(C1=O)C(C)C(C)C)CC,,,,,,
13737,48432,"BARBITURIC ACID, 5,5-DIETHYL-1-(p-ETHOXYPHENYL)-",CCC1(C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)OCC)CC,,,,,,
13738,48433,"Barbituric acid, 5,5-diethyl-1-(1-ethylpropyl)-",CCC(CC)N1C(=O)C(C(=O)NC1=O)(CC)CC,,,,,,
13739,48434,"1,5-Diethyl-5-isopentylbarbituric acid",CCC1(C(=O)NC(=O)N(C1=O)CC)CCC(C)C,,,,,,
13740,48435,"Barbituric acid, 5,5-diethyl-1-isopentyl-",CCC1(C(=O)NC(=O)N(C1=O)CCC(C)C)CC,,,,,,
13741,48436,"1,5-Diethyl-5-isopropenylbarbituric acid",CCC1(C(=O)NC(=O)N(C1=O)CC)C(=C)C,,,,,,
13742,48437,"Barbituric acid, 5,5-diethyl-1-(2-methoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=CC=CC=C2OC)CC,,,,,,
13743,48438,"Barbituric acid, 5,5-diethyl-1-(3-methoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=CC(=CC=C2)OC)CC,,,,,,
13744,48439,"Barbituric acid, 5,5-diethyl-1-(4-methoxyphenethyl)-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=CC=C(C=C2)OC)CC,,,,,,
13745,48440,"BARBITURIC ACID, 5,5-DIETHYL-1-(p-METHOXYPHENYL)-",CCC1(C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)OC)CC,,,,,,
13746,48441,"1,5-Diethyl-5-(3-methyl-2-butenyl)barbituric acid",CCC1(C(=O)NC(=O)N(C1=O)CC)CC=C(C)C,,,,,,
13747,48442,"d,l-5,5-Diethyl-1-(1-methylbutyl)barbituric acid",CCCC(C)N1C(=O)C(C(=O)NC1=O)(CC)CC,,,,,,
13748,48443,"d,l-5,5-Diethyl-1-(2-methylbutyl)barbituric acid",CCC(C)CN1C(=O)C(C(=O)NC1=O)(CC)CC,,,,,,
13749,48444,"Barbituric acid, 5,5-diethyl-1-phenethyl-",CCC1(C(=O)NC(=O)N(C1=O)CCC2=CC=CC=C2)CC,,,,,,
13750,48445,CID 48445,CCC1(C(=O)NC(=NC1=O)NC2=CC=CC=C2)CC,,,,,,
13751,48446,"5-(1,3-Dimethyl-1-butenyl)-5-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione",CC(C)C=C(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13752,48447,"5-(1,3-Dimethylbutyl)-5-methylbarbituric acid",CC(C)CC(C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
13753,48448,"1,5-Dimethyl-5-(1-ethylpropyl)barbituric acid",CCC(CC)C1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
13754,48449,CID 48449,CCSCC1(C(=O)N=C(N(C1=O)C)[O-])C.[Na+],,,,,,
13755,48450,"5-(Ethylsulfanylmethyl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione",CCSCC1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
13756,48451,CID 48451,CCC(C)CC(C)CC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
13757,48452,"5-(2,4-Dimethylhexyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCC(C)CC(C)CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
13758,48453,"Barbituric acid, 1,3-dimethyl-5-isopentyl-",CC(C)CCC1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
13759,48454,"1,5-Dimethyl-5-isopentylbarbituric acid",CC(C)CCC1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
13760,48455,CID 48455,CCC=C(C)C1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
13761,48456,"1,3-Dimethyl-5-(1-methylbutyl)barbituric acid",CCCC(C)C1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
13762,48457,"1,5-Dimethyl-5-(1-methylbutyl)barbituric acid",CCCC(C)C1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
13763,48458,CID 48458,CCCC(C)C1(C(=NC(=S)N(C1=O)C)[O-])C.[Na+],,,,,,
13764,48459,CID 48459,CCCC(C)C1(C(=O)N=C(N(C1=O)C)S)C,,,,,,
13765,48460,"1,5-Dimethyl-5-(1-methylpentyl)barbituric acid",CCCCC(C)C1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
13766,48461,CID 48461,CCC(C)CC(C)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
13767,48462,"5-Ethyl-5-(4-methylhexan-2-yl)-1,3-diazinane-2,4,6-trione",CCC(C)CC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
13768,48463,CID 48463,CCC1(C(=O)NC(=NC1=O)[O-])C(C)CCC(C)C.[Na+],,,,,,
13769,48464,"5-Ethyl-5-(5-methylhexan-2-yl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)CCC(C)C,,,,,,
13770,48465,CID 48465,CCC1(C(=O)NC(=NC1=O)[O-])CC(C)CC(C)C.[Na+],,,,,,
13771,48466,"5-(2,4-Dimethylpentyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CC(C)CC(C)C,,,,,,
13772,48467,"5-Ethyl-5-(3-methylbutan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)C(C)C,,,,,,
13773,48468,CID 48468,CCC1(C(=O)NC(=NC1=O)[O-])C(C)(C)C#C.[Na+],,,,,,
13774,48469,"5-Ethyl-5-(2-methylbut-3-yn-2-yl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)(C)C#C,,,,,,
13775,48470,"Barbituric acid, 5,5-dipentyl-",CCCCCC1(C(=O)NC(=O)NC1=O)CCCCC,,,,,,
13776,48471,CID 48471,C1=CC=C(C=C1)CCC2(C(=O)NC(=NC2=O)[O-])CCC3=CC=CC=C3.[Na+],,,,,,
13777,48472,"5,5-Bis(2-phenylethyl)-1,3-diazinane-2,4,6-trione",C1=CC=C(C=C1)CCC2(C(=O)NC(=O)NC2=O)CCC3=CC=CC=C3,,,,,,
13778,48473,5-(1-Ethoxyethyl)-5-ethylbarbituric acid,CCC1(C(=O)NC(=O)NC1=O)C(C)OCC,,,,,,
13779,48474,CID 48474,CCC1(C(=O)NC(=NC1=O)[O-])CCOCC.[Na+],,,,,,
13780,48475,"5-(2-Ethoxyethyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCOCC,,,,,,
13781,48476,5-(1-Ethoxyethyl)-5-(1-methylbutyl)barbituric acid,CCCC(C)C1(C(=O)NC(=O)NC1=O)C(C)OCC,,,,,,
13782,48477,CID 48477,CCOCCC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
13783,48478,"5-(2-Ethoxyethyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",CCOCCC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
13784,48479,CID 48479,CCOCCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
13785,48480,"5-(2-Ethoxyethyl)-5-phenyl-1,3-diazinane-2,4,6-trione",CCOCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
13786,48481,5-(1-Ethoxyethyl)-5-propylbarbituric acid,CCCC1(C(=O)NC(=O)NC1=O)C(C)OCC,,,,,,
13787,48482,"Barbituric acid, 5-(ethoxymethyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)COCC,,,,,,
13788,48483,"Barbituric acid, 5-(1-ethoxyvinyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)C(=C)OCC,,,,,,
13789,48484,"Ammonium, (p-(1,4-dihydro-3,5-diethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)trimethyl-, iodide",CCOC(=O)C1=C(NC(=C(C1C2=CC=C(C=C2)[N+](C)(C)C)C(=O)OCC)C)C.[I-],,,,,,
13790,48485,"[4-[3,5-Bis(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl]phenyl]-trimethylazanium",CCOC(=O)C1=C(NC(=C(C1C2=CC=C(C=C2)[N+](C)(C)C)C(=O)OCC)C)C,,,,,,
13791,48486,"Ammonium, (p-(1,4-dihydro-3,5-dimethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)benzyldimethyl-, iodide",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](C)(C)CC3=CC=CC=C3)C(=O)OC.[I-],,,,,,
13792,48487,"Benzyl-[4-[3,5-bis(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl]phenyl]-dimethylazanium",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](C)(C)CC3=CC=CC=C3)C(=O)OC,,,,,,
13793,48488,"Ammonium, (p-(1,4-dihydro-3,5-dimethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)butyldimethyl-, iodide",CCCC[N+](C)(C)C1=CC=C(C=C1)C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OC.[I-],,,,,,
13794,48489,"[4-[3,5-Bis(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl]phenyl]-butyl-dimethylazanium",CCCC[N+](C)(C)C1=CC=C(C=C1)C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OC,,,,,,
13795,48490,"Ammonium, (p-(1,4-dihydro-3,5-dimethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)dimethylpentyl-, iodide",CCCCC[N+](C)(C)C1=CC=C(C=C1)C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OC.[I-],,,,,,
13796,48491,"[4-[3,5-Bis(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl]phenyl]-dimethyl-pentylazanium",CCCCC[N+](C)(C)C1=CC=C(C=C1)C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OC,,,,,,
13797,48492,"Ammonium, (m-(1,4-dihydro-3,5-dimethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)trimethyl-, iodide",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)[N+](C)(C)C)C(=O)OC.[I-],,,,,,
13798,48493,"Trimethyl[3-[[2,6-dimethyl-3,5-bis(methoxycarbonyl)-1,4-dihydropyridin]-4-yl]phenyl]aminium",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)[N+](C)(C)C)C(=O)OC,,,,,,
13799,48494,"Ammonium, (p-(1,4-dihydro-3,5-dimethoxycarbonyl-2,6-dimethyl-4-pyridyl)phenyl)trimethyl-, iodide",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](C)(C)C)C(=O)OC.[I-],,,,,,
13800,48495,"[4-[3,5-Bis(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl]phenyl]-trimethylazanium",CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](C)(C)C)C(=O)OC,,,,,,
13801,48496,"(3,4-Dihydroxyphenyl)trimethylammonium bromide",C[N+](C)(C)C1=CC(=C(C=C1)O)O.[Br-],,,,,,
13802,48497,"(3,4-Dihydroxyphenyl)-trimethylazanium",C[N+](C)(C)C1=CC(=C(C=C1)O)O,,,,,,
13803,48498,"(3,5-Dihydroxyphenyl)trimethylammonium bromide",C[N+](C)(C)C1=CC(=CC(=C1)O)O.[Br-],,,,,,
13804,48499,"(3,5-Dihydroxyphenyl)-trimethylazanium",C[N+](C)(C)C1=CC(=CC(=C1)O)O,,,,,,
13805,48500,"(3,5-Dihydroxyphenyl)trimethylammonium bromide bis(dimethylcarbamate) (ester)",CN(C)C(=O)OC1=CC(=CC(=C1)[N+](C)(C)C)OC(=O)N(C)C.[Br-],,,,,,
13806,48501,"[3,5-Bis(dimethylcarbamoyloxy)phenyl]-trimethylazanium",CN(C)C(=O)OC1=CC(=CC(=C1)[N+](C)(C)C)OC(=O)N(C)C,,,,,,
13807,48502,Diisopropyl((3-hydroxy-2-pyridyl)methyl)methylammonium bromide dimethylcarbamate (ester),CC(C)[N+](C)(CC1=NC(=CC=C1)OC(=O)N(C)C)C(C)C.[Br-],,,,,,
13808,48503,[6-(Dimethylcarbamoyloxy)pyridin-2-yl]methyl-methyl-di(propan-2-yl)azanium,CC(C)[N+](C)(CC1=NC(=CC=C1)OC(=O)N(C)C)C(C)C,,,,,,
13809,48504,Dimethylethyl(5-hydroxy-m-tolyl)ammonium bromide,CC[N+](C)(C)C1=CC(=CC(=C1)C)O.[Br-],,,,,,
13810,48505,Ethyl-(3-hydroxy-5-methylphenyl)-dimethylazanium,CC[N+](C)(C)C1=CC(=CC(=C1)C)O,,,,,,
13811,48506,Dimethylethyl(5-hydroxy-o-tolyl)ammonium bromide,CC[N+](C)(C)C1=C(C=CC(=C1)O)C.[Br-],,,,,,
13812,48507,Ethyl-(5-hydroxy-2-methylphenyl)-dimethylazanium,CC[N+](C)(C)C1=C(C=CC(=C1)O)C,,,,,,
13813,48508,Dimethylethyl(3-hydroxy-p-tolyl)ammonium bromide,CC[N+](C)(C)C1=CC(=C(C=C1)C)O.[Br-],,,,,,
13814,48509,Ethyl-(3-hydroxy-4-methylphenyl)-dimethylazanium,CC[N+](C)(C)C1=CC(=C(C=C1)C)O,,,,,,
13815,48510,Dimethyl(3-hydroxyphenyl)(p-nitrobenzyl)ammonium chloride,C[N+](C)(CC1=CC=C(C=C1)[N+](=O)[O-])C2=CC(=CC=C2)O.[Cl-],,,,,,
13816,48511,(3-Hydroxyphenyl)-dimethyl-[(4-nitrophenyl)methyl]azanium,C[N+](C)(CC1=CC=C(C=C1)[N+](=O)[O-])C2=CC(=CC=C2)O,,,,,,
13817,48512,"AMMONIUM, (2,2-DIMETHYL-3-HYDROXYPROPYL)TRIETHYL-, BROMIDE, TROPATE (ester)",CC[N+](CC)(CC)CC(C)(C)COC(=O)C(CO)C1=CC=CC=C1.[Br-],,,,,,
13818,48513,"Triethyl-[3-(3-hydroxy-2-phenylpropanoyl)oxy-2,2-dimethylpropyl]azanium",CC[N+](CC)(CC)CC(C)(C)COC(=O)C(CO)C1=CC=CC=C1,,,,,,
13819,48514,"Azoxybenzene, 5,5'-dichloro-2,2'-dimethyl-",CC1=C(C=C(C=C1)Cl)N=[N+](C2=C(C=CC(=C2)Cl)C)[O-],,,,,,
13820,48515,CID 48515,CCCC1(CN(C1)C)C2CC=CC(=C2)OCCC3=CC=CC=C3,,,,,,
13821,48516,CID 48516,CC(C1(C(=O)NC(=NC1=O)[O-])CC=C)SCC=C.[Na+],,,,,,
13822,48517,"5-Prop-2-enyl-5-(1-prop-2-enylsulfanylethyl)-1,3-diazinane-2,4,6-trione",CC(C1(C(=O)NC(=O)NC1=O)CC=C)SCC=C,,,,,,
13823,48518,CID 48518,CC=CCC1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
13824,48519,CID 48519,CC=CCC1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
13825,48520,5-Allyl-5-sec-butyl-1-methylbarbituric acid,CCC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C,,,,,,
13826,48521,CID 48521,CCCCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13827,48522,5-Allyl-5-butylbarbituric acid,CCCCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13828,48523,CID 48523,CCCCSC(C)C1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13829,48524,"5-(1-Butylsulfanylethyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CCCCSC(C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13830,48525,CID 48525,CCCCSCCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13831,48526,"5-(2-Butylsulfanylethyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CCCCSCCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13832,48527,CID 48527,CCCCSCCC1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
13833,48528,CID 48528,CCCCSCCC1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
13834,48529,CID 48529,CCCCSCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13835,48530,"5-(Butylsulfanylmethyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13836,48531,CID 48531,C=CCC1(C(=O)NC(=NC1=O)S)C2CCC=C2,,,,,,
13837,48532,CID 48532,CCC1(C(=NC(=S)N(C1=O)CC=C)[O-])CC.[Na+],,,,,,
13838,48533,CID 48533,CCC1(C(=O)N=C(N(C1=O)CC=C)S)CC,,,,,,
13839,48534,5-Allyl-5-(1-ethoxyethyl)barbituric acid,CCOC(C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13840,48535,"Barbituric acid, 5-allyl-5-(1-ethoxyvinyl)-",CCOC(=C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13841,48536,CID 48536,CCC1(C(=NC(=S)N(C1=O)CC=C)[O-])CCC(C)C.[Na+],,,,,,
13842,48537,CID 48537,CCC1(C(=O)N=C(N(C1=O)CC=C)S)CCC(C)C,,,,,,
13843,48538,"Barbituric acid, 1-allyl-5-ethyl-5-isopropenyl-",CCC1(C(=O)NC(=O)N(C1=O)CC=C)C(=C)C,,,,,,
13844,48539,CID 48539,CCC(CC)C1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13845,48540,5-Allyl-5-(1-ethylpropyl)barbituric acid,CCC(CC)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13846,48541,CID 48541,CCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13847,48542,Ethallobarbital,CCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13848,48543,CID 48543,CCSC(C)C1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13849,48544,5-[1-(Ethylthio)ethyl]-5-(2-propenyl)barbituric acid,CCSC(C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13850,48545,CID 48545,CCSCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13851,48546,"5-Allyl-5-(ethylthiomethyl)-2-sodiooxy-4,6(1H,5H)-pyrimidinedione",CCSCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13852,48547,CID 48547,CC(C)CCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13853,48548,5-Allyl-5-isopentyl-barbituric acid,CC(C)CCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13854,48549,"Barbituric acid, 5-allyl-5-isopropenyl-",CC(=C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13855,48550,5-Allyl-5-(2-methylallyl)barbituric acid,CC(=C)CC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13856,48551,CID 48551,CC(C=C)C1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13857,48552,"5-But-3-en-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CC(C=C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13858,48553,CID 48553,CC(=C)CC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13859,48554,CID 48554,CC(C=C)C1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
13860,48555,CID 48555,CC(C=C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
13861,48556,"5-(2-Hydroxybutyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CCC(CC1(C(=O)NC(=O)NC1=O)CC=C)O,,,,,,
13862,48557,5-Allyl-1-methyl-5-(1-methylpentyl)barbituric acid,CCCCC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C,,,,,,
13863,48558,5-Allyl-5-(1-methylpentyl)barbituric acid,CCCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13864,48559,"5-But-2-en-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",CC=C(C)C1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13865,48560,5-Allyl-5-pentylbarbituric acid,CCCCCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13866,48561,CID 48561,C=CCC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
13867,48562,"5-(2-Phenylethyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",C=CCC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
13868,48563,CID 48563,CCCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13869,48564,5-Allyl-5-propylbarbituric acid,CCCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13870,48565,CID 48565,CCCSCC1(C(=O)NC(=NC1=O)[O-])CC=C.[Na+],,,,,,
13871,48566,"5-Prop-2-enyl-5-(propylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCSCC1(C(=O)NC(=O)NC1=O)CC=C,,,,,,
13872,48567,CID 48567,CC(C)CC1(C(=O)NC(=NC1=O)[O-])C(C)SCC=C.[Na+],,,,,,
13873,48568,"5-(2-Methylpropyl)-5-(1-prop-2-enylsulfanylethyl)-1,3-diazinane-2,4,6-trione",CC(C)CC1(C(=O)NC(=O)NC1=O)C(C)SCC=C,,,,,,
13874,48569,CID 48569,CC(C)CC1(C(=NC(=NC1=O)S)[O-])C(C)SCC=C.[Na+],,,,,,
13875,48570,CID 48570,CC(C)CC1(C(=O)NC(=NC1=O)S)C(C)SCC=C,,,,,,
13876,48571,CID 48571,CCC1(C(=O)NC(=NC1=O)[O-])CSCC=C.[Na+],,,,,,
13877,48572,5-[(Allylmercapto)methyl]-5-ethylbarbituric acid,CCC1(C(=O)NC(=O)NC1=O)CSCC=C,,,,,,
13878,48573,CID 48573,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CSCC=C.[Na+],,,,,,
13879,48574,"5-Pentan-2-yl-5-(prop-2-enylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCC(C)C1(C(=O)NC(=O)NC1=O)CSCC=C,,,,,,
13880,48575,Benzylbutylbarbiturate,CCCCC1(C(=O)NC(=O)NC1=O)CC2=CC=CC=C2,,,,,,
13881,48576,"Barbituric acid, 1-benzyl-5,5-diallyl-",C=CCC1(C(=O)NC(=O)N(C1=O)CC2=CC=CC=C2)CC=C,,,,,,
13882,48577,CID 48577,CCC1(C(=NC(=S)N(C1=O)CC)[O-])CC2=CC=CC=C2.[Na+],,,,,,
13883,48578,CID 48578,CCC1(C(=O)N=C(N(C1=O)CC)S)CC2=CC=CC=C2,,,,,,
13884,48579,CID 48579,CCC1(C(=NC(=S)N(C1=O)C)[O-])CC2=CC=CC=C2.[Na+],,,,,,
13885,48580,CID 48580,CCC1(C(=O)N=C(N(C1=O)C)S)CC2=CC=CC=C2,,,,,,
13886,48581,CID 48581,CCC1(C(=O)NC(=NC1=O)[O-])CC2=CC=CC=C2.[Na+],,,,,,
13887,48582,"Barbituric acid, 5-benzyl-5-isopropenyl-",CC(=C)C1(C(=O)NC(=O)NC1=O)CC2=CC=CC=C2,,,,,,
13888,48583,"Barbituric acid, 5-benzyl-5-(3-methyl-2-butenyl)-",CC(=CCC1(C(=O)NC(=O)NC1=O)CC2=CC=CC=C2)C,,,,,,
13889,48584,CID 48584,CCC1(C(=O)NC(=NC1=O)[O-])CCOCC2=CC=CC=C2.[Na+],,,,,,
13890,48585,"5-Ethyl-5-(2-phenylmethoxyethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCOCC2=CC=CC=C2,,,,,,
13891,48586,"Barbituric acid, 5-(benzyloxymethyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)COCC2=CC=CC=C2,,,,,,
13892,48587,CID 48587,C1CCC(CC1)CCC2(C(=O)NC(=NC2=O)[O-])CCC3CCCCC3.[Na+],,,,,,
13893,48588,"5,5-Bis(2-cyclohexylethyl)-1,3-diazinane-2,4,6-trione",C1CCC(CC1)CCC2(C(=O)NC(=O)NC2=O)CCC3CCCCC3,,,,,,
13894,48589,"5,5-Bis(2-methyl-2-propenyl)barbituric acid",CC(=C)CC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
13895,48590,"Barbituric acid, 5,5-bis(3-methyl-2-butenyl)-",CC(=CCC1(C(=O)NC(=O)NC1=O)CC=C(C)C)C,,,,,,
13896,48591,CID 48591,C1=CC=C(C=C1)OCCCC2(C(=O)NC(=NC2=O)[O-])CCCOC3=CC=CC=C3.[Na+],,,,,,
13897,48592,"5,5-Bis(3-phenoxypropyl)-1,3-diazinane-2,4,6-trione",C1=CC=C(C=C1)OCCCC2(C(=O)NC(=O)NC2=O)CCCOC3=CC=CC=C3,,,,,,
13898,48593,5-(2-Bromoallyl)-5-(2-cyclopentenyl)barbituric acid,C=C(CC1(C(=O)NC(=O)NC1=O)C2CCC=C2)Br,,,,,,
13899,48594,5-(2-Bromoallyl)-5-(2-cyclopentenyl)-1-methylbarbituric acid,CN1C(=O)C(C(=O)NC1=O)(CC(=C)Br)C2CCC=C2,,,,,,
13900,48595,CID 48595,C=C(CC1(C(=O)NC(=NC1=O)S)C2CCC=C2)Br,,,,,,
13901,48596,"5-(2-Bromoprop-2-en-1-yl)-5-(2-methylprop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione",CC(=C)CC1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
13902,48597,1-(2-Bromo-2-ethylbutyryl)-5-ethyl-5-phenylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C(=O)C(CC)(CC)Br)C2=CC=CC=C2,,,,,,
13903,48598,"BARBITURIC ACID, 1-(p-BROMOPHENYL)-5,5-DIETHYL-",CCC1(C(=O)NC(=O)N(C1=O)C2=CC=C(C=C2)Br)CC,,,,,,
13904,48599,N-Isopropyl-p-methylazoxymethylbenzamide,CC(C)NC(=O)C1=CC=C(C=C1)C[N+](=NC)[O-],,,,,,
13905,48600,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, dicycloheptylcarboxylate, dihydrochloride",C1CCCC(CC1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCCCCC3.Cl.Cl,,,,,,
13906,48601,2-[4-[2-(Cycloheptanecarbonyloxy)ethyl]piperazin-1-yl]ethyl cycloheptanecarboxylate,C1CCCC(CC1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCCCCC3,,,,,,
13907,48602,"ETHANOL, 2,2'-(1,4-PIPERAZINYLENE)DI-, DI(o-METHYLBENZOATE), DIHYDROCHLORIDE",CC1=CC=CC=C1C(=O)OCCN2CCN(CC2)CCOC(=O)C3=CC=CC=C3C.Cl.Cl,,,,,,
13908,48603,2-[4-[2-(2-Methylbenzoyl)oxyethyl]piperazin-1-yl]ethyl 2-methylbenzoate,CC1=CC=CC=C1C(=O)OCCN2CCN(CC2)CCOC(=O)C3=CC=CC=C3C,,,,,,
13909,48604,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, divalerate, dihydrochloride",CCCCC(=O)OCCN1CCN(CC1)CCOC(=O)CCCC.Cl.Cl,,,,,,
13910,48605,2-[4-(2-Pentanoyloxyethyl)piperazin-1-yl]ethyl pentanoate,CCCCC(=O)OCCN1CCN(CC1)CCOC(=O)CCCC,,,,,,
13911,48606,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, dicyclopropylcarboxylate, dihydrochloride",C1CC1C(=O)OCCN2CCN(CC2)CCOC(=O)C3CC3.Cl.Cl,,,,,,
13912,48607,2-[4-[2-(Cyclopropanecarbonyloxy)ethyl]piperazin-1-yl]ethyl cyclopropanecarboxylate,C1CC1C(=O)OCCN2CCN(CC2)CCOC(=O)C3CC3,,,,,,
13913,48608,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, dicyclobutylcarboxylate, dihydrochloride",C1CC(C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCC3.Cl.Cl,,,,,,
13914,48609,2-[4-[2-(Cyclobutanecarbonyloxy)ethyl]piperazin-1-yl]ethyl cyclobutanecarboxylate,C1CC(C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCC3,,,,,,
13915,48610,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, dicyclopentylcarboxylate, dihydrochloride",C1CCC(C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCCC3.Cl.Cl,,,,,,
13916,48611,2-[4-[2-(Cyclopentanecarbonyloxy)ethyl]piperazin-1-yl]ethyl cyclopentanecarboxylate,C1CCC(C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCCC3,,,,,,
13917,48612,"Ethanol, 2,2'-(1,4-piperazinylene)DI-, dicyclohexylcarboxylate, dihydrochloride",C1CCC(CC1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCCCC3.Cl.Cl,,,,,,
13918,48613,2-[4-[2-(Cyclohexanecarbonyloxy)ethyl]piperazin-1-yl]ethyl cyclohexanecarboxylate,C1CCC(CC1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3CCCCC3,,,,,,
13919,48614,"ETHANOL, 2,2'-(1,4-PIPERAZINYLENE)DI-, DI(m-METHYLBENZOATE), DIHYDROCHLORIDE",CC1=CC(=CC=C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3=CC=CC(=C3)C.Cl.Cl,,,,,,
13920,48615,2-[4-[2-(3-Methylbenzoyl)oxyethyl]piperazin-1-yl]ethyl 3-methylbenzoate,CC1=CC(=CC=C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3=CC=CC(=C3)C,,,,,,
13921,48616,"ETHANOL, 2,2'-(1,4-PIPERAZINYLENE)DI-, DI(p-METHYLBENZOATE), DIHYDROCHLORIDE",CC1=CC=C(C=C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3=CC=C(C=C3)C.Cl.Cl,,,,,,
13922,48617,2-[4-[2-(4-Methylbenzoyl)oxyethyl]piperazin-1-yl]ethyl 4-methylbenzoate,CC1=CC=C(C=C1)C(=O)OCCN2CCN(CC2)CCOC(=O)C3=CC=C(C=C3)C,,,,,,
13923,48618,CID 48618,C1CC(=NNC2=CC=CC=C2CC(=O)O)C(=O)NC1,,,,,,
13924,48619,"17-beta-Hydroxy-5-beta,14-beta-androstan-3-one acrylate",C[C@]12CCC(=O)C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@H]3CC[C@@H]4OC(=O)C=C)C,,,,,,
13925,48620,"BUTYRIC ACID, 2-AMINO-4-(12-METHYL-7-BENZ(a)ANTHRYLMETHYL)THIO-",CC1=C2C(=C(C3=CC=CC=C13)CSCCC(C(=O)O)N)C=CC4=CC=CC=C42,,,,,,
13926,48621,"Acetic acid, phenyl-, (4-(dimethylamino)-2,2-diphenyl-1-ethyl)pentyl ester, hydrochloride",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)CC3=CC=CC=C3.[Cl-],,,,,,
13927,48622,"[6-(Dimethylamino)-4,4-diphenylheptan-3-yl] 2-phenylacetate",CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)CC3=CC=CC=C3,,,,,,
13928,48623,"Acetic acid, 2-(2-(2-vinyloxy)ethoxy)ethoxy-, methyl ester",COC(=O)COCCOCCOC=C,,,,,,
13929,48624,"Ammonium, (2-(3-acetyl-2-methyl-1-indolizinyl)-2-methylethyl)dimethyl(1,4-xylyl)-, chloride",CC1=CC=C(C=C1)C[N+](C)(C)CC(C)C2=C3C=CC=CN3C(=C2C)C(=O)C.[Cl-],,,,,,
13930,48625,2-(3-Acetyl-2-methylindolizin-1-yl)propyl-dimethyl-[(4-methylphenyl)methyl]azanium,CC1=CC=C(C=C1)C[N+](C)(C)CC(C)C2=C3C=CC=CN3C(=C2C)C(=O)C,,,,,,
13931,48626,"Ammonium, (ethylenebis(carbonyloxyethylene))bis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13932,48627,"2-[4-[2-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]ethoxy]-4-oxobutanoyl]oxyethyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13933,48628,"Ammonium, ethylenebis(oxyethylene)bis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride",CC1CCCC(C1CCC(C)[N+](C)(C)CCOCCOCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
13934,48629,"2-[2-[2-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]ethoxy]ethoxy]ethyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCOCCOCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13935,48630,"Ammonium, heptamethylenebis(1-methyl-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)propyl)bis(dimethyl-, dibromide, dihydrate",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCCCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
13936,48631,"7-[Dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azaniumyl]heptyl-dimethyl-[4-(2,6,6-trimethylcyclohexen-1-yl)butan-2-yl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)[N+](C)(C)CCCCCCC[N+](C)(C)C(C)CCC2=C(CCCC2(C)C)C,,,,,,
13937,48632,"Ammonium, hexamethylenebis((3-((2,6-dimethyl-2-ethyl)cyclohexyl)-1-methyl)propyl)bis(dimethyl-, dibromide, hemihydrate",CCC1(CCCC(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)CC)C)C)C.[Br-].[Br-],,,,,,
13938,48633,"4-(2-Ethyl-2,6-dimethylcyclohexyl)butan-2-yl-[6-[4-(2-ethyl-2,6-dimethylcyclohexyl)butan-2-yl-dimethylazaniumyl]hexyl]-dimethylazanium",CCC1(CCCC(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)CC)C)C)C,,,,,,
13939,48634,"Ammonium, hexamethylenebis((3-((2,6-dimethyl-2-isobutyl)cyclohexyl)-1-methyl)propyl)bis(dimethyl-, dibromide, sesquihydrate",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)CC(C)C)C)(C)CC(C)C.[Br-].[Br-],,,,,,
13940,48635,"4-[2,6-Dimethyl-2-(2-methylpropyl)cyclohexyl]butan-2-yl-[6-[4-[2,6-dimethyl-2-(2-methylpropyl)cyclohexyl]butan-2-yl-dimethylazaniumyl]hexyl]-dimethylazanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)CC(C)C)C)(C)CC(C)C,,,,,,
13941,48636,"Ammonium, hexamethylenebis(2,6-dimethyl-8-(2,2,6-trimethylcyclohexyl)octyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)CCCC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CC(C)CCCC(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13942,48637,"[2,6-Dimethyl-8-(2,2,6-trimethylcyclohexyl)octyl]-[6-[[2,6-dimethyl-8-(2,2,6-trimethylcyclohexyl)octyl]-dimethylazaniumyl]hexyl]-dimethylazanium",CC1CCCC(C1CCC(C)CCCC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CC(C)CCCC(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13943,48638,"Ammonium, hexamethylenebis(iminocarbonylmethylene)bis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride",CC1CCCC(C1CC(C)C[N+](C)(C)CC(=O)NCCCCCCNC(=O)C[N+](C)(C)CC(C)CC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
13944,48639,"[2-[6-[[2-[Dimethyl-[2-methyl-3-(2,2,6-trimethylcyclohexyl)propyl]azaniumyl]acetyl]amino]hexylamino]-2-oxoethyl]-dimethyl-[2-methyl-3-(2,2,6-trimethylcyclohexyl)propyl]azanium",CC1CCCC(C1CC(C)C[N+](C)(C)CC(=O)NCCCCCCNC(=O)C[N+](C)(C)CC(C)CC2C(CCCC2(C)C)C)(C)C,,,,,,
13945,48640,"Ammonium, hexamethylenebis(2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)butyl)bis(dimethyl-, dibromide, dihydrate",CC1=C(C(CCC1)(C)C)CCC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CC(C)CCC2=C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
13946,48641,"6-[Dimethyl-[2-methyl-4-(2,6,6-trimethylcyclohexen-1-yl)butyl]azaniumyl]hexyl-dimethyl-[2-methyl-4-(2,6,6-trimethylcyclohexen-1-yl)butyl]azanium",CC1=C(C(CCC1)(C)C)CCC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CC(C)CCC2=C(CCCC2(C)C)C,,,,,,
13947,48642,"Ammonium, hexamethylenebis(2-methyl-4-(2,2,6-trimethylcyclohexyl)butyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CC(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13948,48643,"6-[Dimethyl-[2-methyl-4-(2,2,6-trimethylcyclohexyl)butyl]azaniumyl]hexyl-dimethyl-[2-methyl-4-(2,2,6-trimethylcyclohexyl)butyl]azanium",CC1CCCC(C1CCC(C)C[N+](C)(C)CCCCCC[N+](C)(C)CC(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13949,48644,"Ammonium, hexamethylenebis(4-methyl-6-(2,2,6-trimethylcyclohexyl)hexyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCC(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13950,48645,"6-[Dimethyl-[4-methyl-6-(2,2,6-trimethylcyclohexyl)hexyl]azaniumyl]hexyl-dimethyl-[4-methyl-6-(2,2,6-trimethylcyclohexyl)hexyl]azanium",CC1CCCC(C1CCC(C)CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCC(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
13951,48646,"Ammonium, hexamethylenebis(1,5,9,13-tetramethyltetradecyl)bis(dimethyl-, dibromide",CC(C)CCCC(C)CCCC(C)CCCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCCC(C)CCCC(C)CCCC(C)C.[Br-].[Br-],,,,,,
13952,48647,"6-[Dimethyl(6,10,14-trimethylpentadecan-2-yl)azaniumyl]hexyl-dimethyl-(6,10,14-trimethylpentadecan-2-yl)azanium",CC(C)CCCC(C)CCCC(C)CCCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
13953,48648,CID 48648,C[N+](C)(C)CCC=CCC[N+](C)(C)C.[Br-].[Br-],,,,,,
13954,48649,CID 48649,C[N+](C)(C)CCC=CCC[N+](C)(C)C,,,,,,
13955,48650,(4-Hydroxy-5-isopropyl-o-tolyl)trimethylammonium bromide,CC1=CC(=C(C=C1[N+](C)(C)C)C(C)C)O.[Br-],,,,,,
13956,48651,(4-Hydroxy-2-methyl-5-propan-2-ylphenyl)-trimethylazanium,CC1=CC(=C(C=C1[N+](C)(C)C)C(C)C)O,,,,,,
13957,48652,(3-Hydroxy-4-methoxyphenyl)trimethylammonium bromide,C[N+](C)(C)C1=CC(=C(C=C1)OC)O.[Br-],,,,,,
13958,48653,(3-Hydroxy-4-methoxyphenyl)-trimethylazanium,C[N+](C)(C)C1=CC(=C(C=C1)OC)O,,,,,,
13959,48654,(3-Hydroxy-5-methoxyphenyl)trimethylammonium bromide,C[N+](C)(C)C1=CC(=CC(=C1)OC)O.[Br-],,,,,,
13960,48655,(3-Hydroxy-5-methoxyphenyl)-trimethylazanium,C[N+](C)(C)C1=CC(=CC(=C1)OC)O,,,,,,
13961,48656,(5-Hydroxy-2-methoxyphenyl)trimethylammonium bromide,C[N+](C)(C)C1=C(C=CC(=C1)O)OC.[Br-],,,,,,
13962,48657,(5-Hydroxy-2-methoxyphenyl)-trimethylazanium,C[N+](C)(C)C1=C(C=CC(=C1)O)OC,,,,,,
13963,48658,(2-Hydroxy-3-methoxyphenyl)trimethylammonium iodide dimethylcarbamate (ester),CN(C)C(=O)OC1=C(C=CC=C1OC)[N+](C)(C)C.[I-],,,,,,
13964,48659,[2-(Dimethylcarbamoyloxy)-3-methoxyphenyl]-trimethylazanium,CN(C)C(=O)OC1=C(C=CC=C1OC)[N+](C)(C)C,,,,,,
13965,48660,(2-Hydroxy-1-naphthylmethyl)trimethylammonium bromide dimethylcarbamate (ester),CN(C)C(=O)OC1=C(C2=CC=CC=C2C=C1)C[N+](C)(C)C.[Br-],,,,,,
13966,48661,[2-(Dimethylcarbamoyloxy)naphthalen-1-yl]methyl-trimethylazanium,CN(C)C(=O)OC1=C(C2=CC=CC=C2C=C1)C[N+](C)(C)C,,,,,,
13967,48662,"AMMONIUM, (m-HYDROXYPHENETHYL)TRIMETHYL-, PICRATE",C[N+](C)(C)CCC1=CC(=CC=C1)O.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
13968,48663,(3-Hydroxy-4-(phenylazo)phenyl)trimethylammonium iodide dimethylcarbamate (ester),CN(C)C(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)N=NC2=CC=CC=C2.[I-],,,,,,
13969,48664,[3-(Dimethylcarbamoyloxy)-4-phenyldiazenylphenyl]-trimethylazanium,CN(C)C(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)N=NC2=CC=CC=C2,,,,,,
13970,48665,(2-Hydroxyphenyl)trimethylammonium bromide dimethylcarbamate (ester),CN(C)C(=O)OC1=CC=CC=C1[N+](C)(C)C.[Br-],,,,,,
13971,48666,[2-(Dimethylcarbamoyloxy)phenyl]-trimethylazanium,CN(C)C(=O)OC1=CC=CC=C1[N+](C)(C)C,,,,,,
13972,48667,"2-Pyridinemethanaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-triethyl-, bromide",CC[N+](CC)(CC)CC1=C(C=CC=N1)OC(=O)N(C)C.[Br-],,,,,,
13973,48668,[3-(Dimethylcarbamoyloxy)pyridin-2-yl]methyl-triethylazanium,CC[N+](CC)(CC)CC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
13974,48669,((3-Hydroxy-2-pyridyl)methyl)trimethylammonium bromide acetate (ester),CC(=O)OC1=C(N=CC=C1)C[N+](C)(C)C.[Br-],,,,,,
13975,48670,(3-Acetyloxypyridin-2-yl)methyl-trimethylazanium,CC(=O)OC1=C(N=CC=C1)C[N+](C)(C)C,,,,,,
13976,48671,((3-Hydroxy-2-pyridyl)methyl)trimethylammonium bromide benzoate (ester),C[N+](C)(C)CC1=C(C=CC=N1)OC(=O)C2=CC=CC=C2.[Br-],,,,,,
13977,48672,(3-Benzoyloxypyridin-2-yl)methyl-trimethylazanium,C[N+](C)(C)CC1=C(C=CC=N1)OC(=O)C2=CC=CC=C2,,,,,,
13978,48673,(3-Hydroxy-2-pyridyl)methyltrimethylammonium bromide diisopropylcarbamate (ester),CC(C)N(C(C)C)C(=O)OC1=C(N=CC=C1)C[N+](C)(C)C.[Br-],,,,,,
13979,48674,[3-[Di(propan-2-yl)carbamoyloxy]pyridin-2-yl]methyl-trimethylazanium,CC(C)N(C(C)C)C(=O)OC1=C(N=CC=C1)C[N+](C)(C)C,,,,,,
13980,48675,"Ammonium, ((3-hydroxy-2-pyridyl)methyl)trimethyl-, bromide, dimethylcarbamate (ester)",CN(C)C(=O)OC1=C(N=CC=C1)C[N+](C)(C)C.[Br-],,,,,,
13981,48676,[3-(Dimethylcarbamoyloxy)pyridin-2-yl]methyl-trimethylazanium,CN(C)C(=O)OC1=C(N=CC=C1)C[N+](C)(C)C,,,,,,
13982,48677,"Ammonium, ((3-hydroxy-2-pyridyl)methyl)trimethyl-, bromide, diphenylacetate (ester)",C[N+](C)(C)CC1=C(C=CC=N1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
13983,48678,"[3-(2,2-Diphenylacetyl)oxypyridin-2-yl]methyl-trimethylazanium",C[N+](C)(C)CC1=C(C=CC=N1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
13984,48679,"Ammonium, ((3-hydroxy-2-pyridyl)methyl)trimethyl-, bromide, N-methyl-N-(p-tolyl)carbamate (ester)",CC1=CC=C(C=C1)N(C)C(=O)OC2=C(N=CC=C2)C[N+](C)(C)C.[Br-],,,,,,
13985,48680,Trimethyl-[[3-[methyl-(4-methylphenyl)carbamoyl]oxypyridin-2-yl]methyl]azanium,CC1=CC=C(C=C1)N(C)C(=O)OC2=C(N=CC=C2)C[N+](C)(C)C,,,,,,
13986,48681,"Ammonium, (3-hydroxy-4-(p-sulfophenylazo)phenyl)trimethyl-, sodium salt, benzenesulfonate, dimethylcarbamate (ester)",CN(C)C(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)N=NC2=CC=C(C=C2)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
13987,48682,[3-(Dimethylcarbamoyloxy)-4-[(4-sulfophenyl)diazenyl]phenyl]-trimethylazanium,CN(C)C(=O)OC1=C(C=CC(=C1)[N+](C)(C)C)N=NC2=CC=C(C=C2)S(=O)(=O)O,,,,,,
13988,48683,"Ammonium, (2-hydroxy-5-(1,1,3,3-tetramethylbutyl)benzyl)trimethyl-, bromide, dimethylcarbamate (ester)",CC(C)(C)CC(C)(C)C1=CC(=C(C=C1)OC(=O)N(C)C)C[N+](C)(C)C.[Br-],,,,,,
13989,48684,"[2-(Dimethylcarbamoyloxy)-5-(2,4,4-trimethylpentan-2-yl)phenyl]methyl-trimethylazanium",CC(C)(C)CC(C)(C)C1=CC(=C(C=C1)OC(=O)N(C)C)C[N+](C)(C)C,,,,,,
13990,48685,(5-Hydroxy-m-tolyl)trimethylammonium bromide,CC1=CC(=CC(=C1)O)[N+](C)(C)C.[Br-],,,,,,
13991,48686,NoName_183,CC1=CC(=CC(=C1)O)[N+](C)(C)C,,,,,,
13992,48687,(5-Hydroxy-o-tolyl)trimethylammonium bromide,CC1=C(C=C(C=C1)O)[N+](C)(C)C.[Br-],,,,,,
13993,48688,(5-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium,CC1=C(C=C(C=C1)O)[N+](C)(C)C,,,,,,
13994,48689,"Ammonium, (2-hydroxytrimethylene)bis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride, dihydrate",CC1CCCC(C1CCC(C)[N+](C)(C)CC(C[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)O)(C)C.[Cl-].[Cl-],,,,,,
13995,48690,"[3-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]-2-hydroxypropyl]-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CC(C[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)O)(C)C,,,,,,
13996,48691,(3-Mercaptophenyl)trimethylammonium iodide dimethylcarbamate (ester),CN(C)C(=O)SC1=CC=CC(=C1)[N+](C)(C)C.[I-],,,,,,
13997,48692,[3-(Dimethylcarbamoylsulfanyl)phenyl]-trimethylazanium,CN(C)C(=O)SC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
13998,48693,"Ammonium, octamethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Br-].[Br-],,,,,,
13999,48694,"8-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]octyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCCCCCCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
14000,48695,"Ammonium, pentamethylenebis(diethylmethyl-, dibromide",CC[N+](C)(CC)CCCCC[N+](C)(CC)CC.[Br-].[Br-],,,,,,
14001,48696,5-[Diethyl(methyl)azaniumyl]pentyl-diethyl-methylazanium,CC[N+](C)(CC)CCCCC[N+](C)(CC)CC,,,,,,
14002,48697,10-Chloroaporphine hydrochloride,C[NH+]1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C=C(C=C4)Cl.[Cl-],,,,,,
14003,48698,"(6aS)-10-chloro-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline",CN1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C=C(C=C4)Cl,,,,,,
14004,48699,10-Methylaporphine,CC1=CC2=C(C[C@H]3C4=C(CC[NH+]3C)C=CC=C24)C=C1.[Cl-],,,,,,
14005,48700,"5,6,6aalpha,7-Tetrahydro-6,10-dimethyl-4H-dibenzo[de,g]quinoline",CC1=CC2=C(C[C@H]3C4=C(CCN3C)C=CC=C24)C=C1,,,,,,
14006,48701,10-Trifluoromethylaporphine,C[NH+]1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C=C(C=C4)C(F)(F)F.[Cl-],,,,,,
14007,48702,"(6aS)-6-methyl-10-(trifluoromethyl)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline",CN1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C=C(C=C4)C(F)(F)F,,,,,,
14008,48703,Isocorydine hydrochloride,C[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)OC)O)OC)OC.[Cl-],,,,,,
14009,48704,Luteanine,CN1CCC2=CC(=C(C3=C2C1CC4=C3C(=C(C=C4)OC)O)OC)OC,,,,,,
14010,48705,"Arsine, bis(2-chloroethoxy)chloro-",C(CCl)O[As](OCCCl)Cl,,,,,,
14011,48706,"Arsine, dichloro-2-furyl-",C1=COC(=C1)[As](Cl)Cl,,,,,,
14012,48707,CID 48707,C1=CC=C2C(=C1)C(=O)N(C2=O)[C@@H](CC(=O)O)C(=O)[O-],,,,,,
14013,48708,"Butanedioic acid, (1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-, (S)-",C1=CC=C2C(=C1)C(=O)N(C2=O)[C@@H](CC(=O)O)C(=O)O,,,,,,
14014,48709,"6-Azabicyclo(3.2.1)octane, 6-cyclopentyl-1-(m-hydroxyphenyl)-7-methyl-, hydrochloride",CC1C2(CCCC(C2)[NH+]1C3CCCC3)C4=CC(=CC=C4)O.[Cl-],,,,,,
14015,48710,3-(6-Cyclopentyl-7-methyl-6-azabicyclo[3.2.1]octan-1-yl)phenol,CC1C2(CCCC(C2)N1C3CCCC3)C4=CC(=CC=C4)O,,,,,,
14016,48711,7-Ethyl-1-(m-methoxyphenyl)-6-methyl-6-azabicyclo(3.2.1)octane hydrobromide,CCC1C2(CCCC(C2)[NH+]1C)C3=CC(=CC=C3)OC.[Br-],,,,,,
14017,48712,7-Ethyl-1-(3-methoxyphenyl)-6-methyl-6-azabicyclo[3.2.1]octane,CCC1C2(CCCC(C2)N1C)C3=CC(=CC=C3)OC,,,,,,
14018,48713,"4,8,8-Trimethyl-2-azabicyclo(3.2.1)octan-3-one hydrochloride",CC1C2CCC(C2(C)C)NC1=O.Cl,,,,,,
14019,48714,"4,8,8-Trimethyl-2-azabicyclo[3.2.1]octan-3-one",CC1C2CCC(C2(C)C)NC1=O,,,,,,
14020,48715,"6-Methyl-2-piperidinomethyl-3,4,5,6-tetrahydro-1H-azepino(5,4,3-cd)indole",CC1C2=C3C(=C(NC3=CC=C2)CN4CCCCC4)CCN1,,,,,,
14021,48716,"Hexahydro-5,5,7-trimethyl-2H-azepin-2-one hydrochloride",CC1CC(CCC(=O)N1)(C)C.Cl,,,,,,
14022,48717,"Hexahydro-5,5,7-trimethyl-2H-azepin-2-one",CC1CC(CCC(=O)N1)(C)C,,,,,,
14023,48718,"AZETIDINE, 1-(p-AMINOPHENETHYL)-3-(m-METHOXYPHENYL)-3-PROPYL-",CCCC1(CN(C1)CCC2=CC=C(C=C2)N)C3=CC(=CC=C3)OC,,,,,,
14024,48719,"AZETIDINE, 3-(m-METHOXYPHENYL)-3-METHYL-",CC1(CNC1)C2=CC(=CC=C2)OC,,,,,,
14025,48720,"AZETIDINE, 3-(m-METHOXYPHENYL)-3-PENTYL-",CCCCCC1(CNC1)C2=CC(=CC=C2)OC,,,,,,
14026,48721,"5-(2-Ethylbutyl)-5-(2-methylprop-2-enyl)-1,3-diazinane-2,4,6-trione",CCC(CC)CC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14027,48722,CID 48722,CCC(CC)CC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14028,48723,"5-Ethyl-5-(2-ethylbutyl)-1,3-diazinane-2,4,6-trione",CCC(CC)CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14029,48724,CID 48724,CCC(CC)CSCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14030,48725,"5-Ethyl-5-(2-ethylbutylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCC(CC)CSCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14031,48726,CID 48726,CCC1(C(=O)NC(=NC1=O)[O-])C(C)SCC.[Na+],,,,,,
14032,48727,"5-Ethyl-5-(1-ethylsulfanylethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)SCC,,,,,,
14033,48728,CID 48728,CCCCCC(CC)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14034,48729,"5-Ethyl-5-octan-3-yl-1,3-diazinane-2,4,6-trione",CCCCCC(CC)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14035,48730,CID 48730,CCCCC(CC)CC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14036,48731,"5-Ethyl-5-(2-ethylhexyl)-1,3-diazinane-2,4,6-trione",CCCCC(CC)CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14037,48732,"Barbituric acid, 5-ethyl-5-(3-ethyl-2-pentenyl)-",CCC(=CCC1(C(=O)NC(=O)NC1=O)CC)CC,,,,,,
14038,48733,"5-Ethyl-5-pent-2-en-3-yl-1,3-diazinane-2,4,6-trione",CCC(=CC)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14039,48734,5-Ethyl-5-(1-ethylpropyl)-1-methylbarbituric acid,CCC(CC)C1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14040,48735,CID 48735,CCC(CC)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14041,48736,Isomebumal,CCC(CC)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14042,48737,CID 48737,CCCC(C1(C(=NC(=NC1=O)S)[O-])CC)SCC.[Na+],,,,,,
14043,48738,CID 48738,CCCC(C1(C(=O)NC(=NC1=O)S)CC)SCC,,,,,,
14044,48739,CID 48739,CCC(CC)C(C1(C(=O)NC(=NC1=O)[O-])CC)SCC.[Na+],,,,,,
14045,48740,"5-Ethyl-5-(2-ethyl-1-ethylsulfanylbutyl)-1,3-diazinane-2,4,6-trione",CCC(CC)C(C1(C(=O)NC(=O)NC1=O)CC)SCC,,,,,,
14046,48741,CID 48741,CCC1(C(=NC(=NC1=O)S)[O-])C(C)SCC.[Na+],,,,,,
14047,48742,CID 48742,CCC1(C(=O)NC(=NC1=O)S)C(C)SCC,,,,,,
14048,48743,CID 48743,CCC1(C(=O)N=C(N(C1=O)C)[O-])CSCC.[Na+],,,,,,
14049,48744,5-Ethyl-5-((ethylthio)methyl)-1-methylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C)CSCC,,,,,,
14050,48745,CID 48745,CCC1(C(=O)NC(=NC1=O)[O-])C(C(C)C)SCC.[Na+],,,,,,
14051,48746,"5-Ethyl-5-(1-ethylsulfanyl-2-methylpropyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C(C)C)SCC,,,,,,
14052,48747,CID 48747,CCC1(C(=O)NC(=NC1=O)S)CSCC,,,,,,
14053,48748,5-(2-Ethylhexyl)-5-methylbarbituric acid,CCCCC(CC)CC1(C(=O)NC(=O)NC1=O)C,,,,,,
14054,48749,CID 48749,CCCCCCSCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14055,48750,"5-Ethyl-5-(hexylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCCCCSCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14056,48751,"5-Ethyl-2,3-dihydro-2-imino-5-(3-methyl-2-butenyl)-4,6(1H,5H)-pyrimidinedione",CCC1(C(=O)NC(=NC1=O)N)CC=C(C)C,,,,,,
14057,48752,"Barbituric acid, 5-ethyl-5-(1-isobutenyl)-",CCC1(C(=O)NC(=O)NC1=O)C=C(C)C,,,,,,
14058,48753,"Barbituric acid, 5-ethyl-5-(isobutoxymethyl)-",CCC1(C(=O)NC(=O)NC1=O)COCC(C)C,,,,,,
14059,48754,5-Ethyl-5-isobutyl-1-methylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C)CC(C)C,,,,,,
14060,48755,5-Ethyl-5-isobutyl-1-phenylbarbituric acid,CCC1(C(=O)NC(=O)N(C1=O)C2=CC=CC=C2)CC(C)C,,,,,,
14061,48756,CID 48756,CCC1(C(=O)NC(=NC1=O)[O-])CSCC(C)C.[Na+],,,,,,
14062,48757,"5-Ethyl-5-(2-methylpropylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CSCC(C)C,,,,,,
14063,48758,"5-Ethyl-5-(3-methylbut-1-enyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C=CC(C)C,,,,,,
14064,48759,5-Ethyl-5-(1-isopentoxyethyl)barbituric acid,CCC1(C(=O)NC(=O)NC1=O)C(C)OCCC(C)C,,,,,,
14065,48760,CID 48760,CCC1(C(=NC(=S)N(C1=O)C)[O-])CCC(C)C.[Na+],,,,,,
14066,48761,CID 48761,CCC1(C(=O)N=C(N(C1=O)C)S)CCC(C)C,,,,,,
14067,48762,"Barbituric acid, 5-ethyl-5-isopentyl-1-phenyl-",CCC1(C(=O)NC(=O)N(C1=O)C2=CC=CC=C2)CCC(C)C,,,,,,
14068,48763,CID 48763,CCC1(C(=O)NC(=NC1=O)[O-])C(C)SCCC(C)C.[Na+],,,,,,
14069,48764,"5-Ethyl-5-[1-(3-methylbutylsulfanyl)ethyl]-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)SCCC(C)C,,,,,,
14070,48765,CID 48765,CCC1(C(=NC(=NC1=O)S)[O-])C(C)SCCC(C)C.[Na+],,,,,,
14071,48766,CID 48766,CCC1(C(=O)NC(=NC1=O)S)C(C)SCCC(C)C,,,,,,
14072,48767,CID 48767,CCC1(C(=O)NC(=NC1=O)[O-])CSCCC(C)C.[Na+],,,,,,
14073,48768,"5-Ethyl-5-(3-methylbutylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CSCCC(C)C,,,,,,
14074,48769,CID 48769,CCC1(C(=NC(=NC1=O)S)[O-])CSCCC(C)C.[Na+],,,,,,
14075,48770,CID 48770,CCC1(C(=O)NC(=NC1=O)S)CSCCC(C)C,,,,,,
14076,48771,"Barbituric acid, 5-ethyl-5-isopropenyl-",CCC1(C(=O)NC(=O)NC1=O)C(=C)C,,,,,,
14077,48772,"Barbituric acid, 5-ethyl-5-isopropenyl-1-methyl-",CCC1(C(=O)NC(=O)N(C1=O)C)C(=C)C,,,,,,
14078,48773,CID 48773,CCC1(C(=NC(=S)N(C1=O)C)[O-])C(=C)C.[Na+],,,,,,
14079,48774,CID 48774,CCC1(C(=O)N=C(N(C1=O)C)S)C(=C)C,,,,,,
14080,48775,1-Ethyl-5-isopropyl-5-methylbarbituric acid,CCN1C(=O)C(C(=O)NC1=O)(C)C(C)C,,,,,,
14081,48776,CID 48776,CCC1(C(=O)N=C(N(C1=O)C)[O-])CSC(C)C.[Na+],,,,,,
14082,48777,"5-Ethyl-1-methyl-5-(propan-2-ylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)N(C1=O)C)CSC(C)C,,,,,,
14083,48778,CID 48778,CCC(C1(C(=O)NC(=NC1=O)[O-])CC)SC(C)C.[Na+],,,,,,
14084,48779,"5-Ethyl-5-(1-propan-2-ylsulfanylpropyl)-1,3-diazinane-2,4,6-trione",CCC(C1(C(=O)NC(=O)NC1=O)CC)SC(C)C,,,,,,
14085,48780,CID 48780,CCC1(C(=O)NC(=NC1=O)[O-])CCOC.[Na+],,,,,,
14086,48781,"5-Ethyl-5-(2-methoxyethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCOC,,,,,,
14087,48782,"Barbituric acid, 5-ethyl-5-(methoxymethyl)-",CCC1(C(=O)NC(=O)NC1=O)COC,,,,,,
14088,48783,5-Ethyl-5-(2-methylallyl)barbituric acid,CCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14089,48784,CID 48784,CCC1(C(=O)NC(=NC1=O)[O-])C(C)C=C.[Na+],,,,,,
14090,48785,5-Ethyl-5-(1-methylallyl)barbituric acid,CCC1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
14091,48786,CID 48786,CCC1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
14092,48787,CID 48787,CCC1(C(=NC(=NC1=O)S)[O-])C(C)C=C.[Na+],,,,,,
14093,48788,CID 48788,CCC1(C(=O)NC(=NC1=O)S)C(C)C=C,,,,,,
14094,48789,CID 48789,CCC=C(C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
14095,48790,CID 48790,CCC1(C(=O)NC(=NC1=O)S)CC=C(C)C,,,,,,
14096,48791,CID 48791,CCCC(C)SCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14097,48792,"5-Ethyl-5-(pentan-2-ylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCC(C)SCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14098,48793,CID 48793,CCC1(C(=O)NC(=NC1=O)[O-])C(C)(CC)C#C.[Na+],,,,,,
14099,48794,"5-Ethyl-5-(3-methylpent-1-yn-3-yl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)C(C)(CC)C#C,,,,,,
14100,48795,CID 48795,CCCCCCC(C)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14101,48796,5-Ethyl-5-alpha-methylheptylbarbituric acid,CCCCCCC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14102,48797,CID 48797,CCCC(C)CCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14103,48798,"5-Ethyl-5-(4-methylheptyl)-1,3-diazinane-2,4,6-trione",CCCC(C)CCCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14104,48799,"5-Ethyl-5-hept-2-en-2-yl-1,3-diazinane-2,4,6-trione",CCCCC=C(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14105,48800,CID 48800,CCCCCC(C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
14106,48801,"5-Ethyl-1-methyl-5-pent-2-en-2-yl-1,3-diazinane-2,4,6-trione",CCC=C(C)C1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14107,48802,"Barbituric acid, 5-ethyl-1-methyl-5-(3-methyl-2-butenyl)-",CCC1(C(=O)NC(=O)N(C1=O)C)CC=C(C)C,,,,,,
14108,48803,"5-Ethyl-5-(hexan-2-yl)-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione",CCCCC(C)C1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14109,48804,"5-But-2-en-2-yl-5-ethyl-1-methyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)N(C1=O)C)C(=CC)C,,,,,,
14110,48805,"Barbituric acid, 5-ethyl-5-(1-methyl-1-nitroethyl)-",CCC1(C(=O)NC(=O)NC1=O)C(C)(C)[N+](=O)[O-],,,,,,
14111,48806,5-Ethyl-1-methyl-5-pentylbarbituric acid,CCCCCC1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14112,48807,"5-Ethyl-5-(hexan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione",CCCCC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14113,48808,CID 48808,CCCC(C)CC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14114,48809,"5-Ethyl-5-(2-methylpentyl)-1,3-diazinane-2,4,6-trione",CCCC(C)CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14115,48810,CID 48810,CCC1(C(=O)NC(=NC1=O)[O-])CCCC(C)C.[Na+],,,,,,
14116,48811,"5-Ethyl-5-(4-methylpentyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCCC(C)C,,,,,,
14117,48812,CID 48812,CCCCC(C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
14118,48813,CID 48813,CCCSCC1(C(=O)N=C(N(C1=O)C)[O-])CC.[Na+],,,,,,
14119,48814,"5-Ethyl-1-methyl-5-(propylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCSCC1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14120,48815,"Barbituric acid, 5-ethyl-5-(1-naphthyl)-",CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC3=CC=CC=C32,,,,,,
14121,48816,"2-Bromo-N,N-dimethyl-1-adamantanemethanamine hydrochloride hemihydrate",CN(C)CC12CC3CC(C1)CC(C3)C2Br.CN(C)CC12CC3CC(C1)CC(C3)C2Br.O.Cl.Cl,,,,,,
14122,48817,"1-(2-bromo-1-adamantyl)-N,N-dimethylmethanamine",CN(C)CC12CC3CC(C1)CC(C3)C2Br,,,,,,
14123,48818,CID 48818,CC1=CC(=CC(=C1C)C)C(=NN=C(N)S)C,,,,,,
14124,48819,p-(3-Allyl-3-methyl-1-triazeno)benzamide,CN(CC=C)N=NC1=CC=C(C=C1)C(=O)N,,,,,,
14125,48820,"5-(3,3-Dimethyl-1-triazeno)isophthalonitrile",CN(C)N=NC1=CC(=CC(=C1)C#N)C#N,,,,,,
14126,48821,"Barbituric acid, 5-benzyl-5-propyl-",CCCC1(C(=O)NC(=O)NC1=O)CC2=CC=CC=C2,,,,,,
14127,48822,5-(1-Ethoxyethyl)-5-isopentylbarbituric acid,CCOC(C)C1(C(=O)NC(=O)NC1=O)CCC(C)C,,,,,,
14128,48823,"6-Azabicyclo(3.2.1)octane, 6-cyclohexyl-1-(m-hydroxyphenyl)-7-methyl-, hydrochloride",CC1C2(CCCC(C2)[NH+]1C3CCCCC3)C4=CC(=CC=C4)O.[Cl-],,,,,,
14129,48824,3-(6-Cyclohexyl-7-methyl-6-azabicyclo[3.2.1]octan-1-yl)phenol,CC1C2(CCCC(C2)N1C3CCCCC3)C4=CC(=CC=C4)O,,,,,,
14130,48825,"Ammonium, oxydiethlenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride, hemihydrate",CC1CCCC(C1CCC(C)[N+](C)(C)CCOCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
14131,48826,"2-[2-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]ethoxy]ethyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CCOCC[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
14132,48827,(2-Hydroxy-3-methylphenyl)trimethylammonium bromide dimethylcarbamate (ester),CC1=C(C(=CC=C1)[N+](C)(C)C)OC(=O)N(C)C.[Br-],,,,,,
14133,48828,"Ammonium, hexamethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis((2-hydroxyethyl)methyl-, dibromide",CC1CCCC(C1CCC(C)[N+](C)(CCCCCC[N+](C)(CCO)C(C)CCC2C(CCCC2(C)C)C)CCO)(C)C.[Br-].[Br-],,,,,,
14134,48829,"2-Hydroxyethyl-[6-[2-hydroxyethyl-methyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]hexyl]-methyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(CCCCCC[N+](C)(CCO)C(C)CCC2C(CCCC2(C)C)C)CCO)(C)C,,,,,,
14135,48830,"Ammonium, hexamethylenebis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(ethylmethyl-, dibromide",CC[N+](C)(CCCCCC[N+](C)(CC)C(C)CCC1C(CCCC1(C)C)C)C(C)CCC2C(CCCC2(C)C)C.[Br-].[Br-],,,,,,
14136,48831,"Ethyl-[6-[ethyl-methyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]hexyl]-methyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC[N+](C)(CCCCCC[N+](C)(CC)C(C)CCC1C(CCCC1(C)C)C)C(C)CCC2C(CCCC2(C)C)C,,,,,,
14137,48832,"Ammonium, hexamethylenebis((3-((2-isopropyl-5-methyl)cyclopentyl)-1-methyl)propyl)bis(dimethyl-, dibromide, hemihydrate",CC1CCC(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCC2C(C)C)C)C(C)C.[Br-].[Br-],,,,,,
14138,48833,6-[Dimethyl-[4-(2-methyl-5-propan-2-ylcyclopentyl)butan-2-yl]azaniumyl]hexyl-dimethyl-[4-(2-methyl-5-propan-2-ylcyclopentyl)butan-2-yl]azanium,CC1CCC(C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC2C(CCC2C(C)C)C)C(C)C,,,,,,
14139,48834,"Ammonium, ethylenebis(iminocarbonylmethylene)bis(1-methyl-3-(2,2,6-trimethylcyclohexyl)propyl)bis(dimethyl-, dichloride",CC1CCCC(C1CCC(C)[N+](C)(C)CC(=O)NCCNC(=O)C[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C.[Cl-].[Cl-],,,,,,
14140,48835,"[2-[2-[[2-[Dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]acetyl]amino]ethylamino]-2-oxoethyl]-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium",CC1CCCC(C1CCC(C)[N+](C)(C)CC(=O)NCCNC(=O)C[N+](C)(C)C(C)CCC2C(CCCC2(C)C)C)(C)C,,,,,,
14141,48836,"2-(1-Methylethylaminoethyl)-1,4-benzodioxane",CCN(C)C(C)C1COC2=CC=CC=C2O1,,,,,,
14142,48837,"2-(1-Isopropylaminoethyl)-1,4-benzodioxane",CC(C)NC(C)C1COC2=CC=CC=C2O1,,,,,,
14143,48838,"2-(1-Methylaminoethyl)-1,4-benzodioxane",CC(C1COC2=CC=CC=C2O1)NC,,,,,,
14144,48839,"1-Methyl-4-(1-(1,4-benzodioxan-2-yl)ethyl)piperazine",CC(C1COC2=CC=CC=C2O1)N3CCN(CC3)C,,,,,,
14145,48840,"2-(1-Neopentylaminoethyl)-1,4-benzodioxane",CC(C1COC2=CC=CC=C2O1)NCC(C)(C)C,,,,,,
14146,48841,"2-(1-Piperidinoethyl)-1,4-benzodioxane",CC(C1COC2=CC=CC=C2O1)N3CCCCC3,,,,,,
14147,48842,"2-(1-Propylaminoethyl)-1,4-benzodioxane",CCCNC(C)C1COC2=CC=CC=C2O1,,,,,,
14148,48843,"2-(1-Pyrrolidinoethyl)-1,4-benzodioxane",CC(C1COC2=CC=CC=C2O1)N3CCCC3,,,,,,
14149,48844,"1,3-Benzodioxole-2-acetamide, N-(2-diethylaminoethyl)-2-phenyl-, monohydrochloride",CCN(CC)CCNC(=O)CC1(OC2=CC=CC=C2O1)C3=CC=CC=C3.Cl,,,,,,
14150,48845,"N-(2-Diethylaminoethyl)-2-phenyl-1,3-benzodioxole-2-acetamide",CCN(CC)CCNC(=O)CC1(OC2=CC=CC=C2O1)C3=CC=CC=C3,,,,,,
14151,48846,CID 48846,CC(=O)NC1=CC=CC(=C1)C(=O)[O-].[Na+],,,,,,
14152,48847,3-Acetamidobenzoic acid,CC(=O)NC1=CC=CC(=C1)C(=O)O,,,,,,
14153,48848,"Benzoic acid, 3-acetamido-5-heptanamido-2,4,6-triiodo-",CCCCCCC(=O)NC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)O)I,,,,,,
14154,48849,"Benzoic acid, 3-acetamido-5-hexanamido-2,4,6-triiodo-",CCCCCC(=O)NC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)O)I,,,,,,
14155,48850,"Benzoic acid, 3-acetamido-5-octanamido-2,4,6-triiodo-",CCCCCCCC(=O)NC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)O)I,,,,,,
14156,48851,"Benzoic acid, 3-acetamido-2,4,6-triiodo-5-valeramido-",CCCCC(=O)NC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)O)I,,,,,,
14157,48852,p-Allyloxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OCC=C.[Cl-],,,,,,
14158,48853,N-(2-Dimethylaminoethyl)-4-methoxybenzamidine dihydrochloride,C[NH+](C)CC[NH+]=C(C1=CC=C(C=C1)OC)N.[Cl-].[Cl-],,,,,,
14159,48854,N-(2-Dimethylaminoethyl)-4-methoxybenzamidine,CN(C)CCN=C(C1=CC=C(C=C1)OC)N,,,,,,
14160,48855,N-(2-Dimethylaminoethyl)-4-propoxybenzamidine dihydrochloride,CCCOC1=CC=C(C=C1)C(=[NH+]CC[NH+](C)C)N.[Cl-].[Cl-],,,,,,
14161,48856,N-[2-(Dimethylamino)ethyl]-4-propoxybenzamidine,CCCOC1=CC=C(C=C1)C(=NCCN(C)C)N,,,,,,
14162,48857,"Acetanilide, N-(2-(diethylamino)ethyl)-2',6'-dimethyl-",CCN(CC)CCN(C1=C(C=CC=C1C)C)C(=O)C,,,,,,
14163,48858,Dioxadet,CC1(OCC(CO1)(CO)NC2=NC(=NC(=N2)N3CC3)N4CC4)C,,,,,,
14164,48859,"1,3,5-Triazin-2-amine, 4,6-bis(1-aziridinyl)-N-(2,2-dimethyl-1,3-dioxan-5-yl)-",CC1(OCC(CO1)NC2=NC(=NC(=N2)N3CC3)N4CC4)C,,,,,,
14165,48860,"1,3,5-Triazin-2-amine, 4,6-bis(1-aziridinyl)-N-(2,2,5-trimethyl-1,3-dioxan-5-yl)-",CC1(OCC(CO1)N(C)C2=NC(=NC(=N2)N3CC3)N4CC4)C,,,,,,
14166,48861,"m-Dioxane, 5-equatorial-((4,6-bis(1-aziridinyl)-s-triazin-2-yl)amino)-2,2-dimethyl-5-ethyl-",CCN(C1COC(OC1)(C)C)C2=NC(=NC(=N2)N3CC3)N4CC4,,,,,,
14167,48862,"2-(3,4-Dimethoxyphenyl)-5-(4,6-diaziridinyl-2-s-triazinylamino)-m-dioxane-5-methanol",COC1=C(C=C(C=C1)C2OCC(CO2)(CO)NC3=NC(=NC(=N3)N4CC4)N5CC5)OC,,,,,,
14168,48863,"1,3-Dioxane-5-methanol, 5-((4,6-bis(1-aziridinyl)-1,3,5-triazin-2-yl)amino)-2-(1-methylethyl)-",CC(C)C1OCC(CO1)(CO)NC2=NC(=NC(=N2)N3CC3)N4CC4,,,,,,
14169,48864,Furisyl,C1CN1C2=NC(=NC(=N2)NC3(COC(OC3)C4=CC=CO4)CO)N5CC5,,,,,,
14170,48865,"Guanidine, 2-cyano-1-(2-ethoxyethyl)-3-(3-pyridyl)-",CCOCCN=C(NC#N)NC1=CN=CC=C1,,,,,,
14171,48866,"Guanidine, 2-cyano-1-(2-diethylaminoethyl)-3-(3-pyridyl)-",CCN(CC)CCN=C(NC#N)NC1=CN=CC=C1,,,,,,
14172,48867,"2-Cyano-1-(1,3-dimethylbutyl)-3-(4-pyridyl)guanidine",CC(C)CC(C)N=C(NC#N)NC1=CC=NC=C1,,,,,,
14173,48868,"2-Cyano-1-(1,2-dimethylbutyl)-3-(4-pyridyl)guanidine",CCC(C)C(C)N=C(NC#N)NC1=CC=NC=C1,,,,,,
14174,48869,2-Cyano-1-(1-ethyl-2-methylpropyl)-3-(4-pyridyl)guanidine,CCC(C(C)C)N=C(NC#N)NC1=CC=NC=C1,,,,,,
14175,48870,"Guanidine, 2-cyano-1-(2,4-dimethyl-3-pentyl)-3-(4-pyridyl)-",CC(C)C(C(C)C)N=C(NC#N)NC1=CC=NC=C1,,,,,,
14176,48871,2-Cyano-1-(1-cyclopropylethyl)-3-(4-pyridyl)guanidine,CC(C1CC1)N=C(NC#N)NC2=CC=NC=C2,,,,,,
14177,48872,"Guanidine, 2-cyano-1-dicyclopropylmethyl-3-(4-pyridyl)-",C1CC1C(C2CC2)N=C(NC#N)NC3=CC=NC=C3,,,,,,
14178,48873,"Guanidine, 2-cyano-1-cyclohexyl-3-(4-pyridyl)-",C1CCC(CC1)N=C(NC#N)NC2=CC=NC=C2,,,,,,
14179,48874,"Guanidine, 2-cyano-1-(2-ethyl-2-butyl)-3-(4-pyridyl)-",CCC(C)(CC)N=C(NC#N)NC1=CC=NC=C1,,,,,,
14180,48875,"Guanidine, 2-cyano-1-(alpha-methylbenzyl)-3-(4-pyridyl)-",CC(C1=CC=CC=C1)N=C(NC#N)NC2=CC=NC=C2,,,,,,
14181,48876,"Guanidine, 2-cyano-1-cyclohexyl-3-(2-pyridyl)-",C1CCC(CC1)N=C(NC#N)NC2=CC=CC=N2,,,,,,
14182,48877,"GUANIDINE, 1-tert-BUTYL-3-(5-CHLORO-2-PYRIDYL)-2-CYANO-",CC(C)(C)N=C(NC#N)NC1=NC=C(C=C1)Cl,,,,,,
14183,48878,"GUANIDINE, 1-tert-BUTYL-2-HYDROXY-3-(3-PYRIDYL)-",CC(C)(C)N=C(NC1=CN=CC=C1)NO,,,,,,
14184,48879,"GUANIDINE, 2-HYDROXY-1-tert-PENTYL-3-(3-PYRIDYL)-",CCC(C)(C)N=C(NC1=CN=CC=C1)NO,,,,,,
14185,48880,N''-Carbethoxy-N-tert-pentyl-N'-3-pyridylguanidine,CCC(C)(C)N=C(NC1=CN=CC=C1)NC(=O)OCC,,,,,,
14186,48881,"FORMAMIDE, N-((tert-PENTYLAMINO)(3-PYRIDYLAMINO)METHYLENE)-",CCC(C)(C)N=C(NC=O)NC1=CN=CC=C1,,,,,,
14187,48882,"GUANIDINE, 1-tert-PENTYL-2-PYRAZINYL-3-(3-PYRIDYL)-",CCC(C)(C)N=C(NC1=CN=CC=C1)NC2=NC=CN=C2,,,,,,
14188,48883,1-tert-Pentyl-3-(3-pyridyl)-2-pyrimidylguanidine dihydrochloride,CCC(C)(C)[NH+]=C(NC1=C[NH+]=CC=C1)NC2=NC=CC=N2.[Cl-].[Cl-],,,,,,
14189,48884,2-(2-Methylbutan-2-yl)-1-pyridin-3-yl-3-pyrimidin-2-ylguanidine,CCC(C)(C)N=C(NC1=CN=CC=C1)NC2=NC=CC=N2,,,,,,
14190,48885,"GUANIDINE, 1-tert-BUTYL-2-CYANO-3-(2-PYRIDYLMETHYL)-",CC(C)(C)NC(=NCC1=CC=CC=N1)NC#N,,,,,,
14191,48886,"GUANIDINE, 1-tert-BUTYL-2-CYANO-3-(2-PYRIDYLETHYL)-",CC(C)(C)NC(=NCCC1=CC=CC=N1)NC#N,,,,,,
14192,48887,CID 48887,CCCCCCCCCC(=O)OCCC=CC=C,,,,,,
14193,48888,"1,3,7-Trichlorodibenzo-p-dioxin",C1=CC2=C(C=C1Cl)OC3=C(O2)C(=CC(=C3)Cl)Cl,,,,,,
14194,48889,"1,2,3,7-Tetrachlorodibenzo-p-dioxin",C1=CC2=C(C=C1Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,,,,,,
14195,48890,"1,2,3,4,6-Pentachlorodibenzo-p-dioxin",C1=CC2=C(C(=C1)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,"['The polychlorinated dibenzo-p-dioxins and the polychlorinated dibenzofurans are predominantly stored in fat, but they are also excreted in milk and pass the placenta. They also appear in the blood and vital organs at lower concentrations. /Polychlorinated dibenzo-p-dioxins/', 'Incomplete and variable absorption of 1,2,3,7,8-pentaCDD in corn oil was reported in rats, with 19 to 71% of the dose absorbed within the first 2 days after oral exposure.', ""Studies in the rat, guinea pig, hamster, and mouse have found that essentially all of the TCDD-derived radioactivity excreted in the urine and bile corresponds to metabolites of TCDD. The apparent absence of TCDD metabolites in liver and fat suggests that once formed, the metabolites of TCDD are excreted readily. Thus, urinary and biliary elimination of TCDD depends on metabolism of the toxin. The more limited data for other compounds also suggest that this relationship may be true for 1,2,3,7,8-pentaCDD, 2,3,7,8-TBDD, 2,3,7,8-TCDF, 1,2,3,7,8-pentaCDF, 2,3,4,7,8-pentaCDF, and 3,3',4,4'-TCB."", '...The role of dietary fiber or Chlorella in the fecal excretion of PCDDs and PCDFs in rats /was investigated/. Rice bran fibers enhanced the fecal excretion of PCDDs form 0.6 to 2.3 and of PCDFs from 0.5- to 10.4 fold above that of rats on a control diet. Chlorella is a unicellular green algae sold as a health food or health supplement. Chlorella in the diet of rats also enhanced the fecal excretion of PCDDs from 0.8 to 5.6 and PCDFs from 0.9- to 11.1-fold above that of rats on a control diet. Dietary fiber, chlorophyll, and /or lipid in the Chlorella may be factors responsible for the enhanced fecal excretion of PCDDs and PCDFs observed in this study. Thus, fiber and/or Chlorella may be other dietary factors capable of increasing the fecal excretion of PCDDs and PCDFs. /Polychlorinated dibenzo-p-dioxins and dibenzofurans/']","['Little is known about the metabolism of these compounds in mammalian systems. The half-life of some of these compounds in humans can be measured not in hours, days, weeks, or months, but in years. /Polychlorodibenzodioxins/']","['/In a/... study of 48 workers at a German pesticide facility, elimination half times were estimated for several CDD congeners. The estimated half-/life was/ 15.7 years for 1,2,3,7,8-PeCDD... . /1,2,3,7,8-Pentachlorodibenzo-p-dioxin/', 'An elimination half-life of 29.5 days was estimated for 1,2,3,7,8-PCDD in Sprague-Dawley rats following a single oral exposure. /1,2,3,7,8-Pentachlorodibenzo-p-dioxin/']"
14196,48891,"BENZ(c)ACRIDINE, 11-METHYL-",CC1=C2C(=CC=C1)C=C3C=CC4=CC=CC=C4C3=N2,,,,,,
14197,48892,alpha-(1-Aminoethyl)-2-hydroxybenzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1O)O)[NH3+].[Cl-],,,,,,
14198,48893,2-(2-Amino-1-hydroxypropyl)phenol,CC(C(C1=CC=CC=C1O)O)N,,,,,,
14199,48894,alpha-(1-Aminoethyl)-2-methoxybenzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1OC)O)[NH3+].[Cl-],,,,,,
14200,48895,2-Amino-1-(2-methoxyphenyl)propan-1-ol,CC(C(C1=CC=CC=C1OC)O)N,,,,,,
14201,48896,N-(beta-Hydroxyphenethyl)dibenzylamine hydrochloride,C1=CC=C(C=C1)C[NH+](CC2=CC=CC=C2)CC(C3=CC=CC=C3)O.[Cl-],,,,,,
14202,48897,alpha-((Dibenzylamino)methyl)benzyl alcohol,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(C3=CC=CC=C3)O,,,,,,
14203,48898,"BENZYL ALCOHOL, 3,4-DIMETHOXY-alpha-ISOPROPYL-",CC(C)C(C1=CC(=C(C=C1)OC)OC)O,,,,,,
14204,48899,3-Fluoro-alpha-isopropylaminomethylbenzyl alcohol hydrobromide,CC(C)[NH2+]CC(C1=CC(=CC=C1)F)O.[Br-],,,,,,
14205,48900,NoName_3351,CC(C)NCC(C1=CC(=CC=C1)F)O,,,,,,
14206,48901,3-Fluoro-alpha-(propylaminomethyl)benzyl alcohol hydrobromide,CCC[NH2+]CC(C1=CC(=CC=C1)F)O.[Br-],,,,,,
14207,48902,1-(3-Fluorophenyl)-2-(propylamino)ethanol,CCCNCC(C1=CC(=CC=C1)F)O,,,,,,
14208,48903,CID 48903,C1C(COC2=CC=CC=C2C(=N1)C=CC3=CC=CC=C3)O.C1C(COC2=CC=CC=C2C(=N1)C=CC3=CC=CC=C3)O.O,,,,,,
14209,48904,CID 48904,C1C(COC2=CC=CC=C2C(=N1)C=CC3=CC=CC=C3)O,,,,,,
14210,48905,2-(4-Fluorophenyl)-alpha-methyl-6-benzoxazoleacetic acid,CC(C1=CC2=C(C=C1)N=C(O2)C3=CC=C(C=C3)F)C(=O)O,,,,,,
14211,48906,CID 48906,C1C(COC2=CC=CC=C2C(=N1)C=CC3=CC=C(C=C3)[N+](=O)[O-])O.C1C(COC2=CC=CC=C2C(=N1)C=CC3=CC=C(C=C3)[N+](=O)[O-])O.O,,,,,,
14212,48907,CID 48907,C1C(COC2=CC=CC=C2C(=N1)C=CC3=CC=C(C=C3)[N+](=O)[O-])O,,,,,,
14213,48908,beta-4-Aminobenzoyloxy-beta-phenylethyl dimethylamine,CN(C)CC(C1=CC=CC=C1)OC(=O)C2=CC=C(C=C2)N,,,,,,
14214,48909,p-Aminobenzoic acid 2-((1-methylheptyl)amino)ethyl ester citrate (3:1),CCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
14215,48910,2-(Octan-2-ylamino)ethyl 4-aminobenzoate,CCCCCCC(C)NCCOC(=O)C1=CC=C(C=C1)N,,,,,,
14216,48911,p-Aminobenzoic acid 2-((1-methylheptyl)amino)ethyl ester hydrogen sulfate (2:1),CCCCCCC(C)[NH2+]CCOC(=O)C1=CC=C(C=C1)N.OS(=O)(=O)[O-],,,,,,
14217,48912,p-Aminobenzoic acid 2-((1-methylheptyl)amino)ethyl ester d-tartrate (2:1),CCCCCCC(C)NCCOC(=O)C1=CC=C(C=C1)N.CCCCCCC(C)NCCOC(=O)C1=CC=C(C=C1)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
14218,48913,beta-Benzoyloxy-beta-phenylethyl amine,C1=CC=C(C=C1)C(CN)OC(=O)C2=CC=CC=C2,,,,,,
14219,48914,CID 48914,C1=C(C(=C(C(=C1I)N)I)C(=O)[O-])I.[Na+],,,,,,
14220,48915,o-Benzoylbenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2C(=O)C3=CC=CC=C3.[Cl-],,,,,,
14221,48916,3-(2-Methylpiperidin-1-yl)propyl 2-benzoylbenzoate,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2C(=O)C3=CC=CC=C3,,,,,,
14222,48917,"Benzoic acid, 2-(N-benzyl-N-methylamino)ethyl ester, hydrochloride",C[NH+](CCOC(=O)C1=CC=CC=C1)CC2=CC=CC=C2.[Cl-],,,,,,
14223,48918,2-[Benzyl(methyl)amino]ethyl benzoate,CN(CCOC(=O)C1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
14224,48919,"Benzoic acid, 3-(N-benzyl-N-methylamino)propyl ester, hydrochloride",C[NH+](CCCOC(=O)C1=CC=CC=C1)CC2=CC=CC=C2.[Cl-],,,,,,
14225,48920,3-[Benzyl(methyl)amino]propyl benzoate,CN(CCCOC(=O)C1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
14226,48921,p-Benzyloxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OCC3=CC=CC=C3.[Cl-],,,,,,
14227,48922,"Benzoic acid, 3,5-bis(formamido)-2,4,6-triiodo-",C(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC=O)I,,,,,,
14228,48923,CID 48923,CC(=CCCC(=CCCC(=CCN1CCN(CC1)CCOC(=O)C2=CC(=C(C(=C2)OC)OC)OC)C)C)C,,,,,,
14229,48924,CID 48924,CC(=CCCC(=CCCC(=CCN1CCN(CC1)CCOC(=O)C2=CC=CC=C2)C)C)C,,,,,,
14230,48925,"Benzoic acid, 3-(2,4,6-trimethylpiperidino)propyl ester, hydrochloride",CC1CC([NH+](C(C1)C)CCCOC(=O)C2=CC=CC=C2)C.[Cl-],,,,,,
14231,48926,"3-(2,4,6-Trimethylpiperidin-1-yl)propyl benzoate",CC1CC(N(C(C1)C)CCCOC(=O)C2=CC=CC=C2)C,,,,,,
14232,48927,p-Phenoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3.[Cl-],,,,,,
14233,48928,N-beta-Benzoyloxy-beta-phenylethylpiperidine,C1CCN(CC1)CC(C2=CC=CC=C2)OC(=O)C3=CC=CC=C3,,,,,,
14234,48929,gamma-Piperidinopropyl benzoate hydrochloride,C1CC[NH+](CC1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14235,48930,3-Piperidin-1-ylpropyl benzoate,C1CCN(CC1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14236,48931,"Benzoic acid, 2-(2-piperidyl)ethyl ester, hydrochloride",C1CC[NH2+]C(C1)CCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14237,48932,2-Piperidin-2-ylethyl benzoate,C1CCNC(C1)CCOC(=O)C2=CC=CC=C2,,,,,,
14238,48933,p-Propoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14239,48934,gamma-2-Propylpiperidinopropylbenzoate hydrochloride,CCCC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14240,48935,3-(2-Propylpiperidin-1-yl)propyl benzoate,CCCC1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
14241,48936,"BENZOIC ACID, o-(PROPYLTHIO)-, 2-(DIBUTYLAMINO)ETHYL ESTER",CCCCN(CCCC)CCOC(=O)C1=CC=CC=C1SCCC,,,,,,
14242,48937,"BENZOIC ACID, m-(PROPYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCCSC1=CC=CC(=C1)C(=O)OCCN(CC)CC,,,,,,
14243,48938,"BENZOIC ACID, o-(PROPYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCCSC1=CC=CC=C1C(=O)OCCN(CC)CC,,,,,,
14244,48939,"BENZOIC ACID, m-(PROPYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCCSC1=CC=CC(=C1)C(=O)OCCCN(CC)CC,,,,,,
14245,48940,"BENZOIC ACID, o-(PROPYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCCSC1=CC=CC=C1C(=O)OCCCN(CC)CC,,,,,,
14246,48941,"BENZOIC ACID, m-(PROPYLTHIO)-, 2-PIPERIDINOETHYL ESTER",CCCSC1=CC=CC(=C1)C(=O)OCCN2CCCCC2,,,,,,
14247,48942,"BENZOIC ACID, o-(PROPYLTHIO)-, 2-PIPERIDINOETHYL ESTER",CCCSC1=CC=CC=C1C(=O)OCCN2CCCCC2,,,,,,
14248,48943,"Benzoic acid, 1-(3-pyridyl)ethyl ester",CC(C1=CN=CC=C1)OC(=O)C2=CC=CC=C2,,,,,,
14249,48944,gamma-Pyrrolidinopropyl benzoate hydrochloride,C1CC[NH+](C1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14250,48945,3-Pyrrolidin-1-ylpropyl benzoate,C1CCN(C1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14251,48946,"Benzoic acid, 2-(N-methyl-N-phenethylamino)ethyl ester, hydrochloride",C[NH+](CCC1=CC=CC=C1)CCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14252,48947,2-[Methyl(2-phenylethyl)amino]ethyl benzoate,CN(CCC1=CC=CC=C1)CCOC(=O)C2=CC=CC=C2,,,,,,
14253,48948,"Benzoic acid, 3-(N-methyl-N-phenethylamino)propyl ester, hydrochloride",C[NH+](CCCOC(=O)C1=CC=CC=C1)CCC2=CC=CC=C2.[Cl-],,,,,,
14254,48949,3-[Methyl(2-phenylethyl)amino]propyl benzoate,CN(CCCOC(=O)C1=CC=CC=C1)CCC2=CC=CC=C2,,,,,,
14255,48950,"Benzoic acid, 3-(N-methyl-N-(4-phenylbutyl)amino)propyl ester, hydrochloride",C[NH+](CCCCC1=CC=CC=C1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14256,48951,3-[Methyl(4-phenylbutyl)amino]propyl benzoate,CN(CCCCC1=CC=CC=C1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14257,48952,"Benzoic acid, 2-(N-methyl-N-(3-phenylpropyl)amino)ethyl ester, hydrochloride",C[NH+](CCCC1=CC=CC=C1)CCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14258,48953,2-[Methyl(3-phenylpropyl)amino]ethyl benzoate,CN(CCCC1=CC=CC=C1)CCOC(=O)C2=CC=CC=C2,,,,,,
14259,48954,"Benzoic acid, 3-(N-methyl-N-(3-phenylpropyl)amino)propyl ester, hydrochloride",C[NH+](CCCC1=CC=CC=C1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14260,48955,3-[Methyl(3-phenylpropyl)amino]propyl benzoate,CN(CCCC1=CC=CC=C1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14261,48956,"Benzoic acid, 3-(4-methylpiperidino)butyl ester, hydrochloride",CC1CC[NH+](CC1)C(C)CCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14262,48957,"Benzoic acid, 4-(2-methylpiperidino)butyl ester, hydrochloride",CC1CCCC[NH+]1CCCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14263,48958,beta-(3-Methylpiperidino)ethyl benzoate hydrochloride,CC1CCC[NH+](C1)CCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14264,48959,2-(3-Methylpiperidin-1-yl)ethyl benzoate,CC1CCCN(C1)CCOC(=O)C2=CC=CC=C2,,,,,,
14265,48960,"Benzoic acid, 6-(2-methylpiperidino)hexyl ester, hydrochloride",CC1CCCC[NH+]1CCCCCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14266,48961,"Benzoic acid, 5-(2-methylpiperidino)pentyl ester, hydrochloride",CC1CCCC[NH+]1CCCCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14267,48962,gamma-(3-Methylpiperidino)propyl benzoate hydrochloride,CC1CCC[NH+](C1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14268,48963,3-(3-Methylpiperidin-1-yl)propyl benzoate,CC1CCCN(C1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14269,48964,"BENZOIC ACID, m-(METHYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCN(CC)CCOC(=O)C1=CC(=CC=C1)SC,,,,,,
14270,48965,"BENZOIC ACID, m-(METHYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCN(CC)CCCOC(=O)C1=CC(=CC=C1)SC,,,,,,
14271,48966,"Benzoic acid, 3-(2-pentylpiperidino)propyl ester, hydrochloride",CCCCCC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14272,48967,"Benzoic acid, 3-(4-pentylpiperidino)propyl ester, hydrochloride",CCCCCC1CC[NH+](CC1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14273,48968,3-(4-Pentylpiperidin-1-yl)propyl benzoate,CCCCCC1CCN(CC1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14274,48969,p-Phenethyloxybenzoic acid 3-(dimethylamino)propyl ester hydrochloride,C[NH+](C)CCCOC(=O)C1=CC=C(C=C1)OCCC2=CC=CC=C2.[Cl-],,,,,,
14275,48970,"Benzoic acid, 4-phenethoxy-, 3-(dimethylamino)propyl ester",CN(C)CCCOC(=O)C1=CC=C(C=C1)OCCC2=CC=CC=C2,,,,,,
14276,48971,p-Phenethyloxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OCCC3=CC=CC=C3.[Cl-],,,,,,
14277,48972,"o-Hydroxybenzoic acid 3-(2,5-dimethylpiperidino)propyl ester hydrochloride",CC1CCC([NH+](C1)CCCOC(=O)C2=CC=CC=C2)C.[Cl-],,,,,,
14278,48973,"3-(2,5-Dimethylpiperidin-1-yl)propyl benzoate",CC1CCC(N(C1)CCCOC(=O)C2=CC=CC=C2)C,,,,,,
14279,48974,2-Hydroxy-3-methylbenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC=CC(=C1O)C.[Cl-],,,,,,
14280,48975,"Benzoic acid, 2-hydroxy-3-methyl-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)C1=CC=CC(=C1O)C,,,,,,
14281,48976,m-Hydroxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2O.[Cl-],,,,,,
14282,48977,p-Hydroxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)O.[Cl-],,,,,,
14283,48978,"Benzoic acid, o-hydroxy-, 3-(2,4,6-trimethylpiperidino)propyl ester, hydrochloride",CC1CC([NH+](C(C1)C)CCCOC(=O)C2=CC=CC=C2O)C.[Cl-],,,,,,
14284,48979,"3-(2,4,6-Trimethylpiperidin-1-yl)propyl 2-hydroxybenzoate",CC1CC(N(C(C1)C)CCCOC(=O)C2=CC=CC=C2O)C,,,,,,
14285,48980,o-Iodobenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2I.[Cl-],,,,,,
14286,48981,p-Iodobenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)I.[Cl-],,,,,,
14287,48982,p-Isobutoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OCC(C)C.[Cl-],,,,,,
14288,48983,"p-Isopentoxybenzoic acid 3-(2-methylpiperidino)propyl ester, hydrochloride",CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OCCC(C)C.[Cl-],,,,,,
14289,48984,3-(2-Methylpiperidin-1-yl)propyl 4-(3-methylbutoxy)benzoate,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OCCC(C)C,,,,,,
14290,48985,p-Isopropoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)OC(C)C.[Cl-],,,,,,
14291,48986,"Benzoic acid, 2-(isopropylamino)butyl ester, hydrochloride",CCC(COC(=O)C1=CC=CC=C1)[NH2+]C(C)C.[Cl-],,,,,,
14292,48987,2-(Propan-2-ylamino)butyl benzoate,CCC(COC(=O)C1=CC=CC=C1)NC(C)C,,,,,,
14293,48988,p-Isopropylbenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)C(C)C.[Cl-],,,,,,
14294,48989,"Benzoic acid, 3-(2-isopropylpiperidino)propyl ester, hydrochloride",CC(C)C1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14295,48990,"Benzoic acid, 3-(4-isopropylpiperidino)propyl ester, hydrochloride",CC(C)C1CC[NH+](CC1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14296,48991,3-(4-Propan-2-ylpiperidin-1-yl)propyl benzoate,CC(C)C1CCN(CC1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14297,48992,o-Mercaptobenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2S.[Cl-],,,,,,
14298,48993,3-(2-Methylpiperidin-1-yl)propyl 2-sulfanylbenzoate,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2S,,,,,,
14299,48994,"Benzoic acid, 1-methyl-2-(2-methylpiperidino)ethyl ester, hydrochloride",CC1CCCC[NH+]1CC(C)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14300,48995,alpha-Methyl-beta-(3-methylpiperidino)ethyl benzoate hydrochloride,CC1CCC[NH+](C1)CC(C)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14301,48996,1-(3-Methylpiperidin-1-yl)propan-2-yl benzoate,CC1CCCN(C1)CC(C)OC(=O)C2=CC=CC=C2,,,,,,
14302,48997,p-Methylbenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)C.[Cl-],,,,,,
14303,48998,"Benzoic acid, 4-methyl-, 3-(2-methyl-1-piperidinyl)propyl ester",CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)C,,,,,,
14304,48999,alpha-Methyl-gamma-(3-methylpiperidino)propyl benzoate hydrochloride,CC1CCC[NH+](C1)CCC(C)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14305,49000,4-(3-Methylpiperidin-1-yl)butan-2-yl benzoate,CC1CCCN(C1)CCC(C)OC(=O)C2=CC=CC=C2,,,,,,
14306,49001,"Benzoic acid, p-(1-methylpentoxy)-, 3-(2-methylpiperidino)propyl ester, hydrochloride",CCCCC(C)OC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14307,49002,"Benzoic acid, 2-(cyclopentylamino)butyl ester, hydrochloride",CCC(COC(=O)C1=CC=CC=C1)[NH2+]C2CCCC2.[Cl-],,,,,,
14308,49003,2-(Cyclopentylamino)butyl benzoate,CCC(COC(=O)C1=CC=CC=C1)NC2CCCC2,,,,,,
14309,49004,"Benzoic acid, (2-(cyclopentylamino)-1,1-dimethyl)ethyl ester, hydrochloride",CC(C)(C[NH2+]C1CCCC1)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14310,49005,[1-(Cyclopentylamino)-2-methylpropan-2-yl] benzoate,CC(C)(CNC1CCCC1)OC(=O)C2=CC=CC=C2,,,,,,
14311,49006,"Benzoic acid, (2-(cyclopentylamino)-1-methyl)ethyl ester, hydrochloride",CC(C[NH2+]C1CCCC1)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14312,49007,1-(Cyclopentylamino)propan-2-yl benzoate,CC(CNC1CCCC1)OC(=O)C2=CC=CC=C2,,,,,,
14313,49008,"Benzoic acid, 2-(cyclopentylamino)propyl ester, hydrochloride",CC(COC(=O)C1=CC=CC=C1)[NH2+]C2CCCC2.[Cl-],,,,,,
14314,49009,2-(Cyclopentylamino)propyl benzoate,CC(COC(=O)C1=CC=CC=C1)NC2CCCC2,,,,,,
14315,49010,CID 49010,C1=C(C=C(C=C1N)N)C(=O)[O-].[Na+],,,,,,
14316,49011,CID 49011,C1(=C(C(=C(C(=C1I)N)I)N)I)C(=O)[O-].[Na+],,,,,,
14317,49012,N-(2-Hydroxyethyl)dibenzylamine benzoate hydrochloride,C1=CC=C(C=C1)C[NH+](CCOC(=O)C2=CC=CC=C2)CC3=CC=CC=C3.[Cl-],,,,,,
14318,49013,2-(Dibenzylamino)ethyl benzoate,C1=CC=C(C=C1)CN(CCOC(=O)C2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
14319,49014,"Benzoic acid, 3,5-dibutyramido-2,4,6-triiodo-",CCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)CCC)I,,,,,,
14320,49015,"Benzoic acid, 3,5-dihexanamido-2,4,6-triiodo-",CCCCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)CCCCC)I,,,,,,
14321,49016,"p-(2,3-Dihydroxypropoxy)benzoic acid, ethyl ester",CCOC(=O)C1=CC=C(C=C1)OCC(CO)O,,,,,,
14322,49017,"BENZOIC ACID, m-(2,3-DIHYDROXYPROPOXY)-, METHYL ESTER",COC(=O)C1=CC(=CC=C1)OCC(CO)O,,,,,,
14323,49018,"Propyl p-(2,3-dihydroxypropoxy)benzoate",CCCOC(=O)C1=CC=C(C=C1)OCC(CO)O,,,,,,
14324,49019,"Benzoic acid, 1-(3,4-dimethoxyphenyl)-2-(dimethylamino)ethyl ester",CN(C)CC(C1=CC(=C(C=C1)OC)OC)OC(=O)C2=CC=CC=C2,,,,,,
14325,49020,beta-Benzoyloxy-beta-4-methoxyphenylethyl dimethylamine,CN(C)CC(C1=CC=C(C=C1)OC)OC(=O)C2=CC=CC=C2,,,,,,
14326,49021,p-Bromobenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CC1CCCC[NH+]1CCCOC(=O)C2=CC=C(C=C2)Br.[Cl-],,,,,,
14327,49022,"Benzoic acid, p-butoxy-, 2,2-dimethyl-3-(4-methylpiperidino)propyl ester, hydrochloride",CCCCOC1=CC=C(C=C1)C(=O)OCC(C)(C)C[NH+]2CCC(CC2)C.[Cl-],,,,,,
14328,49023,"[2,2-Dimethyl-3-(4-methylpiperidin-1-yl)propyl] 4-butoxybenzoate",CCCCOC1=CC=C(C=C1)C(=O)OCC(C)(C)CN2CCC(CC2)C,,,,,,
14329,49024,"p-Butoxybenzoic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2C(CCCC2C)C.[Cl-],,,,,,
14330,49025,"3-(2,6-Dimethylpiperidin-1-yl)propyl 4-butoxybenzoate",CCCCOC1=CC=C(C=C1)C(=O)OCCCN2C(CCCC2C)C,,,,,,
14331,49026,4-Butoxy-2-hydroxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCCOC1=CC(=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C)O.[Cl-],,,,,,
14332,49027,3-(2-Methylpiperidin-1-yl)propyl 4-butoxy-2-hydroxybenzoate,CCCCOC1=CC(=C(C=C1)C(=O)OCCCN2CCCCC2C)O,,,,,,
14333,49028,4-Butoxy-3-methylbenzoic acid 3-(dimethylamino)propyl ester hydrochloride,CCCCOC1=C(C=C(C=C1)C(=O)OCCC[NH+](C)C)C.[Cl-],,,,,,
14334,49029,3-(Dimethylamino)propyl 4-butoxy-3-methylbenzoate,CCCCOC1=C(C=C(C=C1)C(=O)OCCCN(C)C)C,,,,,,
14335,49030,"Benzoic acid, p-butoxy-, 1-methyl-2-(2-methylpiperidino)ethyl ester, hydrochloride",CCCCOC1=CC=C(C=C1)C(=O)OC(C)C[NH+]2CCCCC2C.[Cl-],,,,,,
14336,49031,1-(2-Methylpiperidin-1-yl)propan-2-yl 4-butoxybenzoate,CCCCOC1=CC=C(C=C1)C(=O)OC(C)CN2CCCCC2C,,,,,,
14337,49032,p-Butoxybenzoic acid 3-(3-methylpiperidino)butyl ester hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OCCC(C)[NH+]2CCCC(C2)C.[Cl-],,,,,,
14338,49033,3-(3-Methylpiperidin-1-yl)butyl 4-butoxybenzoate,CCCCOC1=CC=C(C=C1)C(=O)OCCC(C)N2CCCC(C2)C,,,,,,
14339,49034,o-Butoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCCOC1=CC=CC=C1C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14340,49035,3-(2-Methylpiperidin-1-yl)propyl 2-butoxybenzoate,CCCCOC1=CC=CC=C1C(=O)OCCCN2CCCCC2C,,,,,,
14341,49036,p-Butoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14342,49037,p-Butoxybenzoic acid 3-(3-methylpiperidino)propyl ester hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCC(C2)C.[Cl-],,,,,,
14343,49038,3-(3-Methylpiperidin-1-yl)propyl 4-butoxybenzoate,CCCCOC1=CC=C(C=C1)C(=O)OCCCN2CCCC(C2)C,,,,,,
14344,49039,p-Butoxybenzoic acid 3-(4-methylpiperidino)propyl ester hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCC(CC2)C.[Cl-],,,,,,
14345,49040,3-(4-Methylpiperidin-1-yl)propyl 4-butoxybenzoate,CCCCOC1=CC=C(C=C1)C(=O)OCCCN2CCC(CC2)C,,,,,,
14346,49041,p-sec-Butoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCC(C)OC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14347,49042,"BENZOIC ACID, m-(BUTYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCCCSC1=CC=CC(=C1)C(=O)OCCN(CC)CC,,,,,,
14348,49043,"BENZOIC ACID, o-(BUTYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCCCSC1=CC=CC=C1C(=O)OCCN(CC)CC,,,,,,
14349,49044,"BENZOIC ACID, m-(BUTYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCCCSC1=CC=CC(=C1)C(=O)OCCCN(CC)CC,,,,,,
14350,49045,"BENZOIC ACID, o-(BUTYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCCCSC1=CC=CC=C1C(=O)OCCCN(CC)CC,,,,,,
14351,49046,o-(Butylthio)benzoic acid 2-piperidinoethyl ester,CCCCSC1=CC=CC=C1C(=O)OCCN2CCCCC2,,,,,,
14352,49047,"BENZOIC ACID, p-(BUTYLTHIO)-, 2-PIPERIDINOETHYL ESTER",CCCCSC1=CC=C(C=C1)C(=O)OCCN2CCCCC2,,,,,,
14353,49048,"Benzoic acid, 2-(cyclohexylamino)butyl ester, hydrochloride",CCC(COC(=O)C1=CC=CC=C1)[NH2+]C2CCCCC2.[Cl-],,,,,,
14354,49049,2-(Cyclohexylamino)butyl benzoate,CCC(COC(=O)C1=CC=CC=C1)NC2CCCCC2,,,,,,
14355,49050,"Benzoic acid, (2-cyclohexylamino-1,1-dimethyl)ethyl ester, hydrochloride",CC(C)(C[NH2+]C1CCCCC1)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14356,49051,[1-(Cyclohexylamino)-2-methylpropan-2-yl] benzoate,CC(C)(CNC1CCCCC1)OC(=O)C2=CC=CC=C2,,,,,,
14357,49052,CID 49052,C(CCl)[NH+](CCCl)Cl.[Cl-],,,,,,
14358,49053,"p-Phenoxybenzoic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CC1CCCC([NH+]1CCCOC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)C.[Cl-],,,,,,
14359,49054,"3-(2,6-Dimethylpiperidin-1-yl)propyl 4-phenoxybenzoate",CC1CCCC(N1CCCOC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)C,,,,,,
14360,49055,"BENZOIC ACID, p-(ETHYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCN(CC)CCOC(=O)C1=CC=C(C=C1)SCC,,,,,,
14361,49056,"BENZOIC ACID, m-(ETHYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCN(CC)CCCOC(=O)C1=CC(=CC=C1)SCC,,,,,,
14362,49057,"BENZOIC ACID, o-(ETHYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCN(CC)CCCOC(=O)C1=CC=CC=C1SCC,,,,,,
14363,49058,"BENZOIC ACID, p-(ETHYLTHIO)-, 3-(DIETHYLAMINO)PROPYL ESTER",CCN(CC)CCCOC(=O)C1=CC=C(C=C1)SCC,,,,,,
14364,49059,"BENZOIC ACID, m-(ETHYLTHIO)-, 2-PIPERIDINOETHYL ESTER",CCSC1=CC=CC(=C1)C(=O)OCCN2CCCCC2,,,,,,
14365,49060,"BENZOIC ACID, o-(ETHYLTHIO)-, 2-PIPERIDINOETHYL ESTER",CCSC1=CC=CC=C1C(=O)OCCN2CCCCC2,,,,,,
14366,49061,"Benzoic acid, 4-fluoro-3-iodo-, ((1-diethylamino-1-methyl)propyl) ester, hydrochloride",CCC(C)([NH+](CC)CC)OC(=O)C1=CC(=C(C=C1)F)I.[Cl-],,,,,,
14367,49062,2-(Diethylamino)butan-2-yl 4-fluoro-3-iodobenzoate,CCC(C)(N(CC)CC)OC(=O)C1=CC(=C(C=C1)F)I,,,,,,
14368,49063,p-Heptyloxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCCCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14369,49064,3-(2-Methylpiperidin-1-yl)propyl 4-heptoxybenzoate,CCCCCCCOC1=CC=C(C=C1)C(=O)OCCCN2CCCCC2C,,,,,,
14370,49065,"p-Hexyloxybenzoic acid 3-(2,6-dimethylpiperidino)propyl ester hydrochloride",CCCCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2C(CCCC2C)C.[Cl-],,,,,,
14371,49066,"3-(2,6-Dimethylpiperidin-1-yl)propyl 4-hexoxybenzoate",CCCCCCOC1=CC=C(C=C1)C(=O)OCCCN2C(CCCC2C)C,,,,,,
14372,49067,"Benzoic acid, 3-(2-hexylpiperidino)propyl ester, hydrochloride",CCCCCCC1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14373,49068,"o-Hydroxybenzoic acid 3-(2,3-dimethylpiperidino)propyl ester hydrochloride",CC1CCC[NH+](C1C)CCCOC(=O)C2=CC=CC=C2O.[Cl-],,,,,,
14374,49069,"3-(2,3-Dimethylpiperidin-1-yl)propyl 2-hydroxybenzoate",CC1CCCN(C1C)CCCOC(=O)C2=CC=CC=C2O,,,,,,
14375,49070,"o-Hydroxybenzoic acid 3-(2,4-dimethylpiperidino)propyl ester hydrochloride",CC1CC[NH+](C(C1)C)CCCOC(=O)C2=CC=CC=C2O.[Cl-],,,,,,
14376,49071,"3-(2,4-Dimethylpiperidin-1-yl)propyl 2-hydroxybenzoate",CC1CCN(C(C1)C)CCCOC(=O)C2=CC=CC=C2O,,,,,,
14377,49072,"beta-Benzoyloxy-beta-3,4-methylenedioxyphenylethyl dimethylamine",CN(C)CC(C1=CC2=C(C=C1)OCO2)OC(=O)C3=CC=CC=C3,,,,,,
14378,49073,"Benzoic acid, (2,2-dimethyl-3-morpholinopropyl) ester, hydrochloride",CC(C)(C[NH+]1CCOCC1)COC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14379,49074,"(2,2-Dimethyl-3-morpholin-4-ylpropyl) benzoate",CC(C)(CN1CCOCC1)COC(=O)C2=CC=CC=C2,,,,,,
14380,49075,"Benzoic acid, 3-(2,3-dimethylpiperidino)propyl ester, hydrochloride",CC1CCC[NH+](C1C)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14381,49076,"3-(2,3-Dimethylpiperidin-1-yl)propyl benzoate",CC1CCCN(C1C)CCCOC(=O)C2=CC=CC=C2,,,,,,
14382,49077,"Benzoic acid, 3-(2,4-dimethylpiperidino)propyl ester, hydrochloride",CC1CC[NH+](C(C1)C)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14383,49078,"3-(2,4-Dimethylpiperidin-1-yl)propyl benzoate",CC1CCN(C(C1)C)CCCOC(=O)C2=CC=CC=C2,,,,,,
14384,49079,"Benzoic acid, 3,5-divaleramido-2,4,6-triiodo-",CCCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)CCCC)I,,,,,,
14385,49080,gamma-3-Carbethoxypiperidinopropylbenzoate hydrochloride,CCOC(=O)C1CCC[NH+](C1)CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14386,49081,Ethyl 1-(3-benzoyloxypropyl)piperidine-3-carboxylate,CCOC(=O)C1CCCN(C1)CCCOC(=O)C2=CC=CC=C2,,,,,,
14387,49082,gamma-Diethylamino-beta-dimethylpropyl-4-ethoxy benzoate hydrochloride,CC[NH+](CC)CC(C)(C)COC(=O)C1=CC=C(C=C1)OCC.[Cl-],,,,,,
14388,49083,gamma-Diethylamino-beta-dimethylpropyl-4-ethoxybenzoate,CCN(CC)CC(C)(C)COC(=O)C1=CC=C(C=C1)OCC,,,,,,
14389,49084,p-Ethoxybenzoic acid 3-(diethylamino)propyl ester hydrochloride,CC[NH+](CC)CCCOC(=O)C1=CC=C(C=C1)OCC.[Cl-],,,,,,
14390,49085,4-Ethoxybenzoic acid 3-(diethylamino)propyl ester,CCN(CC)CCCOC(=O)C1=CC=C(C=C1)OCC,,,,,,
14391,49086,p-Ethoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14392,49087,"Benzoic acid, 3-(2-(1-ethylpropyl)piperidino)propyl ester, hydrochloride",CCC(CC)C1CCCC[NH+]1CCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14393,49088,3-(2-Pentan-3-ylpiperidin-1-yl)propyl benzoate,CCC(CC)C1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
14394,49089,"BENZOIC ACID, o-(ETHYLTHIO)-, 2-(DIBUTYLAMINO)ETHYL ESTER",CCCCN(CCCC)CCOC(=O)C1=CC=CC=C1SCC,,,,,,
14395,49090,"BENZOIC ACID, m-(ETHYLTHIO)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCN(CC)CCOC(=O)C1=CC(=CC=C1)SCC,,,,,,
14396,49091,"3',4'-Dihydroxy-2-methylbutyrophenone",CCC(C)C(=O)C1=CC(=C(C=C1)O)O,,,,,,
14397,49092,"3',4'-Dimethoxy-2-methylbutyrophenone",CCC(C)C(=O)C1=CC(=C(C=C1)OC)OC,,,,,,
14398,49093,"Camphane-2-carboxylic acid, (2-morpholinoethyl) ester, hydrochloride",CC1(C2CCC1(C(C2)C(=O)OCC[NH+]3CCOCC3)C)C.[Cl-],,,,,,
14399,49094,"2-Morpholin-4-ylethyl 1,7,7-trimethylbicyclo[2.2.1]heptane-2-carboxylate",CC1(C2CCC1(C(C2)C(=O)OCCN3CCOCC3)C)C,,,,,,
14400,49095,"Carbamic acid, N-(2-chloroethyl)-N-nitro-, methyl ester",COC(=O)N(CCCl)[N+](=O)[O-],,,,,,
14401,49096,"CARBAMIC ACID, 3-(o-CHLOROPHENYL)PROPYL ESTER",C1=CC=C(C(=C1)CCCOC(=O)N)Cl,,,,,,
14402,49097,"Carbamic acid, 2,2-dichloroethyl-, butyl ester",CCCCOC(=O)NCC(Cl)Cl,,,,,,
14403,49098,"Carbamic acid, 2,2-dichloroethyl-, ethyl ester",CCOC(=O)NCC(Cl)Cl,,,,,,
14404,49099,"2,2-Dichloroethylcarbamic acid methyl ester",COC(=O)NCC(Cl)Cl,,,,,,
14405,49100,"Carbamic acid, 2,2-dichloroethyl-, propyl ester",CCCOC(=O)NCC(Cl)Cl,,,,,,
14406,49101,Diisopropylcarbamic acid (2-((dimethylamino)methyl)-3-pyridyl) ester dihydrochloride,CC(C)N(C(C)C)C(=O)OC1=C([NH+]=CC=C1)C[NH+](C)C.[Cl-].[Cl-],,,,,,
14407,49102,"[2-[(dimethylamino)methyl]pyridin-3-yl] N,N-di(propan-2-yl)carbamate",CC(C)N(C(C)C)C(=O)OC1=C(N=CC=C1)CN(C)C,,,,,,
14408,49103,Dimethylcarbamic acid 2-(aminomethyl)phenyl ester hydrochloride,CN(C)C(=O)OC1=CC=CC=C1C[NH3+].[Cl-],,,,,,
14409,49104,"[2-(aminomethyl)phenyl] N,N-dimethylcarbamate",CN(C)C(=O)OC1=CC=CC=C1CN,,,,,,
14410,49105,Dimethylcarbamic acid 2-aminophenyl ester hydrochloride,CN(C)C(=O)OC1=CC=CC=C1[NH3+].[Cl-],,,,,,
14411,49106,"(2-aminophenyl) N,N-dimethylcarbamate",CN(C)C(=O)OC1=CC=CC=C1N,,,,,,
14412,49107,"Carbamic acid, dimethyl-, (2-((N-benzyl-N-methylamino)methyl)-3-pyridyl) ester, dihydrochloride",C[NH+](CC1=CC=CC=C1)CC2=C(C=CC=[NH+]2)OC(=O)N(C)C.[Cl-].[Cl-],,,,,,
14413,49108,"[2-[[benzyl(methyl)amino]methyl]pyridin-3-yl] N,N-dimethylcarbamate",CN(C)C(=O)OC1=C(N=CC=C1)CN(C)CC2=CC=CC=C2,,,,,,
14414,49109,"Carbamic acid, dimethyl-, (2-((diethylamino)methyl)-3-pyridyl) ester, dihydrochloride",CC[NH+](CC)CC1=C(C=CC=[NH+]1)OC(=O)N(C)C.[Cl-].[Cl-],,,,,,
14415,49110,"N,N-Dimethylcarbamic acid 2-[(diethylamino)methyl]pyridin-3-yl ester",CCN(CC)CC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
14416,49111,Dimethylcarbamic acid 1-(dimethylamino)methyl-2-naphthyl ester hydrochloride,C[NH+](C)CC1=C(C=CC2=CC=CC=C21)OC(=O)N(C)C.[Cl-],,,,,,
14417,49112,"[1-[(dimethylamino)methyl]naphthalen-2-yl] N,N-dimethylcarbamate",CN(C)CC1=C(C=CC2=CC=CC=C21)OC(=O)N(C)C,,,,,,
14418,49113,"Carbamic acid, dimethyl-, 2-((dimethylamino)methyl)-3-pyridinyl ester, dihydrochloride",C[NH+](C)CC1=C(C=CC=[NH+]1)OC(=O)N(C)C.[Cl-].[Cl-],,,,,,
14419,49114,2-[(Dimethylamino)methyl]pyridin-3-yl dimethylcarbamate,CN(C)CC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
14420,49115,Dimethylcarbamic acid 3-(dimethylamino)phenyl ester hydrochloride,C[NH+](C)C1=CC(=CC=C1)OC(=O)N(C)C.[Cl-],,,,,,
14421,49116,Dimethylcarbamic acid 5-(dimethylamino)-2-(3-pyridylazo)phenyl ester,CN(C)C1=CC(=C(C=C1)N=NC2=CN=CC=C2)OC(=O)N(C)C,,,,,,
14422,49117,"CARBAMIC ACID, DIMETHYLDITHIO-, tert-BUTYLSULFINYL ESTER",CC(C)(C)S(=O)SC(=S)N(C)C,,,,,,
14423,49118,Dimethylcarbamic acid 2-guanidinophenyl ester nitrate,CN(C)C(=O)OC1=CC=CC=C1[NH+]=C(N)N.[N+](=O)([O-])[O-],,,,,,
14424,49119,"[2-(diaminomethylideneamino)phenyl] N,N-dimethylcarbamate",CN(C)C(=O)OC1=CC=CC=C1N=C(N)N,,,,,,
14425,49120,"Carbamic acid, dimethyl-, (2-((methylamino)methyl)-3-pyridyl) ester, dihydrochloride",C[NH2+]CC1=C(C=CC=[NH+]1)OC(=O)N(C)C.[Cl-].[Cl-],,,,,,
14426,49121,"[2-(methylaminomethyl)pyridin-3-yl] N,N-dimethylcarbamate",CNCC1=C(C=CC=N1)OC(=O)N(C)C,,,,,,
14427,49122,Dimethylcarbamic acid 2-(1-methyl-2-piperidyl)phenyl ester,CN1CCCCC1C2=CC=CC=C2OC(=O)N(C)C,,,,,,
14428,49123,"Carbamic acid, dimethyl-, p-(N-methyl-N-(2-pyridyl)amino)phenyl ester, hydrochloride",C[NH+](C1=CC=C(C=C1)OC(=O)N(C)C)C2=CC=CC=N2.[Cl-],,,,,,
14429,49124,"[4-[methyl(pyridin-2-yl)amino]phenyl] N,N-dimethylcarbamate",CN(C)C(=O)OC1=CC=C(C=C1)N(C)C2=CC=CC=N2,,,,,,
14430,49125,Dimethylcarbamic acid (2-(piperidinomethyl)-3-pyridyl) ester dihydrochloride,CN(C)C(=O)OC1=C([NH+]=CC=C1)C[NH+]2CCCCC2.[Cl-].[Cl-],,,,,,
14431,49126,"N,N-Dimethylcarbamic acid 2-[(1,5-pentanediylamino)methyl]pyridin-3-yl ester",CN(C)C(=O)OC1=C(N=CC=C1)CN2CCCCC2,,,,,,
14432,49127,"N,N-Diphenylcarbamic acid (2-morpholinoethyl) ester, hydrochloride",C1COCC[NH+]1CCOC(=O)N(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
14433,49128,"2-morpholin-4-ylethyl N,N-diphenylcarbamate",C1COCCN1CCOC(=O)N(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
14434,49129,methyl N-(5-propoxy-2H-benzimidazol-2-yl)carbamate,CCCOC1=CC2=NC(N=C2C=C1)NC(=O)OC,,,,,,
14435,49130,"5-But-1-enyl-5-butyl-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)C=CCC,,,,,,
14436,49131,CID 49131,CCCCC1(C(=O)NC(=NC1=O)[O-])CC=CC.[Na+],,,,,,
14437,49132,"5-But-2-enyl-5-butyl-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)CC=CC,,,,,,
14438,49133,CID 49133,CCC(C)C1(C(=O)NC(=NC1=O)[O-])CC=CC.[Na+],,,,,,
14439,49134,"5-Butan-2-yl-5-but-2-enyl-1,3-diazinane-2,4,6-trione",CCC(C)C1(C(=O)NC(=O)NC1=O)CC=CC,,,,,,
14440,49135,CID 49135,CCC(C)C1(C(=NC(=NC1=O)S)[O-])CC=CC.[Na+],,,,,,
14441,49136,CID 49136,CCC(C)C1(C(=O)NC(=NC1=O)S)CC=CC,,,,,,
14442,49137,CID 49137,CCC1(C(=NC(=NC1=O)S)[O-])CC=CC.[Na+],,,,,,
14443,49138,CID 49138,CCC1(C(=O)NC(=NC1=O)S)CC=CC,,,,,,
14444,49139,CID 49139,CC=CCC1(C(=O)NC(NC1=O)[O-])CC(C)C.[Na+],,,,,,
14445,49140,"5-[(E)-but-2-enyl]-2-hydroxy-5-(2-methylpropyl)-1,3-diazinane-4,6-dione",C/C=C/CC1(C(=O)NC(NC1=O)O)CC(C)C,,,,,,
14446,49141,CID 49141,CC=CCC1(C(=O)NC(NC1=O)[S-])CC(C)C.[Na+],,,,,,
14447,49142,"5-[(E)-but-2-enyl]-5-(2-methylpropyl)-2-sulfanyl-1,3-diazinane-4,6-dione",C/C=C/CC1(C(=O)NC(NC1=O)S)CC(C)C,,,,,,
14448,49143,CID 49143,CC=CCC1(C(=NC(=NC1=O)S)[O-])CCC(C)C.[Na+],,,,,,
14449,49144,CID 49144,CC=CCC1(C(=O)NC(=NC1=O)S)CCC(C)C,,,,,,
14450,49145,"5-But-1-enyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCC=CC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
14451,49146,1-Methyl-5-(1-butenyl)-5-isopropylbarbituric acid,CCC=CC1(C(=O)NC(=O)N(C1=O)C)C(C)C,,,,,,
14452,49147,CID 49147,CC=CCC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
14453,49148,"5-But-2-enyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CC=CCC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
14454,49149,CID 49149,CCC=CC1(C(=O)NC(=NC1=O)S)C(C)C,,,,,,
14455,49150,CID 49150,CC=CCC1(C(=NC(=NC1=O)S)[O-])C(C)C.[Na+],,,,,,
14456,49151,CID 49151,CC=CCC1(C(=O)NC(=NC1=O)S)C(C)C,,,,,,
14457,49152,CID 49152,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CC=CC.[Na+],,,,,,
14458,49153,"5-But-2-enyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione",CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=CC,,,,,,
14459,49154,CID 49154,CC=CCC1(C(=O)NC(=NC1=O)[O-])CCC(C)C.[Na+],,,,,,
14460,49155,"5-But-2-enyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione",CC=CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,,,,,,
14461,49156,CID 49156,CCCC(C)C1(C(=NC(=NC1=O)S)[O-])CC=CC.[Na+],,,,,,
14462,49157,CID 49157,CCCC(C)C1(C(=O)NC(=NC1=O)S)CC=CC,,,,,,
14463,49158,CID 49158,CC=CCC1(C(=O)NC(NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
14464,49159,"5-[(E)-but-2-enyl]-2-hydroxy-5-phenyl-1,3-diazinane-4,6-dione",C/C=C/CC1(C(=O)NC(NC1=O)O)C2=CC=CC=C2,,,,,,
14465,49160,"5-But-1-enyl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C=CCC,,,,,,
14466,49161,CID 49161,CCCC1(C(=O)NC(=NC1=O)[O-])CC=CC.[Na+],,,,,,
14467,49162,"5-But-2-enyl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)CC=CC,,,,,,
14468,49163,CID 49163,CCCC1(C(=NC(=NC1=O)S)[O-])CC=CC.[Na+],,,,,,
14469,49164,CID 49164,CCCC1(C(=O)NC(=NC1=O)S)CC=CC,,,,,,
14470,49165,CID 49165,CCCCOCCOCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14471,49166,"5-[2-(2-Butoxyethoxy)ethyl]-5-ethyl-1,3-diazinane-2,4,6-trione",CCCCOCCOCCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14472,49167,5-(1-Butoxyethyl)-5-ethylbarbituric acid,CCCCOC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14473,49168,CID 49168,CCCCOCCC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
14474,49169,"5-(2-Butoxyethyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",CCCCOCCC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
14475,49170,5-(Butoxymethyl)-5-ethylbarbituric acid,CCCCOCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14476,49171,1-Butyl-5-sec-butylbarbituric acid,CCCCN1C(=O)C(C(=O)NC1=O)C(C)CC,,,,,,
14477,49172,CID 49172,CCCCC1(C(=O)NC(=NC1=O)S)C(C)CC,,,,,,
14478,49173,CID 49173,CCCCSCC1(C(=O)NC(=NC1=O)[O-])C(C)CC.[Na+],,,,,,
14479,49174,"5-Butan-2-yl-5-(butylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)NC1=O)C(C)CC,,,,,,
14480,49175,CID 49175,CCCCC1(C(=O)NC(=NC1=O)[O-])CSCCCC.[Na+],,,,,,
14481,49176,"5-Butyl-5-(butylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)CSCCCC,,,,,,
14482,49177,5-Butyl-5-(1-ethoxyethyl)barbituric acid,CCCCC1(C(=O)NC(=O)NC1=O)C(C)OCC,,,,,,
14483,49178,5-sec-Butyl-5-ethyl-1-methylbarbituric acid,CCC(C)C1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14484,49179,5-sec-Butyl-5-ethyl-1-methylbarbituric acid calcium salt,CCC(C)C1(C(=NC(=O)N(C1=O)C)[O-])CC.CCC(C)C1(C(=NC(=O)N(C1=O)C)[O-])CC.[Ca+2],,,,,,
14485,49180,5-Butyl-5-ethyl-1-phenylbarbituric acid,CCCCC1(C(=O)NC(=O)N(C1=O)C2=CC=CC=C2)CC,,,,,,
14486,49181,CID 49181,CCCCC1(C(=O)NC(=NC1=O)[O-])CSCC.[Na+],,,,,,
14487,49182,"5-Butyl-5-(ethylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)CSCC,,,,,,
14488,49183,CID 49183,CCC(C)C1(C(=O)NC(=NC1=O)[O-])CSCC.[Na+],,,,,,
14489,49184,"5-Butan-2-yl-5-(ethylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCC(C)C1(C(=O)NC(=O)NC1=O)CSCC,,,,,,
14490,49185,CID 49185,CCC(C)C1(C(=NC(=NC1=O)S)[O-])CSCC.[Na+],,,,,,
14491,49186,CID 49186,CCC(C)C1(C(=O)NC(=NC1=O)S)CSCC,,,,,,
14492,49187,CID 49187,CCCCNC1=NC(=O)C(C(=O)N1)(CC)CC,,,,,,
14493,49188,CID 49188,CCC(C)C1(C(=O)NC(=NC1=O)S)CC(C)C,,,,,,
14494,49189,"Barbituric acid, 5-butyl-5-isopropenyl-",CCCCC1(C(=O)NC(=O)NC1=O)C(=C)C,,,,,,
14495,49190,CID 49190,CCCCC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
14496,49191,5-Butyl-5-(2-methyl-2-propenyl)barbituric acid,CCCCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14497,49192,"5-(Butan-2-yl)-5-(but-3-en-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione",CCC(C)C1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
14498,49193,CID 49193,CCCCC1(C(=O)NC(=NC1=O)[O-])C(C)C=C.[Na+],,,,,,
14499,49194,"5-But-3-en-2-yl-5-butyl-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
14500,49195,CID 49195,CCC(C)C1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
14501,49196,"5-Butan-2-yl-5-(2-methylprop-2-enyl)-1,3-diazinane-2,4,6-trione",CCC(C)C1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14502,49197,CID 49197,CCCCC1(C(=O)NC(=NC1=O)S)CC(=C)C,,,,,,
14503,49198,CID 49198,CCCCC1(C(=NC(=NC1=O)S)[O-])C(C)C=C.[Na+],,,,,,
14504,49199,CID 49199,CCCCC1(C(=O)NC(=NC1=O)S)C(C)C=C,,,,,,
14505,49200,CID 49200,CCC(C)C1(C(=NC(=NC1=O)S)[O-])CC(=C)C.[Na+],,,,,,
14506,49201,CID 49201,CCC(C)C1(C(=O)NC(=NC1=O)S)CC(=C)C,,,,,,
14507,49202,"Barbituric acid, 5-butyl-5-(3-methyl-2-butenyl)-",CCCCC1(C(=O)NC(=O)NC1=O)CC=C(C)C,,,,,,
14508,49203,5-sec-Butyl-5-(3-methyl-2-butenyl)barbituric acid,CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C(C)C,,,,,,
14509,49204,"5-Butyl-5-(2-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione",CCCCC1(C(=O)NC(=O)NC1=O)CC(C)CC,,,,,,
14510,49205,"5-But-2-en-2-yl-5-butyl-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)C(=CC)C,,,,,,
14511,49206,CID 49206,CCC(C)C1(C(=O)NC(=NC1=O)S)C,,,,,,
14512,49207,CID 49207,CCCCCSC(C)C1(C(=NC(=NC1=O)S)[O-])CCCC.[Na+],,,,,,
14513,49208,CID 49208,CCCCCSC(C)C1(C(=O)NC(=NC1=O)S)CCCC,,,,,,
14514,49209,CID 49209,CCCCC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
14515,49210,"5-Butyl-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
14516,49211,CID 49211,CCC(C)C1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
14517,49212,"5-Butan-2-yl-5-phenethyl-1,3-diazinane-2,4,6-trione",CCC(C)C1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
14518,49213,CID 49213,CCCCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
14519,49214,"5-Butyl-5-prop-1-enyl-1,3-diazinane-2,4,6-trione",CCCCC1(C(=O)NC(=O)NC1=O)C=CC,,,,,,
14520,49215,CID 49215,CCCC1(C(=O)NC(=NC1=O)S)C(C)CC,,,,,,
14521,49216,CID 49216,CCCCSC(C)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14522,49217,"5-(1-Butylsulfanylethyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCCCSC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14523,49218,CID 49218,CCCCSCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14524,49219,"5-(2-Butylsulfanylethyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCCCSCCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14525,49220,CID 49220,CCCCSC(C)C1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
14526,49221,CID 49221,CCCCSC(C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
14527,49222,CID 49222,CCCCSCCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
14528,49223,CID 49223,CCCCSCCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
14529,49224,CID 49224,CCCCSC(C)C1(C(=O)NC(=NC1=O)[O-])CCC.[Na+],,,,,,
14530,49225,"5-(1-Butylsulfanylethyl)-5-propyl-1,3-diazinane-2,4,6-trione",CCCCSC(C)C1(C(=O)NC(=O)NC1=O)CCC,,,,,,
14531,49226,CID 49226,CCCCSCC1(C(=O)N=C(N(C1=O)C)[O-])C.[Na+],,,,,,
14532,49227,"5-(Butylsulfanylmethyl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
14533,49228,CID 49228,CCCCSCC1(C(=O)N=C(N(C1=O)C)[O-])CC.[Na+],,,,,,
14534,49229,"5-(Butylsulfanylmethyl)-5-ethyl-1-methyl-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
14535,49230,CID 49230,CCC(C)SCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14536,49231,"5-(sec-Butylthiomethyl)-5-ethyl-2-sodiooxy-4,6(1H,5H)-pyrimidinedione",CCC(C)SCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14537,49232,CID 49232,CCC1(C(=O)NC(=NC1=O)[O-])CSC(C)(C)C.[Na+],,,,,,
14538,49233,"5-(Tert-butylsulfanylmethyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CSC(C)(C)C,,,,,,
14539,49234,CID 49234,CCCCSCC1(C(=O)N=C(N(C1=O)C)[O-])CC(C)C.[Na+],,,,,,
14540,49235,"5-(Butylsulfanylmethyl)-1-methyl-5-(2-methylpropyl)-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)N(C1=O)C)CC(C)C,,,,,,
14541,49236,CID 49236,CCCCSCC1(C(=O)NC(=NC1=O)[O-])C(C)C.[Na+],,,,,,
14542,49237,"5-(Butylsulfanylmethyl)-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
14543,49238,CID 49238,CCCCSCC1(C(=O)NC(=NC1=O)[O-])C.[Na+],,,,,,
14544,49239,"5-(Butylsulfanylmethyl)-5-methyl-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)NC1=O)C,,,,,,
14545,49240,CID 49240,CCCCSCC1(C(=O)N=C(N(C1=O)C)[O-])CCC.[Na+],,,,,,
14546,49241,"5-(Butylsulfanylmethyl)-1-methyl-5-propyl-1,3-diazinane-2,4,6-trione",CCCCSCC1(C(=O)NC(=O)N(C1=O)C)CCC,,,,,,
14547,49242,CID 49242,CCCCSCCCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14548,49243,"5-(3-Butylsulfanylpropyl)-5-ethyl-1,3-diazinane-2,4,6-trione",CCCCSCCCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14549,49244,CID 49244,CCCCSCCCC1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
14550,49245,CID 49245,CCCCSCCCC1(C(=O)NC(=NC1=O)S)CC,,,,,,
14551,49246,"Barbituric acid, 5-butyl-5-vinyl-",CCCCC1(C(=O)NC(=O)NC1=O)C=C,,,,,,
14552,49247,"Barbituric acid, 1-carbamoylmethyl-5,5-diallyl-",C=CCC1(C(=O)NC(=O)N(C1=O)CC(=O)N)CC=C,,,,,,
14553,49248,"5-Ethyl-5-pent-1-enyl-1,3-diazinane-2,4,6-trione",CCCC=CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14554,49249,CID 49249,CCCCCSC(C)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14555,49250,"5-Ethyl-5-(1-pentylsulfanylethyl)-1,3-diazinane-2,4,6-trione",CCCCCSC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14556,49251,CID 49251,CCCCCSC(C)C1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
14557,49252,CID 49252,CCCCCSC(C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
14558,49253,CID 49253,CCCCCSCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14559,49254,"5-Ethyl-5-(pentylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCCCSCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14560,49255,CID 49255,CCC1(C(=O)NC(=NC1=O)[O-])CCOC2=CC=CC=C2.[Na+],,,,,,
14561,49256,"5-Ethyl-5-(2-phenoxyethyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCOC2=CC=CC=C2,,,,,,
14562,49257,CID 49257,CCC1(C(=O)NC(=NC1=O)[O-])CCCOC2=CC=CC=C2.[Na+],,,,,,
14563,49258,"5-Ethyl-5-(3-phenoxypropyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCCOC2=CC=CC=C2,,,,,,
14564,49259,CID 49259,CCC1(C(=O)NC(=NC1=O)[O-])CCCCCCC2=CC=CC=C2.[Na+],,,,,,
14565,49260,"5-Ethyl-5-(6-phenylhexyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCCCCCC2=CC=CC=C2,,,,,,
14566,49261,"5-Methyl-5-pent-2-en-3-yl-1,3-diazinane-2,4,6-trione",CCC(=CC)C1(C(=O)NC(=O)NC1=O)C,,,,,,
14567,49262,"5-Pent-2-en-3-yl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C(=CC)CC,,,,,,
14568,49263,5-Ethyl-5-(1-propoxyethyl)barbituric acid,CCCOC(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14569,49264,5-Ethyl-5-(propoxymethyl)barbituric acid,CCCOCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14570,49265,"5-Ethyl-5-hept-3-en-4-yl-1,3-diazinane-2,4,6-trione",CCCC(=CCC)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14571,49266,CID 49266,CCCC(CCC)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14572,49267,"5-Ethyl-5-heptan-4-yl-1,3-diazinane-2,4,6-trione",CCCC(CCC)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
14573,49268,"5-(2-Methylprop-2-enyl)-5-pentan-3-yl-1,3-diazinane-2,4,6-trione",CCC(CC)C1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14574,49269,CID 49269,CCCCCCC1(C(=O)NC(=NC1=O)[O-])C(C)SCC.[Na+],,,,,,
14575,49270,"5-(1-Ethylsulfanylethyl)-5-hexyl-1,3-diazinane-2,4,6-trione",CCCCCCC1(C(=O)NC(=O)NC1=O)C(C)SCC,,,,,,
14576,49271,CID 49271,CCCCCCC1(C(=NC(=NC1=O)S)[O-])C(C)SCC.[Na+],,,,,,
14577,49272,CID 49272,CCCCCCC1(C(=O)NC(=NC1=O)S)C(C)SCC,,,,,,
14578,49273,CID 49273,CCSC(C)C1(C(=O)NC(=NC1=O)[O-])CC(C)C.[Na+],,,,,,
14579,49274,"5-(1-Ethylsulfanylethyl)-5-(2-methylpropyl)-1,3-diazinane-2,4,6-trione",CCSC(C)C1(C(=O)NC(=O)NC1=O)CC(C)C,,,,,,
14580,49275,CID 49275,CCCCCCC1(C(=O)NC(=NC1=O)[O-])CSCC.[Na+],,,,,,
14581,49276,"5-(Ethylsulfanylmethyl)-5-hexyl-1,3-diazinane-2,4,6-trione",CCCCCCC1(C(=O)NC(=O)NC1=O)CSCC,,,,,,
14582,49277,CID 49277,CCSCC1(C(=O)N=C(N(C1=O)C)[O-])CC(C)C.[Na+],,,,,,
14583,49278,"5-(Ethylsulfanylmethyl)-1-methyl-5-(2-methylpropyl)-1,3-diazinane-2,4,6-trione",CCSCC1(C(=O)NC(=O)N(C1=O)C)CC(C)C,,,,,,
14584,49279,CID 49279,CCSCC1(C(=NC(=NC1=O)S)[O-])CC(C)C.[Na+],,,,,,
14585,49280,CID 49280,CCSCC1(C(=O)NC(=NC1=O)S)CC(C)C,,,,,,
14586,49281,CID 49281,CCSCC1(C(=O)N=C(N(C1=O)C)[O-])C(C)C.[Na+],,,,,,
14587,49282,"5-(Ethylsulfanylmethyl)-1-methyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CCSCC1(C(=O)NC(=O)N(C1=O)C)C(C)C,,,,,,
14588,49283,CID 49283,CCSCC1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
14589,49284,5-[(Ethylmercapto)methyl]-5-(2-methylallyl)barbituric acid,CCSCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14590,49285,CID 49285,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CSCC.[Na+],,,,,,
14591,49286,"5-(Ethylsulfanylmethyl)-5-pentan-2-yl-1,3-diazinane-2,4,6-trione",CCCC(C)C1(C(=O)NC(=O)NC1=O)CSCC,,,,,,
14592,49287,CID 49287,CCCC1(C(=O)N=C(N(C1=O)C)[O-])CSCC.[Na+],,,,,,
14593,49288,"5-(Ethylsulfanylmethyl)-1-methyl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)N(C1=O)C)CSCC,,,,,,
14594,49289,"Barbituric acid, 5-ethyl-5-vinyl-",CCC1(C(=O)NC(=O)NC1=O)C=C,,,,,,
14595,49290,"Barbituric acid, 5-hexyl-5-methyl-",CCCCCCC1(C(=O)NC(=O)NC1=O)C,,,,,,
14596,49291,5-Hexyl-5-(2-methyl-2-propenyl)barbituric acid,CCCCCCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14597,49292,"Barbituric acid, 5-hexyl-5-phenyl-",CCCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
14598,49293,CID 49293,CC(C)CC1(C(=NC(=NC1=O)S)[O-])CSC.[Na+],,,,,,
14599,49294,CID 49294,CC(C)CC1(C(=O)NC(=NC1=O)S)CSC,,,,,,
14600,49295,CID 49295,CC(C)CC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
14601,49296,"Barbituric acid, 5-(2-isopentenyl)-5-isopropyl-",CC(C)C1(C(=O)NC(=O)NC1=O)CC=C(C)C,,,,,,
14602,49297,5-(2-Isopentenyl)-5-isopropyl-1-methylbarbituric acid,CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C(C)C,,,,,,
14603,49298,"5-(3-Methylbut-1-enyl)-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C=CC(C)C,,,,,,
14604,49299,"Barbituric acid, 5-isopentyl-5-isopropenyl-",CC(C)CCC1(C(=O)NC(=O)NC1=O)C(=C)C,,,,,,
14605,49300,"Barbituric acid, 5-isopentyl-5-methyl-",CC(C)CCC1(C(=O)NC(=O)NC1=O)C,,,,,,
14606,49301,5-Isopentyl-5-(2-methyl-2-propenyl)barbituric acid,CC(C)CCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14607,49302,CID 49302,CC(C)CCC1(C(=O)NC(=NC1=O)[O-])C(C)C=C.[Na+],,,,,,
14608,49303,"5-But-3-en-2-yl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione",CC(C)CCC1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
14609,49304,"Barbituric acid, 5-isopentyl-5-vinyl-",CC(C)CCC1(C(=O)NC(=O)NC1=O)C=C,,,,,,
14610,49305,"Barbituric acid, 5-isopropenyl-5-methyl-",CC(=C)C1(C(=O)NC(=O)NC1=O)C,,,,,,
14611,49306,"Barbituric acid, 5-isopropenyl-5-pentyl-",CCCCCC1(C(=O)NC(=O)NC1=O)C(=C)C,,,,,,
14612,49307,"Barbituric acid, 5-isopropenyl-5-propyl-",CCCC1(C(=O)NC(=O)NC1=O)C(=C)C,,,,,,
14613,49308,5-Isopropyl-5-(1-methyl-2-propenyl)barbituric acid,CC(C)C1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
14614,49309,CID 49309,CC(C)C1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
14615,49310,"5-(2-Methylprop-2-enyl)-5-propan-2-yl-1,3-diazinane-2,4,6-trione",CC(C)C1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14616,49311,"5-pentyl-5-(propan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione",CCCCCC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
14617,49312,Isopropylpropenylbarbitursaure,CC=CC1(C(=O)NC(=O)NC1=O)C(C)C,,,,,,
14618,49313,"5-(2-Methylbutyl)-5-(2-methylprop-2-enyl)-1,3-diazinane-2,4,6-trione",CCC(C)CC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14619,49314,CID 49314,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
14620,49315,5-(1-Methylbutyl)-5-(2-methyl-2-propenyl)barbituric acid,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14621,49316,CID 49316,CCCC(C)C1(C(=O)NC(=NC1=O)S)CC(=C)C,,,,,,
14622,49317,CID 49317,CCCC(C)C1(C(=NC(=NC1=O)S)[O-])CC(=C)C.[Na+],,,,,,
14623,49318,5-(2-Methyl-2-propenyl)-5-pentylbarbituric acid,CCCCCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14624,49319,CID 49319,CCCCCC1(C(=NC(=NC1=O)S)[O-])C(C)C=C.[Na+],,,,,,
14625,49320,CID 49320,CCCCCC1(C(=O)NC(=NC1=O)S)C(C)C=C,,,,,,
14626,49321,5-(2-Methyl-2-propenyl)-5-phenylbarbituric acid,CC(=C)CC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
14627,49322,CID 49322,CC(=C)CC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
14628,49323,5-(2-Methyl-2-propenyl)-5-propylbarbituric acid,CCCC1(C(=O)NC(=O)NC1=O)CC(=C)C,,,,,,
14629,49324,CID 49324,CCCC1(C(=O)NC(=NC1=O)[O-])C(C)C=C.[Na+],,,,,,
14630,49325,"5-But-3-en-2-yl-5-propyl-1,3-diazinane-2,4,6-trione",CCCC1(C(=O)NC(=O)NC1=O)C(C)C=C,,,,,,
14631,49326,CID 49326,CCCC1(C(=O)NC(=NC1=O)[O-])CC(=C)C.[Na+],,,,,,
14632,49327,CID 49327,CCCC1(C(=O)NC(=NC1=O)S)CC(=C)C,,,,,,
14633,49328,CID 49328,CCCC1(C(=NC(=NC1=O)S)[O-])C(C)C=C.[Na+],,,,,,
14634,49329,CID 49329,CCCC1(C(=O)NC(=NC1=O)S)C(C)C=C,,,,,,
14635,49330,CID 49330,CCCC1(C(=NC(=NC1=O)S)[O-])CC(=C)C.[Na+],,,,,,
14636,49331,CID 49331,CC(C1=CC=CC=C1)C2(C(=O)NC(=NC2=O)[O-])CCC3=CC=CC=C3.[Na+],,,,,,
14637,49332,"5-(1-Phenylethyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",CC(C1=CC=CC=C1)C2(C(=O)NC(=O)NC2=O)CCC3=CC=CC=C3,,,,,,
14638,49333,"Barbituric acid, 5-(3-methyl-2-butenyl)-5-phenyl-",CC(=CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2)C,,,,,,
14639,49334,"(8S)-6-[(6S)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol",CC[C@@H](C(=CCC(C)C=C1C[C@](C2CCCN2C1)(C)O)C)O,,,,,,
14640,49335,"Acetanilide, 4'-(2-(4-pyridyl)ethylsulfonyl)-, hydrochloride",CC(=O)NC1=CC=C(C=C1)S(=O)(=O)CCC2=CC=[NH+]C=C2.[Cl-],,,,,,
14641,49336,N-[4-(2-pyridin-4-ylethylsulfonyl)phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)CCC2=CC=NC=C2,,,,,,
14642,49337,"Ethylamine, 2-(4-methoxyphenylsulfonyl)-N-methyl-, hydrochloride",C[NH2+]CCS(=O)(=O)C1=CC=C(C=C1)OC.[Cl-],,,,,,
14643,49338,2-(4-methoxyphenyl)sulfonyl-N-methylethanamine,CNCCS(=O)(=O)C1=CC=C(C=C1)OC,,,,,,
14644,49339,"BENZYLAMINE, N-(2-(p-METHOXYPHENYLSULFONYL)ETHYL)-, HYDROCHLORIDE",COC1=CC=C(C=C1)S(=O)(=O)CC[NH2+]CC2=CC=CC=C2.[Cl-],,,,,,
14645,49340,N-benzyl-2-(4-methoxyphenyl)sulfonylethanamine,COC1=CC=C(C=C1)S(=O)(=O)CCNCC2=CC=CC=C2,,,,,,
14646,49341,"N,N-Dimethyl-2-(4-methoxyphenylsulfonyl)ethylamine hydrochloride",C[NH+](C)CCS(=O)(=O)C1=CC=C(C=C1)OC.[Cl-],,,,,,
14647,49342,4-Methoxyphenyl 2-dimethylaminoethyl sulfone,CN(C)CCS(=O)(=O)C1=CC=C(C=C1)OC,,,,,,
14648,49343,(+-)-3-(p-Tolyl)-4-aminobutyric acid hydrochloride,CC1=CC=C(C=C1)C(CC(=O)O)C[NH3+].[Cl-],,,,,,
14649,49344,4-Amino-3-(4-methylphenyl)butanoic acid,CC1=CC=C(C=C1)C(CC(=O)O)CN,,,,,,
14650,49345,"A'-Neo-30-norgammacerane, 22-propyl-, (17alpha,22S)-",CCCC(C)C1CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C,,,,,,
14651,49346,"A'-Neo-30-norgammacerane, 22-butyl-, (17alpha,22R)-",CCCCC(C)C1CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C,,,,,,
14652,49347,"Benzoic acid, 2-(N-methyl-N-(4-phenylbutyl)amino)ethyl ester, hydrochloride",C[NH+](CCCCC1=CC=CC=C1)CCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14653,49348,2-[Methyl(4-phenylbutyl)amino]ethyl benzoate,CN(CCCCC1=CC=CC=C1)CCOC(=O)C2=CC=CC=C2,,,,,,
14654,49349,p-Pentoxybenzoic acid 3-(2-methylpiperidino)propyl ester hydrochloride,CCCCCOC1=CC=C(C=C1)C(=O)OCCC[NH+]2CCCCC2C.[Cl-],,,,,,
14655,49350,CID 49350,CC(=O)NC1=CC(=CC(=C1)C(=O)[O-])NC(=O)C.[Na+],,,,,,
14656,49351,"3,5-Diacetamidobenzoic acid",CC(=O)NC1=CC(=CC(=C1)C(=O)O)NC(=O)C,,,,,,
14657,49352,"Benzoic acid, 2-(2-(2-methylpiperidino)ethoxy)ethyl ester, hydrochloride",CC1CCCC[NH+]1CCOCCOC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14658,49353,"3-Acetamido-5-acetamidomethyl-2,4,6-triiodobenzoic acid 2,3-dihydroxypropyl ester",CC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)OCC(CO)O)I,,,,,,
14659,49354,Pentomone,CC1([C@@H]2[C@@H](CC3=C(O2)C(=CC=C3)OC)C(=O)[C@@H]4[C@H]1OC5=C(C4)C=CC=C5OC)C,,,,,,
14660,49355,CID 49355,C[NH+]1CCN(CC1)C2=C3C=C(C=CC3=NC4=C(N2)C=C(C=C4)Cl)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
14661,49356,CID 49356,CN1CCN(CC1)C2=C3C=C(C=CC3=NC4=C(N2)C=C(C=C4)Cl)OC,,,,,,
14662,49357,CID 49357,CN1CCN(CC1)C2=C3C=C(C=CC3=NC4=C(N2)C=C(C=C4)Cl)O,,,,,,
14663,49358,CID 49358,COCCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
14664,49359,"5-(2-Methoxyethyl)-5-phenyl-1,3-diazinane-2,4,6-trione",COCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,,,,,,
14665,49360,CID 49360,CCC1(C(=O)NC(=NC1=O)[O-])CCCCC2=CC=CC=C2.[Na+],,,,,,
14666,49361,"5-Ethyl-5-(4-phenylbutyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCCCC2=CC=CC=C2,,,,,,
14667,49362,CID 49362,CCC1(C(=O)NC(=NC1=O)[O-])CCCC2=CC=CC=C2.[Na+],,,,,,
14668,49363,"5-Ethyl-5-(3-phenylpropyl)-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CCCC2=CC=CC=C2,,,,,,
14669,49364,CID 49364,CCCCSC(C)C1(C(=NC(=NC1=O)S)[O-])CCC.[Na+],,,,,,
14670,49365,CID 49365,CCCCSC(C)C1(C(=O)NC(=NC1=O)S)CCC,,,,,,
14671,49366,"Benzoic acid, 1,2-dimethyl-3-(4-methylpiperidino)propyl ester, hydrochloride",CC1CC[NH+](CC1)CC(C)C(C)OC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14672,49367,"Benzoic acid, 2,2-dimethyl-3-(4-methylpiperidino)propyl ester, hydrochloride",CC1CC[NH+](CC1)CC(C)(C)COC(=O)C2=CC=CC=C2.[Cl-],,,,,,
14673,49368,"Benzoic acid, 4-(2-(N-ethyl-N-(4-hydroxybutyl)amino)ethyl)-, ethyl ester, 3,4,5-trimethoxybenzoate (ester)",CCN(CCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC)CCC2=CC=C(C=C2)C(=O)OCC,,,,,,
14674,49369,5-Ethyl-1-phenyl-5-propylbarbituric acid,CCCC1(C(=O)NC(=O)N(C1=O)C2=CC=CC=C2)CC,,,,,,
14675,49370,CID 49370,CCCC(C)C1(C(=NC(=NC1=O)S)[O-])CSCC.[Na+],,,,,,
14676,49371,CID 49371,CCCC(C)C1(C(=O)NC(=NC1=O)S)CSCC,,,,,,
14677,49372,CID 49372,CC(C)CC1(C(=O)NC(=NC1=O)[O-])CSC.[Na+],,,,,,
14678,49373,"5-(2-Methylpropyl)-5-(methylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CC(C)CC1(C(=O)NC(=O)NC1=O)CSC,,,,,,
14679,49374,CID 49374,CC(C)CC1(C(=O)NC(=NC1=O)[O-])CCC2=CC=CC=C2.[Na+],,,,,,
14680,49375,"5-(2-Methylpropyl)-5-(2-phenylethyl)-1,3-diazinane-2,4,6-trione",CC(C)CC1(C(=O)NC(=O)NC1=O)CCC2=CC=CC=C2,,,,,,
14681,49376,CID 49376,CC(C)CCC1(C(=NC(=NC1=O)S)[O-])C(C)C=C.[Na+],,,,,,
14682,49377,CID 49377,CC(C)CCC1(C(=O)NC(=NC1=O)S)C(C)C=C,,,,,,
14683,49378,"1-(3,4-Dihydroxyphenyl)-2-ethyl-3-methylbutan-1-one",CCC(C(C)C)C(=O)C1=CC(=C(C=C1)O)O,,,,,,
14684,49379,"3-Diethylamino-1-(2,5-dimethoxyphenyl)-1-butanol hydrochloride",CC[NH+](CC)C(C)CC(C1=C(C=CC(=C1)OC)OC)O.[Cl-],,,,,,
14685,49380,"alpha-[2-(Diethylamino)propyl]-2,5-dimethoxybenzenemethanol",CCN(CC)C(C)CC(C1=C(C=CC(=C1)OC)OC)O,,,,,,
14686,49381,Fluperlapine,CN1CCN(CC1)C2=NC3=C(CC4=CC=CC=C42)C=CC(=C3)F,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
14687,49382,CID 49382,CCCSCC1(C(=O)NC(=NC1=O)[O-])CC.[Na+],,,,,,
14688,49383,"5-Ethyl-5-(propylsulfanylmethyl)-1,3-diazinane-2,4,6-trione",CCCSCC1(C(=O)NC(=O)NC1=O)CC,,,,,,
14689,49384,Metazachlor,CC1=C(C(=CC=C1)C)N(CN2C=CC=N2)C(=O)CCl,,,,,,
14690,49385,"Acetamide, N-(2-(2-oxo-1-pyrrolidinyl)ethyl)-",CC(=O)NCCN1CCCC1=O,,,,,,
14691,49386,"Formamidine, N,N-dimethyl-N'-furfuryl-",CN(C)C=NCC1=CC=CO1,,,,,,
14692,49387,"N,N-Dimethyl-N'-(8-quinolinyl)formamidine",CN(C)C=NC1=CC=CC2=C1N=CC=C2,,,,,,
14693,49388,N-(2-Fluorenyl)formohydroxamic acid,C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)O,,,,,,
14694,49389,"Acetohydroxamic acid, 2-chloro-N-(2-fluorenyl)-",C1C2=CC=CC=C2C3=C1C=C(C=C3)N(C(=O)CCl)O,,,,,,
14695,49390,"N-9H-Fluoren-2-yl-2,2,2-trifluoro-N-hydroxyacetamide",C1C2=CC=CC=C2C3=C1C=C(C=C3)N(C(=O)C(F)(F)F)O,,,,,,
14696,49391,Magnesium;1-oxido-2-[(1-oxidopyridin-1-ium-3-yl)disulfanyl]pyridin-1-ium;sulfate,C1=CC=[N+](C(=C1)SSC2=C[N+](=CC=C2)[O-])[O-].[O-]S(=O)(=O)[O-].[Mg+2],,,,,,
14697,49392,1-Oxido-2-[(1-oxidopyridin-1-ium-3-yl)disulfanyl]pyridin-1-ium,C1=CC=[N+](C(=C1)SSC2=C[N+](=CC=C2)[O-])[O-],,,,,,
14698,49393,"INDOLE, 1-(alpha-L-ARABINOPYRANOSYL)-6-NITRO-",C1[C@H](C(C([C@@H](O1)ON2C=CC3=C2C=C(C=C3)[N+](=O)[O-])O)O)O,,,,,,
14699,49394,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(1-methyl-3-piperidylmethylene)-, hydrogen sulfate",C[NH+]1CCCC(C1)C=C2C3=CC=CC=C3CCC4=CC=CC=C42.OS(=O)(=O)[O-],,,,,,
14700,49395,"1-Methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidenemethyl)piperidine",CN1CCCC(C1)C=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
14701,49396,"5H-DIBENZO(a,d)CYCLOHEPTENE, 10,11-DIHYDRO-5-(3-PIPERIDINOPROPYLIDENE)-",C1CCN(CC1)CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
14702,49397,"10,11-Dihydro-5-(2-piperidylmethyl)-5H-dibenzo(a,d)cycloheptene",C1CCNC(C1)CC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
14703,49398,CID 49398,CC(C[NH+](C)C)C=C1C2=CC=CC=C2C=CC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
14704,49399,"3-(5-chloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,9,11,13-heptaenylidene)-N,N,2-trimethylpropan-1-amine",CC(CN(C)C)C=C1C2=CC=CC=C2C=CC3=C1C=C(C=C3)Cl,,,,,,
14705,49400,"3-(6-chloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=C(CCC3=CC=CC=C31)C=C(C=C2)Cl,,,,,,
14706,49401,"5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N-methoxy-N-methyl-",CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)OC,,,,,,
14707,49402,"5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-beta,beta,N,N-tetramethyl-",CC(C)(CN(C)C)C=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,,,,
14708,49403,"10,11-Dihydro-beta,N,N-trimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine",CC(CN(C)C)C=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,,,,
14709,49404,"3-(5,6-dimethoxy-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC(=C(C=C31)OC)OC,,,,,,
14710,49405,CID 49405,C[NH+](C)CCC=C1C2=CC=CC=C2C=CC3=C1C=C(C=C3)S(=O)(=O)C.C(=CC(=O)[O-])C(=O)O,,,,,,
14711,49406,"5-(3-dimethylaminopropylidene)-3-methylsulfonyl-5H-dibenzo[a,d]cycloheptene",CN(C)CCC=C1C2=CC=CC=C2C=CC3=C1C=C(C=C3)S(=O)(=O)C,,,,,,
14712,49407,"5H-DIBENZO(a,d)CYCLOHEPTEN-5-OL, 10,11-DIHYDRO-5-(2-(4-METHYLPIPERAZINYL)ETHYL)-",CN1CCN(CC1)CCC2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
14713,49408,"10,11-Dihydro-5-(2-(1-methyl-2-piperidyl)ethyl)-5H-dibenzo(a,d)cyclohepten-5-ol",CN1CCCCC1CCC2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
14714,49409,"10,11-Dihydro-5-(1-methyl-3-pyrrolidinylmethyl)-5H-dibenzo(a,d)cyclohepten-5-ol",CN1CCC(C1)CC2(C3=CC=CC=C3CCC4=CC=CC=C42)O,,,,,,
14715,49410,CID 49410,C1CC2=C(C=C1)C=CC(C3=CC=CC=C3C2)C(=O)N,,,,,,
14716,49411,CID 49411,C[NH+](C)CCCC1C=CC2=C(CCC=C2)CC3=CC=CC=C13.[Cl-],,,,,,
14717,49412,CID 49412,CN(C)CCCC1C=CC2=C(CCC=C2)CC3=CC=CC=C13,,,,,,
14718,49413,CID 49413,C[NH+](C)CCC=C1C=CC2=C(CCC=C2)CC3=CC=CC=C31.[Cl-],,,,,,
14719,49414,CID 49414,CN(C)CCC=C1C=CC2=C(CCC=C2)CC3=CC=CC=C31,,,,,,
14720,49415,CID 49415,CC(C[NH+](C)C)C=C1C=CC2=C(CCC=C2)CC3=CC=CC=C31.[Cl-],,,,,,
14721,49416,CID 49416,CC(CN(C)C)C=C1C=CC2=C(CCC=C2)CC3=CC=CC=C31,,,,,,
14722,49417,CID 49417,CN1CCN(CC1)CCCC2=CC3=C(CC4=C(C=CCC4)C=CC3)C=C2.Cl.Cl,,,,,,
14723,49418,CID 49418,CN1CCN(CC1)CCCC2=CC3=C(CC4=C(C=CCC4)C=CC3)C=C2,,,,,,
14724,49419,CID 49419,C[NH+]1CCCCC1CCC2C=CC3=C(CCC=C3)CC4=CC=CC=C24.[Cl-],,,,,,
14725,49420,CID 49420,CN1CCCCC1CCC2C=CC3=C(CCC=C3)CC4=CC=CC=C24,,,,,,
14726,49421,"1-Methyl-3-(6-tricyclo[10.4.0.03,8]hexadeca-1(12),3(8),4,6,10,13-hexaenylmethyl)pyrrolidine",CN1CCC(C1)CC2=CC3=C(CC4=C(C=CCC4)C=CC3)C=C2,,,,,,
14727,49422,"11H-Dibenzo(b,e)(1,4)diazepin-11-one, 5,10-dihydro-5-(2-(diethylamino)ethyl)-10-(3-(dimethylamino)propyl)-, dihydrochloride",CC[NH+](CC)CCN1C2=CC=CC=C2C(=O)N(C3=CC=CC=C31)CCC[NH+](C)C.[Cl-].[Cl-],,,,,,
14728,49423,"11-[2-(Diethylamino)ethyl]-5-[3-(dimethylamino)propyl]benzo[b][1,4]benzodiazepin-6-one",CCN(CC)CCN1C2=CC=CC=C2C(=O)N(C3=CC=CC=C31)CCCN(C)C,,,,,,
14729,49424,N-(2-Bromoallyl)dibenzylamine hydrochloride,C=C(C[NH+](CC1=CC=CC=C1)CC2=CC=CC=C2)Br.[Cl-],,,,,,
14730,49425,"N,N-Dibenzyl-2-bromo-2-propene-1-amine",C=C(CN(CC1=CC=CC=C1)CC2=CC=CC=C2)Br,,,,,,
14731,49426,Di(p-methoxybenzyl)-beta-chloroethylamine hydrochloride,COC1=CC=C(C=C1)C[NH+](CCCl)CC2=CC=C(C=C2)OC.[Cl-],,,,,,
14732,49427,"2-chloro-N,N-bis[(4-methoxyphenyl)methyl]ethanamine",COC1=CC=C(C=C1)CN(CCCl)CC2=CC=C(C=C2)OC,,,,,,
14733,49428,"N-(2-Chloroethyl)-m,m'-dimethyldibenzylamine hydrochloride",CC1=CC(=CC=C1)C[NH+](CCCl)CC2=CC=CC(=C2)C.[Cl-],,,,,,
14734,49429,"2-chloro-N,N-bis[(3-methylphenyl)methyl]ethanamine",CC1=CC(=CC=C1)CN(CCCl)CC2=CC=CC(=C2)C,,,,,,
14735,49430,"DIBENZYLAMINE, N-(2-CHLOROETHYL)-o,o'-DIMETHYL-, HYDROCHLORIDE",CC1=CC=CC=C1C[NH+](CCCl)CC2=CC=CC=C2C.[Cl-],,,,,,
14736,49431,"2-chloro-N,N-bis[(2-methylphenyl)methyl]ethanamine",CC1=CC=CC=C1CN(CCCl)CC2=CC=CC=C2C,,,,,,
14737,49432,N-(2-Chloroethyl)-4-methoxydibenzylamine hydrochloride,COC1=CC=C(C=C1)C[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
14738,49433,N-benzyl-2-chloro-N-[(4-methoxyphenyl)methyl]ethanamine,COC1=CC=C(C=C1)CN(CCCl)CC2=CC=CC=C2,,,,,,
14739,49434,N-(2-Chloroethyl)-alpha-methyldibenzylamine hydrochloride,CC(C1=CC=CC=C1)[NH+](CCCl)CC2=CC=CC=C2.[Cl-],,,,,,
14740,49435,N-benzyl-N-(2-chloroethyl)-1-phenylethanamine,CC(C1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2,,,,,,
14741,49436,N-(2-Cyanoethyl)dibenzylamine hydrochloride,C1=CC=C(C=C1)C[NH+](CCC#N)CC2=CC=CC=C2.[Cl-],,,,,,
14742,49437,3-(Dibenzylamino)propanenitrile,C1=CC=C(C=C1)CN(CCC#N)CC2=CC=CC=C2,,,,,,
14743,49438,CID 49438,C1=CC=C(C=C1)C[NH+](CC2=CC=CC=C2)C=CC3=CC=CC=C3.[Cl-],,,,,,
14744,49439,N-Styryldibenzylamine,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C=CC3=CC=CC=C3,,,,,,
14745,49440,Ethyl(2-chloroethyl) (3-chloropropyl)amine hydrochloride,CC[NH+](CCCCl)CCCl.[Cl-],,,,,,
14746,49441,3-chloro-N-(2-chloroethyl)-N-ethylpropan-1-amine,CCN(CCCCl)CCCl,,,,,,
14747,49442,CID 49442,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](CC)CC)C.[Cl-],,,,,,
14748,49443,CID 49443,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN(CC)CC)C,,,,,,
14749,49444,"Chromone, 8-((diethylamino)methyl)-2-ethyl-7-methoxy-3-methyl-, hydrochloride",CCC1=C(C(=O)C2=C(O1)C(=C(C=C2)OC)C[NH+](CC)CC)C.[Cl-],,,,,,
14750,49445,8-(Diethylaminomethyl)-2-ethyl-7-methoxy-3-methylchromen-4-one,CCC1=C(C(=O)C2=C(O1)C(=C(C=C2)OC)CN(CC)CC)C,,,,,,
14751,49446,"4H-1-Benzopyran-4-one, 8-((diethylamino)methyl)-7-hydroxy-2-methyl-, hydrochloride",CC[NH+](CC)CC1=C(C=CC2=C1OC(=CC2=O)C)O.[Cl-],,,,,,
14752,49447,8-(Diethylaminomethyl)-7-hydroxy-2-methylchromen-4-one,CCN(CC)CC1=C(C=CC2=C1OC(=CC2=O)C)O,,,,,,
14753,49448,CID 49448,CC[NH+](CC)CC1=C2C(=C(C(=CO2)C)O)C=CC1=O.[Cl-],,,,,,
14754,49449,CID 49449,CCN(CC)CC1=C2C(=C(C(=CO2)C)O)C=CC1=O,,,,,,
14755,49450,CID 49450,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](CC)CC)CC.[Cl-],,,,,,
14756,49451,CID 49451,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN(CC)CC)CC,,,,,,
14757,49452,CID 49452,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](C)C)CC.[Cl-],,,,,,
14758,49453,CID 49453,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN(C)C)CC,,,,,,
14759,49454,CID 49454,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCCCC3)CC.[Cl-],,,,,,
14760,49455,CID 49455,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCCCC3)CC,,,,,,
14761,49456,"4H-1-Benzopyran-4-one, 2,3-diethyl-7-methoxy-8-(4-morpholinylmethyl)-, hydrochloride",CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCOCC3)OC)CC.[Cl-],,,,,,
14762,49457,"2,3-Diethyl-7-methoxy-8-(morpholin-4-ylmethyl)chromen-4-one",CCC1=C(OC2=C(C1=O)C=CC(=C2CN3CCOCC3)OC)CC,,,,,,
14763,49458,"4H-1-Benzopyran-4-one, 2,3-diethyl-7-methoxy-8-(1-piperidinylmethyl)-, hydrochloride",CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCCCC3)OC)CC.[Cl-],,,,,,
14764,49459,"2,3-Diethyl-7-methoxy-8-(piperidin-1-ylmethyl)chromen-4-one",CCC1=C(OC2=C(C1=O)C=CC(=C2CN3CCCCC3)OC)CC,,,,,,
14765,49460,"4H-1-Benzopyran-4-one, 8-((dimethylamino)methyl)-2-ethyl-7-hydroxy-, hydrochloride",CCC1=CC(=O)C2=C(O1)C(=C(C=C2)O)C[NH+](C)C.[Cl-],,,,,,
14766,49461,8-[(Dimethylamino)methyl]-2-ethyl-7-hydroxychromen-4-one,CCC1=CC(=O)C2=C(O1)C(=C(C=C2)O)CN(C)C,,,,,,
14767,49462,CID 49462,CCC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH+](C)C)O)C.[Cl-],,,,,,
14768,49463,CID 49463,CCC1=C(C(=C2C=CC(=O)C(=C2O1)CN(C)C)O)C,,,,,,
14769,49464,CID 49464,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](C)C)C.[Cl-],,,,,,
14770,49465,CID 49465,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN(C)C)C,,,,,,
14771,49466,CID 49466,CC1=COC2=C(C(=O)C=CC2=C1O)C[NH+](C)C.[Cl-],,,,,,
14772,49467,CID 49467,CC1=COC2=C(C(=O)C=CC2=C1O)CN(C)C,,,,,,
14773,49468,CID 49468,CC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](C)C)C.[Cl-],,,,,,
14774,49469,CID 49469,CC1=C(OC2=C(C(=O)C=CC2=C1O)CN(C)C)C,,,,,,
14775,49470,CID 49470,CC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]C)C.[Cl-],,,,,,
14776,49471,CID 49471,CC1=C(OC2=C(C(=O)C=CC2=C1O)CNC)C,,,,,,
14777,49472,CID 49472,CC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCCCC3)C.[Cl-],,,,,,
14778,49473,CID 49473,CC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCCCC3)C,,,,,,
14779,49474,"4H-1-Benzopyran-4-one, 7-methoxy-2,3-dimethyl-8-((methylamino)methyl)-, hydrochloride",CC1=C(OC2=C(C1=O)C=CC(=C2C[NH2+]C)OC)C.[Cl-],,,,,,
14780,49475,"7-Methoxy-2,3-dimethyl-8-(methylaminomethyl)chromen-4-one",CC1=C(OC2=C(C1=O)C=CC(=C2CNC)OC)C,,,,,,
14781,49476,"4H-1-Benzopyran-4-one, 7-methoxy-2,3-dimethyl-8-(1-piperidinylmethyl)-, hydrochloride",CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCCCC3)OC)C.[Cl-],,,,,,
14782,49477,"7-Methoxy-2,3-dimethyl-8-(piperidin-1-ylmethyl)chromen-4-one",CC1=C(OC2=C(C1=O)C=CC(=C2CN3CCCCC3)OC)C,,,,,,
14783,49478,CID 49478,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]C3=CC=CC=C3)C.[Cl-],,,,,,
14784,49479,CID 49479,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CNC3=CC=CC=C3)C,,,,,,
14785,49480,CID 49480,CCC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH2+]C)O)C.[Cl-],,,,,,
14786,49481,CID 49481,CCC1=C(C(=C2C=CC(=O)C(=C2O1)CNC)O)C,,,,,,
14787,49482,CID 49482,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]C)C.[Cl-],,,,,,
14788,49483,CID 49483,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CNC)C,,,,,,
14789,49484,CID 49484,CCC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH+]3CCOCC3)O)C.[Cl-],,,,,,
14790,49485,CID 49485,CCC1=C(C(=C2C=CC(=O)C(=C2O1)CN3CCOCC3)O)C,,,,,,
14791,49486,CID 49486,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCOCC3)C.[Cl-],,,,,,
14792,49487,CID 49487,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCOCC3)C,,,,,,
14793,49488,CID 49488,CCC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH+]3CCCCC3)O)C.[Cl-],,,,,,
14794,49489,CID 49489,CCC1=C(C(=C2C=CC(=O)C(=C2O1)CN3CCCCC3)O)C,,,,,,
14795,49490,CID 49490,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCCCC3)C.[Cl-],,,,,,
14796,49491,CID 49491,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCCCC3)C,,,,,,
14797,49492,2-Ethyl-7-hydroxy-8-morpholinomethylchromone hydrochloride,CCC1=CC(=O)C2=C(O1)C(=C(C=C2)O)C[NH+]3CCOCC3.[Cl-],,,,,,
14798,49493,2-Ethyl-7-hydroxy-8-(morpholin-4-ylmethyl)chromen-4-one,CCC1=CC(=O)C2=C(O1)C(=C(C=C2)O)CN3CCOCC3,,,,,,
14799,49494,2-Ethyl-7-hydroxy-8-piperidinomethylchromone hydrochloride,CCC1=CC(=O)C2=C(O1)C(=C(C=C2)O)C[NH+]3CCCCC3.[Cl-],,,,,,
14800,49495,2-Ethyl-7-hydroxy-8-(piperidin-1-ylmethyl)chromen-4-one,CCC1=CC(=O)C2=C(O1)C(=C(C=C2)O)CN3CCCCC3,,,,,,
14801,49496,"4H-1-Benzopyran-4-one, 2-ethyl-7-methoxy-3-methyl-8-(4-morpholinylmethyl)-, hydrochloride",CCC1=C(C(=O)C2=C(O1)C(=C(C=C2)OC)C[NH+]3CCOCC3)C.[Cl-],,,,,,
14802,49497,2-Ethyl-7-methoxy-3-methyl-8-(morpholin-4-ylmethyl)chromen-4-one,CCC1=C(C(=O)C2=C(O1)C(=C(C=C2)OC)CN3CCOCC3)C,,,,,,
14803,49498,"4H-1-Benzopyran-4-one, 3-ethyl-7-methoxy-2-methyl-8-(4-morpholinylmethyl)-, hydrochloride",CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCOCC3)OC)C.[Cl-],,,,,,
14804,49499,3-Ethyl-7-methoxy-2-methyl-8-(morpholin-4-ylmethyl)chromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CN3CCOCC3)OC)C,,,,,,
14805,49500,"4H-1-Benzopyran-4-one, 3-ethyl-7-methoxy-2-methyl-8-(1-piperidinylmethyl)-, hydrochloride",CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCCCC3)OC)C.[Cl-],,,,,,
14806,49501,3-Ethyl-7-methoxy-2-methyl-8-(piperidin-1-ylmethyl)chromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CN3CCCCC3)OC)C,,,,,,
14807,49502,CID 49502,CC1=COC2=C(C(=O)C=CC2=C1O)C[NH+]3CCOCC3.[Cl-],,,,,,
14808,49503,CID 49503,CC1=COC2=C(C(=O)C=CC2=C1O)CN3CCOCC3,,,,,,
14809,49504,7-Hydroxy-2-methyl-8-piperidinomethylchromone hydrochloride,CC1=CC(=O)C2=C(O1)C(=C(C=C2)O)C[NH+]3CCCCC3.[Cl-],,,,,,
14810,49505,7-Hydroxy-2-methyl-8-(piperidin-1-ylmethyl)chromen-4-one,CC1=CC(=O)C2=C(O1)C(=C(C=C2)O)CN3CCCCC3,,,,,,
14811,49506,CID 49506,CC1=COC2=C(C(=O)C=CC2=C1O)C[NH+]3CCCCC3.[Cl-],,,,,,
14812,49507,CID 49507,CC1=COC2=C(C(=O)C=CC2=C1O)CN3CCCCC3,,,,,,
14813,49508,"Carbamic acid, 3,4,5-trimethoxybenzyl ester",COC1=CC(=CC(=C1OC)OC)COC(=O)N,,,,,,
14814,49509,"CARBANILIC ACID, 2-(sec-BUTYLAMINO)ETHYL ESTER, HYDROCHLORIDE",CCC(C)[NH2+]CCOC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
14815,49510,2-(butan-2-ylamino)ethyl N-phenylcarbamate,CCC(C)NCCOC(=O)NC1=CC=CC=C1,,,,,,
14816,49511,"(2-Cyclohexylamino-1,1-dimethylethyl)carbanilate hydrochloride",CC(C)(C[NH2+]C1CCCCC1)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
14817,49512,[1-(cyclohexylamino)-2-methylpropan-2-yl] N-phenylcarbamate,CC(C)(CNC1CCCCC1)OC(=O)NC2=CC=CC=C2,,,,,,
14818,49513,"Carbanilic acid, 2-(cyclohexylamino)ethyl ester, hydrochloride",C1CCC(CC1)[NH2+]CCOC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
14819,49514,2-(cyclohexylamino)ethyl N-phenylcarbamate,C1CCC(CC1)NCCOC(=O)NC2=CC=CC=C2,,,,,,
14820,49515,1-Cyclohexylamino-2-propanol phenylurethan hydrochloride,C1CCC(CC1)[NH2+]CCCOC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
14821,49516,3-(cyclohexylamino)propyl N-phenylcarbamate,C1CCC(CC1)NCCCOC(=O)NC2=CC=CC=C2,,,,,,
14822,49517,"Carbanilic acid, diester with 2,2'-((2-butoxy-3-methoxyphenethyl)nitrilo)diethanol, hydrochloride",CCCCOC1=C(C=CC=C1OC)CC[NH+](CCOC(=O)NC2=CC=CC=C2)CCOC(=O)NC3=CC=CC=C3.[Cl-],,,,,,
14823,49518,2-[2-(2-butoxy-3-methoxyphenyl)ethyl-[2-(phenylcarbamoyloxy)ethyl]amino]ethyl N-phenylcarbamate,CCCCOC1=C(C=CC=C1OC)CCN(CCOC(=O)NC2=CC=CC=C2)CCOC(=O)NC3=CC=CC=C3,,,,,,
14824,49519,"Carbanilic acid, (4-(dimethylamino)-2,2-diphenyl-1-ethyl)pentyl ester, hydrochloride, hydrate",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)NC3=CC=CC=C3.[Cl-],,,,,,
14825,49520,"[6-(dimethylamino)-4,4-diphenylheptan-3-yl] N-phenylcarbamate",CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)NC3=CC=CC=C3,,,,,,
14826,49521,alpha-Methyl-alpha-dimethylaminomethyl-gamma-phenylpropyl carbanilate hydrochloride,CC(CCC1=CC=CC=C1)(C[NH+](C)C)OC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
14827,49522,alpha-Methyl-alpha-dimethylaminomethyl-phenylpropyl carbanilate,CC(CCC1=CC=CC=C1)(CN(C)C)OC(=O)NC2=CC=CC=C2,,,,,,
14828,49523,"Carbanilic acid, 2-((1-methylbutyl)amino)ethyl ester, hydrochloride",CCCC(C)[NH2+]CCOC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
14829,49524,2-(pentan-2-ylamino)ethyl N-phenylcarbamate,CCCC(C)NCCOC(=O)NC1=CC=CC=C1,,,,,,
14830,49525,"Carbanilic acid, 2-((1-methylheptyl)amino)ethyl ester, hydrochloride",CCCCCCC(C)[NH2+]CCOC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
14831,49526,2-(octan-2-ylamino)ethyl N-phenylcarbamate,CCCCCCC(C)NCCOC(=O)NC1=CC=CC=C1,,,,,,
14832,49527,3-(2-Methylpiperidino)propyl carbanilate hydrochloride,CC1CCCC[NH+]1CCCOC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
14833,49528,beta-2-Piperidylethylphenylurethane hydrochloride,C1CC[NH2+]C(C1)CCOC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
14834,49529,2-piperidin-2-ylethyl N-phenylcarbamate,C1CCNC(C1)CCOC(=O)NC2=CC=CC=C2,,,,,,
14835,49530,7-Chloro-9-(1-methyl-2-piperidyl)methylcarbazole,CN1CCCCC1CN2C3=CC=CC=C3C4=C2C=C(C=C4)Cl,,,,,,
14836,49531,"9-(1,5-Dimethyl-2-piperidyl)methylcarbazole",CC1CCC(N(C1)C)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14837,49532,"9-(1,6-Dimethyl-2-piperidyl)methylcarbazole",CC1CCCC(N1C)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14838,49533,9-(1-Ethyl-3-piperidyl)methylcarbazole,CCN1CCCC(C1)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14839,49534,"Carbazole, 9-(1-ethyl-4-piperidyl)methyl-",CCN1CCC(CC1)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14840,49535,7-Methoxy-9-(1-methyl-3-piperidyl)carbazole,CN1CCCC(C1)N2C3=CC=CC=C3C4=C2C=C(C=C4)OC,,,,,,
14841,49536,6-Methoxy-9-(1-methyl-2-piperidyl)methylcarbazole,CN1CCCCC1CN2C3=C(C=C(C=C3)OC)C4=CC=CC=C42,,,,,,
14842,49537,7-Methoxy-9-(1-methyl-3-piperidyl)methylcarbazole,CN1CCCC(C1)CN2C3=CC=CC=C3C4=C2C=C(C=C4)OC,,,,,,
14843,49538,"Carbazole, 7-methoxy-9-(1-methyl-4-piperidyl)methyl-",CN1CCC(CC1)CN2C3=CC=CC=C3C4=C2C=C(C=C4)OC,,,,,,
14844,49539,6-Methyl-9-(1-methyl-2-piperidyl)methylcarbazole,CC1=CC2=C(C=C1)N(C3=CC=CC=C32)CC4CCCCN4C,,,,,,
14845,49540,"Carbazole, 9-(1-methyl-4-piperidyl)-",CN1CCC(CC1)N2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14846,49541,9-(1-Methyl-3-piperidyl)carbazole,CN1CCCC(C1)N2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14847,49542,"Carbazole, 9-(2-(1-methyl-4-piperidyl)ethyl)-",CN1CCC(CC1)CCN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14848,49543,"Carbazole, 9-(2-piperidinoethyl)-",C1CCN(CC1)CCN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14849,49544,9-(1-Propyl-3-piperidyl)methylcarbazole,CCCN1CCCC(C1)CN2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
14850,49545,"N,N-Dimethyl-3,3-diphenyl-4-(ethoxyformyloxy)-1-methylhexylamine hydrochloride",CCC(C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)OCC.[Cl-],,,,,,
14851,49546,"[6-(Dimethylamino)-4,4-diphenylheptan-3-yl] ethyl carbonate",CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)OCC,,,,,,
14852,49547,"3-(2-Benzoylethyl)-8-propionyl-3,8-diazabicyclo(3.2.1)octane hydrochloride",CCC(=O)N1C2CCC1C[NH+](C2)CCC(=O)C3=CC=CC=C3.[Cl-],,,,,,
14853,49548,"Methyl 3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate",CN1CC2CCC(C1)N2C(=O)OC,,,,,,
14854,49549,"5H-DIBENZO(a,d)CYCLOHEPTENE, 10-11-DIHYDRO-5-(3-ACETYLUREYLENE)-",CC(=O)NC(=O)NC1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
14855,49550,"2-Diethylaminoethyl 5-hydroxydibenzo(a,d)cycloheptadiene-5-carboxylate hydrochloride",CC[NH+](CC)CCOC(=O)C1(C2=CC=CC=C2CCC3=CC=CC=C31)O.[Cl-],,,,,,
14856,49551,"2-(Diethylamino)ethyl 2-hydroxytricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxylate",CCN(CC)CCOC(=O)C1(C2=CC=CC=C2CCC3=CC=CC=C31)O,,,,,,
14857,49552,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-cyano-5-(3-(1-methyl-4-piperazinyl)propyl)-",CN1CCN(CC1)CCCC2(C3=CC=CC=C3CCC4=CC=CC=C42)C#N,,,,,,
14858,49553,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-cyano-5-(1-methyl-3-pyrrolidinyl)methyl-, hydrochloride",C[NH+]1CCC(C1)CC2(C3=CC=CC=C3CCC4=CC=CC=C42)C#N.[Cl-],,,,,,
14859,49554,"2-[(1-Methylpyrrolidin-3-yl)methyl]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carbonitrile",CN1CCC(C1)CC2(C3=CC=CC=C3CCC4=CC=CC=C42)C#N,,,,,,
14860,49555,"5H-DIBENZO(a,d)CYCLOHEPTENE, 10,11-DIHYDRO-5-(2-(4-METHYLPIPERAZINYL)ETHYL)-",CN1CCN(CC1)CCC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
14861,49556,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(2-(4-methylpiperazinyl)ethylidene)-",CN1CCN(CC1)CC=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
14862,49557,"10,11-Dihydro-5-(3-(2-methylpiperidino)propylidene)-5H-dibenzo(a,d)cycloheptene",CC1CCCCN1CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
14863,49558,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(2-(1-methyl-2-piperidyl)ethylidene)-, hydrogen sulfate",C[NH+]1CCCCC1CC=C2C3=CC=CC=C3CCC4=CC=CC=C42.OS(=O)(=O)[O-],,,,,,
14864,49559,"1-Methyl-2-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]piperidine",CN1CCCCC1CC=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
14865,49560,Sodium tetra(4-sulfophenyl)porphinatocopper,C1=CC(=CC=C1C2=C3C=CC(=C(C4=NC(=C(C5=CC=C([N-]5)C(=C6C=CC2=N6)C7=CC=C(C=C7)S(=O)(=O)[O-])C8=CC=C(C=C8)S(=O)(=O)[O-])C=C4)C9=CC=C(C=C9)S(=O)(=O)[O-])[N-]3)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Cu+2],,,,,,
14866,49561,T4SPP;TSPP;Tetraphenylporphine sulfonate,C1=CC(=CC=C1C2=C3C=CC(=C(C4=CC=C(N4)C(=C5C=CC(=N5)C(=C6C=CC2=N6)C7=CC=C(C=C7)S(=O)(=O)O)C8=CC=C(C=C8)S(=O)(=O)O)C9=CC=C(C=C9)S(=O)(=O)O)N3)S(=O)(=O)O,,,,,,
14867,49562,CID 49562,CC(=O)OC1=CC=C(C=C1)C(=CC2=CC=CC=C2)C(=O)OC3CC4CCC(C3)[NH+]4C.[Cl-],,,,,,
14868,49563,CID 49563,CC(=O)OC1=CC=C(C=C1)C(=CC2=CC=CC=C2)C(=O)OC3CC4CCC(C3)N4C,,,,,,
14869,49564,CID 49564,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OC.[Cl-],,,,,,
14870,49565,CID 49565,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OC,,,,,,
14871,49566,CID 49566,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)OC)C4=CC=C(C=C4)Cl.[Cl-],,,,,,
14872,49567,CID 49567,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)OC)C4=CC=C(C=C4)Cl,,,,,,
14873,49568,CID 49568,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)Cl.[Cl-],,,,,,
14874,49569,CID 49569,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
14875,49570,CID 49570,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=C(C=C4)OC)OC.C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)O)C(=O)[O-],,,,,,
14876,49571,CID 49571,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=C(C=C4)OC)OC,,,,,,
14877,49572,[2-(Dimethylamino)-1-phenylethyl] 3-phenylprop-2-enoate,CN(C)CC(C1=CC=CC=C1)OC(=O)C=CC2=CC=CC=C2,,,,,,
14878,49573,CID 49573,CC(C)(C[NH+]1CCOCC1)COC(=O)C=CC2=CC=CC=C2.[Cl-],,,,,,
14879,49574,CID 49574,CC(C)(CN1CCOCC1)COC(=O)C=CC2=CC=CC=C2,,,,,,
14880,49575,CID 49575,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=CC=C4)O,,,,,,
14881,49576,CID 49576,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)O,,,,,,
14882,49577,CID 49577,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC.[Cl-],,,,,,
14883,49578,CID 49578,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC,,,,,,
14884,49579,CID 49579,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=CC=C4)OC.[Cl-],,,,,,
14885,49580,CID 49580,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=CC=C4)OC,,,,,,
14886,49581,CID 49581,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=CC=C4OC.[Cl-],,,,,,
14887,49582,CID 49582,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=CC=C4OC,,,,,,
14888,49583,CID 49583,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)OC.[Cl-],,,,,,
14889,49584,CID 49584,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)OC,,,,,,
14890,49585,CID 49585,C1COCC[NH+]1CCOC(=O)C=CC2=CC=CC=C2.[Cl-],,,,,,
14891,49586,2-Morpholin-4-ylethyl 3-phenylprop-2-enoate,C1COCCN1CCOC(=O)C=CC2=CC=CC=C2,,,,,,
14892,49587,CID 49587,C[NH+]1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)C(F)(F)F.[Cl-],,,,,,
14893,49588,CID 49588,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC=C(C=C4)C(F)(F)F,,,,,,
14894,49589,CID 49589,CN1C2CCC1CC(C2)OC(=O)C(=CC3=CC=CC=C3)C4=CC(=C(C(=C4)OC)OC)OC,,,,,,
14895,49590,CID 49590,CC(N1CCN(CC1)CC=C(C)CCC=C(C)CCC=C(C)C)OC(=O)C=CC2=CC=CC=C2,,,,,,
14896,49591,6-Bromo-3-(4-pyridyl)coumarin,C1=CC2=C(C=C1Br)C=C(C(=O)O2)C3=CC=NC=C3,,,,,,
14897,49592,Diethyl-4-methyl-7-coumarinylammonium hydrogen sulfate,CC[NH+](CC)C1=CC2=C(C=C1)C(=CC(=O)O2)C.OS(=O)(=O)[O-],,,,,,
14898,49593,"Coumarin, 5,7-dihydroxy-3-(3-pyridyl)-, diacetate",CC(=O)OC1=CC2=C(C=C(C(=O)O2)C3=CN=CC=C3)C(=C1)OC(=O)C,,,,,,
14899,49594,CID 49594,CC1=C2C=CC(=O)C=C2OC(=C1C3=C[NH+]=CC=C3)O.[Cl-],,,,,,
14900,49595,CID 49595,CC1=C2C=CC(=O)C=C2OC(=C1C3=CN=CC=C3)O,,,,,,
14901,49596,CID 49596,C1=CC=C(C=C1)C2=C3C=CC(=O)C=C3OC(=C2C4=CN=CC=C4)O,,,,,,
14902,49597,7-Hydroxy-2-methyl-8-morpholinomethylchromone hydrochloride,CC1=CC(=O)C2=C(O1)C(=C(C=C2)O)C[NH+]3CCOCC3.[Cl-],,,,,,
14903,49598,7-Hydroxy-2-methyl-8-(morpholin-4-ylmethyl)chromen-4-one,CC1=CC(=O)C2=C(O1)C(=C(C=C2)O)CN3CCOCC3,,,,,,
14904,49599,"5H-DIBENZO(a,d)CYCLOHEPTENE, 10,11-DIHYDRO-5-(2-(1-METHYL-2-PIPERIDYL)ETHYL)-",CN1CCCCC1CCC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
14905,49600,"9-[3-(Dimethylamino)propyl]tricyclo[10.4.0.03,8]hexadeca-1(12),3,5,7,10,13-hexaen-9-ol",CN(C)CCCC1(C=CC2=C(CCC=C2)CC3=CC=CC=C31)O,,,,,,
14906,49601,CID 49601,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCOCC3)CC.[Cl-],,,,,,
14907,49602,CID 49602,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCOCC3)CC,,,,,,
14908,49603,"9-(2-Carboxyethyl)-6-(diethylamino)-N,N-dimethyl-3H-xanthen-3-iminium chloride",CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](C)C)C=C3O2)CCC(=O)O.[Cl-],,,,,,
14909,49604,[9-(2-Carboxyethyl)-6-(diethylamino)xanthen-3-ylidene]-dimethylazanium,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](C)C)C=C3O2)CCC(=O)O,,,,,,
14910,49605,"1,2-Diphenyl-3-(2-(2,6-xylyloxy)ethyl)guanidine",CC1=C(C(=CC=C1)C)OCCN=C(NC2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
14911,49606,"Guanidine, (2-(N-ethyl-2,6-xylidino)ethyl)-",CCN(CCN=C(N)N)C1=C(C=CC=C1C)C,,,,,,
14912,49607,"GUANIDINE, (2-(p-METHOXYPHENOXY)ETHYL)-",COC1=CC=C(C=C1)OCCN=C(N)N,,,,,,
14913,49608,"Guanidine, (2-(N-methylcycloheptylamino)ethyl)-",CN(CCN=C(N)N)C1CCCCCC1,,,,,,
14914,49609,"Guanidine, (2-(N-methylcyclooctylamino)ethyl)-",CN(CCN=C(N)N)C1CCCCCCC1,,,,,,
14915,49610,"Guanidine, (2-(2,6-xylidino)ethyl)-",CC1=C(C(=CC=C1)C)NCCN=C(N)N,,,,,,
14916,49611,"Guanidine, (4-(2,6-xylyloxy)butyl)-",CC1=C(C(=CC=C1)C)OCCCCN=C(N)N,,,,,,
14917,49612,"Guanidine, (3-(2,6-xylyloxy)propyl)-",CC1=C(C(=CC=C1)C)OCCCN=C(N)N,,,,,,
14918,49613,beta-Heptoyloxy-beta-phenylethyl dimethylamine,CCCCCCC(=O)OC(CN(C)C)C1=CC=CC=C1,,,,,,
14919,49614,4-Cyclohexyl-6-(dimethylamino)-4-phenyl-3-heptanol,CCC(C(CC(C)N(C)C)(C1CCCCC1)C2=CC=CC=C2)O,,,,,,
14920,49615,"7-(Dimethylamino)-4,4-diphenyl-3-heptanol hydrochloride",CCC(C(CCC[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)O.[Cl-],,,,,,
14921,49616,"7-(Dimethylamino)-4,4-diphenylheptan-3-ol",CCC(C(CCCN(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)O,,,,,,
14922,49617,Diethyl-[3-(2-phenylhexanoyloxy)propyl]azanium;chloride,CCCCC(C1=CC=CC=C1)C(=O)OCCC[NH+](CC)CC.[Cl-],,,,,,
14923,49618,3-(Diethylamino)propyl 2-phenylhexanoate,CCCCC(C1=CC=CC=C1)C(=O)OCCCN(CC)CC,,,,,,
14924,49619,"4,4-Diphenyl-6-morpholino-3-hexanol nitrate",CCC(C(CC[NH+]1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3)O.[N+](=O)([O-])[O-],,,,,,
14925,49620,"5-(Dimethylamino)-3,3-diphenyl-2-hexanone hydrobromide",CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)C)[NH+](C)C.[Br-],,,,,,
14926,49621,"5-(Dimethylamino)-3,3-diphenyl-2-hexanone",CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)C)N(C)C,,,,,,
14927,49622,1-Dimethylamino-3-phenyl-4-hexanone,CCC(=O)C(CCN(C)C)C1=CC=CC=C1,,,,,,
14928,49623,"4,4-Diphenyl-5-methyl-6-morpholino-3-hexanone hydrochloride",CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+]3CCOCC3.[Cl-],,,,,,
14929,49624,NoName_4082,CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN3CCOCC3,,,,,,
14930,49625,"3-Hexanone, 4,4-diphenyl-6-piperidino-, nitrate",CCC(=O)C(CC[NH+]1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3.[N+](=O)([O-])[O-],,,,,,
14931,49626,N-methylhept-5-en-2-amine,CC=CCCC(C)NC,,,,,,
14932,49627,"N,1,2,5-Tetramethyl-4-hexenylamine",CC(CC=C(C)C)C(C)NC,,,,,,
14933,49628,"Hexylamine, N-(2-chloroethyl)-N-ethyl-, hydrochloride",CCCCCC[NH+](CC)CCCl.[Cl-],,,,,,
14934,49629,N-(2-chloroethyl)-N-ethylhexan-1-amine,CCCCCCN(CC)CCCl,,,,,,
14935,49630,9-Cyclohexylfluorene-9-carboxylic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1(C2=CC=CC=C2C3=CC=CC=C31)C4CCCCC4.[Cl-],,,,,,
14936,49631,2-(Diethylamino)ethyl 9-cyclohexylfluorene-9-carboxylate,CCN(CC)CCOC(=O)C1(C2=CC=CC=C2C3=CC=CC=C31)C4CCCCC4,,,,,,
14937,49632,"Fluorene-9-carboxylic acid, 1-methyl-2-(1-methyl-2-piperidyl)ethyl ester, hydrochloride",CC(CC1CCCC[NH+]1C)OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24.[Cl-],,,,,,
14938,49633,1-(1-methylpiperidin-2-yl)propan-2-yl 9H-fluorene-9-carboxylate,CC(CC1CCCCN1C)OC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
14939,49634,"Fluorene-9-carboxylic acid, 2-(1-methyl-2-piperidyl)ethyl ester, hydrochloride",C[NH+]1CCCCC1CCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24.[Cl-],,,,,,
14940,49635,2-(1-methylpiperidin-2-yl)ethyl 9H-fluorene-9-carboxylate,CN1CCCCC1CCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
14941,49636,"Fluorene-9-carboxylic acid, 2-(1-methyl-4-piperidyl)ethyl ester, hydrochloride",C[NH+]1CCC(CC1)CCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24.[Cl-],,,,,,
14942,49637,2-(1-methylpiperidin-4-yl)ethyl 9H-fluorene-9-carboxylate,CN1CCC(CC1)CCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
14943,49638,"Fluorene-9-carboxylic acid, 3-(1-methyl-4-piperidyl)propyl ester, hydrochloride",C[NH+]1CCC(CC1)CCCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24.[Cl-],,,,,,
14944,49639,3-(1-methylpiperidin-4-yl)propyl 9H-fluorene-9-carboxylate,CN1CCC(CC1)CCCOC(=O)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
14945,49640,"Fluorene-9-carboxylic acid, 2-(4-pyridyl)ethyl ester, hydrochloride",C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)OCCC4=CC=[NH+]C=C4.[Cl-],,,,,,
14946,49641,2-pyridin-4-ylethyl 9H-fluorene-9-carboxylate,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)OCCC4=CC=NC=C4,,,,,,
14947,49642,"Fluorene-9-carboxylic acid, 3-(2-pyridyl)propyl ester, hydrochloride",C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)OCCCC4=CC=CC=[NH+]4.[Cl-],,,,,,
14948,49643,3-pyridin-2-ylpropyl 9H-fluorene-9-carboxylate,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)OCCCC4=CC=CC=N4,,,,,,
14949,49644,"Fluorene-9-carboxylic acid, 3-(4-pyridyl)propyl ester, hydrochloride",C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)OCCCC4=CC=[NH+]C=C4.[Cl-],,,,,,
14950,49645,3-pyridin-4-ylpropyl 9H-fluorene-9-carboxylate,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)OCCCC4=CC=NC=C4,,,,,,
14951,49646,Furfuryl-bis(2-chloroethyl)amine hydrochloride,C1=COC(=C1)C[NH+](CCCl)CCCl.[Cl-],,,,,,
14952,49647,2-chloro-N-(2-chloroethyl)-N-(furan-2-ylmethyl)ethanamine,C1=COC(=C1)CN(CCCl)CCCl,,,,,,
14953,49648,Tetrahydrofurfuryl-bis(2-chloroethyl)amine hydrochloride,C1CC(OC1)C[NH+](CCCl)CCCl.[Cl-],,,,,,
14954,49649,"Glycin, N-(3-acetamido-5-carbamoyl-2,4,6-triiodobenzoyl)-",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)NCC(=O)O)I)C(=O)N)I,,,,,,
14955,49650,"Glycin, N-(3-acetamido-5-methylcarbamoyl-2,4,6-triiodobenzoyl)-",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)NCC(=O)O)I)C(=O)NC)I,,,,,,
14956,49651,"Glycine, N-(3-hydroxyacetamido-5-methylcarbamoyl-2,4,6-triiodobenzoyl)-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CO)I)C(=O)NCC(=O)O)I,,,,,,
14957,49652,"Glycine, N-(3-methoxyacetamido-5-methylcarbamoyl-2,4,6-triiodobenzoyl)-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)COC)I)C(=O)NCC(=O)O)I,,,,,,
14958,49653,"Glycine, N-(3-methylcarbamoyl-5-propionamido-2,4,6-triiodobenzoyl)-",CCC(=O)NC1=C(C(=C(C(=C1I)C(=O)NCC(=O)O)I)C(=O)NC)I,,,,,,
14959,49654,"GUANIDINE, (2-(p-CHLORO-2,6-XYLYLOXY)ETHYL)-",CC1=CC(=CC(=C1OCCN=C(N)N)C)Cl,,,,,,
14960,49655,CID 49655,CC(CNC1=CC=CC=C1)NN.CC(CNC1=CC=CC=C1)NN.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
14961,49656,N-(2-hydrazinylpropyl)aniline,CC(CNC1=CC=CC=C1)NN,,,,,,
14962,49657,(2-Phenylthioethyl)hydrazine hydrogen sulfate (2:1),C1=CC=C(C=C1)SCCN[NH3+].C1=CC=C(C=C1)SCCN[NH3+].[O-]S(=O)(=O)[O-],,,,,,
14963,49658,2-Phenylsulfanylethylhydrazine,C1=CC=C(C=C1)SCCNN,,,,,,
14964,49659,Fenoldopam mesylate,CS(=O)(=O)O.C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
14965,49660,"Ether, 4-chlorophenyl (4'-chloro-2'-chloromethylaminophenyl)",C1=CC(=CC=C1OC2=C(C=C(C=C2)Cl)NCCl)Cl,,,,,,
14966,49661,N-Allyl-2-(2-cyclopentenyl)-1-methylethylamine,CC(CC1CCC=C1)NCC=C,,,,,,
14967,49662,"Ethylamine, 2-(2-cyclopentenyl)-N,1-dimethyl-",CC(CC1CCC=C1)NC,,,,,,
14968,49663,2-(2-Cyclopentenyl)-1-methylethylamine,CC(CC1CCC=C1)N,,,,,,
14969,49664,"Ethylamine, 2-(2-cyclopentenyl)-N,N,1-trimethyl-",CC(CC1CCC=C1)N(C)C,,,,,,
14970,49665,8-(Benzylaminomethyl)-3-ethyl-7-methoxyflavone hydrochloride,CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH2+]CC3=CC=CC=C3)OC)C4=CC=CC=C4.[Cl-],,,,,,
14971,49666,8-[(Benzylamino)methyl]-3-ethyl-7-methoxy-2-phenylchromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CNCC3=CC=CC=C3)OC)C4=CC=CC=C4,,,,,,
14972,49667,CID 49667,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](CC)CC)C3=CC=CC=C3.[Cl-],,,,,,
14973,49668,CID 49668,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN(CC)CC)C3=CC=CC=C3,,,,,,
14974,49669,8-(Diethylaminomethyl)-3-ethyl-7-methoxyflavone hydrochloride,CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+](CC)CC)OC)C3=CC=CC=C3.[Cl-],,,,,,
14975,49670,8-(Diethylaminomethyl)-3-ethyl-7-methoxy-2-phenylchromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CN(CC)CC)OC)C3=CC=CC=C3,,,,,,
14976,49671,CID 49671,CC[NH+](CC)CC1=C2C(=C(C(=C(O2)C3=CC=CC=C3)C)O)C=CC1=O.[Cl-],,,,,,
14977,49672,CID 49672,CCN(CC)CC1=C2C(=C(C(=C(O2)C3=CC=CC=C3)C)O)C=CC1=O,,,,,,
14978,49673,3'-(Diethylaminomethyl)-4'-methoxy-3-methylflavone hydrochloride,CC[NH+](CC)CC1=C2C(=CC=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)C.[Cl-],,,,,,
14979,49674,8-(Diethylaminomethyl)-2-(4-methoxyphenyl)-3-methylchromen-4-one,CCN(CC)CC1=C2C(=CC=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)C,,,,,,
14980,49675,8-(Diethylaminomethyl)-7-methoxy-3-methylflavone hydrochloride,CC[NH+](CC)CC1=C(C=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3)OC.[Cl-],,,,,,
14981,49676,"Flavone, 8-((diethylamino)methyl)-7-methoxy-3-methyl-",CCN(CC)CC1=C(C=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3)OC,,,,,,
14982,49677,CID 49677,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
14983,49678,CID 49678,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN(C)C)C3=CC=CC=C3,,,,,,
14984,49679,8-(Dimethylamino)methyl-7-hydroxyflavone hydrochloride,C[NH+](C)CC1=C(C=CC2=C1OC(=CC2=O)C3=CC=CC=C3)O.[Cl-],,,,,,
14985,49680,"4H-1-Benzopyran-4-one, 8-[(dimethylamino)methyl]-7-hydroxy-2-phenyl-",CN(C)CC1=C(C=CC2=C1OC(=CC2=O)C3=CC=CC=C3)O,,,,,,
14986,49681,8-(Dimethylaminomethyl)-7-isopropoxy-3-methylflavone hydrochloride,CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+](C)C)OC(C)C)C3=CC=CC=C3.[Cl-],,,,,,
14987,49682,8-[(Dimethylamino)methyl]-3-methyl-2-phenyl-7-propan-2-yloxychromen-4-one,CC1=C(OC2=C(C1=O)C=CC(=C2CN(C)C)OC(C)C)C3=CC=CC=C3,,,,,,
14988,49683,CID 49683,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]CC)C3=CC=CC=C3.[Cl-],,,,,,
14989,49684,CID 49684,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CNCC)C3=CC=CC=C3,,,,,,
14990,49685,3-Ethyl-8-(ethylaminoethyl)-7-methoxyflavone hydrochloride,CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH2+]CC)OC)C3=CC=CC=C3.[Cl-],,,,,,
14991,49686,3-Ethyl-8-(ethylaminomethyl)-7-methoxy-2-phenylchromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CNCC)OC)C3=CC=CC=C3,,,,,,
14992,49687,CID 49687,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]C)C3=CC=CC=C3.[Cl-],,,,,,
14993,49688,CID 49688,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CNC)C3=CC=CC=C3,,,,,,
14994,49689,CID 49689,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCOCC3)C4=CC=CC=C4.[Cl-],,,,,,
14995,49690,CID 49690,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCOCC3)C4=CC=CC=C4,,,,,,
14996,49691,3-Ethyl-7-methoxy-8-(morpholinomethyl)flavone hydrochloride,CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCOCC3)OC)C4=CC=CC=C4.[Cl-],,,,,,
14997,49692,3-Ethyl-7-methoxy-8-(morpholin-4-ylmethyl)-2-phenylchromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CN3CCOCC3)OC)C4=CC=CC=C4,,,,,,
14998,49693,CID 49693,CC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH2+]C)C3=CC=CC=C3.[Cl-],,,,,,
14999,49694,CID 49694,CC1=C(OC2=C(C(=O)C=CC2=C1O)CNC)C3=CC=CC=C3,,,,,,
15000,49695,7-Methoxy-3-methyl-8-(methylaminomethyl)flavone hydrochloride,CC1=C(OC2=C(C1=O)C=CC(=C2C[NH2+]C)OC)C3=CC=CC=C3.[Cl-],,,,,,
15001,49696,7-Methoxy-3-methyl-8-(methylaminomethyl)-2-phenylchromen-4-one,CC1=C(OC2=C(C1=O)C=CC(=C2CNC)OC)C3=CC=CC=C3,,,,,,
15002,49697,4'-Methoxy-3-methyl-3'-(morpholinomethyl)flavone hydrochloride,CC1=C(OC2=CC=CC=C2C1=O)C3=CC(=C(C=C3)OC)C[NH+]4CCOCC4.[Cl-],,,,,,
15003,49698,2-[4-Methoxy-3-(morpholin-4-ylmethyl)phenyl]-3-methylchromen-4-one,CC1=C(OC2=CC=CC=C2C1=O)C3=CC(=C(C=C3)OC)CN4CCOCC4,,,,,,
15004,49699,7-Methoxy-3-methyl-8-(morpholinomethyl)flavone hydrochloride,CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCOCC3)OC)C4=CC=CC=C4.[Cl-],,,,,,
15005,49700,"Flavone, 7-methoxy-3-methyl-8-(morpholinomethyl)-",CC1=C(OC2=C(C1=O)C=CC(=C2CN3CCOCC3)OC)C4=CC=CC=C4,,,,,,
15006,49701,7-Hydroxy-8-morpholinomethylflavone hydrochloride,C1COCC[NH+]1CC2=C(C=CC3=C2OC(=CC3=O)C4=CC=CC=C4)O.[Cl-],,,,,,
15007,49702,7-Hydroxy-8-(morpholin-4-ylmethyl)-2-phenylchromen-4-one,C1COCCN1CC2=C(C=CC3=C2OC(=CC3=O)C4=CC=CC=C4)O,,,,,,
15008,49703,4'-Methoxy-3-methyl-3'-(piperidinomethyl)flavone hydrochloride,CC1=C(OC2=CC=CC=C2C1=O)C3=CC(=C(C=C3)OC)C[NH+]4CCCCC4.[Cl-],,,,,,
15009,49704,2-[4-Methoxy-3-(piperidin-1-ylmethyl)phenyl]-3-methylchromen-4-one,CC1=C(OC2=CC=CC=C2C1=O)C3=CC(=C(C=C3)OC)CN4CCCCC4,,,,,,
15010,49705,"6H-Cyclohepta(b)quinoline 7,8,9,10-tetrahydro-11-(4-methylhexahydro-1H-1,4-diazepin-1-yl)-, dioxalate, monohydrate",C[NH+]1CCC[NH+](CC1)C2=C3CCCCCC3=NC4=CC=CC=C42.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
15011,49706,"11-(4-methyl-1,4-diazepan-1-yl)-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline",CN1CCCN(CC1)C2=C3CCCCCC3=NC4=CC=CC=C42,,,,,,
15012,49707,1-Phenylcyclopropanecarbothioic acid S-(2-(diethylamino)ethyl) ester hydrochloride,CC[NH+](CC)CCSC(=O)C1(CC1)C2=CC=CC=C2.[Cl-],,,,,,
15013,49708,S-[2-(diethylamino)ethyl] 1-phenylcyclopropane-1-carbothioate,CCN(CC)CCSC(=O)C1(CC1)C2=CC=CC=C2,,,,,,
15014,49709,1-Phenylcyclopropanecarboxylic acid 2-(benzylamino)ethyl ester hydrochloride,C1CC1(C2=CC=CC=C2)C(=O)OCC[NH2+]CC3=CC=CC=C3.[Cl-],,,,,,
15015,49710,2-(Benzylamino)ethyl 1-phenylcyclopropane-1-carboxylate,C1CC1(C2=CC=CC=C2)C(=O)OCCNCC3=CC=CC=C3,,,,,,
15016,49711,1-Phenylcyclopropanecarboxylic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1(CC1)C2=CC=CC=C2.[Cl-],,,,,,
15017,49712,1-Phenylcyclopropanecarboxylic acid (2-(diethylamino)ethyl) ester,CCN(CC)CCOC(=O)C1(CC1)C2=CC=CC=C2,,,,,,
15018,49713,1-Phenylcyclopropanecarboxylic acid (3-morpholinopropyl) ester hydrochloride,C1CC1(C2=CC=CC=C2)C(=O)OCCC[NH+]3CCOCC3.[Cl-],,,,,,
15019,49714,3-Morpholin-4-ylpropyl 1-phenylcyclopropane-1-carboxylate,C1CC1(C2=CC=CC=C2)C(=O)OCCCN3CCOCC3,,,,,,
15020,49715,"5,9,10,14b-Tetrahydro-2-chloro-5-(hydroxymethyl)isoquino[2,1-d][1,4]benzodiazepin-6(7H)-one acetate",CC(=O)OCN1C(=O)CN2CCC3=CC=CC=C3C2C4=C1C=CC(=C4)Cl,,,,,,
15021,49716,"5,9,10,14b-Tetrahydro-5,10-dimethylisoquino[2,1-d][1,4]benzodiazepin-6(7H)-one",CC1CN2CC(=O)N(C3=CC=CC=C3C2C4=CC=CC=C14)C,,,,,,
15022,49717,"5-Methyl-6,7,9,10-tetrahydro-5H-isoquino(2,1-d)(1,4)benzodiazepin-6-one",CN1C(=O)CN2CCC3=CC=CC=C3C2C4=CC=CC=C41,,,,,,
15023,49718,"2-Ethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",CC[NH+]1CCC2=CC=CC=C2C1.[Cl-],,,,,,
15024,49719,"2-Ethyl-1,2,3,4-tetrahydroisoquinoline",CCN1CCC2=CC=CC=C2C1,,,,,,
15025,49720,"Isovalerophenone, 3',4'-dihydroxy-",CC(C)CC(=O)C1=CC(=C(C=C1)O)O,,,,,,
15026,49721,"ISOXAZOLO(5,4-d)PYRIMIDINE, 6-tert-BUTYL-3-ISOPROPYL-",CC(C)C1=NOC2=NC(=NC=C12)C(C)(C)C,,,,,,
15027,49722,"Cyclopentyl 3,4-dihydroxyphenyl ketone",C1CCC(C1)C(=O)C2=CC(=C(C=C2)O)O,,,,,,
15028,49723,"2-Propanol, 1-(4-cyclopropylcarbonylphenoxy)-3-(1,2-dihydro-2-imino-4-methylpyridino)-",CC1=CC(=N)N(C=C1)CC(COC2=CC=C(C=C2)C(=O)C3CC3)O,,,,,,
15029,49724,"1,2,3,4-Tetrahydro-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)CCCC3,,,,,,
15030,49725,"trans-8,9-Dihydro-benz(a)anthracene-8,9-diol",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C[C@@H]([C@H]4O)O)C=C32,,,,,,
15031,49726,2'-Ethyl-3-(2-methoxyethyl)aminobutyranilide hydrochloride,CCC1=CC=CC=C1NC(=O)CC(C)[NH2+]CCOC.[Cl-],,,,,,
15032,49727,N-(2-ethylphenyl)-3-(2-methoxyethylamino)butanamide,CCC1=CC=CC=C1NC(=O)CC(C)NCCOC,,,,,,
15033,49728,"Butyranilide, 2'-ethyl-3-(2-methoxyethyl)amino-3-methyl-, cyclohexane sulfamate",CCC1=CC=CC=C1NC(=O)CC(C)(C)[NH2+]CCOC.C1CCC(CC1)NS(=O)(=O)[O-],,,,,,
15034,49729,N-(2-ethylphenyl)-3-(2-methoxyethylamino)-3-methylbutanamide,CCC1=CC=CC=C1NC(=O)CC(C)(C)NCCOC,,,,,,
15035,49730,2'-Ethyl-4-(2-methoxyethyl)aminobutyranilide hydrochloride,CCC1=CC=CC=C1NC(=O)CCC[NH2+]CCOC.[Cl-],,,,,,
15036,49731,N-(2-ethylphenyl)-4-(2-methoxyethylamino)butanamide,CCC1=CC=CC=C1NC(=O)CCCNCCOC,,,,,,
15037,49732,"2',6'-Dimethyl-2-(2-ethoxyethylamino)-acetanilide",CCOCCNCC(=O)NC1=C(C=CC=C1C)C,,,,,,
15038,49733,CID 49733,CC1=C(C(=CC=C1)C)NC(=O)C[NH2+]CC(C)OC.[Cl-],,,,,,
15039,49734,"N-(2,6-dimethylphenyl)-2-(2-methoxypropylamino)acetamide",CC1=C(C(=CC=C1)C)NC(=O)CNCC(C)OC,,,,,,
15040,49735,7-Methoxy-3-methyl-8-(piperidinomethyl)flavone hydrochloride,CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCCCC3)OC)C4=CC=CC=C4.[Cl-],,,,,,
15041,49736,"Flavone, 7-methoxy-3-methyl-8-(piperidinomethyl)-",CC1=C(OC2=C(C1=O)C=CC(=C2CN3CCCCC3)OC)C4=CC=CC=C4,,,,,,
15042,49737,CID 49737,CC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCCCC3)C4=CC=CC=C4.[Cl-],,,,,,
15043,49738,CID 49738,CC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCCCC3)C4=CC=CC=C4,,,,,,
15044,49739,3-Ethyl-7-methoxy-8-(piperidinomethyl)flavone hydrochloride,CCC1=C(OC2=C(C1=O)C=CC(=C2C[NH+]3CCCCC3)OC)C4=CC=CC=C4.[Cl-],,,,,,
15045,49740,3-Ethyl-7-methoxy-2-phenyl-8-(piperidin-1-ylmethyl)chromen-4-one,CCC1=C(OC2=C(C1=O)C=CC(=C2CN3CCCCC3)OC)C4=CC=CC=C4,,,,,,
15046,49741,CID 49741,CCC1=C(OC2=C(C(=O)C=CC2=C1O)C[NH+]3CCCCC3)C4=CC=CC=C4.[Cl-],,,,,,
15047,49742,CID 49742,CCC1=C(OC2=C(C(=O)C=CC2=C1O)CN3CCCCC3)C4=CC=CC=C4,,,,,,
15048,49743,8-(Diethylamino)methyl-7-hydroxyflavone hydrochloride,CC[NH+](CC)CC1=C(C=CC2=C1OC(=CC2=O)C3=CC=CC=C3)O.[Cl-],,,,,,
15049,49744,8-Diethylaminomethyl-7-hydroxyflavone,CCN(CC)CC1=C(C=CC2=C1OC(=CC2=O)C3=CC=CC=C3)O,,,,,,
15050,49745,"ETHER, BIS(alpha-CHLORO-2-NITROBENZYL)",C1=CC=C(C(=C1)C(OC(C2=CC=CC=C2[N+](=O)[O-])Cl)Cl)[N+](=O)[O-],,,,,,
15051,49746,"1H-Benzimidazole, 2-(5-ethyl-2-pyridinyl)-",CCC1=CN=C(C=C1)C2=NC3=CC=CC=C3N2,,,,,,
15052,49747,"Benzimidazole, 2-(6-ethyl-2-pyridyl)-",CCC1=NC(=CC=C1)C2=NC3=CC=CC=C3N2,,,,,,
15053,49748,"Benzimidazole, 5-methyl-2-(6-methyl-2-pyridyl)-",CC1=CC2=C(C=C1)N=C(N2)C3=CC=CC(=N3)C,,,,,,
15054,49749,5-Methoxy-2-(6-methyl-2-pyridyl)benzimidazole,CC1=NC(=CC=C1)C2=NC3=C(N2)C=C(C=C3)OC,,,,,,
15055,49750,"Benzimidazole, 5-chloro-2-(6-methyl-2-pyridyl)-",CC1=NC(=CC=C1)C2=NC3=C(N2)C=C(C=C3)Cl,,,,,,
15056,49751,N-Acetyl-4-nitrophenylhydroxylamine,CC(=O)N(C1=CC=C(C=C1)[N+](=O)[O-])O,,,,,,
15057,49752,"1,3,4-Oxadiazole, 2-(isobutyrylamido)-5-phenyl-",CC(C)CC(=O)NC1=NN=C(O1)C2=CC=CC=C2,,,,,,
15058,49753,"2-(p-Aminophenyl)-5-imino-delta(sup 2)-1,3,4-oxadiazoline dihydrochloride",C1=CC(=CC=C1C2=N[NH2+]C(=[NH2+])O2)N.[Cl-].[Cl-],,,,,,
15059,49754,"5-(4-Aminophenyl)-1,3,4-oxadiazol-2-amine",C1=CC(=CC=C1C2=NN=C(O2)N)N,,,,,,
15060,49755,"N,N-Di-isopropyltryptamine hydrochloride",CC(C)[NH+](CCC1=CNC2=CC=CC=C21)C(C)C.[Cl-],,,,,,
15061,49756,"Indole, 3-(2-(dimethylamino)ethyl)-5-methoxy-2-methyl-",CC1=C(C2=C(N1)C=CC(=C2)OC)CCN(C)C,,,,,,
15062,49757,"Isobutyrophenone, 3',4'-(methylenedioxy)-",CC(C)C(=O)C1=CC2=C(C=C1)OCO2,,,,,,
15063,49758,CID 49758,CC[NH+](CC)CC1=C2C(=C(C(=CO2)C3=CC=CC=C3)O)C=CC1=O.[Cl-],,,,,,
15064,49759,CID 49759,CCN(CC)CC1=C2C(=C(C(=CO2)C3=CC=CC=C3)O)C=CC1=O,,,,,,
15065,49760,CID 49760,CC[NH+](CC)CC1=C2C(=C(C(=C(O2)C)C3=CC=CC=C3)O)C=CC1=O.[Cl-],,,,,,
15066,49761,CID 49761,CCN(CC)CC1=C2C(=C(C(=C(O2)C)C3=CC=CC=C3)O)C=CC1=O,,,,,,
15067,49762,CID 49762,C[NH+](C)CC1=C2C(=C(C(=CO2)C3=CC=CC=C3)O)C=CC1=O.[Cl-],,,,,,
15068,49763,CID 49763,CN(C)CC1=C2C(=C(C(=CO2)C3=CC=CC=C3)O)C=CC1=O,,,,,,
15069,49764,CID 49764,CC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH+]3CCOCC3)O)C4=CC=CC=C4.[Cl-],,,,,,
15070,49765,CID 49765,CC1=C(C(=C2C=CC(=O)C(=C2O1)CN3CCOCC3)O)C4=CC=CC=C4,,,,,,
15071,49766,CID 49766,CC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH+]3CCCCC3)O)C4=CC=CC=C4.[Cl-],,,,,,
15072,49767,CID 49767,CC1=C(C(=C2C=CC(=O)C(=C2O1)CN3CCCCC3)O)C4=CC=CC=C4,,,,,,
15073,49768,CID 49768,C1COCC[NH+]1CC2=C3C(=C(C(=CO3)C4=CC=CC=C4)O)C=CC2=O.[Cl-],,,,,,
15074,49769,CID 49769,C1COCCN1CC2=C3C(=C(C(=CO3)C4=CC=CC=C4)O)C=CC2=O,,,,,,
15075,49770,CID 49770,C1CC[NH+](CC1)CC2=C3C(=C(C(=CO3)C4=CC=CC=C4)O)C=CC2=O.[Cl-],,,,,,
15076,49771,CID 49771,C1CCN(CC1)CC2=C3C(=C(C(=CO3)C4=CC=CC=C4)O)C=CC2=O,,,,,,
15077,49772,CID 49772,CC1=C(C(=C2C=CC(=O)C(=C2O1)C[NH+](C)C)O)C3=CC=CC=C3.[Cl-],,,,,,
15078,49773,CID 49773,CC1=C(C(=C2C=CC(=O)C(=C2O1)CN(C)C)O)C3=CC=CC=C3,,,,,,
15079,49774,2-(2-Chloroethyl)isoindoline hydrochloride,C1C2=CC=CC=C2C[NH+]1CCCl.[Cl-],,,,,,
15080,49775,"2-(2-chloro-ethyl)-2,3-dihydro-1H-isoindole",C1C2=CC=CC=C2CN1CCCl,,,,,,
15081,49776,"1H-1,2,4-Triazole, 3,5-bis(4-pyridyl)-1-isonicotinamido-, dihydrochloride",C1=CC=[N+](C=C1)C2=NN(C(=N2)[N+]3=CC=CC=C3)NC(=O)C4=CC=NC=C4.[Cl-].[Cl-],,,,,,
15082,49777,"N-[3,5-di(pyridin-1-ium-1-yl)-1,2,4-triazol-1-yl]pyridine-4-carboxamide",C1=CC=[N+](C=C1)C2=NN(C(=N2)[N+]3=CC=CC=C3)NC(=O)C4=CC=NC=C4,,,,,,
15083,49778,CID 49778,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)N(C)C)I.[Na+],,,,,,
15084,49779,"5-Acetylamino-N,N-dimethyl-2,4,6-triiodoisophthalamic acid",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)N(C)C)I,,,,,,
15085,49780,CID 49780,CCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)[O-])I.[Na+],,,,,,
15086,49781,"3-Acetamido-5-(ethylcarbamoyl)-2,4,6-triiodobenzoic acid",CCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)O)I,,,,,,
15087,49782,CID 49782,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)N)I.[Na+],,,,,,
15088,49783,"5-Acetylamino-2,4,6-triiodoisophthalamic acid",CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)N)I,,,,,,
15089,49784,CID 49784,CCCCCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCC)I)C(=O)[O-])I.[Na+],,,,,,
15090,49785,"3-(butanoylamino)-2,4,6-triiodo-5-(pentylcarbamoyl)benzoic Acid",CCCCCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCC)I)C(=O)O)I,,,,,,
15091,49786,"Imidazolidine, 2-trifluoromethyl-, hemihydrate",C1CNC(N1)C(F)(F)F.C1CNC(N1)C(F)(F)F.O,,,,,,
15092,49787,2-(Trifluoromethyl)imidazolidine,C1CNC(N1)C(F)(F)F,,,,,,
15093,49788,N-(2-Methylpropyl)-2-oxo-3H-imidazole-1-carboxamide,CC(C)CNC(=O)N1C=CNC1=O,,,,,,
15094,49789,"N,N-Dimethyl-gamma-isopropyl-1-naphthalenebutylamine",CC(C)C(CCN(C)C)CC1=CC=CC2=CC=CC=C21,,,,,,
15095,49790,"1-Naphthalenecarbamic acid, 3-(2-methylpiperidino)propyl ester, hydrochloride",CC1CCCC[NH+]1CCCOC(=O)NC2=CC=CC3=CC=CC=C32.[Cl-],,,,,,
15096,49791,"1,2-Naphthalenediol, monohydrate",C1=CC=C2C(=C1)C=CC(=C2O)O.O,,,,,,
15097,49792,alpha-Isopropyl-alpha-(2-dimethylaminoethyl)-1-naphthylpropionamide,CC(C)C(CCN(C)C)(CC1=CC=CC2=CC=CC=C21)C(=O)N,,,,,,
15098,49793,"Butyronitrile, 4-dimethylamino-2-isopropyl-2-naphthylmethyl-",CC(C)C(CCN(C)C)(CC1=CC=CC2=CC=CC=C21)C#N,,,,,,
15099,49794,"1,4-Dihydro-1-naphthoic acid 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)C1C=CCC2=CC=CC=C12.[Cl-],,,,,,
15100,49795,"2-(Diethylamino)ethyl 1,4-dihydronaphthalene-1-carboxylate",CCN(CC)CCOC(=O)C1C=CCC2=CC=CC=C12,,,,,,
15101,49796,"1-Naphthylamine, 1,2,3,4-tetrahydro-8-chloro-5-(4-chlorobenzyloxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC=C(C=C3)Cl.[Cl-],,,,,,
15102,49797,"8-chloro-5-[(4-chlorophenyl)methoxy]-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine",CN(C)C1CCCC2=C(C=CC(=C12)Cl)OCC3=CC=C(C=C3)Cl,,,,,,
15103,49798,"Acetamide, N-(2-(5-methoxyindan-6-YL)ethyl)-2-phenyl-",COC1=C(C=C2CCCC2=C1)CCNC(=O)CC3=CC=CC=C3,,,,,,
15104,49799,"5-Hexanoylamino-N-methyl-2,4,6-triiodoisophthalamic acid N-methylglucamine salt",CCCCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)NC)I.C[NH2+]CC(C(C(C(CO)O)O)O)O,,,,,,
15105,49800,"3-(hexanoylamino)-2,4,6-triiodo-5-(methylcarbamoyl)benzoic Acid",CCCCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I,,,,,,
15106,49801,"N-Methyl-5-propionylamino-2,4,6-triiodoisophthalamic acid N-methylglucamine salt",CCC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)NC)I.C[NH2+]CC(C(C(C(CO)O)O)O)O,,,,,,
15107,49802,"2,4,6-Triiodo-3-(N-methylcarbamoyl)-5-(propionylamino)benzoic acid",CCC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I,,,,,,
15108,49803,"1,2,6,8-Tetrachlorodibenzo-P-dioxin",C1=CC(=C(C2=C1OC3=C(O2)C=C(C=C3Cl)Cl)Cl)Cl,,,,,,
15109,49804,"3-Furancarboxamide, tetrahydro-N-(((4-(dimethylamino)phenyl)amino)carbonyl)-5-methyl-2-oxo-3-(2-propenyl)-",CC1CC(C(=O)O1)(CC=C)C(=O)NC(=O)NC2=CC=C(C=C2)N(C)C,,,,,,
15110,49805,"(+)-(3S,4S)-trans-3,4-Dihydro-3,4-dihydroxybenz(a)anthracene",C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3C=C[C@@H]([C@H]4O)O,,,,,,
15111,49806,"5-Butyrylamino-N-methyl-2,4,6-triiodoisophthalamic acid N-methylglucamine salt",CCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)NC)I.C[NH2+]CC(C(C(C(CO)O)O)O)O,,,,,,
15112,49807,"3-(Butanoylamino)-5-(methylcarbamoyl)-2,4,6-triiodobenzoic acid",CCCC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I,,,,,,
15113,49808,"Methoxymethyl 6-[4-(4-hydroxyphenyl)-2,2-dimethyl-5-oxoimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1(C(N2C(S1)C(C2=O)N3C(=O)C(NC3(C)C)C4=CC=C(C=C4)O)C(=O)OCOC)C,,,,,,
15114,49809,CID 49809,C1=CC2=C(C(=C1)Cl)N(C(=O)S2)CC(=O)[O-].[K+],,,,,,
15115,49810,CID 49810,CC[NH+](CC)CC(=O)C1=C2CCCC2=CC3=C1CCC3.C(=CC(=O)[O-])C(=O)O,,,,,,
15116,49811,"2-(Diethylamino)-1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ethanone",CCN(CC)CC(=O)C1=C2CCCC2=CC3=C1CCC3,,,,,,
15117,49812,CID 49812,CCC[NH+](CCC)CC(=O)C1=C2CCCC2=CC3=C1CCC3.C(=CC(=O)[O-])C(=O)O,,,,,,
15118,49813,"2-(Dipropylamino)-1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ethanone",CCCN(CCC)CC(=O)C1=C2CCCC2=CC3=C1CCC3,,,,,,
15119,49814,CID 49814,C[NH+](CC1=CC=CC=C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
15120,49815,"2-[Benzyl(methyl)amino]-1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ethanone",CN(CC1=CC=CC=C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4,,,,,,
15121,49816,CID 49816,CC(C)[NH+](CC1=CC=CC=C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
15122,49817,"2-[Benzyl(propan-2-yl)amino]-1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ethanone",CC(C)N(CC1=CC=CC=C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4,,,,,,
15123,49818,CID 49818,C#CC[NH+](CC1=CC=CC=C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
15124,49819,"2-[Benzyl(prop-2-ynyl)amino]-1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ethanone",C#CCN(CC1=CC=CC=C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4,,,,,,
15125,49820,CID 49820,C1CC[NH+](C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
15126,49821,"1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-2-pyrrolidin-1-ylethanone",C1CCN(C1)CC(=O)C2=C3CCCC3=CC4=C2CCC4,,,,,,
15127,49822,CID 49822,C1CC[NH+](CC1)CC(=O)C2=C3CCCC3=CC4=C2CCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
15128,49823,"1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-2-piperidin-1-ylethanone",C1CCN(CC1)CC(=O)C2=C3CCCC3=CC4=C2CCC4,,,,,,
15129,49824,CID 49824,C1CC2=CC3=C(CCC3)C(=C2C1)C(=O)C[NH+]4CCOCC4.C(=CC(=O)[O-])C(=O)O,,,,,,
15130,49825,"1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-2-morpholin-4-ylethanone",C1CC2=CC3=C(CCC3)C(=C2C1)C(=O)CN4CCOCC4,,,,,,
15131,49826,"Ethanone, 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-2-(4-methyl-1-piperazinyl)-, hydrochloride,hydrate (2:4:1)",CN1CCN(CC1)CC(=O)C2=C3CCCC3=CC4=C2CCC4.Cl.Cl,,,,,,
15132,49827,"1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-2-(4-methylpiperazin-1-yl)ethanone",CN1CCN(CC1)CC(=O)C2=C3CCCC3=CC4=C2CCC4,,,,,,
15133,49828,"1H-Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-, (alpha,alpha,alpha-trifluoro-m-tolyl) ester",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4=CC=CC(=C4)C(F)(F)F,,,,,,
15134,49829,"1H-INDOLE-3-ACETIC ACID, 1-(p-CHLOROBENZOYL)-5-METHOXY-2-METHYL-, m-TOLYL ESTER",CC1=CC(=CC=C1)OC(=O)CC2=C(N(C3=C2C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)Cl)C,,,,,,
15135,49830,Vanilloylzygadenine,C[C@H]1CC[C@H]2[C@@](C3[C@H]([C@@H]([C@]4(C5CCC6[C@]7([C@@]5(CC4C3CN2C1)O[C@]6([C@H](CC7)OC(=O)C8=CC(=C(C=C8)O)OC)O)C)O)O)O)(C)O,,,,,,
15136,49831,"2-(3,4-dichlorophenyl)-1H-benzimidazole",C1=CC=C2C(=C1)NC(=N2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
15137,49832,N-Benzoyloxy-3'-methyl-4-methylaminoazobenzene,CC1=CC(=CC=C1)N=NC2=CC=C(C=C2)N(C)OC(=O)C3=CC=CC=C3,,,,,,
15138,49833,Fendona,CC1([C@H]([C@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['1. Dose excretion studies with cypermethrin (as a 1:1 cis/trans mixture) and alphacypermethrin (one of the two disasteroisomer pairs which constitute cis-cypermethrin) were out with, in each case, two volunteers per dose level. The studies included (a) single oral alphacypermethrin doses of 0.25 mg, 0.50 mg and 0.75 mg followed by repeated alphacypermethrin doses at the same levels, daily for five days, (b) repeated oral cypermethrin doses of 0.25 mg, 0.75 mg and 1.5 mg daily for five days, and (c) a single dermal application of 25 mg cypermethrin to the forearm. Urine was monitored for the free and conjugated 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid before and after dosing. 2. Metabolism and rate of excretion of a single oral dose of alphacypermethrin was similar to that of cis cypermethrin, on average, 43% of the dose was excreted as the cyclopropanecarboxylic acid in the first 24 hr urine. There was no increase in urinary metabolite excretion when alphacypermethrin was administered as a repeated oral dose. Subjects excreted, on average, 49% of the dose as the cyclopropanecarboxylic acid in the subsequent 24 hr periods after dosing. 3. There was no increase in the urinary cyclopropanecarboxylic acid excretion when cypermethrin was administered as a repeated oral dose. Subjects excreted, on average, 72% of the trans isomer dose and 45% of the cis isomer dose respectively in the subsequent 24 hr periods after dosing. 4. Approximately 0.1% of the applied dermal dose of 25 mg cypermethrin was excreted within 72 hr as the urinary cyclopropanecarboxylic acid. No conclusions can be drawn from such urinary excretion data as to the concentration of cypermethrin and its metabolites in the skin or other organs, or the possibility of other routes of metabolism or excretion.', '/PYRETHROIDS/ READILY PENETRATE INSECT CUTICLE AS SHOWN BY TOPICAL LD50 TO PERIPLANETA (COCKROACH) ... /PYRETHROIDS/', 'WHEN RADIOACTIVE PYRETHROID IS ADMIN ORALLY TO MAMMALS, IT IS ABSORBED FROM INTESTINAL TRACT OF THE ANIMALS & DISTRIBUTED IN EVERY TISSUE EXAMINED. EXCRETION OF RADIOACTIVITY IN RATS ADMIN TRANS-ISOMER: DOSAGE: 500 MG/KG; INTERVAL 20 DAYS; URINE 36%; FECES 64%; TOTAL 100%. /PYRETHROIDS/', 'Pyrethrins are absorbed through intact skin when applied topically. When animals were exposed to aerosols of pyrethrins with piperonyl butoxide being released into the air, little or none of the combination was systemically absorbed. /Pyrethrins/', 'Although limited absorption may account for the low toxicity of some pyrethroids, rapid biodegradation by mammalian liver enzymes (ester hydrolysis and oxidation) is probably the major factor responsible. Most pyrethroid metabolites are promptly excreted, at least in part, by the kidney. /Pyrethroids/']","['The metabolic pathways for the breakdown of the pyrethroids vary little between mammalian species but vary somewhat with structure. ... Essentially, pyrethrum and allethrin are broken down mainly by oxidation of the isobutenyl side chain of the acid moiety and of the unsaturated side chain of the alcohol moiety with ester hydrolysis playing and important part, whereas for the other pyrethroids ester hydrolysis predominates. /Pyrethrum and pyrethroids/', 'The relative resistance of mammals to the pyrethroids is almost wholly attributable to their ability to hydrolyze the pyrethroids rapidly to their inactive acid & alcohol components, since direct injection into the mammalian CNS leads to a susceptibility similar to that seen in insects. Some additional resistance of homeothermic organisms can also be attributed to the negative temperature coefficient of action of the pyrethroids, which are thus less toxic at mammalian body temperatures, but the major effect is metabolic. Metabolic disposal of the pyrethroids is very rapid, which means that toxicity is high by the iv route, moderate by slower oral absorption, & often unmeasureably low by dermal absorption. /Pyrethroids/', 'FASTEST BREAKDOWN IS SEEN WITH PRIMARY ALCOHOL ESTERS OF TRANS-SUBSTITUTED ACIDS SINCE THEY UNDERGO RAPID HYDROLYTIC & OXIDATIVE ATTACK. FOR ALL SECONDARY ALCOHOL ESTERS & FOR PRIMARY ALCOHOL CIS-SUBSTITUTED CYCLOPROPANECARBOXYLATES, OXIDATIVE ATTACK IS PREDOMINANT. /PYRETHROIDS/', 'Pyrethrins are reportedly inactivated in the GI tract following ingestion. In animals, pyrethrins are rapidly metabolized to water soluble, inactive compounds. /Pyrethrins/', 'Synthetic pyrethroids are generally metabolized in mammals through ester hydrolysis, oxidation, and conjugation, and there is no tendency to accumulate in tissues. In the environment, synthetic pyrethroids are fairly rapidly degraded in soil and in plants. Ester hydrolysis and oxidation at various sites on the molecule are the major degradation processes. /Synthetic pyrethroids/']",
15139,49834,"2-((2,3-Dimethylphenoxy)methyl)-2-imidazoline hydrochloride",CC1=C(C(=CC=C1)OCC2=NCC[NH2+]2)C.[Cl-],,,,,,
15140,49835,"2-[(2,3-dimethylphenoxy)methyl]-4,5-dihydro-1H-imidazole",CC1=C(C(=CC=C1)OCC2=NCCN2)C,,,,,,
15141,49836,CID 49836,C1(=C(SN=C1Cl)C(=O)[O-])Cl.[K+],,,,,,
15142,49837,"3,4-Dichloroisothiazole-5-carboxylic acid",C1(=C(SN=C1Cl)C(=O)O)Cl,,,,,,
15143,49838,"1,2-Dihydro-1,2-dihydroxy-5-methylchrysene",CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)C(C(C=C4)O)O,,,,,"['5-Methyl-1,2-dihydrochrysene-1,2-diol is a known human metabolite of 5-methylchrysene.']",
15144,49839,5-Hydroxymethylchrysene,C1=CC=C2C(=C1)C=CC3=C2C(=CC4=CC=CC=C34)CO,,,,,,
15145,49840,CID 49840,CCN(CC(C[NH2+]C(=N)[NH3+])O)C1=CC=CC=C1.[O-]S(=O)(=O)[O-],,,,,,
15146,49841,2-[3-(N-ethylanilino)-2-hydroxypropyl]guanidine,CCN(CC(CN=C(N)N)O)C1=CC=CC=C1,,,,,,
15147,49842,CID 49842,C1=CC=C(C=C1)N(CC(C[NH2+]C(=N)[NH3+])O)C2=CC=CC=C2.[O-]S(=O)(=O)[O-],,,,,,
15148,49843,1-[3-(Diphenylamino)-2-hydroxypropyl]guanidine,C1=CC=C(C=C1)N(CC(CN=C(N)N)O)C2=CC=CC=C2,,,,,,
15149,49844,CID 49844,CC1=CC=CC=C1NCC(C[NH2+]C(=N)[NH3+])O.[O-]S(=O)(=O)[O-],,,,,,
15150,49845,2-[2-Hydroxy-3-(2-methylanilino)propyl]guanidine,CC1=CC=CC=C1NCC(CN=C(N)N)O,,,,,,
15151,49846,"dl-1-(2-Hydroxy-3-(2,5-xylidino)propyl)guanidine hemisulfate",CC1=CC(=C(C=C1)C)[NH2+]CC(C[NH2+]C(=N)N)O.[O-]S(=O)(=O)[O-],,,,,,
15152,49847,"2-[3-(2,5-Dimethylanilino)-2-hydroxypropyl]guanidine",CC1=CC(=C(C=C1)C)NCC(CN=C(N)N)O,,,,,,
15153,49848,CID 49848,CC1=CC(=C(C=C1)NCC(CN=C([NH3+])N)O)Br.CC1=CC(=C(C=C1)NCC(CN=C([NH3+])N)O)Br.[O-]S(=O)(=O)[O-],,,,,,
15154,49849,2-[3-(2-Bromo-4-methylanilino)-2-hydroxypropyl]guanidine,CC1=CC(=C(C=C1)NCC(CN=C(N)N)O)Br,,,,,,
15155,49850,dl-1-(2-Hydroxy-3-(o-methoxyanilino)propyl)guanidine hemisulfate,COC1=CC=CC=C1NCC(C[NH+]=C([NH3+])N)O.[O-]S(=O)(=O)[O-],,,,,,
15156,49851,2-[2-Hydroxy-3-(2-methoxyanilino)propyl]guanidine,COC1=CC=CC=C1NCC(CN=C(N)N)O,,,,,,
15157,49852,"ANTHRA(9,1,2-cde)BENZO(rst)PENTAPHENE-5,10-DIONE, 15,18-DINITRO-",C1=CC=C2C(=C1)C3=C(C=C4C5=CC(=C6C7=CC=CC=C7C(=O)C8=C6C5=C(C=C8)C9=C4C3=C(C2=O)C=C9)[N+](=O)[O-])[N+](=O)[O-],,,,,,
15158,49853,Phenylphosphonothioic acid O-methyl S-potassium salt,COP(=S)(C1=CC=CC=C1)[O-].[K+],,,,,,
15159,49854,CID 49854,COP(=O)(C1=CC=CC=C1)S,,,,,,
15160,49855,"3,9-Dihydroxy-7,12-dimethylbenz(a)anthracene",CC1=C2C=CC3=C(C2=C(C4=C1C=C(C=C4)O)C)C=CC(=C3)O,,,,,,
15161,49856,Dec-4-en-1-yl acetatato,CCCCCC=CCCCOC(=O)C,,,,,,
15162,49857,"2,6-Bis(acetylaminomethyl)pyridine",CC(=O)NCC1=NC(=CC=C1)CNC(=O)C,,,,,,
15163,49858,CID 49858,CN1C(=NN=CC2=CC=C(C=C2)[N+](=O)[O-])C3=CC=CC=C3C(=N1)Cl,,,,,,
15164,49859,"Ketone, 3-ethyl-2,2-dimethylcyclobutyl methyl (E)-",CC[C@H]1CC(C1(C)C)C(=O)C,,,,,,
15165,49860,3-(3-Ethylsulfonyl)pentyl piperidino ketone,CCC(CCC(=O)N1CCCCC1)S(=O)(=O)CC,,,,,,
15166,49861,Diethyl 2-aminoethyl-(p-chlorophenyl)malonate hydrochloride,CCOC(=O)C(CC[NH3+])(C1=CC=C(C=C1)Cl)C(=O)OCC.[Cl-],,,,,,
15167,49862,Diethyl 2-(2-aminoethyl)-2-(4-chlorophenyl)propanedioate,CCOC(=O)C(CCN)(C1=CC=C(C=C1)Cl)C(=O)OCC,,,,,,
15168,49863,Diethyl 2-aminoethyl-(p-methoxyphenyl)malonate hydrochloride,CCOC(=O)C(CC[NH3+])(C1=CC=C(C=C1)OC)C(=O)OCC.[Cl-],,,,,,
15169,49864,Diethyl 2-(2-aminoethyl)-2-(4-methoxyphenyl)propanedioate,CCOC(=O)C(CCN)(C1=CC=C(C=C1)OC)C(=O)OCC,,,,,,
15170,49865,"Diethyl 2-aminoethyl-(3,4-methylenedioxyphenyl)malonate hydrochloride",CCOC(=O)C(CC[NH3+])(C1=CC2=C(C=C1)OCO2)C(=O)OCC.[Cl-],,,,,,
15171,49866,"Diethyl 2-(2-aminoethyl)-2-(1,3-benzodioxol-5-yl)propanedioate",CCOC(=O)C(CCN)(C1=CC2=C(C=C1)OCO2)C(=O)OCC,,,,,,
15172,49867,Diethyl 2-aminoethyl-phenylmalonate hydrochloride,CCOC(=O)C(CC[NH3+])(C1=CC=CC=C1)C(=O)OCC.[Cl-],,,,,,
15173,49868,Diethyl 2-(2-aminoethyl)-2-phenylpropanedioate,CCOC(=O)C(CCN)(C1=CC=CC=C1)C(=O)OCC,,,,,,
15174,49869,"Diethyl 2-aminoethyl-(3,4-xylyl)malonate hydrochloride",CCOC(=O)C(CC[NH3+])(C1=CC(=C(C=C1)C)C)C(=O)OCC.[Cl-],,,,,,
15175,49870,"Diethyl 2-(2-aminoethyl)-2-(3,4-dimethylphenyl)propanedioate",CCOC(=O)C(CCN)(C1=CC(=C(C=C1)C)C)C(=O)OCC,,,,,,
15176,49871,Diethyl (3-amino-2-propyl)(phenyl)malonate hydrochloride,CCOC(=O)C(C1=CC=CC=C1)(C(C)C[NH3+])C(=O)OCC.[Cl-],,,,,,
15177,49872,Diethyl 2-(1-aminopropan-2-yl)-2-phenylpropanedioate,CCOC(=O)C(C1=CC=CC=C1)(C(C)CN)C(=O)OCC,,,,,,
15178,49873,"Mandelic acid, 3-(diethylamino)-2,2-dimethylpropyl ester, acetate, hydrochloride",CC[NH+](CC)CC(C)(C)COC(=O)C(C1=CC=CC=C1)OC(=O)C.[Cl-],,,,,,
15179,49874,"[3-(Diethylamino)-2,2-dimethylpropyl] 2-acetyloxy-2-phenylacetate",CCN(CC)CC(C)(C)COC(=O)C(C1=CC=CC=C1)OC(=O)C,,,,,,
15180,49875,beta-Mandeloyloxy-beta-phenylethyl dimethylamine,CN(C)CC(C1=CC=CC=C1)OC(=O)C(C2=CC=CC=C2)O,,,,,,
15181,49876,1-(3-Chloromercuri-2-methoxy-1-propyl)-3-methylhydantoin,CN1C(=O)CN(C1=O)CC(C[Hg]Cl)OC,,,,,,
15182,49877,N-(2-Ethoxy-3-hydroxymercuripropyl)barbital,CCC1(C(=O)NC(=O)N(C1=O)CC(C[Hg])OCC)CC.O,,,,,,
15183,49878,"[3-(5,5-Diethyl-2,4,6-trioxo-1,3-diazinan-1-yl)-2-ethoxypropyl]mercury",CCC1(C(=O)NC(=O)N(C1=O)CC(C[Hg])OCC)CC,,,,,,
15184,49879,N-(2-Isopropoxy-3-hydroxymercuripropyl)barbital,CCC1(C(=O)NC(=O)N(C1=O)CC(C[Hg])OC(C)C)CC.O,,,,,,
15185,49880,"[3-(5,5-Diethyl-2,4,6-trioxo-1,3-diazinan-1-yl)-2-propan-2-yloxypropyl]mercury",CCC1(C(=O)NC(=O)N(C1=O)CC(C[Hg])OC(C)C)CC,,,,,,
15186,49881,N-(2-Methoxy-3-hydroxymercuripropyl)barbital,CCC1(C(=O)NC(=O)N(C1=O)CC(C[Hg])OC)CC.O,,,,,,
15187,49882,"[3-(5,5-Diethyl-2,4,6-trioxo-1,3-diazinan-1-yl)-2-methoxypropyl]mercury",CCC1(C(=O)NC(=O)N(C1=O)CC(C[Hg])OC)CC,,,,,,
15188,49883,"10H-Pyrido(3,2-b)(1,4)benzothiazine, 10-(3-(diethylamino)propyl)-",CCN(CC)CCCN1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
15189,49884,CID 49884,COC1=CC=CC=C1C(=O)N(CC(C[Hg])OCCO)C(=O)[O-].O.[Na+],,,,,,
15190,49885,[3-[Carboxy-(2-methoxybenzoyl)amino]-2-(2-hydroxyethoxy)propyl]mercury,COC1=CC=CC=C1C(=O)N(CC(C[Hg])OCCO)C(=O)O,,,,,,
15191,49886,4-Benzylbenzaldehyde,C1=CC=C(C=C1)CC2=CC=C(C=C2)C=O,,,,,,
15192,49887,"Ketone, 4-(2-pyrimidyl)piperazinyl 3,4,5-trimethoxyphenyl",COC1=CC(=CC(=C1OC)OC)C(=O)N2CCN(CC2)C3=NC=CC=N3,,,,,,
15193,49888,"2,3,4,6,8-Pentachlorodibenzofuran",C1=C(C=C(C2=C1C3=CC(=C(C(=C3O2)Cl)Cl)Cl)Cl)Cl,,,,,,
15194,49889,"Ethylamine, 1-(5-chloro-2-thenyl)-, hydrochloride",CC(CC1=CC=C(S1)Cl)[NH3+].[Cl-],,,,,,
15195,49890,1-(5-Chlorothiophen-2-yl)propan-2-amine,CC(CC1=CC=C(S1)Cl)N,,,,,,
15196,49891,"Ethylamine, 1-(3-chloro-2-thenyl)-, hydrochloride",CC(CC1=C(C=CS1)Cl)[NH3+].[Cl-],,,,,,
15197,49892,2-(3-Chlorothiphen-2-yl)-1-methylethylamine,CC(CC1=C(C=CS1)Cl)N,,,,,,
15198,49893,"Ethylamine, 1-(4-chloro-2-thenyl)-, hydrochloride",CC(CC1=CC(=CS1)Cl)[NH3+].[Cl-],,,,,,
15199,49894,1-(4-Chlorothiophen-2-yl)propan-2-amine hydrochloride,CC(CC1=CC(=CS1)Cl)N,,,,,,
15200,49895,"Ethylamine, 1-(3,4-dichloro-2-thenyl)-, hydrochloride",CC(CC1=C(C(=CS1)Cl)Cl)[NH3+].[Cl-],,,,,,
15201,49896,"3,4-Dichloro-alpha-methyl-2-thiopheneethanamine",CC(CC1=C(C(=CS1)Cl)Cl)N,,,,,,
15202,49897,"Ethylamine, 1-(4,5-dichloro-2-thenyl)-, hydrochloride",CC(CC1=CC(=C(S1)Cl)Cl)[NH3+].[Cl-],,,,,,
15203,49898,"1-(4,5-Dichlorothiophen-2-yl)propan-2-amine",CC(CC1=CC(=C(S1)Cl)Cl)N,,,,,,
15204,49899,"Ethylamine, 1-(3,5-dichloro-2-thenyl)-, hydrochloride",CC(CC1=C(C=C(S1)Cl)Cl)[NH3+].[Cl-],,,,,,
15205,49900,"1-(3,5-Dichlorothiophen-2-yl)propan-2-amine",CC(CC1=C(C=C(S1)Cl)Cl)N,,,,,,
15206,49901,"N-[1,5-bis[4-(trifluoromethyl)phenyl]penta-1,4-dien-3-ylideneamino]-5,5-dimethyl-4,6-dihydro-1H-pyrimidin-2-amine",CC1(CNC(=NC1)NN=C(C=CC2=CC=C(C=C2)C(F)(F)F)C=CC3=CC=C(C=C3)C(F)(F)F)C,,,,,,
15207,49902,"Naphthalenesulfonic acid, dinonyl-, ammonium salt",CCCCCCCCCC1=CC2=C(C=C1)C(=CC(=C2)CCCCCCCCC)S(=O)(=O)[O-].[NH4+],,,,,,
15208,49903,"1-Naphthalenesulfonic acid, 3,6-dinonyl-",CCCCCCCCCC1=CC2=C(C=C1)C(=CC(=C2)CCCCCCCCC)S(=O)(=O)O,,,,,,
15209,49904,CID 49904,CN(C)C(=NC1=C(C=CC=C1Cl)Cl)[NH3+].[Cl-],,,,,,
15210,49905,"2-(2,6-Dichlorophenyl)-1,1-dimethylguanidine",CN(C)C(=NC1=C(C=CC=C1Cl)Cl)N,,,,,,
15211,49906,"Guanidine, 2-(2,6-dichlorophenyl)-1-(2-(diethylamino)ethyl)-3,3-dimethyl-, hydrochloride",CC[NH+](CC)CCN=C(NC1=C(C=CC=C1Cl)Cl)N(C)C.[Cl-],,,,,,
15212,49907,"3-(2,6-Dichlorophenyl)-2-[2-(diethylamino)ethyl]-1,1-dimethylguanidine",CCN(CC)CCN=C(NC1=C(C=CC=C1Cl)Cl)N(C)C,,,,,,
15213,49908,"Guanidine, 2-(2,6-dichlorophenyl)-1,1-dimethyl-3-(p-methoxyphenyl)-, hydrochloride",C[NH+](C)C(=NC1=C(C=CC=C1Cl)Cl)NC2=CC=C(C=C2)OC.[Cl-],,,,,,
15214,49909,"2-(2,6-Dichlorophenyl)-3-(4-methoxyphenyl)-1,1-dimethylguanidine",CN(C)C(=NC1=C(C=CC=C1Cl)Cl)NC2=CC=C(C=C2)OC,,,,,,
15215,49910,"Guanidine, 1-(p-chlorophenyl)-2-(2,6-dichlorophenyl)-3,3-dimethyl-, hydrochloride",C[NH+](C)C(=NC1=C(C=CC=C1Cl)Cl)NC2=CC=C(C=C2)Cl.[Cl-],,,,,,
15216,49911,"3-(4-Chlorophenyl)-2-(2,6-dichlorophenyl)-1,1-dimethylguanidine",CN(C)C(=NC1=C(C=CC=C1Cl)Cl)NC2=CC=C(C=C2)Cl,,,,,,
15217,49912,"N-Heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate",CCCCCCC[NH2+]C1CCCC2=C1C=CC(=C2)OC.CS(=O)(=O)[O-],,,,,,
15218,49913,"N-Heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthalenamine",CCCCCCCNC1CCCC2=C1C=CC(=C2)OC,,,,,,
15219,49914,"6-Methoxy-N-octyl-1,2,3,4-tetrahydro-1-naphthylamine",CCCCCCCC[NH2+]C1CCCC2=C1C=CC(=C2)OC.[Cl-],,,,,,
15220,49915,"6-methoxy-N-octyl-1,2,3,4-tetrahydronaphthalen-1-amine",CCCCCCCCNC1CCCC2=C1C=CC(=C2)OC,,,,,,
15221,49916,"6-Methoxy-N-nonyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride",CCCCCCCCC[NH2+]C1CCCC2=C1C=CC(=C2)OC.[Cl-],,,,,,
15222,49917,"6-methoxy-N-nonyl-1,2,3,4-tetrahydronaphthalen-1-amine",CCCCCCCCCNC1CCCC2=C1C=CC(=C2)OC,,,,,,
15223,49918,"N-Cyclohexyl-6-methoxy-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride",COC1=CC2=C(C=C1)C(CCC2)[NH2+]C3CCCCC3.[Cl-],,,,,,
15224,49919,"N-cyclohexyl-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine",COC1=CC2=C(C=C1)C(CCC2)NC3CCCCC3,,,,,,
15225,49920,"N-Cyclopropylmethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine",CN(C1CC1)C2CCC3=C(C2)C=CC(=C3)OC,,,,,,
15226,49921,"N-Cyclopropyl-5-methoxy-1-methyl-1,2,3,4-tetrahydro-2-naphthylamine",CC1C(CCC2=C1C=CC=C2OC)NC3CC3,,,,,,
15227,49922,"N-(3-Chloropropyl)-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine",COC1=CC2=C(CC(CC2)NCCCCl)C=C1,,,,,,
15228,49923,"1,2,3,4,8-Pentachlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,,,
15229,49924,"7,8-Dihydro-7,8-dihydroxy-5-methylchrysene",CC1=CC2=C(C=CC(C2O)O)C3=C1C4=CC=CC=C4C=C3,,,,,,
15230,49925,"5-Ethyl-5-hex-2-en-2-yl-1,3-diazinane-2,4,6-trione",CCCC=C(C)C1(C(=O)NC(=O)NC1=O)CC,,,,,,
15231,49926,"octanoic acid [(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-(2-methyl-1-oxobut-2-enoxy)-2-oxo-4-(1-oxobutoxy)-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-7-yl] ester",CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)C(=CC)C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCC)([C@](C(=O)O3)(C)O)O,,,,,,
15232,49927,"Iron, bis(1,2-ethanediamine-N,N')(ethanedioato(2-)-O,O')-, (OC-6-22)-",C(CN)N.C(CN)N.C(=O)(C(=O)[O-])[O-].[Fe+2],,,,,,
15233,49928,CID 49928,C(CC=CCl)C=CCl,,,,,,
15234,49929,Methyl(butyroxymethyl)nitrosamine,CCCC(=O)OCN(C)N=O,,,,,,
15235,49930,"Methylamine, 1-acetoxy-N-nitroso-N-trideuteromethyl-",[2H]C([2H])([2H])N(COC(=O)C)N=O,,,,,,
15236,49931,"1,2,4,6,7,8-Hexachlorodibenzofuran",C1=C2C3=C(C(=CC(=C3Cl)Cl)Cl)OC2=C(C(=C1Cl)Cl)Cl,,,,,,
15237,49932,"18,19-Dinorstigmastane, 5,14-dimethyl-, (5beta,8alpha,9beta,10alpha,14beta,24xi)-",CCC(CCC(C)C1CCC2(C1CCC3C2CCC4(C3CCCC4)C)C)C(C)C,,,,,,
15238,49933,(3-Cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium ethanesulfonate,CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O.CCS(=O)(=O)[O-],,,,,,
15239,49934,(3-Cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium butanesulfonate,CCCCS(=O)(=O)[O-].CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O,,,,,,
15240,49935,1-Butanesulfonic acid,CCCCS(=O)(=O)O,,,,,,
15241,49936,(3-Cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium hexanesulfonate,CCCCCCS(=O)(=O)[O-].CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O,,,,,,
15242,49937,Hexanesulfonic acid,CCCCCCS(=O)(=O)O,,,,,,
15243,49938,(3-Cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium octanesulfonate,CCCCCCCCS(=O)(=O)[O-].CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O,,,,,,
15244,49939,1-Octanesulfonic acid,CCCCCCCCS(=O)(=O)O,,,,,,
15245,49940,Clausmarin A,CC12CCC(OC1CC3=C(O2)C=C4C(=C3)C=C(C(=O)O4)C(C)(C)C=C)C(C)(C)O,,,,,,
15246,49941,CID 49941,COC1=CC=C(C=C1)C2=C3C(=CC=C2)NC(=C3C=NN=C(N)S)C4=CC=CC=C4,,,,,,
15247,49942,Methyl-[(4-nitrophenyl)methylideneamino]cyanamide,CN(C#N)N=CC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
15248,49943,"Iron, diammine(ethanedioato(2-)-O,O')-, (T-4)-",C(=O)(C(=O)[O-])[O-].N.N.[Fe+2],,,,,,
15249,49944,"Acetanilide, 2',6'-dichloro-2-morpholino-",C1COC(CN1)CC(=O)NC2=C(C=CC=C2Cl)Cl,,,,,,
15250,49945,"Acetanilide, 2-bis(2-(hydroxyethyl)amino)-2',6'-dichloro-",C1=CC(=C(C(=C1)Cl)NC(=O)CN(CCO)CCO)Cl,,,,,,
15251,49946,"Acetanilide, 2',6'-dichloro-2-(4-methylpiperazino)-",CN1CCN(CC1)CC(=O)NC2=C(C=CC=C2Cl)Cl,,,,,,
15252,49947,"2-Amino-N-(2,6-dichlorophenyl)acetamide",C1=CC(=C(C(=C1)Cl)NC(=O)CN)Cl,,,,,,
15253,49948,"Acetanilide, 2-diethylamino-2',4',6'-trichloro-",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)Cl)Cl,,,,,,
15254,49949,"Acetanilide, 2-morpholino-2',4',6'-trichloro-",C1COCCN1CC(=O)NC2=C(C=C(C=C2Cl)Cl)Cl,,,,,,
15255,49950,"2',6'-Dichloro-2-diethylamino-4'-nitroacetanilide",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)[N+](=O)[O-])Cl,,,,,,
15256,49951,"Acetanilide, 4'-amino-2',6'-dichloro-2-diethylamino-",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)N)Cl,,,,,,
15257,49952,"Acetanilide, 2',6'-dichloro-2-diethylamino-4'-dimethylamino-",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)N(C)C)Cl,,,,,,
15258,49953,"Acetanilide, 4'-benzylamino-2',6'-dichloro-2-diethylamino-",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)NCC2=CC=CC=C2)Cl,,,,,,
15259,49954,"Acetanilide, 4'-benzyloxy-2',6'-dichloro-2-diethylamino-",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)OCC2=CC=CC=C2)Cl,,,,,,
15260,49955,"N-(2,6-dichloro-4-methoxyphenyl)-2-(diethylamino)acetamide",CCN(CC)CC(=O)NC1=C(C=C(C=C1Cl)OC)Cl,,,,,,
15261,49956,(3-Cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium decanesulfonate,CCCCCCCCCCS(=O)(=O)[O-].CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O,,,,,,
15262,49957,Decane-1-sulfonic acid,CCCCCCCCCCS(=O)(=O)O,,,,,,
15263,49958,"BENZ(a)ANTHRACENE, 7-(CHLOROMETHYL)-5-FLUORO-12-METHYL-",CC1=C2C3=CC=CC=C3C(=CC2=C(C4=CC=CC=C14)CCl)F,,,,,,
15264,49959,5-Fluoro-7-hydroxymethyl-12-methylbenzanthracene,CC1=C2C3=CC=CC=C3C(=CC2=C(C4=CC=CC=C14)CO)F,,,,,,
15265,49960,CID 49960,C[NH+]1C(=CN=C1C=C2CCC3=C(C2=O)C=CC(=C3)OCC[NH+](C)C)[N+](=O)[O-].[O-]S(=O)(=O)[O-],,,,,,
15266,49961,Fluorocyphenothrin,CC1([C@@H]([C@@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(F)F)C,,,,,,
15267,49962,"Cyclopropanecarboxylic acid, 3-(2,2-difluoroethenyl)-2,2-dimethyl-, cyano(3-phenoxyphenyl)methyl ester, (1R-trans)-",CC1([C@H]([C@@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(F)F)C,,,,,,
15268,49963,"3,4-Epoxy-1,2,3,4-tetrahydrochrysene",C1CC2=C(C3C1O3)C4=C(C=C2)C5=CC=CC=C5C=C4,,,,,,
15269,49964,"Triphenylbis(2,2,2-trifluoroethoxy)phosphorane",C1=CC=C(C=C1)P(C2=CC=CC=C2)(C3=CC=CC=C3)(OCC(F)(F)F)OCC(F)(F)F,,,,,,
15270,49965,"[10-formyl-5,14-dihydroxy-13-methyl-17-(6-oxopyran-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-methylbut-2-enoate",CC(=CC(=O)OC1CCC2(C3CCC4(C(CCC4(C3CCC2(C1)O)O)C5=COC(=O)C=C5)C)C=O)C,,,,,,
15271,49966,"methyl (13S,17S)-13-[(1'R,5S,9'R,11'R,12'R,19'R)-11'-acetyloxy-3-(2-chloroethyl)-12'-ethyl-5'-methoxy-8'-methyl-2,4-dioxospiro[1,3-oxazolidine-5,10'-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene]-4'-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate;sulfuric acid",CC[C@@]1(CC2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]1([C@@H]8N6C)C(=O)N(C(=O)O1)CCCl)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,,,,,,
15272,49967,Vinzolidine,CC[C@@]1(CC2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]1([C@@H]8N6C)C(=O)N(C(=O)O1)CCCl)OC(=O)C)CC)OC)C(=O)OC)O,,,,,,
15273,49968,Metazine,CC(C)NC1=NC(=NC(=N1)N(C)C#N)NC(C)C,,,,,,
15274,49969,5-Phenyldecane-1-sulfonic acid,CCCCCC(CCCCS(=O)(=O)O)C1=CC=CC=C1,,,,,,
15275,49970,"2-Aminodipyrido[1,2-a:3',2'-d]imidazole",C1=CC2=NC3=C(N2C=C1)N=C(C=C3)N,,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
15276,49971,"2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole",CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,"[""Glu-P-1 has known human metabolites that include N-Acetyl-2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole.""]",
15277,49972,"2,2',3,4,4',5,5'-Heptabromobiphenyl",C1=C(C(=CC(=C1Br)Br)Br)C2=CC(=C(C(=C2Br)Br)Br)Br,,,,,,
15278,49973,"2,3,7,8-Tetrabromodibenzofuran",C1=C2C3=CC(=C(C=C3OC2=CC(=C1Br)Br)Br)Br,,,,,,
15279,49974,"1H,7H-Cyclohepta(4,5)pyrrolo(1,2,3-de)quinoxalin-2(3H)-one, 8,9,10,11-tetrahydro-3-(2-(diethylamino)ethyl)-",CCN(CC)CCC1C=CC2=NC3=C(CCCCC3)N4C2=C1C(=O)C4,,,,,,
15280,49975,"1H,7H-Cyclohepta(4,5)pyrrolo(1,2,3-de)quinoxalin-2(3H)-one, 8,9,10,11-tetrahydro-3-(2-(diethylamino)ethyl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (2:1)",CC[NH+](CC)CCC1C=CC2=NC3=C(CCCCC3)N4C2=C1C(=O)C4.CC[NH+](CC)CCC1C=CC2=NC3=C(CCCCC3)N4C2=C1C(=O)C4.[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O,,,,,,
15281,49976,N-Ethoxycarbonylmethyl-N-nitrosourea,CCOC(=O)CN(C(=O)N)N=O,,,,,,
15282,49977,N-Carbamoyl-N-nitroso-3-phenylalanine ethyl ester,CCOC(=O)C(CC1=CC=CC=C1)N(C(=O)N)N=O,,,,,,
15283,49978,"Alanine, N-carbamoyl-N-nitroso-3-phenyl-",C1=CC=C(C=C1)CC(C(=O)O)N(C(=O)N)N=O,,,,,,
15284,49979,N-Carbamoyl-N-nitrosoalanine ethyl ester,CCOC(=O)C(C)N(C(=O)N)N=O,,,,,,
15285,49980,"4-Ethoxy-1,3-benzenediamine dihydrochloride",CCOC1=C(C=C(C=C1)N)N.Cl.Cl,,,,,,
15286,49981,"2,4-Diaminoethoxybenzene",CCOC1=C(C=C(C=C1)N)N,,,,,,
15287,49982,"Acetamide, N-nitroso-N-propyl-",CCCN(C(=O)C)N=O,,,,,,
15288,49983,"1,3-DITHIOLANE, 2-(o-TOLYL)-",CC1=CC=CC=C1C2SCCS2,,,,,,
15289,49984,2-Azidofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)N=[N+]=[N-],,,,,,
15290,49985,2-Methoxy-4-nitrophenol acetate,CC(=O)OC1=C(C=C(C=C1)[N+](=O)[O-])OC,,,,,,
15291,49986,Bis(2-methoxyethyl)nitrosoamine,COCCN(CCOC)N=O,,,,,,
15292,49987,Bis(2-ethoxyethyl)nitrosoamine,CCOCCN(CCOCC)N=O,,,,,,
15293,49988,"Butanoic acid, 3,7-dimethyloctyl ester",CCCC(=O)OCCC(C)CCCC(C)C,,,,,,
15294,49989,CID 49989,C1=CC(=CC(=C1)NC(=O)CS)C(=O)NCC(=O)[O-].[Na+],,,,,,
15295,49990,N-[3-(mercaptoacetylamino)benzoyl]glycine,C1=CC(=CC(=C1)NC(=O)CS)C(=O)NCC(=O)O,,,,,,
15296,49991,"2-(3,5-Dichlorophenoxy)ethylamine",C1=C(C=C(C=C1Cl)Cl)OCCN,,,,,,
15297,49992,"3-(3,5-Dichlorophenoxy)butyric acid",CC(CC(=O)O)OC1=CC(=CC(=C1)Cl)Cl,,,,,,
15298,49993,Hex-3-enyl 2-methylbut-2-enoate,CCC=CCCOC(=O)C(=CC)C,,,,,,
15299,49994,"2,4-Dihydroxy-5-(3-phenylprop-2-enoyl)benzoic acid",C1=CC=C(C=C1)C=CC(=O)C2=CC(=C(C=C2O)O)C(=O)O,,,,,,
15300,49995,"Benzimidazole, 2-(hept-4-YL)-",CCCC(CCC)C1=NC2=CC=CC=C2N1,,,,,,
15301,49996,"2,2',4,5,5'-Pentabromobiphenyl",C1=CC(=C(C=C1Br)C2=CC(=C(C=C2Br)Br)Br)Br,,,,,,
15302,49997,(S)-Fenpropathrin,CC1(C(C1(C)C)C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,,,,,,
15303,49998,"1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,6,7,8,10,10a-dodecahydro-1,4a-dimethyl-7-(1-methylethyl)-, methyl ester",CC(C)C1CCC2C(=CCC3C2(CCCC3(C)C(=O)OC)C)C1,,,,,,
15304,49999,Homobaldrinal,CC(C)CC(=O)OCC1=COC=C2C1=CC=C2C=O,,,,,,
15305,50000,"Glycine, N-(2-hydroxyethyl)-N-(5-ethoxy-1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)-",CCOC1=C(C=NN(C1=O)C)N(CCO)CC(=O)O,,,,,,
